PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	THOMAS, KB				THOMAS, KB			THE PLACEBO IN GENERAL-PRACTICE	LANCET			English	Article											THOMAS, KB (corresponding author), UNIV SOUTHAMPTON,ALDERMOOR HLTH CTR,DEPT PRIMARY MED CARE,SOUTHAMPTON SO1 6ST,HANTS,ENGLAND.							BALINT M, 1957, DOCTOR PATIENT ILLNE; Cartwright Ann, 1967, PATIENTS THEIR DOCTO; CROMBIE DL, 1963, J COLL GEN PRACTIT, V6, P582; EIMERL TS, 1962, THESIS U LIVERPOOL; Lin T, 1962, SCOPE EPIDEMIOLOGY P; Marinker M, 1970, J R Coll Gen Pract, V19, P79; Marinker M, 1967, J R Coll Gen Pract, V14, P59; SHEPHERD M, 1966, PSYCHIATRIC ILLNESS; THOMAS KB, 1987, BRIT MED J, V294, P1200, DOI 10.1136/bmj.294.6581.1200; THOMAS KB, 1974, BRIT MED J, V1, P625, DOI 10.1136/bmj.1.5908.625; THOMAS KB, 1978, BRIT MED J, P1327; THOMAS KB, 1972, THESIS U LIVERPOOL; WILSON RM, 1926, BELOVED PHYSICIAN; 1958, 14 GEN REG OFF SUBJ; 1958, J COLL GEN PRACTIT, V1, P107; 1970, BRIT MED J, V11, P437; 1974, OFFICE POPULATION CE	17	56	57	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 15	1994	344	8929					1066	1067		10.1016/S0140-6736(94)91716-7	http://dx.doi.org/10.1016/S0140-6736(94)91716-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL852	7934451				2023-01-03	WOS:A1994PL85200016
J	BIDANI, A; TZOUANAKIS, AE; CARDENAS, VJ; ZWISCHENBERGER, JB				BIDANI, A; TZOUANAKIS, AE; CARDENAS, VJ; ZWISCHENBERGER, JB			PERMISSIVE HYPERCAPNIA IN ACUTE RESPIRATORY-FAILURE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSITIVE-PRESSURE VENTILATION; END-EXPIRATORY PRESSURE; CRITICALLY ILL PATIENTS; HIGH AIRWAY PRESSURE; HIGH TIDAL VOLUME; MECHANICAL VENTILATION; STATUS-ASTHMATICUS; DISTRESS SYNDROME; PULMONARY-EDEMA; LACTIC-ACIDOSIS	Objective.-To evaluate the potential efficacy of pressure limitation with permissive hypercapnia in the treatment of acute respiratory failure/adult respiratory distress syndrome on the basis of current theories of ventilator-induced lung injury, potential complications of systemic hypercarbia, and available human outcome studies. Data Sources.-Articles were identified through MEDLINE, reference citations of published data, and consultation with authorities in their respective fields. Study Selection.-Animal model experimentation and human clinical trials were selected on the basis of whether they addressed the questions of pressure limitation with or without hypercapnia, the pathophysiologic effects of hypercapnia, or the concept of ventilator-induced parenchymal lung injury. Frequently cited references were preferentially included. Data Extraction.-Data were analyzed with particular emphasis on obtaining the following variables from the clinical studies: peak inspiratory pressures, tidal volumes, minute ventilation, and PCO2. Quantitative aspects of respiratory physiology were used to analyze the theoretical effects of permissive hypercapnia on ventilatory requirements in normal and injured lungs. Data Synthesis.-Extensive animal model data support the hypothesis that ventilator-driven alveolar overdistention can induce significant parenchymal lung injury. The heterogeneous nature of lung injury in adult respiratory distress syndrome, with its small physiologic lung volume, may render the lung susceptible to this type of injury through the use of conventional tidal volumes (10 to 15 mL/kg). Permissive hypercapnia is an approach whereby alveolar overdistention is minimized through either pressure or volume limitation, and the potential deleterious consequences of respiratory acidosis are accepted. Uncontrolled human trials of explicit or implicit permissive hypercapnia have demonstrated improved survival in comparison with models of predictive mortality. Conclusions.-Avoidance of alveolar overdistention through pressure or volume limitation has significant support based on animal models and computer simulation. Deleterious effects of the associated hypercarbia in severe lung injury do not appear to be a significant limiting factor in preliminary human clinical trials. Although current uncontrolled studies suggest benefit, controlled trials are urgently needed to confirm these findings before adoption of the treatment can be endorsed.	UNIV TEXAS,MED BRANCH,DEPT THORAC SURG,GALVESTON,TX 77550	University of Texas System; University of Texas Medical Branch Galveston	BIDANI, A (corresponding author), UNIV TEXAS,MED BRANCH,DEPT INTERNAL MED,DIV PULM,0561,GALVESTON,TX 77555, USA.							ARIEFF AI, 1982, AM J PHYSIOL, V242, pF586, DOI 10.1152/ajprenal.1982.242.6.F586; ASHBAUGH DG, 1967, LANCET, V2, P319; BENDIXEN HH, 1963, NEW ENGL J MED, V269, P991, DOI 10.1056/NEJM196311072691901; BIDANI A, FLUID ELECTROLYTE AC; BOWTON DL, 1989, CRIT CARE MED, V17, P908, DOI 10.1097/00003246-198909000-00014; CARLON GC, 1983, CHEST, V84, P551, DOI 10.1378/chest.84.5.551; COOPER DJ, 1990, ANN INTERN MED, V112, P492, DOI 10.7326/0003-4819-112-7-492; CORBRIDGE TC, 1990, AM REV RESPIR DIS, V142, P311, DOI 10.1164/ajrccm/142.2.311; DARIOLI R, 1984, AM REV RESPIR DIS, V129, P385; DAUGHERTY RM, 1967, AM J PHYSIOL, V5, P1102; DOUGLASS JA, 1992, AM REV RESPIR DIS, V146, P517, DOI 10.1164/ajrccm/146.2.517; DREYFUSS D, 1985, AM REV RESPIR DIS, V132, P880; DREYFUSS D, 1988, AM REV RESPIR DIS, V137, P1159, DOI 10.1164/ajrccm/137.5.1159; DREYFUSS D, 1992, INTENS CARE MED, V18, P139, DOI 10.1007/BF01709236; EPSTEIN RM, 1966, ANESTHESIOLOGY, V27, P654, DOI 10.1097/00000542-196609000-00017; FOEX P, 1972, CARDIOVASC RES, V6, P257, DOI 10.1093/cvr/6.3.257; FUJITA Y, 1989, ANESTH ANALG, V69, P152; GATTINONI L, 1987, AM REV RESPIR DIS, V136, P730, DOI 10.1164/ajrccm/136.3.730; GATTINONI L, 1986, JAMA-J AM MED ASSOC, V256, P881, DOI 10.1001/jama.256.7.881; HERNANDEZ LA, 1989, J APPL PHYSIOL, V66, P2364, DOI 10.1152/jappl.1989.66.5.2364; HICKLING KG, 1990, INTENS CARE MED, V16, P372, DOI 10.1007/BF01735174; HICKLING KG, 1993, RESPIR CARE, V38, P379; HOKA S, 1992, CAN J PHYSIOL PHARM, V70, P1032, DOI 10.1139/y92-142; HURST JM, 1990, ANN SURG, V211, P486, DOI 10.1097/00000658-199004000-00017; IRWIN RL, 1957, ANESTHESIOLOGY, V18, P594, DOI 10.1097/00000542-195707000-00007; KAWANO T, 1987, J APPL PHYSIOL, V62, P27, DOI 10.1152/jappl.1987.62.1.27; KNABE U, 1972, VASCULAR SMOOTH MUSC, P83; KONTOS HA, 1977, STROKE, V8, P358, DOI 10.1161/01.STR.8.3.358; KUPTER Y, 1992, ANN INTERN MED, V117, P484; LASSEN NA, 1968, SCAND J CLIN LAB INV, V22, P247, DOI 10.3109/00365516809167060; LEWANDOWSKI K, 1992, YB INTENSIVE CARE EM, P372; MATALON S, 1983, J APPL PHYSIOL, V54, P803, DOI 10.1152/jappl.1983.54.3.803; MENITOVE SM, 1983, AM J MED, V74, P898, DOI 10.1016/0002-9343(83)91082-3; MORRIS AH, 1994, AM J RESP CRIT CARE, V149, P295, DOI 10.1164/ajrccm.149.2.8306022; MORRIS LR, 1986, ANN INTERN MED, V105, P836, DOI 10.7326/0003-4819-105-6-836; MORRIS ME, 1962, BRIT J ANAESTH, V34, P672, DOI 10.1093/bja/34.10.672; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; OTT NT, 1973, CIRC RES, V33, P160, DOI 10.1161/01.RES.33.2.160; POTKIN RT, 1992, CHEST, V102, P1742, DOI 10.1378/chest.102.6.1742; PRYSROBERTS C, 1971, GENERAL ANESTHESIA, P224; PRYSROBERTS C, 1980, GENERAL ANAESTHESIA, P435; RAHN H, 1976, B EUR PHYSIOPATH RES, V12, P5; RAHN H, 1975, AM REV RESPIR DIS, V112, P165; RAICHLE ME, 1971, BRAIN BLOOD FLOW, P223; ROBIN ED, 1963, NEW ENGL J MED, V268, P917, DOI 10.1056/NEJM196304252681703; SCHIEVE JF, 1953, J CLIN INVEST, V32, P33, DOI 10.1172/JCI102707; SEGREDO V, 1992, NEW ENGL J MED, V327, P524, DOI 10.1056/NEJM199208203270804; SHAPIRO JM, 1993, INTENS CARE MED, V8, P144; SIEJO BK, 1972, J NEUROCHEM, V19, P2483; SIEJO BK, 1971, SCAND J CLIN LAB INV, V28, P113; TENNEY SM, 1967, RESP PHYSIOL, V3, P130, DOI 10.1016/0034-5687(67)90002-3; TSUNO K, 1991, AM REV RESPIR DIS, V143, P1115, DOI 10.1164/ajrccm/143.5_Pt_1.1115; TZOUANAKIS AE, 1993, AM REV RESPIR DIS, V147, pA891; WALLEY KR, 1990, CIRC RES, V67, P628, DOI 10.1161/01.RES.67.3.628; WEBB HH, 1974, AM REV RESPIR DIS, V110, P556; ZAPOL WM, 1979, JAMA-J AM MED ASSOC, V242, P2193, DOI 10.1001/jama.242.20.2193	56	116	125	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 28	1994	272	12					957	962		10.1001/jama.272.12.957	http://dx.doi.org/10.1001/jama.272.12.957			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG737	8084064				2023-01-03	WOS:A1994PG73700024
J	MUSS, HB; THOR, AD; BERRY, DA; KUTE, T; LIU, ET; KOERNER, F; CIRRINCIONE, CT; BUDMAN, DR; WOOD, WC; BARCOS, M; HENDERSON, IC				MUSS, HB; THOR, AD; BERRY, DA; KUTE, T; LIU, ET; KOERNER, F; CIRRINCIONE, CT; BUDMAN, DR; WOOD, WC; BARCOS, M; HENDERSON, IC			C-ERBB-2 EXPRESSION AND RESPONSE TO ADJUVANT THERAPY IN WOMEN WITH NODE-POSITIVE EARLY BREAST-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							REQUIRING PROLONGED OBSERVATION; THYMIDINE LABELING INDEX; DNA FLOW-CYTOMETRY; PROGNOSTIC-SIGNIFICANCE; PROLIFERATIVE ACTIVITY; CELL-PROLIFERATION; BOWEL PROJECT; PROTEIN; P53; OVEREXPRESSION	Background. The role of molecular markers in predicting the response to treatment of breast cancer is poorly defined. The Cancer and Leukemia Group B (CALGB) conducted a randomized adjuvant-chemotherapy trial (CALGB 8541) comparing three doses (high, moderate, and low) of cyclophosphamide, doxorubicin, and fluorouracil in 1572 women with node-positive breast cancer. This study (CALGB 8869) was designed to determine whether the DNA index, the S-phase fraction, c-erbB-2 expression, or p53 accumulation could be used as a marker to identify a subgroup of patients more likely than others to benefit from high doses of chemotherapy. Methods. Tissue blocks were obtained from 442 patients randomly selected from the larger CALGB trial. Paraffin sections from the primary lesions were analyzed for DNA content, S-phase fraction, c-erbB-2 expression, and p53 accumulation. Results. Patients randomly assigned to the high-dose regimen of adjuvant chemotherapy had significantly longer disease-free and overall survival if their tumors had c-erbB-2 overexpression. No further information was gained by adding the data on S-phase fraction or p53 accumulation to the analysis. There was no clear evidence of a dose-response effect in patients with minimal or no c-erbB-2 expression. Conclusions. There is a significant dose-response effect of adjuvant chemotherapy with cyclophosphamide, doxorubicin, and fluorouracil in patients with overexpression of c-erbB-2 but not in patients with no c-erbB-2 expression or minimal c-erbB-2 expression. Overexpression of c-erbB-2 may be a useful marker to identify the patients who are most likely to benefit from high doses of adjuvant chemotherapy.	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,WINSTON SALEM,NC; MASSACHUSETTS GEN HOSP,BOSTON,MA 02114; CANC & LEUKEMIA GRP B,STAT OFF,DURHAM,NC; UNIV N CAROLINA,SCH MED,DEPT MED,CHAPEL HILL,NC; N SHORE UNIV HOSP,NEW YORK HOSP,NEW YORK,NY; EMORY UNIV,ATLANTA,GA 30322; ROSWELL PK MEM INST,DEPT MED,BUFFALO,NY; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143	Wake Forest University; Wake Forest Baptist Medical Center; Harvard University; Massachusetts General Hospital; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; NewYork-Presbyterian Hospital; Northwell Health; North Shore University Hospital; Emory University; Roswell Park Cancer Institute; University of California System; University of California San Francisco			Liu, Edison/C-4141-2008		NATIONAL CANCER INSTITUTE [U10CA031946, U10CA003927, P01CA044768] Funding Source: NIH RePORTER; NCI NIH HHS [CA-44768, CA-31946, CA-03927] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLRED DC, 1992, J CLIN ONCOL, V10, P599, DOI 10.1200/JCO.1992.10.4.599; ALLRED DC, 1993, J NATL CANCER I, V85, P200, DOI 10.1093/jnci/85.3.200; BAISCH H, 1975, RADIAT ENVIRON BIOPH, V12, P31, DOI 10.1007/BF02339807; BARNES DM, 1991, BREAST CANCER RES TR, V18, P11, DOI 10.1007/BF01975438; BLACK MM, 1955, SURG GYNECOL OBSTET, V100, P543; CALLAHAN R, 1992, CANCER, V69, P1582, DOI 10.1002/1097-0142(19920315)69:6+<1582::AID-CNCR2820691313>3.0.CO;2-Y; CARTER CL, 1989, CANCER-AM CANCER SOC, V63, P181, DOI 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H; CLARK GM, 1989, NEW ENGL J MED, V320, P627, DOI 10.1056/NEJM198903093201003; COX DR, 1972, J R STAT SOC B, V34, P187; DEPPERT W, 1990, ONCOGENE, V5, P1701; Early Breast Cancer Trialists' Collaborative Group, 1992, LANCET, V339, P1; EDDY DM, 1992, J CLIN ONCOL, V10, P657, DOI 10.1200/JCO.1992.10.4.657; EDDY DM, 1992, J CLIN ONCOL, V10, P1655; FISHER B, 1986, J CLIN ONCOL, V4, P929, DOI 10.1200/JCO.1986.4.6.929; FISHER ER, 1983, CANCER-AM CANCER SOC, V51, P181, DOI 10.1002/1097-0142(19830115)51:2<181::AID-CNCR2820510202>3.0.CO;2-A; GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049; HARRIS AL, 1992, MONOGR NATL CANC I, V11, P181; HEDLEY DW, 1985, CYTOMETRY, V6, P327, DOI 10.1002/cyto.990060409; HEDLEY DW, 1983, J HISTOCHEM CYTOCHEM, V31, P1333, DOI 10.1177/31.11.6619538; HENSON DE, 1991, CANCER-AM CANCER SOC, V68, P2142, DOI 10.1002/1097-0142(19911115)68:10<2142::AID-CNCR2820681010>3.0.CO;2-D; ISOLA J, 1992, J NATL CANCER I, V84, P1109, DOI 10.1093/jnci/84.14.1109; KALLIONIEMI OP, 1991, INT J CANCER, V49, P650, DOI 10.1002/ijc.2910490504; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KUTE TE, 1988, CYTOMETRY, V9, P494, DOI 10.1002/cyto.990090515; LIU E, 1992, ONCOGENE, V7, P1027; LUPU R, 1992, P NATL ACAD SCI USA, V89, P2287, DOI 10.1073/pnas.89.6.2287; MCGUIRE WL, 1992, NEW ENGL J MED, V326, P1756; MONTENARH M, 1992, Critical Reviews in Oncogenesis, V3, P233; MUSS HB, 1989, HIGH RISK BREAST CAN, P103; OREILLY SM, 1991, BRIT J CANCER, V63, P444, DOI 10.1038/bjc.1991.102; OREILLY SM, 1990, EUR J CANCER, V26, P1035, DOI 10.1016/0277-5379(90)90045-U; OREILLY SM, 1992, EUR J CANCER, V28A, P681, DOI 10.1016/S0959-8049(05)80124-8; Osborne CK, 1991, BREAST DIS, P301; PAIK S, 1990, J CLIN ONCOL, V8, P103, DOI 10.1200/JCO.1990.8.1.103; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; REMVIKOS Y, 1989, J NATL CANCER I, V81, P1383, DOI 10.1093/jnci/81.18.1383; SALMON DJ, 1987, SCIENCE, V235, P177; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SMITH K, 1993, ONCOGENE, V8, P933; SULKES A, 1979, J NATL CANCER I, V62, P513, DOI 10.1093/jnci/62.3.513; TANDON AK, 1989, J CLIN ONCOL, V7, P1120, DOI 10.1200/JCO.1989.7.8.1120; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845; TOIKKANEN S, 1992, J CLIN ONCOL, V10, P1044, DOI 10.1200/JCO.1992.10.7.1044; TSAI CM, 1993, J NATL CANCER I, V85, P897, DOI 10.1093/jnci/85.11.897; WOOD WC, 1994, NEW ENGL J MED, V330, P1253, DOI 10.1056/NEJM199405053301801; ZAMBETTI M, 1992, MONOGR NCI, V11, P77; Zar JH., 1974, BIOSTATISTICAL ANAL; 1978, CANCER, V42, P2809; 1992, LANCET, V339, P71	51	884	909	2	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 5	1994	330	18					1260	1266		10.1056/NEJM199405053301802	http://dx.doi.org/10.1056/NEJM199405053301802			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NJ512	7908410	Bronze			2023-01-03	WOS:A1994NJ51200002
J	ARONSON, JK				ARONSON, JK			WHATS IN A BRAND-NAME	BRITISH MEDICAL JOURNAL			English	Article											ARONSON, JK (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,DEPT CLIN PHARMACOL,OXFORD OX2 6HE,ENGLAND.							1993, CHEM DRUGGIST, V34	1	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 30	1994	308	6937					1140	1141		10.1136/bmj.308.6937.1140	http://dx.doi.org/10.1136/bmj.308.6937.1140			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK182	8173456	Green Published			2023-01-03	WOS:A1994NK18200020
J	MUI, BLS; CULLIS, PR; PRITCHARD, H; MADDEN, TD				MUI, BLS; CULLIS, PR; PRITCHARD, H; MADDEN, TD			INFLUENCE OF PLASMA ON THE OSMOTIC SENSITIVITY OF LARGE UNILAMELLAR VESICLES PREPARED BY EXTRUSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY LIPOPROTEINS; SERUM-INDUCED LEAKAGE; CHOLESTEROL CONTENT; BILAYER-MEMBRANES; RAT PLASMA; LIPOSOMES; RELEASE; SIZE; DISINTEGRATION; INVITRO	In the presence of plasma, the osmotic differential required to trigger lysis of large unilamellar vesicles is significantly decreased with the membrane tension at rupture being reduced from about 36 to about 12 dynes/cm for vesicles composed of palmitoyloleoylphosphatidylcholine: cholesterol (55:45). Despite increasing vesicle sensitivity, however, plasma does not alter the characteristics of osmotically induced lysis. As in the absence of plasma, lysis is not an all or nothing event but instead results in only partial loss of intravesicular solute, so that following membrane resealing the vesicle interior remains hyperosmotic with respect to the external medium. To identify the component responsible for the observed increase in vesicle osmotic sensitivity, plasma was fractionated by density centrifugation. Albumin and other soluble plasma proteins, including those associated with the complement system, were found to exert only a modest influence on vesicle osmotic behavior. In contrast all of the lipoprotein fractions lowered vesicle tolerance to osmotic pressure, with high density lipoprotein exerting an effect comparable to whole plasma.	UNIV BRITISH COLUMBIA,DEPT BIOCHEM,VANCOUVER V6T 1Z3,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT PATHOL,VANCOUVER V6T 1Z3,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT PHARMACOL & THERAPEUT,VANCOUVER V6T 1Z3,BC,CANADA	University of British Columbia; University of British Columbia; University of British Columbia								ALLEN TM, 1992, CANCER RES, V52, P2431; ALLEN TM, 1985, BIOCHIM BIOPHYS ACTA, V818, P205, DOI 10.1016/0005-2736(85)90571-1; ALLEN TM, 1980, BIOCHIM BIOPHYS ACTA, V597, P418, DOI 10.1016/0005-2736(80)90118-2; ALLEN TM, 1983, J PHARMACOL EXP THER, V226, P539; COMISKEY SJ, 1990, BIOCHEMISTRY-US, V29, P3626, DOI 10.1021/bi00467a006; COOPER RA, 1975, J CLIN INVEST, V55, P115, DOI 10.1172/JCI107901; DAMEN J, 1981, BIOCHIM BIOPHYS ACTA, V665, P538, DOI 10.1016/0005-2760(81)90268-X; EPAND RM, 1989, J BIOL CHEM, V264, P4628; EVANS E, 1987, J PHYS CHEM-US, V91, P4219, DOI 10.1021/j100300a003; Fiske CH, 1925, J BIOL CHEM, V66, P375; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; KANELLIS P, 1980, J BIOL CHEM, V255, P1464; KIRBY C, 1980, BIOCHEM J, V186, P591, DOI 10.1042/bj1860591; KLAUSNER RD, 1985, J BIOL CHEM, V260, P3719; LELKES PI, 1982, BIOCHIM BIOPHYS ACTA, V716, P410, DOI 10.1016/0304-4165(82)90034-4; MADDEN TD, 1990, CHEM PHYS LIPIDS, V53, P37, DOI 10.1016/0009-3084(90)90131-A; MAYER LD, 1985, BIOCHIM BIOPHYS ACTA, V817, P193, DOI 10.1016/0005-2736(85)90084-7; MUI BLS, 1993, BIOPHYS J, V64, P443, DOI 10.1016/S0006-3495(93)81385-7; NAKA K, 1992, J AM CHEM SOC, V114, P4011, DOI 10.1021/ja00036a080; NEEDHAM D, 1990, BIOPHYS J, V58, P997, DOI 10.1016/S0006-3495(90)82444-9; OSTRO MJ, 1989, AM J HOSP PHARM, V46, P1576, DOI 10.1093/ajhp/46.8.1576; POWNALL HJ, 1979, BIOCHEMISTRY-US, V18, P574, DOI 10.1021/bi00571a004; RAHMAN A, 1980, CANCER RES, V40, P1532; SCHERPHOF G, 1984, BIOCHEM J, V221, P423, DOI 10.1042/bj2210423; SCHERPHOF G, 1978, BIOCHIM BIOPHYS ACTA, V542, P296, DOI 10.1016/0304-4165(78)90025-9; SCHERPHOF GL, 1984, LIPOSOME TECHNOLOGY, V3, P205; WEINSTEIN JN, 1981, BIOCHIM BIOPHYS ACTA, V647, P270, DOI 10.1016/0005-2736(81)90255-8; Weinstein JN, 1984, LIPOSOME TECHNOLOGY, VIII, P183; Whaley K, 1985, METHODS COMPLEMENT C, P77; WILLS GL, 1984, GUIDEBOOK LIPOPROTEI, V14, P18	30	19	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7364	7370						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125954				2023-01-03	WOS:A1994NA03200053
J	COHEN, TJ; GOLDNER, BG; MACCARO, PC; ARDITO, AP; TRAZZERA, S; COHEN, MB; DIBS, SR				COHEN, TJ; GOLDNER, BG; MACCARO, PC; ARDITO, AP; TRAZZERA, S; COHEN, MB; DIBS, SR			A COMPARISON OF ACTIVE COMPRESSION-DECOMPRESSION CARDIOPULMONARY-RESUSCITATION WITH STANDARD CARDIOPULMONARY-RESUSCITATION FOR CARDIAC ARRESTS OCCURRING IN THE HOSPITAL	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SURVIVAL; CHEST; DOGS; COMA; VEST; CPR	Background. Recent studies have demonstrated improved cardiopulmonary circulation during cardiac arrest with the use of a hand-held suction device (Ambu CardioPump) to perform active compression-decompression cardiopulmonary resuscitation (CPR). The purpose of this study was to compare active compression-decompression with standard CPR during cardiac arrests in hospitalized patients. Methods. All patients over the age of 18 years who had a witnessed cardiac arrest while hospitalized at our center were enrolled in this trial; they were randomly assigned according to their medical-record numbers to receive either active compression-decompression or standard CPR. The study end points were the rates of initial resuscitation, survival at 24 hours, hospital discharge, and neurologic outcome. Compressions were performed according to the recommendations of the American Heart Association (80 to 100 compressions per minute; depth of compression, 3.8 to 5.1 cm [1.5 to 2 in.]; and 50 percent of the cycle spent in compression). Results. Sixty-two patients (45 men and 17 women) with a mean age (+/-SE) of 68+/-2 years were entered into the trial. Sixty-two percent of the patients who underwent active compression-decompression were initially resuscitated, as compared with 30 percent of the patients who received standard CPR (P<0.03); 45 percent of the patients who underwent active compression-decompression survived for at least 24 hours, as compared with 9 percent of patients who underwent standard CPR (P<0.004). Two of the 62 study patients survived to hospital discharge; both were randomly assigned to receive active compression-decompression. Neurologic outcome, as measured by the Glasgow coma score, was better with active compression-decompression (8.0+/-1.3) than with standard CPR (3.5+/-0.3; P<0.02). Conclusions. In this preliminary study, we found that, as compared with standard CPR, active compression-decompression CPR improved the rate of initial resuscitation, survival at 24 hours, and neurologic outcome after in-hospital cardiac arrest. Larger trials will be required to assess the potential benefit in terms of long-term survival.			COHEN, TJ (corresponding author), N SHORE UNIV HOSP, CORNELL UNIV MED COLL, DEPT MED, ELECTROPHYSIOL SECT, MANHASSET, NY 11030 USA.							BIRCHER N, 1980, CRIT CARE MED, V8, P147, DOI 10.1097/00003246-198003000-00012; COHEN TJ, 1992, JAMA-J AM MED ASSOC, V267, P2916, DOI 10.1001/jama.267.21.2916; COHEN TJ, 1992, AM HEART J, V124, P1145, DOI 10.1016/0002-8703(92)90393-A; DAWSONSAUNDERS B, 1990, BASIC CLIN BIOSTATIS; FEINSTEIN AR, 1977, CLIN BIOSTATISTICS; FENELEY MP, 1988, CIRCULATION, V77, P240, DOI 10.1161/01.CIR.77.1.240; HALPERIN HR, 1993, NEW ENGL J MED, V329, P762, DOI 10.1056/NEJM199309093291104; HALPERIN HR, 1992, JAMA-J AM MED ASSOC, V267, P2940, DOI 10.1001/jama.267.21.2940; HALPERIN HR, 1986, CIRCULATION, V74, P1407, DOI 10.1161/01.CIR.74.6.1407; KERN KB, 1985, CRIT CARE MED, V13, P899, DOI 10.1097/00003246-198511000-00009; KOUWENHOVEN WB, 1960, JAMA-J AM MED ASSOC, V173, P1064, DOI 10.1001/jama.1960.03020280004002; LINDNER KH, 1993, CIRCULATION, V88, P1254, DOI 10.1161/01.CIR.88.3.1254; MAIER GW, 1986, CIRCULATION, V74, P51; MULLIE A, 1988, LANCET, V1, P137; RUBEN H, 1966, ACTA ANAESTH SCAND, V10, P31, DOI 10.1111/j.1399-6576.1966.tb00329.x; SACK J B, 1992, Journal of the American Medical Association, V267, P379, DOI 10.1001/jama.267.3.379; SACK JB, 1992, CIRCULATION, V86, P1692, DOI 10.1161/01.CIR.86.6.1692; SHULTZ JJ, 1992, CIRCULATION, V86, P234; TAFFET GE, 1988, JAMA-J AM MED ASSOC, V260, P2069, DOI 10.1001/jama.260.14.2069; TEASDALE G, 1974, LANCET, V2, P81; TORTOLANI AJ, 1990, RESUSCITATION, V20, P115, DOI 10.1016/0300-9572(90)90047-I; TSITLIK JE, 1983, CRIT CARE MED, V11, P685, DOI 10.1097/00003246-198309000-00003; TUCKER KJ, 1993, J AM COLL CARDIOL, V22, P1485, DOI 10.1016/0735-1097(93)90561-E; URBERG M, 1987, J FAM PRACTICE, V25, P41	24	111	111	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 23	1993	329	26					1918	1921		10.1056/NEJM199312233292603	http://dx.doi.org/10.1056/NEJM199312233292603			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM885	8018138				2023-01-03	WOS:A1993MM88500003
J	ARRIAGADA, R; LECHEVALIER, T; PIGNON, JP; RIVIERE, A; MONNET, I; CHOMY, P; TUCHAIS, C; TARAYRE, M; RUFFIE, P				ARRIAGADA, R; LECHEVALIER, T; PIGNON, JP; RIVIERE, A; MONNET, I; CHOMY, P; TUCHAIS, C; TARAYRE, M; RUFFIE, P			INITIAL CHEMOTHERAPEUTIC DOSES AND SURVIVAL IN PATIENTS WITH LIMITED SMALL-CELL LUNG-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BREAST-CANCER; CARCINOMA; INTENSITY; CYCLOPHOSPHAMIDE; METAANALYSIS; CISPLATIN; TRIALS; MODELS	Background. Moderate increases in the initial doses of certain chemotherapeutic drugs, such as cisplatin and cyclophosphamide, may prolong overall survival in patients with limited small-cell lung cancer. Methods. We conducted a prospective study of 105 patients with limited small-cell lung cancer. The patients were randomly assigned to receive higher or lower initial doses of cisplatin (100 or 80 mg per square meter of body-surface area) and cyclophosphamide (300 or 225 mg per square meter daily for four days); all patients received the same doses of doxorubicin and etoposide. The first course of chemotherapy was followed by five additional courses and by three courses of radiotherapy. All patients received the lower doses of cisplatin and cyclophosphamide and the same doses of doxorubicin and etoposide from the second through the sixth cycle of chemotherapy. Results. The median follow-up was 33 months. The two-year survival rate for the 55 patients who received the higher doses of chemotherapy was 43 percent, as compared with 26 percent for the 50 patients who received the lower doses (P = 0.02). The rates of complete response at six months were 67 percent in the higher-dose group and 54 percent in the lower-dose group (P = 0.16). Disease-free survival at two years was 28 percent in the higher-dose group, as compared with 8 percent in the lower-dose group (P = 0.02). Side effects from treatment were not increased in the higher-dose group. Conclusions. Higher initial doses of cyclophosphamide and cisplatin improve disease-free and overall survival in patients with limited small-cell lung cancer.	CTR HOSP INTERCOMMUNAL CRETEIL, F-94010 CRETEIL, FRANCE; CTR FRANCOIS BACLESSE, CAEN, FRANCE; CTR PAUL PAPIN, ANGERS, FRANCE; FDN BERGONIE, F-33076 BORDEAUX, FRANCE	Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; UNICANCER; Centre Francois Baclesse; UNICANCER; Institut de Cancerologie de l'Ouest (ICO); UNICANCER; Institut Bergonie	ARRIAGADA, R (corresponding author), INST GUSTAVE ROUSSY, RUE CAMILLE DESMOULINS, F-94805 VILLEJUIF, FRANCE.			PIGNON, Jean-Pierre/0000-0003-2047-1582				ANTMAN KH, 1993, ANN ONCOL, V4, pS29, DOI 10.1093/annonc/4.suppl_1.S29; ARRIAGADA R, 1989, B CANCER, V76, P605; ARRIAGADA R, 1992, J CLIN ONCOL, V10, P447, DOI 10.1200/JCO.1992.10.3.447; BUDMAN DR, 1992, P AN M AM SOC CLIN, V11, P51; COLDMAN AJ, 1988, MATH BIOSCI, V92, P97, DOI 10.1016/0025-5564(88)90007-7; COPPIN CML, 1987, SEMIN ONCOL, V14, P34; COX DR, 1972, J R STAT SOC B, V34, P187; DETHE H, 1986, 5TH P ANN M ESTRO BA, P319; DEVATHAIRE F, 1993, LUNG CANCER, V8, P301; DINWOODIE WR, 1981, P AM ASSOC CANC RES, V22, P505; FIGUEREDO AT, 1985, J CLIN ONCOL, V3, P54, DOI 10.1200/JCO.1985.3.1.54; FREI E, 1980, AM J MED, V69, P585, DOI 10.1016/0002-9343(80)90472-6; GRALLA RJ, 1981, ANN INTERN MED, V95, P414, DOI 10.7326/0003-4819-95-4-414; GREEN SJ, 1987, J CLIN ONCOL, V5, P1477, DOI 10.1200/JCO.1987.5.9.1477; HENDERSON IC, 1988, J CLIN ONCOL, V6, P1501, DOI 10.1200/JCO.1988.6.9.1501; HRYNIUK W, 1986, J CLIN ONCOL, V4, P1162, DOI 10.1200/JCO.1986.4.8.1162; IHDE D, 1991, LUNG CANCER S, V7, P135; IHDE DC, 1992, NEW ENGL J MED, V327, P1434; JOHNSON DH, 1987, J CLIN ONCOL, V5, P1731, DOI 10.1200/JCO.1987.5.11.1731; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAYE SB, 1992, LANCET, V340, P329, DOI 10.1016/0140-6736(92)91404-V; KLASA RJ, 1991, J CLIN ONCOL, V9, P499, DOI 10.1200/JCO.1991.9.3.499; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MEHTA C, 1982, P AM ASSOC CANC RES, V23, P155; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; PIGNON JP, 1992, NEW ENGL J MED, V327, P1618, DOI 10.1056/NEJM199212033272302; SCHNIPPER LE, 1986, NEW ENGL J MED, V314, P1423; Spiessl B, 1989, TNM ATLAS ILLUSTRATE; TUBIANA M, 1985, CANCER, V55, P2131, DOI 10.1002/1097-0142(19850501)55:9+<2131::AID-CNCR2820551416>3.0.CO;2-Q; Whitehead J., 1983, DESIGN ANAL SEQUENTI; WHITEHEAD J, 1989, PEST 2 0 OPERATING M; 1979, WHO OFFSET PUBLICATI, V48, P319	32	227	231	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 16	1993	329	25					1848	1852		10.1056/NEJM199312163292504	http://dx.doi.org/10.1056/NEJM199312163292504			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML588	8247036				2023-01-03	WOS:A1993ML58800004
J	SOLALCELIGNY, P; LEPAGE, E; BROUSSE, N; REYES, F; HAIOUN, C; LEPORRIER, M; PEUCHMAUR, M; BOSLY, A; PARLIER, Y; BRICE, P; COIFFIER, B; GISSELBRECHT, C				SOLALCELIGNY, P; LEPAGE, E; BROUSSE, N; REYES, F; HAIOUN, C; LEPORRIER, M; PEUCHMAUR, M; BOSLY, A; PARLIER, Y; BRICE, P; COIFFIER, B; GISSELBRECHT, C			RECOMBINANT INTERFERON-ALFA-2B COMBINED WITH A REGIMEN CONTAINING DOXORUBICIN IN PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NON-HODGKINS-LYMPHOMA; LOW-GRADE; PROGNOSTIC FACTORS; SURVIVAL; CHEMOTHERAPY; COMBINATION; MANAGEMENT; STAGE; TRIAL	Background. Interferon alfa and cytotoxic drugs have synergistic effects in patients with non-Hodgkin's lymphoma. In 1986, we designed a clinical trial to evaluate the benefit of concomitant administration of recombinant interferon alfa with a regimen containing doxorubicin in patients with follicular non-Hodgkin's lymphoma. Methods. The trial involved 242 patients with advanced low-grade follicular non-Hodgkin's lymphoma selected on the basis of clinical, radiographic, and biologic criteria. All patients were treated with a regimen consisting of cyclophosphamide, doxorubicin, teniposide, and prednisone (CHVP), given monthly for six cycles and then every two months for one year. After randomization, 123 patients also received interferon alfa-2b at a dosage of 5 million units three times weekly for 18 months. The remaining 119 patients received chemotherapy alone. Results. As compared with the patients treated with CHVP only, the patients treated with CHVP plus interferon alfa had a higher overall rate of response (85 percent vs. 69 percent, P = 0.006), a longer median event-free survival (34 months vs. 19 months, P<0.001), and a higher rate of survival at 3 years (86 percent vs. 69 percent, P = 0.02). Granulocyte toxicity was greater in the patients treated with CHVP plus interferon alfa than in those treated with CHVP alone. There were no treatment-related deaths. Interferon alfa had to be stopped because of toxic effects (fatigue and hepatitis) in 13 patients (11 percent). Conclusions. The addition of interferon alfa to a regimen containing doxorubicin increased the rate of response, event-free survival, and overall survival in patients with advanced follicular non-Hodgkin's lymphoma, without serious toxicity, although some patients were unable to tolerate the side effects.	HOP ST LOUIS,DEPT BIOSTAT & MED INFORMAT SYST,F-75010 PARIS,FRANCE; HOP NECKER ENFANTS MALAD,DEPT PATHOL,F-75730 PARIS 15,FRANCE; HOP HENRI MONDOR,F-94010 CRETEIL,FRANCE; CHU CAEN,F-14033 CAEN,FRANCE; UNIV CATHOLIQUE LOUVAIN,B-1348 LOUVAIN,BELGIUM; CTR HOSP LYON SUD,F-69310 PIERRE BENITE,FRANCE; SCHERING PLOUGH CORP,LEVALLOIS PERRET,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; CHU de Caen NORMANDIE; Universite de Caen Normandie; Universite Catholique Louvain; CHU Lyon; Merck & Company; Schering Plough Corporation	SOLALCELIGNY, P (corresponding author), HOP ST LOUIS,DEPT HEMATOL,CTR HAYEM,1 AVE CL VELLEFAUX,F-75010 PARIS,FRANCE.			Haioun, Corinne/0000-0003-0095-5379				[Anonymous], 1982, CANCER, V49, P2112; BASTION Y, 1991, ANN ONCOL, V2, P123, DOI 10.1093/annonc/2.suppl_2.123; COX DR, 1972, J R STAT SOC B, V34, P187; FOON KA, 1984, NEW ENGL J MED, V311, P1148, DOI 10.1056/NEJM198411013111803; Gallagher C J, 1987, Baillieres Clin Haematol, V1, P141, DOI 10.1016/S0950-3536(87)80048-3; GALLAGHER CJ, 1986, J CLIN ONCOL, V4, P1470, DOI 10.1200/JCO.1986.4.10.1470; HAGENBEEK A, 1992, BLOOD S1, V80, pA288; HORNING SJ, 1984, NEW ENGL J MED, V311, P1471, DOI 10.1056/NEJM198412063112303; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LEONARD RCF, 1991, ANN ONCOL, V2, P655, DOI 10.1093/oxfordjournals.annonc.a058044; LEPAGE E, 1990, HEMATOL ONCOL, V8, P31, DOI 10.1002/hon.2900080105; LICHT JD, 1990, CANCER, V66, P632, DOI 10.1002/1097-0142(19900815)66:4<632::AID-CNCR2820660405>3.0.CO;2-B; MCLAUGHLIN P, 1993, ANN ONCOL, V4, P205, DOI 10.1093/oxfordjournals.annonc.a058457; PORTLOCK CS, 1990, SEMIN ONCOL, V17, P51; PRICE CGA, 1991, ANN ONCOL, V2, P141, DOI 10.1093/annonc/2.suppl_2.141; ROHATINER AZS, 1991, BRIT J HAEMATOL, V79, P26, DOI 10.1111/j.1365-2141.1991.tb08114.x; ROMAGUERA JE, 1991, J CLIN ONCOL, V9, P762, DOI 10.1200/JCO.1991.9.5.762; SMALLEY RV, 1992, NEW ENGL J MED, V327, P1336, DOI 10.1056/NEJM199211053271902; STANLEY KE, 1980, J NATL CANCER I, V65, P25; STEWARD WP, 1988, CANCER-AM CANCER SOC, V61, P441, DOI 10.1002/1097-0142(19880201)61:3<441::AID-CNCR2820610306>3.0.CO;2-N; SULLIVAN KM, 1983, BLOOD, V62, P51; WADLER S, 1990, CANCER RES, V50, P3473; YOUNG RC, 1988, SEMIN HEMATOL, V25, P11; 1986, LANCET, V1, P1346	24	227	232	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 25	1993	329	22					1608	1614		10.1056/NEJM199311253292203	http://dx.doi.org/10.1056/NEJM199311253292203			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ546	8232429				2023-01-03	WOS:A1993MJ54600003
J	JAYES, RL; ZIMMERMAN, JE; WAGNER, DP; DRAPER, EA; KNAUS, WA				JAYES, RL; ZIMMERMAN, JE; WAGNER, DP; DRAPER, EA; KNAUS, WA			DO-NOT-RESUSCITATE ORDERS IN INTENSIVE-CARE UNITS - CURRENT PRACTICES AND RECENT CHANGES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOSPITAL CARDIOPULMONARY RESUSCITATION; ADVANCE DIRECTIVES; LIFE SUPPORT; SYSTEM; DNR; PREDICTION; MORTALITY; OUTCOMES; SEVERITY; FAILURE	Objectives.-To describe the characteristics of patients with do-not-resuscitate (DNR) orders and the frequency and timing of these orders in a representative sample of intensive care units (ICUs) and to compare practices from 1980 to 1990. Design.-Prospective inception cohort. Setting.-A total of 42 ICUs in 40 US hospitals with 200 or more beds; 26 randomly selected hospitals and 14 large, tertiary care hospitals that volunteered to be studied. Participants.-A consecutive sample of 17 440 ICU admissions from 1988 to 1990. Measurements.-Patient demographic characteristics, comorbid conditions, disease, and physiological abnormalities. Main Outcome Measures.-Frequency and timing of DN R orders; ICU resource use before and after DNR orders; and patients' hospital and ICU discharge status. Results.-Physicians wrote DNR orders for 1577 ICU admissions (9%) (hospital range, 1.5% to 22%). Patients with ICU DNR orders were older, more functionally impaired, had more comorbid illness, a higher severity of illness, and required the usp of more ICU resources compared with patients without DNR orders. Compared with data from a similar survey from 1979 to 1982, ICU DNR orders were more frequent in 1988 to 1990 (9% vs 5.4%; P<.001) and preceded 60% of all in-unit deaths compared with only 39% in 1979 to 1982 (P<.001). Do-not-resuscitate orders were written sooner (for 3.6% vs 2.0% of patients on day 1 in the ICU) and patients with DNR orders remained in the ICU longer in 1988 to 1990 (2.8 vs 1.4 days) than in 1979 to 1982, and had lower ICU and hospital mortality rates (64% vs 74%, P<.001; and 85% vs 94%, P<.001). Conclusions.-Over the last decade physicians and patients' families set limits earlier and more frequently in cases likely to have poor outcomes. We attribute this change to a greater dialogue about setting limits to care and a greater knowledge of treatment outcomes among physicians and families. These changes in practice preceded implementation of the Patient Self-determination Act, designed to ensure patient autonomy for decisions about life-sustaining therapy.	GEORGE WASHINGTON UNIV, MED CTR, ICU RES UNIT, 2300 K ST NW, WASHINGTON, DC 20037 USA; GEORGE WASHINGTON UNIV, MED CTR, DEPT MED, WASHINGTON, DC 20037 USA; GEORGE WASHINGTON UNIV, MED CTR, DEPT ANESTHESIOL, WASHINGTON, DC 20037 USA; APACHE MED SYST INC, WASHINGTON, DC USA	George Washington University; George Washington University; George Washington University			Knaus, William/AAX-2138-2020		AHRQ HHS [HSO 5787] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ANNAS GJ, 1991, NEW ENGL J MED, V324, P1210, DOI 10.1056/NEJM199104253241711; [Anonymous], 1974, JAMA-J AM MED ASSOC, V227, P864; [Anonymous], 1991, ANN INTERN MED, V115, P478; AREEN J, 1987, JAMA-J AM MED ASSOC, V258, P229, DOI 10.1001/jama.258.2.229; BEDELL SE, 1986, JAMA-J AM MED ASSOC, V256, P233, DOI 10.1001/jama.256.2.233; BONE RC, 1990, CHEST, V97, P949, DOI 10.1378/chest.97.4.949; CHANG RWS, 1989, LANCET, V2, P143; Cullen D J, 1974, Crit Care Med, V2, P57, DOI 10.1097/00003246-197403000-00001; DANIS M, 1991, NEW ENGL J MED, V324, P882, DOI 10.1056/NEJM199103283241304; DENARDO SJ, 1989, CRIT CARE MED, V17, P4, DOI 10.1097/00003246-198901000-00002; DONNELLY WJ, 1987, ARCH INTERN MED, V147, P37, DOI 10.1001/archinte.147.1.37; EVANS AL, 1985, JAMA-J AM MED ASSOC, V253, P2236, DOI 10.1001/jama.253.15.2236; FOWLER MDM, 1989, HEART LUNG, V18, P424; FRIED C, 1976, NEW ENGL J MED, V295, P390, DOI 10.1056/NEJM197608122950711; GRAY WA, 1991, NEW ENGL J MED, V325, P1393, DOI 10.1056/NEJM199111143252001; GRECO PJ, 1991, ANN INTERN MED, V115, P639, DOI 10.7326/0003-4819-115-8-639; HOLTZMAN J, 1992, CLIN RES, V40, pA584; JONSSON PV, 1988, ARCH INTERN MED, V148, P2373, DOI 10.1001/archinte.148.11.2373; KEENE AR, 1983, CRIT CARE MED, V11, P1, DOI 10.1097/00003246-198301000-00001; KNAUS WA, 1991, SCIENCE, V254, P389, DOI 10.1126/science.1925596; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1981, JAMA-J AM MED ASSOC, V246, P2711, DOI 10.1001/jama.246.23.2711; KNAUS WA, 1985, ANN SURG, V202, P685, DOI 10.1097/00000658-198512000-00004; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; LIPTON HL, 1986, JAMA-J AM MED ASSOC, V256, P1164, DOI 10.1001/jama.256.9.1164; LO B, 1983, ARCH INTERN MED, V143, P1561, DOI 10.1001/archinte.143.8.1561; MCGRATH RB, 1987, ANN EMERG MED, V16, P1365, DOI 10.1016/S0196-0644(87)80420-1; MUPRHY DJ, 1990, J CLIN EPIDEMIOL S, V43, pR5; MURPHY DJ, 1990, JAMA-J AM MED ASSOC, V264, P2103, DOI 10.1001/jama.264.16.2103; MURPHY DJ, 1989, ANN INTERN MED, V111, P199, DOI 10.7326/0003-4819-111-3-199; NIEMANN JT, 1992, NEW ENGL J MED, V327, P1075; PINZANI M, 1987, INTENS CARE MED, V13, P148; RABKIN MT, 1976, NEW ENGL J MED, V295, P364, DOI 10.1056/NEJM197608122950705; RAPOPORT J, 1990, MED CARE, V28, P338, DOI 10.1097/00005650-199004000-00005; ROGERS WH, 1990, JAMA-J AM MED ASSOC, V264, P1989, DOI 10.1001/jama.264.15.1989; RUARK JE, 1988, NEW ENGL J MED, V318, P25, DOI 10.1056/NEJM198801073180106; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949; SCHRAM RB, 1978, NEW ENGL J MED, V299, P875, DOI 10.1056/NEJM197810192991608; STERN SG, 1992, CRIT CARE MED, V20, P1263, DOI 10.1097/00003246-199209000-00013; TAFFET GE, 1988, JAMA-J AM MED ASSOC, V260, P2069, DOI 10.1001/jama.260.14.2069; WEBSTER GC, 1991, CAN J ANAESTH, V38, P553, DOI 10.1007/BF03008184; WOOG RH, 1987, ANAESTH INTENS CARE, V15, P193, DOI 10.1177/0310057X8701500213; YOUNGNER S J, 1985, Journal of the American Medical Association, V253, P54, DOI 10.1001/jama.253.1.54; YOUNGNER SJ, 1987, HASTINGS CENT REP, V17, P24, DOI 10.2307/3562438; ZIMMERMAN JE, 1986, JAMA-J AM MED ASSOC, V255, P351, DOI 10.1001/jama.255.3.351; ZIMMERMAN JE, 1989, CRIT CARE MED S, V17, pS169; 1991, JAMA-J AM MED ASSOC, V265, P1868; 1990, EFFECTIVE DNA POLICI; 1987, LIFE SUSTAINING TREA; 1992, CRIT CARE MED, V20, P320	50	107	110	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 10	1993	270	18					2213	2217		10.1001/jama.270.18.2213	http://dx.doi.org/10.1001/jama.270.18.2213			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME816	8411606				2023-01-03	WOS:A1993ME81600034
J	RIVARA, FP; KOEPSELL, TD; JURKOVICH, GJ; GURNEY, JG; SODERBERG, R				RIVARA, FP; KOEPSELL, TD; JURKOVICH, GJ; GURNEY, JG; SODERBERG, R			THE EFFECTS OF ALCOHOL-ABUSE ON READMISSION FOR TRAUMA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							SCREENING-TEST; INJURIES; INTOXICATION; EMERGENCY; ACCIDENTS	Objective.-To determine the effect of admission for trauma with concurrent acute alcohol intoxication or chronic alcohol abuse on the risk of subsequent recurrence of trauma. Design.-Prospective cohort study. Setting.-Level I regional trauma center. Patients.-A total of 2578 patients 18 years or older admitted with blunt or penetrating trauma within 24 hours of injury and surviving to discharge. All patients had a blood alcohol concentration (BAC) test, a gamma-glutamyltransferase (GGT) test, and the short Michigan Alcohol Screening Test (SMAST) performed on admission. Main Outcome Measurement.-Readmission to the trauma center for new trauma. Average follow-up was 28 months (range, 16 to 40 months). Results.-The overall rate of readmission for new injuries was 1.3 per 1000 patient-months of follow-up. Patients who were intoxicated on the initial admission (BAC >22 mmol/L [100 mg/dL]) were 2.5-fold as likely to be readmitted than those not intoxicated (95% confidence limits, 1.6, 3.9). The relative risks for patients with positive SMAST scores and abnormal GGT values were 2.2 (95% confidence limits, 1.4, 3.5) and 3.5 (95% confidence limits, 2.2, 5.5), respectively. The increased risks remained significant for intoxication and abnormal GGT values after adjustment for gender, race, Medicaid status, and mechanism of injury. Conclusion.-Alcohol abuse is associated with an increased risk of readmission for new trauma. Trauma patients should be screened for alcohol problems; referral of problem drinkers for appropriate care may decrease their risk of admission for subsequent trauma.	UNIV WASHINGTON, DEPT EPIDEMIOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT PEDIAT, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT HLTH SERV, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT SURG, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	RIVARA, FP (corresponding author), HARBORVIEW INJURY PREVENT & RES CTR, 325 9TH AVE, ZX-10, SEATTLE, WA 98104 USA.							BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Baker SP, 1992, THE INJURY FACT BOOK, V2nd; CESARE J, 1990, J TRAUMA, V30, P176, DOI 10.1097/00005373-199002000-00007; CHANG G, 1988, JAMA-J AM MED ASSOC, V260, P2533, DOI 10.1001/jama.260.17.2533; COX DR, 1972, J R STAT SOC B, V34, P187; DEVGUN MS, 1985, ALCOHOL CLIN EXP RES, V9, P235, DOI 10.1111/j.1530-0277.1985.tb05742.x; GENTILELLO LM, 1988, AM J SURG, V156, P558, DOI 10.1016/S0002-9610(88)80553-1; JURKOVICH GJ, 1992, ANN EMERG MED, V21, P704, DOI 10.1016/S0196-0644(05)82783-0; JURKOVICH GJ, 1993, JAMA-J AM MED ASSOC, V270, P51, DOI 10.1001/jama.270.1.51; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LOWENFELS AB, 1984, ANN EMERG MED, V13, P1056, DOI 10.1016/S0196-0644(84)80070-0; MACKENZIE EJ, 1988, ICDMAP DETERMINING I; PAPOZ L, 1986, BRIT MED J, V292, P1234, DOI 10.1136/bmj.292.6530.1234; PATEL S, 1975, J CLIN PATHOL, V28, P414, DOI 10.1136/jcp.28.5.414; POKORNY AD, 1972, AM J PSYCHIAT, V129, P342, DOI 10.1176/ajp.129.3.342; RIVARA FP, 1993, ARCH SURG-CHICAGO, V128, P907; ROSKALI S, 1974, CLIN CHEM, V20, P1121; SELZER ML, 1975, J STUD ALCOHOL, V36, P117, DOI 10.15288/jsa.1975.36.117; SMITH GS, 1988, ANNU REV PUBL HEALTH, V9, P99; SODERSTROM CA, 1987, ARCH SURG-CHICAGO, V122, P1067; SODERSTROM CA, 1989, ADV TRAUMA, V4, P211; Swan KG, 1989, J TRAUMA, V29, P947; WATSON RR, 1986, ALCOHOL CLIN EXP RES, V10, P364, DOI 10.1111/j.1530-0277.1986.tb05108.x; WEISBESKI D, 1989, J TRAUMA, V29, P940, DOI 10.1097/00005373-198907000-00006; 1990, BROADENING BASE TREA; 1985, INJURY AM CONTINUING	26	173	175	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	1993	270	16					1962	1964		10.1001/jama.270.16.1962	http://dx.doi.org/10.1001/jama.270.16.1962			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MC513	8105114				2023-01-03	WOS:A1993MC51300028
J	KELLERMANN, AL; HACKMAN, BB; SOMES, G; KRETH, TK; NAIL, L; DOBYNS, P				KELLERMANN, AL; HACKMAN, BB; SOMES, G; KRETH, TK; NAIL, L; DOBYNS, P			IMPACT OF 1ST-RESPONDER DEFIBRILLATION IN AN URBAN EMERGENCY MEDICAL-SERVICES SYSTEM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOSPITAL CARDIAC-ARREST; AUTOMATIC EXTERNAL DEFIBRILLATOR; AMERICAN-HEART-ASSOCIATION; RAPID DEFIBRILLATION; IMPROVING SURVIVAL; TECHNICIANS; EXPERIENCE; MANAGEMENT; RESUSCITATION; PACEMAKER	Objective.-To evaluate the impact of adding first-responder defibrillation by fire-fighters to an existing advanced life-support emergency medical services system. Design.-Nonrandomized, controlled clinical trial with periodic crossover. Setting.-Memphis, Tenn, a city of 610337 people, which is served by a fire department-based emergency medical services system. All city ambulances provide advanced life support. Patients.-Adult victims of out-of-hospital cardiac arrest due to heart disease. Intervention.-Twenty of 40 participating engine companies were equipped with an automated external defibrillator and ordered to apply it immediately in all cases of cardiac arrest. The other 20 companies were ordered to start cardiopulmonary resuscitation (CPR) immediately and wait for paramedics to arrive. Every 75 days, group roles were reversed. Care otherwise proceeded according to 1986 American Heart Association guidelines. Main Outcome Measures.-Return of spontaneous circulation in the field, survival to hospital admission, survival to hospital discharge, and neurological status at discharge. Results.-During the 39-month study interval, 879 patients were treated by a project engine company. Four hundred thirty-one (49%) of these were found in ventricular fibrillation. Bystander CPR was started in only 12% of cases. Overall, firefighters reached the scene a mean of 2.5 minutes faster than simultaneously dispatched paramedics. Although our automated external defibrillators proved to be reliable and efficacious for terminating ventricular fibrillation and pulseless ventricular tachycardia, patients treated by an automated external defibrillator-equipped engine company were no more likely than CPR-treated controls to be resuscitated (32% vs 34%, respectively), to survive to hospital admission (31% vs 29%), or to survive to hospital discharge (14% vs 10%). Neurological outcomes were also, similar in the two treatment groups. Conclusions.-In a fast-response, urban emergency medical services system served by paramedics, the impact of adding first-responder defibrillation appears to be small. Early defibrillation alone cannot overcome low community rates of by-stander CPR. Careful attention to every link in the ''chain of survival'' is needed to achieve optimal rates of survival after cardiac arrest.	UNIV TENNESSEE CTR HLTH SCI,DIV EMERGENCY MED,MEMPHIS,TN 38163; UNIV TENNESSEE CTR HLTH SCI,DEPT INTERNAL MED,MEMPHIS,TN 38163; UNIV TENNESSEE CTR HLTH SCI,DEPT BIOSTAT & EPIDEMIOL,MEMPHIS,TN 38163	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center					AHRQ HHS [HS 06094-02] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		[Anonymous], 1986, Lancet, V1, P397; CAMPBELL JC, 1991, ANN EMERG MED, V20, P433; COBB LA, 1980, MOD CONC CARDIOV DIS, V49, P31; CUMMINS RO, 1987, JAMA-J AM MED ASSOC, V257, P1605, DOI 10.1001/jama.257.12.1605; CUMMINS RO, 1984, LANCET, V2, P318; CUMMINS RO, 1985, AM J EMERG MED, V3, P114, DOI 10.1016/0735-6757(85)90032-4; CUMMINS RO, 1991, CIRCULATION, V83, P1832, DOI 10.1161/01.CIR.83.5.1832; CUMMINS RO, 1991, ANN EMERG MED, V20, P861; CUMMINS RO, 1990, ANN EMERG MED, V19, P1245, DOI 10.1016/S0196-0644(05)82282-6; CUMMINS RO, 1989, ANN EMERG MED, V12, P1269; EISENBERG MS, 1984, JAMA-J AM MED ASSOC, V251, P1723, DOI 10.1001/jama.251.13.1723; EISENBERG MS, 1980, NEW ENGL J MED, V302, P1379, DOI 10.1056/NEJM198006193022502; EISENBERG MS, 1980, JAMA-J AM MED ASSOC, V243, P1049, DOI 10.1001/jama.243.10.1049; EISENBERG MS, 1984, SUDDEN CARDIAC DEATH; Fleiss JL, 1981, STAT METHODS RATES P; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; GRAY AJ, 1987, BRIT MED J, V294, P1133, DOI 10.1136/bmj.294.6580.1133; JAGGARAO NSV, 1982, LANCET, V2, P73; KELLERMANN AL, 1993, ANN EMERG MED, V22, P47, DOI 10.1016/S0196-0644(05)80249-5; KELLERMANN AL, 1993, ANN EMERG MED, V22, P1269, DOI 10.1016/S0196-0644(05)80105-2; KERBER RE, 1991, STATEMENT EARLY DEFI; MURPHY DM, 1987, J EMERG MED SERV, V12, P67; NEWMAN MM, 1987, J EMERG MED SERV, V12, P40; ORNATO JP, 1984, ANN EMERG MED, V13, P1096, DOI 10.1016/S0196-0644(84)80331-5; ROZKOVEC A, 1983, CLIN CARDIOL, V7, P527; STULTS KR, 1986, CIRCULATION, V73, P701, DOI 10.1161/01.CIR.73.4.701; STULTS KR, 1984, NEW ENGL J MED, V310, P219, DOI 10.1056/NEJM198401263100403; VALENZUELA TD, 1990, ANN EMERG MED, V19, P1407, DOI 10.1016/S0196-0644(05)82609-5; WEAVER WD, 1986, AM J CARDIOL, V57, P1017, DOI 10.1016/0002-9149(86)90667-3; WEAVER WD, 1988, NEW ENGL J MED, V319, P661, DOI 10.1056/NEJM198809153191101; WEAVER WD, 1986, ANN EMERG MED, V15, P1181; 1986, JAMA-J AM MED ASSOC, V255, P2841; 1990, INSTRUCTORS MANNUAL; 1990, ASTM F125590 AM SOC; 1988, LANCET, V1, P350; 1984, JAMA-J AM MED ASSOC, V251, P351; 1992, JAMA-J AM MED ASSOC, V268, P2172; 1991, CURR EMERG CARDIAC C, V2, P1	38	111	112	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 13	1993	270	14					1708	1713		10.1001/jama.270.14.1708	http://dx.doi.org/10.1001/jama.270.14.1708			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA294	8411501				2023-01-03	WOS:A1993MA29400027
J	KERSCHER, M; VOLKENANDT, M; PLEWIG, G; LEHMANN, P				KERSCHER, M; VOLKENANDT, M; PLEWIG, G; LEHMANN, P			COMBINATION PHOTOTHERAPY OF PSORIASIS WITH CALCIPOTRIOL AND NARROW-BAND UVB	LANCET			English	Letter							RADIATION; VULGARIS				KERSCHER, M (corresponding author), LUDWIG MAXIMILIANS UNIV MUNCHEN,DEPT DERMATOL,D-80337 MUNICH,GERMANY.							Goeckerman W., 1925, NW MED, V24, P229; KRAGBALLE K, 1990, DERMATOLOGICA, V181, P211, DOI 10.1159/000247926; KRAGBALLE K, 1991, LANCET, V337, P193, DOI 10.1016/0140-6736(91)92157-W; VANWEELDEN H, 1988, BRIT J DERMATOL, V119, P11; WULF HC, 1989, PHOTODERMATOLOGY, V6, P44	5	70	70	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 9	1993	342	8876					923	923		10.1016/0140-6736(93)91968-R	http://dx.doi.org/10.1016/0140-6736(93)91968-R			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA963	8105177				2023-01-03	WOS:A1993MA96300030
J	STANSFIELD, SK; PIERRELOUIS, M; LEREBOURS, G; AUGUSTIN, A				STANSFIELD, SK; PIERRELOUIS, M; LEREBOURS, G; AUGUSTIN, A			VITAMIN-A SUPPLEMENTATION AND INCREASED PREVALENCE OF CHILDHOOD DIARRHEA AND ACUTE RESPIRATORY-INFECTIONS	LANCET			English	Article							MILD VITAMIN; NORTHEASTERN THAILAND; SCHOOL-CHILDREN; IMMUNE-RESPONSE; TRACT DISEASES; DEFICIENCY; MORBIDITY; TRIAL; MORTALITY; RISK	There is uncertainty over whether vitamin A supplementation reduces morbidity among children with subclinical deficiency of the vitamin. Hence a double-blind, placebo-controlled trial of the effect of vitamin A supplementation on childhood morbidity was conducted among 11 124 children aged 6-83 months in the northwest of Haiti. After a random start, children were sequentially assigned by household units to receive either megadose vitamin A or placebo in three distribution cycles 4 months apart. 2 to 8 weeks after each administration of the vitamin A and placebo capsules, indicators of childhood morbidity were reassessed through interviews conducted in the homes of participating families. The vitamin A group was found to have an increased 2-week prevalence of all symptoms and signs of childhood morbidity assessed, including diarrhoea (rate ratio [RR] = 1.09, 95% confidence interval 1.05-1.14), rhinitis (RR = 1.02, 95% confidence interval 1.00-1.04), cold/flu symptoms (RR = 1.04, 95% confidence interval 1.01-1.06), cough (RR = 1.07, 95% confidence interval 1.03-1.11), and rapid breathing (RR = 1.18, 95% confidence interval 1.09-1.27). The study shows an increased 2-week prevalence of diarrhoea and the symptoms of respiratory infections after vitamin A supplementation.	EYE CARE HAITI, PORT AU PRINCE, HAITI; INST HAITEN ENFANCE, PORT AU PRINCE, HAITI		STANSFIELD, SK (corresponding author), MCGILL UNIV, DEPT EPIDEMIOL & BIOSTAT, 1020 PINE AVE W, MONTREAL H3A 1A2, PQ, CANADA.							ABDELJABER MH, 1991, AM J PUBLIC HEALTH, V81, P1654, DOI 10.2105/AJPH.81.12.1654; ARTHUR P, 1992, LANCET, V339, P361, DOI 10.1016/0140-6736(92)91677-Z; BANDRINATH P, 1991, LANCET, V29, P849; BASSETT DC, 1990, RAPID NUTRITION ASSE; BLACK RE, 1984, AM J CLIN NUTR, V39, P87, DOI 10.1093/ajcn/39.1.87; BLOEM MW, 1990, AM J EPIDEMIOL, V131, P332, DOI 10.1093/oxfordjournals.aje.a115502; BRILLIANT LB, 1985, B WORLD HEALTH ORGAN, V63, P375; COUTSOUDIS A, 1991, AM J CLIN NUTR, V54, P890, DOI 10.1093/ajcn/54.5.890; FRIEDMAN A, 1989, J NUTR, V119, P790, DOI 10.1093/jn/119.5.790; FRIEDMAN A, 1991, J NUTR, V121, P395, DOI 10.1093/jn/121.3.395; GERSHOFF SN, 1977, AM J CLIN NUTR, V30, P1185, DOI 10.1093/ajcn/30.7.1185; HUSSEY GD, 1990, NEW ENGL J MED, V323, P160, DOI 10.1056/NEJM199007193230304; Kartasasmita C B, 1991, Paediatr Indones, V31, P41; KEUSCH GT, 1991, REV INFECT DIS    S6, V13, pS468; KJOLHEDE CL, 1991, AM J EPIDEMIOL, V133, P319, DOI 10.1093/oxfordjournals.aje.a115880; KOTHARI G, 1991, J TROP PEDIATRICS, V37, P141, DOI 10.1093/tropej/37.3.141; MILTON RC, 1987, AM J CLIN NUTR, V46, P827, DOI 10.1093/ajcn/46.5.827; PINNOCK CB, 1988, AUST PAEDIATR J, V24, P286; PINNOCK CB, 1986, AUST PAEDIATR J, V22, P95; RAHMATHULLAH L, 1991, AM J CLIN NUTR, V54, P568, DOI 10.1093/ajcn/54.3.568; SOLON FS, 1978, AM J CLIN NUTR, V31, P360, DOI 10.1093/ajcn/31.2.360; SOMMER A, 1990, ANN NY ACAD SCI, V587, P17, DOI 10.1111/j.1749-6632.1990.tb00129.x; SOMMER A, 1984, AM J CLIN NUTR, V40, P1090, DOI 10.1093/ajcn/40.5.1090; STANTON BF, 1986, AM J DIS CHILD, V140, P584, DOI 10.1001/archpedi.1986.02140200094036; STOLL BJ, 1985, J TROP PEDIATRICS, V31, P36, DOI 10.1093/tropej/31.1.36; TARWOTJO I, 1987, AM J CLIN NUTR, V45, P1466, DOI 10.1093/ajcn/45.6.1466; TIELSCH JM, 1986, AM J EPIDEMIOL, V124, P561, DOI 10.1093/oxfordjournals.aje.a114428; VIJAYARAGHAVAN K, 1990, LANCET, V336, P1342, DOI 10.1016/0140-6736(90)92895-O; 1980, DIAGNOSTIC SITUATION; 1988, VITAMIN A SUPPLEMENT; 1987, WKLY EPIDEMIOL REC, V19, P133; 1992, STATE WORLDS CHILDRE	32	84	86	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 4	1993	342	8871					578	582		10.1016/0140-6736(93)91410-N	http://dx.doi.org/10.1016/0140-6736(93)91410-N			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV963	8102720				2023-01-03	WOS:A1993LV96300010
J	SGARBOSSA, EB; PINSKI, SL; MALONEY, JD				SGARBOSSA, EB; PINSKI, SL; MALONEY, JD			THE ROLE OF PACING MODALITY IN DETERMINING LONG-TERM SURVIVAL IN THE SICK SINUS SYNDROME	ANNALS OF INTERNAL MEDICINE			English	Article						SICK SINUS SYNDROME; CARDIAC PACING, ARTIFICIAL; PACEMAKER, ARTIFICIAL; HEART ATRIUM; HEART VENTRICLE	PACEMAKER SYNDROME; SINGLE-CHAMBER; FOLLOW-UP; ATRIAL-FIBRILLATION; NODE DISEASE; IMPLANTATION; MODE; CONDUCTION; MORBIDITY; MORTALITY	Objective: To determine whether the atrial-based pacing modalities (''physiologic pacing'') improve survival when compared with single-chamber ventricular pacing in patients with the sick sinus syndrome. Design: Retrospective, nonrandomized study. Setting: A tertiary care teaching hospital. Patients: A total of 507 patients with a mean age of 66 years who received an initial pacemaker for the sick sinus syndrome between January 1980 and December 1989. Pacing modes were ventricular (22%), atrial (4%), and dual-chamber (74%). Measurements: Total and cardiovascular mortality rates. Mean follow-up was 66 months. Results: Independent predictors of total mortality by the Cox proportional hazards model were 1) New York Heart Association functional class (hazard ratio = 1.67/class; 95% CI, 1.31 to 2.11); 2) age (hazard ratio = 1.62/12-year increment; CI, 1.28 to 2.05); 3) peripheral vascular disease (hazard ratio = 2.21; CI, 1.42 to 3.42); 4) bundle branch block (hazard ratio = 2.04; CI, 1.33 to 3.13); 5) coronary artery disease (hazard ratio = 1.66; CI, 1.15 to 2.39); and 6) valvular heart disease (hazard ratio = 1.71; CI, 1.08 to 2.69). The same variables were independent predictors of cardiovascular mortality, with cerebrovascular disease reaching borderline statistical significance (hazard ratio = 1.69; CI, 1.00 to 2.86). Using univariate analysis, single-chamber ventricular pacing had more than 40% increased risk for both total and cardiovascular death, but the difference was of borderline statistical significance (total mortality: P = 0.053; hazard ratio = 1.43; CI, 0.99 to 2.07; cardiovascular mortality: P = 0.15; hazard ratio = 1.41; CI = 0.87 to 2.29). Conclusions: Because the role of the ventricular pacing mode as a long-term predictor of total and cardiovascular mortality remains inconclusive, a large, randomized study is necessary to confirm whether physiologic pacing provides a substantial reduction in mortality when compared with ventricular pacing.			SGARBOSSA, EB (corresponding author), CLEVELAND CLIN FDN, DEPT CARDIOL, DESK F15, 9500 EUCLID AVE, CLEVELAND, OH 44195 USA.							ALEXANDER LA, 1992, PACE, V15, P508; ALT E, 1985, PACE, V8, P849, DOI 10.1111/j.1540-8159.1985.tb05904.x; AUSUBEL K, 1985, ANN INTERN MED, V103, P420, DOI 10.7326/0003-4819-103-3-420; BAIG MW, 1991, PROG CARDIOVASC DIS, V33, P283, DOI 10.1016/0033-0620(91)90021-D; BERNSTEIN AD, 1992, AM J CARDIOL, V69, P331, DOI 10.1016/0002-9149(92)90229-R; BERNSTEIN AD, 1987, PACE, V10, P794, DOI 10.1111/j.1540-8159.1987.tb06035.x; BREIVIK K, 1979, ACTA MED SCAND, V206, P153; CAMM AJ, 1990, PACE, V13, P695, DOI 10.1111/j.1540-8159.1990.tb02091.x; DEYO RA, 1991, ANN INTERN MED, V114, P695, DOI 10.7326/0003-4819-114-8-695; EAGLE KA, 1986, ANN INTERN MED, V105, P264, DOI 10.7326/0003-4819-105-2-264; FEUER JM, 1989, AM J CARDIOL, V64, P1376, DOI 10.1016/0002-9149(89)90586-9; FORCINITO M, 1991, J AM COLL CARDIOL, V18, P1, DOI 10.1016/S0735-1097(10)80209-8; FRYE R L, 1984, Journal of the American College of Cardiology, V4, P434; GOLDSCHLAGER N, 1988, POSTGRAD MED, V83, P156, DOI 10.1080/00325481.1988.11700191; GRIFFIN JC, 1991, CLIN CARDIOL, V14, P257; HAYES DL, 1984, AM HEART J, V107, P644, DOI 10.1016/0002-8703(84)90309-0; HELDMAN D, 1990, PACE, V13, P1742, DOI 10.1111/j.1540-8159.1990.tb06883.x; HESSELSON AB, 1992, J AM COLL CARDIOL, V19, P1542, DOI 10.1016/0735-1097(92)90616-U; JELIC V, 1992, PACE, V15, P141, DOI 10.1111/j.1540-8159.1992.tb03057.x; Kulbertus H E, 1983, Cardiovasc Clin, V14, P189; LEE J, 1992, COMPUT APPL BIOSCI, V8, P23; LEVINE PA, 1983, PACE, V6, P279, DOI 10.1111/j.1540-8159.1983.tb04358.x; MABO P, 1991, PACE, V14, P2133, DOI 10.1111/j.1540-8159.1991.tb06484.x; MITSUOKA T, 1988, BRIT HEART J, V60, P338; PASSAMANI E, 1991, NEW ENGL J MED, V324, P1589, DOI 10.1056/NEJM199105303242209; RASMUSSEN K, 1971, AM HEART J, V81, P38, DOI 10.1016/0002-8703(71)90052-4; REDIKER DE, 1988, AM J CARDIOL, V61, P323, DOI 10.1016/0002-9149(88)90938-1; ROPER WL, 1988, NEW ENGL J MED, V319, P1197, DOI 10.1056/NEJM198811033191805; ROSENQVIST M, 1990, CLIN CARDIOL, V13, P43, DOI 10.1002/clc.4960130108; ROSENQVIST M, 1988, AM HEART J, V116, P16, DOI 10.1016/0002-8703(88)90244-X; Rosenqvist Marten, 1992, Cardiology Clinics, V10, P691; RUBENSTEIN JJ, 1972, CIRCULATION, V46, P5, DOI 10.1161/01.CIR.46.1.5; SANTINI M, 1990, AM J CARDIOL, V65, P729, DOI 10.1016/0002-9149(90)91379-K; SASAKI Y, 1988, PACE, V11, P1575, DOI 10.1111/j.1540-8159.1988.tb06277.x; SHAW DB, 1980, BMJ-BRIT MED J, V280, P139, DOI 10.1136/bmj.280.6208.139; SKAGEN K, 1976, ACTA MED SCAND, V199, P13; SMULYAN H, 1992, J CLIN EPIDEMIOL, V45, P53, DOI 10.1016/0895-4356(92)90188-S; STANGL K, 1990, PACE, V13, P2080, DOI 10.1111/j.1540-8159.1990.tb06946.x; STONE JM, 1982, AM HEART J, V104, P1319, DOI 10.1016/0002-8703(82)90162-4; SUTTON R, 1986, PACE, V9, P1110, DOI 10.1111/j.1540-8159.1986.tb06678.x; SUTTON R, 1990, PACE, V13, P1823, DOI 10.1111/j.1540-8159.1990.tb06897.x; TORRESANI J, 1984, PACE, V7, P1148, DOI 10.1111/j.1540-8159.1984.tb05675.x; VANHEMEL NM, 1981, PACE, V4, P8; VOGT P, 1988, PACE, V11, P1896, DOI 10.1111/j.1540-8159.1988.tb06326.x; WELLS CK, 1990, J CLIN EPIDEMIOL, V43, P361, DOI 10.1016/0895-4356(90)90122-6; YUSUF S, 1991, AM J CARDIOL, V68, P954, DOI 10.1016/0002-9149(91)90416-I; YUSUF S, 1984, STAT MED, V3, P409, DOI 10.1002/sim.4780030421; ZANINI R, 1989, PACE, V12, P1065, DOI 10.1111/j.1540-8159.1989.tb01927.x; ZANINI R, 1990, PACE, V13, P2076, DOI 10.1111/j.1540-8159.1990.tb06945.x; 1989, CURRENT POPULATI P25, V1018, P1; 1990, EGRET REFERENCE MANU	51	41	42	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1993	119	5					359	365		10.7326/0003-4819-119-5-199309010-00002	http://dx.doi.org/10.7326/0003-4819-119-5-199309010-00002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ476	8338288				2023-01-03	WOS:A1993LZ47600002
J	GENTLEMAN, D; DEARDEN, M; MIDGLEY, S; MACLEAN, D				GENTLEMAN, D; DEARDEN, M; MIDGLEY, S; MACLEAN, D			FORTNIGHTLY REVIEW - GUIDELINES FOR RESUSCITATION AND TRANSFER OF PATIENTS WITH SERIOUS HEAD-INJURY	BRITISH MEDICAL JOURNAL			English	Article							TRAUMATIC BRAIN INJURY; CRITICALLY ILL PATIENTS; HEMATOMA		WESTERN GEN HOSP,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; LAW HOSP,CARLUKE ML8 5ER,LANARK,SCOTLAND	University of Edinburgh	GENTLEMAN, D (corresponding author), DUNDEE ROYAL INFIRM,DUNDEE DD1 9ND,SCOTLAND.							ANDREWS PJD, 1990, LANCET, V335, P327, DOI 10.1016/0140-6736(90)90614-B; BION JF, 1988, BRIT MED J, V296, P170, DOI 10.1136/bmj.296.6616.170; DESALLES AAF, 1986, J NEUROSURG, V65, P615, DOI 10.3171/jns.1986.65.5.0615; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GENTLEMAN D, 1990, INJURY, V21, P305, DOI 10.1016/0020-1383(90)90047-X; GENTLEMAN D, 1992, INT SURG, V77, P297; GENTLEMAN D, 1990, LANCET, V335, P327; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; LAMBERT SM, 1993, INJURY, V24, P333, DOI 10.1016/0020-1383(93)90058-E; McLaren C A, 1983, J R Coll Surg Edinb, V28, P399; MENDELOW AD, 1979, BRIT MED J, V1, P1240, DOI 10.1136/bmj.1.6173.1240; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; MUNRO HM, 1993, BR J INTENSIVE CARE, V3, P210; REEVE WG, 1990, BRIT MED J, V300, P85, DOI 10.1136/bmj.300.6717.85; ROSE J, 1977, BRIT MED J, V2, P615, DOI 10.1136/bmj.2.6087.615; RUNCIE CJ, 1992, ANAESTHESIA, V47, P327, DOI 10.1111/j.1365-2044.1992.tb02175.x; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; TEASDALE G, 1982, BRIT MED J, V285, P1695, DOI 10.1136/bmj.285.6356.1695; TEASDALE G, 1974, LANCET, V2, P81; TEASDALE GM, 1990, BRIT MED J, V300, P363, DOI 10.1136/bmj.300.6721.363; VYVYAN HAL, 1991, ANAESTHESIA, V46, P395; 1988, RECOMMENDATIONS STAN; 1984, BMJ, V288, P983; 1993, ATLS COURSE MANUAL	25	66	66	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 28	1993	307	6903					547	552		10.1136/bmj.307.6903.547	http://dx.doi.org/10.1136/bmj.307.6903.547			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV180	8400978	Bronze, Green Published			2023-01-03	WOS:A1993LV18000025
J	ALLEN, CMC				ALLEN, CMC			CONSCIOUS BUT PARALYZED - RELEASING THE LOCKED-IN	LANCET			English	Editorial Material											ALLEN, CMC (corresponding author), ADDENBROOKES HOSP,DEPT NEUROL,CAMBRIDGE CB2 2QQ,ENGLAND.							BERNAT JL, 1993, NEUROLOGY, V43, P224, DOI 10.1212/WNL.43.1_Part_1.224; BRAHAMS D, 1992, LANCET, V340, P1534, DOI 10.1016/0140-6736(92)92777-D; HOWARD RS, 1989, BRAIN, V112, P1155, DOI 10.1093/brain/112.5.1155; MOSS AH, 1993, NEUROLOGY, V43, P438, DOI 10.1212/WNL.43.2.438; PATTERSON JR, 1986, STROKE, V17, P758, DOI 10.1161/01.STR.17.4.758; THADANI VM, 1991, NEUROLOGY, V41, P498, DOI 10.1212/WNL.41.4.498; 1993, NEUROLOGY, V43, P222	7	10	11	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 17	1993	342	8864					130	131		10.1016/0140-6736(93)91340-R	http://dx.doi.org/10.1016/0140-6736(93)91340-R			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN042	8101251				2023-01-03	WOS:A1993LN04200006
J	SCHMIDT, GA; WOOD, LDH				SCHMIDT, GA; WOOD, LDH			CRITICAL CARE MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; END-EXPIRATORY PRESSURE; AIRWAY PRESSURE; TIDAL VOLUME; VENTILATION; PEEP				SCHMIDT, GA (corresponding author), UNIV CHICAGO,CHICAGO,IL 60637, USA.			Schmidt, Gregory/0000-0002-5013-6323				CORBRIDGE TC, 1990, AM REV RESPIR DIS, V142, P311, DOI 10.1164/ajrccm/142.2.311; CURTIS SE, 1992, AM REV RESPIR DIS, V145, P348, DOI 10.1164/ajrccm/145.2_Pt_1.348; DREYFUSS D, 1988, AM REV RESPIR DIS, V137, P1159, DOI 10.1164/ajrccm/137.5.1159; GUTIERREZ G, 1992, CRIT CARE MED, V20, P451, DOI 10.1097/00003246-199204000-00004; GUTIERREZ G, 1992, LANCET, V339, P195, DOI 10.1016/0140-6736(92)90002-K; HALL JB, 1992, PRINCIPLES CRITICAL, P1617; HALUSZKA J, 1990, AM REV RESPIR DIS, V141, P1194, DOI 10.1164/ajrccm/141.5_Pt_1.1194; HICKLING KG, 1990, INTENS CARE MED, V16, P372, DOI 10.1007/BF01735174; HUMPHREY H, 1990, CHEST, V97, P1176, DOI 10.1378/chest.97.5.1176; KIISKI R, 1992, AM REV RESPIR DIS, V146, P1131, DOI 10.1164/ajrccm/146.5_Pt_1.1131; LEE PC, 1990, CHEST, V97, P430, DOI 10.1378/chest.97.2.430; MARINI JJ, 1992, AM REV RESPIR DIS, V146, P2, DOI 10.1164/ajrccm/146.1.2; MIRO AM, 1993, CHEST, V103, P266, DOI 10.1378/chest.103.1.266; MITCHELL JP, 1992, AM REV RESPIR DIS, V145, P990, DOI 10.1164/ajrccm/145.5.990; PETROF BJ, 1990, AM REV RESPIR DIS, V141, P281, DOI 10.1164/ajrccm/141.2.281; RONCO JJ, 1992, AM REV RESPIR DIS, V141, P25; TUCHSCHMIDT J, 1992, CHEST, V102, P216, DOI 10.1378/chest.102.1.216; WALLEY KR, 1990, CRIT CARE MED, V18, P336, DOI 10.1097/00003246-199003000-00019; YOUNES M, 1992, AM REV RESPIR DIS, V145, P121, DOI 10.1164/ajrccm/145.1.121; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701	20	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1993	270	2					194	196		10.1001/jama.270.2.194	http://dx.doi.org/10.1001/jama.270.2.194			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL368	8315727				2023-01-03	WOS:A1993LL36800013
J	COATES, A; FORBES, J				COATES, A; FORBES, J			IS CHEMOTHERAPY FOR NONSMALL CELL LUNG-CANCER WORTHWHILE	LANCET			English	Editorial Material							BREAST-CANCER; QUALITY; COSTS		NEWCASTLE MATER MISERICORDIAE HOSP, NEWCASTLE, NSW, AUSTRALIA; AUSTRALIAN NEW ZEALAND BREAST CANC TRIALS GRP, NEWCASTLE, NSW, AUSTRALIA	Calvary Mater Newcastle Hospital	COATES, A (corresponding author), ROYAL PRINCE ALFRED HOSP, CAMPERDOWN, NSW 2050, AUSTRALIA.							COATES A, 1987, NEW ENGL J MED, V317, P1490, DOI 10.1056/NEJM198712103172402; COATES AS, 1993, INTRO NEW TREATMENTS, P447; Early Breast Cancer Trialists' Collaborative Group, 1992, LANCET, V339, P1; GANZ PA, 1989, CANCER, V63, P1271, DOI 10.1002/1097-0142(19890401)63:7<1271::AID-CNCR2820630707>3.0.CO;2-6; GOLDHIRSCH A, 1989, J CLIN ONCOL, V7, P36, DOI 10.1200/JCO.1989.7.1.36; JAAKKIMAINEN L, 1990, J CLIN ONCOL, V8, P1301, DOI 10.1200/JCO.1990.8.8.1301; 1992, LANCET, V339, P71	7	12	12	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 3	1993	342	8862					4	4		10.1016/0140-6736(93)91876-N	http://dx.doi.org/10.1016/0140-6736(93)91876-N			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK985	8100297				2023-01-03	WOS:A1993LK98500005
J	Bachman, JG; Alcser, KH; Doukas, DJ; Lichtenstein, RL; Corning, AD; Brody, H				Bachman, JG; Alcser, KH; Doukas, DJ; Lichtenstein, RL; Corning, AD; Brody, H			Attitudes of Michigan physicians and the public toward legalizing physician-assisted suicide and voluntary euthanasia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DIE	Background. There has been a continuing public debate about assisted suicide and the proper role, if any, of physicians in this practice. Legislative bans and various forms of legalization have been proposed. Methods. We mailed questionnaires to three stratified random samples of Michigan physicians in specialties likely to involve the care of terminally ill patients: 500 in the spring of 1994, 500 in the summer of 1994, and 600 in the spring of 1995. Similar questionnaires were mailed to stratified random samples of Michigan adults: 449 in the spring of 1994 and 899 in the summer of 1994. Several different questionnaire forms were used, all of which included questions about whether physician-assisted suicide should be banned in Michigan or legalized under certain conditions. Results. Usable questionnaires were returned by 1119 of 1518 physicians eligible for the study (74 percent), and 998 of 1307 eligible adults in the sample of the general public (76 percent). Asked to choose between legalization of physician-assisted suicide and an explicit ban, 56 percent of physicians and 66 percent of the public supported legalization, 37 percent of physicians and 26 percent of the public preferred a ban, and 8 percent of each group were uncertain, When the physicians were given a wider range of choices, 40 percent preferred legalization, 37 percent preferred ''no law'' (i.e., no government regulation), 17 percent favored prohibition, and 5 percent were uncertain. If physician-assisted suicide were legal, 35 percent of physicians said they might participate if requested - 22 percent would participate in either assisted suicide or voluntary euthanasia, and 13 percent would participate only in assisted suicide. Support for physician-assisted suicide was lowest among the strongly religious. Conclusions. Most Michigan physicians prefer either the legalization of physician-assisted suicide or no law at all; fewer than one fifth prefer a complete ban on the practice, Given a choice between legalization and a ban, two thirds of the Michigan public prefer legalization and one quarter prefer a ban. (C) 1996, Massachusetts Medical Society.	UNIV MICHIGAN, SCH MED, DEPT FAMILY PRACTICE, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH PUBL HLTH, ANN ARBOR, MI 48109 USA; MICHIGAN STATE UNIV, CTR ETH & HUMANITIES LIFE SCI, E LANSING, MI 48824 USA; MICHIGAN STATE UNIV, DEPT FAMILY PRACTICE, E LANSING, MI 48824 USA; MICHIGAN STATE UNIV, DEPT PHILOSOPHY, E LANSING, MI 48824 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Michigan State University; Michigan State University; Michigan State University	Bachman, JG (corresponding author), UNIV MICHIGAN, INST SOCIAL RES, SURVEY RES CTR, ANN ARBOR, MI 48106 USA.		Doukas, David/ABB-9276-2021; Brody, Howard/GQA-6310-2022					ANNAS GJ, 1994, NEW ENGL J MED, V331, P1240, DOI 10.1056/NEJM199411033311822; BACHMAN JG, 1994, NEW ENGL J MED, V331, P812, DOI 10.1056/NEJM199409223311215; BATTIN MP, 1995, ACAD MED, V70, P583; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2658, DOI 10.1001/jama.267.19.2658; BRODY H, 1992, NEW ENGL J MED, V327, P1384, DOI 10.1056/NEJM199211053271912; CAMPBELL DT, 1959, PSYCHOL BULL, V56, P81, DOI 10.1037/h0046016; COHEN JS, 1994, NEW ENGL J MED, V331, P89, DOI 10.1056/NEJM199407143310206; Dillman D.A., 1978, MAIL TELEPHONE SURVE, V19; FINLAY B, 1985, SOCIOL SOC RES, V69, P548; KAMISAR Y, 1993, HASTINGS CENT REP, V23, P32, DOI 10.2307/3563366; MCCARRICK P M, 1992, Kennedy Institute of Ethics Journal, V2, P79; MILLER FG, 1994, NEW ENGL J MED, V331, P119, DOI 10.1056/NEJM199407143310211; MILLER FG, 1995, HASTINGS CENT REP, V25, P8, DOI 10.2307/3562107; Nunnally J. C., 1978, PSYCHOMETRIC THEORY, V2nd; ORENTLICHER D, 1989, JAMA-J AM MED ASSOC, V262, P1844, DOI 10.1001/jama.262.13.1844; Pellegrino E D, 1992, J Clin Ethics, V3, P95; QUILL TE, 1993, JAMA-J AM MED ASSOC, V270, P870, DOI 10.1001/jama.270.7.870; QUILL TE, 1992, NEW ENGL J MED, V327, P1380, DOI 10.1056/NEJM199211053271911; Quill TE, 1993, DEATH DIGNITY MAKING; Schuman H., 1981, QUESTIONS ANSWERS AT; SCHWARZ N, 1992, CONTEXT AFFECTS SOCI; SINGER PA, 1990, NEW ENGL J MED, V322, P1881, DOI 10.1056/NEJM199006283222610; TENO J, 1991, J AM GERIATR SOC, V39, P827, DOI 10.1111/j.1532-5415.1991.tb02707.x; VOGT WP, 1993, DICT STATISTICS METH; Weir R F, 1992, Law Med Health Care, V20, P116, DOI 10.1111/j.1748-720X.1992.tb01178.x; WOOD FW, 1990, AM PROFILE OPINIONS; 1994, DEATH IS SOUGHT ASSI; 1991, J AM GERIATR SOC, V39, P826; 1994, FINAL REPORT MICHIGA	29	201	201	4	50	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 1	1996	334	5					303	309		10.1056/NEJM199602013340506	http://dx.doi.org/10.1056/NEJM199602013340506			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TV695	8532027				2023-01-03	WOS:A1996TV69500006
J	ANNAS, GJ				ANNAS, GJ			DEATH BY PRESCRIPTION - THE OREGON INITIATIVE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material														Annas, George/0000-0001-5836-7831				ANNAS GJ, 1985, AM J PUBLIC HEALTH, V75, P1096, DOI 10.2105/AJPH.75.9.1096; ANNAS GJ, 1993, NEW ENGL J MED, V328, P1573, DOI 10.1056/NEJM199305273282121; Callahan Daniel, 1993, TROUBLED DREAM LIFE; CAPRON AM, 1992, HASTINGS CENT REP, V22, P30, DOI 10.2307/3562562; COHEN JS, 1994, NEW ENGL J MED, V331, P89, DOI 10.1056/NEJM199407143310206; GIANELLI DM, 1994, AM MED NEWS     0725, P1; GIANELLI DM, 1994, AM MED NEWS     0912, P34; Humphry D., 1992, DYING DIGNITY UNDERS; NULAND SB, 1994, WE DIE, P288; ORENTLICHER D, 1994, MED UNBOUND HUMAN BO, P256; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; SKELLY FJ, 1994, AM MED NEWS     0815, P19; WEILER PC, 1993, MEASURE MALPRACTICE, P55; YANKELOVICH D, 1994, NY TIMES        0917, P23; 1994, DEATH IS SOUGHT ASSI; 1994, AHCPR940592 DEP HLTH, P16; 1992, JAMA-J AM MED ASSOC, V267, P2229; 1994, FINAL REPORT MICHIGA; 1992, HASTINGS CTR REP, V22, P7	19	50	50	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 3	1994	331	18					1240	1243		10.1056/NEJM199411033311822	http://dx.doi.org/10.1056/NEJM199411033311822			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN806	7935680				2023-01-03	WOS:A1994PN80600038
J	KEYS, A				KEYS, A			1944 SYMPOSIUM ON CONVALESCENCE AND REHABILITATION	FASEB JOURNAL			English	Editorial Material											KEYS, A (corresponding author), UNIV MINNESOTA,SCH PUBL HLTH,DIV EPIDEMIOL,MINNEAPOLIS,MN 55454, USA.							KEYS A, 1949, FED PROC, V3, P188	1	1	1	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1994	8	14					1201	1202		10.1096/fasebj.8.14.7958628	http://dx.doi.org/10.1096/fasebj.8.14.7958628			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PT128	7958628				2023-01-03	WOS:A1994PT12800017
J	HEDDLE, NM; KLAMA, L; SINGER, J; RICHARDS, C; FEDAK, P; WALKER, I; KELTON, JG				HEDDLE, NM; KLAMA, L; SINGER, J; RICHARDS, C; FEDAK, P; WALKER, I; KELTON, JG			THE ROLE OF THE PLASMA FROM PLATELET CONCENTRATES IN TRANSFUSION REACTIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FEBRILE	Background. Febrile, nonhemolytic transfusion reactions are the most frequent adverse reactions to platelets. A number of observations argue against the widely held view that these reactions result from the interaction between antileukocyte antibodies in the recipient and leukocytes in the platelet product. We sought to determine whether substances in the plasma or the cells in the product cause reactions to transfused platelets. Methods. We separated standard platelet concentrates into their plasma and cellular components and then transfused both portions in random order. Patients were monitored for reactions during all transfusions. Before each transfusion, the concentration of cytokines (interleukin-1 beta and interleukin-6) was measured in the platelet products. Studies were also performed on the platelet products to determine the effect of storage on the concentration of cytokines. Results. Sixty-four pairs of platelet-product components (the plasma supernatant and the cells) were administered to 12 patients. There were 20 reactions to the plasma supernatant and 6 reactions to the cells (chi-square = 6.50, P = 0.009). Eight transfusions were associated with reactions to both products. The plasma component was more likely to cause severe reactions than the cells (chi-square = 9.6, P < 0.01). A strong positive correlation was observed between the reactions and the concentration of interleukin-1 beta and interleukin-6 in the plasma supernatant (P < 0.001 and P = 0.034, respectively). In vitro studies demonstrated that interleukin-1 beta and interleukin-6 concentrations rise progressively in stored platelets and that these concentrations are related to the leukocyte count in the platelet product. Conclusions. Bioreactive substances in the plasma supernatant of the platelet product cause most febrile reactions associated with platelet transfusions. Removing the plasma supernatant before transfusion can minimize or prevent these reactions.	MCMASTER UNIV,MED CTR,DEPT MED,HAMILTON L8N 3Z5,ON,CANADA; CHEDOKE MCMASTER HOSP,TRANSFUS MED SERV,HAMILTON,ON,CANADA; UNIV BRITISH COLUMBIA,DEPT HLTH CARE & EPIDEMIOL,VANCOUVER V6T 1W5,BC,CANADA; CANADIAN RED CROSS BLOOD TRANSFUS SERV,HAMILTON CTR,HAMILTON,ON,CANADA	McMaster University; McMaster University; University of British Columbia	HEDDLE, NM (corresponding author), MCMASTER UNIV,MED CTR,DEPT PATHOL,RM 2N38,1200 MAIN ST W,HAMILTON L8N 3Z5,ON,CANADA.			Fedak, Paul/0000-0003-0658-9381; Richards, Carl/0000-0002-0081-2231				AARDEN LA, 1987, EUR J IMMUNOL, V17, P1411, DOI 10.1002/eji.1830171004; AVE MT, 1993, BLOOD S1, V82, pA336; CHAMBERS LA, 1990, TRANSFUSION, V30, P219, DOI 10.1046/j.1537-2995.1990.30390194340.x; HEDDLE NM, 1993, TRANSFUSION, V33, P794, DOI 10.1046/j.1537-2995.1993.331094054613.x; KALMIN ND, 1987, TRANSFUSION, V27, P281, DOI 10.1046/j.1537-2995.1987.27387235641.x; LENG B, 1990, 1990 P ISBT AABB JOI, P17; MANGANO MM, 1991, AM J CLIN PATHOL, V95, P733, DOI 10.1093/ajcp/95.5.733; MUYLLE L, 1992, TRANSFUSION MED, V2, P289, DOI 10.1111/j.1365-3148.1992.tb00172.x; MUYLLE L, 1993, TRANSFUSION, V33, P195, DOI 10.1046/j.1537-2995.1993.33393174443.x; PAYNE R, 1957, Vox Sang, V2, P233; PAYNE R, 1960, AM J MED, V29, P449, DOI 10.1016/0002-9343(60)90041-3; PERKINS HA, 1966, VOX SANG, V11, P578, DOI 10.1111/j.1423-0410.1966.tb04256.x; SILLIMAN C, 1992, BLOOD, V80, pA365; STACK G, 1994, TRANSFUSION, V34, P20, DOI 10.1046/j.1537-2995.1994.34194098597.x; WALKER RH, 1990, TECHNICAL MANUAL, P420	15	369	386	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 8	1994	331	10					625	628		10.1056/NEJM199409083311001	http://dx.doi.org/10.1056/NEJM199409083311001			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE382	8052271				2023-01-03	WOS:A1994PE38200001
J	MILLS, M; DAVIES, HTO; MACRAE, WA				MILLS, M; DAVIES, HTO; MACRAE, WA			CARE OF DYING PATIENTS IN-HOSPITAL	BRITISH MEDICAL JOURNAL			English	Article							TERMINAL CANCER; DEATH; FAMILIES; SYMPTOMS; PAIN	Objective-To study the process of care of dying patients in general hospitals. Design-Non-participant observer (MM) carried out regular periods of continuous comprehensive observation in wards where there were dying patients, recording the quantity and quality of care given. Observations were made in 1983. Setting-13 wards (six surgical, six medical, and one specialist unit) in four large teaching hospitals Cbed capacity 503-796) in west of Scotland. Sujects-50 dying patients (29 female, 21 male) with mean age of 66 (range 40-89); 29 were dying from cancer and 21 from non-malignant disease. Results-Final period of hospitalisation ranged from 6 hours to 24 weeks. More than half of all patients retained consciousness until shortly before death. Basic interventions to maintain patients' comfort were often not provided: oral hygiene was often poor, thirst remained unquenched, and little assistance was given to encourage eating, Contact between nurses and the dying patients was minimal; distancing and isolation of patients by most medical and nursing staff were evident; this isolation increased as death approached. Conclusions-Care of many of the dying patients observed in these hospitals was poor. We need to identify and implement practical steps to facilitate high quality care of the dying. Much can be learned from the hospice movement, but such knowledge and skills must be replicated in all settings.	GREATER GLASGOW HLTH BOARD,GLASGOW G1 1PT,LANARK,SCOTLAND; UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT EPIDEMIOL & PUBL HLTH,DUNDEE DD1 9SY,SCOTLAND; UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT ANAESTHET,DUNDEE DD1 9SY,SCOTLAND	University of Dundee; University of Dundee				Davies, Huw/0000-0002-2653-3695				ADDINGTON-HALL J M, 1991, Palliative Medicine, V5, P207, DOI 10.1177/026921639100500305; BOWLING A, 1983, J MED ETHICS, V9, P158, DOI 10.1136/jme.9.3.158; BUCKINGHAM RW, 1976, CAN MED ASSOC J, V115, P1211; CAMERON J, 1983, POSTGRAD MED J, V59, P73, DOI 10.1136/pgmj.59.688.73; CARTWRIGHT A, 1991, J PUBLIC HEALTH MED, V13, P81; Conboy-Hill S, 1986, Int Nurs Rev, V33, P19; DUNLOP RJ, 1989, PALLIAT MED, V0003, P00197, DOI DOI 10.1177/026921638900300305; FOX D, 1976, FUNDAMENTALS RES NUR; HIGGINSON I, 1989, J ROY SOC MED, V82, P264, DOI 10.1177/014107688908200507; HIGGINSON I, 1990, BRIT MED J, V301, P277, DOI 10.1136/bmj.301.6746.277; Higginson I, 1993, Qual Health Care, V2, P112, DOI 10.1136/qshc.2.2.112; HINTON J, 1979, LANCET, V1, P29; HOCKLEY JM, 1988, BRIT MED J, V296, P1715, DOI 10.1136/bmj.296.6638.1715; KANE RL, 1984, LANCET, V1, P890; MAGUIRE P, 1985, BRIT MED J, V291, P1711, DOI 10.1136/bmj.291.6510.1711; OBRIEN T, 1993, MANAGEMENT TERMINAL, P33; PARKES CM, 1984, POSTGRAD MED J, V60, P120, DOI 10.1136/pgmj.60.700.120; RAY M, 1981, CARING ESSENTIAL HUM, P25; SAMAREL N, 1989, INT J NURS STUD, V26, P313, DOI 10.1016/0020-7489(89)90018-7; SAUNDERS C, 1993, MANAGEMENT TERMINAL; SEALE C, 1991, SOC SCI MED, V32, P147, DOI 10.1016/0277-9536(91)90054-G; SIMPSON K H, 1991, Palliative Medicine, V5, P122; SUDNOW D, 1967, PASSONG SOCIAL ORG D; SYKES N P, 1992, Palliative Medicine, V6, P227, DOI 10.1177/026921639200600307; TOWNSEND J, 1990, BRIT MED J, V301, P415, DOI 10.1136/bmj.301.6749.415; VENTAFRIDDA V, 1987, CANCER, V59, P850, DOI 10.1002/1097-0142(19870215)59:4<850::AID-CNCR2820590432>3.0.CO;2-1; Ventafridda V, 1990, J Palliat Care, V6, P7; Webster M E, 1981, Nurs Times, V77, P999; WILKES E, 1984, LANCET, V1, P950; 1993, 1992 GEN REG OFF ANN; 1991, J R COLL PHYSICIANS, V25, P325; 1967, SCOTTISH HLTH SERVIC, V3	32	99	99	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 3	1994	309	6954					583	586		10.1136/bmj.309.6954.583	http://dx.doi.org/10.1136/bmj.309.6954.583			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PF330	8086948	Green Published			2023-01-03	WOS:A1994PF33000023
J	PRODHOM, G; LEUENBERGER, P; KOERFER, J; BLUM, A; CHIOLERO, R; SCHALLER, MD; PERRET, C; SPINNLER, O; BLONDEL, J; SIEGRIST, H; SAGHAFI, L; BLANC, D; FRANCIOLI, P				PRODHOM, G; LEUENBERGER, P; KOERFER, J; BLUM, A; CHIOLERO, R; SCHALLER, MD; PERRET, C; SPINNLER, O; BLONDEL, J; SIEGRIST, H; SAGHAFI, L; BLANC, D; FRANCIOLI, P			NOSOCOMIAL PNEUMONIA IN MECHANICALLY VENTILATED PATIENTS RECEIVING ANTACID, RANITIDINE, OR SUCRALFATE AS PROPHYLAXIS FOR STRESS-ULCER - A RANDOMIZED CONTROLLED TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article						GROSS INFECTION; PEPTIC ULCER; PNEUMONIA; SUCRALFATE; VENTILATORS, MECHANICAL	INTENSIVE-CARE UNIT; CRITICALLY ILL PATIENTS; PROTECTED SPECIMEN BRUSH; MULTIPLE TRAUMA PATIENTS; SELECTIVE DECONTAMINATION; GASTRIC COLONIZATION; INTUBATED PATIENTS; DIGESTIVE-TRACT; BRONCHOALVEOLAR LAVAGE; ANTIBACTERIAL ACTIVITY	Objective: To assess three anti-stress ulcer prophylaxis regimens in mechanically ventilated patients for bacterial colonization, early- and late-onset nosocomial pneumonia, and gastrointestinal bleeding. Design: Randomized controlled trial. Patients: Consecutive eligible patients with mechanical ventilation and a nasogastric tube. Of 258 eligible patients, 244 were assessable. Setting: Medical and surgical intensive care units. Intervention: At intubation, patients were randomly assigned to receive one of the following: antacid (a suspension of aluminum hydroxide and magnesium hydroxide), 20 mL every 2 hours; ranitidine, 150 mg as a continuous intravenous infusion; or sucralfate, 1 g every 4 hours. Measurements: Using predetermined criteria, the incidence of gastric bleeding, gastric colonization, early-onset pneumonia, and late-onset pneumonia was assessed in patients intubated for more than 24 hours. Results: Of 244 assessable patients, macroscopic gastric bleeding was observed in 10%, 4%, and 6% of patients assigned to receive sucralfate, antacid, and ranitidine, respectively (P > 0.2). The incidence of early-onset pneumonia was not statistically different among the three treatment groups (P > 0.2). Among the 213 patients observed for more than 4 days, late-onset pneumonia was observed in 5% of the patients who received sucralfate compared with 16% and 21% of the patients who received antacid or ranitidine, respectively (P = 0.022). Mortality was not statistically different among the three treatment groups. Patients who received sucralfate had a lower median gastric pH (P < 0.001) and less frequent gastric colonization compared with the other groups (P = 0.015). Using molecular typing, 84% of the patients with late-onset gramnegative bacillary pneumonia were found to have gastric colonization with the same bacteria before pneumonia developed. Conclusion: Stress ulcer prophylaxis with sucralfate reduces the risk for late-onset pneumonia in ventilated patients compared with antacid or ranitidine.	CHU VAUDOIS, DIV AUTONOME MED PREVENT HOSP, CH-1011 LAUSANNE, SWITZERLAND; CHU VAUDOIS, DIV PNEUMOL, CH-1011 LAUSANNE, SWITZERLAND; CHU VAUDOIS, DIV GASTROENTEROL, CH-1011 LAUSANNE, SWITZERLAND; CHU VAUDOIS, ANESTHESIOL SERV, CH-1011 LAUSANNE, SWITZERLAND; CHU VAUDOIS, SERV SOINS INTENS MED, CH-1011 LAUSANNE, SWITZERLAND	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)				Blanc, Dominique/0000-0002-0324-8437				ATHERTON ST, 1978, LANCET, V2, P968; BLANC DS, 1993, J CLIN MICROBIOL, V31, P71, DOI 10.1128/JCM.31.1.71-77.1993; BRANDL M, 1984, ANESTHESIA, V34, P257; CHASTRE J, 1988, AM J MED, V85, P499; COLARDYN F, 1990, INTENS CARE MED, V16, pS18; COOK DJ, 1991, AM J MED, V91, P519, DOI 10.1016/0002-9343(91)90189-5; CROSS AS, 1981, AM J MED, V70, P681, DOI 10.1016/0002-9343(81)90596-9; DASCHNER F, 1988, INFECT CONT HOSP EP, V9, P59, DOI 10.1086/645786; DONOWITZ LG, 1986, INFECT CONT HOSP EP, V7, P23, DOI 10.1017/S0195941700063748; DRIKS MR, 1987, NEW ENGL J MED, V317, P1376, DOI 10.1056/NEJM198711263172204; DUMOULIN GC, 1982, LANCET, V1, P242; EDDLESTON JM, 1991, CRIT CARE MED, V19, P1491, DOI 10.1097/00003246-199112000-00009; FAGON JY, 1989, AM REV RESPIR DIS, V139, P877, DOI 10.1164/ajrccm/139.4.877; FLAHERTY J, 1990, J INFECT DIS, V162, P1393, DOI 10.1093/infdis/162.6.1393; FORSTER A, 1982, NOUV PRESSE MED, V11, P2281; GARCIALABATTUT A, 1990, CRIT CARE MED S1, V16, pS19; GARVEY BM, 1989, CRIT CARE MED, V17, P211, DOI 10.1097/00003246-198903000-00002; GOULARTE TA, 1986, AM J INFECT CONTROL, V14, P88; HILLMAN KM, 1982, CRIT CARE MED, V10, P444, DOI 10.1097/00003246-198207000-00005; INGLIS TJJ, 1993, LANCET, V341, P911, DOI 10.1016/0140-6736(93)91208-4; JACOBS S, 1990, JPEN-PARENTER ENTER, V14, P353, DOI 10.1177/0148607190014004353; JEHLE EC, 1990, Z GASTROENTEROL, V28, P315; KAHN RJ, 1982, CRIT CARE MED, V10, P229, DOI 10.1097/00003246-198203000-00109; KAPPSTEIN I, 1991, AM J MED, V91, pS125, DOI 10.1016/0002-9343(91)90464-9; KAPPSTEIN I, 1987, EUR J CLIN MICROBIOL, V6, P216, DOI 10.1007/BF02018225; Karlstadt R, 1989, AM J GASTROENTEROL, V84, P1162; KERVER AJH, 1988, CRIT CARE MED, V16, P1087, DOI 10.1097/00003246-198811000-00001; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LACROIX J, 1989, CRIT CARE MED, V17, P862, DOI 10.1097/00003246-198909000-00003; LANGER M, 1989, AM REV RESPIR DIS, V140, P302, DOI 10.1164/ajrccm/140.2.302; LANGER M, 1987, INTENS CARE MED, V13, P342; LEDINGHAM IM, 1988, LANCET, V1, P785; LOWY FD, 1987, INFECT CONT HOSP EP, V8, P245, DOI 10.1017/S0195941700066121; MAHUL P, 1992, INTENS CARE MED, V18, P20, DOI 10.1007/BF01706421; MARTINETTI G, 1990, RES MICROBIOL, V141, P1151, DOI 10.1016/0923-2508(90)90088-8; MCCARTHY DM, 1991, NEW ENGL J MED, V325, P1017; Peura D A, 1987, Am J Med, V83, P3, DOI 10.1016/0002-9343(87)90804-7; PINGLETON SK, 1986, AM J MED, V80, P827, DOI 10.1016/0002-9343(86)90623-6; PUGIN J, 1991, JAMA-J AM MED ASSOC, V265, P2704, DOI 10.1001/jama.265.20.2704; PUGIN J, 1991, AM REV RESPIR DIS, V143, P1121, DOI 10.1164/ajrccm/143.5_Pt_1.1121; REUSSER P, 1989, J INFECT DIS, V160, P414, DOI 10.1093/infdis/160.3.414; RUDDELL WSJ, 1980, LANCET, V1, P672; RYAN P, 1990, Critical Care Medicine, V18, pS253, DOI 10.1097/00003246-199012001-00148; SALATA RA, 1987, AM REV RESPIR DIS, V135, P426; SCHUSTER DP, 1984, AM J MED, V76, P623, DOI 10.1016/0002-9343(84)90286-9; SIMMS HH, 1991, J TRAUMA, V31, P531, DOI 10.1097/00005373-199104000-00013; SIMON RH, 1986, CARDIOPULMONARY CRIT, P1; STANNARD VA, 1988, BRIT MED J, V296, P155, DOI 10.1136/bmj.296.6616.155; STOUTENBEEK CP, 1984, INTENS CARE MED, V10, P185, DOI 10.1007/BF00259435; STOUTENBEEK CP, 1984, J ANTIMICROB CHEMOTH, V14, P203, DOI 10.1093/jac/14.suppl_B.203; TETTEROO GWM, 1990, LANCET, V335, P704, DOI 10.1016/0140-6736(90)90813-K; TORRES A, 1992, ANN INTERN MED, V116, P540, DOI 10.7326/0003-4819-116-7-540; TRYBA M, 1991, CRIT CARE MED, V19, P942, DOI 10.1097/00003246-199107000-00020; TRYBA M, 1991, AM J MED, V91, pS135, DOI 10.1016/0002-9343(91)90466-B; TRYBA M, 1987, AM J MED, V83, P117, DOI 10.1016/0002-9343(87)90840-0; TRYBA M, 1987, AM J MED, V83, P125, DOI 10.1016/0002-9343(87)90841-2; ULRICH C, 1989, INTENS CARE MED, V15, P424, DOI 10.1007/BF00255597; UNERTL K, 1987, INTENS CARE MED, V13, P106; WILCOX CM, 1988, AM J GASTROENTEROL, V83, P1199; WINTER R, 1989, INTENS CARE MED, V15, P479, DOI 10.1007/BF00255609	60	245	249	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1994	120	8					653	662		10.7326/0003-4819-120-8-199404150-00005	http://dx.doi.org/10.7326/0003-4819-120-8-199404150-00005			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE850	8135449				2023-01-03	WOS:A1994NE85000005
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FLUOXETINE LABELING REVISED TO IDENTIFY PHENYTOIN INTERACTION AND TO RECOMMEND AGAINST USE IN NURSING MOTHERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	16	16	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 13	1994	271	14					1067	1067		10.1001/jama.271.14.1067	http://dx.doi.org/10.1001/jama.271.14.1067			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE228	8151837				2023-01-03	WOS:A1994NE22800007
J	SIKKEMA, J; DEBONT, JAM; POOLMAN, B				SIKKEMA, J; DEBONT, JAM; POOLMAN, B			INTERACTIONS OF CYCLIC HYDROCARBONS WITH BIOLOGICAL-MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; PROTON-MOTIVE FORCE; NATIVE MEMBRANES; PARTITION-COEFFICIENTS; CYTOPLASMIC MEMBRANES; ANESTHETICS; FLUIDITY; PHOSPHOLIPIDS; LIPOSOMES; VESICLES	Many cyclic hydrocarbons, e.g. aromatics, cycloalkanes, and terpenes, are toxic to microorganisms. The primary site of the toxic action is probably the cytoplasmic membrane, but the mechanism of the toxicity is still poorly understood. The effects of cyclic hydrocarbons were studied in liposomes prepared from Escherichia coli phospholipids. The membrane-buffer partition coefficients of the cyclic hydrocarbons revealed that these lipophilic compounds preferentially reside in the membrane. The partition coefficients closely correlated with the partition coefficients of these compounds in a standard octanol-water system. The accumulation of hydro carbon molecules resulted in swelling of the membrane bilayer, as assessed by the release of fluorescence self-quenching of fluorescent fatty acid and phospholipid analogs. Parallel to the expansion of the membrane, an increase in membrane fluidity was observed. These effects on the integrity of the membrane caused an increased passive flux of protons and carboxyfluorescein. In cytochrome c oxidase containing proteoliposomes, both components of the proton motive force, the pH gradient and the electrical potential, were dissipated with increasing concentrations of cyclic hydrocarbons. The dissipating effect was primarily the result of an increased permeability of the membrane for protons (ions). At higher concentrations, cytochrome c oxidase was also inactivated. The effective concentrations of the different cyclic hydrocarbons correlated with their partition coefficients between the membrane and aqueous phase. The impairment of microbial activity by the cyclic hydrocarbons most likely results from hydrophobic interaction with the membrane, which affects the functioning of the membrane and membrane-embedded proteins.	WAGENINGEN UNIV AGR, DEPT FOOD SCI, DIV IND MICROBIOL, 6700 EV WAGENINGEN, NETHERLANDS; UNIV GRONINGEN, DEPT MICROBIOL, 9750 AA HAREN, NETHERLANDS	Wageningen University & Research; University of Groningen			Poolman, Bert/D-1882-2012					ANTUNESMADEIRA MC, 1986, BIOCHIM BIOPHYS ACTA, V861, P159, DOI 10.1016/0005-2736(86)90414-1; ANTUNESMADEIRA MC, 1989, BIOCHIM BIOPHYS ACTA, V982, P161, DOI 10.1016/0005-2736(89)90187-9; ANTUNESMADEIRA MC, 1985, BIOCHIM BIOPHYS ACTA, V820, P165, DOI 10.1016/0005-2736(85)90109-9; ANTUNESMADEIRA MC, 1987, BIOCHIM BIOPHYS ACTA, V901, P61, DOI 10.1016/0005-2736(87)90256-2; ANTUNESMADEIRA MC, 1984, BIOCHIM BIOPHYS ACTA, V778, P49, DOI 10.1016/0005-2736(84)90446-2; CARTWRIGHT CP, 1986, J GEN MICROBIOL, V132, P369; Chapman D., 1984, LIPOSOME TECHNOLOGY, V1, P1; CLEMENT NR, 1981, BIOCHEMISTRY-US, V20, P1534, DOI 10.1021/bi00509a019; DESMET MJ, 1978, BIOCHIM BIOPHYS ACTA, V506, P64, DOI 10.1016/0005-2736(78)90435-2; DEVRIJ W, 1988, J BACTERIOL, V170, P2359, DOI 10.1128/jb.170.5.2359-2366.1988; DEYOUNG LR, 1988, BIOCHEMISTRY-US, V27, P5281, DOI 10.1021/bi00414a050; Eastcott L., 1988, OIL CHEM POLLUT, V4, P191, DOI DOI 10.1016/S0269-8579(88)80020-0; ELFERINK MGL, 1992, J BIOL CHEM, V267, P1375; FRANKS NP, 1987, TRENDS PHARMACOL SCI, V8, P169, DOI 10.1016/0165-6147(87)90160-X; HINKLE PC, 1972, J BIOL CHEM, V247, P1338; HOEKSTRA D, 1984, BIOCHEMISTRY-US, V23, P5675, DOI 10.1021/bi00319a002; KAGAWA Y, 1971, J BIOL CHEM, V235, P769; KATZ Y, 1974, J MEMBRANE BIOL, V17, P69, DOI 10.1007/BF01870173; LABELLA FS, 1981, CAN J PHYSIOL PHARM, V59, P432, DOI 10.1139/y81-067; LEAO C, 1984, BIOCHIM BIOPHYS ACTA, V774, P43, DOI 10.1016/0005-2736(84)90272-4; LENTZ BR, 1989, CHEM PHYS LIPIDS, V50, P171, DOI 10.1016/0009-3084(89)90049-2; LEO A, 1971, CHEM REV, V71, P525, DOI 10.1021/cr60274a001; LIDE K, 1992, HDB CHEM PHYSICS; LIEB WR, 1986, TRANSPORT DIFFUSION, P69; LOLKEMA JS, 1982, BIOCHIM BIOPHYS ACTA, V681, P85, DOI 10.1016/0005-2728(82)90281-X; MACHLEIDT H, 1972, BIOCHIM BIOPHYS ACTA, V255, P178, DOI 10.1016/0005-2736(72)90020-X; Overton E., 1897, Z PHYS CHEM, V22, P189; REKKER RF, 1979, EUR J MED CHEM, V14, P479; Rekker RF., 1977, HYDROPHOBIC FRAGMENT; Riddick J. A., 1986, ORGANIC SOLVENTS, VII; ROTTENBERG H, 1990, BIOCHIM BIOPHYS ACTA, V1018, P1, DOI 10.1016/0005-2728(90)90103-B; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; SEEMAN P, 1971, BIOCHIM BIOPHYS ACTA, V225, P171, DOI 10.1016/0005-2736(71)90210-0; SEEMAN P, 1972, PHARMACOL REV, V24, P583; SHINITZKY M, 1978, BIOCHIM BIOPHYS ACTA, V515, P367, DOI 10.1016/0304-4157(78)90010-2; Sikkema J., 1991, Biodegradation, V2, P15, DOI 10.1007/BF00122421; SIKKEMA J, 1992, J BACTERIOL, V174, P2986, DOI 10.1128/JB.174.9.2986-2992.1992; SMITH MR, 1993, BIOCH MICROBIAL DEGR, P347; Tomlinson E, 1986, PARTITION COEFFICIEN, P101; URIBE S, 1990, APPL ENVIRON MICROB, V56, P2114, DOI 10.1128/AEM.56.7.2114-2119.1990; URIBE S, 1985, J BACTERIOL, V161, P1195, DOI 10.1128/JB.161.3.1195-1200.1985; VELD GI, 1991, BIOCHIM BIOPHYS ACTA, V1065, P203, DOI 10.1016/0005-2736(91)90231-V; VELD GI, 1992, BIOCHIM BIOPHYS ACTA, V1104, P250; Verschueren K., 1983, HDB ENV DATA ORGANIC; YEAGLE PL, 1989, FASEB J, V3, P1833, DOI 10.1096/fasebj.3.7.2469614	45	825	883	1	115	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8022	8028						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132524				2023-01-03	WOS:A1994NB40900032
J	APPLEBY, P; BAIGENT, C; COLLINS, R; FLATHER, M; PARISH, S; PETO, R; BELL, P; HALLS, H; MEAD, G; DIAZ, R; PAOLASSO, E; PAVIOTTI, C; ROMERO, G; CAMPBELL, T; OROURKE, MF; THOMPSON, P; LESAFFRE, E; VANDEWERF, F; VERSTRAETE, M; ARMSTRONG, PW; CAIRNS, JA; MORAN, C; TURPIE, AG; YUSUF, S; GRANDE, P; HEIKKILA, J; KALA, R; BASSAND, JP; BOISSEL, JP; BROCHIER, M; LEIZOROVICZ, A; BRUGGEMANN, T; KARSCH, KR; KASPER, W; LAMMERTS, D; NEUHAUS, KL; MEYER, J; SCHRODER, R; VONESSEN, R; SARAN, RK; ARDISSINO, D; BONADUCE, D; BRUNELLI, C; CERNIGLIARO, C; FORESTI, A; FRANZOSI, MG; GUIDUCCI, D; MAGGIONI, A; MAGNANI, B; MATTIOLI, G; ROSSI, P; SAONTRO, E; TOGNONI, G; VISANI, L; ZENNARO, RG; KANEMOTO, N; KAWAI, C; ARNOLD, AER; BAR, FW; SIMOONS, ML; VERHEUGT, FWA; VERMEER, F; WHITE, HD; SEABRAGOMES, R; FIGUERAS, J; LOPEZSENDON, J; GRIP, L; HERLITZ, J; KARLSSON, JE; WALLENTIN, L; MONNIER, P; ADAMS, PC; BEEN, M; CHAMBERLAIN, DA; DEBONO, D; DOLL, R; DUFF, D; FOX, KAA; SREEHARAN, N; HILLIS, WS; JULIAN, DG; MALCOLM, A; MURRAY, RG; PATTERSON, DLH; POCOCK, S; REID, DS; SANDERCOCK, P; SIGWART, U; SKELDING, J; SKENE, A; SLEIGHT, P; TIMMIS, A; WARLOW, C; WILCOX, RG; ALLEN, A; ANDERSON, J; BRAUNWALD, E; CALIFF, R; GOLD, HK; GRANETT, J; GRAINGER, C; GUERCI, AD; HENNEKENS, C; HONAN, MB; KENNEDY, JW; KNATTERUD, G; LEE, K; LEIMBERGER, J; LENERT, LA; LITTLEJOHN, J; MAYNARD, C; NICKLAS, J; OHMAN, M; OLSON, HG; PASSAMANI, E; RYAN, TJ; SELKER, HP; STUMP, D; TOPOL, EJ; WEAVER, WD; WILLIAMS, DO; WOODLIEF, L				APPLEBY, P; BAIGENT, C; COLLINS, R; FLATHER, M; PARISH, S; PETO, R; BELL, P; HALLS, H; MEAD, G; DIAZ, R; PAOLASSO, E; PAVIOTTI, C; ROMERO, G; CAMPBELL, T; OROURKE, MF; THOMPSON, P; LESAFFRE, E; VANDEWERF, F; VERSTRAETE, M; ARMSTRONG, PW; CAIRNS, JA; MORAN, C; TURPIE, AG; YUSUF, S; GRANDE, P; HEIKKILA, J; KALA, R; BASSAND, JP; BOISSEL, JP; BROCHIER, M; LEIZOROVICZ, A; BRUGGEMANN, T; KARSCH, KR; KASPER, W; LAMMERTS, D; NEUHAUS, KL; MEYER, J; SCHRODER, R; VONESSEN, R; SARAN, RK; ARDISSINO, D; BONADUCE, D; BRUNELLI, C; CERNIGLIARO, C; FORESTI, A; FRANZOSI, MG; GUIDUCCI, D; MAGGIONI, A; MAGNANI, B; MATTIOLI, G; ROSSI, P; SAONTRO, E; TOGNONI, G; VISANI, L; ZENNARO, RG; KANEMOTO, N; KAWAI, C; ARNOLD, AER; BAR, FW; SIMOONS, ML; VERHEUGT, FWA; VERMEER, F; WHITE, HD; SEABRAGOMES, R; FIGUERAS, J; LOPEZSENDON, J; GRIP, L; HERLITZ, J; KARLSSON, JE; WALLENTIN, L; MONNIER, P; ADAMS, PC; BEEN, M; CHAMBERLAIN, DA; DEBONO, D; DOLL, R; DUFF, D; FOX, KAA; SREEHARAN, N; HILLIS, WS; JULIAN, DG; MALCOLM, A; MURRAY, RG; PATTERSON, DLH; POCOCK, S; REID, DS; SANDERCOCK, P; SIGWART, U; SKELDING, J; SKENE, A; SLEIGHT, P; TIMMIS, A; WARLOW, C; WILCOX, RG; ALLEN, A; ANDERSON, J; BRAUNWALD, E; CALIFF, R; GOLD, HK; GRANETT, J; GRAINGER, C; GUERCI, AD; HENNEKENS, C; HONAN, MB; KENNEDY, JW; KNATTERUD, G; LEE, K; LEIMBERGER, J; LENERT, LA; LITTLEJOHN, J; MAYNARD, C; NICKLAS, J; OHMAN, M; OLSON, HG; PASSAMANI, E; RYAN, TJ; SELKER, HP; STUMP, D; TOPOL, EJ; WEAVER, WD; WILLIAMS, DO; WOODLIEF, L			INDICATIONS FOR FIBRINOLYTIC THERAPY IN SUSPECTED ACUTE MYOCARDIAL-INFARCTION - COLLABORATIVE OVERVIEW OF EARLY MORTALITY AND MAJOR MORBIDITY RESULTS FROM ALL RANDOMIZED TRIALS OF MORE THAN 1000 PATIENTS	LANCET			English	Article							LEFT-VENTRICULAR FUNCTION; THROMBOLYTIC THERAPY; INTRAVENOUS STREPTOKINASE; INTRACRANIAL HEMORRHAGE; SYSTEMATIC OVERVIEWS; REPERFUSION; SELECTION; STROKE; METAANALYSIS; ANGIOPLASTY	Large randomised trials have demonstrated that fibrinolytic therapy can reduce mortality in patients with suspected acute myocardial infarction (AMI). The indications for, and contraindications to, this treatment in some categories of patient are disputed, examples being late presentation, elderly patients, and those in cardiogenic shock. This overview aims to help resolve some of the remaining uncertainties. From all trials of fibrinolytic therapy versus control that randomised more than 1000 patients with suspected AMI, information was sought and checked on deaths during the first 5 weeks and on major adverse events occurring during hospitalisation. The nine trials included 58 600 patients, among whom 6177 (10.5%) deaths, 564 (1.0%) strokes, and 436 (0.7%) major non-cerebral bleeds were reported. Fibrinolytic therapy was associated with an excess of deaths during days 0-1 (especially among patients presenting more than 1.2 h after symptom onset, and in the elderly) but this was outweighed by a much larger benefit during days 2-35. This ''early hazard'' should not obscure the very clear overall survival advantage that is produced by fibrinolytic therapy. Benefit was observed among patients presenting with ST elevation or bundle-branch block (BBB)-irrespective of age, sex, blood pressure, heart rate, or previous history of myocardial infarction or diabetes and was greater the earlier treatment began. Among the 45 000 patients presenting with ST elevation or BBB the relation between benefit and delay from symptom onset indicated highly significant absolute mortality reductions of about 30 per 1000 for those presenting within 0-6 h and of about 20 per 1600 for those presenting 7-12 h from onset, and a statistically uncertain benefit of about 10 per 1000 for those presenting at 13-18 h (with more randomised evidence needed in this latter group to assess reliably the net effects of treatment). Fibrinolytic therapy was associated with about 4 extra strokes per 1000 during days 0-1: of these, 2 were associated with early death and so were already accounted for in the overall mortality reduction, 1 was moderately or severely disabling, and 1 was not. This overview indicates that fibrinolytic therapy is beneficial in a much wider range of patients than is currently given such treatment routinely.			APPLEBY, P (corresponding author), RADCLIFFE INFIRM, NUFFIELD DEPT CLIN MED,ICRF,MRC,BHF, CLIN TRIAL SERV UNIT, OXFORD OX2 6HE, ENGLAND.		Maynard, Charles/N-3906-2015; Ardissino, Diego/AAC-4041-2022; Fox, keith A A/I-3742-2013; Thompson, Peter L/P-1071-2014; Verheugt, F.W.A./H-8105-2014; sandercock, peter/GQI-3167-2022; Cairns, John/AAI-8744-2021	Maynard, Charles/0000-0002-1644-7814; sandercock, peter/0000-0001-8484-0135; 				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1989, LANCET, V2, P655; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1993, Lancet, V342, P767; [Anonymous], 1986, Lancet, V1, P397; BAIGENT C, 1993, CIRCULATION, V88, P291; BATES ER, 1991, J AM COLL CARDIOL, V18, P1077, DOI 10.1016/0735-1097(91)90770-A; BATES ER, 1988, J AM COLL CARDIOL, V12, pA44, DOI 10.1016/0735-1097(88)92640-X; BATES ER, 1989, J AM COLL CARDIOL, V13, P12, DOI 10.1016/0735-1097(89)90542-1; BRAUNWALD E, 1989, CIRCULATION, V79, P441, DOI 10.1161/01.CIR.79.2.441; BRAUNWALD E, 1985, J CLIN INVEST, V76, P1713, DOI 10.1172/JCI112160; BRAUNWALD E, 1990, CIRCULATION, V82, P1510, DOI 10.1161/01.CIR.82.4.1510; CALIFF RM, 1989, J AM COLL CARDIOL, V13, P1130, DOI 10.1016/0735-1097(89)90274-X; CHAMBERLAIN DA, 1988, LANCET, V1, P545; CHAMBERLAIN DA, 1990, LANCET, V335, P427; CHAPMAN GD, 1993, AM J CARDIOL, V71, P783, DOI 10.1016/0002-9149(93)90824-V; COLLINS R, 1987, STAT MED, V6, P245, DOI 10.1002/sim.4780060308; COLLINS R, 1991, BRIT HEART J, V66, P250; COLLINS R, 1991, CIRCULATION, V84, P230; CRAGG DR, 1991, ANN INTERN MED, V115, P173, DOI 10.7326/0003-4819-115-3-173; DEJAEGERE PP, 1992, J AM COLL CARDIOL, V19, P289, DOI 10.1016/0735-1097(92)90480-B; Early Breast Cancer Trialists' Collaborative Group, 1990, TREATMENT EARLY BREA, V1; EFRON B, 1977, SCI AM, V236, P119, DOI 10.1038/scientificamerican0577-119; GORE JM, 1991, CIRCULATION, V83, P448, DOI 10.1161/01.CIR.83.2.448; GRAY D, 1993, LANCET, V341, P654, DOI 10.1016/0140-6736(93)90420-L; GRINES CL, 1990, J AM COLL CARDIOL, V16, P223, DOI 10.1016/0735-1097(90)90482-5; GURWITZ JH, 1991, JAMA-J AM MED ASSOC, V265, P1720, DOI 10.1001/jama.265.13.1720; HAMPTON J, 1993, LANCET, V342, P759; HLATKY MA, 1988, AM J CARDIOL, V61, P510, DOI 10.1016/0002-9149(88)90755-2; HONAN MB, 1990, J AM COLL CARDIOL, V16, P359, DOI 10.1016/0735-1097(90)90586-E; HUNT D, 1992, LANCET, V339, P753; HUTTER AM, 1989, J AM COLL CARDIOL, V13, P1127; KETLEY D, 1993, LANCET, V342, P891, DOI 10.1016/0140-6736(93)91945-I; LANGE RA, 1993, NEW ENGL J MED, V328, P726, DOI 10.1056/NEJM199303113281010; LEW AS, 1987, AM J CARDIOL, V59, P1, DOI 10.1016/S0002-9149(87)80059-0; LOUKINEN K L, 1989, Journal of the American College of Cardiology, V13, p94A; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MAGGIONI AP, 1992, NEW ENGL J MED, V327, P1, DOI 10.1056/NEJM199207023270101; MASSEL DR, 1993, BRIT HEART J, V69, P284; MAURI F, 1987, Giornale Italiano di Cardiologia, V17, P37; MIDGETTE AS, 1990, ANN INTERN MED, V113, P961, DOI 10.7326/0003-4819-113-12-961; MULLER DWM, 1990, ANN INTERN MED, V113, P949, DOI 10.7326/0003-4819-113-12-949; PETO R, 1987, STAT MED, V6, P233, DOI 10.1002/sim.4780060306; PFEFFER MA, 1991, JAMA-J AM MED ASSOC, V266, P528, DOI 10.1001/jama.266.4.528; ROSSI P, 1991, AM J CARDIOL, V68, P585, DOI 10.1016/0002-9149(91)90348-O; SCHRODER R, 1986, NEW ENGL J MED, V314, P1465; SCHRODER R, 1989, AM J CARDIOL, V64, P878, DOI 10.1016/0002-9149(89)90835-7; SLOAN MA, 1992, AM J CARDIOL, V69, pA21, DOI 10.1016/0002-9149(92)91169-5; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; TOPOL EJ, 1992, NEW ENGL J MED, V327, P45, DOI 10.1056/NEJM199207023270109; WASSERMAN AG, 1989, AM J CARDIOL, V64, pB17, DOI 10.1016/S0002-9149(89)80004-9; WEAVER WD, 1991, J AM COLL CARDIOL, V18, P657, DOI 10.1016/0735-1097(91)90784-7; WHITE HD, 1992, LANCET, V340, P221, DOI 10.1016/0140-6736(92)90478-L; WILCOX RG, 1988, LANCET, V2, P525; WILCOX RG, 1990, LANCET, V335, P1175; YUSUF S, 1985, EUR HEART J, V6, P556, DOI 10.1093/oxfordjournals.eurheartj.a061905; 1989, LANCET, V2, P899; 1987, LANCET, V2, P872	58	2181	2249	2	29	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 5	1994	343	8893					311	322		10.1016/S0140-6736(94)91161-4	http://dx.doi.org/10.1016/S0140-6736(94)91161-4			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU985	7905143				2023-01-03	WOS:A1994MU98500007
J	TENNANT, F; MOLL, D; DEPAULO, V				TENNANT, F; MOLL, D; DEPAULO, V			TOPICAL MORPHINE FOR PERIPHERAL PAIN	LANCET			English	Letter							INFLAMMATION				TENNANT, F (corresponding author), RES CTR DEPENDENCY DISORDERS & CHRON PAIN,COMMUNITY HLTH PROJECTS,W COVINA,CA 91790, USA.							JORIS JL, 1987, ANESTH ANALG, V66, P1277; JOSHI, 1993, LANCET, V342, P320; JOSHI GP, 1993, ANESTH ANALG, V76, P333; STEIN, 1993, LANCET, V342, P321; STEIN C, 1989, J PHARMACOL EXP THER, V248, P1269	5	15	18	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 23	1993	342	8878					1047	1048		10.1016/0140-6736(93)92900-E	http://dx.doi.org/10.1016/0140-6736(93)92900-E			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD066	8105274				2023-01-03	WOS:A1993MD06600029
J	HAMPTON, J; WILCOX, R; ARMSTRONG, P; AYLWARD, P; BETT, N; CHARBONNIER, B; GULBA, D; HEIKKILA, J; JENSEN, G; LOPEZBESCOS, L; MOULOPOULOS, S; SEABRAGOMES, R; THEROUX, P; TOPOL, E; VANDEWERF, F				HAMPTON, J; WILCOX, R; ARMSTRONG, P; AYLWARD, P; BETT, N; CHARBONNIER, B; GULBA, D; HEIKKILA, J; JENSEN, G; LOPEZBESCOS, L; MOULOPOULOS, S; SEABRAGOMES, R; THEROUX, P; TOPOL, E; VANDEWERF, F			LATE ASSESSMENT OF THROMBOLYTIC EFFICACY (LATE) STUDY WITH ALTEPLASE 6-24 HOURS AFTER ONSET OF ACUTE MYOCARDIAL-INFARCTION	LANCET			English	Article							TISSUE PLASMINOGEN-ACTIVATOR; THERAPY; REPERFUSION; TRIAL	The effect of late thrombolysis in acute myocardial infarction (AMI)-ie, treatment beginning more than 6 h after the onset of symptoms-remains controversial. The Late Assessment of Thrombolytic Efficacy (LATE) study is a large randomised trial designed to resolve this question. 5711 patients with symptoms and electrocardiographic criteria consistent with AMI were randomised double-blind to intravenous alteplase (100 mg over 3 h) or matching placebo, between 6 and 24 h from symptom onset. Both groups received immediate oral aspirin and for later recruits intravenous heparin for 48 h was recommended. All patients were followed up for at least 6 months and 73% were followed up for 1 year. Intention-to-treat analysis of survival revealed a nonsignificant reduction in the alteplase group (397/2836 deaths) compared with placebo (444/2875). 35-day mortality was 8.86% and 10.31%, respectively, a relative reduction of 14.1% (95% CI 0-28.1%). Pre-specified survival analysis according to treatment within 12 h of symptom onset, however, showed a significant reduction in mortality in favour of alteplase: 35-day mortality was 8.90% versus 11.97% for placebo, a relative reduction of 25.6% (p=0.0229, 95% CI 6.3-45.0%). Rates were 8.7% and 9.2%, respectively, for those treated at 12-24 h but subgroup analysis suggests that some patients may benefit even when treated after 12 h. Although treatment with alteplase resulted in an excess of haemorrhagic strokes, by 6 months the number of disabled survivors was the same in both treatment groups and other clinical events were observed with similar frequency in the two groups. We conclude that the time window for thrombolysis with alteplase should be extended to at least 12 h from symptom onset in patients with AMI.	UNIV NOTTINGHAM HOSP, DIV CARDIOVASC MED, NOTTINGHAM NG7 2UH, ENGLAND; ST MICHAELS HOSP, TORONTO M5B 1W8, ONTARIO, CANADA; FLINDERS UNIV S AUSTRALIA, MED CTR, BEDFORD PK, SA 5042, AUSTRALIA; PRINCE CHARLES HOSP, CHERMSIDE, QLD 4032, AUSTRALIA; CLIN CARDIOL TROUSSEAU, Chambray Les Tours, FRANCE; MED HSCH HANNOVER KLINIKEN, HANNOVER, GERMANY; UNIV HELSINKI, CENT HOSP, SF-00100 HELSINKI 10, FINLAND; HVIDOVRE UNIV HOSP, DK-2650 HVIDOVRE, DENMARK; HOSP GREGORIO MARANON, MADRID, SPAIN; ALEXANDRAS MATERN HOSP, ATHENS, GREECE; HOSP SANTA CRUZ, CARNAXIDE, PORTUGAL; MONTREAL HEART INST, MONTREAL H1T 1C8, QUEBEC, CANADA; CLEVELAND CLIN EDUC FDN, CLEVELAND, OH 44106 USA; UNIV ZIEKENHUIS GASTHUISBERG, LOUVAIN, BELGIUM	University of Nottingham; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; Flinders University South Australia; Prince Charles Hospital; Hannover Medical School; University of Helsinki; Helsinki University Central Hospital; University of Copenhagen; General University Gregorio Maranon Hospital; Alexandra Hospital; Universite de Montreal; Cleveland Clinic Foundation; KU Leuven; University Hospital Leuven								[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, Lancet, V1, P397; BEEK AM, 1991, AM J CARDIOL, V68, P1287, DOI 10.1016/0002-9149(91)90232-A; BLEICH SD, 1990, AM J CARDIOL, V66, P1412, DOI 10.1016/0002-9149(90)90525-6; BONADUCE D, 1990, J AM COLL CARDIOL, V16, P1561, DOI 10.1016/0735-1097(90)90301-5; BROWN EJ, 1991, J AM COLL CARDIOL, V17, P1641, DOI 10.1016/0735-1097(91)90660-2; BRUGADA P, 1986, J AM COLL CARDIOL, V8, P1035, DOI 10.1016/S0735-1097(86)80379-5; CHAMBERLAIN DA, 1988, LANCET, V1, P545; COLLEN D, 1983, J CLIN INVEST, V71, P368, DOI 10.1172/JCI110778; GRIECO A, 1984, HEALTH PSYCHOL, V3, P129, DOI 10.1037/0278-6133.3.2.129; HOCHMAN JS, 1987, CIRCULATION, V75, P299, DOI 10.1161/01.CIR.75.1.299; HSIA J, 1990, NEW ENGL J MED, V323, P1433, DOI 10.1056/NEJM199011223232101; HUNT D, 1992, LANCET, V339, P753; MULLER DWM, 1990, ANN INTERN MED, V113, P949, DOI 10.7326/0003-4819-113-12-949; MURRAY N, 1987, BRIT HEART J, V57, P144; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; RENTROP KP, 1989, J AM COLL CARDIOL, V14, P58, DOI 10.1016/0735-1097(89)90054-5; TOPOL EJ, 1992, CIRCULATION, V85, P2090, DOI 10.1161/01.CIR.85.6.2090; VANDEWERF F, 1990, LANCET, V336, P71; WHITE HD, 1992, LANCET, V340, P221, DOI 10.1016/0140-6736(92)90478-L; WILCOX RG, 1988, LANCET, V2, P525; YATEMAN NA, 1993, STAT MED, V12, P1365, DOI 10.1002/sim.4780121208; 1991, MAR AM COLL CARD 40T	23	361	364	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 25	1993	342	8874					759	766						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LY868	8103874				2023-01-03	WOS:A1993LY86800007
J	THOMAS, SHL; BATCHELOR, S; ODOHERTY, MJ				THOMAS, SHL; BATCHELOR, S; ODOHERTY, MJ			THERAPEUTIC AEROSOLS IN CHILDREN	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NEONATAL VENTILATOR CIRCUITS; DELIVERY; LUNG; NEBULIZERS; DEPOSITION; INSULIN	The use and variety of drugs administered to children as inhaled aerosols is increasing, but little is known about how much drug reaches the lung and how it is distributed there in different age groups. In this article the reasons for measuring aerosol deposition in children are discussed and the potential methods for doing this described. Of the methods available, only the use of radiolabelled aerosols gives accurate information on total lung deposition and distribution. The potential risk of the radiation exposure required for these measurements varies with the age of the child but seems to be small. Properly designed studies are expected to clarify the factors affecting lung deposition in children and identify methods of inhalation associated with efficient and predictable delivery of the drug. Measurements of radioaerosol deposition may therefore be justified in children when this information is expected to lead to improvements in the effectiveness or safety of their treatment.	ST THOMAS HOSP, GUYS & ST THOMAS HOSP TRUST, MED PHYS DIRECTORATE, LONDON SE1 7EH, ENGLAND; ST THOMAS HOSP, GUYS & ST THOMAS HOSP TRUST, DEPT NUCL MED, LONDON SE1 7EH, ENGLAND	Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust	THOMAS, SHL (corresponding author), NEWCASTLE UNIV, WOLFSON DEPT CLIN PHARMACOL, NEWCASTLE UPON TYNE NE1 4LP, ENGLAND.							AHRENS RC, 1986, PEDIATR PULM, V2, P19, DOI 10.1002/ppul.1950020108; ALDERSON PO, 1974, J PEDIATR-US, V84, P479, DOI 10.1016/S0022-3476(74)80664-5; [Anonymous], 1991, Ann ICRP, V21, P1; BLACKHALL MI, 1987, EUR J RESPIR DIS, V71, P96; BORGSTROM L, 1990, PHARMACEUT RES, V7, P1068, DOI 10.1023/A:1015951402799; CAMERON D, 1990, CRIT CARE MED, V18, P866, DOI 10.1097/00003246-199008000-00015; CAMERON D, 1990, PAEDIATRIC PULMONOLO, V10, P208; CHUA HL, 1991, AM REV RESPIR DIS, V43, pA706; COLLIS GG, 1990, LANCET, V336, P341, DOI 10.1016/0140-6736(90)91880-J; COLTHORPE P, 1992, PHARMACEUT RES, V9, P764, DOI 10.1023/A:1015851521551; DAHLBACK M, 1989, J AEROSOL MED, V2, P339; DAVIES DS, 1984, EUR J RESPIR DIS, V65, P141; ELLIOTT RB, 1987, AUST PAEDIATR J, V23, P293; EVERARD ML, 1992, ARCH DIS CHILD, V67, P586, DOI 10.1136/adc.67.5.586; EVERARD ML, 1992, ARCH DIS CHILD-FETAL, V67, P826, DOI 10.1136/adc.67.7_Spec_No.826; HINDLE M, 1992, BRIT J CLIN PHARMACO, V34, P311, DOI 10.1111/j.1365-2125.1992.tb05921.x; HUNG OR, 1993, CLIN PHARMACOL THER, V53, P207; LESOUEF PN, 1992, LANCET, V339, P1282, DOI 10.1016/0140-6736(92)91602-5; ODOHERTY MJ, 1993, THORAX, V48, P220, DOI 10.1136/thx.48.3.220; SALMON B, 1990, ARCH DIS CHILD, V65, P401, DOI 10.1136/adc.65.4.401; SILVERMAN M, 1990, ARCH DIS CHILD, V65, P906, DOI 10.1136/adc.65.8.906; THOMAS SHL, 1991, CLIN SCI, V81, P767, DOI 10.1042/cs0810767; WILKIE RA, 1987, J PEDIATR-US, V111, P278, DOI 10.1016/S0022-3476(87)80087-2; WOLFSDORF J, 1969, PEDIATRICS, V43, P799; 1988, SERIES MBI, V16; 1987, ANN ICRP, V18, P219; 1989, SERIES DH2, V14	27	7	7	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 24	1993	307	6898					245	247		10.1136/bmj.307.6898.245	http://dx.doi.org/10.1136/bmj.307.6898.245			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LP314	8369692	Bronze, Green Published			2023-01-03	WOS:A1993LP31400031
J	LEVITT, M; WARR, D; YELLE, L; RAYNER, HL; LOFTERS, WS; PERRAULT, DJ; WILSON, KS; LATREILLE, J; POTVIN, M; WARNER, E; PRITCHARD, KI; PALMER, M; ZEE, B; PATER, JL				LEVITT, M; WARR, D; YELLE, L; RAYNER, HL; LOFTERS, WS; PERRAULT, DJ; WILSON, KS; LATREILLE, J; POTVIN, M; WARNER, E; PRITCHARD, KI; PALMER, M; ZEE, B; PATER, JL			ONDANSETRON COMPARED WITH DEXAMETHASONE AND METOCLOPRAMIDE AS ANTIEMETICS IN THE CHEMOTHERAPY OF BREAST-CANCER WITH CYCLOPHOSPHAMIDE, METHOTREXATE, AND FLUOROURACIL	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HIGH-DOSE METOCLOPRAMIDE; CISPLATIN-INDUCED EMESIS; DOUBLE-BLIND; SEROTONIN ANTAGONIST; NAUSEA; PROPHYLAXIS; MULTICENTER; PREVENTION; CROSSOVER	Background. Although ondansetron was found to be effective as an antiemetic in numerous clinical trials of highly emetogenic combination-chemotherapy regimens that included cisplatin, its role in milder emetogenic regimens has not been fully defined. To address its use with a widely used but less emetogenic regimen, we performed a double-blind, randomized clinical trial comparing ondansetron with dexamethasone and metoclopramide in patients with breast cancer receiving chemotherapy with cyclophosphamide, methotrexate, and fluorouracil. Methods. A total of 165 women with breast cancer from 14 Canadian centers who were about to receive this chemotherapy for the first time were randomly assigned to receive either ondansetron (n = 85) or dexamethasone plus metoclopramide (n = 80), a widely used, standard antiemetic regimen. The patients recorded the incidence of nausea, emesis, and other side effects in diaries, and these data were compared in the two groups. Results. The patients who received dexamethasone and metoclopramide had significantly less less nausea during the first 24 hours after chemotherapy was wise, there were no statistically significant differences in efficacy between the regimens. The incidence of drowsiness and increased appetite was higher in the group given dexamethasone and metoclopramide. Conclusions. For women with breast cancer who are being treated with cyclophosphamide, methotrexate, and fluorouracil, the efficacy of dexamethasone and metoclopramide in controlling nausea and vomiting equaled or exceeded that of ondansetron.	PRINCESS MARGARET HOSP, TORONTO M4X 1K9, ONTARIO, CANADA; ST MICHAELS HOSP, TORONTO M5B 1W8, ONTARIO, CANADA; TORONTO BAYVIEW REG CANC CTR, TORONTO, ON, CANADA; NOTRE DAME HOSP, MONTREAL, PQ, CANADA; HOP HOTEL DIEU, MONTREAL H2W 1T8, QUEBEC, CANADA; VICTORIA CLIN, BRITISH COLUMBIA CANC AGCY, VICTORIA, BC, CANADA; KINGSTON REG CANC CTR, KINGSTON, ON, CANADA; NATL CANC INST CANADA, CLIN TRIALS GRP, KINGSTON, ON, CANADA; OTTAWA REG CANC CTR, OTTAWA, ON, CANADA; LAVAL HOSP, ST FOY, PQ, CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; Universite de Montreal; Universite de Montreal; British Columbia Cancer Agency; Queens University - Canada; Canadian Cancer Trials Group; University of Ottawa; Ottawa Hospital Research Institute	LEVITT, M (corresponding author), UNIV MANITOBA, MANITOBA CANC TREATMENT & RES FDN, DEPT INTERNAL MED, 100 OLIVIA ST, WINNIPEG R3E 0V9, MANITOBA, CANADA.		Zee, Benny Chung Ying/G-5606-2017; Pritchard, Kathleen I/I-2184-2014	Zee, Benny Chung Ying/0000-0002-7238-845X; Pritchard, Kathleen I/0000-0003-0758-9666				ANDREWS DF, 1971, BIOMETRICS, V27, P825, DOI 10.2307/2528821; BONNETERRE J, 1990, J CLIN ONCOL, V8, P1063, DOI 10.1200/JCO.1990.8.6.1063; BUSER K, 1990, P AN M AM SOC CLIN, V9, P331; CANELLOS GP, 1976, CANCER, V38, P1882, DOI 10.1002/1097-0142(197611)38:5<1882::AID-CNCR2820380503>3.0.CO;2-H; CUBEDDU LX, 1990, J CLIN ONCOL, V8, P1721, DOI 10.1200/JCO.1990.8.10.1721; Demulder PHM, 1990, ANN INTERN MED, V113, P834, DOI 10.7326/0003-4819-113-11-834; FETTING JH, 1982, CANCER TREAT REP, V66, P1487; GRUNBERG SM, 1990, NEW ENGL J MED, V322, P846, DOI 10.1056/NEJM199003223221211; HAINSWORTH J, 1991, J CLIN ONCOL, V9, P721, DOI 10.1200/JCO.1991.9.5.721; HESKETH PJ, 1991, J NATL CANCER I, V83, P613, DOI 10.1093/jnci/83.9.613; JONES AL, 1991, LANCET, V338, P483, DOI 10.1016/0140-6736(91)90554-3; LANDIS JR, 1988, STAT MED, V7, P109, DOI 10.1002/sim.4780070114; MARTY M, 1990, NEW ENGL J MED, V322, P816, DOI 10.1056/NEJM199003223221205; PATER JL, 1991, EJC SUPPL, V27, pS298; ROILA F, 1991, J CLIN ONCOL, V9, P675, DOI 10.1200/JCO.1991.9.4.675; TANNOCK IF, 1988, J CLIN ONCOL, V6, P1377, DOI 10.1200/JCO.1988.6.9.1377; WILLAN AR, 1991, EFFECT CANCER QUALIT, P229	17	69	71	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 15	1993	328	15					1081	1084		10.1056/NEJM199304153281503	http://dx.doi.org/10.1056/NEJM199304153281503			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KX178	8455665				2023-01-03	WOS:A1993KX17800003
J	Bonn, D				Bonn, D			What prospects for hormonal contraceptives for men?	LANCET			English	News Item																			0	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 3	1996	347	8997					316	316		10.1016/S0140-6736(96)90482-1	http://dx.doi.org/10.1016/S0140-6736(96)90482-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT485	8569371				2023-01-03	WOS:A1996TT48500023
J	MILLER, FH				MILLER, FH			INFANT RESUSCITATION, A US UK DIVIDE	LANCET			English	Editorial Material											MILLER, FH (corresponding author), BOSTON UNIV,SCH LAW,BOSTON,MA 02215, USA.							BRAHAMS D, 1992, LANCET, V339, P1472, DOI 10.1016/0140-6736(92)92052-H	1	2	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 25	1994	343	8913					1584	1585		10.1016/S0140-6736(94)93051-1	http://dx.doi.org/10.1016/S0140-6736(94)93051-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU354	7911914				2023-01-03	WOS:A1994NU35400004
J	PETRONIS, KR; CARROLL, CE; HELD, PJ; PORT, FK				PETRONIS, KR; CARROLL, CE; HELD, PJ; PORT, FK			EFFECT OF RACE ON ACCESS TO RECOMBINANT-HUMAN-ERYTHROPOIETIN IN LONG-TERM HEMODIALYSIS-PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIALYSIS	Objective.-To quantify access to recombinant human erythropoietin (EPO) among patients with dialysis-dependent end-stage renal disease (ESRD). Design.-National random sample of hemodialysis patients from a random sample of dialysis units, using data abstracted from patients' medical records. Setting.-All US hemodialysis units. Participants.-A total of 4024 Medicare-entitled in-center hemodialysis patients. Main Outcome Measures.-The relative odds that black patients received EPO (compared with white patients). Results.-There was no evidence in this national study that black hemodialysis patients were more or less likely to receive EPO than white patients (P=.74) Conclusions.-Three years after Food and Drug Administration approval and Medicare coverage of EPO, there was no evidence of racial disparity in access to EPO among Medicare patients with ESRD who were receiving long-term hemodialysis. However, there was evidence of greater need for EPO among black patients.	URBAN INST,CTR HLTH POLICY,WASHINGTON,DC; UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,ANN ARBOR,MI; UNIV MICHIGAN,SCH PUBL HLTH,DEPT EPIDEMIOL,ANN ARBOR,MI 48109	Urban Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [N01DK082234] Funding Source: NIH RePORTER; NIDDK NIH HHS [N01-DK-8-2234] Funding Source: Medline; PHS HHS [17-C-90085/3-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		DAUGIRDAS JT, 1993, AM J KIDNEY DIS, V22, P267, DOI 10.1016/S0272-6386(12)70317-7; GAYLIN DS, 1993, JAMA-J AM MED ASSOC, V269, P603, DOI 10.1001/jama.269.5.603; GOTCH FA, 1985, KIDNEY INT, V28, P526, DOI 10.1038/ki.1985.160; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; POWE NR, 1992, JAMA-J AM MED ASSOC, V268, P1434, DOI 10.1001/jama.268.11.1434; 1991, USRDS1991 NIH NAT I, pCH2; 1993, USRDS1993 NIH NAT I, pCH11; 1991, USRDS1991 NIH NAT I, pCH11	9	21	21	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 8	1994	271	22					1760	1763		10.1001/jama.271.22.1760	http://dx.doi.org/10.1001/jama.271.22.1760			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN725	8196119				2023-01-03	WOS:A1994NN72500025
J	KELLERMANN, AL; CONWAY, C; WOLCOTT, R; HACKMAN, BB; BOGAN, S; BERNSTEIN, E; FISH, S; KERL, T; MITCHELL, T; RAMSEY, C; KELEN, GD; SHAHAN, JB; OSBORN, H; BAZAN, L; HARGARTEN, S; LAURENCE, S; HEDGES, JR; HENKEL, G; WINTER, S; YEKRANG, A; BINDER, L; KEMPTON, B; HARRIMAN, D; WINTEMUTE, G; SMITH, H; HAMILTON, G; MORRIS, L				KELLERMANN, AL; CONWAY, C; WOLCOTT, R; HACKMAN, BB; BOGAN, S; BERNSTEIN, E; FISH, S; KERL, T; MITCHELL, T; RAMSEY, C; KELEN, GD; SHAHAN, JB; OSBORN, H; BAZAN, L; HARGARTEN, S; LAURENCE, S; HEDGES, JR; HENKEL, G; WINTER, S; YEKRANG, A; BINDER, L; KEMPTON, B; HARRIMAN, D; WINTEMUTE, G; SMITH, H; HAMILTON, G; MORRIS, L			ACCESS OF MEDICAID RECIPIENTS TO OUTPATIENT CARE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PUBLIC HOSPITAL EMERGENCY; CONSEQUENCES	Background. Visits to the emergency department by Medicaid recipients for nonemergency problems are common and contribute to rising health care costs. However, such patients may have few alternatives. We conducted a telephone survey of 953 ambulatory care sites in 10 cities to determine the availability of appointments for Medicaid recipients with common problems. Methods. Research assistants telephoned all ambulatory care clinics and a stratified sample of private primary care practices in the catchment area served by the hospital emergency department in each city. The assistants identified themselves as Medicaid recipients seeking care for one of three problems (low back pain, dysuria, or sore throat) and asked a standardized series of questions. Data were collected on appointments or walk-in visits authorized at any time, within two days after the call, or after 5 p.m.; copayment requirements; and reasons appointments could not be made. If an appointment was made, it was canceled at the end of each call or shortly thereafter. Several weeks later, private-practice sites in six of the cities were recontacted; the research assistants identified themselves as patients with private insurance and the same problem. Results. An appointment or an authorization for a walk-in visit was obtained from 418 of the 953 practice sites (44 percent); 47 of the sites (5 percent) could not be contacted. Appointment rates for the different types of sites ranged from 72 percent for free-standing urgent care centers to 34 percent for private practices. ''Not accepting Medicaid'' was the most common reason given for not granting an appointment or walk-in visit. Only 72 of the sites (8 percent) offered after-hours care within two working days after the call without a cash copayment. Sixty percent of the 330 private practices that were recontacted agreed to see a patient with private insurance within two working days, but only 26 percent agreed to see a patient with Medicaid within two days (P<0.001). Conclusions. Medicaid recipients in urban areas have limited access to outpatient care apart from that offered by hospital emergency departments.	UNIV TENNESSEE,MEMPHIS,TN; BOSTON UNIV,BOSTON,MA 02215; UNIV S FLORIDA,TAMPA,FL; JOHNS HOPKINS UNIV,BALTIMORE,MD; NEW YORK MED COLL,BRONX,NY; MED COLL WISCONSIN,MILWAUKEE,WI 53226; OREGON HLTH SCI UNIV,PORTLAND,OR 97201; TEXAS TECH UNIV,EL PASO,TX; UNIV CALIF DAVIS,SACRAMENTO,CA; WRIGHT STATE UNIV,DAYTON,OH 45435	University of Tennessee System; University of Tennessee Health Science Center; Boston University; State University System of Florida; University of South Florida; Johns Hopkins University; New York Medical College; Medical College of Wisconsin; Oregon Health & Science University; Texas Tech University System; Texas Tech University; University of California System; University of California Davis; University System of Ohio; Wright State University Dayton			Hedges, Jerris/AAC-1847-2021	Kelen, Gabor/0000-0002-3236-8286				ANDRULIS DP, 1991, ANN EMERG MED, V20, P980, DOI 10.1016/S0196-0644(05)82976-2; ARONOVITZ LG, 1993, GAOHRD PUBLICATION, V9346; BAKER DW, 1991, JAMA-J AM MED ASSOC, V266, P1085, DOI 10.1001/jama.266.8.1085; BINDMAN AB, 1991, JAMA-J AM MED ASSOC, V266, P1091, DOI 10.1001/jama.266.8.1091; BRELLOCHS C, 1990, BUILDING PRIMARY CAR; CROSS LA, 1992, ANN EMERG MED, V21, P1266, DOI 10.1016/S0196-0644(05)81760-3; DALLEK G, 1992, IMPACT MEDICARE PHYS; DERLET RW, 1990, ANN EMERG MED, V19, P262, DOI 10.1016/S0196-0644(05)82041-4; GRUMBACH K, 1993, AM J PUBLIC HEALTH, V83, P372, DOI 10.2105/AJPH.83.3.372; HILLMAN AL, 1991, ACAD MED, V66, P134, DOI 10.1097/00001888-199103000-00003; KELLERMAN AL, 1991, JAMA-J AM MED ASSOC, V266, P1123, DOI 10.1001/jama.266.8.1123; KUSSEROW RP, 1992, CONTROLLING EMERGENC; KUSSEROW RP, 1992, USE EMERGENCY ROOMS; LOWE RA, 1994, ANN EMERG MED, V23, P286, DOI 10.1016/S0196-0644(94)70042-7; LOWE RA, 1993, ANN EMERG MED, V22, P829, DOI 10.1016/S0196-0644(05)80801-7; LYNN SG, 1991, ANN EMERG MED, V20, P287, DOI 10.1016/S0196-0644(05)80942-4; NADEL V, 1993, GAOHRD PUBLICATION, V934; PANE GA, 1991, ANN EMERG MED, V20, P730, DOI 10.1016/S0196-0644(05)80832-7; SHESSER R, 1991, ANN EMERG MED, V20, P743, DOI 10.1016/S0196-0644(05)80835-2; Siegel S., 1988, NONPARAMETRIC STAT B; 1983, NONURGENT USE HOSPIT; 1993, EC REPORT PRESIDENT, P128	22	161	161	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 19	1994	330	20					1426	1430						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK972	8159198				2023-01-03	WOS:A1994NK97200007
J	HALLAM, L				HALLAM, L			PRIMARY MEDICAL-CARE OUTSIDE NORMAL WORKING HOURS - REVIEW OF PUBLISHED WORK	BRITISH MEDICAL JOURNAL			English	Review							GENERAL-PRACTICE; HOURS CALLS; DEPUTIZING SERVICES; EMERGENCY DEPARTMENTS; TELEPHONE ADVICE; MENTAL-HEALTH; 24-HOUR CARE; INNER CITIES; JOB STRESS; EAST-END	Fundamental changes in the delivery of primary medical care outside normal surgery hours are under consideration in Great Britain. Published research into the provision and utilisation of out of hours services shows long term trends towards decreasing personal committment among general practitioners and rising demand from patients for primary and hospital accident and emergency department care. Wide variations exist regionally, locally, and between practices. Previous studies, however, have been limited in scope and provide an inadequate basis for assessing the potential impact of change. The overall demand for care across all sources of provision cannot be measured: there is a lack of data on costs, and evaluative studies comparing alternative patterns of service delivery have rarely been undertaken. A period of experimentation and evaluation of a range of options should precede the wider adoption of any particular models.			HALLAM, L (corresponding author), UNIV MANCHESTER,RUSHOLME HLTH CTR,DEPT GEN PRACTICE,CTR PRIMARY CARE,MANCHESTER M14 5NP,ENGLAND.							BAIN DJG, 1984, BRIT MED J, V289, P471, DOI 10.1136/bmj.289.6443.471; BARLEY SL, 1979, J R COLL GEN PRACT, V29, P752; BLAIR JSG, 1986, J ROY COLL GEN PRACT, V36, P359; BOLLAM MJ, 1988, BRIT MED J, V296, P829, DOI 10.1136/bmj.296.6625.829; BOWLING A, 1987, FAM PRACT, V4, P85, DOI 10.1093/fampra/4.2.85; BRACKENBURY PH, 1985, HLTH TRENDS, V17, P31; BUXTON MJ, 1977, BRIT MED J, V1, P827, DOI 10.1136/bmj.1.6064.827; CALNAN M, 1982, J SOC POLICY, V11, P483, DOI 10.1017/S0047279400022546; CALNAN M, 1984, Journal of Emergency Medicine, V2, P57, DOI 10.1016/0736-4679(84)90049-0; CALNAN M, 1985, SOCIAL HLTH ILLNESS, V5, P149; CARLISLE RD, 1993, BRIT MED J, V306, P1383, DOI 10.1136/bmj.306.6889.1383; CARTWRIGHT A, 1981, GENERAL PRACTICE REV; CAVANAGH AUJM, 1978, BRIT MED J, V2, P34; COHEN J, 1987, FAM PRACT, V4, P81, DOI 10.1093/fampra/4.2.81; COOPER CL, 1989, BRIT MED J, V298, P366, DOI 10.1136/bmj.298.6670.366; CREIGHTON PA, 1982, BRIT MED J, V284, P1090, DOI 10.1136/bmj.284.6322.1090; CROWE MGF, 1976, BRIT MED J, V1, P1582, DOI 10.1136/bmj.1.6025.1582; CUBITT T, 1983, BRIT MED J, V287, P28, DOI 10.1136/bmj.287.6384.28; Cunningham R J, 1980, J R Coll Gen Pract, V30, P745; DAVIES T, 1986, BRIT MED J, V292, P241, DOI 10.1136/bmj.292.6515.241; DAVISON AG, 1983, J ROY SOC MED, V76, P37, DOI 10.1177/014107688307600109; DEER B, 1983, SUNDAY TIMES, V8; DIXON RA, 1988, BRIT MED J, V297, P1519, DOI 10.1136/bmj.297.6662.1519; DIXON RA, 1977, BRIT MED J, V1, P560, DOI 10.1136/bmj.1.6060.560; DRISCOLL PA, 1987, ARCH EMERG MED, V4, P77; FARMER RDT, 1982, RELATIONSHIP USES AC; FEARN R, 1987, SOC SCI MED, V24, P263, DOI 10.1016/0277-9536(87)90053-0; FEGER H, 1992, PULSE           0516, P3; FEGER H, 1992, PULSE           0704, P1; FOROUGHI D, 1989, PRACTITIONER, V233, P657; Fry J, 1984, NHS DATA BOOK; Gabriel R, 1976, J R Coll Gen Pract, V26, P74; GADSBY R, 1987, J ROY COLL GEN PRACT, V37, P462; GILBERT JR, 1978, PRACTITIONER, V220, P21; GRANT JA, 1984, BMJ-BRIT MED J, V288, P1366, DOI 10.1136/bmj.288.6427.1366; GRAVELLE HSE, 1980, DEPUTISING SERVICES; GREEN J, 1992, SOC SCI MED, V35, P987, DOI 10.1016/0277-9536(92)90238-L; Green J, 1991, Health Serv J, V101, P25; HALLAM L, 1992, OUT HOURS CARE GENER; HARRIS A, 1969, BRIT MED J, V298, P63; HOBBS FDR, 1991, BRIT MED J, V302, P329, DOI 10.1136/bmj.302.6772.329; HOBDAY PJ, 1984, BRIT MED J, V289, P663, DOI 10.1136/bmj.289.6446.663; HOBDAY PJ, 1988, J ROY COLL GEN PRACT, V38, P35; Jackson J, 1980, J R Coll Gen Pract, V30, P520; Jeffery R, 1979, Sociol Health Illn, V1, P90, DOI 10.1111/1467-9566.ep11006793; JONES H, 1992, PULSE           0704, P7; KNOX JDE, 1989, PRACTICAL GUIDES GEN, P9; LEWIS B, HLTH SOC SERVICES J, P1139; LINDEN M, 1993, PULSE           0925, P3; LIVINGSTONE AE, 1989, BRIT MED J, V299, P368, DOI 10.1136/bmj.299.6695.368; Lockstone D R, 1976, J R Coll Gen Pract, V26, P68; MAIN JA, 1989, BRIT MED J, V299, P627, DOI 10.1136/bmj.299.6699.627-b; MARSH GN, 1987, J ROY COLL GEN PRACT, V37, P301; MARSH GN, 1987, ARCH DIS CHILD, V62, P392, DOI 10.1136/adc.62.4.392; MAWHINNEY B, 1993, PULSE           1127, P15; MCCARTHY M, 1990, BRIT J GEN PRACT, V40, P19; MILNER PC, 1988, J EPIDEMIOL COMMUN H, V42, P274, DOI 10.1136/jech.42.3.274; MORRISON JM, 1991, BRIT MED J, V303, P1111, DOI 10.1136/bmj.303.6810.1111; MORRISON WG, 1991, BRIT J CLIN PRACT, V45, P95; MORTON DJ, 1979, J R COLL GEN PRACT, V29, P205; MUCKLE DS, 1973, BRIT MED J, V3, P699, DOI 10.1136/bmj.3.5882.699-c; Murray T S, 1977, J R Coll Gen Pract, V27, P209; MYERS P, 1982, J ROY SOC MED, V75, P879; MYERSON S, 1990, FAM PRACT, V7, P91, DOI 10.1093/fampra/7.2.91; MYERSON S, 1991, Medical Science Research, V19, P267; Naidoo A S, 1982, J R Coll Gen Pract, V32, P564; NGUYENVANTAM JS, 1992, BRIT MED J, V305, P157, DOI 10.1136/bmj.305.6846.157; ODWYER F, 1991, ARCH EMERG MED, V8, P196; OLIVER DJ, 1982, BRIT MED J, V284, P1195, DOI 10.1136/bmj.284.6323.1195; PEPIATT R, 1980, PRACTITIONER, V224, P11; PERRY JR, 1990, BRIT J GEN PRACT, V40, P190; PITTS J, 1988, J ROY COLL GEN PRACT, V38, P2; PITTS J, 1990, BRIT MED J, V300, P113; PRINCE A, J PUBLIC HLTH MED, V14, P177; PRUDHOE RH, 1984, BRIT MED J, V288, P718, DOI 10.1136/bmj.288.6418.718-a; Reilly P M, 1981, J R Coll Gen Pract, V31, P223; RIDDELL JA, 1980, BRIT MED J, V280, P1518, DOI 10.1136/bmj.280.6230.1518; RIDSDILLSMITH RM, 1983, UPDATE, V26, P274; ROLAND M, 1984, BRIT MED J, V289, P451, DOI 10.1136/bmj.289.6443.451; ROTH JA, 1972, AM J SOCIOL, V77, P839, DOI 10.1086/225227; SAWYER L, 1982, BRIT MED J, V284, P1531, DOI 10.1136/bmj.284.6328.1531; SHELDON MG, 1984, BRIT MED J, V289, P474, DOI 10.1136/bmj.289.6443.474; SIMPSON R, 1979, 6 ROYAL COMM NAT HLT; SINGH S, 1988, BRIT MED J, V297, P1179, DOI 10.1136/bmj.297.6657.1179; STEVENSON JSK, 1982, BRIT MED J, V284, P947, DOI 10.1136/bmj.284.6320.947; STYLES WM, 1983, J ROY COLL GEN PRACT, V33, P395; SUTHERLAND VJ, 1992, BMJ-BRIT MED J, V304, P1545, DOI 10.1136/bmj.304.6841.1545; TULLOCH AJ, 1984, PRACTITIONER, V228, P663; USHERWOOD TP, 1985, J ROY COLL GEN PRACT, V35, P395; WAKEFORD R, 1984, WORLD MED       0307, P17; WARRY R, 1993, GENERAL PRACTIT 1001, P11; WHITBY M, 1989, PRACTITIONER, V223, P493; WILKIN D, 1987, ANATOMY URGAN GENERA; WILLIAMS BT, 1985, BRIT MED J, V291, P1689, DOI 10.1136/bmj.291.6510.1689; WILLIAMS DJ, 1988, BRIT MED J, V296, P1197, DOI 10.1136/bmj.296.6630.1197; WOOD TCA, 1986, PUBLIC HEALTH, V100, P15; YATES DW, 1987, J ROYAL SOC HLTH, V4, P153; 1992, YOUR CHOICES SPECIAL; 1989, GENERAL PRACTICE NAT; 1976, J R COLL GEN PRACT, V26, P3; 1991, GENERAL MED PRACTITI; 1987, GENERAL MED PRACTITI; 1990, COMMUNITY HOSPITALS; 1993, SOCIAL TRENDS, V23; 1991, HLTH PERSONAL SOCIAL; HLTH CIRCULAR, V84; 1992, BR J GEN PRACT, V42, P90; 1992, PULSE           0404, P1; 1993, GENERAL PRACTIT 0730, P32; 1992, YOUR CHOICES FUTURE; 1984, BRIT MED J, V288, P1627; 1989, JR COLL GEN PRACT, V34, P362; 1984, OUT HOURS PATIENT CA	113	102	102	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 22	1994	308	6923					249	253		10.1136/bmj.308.6923.249	http://dx.doi.org/10.1136/bmj.308.6923.249			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT539	8111262	Green Published			2023-01-03	WOS:A1994MT53900024
J	BROX, JI; STAFF, PH; LJUNGGREN, AE; BREVIK, JI				BROX, JI; STAFF, PH; LJUNGGREN, AE; BREVIK, JI			ARTHROSCOPIC SURGERY COMPARED WITH SUPERVISED EXERCISES IN PATIENTS WITH ROTATOR CUFF DISEASE (STAGE-II IMPINGEMENT SYNDROME)	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LIGAMENTS; TENDONS	Objective-To compare the effectiveness of arthroscopic surgery, a supervised exercise regimen, and placebo soft laser treatment in patients with rotator cuff disease (stage II impingement syndrome). Design-Randomised clinical trial. Setting-Hospital departments of orthopaedics and of physical medicine and rehabilitation. Patients-125 patients aged 18-66 who had had rotator cuff disease for at least three months and whose condition was resistant to treatment. Interventions-Arthroscopic subacromial decompression performed by two experienced surgeons; exercise regimen over three to six months supervised by one experienced physiotherapist; or 12 sessions of detuned soft laser treatment over six weeks. Main outcome measures-Change in the overall Neer shoulder score (pain during previous week and blinded evaluation of function and range of movement by one clinician) after six months. Results-No differences were found between the three groups in duration of sick leave and daily intake of analgesics. After six months the difference in improvement in overall Neer score between surgery and supervised exercises was 4.0 (95% confidence interval -2 to 11) and 2.0 (-1.4 to 5.4) after adjustment for sex. The condition improved significantly compared with placebo in both groups given the active treatments. Treatment costs were higher for those given surgery (720 Pounds v 390 Pounds). Conclusions-Surgery or a supervised exercise regimen significantly, and equally, improved rotator cuff disease compared with placebo.	ULLEVAL UNIV HOSP, DEPT SOCIAL NETWORKS & HLTH, N-0407 OSLO, NORWAY	University of Oslo	BROX, JI (corresponding author), ULLEVAL UNIV HOSP, DEPT PHYS MED & REHABIL, N-0407 OSLO, NORWAY.		Zmistowski, Ben/AAI-7901-2020; Brox, Jens Ivar/N-1601-2018					[Anonymous], 1990, GUIDELINES ATC CLASS; Bergunnud H., 1988, CLIN ORTHOP RELAT R, V231, P234; BJORKENHEIM JM, 1988, CLIN ORTHOP RELAT R, P148; Bohmer AS, 1984, FYSIOTERAPEUTEN, V51, P192; BYE A, 1991, Tidsskrift for den Norske Laegeforening, V111, P337; Cyriax JH, 1982, TXB ORTHOPAEDIC MED, V1; DEROGATIS LR, 1974, BEHAV SCI, V19, P1, DOI 10.1002/bs.3830190102; EDELSON JG, 1992, J BONE JOINT SURG BR, V74, P589, DOI 10.1302/0301-620X.74B4.1624522; Ellman H, 1987, Arthroscopy, V3, P173, DOI 10.1016/S0749-8063(87)80061-0; FU FH, 1991, CLIN ORTHOP RELAT R, P162; HARDY DC, 1986, AM J ROENTGENOL, V147, P557, DOI 10.2214/ajr.147.3.557; HERBERTS P, 1981, ACTA ORTHOP SCAND, V52, P299, DOI 10.3109/17453678109050107; JARVHOLM U, 1989, CLIN ORTHOP RELAT R, V245, P102; LEHMAN RC, 1988, CLIN SPORT MED, V7, P309; Lo Y P, 1990, Br J Sports Med, V24, P173; NEER CS, 1970, J BONE JOINT SURG AM, VA 52, P1090, DOI 10.2106/00004623-197052060-00002; NIRSCHL RP, 1987, INSTRUCTIONAL COURSE, V41, P439; OZAKI J, 1988, J BONE JOINT SURG AM, V70A, P1224, DOI 10.2106/00004623-198870080-00015; Ryan B. F., 1985, MINITAB HDB; TIPTON CM, 1975, MED SCI SPORT EXER, V7, P165; WOO SLY, 1982, BIORHEOLOGY, V19, P397	21	194	196	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 9	1993	307	6909					899	903		10.1136/bmj.307.6909.899	http://dx.doi.org/10.1136/bmj.307.6909.899			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB847	8241852	Green Published, Bronze			2023-01-03	WOS:A1993MB84700016
J	CHRISTAKIS, NA; ASCH, DA				CHRISTAKIS, NA; ASCH, DA			BIASES IN HOW PHYSICIANS CHOOSE TO WITHDRAW LIFE-SUPPORT	LANCET			English	Article							SUSTAINING TREATMENT; ADVANCE DIRECTIVES; DECISION-MAKING; CRITICALLY ILL; CARE; PREFERENCES; EUTHANASIA; ATTITUDES	We have investigated biases in physicians' decisions regarding the form of life support to withdraw from critically ill patients in whom the decision to withdraw has already been made. Using a specially designed instrument that solicited both self-reported preferences and also responses to experimentally varied clinical vignettes, we surveyed 862 American internists, of whom 481 (56%) responded. Physicians do have preferences about the form of life support withdrawn. From most likely to least likely the order is: blood products, haemodialysis, intravenous vasopressors, total parenteral nutrition, antibiotics, mechanical ventilation, tube feedings, and intravenous fluids. Four biases in decision making were also identified. Physicians prefer to withdraw forms of therapy supporting organs that failed for natural rather than iatrogenic reasons, to withdraw recently instituted rather than longstanding interventions, to withdraw forms of therapy resulting in immediate death rather than delayed death, and to withdraw forms of therapy resulting in delayed death when confronted with diagnostic uncertainty. Because these biases may have clinical, social, and ethical consequences counter to patient goals, and because they may affect the underlying decision whether to withdraw life support at all, they may represent impediments to rational and compassionate decision making in critical care.	UNIV PENN, LEONARD DAVIS INST HLTH ECON, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DIV FISIOL VEGETAL, PHILADELPHIA, PA 19104 USA; UNIV PENN, DEPT SOCIOL, PHILADELPHIA, PA 19104 USA; VET AFFAIRS MED CTR, PHILADELPHIA, PA USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center			Christakis, Nicholas A/B-6690-2008; Christakis, Nicholas A/C-3205-2009	Asch, David/0000-0002-7970-286X				[Anonymous], 1983, PRESIDENTS COMMISSIO; BOSK CL, 1980, NEW ENGL J MED, V303, P71, DOI 10.1056/NEJM198007103030203; BRETT AS, 1991, JAMA-J AM MED ASSOC, V266, P825, DOI 10.1001/jama.266.6.825; CARALIS PV, 1992, CRIT CARE MED, V20, P683, DOI 10.1097/00003246-199205000-00023; CASSELL E, 1991, NATURE SUFFERING GOA; CHARLSON ME, 1986, JAMA-J AM MED ASSOC, V255, P1316, DOI 10.1001/jama.255.10.1316; COHEN BJ, 1992, MED DECIS MAKING, V12, P350; CRANE D, 1977, SANCTITY SOCIAL LIFE; DANIS M, 1988, JAMA-J AM MED ASSOC, V260, P797, DOI 10.1001/jama.260.6.797; DANIS M, 1991, NEW ENGL J MED, V324, P882, DOI 10.1056/NEJM199103283241304; EMANUEL EJ, 1988, LANCET, V1, P106; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; FABERLANGENDOEN K, 1992, CRIT CARE MED, V20, P570, DOI 10.1097/00003246-199205000-00005; HOLLANDER M, 1973, NONPARAMETRIC STATIS; LYNN J, 1989, BY NO EXTRAORDINARY; MOWER WR, 1993, ARCH INTERN MED, V153, P375, DOI 10.1001/archinte.153.3.375; NEU S, 1986, NEW ENGL J MED, V314, P14, DOI 10.1056/NEJM198601023140103; NIGHTINGALE SD, 1988, CHEST, V93, P684, DOI 10.1378/chest.93.4.684; PEARLMAN RA, 1982, ANN INTERN MED, V97, P420, DOI 10.7326/0003-4819-97-3-420; RUARK JE, 1988, NEW ENGL J MED, V318, P25, DOI 10.1056/NEJM198801073180106; Samuelson W., 1988, J RISK UNCERTAINTY, V1, P7, DOI [10.1007/BF00055564, DOI 10.1007/BF00055564]; SCHNEIDERMAN LJ, 1988, NEW ENGL J MED, V318, P984, DOI 10.1056/NEJM198804143181509; SMEDIRA NG, 1990, NEW ENGL J MED, V322, P309, DOI 10.1056/NEJM199002013220506; SOLOMON MZ, 1993, AM J PUBLIC HEALTH, V83, P14, DOI 10.2105/AJPH.83.1.14; UHLMANN RF, 1991, ARCH INTERN MED, V151, P495, DOI 10.1001/archinte.151.3.495; VONPREYSSFRIEDMAN SM, 1992, J GEN INTERN MED, V7, P46, DOI 10.1007/BF02599102; WEIR RF, 1989, ABATING TREATMENT CR; WILSON W C, 1992, Journal of the American Medical Association, V267, P949, DOI 10.1001/jama.267.7.949; Zussman Robert, 1992, INTENSIVE CARE MED E; 1991, LANCET, V337, P96	30	143	146	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 11	1993	342	8872					642	646		10.1016/0140-6736(93)91759-F	http://dx.doi.org/10.1016/0140-6736(93)91759-F			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX272	8103146	hybrid			2023-01-03	WOS:A1993LX27200010
J	JOSHI, GP				JOSHI, GP			PERIPHERAL ANALGESIA	LANCET			English	Editorial Material											JOSHI, GP (corresponding author), SW MED CTR,DEPT ANESTHESIOL & PAIN MANAGEMENT,DALLAS,TX 75235, USA.							APPELBOOM T, 1991, ARTHRITIS RHEUM-US, V34, P1048, DOI 10.1002/art.1780340815; BASBAUM AI, 1991, NEW ENGL J MED, V325, P1168, DOI 10.1056/NEJM199110173251610; BJURHOLM A, 1990, ARTHRITIS RHEUM, V33, P859, DOI 10.1002/art.1780330613; JOSHI GP, 1993, ANESTH ANALG, V76, P333; LAWRENCE AJ, 1992, EUR J CLIN PHARMACOL, V43, P351, DOI 10.1007/BF02220608	5	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 7	1993	342	8867					320	320		10.1016/0140-6736(93)91469-3	http://dx.doi.org/10.1016/0140-6736(93)91469-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ868	8101582				2023-01-03	WOS:A1993LQ86800007
J	MARIK, PE; SIBBALD, WJ				MARIK, PE; SIBBALD, WJ			EFFECT OF STORED-BLOOD TRANSFUSION ON OXYGEN DELIVERY IN PATIENTS WITH SEPSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CRITICALLY ILL PATIENTS; ADULT RESPIRATORY-DISTRESS; INTRAMURAL PH; GASTRIC TONOMETRY; CONSUMPTION; ENDOTOXEMIA; VALIDATION; FAILURE; SURGERY; SYSTEM	Background.-Red blood cell transfusion is commonly used to augment systemic oxygen delivery to supranormal levels in patients with sepsis. However, clinical studies have not consistently demonstrated that this therapeutic maneuver is accompanied by an increase in oxygen utilization at either the whole-body level or within individual organs. Study Objectives.-To determine the effect of red blood cell transfusion on gastrointestinal and whole-body oxygen uptake. Design.-Prospective, controlled, interventional study. Setting.-Multidisciplinary intensive care unit of a tertiary care teaching hospital. Patients.-Twenty-three critically ill patients with sepsis undergoing mechanical ventilation. Measurements and Main Results.-Systemic oxygen uptake was measured by indirect calorimetry and calculated by the Fick method. Gastric intramucosal pH as measured by tonometry was used to assess changes in splanchnic oxygen availability. Measurements were made prior to transfusion of 3 U of packed red blood cells. These were then repeated immediately following transfusion, as well as 3 and 6 hours later. There was no increase in systemic oxygen uptake measured by indirect calorimetry in any of the patients studied for up to 6 hours posttransfusion (including those patients with an elevated arterial lactate concentration). However, the calculated systemic oxygen uptake increased in parallel with the oxygen delivery in all the patients. More importantly, we found an inverse association between the change in gastric intramucosal pH and the age of the transfused blood (r=-.71; P<.001). In those patients receiving blood that had been stored for more than 15 days, the gastric intramucosal pH consistently decreased following the red blood cell transfusion. Conclusion.-We failed to demonstrate a beneficial effect of red blood cell transfusion on measured systemic oxygen uptake in patients with sepsis. Patients receiving old transfused red blood cells developed evidence of splanchnic ischemia. We postulate that the poorly deformable transfused red blood cells cause microcirculatory occlusion in some organs, which may lead to tissue ischemia in some organs.	VICTORIA HOSP, RES INST,AC BURTON VASC BIOL LAB,ROOM 482 4 NW, 375 S ST, LONDON N6A 4G5, ONTARIO, CANADA; UNIV WESTERN ONTARIO, DEPT MED, PROGRAM CRIT CARE, LONDON N6A 3K7, ONTARIO, CANADA; UNIV WESTERN ONTARIO, DEPT SURG, LONDON N6A 3K7, ONTARIO, CANADA	University of Victoria; Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)			Marik, Paul E/U-9733-2019					ALEXANDER JW, 1990, ANN SURG, V212, P496, DOI 10.1097/00000658-199010000-00012; ANTONSSON JB, 1990, AM J PHYSIOL, V259, pG519, DOI 10.1152/ajpgi.1990.259.4.G519; APSTEIN CS, 1985, AM J PHYSIOL, V248, pH508, DOI 10.1152/ajpheart.1985.248.4.H508; ARGWAL JB, 1970, J APPL PHYSIOL, V29, P866; BAKER CH, 1984, CIRC SHOCK, V12, P165; BARTLETT RH, 1990, J CRIT CARE, V5, P77, DOI 10.1016/0883-9441(90)90051-A; BIHARI D, 1987, NEW ENGL J MED, V317, P397, DOI 10.1056/NEJM198708133170701; BONE RC, 1992, CRIT CARE MED, V20, P864, DOI 10.1097/00003246-199206000-00025; DIETRICH KA, 1990, CRIT CARE MED, V18, P940, DOI 10.1097/00003246-199009000-00007; DOYLE MP, 1990, J APPL PHYSIOL, V69, P1270, DOI 10.1152/jappl.1990.69.4.1270; FIDDIANGREEN RG, 1983, GASTROENTEROLOGY, V85, P613; FIDDIANGREEN RG, 1989, SPLANCHNIC ISCHEMIA, P349; GANZ W, 1971, AM J CARDIOL, V27, P392, DOI 10.1016/0002-9149(71)90436-X; GREENWALT TJ, 1984, VOX SANG, V47, P261, DOI 10.1111/j.1423-0410.1984.tb01596.x; HEARD SO, 1991, CRIT CARE MED, V19, P271, DOI 10.1097/00003246-199102000-00025; HERSCH M, 1990, SURGERY, V107, P397; Jodal M, 1984, PHYSL INTESTINAL CIR, P83; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LAM C, 1991, MICROVASC RES, V66, P501; LANDOW L, 1991, CRIT CARE MED, V19, P1226, DOI 10.1097/00003246-199110000-00003; LKUNDGREN O, 1973, ACTA PHYSL SCAND, V88, P551; MAETANI S, 1986, ANN SURG, V203, P275, DOI 10.1097/00000658-198603000-00010; Mollison P. L., 1987, BLOOD TRANSFUSION CL, P95; MOORE GL, 1983, DIAGN MED, V6, P33; MORISAKI H, 1992, CRIT CARE MED S1, V20, pS101; MURRAY JF, 1963, J CLIN INVEST, V42, P1150, DOI 10.1172/JCI104800; NELSON DP, 1988, J APPL PHYSIOL, V64, P2410, DOI 10.1152/jappl.1988.64.6.2410; PARKER MM, 1990, CHEST, V97, P126, DOI 10.1378/chest.97.1.126; PEEK CC, 1981, CRIT REV CLIN LAB SC, V13, P173; RASHKIN MC, 1985, CHEST, V87, P580, DOI 10.1378/chest.87.5.580; RONCO JJ, 1993, AM REV RESPIR DIS, V147, P25, DOI 10.1164/ajrccm/147.1.25; RONCO JJ, 1991, J CRIT CARE, V6, P36, DOI 10.1016/0883-9441(91)90031-N; RONCO JJ, 1991, AM REV RESPIR DIS, V143, P1267, DOI 10.1164/ajrccm/143.6.1267; SAADIA R, 1990, BRIT J SURG, V77, P487, DOI 10.1002/bjs.1800770505; SHOEMAKER WC, 1988, CRIT CARE MED, V16, P1117, DOI 10.1097/00003246-198811000-00007; SHOEMAKER WC, 1988, CHEST, V94, P1176, DOI 10.1378/chest.94.6.1176; SIBBALD WJ, 1991, CHEST, V100, pS155, DOI 10.1378/chest.100.3.155S; SIGURDSSON GH, 1992, CRIT CARE MED, V20, P458, DOI 10.1097/00003246-199204000-00005; SILVERMAN HJ, 1992, CHEST, V102, P184, DOI 10.1378/chest.102.1.184; SIMCHON S, 1987, AM J PHYSIOL, V253, pH898, DOI 10.1152/ajpheart.1987.253.4.H898; STUART J, 1990, BLOOD REV, V4, P141, DOI 10.1016/0268-960X(90)90041-P; SUGERMAN HJ, 1970, SURG GYNECOL OBSTETR, V131, P733; TUCHSCHMIDT J, 1992, CHEST, V102, P216, DOI 10.1378/chest.102.1.216; WEG JG, 1991, CRIT CARE MED, V19, P650, DOI 10.1097/00003246-199105000-00011	44	571	586	0	19	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 16	1993	269	23					3024	3029		10.1001/jama.269.23.3024	http://dx.doi.org/10.1001/jama.269.23.3024			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF941	8501845				2023-01-03	WOS:A1993LF94100032
J	CUMMINS, RO; GRAVES, JR; LARSEN, MP; HALLSTROM, AP; HEARNE, TR; CILIBERTI, J; NICOLA, RM; HORAN, S				CUMMINS, RO; GRAVES, JR; LARSEN, MP; HALLSTROM, AP; HEARNE, TR; CILIBERTI, J; NICOLA, RM; HORAN, S			OUT-OF-HOSPITAL TRANSCUTANEOUS PACING BY EMERGENCY MEDICAL TECHNICIANS IN PATIENTS WITH ASYSTOLIC CARDIAC-ARREST	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AUTOMATIC EXTERNAL DEFIBRILLATORS; AMERICAN-HEART-ASSOCIATION; TOTAL CIRCULATORY ARREST; VENTRICULAR-FIBRILLATION; BRADYASYSTOLIC ARREST; IMPROVING SURVIVAL; PACEMAKER; EXPERIENCE; TERMINATION; DEATH	Background. Transcutaneous cardiac pacemakers generate electrical stimuli that pace the heart through external electrodes that adhere to the chest wall. Transcutaneous pacing has been useful in some patients with bradycardia, but its efficacy in patients with asystole and full cardiac arrest has been limited, possibly because of delays in the initiation of pacing. We studied the efficacy of early transcutaneous pacing in patients with out-of-hospital asystolic cardiac arrest. Methods. For three years we provided transcutaneous pacemakers to about half the fire districts in a large emergency-medical-services system (the intervention group). In these districts, we authorized emergency medical technicians (EMTs) to begin transcutaneous pacing in patients with cardiac arrest and primary asystole or post-defibrillation asystole. Pacing was done as early as possible, before endotracheal intubation or intravenous medication. EMTs in the other fire districts (the control group) treated similar patients with basic cardiopulmonary resuscitation but without transcutaneous pacing. Results. The EMTs in the intervention group initiated transcutaneous pacing in 112 of the 278 patients with primary asystole. Of these patients, 22 (8 percent) were admitted to the hospital, and 11 (4 percent) were discharged. Among the 259 patients treated by the EMTs in the control group, 21 (8 percent) were admitted to the hospital, and 5 (2 percent) were discharged. The two groups did not differ significantly with respect to the rate of hospital admission or survival. Survival after early pacing for post-defibrillation asystole was no better than survival after pacing for primary asystole. Conclusions. Transcutaneous pacing appears to offer no benefit in patients with asystolic cardiac arrest, even when it is performed as early as possible by EMTs in the field. Our data suggest that the widespread implementation of early transcutaneous pacing for out-of-hospital asystolic cardiac arrest would be ineffective.	SEATTLE KING CTY DEPT PUBL HLTH,KING CTY EMERGENCY MED SERV DIV,110 PREFONTAINE PL S,SUITE 500,SEATTLE,WA 98104; UNIV WASHINGTON,MED CTR,DEPT MED,CTR EVALUAT EMERGENCY MED SERV,SEATTLE,WA 98195; UNIV WASHINGTON,SCH PUBL HLTH,DEPT BIOSTAT,SEATTLE,WA 98195; OVERLAKE MEM HOSP,BELLEVUE,WA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle					AHRQ HHS [HS05740-03] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ALTAMURA G, 1989, PACE, V12, P331, DOI 10.1111/j.1540-8159.1989.tb02666.x; ALTAMURA G, 1990, PACE, V13, P2038, DOI 10.1111/j.1540-8159.1990.tb06938.x; ALTAMURA G, 1990, PACE, V13, P2026, DOI 10.1111/j.1540-8159.1990.tb06936.x; ARONSON AL, 1986, MED INSTRUM, V20, P27; BAROLD SS, 1988, AM J MED, V85, P817; BARTHELL E, 1988, ANN EMERG MED, V17, P1221, DOI 10.1016/S0196-0644(88)80074-X; BOCKA JJ, 1989, ANN EMERG MED, V18, P1280, DOI 10.1016/S0196-0644(89)80259-8; CLINTON J E, 1985, Journal of Emergency Medicine, V2, P155, DOI 10.1016/0736-4679(85)90390-7; COBB LA, 1980, MOD CONC CARDIOV DIS, V49, P31; COPASS M, 1989, EMT DEFIBRILLATION; CUMMINS R, 1989, PREHOSP DISASTER MED, V4, P70; CUMMINS R, 1989, PREHOSP DISASTER MED, V4, P196; CUMMINS RO, 1987, JAMA-J AM MED ASSOC, V257, P1605, DOI 10.1001/jama.257.12.1605; CUMMINS RO, 1990, ANN EMERG MED, V19, P38, DOI 10.1016/S0196-0644(05)82138-9; CUMMINS RO, 1991, CIRCULATION, V83, P1832, DOI 10.1161/01.CIR.83.5.1832; CUMMINS RO, 1990, ANN EMERG MED, V19, P1245, DOI 10.1016/S0196-0644(05)82282-6; CUMMINS RO, 1988, J AM COLL CARDIOL, V11, P597, DOI 10.1016/0735-1097(88)91537-9; DALSEY WC, 1985, CRIT CARE MED, V13, P399, DOI 10.1097/00003246-198505000-00006; DELUNA AB, 1989, AM HEART J, V117, P151, DOI 10.1016/0002-8703(89)90670-4; EISENBERG M, 1979, AM J PUBLIC HEALTH, V69, P30, DOI 10.2105/AJPH.69.1.30; EISENBERG MS, 1986, SCI AM, V254, P37, DOI 10.1038/scientificamerican0586-37; EISENBERG MS, 1980, NEW ENGL J MED, V302, P1379, DOI 10.1056/NEJM198006193022502; EISENBERG MS, 1980, LANCET, V1, P812; EISENBERG MS, 1980, JAMA-J AM MED ASSOC, V243, P1049, DOI 10.1001/jama.243.10.1049; EISENBERG MS, 1986, CIRCULATION, V74, P9; EISENBERG MS, 1984, SUDDEN CARDIAC DEATH, P44; EITEL DR, 1987, ANN EMERG MED, V16, P531, DOI 10.1016/S0196-0644(87)80678-9; FALK RH, 1983, NEW ENGL J MED, V309, P1166, DOI 10.1056/NEJM198311103091907; FALK RH, 1983, CRIT CARE MED, V11, P779, DOI 10.1097/00003246-198310000-00004; GRAVES J, 1989, RAPIDZAP AUTOMATED D; GREENE HL, 1990, AM J CARDIOL, V65, pB4; HEDGES JR, 1987, CIRCULATION, V76, P1337, DOI 10.1161/01.CIR.76.6.1337; HEDGES JR, 1984, ANN EMERG MED, V13, P822, DOI 10.1016/S0196-0644(84)80450-3; HELLER MB, 1988, AM J EMERG MED, V6, P78, DOI 10.1016/0735-6757(88)90228-8; JAGGARAO NSV, 1982, LANCET, V2, P73; KENYON CJ, 1988, ANN EMERG MED, V17, P711, DOI 10.1016/S0196-0644(88)80618-8; KERN KB, 1990, RESUSCITATION, V20, P221, DOI 10.1016/0300-9572(90)90005-Y; LUCK JC, 1988, AM J CARDIOL, V61, P574, DOI 10.1016/0002-9149(88)90767-9; MADSEN JK, 1988, AM HEART J, V116, P7, DOI 10.1016/0002-8703(88)90242-6; NEUMAR RW, 1991, ANN EMERG MED, V20, P222, DOI 10.1016/S0196-0644(05)80927-8; NEUMAR RW, 1990, RESUSCITATION, V19, P199, DOI 10.1016/0300-9572(90)90103-L; NIEMANN JT, 1986, ANN EMERG MED, V15, P112, DOI 10.1016/S0196-0644(86)80003-8; NOE R, 1986, PACE, V9, P101, DOI 10.1111/j.1540-8159.1986.tb05365.x; OLSON CM, 1985, AM J EMERG MED, V3, P129, DOI 10.1016/0735-6757(85)90035-X; OLSON DW, 1989, ANN EMERG MED, V18, P806, DOI 10.1016/S0196-0644(89)80200-8; PARIS PM, 1985, ANN EMERG MED, V14, P320, DOI 10.1016/S0196-0644(85)80096-2; PETERSON J, 1987, ANN EMERG MED, V16, P493; ROSENTHAL E, 1988, PACE, V11, P2160, DOI 10.1111/j.1540-8159.1988.tb05982.x; STUEVEN H, 1986, ANN EMERG MED, V15, P707, DOI 10.1016/S0196-0644(86)80430-9; STULTS KR, 1984, NEW ENGL J MED, V310, P219, DOI 10.1056/NEJM198401263100403; Syverud S, 1988, Emerg Med Clin North Am, V6, P197; SYVERUD SA, 1986, ANN EMERG MED, V15, P121, DOI 10.1016/S0196-0644(86)80004-X; TACHAKRA SS, 1988, ARCH EMERG MED, V5, P184; VUKOV LF, 1988, ANN EMERG MED, V17, P554, DOI 10.1016/S0196-0644(88)80282-8; WEAVER WD, 1984, CIRCULATION, V69, P943, DOI 10.1161/01.CIR.69.5.943; WEAVER WD, 1986, ANN EMERG MED, V15, P1181; WHITE JM, 1985, ANN EMERG MED, V14, P298, DOI 10.1016/S0196-0644(85)80090-1; ZOLL PM, 1985, CRIT CARE MED, V13, P925; ZOLL PM, 1957, AM J MED, V23, P832, DOI 10.1016/0002-9343(57)90384-4; ZOLL PM, 1952, NEW ENGL J MED, V247, P768, DOI 10.1056/NEJM195211132472005; ZOLL PM, 1985, CIRCULATION, V71, P937, DOI 10.1161/01.CIR.71.5.937; ZOLL PM, 1954, CIRCULATION, V9, P482, DOI 10.1161/01.CIR.9.4.482; 1989, 1990 HEART STROKE FA	63	76	76	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 13	1993	328	19					1377	1382		10.1056/NEJM199305133281903	http://dx.doi.org/10.1056/NEJM199305133281903			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB495	8474514				2023-01-03	WOS:A1993LB49500003
J	JARMAN, B				JARMAN, B			IS LONDON OVERBEDDED	BRITISH MEDICAL JOURNAL			English	Article								Objective-To examine whether there are too many hospital beds in London. Design-Analysis of data from the Hospital In-Patient Enquiry, Mental Health Enquiry, health service indicators, and Emergency Bed Service. Setting-England, London, and inner London. Results-Hospital admission rates for acute plus geriatric services for London residents were very similar to the national values in all age groups. In the special case considered in the Tomlinson report-acute services in inner London-the admission rate was 22% above the value for England. However, the admission rate of inner deprived Londoners was 9% below that of comparable areas outside London. For psychiatry, admission rates in London roughly equalled those in comparable areas. When special health authorities were excluded, in 1990-1 there were 4% more acute plus geriatric beds available per resident in London than in England. Bed provision has been reduced more rapidly in London than nationally. Extrapolating the trend of bed closures forward indicates that beds (all and acute) per resident in London are now at about the national average. Data from the Emergency Bed Service indicate that the pressure on available hospital beds in London has been increasing since 1985. Conclusions-Data regarding bed provision and utilisation for all specialties by London residents do not provide a case for reducing the total hospital bed stock in London at a rate faster than elsewhere. Bed closures should take account of London's relatively poorer social and primary health care circumstances, longer hospital waiting lists, poorer provision of residential homes, and evidence from the Emergency Bed Service of increasing pressure on beds. Higher average costs in London, some unavoidable, are forcing hospital beds to be closed at a faster rate in London than nationally.			JARMAN, B (corresponding author), ST MARYS HOSP,LISSON GROVE HLTH CTR,SCH MED,DEPT GEN PRACTICE,LONDON NW8 8EG,ENGLAND.							Boyle S, 1992, ACUTE HLTH SERVICES; BOYLE S, IN PRESS PRIMARY HLT; JARMAN B, 1992, BRIT MED J, V305, P1130, DOI 10.1136/bmj.305.6862.1130; JARMAN B, 1992, BRIT MED J, V304, P1146, DOI 10.1136/bmj.304.6835.1146; Tomlinson B., 1992, REPORT INQUIRY LONDO; 1993, MAKING LONDON BETTER; 1992, HLTH PERSONAL SOCIAL; 1992, CASELOAD REPORT; 1985, HOSPITAL PATIENT ENQ; 1992, SUMMARY AVAILABLE BE; 1992, RA86912H GOV STAT SE; 1986, PATIENT STATISTICS M; 1992, LONDON HLTH CARE 201	13	17	17	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 10	1993	306	6883					979	982		10.1136/bmj.306.6883.979	http://dx.doi.org/10.1136/bmj.306.6883.979			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KX436	8490480	Bronze, Green Published			2023-01-03	WOS:A1993KX43600025
J	BYRN, C; OLSSON, I; FALKHEDEN, L; LINDH, M; HOSTEREY, U; FOGELBERG, M; LINDER, LE; BUNKETORP, O				BYRN, C; OLSSON, I; FALKHEDEN, L; LINDH, M; HOSTEREY, U; FOGELBERG, M; LINDER, LE; BUNKETORP, O			SUBCUTANEOUS STERILE WATER INJECTIONS FOR CHRONIC NECK AND SHOULDER PAIN FOLLOWING WHIPLASH INJURIES	LANCET			English	Article							LOW-BACK-PAIN; CONVERGENT NEURONS; MYOFASCIAL PAIN; STIMULATION; THERAPY; RELIEF; RAT	In many cases of whiplash injury symptoms persist and do not respond to treatment. There is uncontrolled evidence to suggest that intracutaneous injections of sterile water might help. Since that route may be unacceptable to patients the subcutaneous route is used in the randomised trial reported here. 40 patients with whiplash syndrome, mean age 46 years (24-73) were given subcutaneous injections of 0.3-0.5 ml sterile water or saline over tender and trigger points in the neck and shoulder. A maximum of three treatments were given during the first two months of the study and the patients were followed up for 8 months. The accidents had occurred 4-6 years previously. X-ray examinations revealed no traumatic spinal lesions. Neck mobility and pain levels were evaluated by a physiotherapist immediately before and after the first treatment and after 1, 3, and 8 months. After 3 months, the mean total mobility of the cervical spine had increased by 39-degrees in the sterile water group and 6-degrees in the saline group (p<0.05). Minimum and maximum levels of pain in the weeks just before treatment were evaluated by a visual analogue scale from 0 to 10. After 3 months the minimum pain level had fallen from 2.2 to 1.4 in the sterile water group but was not reduced in the saline group (p<0.02); the maximum had fallen from 8.1 to 3.8 in the sterile water group and from 8.3 to 7.5 in the saline group (p<0.001). After 3 months, 19 of 20 patients in the sterile water group assessed their condition as generally improved but only 6 in the saline group felt that they had got better. After 8 months there were still significant differences for minimum pain score and for mobility but not for maximum pain or for self-assessment of improvement.	LUNDBY HOSP, DEPT NEUROL, GOTHENBURG, SWEDEN; GOTHENBURG UNIV, E HOSP, DEPT ORTHOPAED, TRAFF INJURY REGISTER, S-41124 GOTHENBURG, SWEDEN; GOTHENBURG UNIV, SAHLGRENS HOSP, DEPT PSYCHIAT, S-41345 GOTHENBURG, SWEDEN; BACK HLTH, GOTHENBURG, SWEDEN	University of Gothenburg; Sahlgrenska University Hospital; University of Gothenburg	BYRN, C (corresponding author), GOTHENBURG UNIV, SAHLGRENS HOSP, DEPT ANAESTHESIA, S-41345 GOTHENBURG, SWEDEN.							BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BENGSTSSON J, 1981, UGESKRIFT LAEGER, V15, P3463; BONICA JJ, 1957, JAMA-J AM MED ASSOC, V164, P732, DOI 10.1001/jama.1957.02980070014003; BYRN C, 1991, ACTA ANAESTH SCAND, V35, P52, DOI 10.1111/j.1399-6576.1991.tb03240.x; Costa P.T., 1985, NEO PERSONALITY INVE; CROWE HE, 1928, M W ORTHOPEDIC ASS; FROST A, 1986, SCAND J RHEUMATOL, V15, P153, DOI 10.3109/03009748609102082; FROST FA, 1980, LANCET, V1, P499; Gammon GD, 1941, J CLIN INVEST, V20, P13, DOI 10.1172/JCI101190; GARVEY TA, 1989, SPINE, V14, P962, DOI 10.1097/00007632-198909000-00008; LEBARS D, 1979, PAIN, V6, P305, DOI 10.1016/0304-3959(79)90050-2; LEBARS D, 1979, PAIN, V6, P283, DOI 10.1016/0304-3959(79)90049-6; LYTZEN T, 1989, ACTA OBSTET GYN SCAN, V68, P341, DOI 10.3109/00016348909028669; MELZACK R, 1975, PAIN, V1, P357, DOI 10.1016/0304-3959(75)90073-1; ODENT M, 1975, NOUV PRESSE MED, V4, P188; OLSSON I, 1988, P VAGOCH TRAFIKDEKMI, P111; PARSONS CM, 1945, P SOC EXP BIOL MED, V60, P327; RAJ PP, 1986, PRACTICAL MANAGEMENT, P575; SJOBERG L, 1979, SCAND J PSYCHOL, V20, P1, DOI 10.1111/j.1467-9450.1979.tb00677.x; Spielberger C.D., 1972, ANXIETY CURRENT TREN; Travell JG, 1983, MYOFASCIAL PAIN DYSF; TROLLE GB, 1986, UGESKRIFT LAEGER, V20, P1200; WOOLF CJ, 1986, J NEUROSCI, V6, P1433	23	54	58	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 20	1993	341	8843					449	452		10.1016/0140-6736(93)90204-T	http://dx.doi.org/10.1016/0140-6736(93)90204-T			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN137	8094485				2023-01-03	WOS:A1993KN13700001
J	Rawles, J				Rawles, J			Magnitude of benefit from earlier thrombolytic treatment in acute myocardial infarction: New evidence from Grampian region early anistreplase trial (GREAT)	BMJ-BRITISH MEDICAL JOURNAL			English	Article							THERAPY; PATIENT	Objective-To generalise from the results of the Grampian region early anistreplase trial (GREAT) and to express the benefit of earlier thrombolysis in terms of lives saved per hour of earlier treatment. Design-Multivariate analysis of a randomised double blind trial. Setting-29 rural practices in Grampian region and teaching hospitals in Aberdeen. Subjects-311 patients with suspected acute myocardial infarction and without contraindications to thrombolysis who were seen by their general practitioners within four hours of the start of symptoms. Interventions-Anistreplase 30 units given intravenously, either by general practitioners before hospitalisation or later in hospital. Main outcome measure-Death within 30 months of entry into trial. Results-Death within 30 months was positively related to age (P<0.0001) and to delay between start of symptoms and thrombolytic treatment (P=0.0004). However, the probability of dying rose exponentially with earlier presentation, so death within 30 months was negatively related to the logarithm of the time of randomisation (P=0.0163). In patients presenting two hours after start of symptoms each hour's delay in receiving thrombolysis led to the loss of 21 lives per 1000 within 30 days (95% confidence interval 1 to 94 lives per 1000) (P=0.03) and 69 lives per 1000 within 30 months(16 to 14l livers per 1000) (P=0.0004). Conclusions-The magnitude of the benefit from earlier thrombolysis is such that giving thrombolytic treatment to patients with acute myocardial infarction should be accorded the same degree of urgency as the treatment of cardiac arrest.			Rawles, J (corresponding author), UNIV ABERDEEN, MED ASSESSMENT RES UNIT, ABERDEEN AB9 2ZD, SCOTLAND.							[Anonymous], 1987, Lancet, V2, P871; [Anonymous], 1988, LANCET, V2, P349; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; BAIGENT C, 1993, CIRCULATION, V88, P291; GATENBY R, 1992, BMJ-BRIT MED J, V305, P548; HILLIS WS, 1992, BRIT HEART J, V68, P89; HOFGREN K, 1988, HEART LUNG, V17, P274; LEIZOROVICZ A, 1993, NEW ENGL J MED, V329, P383; MAYNARD C, 1989, AM J CARDIOL, V63, P1296, DOI 10.1016/0002-9149(89)91038-2; RAWLES J, 1995, BRIT MED J, V310, P465, DOI 10.1136/bmj.310.6977.465a; RAWLES J, 1994, J AM COLL CARDIOL, V23, P1, DOI 10.1016/0735-1097(94)90494-4; RAWLES JM, 1988, BRIT MED J, V296, P882, DOI 10.1136/bmj.296.6626.882; RAWLES JM, 1990, EUR HEART J, V11, P643, DOI 10.1093/oxfordjournals.eurheartj.a059770; TRENT R, 1995, INT J CARDIOL, V49, P33, DOI 10.1016/0167-5273(95)02271-W; WEAVER WD, 1993, JAMA-J AM MED ASSOC, V270, P1211, DOI 10.1001/jama.270.10.1211; WESTON CFM, 1994, BMJ-BRIT MED J, V308, P767, DOI 10.1136/bmj.308.6931.767; WILCOX RG, 1990, LANCET, V335, P1175	17	59	61	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 27	1996	312	7025					212	215						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT486	8563585				2023-01-03	WOS:A1996TT48600024
J	GOTZSCHE, PC				GOTZSCHE, PC			IS THERE LOGIC IN THE PLACEBO	LANCET			English	Article							PAIN				GOTZSCHE, PC (corresponding author), RIGSHOSP, NORDIC COCHRANE CTR, RES & DEV SECRETARIAT, 9 BLEGDAMSVEJ, DK-2100 COPENHAGEN 0, DENMARK.							Cochrane A., 1972, PUBLIC HEALTH, DOI DOI 10.1016/S0033-3506(73)80082-4; GAM AN, 1993, PAIN, V52, P63, DOI 10.1016/0304-3959(93)90114-5; KENNEDY W P, 1961, Med World, V95, P203; PECK C, 1991, THEOR MED, V12, P247, DOI 10.1007/BF00489609; SHAPIRO AK, 1968, PSYCHIAT QUART, V42, P653, DOI 10.1007/BF01564309; SHEPHERD M, 1993, PSYCHOL MED, V23, P569, DOI 10.1017/S0033291700025356; WARE JE, 1993, BRIT MED J, V306, P1429, DOI 10.1136/bmj.306.6890.1429; Wulff H. R., 1986, PHILOS MED	8	117	117	0	12	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 1	1994	344	8927					925	926						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ287	7934350				2023-01-03	WOS:A1994PJ28700014
J	BRITTENHAM, GM; GRIFFITH, PM; NIENHUIS, AW; MCLAREN, CE; YOUNG, NS; TUCKER, EE; ALLEN, CJ; FARRELL, DE; HARRIS, JW				BRITTENHAM, GM; GRIFFITH, PM; NIENHUIS, AW; MCLAREN, CE; YOUNG, NS; TUCKER, EE; ALLEN, CJ; FARRELL, DE; HARRIS, JW			EFFICACY OF DEFEROXAMINE IN PREVENTING COMPLICATIONS OF IRON OVERLOAD IN PATIENTS WITH THALASSEMIA MAJOR	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHELATION-THERAPY; CARDIAC-FUNCTION; DESFERRIOXAMINE; STORES; ANEMIA; SURVIVAL	Background. To determine whether deferoxamine prevents the complications of transfusional iron overload in thalassemia major, we evaluated 59 patients (30 were female and 29 male; age range, 7 to 31 years) periodically for 4 to 10 years or until death. Methods. At each follow-up visit, we performed a detailed clinical and laboratory evaluation and measured hepatic iron stores with a noninvasive magnetic device. Results. The body iron burden as assessed by magnetic measurement of hepatic iron stores was closely correlated (R = 0.89, P < 0.001) with the ratio of cumulative transfusional iron load to cumulative deferoxamine use (expressed in millimoles of iron per kilogram of body weight, in relation to grams of deferoxamine per kilogram, transformed into the natural logarithm). Each increase of one unit in the natural logarithm of the ratio (transfusional iron load to deferoxamine use) was associated with an increased risk of impaired glucose tolerance (relative risk, 19.3; 95 percent confidence interval, 4.8 to 77.4), diabetes mellitus (relative risk, 9.2; 95 percent confidence interval, 1.8 to 47.7), cardiac disease (relative risk, 9.9; 95 percent confidence interval, 1.9 to 51.2), and death (relative risk, 12.6; 95 percent confidence interval, 2.4 to 65.4). All nine deaths during the study occurred among the 23 patients who had begun chelation therapy later and used less deferoxamine in relation to their transfusional iron load (P < 0.001). Conclusions. The early use of deferoxamine in an amount proportional to the transfusional iron load reduces the body iron burden and helps protect against diabetes mellitus, cardiac disease, and early death in patients with thalassemia major.	CASE WESTERN RESERVE UNIV, DEPT MED, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, DEPT PHYS, CLEVELAND, OH 44106 USA; MOORHEAD STATE UNIV, DEPT MATH, MOORHEAD, MN 56560 USA; ST JUDE CHILDRENS RES HOSP, MEMPHIS, TN 38105 USA; NHLBI, CLIN HEMATOL BRANCH, BETHESDA, MD 20892 USA; NHLBI, CARDIOL BRANCH, BETHESDA, MD 20892 USA	Case Western Reserve University; Case Western Reserve University; Minnesota State Colleges & Universities; Minnesota State University Moorhead; St Jude Children's Research Hospital; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)					NIADDK NIH HHS [AM-25105] Funding Source: Medline; NIDDK NIH HHS [DK-14370] Funding Source: Medline; FDA HHS [FD-U-000532] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM025105] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K06DK014370] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); FDA HHS; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARRY M, 1974, BMJ-BRIT MED J, V2, P16, DOI 10.1136/bmj.2.5909.16; BORGNAPIGNATTI C, 1985, J PEDIATR-US, V106, P150, DOI 10.1016/S0022-3476(85)80488-1; BRITTENHAM GM, 1988, ANN NY ACAD SCI, V526, P199, DOI 10.1111/j.1749-6632.1988.tb55506.x; BRITTENHAM GM, 1982, NEW ENGL J MED, V307, P1671, DOI 10.1056/NEJM198212303072703; BRITTENHAM GM, 1993, AM J HEMATOL, V42, P81, DOI 10.1002/ajh.2830420116; BRITTENHAM GM, 1992, BLOOD, V80, P569; BRITTENHAM GM, 1994, IRON METABOLISM HLTH, P31; BRONSPIEGELWEINTROB N, 1990, NEW ENGL J MED, V323, P713, DOI 10.1056/NEJM199009133231104; COHEN A, 1984, BRIT J HAEMATOL, V58, P369, DOI 10.1111/j.1365-2141.1984.tb06096.x; COHEN A, 1990, J PEDIATR-US, V117, P326, DOI 10.1016/S0022-3476(05)80556-6; COX DR, 1972, J R STAT SOC B, V34, P187; DESANCTIS V, 1988, ARCH DIS CHILD, V63, P58, DOI 10.1136/adc.63.1.58; EHLERS KH, 1991, J PEDIATR-US, V118, P540, DOI 10.1016/S0022-3476(05)83374-8; Fleiss JL, 1981, STAT METHODS RATES P; FOSBURG MT, 1990, BLOOD, V76, P435; FREEDMAN MH, 1990, AM J DIS CHILD, V144, P565, DOI 10.1001/archpedi.1990.02150290059028; FREEMAN AP, 1989, CLIN LAB HAEMATOL, V11, P299, DOI 10.1111/j.1365-2257.1989.tb00227.x; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI, P740; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LUCARELLI G, 1993, NEW ENGL J MED, V329, P840, DOI 10.1056/NEJM199309163291204; MARCUS RE, 1984, LANCET, V1, P392; Modell B., 1984, CLIN APPROACH THALAS; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PIOMELLI S, 1993, BAILLIERE CLIN HAEM, V6, P287, DOI 10.1016/S0950-3536(05)80073-3; Pippard M J, 1989, Prog Clin Biol Res, V309, P85; POOTRAKUL P, 1988, BLOOD, V71, P1124; PROPPER RD, 1977, NEW ENGL J MED, V297, P418, DOI 10.1056/NEJM197708252970804; PROPPER RD, 1976, NEW ENGL J MED, V294, P1421, DOI 10.1056/NEJM197606242942603; SCHOENFELD D, 1982, BIOMETRIKA, V69, P239, DOI 10.1093/biomet/69.1.239; SMITH RS, 1962, BMJ-BRIT MED J, P1577, DOI 10.1136/bmj.2.5319.1577; WOLFE L, 1985, NEW ENGL J MED, V312, P1600, DOI 10.1056/NEJM198506203122503; ZURLO MG, 1989, LANCET, V2, P27, DOI 10.1016/S0140-6736(89)90264-X	32	649	669	1	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 1	1994	331	9					567	573		10.1056/NEJM199409013310902	http://dx.doi.org/10.1056/NEJM199409013310902			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD699	8047080	Bronze			2023-01-03	WOS:A1994PD69900002
J	WIESEN, AR; HOSPENTHAL, DR; BYRD, JC; GLASS, KL; HOWARD, RS; DIEHL, LF				WIESEN, AR; HOSPENTHAL, DR; BYRD, JC; GLASS, KL; HOWARD, RS; DIEHL, LF			EQUILIBRATION OF HEMOGLOBIN CONCENTRATION AFTER TRANSFUSION IN MEDICAL INPATIENTS NOT ACTIVELY BLEEDING	ANNALS OF INTERNAL MEDICINE			English	Note							UNITED-STATES; BLOOD; COLLECTION		WALTER REED ARMY MED CTR, WASHINGTON, DC 20307 USA	United States Department of Defense; United States Army; Walter Reed National Military Medical Center								Barnes A, 1993, HEMATOLOGY CLIN LAB, P1653; GREENFIELD RH, 1989, ANN EMERG MED, V18, P51, DOI 10.1016/S0196-0644(89)80312-9; GROVERASMUSSEN M, 1961, NEW ENGL J MED, V264, P1034, DOI 10.1056/NEJM196105182642006; HUBER H, 1964, BRIT J HAEMATOL, V10, P567, DOI 10.1111/j.1365-2141.1964.tb00733.x; Johnston M, 1985, TRANSFUSION THERAPY, P35; Jones J, 1993, BLOOD TRANSFUSION CL, P423; KEELING RP, 1987, FUNDAMENTALS CLIN HE, P932; MCCULLOUGH J, 1993, JAMA-J AM MED ASSOC, V269, P2239, DOI 10.1001/jama.269.17.2239; MOLLISON PL, 1947, CLIN SCI, V6, P137; NADLER SB, 1962, SURGERY, V51, P224; OCONNELL B, 1988, TRANSFUSION, V28, P66, DOI 10.1046/j.1537-2995.1988.28188127957.x; Rovin BH., 1989, MANUAL MED THERAPEUT, P221; Sekhsaria S, 1991, J Perinatol, V11, P161; Simon TL, 1991, PRINCIPLES TRANSFUSI, P97; SIMPSON MB, 1984, LABORATORY HEMATOLOG, P1149; SURGENOR DM, 1990, NEW ENGL J MED, V322, P1646, DOI 10.1056/NEJM199006073222306; WALLACE EL, 1993, TRANSFUSION, V33, P139, DOI 10.1046/j.1537-2995.1993.33293158046.x; WIDMANN FK, 1985, TECHNICAL MANUAL AM, P7; WINTROBE MM, 1981, CLIN HEMATOLOGY, P8	19	64	69	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1994	121	4					278	280		10.7326/0003-4819-121-4-199408150-00009	http://dx.doi.org/10.7326/0003-4819-121-4-199408150-00009			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB102	8037410	Green Submitted			2023-01-03	WOS:A1994PB10200009
J	CONNETT, GJ; LEE, BW				CONNETT, GJ; LEE, BW			TREATING CHILDHOOD ASTHMA IN SINGAPORE - WHEN WEST MEETS EAST	BRITISH MEDICAL JOURNAL			English	Article							ESOPHAGEAL	Though Western medicines and ideas about asthma have become popular in many Asian nations, local beliefs about treatment prevail. The multiracial society of Singapore shows a variety of beliefs about causes of asthma attacks (for example, the balance of yin and yang) and types of treatment-herbal remedies, inhaled versus eaten medicines, the influence of Ramadan. Many of the cultural practices mentioned are probably preserved among south east Asian minorities residing in the United Kingdom. Eastern treatments typically take a holistic approach to asthma and do not ignore the psychosomatic component of the disorder.	NATL UNIV SINGAPORE,DEPT PAEDIAT,SINGAPORE 0511,SINGAPORE	National University of Singapore			Connett, Gary/AAU-3686-2020	Connett, Gary/0000-0003-1310-3239				de San Lazaro C, 1986, Arch Dis Child, V61, P97; FITCH KD, 1971, BRIT MED J, V4, P577, DOI 10.1136/bmj.4.5787.577; KONG XT, 1993, ARCH DIS CHILD, V68, P468, DOI 10.1136/adc.68.4.468; RAUSCHER H, 1989, RESPIRATION, V55, P11; SHEEHAN MP, 1992, BRIT J DERMATOL, V126, P179, DOI 10.1111/j.1365-2133.1992.tb07817.x; WILSON NM, 1985, EUR J RESPIR DIS, V66, P25; WILSON NM, 1985, THORAX, V40, P592, DOI 10.1136/thx.40.8.592; ZHU SL, 1989, ASIAN PAC J ALLERGY, V7, P5	8	13	14	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 14	1994	308	6939					1282	1284		10.1136/bmj.308.6939.1282	http://dx.doi.org/10.1136/bmj.308.6939.1282			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM147	8205023	Green Published			2023-01-03	WOS:A1994NM14700023
J	LENFANT, C				LENFANT, C			SPEED URGED FOR THROMBOLYTIC THERAPY IN ACUTE MYOCARDIAL-INFARCTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											LENFANT, C (corresponding author), NHLBI,BETHESDA,MD 20892, USA.							1994, ANN EMERG MED, V23, P311; 1993, JAMA-J AM MED ASSOC, V270, P1211	2	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 9	1994	271	10					738	738						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY288	8114202				2023-01-03	WOS:A1994MY28800007
J	WILDEN, JN				WILDEN, JN			RAPID RESUSCITATION IN SEVERE HEAD-INJURY	LANCET			English	Editorial Material											WILDEN, JN (corresponding author), ROYAL LONDON HOSP,DEPT NEUROSURG,LONDON,ENGLAND.							ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; DeWitt DS, 1988, J NEUROTRAUM, V5, P303, DOI 10.1089/neu.1988.5.303; Foulkes MA, 1991, J NEUROSURG S, V75, P8, DOI 10.3171/sup.1991.75.1s.00s8; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; KONG DL, 1991, CRIT CARE MED, V19, P532, DOI 10.1097/00003246-199104000-00013; MARION DW, 1991, NEUROSURGERY, V29, P869, DOI 10.1227/00006123-199112000-00011; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; PICKARD JD, 1993, J NEUROL NEUROSUR PS, V56, P845, DOI 10.1136/jnnp.56.8.845	10	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 4	1993	342	8884					1378	1378		10.1016/0140-6736(93)92750-N	http://dx.doi.org/10.1016/0140-6736(93)92750-N			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK095	7901679				2023-01-03	WOS:A1993MK09500007
J	MAXWELL, DL; POLKEY, MI; HENRY, JA				MAXWELL, DL; POLKEY, MI; HENRY, JA			HYPONATREMIA AND CATATONIC STUPOR AFTER TAKING ECSTASY	BRITISH MEDICAL JOURNAL			English	Article							DEATHS; MDMA		GUYS HOSP,DEPT MED,LONDON SE1 9RT,ENGLAND; GUYS HOSP,NATL POISONS UNIT,LONDON SE1 9RT,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust								ALGRA A, 1991, CIRCULATION, V83, P1888, DOI 10.1161/01.CIR.83.6.1888; Chambers J, 1991, Health Trends, V23, P122; DOWLING GP, 1987, JAMA-J AM MED ASSOC, V257, P1615, DOI 10.1001/jama.257.12.1615; HENRY JA, 1992, LANCET, V340, P384, DOI 10.1016/0140-6736(92)91469-O; SIEGEL RK, 1986, J PSYCHOACTIVE DRUGS, V18, P349, DOI 10.1080/02791072.1986.10472368	5	100	100	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 27	1993	307	6916					1399	1399		10.1136/bmj.307.6916.1399	http://dx.doi.org/10.1136/bmj.307.6916.1399			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MK420	7903884	Bronze, Green Published			2023-01-03	WOS:A1993MK42000023
J	LEVINSKY, NG				LEVINSKY, NG			THE ORGANIZATION OF MEDICAL-CARE - LESSONS FROM THE MEDICARE END-STAGE RENAL-DISEASE PROGRAM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LIFE		BOSTON CITY HOSP, BOSTON, MA 02118 USA; UNIV HOSP BOSTON, BOSTON, MA 02118 USA	Boston Medical Center	LEVINSKY, NG (corresponding author), BOSTON UNIV, MED CTR, DEPT MED, 88 E NEWTON ST, BOSTON, MA 02118 USA.							AARON HJ, 1984, PAINFUL PRESCRIPTION; ABRAM HS, 1972, PSYCHIAT MED, V3, P51, DOI 10.2190/GKBB-DKN0-AD5M-RBBY; EVANS RW, 1981, JAMA-J AM MED ASSOC, V245, P487, DOI 10.1001/jama.245.5.487; EVANS RW, 1985, NEW ENGL J MED, V312, P553, DOI 10.1056/NEJM198502283120905; GAYLIN DS, 1993, JAMA-J AM MED ASSOC, V269, P603, DOI 10.1001/jama.269.5.603; HALPER T, 1985, MILBANK FUND Q, V63, P52, DOI 10.2307/3349898; MURRAY JS, 1962, T AM SOC ART INT ORG, V8, P315; NISSENSON AR, 1993, KIDNEY INT, V43, pS120; Reiser SJ., 1991, BIOMEDICAL POLITICS, P212; Rettig RA, 1991, BIOMEDICAL POLITICS, P176; RETTING RA, 1991, KIDNEY FAILURE FEDER; SANDERS D, 1968, UCLA LAW REV, V15, P357; SCHUPAK E, 1965, ANN INTERN MED, V62, P509, DOI 10.7326/0003-4819-62-3-509; SHERMAN RA, 1993, AM J KIDNEY DIS, V21, P632, DOI 10.1016/S0272-6386(12)80036-9; Tokars J I, 1993, ASAIO J, V39, P71, DOI 10.1097/00002480-199301000-00016; 1967, GPO933491 PUBL; 1992, USRDS SPECIAL STUDY	17	47	47	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 4	1993	329	19					1395	1399		10.1056/NEJM199311043291907	http://dx.doi.org/10.1056/NEJM199311043291907			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD949	8413437				2023-01-03	WOS:A1993MD94900007
J	WADDEN, TA				WADDEN, TA			TREATMENT OF OBESITY BY MODERATE AND SEVERE CALORIC RESTRICTION - RESULTS OF CLINICAL RESEARCH TRIALS	ANNALS OF INTERNAL MEDICINE			English	Article							WEIGHT-LOSS; FOLLOW-UP; ENERGY-INTAKE; DIET; EXERCISE; MAINTENANCE; PROGRAM; SAFETY; DEXFENFLURAMINE; DISORDER	Recent studies of the treatment of obesity by moderate and severe caloric restriction show that patients treated in randomized trials using a conventional 1200 kcal/d reducing diet, combined with behavior modification, lose approximately 8.5 kg in 20 weeks. They maintain approximately two thirds of this weight loss 1 year later. Patients treated under medical supervision using a very-low-calorie diet (400 to 800 kcal/d) lose approximately 20 kg in 12 to 16 weeks and maintain one half to two thirds of this loss in the following year. Both dietary interventions are associated with increasing weight regain over time, although regain can be minimized with the recognition that obesity, in many cases, is a chronic condition that requires continuing care. Patients who participate in a formal weight-loss maintenance program, exercise regularly, or both are likely to achieve the best long-term results.			WADDEN, TA (corresponding author), SYRACUSE UNIV, CTR HLTH & BEHAV, 804 UNIV AVE, SYRACUSE, NY 13244 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH049451] Funding Source: NIH RePORTER; NIMH NIH HHS [NIMH MH00702-05, NIMH R01-MH49451-01] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDERSEN T, 1984, NEW ENGL J MED, V310, P352, DOI 10.1056/NEJM198402093100604; ANDERSEN T, 1992, INT J OBESITY, V16, P35; ANDERSON JW, 1991, J AM DIET ASSOC, V91, P1582; [Anonymous], 1958, N Y State J Med, V58, P79; BANDINI LG, 1990, AM J CLIN NUTR, V52, P421, DOI 10.1093/ajcn/52.3.421; BROOMFIELD PH, 1988, NEW ENGL J MED, V319, P1567, DOI 10.1056/NEJM198812153192403; BROWNELL KD, 1987, BEHAV THER, V18, P353, DOI 10.1016/S0005-7894(87)80004-7; BROWNELL KD, 1982, J CONSULT CLIN PSYCH, V50, P820, DOI 10.1037/0022-006X.50.6.820; Brownell KD., 1989, LEARN PROGRAM WEIGHT; DAHLKOETTER JA, 1979, J CONSULT CLIN PSYCH, V47, P898, DOI 10.1037/0022-006X.47.5.898; DOHERTY JU, 1991, AM J CLIN NUTR, V53, P854, DOI 10.1093/ajcn/53.4.854; FINER N, 1989, INT J OBESITY, V13, P91; FOSTER GD, 1992, AM J CLIN NUTR, V55, P811, DOI 10.1093/ajcn/55.4.811; KANDERS BS, 1989, INT J OBESITY, V13, P131; KAYMAN S, 1990, AM J CLIN NUTR, V52, P800, DOI 10.1093/ajcn/52.5.800; KING AC, 1991, SPORTS MED, V11, P331, DOI 10.2165/00007256-199111050-00004; KRAMER FM, 1989, INT J OBESITY, V13, P123; LIDDLE RA, 1989, ARCH INTERN MED, V149, P1750, DOI 10.1001/archinte.149.8.1750; LISSNER L, 1991, NEW ENGL J MED, V324, P1839, DOI 10.1056/NEJM199106273242602; MIURA J, 1989, INT J OBESITY, V13, P73; ONEILL M, 1990, NY TIMES        0401, P1; PALGI A, 1985, AM J PUBLIC HEALTH, V75, P1190, DOI 10.2105/AJPH.75.10.1190; PAVLOU KN, 1986, ANN SURG, V203, P136, DOI 10.1097/00000658-198602000-00005; PAVLOU KN, 1989, AM J CLIN NUTR, V49, P1115, DOI 10.1093/ajcn/49.5.1115; PERRI MG, 1989, J CONSULT CLIN PSYCH, V57, P450, DOI 10.1037/0022-006X.57.3.450; PERRI MG, 1988, J CONSULT CLIN PSYCH, V56, P529, DOI 10.1037/0022-006X.56.4.529; PERRI MG, 1984, J CONSULT CLIN PSYCH, V52, P404, DOI 10.1037/0022-006X.52.3.404; SIKAND G, 1988, J AM DIET ASSOC, V88, P487; SMITH DE, 1991, HEALTH PSYCHOL, V10, P378, DOI 10.1037/0278-6133.10.6.378; SPITZER RL, 1992, INT J EAT DISORDER, V11, P191, DOI 10.1002/1098-108X(199204)11:3&lt;191::AID-EAT2260110302&gt;3.0.CO;2-S; STEPTOE A, 1988, HEALTH PSYCHOL, V7, P329, DOI 10.1037/0278-6133.7.4.329; STUNKARD A, 1959, ARCH INTERN MED, V103, P79, DOI 10.1001/archinte.1959.00270010085011; TAYLOR CB, 1991, AM J EPIDEMIOL, V134, P235, DOI 10.1093/oxfordjournals.aje.a116077; TREMBLAY A, 1991, AM J CLIN NUTR, V54, P506, DOI 10.1093/ajcn/54.3.506; VERTES V, 1977, JAMA-J AM MED ASSOC, V238, P2151, DOI 10.1001/jama.238.20.2151; VOLKMAR FR, 1981, ARCH INTERN MED, V141, P426, DOI 10.1001/archinte.141.4.426; WADDEN TA, 1992, ARCH INTERN MED, V152, P961, DOI 10.1001/archinte.152.5.961; WADDEN TA, 1989, INT J OBESITY, V13, P39; WADDEN TA, 1983, ANN INTERN MED, V99, P675, DOI 10.7326/0003-4819-99-5-675; WADDEN TA, 1992, TREATMENT SERIOUSLY, P44; WING RR, 1991, ARCH INTERN MED, V151, P1334, DOI 10.1001/archinte.151.7.1334; WOOD PD, 1988, NEW ENGL J MED, V319, P1173, DOI 10.1056/NEJM198811033191801; YANG MU, 1992, TREATMENT SERIOUSLY, P83; 1989, EXCHANGE LISTS MEAL; [No title captured]	45	347	360	1	28	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1993	119	7	2				688	693		10.7326/0003-4819-119-7_Part_2-199310011-00012	http://dx.doi.org/10.7326/0003-4819-119-7_Part_2-199310011-00012			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA330	8363198				2023-01-03	WOS:A1993MA33000012
J	SOUQUET, PJ; CHAUVIN, F; BOISSEL, JP; CELLERINO, R; CORMIER, Y; GANZ, PA; KAASA, S; PATER, JL; QUOIX, E; RAPP, E; TUMARELLO, D; WILLIAMS, J; WOODS, BL; BERNARD, JP				SOUQUET, PJ; CHAUVIN, F; BOISSEL, JP; CELLERINO, R; CORMIER, Y; GANZ, PA; KAASA, S; PATER, JL; QUOIX, E; RAPP, E; TUMARELLO, D; WILLIAMS, J; WOODS, BL; BERNARD, JP			POLYCHEMOTHERAPY IN ADVANCED NON-SMALL-CELL LUNG-CANCER - A METAANALYSIS	LANCET			English	Article							RANDOMIZED TRIAL; COMBINATION CHEMOTHERAPY; SUPPORTIVE CARE; CARCINOMA; CISPLATIN; VINDESINE	We did a meta-analysis of all published polychemotherapy vs supportive care clinical trials in patients with non-resectable non small cell lung cancer. 7 studies with more than 700 patients were selected. We used the number of deaths at 3, 6, 9, 12, and 18 months as the endpoints because we were unable to obtain all the individual data. Our analysis showed a reduction in mortality during the first 6 months with polychemotherapy. Although small, this increase in survival, together with an improved quality of life, suggests that polychemotherapy should be recommended for patients with non-resectable non small cell lung cancer.	UNITE PHARMACOL CLIN, LYON, FRANCE; HOP LAVAL, CTR PNEUMOL, QUEBEC CITY, PQ, CANADA; UNIV CALIF LOS ANGELES, DEPT MED, LOS ANGELES, CA USA; CTR HOSP STRASBOURG, SERV PNEUMOL, STRASBOURG, FRANCE; ROYAL N SHORE HOSP, DEPT CLIN ONCOL, SYDNEY, AUSTRALIA; TOM BAKER CANC CLIN, CALGARY, AB, CANADA; SOUTHAMPTON GEN HOSP, CRC, SOUTHAMPTON SO9 4XY, HANTS, ENGLAND; UNIV ANCONA, ONCOL CLIN, I-60100 ANCONA, ITALY; NORWEGIAN RADIUM HOSP, OSLO 3, NORWAY; QUEENS UNIV, NCI, CANADA CLIN TRIALS GRP, KINGSTON K7L 3N6, ONTARIO, CANADA	Laval University; University of California System; University of California Los Angeles; CHU Strasbourg; Royal North Shore Hospital; University of Sydney; Tom Baker Cancer Clinic; University of Calgary; University of Southampton; Marche Polytechnic University; University of Oslo; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Queens University - Canada	SOUQUET, PJ (corresponding author), CTR HOSP LYON SUD, SERV PNEUMOL, F-69310 PIERRE BENITE, FRANCE.							ANDERSON G, 1984, SEMIN ONCOL, V12, P21; CELLERINO R, 1988, EUR J CANCER CLIN ON, V24, P1839, DOI 10.1016/0277-5379(88)90095-8; CELLERINO R, 1991, J CLIN ONCOL, V9, P1453, DOI 10.1200/JCO.1991.9.8.1453; CORMIER Y, 1982, CANCER, V50, P845, DOI 10.1002/1097-0142(19820901)50:5<845::AID-CNCR2820500507>3.0.CO;2-S; DURRANT KR, 1971, LANCET, V1, P715; FERNANDEZ C, 1989, ACTA ONCOL, V28, P129; GANZ PA, 1989, CANCER, V63, P1271, DOI 10.1002/1097-0142(19890401)63:7<1271::AID-CNCR2820630707>3.0.CO;2-6; GANZ PA, 1988, CANCER, V61, P849, DOI 10.1002/1097-0142(19880215)61:4<849::AID-CNCR2820610435>3.0.CO;2-B; GLASS GV, 1984, META ANAL SOCIAL RES; GRALLA RJ, 1981, ANN INTERN MED, V95, P414, DOI 10.7326/0003-4819-95-4-414; Hedges L, 1985, STATISTICAL METHODS; JAAKINIMAINEN L, 1989, P ASCO, V8, P221; KAASA S, 1991, CANCER, V67, P2443, DOI 10.1002/1097-0142(19910515)67:10<2443::AID-CNCR2820671008>3.0.CO;2-K; LAING AH, 1975, LANCET, V2, P1161; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; QUOIX E, 1988, LUNG CANCER, V4, pA181; RAPP E, 1988, J CLIN ONCOL, V6, P633, DOI 10.1200/JCO.1988.6.4.633; REGAN J, 1991, BRIT J CANCER, V64, P396, DOI 10.1038/bjc.1991.316; WOODS RL, 1990, BRIT J CANCER, V61, P608, DOI 10.1038/bjc.1990.135	19	490	502	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 3	1993	342	8862					19	21						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK985	8100290				2023-01-03	WOS:A1993LK98500011
J	RAYNOR, DK; BOOTH, TG; BLENKINSOPP, A				RAYNOR, DK; BOOTH, TG; BLENKINSOPP, A			EFFECTS OF COMPUTER-GENERATED REMINDER CHARTS ON PATIENTS COMPLIANCE WITH DRUG REGIMENS	BRITISH MEDICAL JOURNAL			English	Article							INFORMATION; DISCHARGE	Objective To investigate whether a reminder chart improved patients' compliance with their drug regimen after discharge from hospital. Design-Patients were randomly allocated to one of four groups. Two groups received the reminder chart: one also received routine counselling from a nurse and the other received structured counselling from a pharmacist, which included an explanation of the reminder chart. The other two groups received only counselling, either from a nurse or from a pharmacist. Patients were visited about 10 days later: they were questioned about their drug regimen, and their compliance was measured by tablet counting. Setting-The pharmacy in a district general hospital and patients' homes. Patients-197 patients being discharged from hospital who were regularly taking two or more drugs. Intervention-An individualised reminder chart, which listed each person's medicines and when they were to be taken and was automatically generated by a medicine labelling computer. Main outcome measures-Patient's compliance with and knowledge of their drug regimen. Main results-Of the patients who received the reminder chart, 83% (95% confidence interval 74% to 90%) correctly described their dose regimen compared with 47% (37% to 58%) of those without the chart (p < 0.001). The mean compliance score was 86% (81% to 91%) in both groups not given the reminder chart; 91% (87% to 94%) in the group given the chart without an explanation; and 95% (93% to 98%) in the group given the chart and an explanation. A mean compliance score of > 85% was achieved by 63% (53% to 73%) of patients without a reminder chart and by 86% (78% to 93%) of those receiving the chart (p < 0.001). Conclusions-An automatically generated reminder chart is a practical and cost effective aid to compliance.	KILLINGBECK HOSP,LEEDS LS14 6UH,ENGLAND; UNIV BRADFORD,PHARM PRACTICE RES UNIT,BRADFORD BD7 1DP,W YORKSHIRE,ENGLAND; UNIV MANCHESTER,CTR PHARM POSTGRAD EDUC,MANCHESTER M60 7LP,ENGLAND	University of Bradford; University of Manchester	RAYNOR, DK (corresponding author), SEACROFT HOSP,DEPT PHARM,LEEDS LS14 6UH,W YORKSHIRE,ENGLAND.			Blenkinsopp, Alison/0000-0001-8872-2769				ELLIS DA, 1979, BRIT MED J, V1, P456, DOI 10.1136/bmj.1.6161.456; GARDNER MJ, 1989, CONFIDENCE INTERVAL; HALLWORTH RB, 1984, BR J PHARM PRACT, V6, P42; MACDONALD ET, 1977, BMJ-BRIT MED J, V2, P618, DOI 10.1136/bmj.2.6087.618; MAZZUCA SA, 1982, J CHRON DIS, V35, P521, DOI 10.1016/0021-9681(82)90071-6; PARKIN DM, 1976, BMJ-BRIT MED J, V2, P686, DOI 10.1136/bmj.2.6037.686; Raynor DK, 1992, INT J PHARM PRACT, V1, P126; RAYNOR DK, 1991, THESIS U BRADFORD; SANDLER DA, 1989, BRIT MED J, V298, P870, DOI 10.1136/bmj.298.6677.870; SANDLER DA, 1989, BRIT MED J, V299, P1511, DOI 10.1136/bmj.299.6714.1511; Sweeney SJ, 1989, PHARM J, V242; 1989, DISCHARGE PATIENTS H; 1988, PHARM J, V240, P252	13	83	85	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 1	1993	306	6886					1158	1161		10.1136/bmj.306.6886.1158	http://dx.doi.org/10.1136/bmj.306.6886.1158			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LA685	8499815	Green Published, Bronze			2023-01-03	WOS:A1993LA68500018
J	GENSER, N; MAIR, J; MAIER, J; DIENSTL, F; PUSCHENDORF, B; LECHLEITNER, P				GENSER, N; MAIR, J; MAIER, J; DIENSTL, F; PUSCHENDORF, B; LECHLEITNER, P			THROMBIN GENERATION DURING INFUSION OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR	LANCET			English	Letter									UNIV INNSBRUCK, DEPT MED CHEM & BIOCHEM, A-6020 INNSBRUCK, AUSTRIA	University of Innsbruck	GENSER, N (corresponding author), UNIV INNSBRUCK, DEPT INTERNAL MED, A-6020 INNSBRUCK, AUSTRIA.		Mair, Johannes/J-5822-2019					BAGLIN, 1993, LANCET, V341, P504; GULBA DC, 1991, CIRCULATION, V83, P937, DOI 10.1161/01.CIR.83.3.937	2	9	9	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 17	1993	341	8851					1038	1038		10.1016/0140-6736(93)91141-8	http://dx.doi.org/10.1016/0140-6736(93)91141-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY368	8096940				2023-01-03	WOS:A1993KY36800074
J	VISKIN, S; BELHASSEN, B; ROTH, A; REICHER, M; AVERBUCH, M; SHEPS, D; SHALABYE, E; LANIADO, S				VISKIN, S; BELHASSEN, B; ROTH, A; REICHER, M; AVERBUCH, M; SHEPS, D; SHALABYE, E; LANIADO, S			AMINOPHYLLINE FOR BRADYASYSTOLIC CARDIAC-ARREST REFRACTORY TO ATROPINE AND EPINEPHRINE	ANNALS OF INTERNAL MEDICINE			English	Note						AMINOPHYLLINE; CARDIAC ARREST; ASYSTOLE; BRADYARRHYTHMIAS	ATRIOVENTRICULAR-CONDUCTION; MYOCARDIAL-INFARCTION; ADENOSINE; ANTAGONISM; BLOCK	Endogenous adenosine, which accumulates during hypoxia and ischemia, may perpetuate asystole. Therefore, patients with cardiac arrest were prospectively studied to see if their immediate outcome could be improved with aminophylline, a competitive antagonist of adenosine. Fifteen consecutive patients with cardiac arrest due to asystole or to nonperfusing bradyarrhythmias, who failed to respond to intravenous atropine and epinephrine, were treated with aminophylline (rapid intravenous injection of 250 mg). Establishment of a stable heart rhythm with sufficient blood pressure to allow discontinuation of closed-chest cardiac massage was achieved in 11 of 15 (73%) patients. All these 11 patients were alive 60 minutes after resuscitation. One patient survived, without neurologic damage. We conclude that the immediate outcome of patients with asystole refractory to standard treatment may be improved with aminophylline. Further study is warranted to determine if earlier administration of aminophylline during cardiac arrest will improve long-term outcome.	TEL AVIV UNIV, SACKLER SCH MED, TEL AVIV, ISRAEL	Tel Aviv University; Sackler Faculty of Medicine	VISKIN, S (corresponding author), TEL AVIV MED CTR & SCH MED, DEPT CARDIOL, WEIZMAN ST 6, IL-64239 TEL AVIV, ISRAEL.							BELARDINELLI L, 1982, CIRC RES, V51, P569, DOI 10.1161/01.RES.51.5.569; BELARDINELLI L, 1989, PROG CARDIOVASC DIS, V32, P73, DOI 10.1016/0033-0620(89)90015-7; HORI M, 1991, CIRCULATION, V84, P828, DOI 10.1161/01.CIR.84.2.828; LERMAN BB, 1988, J CLIN INVEST, V82, P2127, DOI 10.1172/JCI113834; PARADIS NA, 1990, ANN EMERG MED, V19, P1288, DOI 10.1016/S0196-0644(05)82289-9; PELLEG A, 1990, AM J PHYSIOL, V258, pH1815, DOI 10.1152/ajpheart.1990.258.6.H1815; ROBERTS D, 1990, CHEST, V97, P413, DOI 10.1378/chest.97.2.413; STRASBERG B, 1991, AM J CARDIOL, V67, P527, DOI 10.1016/0002-9149(91)90016-E; VESTAL RE, 1983, CIRCULATION, V67, P162, DOI 10.1161/01.CIR.67.1.162; WESLEY RC, 1986, J AM COLL CARDIOL, V8, P1232, DOI 10.1016/S0735-1097(86)80406-5; 1992, JAMA-J AM MED ASSOC, V268, P2199	11	46	52	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1993	118	4					279	281		10.7326/0003-4819-118-4-199302150-00006	http://dx.doi.org/10.7326/0003-4819-118-4-199302150-00006			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KL457	8420445				2023-01-03	WOS:A1993KL45700006
J	NORRIS, R				NORRIS, R			ACUTE CORONARY-CARE - WHO SHOULD GO TO THE CCU IN 1993	LANCET			English	Editorial Material											NORRIS, R (corresponding author), TRAFFORD CTR MED RES, BRIGHTON, E SUSSEX, ENGLAND.							[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, Lancet, V1, P397; BETT J H N, 1989, Australian and New Zealand Journal of Medicine, V19, P572; BIRKHEAD JS, 1992, BMJ-BRIT MED J, V305, P445, DOI 10.1136/bmj.305.6851.445; CERQUEIRA MD, 1992, CIRCULATION, V86, P643; ROLLAG A, 1992, J INTERN MED, V232, P299, DOI 10.1111/j.1365-2796.1992.tb00589.x; WEAVER WD, 1992, CIRCULATION, V86, P16	7	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 23	1993	341	8839					212	212		10.1016/0140-6736(93)90073-P	http://dx.doi.org/10.1016/0140-6736(93)90073-P			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ219	8093504				2023-01-03	WOS:A1993KJ21900011
J	SMITH, WCS; JESUDASAN, K				SMITH, WCS; JESUDASAN, K			ELIMINATION OF LEPROSY AND PROSPECTS FOR REHABILITATION	LANCET			English	Editorial Material											SMITH, WCS (corresponding author), LEPROSY MISSION,SINGAPORE,SINGAPORE.							NOORDEEN SK, 1991, B WORLD HEALTH ORGAN, V69, P263; NOORDEEN SK, 1992, B WORLD HEALTH ORGAN, V70, P7; PETTIT JHS, 1964, LANCET, V2, P673, DOI 10.1016/S0140-6736(64)92482-1; SMITH WCS, 1992, LEPR REV S, V62, P23; 1982, WHO TECH REP SER, V675; 1991, ELIMINATION LEPROSY; 1985, WHO TECH REP SER, V716	7	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 9	1993	341	8837					89	90		10.1016/0140-6736(93)92563-9	http://dx.doi.org/10.1016/0140-6736(93)92563-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF870	8093410				2023-01-03	WOS:A1993KF87000010
J	Monsein, LH				Monsein, LH			New detachable coils for treating cerebral aneurysms	NATURE MEDICINE			English	Editorial Material							ENDOVASCULAR APPROACH; SACCULAR ANEURYSMS; ELECTROTHROMBOSIS; MORTALITY				Monsein, LH (corresponding author), JOHNS HOPKINS UNIV HOSP,DEPT RADIOL,600 N WOLFE ST,B112C HOUCK,BALTIMORE,MD 21287, USA.							Dandy WE, 1938, ANN SURG, V107, P654, DOI 10.1097/00000658-193805000-00003; GUGLIELMI G, 1991, J NEUROSURG, V75, P1, DOI 10.3171/jns.1991.75.1.0001; GUGLIELMI G, 1991, J NEUROSURG, V75, P8, DOI 10.3171/jns.1991.75.1.0008; HILAL SK, 1988, AM J NEURORADIOL, V9, P1030; INGALL TJ, 1989, STROKE, V20, P718, DOI 10.1161/01.STR.20.6.718; KLEIN GE, 1995, RADIOLOGY, V197, P416; NICHOLS DA, 1995, RADIOLOGY, V197, P58; ROPPER AH, 1984, J NEUROSURG, V60, P909, DOI 10.3171/jns.1984.60.5.0909; SERBINENKO FA, 1974, J NEUROSURG, V41, P125, DOI 10.3171/jns.1974.41.2.0125; VUNUELA F, 1995, SYLLABUS 1995 COURSE, P5; WEIR B, 1987, ANEURYSMS AFFECTING, P23	11	3	3	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1996	2	2					160	161		10.1038/nm0296-160	http://dx.doi.org/10.1038/nm0296-160			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TU060	8574956				2023-01-03	WOS:A1996TU06000031
J	Lip, GYH; Beevers, DG; Coope, JR				Lip, GYH; Beevers, DG; Coope, JR			ABC of atrial fibrillation - Atrial fibrillation in general and hospital practice	BRITISH MEDICAL JOURNAL			English	Article									UNIV BIRMINGHAM,CITY HOSP,DEPT CARDIOL,BIRMINGHAM,W MIDLANDS,ENGLAND	University of Birmingham	Lip, GYH (corresponding author), UNIV BIRMINGHAM,CITY HOSP,DEPT MED,BIRMINGHAM,W MIDLANDS,ENGLAND.							LIP GYH, IN PRESS HEART; PELL JP, 1993, BRIT J GEN PRACT, V43, P152; SUDLOW CM, 1995, BRIT MED J, V311, P558, DOI 10.1136/bmj.311.7004.558; SWEENEY KG, 1995, BRIT J GEN PRACT, V45, P153; 1990, J CLIN PATHOL, V43, P177	5	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 20	1996	312	7024					175	178						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TR325	8563542				2023-01-03	WOS:A1996TR32500031
J	Spitzer, WO; Lewis, MA; Heinemann, LAJ; Thorogood, M; MacRae, KD				Spitzer, WO; Lewis, MA; Heinemann, LAJ; Thorogood, M; MacRae, KD			Third generation oral contraceptives and risk of venous thromboembolic disorders: An international case-control study	BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR-DISEASE; ETHINYLESTRADIOL	Objective - To test whether use of combined oral contraceptives containing third generation progestogens is associated with altered risk of venous thromboembolism. Design - Matched case-control study. Setting - 10 centres in Germany and United Kingdom. Subjects - Cases were 471 women aged 16-44 who had a venous thromboembolism. Controls were 1772 women (at least 3 controls per case) unaffected by venous thromboembolism who were matched with corresponding case for age and for hospital or community setting. Main outcome measures - Odds ratios derived with stratified analyses and unconditional logistic regression to adjust for potential confounding variables. Results - Odds ratios (95% confidence intervals) for venous thromboembolism were: for any oral contraceptives versus no use, 4.0 (3.1 to 5.3); for second generation products (low dose ethinyloestradiol, no gestodene or desogestrel) versus no use, 3.2 (2.3 to 4.3); for third generation products (low dose ethinyloestradiol, gestodene or desogestrel) versus no use, 4.8 (3.4 to 6.7); for third generation products versus second generation products, 1.5 (1.1 to 2.1); for products containing gestodene versus second generation products, 1.5 (1.0 to 2.2); and for products containing desogestrel versus second generation products, 1.5 (1.1 to 2.2). Probability of death due to venous thromboembolism for women using third generation products is about 20 per million users per year, for women using second generation products it is about 14 per million users per year, and for non-users it is five per million per year. Conclusions - Risk of venous thromboembolism was slightly increased in users of third generation oral contraceptives compared with users of second generation products.	MCGILL UNIV,DEPT EPIDEMIOL & BIOSTAT,MONTREAL,PQ,CANADA; CTR EPIDEMIOL & HLTH RES,ZEPERNICK BERLIN,GERMANY; LONDON SCH HYG & TROP MED,LONDON WC1,ENGLAND; CHARING CROSS & WESTMINSTER MED SCH,LONDON,ENGLAND	McGill University; University of London; London School of Hygiene & Tropical Medicine; Imperial College London			Ulmer, Hanno/S-6615-2019	Ulmer, Hanno/0000-0001-5911-1002				COLE P, 1971, BRIT J PREV SOC MED, V25, P242; GOLDZIEHER JW, 1983, J REPROD MED, V28, P53; JUNGHOFFMANN C, 1989, CONTRACEPTION, V40, P299, DOI 10.1016/0010-7824(89)90094-2; KUHL H, 1988, CONTRACEPTION, V38, P477, DOI 10.1016/0010-7824(88)90088-1; LEVIN M L, 1953, Acta Unio Int Contra Cancrum, V9, P531; LEWIS MA, IN PRESS PHARMACOEPI; MIETTINE.OS, 1974, AM J EPIDEMIOL, V99, P325, DOI 10.1093/oxfordjournals.aje.a121617; POULTER N, IN PRESS J CLIN EPID; Spitzer WO, 1993, PHARMACOEPIDEM DR S, V2, P21; STADEL BV, 1981, NEW ENGL J MED, V305, P612, DOI 10.1056/NEJM198109103051104; STADEL BV, 1981, NEW ENGL J MED, V305, P672, DOI 10.1056/NEJM198109173051205; Thorogood M., 1993, PHARMACOEPIDEMIOL DR, V2, P3; VESSEY MP, 1993, METHOD INFORM MED, V32, P222	13	486	494	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 13	1996	312	7023					83	88						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ168	8555935				2023-01-03	WOS:A1996TQ16800022
J	BICKELL, WH; WALL, MJ; PEPE, PE; MARTIN, RR; GINGER, VF; ALLEN, MK; MATTOX, KL				BICKELL, WH; WALL, MJ; PEPE, PE; MARTIN, RR; GINGER, VF; ALLEN, MK; MATTOX, KL			IMMEDIATE VERSUS DELAYED FLUID RESUSCITATION FOR HYPOTENSIVE PATIENTS WITH PENETRATING TORSO INJURIES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANESTHETIZED SWINE; HEMORRHAGE; AORTOTOMY; ANEURYSM; PRESSURE; SHOCK	Background. Fluid resuscitation may be detrimental when given before bleeding is controlled in patients with trauma. The purpose of this study was to determine the effects of delaying fluid resuscitation until the time of operative intervention in hypotensive patients with penetrating injuries to the torso. Methods. We conducted a prospective trial comparing immediate and delayed fluid resuscitation in 598 adults with penetrating torso injuries who presented with a pre; hospital systolic blood pressure less than or equal to 90 mm Hg. The study setting was a city with a single centralized system of prehospital emergency care and a single receiving facility for patients with major trauma. Patients assigned to the immediate-resuscitation group received standard fluid resuscitation before they reached the hospital and in the trauma center, and those assigned to the delayed-resuscitation group received intravenous cannulation but no fluid resuscitation until they reached the operating room. Results. Among the 289 patients who received delayed fluid resuscitation, 203 (70 percent) survived and were discharged from the hospital, as compared with 193 of the 309 patients (62 percent) who received immediate fluid resuscitation (P = 0.04). The mean estimated intraoperative blood loss was similar in the two groups. Among the 238 patients in the delayed-resuscitation group who survived to the postoperative period, 55 (23 percent) had. one or more complications (adult respiratory distress syndrome, sepsis syndrome, acute renal failure, coagulopathy, wound infection, and pneumonia), as compared with 69 of the 227 patients (30 percent) in the immediate-resuscitation group (P = 0.08). The duration of hospitalization was shorter in the delayed-resuscitation group. Conclusions. For hypotensive patients with penetrating torso injuries, delay of aggressive fluid resuscitation until operative intervention improves the outcome.	BAYLOR COLL MED,CORA & WEBB MADING DEPT SURG,HOUSTON,TX 77030; ST FRANCIS HOSP,DEPT EMERGENCY SERV,TULSA,OK; BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030; BEN TAUB GEN HOSP,HOUSTON,TX 77030; HOUSTON EMERGENCY MED SERV,HOUSTON,TX; BROOKE ARMY MED CTR,DEPT SURG,TRAUMA SECT,FT SAM HOUSTON,TX 78234	Baylor College of Medicine; St. Francis Hospital - Oklahoma; Baylor College of Medicine; San Antonio Military Medical Center; United States Department of Defense; United States Army								[Anonymous], 1990, ABBREVIATED INJURY S; BICKELL WH, 1991, SURGERY, V110, P529; BICKELL WH, 1993, ANN EMERG MED, V22, P225, DOI 10.1016/S0196-0644(05)80208-2; BICKELL WH, 1989, J TRAUMA, V29, P409, DOI 10.1097/00005373-198903000-00028; BICKELL WH, 1992, ANN EMERG MED, V21, P1077, DOI 10.1016/S0196-0644(05)80648-1; BICKELL WH, 1989, CIRC SHOCK, V28, P321; BONE RC, 1987, NEW ENGL J MED, V317, P653, DOI 10.1056/NEJM198709103171101; Cannon WB, 1918, J AMER MED ASSOC, V70, P618; Capono A, 1993, J TRAUMA, V35, P984; CAROLINE NL, 1983, EMERGENCY CARE STREE, P57; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; CRAWFORD ES, 1991, J VASC SURG, V13, P348; CRAWFORD ES, 1991, ANN SURG, V213, P417, DOI 10.1097/00000658-199105000-00006; CURKA PA, 1993, ANN EMERG MED, V22, P1688, DOI 10.1016/S0196-0644(05)81307-1; DILLON J, 1966, ARCH SURG-CHICAGO, V93, P537; FOWLER RL, 1988, BASIC TRAUMA LIFE SU, P107; GROSS D, 1988, J TRAUMA, V28, P751, DOI 10.1097/00005373-198806000-00005; HARRIS B H, 1969, Surgical Forum (Chicago), V20, P31; MARTIN RR, 1992, J TRAUMA, V33, P354, DOI 10.1097/00005373-199209000-00004; MATTOX KL, 1989, J TRAUMA, V29, P1104, DOI 10.1097/00005373-198908000-00007; MATTOX KL, 1994, COMPLICATIONS TRAUMA, P305; MILLES G, 1966, SURGERY, V60, P434; OBRIEN PC, 1988, MAYO CLIN PROC, V63, P1245, DOI 10.1016/S0025-6196(12)65412-3; PEPE PE, 1984, NEW ENGL J MED, V311, P281, DOI 10.1056/NEJM198408023110502; SHAFTAN GW, 1964, J CARDIOVASC SURG, V5, P251; SHAFTAN GW, 1965, SURGERY, V58, P851; SHIRES T, 1964, ARCH SURG-CHICAGO, V88, P688; STERN SA, 1993, ANN EMERG MED, V22, P155, DOI 10.1016/S0196-0644(05)80195-7; WANGENST.SL, 1968, SURGERY, V64, P912; WEIGEL CJ, 1991, TRAUMA, P839; WIGGERS CJ, 1950, PHYSL SHOCK, P121; 1993, ADV TRAUMA LIFE SUPP, P75; 1952, SURGERY WORLD WAR 2, P6; 1991, DESCRIPTION EMERGENC; 1989, ADV TRAUMA LIFE SUPP; 1985, ABBREVIATED INJURY S	36	1305	1369	2	41	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 27	1994	331	17					1105	1109		10.1056/NEJM199410273311701	http://dx.doi.org/10.1056/NEJM199410273311701			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN065	7935634				2023-01-03	WOS:A1994PN06500001
J	VERDER, H; ROBERTSON, B; GREISEN, G; EBBESEN, F; ALBERTSEN, P; LUNDSTROM, K; JACOBSEN, T; AGERTOFT, L; HOBOLTH, N; DJERNES, B; GRYTTER, C; HERTEL, J; HOLM, V; HANSEN, US; KAMPER, J; JOHANSEN, KH; NATHAN, E; LANGE, A; PEITERSEN, B; PEDERSENBJERGAARD, L; SKOV, L; SVENNINGSEN, N; CURSTEDT, T; BERTELSEN, A; VESTERGAARD, A; PETERSEN, E				VERDER, H; ROBERTSON, B; GREISEN, G; EBBESEN, F; ALBERTSEN, P; LUNDSTROM, K; JACOBSEN, T; AGERTOFT, L; HOBOLTH, N; DJERNES, B; GRYTTER, C; HERTEL, J; HOLM, V; HANSEN, US; KAMPER, J; JOHANSEN, KH; NATHAN, E; LANGE, A; PEITERSEN, B; PEDERSENBJERGAARD, L; SKOV, L; SVENNINGSEN, N; CURSTEDT, T; BERTELSEN, A; VESTERGAARD, A; PETERSEN, E			SURFACTANT THERAPY AND NASAL CONTINUOUS POSITIVE AIRWAY PRESSURE FOR NEWBORNS WITH RESPIRATORY-DISTRESS SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BIRTH-WEIGHT INFANTS; HYALINE-MEMBRANE DISEASE; REPLACEMENT; TRIAL; LUNG; LESS	Background. In southern Scandinavia most babies with respiratory distress syndrome are initially treated with nasal continuous positive airway pressure. We performed a multicenter trial to investigate whether the addition of a single dose of porcine surfactant administered during a short intubation before the occurrence of serious deterioration could reduce the subsequent need for mechanical ventilation. Methods. We randomly assigned 35 infants with moderate-to-severe respiratory distress syndrome to surfactant therapy (Curosurf, 200 mg per kilogram of body weight) plus nasal continuous positive airway pressure and 33 infants to nasal continuous positive airway pressure alone. The study was not blinded. The indications for mechanical ventilation were a ratio of arterial to alveolar oxygen tension of less than 0.15, severe apneic attacks, or both. Results. Six hours after randomization, when the median age of the babies was 18 hours, the mean ratio of arterial to alveolar oxygen tension was 0.37 in the surfactant-treated babies, as compared with 0.25 in the controls (P<0.001). The need for subsequent mechanical ventilation was reduced with surfactant therapy (to 43 percent of the surfactant-treated babies, as compared with 85 percent of the controls; P = 0.003). When 17 infants with ratios of arterial-to-alveolar oxygen tension of less than 0.15 at randomization were excluded, the need for mechanical ventilation was still significantly reduced in the surfactant-treated group (to 33 percent [9 of 27 babies], as compared with 83 percent [20 of 24 babies] in the control group; P<0.001). After 28 days, two of the surfactant-treated babies had died, as compared with five of the control babies. Conclusions. In babies with moderate-to-severe respiratory distress syndrome treated with nasal continuous positive airway pressure, a single dose of surfactant reduced the need for subsequent mechanical ventilation.	KAROLINSKA HOSP,PERINATAL PATHOL RES UNIT,STOCKHOLM,SWEDEN; UNIV COPENHAGEN HOSP,DEPT PEDIAT,DK-2100 COPENHAGEN,DENMARK; AALBORG HOSP,DEPT PEDIAT,AALBORG,DENMARK	Karolinska Institutet; Karolinska University Hospital; University of Copenhagen; Aalborg University; Aalborg University Hospital	VERDER, H (corresponding author), HOLBAEK CENT HOSP,DEPT PEDIAT,DK-4300 HOLBAEK,DENMARK.		Greisen, Gorm/AAA-6463-2022	Greisen, Gorm/0000-0001-8042-3262				ALLEN LP, 1977, ARCH DIS CHILD, V52, P373, DOI 10.1136/adc.52.5.373; Altman DG, 1991, PRACTICAL STATISTICS; AVERY ME, 1987, PEDIATRICS, V79, P26; BENVENIS.D, 1968, BRIT J ANAESTH, V40, P464, DOI 10.1093/bja/40.6.464; BENVENISTE D, 1976, J PEDIATR-US, V88, P1015, DOI 10.1016/S0022-3476(76)81066-9; BEVILACQUA G, 1993, J PERINAT MED, V21, P329, DOI 10.1515/jpme.1993.21.5.329; BOS J, 1991, SURFACTANT SYSTEM OF THE LUNG, P96; BRENDSTRUP A, 1975, BRIT J ANAESTH, V47, P1335, DOI 10.1093/bja/47.12.1335; FARRELL EE, 1989, AM J OBSTET GYNECOL, V161, P628, DOI 10.1016/0002-9378(89)90367-0; FUJIWARA T, 1980, LANCET, V1, P55; GILBERT R, 1974, AM REV RESPIR DIS, V109, P142; GREGORY GA, 1971, NEW ENGL J MED, V284, P1333, DOI 10.1056/NEJM197106172842401; HALLIDAY HL, 1993, ARCH DIS CHILD-FETAL, V69, P276, DOI 10.1136/adc.69.3_Spec_No.276; HILL A, 1982, PEDIATRICS, V69, P282; JACOBSEN T, 1993, ACTA PAEDIATR, V82, P934, DOI 10.1111/j.1651-2227.1993.tb12603.x; JOBE AH, 1993, NEW ENGL J MED, V328, P861; KAMPER J, 1978, ACTA ANAESTH SCAND, V22, P367, DOI 10.1111/j.1399-6576.1978.tb01312.x; KAMPER J, 1993, ACTA PAEDIATR, V82, P193, DOI 10.1111/j.1651-2227.1993.tb12637.x; KENDIG JW, 1991, NEW ENGL J MED, V324, P865, DOI 10.1056/NEJM199103283241301; LACHMANN B, 1992, INTENS CARE MED, V18, P319, DOI 10.1007/BF01694358; LUNDSTROM KE, 1993, ACTA PAEDIATR, V82, P856, DOI 10.1111/j.1651-2227.1993.tb12579.x; MORTENSSON W, 1987, ACTA RADIOL, V28, P389; PAPILE LA, 1978, J PEDIATR-US, V92, P529, DOI 10.1016/S0022-3476(78)80282-0; ROBERTSON B, 1990, PROG R RES, V25, P237; SPEER CP, 1992, PEDIATRICS, V89, P13; SVENNINGSEN N, 1987, CRIT CARE MED, V15, P918, DOI 10.1097/00003246-198710000-00005; TARNOWMORDI W, 1991, ARCH DIS CHILD-FETAL, V66, P374, DOI 10.1136/adc.66.4_Spec_No.374; VERDER H, 1992, UGESKRIFT LAEGER, V154, P2136; VICTORIN LH, 1990, BIOL NEONATE, V58, P121; 1988, PEDIATRICS, V82, P683; 1992, LANCET, V340, P1363	31	286	305	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 20	1994	331	16					1051	1055		10.1056/NEJM199410203311603	http://dx.doi.org/10.1056/NEJM199410203311603			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL560	8090164				2023-01-03	WOS:A1994PL56000003
J	BROWN, DJ				BROWN, DJ			OPINIONS OF GENERAL-PRACTITIONERS IN NOTTINGHAMSHIRE ABOUT PROVISION OF INTRAPARTUM CARE	BRITISH MEDICAL JOURNAL			English	Article							OBSTETRICS	Objective-To examine the beliefs of general practitioners concerning intrapartum care. Design-Postal questionnaire survey. Subjects-Ah general practitioners with patients in Nottinghamshire Family Health Services Authority in September 1993. Main outcome measures-General practitioners' current involvement in maternity care, and beliefs on intrapartum care. Results-Of 694 general practitioners sent questionnaires, 550 (79.2%) replied. 529 of these were on the obstetric list; 437 had not attended a delivery in the past 12 months; 36 had attended two or more; 358 general practitioners did not wish to provide more intrapartum care; 349 did not feel competent to do so. Reasons for not wanting to provide intrapartum care included current workload (453), disruption to personal life (407), and the fear of litigation (377). General practitioners who already booked women for home delivery were more Likely to wish to do more deliveries (62/42 v 61/316, chi(2) = 85.3; P < 0.0001) and to have more positive attitudes towards increasing women's choice in maternity care (90/22 v 195/151, chi(2) = 227; P < 0.0001). Conclusions-The involvement of general practitioners in intrapartum care in Nottinghamshire is low, and most general practitioners are unwilling to increase their role. However, general practitioners who already book for home delivery are keen to do more.	UNIV NOTTINGHAM,SCH MED,DEPT PUBL HLTH MED,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham				Hamblin-Brown, DJ/0000-0002-7353-8691				Bull M J, 1981, J R Coll Gen Pract, V31, P357; CAMPBELL R, 1987, WHERE BE BORN DEBATE; Campbell R., 1990, POLITICS MATERNITY C; CHAMBERS R, 1993, BRIT J GEN PRACT, V43, P410; KADRI AZ, 1992, BRIT MED J, V304, P112; KIETLY P, 1992, PREGNANCY CARE 1990S; KLEIN M, 1989, EFFECTIVE CARE PREGN, V1; LOUDON I, 1990, BRIT MED J, V301, P703, DOI 10.1136/bmj.301.6754.703; MACKENZIE GM, 1993, BRIT MED J, V307, P452; MARSH GN, 1985, BRIT MED J, V290, P901, DOI 10.1136/bmj.290.6472.901; MARTINBATES C, 1993, BRIT J GEN PRACT, V43, P413; NESBITT TS, 1992, WESTERN J MED, V157, P44; PHAFF J, 1986, PERINATAL HLTH SERVI; SMITH LFP, 1991, BRIT MED J, V303, P1443, DOI 10.1136/bmj.303.6815.1443; SMITH LFP, 1991, BRIT MED J, V303, P1447, DOI 10.1136/bmj.303.6815.1447; Tew M., 1990, SAFER CHILDBIRTH CRI; WALL EM, 1991, J AM BOARD FAM PRACT, V4, P440; YOUNG G, 1987, BRIT MED J, V294, P744, DOI 10.1136/bmj.294.6574.744; YOUNG G, 1993, PRACTITIONER, V237, P736; 1993, CHANGING CHILDBIRTH; 1992, 2ND HOUS COMM SEL CO, V1; 1959, REPORT MATERNITY SER; 1980, PERINATAL NEONATAL M; 1970, DOMICILIARY MIDWIFER; 1981, BRIT MED J, V282, P1171; 1992, YOUR CHOICES FUTURE	26	16	16	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 24	1994	309	6957					777	779		10.1136/bmj.309.6957.777	http://dx.doi.org/10.1136/bmj.309.6957.777			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ282	7950566	Green Published			2023-01-03	WOS:A1994PJ28200023
J	DZIK, WH				DZIK, WH			BLOOD USAGE REVIEWS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							TRANSFUSION				DZIK, WH (corresponding author), HARVARD UNIV,SCH MED,BOSTON,MA, USA.							BABINEAU TJ, 1992, AM J SURG, V164, P22, DOI 10.1016/S0002-9610(05)80640-3; DZIK WH, 1992, CURRENT ISSUES CREAT; GOULD SA, 1986, NEW ENGL J MED, V314, P1653, DOI 10.1056/NEJM198606263142601; LACKRITZ EM, 1992, LANCET, V340, P524, DOI 10.1016/0140-6736(92)91719-O	4	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 21	1994	272	11					896	896		10.1001/jama.272.11.896	http://dx.doi.org/10.1001/jama.272.11.896			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG182	8078172				2023-01-03	WOS:A1994PG18200034
J	ARNOW, PM; BLAND, LA; GARCIAHOUCHINS, S; FRIDKIN, S; FELLNER, SK				ARNOW, PM; BLAND, LA; GARCIAHOUCHINS, S; FRIDKIN, S; FELLNER, SK			AN OUTBREAK OF FATAL FLUORIDE INTOXICATION IN A LONG-TERM HEMODIALYSIS UNIT	ANNALS OF INTERNAL MEDICINE			English	Article						HEMODIALYSIS UNITS, HOSPITAL; FLUORIDE POISONING; HEMODIALYSIS; DEIONIZATION SYSTEMS; WATER	HYPERKALEMIA	Objective: To determine the cause of an outbreak of acute illness and death in a long-term hemodialysis unit. Design: A retrospective cohort and case-control study of patients receiving hemodialysis and a laboratory study of a model deionization system to purify water for hemodialysis. Setting: An outpatient hemodialysis unit of a university hospital. Patients: 12 patients who became severely ill after hemodialysis treatment and 20 patients who did not become ill after receiving hemodialysis treatment in the same unit. Measurements: Medical and dialysis unit records were reviewed to identify and characterize cases. Fluids for dialysis were tested for toxic substances, and fluoride was measured in patients' serum. Resistivity and fluoride were measured in effluent from a model deionization system operated in the same way as the system associated with illness. Results: During five consecutive hemodialysis shifts, 12 of 15 patients receiving dialysis treatment in one room became acutely ill, with severe pruritus, multiple nonspecific symptoms, and/or fatal ventricular fibrillation (3 patients). None of 17 patients treated in the adjacent room became ill (P < 0.0001). Death was associated with longer hemodialysis time and increased age compared with other patients who became ill. Serum concentrations of fluoride in the sick patients were markedly increased to as high as 716 mu mol/L, and the source of fluoride was the temporary deionization system used to purify water for hemodialysis only in the affected room. Operation of a model deionization system showed how fluoride was adsorbed and then displaced in a massive efflux. Conclusions: Because deionization systems are used widely in hemodialysis and can cause fatal fluoride intoxication, careful design and monitoring are essential.	CTR DIS CONTROL & PREVENT, HOSP INFECT PROGRAM, ATLANTA, GA 30333 USA	Centers for Disease Control & Prevention - USA	ARNOW, PM (corresponding author), UNIV CHICAGO HOSP & CLIN, DEPT MED MC5065, 5841 S MARYLAND AVE, CHICAGO, IL 60637 USA.							ABUELO JG, 1993, SEMIN DIALYSIS, V6, P59, DOI 10.1111/j.1525-139X.1993.tb00257.x; ABUKURAH AR, 1972, J AMER MED ASSOC, V222, P816; [Anonymous], 1991, MMWR Recomm Rep, V40, P1; Arduino MJ, 1989, DIALYSIS TRANSPLANT, V18, P655; ARMSTRONG W D, 1964, J Clin Invest, V43, P555; BALTAZAR RF, 1980, CHEST, V78, P660, DOI 10.1378/chest.78.4.660; BERMAN L, 1973, NEW ENGL J MED, V289, P922; Clifford D., 1990, WATER QUALITY TREATM; FLAHERTY JP, 1993, ANN INTERN MED, V119, P1072, DOI 10.7326/0003-4819-119-11-199312010-00003; FUCHS C, 1975, CLIN CHIM ACTA, V60, P157, DOI 10.1016/0009-8981(75)90121-7; HANES CM, 1990, J DENT RES, V69, P282, DOI 10.1177/00220345900690S110; JOHNSON WJ, 1974, KIDNEY INT, V5, P451, DOI 10.1038/ki.1974.64; KESHAVIAH PR, 1989, REPLACEMENT RENAL FU, P189; KUO HC, 1975, ARCH ORAL BIOL, V20, P235, DOI 10.1016/0003-9969(75)90117-X; LEVIN NW, 1990, CLIN DIALYSIS, P172; LUEHMAN DA, 1989, MANUAL WATER TREATME, P109; MCIVOR M, 1983, AM J CARDIOL, V51, P901, DOI 10.1016/S0002-9149(83)80153-2; MCIVOR ME, 1987, ANN EMERG MED, V16, P1165; MCIVOR ME, 1987, ANN EMERG MED, V16, P777; Murray J. J., 1986, APPROPRIATE USE FLUO, P131; PARSONS V, 1975, BMJ-BRIT MED J, V1, P128, DOI 10.1136/bmj.1.5950.128; SCHIFFL HH, 1980, NEPHRON, V26, P69, DOI 10.1159/000181954; SIDDIQUI JY, 1970, P EUR DIAL TRANS, V7, P110; SNEDECOR GW, 1980, STATISTICAL METHODS, P107; TAVES DR, 1968, T AM SOC ART INT ORG, V14, P412; TEPPERMAN PB, 1980, J OCCUP ENVIRON MED, V22, P691, DOI 10.1097/00043764-198010000-00018; Tokars J I, 1993, ASAIO J, V39, P966, DOI 10.1097/00002480-199310000-00027; VLCHEK DL, 1991, QUALITY ASSURANCE GU; YOLKEN R, 1976, PEDIATRICS, V58, P90; 1993, ANSIAAMI RD51992 ASS, P5; 1980, MMWR-MORBID MORTAL W, V29, P134	31	47	48	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1994	121	5					339	344		10.7326/0003-4819-121-5-199409010-00005	http://dx.doi.org/10.7326/0003-4819-121-5-199409010-00005			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD701	8042823				2023-01-03	WOS:A1994PD70100005
J	BUCKMAN, R; LEWITH, G				BUCKMAN, R; LEWITH, G			WHAT DOES HOMEOPATHT DO AND HOW	BRITISH MEDICAL JOURNAL			English	Article							BREAST-CANCER	Robert Buckman, a medical oncologist, and George Lewith, a homoeopathic physician, met in Southampton while filming ''Magic or Medicine?,'' a television series of four programmes about what can and might be learnt from the popularity of complementary medicine. In particular, the series showed how the effect of the patient's and the doctor's beliefs affected the relationship between them. The two doctors so enjoyed talking with each other that they carried on their debate in letters to each other over the next year. We think that their exchange merits a wider readership.	CTR STUDY COMPLEMENTARY MED,SOUTHAMPTON SO15 2DT,HANTS,ENGLAND		BUCKMAN, R (corresponding author), TORONTO SUNNYBROOK REG CANC CTR,2075 BAYVIEW AVE,TORONTO M4N 3M5,ON,CANADA.			Lewith, George/0000-0002-2364-3960				BONADONNA G, 1976, NEW ENGL J MED, V294, P405, DOI 10.1056/NEJM197602192940801; Brigo B, 1991, BERL J RES HOM, V1, P98; BUCKMAN R, 1993, MAGIC MED; FERLEY JP, 1989, BRIT J CLIN PHARMACO, V27, P329, DOI 10.1111/j.1365-2125.1989.tb05373.x; FISHER P, 1989, BRIT MED J, V299, P365, DOI 10.1136/bmj.299.6695.365; KLEIJNEN J, 1991, BRIT MED J, V302, P316, DOI 10.1136/bmj.302.6772.316; LEWITH G, 1987, COMPLEMENTAYR MED RE, V2, P11; PETO R, 1984, LANCET, V2, P1205; REILLY DT, 1986, LANCET, V2, P881; REILLY DT, 1993, COMPLEMENTARY THE S1, V1, P24; SPIEGEL D, 1989, LANCET, V2, P888	11	18	18	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 9	1994	309	6947					103	106		10.1136/bmj.309.6947.103	http://dx.doi.org/10.1136/bmj.309.6947.103			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW716	8038642	Green Published			2023-01-03	WOS:A1994NW71600027
J	THOMAS, DP				THOMAS, DP			VIRAL CONTAMINATION OF BLOOD PRODUCTS	LANCET			English	Editorial Material							HEMOPHILIA-A; PARVOVIRUS-B19; TRANSMISSION; CONCENTRATE				THOMAS, DP (corresponding author), BIO PROD LAB, ELSTREE, HERTS, ENGLAND.							LYON DJ, 1989, LANCET, V1, P1085; MANNUCCI PM, 1994, ANN INTERN MED, V120, P1, DOI 10.7326/0003-4819-120-1-199401010-00001; MANNUCCI PM, 1993, VIROLOGICAL SAFETY A, P253; MCOMISH F, 1993, J CLIN MICROBIOL, V31, P323, DOI 10.1128/JCM.31.2.323-328.1993; MORTIMER PP, 1983, LANCET, V2, P482; NORMANN A, 1992, LANCET, V340, P1232, DOI 10.1016/0140-6736(92)92938-C; PEERLINCK K, 1993, THROMB HAEMOSTASIS, V69, P115; PEERLINCK K, 1993, LANCET, V341, P179, DOI 10.1016/0140-6736(93)90044-H; PROWSE C, 1993, BRIT MED J, V307, P561, DOI 10.1136/bmj.307.6903.561-e; SANTAGOSTINO E, 1994, LANCET, V343, P798, DOI 10.1016/S0140-6736(94)91878-3; TEMPERLEY IJ, 1992, LANCET, V340, P1466; WILLIAMS MD, 1990, VOX SANG, V58, P177, DOI 10.1111/j.1423-0410.1990.tb02086.x	12	12	14	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 25	1994	343	8913					1583	1584		10.1016/S0140-6736(94)93050-3	http://dx.doi.org/10.1016/S0140-6736(94)93050-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU354	7911913				2023-01-03	WOS:A1994NU35400003
J	PIRISI, M; SOARDO, G				PIRISI, M; SOARDO, G			CHEMOTHERAPY-INDUCED ACRAL ERYTHEMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											PIRISI, M (corresponding author), UNIV UDINE,CATTEDRA MED INTERNA,I-33100 UDINE,ITALY.		Pirisi, Mario/ABF-2102-2020						0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 5	1994	330	18					1279	1279						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NJ512	8145783				2023-01-03	WOS:A1994NJ51200006
J	ENGLEMAN, HM; MARTIN, SE; DEARY, IJ; DOUGLAS, NJ				ENGLEMAN, HM; MARTIN, SE; DEARY, IJ; DOUGLAS, NJ			EFFECT OF CONTINUOUS POSITIVE AIRWAY PRESSURE TREATMENT ON DAYTIME FUNCTION IN SLEEP APNOEA/HYPOPNOEA SYNDROME	LANCET			English	Article							APNEA HYPOPNEA SYNDROME; PERFORMANCE; DEPRESSION; HEALTH	Continuous positive airway pressure (CPAP) is the treatment of choice for the sleep apnoea/hypopnoea syndrome (SAHS); it is usually given with the aim of improving daytime cognitive function, mood, and sleepiness. However, its efficacy has not been validated by controlled trials. We have carried out a randomised, placebo-controlled, crossover study of objective daytime sleepiness, symptoms, cognitive function, and mood in a consecutive series of 32 SAHS patients with a median apnoea plus hypopnoea frequency of 28 (range 7-129) per hour slept. Patients were treated with 4 weeks each of CPAP and an oral placebo, which they were told might improve upper airway muscle function during sleep. Assessments on the last day of each treatment included a multiple sleep latency test and tests of symptom scores, mood profiles, and cognitive performance. The patients had significantly less daytime sleepiness on CPAP than during the placebo period (mean sleep latency 7.2 [SE 0.7] vs 6.1 [0.7] min, p = 0.03). There were also improvements with CPAP in symptom ratings (2.1 [0.2] vs 4.3 [0.3], p < 0.001), mood (p < 0.05 for several measures), and cognitive performance, which showed improved vigilance (obstacles hit in Steer Clear ''driving'' test 76 [5] vs 81 [6], p < 0.01), mental flexibility (trail-making B time 66 [5] vs 75 [5] vs p < 0.05), and attention (p < 0.05). Objectively monitored CPAP use averaged only 3.4 (0.4) hours per night, but this study provides evidence of improved cognitive performance even at this low revel of CPAP compliance.	UNIV EDINBURGH,DEPT MED,RESP MED UNIT,EDINBURGH,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,DEPT PSYCHOL,EDINBURGH,MIDLOTHIAN,SCOTLAND	University of Edinburgh; University of Edinburgh			Douglas, Neil/B-1491-2013; Deary, Ian J/C-6297-2009	Deary, Ian J/0000-0002-1733-263X				BEARPARK H, 1987, SLEEP RES, V16, P303; CHARBONNEAU M, 1992, American Review of Respiratory Disease, V145, pA168; CHESHIRE K, 1992, ARCH INTERN MED, V152, P538, DOI 10.1001/archinte.152.3.538; Dement WC, 1978, SLEEP APNEA SYNDROME, P23; DERDERIAN SS, 1988, CHEST, V94, P1023, DOI 10.1378/chest.94.5.1023; DOUGLAS NJ, 1992, LANCET, V339, P347, DOI 10.1016/0140-6736(92)91660-Z; ENGLEMAN HM, 1993, THORAX, V48, P911, DOI 10.1136/thx.48.9.911; ENGLEMAN HM, IN PRESS THORAX; FINDLEY LJ, 1989, AM REV RESPIR DIS, V140, P529, DOI 10.1164/ajrccm/140.2.529; FINDLEY LJ, 1988, AM REV RESPIR DIS, V138, P337, DOI 10.1164/ajrccm/138.2.337; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; GREENBERG GD, 1987, SLEEP, V10, P254, DOI 10.1093/sleep/10.3.254; HUNT SM, 1984, J EPIDEMIOL COMMUN H, V38, P156, DOI 10.1136/jech.38.2.156; Jennum, 1992, J Sleep Res, V1, P240; KRIBBS NB, 1993, AM REV RESPIR DIS, V147, P887, DOI 10.1164/ajrccm/147.4.887; KRIBBS NB, 1993, AM REV RESPIR DIS, V147, P1162, DOI 10.1164/ajrccm/147.5.1162; LAMPHERE J, 1989, CHEST, V96, P1364, DOI 10.1378/chest.96.6.1364; LANGAN SJ, 1991, DIABETOLOGIA, V34, P337, DOI 10.1007/BF00405006; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; MATHEWS G, 1990, BRIT J PSYCHOL, V81, P17; MILLMAN RP, 1989, J CLIN PSYCHIAT, V50, P348; PARTINEN M, 1988, CHEST, V94, P1200, DOI 10.1378/chest.94.6.1200; PETRIE RXA, 1989, PSYCHOPHARMACOLOGY, V99, P393, DOI 10.1007/BF00445565; REEVES-HOCHE M K, 1992, American Review of Respiratory Disease, V145, pA169; REYNOLDS CF, 1984, J CLIN PSYCHIAT, V45, P287; SANGAL RB, 1992, CHEST, V102, P699, DOI 10.1378/chest.102.3.699; THORPY MJ, 1992, SLEEP, V15, P268; WHYTE KF, 1989, Q J MED, V72, P659; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	30	450	460	0	14	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 5	1994	343	8897					572	575		10.1016/S0140-6736(94)91522-9	http://dx.doi.org/10.1016/S0140-6736(94)91522-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY843	7906330				2023-01-03	WOS:A1994MY84300010
J	LEE, RJ; LOW, PS				LEE, RJ; LOW, PS			DELIVERY OF LIPOSOMES INTO CULTURED KB CELLS VIA FOLATE RECEPTOR-MEDIATED ENDOCYTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING; LINES; SIZE	Folic acid was covalently conjugated to 66-nm liposomes via spacers of various lengths in an attempt to target the liposomes to KB cells expressing folate receptors. Spacers of short and intermediate lengths were unable to mediate association of folate-conjugated liposomes with receptor-bearing cells, however, use of a 250 angstrom polyethyleneglycol spacer (PEG, M(r) approximately 3350) permitted avid uptake of the liposomes at approximately 2.5 x 10(5) sites/cell. The binding of folate-PEG liposomes to KB cells could be competitively inhibited by excess free folate or by antiserum against the folate receptor, demonstrating the interaction is mediated by the cell surface folate-binding protein. Following binding, cell-associated folate-PEG liposomes were internalized by folate-receptor-mediated endocytosis at 37-degrees-C but not at 4-degrees-C. These folate-PEG liposomes show potential for delivering large quantities of low molecular weight compounds non-destructively into folate receptor-bearing cells.	PURDUE UNIV, DEPT CHEM, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus				Low, Philip/0000-0001-9042-5528				ALLEN TM, 1991, BIOCHIM BIOPHYS ACTA, V1066, P29, DOI 10.1016/0005-2736(91)90246-5; ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; BERINSTEIN N, 1987, CANCER RES, V47, P5954; BOLHUIS RLH, 1992, INT J CANCER, P78; CANEVARI S, 1992, INT J CANCER, P42; GARELLI N, 1992, BIOCHIM BIOPHYS ACTA, V1127, P41, DOI 10.1016/0005-2760(92)90199-6; ITZINGER DC, 1992, BIOCHIM BIOPHYS ACTA, V1113, P201; KAMEN BA, 1988, J BIOL CHEM, V263, P13602; KANE MA, 1986, J BIOL CHEM, V261, P44; KLIBANOV AL, 1991, BIOCHIM BIOPHYS ACTA, V1062, P142, DOI 10.1016/0005-2736(91)90385-L; LEAMON CP, 1991, P NATL ACAD SCI USA, V88, P5572, DOI 10.1073/pnas.88.13.5572; LEAMON CP, 1993, BIOCHEM J, V291, P855, DOI 10.1042/bj2910855; LEAMON CP, 1992, J BIOL CHEM, V267, P24966; LESERMAN LD, 1980, P NATL ACAD SCI-BIOL, V77, P4089, DOI 10.1073/pnas.77.7.4089; LITZINGER DC, 1992, BIOCHIM BIOPHYS ACTA, V1104, P179, DOI 10.1016/0005-2736(92)90148-F; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; MAYER LD, 1989, CANCER RES, V49, P5922; MILHAUD PG, 1989, BIOCHIM BIOPHYS ACTA, V987, P15, DOI 10.1016/0005-2736(89)90449-5; MOGHIMI SM, 1992, BIOCHIM BIOPHYS ACTA, V1135, P269; PAPAHADJOPOULOS D, 1991, P NATL ACAD SCI USA, V88, P11460, DOI 10.1073/pnas.88.24.11460; PHILLIPS NC, 1991, IMMUNOL LETT, V30, P291, DOI 10.1016/0165-2478(91)90040-H; ROTHBERG KG, 1990, J CELL BIOL, V110, P637, DOI 10.1083/jcb.110.3.637; STEWART JC, 1980, ANAL BIOCHEM, V104, P486; TUREK JJ, 1993, J CELL SCI, V106, P423; WEITMAN SD, 1992, CANCER RES, V52, P3396; [No title captured]	26	631	708	0	71	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3198	3204						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106354				2023-01-03	WOS:A1994MV63100015
J	CROTTY, B				CROTTY, B			ULCERATIVE-COLITIS AND XENOBIOTIC METABOLISM	LANCET			English	Article							INFLAMMATORY BOWEL-DISEASE; CROHNS-DISEASE; HUMAN LIVER; JEWISH POPULATION; DRUG-METABOLISM; SMOKING; INACTIVATION; ASSOCIATION; GENES; RISK	Any hypothesis on the cause of ulcerative colitis must account for genetic influences, geographic and ethnic variations, effects of smoking and oral contraception, anatomical distribution, the relapsing and remitting nature of the disease, and association with primary sclerosing cholangitis. This hypothesis proposes that ulcerative colitis is caused by a reactive xenobiotic metabolite which is conjugated before excretion into bile. The amount of metabolite produced is determined by exposure to its parent compound, by the inherited pattern of metabolism, and by inhibition and induction of enzymes catalysing alternative pathways. Deconjugation by bacteria within the colonic lumen releases the reactive metabolite, damaging the colonic epithelial barrier and exposing the mucosal immune system to luminal contents. Biliary epithelial damage by the metabolite leads to an immune response in those individuals carrying appropriate HLA molecules, thereby initiating an inflammatory process within the biliary tree.			CROTTY, B (corresponding author), UNIV MELBOURNE,HEIDELBERG REPATRIAT HOSP,DEPT MED,BANKSIA ST,W HEIDELBERG,VIC 3081,AUSTRALIA.							ARMSTRONG M, 1992, LANCET, V339, P1017, DOI 10.1016/0140-6736(92)90537-D; AUANSAKUL AC, 1982, DRUG METAB DISPOS, V10, P344; BOYKO EJ, 1987, NEW ENGL J MED, V316, P707, DOI 10.1056/NEJM198703193161202; CAPORASO N, 1989, CANCER RES, V49, P3675; CHAPMAN RW, 1990, INFLAMMATORY BOWEL D, P513; FORRESTER LM, 1992, BIOCHEM J, V281, P359, DOI 10.1042/bj2810359; GEORGE J, 1991, AUST NZ J MED, V21, P356, DOI 10.1111/j.1445-5994.1991.tb04708.x; GILAT T, 1974, GASTROENTEROLOGY, V66, P335; GOLDIN BR, 1986, ANNU REV MICROBIOL, V40, P367, DOI 10.1146/annurev.mi.40.100186.002055; GUDJONSSON H, 1988, TISSUE ANTIGENS, V31, P243, DOI 10.1111/j.1399-0039.1988.tb02090.x; GUENGERICH FP, 1990, ASIA PAC J PHARMACOL, V5, P327; GUENGERICH FP, 1990, CHEM RES TOXICOL, V3, P363, DOI 10.1021/tx00016a015; KATAKURA S, 1989, SCAND J GASTROENTERO, V24, P381, DOI 10.3109/00365528909093063; KNODELL RG, 1991, GASTROENTEROLOGY, V101, P1680, DOI 10.1016/0016-5085(91)90408-D; LANGMAN MJS, 1990, INFLAMM BOWEL DIS, P25; Levine W G, 1981, Prog Drug Res, V25, P361; LINDBERG E, 1992, GUT, V33, P779, DOI 10.1136/gut.33.6.779; LOOCK W, 1988, J CLIN PHARMACOL, V28, P216, DOI 10.1002/j.1552-4604.1988.tb03135.x; MATHAN VI, 1989, GUT, V30, P971, DOI 10.1136/gut.30.7.971; MERRETT MN, 1992, GUT, V33, P1254; MEYER UA, 1990, ADV DRUG RES, V19, P197; MUCKLOW JC, 1988, PHARMACOL THERAPEUT, V36, P105, DOI 10.1016/0163-7258(88)90113-1; PORTER TD, 1991, J BIOL CHEM, V266, P13469; PROBERT CSJ, 1992, GUT, V33, P687, DOI 10.1136/gut.33.5.687; PULLAN RD, 1993, GUT, V34, P676, DOI 10.1136/gut.34.5.676; PULLAN RD, 1993, GASTROENTEROLOGY, V104, pA765; ROZEN P, 1979, GASTROENTEROLOGY, V76, P25; RUTGEERTS P, 1991, LANCET, V338, P771, DOI 10.1016/0140-6736(91)90663-A; SHEPHERD HA, 1983, Q J MED, V52, P503; SIMMONDS NJ, 1993, GUT, V34, P865, DOI 10.1136/gut.34.7.865; TOYODA H, 1993, GASTROENTEROLOGY, V104, P741, DOI 10.1016/0016-5085(93)91009-7; TRUELOVE SC, 1965, BMJ-BRIT MED J, V1, P150, DOI 10.1136/bmj.1.5428.150; TYSK C, 1988, GUT, V29, P990, DOI 10.1136/gut.29.7.990; VESSEY M, 1986, BRIT MED J, V292, P1101, DOI 10.1136/bmj.292.6528.1101; WAKEFIELD AJ, 1989, LANCET, V2, P773; YAMAMOTO I, 1966, JPN J PHARMACOL, V16, P183, DOI 10.1254/jjp.16.183; [No title captured]	37	23	28	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 1	1994	343	8888					35	38		10.1016/S0140-6736(94)90882-6	http://dx.doi.org/10.1016/S0140-6736(94)90882-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN937	7905049				2023-01-03	WOS:A1994MN93700018
J	HUANG, D; OBRIEN, RG; HARMAN, E; AULL, L; REENTS, S; VISSER, J; SHIEH, G; HENDELES, L				HUANG, D; OBRIEN, RG; HARMAN, E; AULL, L; REENTS, S; VISSER, J; SHIEH, G; HENDELES, L			DOES AMINOPHYLLINE BENEFIT ADULTS ADMITTED TO THE HOSPITAL FOR AN ACUTE EXACERBATION OF ASTHMA	ANNALS OF INTERNAL MEDICINE			English	Article						AMINOPHYLLINE; ASTHMA; THERPHYLLINE; ALBUTEROL; METHYLPREDNISOLONE	DOSE-RESPONSE; THEOPHYLLINE; TOXICITY; THERAPY; MODELS	Objective: To determine the effect of adding intravenous theophylline (administered as aminophylline) to nebulizations of albuterol and intravenous methylprednisolone in adults hospitalized for acute asthma. Design: Randomized, placebo-controlled, double-blind study. Setting: Inpatient service of a tertiary-care, university teaching hospital. Patients: 21 adults (22 to 48 years old)-10 in the aminophylline group and 11 in the placebo group. Interventions: Nebulized albuterol, 2.5 or 5.0 mg every 0.5 to 4 hours; intravenous methylprednisolone, 60 mg every 6 hours; and either individualized doses of aminophylline or placebo for 48 hours. Measurements: Forced expiratory volume in 1 second (FEV1), the number of ''as needed'' albuterol nebulizations and total dose, asthma symptom scores, and adverse effects. Results: At admission from the emergency department, the mean +/- SD baseline FEV1 was 49% +/- 19% of the predicted value in the aminophylline group and 43% +/- 13% of the predicted value in the placebo group. The improvement in FEV1 at 3 hours was greater in the aminophylline group (29% +/- 23% compared with 10% +/- 10% in the placebo group; mean difference, 19 percentage points; 95% CI, 3 to 35 percentage points; P = 0.023). At 48 hours, FEV1 was 75% +/- 19% of the predicted value in the aminophylline group and 58% +/- 15% of the predicted value in the placebo group (mean difference, 17 percentage points; CI, 0.2 to 34.8 percentage points; P = 0.048). Aminophylline-treated patients required fewer nebulizations of albuterol (10.3 +/- 3.8 compared with 16.4 +/- 5.3; mean difference, -6.1; CI, -10.3 to -1.8) and less total dosage (34 +/- 16 mg compared with 70 +/- 34 mg; mean difference, -36 mg; CI, -60.6 to -11.3 mg P = 0.02). No statistical differences were observed in asthma symptom scores or frequency of adverse effects. Conclusions: Individualized doses of intravenous theophylline added to frequent nebulizations of albuterol and intravenous methylprednisolone appear to benefit adults admitted to the hospital with acute asthma and are well tolerated when serum concentrations are maintained in the therapeutic range.	UNIV FLORIDA, HLTH SCI CTR, BOX 100486, GAINESVILLE, FL 32610 USA	State University System of Florida; University of Florida			Shieh, Gwowen/E-2837-2013	Shieh, Gwowen/0000-0001-8611-4495				[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; BROWN MB, 1974, J AM STAT ASSOC, V69, P364, DOI 10.2307/2285659; CARTER E, 1993, J PEDIATR-US, V122, P470, DOI 10.1016/S0022-3476(05)83443-2; CONLON M, 1990, COMPUT STAT DATA AN, V9, P237, DOI 10.1016/0167-9473(90)90123-Y; COSTAIN D, 1990, BRIT MED J, V301, P797; FANTA CH, 1986, AM J MED, V80, P5, DOI 10.1016/0002-9343(86)90041-0; GUMPERTZ M, 1989, AM STAT, V43, P203, DOI 10.2307/2685362; HENDELES L, 1977, DRUG INTEL CLIN PHAR, V11, P12, DOI 10.1177/106002807701100101; HENDELES L, 1982, AM J HOSP PHARM, V39, P249, DOI 10.1093/ajhp/39.2.249; HERMANN G, 1987, J LAB CLIN MED, V23, P135; HESS D, 1989, Respiratory Care, V34, P717; JENNE JW, 1992, PULM PHARMACOL, V5, P239, DOI 10.1016/0952-0600(92)90066-P; JOLLEY ME, 1981, J ANAL TOXICOL, V5, P236, DOI 10.1093/jat/5.5.236; MITCHELL CA, 1983, EUR J RESPIR DIS, V64, P340; MORRIS JF, 1971, AM REV RESPIR DIS, V103, P57; OBRIEN RG, 1979, J AM STAT ASSOC, V74, P877, DOI 10.2307/2286416; SCHIFF GD, 1991, ANN INTERN MED, V114, P748, DOI 10.7326/0003-4819-114-9-748; SELF TH, 1990, CHEST, V98, P1317, DOI 10.1378/chest.98.6.1317; SIEGEL D, 1985, AM REV RESPIR DIS, V132, P283; TINKELMAN DG, 1977, J ALLERGY CLIN IMMUN, V59, P109, DOI 10.1016/0091-6749(77)90211-1; VAUGHAN LM, 1986, LANCET, V1, P184; 1991, NIH913042 NAT HEART, P89	22	43	44	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1993	119	12					1155	1160		10.7326/0003-4819-119-12-199312150-00001	http://dx.doi.org/10.7326/0003-4819-119-12-199312150-00001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM121	8239245				2023-01-03	WOS:A1993MM12100001
J	KARLSTROM, E; ABEL, GG				KARLSTROM, E; ABEL, GG			BIOFEEDBACK FOR MUSCULOSKELETAL PAIN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											KARLSTROM, E (corresponding author), BEHAV MED INST ATLANTA,ATLANTA,GA, USA.							FOGEL ER, 1987, BIOFEEDBACK PRACTITI, P390; SHERMAN PA, 1991, AM PAIN SOC B, V1, P11; SHERMAN RA, 1992, SPINAL MANIPULATIVE, P177	3	2	2	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	1993	270	22					2736	2736		10.1001/jama.270.22.2736	http://dx.doi.org/10.1001/jama.270.22.2736			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ821	8133597				2023-01-03	WOS:A1993MJ82100039
J	KHAN, IH; CATTO, GRD; MACLEOD, AM				KHAN, IH; CATTO, GRD; MACLEOD, AM			LESSON OF THE WEEK - SEVERE LACTIC-ACIDOSIS IN PATIENT RECEIVING CONTINUOUS AMBULATORY PERITONEAL-DIALYSIS	BRITISH MEDICAL JOURNAL			English	Article							LACTATE		ABERDEEN ROYAL INFIRM,RENAL UNIT,ABERDEEN AB9 2ZD,SCOTLAND	University of Aberdeen								DIXON SR, 1970, CLIN SCI, V39, P51, DOI 10.1042/cs0390051; FALLER B, 1984, PERITON DIALYSIS B, V4, P10; ING TS, 1981, INT J ARTIF ORGANS, V4, P308, DOI 10.1177/039139888100400611; LIM P-S, 1992, Taiwan yixuehui zazhi, V91, P374; NAPARSTEK Y, 1982, ISRAEL J MED SCI, V18, P513; OH MS, 1985, METABOLISM, V34, P621, DOI 10.1016/0026-0495(85)90088-5; VARIZI ND, 1979, AM J MED, V67, P392	7	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 23	1993	307	6911					1056	1057		10.1136/bmj.307.6911.1056	http://dx.doi.org/10.1136/bmj.307.6911.1056			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD556	8251784	Bronze, Green Published			2023-01-03	WOS:A1993MD55600027
J	ZOLI, G; BALLINGER, A; HEALY, J; ODONNELL, LJD; CLARK, M; FARTHING, MJG				ZOLI, G; BALLINGER, A; HEALY, J; ODONNELL, LJD; CLARK, M; FARTHING, MJG			PROMOTION OF GALLBLADDER EMPTYING BY INTRAVENOUS AMINO-ACIDS	LANCET			English	Article							TOTAL PARENTERAL-NUTRITION; BILIARY SLUDGE; CHOLECYSTOKININ; CONTRACTION; HUMANS; PLASMA	Patients receiving total intravenous nutrition have inert gallbladders; gallbladder sludge and gallstones often develop, but are preventable if gallbladder emptying can be improved. We measured the effect of giving rapid intravenous infusions of aminoacid solutions in eight normal subjects. Four regimens were tested (250 mL over 30 min, 250 mL over 10 min, 125 mL over 5 min, and 50 mL over 5 min). Gallbladder emptying, as measured by ultrasound and cholecystokinin release, depended on both the amount and the rate of aminoacid infusion. Rapid infusion of 125 mL of an aminoacid mixture (Synthamin 14 without electrolytes) over 5 min (2.1 g per min) produced a 64% reduction in gallbladder volume within 30 min, whereas a 50 mL infusion over 5 min produced only a 22% reduction. Intermittent rapid infusion of small amounts of aminoacids may prevent gallstones in patients receiving intravenous nutrition.	ST BARTHOLOMEWS HOSP,DEPT GASTROENTEROL,LONDON EC1A 7BE,ENGLAND; ST BARTHOLOMEWS HOSP,DEPT RADIOL,LONDON EC1A 7BE,ENGLAND; UNIV BOLOGNA,DEPT MED PATHOL,I-40126 BOLOGNA,ITALY	University of London; Queen Mary University London; University of London; Queen Mary University London; University of Bologna				ZOLI, Giorgio/0000-0002-3244-0663				CANO N, 1986, GASTROENTEROLOGY, V91, P313, DOI 10.1016/0016-5085(86)90562-7; DODDS WJ, 1985, AM J ROENTGENOL, V145, P1009, DOI 10.2214/ajr.145.5.1009; FISHER RS, 1982, DIGEST DIS SCI, V27, P1019, DOI 10.1007/BF01391749; HOPMAN WPM, 1985, RADIOLOGY, V157, P37, DOI 10.1148/radiology.157.1.3898222; LEE SP, 1992, NEW ENGL J MED, V326, P589, DOI 10.1056/NEJM199202273260902; LEE SP, 1988, GASTROENTEROLOGY, V94, P170, DOI 10.1016/0016-5085(88)90626-9; LIDDLE RA, 1985, J CLIN INVEST, V75, P1144, DOI 10.1172/JCI111809; LILJA P, 1982, GASTROENTEROLOGY, V83, P256; MESSING B, 1983, GASTROENTEROLOGY, V84, P1012; MESSING B, 1984, GASTROENTEROLOGY, V86, P1183; MURRAY FE, 1992, GUT, V33, P1123, DOI 10.1136/gut.33.8.1123; NEALON WH, 1990, AM J PHYSIOL, V259, pG173, DOI 10.1152/ajpgi.1990.259.2.G173; POTSON GJ, 1990, GASTROENTEROLOGY, V98, P993; SITZMANN JV, 1990, SURG GYNECOL OBSTET, V170, P25	14	26	27	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 15	1993	341	8855					1240	1241						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LC497	8098392				2023-01-03	WOS:A1993LC49700004
J	KEW, J; MORRIS, C; AIHIE, A; FYSH, R; JONES, S; BROOKS, D				KEW, J; MORRIS, C; AIHIE, A; FYSH, R; JONES, S; BROOKS, D			LESSON OF THE WEEK - ARSENIC AND MERCURY INTOXICATION DUE TO INDIAN ETHNIC REMEDIES	BRITISH MEDICAL JOURNAL			English	Article									GUYS HOSP,POISONS UNIT,LONDON SE1,ENGLAND; METROPOLITAN POLICE,FORENS SCI LAB,LONDON,ENGLAND; ST ANDREWS HOSP,LONDON,ENGLAND	Guy's & St Thomas' NHS Foundation Trust	KEW, J (corresponding author), HAMMERSMITH HOSP,DEPT NEUROL,LONDON W12 0HS,ENGLAND.		Sayer, Avan Aihie/A-4359-2012	Aihie Sayer, Avan/0000-0003-1283-6457; Brooks, David/0000-0003-2602-2518				CHHUTTANI PN, 1967, ARCH NEUROL-CHICAGO, V17, P269; Healy M., 1990, ASIAN COMMUNITY MED; KARK RAP, 1979, HDB CLIN NEUROLOGY 1, V36, P147; KAYE S, 1977, HDB EMERGENCY TOXICO, P148; MURPHY MJ, 1981, J NEUROL NEUROSUR PS, V44, P896, DOI 10.1136/jnnp.44.10.896; WINDEBANK AJ, 1984, PERIPHERAL NEUROPATH, P2133	6	89	89	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 20	1993	306	6876					506	507		10.1136/bmj.306.6876.506	http://dx.doi.org/10.1136/bmj.306.6876.506			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN786	8383555	Bronze, Green Published			2023-01-03	WOS:A1993KN78600025
J	HAIN, R; REIF, HJ; KRAUSE, E; LANGEBARTELS, R; KINDL, H; VORNAM, B; WIESE, W; SCHMELZER, E; SCHREIER, PH; STOCKER, RH; STENZEL, K				HAIN, R; REIF, HJ; KRAUSE, E; LANGEBARTELS, R; KINDL, H; VORNAM, B; WIESE, W; SCHMELZER, E; SCHREIER, PH; STOCKER, RH; STENZEL, K			DISEASE RESISTANCE RESULTS FROM FOREIGN PHYTOALEXIN EXPRESSION IN A NOVEL PLANT	NATURE			English	Article							STILBENE SYNTHASE; RESVERATROL; GENE; GRAPEVINES; BOTRYTIS; VITIS	ALTHOUGH phytoalexins1,2 have long been inferred to be important in the defence of plants against fungal infection1,2, there are few reports showing that they provide resistance to infection. Several plants, including grapevine, synthesize the stilbene-type phytoalexin resveratrol3-7 when attacked by pathogens. Stilbenes with fungicidal potential are formed in several unrelated plant species, such as peanut (Arachis hypogaea), grapevine (Vitis vinifera) and pine (Pinus sylvestris)3,5,11-15. Stilbene biosynthesis only specifically requires the presence of stilbene synthase 6,9. Furthermore, the precursor molecules for the formation of hydroxystilbenes are malonyl-CoA and p-coumaroyl-CoA, both present in plants9. To investigate the potential of stilbene biosynthetic genes in a strategy of engineering pathogen resistance, we isolated stilbene synthase genes from grapevine, where they are expressed at a high level, and transferred them into tobacco10. We report here that regenerated tobacco plants containing these genes are more resistant to infection by Botrytis cinerea. This is, to our knowledge, the first report of increased disease resistance in transgenic plants based on an additional foreign phytoalexin.	UNIV MARBURG,FACHBEREICH CHEM,W-3550 MARBURG,GERMANY; MAX PLANCK INST ZUCHTUNGSFORSCH,W-5000 COLOGNE 30,GERMANY	Philipps University Marburg; Max Planck Society	HAIN, R (corresponding author), BAYER AG,PF-E-FU,INST BIOTECHNOL,W-5090 LEVERKUSEN 1,GERMANY.							BEDBROOK J, 1981, PLANT MOL BIOL NEWSL, V2, P24; Cuypers B., 1988, Molecular Plant-Microbe Interactions, V1, P157, DOI 10.1094/MPMI-1-157; DERCKS W, 1989, PHYSIOL MOL PLANT P, V34, P189, DOI 10.1016/0885-5765(89)90043-X; EBEL J, 1986, ANNU REV PHYTOPATHOL, V24, P235; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; Gorham J., 1980, Progress in phytochemistry. Volume 6., P203; HAIN R, 1990, PLANT MOL BIOL, V15, P325, DOI 10.1007/BF00036918; HAIN R, 1985, MOL GEN GENET, V199, P161, DOI 10.1007/BF00330254; INGHAM J, 1972, BOT REV, V38, P3432; INGHAM JL, 1976, PHYTOCHEMISTRY, V15, P1791, DOI 10.1016/S0031-9422(00)97494-6; LANGCAKE P, 1976, PHYSIOL PLANT PATHOL, V9, P77, DOI 10.1016/0048-4059(76)90077-1; LANGCAKE P, 1977, PHYTOCHEMISTRY, V16, P1193, DOI 10.1016/S0031-9422(00)94358-9; LANGCAKE P, 1977, EXPERIENTIA, V33, P151, DOI 10.1007/BF02124034; LINSMAIER EM, 1965, PHYSIOL PLANTARUM, V18, P100, DOI 10.1111/j.1399-3054.1965.tb06874.x; MELCHIOR F, 1991, ARCH BIOCHEM BIOPHYS, V288, P552, DOI 10.1016/0003-9861(91)90234-A; PONT V, 1990, J PHYTOPATHOL, V130, P1, DOI 10.1111/j.1439-0434.1990.tb01147.x; SCHAFER W, 1989, SCIENCE, V246, P247, DOI 10.1126/science.246.4927.247; SCHMELZER E, 1989, PLANT CELL, V1, P993, DOI 10.1105/tpc.1.10.993; SCHOPPNER A, 1979, FEBS LETT, V108, P345; SCHRODER G, 1988, EUR J BIOCHEM, V172, P161, DOI 10.1111/j.1432-1033.1988.tb13868.x; STEIN U, 1985, VITIS, V24, P75; TEGTMEIER KJ, 1982, PHYTOPATHOLOGY, V72, P608, DOI 10.1094/Phyto-72-608	22	466	556	3	69	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 14	1993	361	6408					153	156		10.1038/361153a0	http://dx.doi.org/10.1038/361153a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KG466	8421520				2023-01-03	WOS:A1993KG46600059
J	KAY, AB				KAY, AB			ALTERNATIVE ALLERGY AND THE GENERAL MEDICAL COUNCIL	BRITISH MEDICAL JOURNAL			English	Article								In July 1992 Dr Keith Mumby, a clinical ecologist, appeared before the professional conduct committee of the General Medical Council on five charges to do with his practice of clinical ecology. He was found guilty of two of the charges-touting for publicity and failing to give a patient adequate medical attention-and admonished. The GMC failed, however, to address the issue of the nature of Mumby's treatments-Clinical ecology itself. This is based on the idea that some patients are unusually susceptible to their environment, the diagnosis and treatment are based on an unstandardised provocation-neutralisation test. A variety of medical bodies have failed to find scientific foundation for the technique. The GMC's policy on advertising services to patients is inconsistent, and in this case it has shown a regrettable reluctance to deal with the issue of treatments that are not scientifically validated.			KAY, AB (corresponding author), NAT HEART & LUNG INST,DEPT ALLERGY & CLIN IMMUNOL,LONDON SW3 6LY,ENGLAND.							JEWETT DL, 1990, NEW ENGL J MED, V323, P429, DOI 10.1056/NEJM199008163230701; MILLER JB, 1972, FOOD ALLERGY PROVOCA, P7; RAWLINS MD, 1988, REGULATORY CONTROL S, P147; WATSON J, 1991, MIRACLE ALLERGY CURE; WOOD B, 1992, KEEP TAKING TABLOIDS; 1992, ALLERGY CONVENTIONAL; 1986, J ALLERGY CLIN IMMUN, V78, P269; 1989, ANN INTERN MED, V111, P168; 1986, W J MED, V144, P239; 1986, BMJ, V293, P948; 1983, FED REGISTER, V48, P37716	11	18	18	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 9	1993	306	6870					122	124		10.1136/bmj.306.6870.122	http://dx.doi.org/10.1136/bmj.306.6870.122			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG465	8435610	Green Published, Bronze			2023-01-03	WOS:A1993KG46500028
J	Berlowitz, DR; Ash, AS; Brandeis, GH; Brand, HK; Halpern, JL; Moskowitz, MA				Berlowitz, DR; Ash, AS; Brandeis, GH; Brand, HK; Halpern, JL; Moskowitz, MA			Rating long-term care facilities on pressure ulcer development: Importance of case-mix adjustment	ANNALS OF INTERNAL MEDICINE			English	Article							NURSING-HOMES; QUALITY; MORTALITY; SORES; RISK	Objective: To determine the importance of case-mix adjustment in interpreting differences in rates of pressure ulcer development in Department of Veterans Affairs long-term care facilities. Design: A sample assembled from the Patient Assessment File, a Veterans Affairs administrative database, was used to derive predictors of pressure ulcer development; the resulting model was validated in a separate sample. Facility-level rates of pressure ulcer development, both unadjusted long-term care and adjusted for case mix using the predictive model, were compared. Setting: Department of Veterans Affairs long-term care facilities. Patients: The derivation sample consisted of 31 150 intermediate medicine and nursing home residents who were initially free of pressure ulcers and were institutionalized between October 1991 and April 1993. The validation sample consisted of 17 946 residents institutionalized from April 1993 to October 1993. Measurement: Development of a stage 2 or greater pressure ulcer. Results: 11 factors predicted pressure ulcer development. Validated performance properties of the resulting model were good. Model-predicted rates of pressure ulcer development at individual long-term care facilities varied from 1.9% to 6.3%, and observed rates ranged from 0% to 10.9%. Case-mix-adjusted rates and ranks of facilities differed considerably from unadjusted ratings. For example, among five facilities that were identified as high outliers on the basis of unadjusted rates, two remained as outliers after adjustment for case mix. Conclusions: Gong-term care facilities differ in case mix. Adjustments for case mix result in different judgments about facility performance and should be used when facility incidence rates are compared.	BOSTON UNIV, MED CTR, GEN INTERNAL MED SECT, BOSTON, MA 02118 USA; DEPT VET AFFAIRS, WASHINGTON, DC USA	Boston University	Berlowitz, DR (corresponding author), VET AFFAIRS MED CTR, HLTH SERV RES & DEV FIELD PROGRAM, 200 SPRINGS RD, BEDFORD, MA 01730 USA.		Ash, Arlene/AAG-2914-2019	Ash, Arlene/0000-0002-8448-0253; Berlowitz, Dan/0000-0002-8783-5611				ALLMAN RM, 1986, ANN INTERN MED, V105, P337, DOI 10.7326/0003-4819-105-3-337; ALLMAN RM, 1995, JAMA-J AM MED ASSOC, V273, P865, DOI 10.1001/jama.273.11.865; ALLMAN RM, 1989, NEW ENGL J MED, V320, P850; ANDERSEN KE, 1982, BMJ-BRIT MED J, V284, P1370, DOI 10.1136/bmj.284.6326.1370; BERGSTROM N, 1992, J AM GERIATR SOC, V40, P747, DOI 10.1111/j.1532-5415.1992.tb01845.x; BERLOWITZ DR, 1989, J AM GERIATR SOC, V37, P1043, DOI 10.1111/j.1532-5415.1989.tb06918.x; BERLOWITZ DR, 1993, IMPROVING CARE NURSI; BLUMENTHAL D, 1993, JAMA-J AM MED ASSOC, V269, P2775, DOI 10.1001/jama.269.21.2775; BRANDEIS GH, 1994, J AM GERIATR SOC, V42, P388, DOI 10.1111/j.1532-5415.1994.tb07486.x; BRANDEIS GH, 1990, JAMA-J AM MED ASSOC, V264, P2905, DOI 10.1001/jama.264.22.2905; DALEY J, 1988, JAMA-J AM MED ASSOC, V260, P3617, DOI 10.1001/jama.260.24.3617; GERON SM, 1991, GERONTOLOGIST, V31, P292, DOI 10.1093/geront/31.3.292; GREEN J, 1991, JAMA-J AM MED ASSOC, V265, P1849; GREENFIELD S, 1988, JAMA-J AM MED ASSOC, V260, P2253, DOI 10.1001/jama.260.15.2253; HOSMER EW, 1989, APPL LOGISTIC REGRES; Institute of Medicine (US) Committee on Nursing Home Regulation, 1986, IMPR QUAL CAR NURS H; KANE RA, 1988, INQUIRY-J HEALTH CAR, V25, P132; KANE RL, 1990, J AM GERIATR SOC, V38, P704, DOI 10.1111/j.1532-5415.1990.tb01432.x; KASSIRER JP, 1994, NEW ENGL J MED, V330, P634, DOI 10.1056/NEJM199403033300910; LOCALIO AR, 1995, ANN INTERN MED, V122, P125, DOI 10.7326/0003-4819-122-2-199501150-00009; MCNEIL BJ, 1992, INQUIRY-J HEALTH CAR, V29, P298; MORRIS JN, 1990, GERONTOLOGIST, V30, P293, DOI 10.1093/geront/30.3.293; O'Leary D S, 1993, Jt Comm J Qual Improv, V19, P487; PARK RE, 1990, JAMA-J AM MED ASSOC, V264, P484; RUDMAN D, 1993, J AM GERIATR SOC, V41, P1317, DOI 10.1111/j.1532-5415.1993.tb06482.x; RUDMAN D, 1993, AM J PHYS MED REHAB, V72, P276, DOI 10.1097/00002060-199310000-00005; RUDMAN D, 1993, J GEN INTERN MED, V8, P653, DOI 10.1007/BF02598281; SCHNEIDER DP, 1988, HLTH CARE FINANC REV, V10, P39; SCHWARTZ M, 1994, RISK ADJUSTMENT MEAS; *US AG HLTH CAR PO, 1992, PRESS ULC AD PRED PR; *US HLTH CAR FIN A, 1987, HCFA PUBL; VERSLUYSEN M, 1986, BRIT MED J, V292, P1311, DOI 10.1136/bmj.292.6531.1311; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; WILKING SV, 1990, ANN M AM GER SOC ATL; WU AW, 1995, ANN INTERN MED, V122, P149, DOI 10.7326/0003-4819-122-2-199501150-00013; ZINN JS, 1993, MED CARE, V31, P475, DOI 10.1097/00005650-199306000-00001; 1990, INT J TECHNOL ASSESS, V6, P181	37	73	73	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1996	124	6					557	+		10.7326/0003-4819-124-6-199603150-00003	http://dx.doi.org/10.7326/0003-4819-124-6-199603150-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ529	8597318				2023-01-03	WOS:A1996TZ52900003
J	Leizorovicz, A				Leizorovicz, A			Benefit from earlier thrombolytic therapy is certain, but what is the magnitude of benefit?	BRITISH MEDICAL JOURNAL			English	Editorial Material											Leizorovicz, A (corresponding author), SERV PHARMACOL CLIN,INSERM,BP 3041,F-69394 LYON 03,FRANCE.							Fibrinolytic 'Therapy Trialists' (FTT) Collaborative Group, 1994, LANCET, V343, P311; Rawles J, 1996, BMJ-BRIT MED J, V312, P212; WEAVER WD, 1993, JAMA-J AM MED ASSOC, V270, P1211, DOI 10.1001/jama.270.10.1211; 1993, NEW ENGL J MED, V329, P383; 1992, BRIT MED J, V305, P548	5	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 27	1996	312	7025					215	216						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT486	8563586				2023-01-03	WOS:A1996TT48600025
J	ROILA, F; BALLATORI, E; DEANGELIS, V; TONATO, M; RIVA, E; PANZA, MT; DELFAVERO, A; BASURTO, C; CICCARESE, G; PALLADINO, MA; MOSCONI, AM; ANASTASI, P; PICCIAFUOCO, M; CAMPORA, E; CHIARA, S; ROSSO, R; COGNETTI, F; FERRARESI, V; FABI, A; TONACHELLA, R; CIRULLI, S; SABBATINI, R; FEDERICO, M; DEPENNI, R; SILINGARDI, V; DONATI, D; MAESTRI, A; MALACARNE, P; RICCI, S; MUTTINI, MP; CONTE, PF; SALVATI, F; NUNZIATI, F; SIGNORA, M; CATALANO, G; CASCINU, S; DICOSTANZO, F; TAGLIAVENTI, M; ZANIBONI, A; MERIGGI, F; CORTESI, E; TRINCA, C; LUPORINI, G; LOCATELLI, MC; SANTORO, A; ZUCCHINELLI, P; MANTELLINI, E; FERRETTI, G; BONI, C; MORETTI, G; SCAGLIOTTI, G; DANIELE, O; LISSONI, A; TATEO, S				ROILA, F; BALLATORI, E; DEANGELIS, V; TONATO, M; RIVA, E; PANZA, MT; DELFAVERO, A; BASURTO, C; CICCARESE, G; PALLADINO, MA; MOSCONI, AM; ANASTASI, P; PICCIAFUOCO, M; CAMPORA, E; CHIARA, S; ROSSO, R; COGNETTI, F; FERRARESI, V; FABI, A; TONACHELLA, R; CIRULLI, S; SABBATINI, R; FEDERICO, M; DEPENNI, R; SILINGARDI, V; DONATI, D; MAESTRI, A; MALACARNE, P; RICCI, S; MUTTINI, MP; CONTE, PF; SALVATI, F; NUNZIATI, F; SIGNORA, M; CATALANO, G; CASCINU, S; DICOSTANZO, F; TAGLIAVENTI, M; ZANIBONI, A; MERIGGI, F; CORTESI, E; TRINCA, C; LUPORINI, G; LOCATELLI, MC; SANTORO, A; ZUCCHINELLI, P; MANTELLINI, E; FERRETTI, G; BONI, C; MORETTI, G; SCAGLIOTTI, G; DANIELE, O; LISSONI, A; TATEO, S			DEXAMETHASONE, GRANISETRON, OR BOTH FOR THE PREVENTION OF NAUSEA AND VOMITING DURING CHEMOTHERAPY FOR CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DOUBLE-BLIND; ANTIEMETIC EFFICACY; INDUCED EMESIS; METOCLOPRAMIDE; METHYLPREDNISOLONE; ONDANSETRON; TRIAL; CYCLOPHOSPHAMIDE; PROPHYLAXIS; CMF	Background. Serotonin-receptor antagonists seem to be as effective as corticosteroids in preventing emesis induced by moderately emetogenic antineoplastic agents. We compared the antiemetic effect of a combination of granisetron and dexamethasone with that of granisetron or dexamethasone administered alone. Methods. From December 1992 to January 1994, 428 consecutive patients who were to receive moderately emetogenic chemotherapy for the first time (600 to 1000 mg of cyclophosphamide per square meter of body-surface area, greater than or equal to 50 mg of doxorubicin per square meter, greater than or equal to 75 mg of epirubicin per square meter, or greater than or equal to 300 mg of carboplatin per square meter, alone or in some combination) were enrolled in a double-blind, randomized, multicenter study evaluating the efficacy and toxicity of three antiemetic regimens. The following antiemetic regimens were used: 8 mg of dexamethasone given intravenously before chemotherapy plus 4 mg given orally immediately before chemotherapy and then every six hours for a total of four doses, 3 mg of granisetron given intravenously be fore chemotherapy, or a combination of granisetron and dexamethasone given in the doses used for the single-drug regimens. Results. We evaluated 408 patients (136 receiving dexamethasone, 137 receiving granisetron, and 135 receiving both drugs), In the first 24 hours after chemotherapy, complete protection from vomiting and complete protection from nausea were achieved in 70.6 and 55.1 percent, respectively, of the patients receiving dexamethasone, in 72.3 and 48.2 percent of those receiving granisetron, and in 92.6 and 71.9 percent of those receiving granisetron combined with dexamethasone (P<0.001 for all comparisons). Patients who received granisetron alone had less protection from delayed vomiting and nausea than those who received dexamethasone alone or the two drugs combined. All the regimens were equally well tolerated. Conclusion. Granisetron combined with dexamethasone was the most effective regimen for the prevention of emesis induced by moderately emetogenic chemotherapy.	UNIV LAQUILA,DEPT INTERNAL MED & PUBL HLTH,I-67100 LAQUILA,ITALY; SMITHKLINE BEEHAM ITALY,DEPT MED,MILAN,ITALY; UNIV PERUGIA,DEPT INTERNAL MED & ONCOL SCI,I-06100 PERUGIA,ITALY; NATL INST CANC RES,GENOA,ITALY; REGINA ELENA INST CANC RES,DEPT MED ONCOL,ROME,ITALY; UNIV MODENA,DEPT MED ONCOL,I-41100 MODENA,ITALY; ARCISPEDALE ST ANNA,DIV MED ONCOL,FERRARA,ITALY; ST CHIARA HOSP,DEPT MED ONCOL,PISA,ITALY; FORLANINI HOSP,DEPT PNEUMOL 8,ROME,ITALY; MED ONCOL SERV,PESARO,ITALY; MED ONCOL SERV,TERNI,ITALY; MED ONCOL DIV,BRESCIA,ITALY; UNIV ROMA LA SAPIENZA,DIV MED ONCOL,ROME,ITALY; SAN CARLO BORROMEO HOSP,DIV MED ONCOL,MILAN,ITALY; NATL CANC INST,I-20133 MILAN,ITALY; CIV HOSP,DIV PNEUMOL 2,ALESSANDRIA,ITALY; REGGIO EMILIA HOSP,SERV ONCOL,REGGIO EMILIA,ITALY; UNIV TURIN,DEPT CLIN & BIOL SCI,TURIN,ITALY; MED ONCOL DIV,PADUA,ITALY; UNIV MILAN,ST GERARDO HOSP,DEPT OBSTET & GYNECOL 3,MONZA,ITALY; UNIV PAVIA,INST GYNECOL,I-27100 PAVIA,ITALY	University of L'Aquila; University of Perugia; University of Genoa; IRCCS AOU San Martino IST; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Universita di Modena e Reggio Emilia; University of Ferrara; Arcispedale Sant'Anna; Azienda Ospedaliera San Camillo-Forlanini; Sapienza University Rome; San Carlo Borromeo Hospital; Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Turin; University of Milan; University of Pavia	ROILA, F (corresponding author), POLICLIN HOSP,DIV MED ONCOL,I-06122 PERUGIA,ITALY.		Cascinu, Stefano/G-2399-2017; mosconi, anna maria/AAN-5224-2020; Cascinu, Stefano/AAN-1923-2020; Federico, Massimo/A-6801-2012; Cortesi, Enrico/AAA-2983-2019; Fabi, Alessandra/AAC-1021-2019; Ferraresi, Virginia/A-2075-2019; Cognetti, Francesco/AAC-2637-2019	Cascinu, Stefano/0000-0003-2215-0731; Federico, Massimo/0000-0002-9889-3796; 				BASURTO C, 1988, AM J CLIN ONCOL-CANC, V11, P594, DOI 10.1097/00000421-198810000-00017; BONNETERRE J, 1990, J CLIN ONCOL, V8, P1063, DOI 10.1200/JCO.1990.8.6.1063; CHIARA S, 1987, AM J CLIN ONCOL-CANC, V10, P264, DOI 10.1097/00000421-198706000-00021; DELFAVERO A, 1993, DRUG SAFETY, V9, P410, DOI 10.2165/00002018-199309060-00004; JONES AL, 1991, LANCET, V338, P483, DOI 10.1016/0140-6736(91)90554-3; KAASA S, 1990, EUR J CANCER, V26, P311, DOI 10.1016/0277-5379(90)90227-K; MARKMAN M, 1984, NEW ENGL J MED, V311, P549, DOI 10.1056/NEJM198408303110901; MARSCHNER NW, 1991, EUR J CANCER, V27, P1137, DOI 10.1016/0277-5379(91)90311-Z; MARSCHNER NW, 1991, EUR J CANCER, V27, P1717; MARTY M, 1990, EUR J CANCER, V26, pS28; POLLERA CF, 1989, AM J CLIN ONCOL-CANC, V12, P524, DOI 10.1097/00000421-198912000-00014; ROILA F, 1988, ONCOLOGY, V45, P346, DOI 10.1159/000226638; ROILA F, 1987, EUR J CANCER CLIN ON, V23, P615, DOI 10.1016/0277-5379(87)90255-0; WARR D, 1991, J NATL CANCER I, V83, P1169, DOI 10.1093/jnci/83.16.1169; 1994, SUPPORT CARE CANCER, V2, P171; 1991, LANCET, V338, P478	16	219	223	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 5	1995	332	1					1	5						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PZ497	7990859				2023-01-03	WOS:A1995PZ49700001
J	DALY, DA				DALY, DA			SPEECH CLUTTERING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											DALY, DA (corresponding author), UNIV MICHIGAN,ANN ARBOR,MI 48109, USA.							DALY D, 1988, FREEDOM FLUENCY; Daly D. A., 1993, STUTTERING RELATED D; DALY DA, 1986, ATYPICAL STUTTERER P; DALY DA, 1992, CLUTTERING CLIN PERS; Weiss D., 1964, CLUTTERING	5	1	1	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 17	1994	272	7					565	565		10.1001/jama.272.7.565	http://dx.doi.org/10.1001/jama.272.7.565			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB229	8046816				2023-01-03	WOS:A1994PB22900040
J	RAWLES, J				RAWLES, J			ATTITUDES OF GENERAL-PRACTITIONERS TO PREHOSPITAL THROMBOLYSIS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACUTE MYOCARDIAL-INFARCTION	Objective-To investigate reasons for general practitioners not giving thrombolytic treatment to eligible patients with acute myocardial infarction. Design-Postal questionnaires were sent to 424 general practitioners. Subjects-97 general practitioners who had taken part in the Grampian region early anistreplase trial, 185 whose practices in Scotland were at least 24 km from a district general hospital, and 142 who had attended postgraduate conferences at which thrombolysis had been discussed; 87, 158, and 125 respectively responded. Main outcome measures-Answers to questions about readiness to use thrombolytic treatment. Results-Response rate was 87% (370/424). Almost all respondents (350) were convinced of benefits of thrombolysis for acute myocardial infarction, and 277 were convinced that there were additional benefits from its administration in the community at first opportunity. Most doctors working 16 km or more from hospital thought that giving treatment at home would appreciably save time (200/274). Most doctors agreed that they could make time to give thrombolytic treatment (278), and would be willing to record an electrocardiogram (284), and would be able to interpret it (280). Sixty four respondents (17%) reported using thrombolytic treatment in previous year. Among non-users, 150 (49%) were unwilling to use thrombolytic treatment without further training. While many non-users (210 (69%)) were willing to use thrombolytic treatment without encouragement from Department of Health, 184 (60%) were unwilling to use it unless encouraged to do so by their local cardiologist. Conclusions-The need to become better informed about thrombolysis and lack of encouragement from local cardiologists were important factors preventing wider use of thrombolytic treatment in the community by general practitioners.			RAWLES, J (corresponding author), UNIV ABERDEEN, MED ASSESSMENT RES UNIT, ABERDEEN AB9 2ZD, SCOTLAND.							[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; BIRKHEAD JS, 1992, BMJ-BRIT MED J, V305, P445, DOI 10.1136/bmj.305.6851.445; CHAMBERLAIN DA, 1988, LANCET, V1, P545; COLLINS R, 1991, BRIT HEART J, V66, P250; GATENBY R, 1992, BMJ-BRIT MED J, V305, P548; GEMMILL JD, 1993, BRIT HEART J, V70, P503; GORDON I, 1989, J ROY COLL GEN PRACT, V39, P49; GRAY D, 1993, LANCET, V341, P654, DOI 10.1016/0140-6736(93)90420-L; KETLEY D, 1993, LANCET, V342, P891, DOI 10.1016/0140-6736(93)91945-I; LEIZOROVICZ A, 1993, NEW ENGL J MED, V329, P383; LIDDELL R, 1990, BRIT J GEN PRACT, V40, P318; MCCREA WA, 1993, BRIT HEART J, V70, P219; RAWLES J, 1994, J AM COLL CARDIOL, V23, P1, DOI 10.1016/0735-1097(94)90494-4; RULE S, 1993, POSTGRAD MED J, V69, P190, DOI 10.1136/pgmj.69.809.190; WESTON CFM, 1994, BMJ-BRIT MED J, V308, P767, DOI 10.1136/bmj.308.6931.767; WILCOX RG, 1988, LANCET, V2, P525; 1992, BRIT HEART J, V68, P621	18	18	18	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 6	1994	309	6951					379	382		10.1136/bmj.309.6951.379	http://dx.doi.org/10.1136/bmj.309.6951.379			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB316	8081141	Green Published			2023-01-03	WOS:A1994PB31600024
J	HENRY, JM; MACPHERSON, IA; DONALD, SC				HENRY, JM; MACPHERSON, IA; DONALD, SC			SURVEY OF PRIVATE NURSING-HOMES IN 7 ENGLISH COUNTIES	BRITISH MEDICAL JOURNAL			English	Article									UNIV ABERDEEN,DEPT PUBL HLTH,ABERDEEN AB9 2ZD,SCOTLAND	University of Aberdeen								HENRY JM, 1993, SURVEY NURSING HOMES	1	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 30	1994	309	6950					314	314						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA373	8086870				2023-01-03	WOS:A1994PA37300021
J	CHIRUVOLU, S; WALKER, S; ISRAELACHVILI, J; SCHMITT, FJ; LECKBAND, D; ZASADZINSKI, JA				CHIRUVOLU, S; WALKER, S; ISRAELACHVILI, J; SCHMITT, FJ; LECKBAND, D; ZASADZINSKI, JA			HIGHER-ORDER SELF-ASSEMBLY OF VESICLES BY SITE-SPECIFIC BINDING	SCIENCE			English	Article							ELECTRON-MICROSCOPY; MEMBRANE-FUSION; RECOGNITION; LIPOSOMES; ADHESION; BILAYERS; FORCES; SYSTEM	The association of lipid molecules into spherical vesicles in solution as a result of nonspecific intermolecular forces constitutes a primary self-assembly process. Such vesicles can undergo a secondary self-assembly into higher order structures in a controlled and reversible manner by means of site-specific ligand-receptor (biotin-streptavidin) coupling. Cryoelectron microscopy shows these structures to be composed of tethered, rather than adhering, vesicles in their original, unstressed state. In contrast, vesicles aggregated by nonspecific, such as van der Waals, forces are deformed and stressed, producing unstable structures. Vesicle association by site-specific binding provides a practical mechanism for the production of stable, yet controllable, microstructured biomaterials.	UNIV CALIF SANTA BARBARA,DEPT CHEM ENGN,SANTA BARBARA,CA 93106	University of California System; University of California Santa Barbara					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047334] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47334] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1992, INTERMOLECULAR SURFA; BAILEY SM, 1990, LANGMUIR, V6, P1326, DOI 10.1021/la00097a024; BELLARE JR, 1988, J ELECTRON MICR TECH, V10, P87, DOI 10.1002/jemt.1060100111; BLANKENBURG R, 1989, BIOCHEMISTRY-US, V28, P8214, DOI 10.1021/bi00446a037; Cevc G., 1985, PHOSPHOLIPID BILAYER; CHERNOMORDIK LV, 1987, BIOCHIM BIOPHYS ACTA, V906, P309, DOI 10.1016/0304-4157(87)90016-5; EVANS E, 1987, J PHYS CHEM-US, V91, P4219, DOI 10.1021/j100300a003; Fendler J.H., 1982, MEMBRANE MIMETIC CHE; FLORIN EL, 1994, SCIENCE, V264, P415, DOI 10.1126/science.8153628; GRATZL M, 1976, FEBS LETT, V62, P142, DOI 10.1016/0014-5793(76)80038-5; Green N M, 1975, Adv Protein Chem, V29, P85, DOI 10.1016/S0065-3233(08)60411-8; HASHIMOTO K, 1986, BIOCHIM BIOPHYS ACTA, V856, P556, DOI 10.1016/0005-2736(86)90147-1; HELM CA, 1992, BIOCHEMISTRY-US, V31, P1794, DOI 10.1021/bi00121a030; HUI SW, 1988, BIOCHIM BIOPHYS ACTA, V941, P130, DOI 10.1016/0005-2736(88)90173-3; ISRAELACHVILI JN, 1986, SURFACTANTS SOLUTION, V4, P3; LASIC DD, 1993, LIPOSOMES PHYSICS AP; LEE KD, 1993, BIOPHYS J, V64, P905, DOI 10.1016/S0006-3495(93)81453-X; LOUGHREY HC, 1990, BIOCHIM BIOPHYS ACTA, V1028, P73, DOI 10.1016/0005-2736(90)90267-R; MARRA J, 1986, BIOPHYS J, V50, P815, DOI 10.1016/S0006-3495(86)83522-6; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; MULLER W, 1993, SCIENCE, V262, P1706, DOI 10.1126/science.8259513; PAPAHADJOPOULOS D, 1990, J BIOENERG BIOMEMBR, V22, P157, DOI 10.1007/BF00762944; POWERS DD, 1992, BIOTECHNOL PROGR, V8, P436, DOI 10.1021/bp00017a011; SERVUSS RM, 1987, PHYSICS COMPLEX SUPE, P85; SOWERS AE, 1987, CELL FUSION; WENNERSTROM H, 1979, PHYS REP, V52, P1, DOI 10.1016/0370-1573(79)90087-5; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; Wilchek M, 1990, AVIDIN BIOTIN TECHNO; WIMLEY WC, 1990, BIOCHEMISTRY-US, V29, P1296, DOI 10.1021/bi00457a027	29	175	179	0	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 17	1994	264	5166					1753	1756		10.1126/science.8209255	http://dx.doi.org/10.1126/science.8209255			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NR600	8209255				2023-01-03	WOS:A1994NR60000040
J	MILES, SH				MILES, SH			PHYSICIANS AND THEIR PATIENTS SUICIDES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							LIFE-SUSTAINING TREATMENT; ASSISTED SUICIDE; ETHICAL DILEMMAS; HOPELESSLY ILL; EUTHANASIA; COUNTERTRANSFERENCE; QUALITY; DEATH; CARE; PREFERENCES		UNIV MINNESOTA,SCH MED,MINNEAPOLIS,MN; CTR BIOMED ETH,MINNEAPOLIS,MN	University of Minnesota System; University of Minnesota Twin Cities	MILES, SH (corresponding author), HENNEPIN CTY MED CTR,DEPT MED,MINNEAPOLIS,MN, USA.							ANGELL M, 1989, NEW ENGL J MED, V321, P120; BACH JR, 1992, ARCH PHYS MED REHAB, V73, P179; BENOLIEL JQ, 1987, OMEGA-J DEATH DYING, V18, P341, DOI 10.2190/4Y6G-XQAP-0XYN-LRW9; BONICA JJ, 1991, MT SINAI J MED, V58, P191; BRODY H, 1992, NEW ENGL J MED, V327, P1384, DOI 10.1056/NEJM199211053271912; BUTLER RN, 1975, AM J PSYCHIAT, V132, P893; CAIN J, 1990, OBSTET GYNECOL, V76, P149; CAINE ED, 1993, JAMA-J AM MED ASSOC, V270, P875, DOI 10.1001/jama.270.7.875; CAMPBELL CS, 1992, J MED ETHICS, V18, P128, DOI 10.1136/jme.18.3.128; CASSEL CK, 1990, NEW ENGL J MED, V323, P750, DOI 10.1056/NEJM199009133231110; CHEMTOB CM, 1988, AM J PSYCHIAT, V145, P224; CLARKE PJ, 1981, AM J ORTHOPSYCHIAT, V51, P71, DOI 10.1111/j.1939-0025.1981.tb01349.x; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; CONWELL Y, 1991, NEW ENGL J MED, V325, P1101; CRUZ MTC, 1993, AM J LAW MED, V18, P369; DIEKSTRA RFW, 1993, ANN MED, V25, P5, DOI 10.3109/07853899309147850; GOLDSTEIN LS, 1984, AM J PSYCHOTHER, V38, P392, DOI 10.1176/appi.psychotherapy.1984.38.3.392; Gomez Carlos F., 1991, REGULATING DEATH EUT; GOODWIN JS, 1990, JAMA-J AM MED ASSOC, V264, P326; GREENE MG, 1989, GERONTOLOGIST, V29, P808, DOI 10.1093/geront/29.6.808; HELME T, 1993, BRIT J PSYCHIAT, V163, P456, DOI 10.1192/bjp.163.4.456; HENDIN H, 1981, AM J PSYCHOTHER, V35, P469, DOI 10.1176/appi.psychotherapy.1981.35.4.469; JORSTAD J, 1987, ACTA PSYCHIAT SCAN S, V336, P76; KASS LR, 1980, JAMA-J AM MED ASSOC, V244, P1811, DOI 10.1001/jama.244.16.1811; KASS LR, 1991, PUBLIC INTEREST  WIN, P25; Lifton Robert Jay, 1986, NAZI DOCTORS, P417; MALTSBERGER JT, 1974, ARCH GEN PSYCHIAT, V30, P625; MAX MB, 1990, ANN INTERN MED, V113, P885, DOI 10.7326/0003-4819-113-11-885; MODESTIN J, 1987, BRIT J MED PSYCHOL, V60, P379, DOI 10.1111/j.2044-8341.1987.tb02757.x; ORENTLICHER D, 1990, JAMA-J AM MED ASSOC, V263, P1198, DOI 10.1001/jama.1990.03440090027010; PELLEGRINO ED, 1993, JAMA-J AM MED ASSOC, V270, P874, DOI 10.1001/jama.270.7.874; PICK IB, 1985, INT J PSYCHOANAL, V66, P157; QUILL TE, 1991, ARCH INTERN MED, V151, P463; QUILL TE, 1993, JAMA-J AM MED ASSOC, V270, P870, DOI 10.1001/jama.270.7.870; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; QUILL TE, 1992, NEW ENGL J MED, V327, P1380, DOI 10.1056/NEJM199211053271911; ROENN HS, 1993, ANN INTERN MED, V119, P121; ROSNER F, 1992, NEW YORK STATE J MED, V92, P388; ROTOV M, 1970, AM J PSYCHOTHER, V24, P216; SCHEIDERMAYER DL, 1989, NEW ENGL J MED, V321, P120; SCHNEIDERMAN LJ, 1993, J CLIN ETHIC, V4, P28; SINGER PA, 1990, NEW ENGL J MED, V322, P1881, DOI 10.1056/NEJM199006283222610; STARR TJ, 1986, J GEN INTERN MED, V1, P373, DOI 10.1007/BF02596420; TENO J, 1991, J AM GERIATR SOC, V39, P827, DOI 10.1111/j.1532-5415.1991.tb02707.x; UHLMANN RF, 1991, ARCH INTERN MED, V151, P495, DOI 10.1001/archinte.151.3.495; UHLMANN RF, 1988, J GERONTOL, V43, pM115, DOI 10.1093/geronj/43.5.M115; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; Wolk-Wasserman D, 1987, Crisis, V8, P69	48	48	48	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 8	1994	271	22					1786	1788		10.1001/jama.271.22.1786	http://dx.doi.org/10.1001/jama.271.22.1786			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NN725	8196123				2023-01-03	WOS:A1994NN72500030
J	YANG, EY; HUESTIS, WH				YANG, EY; HUESTIS, WH			OXIDATIVE INTERACTIONS BETWEEN THE ERYTHROCYTE-MEMBRANE AND PHOSPHATIDYLCHOLINE VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED BLOOD-CELLS; LOW-PH ASSOCIATION; VITAMIN-E; LIPID-PEROXIDATION; CROSS-LINKING; HEMOGLOBIN; PROTEINS; SUPEROXIDE; MECHANISM; TRANSGLUTAMINASES	Sonicated unilamellar phosphatidylcholine vesicles induce hemoglobin oxidation in erythrocytes and resealed membrane fragments (buds) at pH 5.5. No such oxidation was observed in vesicle-bud mixtures at pH 7.4, in cells or buds suspended in pH 5.5 buffer, or in cells incubated with multilamellar lipid vesicles at pH 5.5. In buds, vesicle-induced hemoglobin oxidation was accompanied by lipid peroxidation and formation of covalent high molecular weight protein aggregates. The causative relationships among the oxidative events were examined using selective antioxidants and membrane fragments in which the cytoplasmic domain of band 3 was cleaved. Protein cross-linking and lipid peroxidation were found to be independent events, but both were found only in concert with heme oxidation. Further, vesicle-induced hemoglobin oxidation was found to be correlated with quasi-stable adsorption of intact vesicles to cells; intercalation of foreign lipid into the cell bilayer was not required. The inability of multilamellar vesicles to induce these low pH oxidative effects suggests a steric Limitation on this cell-vesicle association. The results suggest that membrane component reorganization and patching induced by low pH may enhance vesicle adsorption, which in turn initiates oxidative damage.	STANFORD UNIV,DEPT CHEM,STANFORD,CA 94305	Stanford University					NHLBI NIH HHS [HL 23787] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL023787] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMES GFL, 1974, J BIOL CHEM, V249, P634; ARVINTE T, 1989, BIOCHIM BIOPHYS ACTA, V981, P51, DOI 10.1016/0005-2736(89)90081-3; ARVINTE T, 1989, BIOCHIM BIOPHYS ACTA, V981, P61, DOI 10.1016/0005-2736(89)90082-5; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BEPPU M, 1990, J BIOL CHEM, V265, P3226; BIABER B, 1977, J LAB CLIN MED, V85, P235; BOSSI L, 1975, BIOCHIM BIOPHYS ACTA, V375, P477, DOI 10.1016/0005-2736(75)90364-8; BURTON GW, 1983, ARCH BIOCHEM BIOPHYS, V221, P281, DOI 10.1016/0003-9861(83)90145-5; BUTIKOFER P, 1989, BLOOD, V74, P1481; CALVEZ JY, 1988, BIOCHEMISTRY-US, V27, P5666, DOI 10.1021/bi00415a041; CLASTER S, 1984, BLOOD, V64, P1079; CLASTER S, 1987, J LAB CLIN MED, V109, P201; COAKLEY WT, 1978, BIOCHIM BIOPHYS ACTA, V512, P318, DOI 10.1016/0005-2736(78)90256-0; CRICHTON RR, 1979, CIBA F S, V65, P57; Davies P J, 1988, Adv Exp Med Biol, V250, P391; DILLARD CJ, 1982, ARCH BIOCHEM BIOPHYS, V216, P204, DOI 10.1016/0003-9861(82)90205-3; DORMANDY TL, 1971, BRIT J HAEMATOL, V20, P457, DOI 10.1111/j.1365-2141.1971.tb07060.x; FLYNN TP, 1983, J CLIN INVEST, V71, P1215, DOI 10.1172/JCI110870; FLYNN TP, 1981, PROG CLIN BIOL RES, V91, P231; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; FREI B, 1989, P NATL ACAD SCI USA, V86, P6377, DOI 10.1073/pnas.86.16.6377; FRIDOVICH I, 1975, ANNU REV BIOCHEM, V44, P147, DOI 10.1146/annurev.bi.44.070175.001051; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HEBBEL RP, 1984, BLOOD, V64, P733; HERSCHBERGER LA, 1982, LIPIDS, V17, P686, DOI 10.1007/BF02534652; HUISMAN THJ, 1986, METHODS HEMATOLOGY, V15; ITABE H, 1988, BIOCHIM BIOPHYS ACTA, V961, P13; JAIN MK, 1980, INTRO BIOL MEMBRANES, P72; JOHNSON GJ, 1979, NEW ENGL J MED, V301, P522, DOI 10.1056/NEJM197909063011004; KIMELBERG HK, 1976, MOL CELL BIOCHEM, V10, P171, DOI 10.1007/BF01731688; KORNBRUST DJ, 1980, LIPIDS, V15, P315, DOI 10.1007/BF02533546; KWEI GY, 1985, NUTR REP INT, V32, P179; LABRAKE CC, 1992, J BIOL CHEM, V267, P16703; LITOV RE, 1981, TOXICOL APPL PHARM, V59, P96, DOI 10.1016/0041-008X(81)90456-7; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; LORAND L, 1976, P NATL ACAD SCI USA, V73, P4479, DOI 10.1073/pnas.73.12.4479; LOW PS, 1985, SCIENCE, V227, P531, DOI 10.1126/science.2578228; LUBIN B, 1982, PEDIATR RES, V16, P928, DOI 10.1203/00006450-198211000-00005; MACDONALD VW, 1983, J LAB CLIN MED, V102, P762; MACHLIN LJ, 1980, VITAMIN E; MANNOJI M, 1985, SCAND J HAEMATOL, V35, P257; MCCAY PB, 1971, LIPIDS, V6, P297, DOI 10.1007/BF02531819; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MISRA HP, 1972, J BIOL CHEM, V247, P6960; PALEK J, 1979, SEMIN HEMATOL, V14, P75; PAPAHADJOPOULOS D, 1973, Biochimica et Biophysica Acta, V330, P8, DOI 10.1016/0005-2736(73)90280-0; PAPAHADJOPOULOS D, 1975, BIOCHIM BIOPHYS ACTA, V401, P317, DOI 10.1016/0005-2736(75)90233-3; PRYOR W A, 1976, FREE RADICALS BIOLOG, P1; Riggs A., 1981, Methods in Enzymology, V76, P5; SALIN ML, 1975, J CLIN INVEST, V56, P1319, DOI 10.1172/JCI108208; SEVANIAN A, 1982, LIPIDS, V17, P269, DOI 10.1007/BF02534941; SHAKLAI N, 1978, ISRAEL J MED SCI, V14, P1152; SHVIRO Y, 1982, BIOCHIM BIOPHYS ACTA, V687, P63, DOI 10.1016/0005-2736(82)90170-5; SIEFRING GE, 1978, BIOCHEMISTRY-US, V17, P2598, DOI 10.1021/bi00606a022; SNYDER LM, 1983, BRIT J HAEMATOL, V53, P379, DOI 10.1111/j.1365-2141.1983.tb02038.x; Steck T L, 1974, Methods Enzymol, V31, P172; Steck T. L., 1974, METHODS MEMBRANE BIO, V2, P245; Stokes J, 1971, BRIT J HAEMATOL, V20, P95; SZEBENI J, 1988, BIOCHEMISTRY-US, V27, P6425, DOI 10.1021/bi00417a034; SZEBENI J, 1985, BIOCHEMISTRY-US, V24, P2827, DOI 10.1021/bi00333a003; SZEBENI J, 1984, BIOCHEM J, V220, P685, DOI 10.1042/bj2200685; TAPPEL AL, 1972, ANN NY ACAD SCI, V203, P12, DOI 10.1111/j.1749-6632.1972.tb27851.x; Tappel AL, 1980, FREE RADICALS BIOL, P1; VANHEMMEN JJ, 1977, ARCH BIOCHEM BIOPHYS, V182, P743, DOI 10.1016/0003-9861(77)90556-2; WALLACE WJ, 1974, BIOCHEM BIOPH RES CO, V57, P1104, DOI 10.1016/0006-291X(74)90810-9; WAUGH SM, 1985, BIOCHEMISTRY-US, V24, P34, DOI 10.1021/bi00322a006; WAUGH SM, 1987, BIOCHEMISTRY-US, V26, P1777, DOI 10.1021/bi00380a041; WEISS SJ, 1981, J CLIN INVEST, V68, P714, DOI 10.1172/JCI110307; WEISS SJ, 1980, J BIOL CHEM, V255, P9912; WINTERBOURN CC, 1976, BIOCHEM J, V155, P493, DOI 10.1042/bj1550493; ZLATKIS A, 1953, J LAB CLIN MED, V41, P486; [No title captured]	72	3	3	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14518	14524						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182058				2023-01-03	WOS:A1994NM06500034
J	HARRINGTON, CR; WISCHIK, CM; MCARTHUR, FK; TAYLOR, GA; EDWARDSON, JA; CANDY, JM				HARRINGTON, CR; WISCHIK, CM; MCARTHUR, FK; TAYLOR, GA; EDWARDSON, JA; CANDY, JM			ALZHEIMERS-DISEASE-LIKE CHANGES IN TAN PROTEIN PROCESSING - ASSOCIATION WITH ALUMINUM ACCUMULATION IN BRAINS OF RENAL DIALYSIS PATIENTS	LANCET			English	Article							PAIRED HELICAL FILAMENTS; NEUROFIBRILLARY TANGLES; MICROPROBE; ISOFORMS; ABSENCE; PLAQUE	Tau protein is a major structural protein of the paired helical filaments (PHFs) found in both neuritic senile plaques and neurofibrillary tangles in Alzheimer's disease (AD). Senile plaques also contain amyloid beta protein (A beta). We did an immunochemical analysis of frontal cortex from 15 dialysis cases, 5 Alzheimer's disease patients, and 6 control cases to see whether AD-like changes in A beta deposition and tau protein were linked to aluminium accumulation. Dialysis patients were used because they are frequently exposed to increased levels of aluminium. 8 of the 15 dialysis cases had insoluble A beta, but there was no association between its presence and the accumulation of aluminium. However, we found AD-like changes in the processing of tau protein. In white matter, truncated tau protein in the PHF-core fraction and endogenously truncated tau in the supernatant fraction were both increased in association with aluminium accumulation in the brain. In grey matter, normal tau protein was depleted and insoluble hyperphosphorylated tau increased in association with aluminium concentration. Protease-resistant PHFs were present in grey matter in 2 dialysis cases, a frequency above that expected for AD in this age group. PHF-core tau in both grey and white matter correlated with decreased levels of normal tau protein in white matter. These findings are consistent with a role for aluminium in the development of AD-like pathology in patients subjected to prolonged aluminium exposure.	NEWCASTLE GEN HOSP, MRC, NEUROCHEM PATHOL UNIT, NEWCASTLE UPON TYNE, TYNE & WEAR, ENGLAND	Newcastle General Hospital	HARRINGTON, CR (corresponding author), UNIV CAMBRIDGE, CTR MRC, DEPT PSYCHIAT, CAMBRIDGE BRAIN BANK LAB, HILLS RD, CAMBRIDGE CB2 2QH, CAMBS, ENGLAND.			Harrington, Charles/0000-0003-2250-3920				ABDELGHANY M, 1993, J BIOL CHEM, V268, P11976; CANDY JM, 1992, J NEUROL SCI, V107, P210, DOI 10.1016/0022-510X(92)90291-R; CANDY JM, 1986, LANCET, V1, P354; CHAFI AH, 1991, NEUROSCI LETT, V123, P61, DOI 10.1016/0304-3940(91)90158-P; DOLL R, 1993, AGE AGEING, V22, P138, DOI 10.1093/ageing/22.2.138; EDWARDSON JA, 1991, ALUMINUM CHEM BIOL M, P85; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5827, DOI 10.1073/pnas.87.15.5827; GUY SP, 1991, NEUROSCI LETT, V121, P166, DOI 10.1016/0304-3940(91)90676-K; HARRINGTON CR, 1991, P NATL ACAD SCI USA, V88, P5842, DOI 10.1073/pnas.88.13.5842; JACOBS RW, 1989, CAN J NEUROL SCI, V16, P498, DOI 10.1017/S0317167100029838; KAWAHARA M, 1992, BIOCHEM BIOPH RES CO, V189, P1317, DOI 10.1016/0006-291X(92)90217-9; KHACHATURIAN ZS, 1985, ARCH NEUROL-CHICAGO, V42, P1097, DOI 10.1001/archneur.1985.04060100083029; LANDSBERG JP, 1992, NATURE, V360, P65, DOI 10.1038/360065a0; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; MATTSON MP, 1993, BRAIN RES, V602, P21, DOI 10.1016/0006-8993(93)90236-G; MORRIS CM, 1989, J NEUROL SCI, V94, P295, DOI 10.1016/0022-510X(89)90238-4; MUKAETOVALADINSKA EB, 1993, AM J PATHOL, V143, P565; MULLAN M, 1993, TRENDS NEUROSCI, V16, P398, DOI 10.1016/0166-2236(93)90007-9; NOVAK M, 1993, EMBO J, V12, P365, DOI 10.1002/j.1460-2075.1993.tb05665.x; PERL DP, 1980, SCIENCE, V208, P297, DOI 10.1126/science.7367858; ROCCA WA, 1991, ANN NEUROL, V30, P381, DOI 10.1002/ana.410300310; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SHIGEMATSU K, 1992, BRAIN RES, V593, P117, DOI 10.1016/0006-8993(92)91272-G; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4506, DOI 10.1073/pnas.85.12.4506	27	121	128	0	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 23	1994	343	8904					993	997		10.1016/S0140-6736(94)90124-4	http://dx.doi.org/10.1016/S0140-6736(94)90124-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NG682	7909090				2023-01-03	WOS:A1994NG68200007
J	EMANUEL, EJ; EMANUEL, LL				EMANUEL, EJ; EMANUEL, LL			THE ECONOMICS OF DYING - THE ILLUSION OF COST SAVINGS AT THE END OF LIFE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CELL LUNG-CANCER; RANDOMIZED TRIAL; CRITICALLY ILL; MEDICAL-CARE; ADVANCE DIRECTIVES; NATIONAL HOSPICE; CHEMOTHERAPY; RESUSCITATION; EXPENDITURES; PREFERENCES		HARVARD UNIV,SCH MED,DIV MED ETH,BOSTON,MA	Harvard University; Harvard Medical School	EMANUEL, EJ (corresponding author), DANA FARBER CANC INST,DIV CANC EPIDEMIOL & CONTROL,44 BINNEY ST,BOSTON,MA 02115, USA.							BAYER R, 1983, NEW ENGL J MED, V309, P1490, DOI 10.1056/NEJM198312153092405; BEDELL SE, 1986, JAMA-J AM MED ASSOC, V256, P233, DOI 10.1001/jama.256.2.233; BLACKHALL LJ, 1987, NEW ENGL J MED, V317, P1281, DOI 10.1056/NEJM198711123172009; BROOKS CH, 1984, MED CARE, V22, P691, DOI 10.1097/00005650-198408000-00002; DORONZIO JC, 1993, NY TIMES        0608, pA25; EMANUEL EI, 1994, WASHINGTON POST 0102, pC3; EMANUEL EJ, 1992, JAMA-J AM MED ASSOC, V267, P2067; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; FRIES JF, 1993, NEW ENGL J MED, V329, P321, DOI 10.1056/NEJM199307293290506; Ginzberg E, 1980, Inquiry, V17, P293; GLEESON K, 1990, ARCH INTERN MED, V150, P1057, DOI 10.1001/archinte.150.5.1057; GODEC MS, 1993, WASHINGTON POST 0502, pC3; GREER DS, 1986, J CHRON DIS, V39, P5, DOI 10.1016/0021-9681(86)90102-5; HAAS JS, 1993, ARCH INTERN MED, V153, P1241, DOI 10.1001/archinte.153.10.1241; HANNAN EL, 1984, INQUIRY-J HEALTH CAR, V21, P338; IHDE DC, 1992, NEW ENGL J MED, V327, P1434; JAAKKIMAINEN L, 1990, J CLIN ONCOL, V8, P1301, DOI 10.1200/JCO.1990.8.8.1301; KANE RL, 1984, LANCET, V1, P890; KIDDER D, 1992, HEALTH SERV RES, V27, P195; LANTOS JD, 1989, AM J MED, V87, P81; LEAF A, 1977, NEW ENGL J MED, V297, P887, DOI 10.1056/NEJM197710202971612; Levit K R, 1991, Health Care Financ Rev, V13, P29; LOCWY EH, 1993, ARCH INTERN MED, V153, P429; Lubitz J, 1984, Health Care Financ Rev, V5, P117; LUBITZ JD, 1993, NEW ENGL J MED, V328, P1092, DOI 10.1056/NEJM199304153281506; LUNDBERG GD, 1993, JAMA-J AM MED ASSOC, V269, P2554, DOI 10.1001/jama.269.19.2554; MAKSOUD A, 1993, ARCH INTERN MED, V153, P1249, DOI 10.1001/archinte.153.10.1249; MCCALL N, 1984, MED CARE, V22, P329, DOI 10.1097/00005650-198404000-00004; MOINPOUR CM, 1989, AM J PUBLIC HEALTH, V79, P1549, DOI 10.2105/AJPH.79.11.1549; MOR V, 1985, HEALTH SERV RES, V20, P407; MURPHY DJ, 1993, ARCH INTERN MED, V153, P1641, DOI 10.1001/archinte.153.14.1641; NEWHOUSE JP, 1993, HEALTH AFFAIR, V12, P152, DOI 10.1377/hlthaff.12.suppl_1.152; RAPP E, 1988, J CLIN ONCOL, V6, P633, DOI 10.1200/JCO.1988.6.4.633; RILEY G, 1987, INQUIRY-J HEALTH CAR, V24, P233; RUCKDESCHEL JC, 1990, J CLIN ONCOL, V8, P1293, DOI 10.1200/JCO.1990.8.8.1293; SCHAPIRA DV, 1993, JAMA-J AM MED ASSOC, V269, P783, DOI 10.1001/jama.269.6.783; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949; SCHNEIDERMAN LJ, 1992, ANN INTERN MED, V117, P599, DOI 10.7326/0003-4819-117-7-599; SCHNEIDERMAN LJ, 1993, ARCH INTERN MED, V153, P437, DOI 10.1001/archinte.153.4.437; SCHROEDER SA, 1981, JAMA-J AM MED ASSOC, V245, P1446, DOI 10.1001/jama.245.14.1446; SCHWARTZ WB, 1987, JAMA-J AM MED ASSOC, V257, P220, DOI 10.1001/jama.257.2.220; SCITOVSKY AA, 1984, MILBANK Q, V62, P591, DOI 10.2307/3349838; SCITOVSKY AA, 1986, ANNU REV PUBL HEALTH, V7, P59, DOI 10.1146/annurev.pu.07.050186.000423; SCITOVSKY AA, 1988, MILBANK Q, V66, P640, DOI 10.2307/3349934; SECKLER AB, 1991, ANN INTERN MED, V115, P92, DOI 10.7326/0003-4819-115-2-92; SINGER PA, 1992, ARCH INTERN MED, V152, P478, DOI 10.1001/archinte.152.3.478; SIU AL, 1986, NEW ENGL J MED, V315, P1259, DOI 10.1056/NEJM198611133152005; SIU AL, 1987, MED SOC CLIN DECISIO, P20; SMEDIRA NG, 1990, NEW ENGL J MED, V322, P309, DOI 10.1056/NEJM199002013220506; SPECTOR WD, 1984, INQUIRY-J HEALTH CAR, V21, P328; STEIBER SR, 1987, HOSPITALS, V61, P72; STEINBROOK R, 1986, NEW ENGL J MED, V314, P457, DOI 10.1056/NEJM198602133140730; TENO J, 1993, CLIN RES, V41, pA551; TOMLINSON T, 1990, JAMA-J AM MED ASSOC, V264, P1276, DOI 10.1001/jama.264.10.1276; TURNBULL AD, 1979, CRIT CARE MED, V7, P20, DOI 10.1097/00003246-197901000-00005; UHLMANN RF, 1988, J GERONTOL, V43, pM115, DOI 10.1093/geronj/43.5.M115; VITELLI CE, 1991, J CLIN ONCOL, V9, P111, DOI 10.1200/JCO.1991.9.1.111; Waldo D R, 1989, Health Care Financ Rev, V10, P111; WOOLHANDLER S, 1991, NEW ENGL J MED, V324, P1253, DOI 10.1056/NEJM199105023241805	59	274	276	1	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 24	1994	330	8					540	544		10.1056/NEJM199402243300806	http://dx.doi.org/10.1056/NEJM199402243300806			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MX436	8302321				2023-01-03	WOS:A1994MX43600006
J	SIMOONS, ML; MAGGIONI, AP; KNATTERUD, G; LEIMBERGER, JD; DEJAEGERE, P; VANDOMBURG, R; BOERSMA, E; FRANZOSI, MG; CALIFF, R; SCHRODER, R; BRAUNWALD, E				SIMOONS, ML; MAGGIONI, AP; KNATTERUD, G; LEIMBERGER, JD; DEJAEGERE, P; VANDOMBURG, R; BOERSMA, E; FRANZOSI, MG; CALIFF, R; SCHRODER, R; BRAUNWALD, E			INDIVIDUAL RISK ASSESSMENT FOR INTRACRANIAL HEMORRHAGE DURING THROMBOLYTIC THERAPY	LANCET			English	Article							ACUTE MYOCARDIAL-INFARCTION; TISSUE PLASMINOGEN-ACTIVATOR; INTRAVENOUS STREPTOKINASE; INTRACEREBRAL HEMORRHAGE; RANDOMIZED TRIAL; PHASE-II; STROKE; EPIDEMIOLOGY; NETHERLANDS; ANGIOPLASTY	Thrombolytic therapy improves outcome in patients with myocardial infarction but is associated with an increased risk of intracranial haemorrhage. For some patients, this risk may outweigh the potential benefits of thrombolytic treatment. Using data from other studies, we developed a model for the assessment of an individual's risk of intracranial haemorrhage during thrombolysis. Data were available from 150 patients with documented intracranial haemorrhage and 294 matched controls. 49 patients with intracranial haemorrhage and 122 controls had been treated with streptokinase, whereas 88 cases and 148 controls had received alteplase. By multivariate analysis, four factors were identified as independent predictors of intracranial haemorrhage; age over 65 years (odds ratio 2.2 [95% CI 1.4-3.5]), bodyweight below 70 kg (2.1 [1.3-3.2]), hypertension on hospital admission (2.0 [1.2-3.2]), and administration of alteplase (1.6 [1.0-2.5]). If the overall incidence of intracranial haemorrhage is assumed to be 0.75%, patients without risk factors who receive streptokinase have a 0.26% probability of intracranial haemorrhage. The risk is 0.96%, 1.32%, and 2.17% in patients with one, two, or three risk factors, respectively. We present a model for individual risk assessment that can be used easily in clinical practice.	ERASMUS UNIV ROTTERDAM, THORAXCTR, 3000 DR ROTTERDAM, NETHERLANDS; MARIO NEGRI INST PHARMACOL RES, I-20157 MILAN, ITALY; DUKE UNIV, DEPT CARDIOL, DURHAM, NC 27706 USA; FREE UNIV BERLIN, W-1000 BERLIN 33, GERMANY; MARYLAND MED RES INST, BALTIMORE, MD USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA	Erasmus University Rotterdam; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Duke University; Free University of Berlin; Harvard University; Brigham & Women's Hospital	SIMOONS, ML (corresponding author), UNIV HOSP ROTTERDAM, THORAXCTR, POB 1738, 3000 DR ROTTERDAM, NETHERLANDS.		Maggioni, Aldo Pietro/AAL-5334-2020	Maggioni, Aldo Pietro/0000-0003-2764-6779				[Anonymous], 1990, LANCET, V336, P65; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; [Anonymous], 1989, NEW ENGL J MED, V320, P618; BONITA R, 1992, LANCET, V339, P342, DOI 10.1016/0140-6736(92)91658-U; BOSSUYT PMM, 1990, KLINISCHE BESLISKUND, P127; BRAUNWALD E, 1987, J AM COLL CARDIOL, V10, P970, DOI 10.1016/S0735-1097(87)80296-6; CALIFF RM, 1988, AM J MED, V85, P353, DOI 10.1016/0002-9343(88)90586-4; CAPLAN LR, 1992, LANCET, V339, P656, DOI 10.1016/0140-6736(92)90804-C; CHESEBRO JH, 1987, CIRCULATION, V76, P142, DOI 10.1161/01.CIR.76.1.142; DEJAEGERE PP, 1992, J AM COLL CARDIOL, V19, P289, DOI 10.1016/0735-1097(92)90480-B; GORE JM, 1991, CIRCULATION, V83, P448, DOI 10.1161/01.CIR.83.2.448; HERMAN B, 1982, STROKE, V13, P629, DOI 10.1161/01.STR.13.5.629; KASE CS, 1992, AM J MED, V92, P384, DOI 10.1016/0002-9343(92)90268-G; MAGGIONI AP, 1992, NEW ENGL J MED, V327, P1, DOI 10.1056/NEJM199207023270101; MARMOT MG, 1992, LANCET, V339, P344, DOI 10.1016/0140-6736(92)91659-V; MUELLER HS, 1987, J AM COLL CARDIOL, V10, P479, DOI 10.1016/S0735-1097(87)80188-2; NEUHAUS KL, 1989, J AM COLL CARDIOL, V14, P1566, DOI 10.1016/0735-1097(89)90399-9; PASSAMANI E, 1987, J AM COLL CARDIOL, V10, pB51, DOI 10.1016/S0735-1097(87)80429-1; SCHRODER R, 1986, NEW ENGL J MED, V314, P1465; SIMOONS ML, 1988, LANCET, V1, P199; SIMOONS ML, 1989, J AM COLL CARDIOL, V14, P1609, DOI 10.1016/0735-1097(89)90003-X; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; TOPOL EJ, 1989, CIRCULATION, V79, P281, DOI 10.1161/01.CIR.79.2.281; TOPOL EJ, 1988, CIRCULATION, V77, P1100, DOI 10.1161/01.CIR.77.5.1100; TOPOL EJ, 1987, NEW ENGL J MED, V317, P581, DOI 10.1056/NEJM198709033171001; VANDEWERF F, 1990, LANCET, V336, P71; VANDEWERF F, 1988, BMJ-BRIT MED J, V297, P1374, DOI 10.1136/bmj.297.6660.1374; VERMEER F, 1986, CIRCULATION, V74, P1379, DOI 10.1161/01.CIR.74.6.1379; VERMEER F, 1988, BRIT HEART J, V59, P527; VERSTRAETE M, 1985, LANCET, V1, P842, DOI 10.1016/S0140-6736(85)92208-1; WALL TC, 1992, J AM COLL CARDIOL, V19, P482, DOI 10.1016/S0735-1097(10)80259-1; WILCOX RG, 1988, LANCET, V2, P525	33	232	237	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 18	1993	342	8886-7					1523	1528		10.1016/S0140-6736(05)80089-3	http://dx.doi.org/10.1016/S0140-6736(05)80089-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM402	7902905	Green Submitted			2023-01-03	WOS:A1993MM40200016
J	QUILL, TE				QUILL, TE			DOCTOR, I WANT TO DIE - WILL YOU HELP ME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOPELESSLY ILL PATIENTS; ASSISTED SUICIDE; PHYSICIANS RESPONSIBILITY; RATIONAL SUICIDE; EUTHANASIA; CARE; DEATH; PAIN		UNIV ROCHESTER, SCH MED, PROGRAM BIOPSYCHOSOC STUDIES, ROCHESTER, NY 14627 USA	University of Rochester	QUILL, TE (corresponding author), GENESEE HOSP, DEPT MED, ROCHESTER, NY 14607 USA.							ALLEBECK P, 1989, J CLIN EPIDEMIOL, V42, P611, DOI 10.1016/0895-4356(89)90003-6; ANGELL M, 1988, NEW ENGL J MED, V319, P1348, DOI 10.1056/NEJM198811173192010; ARIES P, 1982, HOUR OF OUR DEATH; BREITBART W, 1989, ONCOLOGY, P49; BRODY H, 1992, NEW ENGL J MED, V327, P1384, DOI 10.1056/NEJM199211053271912; CASSEL CK, 1990, NEW ENGL J MED, V323, P750, DOI 10.1056/NEJM199009133231110; CASSEL EJ, 1982, NEW ENGL J MED, V306, P639, DOI 10.1056/NEJM198203183061104; CONWELL Y, 1991, NEW ENGL J MED, V325, P1100, DOI 10.1056/NEJM199110103251511; Fisher R., 2011, GETTING YES NEGOTIAT; FOLEY KM, 1985, NEW ENGL J MED, V313, P84, DOI 10.1056/NEJM198507113130205; GARFIELD C, 1978, PSYCHOSOCIAL CARE DY; GAYLIN W, 1988, JAMA-J AM MED ASSOC, V259, P2139; Gomez Carlos F., 1991, REGULATING DEATH EUT; JECKER NS, 1991, J AM GERIATR SOC, V39, P831, DOI 10.1111/j.1532-5415.1991.tb02708.x; KANE RL, 1985, JAMA-J AM MED ASSOC, V253, P2683, DOI 10.1001/jama.253.18.2683; KERR IG, 1988, ANN INTERN MED, V108, P554, DOI 10.7326/0003-4819-108-4-554; Kubler-Ross Elisabeth, 1969, DEATH DYING; MACKENZIE TB, 1987, INT J PSYCHIAT MED, V17, P3; MEIER DE, 1983, J AM GERIATR SOC, V31, P294, DOI 10.1111/j.1532-5415.1983.tb04874.x; NOVACK DH, 1987, J GEN INTERN MED, V2, P346, DOI 10.1007/BF02596174; ORENTLICHER D, 1989, JAMA-J AM MED ASSOC, V262, P1844, DOI 10.1001/jama.262.13.1844; QUILL TE, 1983, ANN INTERN MED, V98, P228, DOI 10.7326/0003-4819-98-2-228; QUILL TE, 1990, ARCH INTERN MED, V150, P1857, DOI 10.1001/archinte.150.9.1857; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; QUILL TE, 1992, NEW ENGL J MED, V327, P1380, DOI 10.1056/NEJM199211053271911; Quill TE, 1993, DEATH DIGNITY MAKING; RHYMES J, 1990, JAMA-J AM MED ASSOC, V264, P369, DOI 10.1001/jama.264.3.369; RICHMAN J, 1992, SUICIDE LIFE-THREAT, V22, P130; SINGER PA, 1990, NEW ENGL J MED, V322, P1881, DOI 10.1056/NEJM199006283222610; SUCHMAN AL, 1988, ANN INTERN MED, V108, P125, DOI 10.7326/0003-4819-108-1-125; TWYEROSS RG, 1984, SYMPTOM CONTROL FAR; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; WANZER SH, 1984, NEW ENGL J MED, V310, P955, DOI 10.1056/NEJM198404123101505; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; ZIMMERMAN JM, 1981, HOSPICE COMPLETE CAR; 1987, HASTINGS CTR REPORT; 1992, JAMA-J AM MED ASSOC, V267, P2229	37	96	96	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	1993	270	7					870	873		10.1001/jama.270.7.870	http://dx.doi.org/10.1001/jama.270.7.870			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR612	8340988				2023-01-03	WOS:A1993LR61200035
J	VERSLUYS, C				VERSLUYS, C			ETHICS OF NEONATAL CARE	LANCET			English	Letter											VERSLUYS, C (corresponding author), WILKELMINA KINDERZIEKENHUIS,UTRECHT,NETHERLANDS.								0	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 27	1993	341	8848					794	795		10.1016/0140-6736(93)90567-Z	http://dx.doi.org/10.1016/0140-6736(93)90567-Z			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU900	8096005				2023-01-03	WOS:A1993KU90000010
J	Cerin, A; Heldaas, K; Moeller, B				Cerin, A; Heldaas, K; Moeller, B			Adverse endometrial effects of long-cycle estrogen and progestogen replacement therapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									TELEMARK CENT HOSP, N-3900 PORSGRUNN, NORWAY; ODENSE HOSP, DK-5000 ODENSE, DENMARK	University of Southern Denmark; Odense University Hospital	Cerin, A (corresponding author), KAROLINSKA HOSP, S-17176 STOCKHOLM, SWEDEN.							DAVID A, 1994, I C S S, V8, P463; ELLERINGTON MC, 1992, BRIT MED BULL, V48, P401, DOI 10.1093/oxfordjournals.bmb.a072553; HAMMARBACK S, 1985, ACTA OBSTET GYN SCAN, V64, P393, DOI 10.3109/00016348509155154; HIRVONEN E, 1995, MATURITAS, V21, P39, DOI 10.1016/0378-5122(94)00862-2; KURMAN RJ, 1985, CANCER, V56, P403, DOI 10.1002/1097-0142(19850715)56:2<403::AID-CNCR2820560233>3.0.CO;2-X	5	33	34	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 7	1996	334	10					668	669		10.1056/NEJM199603073341018	http://dx.doi.org/10.1056/NEJM199603073341018			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX693	8592546				2023-01-03	WOS:A1996TX69300029
J	HOLLAND, BK				HOLLAND, BK			PROSPECTING FOR DRUGS IN ANCIENT TEXTS	NATURE			English	Editorial Material							PENNYROYAL OIL; HEPATOTOXICITY; MENTHOFURAN; GLUTATHIONE; PULEGONE				HOLLAND, BK (corresponding author), UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT PREVENT MED & COMMUNITY HLTH,NEWARK,NJ 07103, USA.							ATHERTON DJ, 1991, LANCET, V338, P510, DOI 10.1016/0140-6736(91)90580-I; BURTON JL, 1990, LANCET, V336, P1565, DOI 10.1016/0140-6736(90)93326-K; FARNSWORTH NR, 1983, NATURAL PRODUCTS DRU; FELLOWS L, 1992, LANCET, V339, P1330, DOI 10.1016/0140-6736(92)91967-D; FROEHLICH O, 1990, Journal of Agricultural and Food Chemistry, V38, P2057, DOI 10.1021/jf00101a012; GORDON WP, 1987, DRUG METAB DISPOS, V15, P589; GORDON WP, 1982, TOXICOL APPL PHARM, V65, P413, DOI 10.1016/0041-008X(82)90387-8; MCMANUS OB, 1993, BIOCHEMISTRY-US, V32, P6128, DOI 10.1021/bi00075a002; REYNOLDS T, 1991, J NATL CANCER I, V83, P594, DOI 10.1093/jnci/83.9.594; RIDDLE JM, 1992, AM SCI, V80, P226; SULLIVAN JB, 1979, JAMA-J AM MED ASSOC, V242, P2873; THOMASSEN D, 1991, DRUG METAB DISPOS, V19, P997; THOMASSEN D, 1990, J PHARMACOL EXP THER, V253, P567; VILLASENOR IM, 1993, CARCINOGENESIS, V14, P123, DOI 10.1093/carcin/14.1.123	14	46	48	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 30	1994	369	6483					702	702		10.1038/369702a0	http://dx.doi.org/10.1038/369702a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NU581	8008059				2023-01-03	WOS:A1994NU58100027
J	BAKER, DW; STEVENS, CD; BROOK, RH				BAKER, DW; STEVENS, CD; BROOK, RH			REGULAR SOURCE OF AMBULATORY CARE AND MEDICAL-CARE UTILIZATION BY PATIENTS PRESENTING TO A PUBLIC HOSPITAL EMERGENCY DEPARTMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CITY MINORITY POPULATION; HEALTH-CARE; ACCESS; ROOM; CONSEQUENCES; HYPERTENSION	Objective.-To determine the regular source of care and the relationship between usual provider and use of medical services among ambulatory emergency department patients. Design.-Cross-sectional survey. Setting.-A public hospital in Los Angeles County, California. Patients.-A total of 1190 stable, ambulatory adults presenting to the emergency department during a 2-week period. Main Outcome Measures.-Self-reported regular source of care, usual health status, and recent physician visits. Results.-A total of 16% of the patients identified ah emergency department as their regular source of care. One fourth of this group reported fair or poor health. African Americans and Latinos were more likely than whites to identify an emergency department as their regular source of care. Patients who identified an emergency department as their regular source of care had 25% fewer physician visits and were less likely to have seen a physician during the preceding 3 months than patients who were usually seen in an office or clinic (relative risk, 0.45;95% confidence interval, 0.28 to 0.70). Of all patients, 56% identified; a regular source of care other than an emergency department, but 24% to 36% of all their recent physician visits still occurred in an emergency department. Conclusion.-Our patients rely heavily on emergency departments for ambulatory physician visits, regardless of their reported regular source of care. However, patients who identify an emergency department as their regular source of ambulatory care used physician services less frequently than patients with access to providers in other settings. These issues require further evaluation with population-based surveys.	UNIV CALIF LOS ANGELES,LOS ANGELES CTY HARBOR MED CTR,DEPT EMERGENCY MED,TORRANCE,CA; VALUE HLTH SCI,SANTA MONICA,CA; UNIV CALIF LOS ANGELES,CTR HLTH SCI,DEPT MED,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,CTR HLTH SCI,DEPT HLTH SERV,LOS ANGELES,CA 90024; RAND CORP,HLTH SCI PROGRAM,SANTA MONICA,CA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; RAND Corporation	BAKER, DW (corresponding author), UNIV CALIF LOS ANGELES,LOS ANGELES CTY HARBOR MED CTR,DEPT MED,DIV GEN INTERNAL MED,TORRANCE,CA 90509, USA.							ADAY LA, 1984, AM J PUBLIC HEALTH, V74, P1331, DOI 10.2105/AJPH.74.12.1331; ADAY LA, 1975, ACCESS MED CARE; Aday LA, 1980, HLTH CARE US EQUITAB; ALPERT JJ, 1969, MED CARE, V7, P55, DOI 10.1097/00005650-196901000-00007; BAKER DW, 1991, JAMA-J AM MED ASSOC, V266, P1085, DOI 10.1001/jama.266.8.1085; BINDMAN AB, 1991, JAMA-J AM MED ASSOC, V266, P1091, DOI 10.1001/jama.266.8.1091; BLOOM BL, 1981, VITAL HLTH STAT 10, V148; BUESCHING DP, 1985, ANN EMERG MED, V14, P672, DOI 10.1016/S0196-0644(85)80886-6; CORNELIUS L, 1991, USUAL SOURCES MED CA, V2; DAVIS K, 1981, ANNU REV PUBL HEALTH, V2, P159, DOI 10.1146/annurev.pu.02.050181.001111; FLEMING NS, 1983, MED CARE, V21, P892, DOI 10.1097/00005650-198309000-00006; GOUGH HG, 1977, MED EDUC, V11, P380, DOI 10.1111/j.1365-2923.1977.tb00636.x; GRUMBACH K, 1993, AM J PUBLIC HEALTH, V83, P372, DOI 10.2105/AJPH.83.3.372; GUTTERMAN JJ, 1985, ANN EMERG MED, V14, P1191; HABENSTREIT B, 1986, NEW YORK STATE J MED, V86, P517; HAYWARD RA, 1991, AM J PUBLIC HEALTH, V81, P434, DOI 10.2105/AJPH.81.4.434; JACOBS AR, 1991, JAMA-J AM MED ASSOC, V216, P307; Jones S L, 1985, J Emerg Nurs, V11, P145; KELLERMAN AL, 1991, JAMA-J AM MED ASSOC, V266, P1123, DOI 10.1001/jama.266.8.1123; PERKOFF GT, 1970, MED CARE, V8, P309, DOI 10.1097/00005650-197008040-00007; SCHOENBORN CA, 1988, VITAL HLTH STAT 10, V166; SHEA S, 1992, AM J PUBLIC HEALTH, V82, P1607, DOI 10.2105/AJPH.82.12.1607; SHEA S, 1992, NEW ENGL J MED, V327, P776, DOI 10.1056/NEJM199209103271107; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; STOCK LM, 1994, ANN EMERG MED, V23, P294, DOI 10.1016/S0196-0644(94)70043-5; VAYDA E, 1975, CAN MED ASSOC J, V112, P961; WEINERMAN RE, 1966, AM J PUBLIC HEALTH, V56, P1037; WOLCOTT BW, 1979, JACEP-J AM COLL EMER, V8, P241; 1980, EMERGENCY DEP REGION, P13; 1992, STATA VERSION 3 0; 1983, RW JOHNSON F UPDATE	31	206	206	0	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 22	1994	271	24					1909	1912		10.1001/jama.271.24.1909	http://dx.doi.org/10.1001/jama.271.24.1909			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NR598	8201734				2023-01-03	WOS:A1994NR59800026
J	SCHREIER, H; MORAN, P; CARAS, IW				SCHREIER, H; MORAN, P; CARAS, IW			TARGETING OF LIPOSOMES TO CELLS EXPRESSING CD4 USING GLYCOSYLPHOSPHATIDYLINOSITOL-ANCHORED GP120 - INFLUENCE OF LIPOSOME COMPOSITION ON INTRACELLULAR TRAFFICKING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; DECAY-ACCELERATING FACTOR; MEMBRANE ANCHOR; COMPLEMENT ACTIVATION; T4 MOLECULE; ATTACHMENT; VESICLES; PROTEINS; BINDING; INVITRO	To test the concept that glycosylphosphatidylinositol (GPI)-anchored proteins might be useful as targeting molecules for liposomes, we engineered a GPI-anchored form of gp120 from human immunodeficiency virus type 1 (termed gp120DAF) using the GPI signal of decay-accelerating factor (DAF). We show that (i) purified gp120DAF spontaneously inserts into liposome membranes via the GPI anchor; (ii) liposomes bearing gp120DAF bind specifically to cells expressing CD4, the cellular receptor for gp120; and (iii) the receptor-bound liposomes are internalized and recycle in Chinese ham ster ovary cells. To test whether the lipid composition of the liposome affects any of these processes, we compared small unilamellar liposomes containing only phosphatidylcholine and cholesterol in a 7:1 molar ratio with artificial viral envelopes that mimic the lipid com position of human immunodeficiency virus type 1. We show that when tagged with gp120DAF, both liposome preparations bind specifically to cells expressing CD4, and both are endocytosed. However, artificial viral en velope liposomes are transported to late endosomes or lysosomes in the cell interior, whereas phosphatidylcholine:cholesterol liposomes are confined to a population of vesicles that remain close to the plasma membrane. Since the binding and internalization of both liposome preparations are mediated by the same receptor, we conclude that the lipid composition of the liposome pro foundry influences the subsequent intracellular trafficking of the liposome-receptor complex.	GENENTECH INC,DEPT NEUROBIOL,S SAN FRANCISCO,CA 94080; VANDERBILT UNIV,SCH MED,CTR LUNG RES,NASHVILLE,TN 37232	Roche Holding; Genentech; Vanderbilt University				Caras, Ingrid/0000-0002-8902-808X				ALOIA RC, 1988, P NATL ACAD SCI USA, V85, P900, DOI 10.1073/pnas.85.3.900; BERMAN PW, 1989, J VIROL, V63, P3489, DOI 10.1128/JVI.63.8.3489-3498.1989; CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0; CARAS IW, 1987, SCIENCE, V238, P1280, DOI 10.1126/science.2446389; CHANDER R, 1992, LIFE SCI, V50, P481, DOI 10.1016/0024-3205(92)90387-5; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; EATON DL, 1986, BIOCHEMISTRY-US, V25, P8343, DOI 10.1021/bi00374a001; HELENIUS A, 1982, CIBA F SYMP, V92, P59; HUANG C, 1978, P NATL ACAD SCI USA, V75, P308, DOI 10.1073/pnas.75.1.308; KELLER GA, 1992, EMBO J, V11, P863, DOI 10.1002/j.1460-2075.1992.tb05124.x; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; LOW MG, 1989, FASEB J, V3, P1600, DOI 10.1096/fasebj.3.5.2522071; MARSH M, 1984, BIOCHEM J, V218, P1; MCDOUGAL JS, 1986, SCIENCE, V231, P382, DOI 10.1126/science.3001934; MEDOF ME, 1984, J EXP MED, V160, P1558, DOI 10.1084/jem.160.5.1558; MORAN P, 1992, J CELL BIOL, V119, P763, DOI 10.1083/jcb.119.4.763; MORAN P, 1991, J BIOL CHEM, V266, P1250; MORAN P, 1992, J IMMUNOL, V149, P1736; RALSTON E, 1981, BIOCHIM BIOPHYS ACTA, V649, P133, DOI 10.1016/0005-2736(81)90019-5; RUBAS W, 1990, J MICROENCAPSUL, V7, P385, DOI 10.3109/02652049009021848; SATO T, 1992, PROG LIPID RES, V31, P345, DOI 10.1016/0163-7827(92)90001-Y; SCHREIER H, 1992, INT J PHARMACEUT, V87, P183, DOI 10.1016/0378-5173(92)90242-T; SCHWENDENER RA, 1990, BIOCHIM BIOPHYS ACTA, V1026, P69, DOI 10.1016/0005-2736(90)90334-K; SECHOY O, 1989, EXP CELL RES, V185, P122, DOI 10.1016/0014-4827(89)90042-6; STECENKO AA, 1992, PHARM PHARM LETT, V1, P127; STEWART JCM, 1980, ANAL BIOCHEM, V104, P10, DOI 10.1016/0003-2697(80)90269-9; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247; Van Meer Gerrit, 1992, Trends in Cell Biology, V2, P332; VOLLER A, 1976, B WORLD HEALTH ORGAN, V53, P55; WEISSING V, 1993, LIPOSOME TECHNOLOGY, V3, P231; WEISSMANN G, 1975, P NATL ACAD SCI USA, V72, P88, DOI 10.1073/pnas.72.1.88; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WRIGHT S, 1989, Advanced Drug Delivery Reviews, V3, P343, DOI 10.1016/0169-409X(89)90027-6	33	29	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9090	9098						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	7907597				2023-01-03	WOS:A1994NB41100072
J	CHAN, TYK; CHAN, JCN; TOMLINSON, B; CRITCHLEY, JAJH				CHAN, TYK; CHAN, JCN; TOMLINSON, B; CRITCHLEY, JAJH			CHINESE HERBAL MEDICINES REVISITED - A HONG-KONG PERSPECTIVE	LANCET			English	Review							PRODUCTS	Chinese herbal medicines (CHM) and Chinese proprietary medicines (CPM) are widely used by people of Chinese origin throughout the world. Although the use of these medicinal materials rarely causes significant toxic effects, cases of severe and even fatal poisoning have occurred after medication with herbs containing aconitine, podophyllin, and anticholinergic substances. Furthermore, CHM and CPM are often adulterated with substituted herbs, heavy metals, and western medicines; such contamination can have important clinical consequences. In Hong Kong, surveillance and legislation are required to control the use of some of these herbal preparations. In other countries, medical practitioners should also be aware of the possibility that these herbal-medicine-related remedies may cause significant clinical problems in their Chinese patients.			CHAN, TYK (corresponding author), CHINESE UNIV HONG KONG, PRINCE WALES HOSP, DEPT CLIN PHARMACOL, SHA TIN, HONG KONG.		Tomlinson, Brian/AAD-9404-2019; Tomlinson, Brian/P-5365-2015; Chan, Thomas/K-3794-2014; Chan, Juliana/B-7918-2016	Tomlinson, Brian/0000-0001-6717-5444; Chan, Juliana/0000-0003-1325-1194				[Anonymous], 1989, MED PLANTS CHINA; BAKER D, 1985, MMWR-MORBID MORTAL W, V38, P612; CHAN H, 1977, CLIN TOXICOL, V10, P273, DOI 10.3109/15563657708992423; Chan Thomas Y. K., 1993, Journal of the Hong Kong Medical Association, V45, P202; CHAN TYK, 1993, AUST NZ J MED, V23, P268, DOI 10.1111/j.1445-5994.1993.tb01730.x; CHAN TYK, 1992, J TROP MED HYG, V95, P296; CHANG HM, 1987, PHARM APPLICATIONS C, P902; CHONGHAI T, 1975, MED J AUSTRALIA, V2, P424, DOI 10.5694/j.1326-5377.1975.tb105939.x; DESMET PAG, 1989, INT PHARM J, V3, P98; DESMET PAG, 1992, ADVERSE EFFECTS HERB, V1, P1; HUXTABLE RJ, 1990, DRUG SAFETY, V5, P126, DOI 10.2165/00002018-199000051-00020; KANGYUM E, 1992, VET HUM TOXICOL, V34, P235; LAM CLK, 1989, H K PRACTNR, V11, P272; LIN HR, 1988, ORIGINAL COLOUR ATLA; NG THK, 1991, J NEUROL SCI, V101, P107, DOI 10.1016/0022-510X(91)90024-2; PENN RG, 1986, IATROGENIC DISEASES, P898; RIES CA, 1975, JAMA-J AM MED ASSOC, V231, P352, DOI 10.1001/jama.231.4.352; SIEGEL RK, 1977, JAMA-J AM MED ASSOC, V237, P24; STEWART PM, 1987, LANCET, V2, P821; TAI YT, 1992, LANCET, V340, P1254, DOI 10.1016/0140-6736(92)92951-B; TAY SAB, 1989, MED J AUSTRALIA, V151, P52, DOI 10.5694/j.1326-5377.1989.tb128456.x; TOMLINSON B, 1993, LANCET, V341, P370, DOI 10.1016/0140-6736(93)90169-H; TSE C Y, 1989, Journal of the Hong Kong Medical Association, V41, P177; VANHERWEGHEM JL, 1993, LANCET, V341, P387, DOI 10.1016/0140-6736(93)92984-2; YEUNG CY, 1990, BIOL NEONATE, V58, P98, DOI 10.1159/000243239	25	116	120	1	22	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 18	1993	342	8886-7					1532	1534		10.1016/S0140-6736(05)80091-1	http://dx.doi.org/10.1016/S0140-6736(05)80091-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM402	7902907				2023-01-03	WOS:A1993MM40200018
J	MULLER, W; RINGSDORF, H; RUMP, E; WILDBURG, G; ZHANG, X; ANGERMAIER, L; KNOLL, W; LILEY, M; SPINKE, J				MULLER, W; RINGSDORF, H; RUMP, E; WILDBURG, G; ZHANG, X; ANGERMAIER, L; KNOLL, W; LILEY, M; SPINKE, J			ATTEMPTS TO MIMIC DOCKING PROCESSES OF THE IMMUNE-SYSTEM - RECOGNITION-INDUCED FORMATION OF PROTEIN MULTILAYERS	SCIENCE			English	Article							SURFACE RECOGNITION; STREPTAVIDIN; MONOLAYERS; LIPIDS	The assemblage of protein multilayers induced by molecular recognition, as seen, for example, in the immune cascade, has been mimicked by using streptavidin as a docking matrix. For these experiments, this protein matrix was organized on liposomes, monolayers at the air-water interface, and self-assembled layers on gold, all three containing biotin lipids. The docking of streptavidin to biotin at liposomal surfaces was confirmed by circular dichroism. Mixed double and triple layers of streptavidin, concanavalin A, antibody Fab fragments, and hormones were prepared at the air-water interface and on gold surfaces and were characterized by fluorescence microscopy and plasmon spectroscopy. With the use of biotin analogs that have lower binding constants it has been possible to achieve multiple formation and competitive replacement of the oriented protein assemblages.	INST ORGAN CHEM,JJ BECHERWEG 18-20,D-55099 MAINZ,GERMANY; MAX PLANCK INST POLYMER RES,D-55021 MAINZ,GERMANY	Max Planck Society			Zhang, Xi/AAF-9871-2021; Zhang, Xi/C-8136-2011					AHLERS M, 1990, ANGEW CHEM INT EDIT, V29, P1269, DOI 10.1002/anie.199012691; AHLERS M, 1991, MAKROMOL CHEM-M SYMP, V46, P307, DOI 10.1002/masy.19910460143; Ahlers M., 1990, ANGEW CHEM, V102, P1310, DOI [10.1002/ange.19901021114, DOI 10.1002/ANGE.19901021114]; BLANKENBURG R, 1989, BIOCHEMISTRY-US, V28, P8214, DOI 10.1021/bi00446a037; CHAIET L, 1964, ARCH BIOCHEM BIOPHYS, V106, P1, DOI 10.1016/0003-9861(64)90150-X; COOPER NR, 1985, ADV IMMUNOL, V37, P151, DOI 10.1016/S0065-2776(08)60340-5; DARST SA, 1991, BIOPHYS J, V59, P387, DOI 10.1016/S0006-3495(91)82232-9; EBATO H, 1992, ANGEW CHEM, V104, P1064; EBATO H, 1992, ANGEW CHEM INT EDIT, V31, P1078; EBERSOLE RC, 1990, J AM CHEM SOC, V112, P3239, DOI 10.1021/ja00164a070; Green N M, 1975, Adv Protein Chem, V29, P85, DOI 10.1016/S0065-3233(08)60411-8; GREEN NM, 1990, METHOD ENZYMOL, V184, P51; HAUSSLING L, 1991, MAKROMOL CHEM-M SYMP, V46, P145, DOI 10.1002/masy.19910460118; HAUSSLING L, 1991, ANGEW CHEM, V103, P568; HENDRICKSON WA, 1989, P NATL ACAD SCI USA, V86, P2190, DOI 10.1073/pnas.86.7.2190; HERRON JN, 1992, LANGMUIR, V8, P1413, DOI 10.1021/la00041a028; MORGAN H, 1992, BIOSENS BIOELECTRON, V7, P405, DOI 10.1016/0956-5663(92)85039-D; MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.biochem.57.1.321; SPINKE J, 1992, THESIS U MAINZ MAINZ	19	189	207	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 10	1993	262	5140					1706	1708		10.1126/science.8259513	http://dx.doi.org/10.1126/science.8259513			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML220	8259513				2023-01-03	WOS:A1993ML22000032
J	MANNHEIMER, C; ELIASSON, T; ANDERSSON, B; BERGH, CH; AUGUSTINSSON, LE; EMANUELSSON, H; WAAGSTEIN, F				MANNHEIMER, C; ELIASSON, T; ANDERSSON, B; BERGH, CH; AUGUSTINSSON, LE; EMANUELSSON, H; WAAGSTEIN, F			EFFECTS OF SPINAL-CORD STIMULATION IN ANGINA-PECTORIS INDUCED BY PACING AND POSSIBLE MECHANISMS OF ACTION	BRITISH MEDICAL JOURNAL			English	Article							ELECTRICAL NERVE-STIMULATION; CORONARY BLOOD-FLOW; OXYGEN-CONSUMPTION; BETA-BLOCKADE; METABOLISM; LACTATE; DISEASE; REPRODUCIBILITY; IMPROVEMENT; ADENOSINE	Objective-To investigate the effects of spinal cord stimulation on myocardial ischaemia, coronary blood flow, and myocardial oxygen consumption in angina pectoris induced by atrial pacing. Design-The heart was paced to angina during a control phase and treatment with spinal cord stimulation. Blood samples were drawn from a peripheral artery and the coronary sinus. Setting-Multidisciplinary pain centre, department of medicine, Ostra Hospital, and Wallenberg Research Laboratory, Sahlgrenska Hospital, Gothenburg, Sweden. Subjects-Twenty patients with intractable angina pectoris, all with a spinal cord stimulator implanted before the study. Results-Spinal cord stimulation increased patients' tolerance to pacing (p<0.001). At the pacing rate comparable to that producing angina during the control recording, myocardial lactate production during control session turned into extraction (p=0.003) and, on the electrocardiogram, ST segment depression decreased, time to ST depression increased, and time to recovery from ST depression decreased (p=0.01; p<0.05, and p <0.05, respectively). Spinal cord stimulation also reduced coronary sinus blood flow (p=0.01) and myocardial oxygen consumption (p=0.02). At the maximum pacing rate during treatment, all patients experienced anginal pain. Myocardial lactate extraction reverted to production (p<0.01) and the magnitude and duration of ST segment depression increased to the same values as during control pacing, indicating that myocardial ischaemia during treatment with spinal cord stimulation gives rise to anginal pain. Conclusions-Spinal cord stimulation has an antianginal and anti-ischaemic effect in severe coronary artery disease. These effects seem to be secondary to a decrease in myocardial oxygen consumption. Furthermore, myocardial ischaemia during treatment gives rise to anginal pain. Thus, spinal cord stimulation does not deprive the patient of a warning signal.	SAHLGRENS UNIV HOSP,DIV CARDIOL,S-41345 GOTHENBURG,SWEDEN; SAHLGRENS UNIV HOSP,DEPT NEUROSURG,S-41345 GOTHENBURG,SWEDEN	Sahlgrenska University Hospital; Sahlgrenska University Hospital	MANNHEIMER, C (corresponding author), OSTRA HOSP,CTR MULTIDISCIPLINARY PAIN,DEPT MED,S-41685 GOTHENBURG,SWEDEN.							AUGUSTINSSON LE, 1985, ANN SURG, V202, P104, DOI 10.1097/00000658-198507000-00017; BLOMBERG S, 1989, EUR HEART J, V10, P437, DOI 10.1093/oxfordjournals.eurheartj.a059507; BRADLEY JV, 1968, DISTRIBUTION FREE ST, P68; CHANDLER MJ, 1993, EUR HEART J, V14, P96, DOI 10.1093/eurheartj/14.1.96; COHEN LS, 1966, AM J CARDIOL, V17, P153, DOI 10.1016/0002-9149(66)90347-X; COOK AW, 1976, NEW YORK STATE J MED, V76, P366; DELANDSHEERE C, 1992, AM J CARDIOL, V69, P1143, DOI 10.1016/0002-9149(92)90926-P; EMANUELSSON H, 1987, AM HEART J, V114, P1360, DOI 10.1016/0002-8703(87)90537-0; FEIGL EO, 1983, PHYSIOL REV, V63, P1, DOI 10.1152/physrev.1983.63.1.1; FORRESTE.JS, 1971, AM J CARDIOL, V27, P237, DOI 10.1016/0002-9149(71)90296-7; GANZ W, 1971, CIRCULATION, V44, P181, DOI 10.1161/01.CIR.44.2.181; GERTZ EW, 1980, CIRCULATION, V61, P256, DOI 10.1161/01.CIR.61.2.256; Gybels J, 1987, Acta Neurochir Suppl (Wien), V38, P64; HOSOBUCHI Y, 1985, APPL NEUROPHYSIOL, V48, P372, DOI 10.1159/000101161; IHLEN H, 1983, CARDIOLOGY, V70, P177, DOI 10.1159/000173591; JACKSON G, 1977, BRIT HEART J, V39, P829; JACOBS MJHM, 1990, J VASC SURG, V12, P354, DOI 10.1067/mva.1990.22787; KNABB RM, 1983, CIRC RES, V53, P33, DOI 10.1161/01.RES.53.1.33; KROGER K, 1989, EUR HEART J, V10, P179, DOI 10.1093/eurheartj/10.suppl_F.179; LEHMANN EL, 1986, TESTING STATISTICAL, P233; LUNDEBERG T, 1988, LANCET, V2, P712; MANNHEIMER C, 1989, BRIT HEART J, V62, P36; MANNHEIMER C, 1988, BRIT HEART J, V59, P56; MANNHEIMER C, 1985, CIRCULATION, V71, P308, DOI 10.1161/01.CIR.71.2.308; MILLER WL, 1979, CIRC RES, V45, P708, DOI 10.1161/01.RES.45.6.708; MOSHER P, 1964, CIRC RES, V14, P250, DOI 10.1161/01.RES.14.3.250; NEILL WA, 1974, J LAB CLIN MED, V83, P428; ODEN A, 1975, ANN STAT, V3, P518, DOI 10.1214/aos/1176343082; REMME WJ, 1992, EUR HEART J S, V13, pP1963; ROBERTSON RM, 1983, AM HEART J, V105, P901, DOI 10.1016/0002-8703(83)90387-3; SANDERSON JE, 1992, EUR HEART J, V13, P628, DOI 10.1093/oxfordjournals.eurheartj.a060226; SIEGFRIED J, 1982, APPL NEUROPHYSIOL, V45, P201; SOWTON G. E., 1967, CARDIOVASC RES, V1, P301, DOI 10.1093/cvr/1.4.301; THADANI U, 1979, CIRCULATION, V60, P1036, DOI 10.1161/01.CIR.60.5.1036	34	149	156	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 21	1993	307	6902					477	480		10.1136/bmj.307.6902.477	http://dx.doi.org/10.1136/bmj.307.6902.477			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU590	8400930	Green Published, Bronze			2023-01-03	WOS:A1993LU59000020
J	ERNST, E				ERNST, E			COMPLEMENTARY MEDICINE - SCRUTINIZING THE ALTERNATIVES	LANCET			English	Editorial Material											ERNST, E (corresponding author), UNIV VIENNA,SCH MED,DEPT PHYS MED & REHABIL,A-1010 VIENNA,AUSTRIA.							DELUZE C, 1992, BRIT MED J, V305, P1249, DOI 10.1136/bmj.305.6864.1249; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; ERNST E, 1990, BRIT J CLIN PHARMACO, V30, P173, DOI 10.1111/j.1365-2125.1990.tb03761.x; ERNST E, 1992, PHLEBOLOGY, V7, P154, DOI 10.1177/026835559200700407; Ernst E, 1990, PHYSIOTHERAPY, V76, P207; FULDER SJ, 1985, LANCET, V2, P542; KLEIJNEN J, 1992, LANCET, V340, P1236; SHEKELLE PG, 1992, ANN INTERN MED, V117, P590, DOI 10.7326/0003-4819-117-7-590	8	26	26	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 26	1993	341	8861					1626	1626		10.1016/0140-6736(93)90763-7	http://dx.doi.org/10.1016/0140-6736(93)90763-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ727	8099995				2023-01-03	WOS:A1993LJ72700009
J	CREDITOR, MC				CREDITOR, MC			HAZARDS OF HOSPITALIZATION OF THE ELDERLY	ANNALS OF INTERNAL MEDICINE			English	Article						HOSPITALIZATION; GERIATRIC ASSESSMENT; BED REST; ACTIVITIES OF DAILY LIVING; SOCIAL ENVIRONMENT	PROSPECTIVE PAYMENT SYSTEM; NURSING-HOME CARE; HIP FRACTURE; BED REST; UNIT	For many older persons, hospitalization results in functional decline despite cure or repair of the condition for which they were admitted. Hospitalization can result in complications unrelated to the problem that caused admission or to its specific treatment for reasons that are explainable and avoidable. Usual aging is often associated with functional change, such as a decline in muscle strength and aerobic capacity; vasomotor instability; reduced bone density; diminished pulmonary ventilation; altered sensory continence, appetite, and thirst; and a tendency toward urinary incontinence. Hospitalization and bed rest superimpose factors such as enforced immobilization, reduction of plasma volume, accelerated bone loss, increased closing volume, and sensory deprivation. Any of these factors may thrust vulnerable older persons into a state of irreversible functional decline. The factors that contribute to a cascade to dependency are identifiable and can be avoided by modification of the usual acute hospital environment by deemphasizing bed rest, removing the hazard of the high hospital bed with rails, and actively facilitating ambulation and socialization. The relationships among physicians, nurses, and other health professionals must reflect the importance of interdisciplinary care and the implementation of shared objectives.			CREDITOR, MC (corresponding author), UNIV KANSAS, MED CTR, 3901 RAINBOW BLVD, KANSAS CITY, KS 66160 USA.				NIA NIH HHS [5K07 AG-00413-03] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [K07AG000413] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BOOTH FW, 1987, CLIN ORTHOP RELAT R, P15; Boyer N, 1986, Nurs Manage, V17, P22; DOWNS FS, 1974, AM J NURS, V74, P434, DOI 10.2307/3469621; DRUZ WS, 1981, J APPL PHYSIOL, V51, P1552, DOI 10.1152/jappl.1981.51.6.1552; FITZGERALD JF, 1988, NEW ENGL J MED, V319, P1392, DOI 10.1056/NEJM198811243192106; FURSTENBERG AL, 1988, AM J APPLIED GERONTO, V7, P193; GREENLEAF JE, 1983, AVIAT SPACE ENVIR MD, V54, P696; HARPER CM, 1988, J AM GERIATR SOC, V36, P1047, DOI 10.1111/j.1532-5415.1988.tb04375.x; HIRSCH CH, 1990, J AM GERIATR SOC, V38, P1296, DOI 10.1111/j.1532-5415.1990.tb03451.x; HOENIG HM, 1991, J AM GERIATR SOC, V39, P220, DOI 10.1111/j.1532-5415.1991.tb01632.x; Huber M, 1991, J Gerontol Nurs, V17, P20; JETTE AM, 1987, ARCH PHYS MED REHAB, V68, P735; KELLIE SE, 1990, AM J PUBLIC HEALTH, V80, P326, DOI 10.2105/AJPH.80.3.326; KEMPER P, 1991, NEW ENGL J MED, V324, P595, DOI 10.1056/NEJM199102283240905; KROLNER B, 1983, CLIN SCI, V64, P537, DOI 10.1042/cs0640537; LAKATTA EG, 1990, HDB BIOL AGING, P195; LAMONT CT, 1983, J AM GERIATR SOC, V31, P282, DOI 10.1111/j.1532-5415.1983.tb04872.x; LEBLANC P, 1970, J APPL PHYSIOL, V28, P448, DOI 10.1152/jappl.1970.28.4.448; MEISSNER P, 1989, GERONTOLOGIST, V29, P524, DOI 10.1093/geront/29.4.524; Mobily P R, 1991, J Gerontol Nurs, V17, P5; MULLER E A, 1970, Archives of Physical Medicine and Rehabilitation, V51, P449; PALMER RM, 1989, ARCH INTERN MED, V149, P2237, DOI 10.1001/archinte.149.10.2237; PALMER RM, 1991, J AM GERIATR SOC, V39, pA62; RESNICK NM, 1985, NEW ENGL J MED, V313, P800, DOI 10.1056/NEJM198509263131307; SAUNDERS RH, 1983, J AM GERIATR SOC, V31, P685, DOI 10.1111/j.1532-5415.1983.tb04155.x; SLOANE PD, 1985, J AM GERIATR SOC, V33, P864, DOI 10.1111/j.1532-5415.1985.tb05442.x; VOGT FB, 1967, AEROSPACE MED, V38, P21; WARD RJ, 1966, GERIATRICS, V21, P139; ZUBEK JP, 1963, SCIENCE, V140, P306, DOI 10.1126/science.140.3564.306	29	919	930	0	46	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1993	118	3					219	223		10.7326/0003-4819-118-3-199302010-00011	http://dx.doi.org/10.7326/0003-4819-118-3-199302010-00011			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ439	8417639				2023-01-03	WOS:A1993KJ43900011
J	Woyka, J				Woyka, J			Hospice at home	BRITISH MEDICAL JOURNAL			English	Article											Woyka, J (corresponding author), HARROW HLTH CARE CTR,HARROW HA1 4LF,MIDDX,ENGLAND.								0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	1995	311	7021					1687	1688		10.1136/bmj.311.7021.1687	http://dx.doi.org/10.1136/bmj.311.7021.1687			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL942	8541758	Green Published			2023-01-03	WOS:A1995TL94200018
J	MAJEWSKI, S; SKOPINSKA, M; BOLLAG, W; JABLONSKA, S				MAJEWSKI, S; SKOPINSKA, M; BOLLAG, W; JABLONSKA, S			COMBINATION OF ISOTRETINOIN AND CALCITRIOL FOR PRECANCEROUS AND CANCEROUS SKIN-LESIONS	LANCET			English	Letter									F HOFFMANN LA ROCHE & CO LTD,PHARMACEUT RES,CH-4002 BASEL,SWITZERLAND	Roche Holding	MAJEWSKI, S (corresponding author), WARSAW ACAD MED & HOSP,DEPT DERMATOL,PL-02008 WARSAW,POLAND.							Bollag W., 1994, Retinoids: from basic science to clinical applications., P267; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; RAINA V, 1991, BRIT J CANCER, V63, P463, DOI 10.1038/bjc.1991.108; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307	4	37	37	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 26	1994	344	8935					1510	1511		10.1016/S0140-6736(94)90330-1	http://dx.doi.org/10.1016/S0140-6736(94)90330-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT995	7968149				2023-01-03	WOS:A1994PT99500052
J	JANKOVIC, M; BROUWERS, P; VALSECCHI, MG; VANVELDHUIZEN, A; HUISMAN, J; KAMPHUIS, R; KINGMA, A; MOR, W; VANDONGENMELMAN, J; FERRONATO, L; MANCINI, MA; SPINETTA, JJ; MASERA, G				JANKOVIC, M; BROUWERS, P; VALSECCHI, MG; VANVELDHUIZEN, A; HUISMAN, J; KAMPHUIS, R; KINGMA, A; MOR, W; VANDONGENMELMAN, J; FERRONATO, L; MANCINI, MA; SPINETTA, JJ; MASERA, G			ASSOCIATION OF 1800 CGY CRANIAL IRRADIATION WITH INTELLECTUAL FUNCTION IN CHILDREN WITH ACUTE LYMPHOBLASTIC-LEUKEMIA	LANCET			English	Article							LONG-TERM SURVIVORS; CENTRAL NERVOUS-SYSTEM; ACUTE LYMPHOCYTIC-LEUKEMIA; CHILDHOOD LEUKEMIA; COGNITIVE FUNCTION; RADIATION; SEQUELAE; NEUROTOXICITY; METHOTREXATE; PROPHYLAXIS	Cranial radiation therapy in childhood acute lymphoblastic leukaemia has been associated with adverse neuropsychological effects, such as low intelligence. However, records show that these associations usually occur when the dose of radiation used is 2400 cGy. We investigated whether a lower dose of 1800 cGy had the same adverse effects on long-term survivors and whether high doses of methotrexate but no radiation therapy would have a more beneficial effect. We evaluated 203 children for six years in a multi-centre European study. The patients were divided into two groups: 129 children treated with 1800 cGy of cranial radiation therapy and 74 children who received high-dose methotrexate but no radiation therapy. We used full scale intelligence quotient, verbal, and performance IQ tests to assess the patient's intelligence. We found a significant decline in full scale intelligence quotient in the irradiated group that increased with the length of time from diagnosis. Younger age at diagnosis was associated with lower full scale intelligence quotient in the radiated group. Our results indicate that a radiation dose of 1800 cGy can have negative effects on neurocognitive function and we continue to question the benefit of low-dose cranial radiation therapy.	NCI,PEDIAT BRANCH,BETHESDA,MD 20892; UNIV MILAN,INST BIOMETRY & MED STAT,I-20122 MILAN,ITALY; UNIV AMSTERDAM,DEPT PAEDIAT,AMSTERDAM,NETHERLANDS; FREE UNIV AMSTERDAM HOSP,DEPT PSYCHOL MED,AMSTERDAM,NETHERLANDS; LEIDEN UNIV,DEPT PAEDIAT,LEIDEN,NETHERLANDS; UNIV GRONINGEN,9700 AB GRONINGEN,NETHERLANDS; ST ANNA CHILDRENS HOSP,VIENNA,AUSTRIA; UNIV ROTTERDAM,DEPT PAEDIAT,ROTTERDAM,NETHERLANDS; UNIV PADUA,I-35100 PADUA,ITALY; UNIV BOLOGNA,I-40126 BOLOGNA,ITALY	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Milan; University of Amsterdam; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Leiden University; Leiden University - Excl LUMC; University of Groningen; Saint Anna Children's Hospital; Erasmus University Rotterdam; University of Padua; University of Bologna	JANKOVIC, M (corresponding author), UNIV MILAN,S GERARDO HOSP MONZA,DEPT PAEDIAT,VIA DONIZETTI 106,I-20052 MONZA,ITALY.		Valsecchi, Maria Grazia/K-8891-2016	Valsecchi, Maria Grazia/0000-0001-5574-3504				BROUWERS P, 1984, J CLIN NEUROPSYCHOL, V6, P325, DOI 10.1080/01688638408401222; BROUWERS P, 1990, AM J PEDIAT HEMATOL, V12, P174; BROUWERS P, 1992, DEV PEDIAT PSYCHOSOC, P79; BROUWERS P, 1991, HDB CLIN TRIALS NEUR, P45; CHESSELLS JM, 1990, ARCH DIS CHILD, V65, P416, DOI 10.1136/adc.65.4.416; COUSENS P, 1988, J CHILD PSYCHOL PSYC, V29, P839, DOI 10.1111/j.1469-7610.1988.tb00757.x; HALBERG FE, 1992, INT J RADIAT ONCOL, V22, P13, DOI 10.1016/0360-3016(92)90976-O; JANKOVIC M, 1991, NEURO ONCOLOGY, P365; JANNOUN L, 1983, ARCH DIS CHILD, V58, P953, DOI 10.1136/adc.58.12.953; JANNOUN L, 1978, AM J PEDIAT HEMATOL, V4, P293; MEADOWS AT, 1984, P AN M AM SOC CLIN, V3, P71; MOORE IMK, 1991, CANCER, V68, P1913; MOSS HA, 1981, AM J MED, V71, P47, DOI 10.1016/0002-9343(81)90257-6; MULHERN RK, 1988, J CLIN ONCOL, V6, P315, DOI 10.1200/JCO.1988.6.2.315; MULHERN RK, 1992, J CONSULT CLIN PSYCH, V60, P477; MULHERN RK, 1991, J CLIN ONCOL, V9, P1348, DOI 10.1200/JCO.1991.9.8.1348; NEGLIA JP, 1991, NEW ENGL J MED, V325, P1300; OCHS J, 1991, J CLIN ONCOL, V9, P145, DOI 10.1200/JCO.1991.9.1.145; PFEFFERBAUMLEVINE B, 1984, AM J PEDIAT HEMATOL, V6, P123; POPLACK DG, 1985, CLINICS ONCOL, V4, P263; RICCARDI R, 1985, J CLIN ONCOL, V3, P12, DOI 10.1200/JCO.1985.3.1.12; RIEHM H, 1990, ACUTE LEUKEMIAS, V2, P439; RIMM IJ, 1987, CANCER, V59, P1506, DOI 10.1002/1097-0142(19870415)59:8<1506::AID-CNCR2820590819>3.0.CO;2-P; RUBENSTEIN CL, 1990, J DEV BEHAV PEDIATR, V11, P301; SAID JA, 1989, J CONSULT CLIN PSYCH, V57, P251, DOI 10.1037/0022-006X.57.2.251; TAMAROFF M, 1985, P ASCO, V4, P165; VECCHI V, 1993, CANCER, V72, P2157; Veerman A J, 1990, Haematol Blood Transfus, V33, P473; Williams J M, 1986, Arch Clin Neuropsychol, V1, P183, DOI 10.1016/0887-6177(86)90018-1	29	138	139	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 23	1994	344	8917					224	227		10.1016/S0140-6736(94)92997-1	http://dx.doi.org/10.1016/S0140-6736(94)92997-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY060	7913156	Green Submitted			2023-01-03	WOS:A1994NY06000009
J	PHILLIPS, GD; HARRISON, NK; CUMMIN, ARC; WARD, J; SHENOY, VS; NEWEY, V; RITCHIE, D; WILLIAMS, IP; MILLARD, FJC				PHILLIPS, GD; HARRISON, NK; CUMMIN, ARC; WARD, J; SHENOY, VS; NEWEY, V; RITCHIE, D; WILLIAMS, IP; MILLARD, FJC			NEW METHOD FOR MEASURING COMPLIANCE WITH LONG-TERM OXYGEN TREATMENT	BRITISH MEDICAL JOURNAL			English	Article									UNIV LONDON ST GEORGES HOSP,DEPT MED PHYS,LONDON SW17 0QT,ENGLAND; ST ALBANS HOSP,DEPT CHEST MED,ST ALBANS AL3 5PN,HERTS,ENGLAND	St Georges University London	PHILLIPS, GD (corresponding author), UNIV LONDON ST GEORGES HOSP,CHEST CLIN,LONDON SW17 0QT,ENGLAND.							[Anonymous], 1981, LANCET, V1, P681; Nocturnal Oxygen Therapy Trial Group, 1980, ANN INTERN MED, V93, P391; Williams B, 1991, Health Trends, V23, P166; 1986, DHSS FPN398 DEP HLTH	4	6	6	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 11	1994	308	6943					1544	1545		10.1136/bmj.308.6943.1544	http://dx.doi.org/10.1136/bmj.308.6943.1544			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR110	8019312	Green Published			2023-01-03	WOS:A1994NR11000025
J	DANTZKER, DR; STEINBERG, H				DANTZKER, DR; STEINBERG, H			PULMONARY AND CRITICAL CARE MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OBSTRUCTIVE SLEEP-APNEA; MONOCLONAL-ANTIBODY; TISSUE OXYGENATION; SEPTIC SHOCK; ENDOTOXIN; FAILURE; PH		LONG ISL JEWISH MED CTR,NEW HYDE PK,NY 11042	Northwell Health	DANTZKER, DR (corresponding author), ALBERT EINSTEIN COLL MED,BRONX,NY 10467, USA.							BENNETT WP, 1993, CANCER RES, V53, P4817; BORING CC, 1992, CA-CANCER J CLIN, V42, P19, DOI 10.3322/canjclin.42.1.19; DANTZKER DR, 1991, AM REV RESPIR DIS, V143, P675, DOI 10.1164/ajrccm/143.3.675; FISHER CJ, 1993, CRIT CARE MED, V21, P318, DOI 10.1097/00003246-199303000-00006; GRUM CM, 1984, J APPL PHYSIOL, V56, P1065, DOI 10.1152/jappl.1984.56.4.1065; GUTIERREZ G, 1992, LANCET, V339, P195, DOI 10.1016/0140-6736(92)90002-K; KIM JS, 1992, J NCI MONOGR, V13, P101; KRIBBS NB, 1993, AM REV RESPIR DIS, V147, P887, DOI 10.1164/ajrccm/147.4.887; KRIBBS NB, 1993, AM REV RESPIR DIS, V147, P1162, DOI 10.1164/ajrccm/147.5.1162; KRYGER MH, 1993, CHEST, V104, P2, DOI 10.1378/chest.104.1.2; MAYNARD N, 1993, JAMA-J AM MED ASSOC, V270, P1203, DOI 10.1001/jama.270.10.1203; MOHSENIFAR Z, 1993, ANN INTERN MED, V119, P794, DOI 10.7326/0003-4819-119-8-199310150-00004; RICHARDSON GE, 1993, SEMIN ONCOL, V20, P105; RONCO JJ, 1991, AM REV RESPIR DIS, V143, P1267, DOI 10.1164/ajrccm/143.6.1267; Sabichi A L, 1993, Oncology (Williston Park), V7, P19; Shapiro L, 1993, New Horiz, V1, P13; SHEPARD JW, 1990, MAYO CLIN PROC, V65, P1260, DOI 10.1016/S0025-6196(12)62750-5; VINCENT JL, 1992, CHEST, V101, P810, DOI 10.1378/chest.101.3.810; WARREN HS, 1993, J EXP MED, V177, P89, DOI 10.1084/jem.177.1.89; WRIGHT CE, 1992, CARDIOVASC RES, V26, P48, DOI 10.1093/cvr/26.1.48; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701	22	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 1	1994	271	21					1709	1710						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN117	8182865				2023-01-03	WOS:A1994NN11700044
J	WEBSTER, NR; WARD, MJ				WEBSTER, NR; WARD, MJ			BATTLEFIELD TRANSFUSIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											WEBSTER, NR (corresponding author), ARMED SERV BLOOD PROGRAM OFF,FALLS CHURCH,VA, USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 26	1994	271	4					319	319						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR221	8295296				2023-01-03	WOS:A1994MR22100033
J	HEISS, MM; MEMPEL, W; JAUCH, KW; DELANOFF, C; MAYER, G; MEMPEL, M; EISSNER, HJ; SCHILDBERG, FW				HEISS, MM; MEMPEL, W; JAUCH, KW; DELANOFF, C; MAYER, G; MEMPEL, M; EISSNER, HJ; SCHILDBERG, FW			BENEFICIAL EFFECT OF AUTOLOGOUS BLOOD-TRANSFUSION ON INFECTIOUS COMPLICATIONS AFTER COLORECTAL-CANCER SURGERY	LANCET			English	Article							TUMOR-GROWTH; METASTASES; RECURRENCE; MORTALITY; TRAUMA; SEPSIS; MODEL	Homologous blood transfusion has been associated with an increased risk of postoperative infectious complications. To test the clinical consequences of this apparently immunosuppressive effect of homologous blood in a controlled trial, we designed a study in which the control group deposited autologous blood before their operations for use should transfusion be needed. We enrolled 120 patients with apparently curable colorectal cancer who were able to predeposit autologous blood (haemoglobin > 12.5 g/dL). 58 patients were assigned to receive homologous blood if blood transfusions were needed during operation, and the other 62 to receive their own predeposited blood followed, if necessary, by homologous blood. Despite the similarity between the groups in factors known to affect the risk of postoperative infections, there was a significant difference in postoperative infection rate between the homologous and autologous blood groups (17 [27%] vs 7 [12%], p < 0.05; unadjusted odds ratio 2.75 [95% CI 1.07-7.11). The rates of non-infectious complications were similar. Probably because their preoperative blood depositing caused the autologous blood patients to have lower haemoglobin concentrations, they were more likely to require transfusion than were the homologous blood group (53 [91%] vs 37 [60%], p < 0.001; relative risk 1.53 [1.24-1.89]).20 (35%) required homologous as well as autologous blood. To adjust for the many infection-related factors, we did multivariate regression analysis; tumour location, preoperative ASA index, and study group assignment were the only significant risk factors. The odds ratio for postoperative infections adjusted for these factors was 2.84 (1.02-7.98, homologous vs autologous). Testing of delayed-type hypersensitivity responses before and after surgery showed decreases in both mean diameter and number of positive reactions in recipients of homologous blood and slight increases in those who received autologous blood. This study shows the clinical potential of blood-transfusion-mediated immunomodulation, which may be important also in tumour immunology.	UNIV MUNICH,KLINIKUM GROSSHADERN,CTR TRANSFUS,DEPT MED 3,W-8000 MUNICH 70,GERMANY; UNIV MUNICH,KLINIKUM GROSSHADERN,DEPT MED INFORMAT BIOMETRY & EPIDEMIOL,W-8000 MUNICH 70,GERMANY	University of Munich; University of Munich	HEISS, MM (corresponding author), UNIV MUNICH,KLINIKUM GROSSHADERN,DEPT SURG,MARCHIONINISTR 15,W-8000 MUNICH 70,GERMANY.							Aldrich John, 1984, LINEAR PROBABILITY L; ALEXANDER JW, 1991, TRANSFUSION, V31, P195, DOI 10.1046/j.1537-2995.1991.31391165165.x; BEYNON J, 1989, DIS COLON RECTUM, V32, P975, DOI 10.1007/BF02552276; BURROWS L, 1982, LANCET, V2, P662; CRAPP AR, 1975, LANCET, V2, P1239; FISCHER E, 1980, HUM IMMUNOL, V3, P187; FRANCIS DMA, 1981, LANCET, V2, P871; GEORGE CD, 1986, AM J SURG, V152, P329, DOI 10.1016/0002-9610(86)90269-2; GOLDMAN M, 1991, TRANSFUSION, V31, P710, DOI 10.1046/j.1537-2995.1991.31892023495.x; JENSEN LS, 1992, BRIT J SURG, V79, P513, DOI 10.1002/bjs.1800790613; JUBERT AV, 1973, J SURG RES, V15, P399, DOI 10.1016/0022-4804(73)90110-8; KEOWN PA, 1979, LANCET, V1, P20; KNIKER WT, 1979, ANN ALLERGY, V43, P73; MEZROW CK, 1992, TRANSFUSION, V32, P27, DOI 10.1046/j.1537-2995.1992.32192116427.x; MURPHY P, 1991, TRANSFUSION, V31, P212, DOI 10.1046/j.1537-2995.1991.31391165169.x; NWILOH J, 1991, AM J SURG, V162, P83, DOI 10.1016/0002-9610(91)90209-V; OPELZ G, 1973, TRANSPLANT P, V5, P253; PALDER SBO, 1984, J TRAUMA, V24, P869; PARK SK, 1971, LANCET, V1, P53; RUSH BF, 1988, ANN SURG, V207, P549, DOI 10.1097/00000658-198805000-00009; SHIRWADKAR S, 1992, J CANCER RES CLIN, V118, P176, DOI 10.1007/BF01410130; SINGH SK, 1987, EUR J CANCER CLIN ON, V23, P1537, DOI 10.1016/0277-5379(87)90097-6; STEPHAN RN, 1987, ARCH SURG-CHICAGO, V122, P62; TARTTER PI, 1988, BRIT J SURG, V75, P789, DOI 10.1002/bjs.1800750822; TINKER J, 1986, TXB ANESTHESIA, P359; TRIULZI DJ, 1992, TRANSFUSION, V32, P517, DOI 10.1046/j.1537-2995.1992.32692367194.x; WAYMACK JP, 1987, ARCH SURG-CHICAGO, V122, P935; WEIDEN PL, 1987, CANCER-AM CANCER SOC, V60, P870, DOI 10.1002/1097-0142(19870815)60:4<870::AID-CNCR2820600425>3.0.CO;2-0	28	315	322	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 27	1993	342	8883					1328	1333		10.1016/0140-6736(93)92247-Q	http://dx.doi.org/10.1016/0140-6736(93)92247-Q			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ039	7901637				2023-01-03	WOS:A1993MJ03900010
J	GREEN, S				GREEN, S			IMMUNOAUGMENTATIVE THERAPY - AN UNPROVED CANCER-TREATMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											GREEN, S (corresponding author), ZOL CONSULTANTS INC,340 W 57TH ST,SUITE 8J,NEW YORK,NY 10019, USA.				NCI NIH HHS [NCI 2R-44-CA-41953-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R44CA041953] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERRY LJ, 1964, BACTERIAL ENDOTOXINS, P151; BURTON, 1980, COMMUNICATION   0518; BURTON L, 1962, T NEW YORK ACAD SCI, V25, P33, DOI 10.1111/j.2164-0947.1962.tb03512.x; BURTON L, 1980, Patent No. 4199497; BURTON L, 1988, L BURTONS IMMUNOAUGM; BURTON L, 1978, Patent No. 4082732; BURTON L, 1978, Patent No. 4082733; BURTON L, 1981, IAT BACKGROUND MATER, V1, P1; BURTON L, 1978, Patent No. 4076701; BURTON LAWRENCE, 1959, TRANS NEW YORK ACAD SCI, V21, P700; CURT GA, 1986, JAMA-J AM MED ASSOC, V255, P505, DOI 10.1001/jama.255.4.505; CURT GA, 1984, NEW ENGL J MED, V311, P859; DAVEY RT, 1992, AIDS ETIOLOGY DIAGNO, P141; FRIEDMAN F, 1962, T NEW YORK ACAD SCI, V25, P29, DOI 10.1111/j.2164-0947.1962.tb03511.x; FRIEDMAN F., 1965, PROC AMER ASS CANCER RES, V6, P20; FRIEDMAN F, 1957, CANCER RES, V17, P208; FRIEDMAN F, 1956, CANCER RES, V16, P1059; FRIEDMAN F, 1957, ANN NY ACAD SCI, V68, P349, DOI 10.1111/j.1749-6632.1957.tb56090.x; HEWITT HB, 1976, BRIT J CANCER, V33, P241, DOI 10.1038/bjc.1976.37; KASSEL R, 1962, T NEW YORK ACAD SCI, V25, P39, DOI 10.1111/j.2164-0947.1962.tb03513.x; KASSEL R, 1963, ANN NY ACAD SCI, V100, P791, DOI 10.1111/j.1749-6632.1963.tb42890.x; KINLEN LJ, 1982, CANCER EPIDEMIOL, P494; LAWRENCE HS, 1959, CELLULAR HUMORAL  ED, P529; Macfarlane Burnet F., 1970, IMMUNOLOGICAL SURVEI; MITCHELL HK, 1961, SCIENCE, V133, P876, DOI 10.1126/science.133.3456.876; MOSS R, 1993, CANCER CHRONICLES, V4, P7; MULLEREBERHARD HJ, 1970, HARVEY LECT, V66, P75; MULVANY JG, 1969, METHOD MICROBIOL, P205, DOI DOI 10.1016/50580-9517(08)70138-7; ONIGBINDE TA, 1992, CLIN CHEM PRINCIPLES, P104; PURTILO DT, 1983, J CLIN IMMUNOL, V3, P197, DOI 10.1007/BF00915343; STUTMAN O, 1973, ISRAEL J MED SCI, V9, P217; Stutman O., 1978, NUDE MOUSE EXPT CLIN, P411; STUTMAN O, 1989, NAT IMMUN, P479; TANFORD C, 1961, PHYSICAL CHEM MACROM, P89; THOMAS L, CITED INDIRECTLY; WILLETT HP, 1984, ZINSSER MICROBIOLOGY, P233; ZAVERTNIK JJ, 1991, DUBIOUS CANCER TREAT, P63; 1985, MMWR MORB MORTAL WKL, V34, P489; 1985, GUIDELINE STERILE DR; 1990, OTAH405 US C PUBL OF; 1980, MED WORLD NEWS  1124, P24	41	10	10	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 13	1993	270	14					1719	1723		10.1001/jama.270.14.1719	http://dx.doi.org/10.1001/jama.270.14.1719			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA294	8411503				2023-01-03	WOS:A1993MA29400029
J	MATSUSHITA, N; SOGAWA, K; EMA, M; YOSHIDA, A; FUJIIKURIYAMA, Y				MATSUSHITA, N; SOGAWA, K; EMA, M; YOSHIDA, A; FUJIIKURIYAMA, Y			A FACTOR-BINDING TO THE XENOBIOTIC RESPONSIVE ELEMENT (XRE) OF P-4501A1 GENE CONSISTS OF AT LEAST 2 HELIX-LOOP-HELIX PROTEINS, AH RECEPTOR AND ARNT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; PLANAR AROMATIC-COMPOUNDS; DIOXIN RECEPTOR; REGULATORY ELEMENTS; INDUCIBLE EXPRESSION; LEVEL EXPRESSION; DNA INTERACTIONS; RNA-POLYMERASE; CLONING; 2,3,7,8-TETRACHLORODIBENZO-PARA-DIOXIN	Xenobiotic responsive element (XRE) is an inducible enhancer element that drives inducible expression of P-4501A1 gene in response to xenobiotic inducers. The XRE-binding factor appears in the nuclei of Hepa-1 cells treated with 3-methylcholanthrene (3-MC). Association of the Ah receptor and Arnt (Ah receptor nuclear translocator) in an XRE-binding complex was examined by anti-Ah receptor and Arnt antibodies. Both antibodies inhibited the sequence-specific XRE-binding activity of nuclear extracts from 3-MC-treated Hepa-1 cells and of the cytosolic fraction which was prepared from the nontreated cells and treated in vitro with 3-MC. These results indicate that Ah receptor and Arnt proteins are components of the XRE-binding factor and suggest that Arnt as well as the Ah receptor are localized in the cytosol of nontreated cells. The Ah receptor present in C4 cells, a mutant of Hepa-1 cells defective in the Arnt function, showed an inducer-dependent association with Arnt synthesized in an in vitro translation system. Co-transfection of the expression plasmids of the Ah receptor and Arnt exhibited synergistically more activated transcription from a reporter gene pMC6.3k consisting of the P-4501A1 gene promoter and enhancer than transfection with either of the two plasmids alone. These findings indicate that the Ah receptor and Arnt proteins form a complex that activates transcription in an inducer-dependent manner.	TOHOKU UNIV,FAC SCI,DEPT CHEM,SENDAI,MIYAGI 980,JAPAN; NAGOYA UNIV,DEPT AGR CHEM,NAGOYA,AICHI 464,JAPAN	Tohoku University; Nagoya University				Ema, Masatsugu/0000-0003-0645-6183				ANDERSON DJ, 1983, METHOD ENZYMOL, V96, P111; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRADFIELD CA, 1991, MOL PHARMACOL, V39, P13; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; DENIS M, 1988, BIOCHEM BIOPH RES CO, V155, P801, DOI 10.1016/S0006-291X(88)80566-7; DENISON MS, 1988, J BIOL CHEM, V263, P17221; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELFERINK CJ, 1990, J BIOL CHEM, V265, P20708; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FUJISAWASEHARA A, 1986, NUCLEIC ACIDS RES, V14, P1465; FUJISAWASEHARA A, 1988, P NATL ACAD SCI USA, V85, P5859, DOI 10.1073/pnas.85.16.5859; FUJISAWASEHARA A, 1987, NUCLEIC ACIDS RES, V15, P4179, DOI 10.1093/nar/15.10.4179; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HANKINSON O, 1983, SOMAT CELL GENET, V9, P497, DOI 10.1007/BF01543050; HAPGOOD J, 1989, P NATL ACAD SCI USA, V86, P60, DOI 10.1073/pnas.86.1.60; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDERS JP, 1991, BIOCHEM J, V276, P273, DOI 10.1042/bj2760273; LEGRAVEREND C, 1982, J BIOL CHEM, V257, P6402; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; PONGRATZ I, 1992, J BIOL CHEM, V267, P13728; PROKIPCAK RD, 1988, ARCH BIOCHEM BIOPHYS, V267, P811, DOI 10.1016/0003-9861(88)90091-4; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; SOGAWA K, 1986, P NATL ACAD SCI USA, V83, P8044, DOI 10.1073/pnas.83.21.8044; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WHITLOCK JP, 1990, ANNU REV PHARMACOL, V30, P251; WILHELMSSON A, 1990, EMBO J, V9, P69, DOI 10.1002/j.1460-2075.1990.tb08081.x	31	146	146	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21002	21006						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407937				2023-01-03	WOS:A1993MA28800057
J	WILLIAMS, JK				WILLIAMS, JK			ESTROGEN THERAPY FOR MYOCARDIAL-ISCHEMIA IN WOMEN	LANCET			English	Editorial Material											WILLIAMS, JK (corresponding author), WAKE FOREST UNIV,BOWMAN GRAY SCH MED,WINSTON SALEM,NC 27103, USA.							ROSANO GMC, 1993, LANCET, V342, P133, DOI 10.1016/0140-6736(93)91343-K	1	3	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 17	1993	342	8864					128	128						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN042	8101247				2023-01-03	WOS:A1993LN04200002
J	GILLON, R				GILLON, R			PATIENTS IN THE PERSISTENT VEGETATIVE STATE - A RESPONSE	BRITISH MEDICAL JOURNAL			English	Article											GILLON, R (corresponding author), ST MARYS HOSP,IMPERIAL COLL SCI TECHNOL & MED,SCH MED,LONDON SW7 2AZ,ENGLAND.							ANDREWS K, 1993, BRIT MED J, V306, P1600, DOI 10.1136/bmj.306.6892.1600; ANDREWS K, 1993, BRIT MED J, V306, P1597, DOI 10.1136/bmj.306.6892.1597; Beauchamp T, 1989, PRINCIPLES BIOMEDICA; GILLON R, 1993, ST MARYS GAZETTE, V99, P17; Gillon Ranan., 1985, PHILOS MED ETHICS; 1993, TIMES           0205, P8; 1992, DISCUSSION PAPER TRE	7	14	14	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1993	306	6892					1602	1603		10.1136/bmj.306.6892.1602	http://dx.doi.org/10.1136/bmj.306.6892.1602			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH128	8329928	Bronze, Green Published			2023-01-03	WOS:A1993LH12800029
J	SAMUELS, MP; POETS, CF; NOYES, JP; HARTMANN, H; HEWERTSON, J; SOUTHALL, DP				SAMUELS, MP; POETS, CF; NOYES, JP; HARTMANN, H; HEWERTSON, J; SOUTHALL, DP			DIAGNOSIS AND MANAGEMENT AFTER LIFE THREATENING EVENTS IN INFANTS AND YOUNG-CHILDREN WHO RECEIVED CARDIOPULMONARY-RESUSCITATION	BRITISH MEDICAL JOURNAL			English	Article							SEVERE ARTERIAL HYPOXEMIA; BLOOD-TRANSFUSION; PARTIAL SEIZURES; SUDDEN-DEATH; APNEA; OBSTRUCTION; EPISODES	Objective-To determine the mechanisms and thereby appropriate management for apparent life threatening events treated with cardiopulmonary resuscitation in infants and young children. Design-Prospective clinical and physiological study. Setting-Royal Brompton Hospital or in patients' homes, or both. Subjects-157 Patients referred at median age 2.8 months (range 1 week to 96 months), 111 (71%) had recurrent events, 44 were born preterm, 19 were siblings of infants who had died suddenly and unexpectedly, and 18 were over 12 months old. Interventions-Multichannel physiological recordings, including oxygenation, in hospital (n=150) and at home (n=61). Additional recordings with electroencephalogram, video, or other respiratory measures were used to confirm diagnoses. Management involved monitoring of oxygen at home, additional inspired oxygen, anticonvulsant treatment, or child protection procedures. Main outcome measures-Abnormalities on recordings compared to published normal data and their correlation with clinical events; sudden death. Results-53 of 150 patients had abnormalities of oxygenation on hospital recordings, 28 of whom had an accompanying clinical event. Home recordings produced physiological data from 34 of 61 patients during subsequent clinical events. Final diagnoses were reached in 77 patients: deliberate suffocation by a parent (18), hypoxaemia induced by epileptic seizure (10), fabricated history and data (Munchausen syndrome by proxy; seven), acute hypoxaemia of probable respiratory origin (40), and changes in peripheral perfusion and skin colour without hypoxaemia (two). Four patients died: three suddenly and unexpectedly (none on home oxygen monitors) and one from pneumonia. Conclusions-Identification of mechanisms is essential to the appropriate management of infants with apparent fife threatening events.			SAMUELS, MP (corresponding author), UNIV KEELE,N STAFFORDSHIRE HOSP CTR,ACAD DEPT PAEDIAT,STOKE ON TRENT ST4 6QG,ENGLAND.							ABRAHAM NG, 1990, PEDIATR PULM, V8, P259, DOI 10.1002/ppul.1950080409; BROWN DC, 1991, ARCH DIS CHILD, V66, P986, DOI 10.1136/adc.66.8.986; DEMAIO JG, 1989, J PEDIATR-US, V114, P1039, DOI 10.1016/S0022-3476(89)80459-7; HOLOWACH J, 1963, NEW ENGL J MED, V268, P21, DOI 10.1056/NEJM196301032680105; JAMES LS, 1957, J PEDIATR-US, V51, P5, DOI 10.1016/S0022-3476(57)80274-1; JOSHI A, 1987, PEDIATRICS, V80, P79; KEETON BR, 1977, BRIT MED J, V2, P600, DOI 10.1136/bmj.2.6087.600; Little G., 1987, PEDIATRICS, V79, P292; OREN J, 1986, PEDIATRICS, V77, P495; POETS CF, 1992, PEDIATRICS, V90, P385; POETS CF, 1991, ARCH DIS CHILD, V66, P676, DOI 10.1136/adc.66.6.676; POETS CF, 1992, ACTA PAEDIATR, V81, P319, DOI 10.1111/j.1651-2227.1992.tb12234.x; POETS CF, 1992, ACTA PAEDIATR, V81, P536, DOI 10.1111/j.1651-2227.1992.tb12290.x; POETS CF, 1992, J PEDIATR-US, V120, P447, DOI 10.1016/S0022-3476(05)80919-9; POETS CF, 1992, PEDIATR PULM, V14, P257; SAMUELS MP, 1991, ARCH DIS CHILD, V66, P257, DOI 10.1136/adc.66.2.257; SAMUELS MP, 1992, ACTA PAEDIATR, V81, P875, DOI 10.1111/j.1651-2227.1992.tb12127.x; SAMUELS MP, 1992, BRIT J HOSP MED, V47, P759; SAMUELS MP, 1992, ARCH DIS CHILD, V67, P162, DOI 10.1136/adc.67.2.162; SMITH PEM, 1989, ELECTROEN CLIN NEURO, V72, P207, DOI 10.1016/0013-4694(89)90245-9; SOUTHALL DP, 1988, ARCH DIS CHILD, V63, P598, DOI 10.1136/adc.63.6.598; SOUTHALL DP, 1987, DEV MED CHILD NEUROL, V29, P784; SOUTHALL DP, 1990, ARCH DIS CHILD, V65, P953, DOI 10.1136/adc.65.9.953; SOUTHALL DP, 1989, EUR J PEDIATR, V148, P353, DOI 10.1007/BF00444133; SOUTHALL DP, 1989, MATERN CHILD HLTH J, V14, P210; STEBBENS VA, 1991, ARCH DIS CHILD, V66, P569, DOI 10.1136/adc.66.5.569; TAYUYBOCO JS, 1989, J PEDIATR-US, V115, P456, DOI 10.1016/S0022-3476(89)80855-8; UPTON CJ, 1992, ARCH DIS CHILD-FETAL, V67, P419, DOI 10.1136/adc.67.4_Spec_No.419	28	54	58	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 20	1993	306	6876					489	492		10.1136/bmj.306.6876.489	http://dx.doi.org/10.1136/bmj.306.6876.489			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN786	8448459	Green Published, Bronze			2023-01-03	WOS:A1993KN78600018
J	BRAHAMS, D				BRAHAMS, D			PERSISTENT VEGETATIVE STATE	LANCET			English	Editorial Material																			0	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	FEB 13	1993	341	8842					428	428						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM416	8094184				2023-01-03	WOS:A1993KM41600020
J	vanderWal, G; OnwuteakaPhilipsen, BD				vanderWal, G; OnwuteakaPhilipsen, BD			Cases of euthanasia and assisted suicide reported to the public prosecutor in North Holland over 10 years	BRITISH MEDICAL JOURNAL			English	Article									VRIJE UNIV AMSTERDAM,INST RES EXTRAMURAL MED,1081 BT AMSTERDAM,NETHERLANDS	Vrije Universiteit Amsterdam								VANDERWAL G, 1994, BRIT MED J, V308, P1346, DOI 10.1136/bmj.308.6940.1346; VANDERWAL G, 1992, EUTHANASIA ASSISTED	2	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 9	1996	312	7031					612	613						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ840	8595336				2023-01-03	WOS:A1996TZ84000026
J	Whynes, DK; Baines, DL; Tolley, KH				Whynes, DK; Baines, DL; Tolley, KH			Explaining variations in general practice prescribing costs per ASTRO-PU (age, sex, and temporary resident originated prescribing unit)	BRITISH MEDICAL JOURNAL			English	Article									UNIV NOTTINGHAM,SCH MED,SCH PUBL HLTH,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham	Whynes, DK (corresponding author), UNIV NOTTINGHAM,DEPT ECON,NOTTINGHAM NG7 2RD,ENGLAND.		Baines, Darrin/ABI-5893-2020	Baines, Darrin/0000-0001-9502-4678				BAKER D, 1991, BRIT MED J, V303, P225, DOI 10.1136/bmj.303.6796.225; CARLISLE RD, 1993, BRIT MED J, V306, P1383, DOI 10.1136/bmj.306.6889.1383; ROBERTS SJ, 1993, BRIT MED J, V307, P485, DOI 10.1136/bmj.307.6902.485; 1994, PRESCRIPTION IMPROVE; 1994, EL942 NHS MAN EX DEP	5	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 24	1996	312	7029					488	489		10.1136/bmj.312.7029.488	http://dx.doi.org/10.1136/bmj.312.7029.488			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX383	8597684	Green Published			2023-01-03	WOS:A1996TX38300029
J	Lewis, MA; Spitzer, WO; Heinemann, LAJ; MacRae, KD; Bruppacher, R; Thorogood, M				Lewis, MA; Spitzer, WO; Heinemann, LAJ; MacRae, KD; Bruppacher, R; Thorogood, M			Third generation oral contraceptives and risk of myocardial infarction: An international case-control study	BRITISH MEDICAL JOURNAL			English	Article								Objective - To test whether use of combined oral contraceptives containing third generation progestogens is associated with altered risk of myocardial infarction. Design - Matched case-control study. Setting - 16 centres in Austria, France, Germany, Switzerland, and the United Kingdom. Subjects - Cases were 153 women aged 16-44 with a myocardial infarction event. Controls were 498 women (at least 3 controls per case) unaffected by myocardial infarction who were matched with their corresponding case for age and for hospital or community setting within four months of the index infarction. Main outcome measures - Odds ratios derived with stratified analyses and unconditional logistic regression to adjust for potential confounding variables. Results - The estimated odds ratio for myocardial infarction of third compared with second generation oral contraceptives among all 651 study subjects was 0.36 (95% confidence interval 0.1 to 1.2) (P=0.11). The odds ratio for the United Kingdom and Germany alone was 0.45 (0.1 to 1.8) (P=0.26). Other odds ratios for the five countries were 3.1 (1.5 to 6.3) (P=0.003) for use of second generation products v no current use and 1.1 (0.4 to 3.4) (P=0.9) for use of third generation products v no current use. Among the confounding variables the independent contribution of smoking (for which adjustment was made in the above estimates) proved to be important (10.1 (5.7 to 17.9), P<0.001). Conclusion - An odds ratio of 0.45 with wide confidence intervals shows that third generation oral contraceptives compared with second generation products are associated with a reduced risk of myocardial infarction or with no difference. This finding from an interim analysis should be interpreted with extreme caution. However, the excess risk of venous thromboembolism associated with the use of third generation products may be balanced by the reduced risk of myocardial infarction associated with the same products.	PIPTA,D-14482 POTSDAM,GERMANY				Ulmer, Hanno/S-6615-2019	Ulmer, Hanno/0000-0001-5911-1002				COLE P, 1971, BRIT J PREV SOC MED, V25, P242; ENGEL HJ, 1987, HERZ, V12, P290; KJAER A, 1989, CONTRACEPTION, V40, P665, DOI 10.1016/0010-7824(89)90070-X; LEVIN M L, 1953, Acta Unio Int Contra Cancrum, V9, P531; LEWIS MA, IN PRESS PHARMACOEPI; MIETTINE.OS, 1974, AM J EPIDEMIOL, V99, P325, DOI 10.1093/oxfordjournals.aje.a121617; POULTER N, IN PRESS J CLIN EPID; Spitzer WO, 1996, BRIT MED J, V312, P83; Spitzer WO, 1993, PHARMACOEPIDEM DR S, V2, P21; THOROGOOD M, 1993, PHARMACOEPIDEM DR S, V2, P21; 1974, ORAL CONTRACEPTIVES	11	155	155	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 13	1996	312	7023					88	90						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ168	8555936				2023-01-03	WOS:A1996TQ16800023
J	PANKRATZ, L; JACKSON, J				PANKRATZ, L; JACKSON, J			HABITUALLY WANDERING PATIENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POPULATION; SERVICES; CARE	Background. Physicians are sometimes confronted with patients who gain admission to one hospital after another, sometimes referred to as ''wandering patients.'' Little is known about the presenting symptoms of these patients, their use of hospital resources, or the costs of their medical care, We analyzed the demographic and clinical characteristics of wandering patients served by Department of Veterans Affairs medical centers (VAMCs), Methods. For each patient they admit, all 159 hospitals in the Veterans Affairs medical system submit demographic and diagnostic information to a central data base at the Data Processing Center in Austin, Texas, We searched these records to identify patients who were admitted to four or more VAMCs within each year from fiscal year 1988 through 1992. Patients so identified in any one year were called ''wanderers''; those identified in all five years were designated ''habitual wanderers, Results. We identified 1013 wanderers in 1988. The number gradually declined each year to 729 in 1992, In 1991 there were 810 wandering patients, who averaged about eight admissions per year and more than 100 days of inpatient care; they accounted for about $26.5 million in costs for inpatient and outpatient care in that year. Only 35 patients wandered in all five years from 1988 through 1992. The most common discharge diagnoses of these 35 men were related to substance abuse (mostly alcoholism) and mental disorders. Their 2268 admissions and 7832 outpatient visits cost an estimated $6.5 million over the five-year period. Conclusions. Patients who are repeatedly admitted to different hospitals - wandering patients - accumulate high numbers of admissions, cause diagnostic confusion, and receive uncoordinated care. Because of the complexity of their disorders, such patients require case management on a regional or national basis.	OREGON HLTH SCI UNIV,DEPT PSYCHIAT,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT PSYCHOL MED,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University	PANKRATZ, L (corresponding author), VET AFFAIRS MED CTR,PSYCHOL SERV 116B,POB 1034,PORTLAND,OR 97207, USA.							ANDERSON GF, 1984, NEW ENGL J MED, V311, P1349, DOI 10.1056/NEJM198411223112105; BUCKLEY R, 1992, COMMUNITY MENT HLT J, V28, P43, DOI 10.1007/BF00756701; CATON CLM, 1981, HOSP COMMUNITY PSYCH, V32, P475; DRAKE RE, 1992, COMMUNITY MENT HLT J, V28, P5, DOI 10.1007/BF00756697; Durance P W, 1992, J Ment Health Adm, V19, P178, DOI 10.1007/BF02521318; FINK P, 1993, GEN HOSP PSYCHIAT, V15, P211, DOI 10.1016/0163-8343(93)90035-M; GELLER JL, 1992, AM J PSYCHIAT, V149, P1526; GELLER JL, 1992, HOSP COMMUNITY PSYCH, V43, P904; Gordon R E, 1975, J Fla Med Assoc, V62, P21; Gordon R E, 1973, JFMA, V60, P27; Hadley T R, 1990, Psychiatr Q, V61, P41, DOI 10.1007/BF01065163; McLean E K, 1990, Int J Soc Psychiatry, V36, P172, DOI 10.1177/002076409003600302; MECHANIC D, 1987, NEW ENGL J MED, V317, P1634, DOI 10.1056/NEJM198712243172605; PANKRATZ L, 1989, DRUG ALCOHOL DEPEN, V24, P115, DOI 10.1016/0376-8716(89)90073-2; PANKRATZ L, 1978, J OPER PSYCHIATR, V9, P42; PANKRATZ L, 1989, PERSPECT HEALTHCARE, V9, P5; PEPPER B, 1981, HOSP COMMUNITY PSYCH, V32, P463; ROSENHECK R, 1993, SCHIZOPHRENIA BULL, V19, P843, DOI 10.1093/schbul/19.4.843; SCHWARTZ SR, 1981, HOSP COMMUNITY PSYCH, V32, P470; SPARR L, 1983, AM J PSYCHIAT, V140, P1016; SURLES RC, 1987, HOSP COMMUNITY PSYCH, V38, P401; VICTOR CR, 1989, BRIT MED J, V299, P725, DOI 10.1136/bmj.299.6701.725	22	25	26	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 29	1994	331	26					1752	1755		10.1056/NEJM199412293312606	http://dx.doi.org/10.1056/NEJM199412293312606			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PZ266	7984197				2023-01-03	WOS:A1994PZ26600006
J	PHAROAH, POD				PHAROAH, POD			FAMILY SPACING, BREAST-FEEDING, AND CONTRACEPTION	LANCET			English	Editorial Material							HEALTH				PHAROAH, POD (corresponding author), UNIV LIVERPOOL,DEPT PUBL HLTH,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND.							KING M, 1990, LANCET, V336, P664, DOI 10.1016/0140-6736(90)92156-C; SCHUFTAN C, 1990, FAM PRACT, V7, P329, DOI 10.1093/fampra/7.4.329; WISNER B, 1988, SOC SCI MED, V26, P963, DOI 10.1016/0277-9536(88)90417-0; 1994, CONTRACEPTION, V50, P55; 1994, CONTRACEPTION, V50, P35	5	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 19	1994	344	8934					1382	1382		10.1016/S0140-6736(94)90565-7	http://dx.doi.org/10.1016/S0140-6736(94)90565-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PR786	7968072				2023-01-03	WOS:A1994PR78600006
J	BERKOWITZ, CD				BERKOWITZ, CD			HOMEOPATHT - KEEPING AN OPEN MIND	LANCET			English	Editorial Material											BERKOWITZ, CD (corresponding author), UNIV CALIF LOS ANGELES,LOS ANGELES CTY HARBOR MED CTR,DEPT PEDIAT,TORRANCE,CA 90509, USA.							CRETICOS PS, 1987, JAMA-J AM MED ASSOC, V258, P2874, DOI 10.1001/jama.258.20.2874; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; JACOBS J, 1994, PEDIATRICS, V93, P719; PACHTER LM, 1994, JAMA-J AM MED ASSOC, V271, P690, DOI 10.1001/jama.271.9.690; PALAFOX N, 1980, CROSS CULTURAL CARIN; REILLY DT, 1986, LANCET, V2, P881; WAPNIR RA, 1991, J PEDIATR, V118, P553; 1981, PUBLIC HLTH LETT, V3, P37	8	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 10	1994	344	8924					701	702		10.1016/S0140-6736(94)92203-9	http://dx.doi.org/10.1016/S0140-6736(94)92203-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF187	7915771				2023-01-03	WOS:A1994PF18700005
J	JACQZAIGRAIN, E; DAOUD, P; BURTIN, P; DESPLANQUES, L; BEAUFILS, F				JACQZAIGRAIN, E; DAOUD, P; BURTIN, P; DESPLANQUES, L; BEAUFILS, F			PLACEBO-CONTROLLED TRIAL OF MIDAZOLAM SEDATION IN MECHANICALLY VENTILATED NEWBORN BABIES	LANCET			English	Article							ARTIFICIAL-VENTILATION; ANESTHESIA; FENTANYL; INFANTS; PAIN; PHARMACOKINETICS; ANALGESIA; INDUCTION; INFUSION; CHILDREN	Although midazolam is used for sedation of mechanically ventilated newborn babies, this treatment has not been evaluated in a randomised trial, We have done a prospective placebo-controlled study of the effects of midazolam on haemodynamic variables and sedation as judged by a five-item behaviour score. 46 newborn babies on mechanical ventilation for respiratory distress syndrome were randomly assigned to receive midazolam (n=24) or placebo (n=22) as a continuous infusion. Doses of midazolam were calculated to obtain plasma concentrations between 200 and 1000 ng/mL within 24 h of starting treatment and to maintain these values throughout the study. Haemodynamic and ventilatory variables were noted every hour, as were complications and possible side-effects of treatment. Mean (SD) duration of inclusion was 7.87 (30.9) h. 1 patient in the treatment group and 7 in the placebo group were withdrawn because of inadequate sedation (p < 0.05). Midazolam gave a significantly better sedative effect than placebo, as estimated by the behaviour score (p < 0.05). Heart rate and blood pressure were reduced by treatment but remained within the normal range for gestational age and there was no effect on ventilatory indices. The incidence of complications was similar in the two groups. No midazolam-related side-effects were noted. Continuous infusion of midazolam at doses adapted to gestational age induces effective sedation in newborn babies on mechanical ventilation, with positive effects on haemodynamic variables. The course of the respiratory distress syndrome was not influenced by this treatment. Midazolam was given over only a few days and the limited effects on heart rate and blood pressure that we report should not encourage long-term administration.	HOP ROBERT DEBRE,DEPT PAEDIAT INTENS CARE,F-75019 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite	JACQZAIGRAIN, E (corresponding author), HOP ROBERT DEBRE,DEPT CLIN PHARMACOL,F-75019 PARIS,FRANCE.		Jacqz-Aigrain, Evelyne/AAW-7089-2021	Jacqz-Aigrain, Evelyne/0000-0002-4285-7067				ANAND KJS, 1992, NEW ENGL J MED, V326, P1, DOI 10.1056/NEJM199201023260101; ANAND KJS, 1987, NEW ENGL J MED, V317, P1321, DOI 10.1056/NEJM198711193172105; BARRIER G, 1989, INTENS CARE MED, V15, pS37, DOI 10.1007/BF00260883; BENSHLOMO I, 1990, BRIT J ANAESTH, V64, P45, DOI 10.1093/bja/64.1.45; BOOKER PD, 1986, BRIT J ANAESTH, V58, P1104, DOI 10.1093/bja/58.10.1104; BURTIN P, 1991, LANCET, V337, P1545, DOI 10.1016/0140-6736(91)93235-2; CRAIG KD, 1984, SOC SCI MED, V19, P1331, DOI 10.1016/0277-9536(84)90021-2; CREVOISIER C, 1983, BR J CLIN PHARM, V16, P51; FRAGEN RJ, 1979, ANESTHESIOLOGY, V51, P172; GEMELLI M, 1990, EUR J PEDIATR, V149, P318, DOI 10.1007/BF02171556; GREENOUGH A, 1983, J PEDIATR-US, V103, P769, DOI 10.1016/S0022-3476(83)80483-1; HARTWIG S, 1991, EUR J PEDIATR, V150, P784, DOI 10.1007/BF02026712; HEIKKILA H, 1984, ACTA ANAESTH SCAND, V28, P683, DOI 10.1111/j.1399-6576.1984.tb02145.x; JACQZAIGRAIN E, 1992, EUR J CLIN PHARMACOL, V42, P329; Kuban KCK, 1993, J INTENSIVE CARE MED, V8, P157, DOI 10.1177/088506669300800402; PAYNE K, 1989, EUR J CLIN PHARMACOL, V37, P267, DOI 10.1007/BF00679782; PERLMAN JM, 1985, NEW ENGL J MED, V312, P1353, DOI 10.1056/NEJM198505233122104; PERSSON MP, 1988, CLIN PHARMACOL THER, V43, P324; PUGLISI CV, 1985, J CHROMATOGR, V344, P199, DOI 10.1016/S0378-4347(00)82020-4; REVES JG, 1979, CAN ANAESTH SOC J, V26, P402, DOI 10.1007/BF03006455; REVES JG, 1985, ANESTHESIOLOGY, V62, P310, DOI 10.1097/00000542-198503000-00017; RITZ R, 1991, Intensive Care Medicine, V17, pS11, DOI 10.1007/BF01731148; ROBIEUX I, 1991, J PEDIATR-US, V118, P971, DOI 10.1016/S0022-3476(05)82220-6; ROSEN DA, 1990, 10TH UPDATE INTENSIV, P758; SHELLY MP, 1991, EUR J ANAESTH, V8, P21; STORK EK, 1985, PEDIATR RES, V18, pA321; TOLIA V, 1991, J PEDIATR-US, V119, P467, DOI 10.1016/S0022-3476(05)82066-9; VACANTI JP, 1984, J PEDIATR SURG, V19, P672, DOI 10.1016/S0022-3468(84)80351-6	28	77	78	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 3	1994	344	8923					646	650		10.1016/S0140-6736(94)92085-0	http://dx.doi.org/10.1016/S0140-6736(94)92085-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE386	7915348				2023-01-03	WOS:A1994PE38600010
J	EISENBERG, M				EISENBERG, M			IMPROVING OUT-OF-HOSPITAL RESUSCITATION	LANCET			English	Editorial Material							AMERICAN-HEART-ASSOCIATION; CARDIAC-ARREST; HEALTH-PROFESSIONALS; STATEMENT; SURVIVAL				EISENBERG, M (corresponding author), UNIV WASHINGTON,MED CTR,EMERGENCY MED SERV,SEATTLE,WA 98195, USA.							BECKER LB, 1991, ANN EMERG MED, V20, P355, DOI 10.1016/S0196-0644(05)81654-3; BENSON NH, 1994, ANN EMERG MED, V23, P1047, DOI 10.1016/S0196-0644(94)70102-4; CLARK JJ, 1994, ANN EMERG MED, V23, P1022, DOI 10.1016/S0196-0644(94)70097-4; CUMMINS RO, 1991, CIRCULATION, V84, P960, DOI 10.1161/01.CIR.84.2.960; CUMMINS RO, 1991, CIRCULATION, V83, P1832, DOI 10.1161/01.CIR.83.5.1832; DULL SM, 1994, ANN EMERG MED, V23, P997, DOI 10.1016/S0196-0644(94)70093-1; EISENBERG MS, 1990, ANN EMERG MED, V19, P179, DOI 10.1016/S0196-0644(05)81805-0; EISENBERG MS, 1994, ANN EMERG MED, V23, P1049, DOI 10.1016/S0196-0644(94)70103-2; LARSEN MP, 1993, ANN EMERG MED, V22, P1652, DOI 10.1016/S0196-0644(05)81302-2; PARTRIDGE JF, 1967, LANCET, V2, P271; PEPE PE, 1994, ANN EMERG MED, V23, P1037, DOI 10.1016/S0196-0644(94)70100-8; ROTTENBERG EM, 1994, ANN EMERG MED, V23, P1027, DOI 10.1016/S0196-0644(94)70098-2; SHUSTER M, 1994, ANN EMERG MED, V23, P1014, DOI 10.1016/S0196-0644(94)70096-6; SOSNA DP, 1994, ANN EMERG MED, V23, P1042, DOI 10.1016/S0196-0644(94)70101-6; WHITE RD, 1994, ANN EMERG MED, V23, P1009, DOI 10.1016/S0196-0644(94)70095-8	15	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 27	1994	344	8922					561	562		10.1016/S0140-6736(94)91961-5	http://dx.doi.org/10.1016/S0140-6736(94)91961-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD424	7914956				2023-01-03	WOS:A1994PD42400005
J	PENSWICK, J; WRIGHT, AL				PENSWICK, J; WRIGHT, AL			SKIN NECROSIS INDUCED BY STREPTOKINASE	BRITISH MEDICAL JOURNAL			English	Letter											PENSWICK, J (corresponding author), BRADFORD ROYAL INFIRM,BRADFORD BD9 6RJ,ENGLAND.							CIMO PL, 1979, AM J HEMATOL, V6, P125, DOI 10.1002/ajh.2830060204; COMP PC, 1990, SEMIN THROMB HEMOST, V16, P293, DOI 10.1055/s-2007-1002682; SMITHSON JE, 1993, BRIT MED J, V306, P973, DOI 10.1136/bmj.306.6883.973-b; 1993, ANROIO, P349	4	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 6	1994	309	6951					378	378		10.1136/bmj.309.6951.378	http://dx.doi.org/10.1136/bmj.309.6951.378			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB316	8081140	Green Published			2023-01-03	WOS:A1994PB31600021
J	EDDY, DM				EDDY, DM			A CONVERSATION WITH MY MOTHER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		EDDY DM, 1992, JAMA-J AM MED ASSOC, V267, P1669, DOI 10.1001/jama.267.12.1669; EDDY DM, 1992, JAMA-J AM MED ASSOC, V267, P1674; HUMPHRY D, 1991, FINAL EXIT	3	49	51	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 20	1994	272	3					179	181		10.1001/jama.272.3.179	http://dx.doi.org/10.1001/jama.272.3.179			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW185	8022025				2023-01-03	WOS:A1994NW18500001
J	RUSSELL, JA				RUSSELL, JA			CANCER-THERAPY - TIME TO LEARN THE IMMUNOBABBLE	LANCET			English	Editorial Material							HIGH-DOSE INTERLEUKIN-2; TUMOR-INFILTRATING LYMPHOCYTES; ACTIVATED KILLER-CELLS; TRIAL				RUSSELL, JA (corresponding author), TOM BAKER CANC CLIN,CALGARY,AB,CANADA.							ATKINS MB, 1993, J CLIN ONCOL, V11, P661, DOI 10.1200/JCO.1993.11.4.661; CURTI BD, 1993, J CLIN ONCOL, V11, P652, DOI 10.1200/JCO.1993.11.4.652; KIM JA, 1993, 37TH ANN C ADV BIOL; LARSON SM, 1993, ACTA ONCOL, V32, P709, DOI 10.3109/02841869309096125; MARINCOLA FM, 1993, J IMMUNOTHER, V13, P282, DOI 10.1097/00002371-199305000-00008; ROSENBERG SA, 1993, JNCI-J NATL CANCER I, V85, P622, DOI 10.1093/jnci/85.8.622; ROSENBERG SA, 1987, NEW ENGL J MED, V316, P889, DOI 10.1056/NEJM198704093161501; ROSENBERG SA, 1986, SCIENCE, V233, P1318, DOI 10.1126/science.3489291; UCHIDA A, 1993, CANCER IMMUNOL IMMUN, V11, P75; YEUNG AW, 1994, CANCER, V71, P3633	10	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 16	1994	344	8916					145	146		10.1016/S0140-6736(94)92753-7	http://dx.doi.org/10.1016/S0140-6736(94)92753-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW810	7912761				2023-01-03	WOS:A1994NW81000005
J	VANDERWAL, G; DILLMANN, RJM				VANDERWAL, G; DILLMANN, RJM			EUTHANASIA IN THE NETHERLANDS	BRITISH MEDICAL JOURNAL			English	Article							ASSISTED SUICIDE; FAMILY DOCTORS; LIFE	The practice of euthanasia in the Netherlands is often used as an argument in debates outside the Netherlands-hence a clear description of the Dutch situation is important. This article summarises recent data and discusses conceptual issues and relevant characteristics of the system of health care. Special emphasis is put on regulation, including relevant data on notification and prosecution. Besides the practice of euthanasia the Dutch are confronted with the gaps in reporting of cases to the public prosecutor and the existence of cases of ending a life without an explicit request. Nevertheless, the ''Dutch experiment'' need not inevitably lead down the slippery slope because of the visibility and openness of this part of medical practice. This will lead to increased awareness, more safeguards, and improvement of medical decisions concerning the end of life.	ROYAL DUTCH MED ASSOC,3502 LB UTRECHT,NETHERLANDS; HLTH PROV N HOLLAND,2001 DC HAARLEM,NETHERLANDS									ANNAS GJ, 1993, NEW ENGL J MED, V328, P1573, DOI 10.1056/NEJM199305273282121; BATTIN MP, 1990, PERSPECT BIOL MED, V34, P73; Bostrom B A, 1989, Issues Law Med, V4, P467; CASSEL CK, 1990, NEW ENGL J MED, V323, P750, DOI 10.1056/NEJM199009133231110; DEWACHTER MAM, 1989, JAMA-J AM MED ASSOC, V262, P3316, DOI 10.1001/jama.262.23.3316; DILLMANN RJM, 1994, EUROPEAN J HLTH LAW, V1, P81; FEBER HRG, 1989, NEDERLANDS JURISTEN, V64, P1441; Fenigsen R, 1989, Hastings Cent Rep, V19, P22, DOI 10.2307/3561967; Gomez Carlos F., 1991, REGULATING DEATH EUT; GUNNING KF, 1991, LANCET, V338, P1010, DOI 10.1016/0140-6736(91)91867-T; KUHSE H, 1988, MED J AUSTRALIA, V148, P623, DOI 10.5694/j.1326-5377.1988.tb116334.x; PIJNENBORG L, 1993, LANCET, V341, P1196, DOI 10.1016/0140-6736(93)91014-D; POLLARD BJ, 1991, MED J AUSTRALIA, V154, P613, DOI 10.5694/j.1326-5377.1991.tb121223.x; RIGTER H, 1988, BMJ-BRIT MED J, V297, P1593, DOI 10.1136/bmj.297.6663.1593; RIGTER H, 1989, HASTINGS CENT REP, V19, P31, DOI 10.2307/3561968; van Delden J J, 1992, Ned Tijdschr Geneeskd, V136, P644; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; VANDELDEN JJM, 1993, BIOETHICS, V7, P323, DOI 10.1111/j.1467-8519.1993.tb00222.x; VANDELDEN JJM, 1993, HASTINGS CENT REP, V23, P24, DOI 10.2307/3562919; VANDERMAAS PJ, 1992, HLTH POLICY S1 S2, V22; VANDERWAL G, 1993, BIOETHICS, V7, P330, DOI 10.1111/j.1467-8519.1993.tb00223.x; VANDERWAL G, 1992, FAM PRACT, V9, P130, DOI 10.1093/fampra/9.2.130; VANDERWAL G, 1992, FAM PRACT, V9, P135, DOI 10.1093/fampra/9.2.135; VANDERWAL G, 1992, EUTHANASIA ASSISTED; VANDERWAL G, IN PRESS J AM GERIAT; VANDERWAL G, 1993, NEDERLANDS JURISTEN, V68, P444; ZYLICZ Z, 1991, LANCET, V338, P1150, DOI 10.1016/0140-6736(91)92010-Y; 1987, BIOETHICS, V1, P163; 1991, MED BESLISSINGEN RON	29	65	65	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 21	1994	308	6940					1346	1349		10.1136/bmj.308.6940.1346	http://dx.doi.org/10.1136/bmj.308.6940.1346			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NM989	8019226	Green Published			2023-01-03	WOS:A1994NM98900028
J	CHEETHAM, JJ; NIR, S; JOHNSON, E; FLANAGAN, TD; EPAND, RM				CHEETHAM, JJ; NIR, S; JOHNSON, E; FLANAGAN, TD; EPAND, RM			THE EFFECTS OF MEMBRANE PHYSICAL-PROPERTIES ON THE FUSION OF SENDAI VIRUS WITH HUMAN ERYTHROCYTE-GHOSTS AND LIPOSOMES - ANALYSIS OF KINETICS AND EXTENT OF FUSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEXAGONAL PHASE; IMMUNODEFICIENCY-VIRUS; CHOLESTEROL SULFATE; ENVELOPED VIRUSES; CELLS; DESTABILIZATION; ACTIVATION; PROTEIN; MODEL; GLYCOPROTEINS	A number of amphiphiles which raise the bilayer to hexagonal phase transition temperature (T-H) of phosphatidylethanolamine (PE) have been shown to inhibit viral fusion. In this study we have further evaluated the mechanism of this inhibition, Several anionic amphiphiles, including cholesterol sulfate, a component of mammalian plasma membranes, lower the final extent of Sendai virus fusion with both human erythrocyte ghosts and liposomes composed of PE and 5% of the ganglioside, G(D1a). A cationic amphiphile slightly increased the final extent of fusion. The fusion rate constant is not greatly affected by the presence of as much as 20% cholesterol sulfate or other charged amphiphiles. The zwitterionic amphiphile, cholesterol phosphorylcholine has no effect on the final extent of fusion but it lowers the fusion rate constant. This amphiphile is potent in raising T-H. The amphiphile cholesterol hemisuccinate (CHEMS) stabilizes the bilayer relative to the hexagonal phase at neutral pH, while at acidic pH the formation of the hexagonal phase is promoted. When CHEMS is added to vesicles of egg PE containing 5% G(D1a), the rate of Sendai virus fusion is little affected at neutral pH but the rate is significantly enhanced at pH 5.0. These results demonstrate that viral fusion can be modulated, in part, by the tendency of the membrane to convert to the hexagonal phase.	MCMASTER UNIV, HLTH SCI CTR, DEPT BIOCHEM, HAMILTON L8N 3Z5, ON, CANADA; HEBREW UNIV JERUSALEM, FAC AGR, SEAGRAM CTR SOIL & WATER SCI, IL-76100 REHOVOT, ISRAEL; SUNY BUFFALO, SCH MED, DEPT MICROBIOL, BUFFALO, NY 14214 USA; SUNY BUFFALO, SCH BIOMED SCI, BUFFALO, NY 14214 USA	McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba; Hebrew University of Jerusalem; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo			, Richard/R-2316-2019	, Richard/0000-0002-9602-9558				Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI DOI 10.1016/0076-6879(66)08014-5; BENTZ J, 1988, BIOPHYS J, V54, P449, DOI 10.1016/S0006-3495(88)82978-3; BENTZ J, 1987, BIOCHEMISTRY-US, V26, P2105, DOI 10.1021/bi00382a008; BOTTEGA R, 1992, BIOCHEMISTRY-US, V31, P9025, DOI 10.1021/bi00152a045; BRYSZEWSKA M, 1991, Medical Science Research, V19, P791; CHEETHAM JJ, 1990, J BIOL CHEM, V265, P12404; CHEETHAM JJ, 1990, BIOCHIM BIOPHYS ACTA, V1024, P367, DOI 10.1016/0005-2736(90)90366-V; ELLENS H, 1985, BIOCHEMISTRY-US, V24, P3099, DOI 10.1021/bi00334a005; ELLENS H, 1989, BIOCHEMISTRY-US, V28, P3692, DOI 10.1021/bi00435a011; EPAND RM, 1992, BIOCHEMISTRY-US, V31, P1550, DOI 10.1021/bi00120a036; EPAND RM, 1985, BIOCHEMISTRY-US, V24, P7092, DOI 10.1021/bi00346a011; EPAND RM, 1988, BIOCHIM BIOPHYS ACTA, V940, P85, DOI 10.1016/0005-2736(88)90011-9; EPAND RM, 1990, BIOCHEM CELL BIOL, V68, P17, DOI 10.1139/o90-003; EPAND RM, 1990, CHEM PHYS LIPIDS, V55, P49, DOI 10.1016/0009-3084(90)90148-K; EPAND RM, 1993, TRENDS BIOCHEM SCI, V18, P81, DOI 10.1016/0968-0004(93)90157-I; EPAND RM, 1992, BIOPOLYMERS, V32, P309, DOI 10.1002/bip.360320403; EPAND RM, 1992, MEMBRANE INTERACTION, P99; GETHING MJ, 1978, P NATL ACAD SCI USA, V75, P2737, DOI 10.1073/pnas.75.6.2737; GRUNER SM, 1985, P NATL ACAD SCI USA, V82, P3665, DOI 10.1073/pnas.82.11.3665; HAYWOOD AM, 1981, BIOCHIM BIOPHYS ACTA, V646, P31, DOI 10.1016/0005-2736(81)90268-6; HAYWOOD AM, 1991, CELL AND MODEL MEMBRANE INTERACTIONS, P149; HAYWOOD AM, 1975, J GEN VIROL, V29, P63, DOI 10.1099/0022-1317-29-1-63; HOEKSTRA D, 1989, BIOSCIENCE REP, V9, P273, DOI 10.1007/BF01114682; HOEKSTRA D, 1984, BIOCHEMISTRY-US, V23, P5675, DOI 10.1021/bi00319a002; HSU MC, 1981, J BIOL CHEM, V256, P3557; KITSON N, 1992, BIOCHIM BIOPHYS ACTA, V1111, P127, DOI 10.1016/0005-2736(92)90282-Q; KLAPPE K, 1986, BIOCHEMISTRY-US, V25, P8252, DOI 10.1021/bi00373a019; LEE RC, 1992, P NATL ACAD SCI USA, V89, P4524, DOI 10.1073/pnas.89.10.4524; LITZINGER DC, 1992, BIOCHIM BIOPHYS ACTA, V1113, P201, DOI 10.1016/0304-4157(92)90039-D; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYTE M, 1979, CHEM PHYS LIPIDS, V24, P45, DOI 10.1016/0009-3084(79)90094-X; MARSH M, 1989, ADV VIRUS RES, V36, P107, DOI 10.1016/S0065-3527(08)60583-7; NIR S, 1986, BIOCHEMISTRY-US, V25, P2155, DOI 10.1021/bi00356a046; NIR S, 1990, CELL BIOPHYS, V17, P181, DOI 10.1007/BF02990496; NIR S, 1986, BIOCHEMISTRY-US, V25, P8261, DOI 10.1021/bi00373a020; NOVICK SL, 1988, P NATL ACAD SCI USA, V85, P7433, DOI 10.1073/pnas.85.20.7433; OHKI S, 1991, BIOMED BIOCHIM ACTA, V50, P199; REED RA, 1987, BIOCHEMISTRY-US, V26, P824, DOI 10.1021/bi00377a025; SCHEID A, 1974, VIROLOGY, V57, P475, DOI 10.1016/0042-6822(74)90187-1; SIEGEL DP, 1993, VIRAL FUSION MECHANI, P475; Sobel AE, 1941, J AM CHEM SOC, V63, P3536, DOI 10.1021/ja01857a516; URYU T, 1992, BIOCHEM PHARMACOL, V43, P2385, DOI 10.1016/0006-2952(92)90317-C; VONECHE V, 1992, P NATL ACAD SCI USA, V89, P3810, DOI 10.1073/pnas.89.9.3810; WATARAI S, 1990, J BIOCHEM-TOKYO, V108, P507, DOI 10.1093/oxfordjournals.jbchem.a123230; YAN JS, 1990, J LIPID RES, V31, P160; YEAGLE PL, 1991, BIOCHIM BIOPHYS ACTA, V1065, P49, DOI 10.1016/0005-2736(91)90009-W	46	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5467	5472						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106528				2023-01-03	WOS:A1994MX57100113
J	CHAO, NJ; SCHMIDT, GM; NILAND, JC; AMYLON, MD; DAGIS, AC; LONG, GD; NADEMANEE, AP; NEGRIN, RS; ODONNELL, MR; PARKER, PM; SMITH, EP; SNYDER, DS; STEIN, AS; WONG, RM; BLUME, KG; FORMAN, SJ				CHAO, NJ; SCHMIDT, GM; NILAND, JC; AMYLON, MD; DAGIS, AC; LONG, GD; NADEMANEE, AP; NEGRIN, RS; ODONNELL, MR; PARKER, PM; SMITH, EP; SNYDER, DS; STEIN, AS; WONG, RM; BLUME, KG; FORMAN, SJ			CYCLOSPORINE, METHOTREXATE, AND PREDNISONE COMPARED WITH CYCLOSPORINE AND PREDNISONE FOR PROPHYLAXIS OF ACUTE GRAFT-VERSUS-HOST DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; TERM FOLLOW-UP; RETROSPECTIVE ANALYSIS; CONTROLLED TRIAL; T-CELLS; LEUKEMIA; PREVENTION; RECIPIENTS; DEPLETION; REGIMEN	Background. Acute graft-versus-host disease (GVHD) following allogeneic bone marrow transplantation remains a serious problem. In a clinical trial, we tested the combination of cyclosporine and prednisone with and without methotrexate for the prevention of GVHD. Methods. One hundred fifty patients with either acute leukemia in first complete remission, chronic myelogenous leukemia in first chronic phase, or lymphoblastic lymphoma in first complete remission were enrolled in the study. All the patients were given fractionated total-body irradiation (1320 cGy) and etoposide (60 mg per kilogram of body weight) in preparation for transplantation, and received bone marrow from genotypically histocompatible donors. To prevent GVHD, they were randomly assigned to prophylactic treatment with either cyclosporine, methotrexate, and prednisone or cyclosporine and prednisone without methotrexate. All the patients received standardized supportive care after transplantation, including intravenous gamma globulin. Results. Patients receiving cyclosporine, methotrexate, and prednisone had a significantly lower incidence of acute GVHD of grades II to IV (9 percent) than those receiving cyclosporine and prednisone (23 percent, P = 0.02). Multivariate regression analysis demonstrated that an increased risk of acute GVHD was associated with an elevated serum creatinine concentration (P = 0.006) and treatment with cyclosporine and prednisone alone (P = 0.02). The lower incidence of acute GVHD was not associated with a higher rate of relapse of leukemia or lymphoma. There was no significant difference in disease-free survival at three years between the two treatment groups (64 percent with the three-drug regimen vs. 59 percent with the two-drug regimen, P = 0.57). Conclusions. The combination of cyclosporine, methotrexate, and prednisone was more effective in preventing acute GVHD of grades II to IV than was the combination of cyclosporine and prednisone without methotrexate.	STANFORD UNIV, BONE MARROW TRANSPLANT PROGRAM, STANFORD, CA 94305 USA; STANFORD UNIV, DEPT HLTH RES & POLICY, STANFORD, CA 94305 USA; CITY HOPE NATL MED CTR, DEPT HEMATOL & BONE MARROW TRANSPLANTAT, DUARTE, CA 91010 USA; CITY HOPE NATL MED CTR, DEPT BIOSTAT, DUARTE, CA 91010 USA	Stanford University; Stanford University; City of Hope; City of Hope					NATIONAL CANCER INSTITUTE [P01CA030206, P01CA049605] Funding Source: NIH RePORTER; NCI NIH HHS [CA-49605, CA-30206] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERTAULTPERES P, 1989, TRANSPLANT P, V21, P904; BLUME, 1987, BLOOD, V69, P1789; BLUME KG, 1993, BLOOD, V81, P2187; BLUME KG, 1987, BLOOD, V69, P1015; CHAO NJ, 1991, BLOOD, V78, P1923; DEEG HJ, 1985, BLOOD, V65, P1325, DOI 10.1182/blood.V65.6.1325.bloodjournal6561325; FORMAN SJ, 1987, TRANSPLANT P, V19, P2605; GLUCKSBERG H, 1974, TRANSPLANTATION, V18, P295, DOI 10.1097/00007890-197410000-00001; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MARANINCHI D, 1987, LANCET, V2, P175; MARTIN PJ, 1990, BLOOD, V76, P1464, DOI 10.1182/blood.V76.8.1464.1464; MARTIN PJ, 1991, BLOOD, V77, P1821; MARTIN PJ, 1985, BLOOD, V66, P664; NASH RA, 1992, BLOOD, V80, P1838; OREILLY RJ, 1985, TRANSPLANT P, V17, P455; RAMSAY NKC, 1982, NEW ENGL J MED, V306, P392, DOI 10.1056/NEJM198202183060703; Santos G., 1987, CLIN TRANSPLANT, V1, P21; SANTOS GW, 1985, EXP HEMATOL, V13, P427; SCHMIDT GM, 1991, NEW ENGL J MED, V324, P1005, DOI 10.1056/NEJM199104113241501; SCHMIDT GM, 1993, TRANSPLANTATION, V55, P551, DOI 10.1097/00007890-199303000-00018; STORB R, 1990, BLOOD, V76, P1037; STORB R, 1985, IMMUNOL REV, V88, P215, DOI 10.1111/j.1600-065X.1985.tb01160.x; STORB R, 1988, BLOOD, V71, P293; STORB R, 1986, BLOOD, V68, P119; STORB R, 1989, BLOOD, V73, P1729; STORB R, 1986, NEW ENGL J MED, V314, P729, DOI 10.1056/NEJM198603203141201; SULLIVAN KM, 1990, NEW ENGL J MED, V323, P705, DOI 10.1056/NEJM199009133231103; TUTSCHKA PJ, 1987, BLOOD, V70, P1382	28	228	228	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 21	1993	329	17					1225	1230		10.1056/NEJM199310213291703	http://dx.doi.org/10.1056/NEJM199310213291703			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB988	8413388				2023-01-03	WOS:A1993MB98800003
J	JONES, A; PECKETT, W; CLARK, E; SHARPE, C; KRIMHOLTZ, S; RUSSELL, M; GOODWIN, T				JONES, A; PECKETT, W; CLARK, E; SHARPE, C; KRIMHOLTZ, S; RUSSELL, M; GOODWIN, T			NURSES KNOWLEDGE OF THE RESUSCITATION STATUS OF PATIENTS AND ACTION IN THE EVENT OF CARDIORESPIRATORY ARREST	BRITISH MEDICAL JOURNAL			English	Article							ORDERS		MT VERNON HOSP,NORTHWOOD HA6 2RN,MIDDX,ENGLAND; HILLINGDON HOSP,MIDDLESEX UB8 3ON,ENGLAND				Sharpe, Claire/B-5619-2015	Sharpe, Claire/0000-0003-1704-8492				AARONS EJ, 1991, BRIT MED J, V303, P1504, DOI 10.1136/bmj.303.6816.1504; ASPLUND K, 1990, J INTERN MED, V228, P139; KAMER RS, 1990, AM J MED, V88, P108, DOI 10.1016/0002-9343(90)90457-O; TUNSTALLPEDOE H, 1992, BRIT MED J, V304, P1347, DOI 10.1136/bmj.304.6838.1347; 1984, CODE PROFESSIONAL CO	5	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1993	306	6892					1577	1578		10.1136/bmj.306.6892.1577	http://dx.doi.org/10.1136/bmj.306.6892.1577			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH128	8329918	Bronze, Green Published			2023-01-03	WOS:A1993LH12800018
J	ARROLL, B; BEAGLEHOLE, R				ARROLL, B; BEAGLEHOLE, R			HYPERTENSION - EXERCISE FOR HYPERTENSION	LANCET			English	Note							PHYSICAL-ACTIVITY		UNIV AUCKLAND,DEPT GEN PRACTICE,AUCKLAND,NEW ZEALAND	University of Auckland	ARROLL, B (corresponding author), UNIV AUCKLAND,DEPT COMMUNITY HLTH,AUCKLAND,NEW ZEALAND.							BLAIR SN, 1992, ANNU REV PUBL HEALTH, V13, P99, DOI 10.1146/annurev.pu.13.050192.000531; Bouchard C, 1988, EXERCISE FITNESS HLT, P147; HAGBERG JM, 1989, AM J CARDIOL, V64, P348, DOI 10.1016/0002-9149(89)90533-X; HARRIS KA, 1987, MED SCI SPORT EXER, V19, P246; HURLEY BF, 1984, MED SCI SPORT EXER, V16, P483, DOI 10.1249/00005768-198410000-00011; JHURLEY BF, 1988, MED SCI SPORTS EXERC, V20, P150; MEREDITH IT, 1990, J HYPERTENS, V8, P859, DOI 10.1097/00004872-199009000-00010; NELSON L, 1986, LANCET, V2, P473, DOI 10.1016/S0140-6736(86)90354-5; PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003; SEALS DR, 1984, MED SCI SPORT EXER, V16, P207; SISCOVICK DS, 1984, NEW ENGL J MED, V311, P874, DOI 10.1056/NEJM198410043111402	11	14	15	2	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 15	1993	341	8855					1248	1249		10.1016/0140-6736(93)91152-C	http://dx.doi.org/10.1016/0140-6736(93)91152-C			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LC497	8098398				2023-01-03	WOS:A1993LC49700010
J	SMITH, MS				SMITH, MS			BABU	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	1	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 12	1993	269	18					2447	2447		10.1001/jama.269.18.2447	http://dx.doi.org/10.1001/jama.269.18.2447			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LA675	8479073				2023-01-03	WOS:A1993LA67500043
J	MACARTHUR, C; LEWIS, M; KNOX, EG				MACARTHUR, C; LEWIS, M; KNOX, EG			ACCIDENTAL DURAL PUNCTURE IN OBSTETRIC PATIENTS AND LONG-TERM SYMPTOMS	BRITISH MEDICAL JOURNAL			English	Article							COMPLICATIONS; ANESTHESIA; MANAGEMENT; BLOCK	Objective-To examine the association between accidental dural puncture and long term headache and related symptoms. Design-Postal questionnaire survey to elucidate new symptoms occurring after childbirth, and linking of these to data in obstetric and anaesthetic case notes. Women were surveyed between 13 months and nine years after delivery. Setting-Birmingham Maternity Hospital. Subjects-4700 women who had delivered their most recent baby under epidural anaesthesia, 74 of whom had suffered an accidental dural puncture. Main outcome measures-Frequencies of new headache or migraine or neck ache starting within three months after childbirth and lasting over six weeks. Results-Among the 74 women who had had an accidental dural puncture there were 17 (23%) who reported one or more of the above symptoms. By comparison, among those who had had an epidural anaesthetic but no recorded puncture, only 329 (7.1%) reported these symptoms. The duration of the headache or migraine or neck ache in the dural tap group ranged from nine weeks to over eight years. Ten of these women reported still unresolved symptoms. Conclusions-Conclusions on causality were tentative. Most women would remember a dural tap, and this might influence their reporting of subsequent symptoms attributable to the event. In addition, detailed characterisation of the symptoms was not available. Nevertheless, the findings provide a clear indication of the need for further study of the possible long term sequelae of accidental dural puncture.	BIRMINGHAM MATERN HOSP,DEPT ANAESTHET,BIRMINGHAM B15 2TG,W MIDLANDS,ENGLAND		MACARTHUR, C (corresponding author), UNIV BIRMINGHAM,SCH MED,DEPT PUBL HLTH & EPIDEMIOL,BIRMINGHAM B15 2TJ,W MIDLANDS,ENGLAND.		MacArthur, Christine/ABA-8601-2021	MacArthur, Christine/0000-0003-0434-2158				ABOULEISH E, 1978, ANESTHESIOLOGY, V49, P291, DOI 10.1097/00000542-197810000-00016; Bromage PR, 1978, EPIDURAL ANALGESIA, V1st; BROWNRIDGE P, 1982, ANAESTH INTENS CARE, V10, P298, DOI 10.1177/0310057X8201000401; BROWNRIDGE P, 1983, ANAESTH INTENS CARE, V11, P4, DOI 10.1177/0310057X8301100102; CAST W, 1974, JAMA-J AM MED ASSOC, V227, P786; CRAWFORD JS, 1972, BRIT J ANAESTH, V44, P1277, DOI 10.1093/bja/44.12.1277; CRAWFORD JS, 1972, BRIT J ANAESTH, V44, P66, DOI 10.1093/bja/44.1.66; KALAS DB, 1972, ANESTH ANAL CURR RES, V51, P192; MACARTHUR C, 1990, BRIT MED J, V301, P9, DOI 10.1136/bmj.301.6742.9; MACARTHUR C, 1992, BRIT MED J, V304, P1279, DOI 10.1136/bmj.304.6837.1279; MACARTHUR C, 1991, HLTH CHILDBIRTH; OKELL RW, 1987, ANAESTHESIA, V42, P1110, DOI 10.1111/j.1365-2044.1987.tb05181.x; ONG B, 1987, CAN J ANAESTH, V34, P294, DOI 10.1007/BF03015169; REYNOLDS F, 1989, BRIT MED J, V299, P751, DOI 10.1136/bmj.299.6702.751; SCOTT DB, 1990, BRIT J ANAESTH, V64, P537, DOI 10.1093/bja/64.5.537; STRIDE PC, 1993, ANAESTHESIA, V48, P247, DOI 10.1111/j.1365-2044.1993.tb06913.x; VANDAM LD, 1956, JAMA-J AM MED ASSOC, V161, P586, DOI 10.1001/jama.1956.02970070018005	17	70	71	1	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 3	1993	306	6882					883	885		10.1136/bmj.306.6882.883	http://dx.doi.org/10.1136/bmj.306.6882.883			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW387	8490410	Green Published, Bronze			2023-01-03	WOS:A1993KW38700016
J	CAMPBELL, IT; SWAN, G				CAMPBELL, IT; SWAN, G			RESUSCITATION - GUIDELINES AND TRAINING IN CARDIOPULMONARY-RESUSCITATION	LANCET			English	Editorial Material											CAMPBELL, IT (corresponding author), WITHINGTON HOSP,DEPT OBSTET & GYNAECOL,MANCHESTER M20 8LR,LANCS,ENGLAND.							HERSHEY CO, 1982, LANCET, V1, P31, DOI 10.1016/S0140-6736(82)92567-3; PEDOE HT, 1992, BRIT MED J, V304, P1347; POSWILLO D, 1990, GENERAL ANAESTHESIA; SACK JB, 1992, JAMA-J AM MED ASSOC, V267, P379; SKINNER DV, 1985, BRIT MED J, V290, P1549, DOI 10.1136/bmj.290.6481.1549; WOOG RH, 1987, ANAESTH INTENS CARE, V15, P193, DOI 10.1177/0310057X8701500213; 1992, RESUSCITATION, V24, P111; 1987, J R COLL PHYSICIANS, V21, P1; 1992, RESUSCITATION, V24, P155; 1992, JAMA-J AM MED ASSOC, V268, P2171	10	3	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 20	1993	341	8843					470	471		10.1016/0140-6736(93)90216-4	http://dx.doi.org/10.1016/0140-6736(93)90216-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN137	8094496				2023-01-03	WOS:A1993KN13700013
J	PANTON, R				PANTON, R			THE FUTURE OF FHSAS .5. FHSAS AND PRESCRIBING	BRITISH MEDICAL JOURNAL			English	Article											PANTON, R (corresponding author), UNIV KEELE,DEPT PHARM POLICY & PRACTICE,KEELE ST5 5BG,STAFFS,ENGLAND.							BAKER JA, 1988, BRIT MED J, V297, P465, DOI 10.1136/bmj.297.6646.465; BRADLEY CP, 1992, BRIT MED J, V304, P294, DOI 10.1136/bmj.304.6822.294; KESSLER A, 1992, CHEM DRUGGIST, V236, P605; NEWTONSYMS FAO, 1988, PHARM J, V294, pR2; PARR C, 1992, PHARM J, V248, P616; 1992, DETERMINING DRUG INF; 1992, LANCET, V340, P341; 1992, STATISTICAL B GENERA; 1990, IMPROVING PRESCRIBIN; 1992, PHARM CARE FUTURE CO; 1991, PHARMACEUTICALS CONS; 1992, IMPEDIMENTS PARALLEL; 1992, EXCESSIVE PRESCRIBIN	13	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 30	1993	306	6873					310	314		10.1136/bmj.306.6873.310	http://dx.doi.org/10.1136/bmj.306.6873.310			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK718	8461652	Green Published, Bronze			2023-01-03	WOS:A1993KK71800024
J	Alappan, R; Perazella, MA; Buller, GK				Alappan, R; Perazella, MA; Buller, GK			Hyperkalemia in hospitalized patients treated with trimethoprim-sulfamethoxazole	ANNALS OF INTERNAL MEDICINE			English	Article								Objective: To determine the effect of standard-dose trimethoprim-sulfamethoxazole on serum potassium concentration in hospitalized patients. Design: Prospective chart review. Setting: Community-based teaching hospital. Patients: 105 patients with various infections were hospitalized and treated. Eighty patients treated with standard-dose trimethoprim-sulfamethoxazole (trimethoprim, less than or equal to 320 mg/d; sulfamethoxazole, less than or equal to 1600 mg/d) composed the treatment group; 25 patients treated with other antibiotic agents served as the control group. Measurements: Serum sodium, potassium, and chloride concentrations; serum carbon dioxide content; anion gap; blood urea nitrogen level; and serum creatinine level. Results: The serum potassium concentration in the treatment group (mean +/- SD) was 3.89 +/- 0.46 mmol/L (95% CI, 3.79 to 3.99 mmol/L), and it increased by 1.21 mmol/L (CI, 1.09 to 1.32 mmol/L) 4.6 +/- 2.2 days after trimethoprim-sulfamethoxazole therapy was initiated. Blood urea nitrogen levels increased from 7.92 +/- 5.7 mmol/L (CI, 6.67 to 9.16 mmol/L) to 9.2 +/- 5.8 mmol/L (CI, 7.9 to 10.5 mmol/L), and serum creatinine levels increased from 102.5 +/- 49.5 mu mol/L (CI, 91.4 to 113.6 mu mol/L) to 126.1 +/- 70.7 mu mol/L (CI, 110.3 to 141.9 mu mol/L). Patients with a serum creatinine level of 106 mu mol/l (1.2 mg/dL) or more developed a higher peak potassium concentration (5.37 +/- 0.59 mmol/L [CI, 5.15 to 5.59 mmol/L]) than patients with a serum creatinine level of less than 106 mu mol/L (4.95 +/- 0.48 mmol/L [CI, 4.80 to 5.08 mmol/L]). Patients with diabetes had a slightly higher peak potassium concentration (5.14 +/- 0.45 mmol/L [CI, 4.93 to 5.35 mmol/L]) than did patients without diabetes (5.08 +/- 0.59 mmol/L [CI, 4.93 to 5.23 mmol/L]), but the difference was not statistically significant. The serum potassium concentration in the control group was 4.33 +/- 0.45 mmol/L (CI, 4.15 to 4.51 mmol/L), and it decreased nonsignificantly over 5 days of therapy. Conclusions: Standard-dose trimethoprim-sulfamethoxazole therapy used to treat various infections leads to an increase in serum potassium concentration. A peak serum potassium concentration greater than 5.0 mmol/L developed in 62.5% of patients; severe hyperkalemia (peak serum potassium concentration greater than or equal to 5.5 mmol/L) occurred in 21.2% of patients. Patients treated with standard-dose trimethoprim-sulfamethoxazole should be monitored closely for the development of hyperkalemia, especially if they have concurrent renal insufficiency (serum creatinine level greater than or equal to 106 mu mol/L).	YALE UNIV, SCH MED, DEPT MED, NEPHROL SECT, NEW HAVEN, CT 06510 USA; ST MARYS HOSP, DEPT MED, YALE PRIMARY CARE PROGRAM, WATERBURY, CT 06706 USA; ST MARYS HOSP, DEPT MED, NEPHROL SECT, WATERBURY, CT 06706 USA	Yale University; Yale University								BERGLUND F, 1975, J UROLOGY, V114, P802, DOI 10.1016/S0022-5347(17)67149-0; BERNS JS, 1991, J AM SOC NEPHROL, V1, P1061; CANADAY DH, 1994, ANN INTERN MED, V120, P437, DOI 10.7326/0003-4819-120-5-199403010-00017; CHOI MJ, 1993, NEW ENGL J MED, V328, P703, DOI 10.1056/NEJM199303113281006; CRYST C, 1988, AM J NEPHROL, V8, P483, DOI 10.1159/000167666; GREENBERG S, 1993, ANN INTERN MED, V119, P291, DOI 10.7326/0003-4819-119-4-199308150-00007; JICK H, 1982, REV INFECT DIS, V4, P426; MODEST GA, 1994, ANN INTERN MED, V120, P437, DOI 10.7326/0003-4819-120-5-199403010-00015; PENNYPACKER LC, 1994, ANN INTERN MED, V120, P437, DOI 10.7326/0003-4819-120-5-199403010-00016; SCHLANGER LE, 1994, KIDNEY INT, V45, P1070, DOI 10.1038/ki.1994.143; VELAZQUEZ H, 1993, ANN INTERN MED, V119, P296, DOI 10.7326/0003-4819-119-4-199308150-00008; 1992, MED ECONOMICS	12	80	82	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1996	124	3					316	320		10.7326/0003-4819-124-3-199602010-00006	http://dx.doi.org/10.7326/0003-4819-124-3-199602010-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TR596	8554227				2023-01-03	WOS:A1996TR59600006
J	SPEVAK, MR; KLEINMAN, PK; BELANGER, PL; PRIMACK, C; RICHMOND, JM				SPEVAK, MR; KLEINMAN, PK; BELANGER, PL; PRIMACK, C; RICHMOND, JM			CARDIOPULMONARY-RESUSCITATION AND RIB FRACTURES IN INFANTS - A POSTMORTEM RADIOLOGIC-PATHOLOGICAL STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							COMPLICATIONS; CPR	Objective.-To determine the incidence of rib fractures visible at autopsy or with postmortem radiographs after cardiopulmonary resuscitation (CPR) in infants younger than 1 year. Design.-Retrospective review. Setting.-Medical examiner's office in a county consisting of a medium-sized city, towns, and rural areas. Patients.-Ninety-one infants (56 males, 35 females; mean age, 2.4 months; age range, 26 hours to 8.5 months) without evidence of child abuse who had undergone CPR before death. Methods.-Medical records, skeletal surveys, and autopsy results were reviewed. Results.-No patient had rib fractures. Conclusions.-Cardiopulmonary resuscitation is unlikely to cause rib fractures in infants.	UNIV MASSACHUSETTS,MED CTR,CHIEF MED EXAMINERS OFF,WORCESTER,MA	University of Massachusetts System; University of Massachusetts Worcester	SPEVAK, MR (corresponding author), UNIV MASSACHUSETTS,MED CTR,IMAGING CTR CHILD ABUSE & NEGLECT,DEPT RADIOL,WORCESTER,MA 01655, USA.							BEDELL SE, 1986, ARCH INTERN MED, V146, P1725, DOI 10.1001/archinte.146.9.1725; CAMERON JM, 1975, ATLAS BATTERED CHILD; FELDMAN KW, 1984, PEDIATRICS, V73, P339; KLEINMAN P K, 1989, Investigative Radiology, V24, pS132, DOI 10.1097/00004424-198912000-00235; KLEINMAN PK, 1987, DIAGNOSTIC IMAGING C, P67; KOUWENHOVEN WB, 1960, JAMA-J AM MED ASSOC, V173, P1064, DOI 10.1001/jama.1960.03020280004002; NAGEL EL, 1981, CRIT CARE MED, V9, P424, DOI 10.1097/00003246-198105000-00037; Patterson R H, 1974, Med Ann Dist Columbia, V43, P389; RIKER WL, 1969, PEDIATR CLIN N AM, V16, P661; THALER MM, 1962, NEW ENGL J MED, V267, P500, DOI 10.1056/NEJM196209062671009; THOMAS PS, 1987, ANN RADIOL, V20, P115	11	75	76	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 24	1994	272	8					617	618		10.1001/jama.272.8.617	http://dx.doi.org/10.1001/jama.272.8.617			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC398	8057518				2023-01-03	WOS:A1994PC39800032
J	DOWNER, SM; CODY, MM; MCCLUSKEY, P; WILSON, PD; ARNOTT, SJ; LISTER, TA; SLEVIN, ML				DOWNER, SM; CODY, MM; MCCLUSKEY, P; WILSON, PD; ARNOTT, SJ; LISTER, TA; SLEVIN, ML			PURSUIT AND PRACTICE OF COMPLEMENTARY THERAPIES BY CANCER-PATIENTS RECEIVING CONVENTIONAL TREATMENT	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To determine what proportion of oncology patients receiving conventional medical treatment also use complementary treatments; to assess which complementary treatments are the most popular and to assess patients' motivation for using them; to evaluate associated advantages and risks. Design-Postal screening questionnaire followed by semistructured interview. Setting-Two hospitals in inner London. Subjects-600 unselected oncology patients aged 18 or over who had known their diagnosis of cancer for at least three months. Main outcome measures-Prevalence and demography of use of complementary therapies; patients' motivation and expectations of complementary therapies; areas of satisfaction and dissatisfaction associated with conventional and complementary therapies. Results-415 (69%) patients returned the questionnaire. 16% had used complementary therapies. The most popular were healing, relaxation, visualisation, diets, homoeopathy, vitamins, herbalism, and the Bristol approach. Patients using complementary therapies tended to be younger, of higher social class, and female. Three quarters used two or more therapies. Therapies were mostly used for anticipated antitumour effect. Ill effects of diets and herb treatments were described. Satisfaction with both conventional and complementary therapies was high, although diets often caused difficulties. Patients using complementary therapies were less satisfied with conventional treatments, largely because of side effects and lack of hope of cure. Benefits of complementary therapies were mainly psychological. Conclusions-A sizeable percentage of patients receiving conventional treatments for cancer also use complementary therapies. Patient satisfaction with complementary therapies, other than dietary therapies, was high even without the hoped for anticancer effect. Patients reported psychological benefits such as hope and optimism.	UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL,DEPT MED ONCOL,LONDON EC1A 7BE,ENGLAND; UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL,DEPT RADIOTHERAPY,LONDON EC1A 7BE,ENGLAND	University of London; Queen Mary University London; University of London; Queen Mary University London			McCluskey, Peter J/H-7607-2013	McCluskey, Peter J/0000-0002-8177-1637				ALDRIDGE D, 1989, BRIT MED J, V299, P1211; BAGENAL FS, 1990, LANCET, V336, P1185; CASSILETH BR, 1984, ANN INTERN MED, V101, P105, DOI 10.7326/0003-4819-101-1-105; Dickson A C, 1985, Oncol Nurs Forum, V12, P49; FULDER S, 1982, STATUS COMPLEMENTARY; LERNER IJ, 1984, CANCER, V53, P815, DOI 10.1002/1097-0142(19840201)53:3+<815::AID-CNCR2820531334>3.0.CO;2-U; SIKORA K, 1970, CANCER CARE, V7, P9; SLEVIN ML, 1990, BRIT MED J, V300, P1458, DOI 10.1136/bmj.300.6737.1458; THOMAS KJ, 1991, BRIT MED J, V302, P207, DOI 10.1136/bmj.302.6770.207; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; 1986, ALTERNATIVE THERAPY	11	245	246	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 9	1994	309	6947					86	89		10.1136/bmj.309.6947.86	http://dx.doi.org/10.1136/bmj.309.6947.86			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW716	8038672	Green Published			2023-01-03	WOS:A1994NW71600015
J	DEPAUW, BE; DERESINSKI, SC; FELD, R; LANEALLMAN, EF; DONNELLY, JP				DEPAUW, BE; DERESINSKI, SC; FELD, R; LANEALLMAN, EF; DONNELLY, JP			CEFTAZIDIME COMPARED WITH PIPERACILLIN AND TOBRAMYCIN FOR THE EMPIRIC TREATMENT OF FEVER IN NEUTROPENIC PATIENTS WITH CANCER - A MULTICENTER RANDOMIZED TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article						CEFTAZIDIME; PIPERACILLIN; TOBRAMYCIN; NEUTROPENIA; FEVER	FEBRILE GRANULOCYTOPENIC PATIENTS; NEGATIVE BACILLARY INFECTIONS; ANTIBIOTIC-THERAPY; ANTIMICROBIAL THERAPY; PLUS PIPERACILLIN; INITIAL THERAPY; GENTAMICIN; CARBENICILLIN; CEPHALOTHIN; TICARCILLIN	Objective: To compare piperacillin and tobramycin with ceftazidime alone for the empiric treatment of fever in the neutropenic patient without evidence of skin infections or anaerobic infections. Design: A multicenter, randomized, controlled trial. Patients: 876 febrile, neutropenic episodes in 696 patients (83% acute leukemia or bone marrow transplantation); 92 episodes were excluded from analysis because of protocol violation. Interventions: Patients received either intravenous ceftazidime (2 g every 8 h) or piperacillin (12 to 18 g/d in 4 to 6 divided doses plus tobramycin (1.7 to 2.0 mg/kg body weight every 8 h). Treatment could be modified at any time at the discretion of the investigator. Measurements: Percentage of satisfactory response, eradication of the infecting organism, development of superinfections, and occurrence of adverse events. Results: As a single agent, ceftazidime was as effective as the combination of piperacillin and tobramycin (62.7% satisfactory responses compared with 61.1%; odds ratio, 1.07; 95% CI, 0.79 to 1.44; P > 0.2). Equivalent responses were also obtained in episodes of profound neutropenia (odds ratio, 0.76; CI, 0.43 to 1.33; P > 0.2). Infectious mortality was 6% for ceftazidime and 8% for the combination therapy. Eradication of the infecting organisms was achieved in 79% of bacteremic episodes treated with ceftazidime compared with 68% of the episodes treated with the combination therapy (odds ratio, 1.76; CI, 0.92 to 3.38; P = 0.08), and rates for gram-negative rod bacteremia were also similar (95% compared with 77%; odds ratio, 5.25; CI, 1.0 to 27.5; P = 0.03). Superinfections developed in 38 episodes in each group. An adverse event occurred in 8% of episodes treated with ceftazidime compared with 20% of episodes treated with combination therapy (P < 0.001). Conclusion: Ceftazidime alone was as effective but safer than the combination of piperacillin and tobramycin for the empiric treatment of febrile, neutropenic patients, even those with profound and prolonged granulocytopenia.	STANFORD UNIV, SCH MED, PALO ALTO, CA 94062 USA; PRINCESS MARGARET HOSP, TORONTO M4X 1K9, ON, CANADA; GLAXO GRP RES LTD, GREENFORD UB6 0HE, MIDDX, ENGLAND	Stanford University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; GlaxoSmithKline	DEPAUW, BE (corresponding author), UNIV NIJMEGEN ST RADBOUD HOSP, DIV HEMATOL, POB 9101, 6500 HB NIJMEGEN, NETHERLANDS.		Donnelly, J Peter/AAC-1041-2019	Donnelly, J Peter/0000-0002-8521-335X				BODEY GP, 1990, CANCER, V65, P9, DOI 10.1002/1097-0142(19900101)65:1<9::AID-CNCR2820650105>3.0.CO;2-C; BODEY GP, 1976, AM J MED SCI, V271, P179, DOI 10.1097/00000441-197603000-00006; BODEY GP, 1972, CANCER-AM CANCER SOC, V29, P1697, DOI 10.1002/1097-0142(197206)29:6<1697::AID-CNCR2820290638>3.0.CO;2-K; BRUMMETT RE, 1989, ANTIMICROB AGENTS CH, V33, P797, DOI 10.1128/AAC.33.6.797; CALANDRA T, 1987, NEW ENGL J MED, V317, P1692; CALANDRA T, 1993, ANN INTERN MED, V119, P584, DOI 10.7326/0003-4819-119-7_Part_1-199310010-00006; DEPAUW B, 1985, ANTIMICROB AGENTS CH, V28, P824, DOI 10.1128/AAC.28.6.824; DEPAUW BE, 1983, J ANTIMICROB CHEMOTH, V12, P93, DOI 10.1093/jac/12.suppl_A.93; DONNELLY JP, 1985, J INFECTION, V11, P205, DOI 10.1016/S0163-4453(85)93063-4; EISENBERG JM, 1987, ANN INTERN MED, V107, P900, DOI 10.7326/0003-4819-107-6-900; ELLIOTT CR, 1988, CLIN INVEST MED, V11, P327; FAINSTEIN V, 1984, ARCH INTERN MED, V144, P1766, DOI 10.1001/archinte.144.9.1766; FAINSTEIN V, 1983, J ANTIMICROB CHEMOTH, V12, P101, DOI 10.1093/jac/12.suppl_A.101; FELD R, 1985, ARCH INTERN MED, V145, P1083, DOI 10.1001/archinte.145.6.1083; FELD R, 1984, ARCH INTERN MED, V144, P1005, DOI 10.1001/archinte.144.5.1005; GRANOWETTER L, 1988, PEDIATR INFECT DIS J, V7, P165, DOI 10.1097/00006454-198803000-00006; HUGHES WT, 1987, NEW ENGL J MED, V316, P1627, DOI 10.1056/NEJM198706253162604; HUGHES WT, 1990, J INFECT DIS, V161, P381, DOI 10.1093/infdis/161.3.381; JOHNSON MP, 1990, J INFECT DIS, V162, P981, DOI 10.1093/infdis/162.4.981; KLASTERSKY J, 1988, EUR J CANCER CLIN ON, V24, pS35; MIDDLEMAN EL, 1972, CANCER-AM CANCER SOC, V30, P573, DOI 10.1002/1097-0142(197208)30:2<573::AID-CNCR2820300238>3.0.CO;2-O; NOVAKOVA I, 1990, SCAND J INFECT DIS, V22, P705, DOI 10.3109/00365549009027124; OHANLEY P, 1989, AM J MED, V87, P605; PICCART M, 1984, ANTIMICROB AGENTS CH, V26, P870, DOI 10.1128/AAC.26.6.870; PIZZO PA, 1986, NEW ENGL J MED, V315, P552, DOI 10.1056/NEJM198608283150905; RAMPHAL R, 1992, ANTIMICROB AGENTS CH, V36, P1062, DOI 10.1128/AAC.36.5.1062; RAMPHAL R, 1983, J ANTIMICROB CHEMOTH, V12, P81, DOI 10.1093/jac/12.suppl_A.81; ROLSTON KVI, 1992, ARCH INTERN MED, V152, P283, DOI 10.1001/archinte.152.2.283; SANDERS JW, 1991, J INFECT DIS, V164, P907, DOI 10.1093/infdis/164.5.907; SCHIMPFF S, 1971, NEW ENGL J MED, V284, P1061, DOI 10.1056/NEJM197105132841904; VERHAGEN CS, 1987, ANTIMICROB AGENTS CH, V31, P191, DOI 10.1128/AAC.31.2.191; WADE JC, 1981, AM J MED, V71, P983, DOI 10.1016/0002-9343(81)90324-7; WADE JC, 1989, J INFECT DIS S7, V11, pS1572; WINSTON DJ, 1991, ANN INTERN MED, V115, P849, DOI 10.7326/0003-4819-115-11-849; YOUNG LS, 1986, NEW ENGL J MED, V315, P580, DOI 10.1056/NEJM198608283150910; ZINNER SH, 1983, J CLIN ONCOL, V1, P597	36	183	187	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1994	120	10					834	844		10.7326/0003-4819-120-10-199405150-00004	http://dx.doi.org/10.7326/0003-4819-120-10-199405150-00004			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK458	8154643				2023-01-03	WOS:A1994NK45800004
J	NIGHTINGALE, SL				NIGHTINGALE, SL			NEW FOOD CODE PUBLISHED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1994, JAMA-J AM MED ASSOC, V271, P812	1	16	16	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 13	1994	271	14					1067	1067		10.1001/jama.271.14.1067	http://dx.doi.org/10.1001/jama.271.14.1067			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE228	8151837				2023-01-03	WOS:A1994NE22800006
J	CALANDRA, T; ZINNER, SH; VISCOLI, C; DEBOCK, R; GAYA, H; MEUNIER, F; KLASTERSKY, J; GLAUSER, MP; NINOVE, D; LANGENAEKEN, J; PAESMANS, M; GALAZZO, M; GIDDEY, M; BILLE, J; HADJDJILANI, A; MASSIMO, L; MORONI, C; CASTAGNOLA, E; SANZ, M; FERSTER, A; DEBOCK, R; MEUNIER, F; KLASTERSKY, J; PADMOS, A; GALLAGHER, J; COMETTA, A; GLAUSER, MP; CALANDRA, T; LOPEZ, A; MARTINEZDALMAU, A; POGLIANI, E; HEMMER, R; DICATO, M; RIES, F; PORCELLINI, A; LEGRAND, JC; PORCELLINI, A; ESTAVOYER, JM; FOLLATH, F; SEITANIDES, B; ZINNER, S; BROWNE, M; NIKOSKELAINEN, J; ROSSI, M; MASERA, G				CALANDRA, T; ZINNER, SH; VISCOLI, C; DEBOCK, R; GAYA, H; MEUNIER, F; KLASTERSKY, J; GLAUSER, MP; NINOVE, D; LANGENAEKEN, J; PAESMANS, M; GALAZZO, M; GIDDEY, M; BILLE, J; HADJDJILANI, A; MASSIMO, L; MORONI, C; CASTAGNOLA, E; SANZ, M; FERSTER, A; DEBOCK, R; MEUNIER, F; KLASTERSKY, J; PADMOS, A; GALLAGHER, J; COMETTA, A; GLAUSER, MP; CALANDRA, T; LOPEZ, A; MARTINEZDALMAU, A; POGLIANI, E; HEMMER, R; DICATO, M; RIES, F; PORCELLINI, A; LEGRAND, JC; PORCELLINI, A; ESTAVOYER, JM; FOLLATH, F; SEITANIDES, B; ZINNER, S; BROWNE, M; NIKOSKELAINEN, J; ROSSI, M; MASERA, G			EFFICACY AND TOXICITY OF SINGLE DAILY DOSES OF AMIKACIN AND CEFTRIAXONE VERSUS MULTIPLE DAILY DOSES OF AMIKACIN AND CEFTAZIDIME FOR INFECTION IN PATIENTS WITH CANCER AND GRANULOCYTOPENIA	ANNALS OF INTERNAL MEDICINE			English	Article						DOSE-RESPONSE RELATIONSHIP, DRUG; AMIKACIN; CEFTAZIDIME; CEFTRIAXONE; DRUG TOXICITY	EMPIRIC ANTIBIOTIC-THERAPY; BETA-LACTAM COMBINATION; RANDOMIZED TRIAL; PLUS AMIKACIN; NEUTROPENIC CHILDREN; AUDITORY TOXICITY; FEBRILE; AMINOGLYCOSIDE; NETILMICIN; TOBRAMYCIN	Objective. To compare the efficacy and toxicity of single daily dosing of amikacin and ceftriaxone with that of multiple daily dosing of amikacin and ceftazidime for febrile episodes in patients with cancer and granulocytopenia. Design: A prospective, randomized, unblinded, multicenter trial. Setting: Twenty-one tertiary care or university medical centers. Patients: Six hundred seventy-seven patients with cancer and granulocytopenia (858 febrile episodes). Interventions: Random assignment to empiric therapy with a single daily dose of amikacin (20 mg/kg) and ceftriaxone (adults, 30 mg/kg; children, 80 mg/kg) (24-hour group) or with multiple daily doses of amikacin (6.5 mg/kg every 8 hours) and ceftazidime (33 mg/kg every 8 hours) (8-hour group). Measurements: Percentage response to each regimen and occurrence of nephrotoxicity and ototoxicity. Results. Single daity dosing of amikacin and ceftriaxone was as effective as multiple daily dosing of amikacin and ceftazidime (71% compared with 74%; difference, -3%; 95% CI, -10% to 3%; P > 0.2). Equivalent responses also were noted for each category of infection. Median peak (30 minutes after a 60-minute infusion) serum concentrations of amikacin were higher in the 24-hour group than in the 8-hour group (45.6 compared with 21 mug/mL, P < 0.001), whereas trough (preinfusion) levels were lower (0.9 compared with 2 mug/mL, P < 0.001). Nephrotoxicity was 3% in the 24-hour group and 2% in the 8-hour group (difference, 1%; CI, -1% to 4%). Increases in serum creatinine, however, were delayed (P = 0.048) and smaller (P = 0.06) in the 24-hour group than in the 8-hour group and occurred almost exclusively after other nephrotoxic drugs were added. Audiometry was only done in 144 patients (21%). Ototoxicity was 9% in the 24-hour group and 7% in the 8-hour group (difference, 2%; CI, -7% to 11 %; P > 0.2). Further infections developed in 15% and 12% of patients, respectively (difference, 3%; CI, -2% to 9%). The overall mortality rate was 11% in both treatment groups (difference, 0%; CI, -5% to 5%). Conclusions: Single daily dosing of amikacin and ceftriaxone was as effective and no more toxic than multiple daily dosing of amikacin and ceftazidime for the empiric therapy of infection in patients with cancer and granulocytopenia.	ROGER WILLIAMS GEN HOSP, DEPT MED, DIV INFECT DIS, PROVIDENCE, RI 02908 USA; INST JULES BORDET, DEPT MED, B-1000 BRUSSELS, BELGIUM; CHU VAUDOIS, DEPT INTERNAL MED, DIV INFECT DIS, CH-1011 LAUSANNE, SWITZERLAND; IST GIANNINA GASLINI, I-16148 GENOA, ITALY; HOSP UNIV LA FE, VALENCIA, SPAIN; HOP UNIV ENFANTS, BRUSSELS, BELGIUM; UNIV ZIEKENHUIS ANTWERPEN, EDEGEM, BELGIUM; KING FAISAL SPECIALIST HOSP & RES CTR, RIYADH, SAUDI ARABIA; GEISINGER MED CLIN, CTR CANC, DANVILLE, PA USA; HOSP GEN VALLE HEBRON, BARCELONA, SPAIN; HOSP XERAL VIGO, VIGO, SPAIN; OSPED SAN GERARDO, MONZA, ITALY; CTR HOSP LUXEMBOURG, LUXEMBOURG, LUXEMBOURG; OSPED CIVILE, PESARO, ITALY; HOP CIVIL, CHARLEROI, BELGIUM; CTR TRAPIANTI MIDOLLO OSSEO, CREMONA, ITALY; CHU BESANCON, F-25030 BESANCON, FRANCE; KANTONSSPITAL, CH-4004 BASEL, SWITZERLAND; METAXAS MEM HOSP, PIRAEUS, GREECE; UNIV TURKU, CENT HOSP, SF-20520 TURKU 52, FINLAND; OSPED MONZA, MONZA, ITALY	Roger Williams Medical Center; Institut Jules Bordet; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Genoa; IRCCS Istituto Giannina Gaslini; Hospital Universitari i Politecnic La Fe; University of Antwerp; King Faisal Specialist Hospital & Research Center; Geisinger Medical Center; Hospital Universitari Vall d'Hebron; Complexo Hospitalario Universitario de Vigo; San Gerardo Hospital; Luxembourg Hospital Center; Universite de Franche-Comte; CHU Besancon; Kantonsspital Aarau AG (KSA); University of Basel; University of Turku	CALANDRA, T (corresponding author), PICOWER INST MED RES, 350 COMMUNITY DR, MANHASSET, NY 11030 USA.		Castagnola, Elio/J-4454-2016; Castagnola, Elio/C-1865-2012; Sanz, Miguel A./F-7485-2018; Calandra, Thierry/D-9017-2015	Castagnola, Elio/0000-0002-5336-8429; Castagnola, Elio/0000-0002-5336-8429; Sanz, Miguel A./0000-0003-1489-1177; Calandra, Thierry/0000-0003-3051-1285				BARZA M, 1980, ANTIMICROB AGENTS CH, V17, P707, DOI 10.1128/AAC.17.4.707; BENDER JF, 1978, J INFECT DIS, V137, P14; BLASER J, 1985, ANTIMICROB AGENTS CH, V27, P343, DOI 10.1128/AAC.27.3.343; BODEY GP, 1979, AM J MED, V67, P608, DOI 10.1016/0002-9343(79)90242-0; BRUMMETT RE, 1989, ANTIMICROB AGENTS CH, V33, P797, DOI 10.1128/AAC.33.6.797; CALANDRA T, 1987, NEW ENGL J MED, V317, P1692; CALANDRA T, 1991, J INFECT DIS, V163, P951; Calandra T, 1991, Infect Dis Clin North Am, V5, P817; DEJONGH CA, 1986, AM J MED, V80, P101; Dixon W. J., 1990, BMDP STATISTICAL SOF; FAINSTEIN V, 1983, J ANTIMICROB CHEMOTH, V12, P101, DOI 10.1093/jac/12.suppl_A.101; FAN ST, 1988, J ANTIMICROB CHEMOTH, V22, P69, DOI 10.1093/jac/22.1.69; FELD R, 1985, ARCH INTERN MED, V145, P1083, DOI 10.1001/archinte.145.6.1083; GERBER AU, 1985, J ANTIMICROB CHEMOTH, V15, P201, DOI 10.1093/jac/15.suppl_A.201; GILBERT DN, 1991, ANTIMICROB AGENTS CH, V35, P399, DOI 10.1128/AAC.35.3.399; HANSEN M, 1988, Journal of Drug Development, V1, P119; ISENBERG HD, 1991, MANUAL CLIN MICROBIO, P2; KAFETZIS DA, 1991, J ANTIMICROB CHEMOTH, V27, P105, DOI 10.1093/jac/27.suppl_C.105; KLASTERSKY J, 1986, ANTIMICROB AGENTS CH, V29, P263, DOI 10.1128/AAC.29.2.263; LAU WK, 1977, AM J MED, V62, P959, DOI 10.1016/0002-9343(77)90669-6; LERNER AM, 1983, LANCET, V1, P1123; Lerner S A, 1980, Am J Otolaryngol, V1, P169, DOI 10.1016/S0196-0709(80)80012-3; LERNER SA, 1986, AM J MED, V80, P98, DOI 10.1016/0002-9343(86)90486-9; LEVISON ME, 1992, ANN INTERN MED, V117, P693, DOI 10.7326/0003-4819-117-8-693; LOVE LJ, 1979, AM J MED, V66, P603, DOI 10.1016/0002-9343(79)91170-7; MALLER R, 1991, J ANTIMICROB CHEMOTH, V27, P121, DOI 10.1093/jac/27.suppl_C.121; MALLER R, 1988, J ANTIMICROB CHEMOTH, V22, P75, DOI 10.1093/jac/22.1.75; MATTIE H, 1989, J ANTIMICROB CHEMOTH, V24, P281, DOI 10.1093/jac/24.3.281; MEUNIER F, 1991, ANTIMICROB AGENTS CH, V35, P873, DOI 10.1128/AAC.35.5.873; MEUNIER F, 1991, J ANTIMICROB CHEMOTH, V27, P129, DOI 10.1093/jac/27.suppl_C.129; MOORE RD, 1984, ANN INTERN MED, V100, P352, DOI 10.7326/0003-4819-100-3-352; NORDSTROM L, 1990, J ANTIMICROB CHEMOTH, V25, P159, DOI 10.1093/jac/25.1.159; NOVAKOVA I, 1991, ANTIMICROB AGENTS CH, V35, P672, DOI 10.1128/AAC.35.4.672; PIZZO PA, 1986, NEW ENGL J MED, V315, P552, DOI 10.1056/NEJM198608283150905; POWELL SH, 1983, J INFECT DIS, V147, P918, DOI 10.1093/infdis/147.5.918; PRINS JM, 1993, LANCET, V341, P335, DOI 10.1016/0140-6736(93)90137-6; ROLSTON KVI, 1992, ARCH INTERN MED, V152, P283, DOI 10.1001/archinte.152.2.283; Sahm D.H., 1991, MANUAL CLIN MICROBIO; Shamody H. J., 1991, MANUAL CLIN MICROBIO, V5, P1117; SHENEP JL, 1988, NEW ENGL J MED, V319, P1053, DOI 10.1056/NEJM198810203191604; SMITH CR, 1977, NEW ENGL J MED, V296, P350, DOI 10.1056/NEJM197702172960701; SMITH CR, 1980, NEW ENGL J MED, V302, P1106, DOI 10.1056/NEJM198005153022002; STURM AW, 1989, J INFECT DIS, V159, P931, DOI 10.1093/infdis/159.5.931; TERBRAAK EW, 1990, AM J MED, V89, P58, DOI 10.1016/0002-9343(90)90099-Y; TULKENS P M, 1988, Journal of Drug Development, V1, P71; VANDERAUWERA P, 1987, ANTIMICROB AGENTS CH, V31, P1061, DOI 10.1128/AAC.31.7.1061; VISCOLI C, 1991, REV INFECT DIS, V13, P397; VISCOLI C, 1991, J ANTIMICROB CHEMOTH, V27, P113, DOI 10.1093/jac/27.suppl_C.113; VOGELMAN B, 1986, J PEDIATR-US, V108, P835, DOI 10.1016/S0022-3476(86)80754-5; WADE JC, 1978, LANCET, V2, P604; WINSTON DJ, 1991, ANN INTERN MED, V115, P849, DOI 10.7326/0003-4819-115-11-849; WINSTON DJ, 1984, AM J MED, V77, P442, DOI 10.1016/0002-9343(84)90100-1; ZINNER SH, 1983, J CLIN ONCOL, V1, P597; [No title captured]	54	184	187	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1993	119	7	1				584	593		10.7326/0003-4819-119-7_Part_1-199310010-00006	http://dx.doi.org/10.7326/0003-4819-119-7_Part_1-199310010-00006			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA291	8363169				2023-01-03	WOS:A1993MA29100006
J	HYMAN, FN; SEMPOS, E; SALTSMAN, J; GLINSMANN, WH				HYMAN, FN; SEMPOS, E; SALTSMAN, J; GLINSMANN, WH			EVIDENCE FOR SUCCESS OF CALORIC RESTRICTION IN WEIGHT-LOSS AND CONTROL - SUMMARY OF DATA FROM INDUSTRY	ANNALS OF INTERNAL MEDICINE			English	Article							OBESITY; DIET; MAINTENANCE; PROGRAM	Data voluntarily supplied by industry were examined to evaluate the success of commercial weight loss programs and products. Information about the safe loss of weight, the maintenance of this lowered weight, and resultant health benefits were reviewed. Information was received from companies that produce over-the-counter preparations designed for persons with a small weight loss goal and from physician-supervised programs for morbidly obese persons placed on very-low-calorie diets. Regardless of the products used, successful weight loss and control was limited and required individualized programs consisting of restricted caloric intake, behavior modification, and exercise. Although some manufacturers of physician-supervised weight loss products for obese persons have defined the effectiveness of their programs with controlled clinical studies, other industry programs have only begun to accurately assess their effectiveness or safety. Given the importance to public health of reducing obesity, rigorous studies on current weight control practices should be pursued aggressively.			HYMAN, FN (corresponding author), USDA, DIV NUTR, WASHINGTON, DC 20204 USA.							ANDERSON JW, 1991, J AM DIET ASSOC, V91, P1582; BRADLEY MH, 1990, CURR THER RES CLIN E, V47, P429; BURGESS NS, 1991, J AM DIET ASSOC, V91, P430; DONNELLY JE, 1991, AM J CLIN NUTR, V54, P56, DOI 10.1093/ajcn/54.1.56; FRIIS R, 1987, J CLIN GASTROENTEROL, V9, P204, DOI 10.1097/00004836-198704000-00019; FUKUDA M, 1989, DIABETES RES CLIN PR, V7, P61, DOI 10.1016/0168-8227(89)90047-8; GATENBY SJ, 1991, INT J OBESITY S1, V15, P29; HEBER D, 1990, INT J OBESITY S2, V14, P106; HOVELL MF, 1988, AM J PUBLIC HEALTH, V78, P663, DOI 10.2105/AJPH.78.6.663; KANDERS BS, 1989, INT J OBESITY, V13, P131; Kirschner M A, 1979, J Med Soc N J, V76, P175; KIRSCHNER MA, 1988, INT J OBESITY, V12, P69; LOCKWOOD DH, 1984, ANNU REV MED, V35, P373, DOI 10.1146/annurev.med.35.1.373; MIURA J, 1989, INT J OBESITY, V13, P73; PAVLOU KN, 1989, AM J CLIN NUTR, V49, P1115, DOI 10.1093/ajcn/49.5.1115; SURATT PM, 1987, CHEST, V92, P631, DOI 10.1378/chest.92.4.631; WADDEN TA, 1990, JAMA-J AM MED ASSOC, V263, P83, DOI 10.1001/jama.263.1.83; WADDEN TA, 1992, IN PRESS ARCH INT ME; WILLIAMSON DF, 1992, AM J PUBLIC HEALTH, V82, P1251, DOI 10.2105/AJPH.82.9.1251	19	22	22	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1993	119	7	2				681	687		10.7326/0003-4819-119-7_Part_2-199310011-00011	http://dx.doi.org/10.7326/0003-4819-119-7_Part_2-199310011-00011			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA330	8363197				2023-01-03	WOS:A1993MA33000011
J	SOUMERAI, SB; SALEMSCHATZ, S; AVORN, J; CASTERIS, CS; ROSSDEGNAN, D; POPOVSKY, MA				SOUMERAI, SB; SALEMSCHATZ, S; AVORN, J; CASTERIS, CS; ROSSDEGNAN, D; POPOVSKY, MA			A CONTROLLED TRIAL OF EDUCATIONAL OUTREACH TO IMPROVE BLOOD-TRANSFUSION PRACTICE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRACTICE GUIDELINES; DECISION-MAKING; STRATEGIES; SURGERY; POLICY; CARE	Objective.-To determine whether brief, face-to-face educational outreach visits can improve the appropriateness of blood product utilization. Design.-Randomized, controlled multicenter trial with 6-month follow-up. Setting.-Surgical and medical services of two pairs of matched community and teaching hospitals in Massachusetts. Participants.-One hundred one transfusing staff surgeons and attending medical physicians. Intervention.-A professionally based transfusion specialist presented one surgical- or medical-service-wide lecture emphasizing appropriate indications, risks, and benefits of red blood cell transfusions; brief, graphic, printed educational guidelines; and one 30-minute visit with each transfusing physician. No data feedback was provided. Educational messages emphasized the lack of utility of the traditional threshold for red blood cell transfusions (hematocrit, 30%) and transfusion risks (eg, viral hepatitis). Measures.-Proportion of red blood cell transfusions classified as compliant or noncompliant with blood transfusion guidelines, or indeterminate 6 months before and 6 months after an experimental educational intervention. Results.-Based on analyses of 1449 medical record audits of red blood cell transfusions that occurred 6 months before and 6 months after the educational intervention, the average proportion of transfusions not in compliance with criteria declined from 0.40 to 0.24 among study surgeons (-40%) compared with an increase from 0.40 to 0.44 (+9%) among control surgeons (P=.006). These effects were consistent across procedure type and specialty. On average, study surgeons in the postintervention period performed transfusions when hematocrits were 2.0 percentage points lower than before the intervention (28.3% preintervention vs 26.3% postintervention), and lower than in the control group (28.3% preintervention and postintervention; P=.04). Likely savings in blood use for surgical services probably exceeded program costs, even without considering reduced risks of infection. No effects were observed among transfusions occurring in medical services, possibly because of substantially lower transfusion rates and lower pretransfusion hematocrits. Conclusions.-Brief, focused educational outreach visits by transfusion specialists can substantially improve the appropriateness and cost-effectiveness of blood product use in surgery. More data are needed regarding the durability of changes in practice patterns and the health and economic benefits of such interventions.	HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,PROGRAM ANAL CLIN STRATEGIES,BOSTON,MA 02115; AMER RED CROSS,BLOOD SERV,NE REG,DEDHAM,MA; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT MED,BOSTON,MA 02215	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; American Red Cross; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	SOUMERAI, SB (corresponding author), HARVARD UNIV,SCH MED,DEPT SOCIAL MED,643 HUNTINGTON AVE,2ND FLOOR,BOSTON,MA 02115, USA.				AHRQ HHS [HSO5300] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ALTER HJ, 1989, CURRENT PERSPECTIVES, P83; [Anonymous], 1977, 9 REV C; AVORN J, 1983, NEW ENGL J MED, V308, P1457, DOI 10.1056/NEJM198306163082406; BLUMBERG N, 1986, TRANSFUSION, V26, P511, DOI 10.1046/j.1537-2995.1986.26687043615.x; DODD RY, 1992, NEW ENGL J MED, V327, P419, DOI 10.1056/NEJM199208063270610; FORBES JM, 1991, TRANSFUSION, V31, P318, DOI 10.1046/j.1537-2995.1991.31491213295.x; GOODNOUGH LT, 1991, JAMA-J AM MED ASSOC, V265, P86, DOI 10.1001/jama.265.1.86; LOMAS J, 1991, JAMA-J AM MED ASSOC, V265, P2202, DOI 10.1001/jama.265.17.2202; LOMAS J, 1989, NEW ENGL J MED, V321, P1306, DOI 10.1056/NEJM198911093211906; MOZES B, 1989, TRANSFUSION, V29, P473, DOI 10.1046/j.1537-2995.1989.29689318442.x; PALERMO G, 1980, TRANSFUSION, V20, P704, DOI 10.1046/j.1537-2995.1980.20681057160.x; RASKIN IE, 1991, EVAL HEALTH PROF, V14, P161, DOI 10.1177/016327879101400203; SALEMSCHATZ SR, 1990, JAMA-J AM MED ASSOC, V264, P476, DOI 10.1001/jama.264.4.476; SALEMSCHATZ SR, IN PRESS MED CARE; SNEDECOR GW, 1985, JAMA-J AM MED ASSOC, V253, P1774; SOUMERAI SB, 1984, MILBANK FUND Q, V62, P447, DOI 10.2307/3349860; SOUMERAI SB, 1986, MED CARE, V24, P313, DOI 10.1097/00005650-198604000-00003; SOUMERAI SB, 1989, MILBANK Q, V67, P268, DOI 10.2307/3350142; SOUMERAI SB, 1990, JAMA-J AM MED ASSOC, V263, P549, DOI 10.1001/jama.263.4.549; SURGENOR DM, 1990, NEW ENGL J MED, V322, P1646, DOI 10.1056/NEJM199006073222306; TARTTER PI, 1985, TRANSFUSION, V25, P113, DOI 10.1046/j.1537-2995.1985.25285169199.x; TRIULZI DJ, 1992, SURGERY, V32, P517; WALKER RH, 1987, AM J CLIN PATHOL, V88, P374, DOI 10.1093/ajcp/88.3.374; WATKINS GM, 1974, SURG GYNECOL OBSTET, V139, P161; WELCH HG, 1992, ANN INTERN MED, V116, P393, DOI 10.7326/0003-4819-116-5-393; 1992, ANN INTERN MED, V116, P403	26	158	158	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	1993	270	8					961	966		10.1001/jama.270.8.961	http://dx.doi.org/10.1001/jama.270.8.961			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LT567	8123097	Green Submitted			2023-01-03	WOS:A1993LT56700027
J	Tucker, JS; Hall, MH; Howie, PW; Reid, ME; Barbour, RS; Florey, CD; McIlwaine, GM				Tucker, JS; Hall, MH; Howie, PW; Reid, ME; Barbour, RS; Florey, CD; McIlwaine, GM			Should obstetricians see women with normal pregnancies? A multicentre randomised controlled trial of routine antenatal care by general practitioners and midwives compared with shared care led by obstetricians	BRITISH MEDICAL JOURNAL			English	Article							HYPERTENSION	Objective-To compare routine antenatal care provided by general practitioners and midwives with obstetrician led shared care. Design-Multicentre randomised controlled trial. Setting-51 general practices linked to nine Scottish maternity hospitals. Subjects-1765 women at low risk of antenatal complications. Intervention-Routine antenatal care by general practitioners and midwives according to a care plan and protocols for managing complications. Main outcome measures-Comparisons of health service use, indicators of quality of care, and women's satisfaction. Results-Continuity of carer was improved for the general practitioner and midwife group as the number of carers was less (median 5 carers v 7 for shared care group, P < 0.0001) and the number of routine visits reduced (10.9 v 11.7, P < 0.0001). Fewer women in the general practitioner and midwife group had antenatal admissions (27% (222/834) v 32% (266/840), P < 0.05), non-attendances (7% (57) v 11% (89), P < 0.01) and daycare (12% (102) v 7% (139), P < 0.05) but more were referred (49% (406) v 36% (305), P < 0.0001). Rates of antenatal diagnoses did not differ except that fewer women in the general practitioner and midwife group had hypertensive disorders (pregnancy induced hypertension, 5% (37) v 8% (70), P < 0.01) and fewer had labour induced (18% (149) v 24% (201), P < 0.01). Few failures to comply with the care protocol occurred, but more Rhesus negative women in the general practitioner and midwife group did not have an appropriate antibody check (2.5% (20) v 0.4% (3), P < 0.0001). Both groups expressed high satisfaction with care (68% (453/663) v 65% (430/656), P=0.5) and acceptability of allocated style of care (93% (618) v 94% (624), P=0.6). Access to hospital support before labour was similar (45% (302) v 48% (312) visited labour rooms before giving birth, P=0.6). Conclusion-Routine specialist visits for women initially at low risk of pregnancy complications offer little or no clinical or consumer benefit.	ABERDEEN MATERN HOSP,DEPT OBSTET & GYNAECOL,ABERDEEN AB9 2ZA,SCOTLAND; UNIV DUNDEE,DEPT OBSTET & GYNAECOL,DUNDEE,SCOTLAND; UNIV GLASGOW,DEPT PUBL HLTH,GLASGOW G12 8RZ,LANARK,SCOTLAND; UNIV GLASGOW,DEPT SOCIAL & ECON RES,GLASGOW G12 8RZ,LANARK,SCOTLAND; UNIV HULL,DEPT PUBL HLTH MED,KINGSTON HULL HU6 7RX,N HUMBERSIDE,ENGLAND; GREATER GLASGOW HLTH BOARD,DEPT PUBL HLTH,GLASGOW G2 4JT,LANARK,SCOTLAND	University of Aberdeen; University of Dundee; University of Glasgow; University of Glasgow; University of Hull	Tucker, JS (corresponding author), UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT EPIDEMIOL & PUBL HLTH,DUNDEE DD1 9SY,SCOTLAND.		Sandall, Jane/D-4146-2009	Sandall, Jane/0000-0003-2000-743X				DAWSON A, 1994, HOME ANTENATAL CARE; Dean A. G., 1990, EPI INFO VERSION 5 W; *DEP HLTH SOC SERV, 1982, 1 DHSS MAT SERV ADV; *EXP MAT GROUP, 1993, CHANG CHILDB REP EXP; *GRAMP AR MAT SERV, 1989, GRAMP INT ANT CAR SC; HALL MH, 1980, LANCET, V2, P78; *HC HLTH COMM, 1992, 2 HC HLTH COMM MAT S, V1; Hill A M, 1993, Qual Health Care, V2, P152, DOI 10.1136/qshc.2.3.152; HOFMEYR GJ, 1991, BRIT J OBSTET GYNAEC, V98, P756, DOI 10.1111/j.1471-0528.1991.tb13479.x; JAMES JK, 1995, BRIT MED J, V310, P37; LITTLE BC, 1984, LANCET, V1, P865; MANCIA G, 1983, LANCET, V2, P695; Mason V., 1989, WOMENS EXPERIENCE MA; MCILWAINE GM, 1992, DHHS PUBLICATION PHS, P56; Ministry of Health, 1929, MAT MORT CHILDB ANT; PICKERING TG, 1988, JAMA-J AM MED ASSOC, V259, P225, DOI 10.1001/jama.259.2.225; Pocock SJ., 2013, CLIN TRIALS PRACTICA; PORTER M, 1984, SOC SCI MED, V19, P1197, DOI 10.1016/0277-9536(84)90370-8; REID M, 1983, COMP DELIVERY ANTENA; ROBERTSON WB, 1987, HYPERTENS PREGNANCY, P101; ROBSON J, 1986, J ROY COLL GEN PRACT, V36, P274; *ROYAL COLL OBST G, 1982, REP RCOG WORK PART A; *SCOTT OFF HOM HLT, 1993, PROV MAT SERV SCOTL; *SPSS INC, 1993, SPSS WIND REL 6; THOMAS H, 1987, J ROY COLL GEN PRACT, V37, P544; TUCKER J, 1994, J PUBLIC HEALTH MED, V16, P60, DOI 10.1093/oxfordjournals.pubmed.a042937; TURNBULL D, 1995, ESTABLISHMENT MIDWIF; WALKER P, 1995, BRIT MED J, V310, P36, DOI 10.1136/bmj.310.6971.36; WOOD J, 1991, BRIT J GEN PRACT, V41, P26	29	65	65	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 2	1996	312	7030					554	559		10.1136/bmj.312.7030.554	http://dx.doi.org/10.1136/bmj.312.7030.554			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TY885	8595287	Green Published			2023-01-03	WOS:A1996TY88500029
J	Price, D				Price, D			Lessons for health care rationing from the case of child B	BRITISH MEDICAL JOURNAL			English	Article								More details have emerged about the child B leukaemia case with the publication of the All England Law Report on the Appeal Court decision. At the time the view was widely held that the controversy might have been avoided if the responsible health authority had consulted the public. The law report reveals, however, that the courts adopted a moral language widely at variance with that of the patient's doctor. The courts were concerned to support a utilitarian decision procedure based on calculations of the greatest overall good; the doctor was concerned with the best interests of a sick child. The doctor-patient relationship may be damaged when public consideration transforms the issue in this way. Also, the Appeal Court supported a decision which claimed to have ''weighed'' opposing evaluations, but it excused the health authority from describing how that weighing took place. One of the main criticisms of the utilitarian approach, however, is that weighing of this type is extremely difficult to justify. By its ruling the court has made legal challenge on the grounds of inadequate consultation virtually impossible to substantiate.			Price, D (corresponding author), NORTHUMBRIA UNIV,SOCIAL WELFARE RES UNIT,NEWCASTLE TYNE NE1 8ST,TYNE & WEAR,ENGLAND.		Price, Donald D./A-3094-2008	Price, Donald D./0000-0002-8971-7184				HALL C, 1995, INDEPENDENT     0311, P1; SMITH R, 1995, BRIT MED J, V310, P686, DOI 10.1136/bmj.310.6981.686	2	14	14	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 20	1996	312	7024					167	169						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TR325	8563539				2023-01-03	WOS:A1996TR32500027
J	Vento, S; Cainelli, F; Mirandola, F; Cosco, L; DiPerri, G; Solbiati, M; Ferraro, T; Concia, E				Vento, S; Cainelli, F; Mirandola, F; Cosco, L; DiPerri, G; Solbiati, M; Ferraro, T; Concia, E			Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus	LANCET			English	Article							NON-B HEPATITIS; NON-A; IMMUNOSUPPRESSIVE THERAPY; RNA	Background Fulminant hepatitis on withdrawal of chemotherapy has boon described in chronic hepatitis B virus infection, but not in hepatitis C virus (HCV) infection. The relation beween HCV and immune response to this virus, and disease severity, has not been examined. We present two patients with HCV who developed fulminant liver failure after chemotherapy was stopped. Patients and findings Two patients with chronic HCV infection and malignant lymphoma received chemotherapy (cyclophosphamide, adriamycin, vincristine, bleomycin, etoposide, and prednisolone in patient 1; doxorubicin, bleomycin, vinblastine, and dacarbazine in patient 2), on withdrawal of which both developed fulminant hepatitis. Alanine aminotransferase (ALT) concentrations were greatly raised (6030 and 3870 IU/L in patients 1 and 2, respectively), and serum HCV-RNA was low in both patients when severe disease developed (10(2) genome equivalents per mL). Patient 1 died, and necropsy showed massive liver necrosis. Interpretation The findings suggest an immune-mediated mechanism for hepatocyte damage in HCV infection. Careful monitoring of ALT concentrations is necessary in such patients during and after chemotherapy.	A PUGLIESE HOSP,INFECT DIS UNIT,CATANZARO,ITALY		Vento, S (corresponding author), UNIV VERONA,DEPT INFECT DIS,VIA LOCCHI 12,I-37124 VERONA,ITALY.		Vento, Sandro/I-1662-2017	Vento, Sandro/0000-0003-0084-4062; Cainelli, Francesca/0000-0003-1838-3946				BIRD GLA, 1989, Q J MED, V73, P895; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COCK KM, 1986, ANN INTERN MED, V105, P546; CRISTIANO K, 1991, HEPATOLOGY, V14, P51, DOI 10.1002/hep.1840140109; DIENES HP, 1982, HEPATOLOGY, V2, P562; FAN FS, 1991, BONE MARROW TRANSPL, V8, P417; FONG TL, 1994, GASTROENTEROLOGY, V107, P196, DOI 10.1016/0016-5085(94)90077-9; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; MANZINI P, 1995, HEPATOLOGY, V21, P328, DOI 10.1016/0270-9139(95)90088-8; SIMMONDS P, 1993, J GEN VIROL, V74, P2391, DOI 10.1099/0022-1317-74-11-2391; Urdea M S, 1991, Nucleic Acids Symp Ser, P197; WRIGHT TL, 1991, ANN INTERN MED, V115, P111, DOI 10.7326/0003-4819-115-2-111	12	139	142	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 13	1996	347	8994					92	93		10.1016/S0140-6736(96)90212-3	http://dx.doi.org/10.1016/S0140-6736(96)90212-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP281	8538348				2023-01-03	WOS:A1996TP28100011
J	HUNTINGTON, J; CONNELL, FA				HUNTINGTON, J; CONNELL, FA			FOR EVERY DOLLAR SPENT - THE COST SAVINGS ARGUMENT FOR PRENATAL-CARE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							LOW-BIRTH-WEIGHT; MEDICAID; PROJECT; IMPACT; INFANT; BARRIERS; WOMEN		UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,DEPT HLTH SERV,SEATTLE,WA 98195; GRP HLTH COOPERAT PUGET SOUND,SEATTLE,WA 98112	University of Washington; University of Washington Seattle; Group Health Cooperative					PHS HHS [MCJ 9043] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BUESCHER PA, 1987, AM J OBSTET GYNECOL, V156, P204, DOI 10.1016/0002-9378(87)90239-0; CURRY M, 1987, ACCESS PRENATAL CARE; ENKIN M, 1982, CLIN DEV MED, V81, P266; GORSKY RD, 1989, HEALTH SERV RES, V24, P583; GUYER B, 1990, JAMA-J AM MED ASSOC, V264, P2264, DOI 10.1001/jama.264.17.2264; HAAS JS, 1993, JAMA-J AM MED ASSOC, V269, P87, DOI 10.1001/jama.269.1.87; HALL MH, 1980, LANCET, V2, P78; Huntington JL, 1913, BOSTON MED SURG J, V169, P763, DOI 10.1056/NEJM191311201692108; KORENBROT CC, 1984, MOBIUS, V4, P34; Lazarus E S, 1990, Med Anthropol, V12, P269; Leavitt J.W., 1986, BROUGHT BED CHILDBEA; Lennie J A, 1987, Health Care Financ Rev, V8, P83; LEPPERT PC, 1985, J NURSE-MIDWIFERY, V30, P285, DOI 10.1016/0091-2182(85)90044-8; LEVENO KJ, 1985, OBSTET GYNECOL, V66, P599; MOORE TR, 1986, AM J OBSTET GYNECOL, V154, P29, DOI 10.1016/0002-9378(86)90387-X; Morales W J, 1985, J Fla Med Assoc, V72, P852; OAKLEY A, 1990, BRIT J OBSTET GYNAEC, V97, P155, DOI 10.1111/j.1471-0528.1990.tb01741.x; PEOPLES MD, 1984, AM J PUBLIC HEALTH, V74, P549, DOI 10.2105/AJPH.74.6.549; PIPER JM, 1990, JAMA-J AM MED ASSOC, V264, P2219, DOI 10.1001/jama.264.17.2219; POLAND ML, 1987, AM J OBSTET GYNECOL, V157, P297, DOI 10.1016/S0002-9378(87)80156-4; SARDELL A, 1990, J HEALTH POLIT POLIC, V15, P271, DOI 10.1215/03616878-15-2-271; SCHRAMM WF, 1992, PUBLIC HEALTH REP, V107, P647; SCHWARTZ RM, 1989, FAM PLANN PERSPECT, V21, P170, DOI 10.2307/2135808; SOKOL RJ, 1980, OBSTET GYNECOL, V56, P150; STCLAIR PA, 1990, PUBLIC HEALTH REP, V105, P264; STROBINO DM, 1986, AM J PUBLIC HEALTH, V76, P274, DOI 10.2105/AJPH.76.3.274; Thompson JE, 1990, NEW PERSPECTIVES PAR, P9; Wertz Richard W., 1989, LYING HIST CHILDBIRT; WILSON AL, 1992, AM J PERINAT, V9, P281, DOI 10.1055/s-2007-994790; 1988, OTAH345 OFF TECHN AS; [No title captured]	31	70	71	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 10	1994	331	19					1303	1307		10.1056/NEJM199411103311910	http://dx.doi.org/10.1056/NEJM199411103311910			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PP752	7935689				2023-01-03	WOS:A1994PP75200010
J	ASHTON, LJ; LEARMONT, J; LUO, K; WYLIE, B; STEWART, G; KALDOR, JM				ASHTON, LJ; LEARMONT, J; LUO, K; WYLIE, B; STEWART, G; KALDOR, JM			HIV-INFECTION IN RECIPIENTS OF BLOOD PRODUCTS FROM DONORS WITH KNOWN DURATION OF INFECTION	LANCET			English	Note							TRANSFUSION; AIDS; AUSTRALIA; PEOPLE	From a registry of people with transfusion-acquired HIV infection, 25 recipients were identified for whom the dates of HIV infection in the 8 corresponding donors could be established. Longer times to AIDS and to death in recipients were independently associated (p<0.01) with the receipt of blood from donors who developed AIDS more than 10 years after HIV infection, as well as with older age and fewer transfusions. Sex, zidovudine treatment, and severity of illness at transfusion were not significantly associated with survival.	UNIV NEW S WALES,NATL CTR HIV EPIDEMIOL & CLIN RES,SYDNEY,NSW 2010,AUSTRALIA; NEW S WALES RED CROSS,BLOOD TRANSFUS SERV,SYDNEY,NSW,AUSTRALIA; WESTMEAD HOSP,DEPT IMMUNOPATHOL,WESTMEAD,NSW 2145,AUSTRALIA	University of New South Wales Sydney; Kirby Institute; Australian Red Cross Blood Service; University of Sydney			Wylie, Bruce/H-3182-2014; Kaldor, John M/D-4545-2011	Wylie, Bruce/0000-0002-7374-1083; 				BLAXHULT A, 1990, AIDS, V4, P125, DOI 10.1097/00002030-199002000-00005; KALDOR J, 1993, MED J AUSTRALIA, V158, P10, DOI 10.5694/j.1326-5377.1993.tb121640.x; KOPECSCHRADER E, 1993, AIDS, V7, P1009, DOI 10.1097/00002030-199307000-00016; LEARMONT J, 1992, LANCET, V340, P863, DOI 10.1016/0140-6736(92)93281-Q; SWANSON CE, 1990, AIDS, V4, P749, DOI 10.1097/00002030-199008000-00006; WARD JW, 1989, NEW ENGL J MED, V321, P947, DOI 10.1056/NEJM198910053211406	6	25	27	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 10	1994	344	8924					718	720		10.1016/S0140-6736(94)92210-1	http://dx.doi.org/10.1016/S0140-6736(94)92210-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF187	7915778				2023-01-03	WOS:A1994PF18700012
J	CHIEN, KY; CHIANG, CM; HSEU, YC; VYAS, AA; RULE, GS; WU, WG				CHIEN, KY; CHIANG, CM; HSEU, YC; VYAS, AA; RULE, GS; WU, WG			2 DISTINCT TYPES OF CARDIOTOXIN AS REVEALED BY THE STRUCTURE AND ACTIVITY RELATIONSHIP OF THEIR INTERACTION WITH ZWITTERIONIC PHOSPHOLIPID DISPERSIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NAJA-NAJA-ATRA; MEMBRANE-FUSION; PHOSPHATIDYLSERINE VESICLES; NIGRICOLLIS; CURVATURE; KINETICS; VENOM	Cardiotoxins (CTXs) are a group of homologous proteins found in cobra snake venom and consist of 60-62 amino acid residues. Although CTXs are known to consist of three extended beta-sheet loops similar to neurotoxins, the target and interaction of CTXs with membranes unlike those of neurotoxins are not well understood. Herein, we report comparative studies of 10 CTXs purified from Taiwan cobra (Naja naja atra) and Mozambique spitting cobra (Naja mossambica mossambica) snake venoms with respect to their interactions with zwitterionic phospholipids. Based on the CTX-induced mixing of sphingomyelin vesicles and the binding of CTX to lysophosphatidylcholine micelles, two distinct types of CTX, i.e. P- and S-type CTX, are identified. P-type CTXs are characterized by the presence of Pro-31 within a putative phospholipid binding site near the tip of loop 2; whereas S-type CTXs are characterized by the presence of Ser-29 within the same but more hydrophilic region. Although binding of all CTXs to phospholipid membranes involves a phospholipid binding site at loop 1, P-type CTXs exhibit higher fusion and binding activity than S-type CTXs, presumably due to the additional phospholipid binding site at loop 2. The binding modes of P- and S-type CTX are thus different. Analysis of the primary structures of 46 CTXs from the genus Naja indicates that these two types of CTXs exist in all species examined. Reasonable structure/activity correlation can be detected for the effects of CTXs on muscle and red blood cells, although notable exceptions are also found. S-type CTXs are generally found to exhibit higher muscle cell depolarization activity, whereas P-type CTXs are found to possess a higher hemolytic activity. Thus the mechanism of action of CTXs seems to involve CTX-membrane interactions and depends on the type of the cell membrane and CTX molecules under study. The two lipid binding sites in P-type CTXs and one lipid binding site in S-type CTXs show large variation in their amino acid residues, but they do display some common distribution of residue type. Analogous to the signal sequences for protein import, these regions are characterized by the coexistence of an exposed hydrophobic surface flanked on either side by a cationic residue. A hypothesis is proposed to explain the general cytotoxic and specific cardiotoxic effect of CTXs based on the two CTX subtypes in snake venom.	NATL TSING HUA UNIV, INST LIFE SCI, HSINCHU 30043, TAIWAN; UNIV VIRGINIA, DEPT BIOCHEM, CHARLOTTESVILLE, VA 22908 USA	National Tsing Hua University; University of Virginia			Rule, Gordon S/Q-2422-2015	Rule, Gordon S/0000-0002-4396-3363				BATENBURG AM, 1985, BIOCHEMISTRY-US, V24, P7101, DOI 10.1021/bi00346a013; BATENBURG AM, 1988, BIOSCIENCE REP, V8, P299, DOI 10.1007/BF01115220; BHASKARAN R, 1994, J MOL BIOL, V235, P1291, DOI 10.1006/jmbi.1994.1082; BLUMENTHAL R, 1987, CURR TOP MEMBR TRANS, V29, P203; BOUGIS P, 1983, MOL CELL BIOCHEM, V55, P49, DOI 10.1007/BF00229242; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CHIEN KY, 1991, J BIOL CHEM, V266, P3252; DESORMEAUX A, 1992, BIOCHEMISTRY-US, V31, P12173, DOI 10.1021/bi00163a029; DUFOURCQ J, 1982, TOXICON, V20, P165, DOI 10.1016/0041-0101(82)90187-8; Dufton M.J., 1991, P259; FLETCHER JE, 1993, TOXICON, V31, P669, DOI 10.1016/0041-0101(93)90375-S; GATINEAU E, 1987, BIOCHEMISTRY-US, V26, P8046, DOI 10.1021/bi00399a004; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; GROGNET JM, 1988, EUR J BIOCHEM, V172, P383, DOI 10.1111/j.1432-1033.1988.tb13898.x; HARVEY AL, 1985, J TOXICOL-TOXIN REV, V4, P41, DOI 10.3109/15569548509014413; HARVEY AL, 1991, HDB NATURALTOXINS, V5, P103; HILLE JDR, 1981, BIOCHEMISTRY-US, V20, P4068, DOI 10.1021/bi00517a019; HODGES SJ, 1987, EUR J BIOCHEM, V165, P373, DOI 10.1111/j.1432-1033.1987.tb11450.x; LAUTERWEIN J, 1978, FEBS LETT, V93, P181, DOI 10.1016/0014-5793(78)81100-4; LOUW AI, 1978, BIOCHIM BIOPHYS ACTA, V512, P163, DOI 10.1016/0005-2736(78)90227-4; LOYTER A, 1988, METHOD BIOCHEM ANAL, V33, P129; MENEZ A, 1990, BIOCHIMIE, V72, P575, DOI 10.1016/0300-9084(90)90121-V; OCONNELL JF, 1993, EUR J BIOCHEM, V213, P891, DOI 10.1111/j.1432-1033.1993.tb17833.x; REES B, 1993, CHEM RES TOXICOL, V6, P385, DOI 10.1021/tx00034a001; REES B, 1990, J MOL BIOL, V214, P281, DOI 10.1016/0022-2836(90)90161-E; Samson M. S. P., 1991, PROG BIOPHYS MOL BIO, V55, P139; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SINGHAL AK, 1993, BIOCHEMISTRY-US, V32, P8036, DOI 10.1021/bi00082a026; SUN JJ, 1986, TOXICON, V24, P233, DOI 10.1016/0041-0101(86)90149-2; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; WILSCHUT J, 1980, BIOCHEMISTRY-US, V19, P6011, DOI 10.1021/bi00567a011; WILSCHUT J, 1981, BIOCHEMISTRY-US, V20, P3126, DOI 10.1021/bi00514a022; WU WG, 1993, FASEB J, V7, pA1235	34	107	117	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14473	14483						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182052				2023-01-03	WOS:A1994NM06500028
J	WOOD, WC; BUDMAN, DR; KORZUN, AH; COOPER, MR; YOUNGER, J; HART, RD; MOORE, A; ELLERTON, JA; NORTON, L; FERREE, CR; BALLOW, AC; FREI, E; HENDERSON, IC				WOOD, WC; BUDMAN, DR; KORZUN, AH; COOPER, MR; YOUNGER, J; HART, RD; MOORE, A; ELLERTON, JA; NORTON, L; FERREE, CR; BALLOW, AC; FREI, E; HENDERSON, IC			DOSE AND DOSE INTENSITY OF ADJUVANT CHEMOTHERAPY FOR STAGE-II, NODE-POSITIVE BREAST-CARCINOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CANCER	Background. Adjuvant chemotherapy is widely used for breast cancer and is known to extend survival. Some clinicians seek a greater survival benefit by increasing the intensity of the dose, whereas others lower it to diminish toxicity. Methods. The Cancer and Leukemia Group B (CALGB) conducted a randomized trial of different levels of doses and dose intensity (dose per unit of time) of adjuvant chemotherapy in 1572 women with node-positive, stage II breast cancer who were assigned to three treatment groups. One group received 400 mg of cyclophosphamide per square meter of body-surface area and 40 mg of doxorubicin per square meter once every 28 days and 400 mg of fluorouracil per square meter twice every 28 days, for six cycles. Another group received 50 percent higher doses of the three drugs (600 mg, 60 mg, and 600 mg, respectively) but for only four cycles, so that the total dose was identical in these two groups but the dose intensity was higher in the second. The third group of women received half the total dose used in the other two groups and at half the dose intensity used in the second group. Results. After a median of 3.4 years of follow-up, the women treated with a high or moderate dose intensity had significantly longer disease-free survival (P<0.001) and overall survival (P = 0.004) than those treated with a low dose intensity, in three-way log-rank comparisons. However, the difference in survival between the two groups treated with a moderate or high dose intensity was not significant. These results are consistent with either a dose-response effect or a threshold level of the dose or dose intensity. Conclusions. The doses of chemotherapy used to treat breast cancer, especially early breast cancer, should not be reduced if the maximal benefit is to be achieved.	N SHORE UNIV HOSP,MANHASSET,NY; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,WINSTON SALEM,NC; MASSACHUSETTS GEN HOSP,BOSTON,MA 02114; ST LUKES HOSP,MILWAUKEE,WI; NEW YORK HOSP,NEW YORK,NY 10021; CORNELL UNIV,MED CTR,NEW YORK,NY 10021; S NEVADA CANC RES FDN,LAS VEGAS,NV; MEM SLOAN KETTERING CANC CTR,NEW YORK,NY 10021; FRONTIER SCI TECHNOL & RES FDN,AMHERST,MA; DANA FARBER CANC INST,BOSTON,MA; UNIV CALIF SAN FRANCISCO,SCH MED,SAN FRANCISCO,CA	Northwell Health; North Shore University Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Wake Forest University; Wake Forest Baptist Medical Center; Harvard University; Massachusetts General Hospital; NewYork-Presbyterian Hospital; Cornell University; Memorial Sloan Kettering Cancer Center; Frontier Science Foundation; Harvard University; Dana-Farber Cancer Institute; University of California System; University of California San Francisco	WOOD, WC (corresponding author), EMORY UNIV,SCH MED,WINSHIP CANC CTR,DEPT SURG,1364 CLIFTON RD NE,ATLANTA,GA 30322, USA.				NATIONAL CANCER INSTITUTE [U10CA035421, U10CA033601, U10CA035279, U10CA012449] Funding Source: NIH RePORTER; NCI NIH HHS [CA-35279, U10 CA035421, U10 CA033601, CA-33601, CA-12449] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABELOFF MD, 1981, P AM ASSOC CANC RES, V22, P440; BONADONNA G, 1989, J CLIN ONCOL, V7, P1380, DOI 10.1200/JCO.1989.7.10.1380; BONADONNA G, 1981, NEW ENGL J MED, V304, P10, DOI 10.1056/NEJM198101013040103; BUDMAN DR, 1990, CANCER INVEST, V8, P571, DOI 10.3109/07357909009018922; BUZDAR AU, 1979, JAMA-J AM MED ASSOC, V242, P1509, DOI 10.1001/jama.242.14.1509; CANELLOS GP, 1988, J CLIN ONCOL, V6, P1363, DOI 10.1200/JCO.1988.6.9.1363; Cochran W.G, 1957, STAT METHODS, V6th ed; COX DR, 1972, J R STAT SOC B, V34, P187; FISHER B, 1990, J CLIN ONCOL, V8, P1005, DOI 10.1200/JCO.1990.8.6.1005; FISHER B, 1987, ADJUVANT THERAPY CAN, P283; GELMAN R, 1990, J CLIN ONCOL, V8, P548, DOI 10.1200/JCO.1990.8.3.548; HENDERSON IC, 1988, J CLIN ONCOL, V6, P1501, DOI 10.1200/JCO.1988.6.9.1501; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KORZUN A, 1988, P AN M AM SOC CLIN, V7, P12; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; 1983, MANUAL STAGING CANCE, P127; 1988, NEW ENGL J MED, V319, P1681; 1985, CANCER RES, V45, P4454	19	572	579	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 5	1994	330	18					1253	1259		10.1056/NEJM199405053301801	http://dx.doi.org/10.1056/NEJM199405053301801			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NJ512	8080512				2023-01-03	WOS:A1994NJ51200001
J	MEYER, TJ; HILL, NS				MEYER, TJ; HILL, NS			NONINVASIVE POSITIVE PRESSURE VENTILATION TO TREAT RESPIRATORY-FAILURE	ANNALS OF INTERNAL MEDICINE			English	Review							OBSTRUCTIVE SLEEP-APNEA; CHRONIC ALVEOLAR HYPOVENTILATION; DUCHENNE MUSCULAR-DYSTROPHY; NOCTURNAL NASAL VENTILATION; MECHANICAL VENTILATION; PULMONARY-DISEASE; NEUROMUSCULAR DISEASE; SUPPORT VENTILATION; FACE MASK; BODY RESPIRATORS	Purpose: To review the clinical use of noninvasive positive pressure ventilation, including its efficacy with acute and chronic forms of respiratory failure, its mechanism of action, and its implementation. Data Sources: Studies were identified through a MEDLINE search using the keywords respiratory failure and mechanical ventilation and through a manual review of reference lists of published articles. Study Selection: All original studies relating to the use of noninvasive positive pressure ventilation in respiratory failure were included. Because of the paucity of controlled trials, cohort studies were not excluded. Data Extraction: Study design, numbers and diagnoses of patients, ventilator modes, and success and complication rates were extracted and compiled. Results: For acute respiratory failure, studies report improved gas exchange and avoidance of intubation in 60% to 80% of patients with chronic obstructive pulmonary disease, restrictive thoracic disease, congestive heart failure, pneumonia, or postoperative extubation failure. However, the patients were highly selected, and relatively few studies have been published, only one of which was a randomized controlled trial. For chronic respiratory failure due to restrictive thoracic disease, all studies report improved gas exchange and symptoms of hypoventilation after prolonged nocturnal use, although no study was controlled. Some cohort studies of patients with severe chronic obstructive pulmonary disease yielded favorable results, but longer-term, randomized, controlled studies showed minimal, if any, benefit. Conclusion: Noninvasive positive pressure ventilation is effective in the treatment of chronic respiratory failure due to restrictive thoracic diseases. The routine use of such treatment for chronic respiratory failure due to chronic obstructive pulmonary disease and for acute respiratory failure needs to be studied in randomized controlled trials in better-defined patient subsets.	BROWN UNIV, SCH MED, PROVIDENCE, RI 02912 USA	Brown University					NHLBI NIH HHS [HL-45050] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045050] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBA A, 1984, REHABILITATION GAZET, V24, P47; AMBROSINO N, 1990, EUR RESPIR J, V3, P502; AMBROSINO N, 1992, CHEST, V101, P385, DOI 10.1378/chest.101.2.385; [Anonymous], 1983, ANN INTERN MED, V99, P612, DOI 10.7326/0003-4819-99-5-612; BACH JR, 1987, CHEST, V92, P168, DOI 10.1378/chest.92.1.168; BACH JR, 1990, CHEST, V97, P52, DOI 10.1378/chest.97.1.52; BACH JR, 1987, CHEST, V91, P859, DOI 10.1378/chest.91.6.859; BARACH AL, 1950, B NEW YORK ACAD MED, V26, P370; BENHAMOU D, 1992, CHEST, V102, P912, DOI 10.1378/chest.102.3.912; BERGOFSKY EH, 1979, AM REV RESPIR DIS, V119, P643; BERTHONJONES M, 1987, AM REV RESPIR DIS, V135, P144; BLITZER B, DIRECTORY SOURCES VE; BOTT J, 1993, LANCET, V341, P1555, DOI 10.1016/0140-6736(93)90696-E; BRANTHWAITE MA, 1991, THORAX, V46, P208, DOI 10.1136/thx.46.3.208; BRAUN N M T, 1984, Chest, V85, p59S, DOI 10.1378/chest.85.6_Supplement.59S-a; BRAUN NMT, 1988, CLIN CHEST MED, V9, P153; BRAUN NMT, 1987, AM REV RESPIR DIS, V135, P523; BROCHARD L, 1987, AM REV RESPIR DIS, V136, P411, DOI 10.1164/ajrccm/136.2.411; BROCHARD L, 1990, NEW ENGL J MED, V323, P1523, DOI 10.1056/NEJM199011293232204; BRYANT LR, 1967, J AMER MED ASSOC, V199, P149; CARREY Z, 1990, CHEST, V97, P150, DOI 10.1378/chest.97.1.150; CARROLL N, 1988, THORAX, V43, P349, DOI 10.1136/thx.43.5.349; CELLI B, 1989, AM REV RESPIR DIS, V140, P1251, DOI 10.1164/ajrccm/140.5.1251; CHEVROLET JC, 1991, CHEST, V100, P775, DOI 10.1378/chest.100.3.775; COLLIER CR, 1954, J APPL PHYSIOL, V6, P531, DOI 10.1152/jappl.1954.6.9.531; CROPP A, 1987, AM REV RESPIR DIS, V135, P1056; CULLEN JH, 1957, AM REV TUBERC PULM, V76, P33; CURRAN FJ, 1981, ARCH PHYS MED REHAB, V62, P270; CURTIS JK, 1968, J AMER MED ASSOC, V206, P1037, DOI 10.1001/jama.1968.03150050025004; DIMARCO AF, 1987, CHEST, V92, P952, DOI 10.1378/chest.92.5.952; Drinker P, 1929, J CLIN INVEST, V7, P229, DOI 10.1172/JCI100226; ELLIOTT M, 1990, American Review of Respiratory Disease, V141, pA322; ELLIOTT MW, 1991, EUR RESPIR J, V4, P1044; ELLIS ER, 1987, AM REV RESPIR DIS, V136, P188, DOI 10.1164/ajrccm/136.1.188; ELLIS ER, 1987, AM REV RESPIR DIS, V135, P148; ELLIS ER, 1988, CHEST, V94, P811, DOI 10.1378/chest.94.4.811; Emerson JH, 1978, EVOLUTION IRON LUNGS; Eve FC, 1932, LANCET, V2, P995; FRAIMOW W, 1960, AM REV RESPIR DIS, V81, P815; GAIL DB, 1990, AM REV RESPIR DIS, V142, P474; GARAY SM, 1981, AM J MED, V70, P269, DOI 10.1016/0002-9343(81)90761-0; GAY PC, 1991, MAYO CLIN PROC, V66, P695, DOI 10.1016/S0025-6196(12)62081-3; GOGLIO C, 1992, CHEST, V101, P1533; GOLDSTEIN RS, 1987, AM REV RESPIR DIS, V135, P1049; GOLDSTEIN RS, 1991, CHEST, V99, P408, DOI 10.1378/chest.99.2.408; GRENVIK A, 1980, International Anesthesiology Clinics, V18, P1; GUTIERREZ M, 1988, AM REV RESPIR DIS, V138, P617, DOI 10.1164/ajrccm/138.3.617; HECKMATT JZ, 1990, LANCET, V335, P579, DOI 10.1016/0140-6736(90)90357-B; HILL NS, 1992, AM REV RESPIR DIS, V145, P365, DOI 10.1164/ajrccm/145.2_Pt_1.365; HILL NS, 1986, CHEST, V90, P897, DOI 10.1378/chest.90.6.897; HILL NS, 1992, CHEST, V102, P1656, DOI 10.1378/chest.102.6.1656; HODSON ME, 1991, EUR RESPIR J, V4, P524; HOEPPNER VH, 1984, AM REV RESPIR DIS, V129, P240; HOO GWS, 1991, AM REV RESPIR DIS, V143, pA79; HYLAND RH, 1981, AM REV RESPIR DIS, V124, P180; KACMAREK R M, 1988, Respiratory Care, V33, P99; KERBY GR, 1987, AM REV RESPIR DIS, V135, P738; LASSEN HCA, 1953, LANCET, V264, P37; LEGER P, 1989, Respiratory Care, V34, P73; LEVY RD, 1989, CHEST, V95, P95, DOI 10.1378/chest.95.1.95; MACINTYRE NR, 1986, CHEST, V89, P677, DOI 10.1378/chest.89.5.677; MACKLEM PT, 1990, AM REV RESPIR DIS, V142, P274, DOI 10.1164/ajrccm/142.2.274; MARINI JJ, 1985, CHEST, V87, P612, DOI 10.1378/chest.87.5.612; MARINO W, 1991, CHEST, V99, P681, DOI 10.1378/chest.99.3.681; MEDURI GU, 1989, CHEST, V95, P865, DOI 10.1378/chest.95.4.865; MEDURI GU, 1991, CHEST, V100, P445, DOI 10.1378/chest.100.2.445; MILLMAN RP, 1988, AM J RHINOL, V2, P177; MOHR CH, 1990, CHEST, V97, P91, DOI 10.1378/chest.97.1.91; NAVA S, 1993, CHEST, V103, P143, DOI 10.1378/chest.103.1.143; OLSEN KD, 1990, MAYO CLIN PROC, V65, P1095, DOI 10.1016/S0025-6196(12)62722-0; PENNOCK BE, 1991, CHEST, V100, P1371, DOI 10.1378/chest.100.5.1371; PIPER AJ, 1992, CHEST, V102, P846, DOI 10.1378/chest.102.3.846; PLUM F, 1951, NEW ENGL J MED, V245, P235, DOI 10.1056/NEJM195108162450701; PLUM F, 1951, AM J MED SCI, V221, P417, DOI 10.1097/00000441-195104000-00009; RIDEAU Y, 1986, 4TH INT C NEUR DIS L, V9, P55; ROCHESTER DF, 1977, AM J MED, V63, P223, DOI 10.1016/0002-9343(77)90236-4; ROCHESTER DF, 1988, AM REV RESPIR DIS, V138, P516, DOI 10.1164/ajrccm/138.3.516; RODENSTEIN DO, 1989, EUR RESPIR J, V2, P473; ROUSSOS C, 1985, CHEST, V88, pS124, DOI 10.1378/chest.88.2.124S; SACKS H, 1982, AM J MED, V72, P233, DOI 10.1016/0002-9343(82)90815-4; SANDERS MH, 1990, CHEST, V98, P317, DOI 10.1378/chest.98.2.317; SCANO G, 1990, CHEST, V97, P322, DOI 10.1378/chest.97.2.322; SCHARF SM, 1978, AM REV RESPIR DIS, V117, P391; SEIKER HO, 1956, AM REV TUBERC, V74, P309; SHAPIRO SH, 1992, LANCET, V340, P1425, DOI 10.1016/0140-6736(92)92620-U; SPLAINGARD ML, 1985, ARCH PHYS MED REHAB, V66, P239, DOI 10.1016/0003-9993(85)90157-1; SPLAINGARD ML, 1983, CHEST, V84, P376, DOI 10.1378/chest.84.4.376; STAUFFER JL, 1982, RESPIR CARE, V27, P417; STERNBURG L, 1986, VIEW SEESAW; STROHL KP, 1980, J APPL PHYSIOL, V49, P638, DOI 10.1152/jappl.1980.49.4.638; STRUMPF D A, 1990, Respiratory Care, V35, P415; STRUMPF DA, 1991, AM REV RESPIR DIS, V144, P1234, DOI 10.1164/ajrccm/144.6.1234; STRUMPF DA, 1990, CHEST, V98, P474, DOI 10.1378/chest.98.2.474; SULLIVAN CE, 1981, LANCET, V1, P862; SURATT PM, 1986, CHEST, V90, P324, DOI 10.1378/chest.90.3.324; UDWADIA ZF, 1992, THORAX, V47, P715, DOI 10.1136/thx.47.9.715; WALDHORN RE, 1992, CHEST, V101, P516, DOI 10.1378/chest.101.2.516; WEINGARTEN WS, 1978, REHABILITATION GAZET, V21, P34; WIERS PWJ, 1977, THORAX, V32, P221, DOI 10.1136/thx.32.2.221; WOOLLAM CHM, 1976, ANAESTHESIA, V31, P666, DOI 10.1111/j.1365-2044.1976.tb11849.x; WOOLLAM CHM, 1976, ANAESTHESIA, V31, P537, DOI 10.1111/j.1365-2044.1976.tb12364.x; ZIBRAK JD, 1988, AM REV RESPIR DIS, V138, P1515, DOI 10.1164/ajrccm/138.6.1515; 1983, CHEST, V84, P76	103	146	152	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1994	120	9					760	770		10.7326/0003-4819-120-9-199405010-00008	http://dx.doi.org/10.7326/0003-4819-120-9-199405010-00008			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH251	8147550				2023-01-03	WOS:A1994NH25100008
J	TOBIN, MJ				TOBIN, MJ			CURRENT CONCEPTS - MECHANICAL VENTILATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							END-EXPIRATORY PRESSURE; ACUTE RESPIRATORY-FAILURE; POSITIVE AIRWAY PRESSURE; QUANTITATIVE CULTURE TECHNIQUES; OBSTRUCTIVE PULMONARY-DISEASE; PROTECTED SPECIMEN BRUSH; INSPIRATORY WORK; FLOW OBSTRUCTION; PRONE POSITION; AUTO-PEEP		VET AFFAIRS EDWARD HINES JR HOSP,HINES,IL	US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital	TOBIN, MJ (corresponding author), LOYOLA UNIV,STRITCH SCH MED,DIV PULM & CRIT CARE MED,2160 S 1ST AVE,MAYWOOD,IL 60153, USA.							ALBERT RK, 1985, CHEST, V87, P2, DOI 10.1378/chest.87.1.2; [Anonymous], 1992, Respir Care, V37, P1000; ARGIRAS EP, 1987, BRIT J ANAESTH, V59, P1278, DOI 10.1093/bja/59.10.1278; BROCHARD L, 1987, AM REV RESPIR DIS, V136, P411, DOI 10.1164/ajrccm/136.2.411; BROCHARD L, 1990, NEW ENGL J MED, V323, P1523, DOI 10.1056/NEJM199011293232204; CHEVROLET JC, 1991, CHEST, V100, P775, DOI 10.1378/chest.100.3.775; CONNORS AF, 1981, AM REV RESPIR DIS, V124, P537; DARIOLI R, 1984, AM REV RESPIR DIS, V129, P385; DREYFUSS D, 1988, AM REV RESPIR DIS, V137, P1159, DOI 10.1164/ajrccm/137.5.1159; DUNCAN AW, 1986, ANAESTH INTENS CARE, V14, P236, DOI 10.1177/0310057X8601400304; ELLIOTT M, 1994, PRINCIPLES PRACTICE, P427; FAGON JY, 1988, AM REV RESPIR DIS, V138, P110, DOI 10.1164/ajrccm/138.1.110; FAGON JY, 1989, AM REV RESPIR DIS, V139, P877, DOI 10.1164/ajrccm/139.4.877; FIELD S, 1982, AM REV RESPIR DIS, V126, P9; GAMMON RB, 1992, CHEST, V102, P568, DOI 10.1378/chest.102.2.568; GATTINONI L, 1988, ANESTHESIOLOGY, V69, P824, DOI 10.1097/00000542-198812000-00005; GIBNEY RTN, 1982, CHEST, V82, P692, DOI 10.1378/chest.82.6.692; GUREVITCH MJ, 1989, CRIT CARE MED, V17, P354, DOI 10.1097/00003246-198904000-00011; HANSENFLASCHEN J, 1993, AM REV RESPIR DIS, V147, P234, DOI 10.1164/ajrccm/147.1.234; HEFFNER JE, 1990, CRIT CARE CLIN, V6, P533; HERNANDEZ LA, 1990, J APPL PHYSIOL, V69, P2057, DOI 10.1152/jappl.1990.69.6.2057; HICKLING KG, 1990, INTENS CARE MED, V16, P372, DOI 10.1007/BF01735174; HILL NS, 1993, AM REV RESPIR DIS, V147, P1050, DOI 10.1164/ajrccm/147.4.1050; HUBMAYR RD, 1990, CRIT CARE MED, V18, P103, DOI 10.1097/00003246-199001000-00022; IBSEN B, 1954, P ROY SOC MED, V47, P72, DOI 10.1177/003591575404700120; JUBRAN A, 1993, AM REV RESPIR DIS, V147, pA875; KAEM, 1990, CRIT CARE CLIN, V6, P551; KATZ JA, 1985, ANESTHESIOLOGY, V63, P598, DOI 10.1097/00000542-198512000-00008; KOLOBOW T, 1987, AM REV RESPIR DIS, V135, P312; LANGER M, 1988, CHEST, V94, P103, DOI 10.1378/chest.94.1.103; MACINTYRE NR, 1986, CHEST, V89, P677, DOI 10.1378/chest.89.5.677; MALO J, 1984, J APPL PHYSIOL, V57, P1002, DOI 10.1152/jappl.1984.57.4.1002; MARINI JJ, 1985, CHEST, V87, P612, DOI 10.1378/chest.87.5.612; MATHRU M, 1982, CRIT CARE MED, V10, P423, DOI 10.1097/00003246-198207000-00001; MUSCEDERE J G, 1992, American Review of Respiratory Disease, V145, pA454; NISHIMURA M, 1990, CHEST, V97, P600, DOI 10.1378/chest.97.3.600; PEPE PE, 1982, AM REV RESPIR DIS, V126, P166; PETERSEN GW, 1983, CRIT CARE MED, V11, P67, DOI 10.1097/00003246-198302000-00002; PIERSON DJ, 1990, CRIT CARE CLIN, V6, P711; PINSKY MR, 1990, CRIT CARE CLIN, V6, P663; ROSSI A, 1985, AM REV RESPIR DIS, V131, P672; SASSOON CSH, 1990, CRIT CARE CLIN, V6, P605; SASSOON CSH, 1992, AM REV RESPIR DIS, V145, P1219, DOI 10.1164/ajrccm/145.5.1219; SLUTSKY AS, 1993, CHEST, V104, P1833, DOI 10.1378/chest.104.6.1833; SMITH TC, 1988, J APPL PHYSIOL, V65, P1488, DOI 10.1152/jappl.1988.65.4.1488; TOBIN M J, 1991, Respiratory Care, V36, P395; TOBIN MJ, 1986, AM REV RESPIR DIS, V134, P1111; TOBIN MJ, 1989, CHEST, V96, P449, DOI 10.1378/chest.96.3.449; TOBIN MJ, 1988, AM REV RESPIR DIS, V138, P1625, DOI 10.1164/ajrccm/138.6.1625; Tobin MJ, 1994, PRINCIPLES PRACTICE, P1177; TOCINO IM, 1985, AM J ROENTGENOL, V144, P901, DOI 10.2214/ajr.144.5.901; TORRES A, 1992, ANN INTERN MED, V116, P540, DOI 10.7326/0003-4819-116-7-540; TUXEN DV, 1992, AM REV RESPIR DIS, V146, P1136, DOI 10.1164/ajrccm/146.5_Pt_1.1136; TUXEN DV, 1994, PRINCIPLES PRACTICE, P371; ULYATT DB, 1991, CRIT CARE MED, V19, P985, DOI 10.1097/00003246-199107000-00029; WARD ME, 1988, ANESTHESIOLOGY, V69, P29, DOI 10.1097/00000542-198807000-00005; WIENER CM, 1990, J APPL PHYSIOL, V68, P1386, DOI 10.1152/jappl.1990.68.4.1386; YANG KL, 1991, NEW ENGL J MED, V324, P1445, DOI 10.1056/NEJM199105233242101	58	176	184	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 14	1994	330	15					1056	1061		10.1056/NEJM199404143301507	http://dx.doi.org/10.1056/NEJM199404143301507			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF022	8080509				2023-01-03	WOS:A1994NF02200007
J	LENFANT, C				LENFANT, C			HOSPITAL DELAYS COMPOUND PATIENT AND TRANSPORT DELAYS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											LENFANT, C (corresponding author), NHLBI,BETHESDA,MD 20892, USA.								0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 9	1994	271	10					738	738						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY288	8114202				2023-01-03	WOS:A1994MY28800008
J	MULROW, CD; GERETY, MB; KANTEN, D; CORNELL, JE; DENINO, LA; CHIODO, L; AGUILAR, C; ONEIL, MB; ROSENBERG, J; SOLIS, RM				MULROW, CD; GERETY, MB; KANTEN, D; CORNELL, JE; DENINO, LA; CHIODO, L; AGUILAR, C; ONEIL, MB; ROSENBERG, J; SOLIS, RM			A RANDOMIZED TRIAL OF PHYSICAL REHABILITATION FOR VERY FRAIL NURSING-HOME RESIDENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESOURCE UTILIZATION GROUPS; LONG-TERM CARE; IMPACT; MUSCLE; EFFICACY; THERAPY; UNIT	Background.-Past studies suggest multidisciplinary interventions that include physical therapy (PT) can improve function of nursing home residents. This trial specifically evaluates effects of PT for frail long-stay nursing home residents. Design.-Randomized, controlled trial. Setting.-One academic nursing home and eight community nursing homes. Patients.-A total of 194 elderly nursing home residents dependent in at least two activities of daily living residing in the nursing home for at least 3 months. Interventions.-Patients were randomized to individually tailored one-on-one PT sessions or friendly visits (FVs) three times a week for 4 months. Physical therapy included range-of-motion, strength, balance, transfer, and mobility exercises. Main Outcome Measures.-Performance-based physical function assessed by the Physical Disability Index; self-perceived health status assessed with the Sickness Impact Profile; observer-reported activities of daily living; and falls. Results.-Eighty-nine percent and 92% of PT and FV sessions, respectively, were attended; 5% and 9% of subjects dropped out in the PT group and FV group, respectively. Compared with the FV group, the PT group experienced no significant improvements in overall Physical Disability Index, Sickness Impact Profile, or activities of daily living scores. A 15.5% improvement in the mobility subscale of the Physical Disability Index was seen (95% confidence interval [CI], 6.4% to 24.7%); no benefits in range-of-motion, strength, or balance subscales were found. Compared with the FV group, the PT group used assistive devices for bed mobility tasks less often (P=.06) and were less likely to use assistive devices and wheelchairs for locomotion (P<.005). There were 79 falls in the PT group vs 60 falls in the FV group (P=.11). Charge for the 4-month PT program was $1220 per subject (95% CI, $412 to $1832). Conclusion.-This standardized physical therapy program provided modest mobility benefits for very frail long-stay nursing home residents with physical disability due to multiple comorbid conditions.	UNIV TEXAS,HLTH SCI CTR,DEPT MED,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio	MULROW, CD (corresponding author), AUDIE L MURPHY MEM VET ADM MED CTR,CTR GERIATR RES EDUC & CLIN,2400 MERTON MINTER BLVD,SAN ANTONIO,TX 78284, USA.				NIA NIH HHS [UO1AG09117] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [U01AG009117] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Applegate W B, 1987, Clin Geriatr Med, V3, P145; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BOCK RD, 1975, MULTIVARIATE STATIST; BOHANNON RW, 1986, PHYS THER, V66, P206, DOI 10.1093/ptj/66.2.206; CHIODO LK, 1992, PHYS THER, V72, P168, DOI 10.1093/ptj/72.3.168; COHEN MA, 1986, MED CARE, V12, P1161; COONEY LM, 1985, MED CARE, V23, P123, DOI 10.1097/00005650-198502000-00003; FIATARONE MA, 1990, JAMA-J AM MED ASSOC, V263, P3029, DOI 10.1001/jama.263.22.3029; FISHER NM, 1991, ARCH PHYS MED REHAB, V72, P181; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRIES BE, 1985, MED CARE, V23, P110, DOI 10.1097/00005650-198502000-00002; GERETY MB, 1993, J GERONTOL, V48, pM33, DOI 10.1093/geronj/48.2.M33; GORDON BE, 1960, J CHRONIC EDIS, V15, P311; GRIMALDI PL, 1987, CASE MIX PAYMENT SYS; HADLEY EC, 1993, GERONTOLOGIST, V33, P204; HOGAN DB, 1987, CAN MED ASSOC J, V136, P713; HUGHES SL, 1984, MED CARE, V22, P460, DOI 10.1097/00005650-198405000-00010; Institute of Medicine report, 1986, IMPROVING QUALITY CA; JIROVEC MM, 1991, INT J NURS STUD, V28, P145, DOI 10.1016/0020-7489(91)90004-M; KANTEN DN, 1993, J AM GERIATR SOC, V41, P662, DOI 10.1111/j.1532-5415.1993.tb06741.x; KAPLAN J, 1975, GERONTOLOGIST, V15, P393, DOI 10.1093/geront/15.5_Part_1.393; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; LEMKE S, 1986, J GERONTOL, V41, P268, DOI 10.1093/geronj/41.2.268; LI L, 1993, J AM GERIATR SOC, V41, pSA29; LIEM PH, 1986, J GERONTOL, V41, P44, DOI 10.1093/geronj/41.1.44; MARINO M, 1982, AM J SPORT MED, V10, P360, DOI 10.1177/036354658201000608; MCMURDO MET, 1993, AGE AGEING, V22, P11, DOI 10.1093/ageing/22.1.11; MULROW CD, 1993, J AM GERIATR SOC, V41, P326, DOI 10.1111/j.1532-5415.1993.tb06712.x; Murtaugh C M, 1988, Health Serv Res, V23, P467; ONEIL MB, 1992, PHYS THER, V72, P596, DOI 10.1093/ptj/72.8.596; PARRY F, 1982, J AM GERIATR SOC, V31, P482; ROTHMAN ML, 1989, MED CARE, V27, pS157, DOI 10.1097/00005650-198903001-00013; RUBENSTEIN LV, 1992, PHYS THER, V72, P173, DOI 10.1093/ptj/72.3.173; RUBENSTEIN LZ, 1984, NEW ENGL J MED, V311, P1664, DOI 10.1056/NEJM198412273112604; SAUVAGE LR, 1992, AM J PHYS MED REHAB, V71, P333, DOI 10.1097/00002060-199212000-00005; SCHUMAN JE, 1980, ARCH PHYS MED REHAB, V61, P310; SHEIKH J I, 1986, Clinical Gerontologist, V5, P165; SMITH DW, 1987, MED CARE, V25, P120, DOI 10.1097/00005650-198702000-00005; WEILAND D, 1986, JAMA-J AM MED ASSOC, V255, P2622; 1988, RED BOOK ANN PHARM R; 1987, SAS STAT GUIDE PERSO	41	200	200	2	30	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 16	1994	271	7					519	524		10.1001/jama.271.7.519	http://dx.doi.org/10.1001/jama.271.7.519			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MV423	8301766				2023-01-03	WOS:A1994MV42300034
J	COX, P				COX, P			INDICATORS FOR POTENTIAL-DRUG USE	LANCET			English	Editorial Material											COX, P (corresponding author), ACAD UNIT PUBL HLTH MED,LEEDS,ENGLAND.								0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 4	1993	342	8884					1376	1377		10.1016/0140-6736(93)92747-H	http://dx.doi.org/10.1016/0140-6736(93)92747-H			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK095	7901676				2023-01-03	WOS:A1993MK09500004
J	FLAHERTY, JP; GARCIAHOUCHINS, S; CHUDY, R; ARNOW, PM				FLAHERTY, JP; GARCIAHOUCHINS, S; CHUDY, R; ARNOW, PM			AN OUTBREAK OF GRAM-NEGATIVE BACTEREMIA TRACED TO CONTAMINATED O-RINGS IN REPROCESSED DIALYZERS	ANNALS OF INTERNAL MEDICINE			English	Article						BACTEREMIA; GRAM-NEGATIVE BACTERIA; HEMODIALYSIS; DISINFECTION; EQUIPMENT CONTAMINATION	HIGH-FLUX DIALYSIS; PYROGENIC REACTIONS; HEMODIALYSIS	Objective: To investigate an outbreak of gram-negative bacteremia in an outpatient hemodialysis unit and to identify the source of contaminating bacteria and the route by which bacteria gained access to the bloodstream. Design: A matched-pair, case-control study and a bacteriologic investigation of the hemodialysis unit and the implicated dialyzers. Setting: A university outpatient hemodialysis unit. Patients: Eleven patients receiving long-term hemodialysis who had a total of 12 episodes of primary gram-negative bacteremia and 12 matched controls. Measurements: Clinical and demographic data were obtained for patients and controls. Dialysis unit procedures were observed for compliance with aseptic technique. Cultures of potential environmental sources of bacteria were obtained. Hemodialyzers from bacteremic and nonbacteremic patients were dismantled, and the component parts were cultured. Inoculation of O-rings (from Hemoflow F-80 dialyzer) with bacteria and simulated dialysis were done. Results: During January to October 1988, 12 episodes of primary gram-negative bacteremia caused by Pseudomonas cepacia, Xanthomonas maltophilia, Citrobacter freundii, Acinetobacter calcoaceticus var. anitratus, or Enterobacter cloacae occurred in 11 patients. In 11 episodes, symptoms developed within 3 hours of starting hemodialysis. Intravenous antibiotics were administered for 11 episodes, 3 episodes resulted in hospitalization, and all patients recovered. Case patients were more likely to have received high-flux dialysis with Hemoflow F-80 dialyzers (odds ratio congruent-to 11) than were controls. O-rings from dialyzers used by bacteremic patients were culture positive for the organism responsible for bacteremia. Three of the four dialyzers were disinfected using the standard automated method and were recultured 72 hours later; the O-rings of all three dialyzers remained culture positive. Simulated dialysis using dialyzers with contaminated O-rings caused blood pathway contamination despite intervening reprocessing. When the disinfection method for F-80 dialyzers included removal and complete disinfection of the O-rings, O-ring and blood pathway cultures were consistently negative. After this procedure was made routine, no episodes of primary gram-negative bacteremia occurred during the next 6 months. Conclusions: Because dialyzers with removable headers and O-rings are widely used in patients receiving long-term hemodialysis, disinfection procedures should include measures to ensure adequate disinfection of O-rings.	UNIV CHICAGO, CHICAGO, IL 60637 USA	University of Chicago								ALTER MJ, 1988, JAMA-J AM MED ASSOC, V260, P2073, DOI 10.1001/jama.260.14.2073; ALTER MJ, 1991, T AM SOC ART INT ORG, V37, P97; BECKSAGUE CM, 1990, AM J NEPHROL, V10, P397, DOI 10.1159/000168155; Bland L A, 1989, ASAIO Trans, V35, P314, DOI 10.1097/00002480-198907000-00044; BOLAN G, 1985, J INFECT DIS, V152, P1013, DOI 10.1093/infdis/152.5.1013; FAVERO MS, 1975, HEALTH LAB SCI, V12, P321; FLEMING SJ, 1991, AM J NEPHROL, V11, P27, DOI 10.1159/000168268; GOETZ A, 1983, ARCH INTERN MED, V143, P1909, DOI 10.1001/archinte.143.10.1909; GORDON SM, 1992, J AM SOC NEPHROL, V2, P1436; JONES DM, 1970, BRIT MED J, V3, P135, DOI 10.1136/bmj.3.5715.135; KUEHNEL E, 1976, DIALYSIS TRANSPLANT, V5, P44; LOWRY PW, 1990, J INFECT DIS, V161, P85, DOI 10.1093/infdis/161.1.85; MURPHY J, 1987, AM SOC ARTIF INTERN, V16, P51; POLLAK VE, 1986, NEPHRON, V42, P217, DOI 10.1159/000183670; ROBSON MD, 1986, AM J NEPHROL, V6, P101, DOI 10.1159/000167063; SHUSTERMAN NH, 1989, AM J KIDNEY DIS, V14, P81, DOI 10.1016/S0272-6386(89)80181-7; SMOLLICH BP, 1991, NEPHROL DIAL TRANSPL, V6, P83; TOBIN BM, 1970, BRIT MED J, V3, P226, DOI 10.1136/bmj.3.5716.226-b; UMAN SJ, 1977, AM J MED, V62, P667, DOI 10.1016/0002-9343(77)90868-3; VONALBERTINI B, 1991, AM J NEPHROL, V11, P169, DOI 10.1159/000168298; WAGNILD JP, 1977, AM J MED, V62, P672, DOI 10.1016/0002-9343(77)90869-5; 1981, AM NATIONAL STANDARD; 1986, MMWR, V35, P417	23	53	57	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1993	119	11					1072	1078		10.7326/0003-4819-119-11-199312010-00003	http://dx.doi.org/10.7326/0003-4819-119-11-199312010-00003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ335	8239225				2023-01-03	WOS:A1993MJ33500003
J	WORCESTER, MC; HARE, DL; OLIVER, RG; REID, MA; GOBLE, AJ				WORCESTER, MC; HARE, DL; OLIVER, RG; REID, MA; GOBLE, AJ			EARLY PROGRAMS OF HIGH AND LOW-INTENSITY EXERCISE AND QUALITY-OF-LIFE AFTER ACUTE MYOCARDIAL-INFARCTION	BRITISH MEDICAL JOURNAL			English	Article							SCALE	Objective-To determine whether a group programme of light exercise could improve quality of life in patients after acute myocardial infarction to the same extent as a high intensity exercise training programme. Setting-Australian teaching hospital. Patients-224 men from a consecutive series of 339 men under 70 admitted to a coronary care unit with transmural acute myocardial infarction. Intervention-Patients were randomly allocated in hospital to a group programme lasting eight weeks of either high intensity exercise training or light exercise. Main outcome measures-Physical working capacity based on metabolic equivalents achieved from treadmill exercise tests at entry, after 11 weeks, and after one year. Quality of life based on self report scores of anxiety, depression, denial, and wellbeing and interview assessments of activities and psychosocial adjustment at entry, after four months, and after one year. Results-The two groups were well matched at entry. At 11 weeks the mean results of treadmill testing were 10.7 (95% confidence interval 10.20 to 11.20) metabolic equivalents for exercise training and 9.7 (9.26 to 10.14) for light exercise (t=2.85, df=181, p=0.005). Apart from this small temporary benefit in mean physical working capacity, there were no significant differences between groups. Improvement in occupational adjustment score from baseline to four months was greater after exercise training than after light exercise, but at one year repeated measures analysis of variance showed no significant effects of treatment or interaction between treatment and time point. Conclusion-The effects on quality of life of a low cost programme of light exercise are similar to those obtained from a high intensity exercise training programme.	AUSTIN HOSP,DEPT CARDIOL,HEIDELBERG,VIC 3084,AUSTRALIA	Austin Research Institute; Florey Institute of Neuroscience & Mental Health	WORCESTER, MC (corresponding author), HEART RES CTR,POB 607,CARLTON,VIC 3053,AUSTRALIA.			Hare, David Linley/0000-0001-9554-6556				BALKE B, 1959, U S Armed Forces Med J, V10, P675; BLUMENTHAL JA, 1988, AM J CARDIOL, V61, P26, DOI 10.1016/0002-9149(88)91298-2; BLUMENTHAL JA, 1988, J CARDIOPULM REHABIL, V8, P183, DOI DOI 10.1097/00008483-198805000-00003; Broom L, 1977, INVESTIGATING SOCIAL; BRUCE RA, 1973, AM HEART J, V85, P546, DOI 10.1016/0002-8703(73)90502-4; BRUCE RA, 1974, CONTROVERSY INTERNAL, V2; CLAUSEN JP, 1969, CIRCULATION, V40, P143, DOI 10.1161/01.CIR.40.2.143; DEBUSK RF, 1979, AM J CARDIOL, V44, P1223, DOI 10.1016/0002-9149(79)90433-8; DIMSDALE JE, 1982, AM J PSYCHIAT, V139, P1477; EWART CK, 1983, AM J CARDIOL, V51, P1077; Eysenck H.J., 1964, MANUAL EYSENCK PERSO, DOI DOI 10.1007/SPRINGERREFERENCE_184643; FOLSTEIN MF, 1973, PSYCHOL MED, V3, P479, DOI 10.1017/S0033291700054283; GOBLE AJ, 1991, BRIT HEART J, V65, P126; GURLAND BJ, 1972, ARCH GEN PSYCHIAT, V27, P259; HACKETT TP, 1974, J PSYCHOSOM RES, V18, P93, DOI 10.1016/0022-3999(74)90072-5; Inc S. P. S. S., 1988, SPSS X USERS GUIDE; JENKINS CD, 1983, JAMA-J AM MED ASSOC, V250, P782, DOI 10.1001/jama.250.6.782; Laughlin, 1976, HDB IPAT DEPRESSION; MAYOU R, 1978, J PSYCHOSOM RES, V22, P447, DOI 10.1016/0022-3999(78)90068-5; NORRIS RM, 1969, LANCET, V1, P274; NORRIS RM, 1970, LANCET, V2, P485; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; Prineas R., 1982, MINNESOTA CODE MANUA; SAETERHAUG A, 1989, J CARDIOPULM REHABIL, V7, P268; SPIELBERGER CD, 1970, MANUAL STATE TRAIT A; STERN MJ, 1983, ARCH INTERN MED, V143, P1719, DOI 10.1001/archinte.143.9.1719; STERN MJ, 1976, J CHRON DIS, V29, P513, DOI 10.1016/0021-9681(76)90015-1; TAYLOR CB, 1986, J PSYCHOSOM RES, V30, P581, DOI 10.1016/0022-3999(86)90031-0; WEISSMAN MM, 1975, ARCH GEN PSYCHIAT, V32, P357; WIKLUND I, 1984, J PSYCHOSOM RES, V28, P309, DOI 10.1016/0022-3999(84)90053-9; WOLK MJ, 1972, CIRCULATION, V45, P1125, DOI 10.1161/01.CIR.45.5.1125; 1959, WHO TECH REP SER, V168, P25; 1979, CIRCULATION, V59, P1084	33	38	40	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 13	1993	307	6914					1244	1247		10.1136/bmj.307.6914.1244	http://dx.doi.org/10.1136/bmj.307.6914.1244			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MH001	8281056	Bronze, Green Published			2023-01-03	WOS:A1993MH00100019
J	MAXWELL, M; HEANEY, D; HOWIE, JGR; NOBLE, S				MAXWELL, M; HEANEY, D; HOWIE, JGR; NOBLE, S			GENERAL-PRACTICE FUNDHOLDING - OBSERVATIONS ON PRESCRIBING PATTERNS AND COSTS USING THE DEFINED DAILY DOSE METHOD	BRITISH MEDICAL JOURNAL			English	Article							BUDGET	Objective-To compare prescribing patterns between a group of fundholding practices and a group of non-fundholding practices in north east Scotland using a method which provides more accurate statements about volumes prescribed than standard NHS statistics. Design-The pharmacy practice division of the National Health Service in Scotland provided data for selected British National Formulary sections over two years. Each prescription issued was converted using the World Health Organisation ''defined daily dose'' mechanism. Setting-Six fundholding groups (nine practices) in Grampian and Tayside regions and six non-fundholding practices in Grampian. Results-During the past two years both fund-holding and control practices reduced the volume of their prescribing for the classes of drug analysed. The unit costs of drugs in some classes, however, rose substantially, contributing to higher costs per patient. The unit costs rose more in the control practices (24%) than in the fundholding practices (11% in Tayside, 16% in Grampian). Conclusion-The use of defined daily doses helped identify cost and volume trends in specific areas of prescribing in fundholding and control practices. The basis on which funds are set needs improving, and defined daily doses may prove useful for setting volume targets within drug classes for all practices, whether fundholding or not.	LOTHIAN HLTH BOARD,EDINBURGH EH8 9RS,SCOTLAND		MAXWELL, M (corresponding author), UNIV EDINBURGH,DEPT GEN PRACTICE,EDINBURGH EH8 9DX,SCOTLAND.			Maxwell, Margaret/0000-0003-3318-9500				BAIN J, 1993, BRIT MED J, V306, P1185, DOI 10.1136/bmj.306.6886.1185; BAIN J, 1992, BRIT MED J, V304, P971, DOI 10.1136/bmj.304.6832.971; BAIN J, 1991, BRIT MED J, V302, P771, DOI 10.1136/bmj.302.6779.771; COULTER A, 1993, BRIT MED J, V306, P433, DOI 10.1136/bmj.306.6875.433; GLENNERSTER H, 1992, FOOTHOLD FUNDHOLDING; Howie J G, 1993, Health Bull (Edinb), V51, P94; Howie J G, 1992, Health Bull (Edinb), V50, P316; NEWTON J, 1993, BRIT MED J, V306, P375, DOI 10.1136/bmj.306.6874.375; PURVES IN, 1993, BRIT MED J, V306, P496, DOI 10.1136/bmj.306.6876.496; SLEATOR DJD, 1993, BRIT J GEN PRACT, V43, P102; WUATT TD, 1990, BMJ, V300, P441; 1986, NORDIC STATISTICS 1; 1989, WORKING PATIENTS; 1985, NORDIC STATISTICS 3; 1991, GUIDELINES DEFINED D; 1990, FUNDING GENERAL PRAC; 1985, NORDIC STATISTICS 2; 1993, TREATMENT DEPRESSION	18	115	117	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 6	1993	307	6913					1190	1194		10.1136/bmj.307.6913.1190	http://dx.doi.org/10.1136/bmj.307.6913.1190			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF824	8305075	Bronze, Green Published			2023-01-03	WOS:A1993MF82400027
J	FILOS, KS; GOUDAS, LC; PATRONI, O; TASSOUDIS, V				FILOS, KS; GOUDAS, LC; PATRONI, O; TASSOUDIS, V			ANALGESIA WITH EPIDURAL NIMODIPINE	LANCET			English	Letter							ANTAGONISTS				FILOS, KS (corresponding author), UNIV PATRAS,SCH MED,DEPT ANAESTHESIOL & CRIT CARE MED,GR-26500 PATRAI,GREECE.			Goudas, Leonidas C./0000-0002-3614-3455				KAVALIERS M, 1987, BRAIN RES, V408, P403, DOI 10.1016/0006-8993(87)90415-X; LEHMANN KA, 1989, ANAESTHESIST, V38, P110; LEWIS PJ, 1988, NEUROSURGERY, V22, P492; LJUNGGREN B, 1984, J NEUROSURG, V61, P864, DOI 10.3171/jns.1984.61.5.0864; VONBORMANN B, 1985, ANAESTHESIST, V34, P429	5	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 23	1993	342	8878					1047	1047		10.1016/0140-6736(93)92899-5	http://dx.doi.org/10.1016/0140-6736(93)92899-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD066	8105273				2023-01-03	WOS:A1993MD06600028
J	ANNAS, GJ				ANNAS, GJ			PHYSICIAN-ASSISTED SUICIDE - MICHIGANS TEMPORARY SOLUTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							EUTHANASIA							Annas, George/0000-0001-5836-7831				Annas G., 1993, STANDARD CARE LAW AM; ANNAS GJ, 1991, HASTINGS CENT REP, V21, P33, DOI 10.2307/3562337; CASSEL CK, 1990, NEW ENGL J MED, V323, P750, DOI 10.1056/NEJM199009133231110; Foderaro Lisa W, 1991, N Y Times Web, P25; GIANELLI D, 1992, AM MED NEWS     1005, P37; KAMISAR Y, 1993, HASTINGS CENT REP, V23, P32, DOI 10.2307/3563366; KEVORKIAN J, 1991, PRESCRIPTION MED; Lifton Robert Jay, 1986, NAZI DOCTORS MED KIL; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; Quill TE, 1993, DEATH DIGNITY MAKING; Smith George P, 1989, Univ Calif Davis Law Rev, V22, P275; SOLOMON MZ, 1993, AM J PUBLIC HEALTH, V83, P14, DOI 10.2105/AJPH.83.1.14; THOMAS L, 1980, ANN AM ACAD POLIT SS, V447, P1, DOI 10.1177/000271628044700102; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; 1989, PRESCRIBING PRACTICE; 1993, LANCET, V341, P209; 1988, JAMA-J AM MED ASSOC, V259, P272; 1992, JAMA-J AM MED ASSOC, V267, P2229	18	30	30	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 27	1993	328	21					1573	1576		10.1056/NEJM199305273282121	http://dx.doi.org/10.1056/NEJM199305273282121			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LC941	8479510	Green Published			2023-01-03	WOS:A1993LC94100036
J	HUGHES, W; LEOUNG, G; KRAMER, F; BOZZETTE, SA; SAFRIN, S; FRAME, P; CLUMECK, N; MASUR, H; LANCASTER, D; CHAN, C; LAVELLE, J; ROSENSTOCK, J; FALLOON, J; FEINBERG, J; LAFON, S; ROGERS, M; SATTLER, F				HUGHES, W; LEOUNG, G; KRAMER, F; BOZZETTE, SA; SAFRIN, S; FRAME, P; CLUMECK, N; MASUR, H; LANCASTER, D; CHAN, C; LAVELLE, J; ROSENSTOCK, J; FALLOON, J; FEINBERG, J; LAFON, S; ROGERS, M; SATTLER, F			COMPARISON OF ATOVAQUONE (566C80) WITH TRIMETHOPRIM-SULFAMETHOXAZOLE TO TREAT PNEUMOCYSTIS-CARINII PNEUMONIA IN PATIENTS WITH AIDS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; HYDROXYNAPHTHOQUINONE; PENTAMIDINE; POTENT	Background. Both trimethoprim-sulfamethoxazole and pentamidine are effective as treatments for Pneumocystis carinii pneumonia, but adverse effects frequently limit their use. Atovaquone (566C80) is a new hydroxynaphthoquinone with activity against P. carinii. Methods. We conducted a double-blind, multicenter study in patients with the acquired immunodeficiency syndrome and mild or moderately severe P. carinii pneumonia. They were randomly assigned to 21 days of orally administered treatment three times daily with either atovaquone (750 mg) or trimethoprim (320 mg) plus sulfamethoxazole (1600 mg). Results. Of the 322 patients with histologically confirmed P. carinii pneumonia, 160 received atovaquone and 162 received trimethoprim-sulfamethoxazole. Of those who could be evaluated for therapeutic efficacy, 28 of 138 patients given atovaquone (20 percent) and 10 of 146 patients given trimethoprim-sulfamethoxazole (7 percent) did not respond (P = 0.002). Treatment-limiting adverse effects required a change of therapy in 11 patients in the atovaquone group (7 percent) and 33 patients in the trimethoprim-sulfamethoxazole group (20 percent) (P = 0.001). Therapy involving only the initial drug was successful and free of adverse effects in 62 percent of those assigned to atovaquone and 64 percent of those assigned to trimethoprim-sulfamethoxazole. Within four weeks of the completion of treatment, there were 11 deaths in the atovaquone group (4 due to P. carinii pneumonia) and 1 death in the trimethoprim-sulfamethoxazole group (P = 0.003). Diarrhea at entry was associated with lower plasma drug concentrations (P = 0.009), therapeutic failure (P<0.001), and death (P<0.001) in the atovaquone group but not in the trimethoprim-sulfamethoxazole group. Conclusions. For the treatment of P. carinii pneumonia, atovaquone is less effective than trimethoprim-sulfamethoxazole, but it has fewer treatment-limiting adverse effects.	DAVIES MED CTR, DEPT MED, SAN FRANCISCO, CA USA; LOS ANGELES CTY HOSP, LOS ANGELES, CA USA; UNIV SO CALIF, LOS ANGELES, CA 90089 USA; UNIV CALIF SAN DIEGO, LA JOLLA, CA 92093 USA; UNIV CINCINNATI, CINCINNATI, OH 45221 USA; HOP UNIV ST PIERRE, B-1000 BRUSSELS, BELGIUM; NIH, DEPT CRIT CARE MED, BETHESDA, MD 20892 USA; UNIV TENNESSEE CTR HLTH SCI, REG MED CTR, DEPT MED, MEMPHIS, TN 38163 USA; WELLESLEY COLL HOSP, TORONTO M4Y 1J3, ONTARIO, CANADA; GEORGETOWN UNIV, MED CTR, WASHINGTON, DC 20007 USA; SAN FRANCISCO GEN HOSP, SAN FRANCISCO, CA 94110 USA; UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA; INFECT DIS RES CONSORTIUM, ATLANTA, GA USA; JOHNS HOPKINS UNIV HOSP, BALTIMORE, MD 21205 USA; BURROUGHS WELLCOME CO, DEPT INFECT DIS & IMMUNOL, RES TRIANGLE PK, NC 27709 USA; NIAID, DIV AIDS, AIDS CLIN TRIALS GRP, BETHESDA, MD 20892 USA; NIAID, CALIF CLIN TRIALS GRP, BETHESDA, MD 20892 USA	California Pacific Medical Center; University of Southern California; University of California System; University of California San Diego; University System of Ohio; University of Cincinnati; Universite Libre de Bruxelles; Vrije Universiteit Brussel; National Institutes of Health (NIH) - USA; University of Tennessee System; University of Tennessee Health Science Center; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; Georgetown University; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; Johns Hopkins University; Johns Hopkins Medicine; Burroughs Wellcome Fund; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	HUGHES, W (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT INFECT DIS, 332 N LAUDERDALE, MEMPHIS, TN 38105 USA.			feinberg, judith/0000-0003-4206-7214				[Anonymous], 1989, SAS STAT USERS GUIDE, V2; FALLOON J, 1991, NEW ENGL J MED, V325, P1534, DOI 10.1056/NEJM199111283252202; FLEISS JL, 1973, STATISTICAL METHODS, P29; FRY M, 1984, BIOCHEM PHARMACOL, V33, P2115, DOI 10.1016/0006-2952(84)90581-1; GELLER NL, 1987, BIOMETRICS, V43, P213, DOI 10.2307/2531962; HAMMOND DJ, 1985, MOL BIOCHEM PARASIT, V14, P97, DOI 10.1016/0166-6851(85)90109-4; HUDSON AT, 1985, PARASITOLOGY, V90, P45, DOI 10.1017/S0031182000049003; HUGHES WT, 1990, ANTIMICROB AGENTS CH, V34, P225, DOI 10.1128/AAC.34.2.225; HUGHES WT, 1991, J INFECT DIS, V163, P843, DOI 10.1093/infdis/163.4.843; HUGHES WT, 1978, J PEDIATR-US, V92, P285, DOI 10.1016/S0022-3476(78)80028-6; MAKUCH R, 1978, CANCER TREAT REP, V62, P1037; MASUR H, 1990, NEW ENGL J MED, V323, P1500, DOI 10.1056/NEJM199011223232131; SATTLER FR, 1988, ANN INTERN MED, V109, P280, DOI 10.7326/0003-4819-109-4-280	13	235	237	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 27	1993	328	21					1521	1527		10.1056/NEJM199305273282103	http://dx.doi.org/10.1056/NEJM199305273282103			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LC941	8479489				2023-01-03	WOS:A1993LC94100003
J	LOBO, RA				LOBO, RA			HORMONE REPLACEMENT THERAPY - ESTROGEN REPLACEMENT AFTER TREATMENT FOR BREAST-CANCER	LANCET			English	Editorial Material							ESTROGEN; WOMEN				LOBO, RA (corresponding author), UNIV SO CALIF,SCH MED,DIV REPROD ENDOCRINOL & INFERTIL,LOS ANGELES,CA 90033, USA.							BERGKVIST L, 1989, AM J EPIDEMIOL, V130, P221, DOI 10.1093/oxfordjournals.aje.a115328; DARBRE PD, 1990, J STEROID BIOCHEM, V37, P753, DOI 10.1016/0960-0760(90)90416-I; EDEN JA, 1992, MED J AUSTRALIA, V157, P247, DOI 10.5694/j.1326-5377.1992.tb137129.x; EDEN JA, 1992, MED J AUSTRALIA, V157, P175, DOI 10.5694/j.1326-5377.1992.tb137081.x; LOBO RA, 1991, J CLIN ENDOCR METAB, V73, P925, DOI 10.1210/jcem-73-5-925; ROSEN PP, 1989, J CLIN ONCOL, V7, P355, DOI 10.1200/JCO.1989.7.3.355; Spicer D, 1990, Oncology (Williston Park), V4, P49; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; STOLL BA, 1989, EUR J CANCER CLIN ON, V25, P1909, DOI 10.1016/0277-5379(89)90372-6; VASSILOPOULOUSELLIN R, 1992, AM J MED SCI, V304, P145, DOI 10.1097/00000441-199209000-00001; 1991, TECHNICAL B AM COLLE, V158	11	23	23	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 22	1993	341	8856					1313	1314		10.1016/0140-6736(93)90820-7	http://dx.doi.org/10.1016/0140-6736(93)90820-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD253	8098453				2023-01-03	WOS:A1993LD25300008
J	GRAY, D; KEATING, NA; MURDOCK, J; SKENE, AM; HAMPTON, JR				GRAY, D; KEATING, NA; MURDOCK, J; SKENE, AM; HAMPTON, JR			IMPACT OF HOSPITAL THROMBOLYSIS POLICY ON OUT-OF-HOSPITAL RESPONSE TO SUSPECTED MYOCARDIAL-INFARCTION	LANCET			English	Article							TISSUE PLASMINOGEN-ACTIVATOR; TRIAL; EDUCATION; PATIENT; DELAY	The treatment of acute myocardial infarction changed when several trials reported that thrombolytic agents given within a few hours of infarction improved outcome. We present data from the Nottingham Heart Attack Register comparing 1982-84, when thrombolysis was not available, and 1989-90, when it was hospital policy to give thrombolysis to all patients who arrived within 6 hours of the onset of symptoms, in the absence of a specific contraindication. The number of patients referred with symptoms suggestive of acute myocardial infarction increased by 75% from 1982 to 1990; a diagnosis of ''possible infarction'' was made in about half of all patients in 1982-84 and 23% in 1989-90. Our current thrombolytic policy has had little impact on patient and general practitioner (GP) behaviour. The GP was contacted by most patients. The median time between the onset of a patient's symptoms and admission to hospital when the GP was involved was 229 min in 1 982-84 and 21 0 min in 1989-90; when he was not involved in arranging the admission median times to admission were 89 min and 75 min, respectively. By 6 hours from symptom onset, 60% of patients had been admitted; by 12 hours, about 70% were in hospital and by 24 hours, 80%. Of 7855 patients admitted with suspected acute myocardial infarction in 1989-90, 4465 were admitted within 6 hours of symptom onset. Of these, 736 (16%) patients received a thrombolytic drug, 389 (9%) patients had a specific, documented contraindication to thrombolysis. Although we estimate that the policy has saved about 8 lives per year, it is not surprising that there has been no improvement in overall case fatality after myocardial infarction.	UNIV NOTTINGHAM, DEPT MATH, BRITISH HEART FDN, CARDIOVASC STAT UNIT, NOTTINGHAM NG7 2RD, ENGLAND	University of Nottingham	GRAY, D (corresponding author), UNIV NOTTINGHAM HOSP, QUEENS MED CTR, DIV CARDIOVASC MED, NOTTINGHAM NG7 2UH, ENGLAND.							ALTHOUSE R, 1990, AM J CARDIOL, V66, P1298, DOI 10.1016/0002-9149(90)91157-2; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, Lancet, V1, P397; ARMSTRONG A, 1972, BRIT HEART J, V34, P67; BIRKHEAD JS, 1992, BMJ-BRIT MED J, V305, P445, DOI 10.1136/bmj.305.6851.445; BOSSAERT L, 1991, EUR HEART J, V12, P965; BOUTEN MJM, 1992, EUR HEART J, V13, P925, DOI 10.1093/oxfordjournals.eurheartj.a060294; BRUGEMANN J, 1992, EUR HEART J, V13, P787; CHAMBERLAIN DA, 1988, LANCET, V1, P545; HERLITZ J, 1989, AM J CARDIOL, V64, P90, DOI 10.1016/0002-9149(89)90659-0; HO MT, 1989, ANN EMERG MED, V18, P727, DOI 10.1016/S0196-0644(89)80004-6; JAGGER JD, 1987, LANCET, V1, P34; KENNEDY JW, 1988, CIRCULATION, V77, P345, DOI 10.1161/01.CIR.77.2.345; OROURKE MF, 1989, THROMBOLYSIS CARDIOV, P302; PELL ACH, 1992, BMJ-BRIT MED J, V304, P83, DOI 10.1136/bmj.304.6819.83; RAWLES JM, 1988, BRIT MED J, V296, P882, DOI 10.1136/bmj.296.6626.882; ROWLEY JM, 1992, BRIT HEART J, V67, P255; ROWLEY JM, 1982, BRIT MED J, V284, P1741, DOI 10.1136/bmj.284.6331.1741; SCHOFER J, 1990, AM J CARDIOL, V66, P1429, DOI 10.1016/0002-9149(90)90528-9; WILCOX RG, 1988, LANCET, V2, P525; WILCOX RG, 1992, 14TH C EUR SOC CARD, P2429; 1987, REV FED ARG CARDIOL, V16, P238	22	47	47	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 13	1993	341	8846					654	657		10.1016/0140-6736(93)90420-L	http://dx.doi.org/10.1016/0140-6736(93)90420-L			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR613	8095570				2023-01-03	WOS:A1993KR61300004
J	PATTERSON, DR; MILLERPERRIN, C; MCCORMICK, TR; HUDSON, LD				PATTERSON, DR; MILLERPERRIN, C; MCCORMICK, TR; HUDSON, LD			WHEN LIFE-SUPPORT IS QUESTIONED EARLY IN THE CARE OF PATIENTS WITH CERVICAL-LEVEL QUADRIPLEGIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SPINAL-CORD INJURY; DEPRESSION				PATTERSON, DR (corresponding author), UNIV WASHINGTON,SCH MED,SEATTLE,WA 98104, USA.							ABRAMS KS, 1981, PARAPLEGIA, V19, P253, DOI 10.1038/sc.1981.49; CHARLIFUE SW, 1991, ARCH PHYS MED REHAB, V72, P488; CREWE N M, 1979, Archives of Physical Medicine and Rehabilitation, V60, P252; CUSHMAN LA, 1990, ARCH PHYS MED REHAB, V71, P191; DUCHARME SH, 1980, SCI DIG, V2, P29; ELGHATIT AZ, 1975, J CHRON DIS, V28, P383, DOI 10.1016/0021-9681(75)90034-X; FINK SL, 1968, J MARRIAGE FAM, V30, P64, DOI 10.2307/350223; Fleetwood J, 1989, Nursing, V19, P62; FRANK RG, 1987, CLIN PSYCHOL REV, V7, P611, DOI 10.1016/0272-7358(87)90009-2; GARDNER BP, 1985, BRIT MED J, V291, P1620, DOI 10.1136/bmj.291.6509.1620; GEISLER WO, 1983, PARAPLEGIA, V21, P364, DOI 10.1038/sc.1983.60; MAYNARD FM, 1987, ARCH PHYS MED REHAB, V68, P862; Morris J, 1986, J HEAD TRAUMA REHAB, V1, P31; Nyquist R H, 1967, Paraplegia, V5, P22; PALMER JB, 1985, ARCH PHYS MED REHAB, V66, P253, DOI 10.1016/0003-9993(85)90164-9; PATTERSON DR, IN PRESS PSYCHOL B; Ridley B, 1989, Rehabil Nurs, V14, P250; SIEGEL M, 1969, 17TH P VET ADM SPIN, V18, P230; SIEGEL M, 1970, PSYCHOL ASPECTS DISA, V17, P9; SIEGEL M, 1971, RES UTILIZATION REHA; SIEGEL MS, 1969, MED CLIN N AM, V53, P713, DOI 10.1016/S0025-7125(16)32767-5; SKIPPER JK, 1968, J REHABIL, V34, P16; SOMERVILLE J, 1990, AM MED NEWS     0202, P6; STOVER SL, 1986, SPINAL CORD INJURY F; Trieschmann RB, 1988, SPINAL CORD INJURIES; Vargo F.A., 1984, J APPL REHABIL COUNS, V15, P28, DOI 10.1891/0047-2220.15.1.28; VARGO FA, 1984, INT J ADV COUNS, V7, P253, DOI 10.1007/BF00379147; WESTBROOK MT, 1986, REHABIL PSYCHOL, V31, P79, DOI 10.1037//0090-5550.31.2.79; WHITENECK GG, 1985, COLLABORATIVE STUDY; YORKSTON KM, 1992, AUGMENTATIVE COMMUNI; 1991, AM REV RESPIR DIS, V144, P726	31	42	42	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 18	1993	328	7					506	509		10.1056/NEJM199302183280712	http://dx.doi.org/10.1056/NEJM199302183280712			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KM417	8421482				2023-01-03	WOS:A1993KM41700012
J	Ifudu, O; Feldman, J; Friedman, EA				Ifudu, O; Feldman, J; Friedman, EA			The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RECOMBINANT-HUMAN-ERYTHROPOIETIN; AMBULATORY PERITONEAL-DIALYSIS; ANEMIA; FAILURE; UREMIA	Background. Anemia (characterized by a hematocrit of 30 percent or lower) persists in 40 to 60 percent of patients treated for end-stage renal disease with maintenance hemodialysis, despite concomitant erythropoietin (epoetin) therapy. We tested the hypothesis that inadequate dialysis is a key reason for the insufficient response to erythropoietin in patients with end-stage renal disease who are receiving hemodialysis. Methods. We prospectively studied 135 randomly selected patients undergoing hemodialysis who had been receiving intravenous erythropoietin for at least four months. The adequacy of dialysis was assessed by measuring the percent reduction in the blood urea nitrogen concentration and the serum albumin concentration. The hematocrit was measured weekly for four weeks, transferrin saturation was measured, and coexisting illnesses were documented. To determine the effect of an increased level of dialysis on the hematocrit, the thrice-weekly schedule of dialysis was increased to raise the mean urea-reduction value from 60.7 to 72.0 percent for six weeks in 20 consecutive patients whose base-line urea-reduction value was less than 65 percent. The change in the hematocrit in these patients was compared with that observed in the next 20 patients who had an equivalent base-line urea-reduction value but whose level of dialysis was not altered. Results. The mean (+/-SD) hematocrit of the entire group was 29.2+/-4 percent, and the mean thrice-weekly dose of erythropoietin was 59+/-29 U per kilogram of body weight. The mean serum albumin concentration was 3.8+/-0.4 g per deciliter, the mean urea-reduction value was 62+/-4.8 percent, and the mean transferrin saturation was 20+/-9 percent. Multiple regression analysis revealed direct correlations between the hematocrit and the serum albumin concentration (P=0.009) and between the hematocrit and the urea-reduction value (P=0.012) after adjustment for other factors. A logistic-regression analysis indicated that an 11 percent increase in the urea-reduction value doubled the odds that a patient would have a hematocrit above 30 percent. After six weeks of increased intensity of dialysis in 20 patients with base-line urea-reduction values of less than 65 percent, the mean (+/-SE) hematocrit rose from 28.4+/-0.78 percent to 32.3+/-0.71 percent (P=0.002); there was no significant change in a control group of 20 patients with equivalent base-line urea-reduction values in whom the dialysis level was not altered (28.2+/-0.84 percent to 26.3+/-0.85 percent; P=0.175). Conclusions. In patients with end-stage renal disease, inadequate hemodialysis is associated with a suboptimal response to erythropoietin therapy, Increasing the intensity of dialysis in patients with anemia who are receiving inadequate dialysis results in a significant increase in the hematocrit. (C) 1996, Massachusetts Medical Society.	SUNY HLTH SCI CTR,DEPT PREVENT MED & COMMUNITY HLTH,BROOKLYN,NY 11203	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Ifudu, O (corresponding author), SUNY HLTH SCI CTR,DEPT MED,RENAL DIS DIV,450 CLARKSON AVE,BOX 52,BROOKLYN,NY 11203, USA.							BIA MJ, 1989, KIDNEY INT, V36, P852, DOI 10.1038/ki.1989.271; CARO J, 1979, J LAB CLIN MED, V93, P449; ESCHBACH JW, 1992, KIDNEY INT, V42, P407, DOI 10.1038/ki.1992.302; ESCHBACH JW, 1989, KIDNEY INT, V35, P134, DOI 10.1038/ki.1989.18; ESCHBACH JW, 1989, ANN INTERN MED, V111, P992, DOI 10.7326/0003-4819-111-12-992; ESCHBACH JW, 1970, ARCH INTERN MED, V126, P812, DOI 10.1001/archinte.126.5.812; ESSERS U, 1974, P EUR DIAL TRANS, V11, P389; GOODNOUGH LT, 1994, CLIN NEPHROL, V41, P303; HAKIM RM, 1994, AM J KIDNEY DIS, V23, P661, DOI 10.1016/S0272-6386(12)70276-7; HELD PJ, 1994, AM J KIDNEY DIS, V24, P974, DOI 10.1016/S0272-6386(12)81108-5; IFUDU O, 1994, JAMA-J AM MED ASSOC, V271, P29, DOI 10.1001/jama.271.1.29; IFUDU O, 1995, ASAIO J, V41, pM426, DOI 10.1097/00002480-199507000-00045; IFUDU O, 1994, CLIN RES, V42, pA263; INGELFINGER JA, 1994, BIOSTATISTICS CLIN M, P166; KOCH KM, 1974, NEPHRON, V12, P405, DOI 10.1159/000180353; KOPPLE JD, 1994, AM J KIDNEY DIS, V24, P968, DOI 10.1016/S0272-6386(12)81071-7; LUNDIN AP, 1989, SEMIN NEPHROL, V9, P22; MARKSON J L, 1956, Scott Med J, V1, P320; MCGONIGLE RJS, 1984, KIDNEY INT, V25, P430, DOI 10.1038/ki.1984.35; Norusis M.J., 1993, SPSS WINDOWS ADV STA, P1; ORTEGA JA, 1977, AM J HEMATOL, V2, P299, DOI 10.1002/ajh.2830020312; POWE NR, 1992, JAMA-J AM MED ASSOC, V268, P1434, DOI 10.1001/jama.268.11.1434; POWE NR, 1993, KIDNEY INT, V43, P1125, DOI 10.1038/ki.1993.158; RADTKE HW, 1981, J CLIN INVEST, V67, P1623, DOI 10.1172/JCI110197; RAO DS, 1993, NEW ENGL J MED, V328, P171, DOI 10.1056/NEJM199301213280304; VANWYCK DB, 1989, KIDNEY INT, V35, P712, DOI 10.1038/ki.1989.43; WALLNER SF, 1981, J LAB CLIN MED, V97, P170; ZAPPACOSTA AR, 1982, AM J MED, V72, P53, DOI 10.1016/0002-9343(82)90577-0; 1992, 1992 SE KIDN COUNC A; 1994, ANN INTERN MED, V121, P62	30	230	237	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 15	1996	334	7					420	425		10.1056/NEJM199602153340702	http://dx.doi.org/10.1056/NEJM199602153340702			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU696	8552143				2023-01-03	WOS:A1996TU69600002
J	Tallal, P; Miller, SL; Bedi, G; Byma, G; Wang, XQ; Nagarajan, SS; Schreiner, C; Jenkins, WM; Merzenich, MM				Tallal, P; Miller, SL; Bedi, G; Byma, G; Wang, XQ; Nagarajan, SS; Schreiner, C; Jenkins, WM; Merzenich, MM			Language comprehension in language-learning impaired children improved with acoustically modified speech	SCIENCE			English	Article							DEVELOPMENTAL APHASIA; READING DISABILITIES; AUDITORY-PERCEPTION; PREVALENCE; DELAY; RETARDATION; DISORDERS; INFANTS; YOUNG	A speech processing algorithm was developed to create more salient versions of the rapidly changing elements in the acoustic waveform of speech that have been shown to be deficiently processed by language-learning impaired (LLI) children. LLI children received extensive daily training, over a 4-week period, with listening exercises in which all speech was translated into this synthetic form. They also received daily training with computer ''games'' designed to adaptively drive improvements in temporal processing thresholds, Significant improvements in speech discrimination and language comprehension abilities were demonstrated in two independent groups of LLI children.	UNIV CALIF SAN FRANCISCO, WM KECK CTR INTEGRAT NEUROSCI, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, COLEMAN LAB, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Tallal, P (corresponding author), RUTGERS STATE UNIV, CTR MOLEC & BEHAV NEUROSCI, NEWARK, NJ 07102 USA.			Schreiner, Christoph/0000-0002-4571-4328	NIDCD NIH HHS [R01 DC002260] Funding Source: Medline; NINDS NIH HHS [R01 NS010414] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS010414] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC002260] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		[Anonymous], 1982, ANN DYSLEXIA, DOI DOI 10.1007/BF02647960; [Anonymous], 1991, WECHSLER INTELLIGENC; BEITCHMAN JH, 1986, J SPEECH HEAR DISORD, V51, P98, DOI 10.1044/jshd.5102.98; BENASICH AA, 1993, ANN NY ACAD SCI, V682, P312, DOI 10.1111/j.1749-6632.1993.tb22978.x; BISHOP DVM, 1990, J CHILD PSYCHOL PSYC, V31, P1027, DOI 10.1111/j.1469-7610.1990.tb00844.x; CATTS HW, 1993, J SPEECH HEAR RES, V36, P948, DOI 10.1044/jshr.3605.948; CURTISS S, 1992, J SPEECH HEAR RES, V35, P373, DOI 10.1044/jshr.3502.373; CURTISS S, UNPUB CURTISS YAMADA; DiSimoni F., 1978, TOKEN TEST CHILDREN; Eimas P. D., 1987, CATEGORICAL PERCEPTI, P161; Goldman R, 2015, GOLDMAN FRISTOE TEST; Goldman R., 1974, GOLDMAN FRISTOE WOOD; GORDONSALANT S, 1993, J SPEECH HEAR RES, V36, P1276, DOI 10.1044/jshr.3606.1276; HENDERSON JL, 1995, 61ST BIENN M SOC RES; KUHL PK, 1992, SCIENCE, V255, P606, DOI 10.1126/science.1736364; LANGHANS T, 1982, 1982 P IEEE INT C AC, P156; LEONARD LB, 1989, APPL PSYCHOLINGUIST, V10, P179, DOI 10.1017/S0142716400008511; LIBERMAN IY, 1974, J EXP CHILD PSYCHOL, V18, P201, DOI 10.1016/0022-0965(74)90101-5; Merzenich MM, 1996, SCIENCE, V271, P77, DOI 10.1126/science.271.5245.77; Merzenich MM., 1995, MATURATIONAL WINDOWS, P247; PORTNOFF MR, 1981, IEEE T ACOUST SPEECH, V29, P374, DOI 10.1109/TASSP.1981.1163581; RISSMAN M, 1990, J SPEECH LANGUAGE PA, V14, P49; SCARBOROUGH HS, 1990, CHILD DEV, V61, P1728, DOI 10.2307/1130834; SILVA PA, 1980, DEV MED CHILD NEUROL, V22, P768; Stark R., 1988, LANGUAGE SPEECH READ; STARK RE, 1984, ANN DYSLEXIA, V34, P49, DOI 10.1007/BF02663613; STEINSCHNEIDER M, 1990, BRAIN RES, V519, P158, DOI 10.1016/0006-8993(90)90074-L; STEVENSON J, 1976, DEV MED CHILD NEUROL, V18, P431; TALLAL P, 1978, BRAIN LANG, V5, P13, DOI 10.1016/0093-934X(78)90003-2; TALLAL P, 1973, NEUROPSYCHOLOGIA, V11, P389, DOI 10.1016/0028-3932(73)90025-0; TALLAL P, 1980, BRAIN LANG, V9, P182, DOI 10.1016/0093-934X(80)90139-X; TALLAL P, 1973, NATURE, V241, P468, DOI 10.1038/241468a0; TALLAL P, 1975, NEUROPSYCHOLOGIA, V13, P69, DOI 10.1016/0028-3932(75)90049-4; TALLAL P, 1985, BRAIN LANG, V25, P314, DOI 10.1016/0093-934X(85)90087-2; TALLAL P, 1974, NEUROPSYCHOLOGIA, V12, P83, DOI 10.1016/0028-3932(74)90030-X; TALLAL P, 1985, NEUROPSYCHOLOGIA, V23, P527, DOI 10.1016/0028-3932(85)90006-5; TALLAL P, 1994, UNPUB COMPUTERIZED V; Tallal P., 1980, NONSPEECH LANGUAGE C, P449; TORGESEN JK, 1994, J LEARN DISABIL, V27, P276, DOI 10.1177/002221949402700503; WILLIAMS DM, 1980, J OTOLARYNGOL S, V7, P5; 1988, JAN P NAT C LEARN DI	41	830	873	1	111	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 5	1996	271	5245					81	84		10.1126/science.271.5245.81	http://dx.doi.org/10.1126/science.271.5245.81			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TP022	8539604				2023-01-03	WOS:A1996TP02200048
J	EDLIN, BR; IRWIN, KL; FARUQUE, S; MCCOY, CB; WORD, C; SERRANO, Y; INCIARDI, JA; BOWSER, BP; SCHILLING, RF; HOLMBERG, SD; ELBASSEL, N; CABRERA, A; FLORES, Y; GUZMAN, N; HOGAN, R; MELENDEZ, N; NIEVES, E; OCASIO, A; RIVERA, G; RIZZOLO, A; STEELE, F; TURSO, S; BIDASSIE, B; KUOHSIEN, S; STRAUSS, D; MCCOY, HV; MCBRIDE, DC; WEATHERBY, N; RIVERS, JE; ALONSO, E; ARISTIDE, G; ASHELY, M; BOWENS, S; BUCKWALDEN, D; COMERFORD, S; DEVEAUXSHEPARD, V; DYER, E; GALVEZ, M; GRIFFIN, J; JONES, M; LOCASCIO, V; MAGILNER, L; MENDEZ, N; MCKAY, C; MCQUEEN, L; MILES, C; MIRANDA, R; PAGAN, L; PIERRE, RM; SALAS, R; SEOANE, L; SHABAZZ, B; WALDEN, E; FLECHER, MA; GARCIAMORALES, R; EVANS, PE; WORD, CO; BALLESTEROS, C; BYRD, S; CURTIS, W; DOGAN, D; GARNER, A; GRIFFIN, M; HAWKINS, C; HUNTERGAMBLE, D; IREGUI, C; JUSTICE, M; LEE, M; LODICO, M; MCGILROY, J; PATTERSON, V; PENN, S; PERKINS, C; PERSAUD, M; RICHARDSON, C; ROBERTSON, N; BACK, A; LARSEN, S; SCHMIDT, DS; BYERS, RH; LUDWIG, D; JOHNSON, R; WONG, L; DUSHKU, J				EDLIN, BR; IRWIN, KL; FARUQUE, S; MCCOY, CB; WORD, C; SERRANO, Y; INCIARDI, JA; BOWSER, BP; SCHILLING, RF; HOLMBERG, SD; ELBASSEL, N; CABRERA, A; FLORES, Y; GUZMAN, N; HOGAN, R; MELENDEZ, N; NIEVES, E; OCASIO, A; RIVERA, G; RIZZOLO, A; STEELE, F; TURSO, S; BIDASSIE, B; KUOHSIEN, S; STRAUSS, D; MCCOY, HV; MCBRIDE, DC; WEATHERBY, N; RIVERS, JE; ALONSO, E; ARISTIDE, G; ASHELY, M; BOWENS, S; BUCKWALDEN, D; COMERFORD, S; DEVEAUXSHEPARD, V; DYER, E; GALVEZ, M; GRIFFIN, J; JONES, M; LOCASCIO, V; MAGILNER, L; MENDEZ, N; MCKAY, C; MCQUEEN, L; MILES, C; MIRANDA, R; PAGAN, L; PIERRE, RM; SALAS, R; SEOANE, L; SHABAZZ, B; WALDEN, E; FLECHER, MA; GARCIAMORALES, R; EVANS, PE; WORD, CO; BALLESTEROS, C; BYRD, S; CURTIS, W; DOGAN, D; GARNER, A; GRIFFIN, M; HAWKINS, C; HUNTERGAMBLE, D; IREGUI, C; JUSTICE, M; LEE, M; LODICO, M; MCGILROY, J; PATTERSON, V; PENN, S; PERKINS, C; PERSAUD, M; RICHARDSON, C; ROBERTSON, N; BACK, A; LARSEN, S; SCHMIDT, DS; BYERS, RH; LUDWIG, D; JOHNSON, R; WONG, L; DUSHKU, J			INTERSECTING EPIDEMICS - CRACK COCAINE USE AND HIV-INFECTION AMONG INNER-CITY YOUNG-ADULTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; SEXUALLY-TRANSMITTED DISEASES; DRUG-USERS; RISK; SEX; PROSTITUTION; SYPHILIS; SMOKERS; AIDS	Background and Methods. The smoking of ''crack'' cocaine is thought to be associated with high-risk sexual practices that accelerate the spread of infection with the human immunodeficiency virus (HIV). We studied 2323 young adults, 18 to 29 years of age, who smoked crack regularly or who had never smoked crack. The study participants, recruited from the streets of inner-city neighborhoods in New York, Miami, and San Francisco, were interviewed and tested for HIV. This report presents the findings for the 1967 participants (85 percent) who had never injected drugs. Results. Of the 1137 crack smokers, 15.7 percent were positive for HIV antibody, as compared with 5.2 percent of the 830 nonsmokers (prevalence ratio adjusted for the city, 2.4; 99 percent confidence interval, 1.7 to 3.6). The prevalence of HIV was highest among the crack-smoking women in New York (29.6 percent) and Miami (23.0 percent). In these two cities, of the 283 women who had sex in exchange for money or drugs, 30.4 percent were infected with HIV as compared with 9.1 percent of the 286 other women (prevalence ratio, 3.1; 99 percent confidence interval, 1.9 to 5.1); of the 91 men who had anal sex with other men, 42.9 percent were infected with HIV as compared with 9.3 percent of the 582 men who did not have anal sex with other men (prevalence ratio, 4.7; 99 percent confidence interval, 3.0 to 7.4). In multivariable analyses, these high-risk sexual practices accounted for the higher prevalence of HIV infection among the crack smokers, as compared with those who did not smoke crack. Women who had recently had unprotected sex in exchange for money or drugs were as likely to be infected as men who had had sex with men (40.9 percent vs. 42.9 percent). Conclusions. In poor, inner-city communities young smokers of crack cocaine, particularly women who have sex in exchange for money or drugs, are at high risk for HIV infection. Crack use promotes the heterosexual transmission of HIV.	ASSOC DRUG ABUSE PREVENT & TREATMENT,NEW YORK,NY; UNIV MIAMI,MIAMI,FL 33152; BAYVIEW HUNTERS POINT FDN,SAN FRANCISCO,CA; UNIV DELAWARE,NEWARK,DE; CALIF STATE UNIV HAYWARD,HAYWARD,CA 94542; COLUMBIA UNIV,NEW YORK,NY	University of Miami; University of Delaware; California State University System; California State University East Bay; Columbia University	EDLIN, BR (corresponding author), CTR DIS CONTROL & PREVENT,DIV HIV AIDS E45,1600 CLIFTON RD,ATLANTA,GA 30333, USA.		Edlin, Brian/F-2966-2018	Edlin, Brian/0000-0001-8172-8797	PHS HHS [U64/CCU904-453, U64/CCU404539, U64/CCU204582] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALLEN DF, 1987, COCAINE CRISIS, P15; ANTHONY JC, 1991, J DRUG ISSUES, V21, P739, DOI 10.1177/002204269102100405; BOOTH RE, 1993, AM J PUBLIC HEALTH, V83, P1144, DOI 10.2105/AJPH.83.8.1144; Bourgois P., 1989, CONTEMP DRUG PROBL, V16, P619; BOWSER BP, 1989, J NATL MED ASSOC, V81, P538; Breiman L., 1984, CLASSIFICATION REGRE, DOI 10.1201/9781315139470; CHIASSON MA, 1991, AIDS, V5, P1121, DOI 10.1097/00002030-199109000-00011; CHIRGWIN K, 1991, AM J PUBLIC HEALTH, V81, P1576, DOI 10.2105/AJPH.81.12.1576; COHEN S, 1987, COCAINE CRISIS, P27; DUNLAP E, 1992, J PSYCHOACTIVE DRUGS, V24, P307, DOI 10.1080/02791072.1992.10471656; DUPONT RL, 1991, OFFICE SUBSTANCE ABU, V9; EDLIN BR, 1992, J PSYCHOACTIVE DRUGS, V24, P363, DOI 10.1080/02791072.1992.10471660; ELLERBROCK TV, 1992, NEW ENGL J MED, V327, P1704, DOI 10.1056/NEJM199212103272402; FARLEY TA, 1990, SEX TRANSM DIS, V17, P163, DOI 10.1097/00007435-199010000-00003; FULLILOVE RE, 1990, JAMA-J AM MED ASSOC, V263, P851, DOI 10.1001/jama.263.6.851; HAMID A, 1992, J PSYCHOACTIVE DRUGS, V24, P337, DOI 10.1080/02791072.1992.10471658; Inciardi J., 1993, WOMEN CRACK COCAINE, P147; Inciardi J. A., 1987, CONTEMP DRUG PROBL, V14, P461; INCIARDI JA, 1986, WAR DRUGS HEROIN COC, P121; MARX R, 1991, SEX TRANSM DIS, V18, P92, DOI 10.1097/00007435-199118020-00008; RATNER MS, 1993, CRACK PIPE PIMP ETHN; Rinfret M, 1991, NIDA Res Monogr, V110, P297; ROLFS RT, 1990, AM J PUBLIC HEALTH, V80, P853, DOI 10.2105/AJPH.80.7.853; SANCHEZMARTINEZ D, 1991, J INFECT DIS, V164, P1196, DOI 10.1093/infdis/164.6.1196; SMART RG, 1991, AM J DRUG ALCOHOL AB, V17, P13, DOI 10.3109/00952999108992806; WASHTON AM, 1987, COCAINE CRISIS, P45; WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61, DOI 10.1097/00007435-199219020-00001; 1987, LANCET, V2, P1061; 1990, SAS STAT USERS GUIDE; 1993, 4 DEP HLTH HUM SERV; 1991, DHHS ADM921887 DEP H	31	460	466	0	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 24	1994	331	21					1422	1427		10.1056/NEJM199411243312106	http://dx.doi.org/10.1056/NEJM199411243312106			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PU533	7969281				2023-01-03	WOS:A1994PU53300006
J	GOLDSTEIN, RS; GORT, EH; STUBBING, D; AVENDANO, MA; GUYATT, GH				GOLDSTEIN, RS; GORT, EH; STUBBING, D; AVENDANO, MA; GUYATT, GH			RANDOMIZED CONTROLLED TRIAL OF RESPIRATORY REHABILITATION	LANCET			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; HEALTH-STATUS	Disability associated with chronic obstructive pulmonary disease has led to the development of rehabilitation programmes that aim to increase exercise tolerance and improve quality of life. Many reports of the benefits of rehabilitation have been from uncontrolled trials and unsupervised programmes. In view of asked of patients, their families, professionals, rehabilitation should be justified by a demonstration of sustained improvement over conventional treatment. We undertook a prospective randomised controlled trial of respiratory rehabilitation in 89 subjects (44 men, 45 women) aged 66 (SD 7) years with severe but stable chronic obstructive pulmonary disease who received rehabilitation or conventional community care. The treatment group were rehabilitated as inpatients for 8 weeks and supervised as outpatients for 16 weeks. Primary outcome measures of exercise tolerance and quality of life were made at baseline and repeated at 12, 18, and 24 weeks. The difference between baseline and last follow-up was significant for 6 min walk distance (37.9 m [95% CI 10.8-65.0], p=0.0067) and submaximal cycle time (4.7 min [2.1-7.3]), There were also significant differences in questionnaire (p=0.0061), emotional function (p=0.0150), mastery (p=0.0002), and dyspnoea index (p=0.0053). Improvements in exercise tolerance and quality of life can be achieved and sustained for 6 months in patients undergoing respiratory rehabilitation compared with those receiving conventional care.	UNIV TORONTO, DEPT MED, TORONTO, ON, CANADA; MCMASTER UNIV, DEPT MED, TORONTO, ON, CANADA; MCMASTER UNIV, DEPT CLIN EPIDEMIOL, TORONTO, ON, CANADA	University of Toronto; McMaster University; McMaster University								[Anonymous], 1987, AM REV RESPIR DIS, V136, P1285; [Anonymous], 1987, AM REV RESPIR DIS, V136, P1299; ATKINS CJ, 1984, J CONSULT CLIN PSYCH, V52, P591, DOI 10.1037/0022-006X.52.4.591; BLACK LF, 1969, AM REV RESPIR DIS, V99, P696; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; BRUNDIN A, 1974, SCAND J RESPIR DIS, V55, P25; BURROWS B, 1969, NEW ENGL J MED, V280, P397, DOI 10.1056/NEJM196902202800801; BURROWS B, 1971, CHEST, V60, P25; DONNER CF, 1992, EUR RESPIR J, V5, P266; DUDLEY DL, 1980, CHEST, V77, P413, DOI 10.1378/chest.77.3.413; FLETCHER C, 1977, BMJ-BRIT MED J, V1, P1645, DOI 10.1136/bmj.1.6077.1645; GUYATT GH, 1987, AM REV RESPIR DIS, V135, P1069; GUYATT GH, 1987, THORAX, V42, P773, DOI 10.1136/thx.42.10.773; GUYATT GH, 1984, THORAX, V39, P818, DOI 10.1136/thx.39.11.818; HAAS A, 1969, MED CLIN N AM, V53, P593, DOI 10.1016/S0025-7125(16)32756-0; ISAWA T, 1978, AM REV RESPIR DIS, V118, P55; JAESCHKE R, 1989, CONTROL CLIN TRIALS, V10, P407, DOI 10.1016/0197-2456(89)90005-6; Jones NL., 1988, CLIN EXERCISE TESTIN, V3rd edn; LERTZMAN MM, 1976, AM REV RESPIR DIS, V114, P1145; MAHLER DA, 1984, CHEST, V85, P751, DOI 10.1378/chest.85.6.751; MCGAVIN CR, 1977, THORAX, V32, P307, DOI 10.1136/thx.32.3.307; MUNGALL IPF, 1979, THORAX, V34, P254, DOI 10.1136/thx.34.2.254; PAEZ PN, 1967, AM REV RESPIR DIS, V95, P944; PETTY TL, 1970, CHEST, V57, P204, DOI 10.1378/chest.57.2.204; ROCHESTER DF, 1985, AM REV RESPIR DIS, V132, P42; SAHN S A, 1980, Chest, V77, P311, DOI 10.1378/chest.77.2_Supplement.311; SERGYSELS R, 1979, RESPIRATION, V38, P105, DOI 10.1159/000194066; SINCLAIR DJM, 1980, BMJ-BRIT MED J, V280, P519, DOI 10.1136/bmj.280.6213.519; TOSHIMA MT, 1990, HEALTH PSYCHOL, V9, P237, DOI 10.1037/0278-6133.9.3.237; WIJKSTRA PJ, 1994, EUR RESPIR J, V7, P269, DOI 10.1183/09031936.94.07020269; 1981, J R COLL PHYSICIANS, V15, P69; 1980, BRIT MED J, V1, P519	33	356	363	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 19	1994	344	8934					1394	1397		10.1016/S0140-6736(94)90568-1	http://dx.doi.org/10.1016/S0140-6736(94)90568-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR786	7968075				2023-01-03	WOS:A1994PR78600009
J	PIJNENBORG, L; VANDELDEN, JJM; KARDAUN, JWPF; GLERUM, JJ; van der Maas, PJ				PIJNENBORG, L; VANDELDEN, JJM; KARDAUN, JWPF; GLERUM, JJ; van der Maas, PJ			NATIONWIDE STUDY OF DECISIONS CONCERNING THE END OF LIFE IN GENERAL-PRACTICE IN THE NETHERLANDS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							FAMILY DOCTORS; PATIENT; PHYSICIAN; EUTHANASIA	Objective-To gain insight into decisions made in general practice about the end of life. Design-Study I: interviews with 405 physicians. Study II: analysis of death certificates with data obtained on 5197 cases in which decisions about the end of life may have been made. Study III: prospective study with doctors from study I: questionnaires used to collect information about 2257 deaths. The information was representative for all deaths in the Netherlands. Results-Over two fifths of all patients in the Netherlands die at home. General practitioners took fewer decisions about the end of life than hospital doctors and doctors in nursing homes (34%, 40%, and 56% of all dying patients, respectively). Specifically, decisions to withhold or withdraw treatment to prolong life were taken less often. Euthanasia or assisted suicide, however, was performed in 3.2% of all deaths in general practice compared with 1.4% in hospital practice. In over half of the cases concerning pain relief or non-treatment general practitioners did not discuss the decision with the patient, mostly because of incapacity of the patient, but in 20% of cases for ''paternalistic'' reasons. Older general practitioners discussed such decisions less often with their patients. Colleagues were consulted more often if the general practitioner worked in group practice. Conclusion-Differences in work situation between general practitioners and hospital doctors and differences between the group of general practitioners contribute to differences in the number and type of decisions about the end of life as well as in the decision making process.	UNIV UTRECHT, CTR BIOETH & HLTH LAW, UTRECHT, NETHERLANDS; STAT NETHERLANDS, VOORBURG, NETHERLANDS	Utrecht University	PIJNENBORG, L (corresponding author), ERASMUS UNIV ROTTERDAM, DEPT PUBL HLTH, POB 1738, 3000 DR ROTTERDAM, NETHERLANDS.							BATTIN MP, 1994, LEAST WORST DEATH ES, P130; Beauchamp T, 1989, PRINCIPLES BIOMEDICA; EMANUEL EJ, 1992, JAMA-J AM MED ASSOC, V267, P2221, DOI 10.1001/jama.267.16.2221; HOFFMASTER CB, 1991, SOC SCI MED, V33, P647, DOI 10.1016/0277-9536(91)90018-8; ORR RD, 1991, J FAM PRACTICE, V33, P500; PIJNENBORG L, 1993, LANCET, V341, P1196, DOI 10.1016/0140-6736(93)91014-D; SIEGLER M, 1985, ARCH INTERN MED, V145, P713, DOI 10.1001/archinte.145.4.713; van der Maas P. J., 1992, EUTHANASIA OTHER MED; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; VANDERWAL G, 1992, FAM PRACT, V9, P130, DOI 10.1093/fampra/9.2.130; VANDERWAL G, 1994, BRIT MED J, V308, P1346, DOI 10.1136/bmj.308.6940.1346; 1987, BIOETHICS, V1, P163; 1992, END LIFE MED PRACTIC	13	15	15	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 5	1994	309	6963					1209	1212		10.1136/bmj.309.6963.1209	http://dx.doi.org/10.1136/bmj.309.6963.1209			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ662	7987154	Green Published			2023-01-03	WOS:A1994PQ66200024
J	BOULTONJONES, M				BOULTONJONES, M			DIALYSIS MEMBRANES - CLINICAL EFFECTS	LANCET			English	Editorial Material							COMPLEMENT ACTIVATION; DIALYZER				BOULTONJONES, M (corresponding author), ROYAL INFIRM,RENAL UNIT,GLASGOW,SCOTLAND.							CRADDOCK PR, 1977, J CLIN INVEST, V59, P879, DOI 10.1172/JCI108710; FINK MP, 1991, CRIT CARE MED, V19, P627, DOI 10.1097/00003246-199105000-00009; HAKIM RM, 1984, NEW ENGL J MED, V311, P878, DOI 10.1056/NEJM198410043111403; PARNES EL, 1991, KIDNEY INT, V40, P1148, DOI 10.1038/ki.1991.327; Simpson K., 1993, Nephrology Dialysis Transplantation, V8, P946	5	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 27	1994	344	8922					559	559		10.1016/S0140-6736(94)91958-5	http://dx.doi.org/10.1016/S0140-6736(94)91958-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD424	7914953				2023-01-03	WOS:A1994PD42400002
J	PARTHASARATHY, RV; MARTIN, CR				PARTHASARATHY, RV; MARTIN, CR			SYNTHESIS OF POLYMERIC MICROCAPSULE ARRAYS AND THEIR USE FOR ENZYME IMMOBILIZATION	NATURE			English	Article							GLUCOSE-OXIDASE; TEMPLATE SYNTHESIS; COVALENT ELECTROPOLYMERIZATION; ELECTRONIC CONDUCTIVITIES; POLYPYRROLE FILMS; MICROTUBULES; SENSORS	CURRENT methods for immobilizing enzymes for use in bioreactors and biosensors(1-20) include adsorption on or covalent attachment to a support(2-4), micro-encapsulation(5,6), and entrapment within a membrane/film(7,8,11-20) or gel(9). The ideal immobilization method should employ mild chemical conditions, allow for large quantities of enzyme to be immobilized, provide a large surface area for enzyme-substrate contact within a small total volume, minimize barriers to mass transport of substrate and product, and provide a chemically and mechanically robust system. Here we describe a method for enzyme immobilization that satisfies all of these criteria. We have developed a template-based synthetic method that yields hollow polymeric microcapsules of uniform diameter and length. These microcapsules are arranged in a high-density array in which the individual capsules protrude from a surface like the bristles of a brush. We have developed procedures for filling these microcapsules with high concentrations of enzymes. The enzyme-loaded microcapsule arrays function as enzymatic bioreactors in both aqueous solution and organic solvents.	COLORADO STATE UNIV,DEPT CHEM,FT COLLINS,CO 80523	Colorado State University			Martin, Charles/AAA-1040-2019; Way, James Douglas/A-9408-2010	Way, James Douglas/0000-0001-9612-8508				ALMEIDA NF, 1993, BIOTECHNOL BIOENG, V42, P1037, DOI 10.1002/bit.260420904; BAKER RW, 1991, MEMBRANE SEPARATION, V2, P151; BARTLETT PN, 1987, J ELECTROANAL CHEM, V224, P37, DOI 10.1016/0022-0728(87)85082-9; BARTLETT PN, 1992, J CHEM SOC FARADAY T, V88, P2677, DOI 10.1039/ft9928802677; BURGMAYER P, 1986, HDB CONDUCTING POLYM, V1, pCH15; CAI ZH, 1989, J AM CHEM SOC, V111, P4138, DOI 10.1021/ja00193a077; DALVIE SK, 1992, BIOTECHNOL BIOENG, V40, P1174; ELLERBY LM, 1992, SCIENCE, V255, P1113, DOI 10.1126/science.1312257; FORTIER G, 1991, BIOTECHNOL BIOENG, V37, P854, DOI 10.1002/bit.260370909; FOULDS NC, 1986, J CHEM SOC FARAD T 1, V82, P1259, DOI 10.1039/f19868201259; FOULDS NC, 1988, ANAL CHEM, V60, P2473, DOI 10.1021/ac00173a008; GEORGER JH, 1987, J AM CHEM SOC, V109, P6169, DOI 10.1021/ja00254a042; GU KF, 1988, BIOREACTOR IMMOBILIZ, P59; KAJIYA Y, 1991, ANAL CHEM, V63, P49, DOI 10.1021/ac00001a009; KLEI HE, 1985, IMMOBILIZED CELLS EN, pCH4; KOOPAL CGJ, 1992, SYNTHETIC MET, V51, P397, DOI 10.1016/0379-6779(92)90295-T; MAIDAN R, 1992, ANAL CHEM, V64, P2889, DOI 10.1021/ac00047a003; MARCHESIELLO M, 1992, ELECTROCHIM ACTA, V37, P1987, DOI 10.1016/0013-4686(92)87113-E; MARCHESIELLO M, 1993, J ELECTROANAL CHEM, V358, P35, DOI 10.1016/0022-0728(93)80429-L; MARTIN CR, 1990, J AM CHEM SOC, V112, P8976, DOI 10.1021/ja00180a050; MARTIN CR, 1991, ADV MATER, V3, P457, DOI 10.1002/adma.19910030914; MARTIN CR, 1993, SYNTHETIC MET, V55, P1165, DOI 10.1016/0379-6779(93)90218-L; MARTIN CR, IN PRESS ELECTROCHIM; PENNER RM, 1988, J PHYS CHEM-US, V92, P5274, DOI 10.1021/j100329a042; POOL R, 1990, SCIENCE, V247, P1410; SOBER HA, 1968, HDB BIOCH, pC11; SUN ZS, 1992, ANAL CHEM, V64, P1112, DOI 10.1021/ac00034a008; TATSUMA T, 1993, J ELECTROANAL CHEM, V356, P245, DOI 10.1016/0022-0728(93)80523-K; UMANA M, 1986, ANAL CHEM, V58, P2979, DOI 10.1021/ac00127a018; WOLOWACZ SE, 1992, ANAL CHEM, V64, P1541, DOI 10.1021/ac00038a008; WOODWARD J, 1985, IMMOBILIZED CELLS EN; YONHIN BFY, 1993, ANAL CHEM, V65, P2067, DOI 10.1021/ac00063a022; ZAKS A, 1988, J BIOL CHEM, V263, P3194; 1972, WORTHINGTON ENZYME M, P41	34	325	351	3	182	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 26	1994	369	6478					298	301		10.1038/369298a0	http://dx.doi.org/10.1038/369298a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NN109	8183367				2023-01-03	WOS:A1994NN10900042
J	STODDARD, JJ; STPETER, RF; NEWACHECK, PW				STODDARD, JJ; STPETER, RF; NEWACHECK, PW			HEALTH-INSURANCE STATUS AND AMBULATORY CARE FOR CHILDREN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							A STREPTOCOCCAL INFECTIONS; ACUTE RHEUMATIC-FEVER; UNITED-STATES; MEDICAL-CARE; OTITIS-MEDIA; ACCESS; SERVICES; DIAGNOSIS; LANGUAGE; DECADE	Background. Many children in the United States lack health insurance. We tested the hypothesis that these children are less likely than children with insurance to visit a physician when they have specific conditions for which care is considered to be indicated. Methods. We examined the association between whether children were covered by health insurance and whether they received medical attention from a physician for pharyngitis, acute earache, recurrent ear infections, or asthma. Data were obtained on the subsample of 7578 children and adolescents 1 through 17 years of age who were included in the 1987 National Medical Expenditures Survey, a national probability sample of the civilian, noninstitutionalized population. Results. Uninsured children were more likely than children with health insurance to receive no care from a physician for all four conditions (unadjusted odds ratios, 2.38 for pharyngitis; 2.04 for acute earache; 2.84 for recurrent ear infections; and 1.87 for asthma). Multiple logistic-regression analysis was subsequently used to control for age, sex, family size, race or ethnic group, region of the country, place of residence (rural vs. urban), and household income. After adjustment for these factors, uninsured children remained significantly more likely than insured children to go without a visit to a physician for pharyngitis (adjusted odds ratio, 1.72; 95 percent confidence interval, 1.11 to 2.68), acute earache (1..85; 95 percent confidence interval, 1.15 to 2.99), recurrent ear infections (2.12; 95 percent confidence interval, 1.28 to 3.51), and asthma (1.72; 95 percent confidence interval, 1.05 to 2.83). Conclusions. As compared with children with health insurance, children who lack health insurance are less likely to receive medical care from a physician when it seems reasonably indicated and are therefore at risk for substantial avoidable morbidity.	US DEPT HHS,OFF DIS PREVENT & HLTH PROMOT,WASHINGTON,DC; UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	STODDARD, JJ (corresponding author), UNIV WISCONSIN,SCH MED,DEPT PEDIAT,DIV GEN PEDIAT & ADOLESCENT MED,H6-4 CLIN SCI CTR,MADISON,WI 53792, USA.							BAKER RB, 1992, PEDIATRICS, V90, P1006; BILLINGS J, 1993, HEALTH AFFAIR, V12, P162, DOI 10.1377/hlthaff.12.1.162; BISNO AL, 1991, NEW ENGL J MED, V325, P783, DOI 10.1056/NEJM199109123251106; BUTLER JA, 1985, PEDIATRICS, V76, P495; CUNNINGHAM PJ, 1990, HEALTH AFFAIR, V9, P76, DOI 10.1377/hlthaff.9.4.76; DAJANI AS, 1991, PEDIATR INFECT DIS J, V10, pS25, DOI 10.1097/00006454-199110001-00006; HARDY AM, 1991, DEP HLTH HUMAN SE 10, V180; HAYWARD RA, 1991, AM J PUBLIC HEALTH, V81, P434, DOI 10.2105/AJPH.81.4.434; HAYWARD RA, 1991, AM J PUBLIC HEALTH, V81, P838; JANZ NK, 1984, HEALTH EDUC QUART, V11, P1, DOI 10.1177/109019818401100101; KASPER JD, 1987, MED CARE, V25, P386, DOI 10.1097/00005650-198705000-00003; KLEIN JO, 1991, PEDIATR INFECT DIS J, V10, pS3, DOI 10.1097/00006454-199110001-00001; LEIBOWITZ A, 1985, PEDIATRICS, V75, P942; LEVEY LA, 1986, AM J PUBLIC HEALTH, V76, P1000, DOI 10.2105/AJPH.76.8.1000; Lohr K N, 1986, Med Care, V24, pS1; MYER CM, 1991, PEDIATR ANN, V20, P622, DOI 10.3928/0090-4481-19911101-10; NEWACHECK PW, 1986, PEDIATRICS, V78, P813; PARADISE JL, 1978, NEW ENGL J MED, V298, P409, DOI 10.1056/NEJM197802232980801; PATTEMORE PK, 1990, AM REV RESPIR DIS, V142, P549, DOI 10.1164/ajrccm/142.3.549; ROSENBACH ML, 1989, AM J PUBLIC HEALTH, V79, P1220, DOI 10.2105/AJPH.79.9.1220; SHAH BV, 1984, RTILOGIT PROCEDURE L; TEELE DW, 1990, J INFECT DIS, V162, P685, DOI 10.1093/infdis/162.3.685; WALLACE MR, 1989, JAMA-J AM MED ASSOC, V262, P2557, DOI 10.1001/jama.262.18.2557; WEISS KB, 1990, JAMA-J AM MED ASSOC, V264, P1683, DOI 10.1001/jama.264.13.1683; WOOD DL, 1990, PEDIATRICS, V86, P666; WRIGHT PF, 1991, PEDIATR ANN, V20, P617, DOI 10.3928/0090-4481-19911101-09; 1993, PRESIDENTS HLTH SECU; [No title captured]; 1991, PB91190165	29	134	134	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 19	1994	330	20					1421	1425		10.1056/NEJM199405193302006	http://dx.doi.org/10.1056/NEJM199405193302006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NK972	8159197				2023-01-03	WOS:A1994NK97200006
J	DAHL, JB				DAHL, JB			ANTIHISTAMINE PROPHYLAXIS AND GENERAL-ANESTHESIA	LANCET			English	Editorial Material							ADVERSE REACTIONS; ANESTHESIA				DAHL, JB (corresponding author), UNIV COPENHAGEN,BISPEBJERG HOSP,DEPT ANAESTHESIOL,DK-1168 COPENHAGEN,DENMARK.							Fisher, 1988, THEORETICAL SURG, V3, P145; FISHER MM, 1981, ANAESTH INTENS CARE, V9, P226, DOI 10.1177/0310057X8100900304; FISHER MM, 1990, DRUG SAFETY, V5, P86, DOI 10.2165/00002018-199005020-00002; LORENZ W, 1984, CLIN ANAESTHESIOL, V2, P403; OSTERGAARD D, 1989, MED TOXICOL ADV DRUG, V4, P351, DOI 10.1007/BF03259917	5	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 16	1994	343	8903					929	930		10.1016/S0140-6736(94)90059-0	http://dx.doi.org/10.1016/S0140-6736(94)90059-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF700	7909004				2023-01-03	WOS:A1994NF70000003
J	PARSONS, RW; JAMROZIK, KD; HOBBS, MST; THOMPSON, DL				PARSONS, RW; JAMROZIK, KD; HOBBS, MST; THOMPSON, DL			EARLY IDENTIFICATION OF PATIENTS AT LOW-RISK OF DEATH AFTER MYOCARDIAL-INFARCTION AND POTENTIALLY SUITABLE FOR EARLY HOSPITAL DISCHARGE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CONTROLLED TRIAL	Objectives-To find (a) whether data available shortly after admission for acute myocardial infarction can provide a reliable prognostic indicator of survival at 28 days, and (b) whether such an indicator might be used to identify patients at low risk of death and suitable for early discharge. Design-Retrospective analysis of data collected on patients admitted to a coronary care unit for acute myocardial infarction. A validation sample was selected at random from these patients. Setting-Coronary care units in Perth, Western Australia. Subjects-6746 patients aged under 65 and resident in the Perth Statistical Division who during 1984-92 were admitted to a coronary care unit with symptoms of myocardial infarction. Main outcome measures-Sensitivity and specificity of several models for predicting survival at 28 days after myocardial infarction, and detailed performance characteristics of a particular model. Results-Patients with a pulse rate of 100 beats/min or less, aged 60 or under, and with symptoms typical of myocardial infarction, no past history of myocardial infarction or diabetes, and no significant Q wave in the admission electrocardiogram had a very high chance of survival at 28 days (99.2%). These patients made up one third of all patients studied. Conclusion-The prognostic index identifies patients very soon after admission who are at low risk of death and potentially eligible for early discharge from hospital or the coronary care unit. Computing the index does not need complex cardiac investigations.	QUEEN ELIZABETH II MED CTR, DEPT CARDIOVASC MED, PERTH, WA 6009, AUSTRALIA	University of Western Australia	PARSONS, RW (corresponding author), UNIV WESTERN AUSTRALIA, DEPT PUBL HLTH, PERTH, WA 6009, AUSTRALIA.							ABRAHAM AS, 1975, NEW ENGL J MED, V292, P719, DOI 10.1056/NEJM197504032921403; AHLMARK G, 1979, ACTA MED SCAND, V206, P87; BLOCH A, 1974, AM J CARDIOL, V34, P152, DOI 10.1016/0002-9149(74)90193-3; DUBOIS C, 1988, AM J CARDIOL, V61, P216, DOI 10.1016/0002-9149(88)90918-6; Fletcher RH, 1988, CLIN EPIDEMIOLOGY ES, V2nd; GRODEN B. M., 1967, SCOT MED J, V12, P435; HANDS ME, 1986, CIRCULATION, V73, P885, DOI 10.1161/01.CIR.73.5.885; HARPUR JE, 1971, LANCET, V2, P1331; HAYES MJ, 1974, BRIT MED J, V2, P10; HUTTER AM, 1973, NEW ENGL J MED, V288, P1141, DOI 10.1056/NEJM197305312882201; LEVINE SA, 1952, JAMA-J AM MED ASSOC, V148, P1365, DOI 10.1001/jama.1952.02930160001001; Mallory GK, 1939, AM HEART J, V18, P647; MARIK PE, 1991, HEART LUNG, V20, P16; MCNEER JF, 1978, NEW ENGL J MED, V298, P229, DOI 10.1056/NEJM197802022980501; MOLSTAD P, 1993, J INTERN MED, V233, P393, DOI 10.1111/j.1365-2796.1993.tb00690.x; NORRIS RM, 1969, LANCET, V1, P274; OH W, 1976, SMJ Singapore Medical Journal, V17, P40; PRINEAS RJ, 1982, MANUAL ELECTROCARDIO; PRYOR DB, 1983, ANN INTERN MED, V99, P528, DOI 10.7326/0003-4819-99-4-528; Rose G, 1972, Mod Concepts Cardiovasc Dis, V41, P59; Swan H J, 1976, Am J Cardiol, V37, P413, DOI 10.1016/0002-9149(76)90292-7; TOPOL EJ, 1988, NEW ENGL J MED, V318, P1083, DOI 10.1056/NEJM198804283181702; WENGER NK, 1982, CIRCULATION, V65, P421, DOI 10.1161/01.CIR.65.3.421; WENGER NK, 1973, JAMA-J AM MED ASSOC, V224, P511, DOI 10.1001/jama.224.4.511; *WHO MONICA PROJ P, 1988, J CLIN EPIDEMIOL, V41, P105, DOI [DOI 10.1016/0895-4356(88)90084-4, 10.1016/0895-4356(88)90084-4]; 1991, SAS RELEASE 6 07; 1990, EGRET EPIDEMIOLOGICA; 1990, MONICA MANUAL	28	22	22	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 16	1994	308	6935					1006	1010		10.1136/bmj.308.6935.1006	http://dx.doi.org/10.1136/bmj.308.6935.1006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH089	8167512	Green Published			2023-01-03	WOS:A1994NH08900018
J	MARKOWITZ, SB; NUNEZ, CM; KLITZMAN, S; MUNSHI, AA; KIM, WS; EISINGER, J; LANDRIGAN, PJ				MARKOWITZ, SB; NUNEZ, CM; KLITZMAN, S; MUNSHI, AA; KIM, WS; EISINGER, J; LANDRIGAN, PJ			LEAD-POISONING DUE TO HAI GE FEN - THE PORPHYRIN CONTENT OF INDIVIDUAL ERYTHROCYTES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							PUBLIC-HEALTH SURVEILLANCE; PHYSICIAN RECOGNITION; BLOOD LEAD; INTOXICATION; PROTOPORPHYRIN; EXPOSURE; EVENTS	A 45-year-old Korean man developed abdominal colic, muscle pain, and fatigue. Following a 3-week hospitalization, acute intermittent porphyria was diagnosed based on the symptoms and a high level of urinary delta-aminolevulinic acid (378 mu mol/L [4.95 mg/dL]). However, discovery of an elevated blood lead level (3.7 mu mol/L [76 mu g/dL]) subsequently led to the correct diagnosis. No occupational source of lead exposure was identified. The patient reported ingesting a Chinese herbal preparation for 4 weeks prior to becoming ill. A public health investigation revealed that the source of lead exposure was hai ge fen (clamshell powder), one of the 36 ingredients of the Chinese herbal medicine. We used fluorescence image-based cytometry to determine the frequency distribution of the zinc protoporphyrin content in circulating red blood cells and found that 70% of the patient's cells contained elevated levels of zinc protoporphyrin consistent with the duration of lead exposure and effect of lead on heme synthesis. Analysis of zinc protoporphyrin content in circulating red blood cell distributions may be useful in the diagnosis, therapy, and kinetic modeling of lead poisoning. Environmental lead poisoning is best addressed through the close collaboration of clinicians, public health specialists, and laboratory scientists.	MT SINAI SCH MED, DEPT PHYSIOL & BIOPHYS, NEW YORK, NY USA; NEW YORK CITY DEPT HLTH, NEW YORK, NY USA	Icahn School of Medicine at Mount Sinai; New York City Department of Health & Mental Hygiene	MARKOWITZ, SB (corresponding author), MT SINAI SCH MED, DIV ENVIRONM & OCCUPAT MED, BOX 1057, 1 GUSTAVE L LEVY PL, NEW YORK, NY 10029 USA.				PHS HHS [P30E500928] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BASER ME, 1992, AM J PUBLIC HEALTH, V82, P1113, DOI 10.2105/AJPH.82.8.1113; BIRD TD, 1982, JAMA-J AM MED ASSOC, V247, P813, DOI 10.1001/jama.247.6.813; BLUMBERG WE, 1977, J LAB CLIN MED, V89, P712; CHAMBERLAIN AC, 1985, PROC R SOC SER B-BIO, V224, P149, DOI 10.1098/rspb.1985.0027; EISINGER J, 1978, Q REV BIOPHYS, V11, P439, DOI 10.1017/S0033583500005631; EISINGER J, 1982, MED HIST, V26, P279, DOI 10.1017/S0025727300041508; FRANZBLAU A, 1989, ARCH ENVIRON HEALTH, V44, P385, DOI 10.1080/00039896.1989.9935912; HARRIS RW, 1967, J AMER MED ASSOC, V202, P544, DOI 10.1001/jama.202.6.544; HINDMARSH JT, 1986, CRC CR REV CL LAB SC, V23, P315, DOI 10.3109/10408368609167122; HRYHORCZUK DO, 1985, AM J IND MED, V8, P33, DOI 10.1002/ajim.4700080105; KARLOG O, 1958, ACTA PHARMACOL TOX, V15, P8; KLEIN M, 1970, NEW ENGL J MED, V283, P669, DOI 10.1056/NEJM197009242831302; MULLAN RJ, 1991, AM J IND MED, V19, P775, DOI 10.1002/ajim.4700190610; NORTIER JWR, 1980, VET HUM TOXICOL, V22, P145; PIOMELLI S, 1977, CLIN CHEM, V23, P264; PIOMELLI S, 1975, J CLIN INVEST, V56, P1519, DOI 10.1172/JCI108233; RUTSTEIN DD, 1983, AM J PUBLIC HEALTH, V73, P1054, DOI 10.2105/AJPH.73.9.1054; SASSAROLI M, 1992, CYTOMETRY, V13, P339, DOI 10.1002/cyto.990130403; SMITH DC, 1992, MMWR-MORBID MORTAL W, V41, P781; 1993, MMWR MORB MORTAL WKL, V42, P254; 1993, DRINKING WATER REGUL; 1984, MMWR MORB MORTAL WKL, V33, P45	22	67	69	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 23	1994	271	12					932	934		10.1001/jama.271.12.932	http://dx.doi.org/10.1001/jama.271.12.932			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA743	8120963				2023-01-03	WOS:A1994NA74300030
J	GULBA, DC; SCHMID, C; BORST, HG; LICHTLEN, P; DIETZ, R; LUFT, FC				GULBA, DC; SCHMID, C; BORST, HG; LICHTLEN, P; DIETZ, R; LUFT, FC			MEDICAL COMPARED WITH SURGICAL-TREATMENT FOR MASSIVE PULMONARY-EMBOLISM	LANCET			English	Note							MORTALITY	We compared embolectomy (when available) with thrombolysis in patients with shock and massive pulmonary embolism. 13 patients were operated on, 10 (77%) of whom survived. The inferior vena cava was routinely clipped. The 24 medically treated patients were given alteplase until systemic and pulmonary artery pressures stabilised and heparin thereafter; 16 (67%) survived. Major haemorrhage occurred in 28% of medically treated patients, but was not fatal. 1 patient had a small cerebral haemorrhage that resolved without drainage. One-fifth of the medical group had a re-embolism, which suggests that temporary caval umbrellas are indicated in medically treated patients. Thrombolysis may provide a life-saving option and a randomised trial is warranted.	UNIV HANNOVER,DEPT MED,DIV CARDIOL,W-3000 HANNOVER,GERMANY; UNIV HANNOVER,DEPT THORAC & VASC SURG,W-3000 HANNOVER,GERMANY; FREE UNIV BERLIN,W-1000 BERLIN,GERMANY	Leibniz University Hannover; Leibniz University Hannover; Free University of Berlin				Luft, Friedrich/0000-0002-8635-1199				ALPERT JS, 1976, JAMA-J AM MED ASSOC, V236, P1477, DOI 10.1001/jama.236.13.1477; CHAVAN A, 1993, Z KARDIOL, V82, P191; COME PC, 1987, J AM COLL CARDIOL, V10, P971, DOI 10.1016/S0735-1097(87)80333-9; GOLDHABER SZ, 1993, LANCET, V341, P507, DOI 10.1016/0140-6736(93)90274-K; JARDIN F, 1987, J AM COLL CARDIOL, V10, P1201, DOI 10.1016/S0735-1097(87)80119-5; LILIENFELD DE, 1990, CHEST, V98, P1067, DOI 10.1378/chest.98.5.1067; SCHMID C, 1991, ANN THORAC SURG, V52, P1102, DOI 10.1016/0003-4975(91)91288-7; THERY C, 1990, EUR HEART J, V11, P334, DOI 10.1093/oxfordjournals.eurheartj.a059707; Wittlich N, 1992, J Am Soc Echocardiogr, V5, P515	9	143	151	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 5	1994	343	8897					576	577		10.1016/S0140-6736(94)91523-7	http://dx.doi.org/10.1016/S0140-6736(94)91523-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY843	7906331				2023-01-03	WOS:A1994MY84300011
J	DRUMMOND, N; ABDALLA, M; BEATTIE, JAG; BUCKINGHAM, JK; LINDSAY, T; OSMAN, LM; ROSS, SJ; ROYCHAUDHURY, A; RUSSELL, L; TURNER, M; FRIEND, JAR; LEGGE, JS; DOUGLAS, JG				DRUMMOND, N; ABDALLA, M; BEATTIE, JAG; BUCKINGHAM, JK; LINDSAY, T; OSMAN, LM; ROSS, SJ; ROYCHAUDHURY, A; RUSSELL, L; TURNER, M; FRIEND, JAR; LEGGE, JS; DOUGLAS, JG			EFFECTIVENESS OF ROUTINE SELF-MONITORING OF PEAK FLOW IN PATIENTS WITH ASTHMA	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; MANAGEMENT; SCALE	Objective-To evaluate the effectiveness of routine self monitoring of peak flow for asthma outpatients. Design-Pragmatic randomised trial. Setting-Hospital outpatient clinics and general practices in north east Scotland. Main outcome measures-Use of bronchodilators and inhaled and oral steroids; number of general practice consultations and hospital admissions for asthma; sleep disturbance and other restrictions on normal activity; psychological aspects of health including perceived control of asthma. Results-After one year there were no significant differences between patients randomised between self monitoring of peak flow and conventional monitoring. However, those given a peak flow meter recorded an increase in general practice consultations that was nearly significant. Among patients whose asthma was judged on entry to be more severe, those allocated to self monitoring used more than twice as many oral steroids (2.2; 95% confidence interval 1.1 to 4.6). Patients who already possessed a peak flow meter at the start of the study recorded higher morbidity over the course of the year than those eligible for randomisation. Conclusion-Prescribing peak flow meters and giving self management guidelines to all asthma patients is unlikely to improve mortality or morbidity. Patients whose asthma is severe may benefit from such an intervention.	CITY HOSP,ABERDEEN ROYAL HOSP TRUST,THORAC MED UNIT,ABERDEEN AB9 8AU,ABERDEEN,SCOTLAND		DRUMMOND, N (corresponding author), UNIV ABERDEEN,HLTH SERV RES UNIT,ABERDEEN AB9 2ZD,ABERDEEN,SCOTLAND.		Russell, Ian T/H-1181-2012					AITKEN M, 1989, STATISTICAL MODELLIN; [Anonymous], 1990, SPSS REFERENCE GUIDE; Averill B.A., 1980, CIENC BIOL COIMBRA, V5, P167; BEASLEY R, 1989, THORAX, V44, P200, DOI 10.1136/thx.44.3.200; British Thoracic Society (BTS), 1993, THORAX, V48, pS1; CHARLTON I, 1990, PRACTITIONER, V234, P30; CHARLTON I, 1990, BRIT MED J, V301, P1355, DOI 10.1136/bmj.301.6765.1355; CONNOLLY CK, 1987, RESPIRATION, V52, P22, DOI 10.1159/000195300; HYLAND ME, 1991, RESP MED, V85, P13, DOI 10.1016/S0954-6111(06)80163-0; JANSONBJERKLIE S, 1988, HEART LUNG, V17, P543; JONES K, 1991, BRIT J GEN PRACT, V41, P224; NUNN AJ, 1989, BRIT MED J, V298, P1068, DOI 10.1136/bmj.298.6680.1068; OSMAN LM, 1994, BRIT MED J, V308, P568, DOI 10.1136/bmj.308.6928.568; PERKS WH, 1979, THORAX, V34, P79, DOI 10.1136/thx.34.1.79; Pocock SJ., 2013, CLIN TRIALS PRACTICA; RUSSELL I, 1983, EC MED EVALUATION HL; SCHWARTZ D, 1967, J CHRON DIS, V20, P637, DOI 10.1016/0021-9681(67)90041-0; TOBIN DL, 1987, ANN ALLERGY, V59, P273; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; 1994, BRIT MED J, V308, P559; 1987, SIR VERSION 3 ENV MA; 1982, BRIT MED J, V2, P1251; [No title captured]	23	101	102	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 26	1994	308	6928					564	567		10.1136/bmj.308.6928.564	http://dx.doi.org/10.1136/bmj.308.6928.564			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY714	8148679				2023-01-03	WOS:A1994MY71400019
J	DALAKAS, MC; ILLA, I; DAMBROSIA, JM; SOUEIDAN, SA; STEIN, DP; OTERO, C; DINSMORE, ST; MCCROSKY, S				DALAKAS, MC; ILLA, I; DAMBROSIA, JM; SOUEIDAN, SA; STEIN, DP; OTERO, C; DINSMORE, ST; MCCROSKY, S			A CONTROLLED TRIAL OF HIGH-DOSE INTRAVENOUS IMMUNE GLOBULIN INFUSIONS AS TREATMENT FOR DERMATOMYOSITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INCLUSION-BODY MYOSITIS; MEMBRANE ATTACK COMPLEX; MEDIATED CYTO-TOXICITY; INFLAMMATORY MYOPATHIES; MONONUCLEAR-CELLS; PLASMA-EXCHANGE; GAMMA-GLOBULIN; POLYMYOSITIS; THERAPY; IMMUNOGLOBULIN	Background. Dermatomyositis is a clinically distinct myopathy characterized by rash and a complement-mediated microangiopathy that results in the destruction of muscle fibers. In some patients the condition becomes resistant to therapy and causes severe physical disabilities. Methods. We conducted a double-blind, placebo-controlled study of 15 patients (age, 18 to 55 years) with biopsy-proved, treatment-resistant dermatomyositis. The patients continued to receive prednisone (mean daily dose, 25 mg) and were randomly assigned to receive one infusion of immune globulin (2 g per kilogram of body weight) or placebo per month for three months, with the option of crossing over to the alternative therapy for three more months. Clinical response was gauged by assessing muscle strength, neuromuscular symptoms, and changes in the rash. Changes in immune-mediated muscle abnormalities were determined by repeated muscle biopsies. Results. The eight patients assigned to immune globulin had a significant improvement in scores of muscle strength (P<0.018) and neuromuscular symptoms (P<0.035), whereas the seven patients assigned to placebo did not With crossovers, a total of 12 patients received immune globulin. Of these, nine with severe disabilities had a major improvement to nearly normal function. Their mean muscle-strength scores increased from 74.5 to 84.7, and their neuromuscular symptoms improved. Two of the other three patients had mild improvement, and one had no change in his condition. Of 11 placebo-treated patients, none had major improvement, 3 had mild improvement, 3 had no change in their condition, and 5 had worsening of their condition. Repeated biopsies in five patients of muscles whose strength improved to almost normal showed an increase in muscle-fiber diameter (P<0.04), an increase in the number and a decrease in the diameter of capillaries (P<0.01), resolution of complement deposits on capillaries, and a reduction in the expression of intercellular adhesion molecule 1 and major-histocompatibility-complex class I antigens. Conclusions. High-dose intravenous immune globulin is a safe and effective treatment for refractory dermatomyositis.	NINCDS,BIOMETRY & FIELD STUDIES BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	DALAKAS, MC (corresponding author), NINCDS,MED NEUROL BRANCH,NEUROMUSCULAR DIS SECT,BLDG 10,RM 4N248,BETHESDA,MD 20892, USA.		ILLA, Isabel/AAD-1816-2019					BACCHI VF, 1992, LANCET, V340, P63, DOI 10.1016/0140-6736(92)92486-Y; BALLOW M, 1991, CANCER, V68, P1430, DOI 10.1002/1097-0142(19910915)68:6+<1430::AID-CNCR2820681405>3.0.CO;2-4; BANKER BQ, 1986, MYOLOGY, P1385; BASTA M, 1989, J CLIN INVEST, V84, P1974, DOI 10.1172/JCI114387; BLASCZYK R, 1993, LANCET, V341, P789, DOI 10.1016/0140-6736(93)90563-V; CHERIN P, 1991, AM J MED, V91, P162, DOI 10.1016/0002-9343(91)90009-M; DALAKAS M, 1990, CURR OPIN NEUROL NEU, V3, P689; DALAKAS MC, 1991, NEW ENGL J MED, V325, P1487, DOI 10.1056/NEJM199111213252107; DALAKAS MC, 1992, CLIN NEUROPHARMACOL, V15, P327, DOI 10.1097/00002826-199210000-00001; DALAKAS MC, 1992, CURR OPIN NEUROL NEU, V5, P645; DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602; DALAKAS MC, 1988, POLYMYOSITIS DERMATO; DALAKAS MC, 1992, HDB CLIN NEUROLOGY, V18, P369; Daniels L, 1972, MUSCLE TESTING TECHN, P2; DUSTIN ML, 1991, ANNU REV IMMUNOL, V9, P27, DOI 10.1146/annurev.iy.09.040191.000331; DWYER JM, 1992, NEW ENGL J MED, V326, P107; EMSLIESMITH AM, 1989, HUM PATHOL, V20, P224, DOI 10.1016/0046-8177(89)90128-7; EMSLIESMITH AM, 1990, ANN NEUROL, V27, P343, DOI 10.1002/ana.410270402; ENGEL AG, 1982, ANN NEUROL, V12, P289, DOI 10.1002/ana.410120314; ENGEL AG, 1986, HUM PATHOL, V17, P704, DOI 10.1016/S0046-8177(86)80180-0; ENGEL AG, 1984, ANN NEUROL, V16, P209, DOI 10.1002/ana.410160207; GELFAND EW, 1990, CLIN IMMUNOL IMMUNOP, V55, P492; GELFAND EW, 1989, CLIN IMMUNOL IMMUNOP, V53, pS1, DOI 10.1016/0090-1229(89)90064-0; ILLA I, 1992, ANN NEUROL, V31, P46, DOI 10.1002/ana.410310109; KISSEL JT, 1986, NEW ENGL J MED, V314, P329, DOI 10.1056/NEJM198602063140601; LANG BA, 1991, AM J MED, V91, P169, DOI 10.1016/0002-9343(91)90010-U; LEHMANN EL, 1975, NONPARAMETRICS; MAHONEY F I, 1965, Md State Med J, V14, P61; MILLER FW, 1992, NEW ENGL J MED, V326, P1380, DOI 10.1056/NEJM199205213262102; ROIFMAN CM, 1987, JAMA-J AM MED ASSOC, V258, P513, DOI 10.1001/jama.1987.03400040111034; Rowland L P, 1977, Adv Neurol, V17, P63; ROWLAND LP, 1989, MERRITTS TXB NEUROLO, P733; SOUEIDAN SA, 1993, PEDIATR RES, V33, pS95, DOI 10.1203/00006450-199304001-00017; SOUEIDAN SA, 1993, NEUROLOGY, V43, P876, DOI 10.1212/WNL.43.5.876; STEIN DP, 1993, ANN NEUROL, V34, P268; STEIN DP, 1993, NEUROLOGY S, V43, P356; VANDERMECHE FGA, 1992, NEW ENGL J MED, V326, P1123, DOI 10.1056/NEJM199204233261705; WHITAKER JN, 1972, NEW ENGL J MED, V286, P333, DOI 10.1056/NEJM197202172860701	38	788	819	0	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 30	1993	329	27					1993	2000		10.1056/NEJM199312303292704	http://dx.doi.org/10.1056/NEJM199312303292704			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN573	8247075				2023-01-03	WOS:A1993MN57300004
J	KULKARNI, ML; SURESHKUMAR, C; VENKATARAMANA, V				KULKARNI, ML; SURESHKUMAR, C; VENKATARAMANA, V			COLORINGS, FLAVORINGS, AND SUGARS IN CHILDRENS MEDICINES IN INDIA	BMJ-BRITISH MEDICAL JOURNAL			English	Article											KULKARNI, ML (corresponding author), JJM MED COLL, DEPT PAEDIAT, DAVANAGERE 577004, INDIA.							HOLMES A, 1987, BRIT DENT J, V163, P240, DOI 10.1038/sj.bdj.4806259; KOLLY M, 1989, ANN ALLERGY, V62, P21; KUMAR A, 1991, PEDIATRICS, V87, P352; POLLOCK I, 1989, BRIT MED J, V299, P649, DOI 10.1136/bmj.299.6700.649; 1989, PEDIATRICS, V73, P405	5	4	4	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 25	1993	307	6907					773	773		10.1136/bmj.307.6907.773	http://dx.doi.org/10.1136/bmj.307.6907.773			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ478	8219950	Bronze, Green Published			2023-01-03	WOS:A1993LZ47800025
J	POWELLTUCK, J				POWELLTUCK, J			GLUTAMINE, PARENTERAL-FEEDING, AND INTESTINAL NUTRITION	LANCET			English	Editorial Material							METABOLISM; MUSCLE				POWELLTUCK, J (corresponding author), ROYAL LONDON HOSP,DEPT MED,LONDON,ENGLAND.							ADIBI SA, 1987, DIPEPTIDES NEW SUBST; DEUTZ NEP, 1992, CLIN SCI, V83, P607, DOI 10.1042/cs0830607; HAUSSINGER D, 1993, LANCET, V341, P1330, DOI 10.1016/0140-6736(93)90828-5; HAUSSINGER D, 1989, METABOLISM, V38, P14, DOI 10.1016/0026-0495(89)90133-9; RENNIE MJ, 1986, LANCET, V2, P1008; SOUBA WW, 1985, JPEN-PARENTER ENTER, V9, P608, DOI 10.1177/0148607185009005608; TAMARAPPOO BK, 1990, MINER ELECTROL METAB, V16, P322; VANDERHULST RRWJ, 1993, LANCET, V341, P1363, DOI 10.1016/0140-6736(93)90939-E; WINDMUELLER HG, 1980, J BIOL CHEM, V255, P107	9	6	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 21	1993	342	8869					451	452		10.1016/0140-6736(93)91589-E	http://dx.doi.org/10.1016/0140-6736(93)91589-E			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU075	8102425				2023-01-03	WOS:A1993LU07500006
J	PELLEGRINO, ED				PELLEGRINO, ED			COMPASSION NEEDS REASON TOO	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											PELLEGRINO, ED (corresponding author), GEORGETOWN UNIV,MED CTR,WASHINGTON,DC 20007, USA.							ARKES H, 1992, 1ST THINGS, V20, P46; BRODY H, 1993, J CLIN ETHIC, V4, P112; CASSEL CK, 1990, NEW ENGL J MED, V323, P750, DOI 10.1056/NEJM199009133231110; JONSEN AR, 1991, THEOR MED, V12, P295, DOI 10.1007/BF00489890; KAMISAR Y, 1993, HASTINGS CENT REP, V23, P32, DOI 10.2307/3563366; KASS LR, 1989, PUBLIC INTEREST, V94, P25; KEVORKIAN J, 1991, PRESCRIPTION MED GOO; Lynn J, 1988, J Palliat Care, V4, P100; Pellegrino E D, 1992, J Clin Ethics, V3, P95; QUILL TE, 1993, JAMA-J AM MED ASSOC, V270, P870, DOI 10.1001/jama.270.7.870; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; UBEL PA, 1993, ISSUES LAW MED, V8, P487; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; WESLEY P, 1993, J LAW MED, V8, P467; 1988, JAMA-J AM MED ASSOC, V259, P272; 1991, JAMA-J AM MED ASSOC, V267, P2229	16	38	38	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	1993	270	7					874	875		10.1001/jama.270.7.874	http://dx.doi.org/10.1001/jama.270.7.874			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LR612	8340989				2023-01-03	WOS:A1993LR61200036
J	NICOLAOU, KC; RIEMER, C; KERR, MA; RIDEOUT, D; WRASIDLO, W				NICOLAOU, KC; RIEMER, C; KERR, MA; RIDEOUT, D; WRASIDLO, W			DESIGN, SYNTHESIS AND BIOLOGICAL-ACTIVITY OF PROTAXOLS	NATURE			English	Article							WATER-SOLUBLE PRODRUGS; ANTITUMOR-ACTIVITY; TAXOL; CELLS; MICROTUBULES; AGENTS; ASSAY	TAXOL1-6 is a product isolated from the Pacific yew tree (Taxus brevifolia) and is a potent microtubule-stabilizing agent which has recently been approved for treatment of otherwise intractable ovarian cancer. Despite taxol's therapeutic promise, its aqueous insolubility (<0.004 mg ml-1) hampers its clinical application. Here we report the design, synthesis and biological activity of a series of taxol-releasing compounds (protaxols) with improved pharmacological properties. These prodrugs were designed to increase their aqueous solubility and allow for taxol release under basic or physiological conditions. We demonstrate the stability of these prodrugs at pH less-than-or-equal-to 7 and their ability to release taxol in a basic medium. Taxol-like microtubule-stabilizing activity7-9 appears after the release of taxol. In vitro these prodrugs have cytotoxic properties against tumour cell lines comparable to those of taxol; moreover, human plasma catalyses the release of active taxol. These protaxols have greater potential as anticancer agents than the parent compounds taxol and taxotere (Fig. 1a).	UNIV CALIF SAN DIEGO, DEPT CHEM, LA JOLLA, CA 92093 USA; SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, DRUG DISCOVERY UNIT, LA JOLLA, CA 92037 USA	University of California System; University of California San Diego; Scripps Research Institute; Scripps Research Institute	NICOLAOU, KC (corresponding author), SCRIPPS RES INST, DEPT CHEM, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.							DEBRABANDER M, 1981, P NATL ACAD SCI-BIOL, V78, P5608; DEUTSCH HM, 1989, J MED CHEM, V32, P788, DOI 10.1021/jm00124a011; KEIZER HG, 1989, J NATL CANCER I, V81, P706, DOI 10.1093/jnci/81.9.706; KINGSTON DGI, 1991, PHARMACOL THERAPEUT, V52, P1, DOI 10.1016/0163-7258(91)90085-Z; LONGNECKER SM, 1987, CANCER TREAT REP, V71, P53; MATHEW AE, 1992, J MED CHEM, V35, P145, DOI 10.1021/jm00079a019; MERLOCK R, IN PRESS ANAL BIOCH; NICOLAOU KC, IN PRESS ANGEW CHEM; POITIER P, 1992, CHEM SOC REV, V21, P113; ROWINSKY EK, 1991, PHARMACOL THERAPEUT, V52, P35, DOI 10.1016/0163-7258(91)90086-2; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; SWINDELL CS, 1991, ORG PREP PROCED INT, V23, P465, DOI 10.1080/00304949109458240; SWINDELL CS, 1991, J MED CHEM, V34, P1176, DOI 10.1021/jm00107a042; WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021/ja00738a045; ZHAO ZY, 1991, J NAT PROD, V54, P1607, DOI 10.1021/np50078a018	17	118	157	3	34	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 29	1993	364	6436					464	466		10.1038/364464a0	http://dx.doi.org/10.1038/364464a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	LP640	8101355				2023-01-03	WOS:A1993LP64000061
J	COLLEN, D				COLLEN, D			TOWARDS IMPROVED THROMBOLYTIC THERAPY	LANCET			English	Review							UROKINASE				COLLEN, D (corresponding author), CATHOLIC UNIV LEUVEN,CTR MOLEC & VASC BIOL,B-3000 LOUVAIN,BELGIUM.							[Anonymous], 1986, Lancet, V1, P397; BODE C, 1985, SCIENCE, V229, P765, DOI 10.1126/science.4023710; BRAUNWALD E, 1989, CIRCULATION, V79, P441, DOI 10.1161/01.CIR.79.2.441; COLLEN D, 1991, CIRCULATION, V84, P1216, DOI 10.1161/01.CIR.84.3.1216; COLLEN D, 1993, CIRCULATION, V87, P996, DOI 10.1161/01.CIR.87.3.996; COLLEN D, 1991, BLOOD, V78, P3114; COLLEN D, IN PRESS CIRCULATION; COLLEN D, IN PRESS THROMB HAEM; DAVIES MJ, 1985, BRIT HEART J, V53, P363; DEWOOD MA, 1980, NEW ENGL J MED, V303, P897, DOI 10.1056/NEJM198010163031601; GARDELL SJ, 1989, J BIOL CHEM, V264, P17947; GOLD HK, 1990, NEW ENGL J MED, V323, P1483, DOI 10.1056/NEJM199011223232110; HOLVOET P, 1993, BLOOD, V81, P696; HORTON R, 1993, LANCET, V341, P1188, DOI 10.1016/0140-6736(93)91011-A; LIJNEN HR, 1990, BIOTECHNOL THER, V1, P273; NEUHAUS KL, 1992, J AM COLL CARDIOL, V19, P885, DOI 10.1016/0735-1097(92)90265-O; RUNGE MS, 1990, CIRCULATION, V82, P655, DOI 10.1161/01.CIR.82.2.655; SOBEL BE, 1990, CORONARY ARTERY DIS, V1, P3, DOI 10.1097/00019501-199001000-00002; SOBEL BE, 1992, AM J CARDIOL, V70, P385, DOI 10.1016/0002-9149(92)90624-8; 1992, CIRCULATION, V86, P15; 1992, LANCET, V339, P753; 1990, LANCET, V336, P71; 1992, CIRCULATION, V86, P455	23	44	47	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 3	1993	342	8862					34	36		10.1016/0140-6736(93)91888-S	http://dx.doi.org/10.1016/0140-6736(93)91888-S			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK985	8100296				2023-01-03	WOS:A1993LK98500017
J	BERDEN, HJJM; WILLEMS, FF; HENDRICK, JMA; PIJLS, NHJ; KNAPE, JTA				BERDEN, HJJM; WILLEMS, FF; HENDRICK, JMA; PIJLS, NHJ; KNAPE, JTA			HOW FREQUENTLY SHOULD BASIC CARDIOPULMONARY-RESUSCITATION TRAINING BE REPEATED TO MAINTAIN ADEQUATE SKILLS	BRITISH MEDICAL JOURNAL			English	Article							RETENTION		CATHOLIC UNIV NIJMEGEN,RADBOUD HOSP,DEPT CARDIOL,NIJMEGEN,NETHERLANDS; CATHARINA HOSP,DEPT CARDIOL,EINDHOVEN,NETHERLANDS; UNIV UTRECHT HOSP,DEPT ANAESTHESIOL,3511 GV UTRECHT,NETHERLANDS	Radboud University Nijmegen; Catharina Hospital; Utrecht University; Utrecht University Medical Center	BERDEN, HJJM (corresponding author), DUTCH COLL GEN PRACTITIONERS,POSTBOX 3231,3502 GE UTRECHT,NETHERLANDS.		Berden, Hubert/GQB-0441-2022					BERDEN HJJ, 1992, RESUSCITATION, V23, P31; KAYE W, 1986, CRIT CARE MED, V14, P620, DOI 10.1097/00003246-198607000-00007; KAYE W, 1991, RESUSCITATION, V21, P67, DOI 10.1016/0300-9572(91)90080-I; SERAJ MA, 1990, RESUSCITATION, V20, P31, DOI 10.1016/0300-9572(90)90084-R; WEAVER FJ, 1979, JAMA-J AM MED ASSOC, V241, P901, DOI 10.1001/jama.241.9.901	5	136	142	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1993	306	6892					1576	1577		10.1136/bmj.306.6892.1576	http://dx.doi.org/10.1136/bmj.306.6892.1576			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH128	8329917	Bronze, Green Published			2023-01-03	WOS:A1993LH12800017
J	FIGUEROA, M; GEHLSEN, J; HAMMOND, D; ONDREYCO, S; PIRO, L; POMEROY, T; WILLIAMS, F; MCMILLAN, R				FIGUEROA, M; GEHLSEN, J; HAMMOND, D; ONDREYCO, S; PIRO, L; POMEROY, T; WILLIAMS, F; MCMILLAN, R			COMBINATION CHEMOTHERAPY IN REFRACTORY IMMUNE THROMBOCYTOPENIC PURPURA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NON-HODGKINS-LYMPHOMA; THERAPY; LEUKEMIA; ITP	Background. Chronic idiopathic thrombocytopenic purpura is a destructive thrombocytopenia caused by an autoantibody. About 80 percent of patients with chronic idiopathic thrombocytopenic purpura have remissions after either corticosteroid therapy or splenectomy. Some patients with resistant disease respond to other agents, but a substantial group are refractory to therapy. Methods. We used combination chemotherapy to treat 10 patients with refractory immune thrombocytopenia. An average of 6.8 (range, 3 to 10) previous therapies, including corticosteroids and splenectomy, had been unsuccessful in these patients. The patients received from three to eight cycles of therapy consisting of cyclophosphamide and prednisone combined with either vincristine (one patient), vincristine and procarbazine (four patients), or etoposide (six patients, including one patient who received four cycles each containing procarbazine and etoposide) Results. Among the 10 patients, 6 had complete responses (platelet count, >180,000 per cubic millimeter); of these, 4 patients had responses that persisted for more than 11, 30, 54, or 126 months, 1 had a relapse 9 months after therapy but had a remission with further therapy and remained in remission for 48 months before dying of an unrelated illness, and another relapsed just before her fifth course of therapy. Two patients had partial responses (platelet count, >50,000 per cubic millimeter); the platelet counts in one remained stable for more than nine months after the end of therapy, and the other patient relapsed. The remaining two patients had no response. Complete responses were associated with a disappearance or marked decrease in the level of platelet-associated auto-antibody. Conclusions. Combination chemotherapy is beneficial in some patients in whom immune thrombocytopenia is refractory to corticosteroids and splenectomy.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA	Scripps Research Institute					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037945] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00833] Funding Source: Medline; NHLBI NIH HHS [HL37945] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHN YS, 1977, ANNU REV MED, V28, P299, DOI 10.1146/annurev.me.28.020177.001503; ANDERSON T, 1977, CANCER TREAT REP, V61, P1057; BERCHTOLD P, 1989, BLOOD, V74, P2309; CHAO NJ, 1990, BLOOD, V76, P1293; COLEMAN CN, 1989, CANCER PRINCIPLES PR, V2, P2181; DENOTTOLANDER GJ, 1984, SCAND J HAEMATOL, V32, P101; DIFINO SM, 1980, AM J MED, V69, P430, DOI 10.1016/0002-9343(80)90016-9; FISHER RI, 1992, P AN M AM SOC CLIN, V11, P315; JACOBS P, 1986, Q J MED, V58, P153; JIJI RM, 1973, ARCH INTERN MED, V132, P380, DOI 10.1001/archinte.132.3.380; KALDOR JM, 1990, NEW ENGL J MED, V322, P1, DOI 10.1056/NEJM199001043220101; KALDOR JM, 1990, NEW ENGL J MED, V322, P7, DOI 10.1056/NEJM199001043220102; KELTON JG, 1982, SEMIN THROMB HEMOST, V8, P83, DOI 10.1055/s-2007-1005045; LIGHTSEY AL, 1975, JAMA-J AM MED ASSOC, V232, P734, DOI 10.1001/jama.232.7.734; MCMILLAN R, 1981, NEW ENGL J MED, V304, P1135, DOI 10.1056/NEJM198105073041904; MCMILLAN R, 1987, BLOOD, V70, P1040; PICOZZI VJ, 1980, AM J MED, V69, P690, DOI 10.1016/0002-9343(80)90419-2; PUI CH, 1991, NEW ENGL J MED, V325, P1682, DOI 10.1056/NEJM199112123252402; RODGERS GM, 1980, ANN INTERN MED, V92, P713; ROSSE WF, 1983, CLIN HAEMATOL, V12, P267	20	105	108	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 29	1993	328	17					1226	1229		10.1056/NEJM199304293281703	http://dx.doi.org/10.1056/NEJM199304293281703			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ061	8464433				2023-01-03	WOS:A1993KZ06100003
J	INGLIS, TJJ; SHERRATT, MJ; SPROAT, LJ; GIBSON, JS; HAWKEY, PM				INGLIS, TJJ; SHERRATT, MJ; SPROAT, LJ; GIBSON, JS; HAWKEY, PM			GASTRODUODENAL DYSFUNCTION AND BACTERIAL-COLONIZATION OF THE VENTILATED LUNG	LANCET			English	Article							MULTIPLE TRAUMA PATIENTS; RESPIRATORY-TRACT; NOSOCOMIAL PNEUMONIA; COLONIZATION; DECONTAMINATION; CIMETIDINE; INFECTIONS; FLORA	The source of ventilator-associated pneumonia (gastric or oropharyngeal flora) remains controversial. We investigated the source of bacterial colonisation of the ventilated lung in 100 consecutive intensive-care patients. Gram-negative bacilli were isolated from the lower respiratory tract in 19 patients. Bacteria isolated from the stomach contents either previously or at the same time were identical to lower respiratory isolates in 11 patients. No gram-negative oropharyngeal isolate was identical to a lower respiratory tract isolate. Gastric bacterial overgrowth with gram-negative bacilli was associated with the presence of bilirubin in the stomach contents. Detectable bilirubin was also associated with subsequent acquisition of gram-negative bacilli in the lower respiratory tract. Only 5 gastric aspirate specimens with pH <3.5 contained gram-negative bacilli. These results establish a relation between duodenal reflux and subsequent bacterial colonisation of the lower respiratory tract. Restoration of normal gastroduodenal motility might help prevent pneumonia in intensive-care patients.	UNIV LEEDS,DEPT MICROBIOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND; GEN INFIRM,INTENS CARE UNIT,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND	University of Leeds; Leeds General Infirmary			Sherratt, Michael J/A-1175-2015	Sherratt, Michael J/0000-0003-4759-6617				ATHERTON ST, 1978, LANCET, V2, P968; CRAIG CP, 1984, AM J INFECT CONTROL, V12, P233, DOI 10.1016/0196-6553(84)90114-7; CRAVEN DE, 1986, AM REV RESPIR DIS, V133, P792; DONOWITZ LG, 1986, INFECT CONT HOSP EP, V7, P23, DOI 10.1017/S0195941700063748; DRIKS MR, 1987, NEW ENGL J MED, V317, P1376, DOI 10.1056/NEJM198711263172204; DUMOULIN GC, 1982, LANCET, V1, P242; GRAY JDA, 1967, GUT, V8, P574, DOI 10.1136/gut.8.6.574; GRAYCEY M, 1983, HUMAN INTESTINAL MIC, P495; HAMMOND JMJ, 1992, LANCET, V340, P5, DOI 10.1016/0140-6736(92)92422-C; Hawkey PM, 1989, MED BACTERIOLOGY PRA; HAWKEY PM, 1989, MED BACTERIOLOGY PRA, P247; INGLIS T, 1991, BR J ANAESTHESIOL, V68, P499; JOHANSON WG, 1972, ANN INTERN MED, V77, P701, DOI 10.7326/0003-4819-77-5-701; Malloy HT, 1937, J BIOL CHEM, V119, P481; POWER I, 1989, ANAESTHESIA, V44, P563, DOI 10.1111/j.1365-2044.1989.tb11442.x; RUDDELL WSJ, 1980, LANCET, V1, P672; STOUTENBEEK CP, 1984, INTENS CARE MED, V10, P185, DOI 10.1007/BF00259435; STOUTENBEEK CP, 1987, J TRAUMA, V27, P357, DOI 10.1097/00005373-198704000-00003; WOODS CR, 1992, J CLIN MICROBIOL, V30, P2921, DOI 10.1128/JCM.30.11.2921-2929.1992	19	133	135	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 10	1993	341	8850					911	913		10.1016/0140-6736(93)91208-4	http://dx.doi.org/10.1016/0140-6736(93)91208-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW981	8096263				2023-01-03	WOS:A1993KW98100002
J	Blenkinsopp, A; Bradley, C				Blenkinsopp, A; Bradley, C			Over the counter drugs: Patients, society, and the increase in self medication	BRITISH MEDICAL JOURNAL			English	Article								Self medication with over the counter medicines has long been a feature of the lay health system. With the reclassification of certain drugs, the public can buy preparations that were previously available only on prescription. Sales of over the counter medicines are now equivalent to a third of the NHS drugs bill; governments throughout the world see self medication as a way of shifting some of the cost of health care onto consumers. The trend towards increased self care and with it the increasing empowerment of patients has many potential benefits; collaboration between doctors and pharmacists will be critical.	UNIV BIRMINGHAM,SCH MED,DEPT GEN PRACTICE,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Birmingham	Blenkinsopp, A (corresponding author), KEELE UNIV,DEPT PHARM POLICY & PRACTICE,KEELE ST5 5BG,STAFFS,ENGLAND.			Blenkinsopp, Alison/0000-0001-8872-2769				ANDERSEN M, 1994, BRIT MED J, V309, P494; BLENKINSOPP A, 1991, BR J GEN PRACT, V41, P16; BRADLEY B, 1994, J CLIN PHARM THER, V19, P7, DOI 10.1111/j.1365-2710.1994.tb00802.x; BRANSTAD JO, 1994, SOC SCI MED, V39, P207, DOI 10.1016/0277-9536(94)90329-8; Emmerton L, 1994, INT J PHARM PRACT, V3, P27; GIBSON P, 1993, BRIT MED J, V306, P1514, DOI 10.1136/bmj.306.6891.1514; HANNAY DR, 1989, SYMPTOM ICEBERG STUD; HEATH I, 1994, BRIT MED J, V309, P623, DOI 10.1136/bmj.309.6955.623; HERXHEIMER A, 1994, BRIT J GEN PRACT, V44, P339; LAWSON D, 1995, OTC DIRECTORY 1995 9; MORLEY A, 1983, PHARM J, V231, P387; *NUFF FDN, 1986, PHARM COMM INQ APP N; PLATTEN A, 1994, MODEL STANDARDS SELF, V9; *PROPR ASS GREAT B, 1995, ANN REP; *PROPR ASS GREAT B, 1987, EVER HLTH CAR CONS S; *PROPR ASS GREAT B, 1995, OTC DIR 1995 96; RAITH H, 1992, SCRIP MAGAZINE   MAR, P20; *ROYAL PHARM SOC G, 1995, MED ETH PRACT; SMITH FJ., 1993, INT J PHARM PRACT, V2, P86; SMITH MBH, 1993, JAMA-J AM MED ASSOC, V269, P2258, DOI 10.1001/jama.269.17.2258; WHITAKER MJ, 1994, PHARM J, V253, P867; Wilson M., 1992, INT J PHARM PRACT, V1, P152; 1994, LANCET, V343, P1374	23	136	142	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 9	1996	312	7031					629	632						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ840	8595343				2023-01-03	WOS:A1996TZ84000034
J	Hensel, WA				Hensel, WA			My living will	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 28	1996	275	8					588	588		10.1001/jama.275.8.588	http://dx.doi.org/10.1001/jama.275.8.588			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW627	8594232				2023-01-03	WOS:A1996TW62700007
J	Lip, GYH; Watson, RDS; Singh, SP				Lip, GYH; Watson, RDS; Singh, SP			ABC of atrial fibrillation - Cardioversion of atrial fibrillation	BRITISH MEDICAL JOURNAL			English	Article									UNIV BIRMINGHAM,CITY HOSP,DEPT CARDIOL,BIRMINGHAM,W MIDLANDS,ENGLAND	University of Birmingham	Lip, GYH (corresponding author), UNIV BIRMINGHAM,CITY HOSP,DEPT MED,BIRMINGHAM,W MIDLANDS,ENGLAND.							CLARK A, 1991, BRIT J HOSP MED, V46, P114; LAUPACIS A, 1995, CHEST S, V108, P352; LIP GYH, 1995, POSTGRAD MED J, V71, P457, DOI 10.1136/pgmj.71.838.457; 1993, J AM COLL CARDIOL, V22, P336	4	13	13	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 13	1996	312	7023					112	115						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ168	8555897				2023-01-03	WOS:A1996TQ16800036
J	KritzSilverstein, D; BarrettConnor, E				KritzSilverstein, D; BarrettConnor, E			Long-term postmenopausal hormone use, obesity, and fat distribution in older women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; BODY-FAT; REPLACEMENT THERAPY; ADIPOSE-TISSUE; RISK-FACTORS; MENOPAUSE; POPULATION; ASSOCIATION; GOTHENBURG; HISTORY	Objective.-To determine whether long-term postmenopausal hormone replacement is associated with measures of obesity and body composition in elderly women. Design.-A 15-year prospective and cross-sectional cohort study. Setting.-Rancho Bernardo, a geographically defined community in Southern California. Participants.-A total of 671 women aged 65 to 94 years, who were initially enrolled in the Rancho Bernardo Study between 1972 and 1974 and participated in a 1988 to 1991 follow-up clinic visit. These women had never used hormone replacement therapy (n=194), used hormones intermittently (n=331), or used hormones continuously (n=146) for the 15 years between baseline and follow-up. Main Outcome Measures.-Height and weight were obtained at both clinic visits; differences in body mass index (BMI) between baseline and follow-up were computed. At follow-up, waist and hip circumferences and bioelectric impedance were measured. Results.-Age-adjusted comparisons indicated intermittent and continuous hormone users had significantly lower mean BMIs at baseline than women who had never used hormone replacement therapy. After adjustment for potentially confounding covariates, there were no significant differences between estrogen users and nonusers in BMI at follow-up, change in weight or BMI between baseline and follow-up, or waist-hip ratio or fat mass at follow-up. Conclusion.-Hormone replacement therapy, whether used intermittently or continuously for 15 or more years, is not associated with the weight gain and central obesity that is commonly observed in postmenopausal women.	UNIV CALIF SAN DIEGO,DEPT FAMILY & PREVENT MED,DIV EPIDEMIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego					AHRQ HHS [HS06726] Funding Source: Medline; NIA NIH HHS [AG07181] Funding Source: Medline; NIDDK NIH HHS [DK31801] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS006726] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031801] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG007181, R37AG007181] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARRETTCONNOR E, 1980, AM J EPIDEMIOL, V111, P705, DOI 10.1093/oxfordjournals.aje.a112948; GOODMAN MT, 1990, AM J EPIDEMIOL, V131, P815, DOI 10.1093/oxfordjournals.aje.a115572; HAARBO J, 1991, METABOLISM, V40, P1323, DOI 10.1016/0026-0495(91)90037-W; HART DM, 1978, FRONT HORM RES, V5, P174; HARTZ AJ, 1983, PREV MED, V12, P351, DOI 10.1016/0091-7435(83)90244-X; HARTZ AJ, 1984, AM J EPIDEMIOL, V119, P71, DOI 10.1093/oxfordjournals.aje.a113727; HASSAGER C, 1989, METABOLISM, V38, P662, DOI 10.1016/0026-0495(89)90104-2; KAYE SA, 1990, INT J OBESITY, V14, P583; KULLER L, 1990, SERONO S; KULLER LH, 1994, EXP GERONTOL, V29, P495, DOI 10.1016/0531-5565(94)90030-2; KUSHNER RF, 1992, J AM COLL NUTR, V11, P199; LAPIDUS L, 1984, BMJ-BRIT MED J, V289, P1257, DOI 10.1136/bmj.289.6454.1257; LEY CJ, 1992, AM J CLIN NUTR, V55, P950, DOI 10.1093/ajcn/55.5.950; LUKASKI HC, 1985, AM J CLIN NUTR, V41, P810, DOI 10.1093/ajcn/41.4.810; LUNDGREN H, 1989, INT J OBESITY, V13, P413; MATTHEWS KA, 1989, NEW ENGL J MED, V321, P641, DOI 10.1056/NEJM198909073211004; NACHTIGALL LE, 1979, OBSTET GYNECOL, V54, P74, DOI 10.1097/00006250-197907000-00017; NOTELOVITZ M, 1982, CURR THER RES CLIN E, V31, P746; NOTELOVITZ M, 1975, S AFR MED J, V49, P2251; STAMPFER MJ, 1985, NEW ENGL J MED, V313, P1044, DOI 10.1056/NEJM198510243131703; TONKELAAR I, 1990, INT J OBESITY, V14, P753; Tonkelaar I D, 1989, Int J Obes, V13, P817; UTIAN WH, 1978, MATURITAS, V1, P3, DOI 10.1016/0378-5122(78)90003-8; WING RR, 1991, ARCH INTERN MED, V151, P97, DOI 10.1001/archinte.151.1.97; WING RR, 1991, ARTERIOSCLER THROMB, V11, P1250, DOI 10.1161/01.ATV.11.5.1250; 1995, JAMA-J AM MED ASSOC, V273, P199	26	86	88	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 3	1996	275	1					46	49						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TM238	8531286				2023-01-03	WOS:A1996TM23800021
J	NELSON, ME; FIATARONE, MA; MORGANTI, CM; TRICE, I; GREENBERG, RA; EVANS, WJ				NELSON, ME; FIATARONE, MA; MORGANTI, CM; TRICE, I; GREENBERG, RA; EVANS, WJ			EFFECTS OF HIGH-INTENSITY STRENGTH TRAINING ON MULTIPLE RISK-FACTORS FOR OSTEOPOROTIC FRACTURES - A RANDOMIZED CONTROLLED TRIAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BONE-MINERAL DENSITY; WEIGHT-BEARING EXERCISE; POSTMENOPAUSAL WOMEN; SKELETAL-MUSCLE; OLDER MEN; CALCIUM SUPPLEMENTATION; PREMENOPAUSAL WOMEN; PHYSICAL-ACTIVITY; BODY-COMPOSITION; ELDERLY PERSONS	Objective.-To determine how multiple risk factors for osteoporotic fractures could be modified by high-intensity strength training exercises in postmenopausal women. Design.-Randomized controlled trial of 1-year duration. Setting.-Exercise laboratory at Tufts University, Boston, Mass. Population.-Forty postmenopausal white women, 50 to 70 years of age, participated in the study; 39 women completed the study. The subjects were sedentary and estrogen-deplete. Interventions.-High-intensity strength training exercises 2 days per week using five different exercises (n=20) vs untreated controls (n=19). Main Outcome Measures.-Dual-energy x-ray absorptiometry for bone status, one repetition maximum for muscle strength, 24-hour urinary creatinine for muscle mass, and backward tandem walk for dynamic balance. Results.-Femoral neck bone mineral density and lumbar spine bone mineral density increased by 0.005+/-0.039 g/cm(2) (0.9%+/-4.5%) (mean+/-SD) and 0.009+/-0.033 g/cm(2) (1.0%+/-3.6%), respectively, in the strength-trained women and decreased by -0.022+/-0.035 g/cm(2) (-2.5%+/-3.8%) and -0.019+/-0.035 g/cm(2) (-1.8%+/-3.5%), respectively, in the controls (P=.02 and .04). Total body bone mineral content was preserved in the strength-trained women (+2.0+/-68 g; 0.0%+/-3.0%) and tended to decrease in the controls (-33+77 g; -1.2%+/-3.4%, P=.12). Muscle mass, muscle strength, and dynamic balance increased in the strength-trained women and decreased in the controls (P=.03 to <.001). Conclusions.-High-intensity strength training exercises are an effective and feasible means to preserve bone density while improving muscle mass, strength, and balance in postmenopausal women.	HARVARD UNIV,SCH MED,DIV AGING,BOSTON,MA 02115; PENN STATE UNIV,NOLL PHYSIOL RES CTR,UNIVERSITY PK,PA	Harvard University; Harvard Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	NELSON, ME (corresponding author), TUFTS UNIV,JEAN MAYER USDA HUMAN NUTR RES CTR AGING,711 WASHINGTON ST,BOSTON,MA 02111, USA.				NIDDK NIH HHS [P01-DK42618] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK042618] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AINSWORTH BE, 1993, J CLIN EPIDEMIOL, V46, P1403, DOI 10.1016/0895-4356(93)90140-V; AVIOLI LV, 1991, CALCIFIED TISSUE INT, V49, pS5, DOI 10.1007/BF02555078; BEVIER WC, 1989, J BONE MINER RES, V4, P421; BORG G, 1970, ACTA MED SCAND, V187, P17; BREWER V, 1983, MED SCI SPORT EXER, V15, P445; BUTLER RN, 1993, GERIATRICS, V48, P11; CAVANAUGH DJ, 1988, BONE, V9, P201, DOI 10.1016/8756-3282(88)90031-2; CHAMAY A, 1972, J BIOMECH, V5, P173, DOI 10.1016/0021-9290(72)90053-X; CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305; CHOW R, 1987, BMJ-BRIT MED J, V295, P1441, DOI 10.1136/bmj.295.6611.1441; CUMMINGS SR, 1994, NEW ENGL J MED, V331, P872, DOI 10.1056/NEJM199409293311310; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; DALSKY GP, 1988, ANN INTERN MED, V108, P824, DOI 10.7326/0003-4819-108-6-824; DAWSONHUGHES B, 1990, NEW ENGL J MED, V323, P878, DOI 10.1056/NEJM199009273231305; DAWSONHUGHES B, 1987, CALCIFIED TISSUE INT, V40, P310, DOI 10.1007/BF02556691; DOYLE F, 1970, LANCET, V1, P391, DOI 10.1016/S0140-6736(70)91520-5; EVANS WJ, 1993, J NUTR, V123, P465, DOI 10.1093/jn/123.suppl_2.465; FIATARONE MA, 1990, JAMA-J AM MED ASSOC, V263, P3029, DOI 10.1001/jama.263.22.3029; FIATARONE MA, 1994, NEW ENGL J MED, V330, P1769, DOI 10.1056/NEJM199406233302501; FRONTERA WR, 1991, J APPL PHYSIOL, V71, P644, DOI 10.1152/jappl.1991.71.2.644; FRONTERA WR, 1990, J APPL PHYSIOL, V68, P329, DOI 10.1152/jappl.1990.68.1.329; FRONTERA WR, 1988, J APPL PHYSIOL, V64, P1038, DOI 10.1152/jappl.1988.64.3.1038; GLEESON PB, 1990, J BONE MINER RES, V5, P153, DOI 10.1002/jbmr.5650050208; HEYMSFIELD SB, 1983, AM J CLIN NUTR, V37, P478, DOI 10.1093/ajcn/37.3.478; JOHNSON J, 1991, CALCIFIED TISSUE INT, V49, P174, DOI 10.1007/BF02556113; JOHNSTON C, 1993, BONE DENSITY MEASURE, P137; KRALL EA, 1994, AM J MED, V96, P20, DOI 10.1016/0002-9343(94)90111-2; LARSEN K, 1972, CLIN CHIM ACTA, V41, P209, DOI 10.1016/0009-8981(72)90513-X; MCDONAGH MJN, 1984, EUR J APPL PHYSIOL, V52, P139, DOI 10.1007/BF00433384; MICHEL BA, 1989, ARCH INTERN MED, V149, P2325, DOI 10.1001/archinte.149.10.2325; NELSON ME, 1988, J CLIN ENDOCR METAB, V66, P927, DOI 10.1210/jcem-66-5-927; NELSON ME, 1991, AM J CLIN NUTR, V53, P1304, DOI 10.1093/ajcn/53.5.1304; NEVITT MC, 1989, JAMA-J AM MED ASSOC, V261, P2663, DOI 10.1001/jama.261.18.2663; NOTELOVITZ M, 1991, J BONE MINER RES, V6, P583, DOI 10.1002/jbmr.5650060609; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; POCOCK N, 1989, J BONE MINER RES, V4, P441; PREECE MA, 1974, CLIN CHIM ACTA, V54, P235, DOI 10.1016/0009-8981(74)90241-1; PRINCE RL, 1991, NEW ENGL J MED, V325, P1189, DOI 10.1056/NEJM199110243251701; PRUITT LA, 1992, J BONE MINER RES, V7, P179; ROCKWELL JC, 1990, J CLIN ENDOCR METAB, V71, P988, DOI 10.1210/jcem-71-4-988; SOROCK GS, 1988, J GERONTOL, V43, pM134, DOI 10.1093/geronj/43.5.M134; TINETTI ME, 1993, JAMA-J AM MED ASSOC, V269, P65, DOI 10.1001/jama.269.1.65; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; WHIPPLE RH, 1987, J AM GERIATR SOC, V35, P13, DOI 10.1111/j.1532-5415.1987.tb01313.x; ZYLSTRA S, 1989, INT J SPORTS MED, V10, P181, DOI 10.1055/s-2007-1024897; 1990, SAS USERS GUIDE STAT; 1989, RECOMMENDED DIETARY	48	719	733	2	67	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 28	1994	272	24					1909	1914		10.1001/jama.272.24.1909	http://dx.doi.org/10.1001/jama.272.24.1909			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX927	7990242				2023-01-03	WOS:A1994PX92700035
J	TUCKER, J				TUCKER, J			PRIMARY-CARE	LANCET			English	Letter											TUCKER, J (corresponding author), UNIV DUNDEE,DEPT EPIDEMIOL & PUBL HLTH,SCOTTISH ANTENATAL CARE TRIAL,DUNDEE DD1 9SY,SCOTLAND.							FAWDRY R, 1990, PRACTITIONER, V234, P352; ORTON, 1994, LANCET, V344, P1413; TUCKER J, 1994, J PUBLIC HEALTH MED, V16, P60, DOI 10.1093/oxfordjournals.pubmed.a042937; 1984, J R SOC MED, V77, P340; 1982, 1 DEP HLTH SOC SERV	5	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 17	1994	344	8938					1707	1707						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX302	7996986				2023-01-03	WOS:A1994PX30200047
J	EMANUEL, EJ				EMANUEL, EJ			THE HISTORY OF EUTHANASIA DEBATES IN THE UNITED-STATES AND BRITAIN	ANNALS OF INTERNAL MEDICINE			English	Review							ACTIVE EUTHANASIA; LIFE	Debates about the ethics of euthanasia and physician-assisted suicide date from ancient Greece and Pome. After the development of ether, physicians began advocating the use of anesthetics to relieve the pains of death. In 1870, Samuel Williams first proposed using anesthetics and morphine to intentionally end a patient's life. Over the next 35 years, debates about the ethics of euthanasia raged in the United States and Britain,culminating in 1906 in an Ohio bill to legalize euthanasia, a bill that was ultimately defeated. The arguments propounded for and against euthanasia in the 19th century are identical to contemporary arguments. Such similarities suggest four conclusions: Public interest in euthanasia 1) is not linked with advances in biomedical technology; 2) it flourishes in times of economic recession, in which individualism and social Darwinism are invoked to justify public policy; 3) it arises when physician authority over medical decision making is challenged; and 4) it occurs when terminating life-sustaining medical interventions become standard medical practice and interest develops in extending such practices to include euthanasia.			EMANUEL, EJ (corresponding author), DANA FARBER CANC INST, 44 BINNEY ST, BOSTON, MA 02115 USA.							ALEXANDER L, 1949, NEW ENGL J MED, V241, P39, DOI 10.1056/NEJM194907142410201; AMUNDSEN DW, 1978, HASTINGS CENT REP, V8, P23, DOI 10.2307/3560974; Bach A, 1896, MED LEG J, V14, P103; BACON F, 1924, NEW ATLANTIS; BALDWIN SE, 1899, ST PAUL MED J, V1, P875; Bannister Robert C., 1988, SOCIAL DARWINISM SCI; BINDING K, 1992, ISSUES LAW MED, V8, P231; BROCK DW, 1992, HASTINGS CENT REP, V22, P10, DOI 10.2307/3562560; Bullar Joseph, 1866, BRIT MED J, V2, P10; BURNIE WG, 1899, LANCET, V1, P561; Carrick P, 1985, MED ETHICS ANTIQUITY; CASSEL CK, 1990, NEW ENGL J MED, V323, P750, DOI 10.1056/NEJM199009133231110; COSTIGAN G, 1906, NY TIMES        0206, P8; Degler C., 1991, SEARCH HUMAN NATURE; DEWACHTER MAM, 1989, JAMA-J AM MED ASSOC, V262, P3316, DOI 10.1001/jama.262.23.3316; Douglas CE, 1936, BRIT MED J, V1936, P33; DRINK ERP, 1929, JAMA-J AM MED ASSOC, V92, P1658; Edelstein L, 1967, ANCIENT MED SELECTED; EMANUEL EJ, 1991, ENDS HUMAN LIFE; Fleming RA, 1936, BRIT MED J, V1936, P86; FONER E, 1992, SOCIAL DARWINISM AM, pR20; FYE WB, 1978, B HIST MED, V52, P492; GARVER KL, 1991, AM J HUM GENET, V49, P1109; Gillon R., 1969, EUTHANASIA RIGHT DEA; GOUREVITCH D, 1969, Bulletin of the History of Medicine, V43, P501; Griffiths G, 1936, BRIT MED J, V1936, P134; HELME T, 1991, J MED ETHICS, V17, P25, DOI 10.1136/jme.17.1.25; HITCHCOCK FE, 1889, T MAINE MED SOC, V10, P30; Hofstadter Richard, 1992, SOCIAL DARWINISM AM; HUME D, 1854, PHILOS WORKS, V4, P535; JACOBI A, 1912, MED REV REV, V18, P362; KAMISAR Y, 1958, MINN LAW REV, V42, P969; KASS LR, 1989, PUBLIC INTEREST, P25; Lifton Robert Jay, 1986, NAZI DOCTORS MED KIL; Manson JS, 1936, BRIT MED J, V1936, P87; McGarry PJ, 1936, BRIT MED J, V1936, P134; MILLARD CK, 1931, PUBLIC HLTH, V45, P39; MILLARD CK, 1935, BRIT MED J, V2, P1181; MISBIN RI, 1991, NEW ENGL J MED, V325, P1307, DOI 10.1056/NEJM199110313251811; MORE T, 1984, UTOPIA OTHER WRITING; MUNK W, 1887, EUTHANASIA MED TREAT; PERNICK MS, 1985, CALCULUS SUFFERING; Pfafflin F, 1986, Med Law, V5, P1; PLINY, 1969, LETT PANEGYERICUS, V1, pR22; Proctor Robert N., 1988, RACIAL HYGIENE MED N; RACHELS J, 1975, NEW ENGL J MED, V292, P78, DOI 10.1056/NEJM197501092920206; RACHELS J., 1986, END LIFE EUTHANASIA; REICHEL W, 1989, LANCET, V2, P1321; REISER SJ, 1975, DILEMMAS EUTHANASIA; Richards WG, 1936, BRIT MED J, V1936, P390; ROBINSON V, 1903, MED REV REV, V19, P143; Rosenberg Charles E., 1987, CARE STRANGERS RISE; Rosenberg LJ, 1901, J AMER MED ASSOC, V36, P108; Ross Dorothy., 1991, ORIGINS AM SOCIAL SC; RUPP A, 1906, NY TIMES        0130, P8; SINGER PA, 1990, NEW ENGL J MED, V322, P1881, DOI 10.1056/NEJM199006283222610; Starr P., 1982, SOCIAL TRANSFORMATIO; TOLLEMACHE L, 1873, FORTNIGHTLY REV, P218; TOMLINSON A, 1906, NY TIMES        0211, P8; Tredgold AF, 1936, BRIT MED J, V1936, P33; WARREN JC, 1848, ETHERIZATION SURGICA, P69; WELLS SR, 1907, T MED LEGAL SOC YEAR, V4, P1; WILLIAMS CB, 1894, MED REC, V70, P909; WILLIAMS G, 1958, MINN LAW REV, V43, P1; Williams G. L., 1957, SANCTITY LIFE CRIMIN; WILLIAMS SD, 1872, EUTHANASIA; Williamson Jeffrey Gale, 1980, AM INEQUALITY MACROE; WILSON R, 1896, PRACTITIONER, V56, P631; WOLF SM, 1989, HASTINGS CENT REP, V19, pS13; Wood Gordon S., 1991, RADICALISM AM REVOLU; 1906, NY TIMES        0124, P2; 1897, BRIT MED J, V1, P934; 1870, SATURDAY REV, V30, P632; 1871, SPECTATOR, V44, P34; 1904, JAMA-J AM MED ASSOC, V43, P896; 1934, MED REC, V139, P257; 1873, POPULAR SCI MONTHLY, V3, P90; 1935, TIME            1118, P53; 1936, BRIT MED J, V1, P186; 1879, APR P S CAR MED ASS, P14; 1931, PUBLIC HLTH, V45, P33; 1872, SATURDAY REV, V34, P43; 1988, JAMA-J AM MED ASSOC, V259, P272; 1885, JAMA-J AM MED ASSOC, V5, P382; 1935, BRIT MED J, V2, P1168; 1902, SPECTATOR, V88, P134; 1935, TIME            1125, P39; 1873, MED SURGICAL REPORTE, V29, P122; 1899, LANCET, V1, P489; 1914, JAMA-J AM MED ASSOC, V62, P705; 1926, JAMA-J AM MED ASSOC, V87, P1491; 1885, MED LEG J, V2, P312; 1936, MED REC, V143, P177; 1906, MED REC, V69, P184; 1879, MED SURGICAL REPORTE, V41, P479; 1885, MED REC, V28, P322; 1939, LANCET, V2, P1369; 1935, TIME            1202, P34; 1919, JAMA-J AM MED ASSOC, V72, P1557; 1934, PRACTITIONER, V132, P485; 1905, AM MED, V10, P1093; 1906, BRIT MED J, V1, P638; 1903, JAMA-J AM MED ASSOC, V41, P1094; 1935, BRIT MED J, V2, P856; 1899, LANCET, V1, P532; 1936, LANCET, V2, P1215; 1906, NY TIMES        0106, P8; 1935, NEWSWEEK        1116, V6, P40; 1884, BOSTON MED SURGICAL, V110, P19; 1906, ST LOUIS MED REV, V53, P66; 1899, INTERSTATE MED J, V6, P488	111	70	73	1	27	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1994	121	10					793	802		10.7326/0003-4819-121-10-199411150-00010	http://dx.doi.org/10.7326/0003-4819-121-10-199411150-00010			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ928	7944057				2023-01-03	WOS:A1994PQ92800010
J	ALVAREZ, FJ; DELRIO, MC				ALVAREZ, FJ; DELRIO, MC			DRUGS AND DRIVING	LANCET			English	Editorial Material											ALVAREZ, FJ (corresponding author), UNIV VALLADOLID,FAC MED,DEPT PHARMACOL & THERAPEUT,DRUGS & ALCOHOL RES GRP,VALLADOLID,SPAIN.		Alvarez, Francisco/GZL-1953-2022; Alvarez, F. Javier/E-7204-2016; Alvarez, F. Javier/X-2294-2019	Alvarez, F. Javier/0000-0002-7566-5678; Alvarez, F. Javier/0000-0002-7566-5678				DEGIER JJ, 1993, IHP9339 U LIMB I HUM; 1985, JAMA-J AM MED ASSOC, V257, P2618; 1985, EUROPEAN HLTH ALL SE, V1; 1991, OFF J EEC; 1991, III916390EN; 1986, JAMA-J AM MED ASSOC, V255, P522; 1992, OFF J EEC; 1992, EUROPEAN COMMISSION	8	24	26	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 30	1994	344	8918					282	282						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ233	7914258				2023-01-03	WOS:A1994NZ23300004
J	FIATARONE, MA; ONEILL, EF; RYAN, ND; CLEMENTS, KM; SOLARES, GR; NELSON, ME; ROBERTS, SB; KEHAYIAS, JJ; LIPSITZ, LA; EVANS, WJ				FIATARONE, MA; ONEILL, EF; RYAN, ND; CLEMENTS, KM; SOLARES, GR; NELSON, ME; ROBERTS, SB; KEHAYIAS, JJ; LIPSITZ, LA; EVANS, WJ			EXERCISE TRAINING AND NUTRITIONAL SUPPLEMENTATION FOR PHYSICAL FRAILTY LN VERY ELDERLY PEOPLE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BODY-COMPOSITION; SKELETAL-MUSCLE; NURSING-HOME; STRENGTH; MEN; MORPHOLOGY; SPEED; WOMEN; AGE; OLD	Background. Although disuse of skeletal muscle and undernutrition are often cited as potentially reversible causes of frailty in elderly people, the efficacy of interventions targeted specifically at these deficits has not been carefully studied. Methods. We conducted a randomized, placebo-controlled trial comparing progressive resistance exercise training, multinutrient supplementation, both interventions, and neither in 100 frail nursing home residents over a 10-week period. Results. The mean (+/-SE) age of the 63 women and 37 men enrolled in the study was 87.1+/-0.6 years (range, 72 to 98); 94 percent of the subjects completed the study. Muscle strength increased by 113+/-8 percent in the subjects who underwent exercise training, as compared with 3+/-9 percent in the nonexercising subjects (P<0.001). Gait velocity increased by 11.8+/-3.8 percent in the exercisers but declined by 1.0+/-3.8 percent in the nonexercisers (P = 0.02). Stair-climbing power also improved in the exercisers as compared with the nonexercisers (by 28.4+/-6.6 percent vs. 3.6+/-6.7 percent, P = 0.01), as did the level of spontaneous physical activity. Cross-sectional thigh-muscle area increased by 2.7+/-1.8 percent in the exercisers but declined by 1.8+/-2.0 percent in the nonexercisers (P = 0.11). The nutritional supplement had no effect on any primary outcome measure. Total energy intake was significantly increased only in the exercising subjects who also received nutritional supplementation. Conclusions. High-intensity resistance exercise training is a feasible and effective means of Counteracting muscle weakness and physical frailty in very elderly people. in contrast, multinutrient supplementation without concomitant exercise does not reduce muscle weakness or physical frailty.	HEBREW REHABIL CTR AGED, ROSLINDALE, MA USA; HARVARD UNIV, SCH MED, DIV AGING, BOSTON, MA 02115 USA; BETH ISRAEL HOSP, DEPT MED, BOSTON, MA 02215 USA; BRIGHAM & WOMENS HOSP, DIV GERONTOL, BOSTON, MA 02115 USA; TUFTS UNIV NEW ENGLAND MED CTR, DEPT RADIAT ONCOL, DIV MED PHYS, BOSTON, MA 02111 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital; Tufts Medical Center	FIATARONE, MA (corresponding author), TUFTS UNIV, DEPT AGR, HUMAN NUTR RES CTR AGING, 711 WASHINGTON ST, BOSTON, MA 02111 USA.				NATIONAL INSTITUTE ON AGING [U01AG009078, P01AG004390] Funding Source: NIH RePORTER; NIA NIH HHS [AGO4390, UO1 AG09078] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANIANSSON A, 1983, SCAND J REHABIL MED, P92; [Anonymous], 1990, MED SCI SPORT EXER, V22, P265; [Anonymous], 1985, ENERGY PROTEIN REQUI; BASIOTIS PP, 1987, J NUTR, V117, P1638, DOI 10.1093/jn/117.9.1638; BASSEY EJ, 1992, CLIN SCI, V82, P321, DOI 10.1042/cs0820321; BENDALL MJ, 1989, AGE AGEING, V18, P327, DOI 10.1093/ageing/18.5.327; Blankfort-Doyle W, 1989, AGING MOTOR BEHAV, P201; BORKAN GA, 1983, J GERONTOL, V38, P673, DOI 10.1093/geronj/38.6.673; BORTZ WM, 1982, JAMA-J AM MED ASSOC, V248, P1203, DOI 10.1001/jama.248.10.1203; BROCKLEHURST JC, 1968, GERONTOL CLIN, V10, P309, DOI 10.1159/000245198; COHN SH, 1980, AM J PHYSIOL, V239, pE524, DOI 10.1152/ajpendo.1980.239.6.E524; DELORME TL, 1945, J BONE JOINT SURG, V27, P645; DRINKA PJ, 1991, J AM GERIATR SOC, V39, P1008, DOI 10.1111/j.1532-5415.1991.tb04050.x; EFTHIMIOU J, 1988, AM REV RESPIR DIS, V137, P1075, DOI 10.1164/ajrccm/137.5.1075; EVANS WJ, 1993, J NUTR, V123, P465, DOI 10.1093/jn/123.suppl_2.465; Fiatarone M A, 1990, TOP GERIATR REHABIL, V5, P63, DOI DOI 10.1097/00013614-199001000-00009; FIATARONE MA, 1990, JAMA-J AM MED ASSOC, V263, P3029, DOI 10.1001/jama.263.22.3029; FIATARONE MA, 1993, J GERONTOL, V48, P77, DOI 10.1093/geronj/48.Special_Issue.77; FIATARONE MA, 1993, J AM GERIATR SOC, V41, P333, DOI 10.1111/j.1532-5415.1993.tb06714.x; FISHER NM, 1991, ARCH PHYS MED REHAB, V72, P181; FLECK SJ, 1987, DESIGNING RESISTANCE; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; HANSENSMITH FM, 1979, BRIT J NUTR, V41, P275, DOI 10.1079/BJN19790036; HUBERT HB, 1993, J RHEUMATOL, V20, P480; JEEJEEBHOY KN, 1986, GUT, V27, P25, DOI 10.1136/gut.27.Suppl_1.25; JONES DA, 1989, Q J EXP PHYSIOL CMS, V74, P233, DOI 10.1113/expphysiol.1989.sp003268; KLITGAARD H, 1990, ACTA PHYSIOL SCAND, V140, P41, DOI 10.1111/j.1748-1716.1990.tb08974.x; LAPORTE RE, 1979, AM J EPIDEMIOL, V109, P158, DOI 10.1093/oxfordjournals.aje.a112671; LARSSON L, 1979, J APPL PHYSIOL, V46, P451, DOI 10.1152/jappl.1979.46.3.451; MCDONAGH MJN, 1984, EUR J APPL PHYSIOL, V52, P139, DOI 10.1007/BF00433384; MEREDITH CN, 1992, J AM GERIATR SOC, V40, P155, DOI 10.1111/j.1532-5415.1992.tb01937.x; MOLLOY DW, 1988, AGE AGEING, V17, P303, DOI 10.1093/ageing/17.5.303; ORY MG, 1993, J AM GERIATR SOC, V41, P283, DOI 10.1111/j.1532-5415.1993.tb06707.x; ROBERTS SB, 1992, INT J OBESITY, V16, P969; RUSSELL DM, 1983, AM J CLIN NUTR, V38, P229, DOI 10.1093/ajcn/38.2.229; VELLAS B, 1992, NUTRITION, V8, P105; WATERS R, 1990, GAIT REHABILITATION, P65; YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4; Zar J.H., 2010, BIOSTAT ANAL; 1989, RECOMMENDED DIETARY	40	1940	1974	5	215	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 23	1994	330	25					1769	1775		10.1056/NEJM199406233302501	http://dx.doi.org/10.1056/NEJM199406233302501			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR295	8190152	Bronze			2023-01-03	WOS:A1994NR29500001
J	HAYES, MA; TIMMINS, AC; YAU, EHS; PALAZZO, M; HINDS, CJ; WATSON, D				HAYES, MA; TIMMINS, AC; YAU, EHS; PALAZZO, M; HINDS, CJ; WATSON, D			ELEVATION OF SYSTEMIC OXYGEN DELIVERY IN THE TREATMENT OF CRITICALLY ILL PATIENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RISK SURGICAL PATIENTS; SEPTIC SHOCK; THERAPEUTIC GOALS; CLINICAL-TRIAL; ORGAN FAILURE; SUPRANORMAL VALUES; MORTALITY; SURVIVORS; MORBIDITY; PATTERNS	Background. Elevation of systemic oxygen delivery and consumption has been associated with an improved outcome in critically ill patients. We conducted a randomized trial to determine whether boosting oxygen delivery by infusing the inotropic agent dobutamine would improve the outcome in a diverse group of such patients. Methods. On the basis of previously published recommendations, we established the following goals: a cardiac index above 4.5 liters per minute per square meter of body-surface area, oxygen delivery above 600 ml per minute per square meter, and oxygen consumption above 170 ml per minute per square meter. If these goals were not achieved with volume expansion alone, patients were randomly assigned to a treatment or control group. The treatment group received intravenous dobutamine (5 to 200 mu g per kilogram of body weight per minute) until all three goals had been achieved. Dobutamine was administered to the control group only if the cardiac index was below 2.8 liters per minute per square meter. Results. A total of 109 patients were studied. In nine patients the therapeutic goals were achieved with volume expansion alone; all nine patients survived to leave the hospital. Fifty patients were randomly assigned to the treatment group, and 50 to the control group. During treatment, there were no differences between the two groups in mean arterial pressure or oxygen consumption, despite a significantly higher cardiac index and level of oxygen delivery in the treatment group (P < 0.05). Although the predicted risk of death during hospitalization was 34 percent for both groups, the in-hospital mortality was lower in the control group (34 percent) than in the treatment group (54 percent) (P = 0.04; 95 percent confidence interval, 0.9 to 39.1 percent). Conclusions. The use of dobutamine to boost the cardiac index and systemic oxygen delivery failed to improve the outcome in this heterogeneous group of critically ill patients. Contrary to what might have been expected, our results suggest that in some cases aggressive efforts to increase oxygen consumption may have been detrimental.	ST BARTHOLOMEWS HOSP SMITHFIELD,DEPT ANESTHESIA,LONDON EC1A 7BE,ENGLAND; ST BARTHOLOMEWS HOSP SMITHFIELD,DEPT INTENS CARE,LONDON,ENGLAND; ST BARTHOLOMEWS HOSP HOMERTON,DEPT ANESTHESIA,LONDON,ENGLAND; ST BARTHOLOMEWS HOSP HOMERTON,DEPT INTENS CARE,LONDON,ENGLAND; CHARING CROSS HOSP,DEPT ANESTHESIA,LONDON,ENGLAND; CHARING CROSS HOSP,DEPT INTENS CARE,LONDON,ENGLAND	Imperial College London; Imperial College London								BARTON R, 1989, CHEST, V96, P1153, DOI 10.1378/chest.96.5.1153; BLAND RD, 1985, CRIT CARE MED, V13, P85, DOI 10.1097/00003246-198502000-00006; BONE RC, 1987, NEW ENGL J MED, V317, P653, DOI 10.1056/NEJM198709103171101; BOYD O, 1993, JAMA-J AM MED ASSOC, V270, P2699, DOI 10.1001/jama.270.22.2699; EDWARDS JD, 1989, CRIT CARE MED, V17, P1098, DOI 10.1097/00003246-198911000-00002; FLEMING A, 1992, ARCH SURG-CHICAGO, V127, P1175; HAYES MA, 1993, CHEST, V103, P886, DOI 10.1378/chest.103.3.886; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1989, CRIT CARE CLIN, V5, P221; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; MARTIN C, 1990, ACTA ANAESTH SCAND, V34, P413, DOI 10.1111/j.1399-6576.1990.tb03114.x; PINSKY MR, 1993, YB INTENSIVE EMERGEN, P373; POCOCK SJ, 1992, BMJ-BRIT MED J, V305, P235, DOI 10.1136/bmj.305.6847.235; POCOCK SJ, 1983, CLIN TRIALS PRACTICA, P231; SHOEMAKER WC, 1988, CRIT CARE MED, V16, P1117, DOI 10.1097/00003246-198811000-00007; SHOEMAKER WC, 1973, ARCH SURG-CHICAGO, V106, P630; SHOEMAKER WC, 1988, CHEST, V94, P1176, DOI 10.1378/chest.94.6.1176; SHOEMAKER WC, 1990, ARCH SURG-CHICAGO, V125, P1332; TUCHSCHMIDT J, 1992, CHEST, V102, P216, DOI 10.1378/chest.102.1.216; YU MH, 1993, CRIT CARE MED, V21, P830, DOI 10.1097/00003246-199306000-00009	20	1006	1042	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 16	1994	330	24					1717	1722		10.1056/NEJM199406163302404	http://dx.doi.org/10.1056/NEJM199406163302404			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR109	7993413				2023-01-03	WOS:A1994NR10900004
J	MAIER, RF; OBLADEN, M; SCIGALLA, P; LINDERKAMP, O; DUC, G; HIERONIMI, G; HALLIDAY, HL; VERSMOLD, HT; MORIETTE, G; JORCH, G; VERELLEN, G; SEMMEKROT, BA; GRAUEL, EL; HOLLAND, BM; WARDROP, CAJ				MAIER, RF; OBLADEN, M; SCIGALLA, P; LINDERKAMP, O; DUC, G; HIERONIMI, G; HALLIDAY, HL; VERSMOLD, HT; MORIETTE, G; JORCH, G; VERELLEN, G; SEMMEKROT, BA; GRAUEL, EL; HOLLAND, BM; WARDROP, CAJ			THE EFFECT OF EPOETIN-BETA (RECOMBINANT-HUMAN-ERYTHROPOIETIN) ON THE NEED FOR TRANSFUSION IN VERY-LOW-BIRTH-WEIGHT INFANTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ERYTHROID PROGENITORS; PREMATURITY; ANEMIA; INVIVO	Background. Anemia of prematurity is characterized by low reticulocyte counts and inadequate erythropoietin response, for which many very-low-birth-weight infants receive multiple blood transfusions. We investigated whether early treatment of such infants with recombinant human erythropoietin would reduce their need for transfusions. Methods. We performed a controlled, blinded trial in 241 infants with very low birth weights at 12 centers in six European countries. When three days old, the infants were randomly assigned either to the epoetin group or to the control group. Those in the epoetin group received 250 IU of epoetin beta per kilogram of body weight subcutaneously three times a week from day 3 to day 42 (for a total of 17 doses); those in the control group did not receive this drug. Infants in both groups received oral iron (2 mg per day) from day 14 onward. Results. The control infants needed a mean of 1.25 transfusions each, as compared with 0.87 transfusion for epoetin-treated infants (P = 0.013). The median cumulative volume of blood transfused per kilogram per day was 0.41 mi in the control group (first quartile, 0 ml; third quartile, 0.8 ml) and 0.09 ml in the epoetin group (first quartile, 0 ml; third quartile, 0.8 ml) (P = 0.044). The rate of success, defined as an absence of need for transfusions and a hematocrit that never fell below 32 percent, was 4.1 percent in the control group and 27.5 percent in the epoetin group (P = 0.008). Epoetin was most beneficial in boys with birth weights of 1200 g or more and a base-line hematocrit of 48 percent or more. No toxic effects were observed in the epoetin group; as compared with the control group, the epoetin group had an increased incidence of septicemia (14 vs. 7 episodes, P not significant) and reduced weight gain (520 vs. 571 g, P = 0.02). Conclusions, Infants with very low birth weights have less need of transfusions if given epoetin beta during the first six weeks of life (250 IU per kilogram three times a week). We recommend early epoetin treatment for all such infants, but further studies of nutrition and iron supplementation during treatment are needed.	FREE UNIV BERLIN, KLINIKUM RUDOLF VIRCHOW, DEPT NEONATOL, D-14059 BERLIN, GERMANY; FREE UNIV BERLIN, KLINIKUM STEGLITZ, W-1000 BERLIN, GERMANY; BOEHRINGER MANNHEIM GMBH, W-6800 MANNHEIM, GERMANY; UNIV HEIDELBERG, HEIDELBERG, GERMANY; UNIV ZURICH, ZURICH, SWITZERLAND; ROYAL MATERN HOSP, BELFAST, NORTH IRELAND; CHU COCHIN PORT ROYAL, PARIS, FRANCE; UNIV MUNSTER, W-4400 MUNSTER, GERMANY; UNIV CATHOLIQUE LOUVAIN, B-1200 BRUSSELS, BELGIUM; UNIV NIJMEGEN HOSP, 6500 HB NIJMEGEN, NETHERLANDS; HUMBOLDT UNIV BERLIN, BERLIN, GERMANY; UNIV GLASGOW, QUEEN MOTHERS HOSP, GLASGOW, SCOTLAND; UNIV WALES COLL CARDIFF, DEPT HEMATOL, CARDIFF, WALES; OLGA HOSP, STUTTGART, GERMANY	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Ruprecht Karls University Heidelberg; University of Zurich; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Munster; Universite Catholique Louvain; Radboud University Nijmegen; Humboldt University of Berlin; University of Glasgow; Cardiff University; General Hospital of N. Ionia Agia Olga; Klinikum Stuttgart				Halliday, Henry/0000-0001-7978-4992				BECHENSTEEN AG, 1993, ARCH DIS CHILD-FETAL, V69, P19, DOI 10.1136/adc.69.1_Spec_No.19; BECK D, 1991, EUR J PEDIATR, V150, P767, DOI 10.1007/BF02026707; BROWN MS, 1984, J PEDIATR-US, V105, P793, DOI 10.1016/S0022-3476(84)80309-1; BROWN MS, 1990, J PEDIATR-US, V116, P773, DOI 10.1016/S0022-3476(05)82670-8; CARNIELLI V, 1992, J PEDIATR-US, V121, P98, DOI 10.1016/S0022-3476(05)82552-1; DESSYPRIS EN, 1988, BLOOD, V72, P2060; EMMERSON AJB, 1993, ARCH DIS CHILD-FETAL, V68, P291, DOI 10.1136/adc.68.3_Spec_No.291; GARNER A, 1984, PEDIATRICS, V74, P127; HALPERIN DS, 1990, J PEDIATR-US, V116, P779, DOI 10.1016/S0022-3476(05)82671-X; HALPERIN DS, 1992, EUR J PEDIATR, V151, P661, DOI 10.1007/BF01957568; KINMOND S, 1993, BMJ-BRIT MED J, V306, P172, DOI 10.1136/bmj.306.6871.172; KOENIG JM, 1990, PEDIATR RES, V27, P583, DOI 10.1203/00006450-199006000-00009; OBLADEN M, 1988, EUR J PEDIATR, V147, P399, DOI 10.1007/BF00496419; OBLADEN M, 1991, CONTRIB NEPHROL, V88, P314; OHLS RK, 1991, J PEDIATR-US, V119, P781, DOI 10.1016/S0022-3476(05)80303-8; PAPILE LA, 1978, J PEDIATR-US, V92, P529, DOI 10.1016/S0022-3476(78)80282-0; RHONDEAU SM, 1988, J PEDIATR-US, V112, P935, DOI 10.1016/S0022-3476(88)80223-3; SHANNON KM, 1991, J PEDIATR-US, V118, P949, DOI 10.1016/S0022-3476(05)82217-6; SHANNON KM, 1990, AM J PEDIAT HEMATOL, V12, P14; SHANNON KM, 1992, J PEDIATR-US, V120, P586, DOI 10.1016/S0022-3476(05)82488-6; SHANNON KM, 1987, NEW ENGL J MED, V317, P728, DOI 10.1056/NEJM198709173171203; STOCKMAN JA, 1984, J PEDIATR-US, V105, P786, DOI 10.1016/S0022-3476(84)80308-X; STRAUSS RG, 1991, AM J DIS CHILD, V145, P904, DOI 10.1001/archpedi.1991.02160080082025; WARDROP CAJ, 1978, ARCH DIS CHILD, V53, P855, DOI 10.1136/adc.53.11.855; 1988, PEDIATRICS, V82, P37	25	212	213	1	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 28	1994	330	17					1173	1178		10.1056/NEJM199404283301701	http://dx.doi.org/10.1056/NEJM199404283301701			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NG586	8139627	Bronze			2023-01-03	WOS:A1994NG58600001
J	TREASURE, J; SCHMIDT, U; TROOP, N; TILLER, J; TODD, G; KEILEN, M; DODGE, E				TREASURE, J; SCHMIDT, U; TROOP, N; TILLER, J; TODD, G; KEILEN, M; DODGE, E			FIRST STEP IN MANAGING BULIMIA-NERVOSA - CONTROLLED TRIAL OF THERAPEUTIC MANUAL	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ANOREXIA-NERVOSA; OLDER ADULTS; BIBLIOTHERAPY; MANAGEMENT; EFFICACY	Objective-To test the short term efficacy of a self directed treatment manual for bulimia nervosa. Design-Randomised controlled trial of the manual against cognitive behavioural therapy and a waiting list. Setting-Tertiary referral centre. Subjects-81 consecutive referrals presenting with bulimia nervosa or atypical bulimia nervosa. Main outcome measures-Frequency of binge eating, vomiting, and other behaviours to control weight as well as abstinence from these behaviours. Results-Cognitive behavioural treatment produced a significant reduction in the frequency of binge eating, vomiting, and other behaviours to control weight. The manual significantly reduced frequency of binge eating and weight control behaviours other than vomiting, and there was no change in the group on the waiting list. Full remission was achieved in five (24%) of the group assigned to cognitive behavioural treatment, nine (22%) of the group who used the manual, and two (11%) of the group on the waiting list. Conclusions-A self directed treatment manual may be a useful first intervention in the treatment of bulimia nervosa.	ST MARYS HOSP, DEPT PSYCHIAT, LONDON W2 1NY, ENGLAND; UNIV COLOGNE, W-5000 COLOGNE, GERMANY	Imperial College London; University of Cologne	TREASURE, J (corresponding author), INST PSYCHIAT, EATING DISORDER RES GRP, LONDON SE5 8AF, ENGLAND.			Treasure, Janet/0000-0003-0871-4596				AGRAS WS, 1992, AM J PSYCHIAT, V149, P82; ALBERT T, 1992, BRIT MED J, V305, P1266, DOI 10.1136/bmj.305.6864.1266; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; DAVIS R, 1990, J CONSULT CLIN PSYCH, V58, P882, DOI 10.1037/0022-006X.58.6.882; DONNAN P, 1990, BRIT J GEN PRACT, V40, P498; Fairburn C. G., 1989, COGNITIVE BEHAV THER, P277; FAIRBURN CG, 1991, ARCH GEN PSYCHIAT, V48, P463; FAIRBURN CG, 1990, GUT, V31, P1220, DOI 10.1136/gut.31.11.1220; First M.B., 1989, STRUCTURED CLIN INTE; FREEMAN CP, 1991, J PSYCHOSOM RES, V35, P41, DOI 10.1016/0022-3999(91)90112-2; GARDNER MJ, 1991, BRIT MED J; GARNER DM, 1993, AM J PSYCHIAT, V150, P37; GARNER DM, 1986, PSYCHOTHER PSYCHOSOM, V46, P67, DOI 10.1159/000287963; GARNER DM, 1983, INT J EAT DISORDER, V2, P15, DOI 10.1002/1098-108X(198321)2:2<15::AID-EAT2260020203>3.0.CO;2-6; GHOSH A, 1988, BRIT J PSYCHIAT, V152, P234, DOI 10.1192/bjp.152.2.234; GUY W, 1976, ECDEU ASSESSMENT MAN, P516; HENDERSON M, 1987, BRIT J PSYCHIAT, V150, P18, DOI 10.1192/bjp.150.1.18; Hoek Hans Wijbrand, 1993, International Review of Psychiatry, V5, P61, DOI 10.3109/09540269309028295; KENDLER KS, 1991, AM J PSYCHIAT, V148, P1627; NORMAN DK, 1986, PSYCHIAT RES, V19, P199, DOI 10.1016/0165-1781(86)90098-3; NORUSIS MJ, 1988, SPSS PC PLUS V20 BAS; OLMSTED MP, 1991, BEHAV RES THER, V29, P71, DOI 10.1016/S0005-7967(09)80009-0; ROBSON P, 1989, PSYCHOL MED, V19, P513, DOI 10.1017/S003329170001254X; RUSSELL G, 1979, PSYCHOL MED, V9, P429, DOI 10.1017/S0033291700031974; SAVAGE SA, 1990, BRIT J CLIN PSYCHOL, V29, P373, DOI 10.1111/j.2044-8260.1990.tb00900.x; SCHMIDT U, 1993, INT J EAT DISORDER, V13, P273, DOI 10.1002/1098-108X(199304)13:3&lt;273::AID-EAT2260130305&gt;3.0.CO;2-B; Schmidt U., 1993, GETTING BETTER BIT E; SCOGIN F, 1989, J CONSULT CLIN PSYCH, V57, P403, DOI 10.1037/0022-006X.57.3.403; SCOGIN F, 1990, J CONSULT CLIN PSYCH, V58, P665; SORBY NGD, 1991, BRIT J GEN PRACT, V41, P417; TROOP N, 1993, BMJ-BRIT MED J, V307, P577, DOI 10.1136/bmj.307.6904.577; WALSH BT, 1991, AM J PSYCHIAT, V148, P1206; 1992, CR14 ROYAL COLL PSYC; 1992, LONDON HLTH CARE 201; 1991, ARCH GEN PSYCHIAT, V49, P139	35	72	72	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 12	1994	308	6930					686	689		10.1136/bmj.308.6930.686	http://dx.doi.org/10.1136/bmj.308.6930.686			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA869	8142791	Green Published			2023-01-03	WOS:A1994NA86900018
J	LENFANT, C				LENFANT, C			REDUCING THE DELAYS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											LENFANT, C (corresponding author), NHLBI,BETHESDA,MD 20892, USA.								0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 9	1994	271	10					738	738						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY288	8114202				2023-01-03	WOS:A1994MY28800009
J	REES, M				REES, M			ON MENSTRUAL BLEEDING WITH HORMONE REPLACEMENT THERAPY	LANCET			English	Editorial Material							PROGESTOGEN; WOMEN				REES, M (corresponding author), JOHN RADCLIFFE HOSP,NUFFIELD DEPT OBSTET & GYNAECOL,OXFORD OX3 9DU,ENGLAND.							ANDERSSON K, 1992, OBSTET GYNECOL, V79, P963; CHRISTIANSEN C, 1990, BRIT J OBSTET GYNAEC, V97, P1087, DOI 10.1111/j.1471-0528.1990.tb02495.x; COOPE J, 1992, MATURITAS, V15, P151, DOI 10.1016/0378-5122(92)90249-4; HALLBERG L, 1966, ACTA OBSTET GYN SCAN, V45, P320, DOI 10.3109/00016346609158455; HAWTHORN RJS, 1991, BRIT J OBSTET GYNAEC, V98, P939, DOI 10.1111/j.1471-0528.1991.tb13519.x; MACLENNAN AH, 1993, MED J AUSTRALIA, V159, P102, DOI 10.5694/j.1326-5377.1993.tb137744.x; REES MCP, 1991, BRIT J OBSTET GYNAEC, V98, P106, DOI 10.1111/j.1471-0528.1991.tb10322.x; REES MCP, 1993, WOMENS PROBLEMS GENE, P171; SPORRONG T, 1992, BRIT J OBSTET GYNAEC, V99, P399, DOI 10.1111/j.1471-0528.1992.tb13757.x; STALAND B, 1981, MATURITAS, V3, P14	10	10	10	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 29	1994	343	8892					250	250		10.1016/S0140-6736(94)91108-8	http://dx.doi.org/10.1016/S0140-6736(94)91108-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT440	7905092				2023-01-03	WOS:A1994MT44000006
J	QUINN, MW; WILD, J; DEAN, HG; HARTLEY, R; RUSHFORTH, JA; PUNTIS, JWL; LEVENE, MI				QUINN, MW; WILD, J; DEAN, HG; HARTLEY, R; RUSHFORTH, JA; PUNTIS, JWL; LEVENE, MI			RANDOMIZED DOUBLE-BLIND CONTROLLED TRIAL OF EFFECT OF MORPHINE ON CATECHOLAMINE CONCENTRATIONS IN VENTILATED PRETERM BABIES	LANCET			English	Article							STRESS RESPONSE; INFANTS; PRETERM; PANCURONIUM; ANESTHESIA; ANALGESIA; FENTANYL; SURGERY; BIRTH	A sick premature baby who requires intensive care will undergo many uncomfortable procedures. It is now accepted that such babies perceive pain and need adequate analgesia, but little is known about the effects of sedation in these patients. We investigated the use of morphine to provide analgesia and sedation for ventilated preterm babies in a randomised, double-blind, placebo-controlled trial. 41 mechanically ventilated babies who had been treated with surfactant (Curosurf) for hyaline membrane disease were randomly assigned morphine in 5% dextrose (100 mug/kg per h for 2 h followed by 25 mug/kg per h continuous infusion) or 5% dextrose (placebo). Plasma catecholamine concentrations were measured 1 h after the first dose of surfactant and 24 h later. Blood pressure was measured at study entry and after 6 h. The morphine and placebo groups showed no differences in method of delivery, Apgar scores, birthweight, gestation, or catecholamine concentrations at baseline. Morphine-treated babies showed a significant reduction in adrenaline concentrations during the first 24 h (median change -0.4 [95% CI -1.1 to -0.3] nmol/L, p<0.001), which was not seen in the placebo group (median change 0.2 [-0.6 to 0.6] nmol/L, p=0.79). There was a non-significant reduction in noradrenaline concentration in the morphine group. Blood pressure showed a slight but non-significant fall (median -4 mm Hg) in morphine-treated babies. The incidence of intraventricular haemorrhage, patent ductus arteriosus, and pneumothorax, the number of ventilator days, and the numbers of deaths did not differ significantly between the groups. Morphine, in the dose regimen we used, is safe and effective in reducing adrenaline concentrations in preterm ventilated babies.	GEN INFIRM,DEPT CLIN MED,ACAD UNIT PAEDIAT & CHILD HLTH,D FLOOR,CLARENDON WING,LEEDS LS2 9NS,ENGLAND	Leeds General Infirmary								ANAND KJS, 1992, NEW ENGL J MED, V326, P1, DOI 10.1056/NEJM199201023260101; ANAND KJS, 1987, LANCET, V1, P243; ANAND KJS, 1987, NEW ENGL J MED, V317, P1321, DOI 10.1056/NEJM198711193172105; ARNOLD JH, 1990, ANESTHESIOLOGY, V73, P1136, DOI 10.1097/00000542-199012000-00011; CABAL LA, 1985, PEDIATRICS, V75, P284; COMLINE RS, 1965, J PHYSIOL-LONDON, V178, P211, DOI 10.1113/jphysiol.1965.sp007624; DAHLSTROM B, 1979, CLIN PHARMACOL THER, V26, P354; DAPRADA M, 1976, LIFE SCI, V19, P1161, DOI 10.1016/0024-3205(76)90251-4; EKBLAD H, 1992, BIOL NEOATE, V6, P294; FAXELIUS G, 1984, J PEDIATR-US, V105, P144, DOI 10.1016/S0022-3476(84)80381-9; HALLIDAY H, IN PRESS ARCH DIS CH; HARTLEY R, 1993, BRIT J CLIN PHARMACO, V35, P314; HARTLEY R, 1993, BIOMED CHROMATOGR, V7, P34, DOI 10.1002/bmc.1130070109; LEVENE MI, 1992, ARCH DIS CHILD-FETAL, V67, P870, DOI 10.1136/adc.67.7_Spec_No.870; MORRISON JFJ, 1988, BRIT MED J, V296, P1427, DOI 10.1136/bmj.296.6634.1427; QUINN MW, 1992, EARLY HUM DEV, V30, P241, DOI 10.1016/0378-3782(92)90073-P; STOPFKUCHEN H, 1991, EUR J PEDIATR, V150, P503, DOI 10.1007/BF01958433; SURY MRJ, 1990, ANN ROY COLL SURG, V72, P324; TEMPEL A, 1991, DEV BRAIN RES, V64, P19, DOI 10.1016/0165-3806(91)90204-V; WATKINS AMC, 1989, EARLY HUM DEV, V19, P103, DOI 10.1016/0378-3782(89)90120-5; WAY WL, 1965, CLIN PHARMACOL THER, V6, P454	21	105	109	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 7	1993	342	8867					324	327		10.1016/0140-6736(93)91472-X	http://dx.doi.org/10.1016/0140-6736(93)91472-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ868	8101584				2023-01-03	WOS:A1993LQ86800010
J	KATZ, J				KATZ, J			PREOP ANALGESIA FOR POSTOP PAIN	LANCET			English	Editorial Material									UNIV TORONTO,DEPT BEHAV SCI,TORONTO M5S 1A1,ONTARIO,CANADA; UNIV TORONTO,DEPT ANAESTHESIA,TORONTO M5S 1A1,ONTARIO,CANADA	University of Toronto; University of Toronto	KATZ, J (corresponding author), UNIV TORONTO,TORONTO GEN HOSP,DEPT PSYCHOL,TORONTO M5G 1L7,ONTARIO,CANADA.		Katz, Joel/HDO-1635-2022; Katz, Joel/J-7015-2014	Katz, Joel/0000-0002-8686-447X				CODERRE TJ, 1993, PAIN, V52, P259, DOI 10.1016/0304-3959(93)90161-H; DAHL JB, 1992, BRIT J ANAESTH, V69, P4, DOI 10.1093/bja/69.1.4; DAHL JB, 1993, ANESTHESIOLOGY, V78, P801, DOI 10.1097/00000542-199304000-00044; DIERKING GW, 1992, BRIT J ANAESTH, V68, P344, DOI 10.1093/bja/68.4.344; KATZ J, 1992, ANESTHESIOLOGY, V77, P439, DOI 10.1097/00000542-199209000-00006; PRYLE BJ, 1993, ANAESTHESIA, V48, P120; WOOLF CJ, 1986, NEUROSCI LETT, V64, P221, DOI 10.1016/0304-3940(86)90104-7	7	9	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 10	1993	342	8863					65	66		10.1016/0140-6736(93)91279-U	http://dx.doi.org/10.1016/0140-6736(93)91279-U			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LL789	8100906	Green Submitted			2023-01-03	WOS:A1993LL78900003
J	SIXMA, HJ; LANGERAK, EH; SCHRIJVERS, GJP; VANDERBENT, J				SIXMA, HJ; LANGERAK, EH; SCHRIJVERS, GJP; VANDERBENT, J			ATTEMPTING TO REDUCE HOSPITAL COSTS BY STRENGTHENING PRIMARY CARE INSTITUTIONS - THE DUTCH HEALTH-CARE DEMONSTRATION PROJECT IN THE NEW TOWN OF ALMERE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOME		ALMERE HLTH CARE CORP,ALMERE,NETHERLANDS; UNIV UTRECHT,INST HLTH SERV RES,UTRECHT,NETHERLANDS; NATL HOSP INST,UTRECHT,NETHERLANDS	Netherlands Institute for Health Services Research; Utrecht University	SIXMA, HJ (corresponding author), NETHERLANDS INST PRIMARY HLTH CARE,UTRECHT,NETHERLANDS.							BAKKER DH, 1992, AUG INT MED GEOGR S; CHALLIS D, 1987, BR J SOCIAL WORK, V18, P13; FOETS M, 1992, DUTCH NATIONAL SURVE; HELSLOOT RSM, 1991, CHALLENGES OPEN EVA; HUGHES SL, 1987, HEALTH SERV RES, V22, P19; Lamberts H., 1987, ICPC INT CLASSIFICAT; SCHRIJVERS AJP, 1991, JAMA-J AM MED ASSOC, V266, P2215, DOI 10.1001/jama.266.16.2215; SIXMA H, 1992, EHBO ALMERE, V2; SIXMA HJM, 1991, ZIEKTEN VERRICHTINGE; THORSLUND M, 1988, HEALTH POLICY, V10, P41, DOI 10.1016/0168-8510(88)90086-3; VANDEBENT J, 1993, KLINISCHE CONSUMPTIE; VANDERVELDEN J, 1992, DUTCH NATIONAL SURVE; Vertrees J C, 1989, Health Care Financ Rev, V10, P65; 1981, HLTH ALL SERIES, V1; [No title captured]; 1986, MONTH B POPUL STAT; 1988, POPULATION STATISTIC; 1983, PROJECTPLAN ALMERE 1	18	1	1	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 19	1993	269	19					2567	2572						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB450	8487425				2023-01-03	WOS:A1993LB45000041
J	WIENER, C				WIENER, C			VENTILATORY MANAGEMENT OF RESPIRATORY-FAILURE IN ASTHMA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							END-EXPIRATORY PRESSURE; AIR-FLOW OBSTRUCTION; MECHANICAL VENTILATION; AUTO-PEEP; EXPERIENCE				WIENER, C (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV PULM & CRIT CARE MED,720 RUTLAND AVE,ROSS 858,BALTIMORE,MD 21205, USA.							BRAMAN SS, 1990, JAMA-J AM MED ASSOC, V264, P366, DOI 10.1001/jama.264.3.366; CASSIDY SS, 1989, HEART LUNG INTERACTI, P463; DARIOLI R, 1984, AM REV RESPIR DIS, V129, P385; HALL JB, 1990, MED CLIN N AM, V74, P779, DOI 10.1016/S0025-7125(16)30552-1; MANSEL JK, 1990, AM J MED, V89, P42, DOI 10.1016/0002-9343(90)90096-V; MYERBURG RJ, 1988, HEART DISEASE TXB CA, P742; PEPE PE, 1982, AM REV RESPIR DIS, V126, P166; ROGERS PL, 1991, CHEST, V99, P492, DOI 10.1378/chest.99.2.492; SCHARF SM, 1977, AM J PHYSIOL, V232, pH35, DOI 10.1152/ajpheart.1977.232.1.H35; SCOGGIN CH, 1977, JAMA-J AM MED ASSOC, V238, P1158, DOI 10.1001/jama.238.11.1158; TUXEN DV, 1989, AM REV RESPIR DIS, V140, P5, DOI 10.1164/ajrccm/140.1.5	11	13	14	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 28	1993	269	16					2128	2131		10.1001/jama.269.16.2128	http://dx.doi.org/10.1001/jama.269.16.2128			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY366	8468769				2023-01-03	WOS:A1993KY36600037
J	Southall, DP; Ellis, J; McMaster, P; McMaster, H; Willock, A; Plunkett, M				Southall, DP; Ellis, J; McMaster, P; McMaster, H; Willock, A; Plunkett, M			Medical evacuation from Mostar	LANCET			English	Article											Southall, DP (corresponding author), KEELE UNIV,N STAFFS HOSP,ACAD DEPT PAEDIAT,STOKE ON TRENT ST4 6QG,STAFFS,ENGLAND.							[Anonymous], 1991, CONVENTION RIGHTS CH; MORLEY D, 1986, MY NAME IS TODAY; Ressler Everett M., 1992, EVACUATION CHILDREN; SOUTHALL D, IN PRESS PROGRAMME I; 1994, INTRO IOM SPECIAL ME	5	6	6	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 27	1996	347	8996					244	245		10.1016/S0140-6736(96)90411-0	http://dx.doi.org/10.1016/S0140-6736(96)90411-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT069	8551888				2023-01-03	WOS:A1996TT06900017
J	SIRMON, MD				SIRMON, MD			TOBACCO, TULIPS, AND TERMINAL CARE	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											SIRMON, MD (corresponding author), UNIV SO ALABAMA, COLL MED, DIV NEPHROL HYPERTENS, 2451 FILLINGIM ST, MOBILE, AL 36617 USA.								0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1993	119	10					1042	1043		10.7326/0003-4819-119-10-199311150-00012	http://dx.doi.org/10.7326/0003-4819-119-10-199311150-00012			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG672	8214982				2023-01-03	WOS:A1993MG67200012
J	BAKER, MD; BELL, LM; AVNER, JR				BAKER, MD; BELL, LM; AVNER, JR			OUTPATIENT MANAGEMENT WITHOUT ANTIBIOTICS OF FEVER IN SELECTED INFANTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FEBRILE INFANTS; OBSERVATION SCALES; SERIOUS ILLNESS; AGE; CEFTRIAXONE; YOUNGER	Background. In many academic centers it is standard practice to hospitalize all febrile infants younger than two months of age, whereas in community settings such infants are often cared for as outpatients. Methods. We conducted a controlled study of 747 consecutive infants 29 through 56 days of age who had temperatures of at least 38.2-degrees-C. After a complete history taking, physical examination, and sepsis workup, the 460 infants with laboratory or clinical findings suggestive of serious bacterial illness were hospitalized and treated with antibiotics. The screening criteria for serious bacterial illness included a white-cell count of at least 15,000 per cubic millimeter, a spun urine specimen that had 10 or more white cells per high-power field or that was positive on bright-field microscopy, cerebrospinal fluid with a white-cell count of 8 or more per cubic millimeter or a positive Gram's stain, or a chest film showing an infiltrate. The 287 infants who had unremarkable examinations and normal laboratory results were assigned to either inpatient observation without antibiotics (n = 148) or outpatient care without antibiotics but with reexaminations after 24 and 48 hours (n = 139). Results. Serious bacterial illness was diagnosed in 65 infants (8.7 percent). Of these 65 infants, 64 were identified by our screening criteria for inpatient care and antibiotic treatment (sensitivity = 98 percent; 95 percent confidence interval, 92 to 100). Of the 287 infants assigned to observation and no antibiotics, 286 (99.7 percent) did not have serious bacterial illness. Only two infants assigned to outpatient observation were subsequently admitted to the hospital; neither was found to have a serious illness. Out-patient care without antibiotics of the febrile infants at low risk for serious illness resulted in a savings of about $3,100 per patient. Conclusions. With the use of strict screening criteria, a substantial number of febrile one-to-two-month-old infants can be cared for safely as outpatients and without antibiotics.	CHILDRENS HOSP PHILADELPHIA,DIV ALLERGY IMMUNOL & INFECT DIS,PHILADELPHIA,PA 19104; UNIV PENN,PHILADELPHIA,PA 19104	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania	BAKER, MD (corresponding author), CHILDRENS HOSP PHILADELPHIA,DIV GEN PEDIAT,EMERGENCY MED SECT,34TH ST & CIV CTR BLVD,PHILADELPHIA,PA 19104, USA.		Baker, Mark/N-7720-2019					BAKER MD, 1990, PEDIATRICS, V85, P1040; BARAFF LJ, 1991, PEDIATR INFECT DIS J, V10, P795, DOI 10.1097/00006454-199111000-00001; BASKIN MN, 1992, J PEDIATR-US, V120, P22, DOI 10.1016/S0022-3476(05)80591-8; CASPE WB, 1983, PEDIATR INFECT DIS J, V2, P131, DOI 10.1097/00006454-198303000-00013; DAGAN R, 1988, J PEDIATR-US, V112, P355, DOI 10.1016/S0022-3476(88)80312-3; DEANGELIS C, 1983, AM J DIS CHILD, V137, P1146, DOI 10.1001/archpedi.1983.02140380006003; DEANGELIS C, 1983, AM J DIS CHILD, V137, P1150, DOI 10.1001/archpedi.1983.02140380010004; GREENE JW, 1981, CLIN PEDIATR, V20, P375, DOI 10.1177/000992288102000601; KING JC, 1987, SOUTHERN MED J, V80, P948, DOI 10.1097/00007611-198708000-00004; LIEU TA, 1992, PEDIATRICS, V89, P1135; MCCARTHY P, 1992, PEDIATRICS, V89, P1251; MCCARTHY PL, 1982, PEDIATRICS, V70, P802; PHILIP AGS, 1980, PEDIATRICS, V65, P1036; POWELL KR, 1990, PEDIATR INFECT DIS J, V9, P153, DOI 10.1097/00006454-199003000-00001; WALD ER, 1991, AM J DIS CHILD, V145, P1359, DOI 10.1001/archpedi.1991.02160120027012	15	312	325	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 11	1993	329	20					1437	1441		10.1056/NEJM199311113292001	http://dx.doi.org/10.1056/NEJM199311113292001			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF292	8413453	Bronze			2023-01-03	WOS:A1993MF29200001
J	MILNER, SM; HODGETTS, TJ; RYLAH, LTA				MILNER, SM; HODGETTS, TJ; RYLAH, LTA			THE BURNS-CALCULATOR - A SIMPLE PROPOSED GUIDE FOR FLUID RESUSCITATION	LANCET			English	Article							CHILDREN	Most burn casualties will receive their primary care in an emergency department. These departments are staffed by doctors with a varying degree of supervision, and their experience of the treatment of burns is often very modest. Evidently there is a need for a simple method to calculate the fluid requirements of these patients. The Burns Calculator is designed for use during the first eight hours post-injury and is based upon the Parkland resuscitation formula, using only Hartmann's solution BP. It is expected that the patient will have received expert aid by the end of this time. Values for children have been predetermined using body surface area nomograms. The calculator will assist the non-specialist to determine the correct amount of fluid needed to resuscitate a burned patient, and perhaps decrease morbidity and mortality associated with this injury.	ST ANDREWS HOSP,REG BURNS UNIT,BILLERICAY,ESSEX,ENGLAND; ROYAL ARMY MED COLL,LONDON SW1P 4RJ,ENGLAND		MILNER, SM (corresponding author), CHEM & BIOL DEF ESTAB,SALISBURY,WILTS,ENGLAND.							Baxter C R, 1974, Clin Plast Surg, V1, P693; BAXTER CR, 1981, J TRAUMA, V21, P687, DOI 10.1097/00005373-198108001-00016; GRAVES TA, 1988, J TRAUMA, V28, P1656, DOI 10.1097/00005373-198812000-00007; HAMMOND JS, 1987, J TRAUMA, V27, P1161, DOI 10.1097/00005373-198710000-00011; HERNDON DN, 1985, PEDIATR CLIN N AM, V32, P1311; HERNDON DN, 1987, CURR PROB SURG, P347; Lund C.C., 1944, SURG GYNECOL OBSTET, V79, P352; MILNER SM, 1993, BRIT J HOSP MED, V50, P163; MONAFO WW, 1993, CRITICAL CARE BURNED; Muir IFK, 1987, BURNS THEIR TREATMEN; OAKLEY P, 1993, BRIT MED J, V306, P1613, DOI 10.1136/bmj.306.6892.1613; PRUITT BA, 1987, CLIN SURG, P2823; RYLAH LTA, 1991, ANESTHESIOLOGY, V5, P35; 1988, ADV TRAUMA LIFE SUPP, P206; 1993, ADV PAEDIATRIC LIFE	15	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 30	1993	342	8879					1089	1091		10.1016/0140-6736(93)92067-4	http://dx.doi.org/10.1016/0140-6736(93)92067-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME822	8105315				2023-01-03	WOS:A1993ME82200013
J	BANG, A				BANG, A			TOWARDS BETTER ORAL REHYDRATION	LANCET			English	Editorial Material											BANG, A (corresponding author), SEARCH,GANDCHOROLI 442605,INDIA.							BARI A, 1989, Journal of Diarrhoeal Diseases Research, V7, P1; BRYANT J, 1980, CEREAL BASED ORAL RE; GORE SM, 1992, BMJ-BRIT MED J, V304, P287, DOI 10.1136/bmj.304.6822.287; KHIN MU, 1986, HUM NUJTR CLIN NUTR, V40, P249; MATHURAM S, 1990, J PEDIATR, V116, P868; MOLLA AM, 1989, J PEDIATR GASTR NUTR, V8, P81, DOI 10.1097/00005176-198901000-00015; WILSON R, 1990, CEREAL BASED ORAL RE, P13; 1992, PROGRAMME CONTROL DI, P36	8	1	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 25	1993	342	8874					755	756		10.1016/0140-6736(93)91534-S	http://dx.doi.org/10.1016/0140-6736(93)91534-S			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LY868	8103870				2023-01-03	WOS:A1993LY86800003
J	YESALIS, CE; KENNEDY, NJ; KOPSTEIN, AN; BAHRKE, MS				YESALIS, CE; KENNEDY, NJ; KOPSTEIN, AN; BAHRKE, MS			ANABOLIC-ANDROGENIC STEROID USE IN THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DRUG-USE; DEPENDENCE; SCHOOL; SYMPTOMS; MEN	Objective.- To estimate the size of the anabolic-androgenic steroid (AAS) user population in the United States, to examine characteristics of AAS users, and to explore the association between AAS use and the use of other illicit drugs as well as self-reported aggressive behaviors. Design.- A cross-sectional study using data from the 1991 National Household Survey on Drug Abuse. Study Population.- The survey covered the population aged 12 years and older living in households in the United States. The results of the survey were based on personal interviews combined with self-administered questionnaires from 32 594 respondents. These respondents were randomly selected by means of a stratified multistage area sample of the household population. Results.- Estimates based on data from the National Household Survey on Drug Abuse indicated that there are more than 1 million current or former AAS users in this country, with more than half of the lifetime user population being 26 years of age or older. More than 300 000 individuals used AAS in the past year. Males had higher levels of AAS use during their lifetime than females (0.9% and 0.1%, respectively; P<.01). The median age of first use of AAS for the study population was 18 years; for 12- to 17-year-olds, the median age of initiation was 15 years. Among 12- to 34-year-olds, AAS use was significantly and positively associated with the use of other illicit drugs (P<.05), cigarettes (12- to 17-year-olds only; P<.01), and alcohol (P<.01). Furthermore, AAS use is highly correlated with self-reported aggressive behavior (P<.01) and crimes against property (P<.01). Conclusions.- These results indicate that AAS use impacts a large number of men and women from various racial and age groups across the nation. While causal inferences cannot be made regarding the associations between AAS use and use of other drugs as well as antisocial behavior, these findings should enhance our ability to profile the typical AAS user.	CTR SUBST ABUSE PREVENT, POLICY & PLANNING UNIT, ROCKVILLE, MD USA; NIDA, STAT & ANAL BRANCH, ROCKVILLE, MD USA; UNIV ILLINOIS, DEPT EPIDEMIOL & BIOSTAT, CHICAGO, IL 60680 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	YESALIS, CE (corresponding author), PENN STATE UNIV, DEPT HLTH POLICY & ADM, 115 HENDERSON BLDG, UNIV PK, PA 16802 USA.							ANDERSON W, 1991, PHYSICIAN SPORTSMED, V2, P91; ANNITTO WJ, 1980, J CLIN PSYCHIAT, V41, P143; [Anonymous], 1990, LANCET, V336, P955; Bahrke M. S., 1993, ANABOLIC STEROIDS SP, P161; BAHRKE MS, 1990, NEW ENGL J MED, V323, P834; BAHRKE MS, 1992, AM J SPORT MED, V20, P717, DOI 10.1177/036354659202000613; Brower K. J., 1989, CLIN SPORTS MED, V1, P171; BROWER KJ, 1989, AM J PSYCHIAT, V146, P1075; BROWER KJ, 1989, J CLIN PSYCHIAT, V50, P31; BROWER KJ, 1990, AM J PSYCHIAT, V147, P510; BROWER KJ, 1991, BRIT J ADDICT, V86, P759; BUCKLEY W E, 1988, Journal of the American Medical Association, V260, P3441, DOI 10.1001/jama.260.23.3441; CHOI P Y L, 1990, Human Psychopharmacology, V5, P349, DOI 10.1002/hup.470050407; Cochran WG, 1977, SAMPLING TECHNIQUES, V3rd; CONACHER GN, 1989, AM J PSYCHIAT, V146, P679; DALBY JT, 1992, AM J PSYCHIAT, V149, P271; Dillman D.A., 1978, MAIL TELEPHONE SURVE, V19; DIMEFF R, 1991, Medicine and Science in Sports and Exercise, V23, pS18; Duchaine D, 1989, UNDERGROUND STEROID, V2; DURANT RH, 1993, NEW ENGL J MED, V328, P922, DOI 10.1056/NEJM199304013281304; ELOFSON G, 1990, PHYSICIAN SPORTSMED, V19, P15; FRIEDL KE, 1993, ANABOLIC STEROIDS SP, P107; FRIENHAR J, 1985, J CLIN PSYCHIAT, V46, P354; Goldman B, 1984, DEATH LOCKER ROOM ST; HANNAN CJ, 1991, PSYCHONEUROENDOCRINO, V16, P335, DOI 10.1016/0306-4530(91)90019-P; HAUPT HA, 1984, AM J SPORT MED, V12, P469, DOI 10.1177/036354658401200613; HAYS L, 1992, J CLIN PSYCHIAT, V53, P130; HAYS LR, 1990, AM J PSYCHIAT, V147, P122; JOHNSTON LD, 1990, MONITORING FUTURE CO; JOHNSTON LD, 1991, MONITORING FUTURE CO; Kochakian C.D., 1993, ANABOLIC STEROIDS SP, P3; KOCHAKIAN CD, 1976, ANABOLIC ANDROGENIC; KROWCHUK DP, 1989, AM J DIS CHILD, V143, P486, DOI 10.1001/archpedi.1989.02150160116023; KRUSKEMPER HL, 1968, ANABOLIC STEROIDS; Lefavi R. G., 1990, J SPORT BEHAVIOR, V13, P157, DOI [10.1002/hup.470050407, DOI 10.1002/HUP.470050407]; LINDSTROM M, 1990, J INTERN MED, V227, P407, DOI 10.1111/j.1365-2796.1990.tb00179.x; MCCLARY SA, 1985, J DRUG EDUC, V15, P49, DOI 10.2190/0CE6-NDFE-BY7P-U6XJ; PERRY PJ, 1990, AM J SPORT MED, V18, P422, DOI 10.1177/036354659001800416; POPE HG, 1988, PHYSICIAN SPORTSMED, V16, P75, DOI 10.1080/00913847.1988.11709554; POPE HG, 1988, AM J PSYCHIAT, V145, P487; POPE HG, 1990, J CLIN PSYCHIAT, V51, P28; ROSS J, 1989, 1988 1989 SURVEY SUB; RYAN AJ, 1981, FED PROC, V40, P2682; SMART RG, 1978, DRUG ALCOHOL DEPEN, V3, P265, DOI 10.1016/0376-8716(78)90080-7; STRAUSS R H, 1985, Journal of the American Medical Association, V253, P2871, DOI 10.1001/jama.253.19.2871; SU TP, 1993, JAMA-J AM MED ASSOC, V269, P2760, DOI 10.1001/jama.269.21.2760; TAYLOR W N, 1987, Chiropractic Sports Medicine, V1, P47; Taylor W. N., 1991, MACHO MED HIST ANABO; TAYLOR WN, 1987, PHYSICIAN SPORTSMED, V15, P140, DOI 10.1080/00913847.1987.11709356; TAYLOR WN, 1982, ANABOLIC STEROIDS AT; TRICKER R, 1989, J DRUG EDUC, V19, P313, DOI 10.2190/EGT5-4YWD-QX15-FLKK; UZYCH L, 1992, CAN J PSYCHIAT, V37, P23, DOI 10.1177/070674379203700106; Wadler G., 1989, DRUGS ATHLETE; WHITEHEAD R, 1992, J FAM PRACTICE, V35, P401; WILSON JD, 1988, ENDOCR REV, V9, P181, DOI 10.1210/edrv-9-2-181; Wright J E, 1980, Exerc Sport Sci Rev, V8, P149, DOI 10.1249/00003677-198000080-00007; WRIGHT JE, 1982, ANABOLIC STEROIDS SP, V2; WRIGHT JE, 1978, ANABOLIC STEROIDS SP; Yesalis C. E., 1993, ANABOLIC STEROIDS SP, P49; YESALIS CE, 1989, SPORTS MED, V8, P129, DOI 10.2165/00007256-198908030-00001; 1977, MED SCI SPORTS EXERC, V9, P11; 1991, REPORT INTERAGENCY T; 1992, ADM921887 NAT I DRUG; 1984, MED SCI SPORTS EXERC, V19, P13; [No title captured]; 1990, JAMA-J AM MED ASSOC, V264, P2923; 1990, ANABOLIC REFERENCE U, V22, P3	67	254	259	0	24	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	1993	270	10					1217	1221		10.1001/jama.270.10.1217	http://dx.doi.org/10.1001/jama.270.10.1217			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV649	8355384				2023-01-03	WOS:A1993LV64900027
J	NOVACK, DH				NOVACK, DH			ADRIENNE	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											NOVACK, DH (corresponding author), RHODE ISL HOSP, 593 EDDY ST, PROVIDENCE, RI 02903 USA.								0	2	2	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1993	119	5					424	425		10.7326/0003-4819-119-5-199309010-00013	http://dx.doi.org/10.7326/0003-4819-119-5-199309010-00013			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ476	8338298				2023-01-03	WOS:A1993LZ47600013
J	BURKE, DP; BOWDEN, DF				BURKE, DP; BOWDEN, DF			MODIFIED PEDIATRIC RESUSCITATION CHART	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To determine whether a modified paediatric resuscitation reference chart improves the speed and accuracy of calculation of doses of drugs in simulated paediatric cardiopulmonary arrests when compared with the chart devised by Oakley. Design-A prospective study in which a series of randomly assigned questions was used to compare the performance of doctors using the two charts. Setting-Accident and emergency departments in two hospitals. Subjects-31 senior house officers. Main outcome measures-The speed and accuracy of calculation of volumes of drugs to be administered. Results-The modified chart significantly increased the accuracy of the calculations (62/62 v 43/62, p < 0.05), the speed of correct calculations (6.8 s v 36.0 s, p < 0.0001), and the number of calculations that were completed (62/62 v 50/62, p < 0.001). Conclusions-The modified paediatric resuscitation chart should supersede the existing chart.	DUDLEY RD GEN HOSP,DEPT ACCID & EMERGENCY,BIRMINGHAM B18 7QH,W MIDLANDS,ENGLAND		BURKE, DP (corresponding author), ROYAL HOSP WOLVERHAMPTON,DEPT ACCID & EMERGENCY,WOLVERHAMPTON WV2 1BT,ENGLAND.							OAKLEY PA, 1988, BRIT MED J, V297, P817, DOI 10.1136/bmj.297.6652.817	1	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 24	1993	306	6885					1096	1098		10.1136/bmj.306.6885.1096	http://dx.doi.org/10.1136/bmj.306.6885.1096			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ565	8495154	Green Published, Bronze			2023-01-03	WOS:A1993KZ56500020
J	HERRSTEDT, J; SIGSGAARD, T; BOESGAARD, M; JENSEN, TP; DOMBERNOWSKY, P				HERRSTEDT, J; SIGSGAARD, T; BOESGAARD, M; JENSEN, TP; DOMBERNOWSKY, P			ONDANSETRON PLUS METOPIMAZINE COMPARED WITH ONDANSETRON ALONE IN PATIENTS RECEIVING MODERATELY EMETOGENIC CHEMOTHERAPY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CISPLATIN-INDUCED EMESIS; HIGH-DOSE METOCLOPRAMIDE; DOUBLE-BLIND; INDUCED NAUSEA; SEROTONIN ANTAGONIST; ANTIEMETIC EFFICACY; RANDOMIZED TRIAL; DEXAMETHASONE; PROPHYLAXIS; RECEPTORS	Background and Methods. The serotonin (5-hydroxytryptamine3) antagonists have improved the treatment of acute chemotherapy-induced nausea and vomiting, but their ability to prevent delayed nausea and vomiting seems less pronounced. The results of a preliminary open trial suggested that the addition of a selective dopamine D2 antagonist could improve the antiemetic efficacy of the serotonin antagonists. In a randomized, double-blind, crossover trial, we compared oral treatment with ondansetron (8 mg twice a day) and the dopamine D2 antagonist metopimazine (30 mg four times a day) with treatment with ondansetron alone for three days in 30 patients who had vomited during the previous cycle of chemotherapy. All the patients received moderately emetogenic chemotherapy. Results, Combination treatment with ondansetron and metopimazine significantly reduced the incidence of acute (P = 0.006) and delayed (P = 0.02) nausea and acute (P = 0.02) and delayed (P = 0.006) vomiting, as compared with treatment with ondansetron alone. Patients had significantly fewer days of nausea (P = 0.03) and vomiting (P = 0.003) if they received combination therapy. Sixty-seven percent of the patients preferred ondansetron and metopimazine, and 33 percent favored ondansetron alone (P = 0.10). Adverse reactions were mild with both regimens. With the exception of constipation, which was reported more frequently with combination therapy (P = 0.03), there were no significant differences in adverse reactions. Conclusions. Ondansetron plus metopimazine is a highly effective and safe antiemetic regimen that is markedly superior to treatment with ondansetron alone in patients receiving moderately emetogenic chemotherapy.			HERRSTEDT, J (corresponding author), UNIV COPENHAGEN,HERLEV HOSP,DEPT ONCOL 54B1,DK-2730 COPENHAGEN,DENMARK.		Herrstedt, Jørn/AAB-7400-2022					BATEMAN DN, 1985, BRIT MED J, V291, P930, DOI 10.1136/bmj.291.6500.930; BONNETERRE J, 1990, J CLIN ONCOL, V8, P1063, DOI 10.1200/JCO.1990.8.6.1063; BREGNI M, 1991, EUR J CANCER, V27, P561, DOI 10.1016/0277-5379(91)90217-2; CARR BI, 1985, J CLIN ONCOL, V3, P1127, DOI 10.1200/JCO.1985.3.8.1127; CLAVEL M, 1978, LYON MED, V239, P307; DELFAVERO A, 1990, EUR J CLIN PHARMACOL, V38, P115, DOI 10.1007/BF00265968; Demulder PHM, 1990, ANN INTERN MED, V113, P834, DOI 10.7326/0003-4819-113-11-834; DICATO MA, 1991, EUR J CANCER, V27, pS18; FOZARD JR, 1978, EUR J PHARMACOL, V49, P109, DOI 10.1016/0014-2999(78)90228-5; GANDARA DR, 1990, P AN M AM SOC CLIN, V9, P328; GRALLA RJ, 1987, MED CLIN N AM, V71, P289, DOI 10.1016/S0025-7125(16)30871-9; GRUNBERG SM, 1993, EUR J CANCER, V29A, pS39, DOI 10.1016/S0959-8049(05)80260-6; HAINSWORTH J, 1991, J CLIN ONCOL, V9, P721, DOI 10.1200/JCO.1991.9.5.721; HAMIK A, 1989, CANCER CHEMOTH PHARM, V24, P307, DOI 10.1007/BF00304763; HERRSTEDT J, 1990, BRIT J CLIN PHARMACO, V30, P237, DOI 10.1111/j.1365-2125.1990.tb03770.x; HERRSTEDT J, 1991, EJC SUPPL, V27, pS294; ISRAEL L, 1978, J INT MED RES, V6, P235, DOI 10.1177/030006057800600311; KAASA S, 1990, EUR J CANCER, V26, P311, DOI 10.1016/0277-5379(90)90227-K; KELLEY SL, 1986, CANCER TREAT REP, V70, P469; KILPATRICK GJ, 1987, NATURE, V330, P746, DOI 10.1038/330746a0; KRIS MG, 1989, J CLIN ONCOL, V7, P108, DOI 10.1200/JCO.1989.7.1.108; MARSCHNER NW, 1991, EUR J CANCER, V27, P1137, DOI 10.1016/0277-5379(91)90311-Z; MARSCHNER NW, 1991, EUR J CANCER, V27, P1717; MARTY M, 1990, NEW ENGL J MED, V322, P816, DOI 10.1056/NEJM199003223221205; MARTY M, 1990, EUR J CANCER, V26, pS28; MINER WD, 1986, BRIT J PHARMACOL, V88, P497, DOI 10.1111/j.1476-5381.1986.tb10228.x; MOERTEL CG, 1973, J CLIN PHARMACOL, V13, P283, DOI 10.1002/j.1552-4604.1973.tb00269.x; OLVER IN, 1986, CANCER TREAT REP, V70, P555; POCOCK SJ, 1983, CLIN TRIALS PRACTICA, P110; ROILA F, 1991, J CLIN ONCOL, V9, P675, DOI 10.1200/JCO.1991.9.4.675; Siegel S., 1956, NONPARAMETRIC STAT B; SLEDGE GW, 1990, P AN M AM SOC CLIN, V9, P323; SMITH DB, 1991, LANCET, V338, P487, DOI 10.1016/0140-6736(91)90555-4; SMYTH JF, 1991, BRIT MED J, V303, P1423, DOI 10.1136/bmj.303.6815.1423; Stroyer I, 1976, Ugeskr Laeger, V138, P1769; [No title captured]	36	77	81	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 15	1993	328	15					1076	1080		10.1056/NEJM199304153281502	http://dx.doi.org/10.1056/NEJM199304153281502			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KX178	8455664	Bronze			2023-01-03	WOS:A1993KX17800002
J	PALEVSKY, PM; RENDULIC, D; DIVEN, WF				PALEVSKY, PM; RENDULIC, D; DIVEN, WF			MALTOSE-INDUCED HYPONATREMIA	ANNALS OF INTERNAL MEDICINE			English	Note						MALTOSE; HYPONATREMIA; IMMUNOGLOBULINS; INTRAVENOUS; KIDNEY FAILURE, ACUTE; HYPERTONICITY	HYPERGLYCEMIA	Although hyponatremia is usually indicative of hypotonicity, the accumulation in the plasma of high concentrations of glucose, mannitol, sorbitol, glycerol, or radiocontrast agents may lead to hyponatremia with hypertonicity. We describe a patient with renal failure in whom maltose intoxication, resulting from treatment with intravenous immune globulin, produced severe hyponatremia. During repeated infusions of intravenous immune globulin, the serum sodium concentration decreased in association with an increase in serum osmolality, a rising osmolal gap, and an accumulation of maltose in the blood. Maltose-containing intravenous solutions should be used with caution in patients with renal insufficiency; the development of hyponatremia during maltose infusion should suggest hypertonicity due to the accumulation of maltose.	VET AFFAIRS MED CTR, PITTSBURGH, PA USA; UNIV PITTSBURGH, SCH MED, PITTSBURGH, PA 15261 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			Palevsky, Paul M./Q-1491-2019	Palevsky, Paul M./0000-0002-7334-5400				ANDERSON RJ, 1985, ANN INTERN MED, V102, P164, DOI 10.7326/0003-4819-102-2-164; AVIRAM A, 1967, AM J MED, V42, P648, DOI 10.1016/0002-9343(67)90066-6; DEFRONZO RA, 1980, ARCH INTERN MED, V140, P897, DOI 10.1001/archinte.140.7.897; FUNKE C, 1977, NUTR METAB, V21, P115; KATZ MA, 1973, NEW ENGL J MED, V289, P843, DOI 10.1056/NEJM197310182891607; MORAN SM, 1985, WESTERN J MED, V142, P49; OCHS HD, 1980, LANCET, V2, P1158; SCHRIER RW, 1987, CLIN DISORDERS FLUID, P461; SILVERMAN M, 1973, J CLIN INVEST, V52, P2486, DOI 10.1172/JCI107439; TAHARA Y, 1990, AM J CLIN NUTR, V52, P689, DOI 10.1093/ajcn/52.4.689	10	37	37	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1993	118	7					526	528		10.7326/0003-4819-118-7-199304010-00007	http://dx.doi.org/10.7326/0003-4819-118-7-199304010-00007			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU079	8442623				2023-01-03	WOS:A1993KU07900007
J	WERLER, MM; SHAPIRO, S; MITCHELL, AA				WERLER, MM; SHAPIRO, S; MITCHELL, AA			PERICONCEPTIONAL FOLIC-ACID EXPOSURE AND RISK OF OCCURRENT NEURAL-TUBE DEFECTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SUPPLEMENTATION; PREVENTION; PREGNANCY; FOLATE; CLEFTS	Objectives.-A recent controlled trial has established that use of a 4-mg folic acid supplement before and during early pregnancy reduces the risk of recurrent neural tube defects (NTDs) by 72%. The present study was designed to determine whether folic acid also reduces the risk of first (occurrent) NTDs. Design.-Case-control study. Setting.-Tertiary and birth hospitals in metropolitan areas of Boston, Mass, Philadelphia, Pa, and Toronto, Ontario. Participants.-Mothers of 436 occurrent cases with NTDs and mothers of 2615 controls with other major malformations. Main Outcome Measures.-The prevalence of use of multivitamins containing folic acid was compared between mothers of cases and controls. Results.-The mothers of 17% of cases and 3% of controls reported knowledge of the folic acid-NTD hypothesis and were excluded from further analysis. For daily use of multivitamins containing folic acid in the periconceptional period (28 days before through 28 days after the last menstrual period), the relative risk (RR) (and 95% confidence interval) was 0.4 (0.2 to 0.6). The most commonly used dose of folic acid was 0.4 mg, and the RR estimate was 0.3 (95% confidence interval, 0.1 to 0.6). For dietary folate, there was a dose-related decline in risk according to the quintile of intake (P for trend=.02). Conclusion.-These findings suggest that dally periconceptional intake of 0.4 mg of folic acid (the dose most commonly contained in over-the-counter multivitamin preparations) reduces the risk of occurrent NTDs by approximately 60%. A relatively high dietary intake of folate may also reduce the risk.			WERLER, MM (corresponding author), BOSTON UNIV,SCH MED,SLONE EPIDEMIOL UNIT,1371 BEACON ST,BROOKLINE,MA 02146, USA.			Mitchell, Allen/0000-0003-0950-6799; Werler, Martha/0000-0003-3392-6814	PHS HHS [MCJ-2505667] Funding Source: Medline; FDA HHS [FD-U-000082-10] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); FDA HHS		BOWER C, 1989, MED J AUSTRALIA, V150, P613, DOI 10.5694/j.1326-5377.1989.tb136723.x; ELWOOD JM, 1980, EPIDEMIOLOGY ANENCEP; LAURENCE KM, 1981, BRIT MED J, V282, P1509, DOI 10.1136/bmj.282.6275.1509; MANTEL N, 1959, J NATL CANCER I, V22, P719; MILLS JL, 1989, NEW ENGL J MED, V321, P430, DOI 10.1056/NEJM198908173210704; MILUNSKY A, 1989, JAMA-J AM MED ASSOC, V262, P2847, DOI 10.1001/jama.262.20.2847; MITCHELL AA, 1981, JAMA-J AM MED ASSOC, V245, P2311; MULINARE J, 1988, JAMA-J AM MED ASSOC, V260, P3141, DOI 10.1001/jama.260.21.3141; SMITHELLS RW, 1983, LANCET, V1, P1027; SUBAR AF, 1990, AM J EPIDEMIOL, V132, P1091, DOI 10.1093/oxfordjournals.aje.a115752; TOLAROVA M, 1987, SCAND J PLAST RECONS, V21, P19, DOI 10.3109/02844318709083574; WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780; YEN IH, 1992, AM J DIS CHILD, V146, P857, DOI 10.1001/archpedi.1992.02160190089028; 1991, LANCET, V338, P131; 1971, STATISTICAL ASPECTS	15	427	434	1	15	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 10	1993	269	10					1257	1261		10.1001/jama.269.10.1257	http://dx.doi.org/10.1001/jama.269.10.1257			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP885	8437302				2023-01-03	WOS:A1993KP88500023
J	BROMHAM, DR; CARTMILL, RSV				BROMHAM, DR; CARTMILL, RSV			KNOWLEDGE AND USE OF SECONDARY CONTRACEPTION AMONG PATIENTS REQUESTING TERMINATION OF PREGNANCY	BRITISH MEDICAL JOURNAL			English	Article											BROMHAM, DR (corresponding author), ST JAMES UNIV HOSP,FERTIL CONTROL UNIT,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND.							BROOK SJ, 1991, BR J FAMILY PLANNING, V17, P18; DUNCAN G, 1990, BRIT J FAM PLANN, V15, P112; Griffiths M, 1990, BRIT J FAM PLANN, V16, P16; MELVILLE AWT, 1992, MED AUDIT NEWS, V2, P130; 1992, EMERGENCY POSTCOITAL	5	46	47	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 27	1993	306	6877					556	557		10.1136/bmj.306.6877.556	http://dx.doi.org/10.1136/bmj.306.6877.556			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP886	8461770	Bronze, Green Published			2023-01-03	WOS:A1993KP88600022
J	COHEN, IL; LAMBRINOS, J; FEIN, IA				COHEN, IL; LAMBRINOS, J; FEIN, IA			MECHANICAL VENTILATION FOR THE ELDERLY PATIENT IN INTENSIVE-CARE - INCREMENTAL CHARGES AND BENEFITS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LIFE; AGE; SURVIVAL; FAILURE; QUALITY; COSTS; UNIT	Objective.-To evaluate the cost-effectiveness of prolonged mechanical ventilation in patients 80 years of age and older in the intensive care unit (ICU). Design.-A retrospective review of consecutive ICU patients requiring 3 or more days of mechanical ventilation. Cost-effectiveness analysis was performed by assessing incremental hospital charges from hospital billing records; charges were then related to years of life saved. A telephone survey was used to follow up hospital survivors for a minimum of 4 years after discharge. Setting.-A 20-bed medical-surgical ICU in a 420-bed, tertiary-care community teaching hospital. Patients.-The study included all patients aged 80 years or older taken from a comprehensive database of all patients admitted to the ICU requiring mechanical ventilation from April 1, 1985, through October 31, 1987 (n=512). Of 59 potential candidates, 45 were found to have complete billing records and were the subject of further analysis. Results.-Of the 45 patients in the group under analysis, 10 survived to leave the hospital. Of these, two were alive and one could not be located at the time of follow-up. The charge per year of life saved is estimated to be between $51 854 and $75 090 in 1985-1987 dollars. Of 22 patients whose age in years plus duration of mechanical ventilation in days totaled 100 or greater, only two survived hospitalization and neither was alive at follow-up. The cost per year of life saved in this subset of patients was $181 308 in 1985-1987 dollars. One of these patients was discharged to a nursing home and died there 4.5 years later, after multiple hospital readmissions. The other patient died at home 2 months after hospital discharge Conclusion.-Based on hospital charges and life expectancy, the cost-effectiveness of prolonged mechanical ventilation in ICU patients age 80 years and over was poor in our population when the combination of age and duration ot mechanical ventilation exceeded 100. Further studies using this type of analysis may prove valuable in both clinical and administrative decision-making processes.	UNION UNIV, DEPT MED, ALBANY, NY 12208 USA; UNION COLL, INST GRAD MANAGEMENT, SCHENECTADY, NY 12308 USA	Union College; Union College	COHEN, IL (corresponding author), UNION UNIV, DEPT SURG, A-162, 47 NEW SCOTLAND AVE, ALBANY, NY 12208 USA.		Fein, I. Alan/J-2576-2019					BAKER R, 1991, ANESTHESIOL CLIN N A, V9, P437; BERMAN HJ, 1990, FINANC MANAGE, P109; BOUBJERG RR, 1987, IND L REV, V19, P857; CAMPION EW, 1981, JAMA-J AM MED ASSOC, V246, P2052, DOI 10.1001/jama.246.18.2052; CHELLURI L, 1992, CRIT CARE MED, V20, P757, DOI 10.1097/00003246-199206000-00010; CULLEN DJ, 1977, ANESTHESIOLOGY, V47, P203, DOI 10.1097/00000542-197708000-00011; DAVIS H, 1980, JAMA-J AM MED ASSOC, V243, P43; FEDULLO AJ, 1983, CRIT CARE MED, V11, P155, DOI 10.1097/00003246-198303000-00001; GIBBS J, 1982, HEW100790110 BLU CRO; GOLDBERG AI, 1988, CHEST, V94, P1277, DOI 10.1378/chest.94.6.1277; KNAUS W A, 1989, American Review of Respiratory Disease, V140, pS8; LAMBRINOS J, 1987, MANAGING CRITICAL CA, P358; LAPUMA J, 1990, JAMA-J AM MED ASSOC, V263, P2917, DOI 10.1001/jama.263.21.2917; LEAF A, 1977, NEW ENGL J MED, V297, P887, DOI 10.1056/NEJM197710202971612; LEAPE LL, 1990, JAMA-J AM MED ASSOC, V263, P669, DOI 10.1001/jama.263.5.669; LEGALL JR, 1982, CRIT CARE MED, V10, P575; MCLEAN RF, 1985, CRIT CARE MED, V13, P625, DOI 10.1097/00003246-198508000-00002; MOORE MJ, 1988, J POLICY ANAL MANAG, V7, P476, DOI 10.2307/3323726; NUNN JF, 1979, BRIT MED J, V1, P1525, DOI 10.1136/bmj.1.6177.1525; ODONNELL A, 1991, CHEST, V100, pS29; PESAU B, 1992, CRIT CARE MED, V20, P489, DOI 10.1097/00003246-199204000-00010; ROSEN RL, 1988, CLIN CHEST MED, V9, P163; SAGE WM, 1986, CRIT CARE MED, V14, P777, DOI 10.1097/00003246-198609000-00004; SCHMIDT CD, 1983, CRIT CARE MED, V11, P407, DOI 10.1097/00003246-198306000-00001; SCITOVSKY AA, 1988, MILBANK Q, V66, P640, DOI 10.2307/3349934; SWINBURNE AJ, 1991, CHEST, V100, pS79; TRAN DD, 1990, CRIT CARE MED, V18, P474, DOI 10.1097/00003246-199005000-00002; ZAREN B, 1987, CRIT CARE MED, V15, P743, DOI 10.1097/00003246-198708000-00006; 1981, FED REG         0219, V14, P13193; 1992, EC REPORT PRESIDENT, P361; 1986, GAOHRD8625 US GEN AC; 1992, NATIONAL ISSUES FORU	32	90	94	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 24	1993	269	8					1025	1029		10.1001/jama.269.8.1025	http://dx.doi.org/10.1001/jama.269.8.1025			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM603	8429584				2023-01-03	WOS:A1993KM60300032
J	KAGIWADA, S; MURATA, M; HISHIDA, R; TAGAYA, M; YAMASHINA, S; OHNISHI, S				KAGIWADA, S; MURATA, M; HISHIDA, R; TAGAYA, M; YAMASHINA, S; OHNISHI, S			INVITRO FUSION OF RABBIT LIVER GOLGI MEMBRANES WITH LIPOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; ENDOPLASMIC-RETICULUM; PLASMA-MEMBRANE; VESICULAR TRANSPORT; RAT-LIVER; PROTEIN; PHOSPHOLIPIDS; APPARATUS; VESICLES; REQUIRES	Fusion of Golgi membranes isolated from rabbit liver with liposomes was studied by lipid mixing of fluorescent lipid analogues and internal content mixing and by electron microscopic observation of transfer of horseradish peroxidase from liposomes into Golgi membranes. A monoclonal antibody was used to confirm fusion of Golgi membranes but not other contaminating vesicles. Fusion was rapid and efficient, reaching about 20% of the maximum after a 5-min incubation using small or large unilamellar dioleoylphosphatidylcholine vesicles. The fusion was dependent on temperature, decreasing at lower temperatures, and becoming nearly zero below 10-degrees-C. The addition of ATP, GTP, cytosolic factors, or N-ethylmaleimide did not affect fusion. Treatments of Golgi membranes with 0.1 M Na2CO3 or 1 M KCl did not cause any changes in fusion. However, treatment with proteases inhibited fusion. These results suggest that Golgi integral membrane protein(s) are involved in fusion. Changing the medium to an isoosmotic substance, sucrose, in place of KCl or NaCl inhibited fusion. The binding assay of fluorescent liposomes to Golgi membranes showed that lowering the temperature or replacing salts with sucrose did not affect binding. However, treatment of Golgi membranes with proteases inhibited binding. Addition of phosphatidylserine or phosphatidylethanolamine to dioleoylphosphatidylcholine liposomes caused a 2-fold increase in binding and fusion. Fusion between Golgi membranes by themselves did not occur. These results provide some information on the mechanism of intracellular vesicular transport.	OSAKA UNIV,INST SCI & IND RES,IBARAKI,OSAKA 567,JAPAN; KITASATO UNIV,SCH MED,DEPT ANAT,SAGAMIHARA,KANAGAWA 228,JAPAN	Osaka University; Kitasato University	KAGIWADA, S (corresponding author), KYOTO UNIV,FAC SCI,DEPT BIOPHYS,KYOTO 606,JAPAN.							ALKAISSI E, 1983, J IMMUNOL METHODS, V58, P127, DOI 10.1016/0022-1759(83)90269-7; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BALCH WE, 1989, J BIOL CHEM, V264, P16965; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BECKERS CJM, 1990, J BIOL CHEM, V265, P18298; BENNETT MK, 1988, EMBO J, V7, P4075, DOI 10.1002/j.1460-2075.1988.tb03301.x; BISHOP WR, 1988, ANNU REV CELL BIOL, V4, P579, DOI 10.1146/annurev.cb.04.110188.003051; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BREW K, 1975, J BIOL CHEM, V250, P1434; CHLAPOWSKI FJ, 1971, J CELL BIOL, V50, P634, DOI 10.1083/jcb.50.3.634; DECURTIS I, 1989, CELL, V58, P719, DOI 10.1016/0092-8674(89)90106-2; DESILVA NS, 1981, J BIOL CHEM, V256, P5845; DEWALD B, 1973, J BIOL CHEM, V248, P7223; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; ELLENS H, 1985, BIOCHEMISTRY-US, V24, P3099, DOI 10.1021/bi00334a005; FREISCHER S, 1974, METHOD ENZYMOL, V31, P6; FRIES E, 1980, P NATL ACAD SCI-BIOL, V77, P3870, DOI 10.1073/pnas.77.7.3870; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; GRUENBERG J, 1989, ANNU REV CELL BIOL, V5, P453; HOEKSTRA D, 1984, BIOCHEMISTRY-US, V23, P5675, DOI 10.1021/bi00319a002; KAPLAN MR, 1985, J CELL BIOL, V101, P446, DOI 10.1083/jcb.101.2.446; KEARNEY JF, 1979, J IMMUNOL, V123, P1548; KOBAYASHI T, 1988, CELL, V55, P797, DOI 10.1016/0092-8674(88)90135-3; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTINEZBAZENET C, 1988, BIOCHIM BIOPHYS ACTA, V943, P35, DOI 10.1016/0005-2736(88)90344-6; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MILLS JT, 1984, P NATL ACAD SCI-BIOL, V81, P1385, DOI 10.1073/pnas.81.5.1385; MOREAU P, 1991, J BIOL CHEM, V266, P4322; Ohnishi Shun-Ichi, 1988, Curr Top Membr Transp, V32, P257, DOI 10.1016/S0070-2161(08)60137-9; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROTHMAN JE, 1987, J BIOL CHEM, V262, P12502; SARASTE J, 1986, P NATL ACAD SCI USA, V83, P6425, DOI 10.1073/pnas.83.17.6425; SCHWANINGER R, 1991, J BIOL CHEM, V266, P13055; SHEN DF, 1982, BIOCHIM BIOPHYS ACTA, V689, P31, DOI 10.1016/0005-2736(82)90185-7; SINGLETON WS, 1965, J AM OIL CHEM SOC, V42, P53, DOI 10.1007/BF02558256; SLEIGHT RG, 1984, J CELL BIOL, V99, P742, DOI 10.1083/jcb.99.2.742; SLEIGHT RG, 1985, J BIOL CHEM, V260, P1146; STEGMANN T, 1989, ANNU REV BIOPHYS BIO, V18, P187, DOI 10.1146/annurev.bb.18.060189.001155; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; STUTZIN A, 1986, FEBS LETT, V197, P274, DOI 10.1016/0014-5793(86)80341-6; SWANSON MA, 1955, METHOD ENZYMOL, V2, P541, DOI 10.1016/S0076-6879(55)02247-7; SZOKA F, 1978, P NATL ACAD SCI USA, V75, P4194, DOI 10.1073/pnas.75.9.4194; TABAS I, 1979, J BIOL CHEM, V254, P1655; TOOZE SA, 1990, CELL, V60, P837, DOI 10.1016/0092-8674(90)90097-X; WATERS M G, 1991, Current Opinion in Cell Biology, V3, P615, DOI 10.1016/0955-0674(91)90031-S; WEIDMAN PJ, 1989, J CELL BIOL, V108, P1589, DOI 10.1083/jcb.108.5.1589; WHITE JM, 1990, ANNU REV PHYSIOL, V52, P675, DOI 10.1146/annurev.ph.52.030190.003331	49	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1430	1435						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8419344				2023-01-03	WOS:A1993KG07700099
J	Scarabin, PY; Billaud, E; PluBureau, G; Agher, R				Scarabin, PY; Billaud, E; PluBureau, G; Agher, R			HRT and ACE activity in postmenopausal women	LANCET			English	Letter							ANGIOTENSIN-CONVERTING ENZYME		HOP BROUSSAIS,SERV PHARMACOL,F-75674 PARIS 14,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite	Scarabin, PY (corresponding author), HOP BROUSSAIS,INSERM,U258,F-75674 PARIS 14,FRANCE.							BONITHONKOPP C, 1994, CIRCULATION, V89, P952, DOI 10.1161/01.CIR.89.3.952; CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; CUSHMAN DW, 1971, BIOCHEM PHARMACOL, V20, P1637, DOI 10.1016/0006-2952(71)90292-9; PROUDLER AJ, 1995, LANCET, V346, P89, DOI 10.1016/S0140-6736(95)92114-1; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P	5	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 13	1996	347	8994					122	122		10.1016/S0140-6736(96)90248-2	http://dx.doi.org/10.1016/S0140-6736(96)90248-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP281	8538318				2023-01-03	WOS:A1996TP28100050
J	VOSS, M; KNOTTENBELT, JD; PEDEN, MM				VOSS, M; KNOTTENBELT, JD; PEDEN, MM			PATIENTS WHO REATTEND AFTER HEAD-INJURY - A HIGH-RISK GROUP	BRITISH MEDICAL JOURNAL			English	Article							TRAUMA	Objective-To assess risk factors for important neurosurgical effects in patients who reattend after head injury. Design-Retrospective study. Subject -606 patients who reattended a trauma unit after minor head injury. Main outcome measures-Intracranial abnormality detected on computed tomography or the need for neurosurgical intervention. Results-Five patients died: two from unrelated causes and three from raised intracranial pressure. On multiple regression analysis the only significant predictor for both abnormality on computed tomography (14.4% of reattenders) and the need for operation (5% of reattenders) was vault fracture seen on the skull radiograph (P<10(-6)); predictors for abnormal computed tomogram were a Glasgow coma scale score <15 at either first or second attendance (P<0.0001) and convulsion at second attendance (P<0.05); predictive for operation only was penetrating injury of the skull (P<10(-6)). On contingency table analysis these associations were confirmed. In addition significant associations with both abnormality on computed tomography and operation were focal neurological abnormality, weakness, or speech disturbance. Amnesia or loss of consciousness at the time of initial injury, personality change, and seizures were significantly associated only with abnormality on computed tomography. Headache, dizziness, nausea, and vomiting were common in reattenders but were found to have no independent significance. Conclusions-All patients who reattend after head injury should undergo computed tomography as at least 14% of scans can be expected to yield positive results. Where this facility is not available patients with predictors for operation should be urgently referred for neurosurgical opinion. Other patients can be readmitted and need referral only if symptoms persist despite symptomatic treatment or there is neurological deterioration while under observation. These patients are a high risk group and should be treated seriously.	GROOTE SCHUUR HOSP,TRAUMA UNIT,CAPE TOWN,SOUTH AFRICA; S AFRICAN MRC,CAPE TOWN,SOUTH AFRICA	University of Cape Town; South African Medical Research Council				Mary, Margaret/0000-0003-0872-9851				DUUS BR, 1993, BRIT J SURG, V80, P988, DOI 10.1002/bjs.1800800817; GUSTAFFSON T, 1985, EPISTAT STATISTICAL; HARAD FT, 1992, J TRAUMA, V32, P359, DOI 10.1097/00005373-199203000-00014; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; JONES RK, 1974, SURG NEUROL, V2, P101; MASTERS SJ, 1987, NEW ENGL J MED, V316, P84, DOI 10.1056/NEJM198701083160205; MOHANTY SK, 1991, J TRAUMA, V31, P801, DOI 10.1097/00005373-199106000-00010; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; TEASDALE GM, 1990, BRIT MED J, V300, P363, DOI 10.1136/bmj.300.6721.363; 1990, SAS USERS GUIDE STAT; 1984, BRIT MED J, V288, P983	11	37	38	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 25	1995	311	7017					1395	1398		10.1136/bmj.311.7017.1395	http://dx.doi.org/10.1136/bmj.311.7017.1395			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG902	8520273	Green Published			2023-01-03	WOS:A1995TG90200017
J	STERN, RS				STERN, RS			DRUG PROMOTION FOR AN UNLABELED INDICATION - THE CASE OF TOPICAL TRETINOIN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									HARVARD UNIV,SCH MED,BOSTON,MA	Harvard University; Harvard Medical School	STERN, RS (corresponding author), BETH ISRAEL HOSP,DEPT DERMATOL,330 BROOKLINE AVE,BOSTON,MA 02215, USA.							DELOZIER JE, 1987, DHHS PHS821364 NAT C; HOROWITZ GL, 1981, NEW ENGL J MED, V305, P924, DOI 10.1056/NEJM198110153051605; KESSLER DA, 1991, NEW ENGL J MED, V325, P201, DOI 10.1056/NEJM199107183250310; KRIPKE ML, 1980, J AM ACAD DERMATOL, V2, P439, DOI 10.1016/S0190-9622(80)80373-2; LIMERICK Z, 1977, READERS GUIDE PERIOD, V36; RANDALL T, 1991, JAMA-J AM MED ASSOC, V266, P11, DOI 10.1001/jama.266.1.11; SCHAPPERT SM, 1993, DHHS PHS931250 NAT C; WEISS JS, 1988, JAMA-J AM MED ASSOC, V259, P527, DOI 10.1001/jama.259.4.527; Weiss JS, 1988, JAMA-J AM MED ASSOC, V260, P926; WEISS JS, 1988, JAMA-J AM MED ASSOC, V259, P3274; 1987, DRUG TOPICS RED BOOK; 1985, J AM ACAD DERMATOL, V13, pA60; 1989, J AM ACAD DERMATOL, V20, pA100; 1980, VITAL HLTH STATIST 2, V90; 1991, DRUG TOPICS RED BOOK; 1991, FDC REPORTS PINK SHE, V53; 1978, NY TIMES INDEX BOOK, V65; 1978, FDA DRUG B, V8, P26	18	13	13	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 17	1994	331	20					1348	1349		10.1056/NEJM199411173312006	http://dx.doi.org/10.1056/NEJM199411173312006			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR216	7935705				2023-01-03	WOS:A1994PR21600006
J	WOOLF, GM; PETROVIC, LM; ROJTER, SE; WAINWRIGHT, S; VILLAMIL, FG; KATKOV, WN; MICHIELETTI, P; WANLESS, IR; STERMITZ, FR; BECK, JJ; VIERLING, JM				WOOLF, GM; PETROVIC, LM; ROJTER, SE; WAINWRIGHT, S; VILLAMIL, FG; KATKOV, WN; MICHIELETTI, P; WANLESS, IR; STERMITZ, FR; BECK, JJ; VIERLING, JM			ACUTE HEPATITIS ASSOCIATED WITH THE CHINESE HERBAL PRODUCT JIN BU HUAN	ANNALS OF INTERNAL MEDICINE			English	Article						HEPATITIS, TOXIC; JIN BU HUAN; MEDICINE, HERBAL; QUALITY CONTROL	VENO-OCCLUSIVE DISEASE; MEDICINE; TOXICITY; HEPATOTOXICITY; MEDICATION; LIVER	Objective: To describe the hepatotoxicity associated with ingestion of the Chinese herbal product Jin Bu Huan Anodyne Tablets (Lycopodium serratum) and to propose possible mechanisms of injury. Design: Retrospective analysis. Setting: Academic hepatology units and private practice facilities. Patients: Seven previously healthy patients. Measurements: Clinical, laboratory, radiologic, and histologic studies. Results: Acute hepatitis occurred after a mean of 20 weeks (range, 7 to 52 weeks) of Jin Bu Huan ingestion and resolved in six patients within a mean of 8 weeks (range, 2 to 30 weeks); another patient is currently improving. Hepatitis was associated with symptoms of fever, fatigue, nausea, pruritus, and abdominal pain and with signs of jaundice and hepatomegaly. Biopsy specimens showed that one patient had hepatitis with eosinophils (consistent with a drug reaction) and the other had mild hepatitis, moderate fibrosis, and microvesicular steatosis. Decreasing the Jin Bu Huan dose in one patient improved liver test results. Reusing Jin Bu Huan in two other patients caused abrupt recrudescence of hepatitis. Conclusion: Jin Bu Huan can cause liver injury. Although the hepatotoxic mechanisms are not defined, they may include hypersensitive or idiosyncratic reactions or direct toxicity to active metabolites. Hepatotoxicity caused by herbal products underscores the importance of national surveillance programs and quality control of the manufacture of these products.	CEDARS SINAI MED CTR, LIVER TRANSPLANTAT PROGRAM, LOS ANGELES, CA 90048 USA; CTR DIS CONTROL & PREVENT, NATL CTR ENVIRONM HLTH, DIV ENVIRONM HAZARDS & HLTH EFFECTS, ATLANTA, GA 30341 USA; TORONTO HOSP, DIV GEN, DIV GASTROENTEROL, TORONTO M5G 2C4, ON, CANADA; ST JOHNS HOSP, DIV GASTROENTEROL, SANTA MONICA, CA 90404 USA; COLORADO STATE UNIV, DEPT CHEM, FT COLLINS, CO 80523 USA	Cedars Sinai Medical Center; Centers for Disease Control & Prevention - USA; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Colorado State University	WOOLF, GM (corresponding author), CEDARS SINAI MED CTR, HEPATOL PROGRAM, 8700 BEVERLY BLVD, SUITE 7511, LOS ANGELES, CA 90048 USA.							BEUERS U, 1991, LANCET, V337, P372, DOI 10.1016/0140-6736(91)91012-J; CASTOT A, 1992, GASTROEN CLIN BIOL, V16, P916; CHAN H, 1977, CLIN TOXICOL, V10, P273, DOI 10.3109/15563657708992423; CHAN MY, 1989, AM J CHINESE MED, V17, P165, DOI 10.1142/S0192415X89000255; CHANG HM, 1986, PHARM APPLICATIONS C, P552; Clark F., 1992, Morbidity and Mortality Weekly Report, V41, P812; DHARMANANDA S, 1993, I TRADITIONAL MED, P1; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; HARVEY J, 1981, BRIT MED J, V282, P186, DOI 10.1136/bmj.282.6259.186; Horowitz R. S., 1993, Morbidity and Mortality Weekly Report, V42, P633; HUXTABLE RJ, 1986, NEW ENGL J MED, V315, P1095; KATZ M, 1990, J CLIN GASTROENTEROL, V12, P203, DOI 10.1097/00004836-199004000-00021; KESSLER DA, 1993, JAMA-J AM MED ASSOC, V269, P2765, DOI 10.1001/jama.269.21.2765; LARREY D, 1992, ANN INTERN MED, V117, P129, DOI 10.7326/0003-4819-117-2-129; LIU GQ, 1982, ARCH INT PHARMACOD T, V258, P39; LOEPER J, 1994, GASTROENTEROLOGY, V106, P464, DOI 10.1016/0016-5085(94)90606-8; MACGREGOR FB, 1989, BRIT MED J, V299, P1156, DOI 10.1136/bmj.299.6708.1156; MATTOCKS AR, 1968, NATURE, V217, P723, DOI 10.1038/217723a0; MCGEE JO, 1976, J CLIN PATHOL, V29, P788, DOI 10.1136/jcp.29.9.788; MOHABBAT O, 1976, LANCET, V2, P269; RIES CA, 1975, JAMA-J AM MED ASSOC, V231, P352, DOI 10.1001/jama.231.4.352; SMITH BC, 1993, AUST NZ J MED, V23, P526, DOI 10.1111/j.1445-5994.1993.tb01846.x; TANDON BN, 1976, LANCET, V2, P271; VERHOEF MJ, 1990, CAN MED ASSOC J, V142, P121; Woolf G. M., 1993, Morbidity and Mortality Weekly Report, V42, P920; YEONG ML, 1993, INT J EXP PATHOL, V74, P211; Zimmerman H. J., 1978, HEPATOTOXICITY ADVER; 1993, UNSUBSTANTIATED CLAI; 1991, IMPORTANT INFORMATIO	29	155	157	1	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1994	121	10					729	735		10.7326/0003-4819-121-10-199411150-00001	http://dx.doi.org/10.7326/0003-4819-121-10-199411150-00001			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ928	7944049				2023-01-03	WOS:A1994PQ92800001
J	SOUTHERN, DA; READ, MS				SOUTHERN, DA; READ, MS			LESSON OF THE WEEK - OVERDOSAGE OF OPIATE FROM PATIENT-CONTROLLED ANALGESIA DEVICES	BRITISH MEDICAL JOURNAL			English	Article											SOUTHERN, DA (corresponding author), UNIV WALES HOSP,CARDIFF CF4 4XW,S GLAM,WALES.							GREY TC, 1988, JAMA-J AM MED ASSOC, V259, P2240, DOI 10.1001/jama.1988.03720150022025; GROVER ER, 1992, ANAESTHESIA, V47, P402, DOI 10.1111/j.1365-2044.1992.tb02221.x; KEERISZANTO M, 1971, CAN ANAESTH SOC J, V18, P581, DOI 10.1007/BF03026023; NORTCUTT WG, 1992, BRIT J ANAESTH, V69, P95; THOMAS DW, 1988, ANAESTHESIA, V43, P770, DOI 10.1111/j.1365-2044.1988.tb05753.x	5	23	23	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 15	1994	309	6960					1002	1002		10.1136/bmj.309.6960.1002	http://dx.doi.org/10.1136/bmj.309.6960.1002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PM417	7950692	Green Published			2023-01-03	WOS:A1994PM41700029
J	HYNDMAN, SJ; WILLIAMS, DRR; MERRILL, SL; LIPSCOMBE, JM; PALMER, CR				HYNDMAN, SJ; WILLIAMS, DRR; MERRILL, SL; LIPSCOMBE, JM; PALMER, CR			RATES OF ADMISSION TO HOSPITAL FOR ASTHMA	BRITISH MEDICAL JOURNAL			English	Article							ACUTE CHILDHOOD ASTHMA; TRENDS; CHILDREN; INCREASE; HEALTH; CARE	Objective-To describe trends in hospital admission rates for asthma in England and Wales (1976-85), the East Anglian region (from 1976 to 1991-2), and Wales (1980-90). Design-Descriptive study. Setting-Hospitals in England and Wales; hospitals in the East Anglian Regional Health Authority; hospitals in Wales. Main outcome measures-Hospital admissions for asthma as principal diagnosis in England and Wales (Hospital In-patient Enquiry, 1976-85), for the East Anglian region (Hospital In-patient Enquiry, 1976-7; Hospital Activity Analysis, 1978-86; Regional Information System, 1987-8 to 1991-2), and for Wales (Hospital Activity Analysis, l980-90). Results-Rates for England and Wales as a whole showed a steady upward trend throughout the period examined. Rates in East Anglia, though they were similar to the national trends in the early years, showed a peak in 1985 (for males and females) with some indication of a decline in rates thereafter. Rates for Wales showed an upward trend until 1988 (for both males and females) after which they showed a decline. Conclusions-Interpretation of the East Anglian trends is made more difficult by the change in England in 1987 of the system for the collection of hospital admission data. The fact that the rates for the East Anglian region seem to decline before this change and other considerations suggest that the observed trends, although partly reflecting the disruption of the coding during the changeover in systems, may not be entirely artefactual. The possible roles of diagnostic transfer and changes in the delivery of care, asthma treatment, admission and readmission policies, and the severity and prevalence of asthma in changing admission rates are considered. The changing bends in admission rates for East Anglia and Wales reflect recently published trends for mortality from asthma in England.			HYNDMAN, SJ (corresponding author), UNIV CAMBRIDGE,INST PUBL HLTH,DEPT COMMUNITY MED,HLTH SERV RES GRP,UNIV FORVIE SITE,CAMBRIDGE CB2 2SR,CAMBS,ENGLAND.							ANDERSON HR, 1990, THORAX, V45, P431, DOI 10.1136/thx.45.6.431; ANDERSON HR, 1989, THORAX, V44, P614, DOI 10.1136/thx.44.8.614; ANDERSON HR, 1978, ARCH DIS CHILD, V53, P295, DOI 10.1136/adc.53.4.295; ANDERSON HR, 1980, BRIT MED J, V281, P1191, DOI 10.1136/bmj.281.6249.1191; [Anonymous], 1990, BMJ, V301, P797; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; CARMAN PG, 1990, MED J AUSTRALIA, V152, P23, DOI 10.5694/j.1326-5377.1990.tb124423.x; CHARLTON I, 1991, BRIT J GEN PRACT, V41, P227; CLARK TJH, 1990, OCCURRENCE COST ASTH; GARDNER MJ, 1989, STATISTICS CONFIDENC; HALFON N, 1986, AM J PUBLIC HEALTH, V76, P1308, DOI 10.2105/AJPH.76.11.1308; KHOT A, 1984, BRIT MED J, V289, P235, DOI 10.1136/bmj.289.6439.235; MITCHELL EA, 1985, ARCH DIS CHILD, V60, P376, DOI 10.1136/adc.60.4.376; MITCHELL EA, 1989, EUR RESPIR J, V2, P470; NINAN TK, 1992, BRIT MED J, V304, P873, DOI 10.1136/bmj.304.6831.873; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; STORR J, 1988, ARCH DIS CHILD, V63, P774, DOI 10.1136/adc.63.7.774; STRACHAN DP, 1992, BRIT MED J, V304, P819, DOI 10.1136/bmj.304.6830.819; TAYLOR DR, 1993, THORAX, V48, P134, DOI 10.1136/thx.48.2.134; 1993, HOSPITAL EPISODE STA, V1; 1980, HOSPITAL INPATIENT E; 1990, BRIT MED J, V301, P651	22	87	87	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 18	1994	308	6944					1596	1600		10.1136/bmj.308.6944.1596	http://dx.doi.org/10.1136/bmj.308.6944.1596			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NT528	8025425	Green Published			2023-01-03	WOS:A1994NT52800016
J	NIGHTINGALE, SL				NIGHTINGALE, SL			PUBLIC HEARING ON PROPOSED SWITCH OF ACYCLOVIR FROM PRESCRIPTION TO OVER-THE-COUNTER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							FED REGISTER, V59, P10650	1	16	16	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 13	1994	271	14					1067	1067		10.1001/jama.271.14.1067	http://dx.doi.org/10.1001/jama.271.14.1067			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE228	8151837				2023-01-03	WOS:A1994NE22800005
J	GOOPTU, C; MULLEY, GP				GOOPTU, C; MULLEY, GP			SURVEY OF ELDERLY PEOPLE WHO GET STUCK IN THE BATH	BRITISH MEDICAL JOURNAL			English	Article									ST JAMES UNIV HOSP,DEPT MED ELDERLY,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND	Saint James's University Hospital								Clarke M, 1984, Health Trends, V16, P3; PENN ND, 1989, BRIT MED J, V298, P1158, DOI 10.1136/bmj.298.6681.1158-a; 1990, OLD CLEAN REPORT BAT	3	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 19	1994	308	6931					762	762		10.1136/bmj.308.6931.762	http://dx.doi.org/10.1136/bmj.308.6931.762			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC348	8142833	Green Published			2023-01-03	WOS:A1994NC34800023
J	ROSELL, R; GOMEZCODINA, J; CAMPS, C; MAESTRE, J; PADILLE, J; CANTO, A; MATE, JL; LI, SR; ROIG, J; OLAZABAL, A; CANELA, M; ARIZA, A; SKACEL, Z; MORERAPRAT, J; ABAD, A				ROSELL, R; GOMEZCODINA, J; CAMPS, C; MAESTRE, J; PADILLE, J; CANTO, A; MATE, JL; LI, SR; ROIG, J; OLAZABAL, A; CANELA, M; ARIZA, A; SKACEL, Z; MORERAPRAT, J; ABAD, A			A RANDOMIZED TRIAL COMPARING PREOPERATIVE CHEMOTHERAPY PLUS SURGERY WITH SURGERY ALONE IN PATIENTS WITH NON-SMALL-CELL LUNG-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PHASE-II TRIAL; NEOADJUVANT CHEMOTHERAPY; SURGICAL-TREATMENT; RADIATION-THERAPY; CARCINOMA; SURVIVAL; CISPLATIN; IFOSFAMIDE; MITOMYCIN; RESECTION	Background. The efficacy of surgery for patients with non-small-cell lung cancer is limited, although recent studies suggest that preoperative chemotherapy may improve survival. We conducted a randomized trial to examine the possible benefit of preoperative chemotherapy and surgery for the treatment of patients with non-small-cell lung cancer. Methods. We studied 60 patients (59 men and 1 woman) with stage IIIA non-small-cell lung cancer. The patients were randomly assigned to receive either surgery alone or three courses of chemotherapy (6 mg of mitomycin per square meter of body-surface area, 3 g of ifosfamide per square meter, and 50 mg of cisplatin per square meter) given intravenously at three-week intervals and followed by surgery. All patients received mediastinal radiation after surgery. The resected tumors were evaluated by means of K-ras oncogene analysis and flow cytometry. Results. The median period of survival was 26 months in the patients with chemotherapy plus surgery, as compared with 8 months in the patients treated with surgery alone (P<0.001); the median period of disease-free survival was 20 months in the former group, as compared with 5 months in the latter (P<0.001). The rate of recurrence was 56 percent in the group treated with chemotherapy plus surgery and 74 percent in the group treated with surgery alone. The prevalence of mutated K-ras oncogenes was 15 percent among the patients receiving preoperative chemotherapy and 42 percent among those treated with surgery alone (P = 0.05). Most of the patients treated with chemotherapy plus surgery had tumors that consisted of diploid cells, whereas the patients treated with surgery alone had tumors with aneuploid cells. Conclusions. Preoperative chemotherapy increases the median survival in patients with non-small-cell lung cancer.	HOSP LA FE, DEPT THORAC SURG, VALENCIA, SPAIN; HOSP GEN VALENCIA, DEPT MED ONCOL, VALENCIA, SPAIN; HOSP GEN VALENCIA, DEPT THORAC SURG, VALENCIA, SPAIN; UNIV BARCELONA, HOSP BADALONA GERMANS TRIAS & PUJOL, DEPT THORAC SURG, BARCELONA 7, SPAIN; UNIV BARCELONA, HOSP BADALONA GERMANS TRIAS & PUJOL, DEPT PNEUMOL, BARCELONA 7, SPAIN; UNIV BARCELONA, HOSP BADALONA GERMANS TRIAS & PUJOL, DEPT RADIOL, BARCELONA 7, SPAIN; UNIV BARCELONA, HOSP BADALONA GERMANS TRIAS & PUJOL, DEPT PATHOL, BARCELONA 7, SPAIN; HOSP LA FE, DEPT MED ONCOL, VALENCIA, SPAIN	Hospital Universitari i Politecnic La Fe; Hospital Germans Trias i Pujol; University of Barcelona; Hospital Germans Trias i Pujol; University of Barcelona; Hospital Germans Trias i Pujol; University of Barcelona; Hospital Germans Trias i Pujol; University of Barcelona; Hospital Universitari i Politecnic La Fe	ROSELL, R (corresponding author), UNIV BARCELONA, HOSP GERMANS TRIAS & PUJOL, DEPT MED ONCOL, BOX 72, E-08916 BADALONA, SPAIN.		Herrero, Carlos Camps/L-3073-2017; SANZ, JOSE LUIS MATE/O-3158-2019	Herrero, Carlos Camps/0000-0002-0648-5403; SANZ, JOSE LUIS MATE/0000-0002-4829-3426; Roig, Jordi/0000-0002-5593-7090				BAINS MS, 1991, CHEST, V100, P826, DOI 10.1378/chest.100.3.826; BROOKMEYER R, 1982, BIOMETRICS, V38, P29, DOI 10.2307/2530286; BURKES RL, 1992, J CLIN ONCOL, V10, P580, DOI 10.1200/JCO.1992.10.4.580; COTTRELL JJ, 1992, CLIN CHEST MED, V13, P47; CULLEN MH, 1988, BRIT J CANCER, V58, P359, DOI 10.1038/bjc.1988.219; CYBULSKY IJ, 1992, ANN THORAC SURG, V54, P533, DOI 10.1016/0003-4975(92)90449-E; DAUTZENBERG B, 1990, CANCER, V65, P2435, DOI 10.1002/1097-0142(19900601)65:11<2435::AID-CNCR2820651105>3.0.CO;2-2; DESLAURIERS J, 1989, J THORAC CARDIOV SUR, V97, P504; DIXON WJ, 1983, BMDP STATISTICAL SOF, P555; FABER LP, 1989, ANN THORAC SURG, V47, P669, DOI 10.1016/0003-4975(89)90115-X; FOSSELLA FV, 1991, P AN M AM SOC CLIN, V10, P240; GOMEZCODINA J, 1991, EJC SUPPL, V27, pS167; HIDDEMANN W, 1984, CYTOMETRY, V5, P445, DOI 10.1002/cyto.990050502; LODDENKEMPER R, 1983, THORAC CARDIOV SURG, V31, P334, DOI 10.1055/s-2007-1022013; MARTINI N, 1993, ANN THORAC SURG, V55, P1365, DOI 10.1016/0003-4975(93)91072-U; MARTINI N, 1987, SURG CLIN N AM, V67, P1037; MARTINI N, 1988, ANN THORAC SURG, V45, P370, DOI 10.1016/S0003-4975(98)90007-8; MARTINI N, 1992, ANN THORAC SURG, V54, P460, DOI 10.1016/0003-4975(92)90435-7; MITSUDOMI T, 1991, CANCER RES, V51, P4999; MOUNTAIN CF, 1990, CHEST, V97, P1045, DOI 10.1378/chest.97.5.1045; MOUNTAIN CF, 1986, CHEST, V89, pS225, DOI 10.1378/chest.89.4.225S; MURREN JR, 1991, AM REV RESPIR DIS, V143, P889, DOI 10.1164/ajrccm/143.4_Pt_1.889; NARUKE T, 1988, ANN THORAC SURG, V46, P603, DOI 10.1016/S0003-4975(10)64717-0; PASS HI, 1992, ANN THORAC SURG, V53, P992, DOI 10.1016/0003-4975(92)90373-C; RATTO GB, 1990, J THORAC CARDIOV SUR, V99, P416; ROSELL R, 1993, ONCOGENE, V8, P2407; ROSELL R, 1990, J SURG ONCOL, V45, P124, DOI 10.1002/jso.2930450213; ROSELL R, 1992, P AN M AM SOC CLIN, V11, P287; SKARIN A, 1989, J SURG ONCOL, V40, P266, DOI 10.1002/jso.2930400413; Slebos R J, 1992, Diagn Mol Pathol, V1, P136, DOI 10.1097/00019606-199206000-00007; SLEBOS RJC, 1990, NEW ENGL J MED, V323, P561, DOI 10.1056/NEJM199008303230902; STRAUSS GM, 1992, J CLIN ONCOL, V10, P1237, DOI 10.1200/JCO.1992.10.8.1237; WATANABE Y, 1991, ANN THORAC SURG, V51, P253, DOI 10.1016/0003-4975(91)90797-T; WEIDEN PL, 1991, J NATL CANCER I, V83, P266, DOI 10.1093/jnci/83.4.266; YU JM, 1991, CANCER-AM CANCER SOC, V68, P76, DOI 10.1002/1097-0142(19910701)68:1<76::AID-CNCR2820680115>3.0.CO;2-L	35	990	1016	0	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 20	1994	330	3					153	158		10.1056/NEJM199401203300301	http://dx.doi.org/10.1056/NEJM199401203300301			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ863	8043059	Bronze			2023-01-03	WOS:A1994MQ86300001
J	MADUKE, M; ROISE, D				MADUKE, M; ROISE, D			IMPORT OF A MITOCHONDRIAL PRESEQUENCE INTO PROTEIN-FREE PHOSPHOLIPID-VESICLES	SCIENCE			English	Article							ENDOPLASMIC-RETICULUM; MEMBRANE-PROTEIN; SYNTHETIC PRESEQUENCE; YEAST MITOCHONDRIA; SIGNAL PEPTIDE; TRANSLOCATION; INSERTION; HYPOTHESIS; BILAYERS	A synthetic mitochondrial presequence has been shown to translocate across pure phospholipid bilayers. The presequence was fluorescently labeled so that its association with membranes could be monitored spectroscopically. In the presence of large unilamellar vesicles, the presequence showed time- and potential-dependent protection from reaction with added trypsin and dithionite. The protection was rapidly reversed by treatment of the vesicles with detergent. If the vesicles contained trypsin, the added presequence became sensitive to digestion by,the protease. The results show that a mitochondrial presequence can translocate across phospholipid bilayers that lack a hydrophilic translocation pore.	UNIV CALIF SAN DIEGO, DEPT CHEM, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego				Maduke, Merritt/0000-0001-7787-306X	NIGMS NIH HHS [T32-GM08326] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008326] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; CHEN LB, 1988, ANNU REV CELL BIOL, V4, P155, DOI 10.1146/annurev.cb.04.110188.001103; CHEN LB, 1981, COLD SPRING HARB SYM, V46, P141, DOI 10.1101/SQB.1982.046.01.018; DEKROON AIPM, 1991, BIOCHIM BIOPHYS ACTA, V1068, P111, DOI 10.1016/0005-2736(91)90199-I; DUMONT ME, 1984, J BIOL CHEM, V259, P4147; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; FREY S, 1990, BIOCHEM J, V272, P713, DOI 10.1042/bj2720713; FURUYA S, 1991, EMBO J, V10, P1759, DOI 10.1002/j.1460-2075.1991.tb07700.x; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; GLASER SM, 1990, J BIOL CHEM, V265, P8817; GLASER SM, 1990, J BIOL CHEM, V265, P8808; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; KELLARIS KV, 1991, J CELL BIOL, V114, P21, DOI 10.1083/jcb.114.1.21; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; MADUKE M, UNPUB; MCINTYRE JC, 1991, BIOCHEMISTRY-US, V30, P11819, DOI 10.1021/bi00115a012; NICCHITTA CV, 1991, CELL, V65, P587, DOI 10.1016/0092-8674(91)90091-C; ONO H, 1988, J BIOL CHEM, V263, P3188; PAK YK, 1990, J BIOL CHEM, V265, P14298; Penefsky H S, 1979, Methods Enzymol, V56, P527; PFANNER N, 1992, CELL, V68, P999, DOI 10.1016/0092-8674(92)90069-O; ROISE D, 1992, P NATL ACAD SCI USA, V89, P608, DOI 10.1073/pnas.89.2.608; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; ROISE D, 1988, J BIOL CHEM, V263, P4509; ROISE D, 1988, EMBO J, V7, P649, DOI 10.1002/j.1460-2075.1988.tb02859.x; SIMON SM, 1992, P NATL ACAD SCI USA, V89, P3770, DOI 10.1073/pnas.89.9.3770; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SINGER SJ, 1987, P NATL ACAD SCI USA, V84, P1015, DOI 10.1073/pnas.84.4.1015; SKERJANC IS, 1987, EMBO J, V6, P3117, DOI 10.1002/j.1460-2075.1987.tb02621.x; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; SWANSON ST, 1992, BIOCHEMISTRY-US, V31, P5746, DOI 10.1021/bi00140a009; THEG SM, 1992, BIOCHEMISTRY-US, V31, P5053, DOI 10.1021/bi00136a018; VANTHOF R, 1991, FEBS LETT, V291, P350, DOI 10.1016/0014-5793(91)81318-3; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; VONHEIJNE G, 1979, EUR J BIOCHEM, V97, P175; WICKNER W, 1979, ANNU REV BIOCHEM, V48, P23, DOI 10.1146/annurev.bi.48.070179.000323; WIEDMANN M, 1989, FEBS LETT, V257, P263, DOI 10.1016/0014-5793(89)81549-2	39	81	81	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 16	1993	260	5106					364	367		10.1126/science.8385804	http://dx.doi.org/10.1126/science.8385804			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KX800	8385804				2023-01-03	WOS:A1993KX80000042
J	BROOME, IJ				BROOME, IJ			ANESTHESIA - HEARING-LOSS AND DURAL PUNCTURE	LANCET			English	Editorial Material							SPINAL-ANESTHESIA				BROOME, IJ (corresponding author), FALKIRK & DIST ROYAL INFIRM, DEPT ANAESTHESIA, FALKIRK, SCOTLAND.							FOG J, 1990, ANESTH ANALG, V70, P517; LEE CM, 1986, ANESTH ANALG, V65, P312, DOI 10.1213/00000539-198603000-00016; MICHEL O, 1992, ANN OTO RHINOL LARYN, V101, P390, DOI 10.1177/000348949210100503; SUNDBERG A, 1992, ANAESTHESIA, V47, P981, DOI 10.1111/j.1365-2044.1992.tb03205.x; VANDAM LD, 1956, JAMA-J AM MED ASSOC, V161, P586, DOI 10.1001/jama.1956.02970070018005	5	7	7	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 13	1993	341	8846					667	668		10.1016/0140-6736(93)90429-K	http://dx.doi.org/10.1016/0140-6736(93)90429-K			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR613	8095578				2023-01-03	WOS:A1993KR61300013
J	Jernigan, DB; Hofmann, J; Cetron, MS; Genese, CA; Nuorti, JP; Fields, BS; Benson, RF; Carter, RJ; Edelstein, PH; Guerrero, IC; Paul, SM; Lipman, HB; Breiman, RF				Jernigan, DB; Hofmann, J; Cetron, MS; Genese, CA; Nuorti, JP; Fields, BS; Benson, RF; Carter, RJ; Edelstein, PH; Guerrero, IC; Paul, SM; Lipman, HB; Breiman, RF			Outbreak of Legionnaires' disease among cruise ship passengers exposed to a contaminated whirlpool spa	LANCET			English	Article							LEGIONELLA-PNEUMOPHILA SEROGROUP-1; POLYMERASE CHAIN-REACTION; PONTIAC FEVER; PNEUMONIA	Background Outbreaks of travel-related Legionnaires' disease present a public-health challenge since rapid, sensitive, and specific diagnostic tests are not widely used and because detection of clusters of disease among travellers is difficult. We report an outbreak of Legionnaires' disease among cruise ship passengers that occurred in April, 1994, but that went unrecognised until July, 1994. Methods After rapid diagnosis of Legionnaires' disease in three passengers by urine antigen testing, we searched for additional cases of either confirmed (laboratory evidence of infection) or probable Legionnaires' disease (pneumonia of undetermined cause). A case-control study was conducted to compare exposures and activities on the ship and in ports of call between each case-passenger and two or three matched control-passengers. Water samples from the ship, from sites on Bermuda, and from the ship's water source in New York City were cultured for legionellae and examined with PCR. Findings 50 passengers with Legionnaires' disease (16 confirmed, 34 probable) were identified from nine cruises embarking between April 30 and July 9, 1994. Exposure to whirlpool spas was strongly associated with disease (odds ratio 16.2, 95% CI 2.8-351.7); risk of acquiring Legionnaires' disease increased by 64% (95% CI 12-140) for every hour spent in the spa water. Passengers spending time around the whirlpool spas, but not in the water, were also significantly more likely to have acquired infection. Legionella pneumophila serogroup 1 was isolated only from the sand filter in the ship's whirlpool spa. This isolate matched a clinical isolate from the respiratory secretions of a case-passenger as judged by monoclonal antibody subtyping and by arbitrarily primed PCR. Interpretation This investigation shows the benefit of obtaining a recent travel history, the usefulness or urine antigen testing for rapid diagnosis of legionella infection, and the need for improved surveillance for travel-related Legionnaires' disease. New strategies for whirlpool spa maintenance and decontamination may help to minimise transmission of legionellae from these aerosol-producing devices.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,BIOSTAT & INFORMAT MANAGEMENT BRANCH,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,DIV FIELD EPIDEMIOL,EPIDEM INTELLIGENCE SERV,ATLANTA,GA 30333; NEW JERSEY STATE DEPT HLTH,DIV EPIDEMIOL,TRENTON,NJ; HOSP UNIV PENN,PHILADELPHIA,PA 19104; TOMS RIVER COMMUNITY MED CTR,TOMS RIVER,NJ	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; New Jersey Department of Health & Senior Services; University of Pennsylvania; Pennsylvania Medicine	Jernigan, DB (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,CHILDHOOD & RESP DIS BRANCH,MS CO9,1600 CLIFTON RD,ATLANTA,GA 30333, USA.		Paul, Steve/ABE-5400-2020; Edelstein, Paul/I-5527-2019	Edelstein, Paul/0000-0002-4069-5279				AGUEROROSENFELD ME, 1988, J CLIN MICROBIOL, V26, P1775, DOI 10.1128/JCM.26.9.1775-1778.1988; BARON PA, 1986, ENVIRON RES, V39, P8, DOI 10.1016/S0013-9351(86)80003-2; EDELSTEIN PH, 1985, MANUAL CLIN MICROBIO, P373; EDELSTEIN PH, 1992, MANUAL CLIN LAB IMMU, P459; GOLDBERG DJ, 1989, LANCET, V1, P316; GOMEZLUS P, 1993, J CLIN MICROBIOL, V31, P1940, DOI 10.1128/JCM.31.7.1940-1942.1993; GRIST NR, 1979, ANN INTERN MED, V90, P563, DOI 10.7326/0003-4819-90-4-563; HOGE CW, 1991, EPIDEMIOL REV, V13, P329, DOI 10.1093/oxfordjournals.epirev.a036076; JOLY JR, 1986, J CLIN MICROBIOL, V23, P768, DOI 10.1128/JCM.23.4.768-771.1986; Joseph C A, 1994, Commun Dis Rep CDR Rev, V4, pR109; Joseph C A, 1993, Commun Dis Rep CDR Rev, V3, pR124; KALLINGS I, 1991, TRAVEL MED, V2, P228; KAUFMANN AF, 1981, AM J EPIDEMIOL, V114, P337, DOI 10.1093/oxfordjournals.aje.a113200; KOHLER RB, 1986, DIAGN MICR INFEC DIS, V4, pS47, DOI 10.1016/S0732-8893(86)80042-6; MANGIONE EJ, 1985, JAMA-J AM MED ASSOC, V253, P535; MARSTON BJ, 1994, ARCH INTERN MED, V154, P2417, DOI 10.1001/archinte.154.21.2417; MILLER LA, 1993, J INFECT DIS, V168, P769, DOI 10.1093/infdis/168.3.769; PLOUFFE JF, 1995, CLIN INFECT DIS, V20, P1286, DOI 10.1093/clinids/20.5.1286; REINGOLD AL, 1984, J INFECT DIS, V149, P819, DOI 10.1093/infdis/149.5.819; SANDEN GN, 1993, J CLIN MICROBIOL, V31, P170, DOI 10.1128/JCM.31.1.170-172.1993; SPITALNY KC, 1984, AM J EPIDEMIOL, V120, P809, DOI 10.1093/oxfordjournals.aje.a113953; THOMAS DL, 1993, ARCH INTERN MED, V153, P2597, DOI 10.1001/archinte.153.22.2597; VOGT RL, 1987, ANN INTERN MED, V107, P596, DOI 10.7326/0003-4819-107-4-596_1; 1994, CRUISE IND OVERVIEW; 1985, US DEP HLTH HUMAN SE; 1994, COMMUNICAB DIS REP, V4, P25; 1989, US DEP HLTH HUMAN SE, P12; 1991, COMMUNICAB DIS REP, V1, P157; 1994, MMWR-MORBID MORTAL W, V43, P521; 1992, PROCEDURES RECOVERY	30	134	143	0	17	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 24	1996	347	9000					494	499		10.1016/S0140-6736(96)91137-X	http://dx.doi.org/10.1016/S0140-6736(96)91137-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW697	8596266	hybrid			2023-01-03	WOS:A1996TW69700008
J	Coast, J; Inglis, A; Frankel, S				Coast, J; Inglis, A; Frankel, S			Alternatives to hospital care: What are they and who should decide?	BRITISH MEDICAL JOURNAL			English	Article							BEDS	Objective-To examine potential for alternatives to care in hospitals for acute admissions, and to compare the decisions about these alternatives made by clinicians with different backgrounds. Design-Standardised tool was used to identify patients who could potentially be treated in an alternative form of care. Information about such patients was assessed by three panels of clinicians: general practitioners without experience of general practitioner beds, general practitioners with experience of general practitioner beds, and consultants. Setting-One hospital for acute admissions in a rural area of the South and West region of England. Subjects-Of 620 patients admitted to specialties of general medicine and care of the elderly, details of 112 were assessed by panels. Main outcome measures-Proportion of hospitalised patients who could have received alternative care and identification of most appropriate alternative form of care. Results-Both general practitioner panels estimated that between 51 and 89 of the hospitalised patients could have received alternative care (equivalent to 8-14% of all admissions). Consultants estimated that between 25 and 55 patients could have had alternative care (5.5-9% of all admissions). General practitioner bed and urgent outpatient appointment were the main alternatives chosen by all three panels. Conclusion-About 10% of admissions to general hospital might be suitable for alternative forms of care. Doctors with different backgrounds made similar overall assessments of most appropriate forms of care.			Coast, J (corresponding author), UNIV BRISTOL,DEPT MED SOCIOL,BRISTOL BS8 2PR,AVON,ENGLAND.			Coast, Joanna/0000-0002-3537-5166				ANDERSON P, 1988, BRIT MED J, V297, P910, DOI 10.1136/bmj.297.6653.910; BEECH R, 1987, BRIT MED J, V294, P685, DOI 10.1136/bmj.294.6573.685; Cox David R., 1958, PLANNING EXPT; HOBBS R, 1995, BRIT MED J, V310, P207, DOI 10.1136/bmj.310.6974.207; INGLIS AL, 1995, MED CARE, V33, P952, DOI 10.1097/00005650-199509000-00006; JACOBS CM, 1992, ISD A REV SYSTEM ADU; LAURANCE J, 1993, TIMES           0111, P7; STRUMWASSER I, 1990, MED CARE, V28, P95, DOI 10.1097/00005650-199002000-00001; Torrance N, 1972, J R Coll Gen Pract, V22, P211; Victor C, 1993, Health Trends, V25, P94; VICTOR CR, 1994, J PUBLIC HEALTH MED, V16, P286; 1992, INDEPENDENT     0330, P9	12	41	41	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 20	1996	312	7024					162	166						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TR325	8563538				2023-01-03	WOS:A1996TR32500026
J	LEVETOWN, M; POLLACK, MM; CUERDON, TT; RUTTIMANN, UE; GLOVER, JJ				LEVETOWN, M; POLLACK, MM; CUERDON, TT; RUTTIMANN, UE; GLOVER, JJ			LIMITATIONS AND WITHDRAWALS OF MEDICAL INTERVENTION IN PEDIATRIC CRITICAL CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NOT-RESUSCITATE ORDERS; INTENSIVE-CARE; ILL PATIENTS; ETHICS	Objective.-To investigate the use and implementation in pediatric intensive care units (PICUs) of three levels of restriction of medical intervention: do not resuscitate (DNR), additional limitations of medical interventions beyond DNR, and withdrawal of care. Design.-Consecutive patients admitted between December 1989 and January 1992. Setting.-A total of 16 PICUs randomly selected to represent variability in size, teaching status, and presence or absence of a pediatric intensivist and unit coordination. Main Outcome Measures.-Profiles of children undergoing restrictions of medical interventions including the influence of chronic disease, the justifications for restrictions, and description of implementation practices. Patients.-All pediatric admissions undergoing restrictions (n = 119) drawn from 5415 consecutive PICU admissions. Results.-A total of 94 (79%) of the restriction patients died during the PICU course, representing 38% of all deaths. A total of 73 restrictions (61%) resulted from acute disease, most involving the central nervous system or respiratory system. Restrictions were evenly divided between DNR (39%), additional limitations of medical intervention beyond DNR (27%), and withdrawals of medical intervention (34%). Survival decreased with increasing levels of restriction from 35% of DNR patients to 9% of patients with additional limitations and 2% of withdrawal patients. Imminent death was cited as the justification for restrictions in 70% of cases, no relational potential was cited in 22%, and excessive burden was cited in 8%. Conclusions.-Restrictions of medical intervention were used in all PICUs surveyed. Although severe chronic disease was common among restriction patients, acute disease was the predominant event precipitating placement of restrictions. Imminent death, not quality of life or excessive burden, was the most common justification.	CHILDRENS NATL MED CTR,DEPT CRIT CARE MED,WASHINGTON,DC 20010; CHILDRENS NATL MED CTR,CTR HLTH SERV & CLIN RES,CHILDRENS RES INST,WASHINGTON,DC; CHILDRENS NATL MED CTR,DEPT PEDIAT,WASHINGTON,DC; GEORGE WASHINGTON UNIV,SCH MED,DEPT PEDIAT,WASHINGTON,DC 20052; GEORGE WASHINGTON UNIV,SCH MED,DEPT ANESTHESIOL,WASHINGTON,DC; GEORGE WASHINGTON UNIV,SCH MED,DEPT HLTH CARE SCI,WASHINGTON,DC; NIAAA,BETHESDA,MD	Children's National Health System; Children's National Health System; Children's National Health System; George Washington University; George Washington University; George Washington University; National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)					PHS HHS [MCH-110584] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Adams FH, 1989, HEART DISEASE INFANT; American College of Physicians Ethics Manual, 1989, ANN INTERN MED, V111, P327; [Anonymous], 1985, CHILD ABUSE AMENDMEN; [Anonymous], 1990, CRIT CARE MED, V18, P1435; ARRAS JD, 1984, HASTINGS CENT REP, V14, P25, DOI 10.2307/3561882; BEDELL SE, 1986, JAMA-J AM MED ASSOC, V256, P233, DOI 10.1001/jama.256.2.233; BEHRMAN RE, 1987, NELSON TXB PEDIATRIC; DUFF RS, 1973, NEW ENGL J MED, V289, P890, DOI 10.1056/NEJM197310252891705; FABERLANGENDOEN K, 1992, CRIT CARE MED, V20, P570, DOI 10.1097/00003246-199205000-00005; HAINES IE, 1990, MED J AUSTRALIA, V153, P225, DOI 10.5694/j.1326-5377.1990.tb136867.x; JECKER NS, 1991, HASTINGS CENT REP, V21, P5, DOI 10.2307/3563315; JONSSON PV, 1988, ARCH INTERN MED, V148, P2373, DOI 10.1001/archinte.148.11.2373; LANTOS JD, 1993, CRIT CARE MED, V21, P52, DOI 10.1097/00003246-199301000-00012; MINK RB, 1992, PEDIATRICS, V89, P961; Nelson L J, 1989, Law Med Health Care, V17, P316; NELSON LJ, 1992, CRIT CARE MED, V20, P427, DOI 10.1097/00003246-199203000-00022; POLLACK MM, 1987, NEW ENGL J MED, V316, P134, DOI 10.1056/NEJM198701153160304; POLLACK MM, 1994, JAMA-J AM MED ASSOC, V272, P941, DOI 10.1001/jama.272.12.941; RUDOLPH AE, 1991, PEDIATRICS; SCHAFFNER KF, 1988, CRIT CARE MED, V16, P1069, DOI 10.1097/00003246-198810000-00022; SMEDIRA NG, 1990, NEW ENGL J MED, V322, P309, DOI 10.1056/NEJM199002013220506; Smith, 1982, RECOGNIZABLE PATTERN; TOMLINSON T, 1988, NEW ENGL J MED, V318, P43, DOI 10.1056/NEJM198801073180109; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; WHITELAW A, 1986, LANCET, V2, P328; ZIMMERMAN JE, 1986, JAMA-J AM MED ASSOC, V255, P351, DOI 10.1001/jama.255.3.351; 1987, GUIDELINES TERMINATI; 1992, CODE MED ETHICS CURR	28	50	53	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 26	1994	272	16					1271	1275		10.1001/jama.272.16.1271	http://dx.doi.org/10.1001/jama.272.16.1271			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN068	7933372				2023-01-03	WOS:A1994PN06800033
J	SWIFT, PGF; HEARNSHAW, JR; BOTHA, JL; WRIGHT, G; RAYMOND, NT; JAMIESON, KF				SWIFT, PGF; HEARNSHAW, JR; BOTHA, JL; WRIGHT, G; RAYMOND, NT; JAMIESON, KF			A DECADE OF DIABETES - KEEPING CHILDREN OUT-OF-HOSPITAL	BRITISH MEDICAL JOURNAL			English	Article							INSULIN	Objectives-To document the number of children aged less than 15 years who developed diabetes and were managed within one large health district, and to evaluate the outcome of those children managed without hospital admission at diagnosis. Design-A retrospective study over 1979-88, when a paediatrician and a physician with special interests in childhood diabetes initiated joint clinics. Data collected from the district diabetes register and files of consultants and health visitors specialising in diabetes. Setting-Referral of children to consultants in Leicestershire (total population 863 000). Main outcome measures-The proportion of children managed without hospital admission, comparison of readmission rates and glycated haemoglobin concentrations between children admitted and those not admitted. Results-Over 10 years 236 children aged 10-14 years developed diabetes (annual incidence rate 12.8/100 000 child population (95% confidence interval 11.3 to 14.7)). In total 138 were not admitted to hospital but received supervised management based at home. Admitted children were younger or acidotic or their family doctors did not contact the diabetes team. Duration of admission declined from seven days in 1979-80 to three days in 1987-8. Ninety two were not admitted to hospital during the 10 years for any reason. Significantly fewer children who received management at home were readmitted for reasons related to diabetes than the group treated in hospital (30 (22%) v 40 (41%); p = 0.004). Concentrations of glycated haemoglobin were no different between the two groups. Conclusions-Children with newly diagnosed diabetes may be safely and effectively managed out of hospital. Domiciliary or community based management depends on the commitment of consultants specialising in diabetes working in close cooperation with general practitioners, specialist nurses in diabetes, and dietitians.	UNIV LEICESTER,DEPT EPIDEMIOL & PUBL HLTH,LEICESTER LE1 7RH,ENGLAND	University of Leicester	SWIFT, PGF (corresponding author), LEICESTER ROYAL INFIRM,LEICESTER LE1 5WW,ENGLAND.			Raymond, Neil/0000-0003-2855-2117				GALATZER A, 1982, DIABETES CARE, V5, P414, DOI 10.2337/diacare.5.4.414; HEARNSHAW JR, 1986, DIABETES 1985, P31; Laron Z, 1979, Diabetes Care, V2, P342, DOI 10.2337/diacare.2.4.342; LESSING DN, 1992, ARCH DIS CHILD, V67, P1011, DOI 10.1136/adc.67.8.1011; Lindsay M., 1985, CARE CHILD DIABETES; LIPMAN T, 1986, DIABETES ED, V14, P41; MCNALLY PG, 1990, Q J MED, V76, P831; METCALFE MA, 1991, BRIT MED J, V302, P443, DOI 10.1136/bmj.302.6774.443; RAYNER PHW, 1984, PRACTICAL DIABETES, V1, P5; SCHNEIDER AJ, 1983, AM J DIS CHILD, V137, P782, DOI 10.1001/archpedi.1983.02140340062017; SIMELL T, 1991, LANCET, V337, P656, DOI 10.1016/0140-6736(91)92464-D; Walker J., 1989, CHRONICLE DIABETIC S; WALKER JB, 1953, LANCET, V2, P445; 1990, DIABETES CARE, V13, P1118; 1990, DIABETIC MED, V7, P457; 1985, SAS USERS GUIDE BASI; 1986, MINIMAL ED FACILITIE; 1991, LANCET, V337, P648; 1990, DIABETES, V39, P858	19	34	34	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 10	1993	307	6896					96	98		10.1136/bmj.307.6896.96	http://dx.doi.org/10.1136/bmj.307.6896.96			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LM585	8343736	Bronze, Green Published			2023-01-03	WOS:A1993LM58500023
J	BRUERA, E; DESTOUTZ, N; VELASCOLEIVA, A; SCHOELLER, T; HANSON, J				BRUERA, E; DESTOUTZ, N; VELASCOLEIVA, A; SCHOELLER, T; HANSON, J			EFFECTS OF OXYGEN ON DYSPNEA IN HYPOXEMIC TERMINAL-CANCER PATIENTS	LANCET			English	Article							BREATHLESSNESS; DISEASE	Dyspnoea is a frequent and devastating symptom of advanced cancer. The purpose of this prospective, double-blind, crossover trial was to assess the effects of supplemental oxygen on the intensity of dyspnoea. 14 patients with hypoxaemic dyspnoea due to advanced cancer were randomised to receive either oxygen or air; the gases were delivered at 5 L/min by mask. After 5 min of stable oxygen saturation (pulse oximetry), patients were crossed over to receive the other treatment. The crossover was repeated twice. Dyspnoea was assessed with a visual analogue scale (0 = no dyspnoea, 100 = worst dyspnoea). Mean difference in dyspnoea visual analogue scale between air and oxygen treatment was 20.5 (95% confidence interval 13.5 to 27.6). 12 patients consistently preferred oxygen to air; similarly, the investigator consistently chose oxygen for the same 12 patients. In a global rating questionnaire, patients reported little or no benefit during the air phase compared with moderate to much benefit during the oxygen phase. We conclude that oxygen is beneficial to patients with hypoxia and dyspnoea at rest.			BRUERA, E (corresponding author), EDMONTON GEN HOSP,PALLIAT CARE PROGRAM,11111 JASPER AVE,EDMONTON,ALBERTA,CANADA.		Bruera, Eduardo/AAA-1550-2022					BANNISTER RG, 1954, J PHYSIOL-LONDON, V125, P118, DOI 10.1113/jphysiol.1954.sp005145; BILLINGS JA, 1985, OUT PATIENT MANAGEME, V41, P80; CAMPBELL EJ, 1963, BRIT MED BULL, V19, P36, DOI 10.1093/oxfordjournals.bmb.a070002; CHRONOS N, 1988, CLIN SCI, V74, P531, DOI 10.1042/cs0740531; CM Saunders, 1978, MANAGEMENT TERMINAL, P99; Enck R E, 1989, Am J Hosp Care, V6, P11, DOI 10.1177/104990918900600403; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; HILLS M, 1979, BRIT J CLIN PHARMACO, V8, P7, DOI 10.1111/j.1365-2125.1979.tb05903.x; JAESCHKE R, 1991, EFFECT CANCER QUALIT, P65; LISS HP, 1988, AM REV RESPIR DIS, V137, P1285, DOI 10.1164/ajrccm/137.6.1285; MOORE DP, 1992, LANCET, V339, P850, DOI 10.1016/0140-6736(92)90288-E; RESTRICK LJ, 1992, LANCET, V340, P1192, DOI 10.1016/0140-6736(92)92893-K; REUBEN DB, 1986, CHEST, V89, P234, DOI 10.1378/chest.89.2.234; SIMON PM, 1990, AM REV RESPIR DIS, V142, P1009, DOI 10.1164/ajrccm/142.5.1009; STARK RD, 1988, EUR RESPIR J, V1, P280; SWINBURN CR, 1991, AM REV RESPIR DIS, V143, P913, DOI 10.1164/ajrccm/143.5_Pt_1.913; WASSERMAN K, 1988, ANNU REV MED, V39, P503, DOI 10.1146/annurev.med.39.1.503	17	131	133	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 3	1993	342	8862					13	14		10.1016/0140-6736(93)91880-U	http://dx.doi.org/10.1016/0140-6736(93)91880-U			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK985	8100289				2023-01-03	WOS:A1993LK98500009
J	LILLIEBLANTON, M; ANTHONY, JC; SCHUSTER, CR				LILLIEBLANTON, M; ANTHONY, JC; SCHUSTER, CR			PROBING THE MEANING OF RACIAL ETHNIC-GROUP COMPARISONS IN CRACK COCAINE SMOKING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To probe the meaning of reported racial and ethnic group differences in the prevalence of crack cocaine smoking and to estimate the degree to which crack cocaine smoking is associated with personal factors specific to race/ethnicity. Design.-Through reanalysis of data from the 1988 National Household Survey of Drug Abuse (NHSDA), we compared racial/ethnic group differences in crack cocaine smoking. To hold constant social and environmental risk factors that might potentially confound racial comparisons, we used an epidemiologic strategy that involves poststratification of respondents into neighborhood risk sets. A conditional logistic regression model was used to estimate the relative odds of crack use by race/ethnicity. Patients or Other Participants.-The 1988 NHSDA interviewed 8814 individuals residing within households in the United States. Subjects were selected using a multistage area probability sampling of all residents aged 12 years and older. Results.-Once respondents were grouped into neighborhood clusters, the relative odds (RO) of crack use did not differ significantly for African Americans (RO, 0.85; 95% confidence interval [CI], 0.37 to 1.93) or for Hispanic Americans (RO, 0.88; 95% CI, 0.47 to 1.67) compared with white Americans. Conclusion.-Findings of race-associated differences are often presented as if a person's race has intrinsic explanatory power. This analysis provides evidence that, given similar social and environmental conditions, crack use does not strongly depend on race-specific (eg, biologic) personal factors. Although the study finding does not refute the previous analysis, it provides evidence that prevalence estimates unadjusted for social environmental risk factors may lead to misunderstanding about the role of race or ethnicity in the epidemiology of crack use. Future research should seek to identify which characteristics of the neighborhood social environment are important and potentially modifiable determinants of drug use.	NIDA,ADDICT RES CTR,POB 5180,BALTIMORE,MD 21224; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BALTIMORE,MD 21218; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT MENTAL HYG,BALTIMORE,MD 21218	National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); Johns Hopkins University; Johns Hopkins University; Maryland Department of Health & Mental Hygiene			Anthony, Jim/H-3637-2011	Anthony, Jim/0000-0001-7176-0929	NIDA NIH HHS [DA04392] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004392] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Anthony J C, 1991, NIDA Res Monogr, V110, P71; ANTHONY JC, 1989, AM J EPIDEMIOL, V129, P543, DOI 10.1093/oxfordjournals.aje.a115166; BASSETT MT, 1986, AM J PUBLIC HEALTH, V76, P1400, DOI 10.2105/AJPH.76.12.1400; HENDERSON AS, 1988, INTRO SOCIAL PSYCHIA; JONES CP, 1991, AM J EPIDEMIOL, V134, P1079, DOI 10.1093/oxfordjournals.aje.a116011; LESSE S, 1987, AM J PSYCHOTHER, V41, P336, DOI 10.1176/appi.psychotherapy.1987.41.3.336; PETRONIS KR, 1990, SOC PSYCH PSYCH EPID, V25, P193; PETRONIS KR, 1989, DRUG ALCOHOL DEPEN, V23, P219, DOI 10.1016/0376-8716(89)90084-7; Schlesselman JJ, 1982, CASE CONTROL STUDIES; 1991, HRSPDV902 US DEP HLT; 1990, ADM901692 US DEP HLT	11	140	141	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 24	1993	269	8					993	997		10.1001/jama.269.8.993	http://dx.doi.org/10.1001/jama.269.8.993			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KM603	8429605				2023-01-03	WOS:A1993KM60300026
J	Gurwitz, JH; Gore, JM; Goldberg, RJ; Rubison, M; Chandra, N; Rogers, WJ				Gurwitz, JH; Gore, JM; Goldberg, RJ; Rubison, M; Chandra, N; Rogers, WJ			Recent age-related trends in the use of thrombolytic therapy in patients who have had acute myocardial infarction	ANNALS OF INTERNAL MEDICINE			English	Article							ELDERLY PATIENTS; MORTALITY; PROGNOSIS; OUTCOMES; WOMEN; CARE	Objective: To examine recent trends in the use of thrombolytic therapy in elderly patients who have had acute myocardial infarction and to determine whether failure to meet time-to-hospital presentation and electrocardiographic criteria might explain age-related differences in the use of thrombolytic therapy. Design: A national registry of patients who have had acute myocardial infarction. Setting: 1249 U.S. hospitals. Patients: 350 755 patients who had an acute myocardial infarction from 1 July 1990 to 30 September 1994. Measurements: Trends in the proportions of patients who received thrombolytic therapy were examined according to age and sex. The association between age and treatment with a thrombolytic agent was determined by crude and multivariable-adjusted analyses. Results: Use of a thrombolytic agent was inversely related to patient age: Almost 51% of patients younger than age 55 years received a thrombolytic agent during hospitalization for acute myocardial infarction; this proportion decreased to 43.6% for patients aged 55 to 64 years, 33.0% for those aged 65 to 74 years, 19.0% for those aged 75 to 84 years, and 7.4% for those aged 85 years or older. However, relative increases in the use of thrombolytic therapy over time were greatest for patients in the oldest age groups. Between 1 July 1990 and 30 June 1991, 16.0% of patients aged 75 to 84 years received a thrombolytic agent compared with 21.4% between 1 June 1993 and 30 September 1994 (a 33.8% relative increase in use). Among persons aged 85 years or older, the proportion of treated patients increased from 5.3% to 9.1% over this same period (a 71.7% relative increase in use). Increases in thrombolytic use were most prominent for older women. After adjustment for sex, diagnosis by initial electrocardiogram, electrocardiogram-based infarction description, time from symptom onset to hospital presentation, and period of the acute myocardial infarction, the odds of receiving a thrombolytic agent were significantly reduced for patients in the older age groups compared with the odds for patients younger than age 55 years (for patients aged 75 to 84 years, the adjusted odds ratio was 0.27 [95% CI, 0.26 to 0.28]; for patients aged 85 years or older, the odds ratio was 0.09 [CI, 0.08 to 0.10]). Conclusions: Although older patients who have had acute myocardial infarction less commonly receive a thrombolytic agent, use of thrombolytic therapy in this population is expanding. However, substantial differences across age groups persist in the likelihood of receiving treatment, even after adjustment for potentially confounding factors. Age-related differences in thrombolytic use may not be completely explained by the degree to which older patients do not meet conventional eligibility criteria for thrombolytic therapy.	UNIV MASSACHUSETTS, MED CTR, DEPT MED, WORCESTER, MA 01655 USA; CLINTRIALS RES INC, LEXINGTON, KY 40504 USA; JOHNS HOPKINS UNIV, BAYVIEW MED CTR, DIV CARDIOL, BALTIMORE, MD 21224 USA; UNIV ALABAMA, MED CTR, BIRMINGHAM, AL 35294 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; UNIV MASSACHUSETTS, SCH MED, WORCESTER, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; Johns Hopkins University; University of Alabama System; University of Alabama Birmingham; Harvard University; Harvard Medical School; University of Massachusetts System; University of Massachusetts Worcester	Gurwitz, JH (corresponding author), BRIGHAM & WOMENS HOSP, PROGRAM ANAL CLIN STRATEGIES, 221 LONGWOOD AVE, SUITE 341, BOSTON, MA 02115 USA.				NIA NIH HHS [K08 AG00510] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [K08AG000510] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], 1986, LANCET, V1, P397; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; AYANIAN JZ, 1994, NEW ENGL J MED, V331, P1136, DOI 10.1056/NEJM199410273311707; CHAMBERLAIN DA, 1988, LANCET, V1, P545; ELLERBECK EF, 1995, JAMA-J AM MED ASSOC, V273, P1509, DOI 10.1001/jama.273.19.1509; GOLDBERG RJ, 1992, AM J CARDIOL, V70, P421, DOI 10.1016/0002-9149(92)91183-5; Gunnar R M, 1990, Circulation, V82, P664; GUNNAR RM, 1990, J AM COLL CARDIOL, V16, P249, DOI 10.1016/0735-1097(90)90575-A; GURWITZ JH, 1991, JAMA-J AM MED ASSOC, V265, P1720, DOI 10.1001/jama.265.13.1720; GURWITZ JH, 1992, JAMA-J AM MED ASSOC, V268, P1417, DOI 10.1001/jama.1992.03490110055029; GURWITZ JH, 1992, AM J MED, V93, P605, DOI 10.1016/0002-9343(92)90192-E; GURWITZ JH, 1994, ARCH INTERN MED, V154, P2202; GURWITZ JH, 1993, INCLUSION ELDERLY IN, P205; KANNEL WB, 1984, NEW ENGL J MED, V311, P1144, DOI 10.1056/NEJM198411013111802; KLINKENBERGKNOL EC, 1987, LANCET, V1, P349; KRUMHOLZ HM, 1994, J AM GERIATR SOC, V42, P127, DOI 10.1111/j.1532-5415.1994.tb04938.x; KRUMHOLZ HM, 1992, NEW ENGL J MED, V327, P7, DOI 10.1056/NEJM199207023270102; MAGGIONI AP, 1993, NEW ENGL J MED, V329, P1442, DOI 10.1056/NEJM199311113292002; MEDALIE JH, 1976, ANN INTERN MED, V84, P526, DOI 10.7326/0003-4819-84-5-526; MEEHAN TP, 1995, ANN INTERN MED, V122, P928, DOI 10.7326/0003-4819-122-12-199506150-00007; NADELMANN J, 1990, AM J CARDIOL, V66, P533, DOI 10.1016/0002-9149(90)90477-I; PASHOS CL, 1993, JAMA-J AM MED ASSOC, V270, P1832, DOI 10.1001/jama.270.15.1832; PASHOS CL, 1994, J AM COLL CARDIOL, V23, P1023, DOI 10.1016/0735-1097(94)90585-1; PFEFFER MA, 1991, JAMA-J AM MED ASSOC, V266, P528, DOI 10.1001/jama.266.4.528; ROGERS WJ, 1994, CIRCULATION, V90, P2103, DOI 10.1161/01.CIR.90.4.2103; ROGERS WJ, 1995, AM J MED, V99, P195, DOI 10.1016/S0002-9343(99)80140-5; SIGURDSSON E, 1995, ANN INTERN MED, V122, P96, DOI 10.7326/0003-4819-122-2-199501150-00003; SIMOONS ML, 1993, LANCET, V342, P1523, DOI 10.1016/S0140-6736(05)80089-3; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; TOPOL EJ, 1992, NEW ENGL J MED, V327, P45, DOI 10.1056/NEJM199207023270109; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; WALKER SH, 1967, BIOMETRIKA, V54, P167, DOI 10.2307/2333860; WEAVER WD, 1991, J AM COLL CARDIOL, V18, P657, DOI 10.1016/0735-1097(91)90784-7; WENGER NK, 1993, NEW ENGL J MED, V329, P247, DOI 10.1056/NEJM199307223290406; WILCOX RG, 1988, LANCET, V2, P525; YARZEBSKI J, 1994, AM HEART J, V128, P255, DOI 10.1016/0002-8703(94)90477-4; 1992, CARDIOLOGY, V21, P5	37	118	121	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1996	124	3					283	+		10.7326/0003-4819-124-3-199602010-00001	http://dx.doi.org/10.7326/0003-4819-124-3-199602010-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TR596	8554222				2023-01-03	WOS:A1996TR59600001
J	Palevsky, PM; Bhagrath, R; Greenberg, A				Palevsky, PM; Bhagrath, R; Greenberg, A			Hypernatremia in hospitalized patients	ANNALS OF INTERNAL MEDICINE			English	Article						hypernatremia; hospitalization; sodium; fluid therapy; water-electrolyte balance	HYPONATREMIA; DEHYDRATION	Objective: To determine the incidence, clinical characteristics, and outcome for general medical-surgical hospital patients with hypernatremia. Design: A prospective cohort study. Setting: A 942-bed urban university hospital. Patients: All patients who developed a serum sodium concentration of 150 mmol/L or greater during a 3-month observation period. Measurements: Daily fluid balance, mental status, and serum and urine electrolytes and osmolality. Results: 103 patients were identified. Eighteen patients were hypernatremic on hospital admission, and 85 developed hypernatremia during hospitalization. Patients who developed hypernatremia during hospitalization were younger than patients who developed hypernatremia before hospital admission (mean age +/- SD, 58.9 +/- 19.2 years compared with 76.6 +/- 16.6 years; P < 0.01) but did not differ in age from the patients of the general hospitalized population. Eighty-nine percent of patients who developed hypernatremia during hospitalization had urine concentrating defects, primarily as the result of the use of diuretics or of solute diuresis, whereas only 50% of patients who were hypernatremic on admission could be shown to have concentrating defects (P < 0.01). Fifty-five percent of all hypernatremic patients had increased insensible water losses, and 35% had increased enteral water losses. Eighty-six percent of patients with hospital-acquired hypernatremia lacked free access to water, 74% had enteral water intake of less than 1 L/d, and 94% received less than 1 L of intravenous electrolyte-free water per day during the development of hypernatremia. No supplemental electrolyte-free water was prescribed during the first 24 hours of hypernatremia in 49% of patients. The duration of hypernatremia was shorter in patients who were hypernatremic on admission (median duration, 3 days) than in patients with hospital-acquired hypernatremia (median duration, 5 days; P < 0.05). Mortality was 41% for all patients, but hypernatremia was judged to have contributed to mortality in only 16% of patients. Conclusions: Although the development of hypernatremia before hospital admission occurs primarily in geriatric patients, hospital-acquired hypernatremia was more common in our cohort and had an age distribution similar to that of the general hospitalized population. Hospital-acquired hypernatremia was primarily iatrogenic, resulting from inadequate and inappropriate prescription of fluids to patients with predictably increased water losses and impaired thirst or restricted free water intake or both. Treatment of hypernatremia is often inadequate or delayed. Efforts to manage hypernatremia better and altogether avoid hospital-acquired hypernatremia should focus on both physician education and the development of hospital systems to prevent errors in fluid prescription.	VET AFFAIRS MED CTR, MED SERV, PITTSBURGH, PA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA)	Palevsky, PM (corresponding author), UNIV PITTSBURGH, SCH MED, DIV RENAL ELECTROLYTE, A919 SCAIFE HALL, 3550 TERRACE ST, PITTSBURGH, PA 15261 USA.		Palevsky, Paul M./Q-1491-2019	Palevsky, Paul M./0000-0002-7334-5400; Greenberg, Arthur/0000-0002-2838-8401				ANDERSON RJ, 1985, ANN INTERN MED, V102, P164, DOI 10.7326/0003-4819-102-2-164; BECK LH, 1987, ANN INTERN MED, V107, P768, DOI 10.7326/0003-4819-107-5-768; BRENNAN J, 1990, J CRIT ILLNESS, V5, P330; DAGGETT P, 1979, BRIT MED J, V1, P1177, DOI 10.1136/bmj.1.6172.1177; FITZSIMONS JT, 1976, KIDNEY INT, V10, P3, DOI 10.1038/ki.1976.74; GULLANS SR, 1993, ANNU REV MED, V44, P289, DOI 10.1146/annurev.me.44.020193.001445; HIMMELSTEIN DU, 1983, J AM GERIATR SOC, V31, P466, DOI 10.1111/j.1532-5415.1983.tb05118.x; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; LONG CA, 1991, POSTGRAD MED J, V67, P643, DOI 10.1136/pgmj.67.789.643; MACDONALD NJ, 1989, BRIT MED J, V299, P1426, DOI 10.1136/bmj.299.6713.1426; MAHOWALD JM, 1981, J AM GERIATR SOC, V29, P177, DOI 10.1111/j.1532-5415.1981.tb01761.x; PALEVSKY PM, 1992, CURRENT THERAPY NEPH; Plum F, 1966, DIAGNOSIS STUPOR COM; SNYDER NA, 1987, ANN INTERN MED, V107, P309, DOI 10.7326/0003-4819-107-2-309; TIERNEY WM, 1986, J GEN INTERN MED, V1, P380, DOI 10.1007/BF02596422	16	212	227	0	15	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1996	124	2					197	+		10.7326/0003-4819-124-2-199601150-00002	http://dx.doi.org/10.7326/0003-4819-124-2-199601150-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ016	8533994				2023-01-03	WOS:A1996TQ01600002
J	KUNG, C; HAYES, E; MANN, KG				KUNG, C; HAYES, E; MANN, KG			A MEMBRANE-MEDIATED CATALYTIC EVENT IN PROTHROMBIN ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE FACTOR-V; GAMMA-CARBOXYGLUTAMIC ACID; COAGULATION FACTOR VA; PHOSPHOLIPID-VESICLES; PHASE-TRANSITIONS; ACTIVE-SITE; FACTOR-XA; PHOSPHATIDYLCHOLINE LIPOSOMES; FLUORESCENCE DEPOLARIZATION; COFACTOR DEPENDENCE	Prothrombinase assembly takes place on the surface of unsaturated phosphatidylcholine (PC), phosphatidyl-serine (PS) membranes in the presence of Ca2+, through the rapid association of membrane-bound factor Va and factor Xa. The present study uses saturated PCPS (75:25, w/w) vesicles to study prothrombinase assembly and catalytic properties in order to differentiate the influences of the membrane upon catalyst assembly, substrate delivery, and peptide bond cleavage. In contrast to studies using unsaturated phospholipid, prothrombin activation studies using saturated PCPS (75:25, w/w) (C14:0, C16:0, and C18:0) revealed up to a 20-fold decrease in prothrombinase activity. C18:0 membranes support at least 50% of the prothrombinase binding capacity (K-dVa-Xa = 1 nM and n(Va-Xa) = 1.1) of C18:1 PCPS (75:25, w/w). Thus, the 95% loss in activity cannot be explained by gross alterations in catalyst concentration or assembly. Stopped-flow studies with saturated lipids demonstrate that factor Va, factor Xa, and prothrombin have decreased k(on) values. Compensatory changes in k(off) leave the K-d values for these protein-lipid interactions almost unchanged relative to unsaturated PCPS. The profoundly decreased activation rate on saturated phospholipid membranes as compared to unsaturated phospholipids is in part due to slowed substrate/enzyme delivery caused by the saturated lipids. However, studies using prethrombin-1 and C18:0 PCPS (75:25, w/w) also revealed a 15-fold decrease in activity for preassembled prothrombinase. Although there was a slight change in K-m (+2-fold), the major cause of the decrease is an 18-fold decrease in k(cat). Similar differences for K-m and k(cat) values were obtained for prothrombin. Substrate delivery is thus only partially responsible for the diminished prothrombinase activity observed with saturated phospholipids. Since the activity of prothrombinase is decreased for both prothrombin and, prethrombin-1 principally by reducing k(cat), it appears that catalyst formation on saturated phospholipids somehow compromises the proteolytic activity of the enzyme complex. This implies that the phospholipid bilayer serves not merely as a surface for condensing the proteins but also as a functional element of the prothrombinase enzyme.	UNIV VERMONT,COLL MED,DEPT BIOCHEM,BURLINGTON,VT 05405	University of Vermont					NHLBI NIH HHS [P01HL46703] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046703] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLOOM JW, 1979, BIOCHEMISTRY-US, V18, P4419, DOI 10.1021/bi00587a023; BUTENAS S, 1992, BIOCHEMISTRY-US, V31, P5399, DOI 10.1021/bi00138a023; COOPER RA, 1978, BIOCHEMISTRY-US, V17, P327, DOI 10.1021/bi00595a021; CUTSFORTH GA, 1989, BIOCHEMISTRY-US, V28, P7453, DOI 10.1021/bi00444a045; CUTSFORTH GA, 1991, THROMB HAEMOSTASIS, V65, P8582; DOMBROSE FA, 1979, J BIOL CHEM, V254, P5027; Fersht A., 1985, ENZYME STRUCTURE MEC; GERADS I, 1990, BIOCHEMISTRY-US, V29, P7967, DOI 10.1021/bi00486a027; GIESEN PLA, 1991, J BIOL CHEM, V266, P1379; Gomori G, 1942, J LAB CLIN MED, V27, P955; GOVERSRIEMSLAG JWP, 1992, BIOCHEMISTRY-US, V31, P10000, DOI 10.1021/bi00156a020; HIGGINS DL, 1983, J BIOL CHEM, V258, P6503; HIGGINS DL, 1985, J BIOL CHEM, V260, P3604; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; ISAACS BS, 1986, BIOCHEMISTRY-US, V25, P4958, DOI 10.1021/bi00365a036; Jesty J, 1976, Methods Enzymol, V45, P95; JONES ME, 1985, THROMB RES, V39, P711, DOI 10.1016/0049-3848(85)90255-5; JONES ME, 1986, BIOCHEMISTRY-US, V25, P567, DOI 10.1021/bi00351a009; KALAFATIS M, 1994, BIOCHEMISTRY-US, V33, P486, DOI 10.1021/bi00168a013; KALAFATIS M, 1990, J BIOL CHEM, V265, P21580; KRIEG UC, 1987, BIOCHEMISTRY-US, V26, P103, DOI 10.1021/bi00375a015; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P9684; KRISHNASWAMY S, 1993, METHOD ENZYMOL, V222, P260; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P5714; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3708; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P3823; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPE PD, 1984, J BIOL CHEM, V259, P9959; LAWSON JH, 1992, J BIOL CHEM, V267, P4834; LECOMPTE MF, 1987, J BIOL CHEM, V262, P1935; LECOMPTE MF, 1994, J BIOL CHEM, V269, P1905; LENTZ BR, 1976, BIOCHEMISTRY-US, V15, P4529, DOI 10.1021/bi00665a030; LENTZ BR, 1976, BIOCHEMISTRY-US, V15, P4521, DOI 10.1021/bi00665a029; LENTZ BR, 1989, BIOCHEMISTRY-US, V28, P7459; MALHOTRA OP, 1985, J BIOL CHEM, V260, P279; Mann K G, 1976, Methods Enzymol, V45, P123; MANN KG, 1981, METHOD ENZYMOL, V80, P286; MANN KG, 1990, BLOOD, V76, P1; MANN KG, 1992, SEMIN HEMATOL, V29, P213; MANN KG, 1990, BLOOD, V76, P755; MANN KG, 1987, PROTEASES BIOL CONTR, P235; MAYER LD, 1983, BIOCHIM BIOPHYS ACTA, V734, P48, DOI 10.1016/0005-2736(83)90073-1; NELSESTUEN GL, 1976, J BIOL CHEM, V251, P5648; NESHEIM ME, 1981, J BIOL CHEM, V256, P6537; NESHEIM ME, 1984, J BIOL CHEM, V259, P1447; NESHEIM ME, 1983, J BIOL CHEM, V258, P5386; ODEGAARD BH, 1987, J BIOL CHEM, V262, P11237; ORTEL TL, 1992, J BIOL CHEM, V267, P4189; PEI G, 1993, J BIOL CHEM, V268, P3226; ROSING J, 1988, BIOCHEMISTRY-US, V27, P8, DOI 10.1021/bi00401a002; ROSING J, 1988, BIOCHEMISTRY-US, V27, P9048, DOI 10.1021/bi00425a025; ROSING J, 1993, J BIOL CHEM, V268, P21130; SEELIG A, 1977, BIOCHEMISTRY-US, V16, P45, DOI 10.1021/bi00620a008; Shattil S J, 1978, Prog Hemost Thromb, V4, P59; STUBBS CD, 1983, ESSAYS BIOCHEM, V19, P1; TANS G, 1979, EUR J BIOCHEM, V95, P449, DOI 10.1111/j.1432-1033.1979.tb12984.x; TENDIAN SW, 1990, BIOCHEMISTRY-US, V29, P6720, DOI 10.1021/bi00480a023; TOWBIN H, 1979, P NATL ACAD SCI USA, V19, P665; TRACY PB, 1986, BIOCH PLATELETS, P295; WALKER RK, 1993, J BIOL CHEM, V268, P13920; WEI GJ, 1982, BIOCHEMISTRY-US, V21, P1949, DOI 10.1021/bi00537a039; WILLIAMS EB, 1989, J BIOL CHEM, V264, P7536; WILLIAMS EB, 1993, METHOD ENZYMOL, V222, P503; WU JR, 1991, BIOPHYS J, V60, P70, DOI 10.1016/S0006-3495(91)82031-8	65	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25838	25848						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929289				2023-01-03	WOS:A1994PQ49100089
J	SCHIFFL, H; LANG, SM; KONIG, A; STRASSER, T; HAIDER, MC; HELD, E				SCHIFFL, H; LANG, SM; KONIG, A; STRASSER, T; HAIDER, MC; HELD, E			BIOCOMPATIBLE MEMBRANES IN ACUTE-RENAL-FAILURE - PROSPECTIVE CASE-CONTROLLED STUDY	LANCET			English	Article							INTENSIVE-CARE UNIT; LEUKOTRIENE-B4; ACTIVATION; COMPLEMENT; DIALYSIS	The mortality of critically ill patients with acute renal failure has been halved through intervention by haemodialysis. However, several reports suggest that the course df the disorder may be prolonged by this procedure. Our prospective randomised study was done to see whether the generation of inflammatory mediators by bio-incompatible membranes has an adverse effect on the outcome of acute renal failure. 52 patients, similar in age, severity of acute renal failure, general disease status (APACHE II),and management of acute renal failure or its related conditions, were divided into two groups. Haemodialysis was done with cuprophane or polyacrylonitrile membranes. Cuprophane membranes induced intense activation of the complement system (as judged by measurement of C3a) and lipooxygenase pathway (leukotriene 84) resulting in alterations of neutrophil kinetics and function. The cuprophane group had a lower survival rate (38 vs 65%), a higher proportion of patients dying from sepsis (71 vs 40%), required more haemodialysis sessions (12 vs 9), and demonstrated delayed resolution and recovery from acute renal failure than the polyacrylonitrile group. The difference in mortality regarding lethal sepsis as cause of death was statistically significant. Our observations indicate that the outcome of critically ill patients with acute renal failure may be influenced by bio-incompatibility reactions to the dialysis membrane. These results have direct implications for such patients on haemodialysis.			SCHIFFL, H (corresponding author), UNIV MUNICH, KLINIKUM INNENSTADT, MED KLIN, ZIEMSSENSTR 1, D-80336 MUNICH, GERMANY.							ASAD SN, 1987, BLOOD PURIFICATION P, P54; BADR K, 1992, KIDNEY INT       S38, V421, pS101; BLAGG CR, 1983, REPLACEMENT RENAL FU, P611; CAMERON JS, 1986, INTENS CARE MED, V12, P64; CHENOWETH D E, 1986, Complement, V3, P152; CONGER JD, 1990, SEMIN DIALYSIS, V3, P146, DOI 10.1111/j.1525-139X.1990.tb00031.x; CORWIN HL, 1988, INTENS CARE MED, V14, P86; Dinarello C A, 1988, Kidney Int Suppl, V24, pS21; HIMMELFARB J, 1991, AM J KIDNEY DIS, V17, P271, DOI 10.1016/S0272-6386(12)80473-2; IVANOVICH P, 1983, KIDNEY INT, V24, P758, DOI 10.1038/ki.1983.224; Johnson K J, 1993, Curr Opin Nephrol Hypertens, V2, P625, DOI 10.1097/00041552-199307000-00014; KENNEDY AC, 1973, Q J MED, V42, P73; KJELLSTRAND CM, 1981, T AM SOC ART INT ORG, V27, P45; KLAUSNER JM, 1989, AM J PHYSIOL, V256, pF794, DOI 10.1152/ajprenal.1989.256.5.F794; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LEVIN N W, 1991, Journal of the American Society of Nephrology, V2, P335; MYERS BD, 1986, NEW ENGL J MED, V314, P97; NATH KA, 1992, KIDNEY INT, V42, pS109; SCHULMAN G, 1991, KIDNEY INT, V40, P1069, DOI 10.1038/ki.1991.316; SOLEZ K, 1979, MEDICINE, V58, P362, DOI 10.1097/00005792-197909000-00003; STRASSER T, 1991, KLIN WOCHENSCHR, V69, P808, DOI 10.1007/BF01744274; STRASSER T, 1990, BIOCHIM BIOPHYS ACTA, V1046, P326, DOI 10.1016/0005-2760(90)90249-W; TURNEY JH, 1992, ADV RENAL MED, P314; VANHOLDER R, 1993, NEPHRON, V63, P409, DOI 10.1159/000187244	24	278	283	1	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 27	1994	344	8922					570	572		10.1016/S0140-6736(94)91964-X	http://dx.doi.org/10.1016/S0140-6736(94)91964-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD424	7914959				2023-01-03	WOS:A1994PD42400008
J	VELDE, ERT; VANLEUSDEN, HAIM				VELDE, ERT; VANLEUSDEN, HAIM			HORMONAL TREATMENT FOR THE CLIMACTERIC - ALLEVIATION OF SYMPTOMS AND PREVENTION OF POSTMENOPAUSAL DISEASE	LANCET			English	Article							ESTROGEN REPLACEMENT THERAPY; BREAST-CANCER; PROGESTOGEN REPLACEMENT; TRANSDERMAL ESTRADIOL; RISK-FACTORS; WOMEN		RIJNSTATE EG HOSP, DEPT OBSTET & GYNAECOL, 6800 EK ARNHEM, NETHERLANDS	Rijnstate Hospital	VELDE, ERT (corresponding author), UNIV HOSP UTRECHT, DEPT OBSTET & GYNAECOL, POB 85500, 3508 GA UTRECHT, NETHERLANDS.							BARLOW DH, 1991, BR MED B, V48, P356; BARRETTCONNOR E, 1992, BRIT MED BULL, V48, P345, DOI 10.1093/oxfordjournals.bmb.a072550; BARRETTCONNOR E, 1989, JAMA-J AM MED ASSOC, V261, P2095, DOI 10.1001/jama.261.14.2095; BARRETTCONNOR E, 1991, ANN INTERN MED, V115, P455, DOI 10.7326/0003-4819-115-6-455; BERGKVIST L, 1988, INT J EPIDEMIOL, V17, P732, DOI 10.1093/ije/17.4.732; CAMPBELL S, 1977, CLIN OBSTET GYNAECOL, V4, P31; CAULEY JA, 1990, AM J OBSTET GYNECOL, V163, P1438, DOI 10.1016/0002-9378(90)90602-4; FELSON DT, 1993, NEW ENGL J MED, V329, P1141, DOI 10.1056/NEJM199310143291601; FURUHJELM M, 1984, ACTA OBSTET GYN SCAN, V63, P655, DOI 10.3109/00016348409155556; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GRADY D, 1992, ANN INTERN MED, V117, P1038; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; HILLARD TC, 1992, FERTIL STERIL, V58, P959; JUDD HL, 1987, MENOPAUSE PHYSL PHAR, P327; KEY TJA, 1988, EUR J CANCER CLIN ON, V24, P29, DOI 10.1016/0277-5379(88)90173-3; KUHL H, 1990, MATURITAS, V12, P171, DOI 10.1016/0378-5122(90)90003-O; LAW MR, 1991, BMJ-BRIT MED J, V303, P453, DOI 10.1136/bmj.303.6800.453; LEATHER AT, 1991, OBSTET GYNECOL, V78, P1008; LEE SJ, 1988, HUM REPROD, V3, P851, DOI 10.1093/oxfordjournals.humrep.a136796; OLDENHAVE A, 1977, AM J OBSTET GYNECOL, V4, P31; PADWICK ML, 1986, NEW ENGL J MED, V315, P930, DOI 10.1056/NEJM198610093151504; PERSSON I, 1992, LANCET, V340, P1044, DOI 10.1016/0140-6736(92)93064-T; RAZ R, 1993, NEW ENGL J MED, V329, P753, DOI 10.1056/NEJM199309093291102; RIJPKEMA AHM, 1990, MATURITAS, V12, P259, DOI 10.1016/0378-5122(90)90007-S; SPEROFF L, 1992, BR MED B, V48, P426; STEINBERG KK, 1991, JAMA-J AM MED ASSOC, V265, P1985, DOI 10.1001/jama.265.15.1985; STEINGOLD KA, 1991, J CLIN ENDOCR METAB, V73, P275, DOI 10.1210/jcem-73-2-275; TEVELDE ER, 1993, LANCET, V341, P1125, DOI 10.1016/0140-6736(93)93133-L; TRELOAR AE, 1967, INT J FERTIL, V12, P77; TZIGOUNIS VA, 1980, ACTA ENDOCR-COP    S, V233, P45; VANERPECUM KJ, 1991, GASTROENTEROLOGY, V100, P482, DOI 10.1016/0016-5085(91)90220-F; Wren BG, 1988, MENOPAUSE, P181	32	28	30	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 12	1994	343	8898					654	658		10.1016/S0140-6736(94)92642-5	http://dx.doi.org/10.1016/S0140-6736(94)92642-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA093	7906817				2023-01-03	WOS:A1994NA09300015
J	IFUDU, O; MAYERS, J; MATTHEW, J; TAN, CC; CAMBRIDGE, A; FRIEDMAN, EA				IFUDU, O; MAYERS, J; MATTHEW, J; TAN, CC; CAMBRIDGE, A; FRIEDMAN, EA			DISMAL REHABILITATION IN GERIATRIC INNER-CITY HEMODIALYSIS-PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							STAGE RENAL-DISEASE; RECOMBINANT HUMAN ERYTHROPOIETIN; FUNCTIONAL STATUS; CLINICAL-TRIAL; DIALYSIS; LIFE; MORTALITY; SURVIVAL; THERAPY; QUALITY	Objective.-To assess the extent of functional and vocational rehabilitation achieved by elderly inner-city patients sustained on maintenance hemodialysis. Design.-Inception cohort study of elderly patients who have end-stage renal disease using a modified Karnofsky rating system. The need for a wheelchair, participation in household activities, and effect of comorbid conditions were noted. Current status was compared with patient's recollection of functional activity level 2 years before commencing maintenance hemodialysis. Setting.-Seven outpatient, hospital-affiliated and private hemodialysis units in Brooklyn, NY. Patients.-One hundred four patients aged 65 years or older who were receiving maintenance hemodialysis for at least 6 months. Main Outcome Measures.-A score of 76 or greater on a modified Karnofsky scale indicated independent function at a level that permitted participation in activities beyond those mandated by the hemodialysis regimen. A comorbidity score 6 or greater on a newly constructed index correlated with severe debility. Employment status was also recorded. Results.-Present functional activity had deteriorated to a modified Karnofsky score of 66+/-12.3 (+/-SD) compared with patients' recollection of a mean score of 84+/-14.3 (P<.001) 2 years before initiation of hemodialysis. Diabetic patients had a lower score than nondiabetic patients. The mean comorbidity index of the entire study group was 7.8+/-2.9 (mean+/-SD). Within the diabetic subset, severe debility constrained 71 patients (68%) to limit all activity to their residence with the exception of travel to and from their dialysis facility. By contrast, 2 years prior to commencing dialytic therapy, 81 diabetic patients (78%) had interests and activities that took them outside their homes (P<.001). Generalized weakness was the most common explanation given for the lack of outside activity by nine patients (9%) who were wheelchair bound. Erythropoietin, though regularly administered to 87 patients (84%) in the study group, was unsuccessful in raising mean hematocrit reading above 0.28+/-0.05 (mean+/-SD). Conclusions.-Maintenance hemodialysis does not return inner-city elderly patients to their predialysis level of functioning. Few elderly, diabetic hemodialysis patients conduct any substantive portion of their lives outside their homes. For nondiabetic patients, the modified Karnofsky score of whites (70.4+/-11.9) and blacks (66.5+/-15.3), though low, was equivalent (P<.4).			IFUDU, O (corresponding author), SUNY HLTH SCI CTR,DEPT MED,DIV RENAL DIS,BOX 52,450 CLARKSON AVE,BROOKLYN,NY 11203, USA.							AVRAM MR, 1991, AM J KIDNEY DIS, V26, P342; BONNEY S, 1978, ARCH INTERN MED, V138, P1510, DOI 10.1001/archinte.138.10.1510; BRANCHE GC, 1991, AM J MED, V91, P37; CANTOR M, 1976, GERONTOLOGIST, V16, P17, DOI 10.1093/geront/16.1_Part_1.17; CARDENAS DD, 1982, NEPHRON, V62, P626; CARLSON DM, 1987, MAYO CLIN PROC, V62, P338, DOI 10.1016/S0025-6196(12)65436-6; CHESTER AC, 1979, ARCH INTERN MED, V139, P1001, DOI 10.1001/archinte.139.9.1001; EASTERLING RE, 1977, T AM SOC ART INT ORG, V23, P28; Eggers P W, 1984, Health Care Financ Rev, V5, P69; EGGERS PW, 1990, AM J KIDNEY DIS, V15, P414, DOI 10.1016/S0272-6386(12)70359-1; ESCHBACH JW, 1987, NEW ENGL J MED, V316, P73, DOI 10.1056/NEJM198701083160203; ESCHBACH JW, 1989, ANN INTERN MED, V111, P992, DOI 10.7326/0003-4819-111-12-992; EVANS RW, 1985, NEW ENGL J MED, V312, P553, DOI 10.1056/NEJM198502283120905; FRANCIS CK, 1990, AM J MED, V91, P29; GILLUM RF, 1974, JAMA-J AM MED ASSOC, V228, P1563; GUTMAN RA, 1988, ANN INTERN MED, V108, P898, DOI 10.7326/0003-4819-108-6-898; GUTMAN RA, 1981, NEW ENGL J MED, V304, P309, DOI 10.1056/NEJM198102053040601; GUTMAN RA, 1978, POSTGRAD MED, V64, P183, DOI 10.1080/00325481.1978.11714980; HELD PJ, 1987, JAMA-J AM MED ASSOC, V257, P645, DOI 10.1001/jama.257.5.645; HUTCHINSON TA, 1979, J CHRON DIS, V32, P661, DOI 10.1016/0021-9681(79)90096-1; IGLEHART JK, 1993, NEW ENGL J MED, V328, P366, DOI 10.1056/NEJM199302043280528; JULIUS M, 1989, AM J KIDNEY DIS, V13, P61, DOI 10.1016/S0272-6386(89)80118-0; Karnofsky DA, 1949, CLIN EVALUATION CHEM, P191; KRAUS JF, 1980, AM J EPIDEMIOL, V111, P407, DOI 10.1093/oxfordjournals.aje.a112915; LOWRIE EG, 1990, AM J KIDNEY DIS, V15, P458, DOI 10.1016/S0272-6386(12)70364-5; MCCLELLAN WM, 1991, J CLIN EPIDEMIOL, V44, P83, DOI 10.1016/0895-4356(91)90204-M; MCKEVITT PM, 1990, AJKD, V26, P346; NEU S, 1986, NEW ENGL J MED, V314, P14, DOI 10.1056/NEJM198601023140103; PORT FK, 1989, AM J NEPHROL, V9, P145, DOI 10.1159/000167954; PRETCHERS MK, 1988, GERONTOLOGIST, V28, P213; REUBEN DB, 1992, AM J MED, V93, P663, DOI 10.1016/0002-9343(92)90200-U; RICHARDSON YW, 1987, TRANSPLANT P, V19, P111; ROSTAND SG, 1982, NEW ENGL J MED, V306, P1276, DOI 10.1056/NEJM198205273062106; SHAPIRO FL, 1983, AM SOC ARTIF INT ORG, V6, P176; SHIDEMAN JR, 1976, ARCH INTERN MED, V136, P1126, DOI 10.1001/archinte.136.10.1126; Uva J L, 1990, JAMA, V263, P139, DOI 10.1001/jama.263.1.135; WESTLIE L, 1984, T AM SOC ART INT ORG, V30, P21; WRIGHT LF, 1991, AM J KIDNEY DIS, V17, P25, DOI 10.1016/S0272-6386(12)80245-9; 1990, USRDS NIH1990 NAT I	39	89	91	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	1994	271	1					29	33		10.1001/jama.271.1.29	http://dx.doi.org/10.1001/jama.271.1.29			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN725	8258883				2023-01-03	WOS:A1994MN72500026
J	ADAMS, WL; YUAN, Z; BARBORIAK, JJ; RIMM, AA				ADAMS, WL; YUAN, Z; BARBORIAK, JJ; RIMM, AA			ALCOHOL-RELATED HOSPITALIZATIONS OF ELDERLY PEOPLE - PREVALENCE AND GEOGRAPHIC-VARIATION IN THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICARE PATIENTS; CONSUMPTION; DRINKERS; DRINKING; ABUSE; AGE	Objective.- To determine the prevalence, geographic variation, and charges to Medicare of alcohol-related hospitalizations among elderly people in the United States. Design.- A cross-sectional prevalence study using 1989 hospital claims data from the Health Care Financing Administration (HCFA). Rates were determined using (1) hospital claims records from the HCFA's Medicare Provider Analysis and Review Record (MEDPAR) database for all Medicare Part A beneficiaries aged 65 years and older, (2) county population estimates for 1985 from the Bureau of the Census; and (3) per capita consumption of alcohol by state in 1989 as estimated by the US Department of Health and Human Services. Setting.- Data include all hospital inpatient Medicare Part A beneficiaries aged 65 years and older in the United States in 1989. Results.- The prevalence of alcohol-related hospitalizations among people aged 65 years and older nationality in 1989 was 54.7 per 10 000 population for men and 14.8 per 10 000 for women. Comparison with hospital records showed that MEDPAR data had a sensitvity of 77% to detect alcohol-related hospitalizations. There was considerable geographic variation; prevalence ranged from 18.9 per 10 000 in Arkansas to 77.0 per 10 000 in Alaska. A strong correlation existed between alcohol-related hospitalizations and per capita consumption of alcohol by state (Spearman correlation coefficient, .64; P<.0001). In 1989, the hospital-associated charges to Medicare for all admissions where the primary diagnosis was alcohol related (N=33 039) totaled $233 543 500. Median charge per hospital stay was $4514. Conclusions.- Alcohol-related hospitalizations among elderly people are common; rates were similar to those for myocardial infarction as detected by the same method. The charges to Medicare for this preventable problem are considerable. Ecological analysis suggests that per capita consumption in the total US population predicts alcohol-related hospitalizations in the elderly population.	MED COLL WISCONSIN,DEPT MED,MILWAUKEE,WI 53226; MED COLL WISCONSIN,DEPT PHARMACOL,MILWAUKEE,WI 53226; MED COLL WISCONSIN,DIV BIOSTAT & CLIN EPIDEMIOL,MILWAUKEE,WI 53226	Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin								ADAMS WL, 1990, J AM GERIATR SOC, V38, P211, DOI 10.1111/j.1532-5415.1990.tb03493.x; BAILEY MB, 1965, Q J STUD ALCOHOL, V26, P19; BARNES GM, 1979, J AM GERIATR SOC, V27, P244, DOI 10.1111/j.1532-5415.1979.tb06125.x; BLAZER D, 1987, ARCH GEN PSYCHIAT, V44, P736; BRISTOW MF, 1992, BRIT J ADDICT, V87, P291; CAHALAN D, 1968, J STUD ALCOHOL, V29, P139; COULEHAN JL, 1987, ARCH INTERN MED, V147, P349, DOI 10.1001/archinte.147.2.349; CURTIS JR, 1989, J AM GERIATR SOC, V37, P310, DOI 10.1111/j.1532-5415.1989.tb05496.x; FISHER ES, 1990, AM J PUBLIC HEALTH, V80, P1487, DOI 10.2105/AJPH.80.12.1487; FISHER ES, 1992, AM J PUBLIC HEALTH, V82, P243, DOI 10.2105/AJPH.82.2.243; GLYNN RJ, 1985, AM J PUBLIC HEALTH, V75, P1413, DOI 10.2105/AJPH.75.12.1413; GOLDBERG KC, 1992, JAMA-J AM MED ASSOC, V267, P1473, DOI 10.1001/jama.267.11.1473; HSIA DC, 1988, NEW ENGL J MED, V318, P352, DOI 10.1056/NEJM198802113180604; Kirkpatrick B, 1988, Psychiatr Med, V6, P65; MANDERSCHEID RW, 1990, ADM901708 US DEP HLT; MANN RE, 1991, J STUD ALCOHOL, V52, P361, DOI 10.15288/jsa.1991.52.361; MCKIM WA, 1991, CAN J PUBLIC HEALTH, V82, P231; MEYERS A R, 1981, International Journal of Aging and Human Development, V14, P31, DOI 10.2190/XCDE-9EQY-5DNR-BUX7; Molgaard C A, 1990, J Community Health, V15, P239, DOI 10.1007/BF01350290; MOORE RD, 1986, J MED EDUC, V61, P46; MYERS JK, 1984, ARCH GEN PSYCHIAT, V41, P959; RUSH BR, 1986, J STUD ALCOHOL, V47, P1; SCHUCKIT MA, 1980, J CLIN PSYCHIAT, V41, P412; SMART RG, 1981, J PSYCHOACTIVE DRUGS, V13, P153, DOI 10.1080/02791072.1981.10524297; SMART RG, 1987, BRIT J ADDICT, V82, P285; STINSON FS, 1989, ALCOHOL HEALTH RES W, V13, P80; 1980, PHS801260 US DEP HLT; 1991, 20 US DEP HLTH HUM S; 1989, COUNTY POPULATION ES	29	172	173	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	1993	270	10					1222	1225		10.1001/jama.270.10.1222	http://dx.doi.org/10.1001/jama.270.10.1222			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LV649	8355385				2023-01-03	WOS:A1993LV64900028
J	CZEIZEL, AE				CZEIZEL, AE			PREVENTION OF CONGENITAL-ABNORMALITIES BY PERICONCEPTIONAL MULTIVITAMIN SUPPLEMENTATION	BRITISH MEDICAL JOURNAL			English	Article							NEURAL-TUBE DEFECTS; FOLATE METABOLISM; RECURRENCE	Objective-To study the effect of periconceptional multivitamin supplementation on neural tube defects and other congenital abnormality entities. Design-Randomised controlled trial of supplementation with multivitamins and trace elements. Setting-Hungarian family planning programme. Subjects-4156 pregnancies with known outcome and 3713 infants evaluated in the eighth month of life. Interventions-A single tablet of a multivitamin including 0.8 mg of folic acid or trace elements supplement daily for at least one month before conception and at least two months after conception. Main outcome measures-Number of major and mild congenital abnormalities. Results-The rate of all major congenital abnormalities was significantly lower in the group given vitamins than in the group given trace elements and this difference cannot be explained totally by the significant reduction of neural tube defects. The rate of major congenital abnormalities other than neural tube defects and genetic syndromes was 9.0/1000 in pregnancies with known outcome in the vitamin group and 16.6/1000 in the trace element group; relative risk 1.85 (95% confidence interval 1.02 to 3.38); difference, 7.6/1000. The rate of all major congenital abnormalities other than neural tube defects and genetic syndromes diagnosed up to the eighth month of life was 14.7/1000 informative pregnancies in the vitamin group and 28.3/1000 in the trace element group; relative risk 1.95 (1.23 to 3.09); difference, 13.6/1000. The rate of some congenital abnormalities was lower in the vitamin group than in the trace element group but the differences for each group of abnormalities were not significant. Conclusions-Periconceptional multivitamin supplementation can reduce not only the rate of neural tube defects but also the rate of other major non-genetic syndromatic congenital abnormalities. Further studies are needed to differentiate the chance effect and vitamin dependent effect.	WHO,COLLABORATING CTR COMMUNITY CONTROL HEREDITARY DIS,NATL INST HYG,DEPT HUMAN GENET & TERATOL,BUDAPEST,HUNGARY	World Health Organization								BAIRD CDC, 1954, CIRC RES, V2, P544, DOI 10.1161/01.RES.2.6.544; CZEIZEL A, 1970, BRIT J PREV SOC MED, V24, P205; CZEIZEL A, 1972, BRIT J PREV SOC MED, V26, P15; CZEIZEL A, 1988, J MED GENET, V25, P2, DOI 10.1136/jmg.25.1.2; CZEIZEL A E, 1992, Genetic Counseling, V3, P61; CZEIZEL AE, 1992, ARCH GYNECOL OBSTET, V251, P181, DOI 10.1007/BF02718384; CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; CZEIZEL AE, 1993, BRIT MED J, V306, P499, DOI 10.1136/bmj.306.6876.499; CZEIZEL AE, 1988, MULTIPLE CONGENITAL; ERBE RW, 1984, AM J MED GENET, V17, P277, DOI 10.1002/ajmg.1320170120; LAURENCE KM, 1981, BRIT MED J, V282, P1509, DOI 10.1136/bmj.282.6275.1509; LORBER J, 1984, BRIT MED J, V289, P281, DOI 10.1136/bmj.289.6440.281; MILUNSKY A, 1968, J PEDIATR-US, V72, P790, DOI 10.1016/S0022-3476(68)80430-5; MONIE IW, 1957, ANAT REC, V127, P711, DOI 10.1002/ar.1091270407; MONIE IW, 1963, ANAT REC, V147, P397, DOI 10.1002/ar.1091470311; NELSON MM, 1952, J NUTR, V48, P61, DOI 10.1093/jn/48.1.61; SMITHELLS RW, 1989, LANCET, V2, P498; SMITHELLS RW, 1980, LANCET, V1, P339; THIERSCH JB, 1952, AM J OBSTET GYNECOL, V63, P1298; TOLAROVA M, 1982, LANCET, V2, P217; YATES JRW, 1987, CLIN GENET, V31, P279; ZEIZEL A, 1974, BR J PREV SOC MED, V28, P265; 1991, LANCET, V338, P131	23	266	281	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 19	1993	306	6893					1645	1648		10.1136/bmj.306.6893.1645	http://dx.doi.org/10.1136/bmj.306.6893.1645			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ337	8324432	Green Published, Bronze			2023-01-03	WOS:A1993LJ33700018
J	HODES, RM				HODES, RM			A BIRTH IN TEDDA	ANNALS OF INTERNAL MEDICINE			English	Editorial Material						ATTITUDE TO DEATH; MIDWIFERY; DEVELOPING COUNTRIES; ETHIOPIA; PHYSICIANS ROLE		A Western physician in rural Ethiopia finds himself helpless when a local woman insists on delivering a baby her own way. A chicken and frankincense are used to ward off an evil spirit, and the woman delivers a discourse on her delivery techniques.			HODES, RM (corresponding author), AMER JOINT DISTRIBUT COMM, POB 7600, ADDIS ABABA, ETHIOPIA.								0	3	3	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1993	118	9					738	740		10.7326/0003-4819-118-9-199305010-00013	http://dx.doi.org/10.7326/0003-4819-118-9-199305010-00013			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY502	8460862				2023-01-03	WOS:A1993KY50200012
J	VANDENBROUCKEGRAULS, CMJE				VANDENBROUCKEGRAULS, CMJE			PNEUMONIA - TOWARDS BETTER PREVENTION OF PNEUMONIA IN THE INTENSIVE-CARE UNIT	LANCET			English	Editorial Material							RESPIRATORY-TRACT; DECONTAMINATION				VANDENBROUCKEGRAULS, CMJE (corresponding author), ACAD ZIEKENHUIS,DEPT CLIN MICROBIOL,UTRECHT,NETHERLANDS.		Vandenbroucke-Grauls, Christina/AAO-7953-2020	Vandenbroucke-Grauls, Christina/0000-0003-2074-1597				ATHERTON ST, 1978, LANCET, V2, P968; GODARD J, 1990, INTENS CARE MED, V16, P307, DOI 10.1007/BF01706355; HEYLAND D, 1992, CHEST, V101, P187, DOI 10.1378/chest.101.1.187; JOHANSON WG, 1972, ANN INTERN MED, V77, P70; PUGIN J, 1991, JAMA-J AM MED ASSOC, V265, P2704, DOI 10.1001/jama.265.20.2704; VANDENBROUCKEGRAULS CMJE, 1991, LANCET, V338, P859, DOI 10.1016/0140-6736(91)91510-2	6	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 10	1993	341	8850					932	932		10.1016/0140-6736(93)91219-C	http://dx.doi.org/10.1016/0140-6736(93)91219-C			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW981	8096272				2023-01-03	WOS:A1993KW98100011
J	GRAY, WA				GRAY, WA			OUTCOME PREDICTION - NEARLY SUCCESSFUL RESUSCITATION	LANCET			English	Editorial Material											GRAY, WA (corresponding author), PRESBYTERIAN HOSP,DIV CARDIOL,ALBUQUERQUE,NM 87102, USA.								0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 3	1993	341	8849					866	866		10.1016/0140-6736(93)93068-C	http://dx.doi.org/10.1016/0140-6736(93)93068-C			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KV811	8096569				2023-01-03	WOS:A1993KV81100011
J	KELLER, AS; LINK, RN; BICKELL, NA; CHARAP, MH; KALET, AL; SCHWARTZ, MD				KELLER, AS; LINK, RN; BICKELL, NA; CHARAP, MH; KALET, AL; SCHWARTZ, MD			DIABETIC-KETOACIDOSIS IN PRISONERS WITHOUT ACCESS TO INSULIN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note								Objective.-To assess the cause and clinical severity of diabetic ketoacidosis in male prisoners hospitalized in New York City. Design.-Retrospective chart review. Setting.-A municipal hospital in New York City. Patients.-Forty-nine adult male prisoners with a total of 54 hospital admissions for diabetic ketoacidosis between January 1, 1989, and June 30, 1991. Main Outcome Measures.-Charts were reviewed for diabetic and medical history, time from arrest until hospitalization, cause of diabetic ketoacidosis, admission laboratory data, and hospital course. Results.-Thirty-eight (70%) of the 54 admissions for diabetic ketoacidosis among prisoners occurred because prisoners had not received insulin during the period immediately following arrest (mean number of days from arrest until hospitalization was 2.5). All of these individuals had a history of insulin-dependent diabetes and were reportedly compliant with their insulin regimen at the time of arrest. Admission laboratory data for this group of prisoners included a mean serum glucose level of 27.4 mmol/L (495 mg/dL) and a mean serum bicarbonate level of 14.4 mmol/L. Mean number of days in the hospital was 3.4 including a mean of 1 day in an intensive care unit. Conclusions.-Inadequate access to medication results in serious sequelae for recently arrested prisoners in New York City with insulin-dependent diabetes. Access to health care for recently arrested prisoners needs to be improved.	NYU,SCH MED,DEPT MED,NEW YORK,NY 10003	New York University			Kalet, Adina/AAA-3440-2021	Kalet, Adina/0000-0003-4855-0223; Schwartz, Mark/0000-0002-7123-0060				Clements R S Jr, 1978, Diabetes Care, V1, P314; DUBLER NN, 1986, STANDARDS HLTH SERVI; FOSTER DW, 1983, NEW ENGL J MED, V309, P159; GANGI R, 1992, PRESENTATION TASK FO; HAMBLIN PS, 1989, MED J AUSTRALIA, V151, P439, DOI 10.5694/j.1326-5377.1989.tb101253.x; HAMBURG MA, 1992, FINAL REPORT NEW YOR; NAVARRO M, 1992, NY TIMES        0213, V13, pB3; RAAB S, 1992, NEW YORK TIMES  0305, pB1; Raab Selwyn, 1992, NY TIMES, P25; 1992, ANN INTERN MED, V117, P71; 1992, 1992 POLICY COMPENDI; 1992, DIABETES CARE S2, V15, P42	12	10	10	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 3	1993	269	5					619	621		10.1001/jama.269.5.619	http://dx.doi.org/10.1001/jama.269.5.619			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ444	8421367				2023-01-03	WOS:A1993KJ44400029
J	Lee, MA; Nelson, HD; Tilden, VP; Ganzini, L; Schmidt, TA; Tolle, SW				Lee, MA; Nelson, HD; Tilden, VP; Ganzini, L; Schmidt, TA; Tolle, SW			Legalizing assisted suicide - Views of physicians in Oregon	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EUTHANASIA; LIFE; DEPRESSION; ATTITUDES; AID	Background. Since the Oregon Death with Dignity Act was passed in November 1994, physicians in Oregon have faced the prospect of legalized physician-assisted suicide. We studied the attitudes and current practices of Oregon physicians in relation to assisted suicide. Methods. From March to June 1995, we conducted a cross-sectional mailed survey of all physicians who might be eligible to prescribe a lethal dose of medication if the Oregon law is upheld, Physicians were asked to complete and return a confidential 56-item questionnaire. Results. Of the 3944 eligible physicians who received the questionnaire, 2761 (70 percent) responded. Sixty percent of the respondents thought physician-assisted suicide should be legal in some cases, and nearly half (46 percent) might be willing to prescribe a lethal dose of medication if it were legal to do so; 31 percent of the respondents would be unwilling to do so on moral grounds. Twenty-one percent of the respondents have previously received requests for assisted suicide, and 7 percent have complied. Half the respondents were not sure what to prescribe for this purpose, and 83 percent cited financial pressure as a possible reason for such requests. The respondents also expressed concern about complications of suicide attempts and doubts about their ability to predict survival at six months accurately. Conclusions. Oregon physicians have a more favorable attitude toward legalized physician-assisted suicide, are more willing to participate, and are currently participating in greater numbers than other surveyed groups of physicians in the United States. A sizable minority of physicians in Oregon objects to legalization and participation on moral grounds. Regardless of their attitudes, physicians had a number of reservations about the practical applications of the act. (C) 1996, Massachusetts Medical Society.	OREGON HLTH SCI UNIV,SCH MED,DEPT MED,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,SCH MED,DEPT PSYCHIAT,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,SCH MED,DEPT EMERGENCY MED,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,SCH NURSING,RES OFF,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,CTR BIOMED INFORMAT COMMUN,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University	Lee, MA (corresponding author), OREGON HLTH SCI UNIV,CTR ETH HLTH CARE L101,PORTLAND,OR 97201, USA.							ALPERS A, 1995, JAMA-J AM MED ASSOC, V274, P483, DOI 10.1001/jama.274.6.483; BATTIN MP, 1991, J PAIN SYMPTOM MANAG, V6, P298, DOI 10.1016/0885-3924(91)90053-7; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2658, DOI 10.1001/jama.267.19.2658; CARALIS PV, 1992, CRIT CARE MED, V20, P683, DOI 10.1097/00003246-199205000-00023; COHEN JS, 1994, NEW ENGL J MED, V331, P89, DOI 10.1056/NEJM199407143310206; CROSBY C, 1992, INTERNIST, V31, P10; DUBERSEIN PR, 1995, J AM GERIATR SOC, V43, P395, DOI 10.1111/j.1532-5415.1995.tb05814.x; EMANUEL EJ, 1994, ANN INTERN MED, V121, P793, DOI 10.7326/0003-4819-121-10-199411150-00010; FRIED TR, 1993, ARCH INTERN MED, V153, P722, DOI 10.1001/archinte.153.6.722; GATES V, 1995, OREGON HLTH PLAN REP, P71; HEILIG S, 1989, SF MED, V61, P24; KEISLING P, 1995, OREGON BLUE BOOK, P296; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; KOENIG HG, 1988, ARCH INTERN MED, V148, P1929, DOI 10.1001/archinte.148.9.1929; KRUSE JA, 1988, JAMA-J AM MED ASSOC, V260, P1739, DOI 10.1001/jama.260.12.1739; MEIER D, 1993, SURVEY END LIFE PRAC; MISBIN RI, 1991, NEW ENGL J MED, V325, P1307, DOI 10.1056/NEJM199110313251811; NIELSEN AC, 1980, ARCH GEN PSYCHIAT, V37, P999; OVERMYER M, 1991, PHYSICIANS MANAGE, V31, P40; SHAPIRO RS, 1994, ARCH INTERN MED, V154, P575, DOI 10.1001/archinte.154.5.575; SINGER PA, 1990, NEW ENGL J MED, V322, P1881, DOI 10.1056/NEJM199006283222610; TENO JM, 1994, J AM GERIATR SOC, V42, P1202, DOI 10.1111/j.1532-5415.1994.tb06990.x; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; 1992, JAMA-J AM MED ASSOC, V267, P2229; 1995, ACAD MED, V70, P583; 1995, J AM GERIATR SOC, V42, P579; 1994, POISITON STATEMENT A; 1994, OREGON VOTERS PAMPHL; 1991, INITATIVE 119 WSMA M	29	208	208	0	20	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 1	1996	334	5					310	315		10.1056/NEJM199602013340507	http://dx.doi.org/10.1056/NEJM199602013340507			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TV695	8532028				2023-01-03	WOS:A1996TV69500007
J	Collier, J				Collier, J			Medicines mismatch	LANCET			English	Editorial Material							DRUG				Collier, J (corresponding author), ST GEORGE HOSP,SCH MED,DEPT CLIN PHARMACOL,CRANMER TERRACE,LONDON,ENGLAND.							CHANDRA S, 1995, OCT NAT MED DRUG POL; GREENHALGH T, 1987, SOC SCI MED, V25, P307, DOI 10.1016/0277-9536(87)90233-4; KRISHNASWAMY K, 1985, EUR J CLIN PHARMACOL, V29, P363, DOI 10.1007/BF00544095; PHADKE A, 1995, STUDY SUPPLY USE PHA, P152	4	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 27	1996	347	8996					212	212		10.1016/S0140-6736(96)90400-6	http://dx.doi.org/10.1016/S0140-6736(96)90400-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TT069	8551877				2023-01-03	WOS:A1996TT06900006
J	CAULEY, JA; SEELEY, DG; ENSRUD, K; ETTINGER, B; BLACK, D; CUMMINGS, SR				CAULEY, JA; SEELEY, DG; ENSRUD, K; ETTINGER, B; BLACK, D; CUMMINGS, SR			ESTROGEN REPLACEMENT THERAPY AND FRACTURES IN OLDER WOMEN	ANNALS OF INTERNAL MEDICINE			English	Article						ESTROGEN REPLACEMENT THERAPY; FRACTURES; OSTEOPOROSIS, POSTMENOPAUSAL; AGE FACTORS; BONE DENSITY	POST-MENOPAUSAL WOMEN; HIP FRACTURE; ELDERLY WOMEN; POSTMENOPAUSAL OSTEOPOROSIS; BONE-DENSITY; CIGARETTE-SMOKING; PHYSICAL-ACTIVITY; TRABECULAR BONE; RISK; DISEASE	Objective: To determine the relation between estrogen replacement therapy and fractures. Design: Prospective cohort study. Setting: Four clinical centers in Baltimore County, Maryland; Minneapolis, Minnesota; Portland, Oregon; and the Monongahela Valley, Pennsylvania. Participants: 9704 ambulatory, nonblack women 65 years of age or older. Measurements: Estrogen use, medical history, and anthropometric data were obtained by questionnaire, interview, and examination. Appendicular bone mass was measured by single-photon absorptiometry. Incident fractures were validated by radiographic report. Results: After adjustment for potential confounders, current estrogen use was associated with a decrease int he risk for wrist fractures (relative risk [RR], 0.39; 95% Cl, 0.24 to 0.64) and for all nonspinal fractures (RR, 0.66; Cl, 0.54 to 0.80) when compared with no estrogen use. Results were similar for women using unopposed estrogen or estrogen plus progestin, for women younger or older than 75 years of age, and for current smokers or nonsmokers. The effect of estrogen remained after adjustment was made for appendicular bone mass. The relative risk for hip fracture tended to be lower among current users (RR, 0.60; Cl, 0.36 to 1.02) than among never-users. Estrogen was most effective in preventing hip fracture among those older than 75 years. Current users who started estrogen within 5 years of menopause had a decreased risk for hip fractures (RR, 0.29; Cl, 0.09 to 0.92), wrist fractures (RR, 0.29; Cl, 0.13 to 0.68), and all nonspinal fractures (RR, 0.50; Cl, 0.36 to 0.70) when compared with women who had never used estrogen. Previous use of estrogen for more than 10 years or use begun soon after menopause had no substantial effect on the risk for fractures. Conclusions: Current use of estrogen appears to decrease the risk for fracture in older women. These results suggest that for protection against fractures, estrogen should be initiated soon after menopause and continued indefinitely.	UNIV CALIF SAN FRANCISCO, DEPT EPIDEMIOL & BIOSTAT, SAN FRANCISCO, CA 94143 USA; VET AFFAIRS MED CTR, DEPT MED, MINNEAPOLIS, MN 55417 USA; KAISER PERMANENTE MED CARE PROGRAM, DIV RES, OAKLAND, CA 94611 USA; UNIV MINNESOTA, MINNEAPOLIS, MN 55455 USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; Kaiser Permanente; University of Minnesota System; University of Minnesota Twin Cities	CAULEY, JA (corresponding author), UNIV PITTSBURGH, GRAD SCH PUBL HLTH, DEPT EPIDEMIOL, A524 CRABTREE HALL, 130 DESOTO ST, PITTSBURGH, PA 15261 USA.		Cauley, Jane A/N-4836-2015	Cauley, Jane A/0000-0003-0752-4408; Ensrud, Kristine/0000-0002-9069-3036	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG005395] Funding Source: NIH RePORTER; NIADDK NIH HHS [1-R01-AM35584] Funding Source: Medline; NIAMS NIH HHS [1-R01-AR35582] Funding Source: Medline; NIA NIH HHS [1-R01-AG05395] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARON JA, 1990, AM J OBSTET GYNECOL, V162, P502, DOI 10.1016/0002-9378(90)90420-C; BARRETTCONNOR E, 1989, JAMA-J AM MED ASSOC, V261, P2095, DOI 10.1001/jama.261.14.2095; BUSH TL, 1991, 31ST ANN C CARD DIS; CAULEY JA, 1989, AM J EPIDEMIOL, V129, P1120, DOI 10.1093/oxfordjournals.aje.a115234; CAULEY JA, 1990, AM J OBSTET GYNECOL, V163, P1438, DOI 10.1016/0002-9378(90)90602-4; CAULEY JA, 1987, J CHRON DIS, V40, P115, DOI 10.1016/0021-9681(87)90062-2; CHRISTIANSEN C, 1990, J CLIN ENDOCR METAB, V71, P836, DOI 10.1210/jcem-71-4-836; CIVITELLI R, 1988, CALCIFIED TISSUE INT, V42, P77, DOI 10.1007/BF02556338; CUMMINGS SR, 1987, AM J EPIDEMIOL, V126, P796, DOI 10.1093/oxfordjournals.aje.a114716; CUMMINGS SR, 1990, JAMA-J AM MED ASSOC, V263, P665, DOI 10.1001/jama.263.5.665; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; ETTINGER B, 1985, ANN INTERN MED, V102, P319, DOI 10.7326/0003-4819-102-3-319; FELSON DT, 1993, NEW ENGL J MED, V329, P1141, DOI 10.1056/NEJM199310143291601; GALLAGHER JC, 1991, AM J MED, V90, P171; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; HUTCHINSON TA, 1979, LANCET, V2, P705; JOHNSON RE, 1981, AM J PUBLIC HEALTH, V71, P138, DOI 10.2105/AJPH.71.2.138; KANIS JA, 1992, BRIT MED J, V305, P1124, DOI 10.1136/bmj.305.6862.1124; KIEL DP, 1992, ANN INTERN MED, V116, P716, DOI 10.7326/0003-4819-116-9-716; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; KREIGER N, 1982, AM J EPIDEMIOL, V116, P141, DOI 10.1093/oxfordjournals.aje.a113388; LINDENSTROM E, 1993, STROKE, V24, P1468, DOI 10.1161/01.STR.24.10.1468; LINDSAY R, 1990, OBSTET GYNECOL, V76, P290; LUFKIN EG, 1992, ANN INTERN MED, V117, P1, DOI 10.7326/0003-4819-117-1-1; MARX CW, 1992, J BONE MINER RES, V7, P1275; MAXIM P, 1994, IN PRESS OSTEOPOROSI; MICHNOVICZ JJ, 1986, NEW ENGL J MED, V315, P1305, DOI 10.1056/NEJM198611203152101; NAESSEN T, 1990, ANN INTERN MED, V113, P95, DOI 10.7326/0003-4819-113-2-95; NEVITT MC, 1992, AM J EPIDEMIOL, V135, P490, DOI 10.1093/oxfordjournals.aje.a116315; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; PAGANINIHILL A, 1981, ANN INTERN MED, V95, P28, DOI 10.7326/0003-4819-95-1-28; PECK WA, 1993, AM J MED, V94, P646; PHILLIPS SK, 1993, CLIN SCI, V84, P95, DOI 10.1042/cs0840095; QUIGLEY MET, 1987, AM J OBSTET GYNECOL, V156, P1516; RIIS BJ, 1987, AM J OBSTET GYNECOL, V156, P61, DOI 10.1016/0002-9378(87)90203-1; SCHLENKER RA, 1976, CALC TISS RES, V20, P41, DOI 10.1007/BF02546396; SEELEY DG, 1991, ANN INTERN MED, V115, P837, DOI 10.7326/0003-4819-115-11-837; SEELEY DG, 1994, IN PRESS ARCH INTERN; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; VOGEL JM, 1987, OSTEOPOROSIS UPDATE, P219; WASNICH RD, 1986, OBSTET GYNECOL, V67, P457; WEISS NS, 1980, NEW ENGL J MED, V303, P1195, DOI 10.1056/NEJM198011203032102; WILLIAMS AR, 1982, OBSTET GYNECOL, V60, P695	43	680	689	0	18	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1995	122	1					9	16		10.7326/0003-4819-122-1-199501010-00002	http://dx.doi.org/10.7326/0003-4819-122-1-199501010-00002			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY502	7985914				2023-01-03	WOS:A1995PY50200002
J	MOORE, P; HEPWORTH, JT				MOORE, P; HEPWORTH, JT			USE OF PERINATAL AND INFANT HEALTH-SERVICES BY MEXICAN-AMERICAN MEDICAID ENROLLEES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRENATAL-CARE; HHANES 1982-84; LOW-INCOME; CHILDREN; ACCULTURATION; ACCESS	Objectives.-Lack of health insurance and a regular source of medical care are barriers affecting use of health services by Mexican Americans. We studied perinatal and infant health service use by Mexican-American women and non-Hispanic white women and their infants enrolled in Arizona's Medicaid program and explored characteristics associated with use of health services. Design.-A descriptive comparative study that used data collected from office records, birth certificates, and household interviews. Setting.-Participants resided in the state's most populous county and were enrolled in the Arizona Health Care Cost Containment System, a health maintenance organization-oriented Medicaid demonstration project. Subjects.-Random sample of 308 Mexican-American mother-infant dyads and 312 non-Hispanic white mother-infant dyads. The women were enrolled before the sixth month of pregnancy and for 60 days post partum; their infants were continuously enrolled throughout their first year. Outcome Measures.-Timing and number of prenatal visits and a modified Kessner Index, postpartum visits, number and purpose of office visits during the infants' first year, and immunizations received. Results.-Mexican Americans averaged fewer prenatal visits than non-Hispanic whites (8.6 vs 10.2 visits) and were less likely to have ''adequate'' care (41.1% vs 52.8%). Both groups of mothers are well below the 68% of women nationally who receive adequate prenatal care. Controlling for important socioeconomic status and cultural characteristics, ethnicity had a strong independent effect on the number of prenatal visits and adequacy of prenatal care. Mexican-American infants made fewer visits (8.2 vs 9.8) and completed fewer age-appropriate immunizations than non-Hispanic whites. Conclusions.-Health insurance and a regular source of care are insufficient conditions for ensuring adequate use of maternal and child health services by Mexican-American Medicaid enrollees. Factors associated with their less frequent use of these preventive health services include higher numbers of children, transportation problems, and less assistance from their support system.			MOORE, P (corresponding author), ARIZONA STATE UNIV,COLL NURSING,TEMPE,AZ 85287, USA.		Sandall, Jane/D-4146-2009	Sandall, Jane/0000-0003-2000-743X	AHRQ HHS [HS 06127] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Aday LA, 1980, HLTH CARE US EQUITAB; ANDERSEN R, 1981, J HEALTH SOC BEHAV, V22, P78, DOI 10.2307/2136370; BARRERA M, 1981, SOCIAL NETWORKS SOCI; CAREY T, 1990, J CLIN EPIDEMIOL, V43, P1213, DOI 10.1016/0895-4356(90)90022-H; COHEN J., 1983, APPL MULTIPLE REGRES, V2; Cuellar I, 1980, HISP J BEHAV SCI, V2, P199, DOI DOI 10.1177/07399863950173001; Davis Susan F., 1992, Morbidity and Mortality Weekly Report, V41, P11; FREUND DA, 1989, HLTH CARE FINANCING, V2, P81; GERGEN PJ, 1988, AM J PUBLIC HEALTH, V78, P1446, DOI 10.2105/AJPH.78.11.1446; GUENDELMAN S, 1990, AM J PUBLIC HEALTH, V80, P61, DOI 10.2105/AJPH.80.Suppl.61; GUYER B, 1990, JAMA-J AM MED ASSOC, V264, P2264, DOI 10.1001/jama.264.17.2264; HEPWORTH J, 1991, NOV AM PUBL HLTH ASS; HUGHES D, 1989, HLTH AM CHILDREN; KRIEGER JW, 1992, AM J PUBLIC HEALTH, V82, P185, DOI 10.2105/AJPH.82.2.185; MILLER CA, 1989, MONITORING CHILDRENS; MOORE P, 1984, PB85243095AS; Olson D. H., 1989, CIRCUMPLEX MODEL FAM; ROBERTS RE, 1991, JAMA-J AM MED ASSOC, V265, P248; ROSENBACH ML, 1989, AM J PUBLIC HEALTH, V79, P1220, DOI 10.2105/AJPH.79.9.1220; ROSENSTOCK IM, 1974, HEALTH EDUC QUART, V2, P354, DOI 10.1177/109019817400200405; SCRIBNER R, 1989, AM J PUBLIC HEALTH, V79, P1263, DOI 10.2105/AJPH.79.9.1263; SOLIS JM, 1990, AM J PUBLIC HEALTH, V80, P11, DOI 10.2105/AJPH.80.Suppl.11; STARFIELD B, 1985, MILBANK FUND Q, V63, P523, DOI 10.2307/3349846; STCLAIR PA, 1990, PUBLIC HEALTH REP, V105, P264; STPETER RF, 1992, JAMA-J AM MED ASSOC, V267, P2760, DOI 10.1001/jama.267.20.2760; TREVINO FM, 1983, US DHHS PH841232 PUB; VENTURA SJ, 1985, PUBLIC HEALTH REP, V100, P647; 1991, CLOSING DECADE ARIZO; 1991, P20 US DEP COMM BUR; 1991, US DHHS PHS9150212 P; 1988, GUIDELINES HLTH SUPE, V2; [No title captured]; 1988, PRENATAL CARE REACHI; 1991, 40 NAT CTR HLTH STAT; 1985, PLAN OPERATION HISPA; 1989, US DHHS PHS891501 10	36	71	72	1	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 27	1994	272	4					297	304		10.1001/jama.272.4.297	http://dx.doi.org/10.1001/jama.272.4.297			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NX806	8028143				2023-01-03	WOS:A1994NX80600032
J	WARD, BJ; TATE, PA				WARD, BJ; TATE, PA			ATTITUDES AMONG NHS DOCTORS TO REQUESTS FOR EUTHANASIA	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To explore NHS doctors' attitudes to competent patients' requests for euthanasia and to estimate the proportion of doctors who have taken active steps to hasten a patient's death. Design-Anonymous postal questionnaire, with no possibility of follow up. The survey was conducted from December 1992 to March 1993. Subjects-All (221) general practitioners and 203 hospital consultants in one area of England. Results-273 doctors responded to a question on whether a patient had ever asked them to hasten death. Of these, 163 had been asked to; 124 of these had been asked to take active steps to hasten death; 38 of 119 (32%) of these had complied with such a request (95% confidence interval 23% to 40%). This proportion represented 12% of all those who returned a completed questionnaire and 9% of all those who had been sent a questionnaire (95% confidence interval 6.3% to 11.7%). A larger proportion of the respondents (142/307 (46%)), however, would consider taking active steps to bring about the death of a patient if it was legal to do so. Conclusions-Many doctors face difficult decisions about euthanasia. For the benefit of both patients and doctors euthanasia should be discussed more openly.	UNIV CAMBRIDGE,DEPT ANAT,CAMBRIDGE CB2 3DY,ENGLAND	University of Cambridge								KUHSE H, 1988, MED J AUSTRALIA, V148, P623, DOI 10.5694/j.1326-5377.1988.tb116334.x; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; VANDERWAL G, 1992, FAM PRACT, V9, P130, DOI 10.1093/fampra/9.2.130; 1988, BRIT MED J, V296, P1376; 1987, ATTITUDES EUTHANASIA	5	112	113	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 21	1994	308	6940					1332	1334		10.1136/bmj.308.6940.1332	http://dx.doi.org/10.1136/bmj.308.6940.1332			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM989	8019219	Green Published			2023-01-03	WOS:A1994NM98900020
J	LEE, DKP; SWINBURNE, AJ; FEDULLO, AJ; WAHL, GW				LEE, DKP; SWINBURNE, AJ; FEDULLO, AJ; WAHL, GW			WITHDRAWING CARE - EXPERIENCE IN A MEDICAL INTENSIVE-CARE UNIT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LIFE-SUPPORT; PATIENT; ILLUSION; FAMILIES; FUTILITY	Objective.-To describe the process and outcomes of withdrawing life-sustaining interventions in a medical intensive care unit (MICU). Design.-Retrospective case series. Setting.-Medical intensive care unit in a community teaching hospital. Patients.-Consecutive series of 28 patients in whom mechanical ventilation, dialysis, and/or vasopressors were withdrawn. We distinguished physiological, neurological, and functional rationales for care withdrawal. Main Outcome Measures.-Duration of discussions, MICU length of stay, and hospital survival. Results.-Mean +/-SD Acute Physiology and Chronic Health Evaluation (APACHE II) score was 27.1 +/- 7.3 on MICU admission, and average +/-SD predicted hospital mortality was 61% +/- 22%. Discussions leading to withdrawal of care occurred over an average +/-SD of 5.2 +/- 5.5 days, with decisions achieved soonest in cases with poor neurological prognosis. Average +/-SD MICU length of stay was 1.4 +/- 1.8 days following a decision to withdraw MICU care, and only four patients received more than 48 hours of additional MICU care. Four patients were discharged alive from the hospital. Conclusions.-Patients and their surrogates willingly considered outcomes in addition to mortality when considering withdrawal of life-sustaining interventions. Finding an accommodation between physician judgments and patient preferences took time and effort but was an effective means of limiting ineffective life-sustaining efforts. Withdrawing futile or unwanted care was not always fatal.	UNIV ROCHESTER,SCH MED & DENT,DEPT DERMATOL,ROCHESTER,NY 14642	University of Rochester	LEE, DKP (corresponding author), ROCHESTER GEN HOSP,PULM UNIT,1425 PORTLAND AVE,ROCHESTER,NY 14621, USA.							[Anonymous], 1991, ANN INTERN MED, V115, P478; [Anonymous], 1990, CRIT CARE MED, V18, P1435; BONE RC, 1990, CHEST, V97, P949, DOI 10.1378/chest.97.4.949; CALLAHAN D, 1991, HASTINGS CENT REP, V21, P30, DOI 10.2307/3562999; CHELLURI L, 1993, JAMA-J AM MED ASSOC, V269, P3119, DOI 10.1001/jama.269.24.3119; DANIS M, 1988, JAMA-J AM MED ASSOC, V260, P797, DOI 10.1001/jama.260.6.797; EDWARDS MJ, 1992, ANN INTERN MED, V117, P254, DOI 10.7326/0003-4819-117-3-254; FABERLANGENDOEN K, 1992, CRIT CARE MED, V20, P570, DOI 10.1097/00003246-199205000-00005; FABERLANGENDOEN K, 1991, ARCH INTERN MED, V151, P235, DOI 10.1001/archinte.151.2.235; FEINSTEIN AR, 1986, ANN INTERN MED, V105, P413, DOI 10.7326/0003-4819-105-3-413; GOLDSTEIN RL, 1986, CRIT CARE MED, V14, P783, DOI 10.1097/00003246-198609000-00005; GRECO PJ, 1991, ANN INTERN MED, V115, P639, DOI 10.7326/0003-4819-115-8-639; GUYATT GH, 1993, ANN INTERN MED, V118, P622, DOI 10.7326/0003-4819-118-8-199304150-00009; JENNETT B, 1975, LANCET, V1, P480; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LANTOS JD, 1989, AM J MED, V87, P81; LUCE JM, 1992, CHEST, V101, P1185, DOI 10.1378/chest.101.5.1185; ORENTLICHER D, 1992, JAMA-J AM MED ASSOC, V267, P2101, DOI 10.1001/jama.267.15.2101; PELLEGRINO ED, 1981, B NEW YORK ACAD MED, V57, P70; RUARK JE, 1988, NEW ENGL J MED, V318, P25, DOI 10.1056/NEJM198801073180106; SCHNEIDERMAN LJ, 1988, NEW ENGL J MED, V318, P984, DOI 10.1056/NEJM198804143181509; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949; SCHNEIDERMAN LJ, 1993, ARCH INTERN MED, V153, P437, DOI 10.1001/archinte.153.4.437; SIEGLER M, 1981, B NEW YORK ACAD MED, V57, P56; SMEDIRA NG, 1990, NEW ENGL J MED, V322, P309, DOI 10.1056/NEJM199002013220506; SNIDER GL, 1991, AM REV RESPIR DIS, V143, P665, DOI 10.1164/ajrccm/143.3.665; SPICHER JE, 1987, ARCH INTERN MED, V147, P421, DOI 10.1001/archinte.147.3.421; TOMLINSON T, 1988, NEW ENGL J MED, V318, P43, DOI 10.1056/NEJM198801073180109; 1987, GUIDELINES TERMINATI; 1991, JAMA-J AM MED ASSOC, V265, P1868	30	67	68	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 4	1994	271	17					1358	1361		10.1001/jama.271.17.1358	http://dx.doi.org/10.1001/jama.271.17.1358			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH487	8158822				2023-01-03	WOS:A1994NH48700029
J	ANDREOTTI, F; KLUFT, C; HACKETT, DR; DAVIES, GJ; MASERI, A				ANDREOTTI, F; KLUFT, C; HACKETT, DR; DAVIES, GJ; MASERI, A			THROMBIN GENERATION AFTER FAST OR PROLONGED REGIMENS OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR	LANCET			English	Letter									ROYAL POSTGRAD MED SCH, LONDON W12 0HS, ENGLAND; TNO, IVVO, GAUBIUS LAB, 2313 AD LEIDEN, NETHERLANDS	Imperial College London; Netherlands Organization Applied Science Research	ANDREOTTI, F (corresponding author), UNIV CATTOLICA SACRO CUORE, IST CARDIOL, I-00168 ROME, ITALY.		Andreotti, Felicita/A-9962-2019	Andreotti, Felicita/0000-0002-1456-6430				GENSER N, 1993, LANCET, V341, P1038, DOI 10.1016/0140-6736(93)91141-8; HASKEL EJ, 1991, CIRCULATION, V83, P1048, DOI 10.1161/01.CIR.83.3.1048; KHAN MI, 1990, AM J CARDIOL, V65, P1051, DOI 10.1016/0002-9149(90)90313-P; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001	4	14	14	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 9	1993	342	8876					937	938		10.1016/0140-6736(93)91991-T	http://dx.doi.org/10.1016/0140-6736(93)91991-T			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA963	8105201				2023-01-03	WOS:A1993MA96300057
J	BEARDON, PHG; MCGILCHRIST, MM; MCKENDRICK, AD; MCDEVITT, DG; MACDONALD, TM				BEARDON, PHG; MCGILCHRIST, MM; MCKENDRICK, AD; MCDEVITT, DG; MACDONALD, TM			PRIMARY NONCOMPLIANCE WITH PRESCRIBED MEDICATION IN PRIMARY-CARE	BRITISH MEDICAL JOURNAL			English	Article							NONCOMPLIANCE	Objective-To determine the rate of patients not redeeming their prescriptions (primary non-compliance) and assess the factors influencing this. Design-Observational study comparing copies of prescriptions written by general practitioners with those dispensed by pharmacists and subsequent case record review. Setting-A large rural general practice in Tayside. Subjects-All 4854 patients who received prescriptions (20 921) written between january 1989 and March 1989. Main outcome measures-The rate of non-redemption of prescriptions. Results-Seven hundred and two patients (14.5%) did not redeem 1072 (5.2%) prescriptions during the study period, amounting to 11.5% of men and 16.3% of women. Non-redemption was highest in women aged 16-29 (27.6% of women) and men aged 40-49 (18.3% of men). Of prescriptions issued to women for oral contraceptives 24.8% were not redeemed during the study period. In those who redeemed prescriptions 17% were not exempt from prescription charges compared with 33% of patients who failed to redeem them. The non-redemption rate was highest for prescriptions issued at the weekends, although this was a small proportion of all prescribing. Prescriptions issued by trainee general practitioners were also less likely to be redeemed. Conclusions-Non-redemption varies with age, sex, general practitioner, exemption status, and with day of the week the prescription was written. Observational studies of drug exposure can be more accurately estimated from dispensing rather than prescribing data.	UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT PHARMACOL & CLIN PHARMACOL,MED MONITORING UNIT,DUNDEE DD1 9SY,SCOTLAND; CARNOUSTIE HLTH CTR,TAYSIDE DD7 7RB,ENGLAND	University of Dundee				MacDonald, Thomas/0000-0001-5189-6669				BEGG D, 1984, J ROY COLL GEN PRACT, V34, P272; COL N, 1990, ARCH INTERN MED, V150, P841, DOI 10.1001/archinte.150.4.841; FEELY M, 1989, GERIATRIC MED    JUN, P14; GRAHAM D J, 1988, American Journal of Preventive Medicine, V4, P15; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; RASHID A, 1982, BRIT MED J, V284, P24, DOI 10.1136/bmj.284.6308.24; WATERS WHR, 1976, BRIT MED J, V1, P1062, DOI 10.1136/bmj.1.6017.1062; WISEMAN IC, 1991, S AFR MED J, V79, P155; WONNACOTT TH, 1977, INTRO STATISTICS, P223	9	264	273	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 2	1993	307	6908					846	848		10.1136/bmj.307.6908.846	http://dx.doi.org/10.1136/bmj.307.6908.846			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA293	8401129	Green Published, Bronze			2023-01-03	WOS:A1993MA29300024
J	GOLDACRE, M; SEAGROATT, V; HAWTON, K				GOLDACRE, M; SEAGROATT, V; HAWTON, K			SUICIDE AFTER-DISCHARGE FROM PSYCHIATRIC INPATIENT CARE	LANCET			English	Article							IOWA RECORD-LINKAGE; MORTALITY	People with a history of psychiatric disorder are at higher risk of suicide than people without such a history. The policy of reducing inpatient care in psychiatry has probably meant that some of the risk of suicide has shifted from the hospital to the community setting. We have quantified the risk of suicide within a year of psychiatric discharge in a population-based study in the Oxford health region, UK. We calculated suicide rates per 1000 person-years at risk (time from discharge to death, subsequent readmission, or the end of the study) and the standardised mortality ratio (SMR) for suicide, taking the value among the general population as 1. Among male patients the SMR for suicide (defined by coroner's verdict of suicide) in the first 28 days after discharge from inpatient care was 213 (95% CI 137-317); the equivalent SMR for female patients was 134 (67-240). The result was similar when we defined suicide more broadly as a suicide, open, or misadventure verdict. The suicide rate in the first 28 days after discharge was 7.1 (4.1-12) times higher for male patients and 3.0 (1.5-6.0) times higher for female patients than the rate during the remaining 48 weeks of the first year after discharge. Most of the patients studied (both those who committed suicide and those who did not) had been psychiatric inpatients for only a short time. The findings confirm that there is significant clustering of suicide soon after discharge from psychiatric care. Skilled support after discharge for high-risk patients in the community is essential. Audit of suicides that occur soon after discharge may help identify the patients at highest risk and thereby reduce the number of avoidable deaths.	UNIV OXFORD,WARNEFORD HOSP,DEPT PSYCHIAT,OXFORD OX3 7J,ENGLAND	University of Oxford	GOLDACRE, M (corresponding author), UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,HLTH CARE EPIDEMIOL UNIT,OLD RD,OXFORD OX3 7LF,ENGLAND.							Acheson E.D., 1967, MED RECORD LINKAGE; BAKER RJ, 1978, GLIM SYSTEM; BARRACLOUGH B, 1974, BRIT J PSYCHIAT, V125, P355, DOI 10.1192/bjp.125.4.355; BLACK DW, 1985, JAMA-J AM MED ASSOC, V253, P58, DOI 10.1001/jama.253.1.58; BLACK DW, 1989, SUICIDE LIFE-THREAT, V19, P78; Charlton J., 1992, Population Trends, P10; COLEMAN M, 1986, INT J EPIDEMIOL, V15, P134, DOI 10.1093/ije/15.1.134; GILL LE, 1987, TXB MED RECORD LINKA, P39; HAWTON K, 1992, BMJ-BRIT MED J, V304, P1000, DOI 10.1136/bmj.304.6833.1000; HAWTON K, 1987, BRIT J PSYCHIAT, V150, P145, DOI 10.1192/bjp.150.2.145; HENDERSON J, 1992, J EPIDEMIOL COMMUN H, V46, P297, DOI 10.1136/jech.46.3.297; HOFFMANN H, 1987, SOC PSYCH PSYCH EPID, V22, P93, DOI 10.1007/BF00584011; MILES CP, 1977, J NERV MENT DIS, V164, P231, DOI 10.1097/00005053-197704000-00002; MONK M, 1987, EPIDEMIOL REV, V9, P51, DOI 10.1093/oxfordjournals.epirev.a036308; ODEGARD O, 1952, ACTA PSYCH NEUROL, V27, P353, DOI 10.1111/j.1600-0447.1952.tb04667.x; PIERCE J, 1964, ARCH GEN PSYCHIAT, V10, P43; POUNDER DJ, 1992, BRIT MED J, V305, P472, DOI 10.1136/bmj.305.6851.472; ROY A, 1983, COMPR PSYCHIAT, V24, P487, DOI 10.1016/0010-440X(83)90040-8; ROY A, 1984, CAN J PSYCHIAT, V29, P319, DOI 10.1177/070674378402900408; SCHNEIDMAN ES, 1981, SUICIDE LIFE-THREAT, V11, P325; SEAGROATT V, 1991, BRIT MED J, V303, P1431, DOI 10.1136/bmj.303.6815.1431; SURTEES J, 1992, BRIT MED J, V305, P716, DOI 10.1136/bmj.305.6855.716-a; 1992, LANCET, V340, P700; 1992, HLTH NATION STRATEGY; 1982, STEERING GROUP HLTH	25	297	300	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 31	1993	342	8866					283	286		10.1016/0140-6736(93)91822-4	http://dx.doi.org/10.1016/0140-6736(93)91822-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ163	8101307				2023-01-03	WOS:A1993LQ16300015
J	CUMMINS, RO				CUMMINS, RO			CODE MAGIC	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 23	1993	269	24					3076	3076		10.1001/jama.269.24.3076	http://dx.doi.org/10.1001/jama.269.24.3076			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH145	8505799				2023-01-03	WOS:A1993LH14500001
J	ANDREWS, K				ANDREWS, K			PATIENTS IN THE PERSISTENT VEGETATIVE STATE - PROBLEMS IN THEIR LONG-TERM MANAGEMENT	BRITISH MEDICAL JOURNAL			English	Article								Physicians responsible for the long term management of patients in the persistent vegetative state face several problems. These include deciding whether tube feeding is treatment or nutritional care, whether withdrawal of tube feeding is an appropriate form of management, what clinical advantage there is in active treatment; at what level of awareness can a patient be said to have a quality of life; and who should determine a patient's right to die. These problems are determined more by social, legal, emotional, cultural, religious, and economic forces than by clinical facts.	ROYAL HOSP & HOME,RES SERV,LONDON SW15 3SW,ENGLAND		ANDREWS, K (corresponding author), ROYAL HOSP & HOME,MED SERV,LONDON SW15 3SW,ENGLAND.							ANDREWS K, 1993, BRIT MED J, V306, P1597, DOI 10.1136/bmj.306.6892.1597	1	24	24	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1993	306	6892					1600	1602		10.1136/bmj.306.6892.1600	http://dx.doi.org/10.1136/bmj.306.6892.1600			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH128	8329927	Bronze, Green Published			2023-01-03	WOS:A1993LH12800028
J	BUSCH, ORC; HOP, WCJ; VANPAPENDRECHT, MAWH; MARQUET, RL; JEEKEL, J				BUSCH, ORC; HOP, WCJ; VANPAPENDRECHT, MAWH; MARQUET, RL; JEEKEL, J			BLOOD-TRANSFUSIONS AND PROGNOSIS IN COLORECTAL-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TUMOR-GROWTH; RECURRENCE; DEFENSES; SURVIVAL; CELLS; COLON	Background. Blood transfusions may adversely affect the prognosis of patients treated surgically for cancer, although definite proof of this adverse effect has not been reported, Methods. We carried out a randomized trial to investigate whether the prognosis in patients with colorectal cancer would be improved by a program of autologous blood transfusion as compared with the current practice of allogeneic transfusion. Patients in the autologous-transfusion group were required to donate two units of blood before surgery. Results. A total of 475 patients were evaluated. We found no significant difference in prognosis between the allogeneic-transfusion group (236 patients) and the autologous-transfusion group (239 patients); colorectal cancer-specific survival rates at four years were 67 percent and 62 percent, respectively (P = 0.39). Among the 423 patients who underwent curative surgery, 66 percent of those in the allogeneic-transfusion group and 63 percent of those in the autologous-transfusion group had no recurrence of colorectal cancer at four years (P = 0.93). We also found that the risk of recurrence was significantly increased in patients who received blood transfusions, either allogeneic or autologous, as compared with patients who did not require transfusions; the relative rates of recurrence were 2.1 (P = 0.01) and 1.8 (P = 0.04), respectively; these rates did not differ significantly from each other. Conclusions. The use of autologous blood as compared with allogeneic blood for transfusion does not improve the prognosis in patients with colorectal cancer. Regardless of their type, transfusions are associated with poor prognosis, probably because of the circumstances that necessitate them.	UNIV HOSP ROTTERDAM DIJKZIGT,DEPT SURG,DR MOLEWATERPLEIN 40,3015 GD ROTTERDAM,NETHERLANDS; ERASMUS UNIV,DEPT EPIDEMIOL & BIOSTAT,3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam			Busch, Olivier/AAC-3650-2020					BENTZEN SM, 1990, EUR J CANCER, V26, P457, DOI 10.1016/0277-5379(90)90016-M; BLUMBERG N, 1989, TRANSFUSION, V29, P236, DOI 10.1046/j.1537-2995.1989.29389162731.x; BRUNSON ME, 1990, TRANSFUSION, V30, P651, DOI 10.1046/j.1537-2995.1990.30790385527.x; BURROWS L, 1982, LANCET, V2, P662; COX DR, 1972, J R STAT SOC B, V34, P187; FRANCIS DMA, 1991, BRIT J SURG, V78, P1420, DOI 10.1002/bjs.1800781205; FRANCIS DMA, 1987, SURGERY, V102, P485; FRANKISH PD, 1985, BRIT MED J, V290, P1827, DOI 10.1136/bmj.290.6484.1827-b; GANTT CL, 1981, LANCET, V2, P363; HEISS MM, 1992, P AN M AM SOC CLIN, V11, P172; HERBERMAN RB, 1981, SCIENCE, V214, P24, DOI 10.1126/science.7025208; JEEKEL J, 1982, EUR SURG RES, V14, P124; Miettinen O S, 1983, Stat Med, V2, P267, DOI 10.1002/sim.4780020222; NATHANSON SD, 1985, ARCH SURG-CHICAGO, V120, P734; NESS PM, 1992, TRANSFUSION, V32, P31, DOI 10.1046/j.1537-2995.1992.32192116429.x; SINGH SK, 1987, EUR J CANCER CLIN ON, V23, P1537, DOI 10.1016/0277-5379(87)90097-6; SINGH SK, 1987, TRANSPLANT P, V19, P1473; SINGH SK, 1988, BRIT J SURG, V75, P377, DOI 10.1002/bjs.1800750427; TARTTER PI, 1988, TRANSPLANT P, V20, P1108; TAYLOR RMR, 1988, BRIT J SURG, V75, P1049, DOI 10.1002/bjs.1800751102; TURNBULL RB, 1967, ANN SURG, V166, P420; VANPABST WPV, 1988, EUR J CANCER CLIN ON, V24, P741, DOI 10.1016/0277-5379(88)90309-4; VANPAPENDRECHT MAWH, 1991, NETH J SURG, V43, P85; VANPAPENDRECHT MAWH, 1992, VOX SANG, V62, P102; WAYMACK JP, 1988, J SURG ONCOL, V39, P159; WEIDEN PL, 1987, CANCER-AM CANCER SOC, V60, P870, DOI 10.1002/1097-0142(19870815)60:4<870::AID-CNCR2820600425>3.0.CO;2-0; 1986, JAMA-J AM MED ASSOC, V256, P2378	27	465	469	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 13	1993	328	19					1372	1376		10.1056/NEJM199305133281902	http://dx.doi.org/10.1056/NEJM199305133281902			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB495	8292113				2023-01-03	WOS:A1993LB49500002
J	MORTONJONES, TJ; PRINGLE, MAL				MORTONJONES, TJ; PRINGLE, MAL			PRESCRIBING COSTS IN DISPENSING PRACTICES	BRITISH MEDICAL JOURNAL			English	Article								Objective-To examine differences in prescribing between dispensing and non-dispensing practices. Setting-The 108 practices covered by Lincolnshire Family Health Services Authority. Design-Analysis of prescribing data for 1990-1 from PD2 reports from the Prescription Pricing Authority in relation to data on practice characteristics obtained from Lincolnshire Family Health Services Authority; and aggregated level 3 prescribing and cost information (PACT data) for 10 selected drugs from the Prescription Pricing Authority to examine amounts prescribed. Main outcome measures-Prescribing cost per patient, items per patient, and cost per item in dispensing and non-dispensing practices. Results-Dispensing practices had higher prescribing costs per patient than non-dispensing practices. This difference held for non-dispensing patients within dispensing practices. Structural features failed to explain the differences in prescribing cost, except for the higher numbers of elderly patients in dispensing practices (which explained 13% of the difference) and the number of partners (5%). The main determinant of the difference was the lower use of generic drugs in dispensing practices (84%). Dispensing patients were prescribed lower quantities of drugs on average for each item. Conclusions-Dispensing practices could reduce their prescribing expenditure to that of non-dispensing practices by increasing their prescribing of generic drugs. The shorter prescribing intervals for dispensing patients may be due to dispensing fees being related to the number of prescribed items.	QUEENS MED CTR,DEPT GEN PRACTICE,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham								BRADLEY CP, 1991, FAM PRACT, V8, P276, DOI 10.1093/fampra/8.3.276; DYER C, 1988, BRIT MED J, V296, P735; FORSTER DP, 1991, BRIT J GEN PRACT, V41, P67; GEDDES GL, 1992, BRIT MED J, V305, P478, DOI 10.1136/bmj.305.6851.478; GILLEGHAN JD, 1991, 54 ROYAL COLL GEN PR; HARRIS CM, 1990, ANAL PRESCRIBING GEN; JENNINGS SJ, 1988, BRIT MED J, V296, P936, DOI 10.1136/bmj.296.6626.936-h; MORTONJONES AJ, 1992, BRIT MED J, V305, P478, DOI 10.1136/bmj.305.6851.478-a; MORTONJONES AJ, IN PRESS BMJ; ROBERTS D, 1992, BRIT MED J, V305, P187, DOI 10.1136/bmj.305.6846.187-c; 1991, 1990 1991 PRESCR PRI, P8; 1991, HLTH SERVICES INDICA	12	37	39	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 8	1993	306	6887					1244	1246		10.1136/bmj.306.6887.1244	http://dx.doi.org/10.1136/bmj.306.6887.1244			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB804	8499855	Bronze, Green Published			2023-01-03	WOS:A1993LB80400019
J	PIJNENBORG, L; van der Maas, PJ; VANDELDEN, JJM; LOOMAN, CWN				PIJNENBORG, L; van der Maas, PJ; VANDELDEN, JJM; LOOMAN, CWN			LIFE-TERMINATING ACTS WITHOUT EXPLICIT REQUEST OF PATIENT	LANCET			English	Article								In the Dutch nationwide study on medical decisions concerning the end of life (MDEL) life-terminating acts without the explicit request of the patient (LAWER) were noted in 0.8% of all deaths. We present here quantitative information and a discussion of the main issues raised by LAWER. In 59% of LAWER the physician had some information about the patient's wish; in 41% discussion on the decision would no longer have been possible. In LAWER patients tend to be younger and more likely to be male and to have cancer than in non-acute deaths generally. The physician (specialist or general practitioner) knew the patient on average 2.4 years and 7.2 years, respectively. Life was shortened by between some hours and a week at most in 86%. ln 83% the decision has been discussed with relatives and in 70% with a colleague. In nearly all cases, according to the physician, the patient was suffering unbearably, there was no chance of improvement, and palliative possibilities were exhausted. MDEL probably will increase in number in future but interviews with Dutch physicians suggest a possible fall in LAWER, even though there will always be some situations in which a well-considered LAWER decision may have to be made.	UNIV UTRECHT, CTR BIOETH & HLTH LAW, UTRECHT, NETHERLANDS	Utrecht University	PIJNENBORG, L (corresponding author), ERASMUS UNIV, DEPT PUBL HLTH, POB 1738, 3000 DR ROTTERDAM, NETHERLANDS.		Lindtjorn, Bernt/K-9465-2018	Lindtjorn, Bernt/0000-0002-6267-6984				KUHSE H, 1992, BIOETHICS NEWS, V11, P1; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; van der Maas PJ, 1992, HEALTH POLICY, V22, P1; VANDELDEN JJM, IN PRESS BIOETHICS; VANDERWAL G, 1991, HUISARTS WET, V34, P523; 1992, LANCET, V340, P757; 1988, JAMA-J AM MED ASSOC, V259, P272; 1992, END LIFE MED PRACTIC	8	87	87	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 8	1993	341	8854					1196	1199		10.1016/0140-6736(93)91014-D	http://dx.doi.org/10.1016/0140-6736(93)91014-D			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB017	8098087				2023-01-03	WOS:A1993LB01700016
J	SANCHEZ, JL; DEFRAITES, RF; SHARP, TW; HANSON, RK				SANCHEZ, JL; DEFRAITES, RF; SHARP, TW; HANSON, RK			MEFLOQUINE OR DOXYCYCLINE PROPHYLAXIS IN UNITED-STATES TROOPS IN SOMALIA	LANCET			English	Letter							MALARIA		USN,MED RES INST,BETHESDA,MD 20814; USN,ENVIRONM & PREVENT MED UNIT 6,HONOLULU,HI	Naval Medical Research Center (NMRC); United States Department of Defense; United States Navy; United States Department of Defense; United States Navy	SANCHEZ, JL (corresponding author), WALTER REED ARMY INST RES,DIV PREVENT MED,WASHINGTON,DC 20307, USA.							ARTHUR JD, 1990, LANCET, V35, P972; BERN JL, 1992, J TROP MED HYG, V95, P167; LOBEL HO, 1991, JAMA-J AM MED ASSOC, V265, P361, DOI 10.1001/jama.265.3.361; PATCHEN LC, 1989, NEW ENGL J MED, V321, P1415; ROUVEIX B, 1989, ANN INTERN MED, V110, P577, DOI 10.7326/0003-4819-110-7-577; STEFFEN R, 1990, B WORLD HEALTH ORGAN, V68, P313; WEINKE T, 1991, AM J TROP MED HYG, V45, P86, DOI 10.4269/ajtmh.1991.45.86	7	37	37	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 17	1993	341	8851					1021	1022		10.1016/0140-6736(93)91107-W	http://dx.doi.org/10.1016/0140-6736(93)91107-W			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY368	8096898				2023-01-03	WOS:A1993KY36800030
J	LUBITZ, JD; RILEY, GF				LUBITZ, JD; RILEY, GF			TRENDS IN MEDICARE PAYMENTS IN THE LAST YEAR OF LIFE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OLDER PERSONS; CARE; DEATH; ILL	Background. Increased attention is being paid to the amount and types of medical services rendered in the period before death. There is a popular impression that a greater share of resources is being devoted to dying patients than in the past. We examined trends in the proportion of Medicare expenditures for persons 65 years old or older in their last year of life to determine whether there were any changes from 1976 to 1988. Methods. Using Medicare program data for 1976, 1980, 1985, and 1988, we classified Medicare payments according to whether they were made for people in their last year of life (decedents) or for survivors. We also assigned expenses for care in the last year of life according to intervals of 30 days before the person's death and examined trends according to age. Results. Reflecting the large overall increase in Medicare spending, Medicare costs for decedents rose from $3,488 per person-year in 1976 to $13,316 in 1988. However, Medicare payments for decedents as a percentage of the total Medicare budget changed little, fluctuating between 27.2 and 30.6 percent during the study period. Payments for care during the last 60 days of life expressed as a percentage of payments for the last year also held steady at about 52 percent. Furthermore, the pattern of lower payments for older as compared with younger decedents also prevailed throughout the study period. Conclusions. The same forces that have acted to increase overall Medicare expenditures have affected care for both decedents and survivors. There is no evidence that persons in the last year of life account for a larger share of Medicare expenditures than in earlier years.			LUBITZ, JD (corresponding author), HLTH CARE FINANCING ADM,6325 SECUR BLVD,RM 2504,OAK MEADOWS BLDG,BALTIMORE,MD 21207, USA.							ANDERSON K, 1991, US TODAY        0311, pB3; BAYER R, 1983, NEW ENGL J MED, V309, P1490, DOI 10.1056/NEJM198312153092405; Brock Dwight B., 1992, P315; CLARK N, 1992, WALL STREET J   0226, pA12; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; FORSTER LE, 1988, ARCH INTERN MED, V148, P2540, DOI 10.1001/archinte.148.12.2540; FREUDENHEIM M, 1990, NY TIMES        0205, pA1; GURALNIK JM, 1991, AM J PUBLIC HEALTH, V81, P443, DOI 10.2105/AJPH.81.4.443; KIDDER D, 1992, HEALTH SERV RES, V27, P195; LAWTON MP, 1990, MILBANK Q, V68, P1, DOI 10.2307/3350075; Levit K R, 1991, Health Care Financ Rev, V13, P29; Lubitz J, 1984, Health Care Financ Rev, V5, P117; McMillan A, 1990, Health Care Financ Rev, V12, P1; MORALES P, 1990, COTTAGE GROVE S 1107, pA4; OLESKER M, 1992, BALTIMORE SUN   0114, pD1; ROOS NP, 1987, MILBANK Q, V65, P231, DOI 10.2307/3350021; SCITOVSKY AA, 1984, MILBANK Q, V62, P591, DOI 10.2307/3349838; SCITOVSKY AA, 1988, MILBANK Q, V66, P640, DOI 10.2307/3349934; SMEDIRA NG, 1990, NEW ENGL J MED, V322, P309, DOI 10.1056/NEJM199002013220506; SPECTOR WD, 1984, INQUIRY-J HEALTH CAR, V21, P328; Tukey J.W., 1977, EXPLORATORY DATA ANA, V2; 1991, IMPACT MEDICARE HOSP; 1991, MEDICARE AM HLTH CAR; 1990, MON VITAL STAT REP S, V39	24	498	503	1	19	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 15	1993	328	15					1092	1096		10.1056/NEJM199304153281506	http://dx.doi.org/10.1056/NEJM199304153281506			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KX178	8455667				2023-01-03	WOS:A1993KX17800006
J	FISCHER, AA				FISCHER, AA			PAIN RELIEF - STERILE WATER FOR WHIPLASH SYNDROME	LANCET			English	Editorial Material											FISCHER, AA (corresponding author), CUNY MT SINAI SCH MED,DEPT REHABIL MED,NEW YORK,NY 10029, USA.							Fischer AA, 1990, J MANUAL MED, V5, P145; Fischer AA, 1987, CLIN J PAIN, V2, P207; KRAUS H, 1991, MT SINAI J MED, V58, P235; TRAVELL JG, 1983, TRIGGER POINT MANUAL, V1; [No title captured]	5	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 20	1993	341	8843					470	470		10.1016/0140-6736(93)90215-3	http://dx.doi.org/10.1016/0140-6736(93)90215-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN137	8094495				2023-01-03	WOS:A1993KN13700012
J	Allen, K; Blascovich, J				Allen, K; Blascovich, J			The value of service dogs for people with severe ambulatory disabilities - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SOCIAL ACKNOWLEDGMENTS; DEPRESSION; STRESS; CHILDREN; SUPPORT	Objective.-To assess the value of service dogs for people with ambulatory disabilities. Design.-Randomized, controlled clinical trial. Setting.-Environments of study participants. Participants.-Forty-eight individuals with severe and chronic ambulatory disabilities requiring use of wheelchairs who were recruited from advocacy and support groups for persons with muscular dystrophy, multiple sclerosis, traumatic brain injury, and spinal cord injury. Participants were matched on age, sex, marital status, race, and the nature and severity of the disability in order to create 24 pairs. Within each pair, participants were randomly assigned to either the experimental group or a wait-list control group. Intervention.-Experimental group members received trained-service dogs 1 month after the study began, and subjects in the wait-list control group received dogs in month 13 of the study. Main Outcome Measures.-Dependent variables evaluated were self-reported assessments of psychological well-being, internal locus of control, community integration, school attendance, part-time work status, self-esteem, marital status, living arrangements, and number of biweekly paid and unpaid assistance hours. Data collection occurred every 6 months over a 2-year period, resulting in five data collection points for all subjects. Results.-Significant positive changes in all but two dependent measures were associated with the presence of a service dog both between and within groups (P<.001). Psychologically, all participants showed substantial improvements in self-esteem, internal locus of control, and psychological well-being within 6 months after receiving their service dog. Socially, all participants showed similar improvements in community integration. Demographically, all participants showed increases in school attendance and/or part-time employment. Economically, all participants showed dramatic decreases in the number of both paid and unpaid assistance hours. Conclusions.-Trained service dogs can be highly beneficial and potentially cost-effective components of independent living for people with physical disabilities.	SUNY BUFFALO,DEPT MED,BUFFALO,NY; UNIV CALIF SANTA BARBARA,DEPT PSYCHOL,SANTA BARBARA,CA 93106	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; University of California System; University of California Santa Barbara								ALLEN K, 1994, REHABIL PSYCHOL, V39, P29, DOI 10.1037/h0080313; ALLEN KM, 1991, J PERS SOC PSYCHOL, V61, P582, DOI 10.1037/0022-3514.61.4.582; Americans with Disabilities Act, SPRINGER REFERENCE, DOI [10.1007/springerreference_44126, DOI 10.1007/SPRINGERREFERENCE_44126]; BATAVIA AI, 1991, J HEALTH POLIT POLIC, V16, P523, DOI 10.1215/03616878-16-3-523; Bradburn N.M., 1969, STRUCTURE PSYCHOL WE, DOI DOI 10.1037/T10756-000; *CAN COMP IND, 1994, CAN COMP IND PROGR I; COVINSKY KE, 1994, JAMA-J AM MED ASSOC, V272, P1839, DOI 10.1001/jama.272.23.1839; EATON L, 1994, NY TIMES        0911, P1; EDDY J, 1988, J PSYCHOL, V122, P39, DOI 10.1080/00223980.1988.10542941; EISENBERG MG, 1982, DISABLED PEOPLE 2 CL; FITZPATRICK R, 1991, SOC SCI MED, V33, P605, DOI 10.1016/0277-9536(91)90218-2; FRIEDLAND J, 1992, SOC SCI MED, V34, P395, DOI 10.1016/0277-9536(92)90299-6; HARTMANN C, 1988, Biofactors, V1, P41; KEENAN MP, 1989, CHANGING NEEDS LONG; KINNEY WB, 1992, ARCH PHYS MED REHAB, V73, P863; Kirk Roger, 1982, EXPT DESIGN PROCEDUR, V2nd; LAPLANTE MP, 1989, 1 U CAL I HLTH AG; LITVAK SIMI, 1987, ATTENDING AM PERSONA; MADER B, 1989, CHILD DEV, V60, P1529, DOI 10.1111/j.1467-8624.1989.tb04023.x; MARINELLI RP, 1977, PSYCHOL SOCIAL IMPAC; PAULHUS D, 1983, J PERS SOC PSYCHOL, V44, P1253, DOI 10.1037/0022-3514.44.6.1253; Rosenberg M., 1965, MEASUREMENT SELF EST; TURNER RJ, 1990, J NERV MENT DIS, V178, P343, DOI 10.1097/00005053-199006000-00001; VALENTINE DP, 1993, SOC WORK HEALTH CARE, V19, P109, DOI 10.1300/J010v19n01_07; VARNI JW, 1991, ARCH PHYS MED REHAB, V72, P1053; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; *WORLD I DIS, 1988, REP NAT COUNC HAND M	27	106	107	1	53	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1996	275	13					1001	1006		10.1001/jama.275.13.1001	http://dx.doi.org/10.1001/jama.275.13.1001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UC123	8596231				2023-01-03	WOS:A1996UC12300027
J	Griffiths, C; Naish, J; Sturdy, P; Pereira, F				Griffiths, C; Naish, J; Sturdy, P; Pereira, F			Prescribing and hospital admissions for asthma in east London	BRITISH MEDICAL JOURNAL			English	Article									UNIV LONDON QUEEN MARY & WESTFIELD COLL,DEPT EPIDEMIOL & MED STAT,LONDON,ENGLAND	University of London; Queen Mary University London	Griffiths, C (corresponding author), UNIV LONDON QUEEN MARY & WESTFIELD COLL,ST BARTHOLOMEWS & ROYAL LONDON SCH MED & DENT,LONDON E1 4NS,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CAMPBELL M, 1995, BRIT MED J, V310, P1069, DOI 10.1136/bmj.310.6986.1069b; NAISH J, 1995, BRIT MED J, V310, P97, DOI 10.1136/bmj.310.6972.97; SHINE C, 1995, BRIT MED J, V310, P1070, DOI 10.1136/bmj.310.6986.1070a; STURDY P, 1995, BRIT MED J, V311, P1547, DOI 10.1136/bmj.311.7019.1547; 1994, HLTH E ANN PUBLIC HL	5	37	37	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 24	1996	312	7029					481	482		10.1136/bmj.312.7029.481	http://dx.doi.org/10.1136/bmj.312.7029.481			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX383	8597680	Green Published			2023-01-03	WOS:A1996TX38300024
J	SOLOMON, R; WERNER, C; MANN, D; DELIA, J; SILVA, P				SOLOMON, R; WERNER, C; MANN, D; DELIA, J; SILVA, P			EFFECTS OF SALINE, MANNITOL, AND FUROSEMIDE ON ACUTE DECREASES IN RENAL-FUNCTION INDUCED BY RADIOCONTRAST AGENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MAJOR ANGIOGRAPHY; CARDIAC-CATHETERIZATION; CONTRAST NEPHROPATHY; CORONARY ANGIOGRAPHY; RISK-FACTORS; FAILURE; DYSFUNCTION; INSUFFICIENCY; MEDIA; NEPHROTOXICITY	Background. Injections of radiocontrast agents are a frequent cause of acute decreases in renal function, occurring most often in patients with chronic renal insufficiency and diabetes mellitus. Methods. We prospectively studied 78 patients with chronic renal insufficiency (mean [+/-SD] serum creatinine concentration, 2.1+/-0.6 mg per deciliter [186+/-53 mu mol per liter]) who underwent cardiac angiography. The patients were randomly assigned to receive 0.45 percent saline alone for 12 hours before and 12 hours after angiography, saline plus mannitol, or saline plus furosemide. The mannitol and furosemide were given just before angiography. Serum creatinine was measured before and far 48 hours after angiography, and urine was collected for 24 hours after angiography. An acute radiocontrast-induced decrease in renal function was defined as an increase in the base-line serum creatinine concentration of at least 0.5 mg per deciliter (44 mu mol per liter) within 48 hours after the injection of radiocontrast agents. Results. Twenty of the 78 patients (26 percent) had an increase in the serum creatinine concentration of at least 0.5 mg per deciliter after angiography. Among the 28 patients in the saline group, 3 (11 percent) had such an increase in serum creatinine, as compared with 7 of 25 in the mannitol group (28 percent) and 10 of 25 in the furosemide group (40 percent) (P = 0.05). The mean increase in serum creatinine 48 hours after angiography was significantly greater in the furosemide group (P = 0.01) than in the saline group. Conclusions. In patients with chronic renal insufficiency who are undergoing cardiac angiography, hydration with 0.45 percent saline provides better protection against acute decreases in renal function induced by radiocontrast agents than does hydration with 0.45 percent saline plus mannitol or furosemide.	NEW ENGLAND DEACONESS HOSP,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA	Harvard University; Harvard Medical School	SOLOMON, R (corresponding author), JOSLIN DIABET CTR,1 JOSLIN PL,BOSTON,MA 02215, USA.			D'Elia, John/0000-0001-9482-581X				ANTO HR, 1981, ARCH INTERN MED, V141, P1652, DOI 10.1001/archinte.141.12.1652; BARRETT BJ, 1992, KIDNEY INT, V41, P1274, DOI 10.1038/ki.1992.189; BERNS AS, 1989, KIDNEY INT, V36, P730, DOI 10.1038/ki.1989.254; BERONIADE VC, 1981, 8TH INT C NEPHR ATH, P380; Brown RS, 1990, J AM SOC NEPHROL, V1, p330A; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; CRONIN RE, 1978, KIDNEY INT, V14, P187, DOI 10.1038/ki.1978.106; DAVIDSON CJ, 1989, ANN INTERN MED, V110, P119, DOI 10.7326/0003-4819-110-2-119; DELIA JA, 1982, AM J MED, V72, P719, DOI 10.1016/0002-9343(82)90536-8; EISENBERG RL, 1980, AM J MED, V68, P43, DOI 10.1016/0002-9343(80)90163-1; GOMES AS, 1989, RADIOLOGY, V170, P65, DOI 10.1148/radiology.170.1.2909121; GUSSENHOVEN MJE, 1991, J CARDIOVASC SURG, V32, P81; HEYMAN SN, 1991, KIDNEY INT, V40, P632, DOI 10.1038/ki.1991.255; HOU SH, 1983, AM J MED, V74, P243, DOI 10.1016/0002-9343(83)90618-6; LAUTIN EM, 1991, AM J ROENTGENOL, V157, P49, DOI 10.2214/ajr.157.1.2048539; LEVY E, 1993, J AM SOC NEPHROL, V4, pA319; MANSKE CL, 1990, AM J MED, V89, P615, DOI 10.1016/0002-9343(90)90180-L; MARTINPAREDERO V, 1983, ARCH SURG-CHICAGO, V118, P1417; MASON RA, 1985, JAMA-J AM MED ASSOC, V253, P1001, DOI 10.1001/jama.253.7.1001; MENASHE PI, 1988, CRIT CARE MED, V16, P1106, DOI 10.1097/00003246-198811000-00005; MORRIS CR, 1972, J CLIN INVEST, V51, P1555, DOI 10.1172/JCI106952; NORA N, 1989, KIDNEY INT, V35, P414; OGUAGHA C, 1981, 8TH INT C NEPHR ATH, P290; OLD CW, 1981, CLIN RES, V29, pA470; PERNEGER TV, 1993, J AM SOC NEPHROL, V4, pA256; PORTER GA, 1989, AM J CARDIOL, V64, pE22, DOI 10.1016/0002-9149(89)90730-3; RICH MW, 1990, ARCH INTERN MED, V150, P1237, DOI 10.1001/archinte.150.6.1237; SWARTZ RD, 1978, AM J MED, V65, P31, DOI 10.1016/0002-9343(78)90689-7; TALIERCIO CP, 1986, ANN INTERN MED, V104, P501, DOI 10.7326/0003-4819-104-4-501; VOSNIDES G, 1981, 8TH INT C NEPHR ATH, P306; WEINRAUCH LA, 1977, ANN INTERN MED, V86, P56, DOI 10.7326/0003-4819-86-1-56; WEINSTEIN JM, 1992, NEPHRON, V62, P413, DOI 10.1159/000187090; WEISBERG LS, 1994, KIDNEY INT, V45, P259, DOI 10.1038/ki.1994.32	33	866	923	0	25	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 24	1994	331	21					1416	1420		10.1056/NEJM199411243312104	http://dx.doi.org/10.1056/NEJM199411243312104			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU533	7969280				2023-01-03	WOS:A1994PU53300004
J	ROSENBLUM, LS; CASTRO, KG; DOOLEY, S; MORGAN, M; COLBERT, G				ROSENBLUM, LS; CASTRO, KG; DOOLEY, S; MORGAN, M; COLBERT, G			EFFECT OF HIV-INFECTION AND TUBERCULOSIS ON HOSPITALIZATIONS AND COST OF CARE FOR YOUNG-ADULTS IN THE UNITED-STATES, 1985 TO 1990	ANNALS OF INTERNAL MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS-INFECTION; RESISTANT MYCOBACTERIUM-TUBERCULOSIS; INTRAVENOUS DRUG-USERS; CLINICAL-FEATURES; MEDICAL-CARE; OUTBREAK; AIDS; TRANSMISSION; MANAGEMENT; IMPACT	Objective: To evaluate the effect of human immunodeficiency virus (HIV) infection and tuberculosis on hospitalizations and the cost of care. Design: National Hospital Discharge Survey, a nationally representative survey of discharges from U.S. nonfederal short-stay hospitals, and statewide billing information. Patients: Patients 15 to 44 years of age with a listed diagnosis of HIV infection (n = 418 200) or active tuberculosis (n = 77 700) during 1985-1990. Results: During 1985-1990, hospitalizations related to HIV infection increased sixfold, from 18 to 102 per 100 000 persons; during 1988-1990, hospitalizations related to-tuberculosis increased twofold, from 8 to 16 per 100 000 persons. The prevalence of tuberculosis among HIV-infected patients increased from 2.4% in 1985-1988 to 5.1% in 1989-1990 (P = 0.003). The prevalence of HIV infection among patients with tuberculosis increased from 11% in 1985-1988 to 28% in 1989 to 39% in 1990 (P < 0.001). Infection with HIV was more prevalent among patients with extrapulmonary tuberculosis (31%) than among those with pulmonary tuberculosis (18%) (P = 0.01). An increase in the duration of hospital stay was associated with both tuberculosis and HIV infection. From 1985 to 1990, inpatient care costs increased 7.7-fold and 3.2-fold for HIV and tuberculosis hospitalizations, respectively. During this period, HIV and tuberculosis hospitalizations resulted in 5 793 000 and 1 107 900 days of care, respectively, with an estimated direct cost of $5.7 to $7.4 billion and $0.89 to $1.07 billion, respectively. Estimated national costs of inpatient care for HIV infection or tuberculosis or both totaled $6.4 to $8.1 billion, 5% of which was for patients with both HIV infection and tuberculosis. Conclusions: This is the first study to use a nationally representative sample of hospitals, combined with cost data, to estimate hospitalizations and their costs for HIV and tuberculosis care. Our findings suggest that the convergence of the HIV and tuberculosis epidemics has had an increasing effect on morbidity and the cost of care among young adults in the United States. The increasing prevalence of comorbidity of HIV infection and tuberculosis in inpatients underscores the need for strict infection control of tuberculosis on the part of hospitals, increased attention to prevention, and early identification and treatment of HIV infection and tuberculosis to reduce morbidity, hospitalizations, and the cost of care.	CTR DIS CONTROL & PREVENT, DIV HIV AIDS, SURVEILLANCE BRANCH, ATLANTA, GA 30333 USA	Centers for Disease Control & Prevention - USA			Castro, Kenneth G/P-1882-2018	Castro, Kenneth G/0000-0001-7964-6354				ANDRULIS DP, 1992, JAMA-J AM MED ASSOC, V267, P2482, DOI 10.1001/jama.267.18.2482; ANDRULIS DP, 1989, JAMA-J AM MED ASSOC, V262, P784, DOI 10.1001/jama.262.6.784; [Anonymous], 1990, MMWR Recomm Rep, V39, P1; [Anonymous], 1993, MMWR Recomm Rep, V42, P1; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; [Anonymous], 1994, MMWR MORB MORTAL WKL; BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280; BURWEN D, 1993, MAY AM LUNG ASS AM T; Centers for Disease Control and Prevention, 1987, MMWR-MORBID MORTAL W, V36, p1S; Centers for Disease Control (CDC), 1990, MMWR Morb Mortal Wkly Rep, V39, P718; Centers for Disease Control (CDC), 1991, MMWR Morb Mortal Wkly Rep, V40, P585; Dooley S W Jr, 1990, MMWR Recomm Rep, V39, P1; DOOLEY SW, 1992, ANN INTERN MED, V117, P257, DOI 10.7326/0003-4819-117-3-257; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; FARNHAM PG, 1994, IN PRESS READINGS PU; FINKLER SA, 1982, ANN INTERN MED, V96, P102, DOI 10.7326/0003-4819-96-1-102; FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177; GREEN J, 1990, JAMA-J AM MED ASSOC, V264, P1261, DOI 10.1001/jama.264.10.1261; HAUPT BJ, 1992, VITAL HLTH STATI 111, V13; HELLINGER FJ, 1991, INQUIRY-J HEALTH CAR, V28, P213; HELLINGER FJ, 1993, JAMA-J AM MED ASSOC, V270, P474, DOI 10.1001/jama.270.4.474; HOPEWELL PC, 1992, CLIN INFECT DIS, V15, P540, DOI 10.1093/clind/15.3.540; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; RAVIGLIONE MC, 1992, B WORLD HEALTH ORGAN, V70, P515; ROSENBLUM L, 1993, AM J PUBLIC HEALTH, V83, P1457, DOI 10.2105/AJPH.83.10.1457; ROSENBLUM LS, 1992, J ACQ IMMUN DEF SYND, V5, P497; SCITOVSKY AA, 1987, PUBLIC HEALTH REP, V102, P5; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SELWYN PA, 1989, AIDS, V3, pS201, DOI 10.1097/00002030-198901001-00029; SHAH BY, 1981, SESUDAAN STANDARD ER, P1; SNIDER DE, 1992, NEW ENGL J MED, V326, P703, DOI 10.1056/NEJM199203053261011; 1980, DHHS PHS801260 PUB; 1992, TUBERCULOSIS STATIST, P14; 1990, MMWR-MORBID MORTAL W, V39, P110; 1990, MMWR-MORBID MORTAL W, V39, P9; 1993, MMWR-MORBID MORTAL W, V42, P696; 1989, MMWR-MORBID MORTAL W, V38, P243; 1989, AIDS PUBLIC INFORMAT; 1993, MMWR-MORBID MORTAL W, V42, P11; 1989, MMWR-MORBID MORTAL W, V38, P236; 1993, MMWR-MORBID MORTAL W, V42, P703; 1989, CURRENT POPULATI P25, V1044, P13; 1986, SUGI SUPPLEMENTAL LI, P269; 1992, STATISTICAL ABSTRACT, P471	45	40	40	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1994	121	10					786	792		10.7326/0003-4819-121-10-199411150-00009	http://dx.doi.org/10.7326/0003-4819-121-10-199411150-00009			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ928	7944056				2023-01-03	WOS:A1994PQ92800009
J	KUMAR, L				KUMAR, L			DONOR LEUKOCYTE INFUSIONS FOR RELAPSE IN CHRONIC MYELOGENOUS LEUKEMIA	LANCET			English	Editorial Material							BONE-MARROW TRANSPLANTATION; CHRONIC MYELOID-LEUKEMIA; LEUKOCYTE INFUSIONS; IMMUNOTHERAPY; TRANSFUSIONS				KUMAR, L (corresponding author), ALL INDIA INST MED SCI,INST ROTARY CANC HOSP,DEPT MED ONCOL,NEW DELHI,INDIA.							ANTIN JH, 1993, BLOOD, V82, P2273; ARCESE W, 1993, BLOOD, V82, P3211; BAR BMAM, 1993, J CLIN ONCOL, V11, P513; CULLIS JO, 1992, BLOOD, V79, P1379; DROBYSKI WR, 1993, BLOOD, V82, P2310; HERTENSTEIN B, 1993, TRANSPLANTATION, V56, P1114, DOI 10.1097/00007890-199311000-00013; KOLB HJ, 1993, SEMIN HEMATOL, V30, P37; KOLB HJ, 1990, BLOOD, V76, P2462, DOI 10.1182/blood.V76.12.2462.2462; KUMAR L, 1994, J CLIN ONCOL, V12, P1710, DOI 10.1200/JCO.1994.12.8.1710; MRSIC M, 1992, BONE MARROW TRANSPL, V9, P269; PORTER DL, 1994, NEW ENGL J MED, V330, P100, DOI 10.1056/NEJM199401133300204	11	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 22	1994	344	8930					1101	1102		10.1016/S0140-6736(94)90624-6	http://dx.doi.org/10.1016/S0140-6736(94)90624-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN066	7934489				2023-01-03	WOS:A1994PN06600003
J	LOCKE, SE; RANSIL, BJ; ZACHARIAE, R; MOLAY, F; TOLLINS, K; COVINO, NA; DANFORTH, D				LOCKE, SE; RANSIL, BJ; ZACHARIAE, R; MOLAY, F; TOLLINS, K; COVINO, NA; DANFORTH, D			EFFECT OF HYPNOTIC SUGGESTION ON THE DELAYED-TYPE HYPERSENSITIVITY RESPONSE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CELL-MEDIATED-IMMUNITY; VARICELLA-ZOSTER VIRUS; SKIN-TEST; GUIDED IMAGERY; MULTI-TEST; MODULATION; RELAXATION; IMMEDIATE; ANTIGENS; SYSTEM	Objective.-To determine whether individuals selected for good general health, high hypnotizability, and the ability to alter skin temperature under hypnotic suggestion can influence the delayed-type hypersensitivity (DTH) response to varicella-zoster (VZ) antigen under hypnotic suggestion. Design.-A blinded clinical trial using a repeated measures design with subjects serving as their own controls. Subjects were randomly assigned to undergo a predetermined sequence of four different experimental conditions, occurring at weekly intervals, with each condition including VZ skin testing: (1) hypnosis with suggestions to enhance the DTH response to VZ antigen; (2) hypnosis with suggestions to suppress the DTH response; (3) hypnosis with suggestions for relaxation only; and (4) skin testing without hypnosis. Setting.-A National Institutes of Health-supported clinical research center in a teaching hospital. Subjects.-A stratified sample of 24 ambulatory, healthy, highly hypnotizable, volunteer college students selected for their above-average ability to alter skin temperature after hypnotic suggestions and their positive baseline responses to VZ antigen. There were 11 males and 13 females with a mean+/-SD age of 22+/-6 years. The mean+/-SD hypnotizability score (Harvard Group Scale of Hypnotic Susceptibility) was 11+/-1. Interventions.-Intradermal skin testing with VZ antigen (Mantoux method) and hypnotic suggestion. Main Outcome Measures.-Areas of induration of the DTH response measured at 24 and 48 hours after injection of antigen. Results.-The area of the DM response was not affected by the experimental interventions. The area of erythema was likewise unaffected.	HARVARD UNIV,SCH MED,BOSTON,MA; BETH ISRAEL HOSP,CHARLES A DANA RES INST,BOSTON,MA 02215; BETH ISRAEL HOSP,HARVARD THORNDIKE LAB,BOSTON,MA 02215; BETH ISRAEL HOSP,DEPT MED,BOSTON,MA 02215; AARHUS UNIV,DEPT PSYCHOL,AARHUS,DENMARK; BETH ISRAEL HOSP,DEPT NURSING,BOSTON,MA 02215	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Aarhus University; Harvard University; Beth Israel Deaconess Medical Center	LOCKE, SE (corresponding author), BETH ISRAEL HOSP,DEPT PSYCHIAT,330 BROOKLINE AVE,BOSTON,MA 02215, USA.				NCRR NIH HHS [RR-01032] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001032] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BABA K, 1987, J CLIN MICROBIOL, V25, P2193, DOI 10.1128/JCM.25.11.2193-2196.1987; BALASCHAK B, 1972, INT J CLIN EXP HYP, V20, P38, DOI 10.1080/00207147208409274; BATES SE, 1979, CANCER, V43, P2306, DOI 10.1002/1097-0142(197906)43:6<2306::AID-CNCR2820430621>3.0.CO;2-K; BERGER R, 1985, POSTGRAD MED J, V61, P137; BERGER R, 1985, POSTGRAD MED J S4, V6, P143; BLACK S, 1963, BRIT MED J, V6, P1649; Brodman K., 1949, CORNELL MED INDEX HL; BURKE BL, 1982, ARCH INTERN MED, V142, P291, DOI 10.1001/archinte.142.2.291; COE WC, 1976, INT J CLIN EXP HYP, V24, P281; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; DIAMOND MJ, 1984, AM J CLIN HYPN, V27, P3, DOI 10.1080/00029157.1984.10402582; DUCHATEAU J, 1985, POSTGRAD MED J, V61, P147; DVORAK HF, 1974, LAB INVEST, V31, P111; GROSSMAN J, 1974, J ALLERGY CLIN IMMUN, V55, P268; HALL NRS, 1991, PSYCHONEUROIMMUNOLOG, P1067; HENOCQ E, 1979, LANCET, V1, P674; JEMMOTT JB, 1984, PSYCHOL BULL, V95, P78, DOI 10.1037/0033-2909.95.1.78; JUST M, 1985, POSTGRAD MED J, V61, P129; KAMIYA H, 1977, J INFECT DIS, V136, P784, DOI 10.1093/infdis/136.6.784; KIECOLTGLASER JK, 1992, J CONSULT CLIN PSYCH, V60, P569, DOI 10.1037/0022-006X.60.4.569; KNIKER WT, 1979, ANN ALLERGY, V43, P73; KNIKER WT, 1984, ANN ALLERGY, V52, P75; Kramer E, 1969, Am J Clin Hypn, V11, P175; LARUSSA P, 1985, J INFECT DIS, V152, P869, DOI 10.1093/infdis/152.5.869; LAWRENCE JR, 1982, INT J CLIN EXP HYP, V30, P167; LESOURD B, 1982, CLIN EXP IMMUNOL, V50, P635; LOCKE SE, 1987, ANN NY ACAD SCI, V496, P745, DOI 10.1111/j.1749-6632.1987.tb35841.x; MURPHREE JT, 1979, ANN ALLERGY, V43, P279; PLOTKIN SA, 1985, POSTGRAD MED J, V61, P7; REYHER J, 1976, AM J CLIN HYPN, V19, P103; Sadock, 1989, COMPREHENSIVE TXB PS, P1240; SEYMOUR GE, 1976, J PSYCHOSOM RES, V20, P469, DOI 10.1016/0022-3999(76)90011-8; Shor RE, 1962, HARVARD GROUP SCALE; SMALL MM, 1969, INT J CLIN EXP HYP, V17, P251, DOI 10.1080/00207146908407248; SMITH GR, 1992, PSYCHOSOMATICS, V33, P444, DOI 10.1016/S0033-3182(92)71949-5; SMITH GR, 1985, ARCH INTERN MED, V145, P2110, DOI 10.1001/archinte.145.11.2110; SMITH GR, 1983, PSYCHOSOM MED, V45, P444; SOKAL J, 1973, NEW ENGL J MED, V293, P501; STEELE RW, 1986, J IMMUNOL METHODS, V86, P213, DOI 10.1016/0022-1759(86)90455-2; STERN D B, 1978, American Journal of Clinical Hypnosis, V21, P109; VANROOD YR, 1993, J BEHAV MED, V16, P163, DOI 10.1007/BF00844891; VONBLOMBERG M, 1978, IMMUNOLOGY, V35, P361; WEITZENHOFFER AM, 1992, STANFORD HYPNOTIC SU; ZACHARIAE R, 1989, ALLERGY, V44, P537, DOI 10.1111/j.1398-9995.1989.tb04198.x; ZACHARIAE R, 1990, PSYCHOTHER PSYCHOSOM, V54, P32, DOI 10.1159/000288374; ZACHARIAE R, 1993, ALLERGY, V48, P6, DOI 10.1111/j.1398-9995.1993.tb02168.x	46	24	24	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 6	1994	272	1					47	52		10.1001/jama.272.1.47	http://dx.doi.org/10.1001/jama.272.1.47			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NU485	8007079				2023-01-03	WOS:A1994NU48500029
J	MENICHETTI, F; DELFAVERO, A; MARTINO, P; BUCANEVE, G; MICOZZI, A; DANTONIO, D; RICCI, P; CAROTENUTO, M; LISO, V; NOSARI, AM; BARBUI, T; FASOLA, G; MANDELLI, F; MONTILLO, M; BARBABIETOLA, G; DINOTA, A; PAGANO, L; JACOPINO, P; ISABELLA, N; FONTANA, R; LANDONIO, G; BROCCIA, G; CUDILLO, L; DIFAZIO, S; PACILLI, L; MONACO, M; CARELLA, AM; CHIERICHINI, A; QUINTINI, G; GABBAS, A; CITARELLA, P; DALLASTA, A; RONCONI, F; DORE, F; GALIENI, P				MENICHETTI, F; DELFAVERO, A; MARTINO, P; BUCANEVE, G; MICOZZI, A; DANTONIO, D; RICCI, P; CAROTENUTO, M; LISO, V; NOSARI, AM; BARBUI, T; FASOLA, G; MANDELLI, F; MONTILLO, M; BARBABIETOLA, G; DINOTA, A; PAGANO, L; JACOPINO, P; ISABELLA, N; FONTANA, R; LANDONIO, G; BROCCIA, G; CUDILLO, L; DIFAZIO, S; PACILLI, L; MONACO, M; CARELLA, AM; CHIERICHINI, A; QUINTINI, G; GABBAS, A; CITARELLA, P; DALLASTA, A; RONCONI, F; DORE, F; GALIENI, P			PREVENTING FUNGAL INFECTION IN NEUTROPENIC PATIENTS WITH ACUTE-LEUKEMIA - FLUCONAZOLE COMPARED WITH ORAL AMPHOTERICIN-B	ANNALS OF INTERNAL MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; CANDIDIASIS; TRIAL	Objective: To compare the efficacy and tolerability of fluconazole and oral amphotericin B in preventing fungal infection in neutropenic patients with acute leukemia. Design: A randomized, controlled, multicenter trial. Setting: 30 hematologic units in tertiary care or university hospitals. Patients: 820 consecutive, afebrile, adult patients with acute leukemia and chemotherapy-induced neutropenia. Intervention: Patients were randomly assigned to receive fluconazole, 150 mg, as a once-daily capsule, or amphotericin B suspension, 500 mg every 6 hours. Measurements: An intention-to-treat analysis was done for 820 patients: 420 treated with fluconazole and 400 treated with oral amphotericin B. Results: Definite systemic fungal infection occurred in 2.6% of fluconazole recipients and 2.5% of amphotericin B recipients; suspected systemic fungal infection requiring the empiric use of intravenous amphotericin B occurred in 16% of fluconazole recipients and 21% of oral amphotericin B recipients, a difference of 5 percentage points (95% CI for difference, - 0.02% to 10%; P = 0.07). Superficial fungal infection was documented in 1.7% of fluconazole recipients compared with 2.7% of amphotericin B recipients, a difference of one percentage point (CI of difference, - 0.9% to 3%; P > 0.2). The distribution of fungal isolates in systemic and superficial fungal infection was similar in both groups. The overall mortality rate accounted for 10% in both groups. An excellent compliance was documented for 90% of patients treated with fluconazole compared with 72% of those treated with amphotericin B suspension, a difference of 18 percentage points (CI for difference, 13% to 23%). Side effects were documented less frequently in fluconazole than in amphotericin B recipients (1.4% compared with 7%, a difference of 5.6 percentage points; CI for difference, 2% to 8%; P < 0.01). Conclusion: Fluconazole was at least as effective as oral amphotericin B in preventing systemic and superficial fungal infection and the empiric use of amphotericin B in neutropenic patients with acute leukemia but was better tolerated.	UNIV PERUGIA, IST CLIN MED 1, PERUGIA, ITALY; UNIV ROMA LA SAPIENZA, IST EMATOL, ROME, ITALY; OSPED PESCARA, DIV EMATOL, PESCARA, ITALY; UNIV BOLOGNA, IST EMATOL, BOLOGNA, ITALY; UNIV BARI, IST EMATOL, BARI, ITALY; OSPED NIGUARDA CA GRANDA, DIV TALAMONA, MILAN, ITALY; OSPED RIUNITI BERGAMO, DIV EMATOL, I-24100 BERGAMO, ITALY; OSPED UDINE, CATTEDRA EMATOL, UDINE, ITALY; UNIV ANCONA, IST CLIN MED, ANCONA, ITALY; OSPED POTENZA, DIV EMATOL, POTENZA, ITALY; UNIV CATTOLICA SACRO CUORE, IST SEMEIOT MED, ROME, ITALY; OSPED REGGIO CALABRIA, DIV EMATOL, CALABRIA, ITALY; OSPED MOLINETTE, DIV EMATOL, TURIN, ITALY; UNIV NAPLES, SEZ EMATOL, NAPLES, ITALY; OSPED NIGUARDA CA GRANDA, DIV FALCK, MILAN, ITALY; OSPED ONCOL BUSINCO, CAGLIARI, ITALY; OSPED S EUGENIO, DIV EMATOL, ROME, ITALY; UNIV CATANIA, CATTEDRA EMATOL, CATANIA, ITALY; OSPED SCLAVO, DIV EMATOL, SIENA, ITALY; OSPED S CAMILLO ROMA, DIV EMATOL, ROME, ITALY; OSPED FOGGIA, DIV EMATOL, FOGGIA, ITALY; OSPED SAN MARTINO GENOVA, DIV EMATOL, GENOA, ITALY; OSPED LATINA, DIV EMATOL, LATINA, ITALY; UNIV PALERMO, MED CLIN, PALERMO, ITALY; OSPED NUORO, DIV EMATOL, NUORO, ITALY; UNIV PALERMO, CATTEDRA EMATOL, PALERMO, ITALY; OSPED REGGIO EMILIA, DIV EMATOL, REGGIO EMILIA, ITALY; OSPED AVELLINO, DIV EMATOL, AVELLINO, ITALY; OSPED SASSARI, IST EMATOL, SASSARI, ITALY	University of Perugia; Sapienza University Rome; University of Bologna; Universita degli Studi di Bari Aldo Moro; IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedale Niguarda Ca' Granda; Ospedali Riuniti di Bergamo; University of Udine; Marche Polytechnic University; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette; University of Naples Federico II; IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedale Niguarda Ca' Granda; Sant'Eugenio Hospital; University of Catania; University of Genoa; IRCCS AOU San Martino IST; University of Palermo; University of Palermo	MENICHETTI, F (corresponding author), UNIV PERUGIA, OSPED POLICLIN MONTELUCE, IST MALATTIE INFETT, I-06122 PERUGIA, ITALY.		pagano, livio/A-2024-2008; pagano, livio/J-3020-2018	pagano, livio/0000-0001-8287-928X				CLIFT RA, 1984, AM J MED, V77, P34; DEGREGORIO MW, 1982, AM J MED, V73, P543, DOI 10.1016/0002-9343(82)90334-5; DELFAVERO A, 1991, ANN INTERN MED, V115, P7, DOI 10.7326/0003-4819-115-1-7; DICK JD, 1980, ANTIMICROB AGENTS CH, V18, P158, DOI 10.1128/AAC.18.1.158; EZDINLI EZ, 1979, JAMA-J AM MED ASSOC, V242, P258, DOI 10.1001/jama.242.3.258; GOODMAN JL, 1992, NEW ENGL J MED, V326, P845, DOI 10.1056/NEJM199203263261301; MERZ WG, 1984, J CLIN MICROBIOL, V20, P1194, DOI 10.1128/JCM.20.6.1194-1195.1984; MEUNIER F, 1991, DRUG INVEST, V3, P258, DOI 10.1007/BF03259575; MEUNIER F, 1987, REV INFECT DIS, V9, P408; MEUNIER F, 1989, AM J MED, V86, P668; MILLIKEN S, 1988, BONE MARROW TRANSPL, V3, P324; PERSONS DA, 1991, NEW ENGL J MED, V325, P1315; PIZZO PA, 1982, AM J MED, V72, P101, DOI 10.1016/0002-9343(82)90594-0; ROZENBERGARSKA M, 1991, J ANTIMICROB CHEMOTH, V27, P369, DOI 10.1093/jac/27.3.369; SCHIMPFF SC, 1972, ANN INTERN MED, V77, P707, DOI 10.7326/0003-4819-77-5-707; SCHULER U, 1992, NEW ENGL J MED, V326, P892; SCHULER U, 1992, 18TH ANN M EUR GROUP, P86; WINGARD JR, 1991, NEW ENGL J MED, V325, P1274, DOI 10.1056/NEJM199110313251803; WINSTON DJ, 1993, ANN INTERN MED, V118, P495, DOI 10.7326/0003-4819-118-7-199304010-00003; 1990, BLOOD S1, V76, P314; 1990, BLOOD S1, V76, P340	21	121	122	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1994	120	11					913	918		10.7326/0003-4819-120-11-199406010-00003	http://dx.doi.org/10.7326/0003-4819-120-11-199406010-00003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN110	8172437				2023-01-03	WOS:A1994NN11000003
J	DANIS, M; GARRETT, J; HARRIS, R; PATRICK, DL				DANIS, M; GARRETT, J; HARRIS, R; PATRICK, DL			STABILITY OF CHOICES ABOUT LIFE-SUSTAINING TREATMENTS	ANNALS OF INTERNAL MEDICINE			English	Article						LIFE SUPPORT CARE; PATIENT PARTICIPATION; DECISION MAKING; LIVING WILLS; TREATMENT REFUSAL	ADVANCE DIRECTIVES; HEALTH; CARE	Objective: To examine the stability of patients' choices for life-sustaining treatments. Design: A longitudinal cohort study. Setting: Primary care practices in central North Carolina. Patients: Medicare recipients (n = 2536). Intervention: Participants were asked about demographic characteristics, health status, well-being, depression, social support, use of a living will, and desire for life-sustaining treatments if they were to become terminally ill. These questions were repeated 2 years later (n = 2073, 82% follow-up). Results: The population tended to choose to forego one more treatment at follow-up than they did at baseline. A choice to forego treatment was twice as stable as a choice to receive treatment. Patients with a living will were less likely to change their wishes (14%) than those without a living will (41%). Persons were more likely to want increased treatment at a later time if they had been hospitalized (23% compared with 18%), had had an accident (29% compared with 19%), had become more immobile (23% compared with 19%), had become more depressed (25% compared with 15%), or had less social support (25% compared with 14%). Conclusions: Most patients (85%) who had chosen to forego life-sustaining treatments did not change their choices. Nonetheless, these data suggest that it is important to review patients' preferences for life-sustaining treatments rather than to assume the stability of their choices.	UNIV N CAROLINA, SHEPS CTR HLTH SERV, CHAPEL HILL, NC 27599 USA; UNIV WASHINGTON, SCH PUBL HLTH & COMMUNITY MED, DEPT HLTH SERV, SEATTLE, WA 98195 USA	University of North Carolina; University of North Carolina Chapel Hill; University of Washington; University of Washington Seattle	DANIS, M (corresponding author), UNIV N CAROLINA, DEPT MED, DIV GEN MED, CB 7110, 5025A OLD CLIN BLDG, CHAPEL HILL, NC 27599 USA.		Patrick, Donald/Y-2460-2019	Patrick, Donald/0000-0003-0756-0492				DANIS M, 1991, NEW ENGL J MED, V324, P882, DOI 10.1056/NEJM199103283241304; EVERHART MA, 1990, CHEST, V97, P159, DOI 10.1378/chest.97.1.159; GAMBLE ER, 1991, ARCH INTERN MED, V151, P277, DOI 10.1001/archinte.151.2.277; GARRETT JM, 1993, J GEN INTERN MED, V8, P361, DOI 10.1007/BF02600073; GRECO PJ, 1991, ANN INTERN MED, V115, P639, DOI 10.7326/0003-4819-115-8-639; Kaplan R., 1990, QUALITY LIFE ASSESSM, P131; KAPLAN RM, 1976, HEALTH SERV RES, V11, P478; MENIKOFF JA, 1992, NEW ENGL J MED, V327, P1165, DOI 10.1056/NEJM199210153271612; MOSSEY JM, 1982, AM J PUBLIC HEALTH, V72, P800, DOI 10.2105/AJPH.72.8.800; PATRICK DL, 1988, J GEN INTERN MED, V3, P218, DOI 10.1007/BF02596335; PATRICK DL, 1973, J HEALTH SOC BEHAV, V14, P6, DOI 10.2307/2136932; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1983, DECIDING FOREGO LIFE; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; SEHGAL A, 1992, JAMA-J AM MED ASSOC, V267, P59, DOI 10.1001/jama.267.1.59; SILVERSTEIN MD, 1991, MAYO CLIN PROC, V66, P906, DOI 10.1016/S0025-6196(12)61577-8; 1987, GUIDELINES TERMINATI	16	194	194	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1994	120	7					567	573		10.7326/0003-4819-120-7-199404010-00006	http://dx.doi.org/10.7326/0003-4819-120-7-199404010-00006			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC764	8116994				2023-01-03	WOS:A1994NC76400006
J	GAFFNEY, G; SELLERS, S; FLAVELL, V; SQUIER, M; JOHNSON, A				GAFFNEY, G; SELLERS, S; FLAVELL, V; SQUIER, M; JOHNSON, A			CASE-CONTROL STUDY OF INTRAPARTUM CARE, CEREBRAL-PALSY, AND PERINATAL DEATH	BRITISH MEDICAL JOURNAL			English	Article							ASPHYXIA	Objective-To investigate the relation between suboptimal intrapartum obstetric care and cerebral palsy or death. Design-Case-control study. Setting-Oxford Regional Health Authority. Subjects-141 babies who subsequently developed cerebral palsy and 62 who died intrapartum or neonatally, 1984-7. All subjects were born at term of singleton pregnancies and had no congenital anomaly. Two controls, matched for place and time of birth, were selected for each index case. Main outcome measures-Adverse antenatal factors and suboptimal intrapartum care (by using predefined criteria). Results-Failure to respond to signs of severe fetal distress was more common in cases of cerebral palsy (odds ratio 4.5; 95% confidence interval 2.4 to 8.4) and in cases of death (26.1; 6.2 to 109.7) than among controls. This association persisted even after adjustment for increased incidence of a complicated obstetric history in cases of cerebral palsy. Neonatal encephalopathy is regarded as the best clinical indicator of birth asphyxia; only two thirds (23/33) of the children with cerebral palsy in whom there had been a suboptimal response to fetal distress, however, had evidence of neonatal encephalopathy; these 23 formed 6.8% of all children with cerebral palsy born to residents of the region in the four years studied. Conclusion-There is an association between quality of intrapartum care and death. The findings also suggest an association between suboptimal care and cerebral palsy, but this seems to have a role in only a small proportion of all cases of cerebral palsy. The contribution of adverse antenatal factors in the origin of cerebral palsy needs further study.	RADCLIFFE INFIRM,NATL PERINATAL EPIDEMIOL UNIT,OXFORD OX2 6HE,OXON,ENGLAND; JOHN RADCLIFFE MATERN HOSP,OXFORD OX3 9DU,OXON,ENGLAND; RADCLIFFE INFIRM,DEPT NEUROPATHOL,OXFORD OX2 6HE,OXON,ENGLAND	Radcliffe Infirmary; University of Oxford; Radcliffe Infirmary			Sandall, Jane/D-4146-2009	Sandall, Jane/0000-0003-2000-743X; Johnson, Anne/0000-0003-1330-7100				BLAIR E, 1988, J PEDIATR-US, V112, P515, DOI 10.1016/S0022-3476(88)80161-6; BLAIR E, 1990, AM J OBSTET GYNECOL, V162, P229, DOI 10.1016/0002-9378(90)90856-3; BRESLOW NE, 1980, INT AGENCY RES CANCE, V32; BRYCE R, 1989, EFFECTIVE CARE PREGN, P1313; FREEMAN JM, 1988, PEDIATRICS, V82, P240; Gilles FH, 1983, DEV HUMAN BRAIN GROW, P227; HAGBERG B, 1989, ACTA PAEDIATR SCAND, V78, P283, DOI 10.1111/j.1651-2227.1989.tb11071.x; JOHNSON A, 1989, COMMUNITY MED, V11, P352; MACDONALD D, 1985, AM J OBSTET GYNECOL, V152, P524, DOI 10.1016/0002-9378(85)90619-2; MYERS RE, 1972, AM J OBSTET GYNECOL, V112, P246, DOI 10.1016/0002-9378(72)90124-X; NAEYE RL, 1989, AM J DIS CHILD, V143, P1154, DOI 10.1001/archpedi.1989.02150220044018; NELSON KB, 1988, J PEDIATR-US, V112, P572, DOI 10.1016/S0022-3476(88)80169-0; NELSON KB, 1986, NEW ENGL J MED, V315, P81, DOI 10.1056/NEJM198607103150202; NELSON KB, 1989, CLIN PERINATOL, V16, P995, DOI 10.1016/S0095-5108(18)30617-1; NISWANDER K, 1984, LANCET, V2, P827; PANETH N, 1983, OBSTET GYNECOL, V61, P547; RICHMOND S, IN PRESS OBSTET GYNE; SARNAT HB, 1976, ARCH NEUROL-CHICAGO, V33, P696, DOI 10.1001/archneur.1976.00500100030012; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SIMS ME, 1985, AM J OBSTET GYNECOL, V151, P721, DOI 10.1016/0002-9378(85)90503-4; STANLEY FJ, 1992, BRIT MED J, V304, P1658, DOI 10.1136/bmj.304.6843.1658; TORFS CP, 1990, J PEDIATR-US, V116, P615, DOI 10.1016/S0022-3476(05)81615-4; 1989, WORKING PARTY RESUSC; 1989, EGRET EPIDEMIOLOGICA; 1988, OPCS MONITOR, pDH3	25	129	130	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 19	1994	308	6931					743	750		10.1136/bmj.308.6931.743	http://dx.doi.org/10.1136/bmj.308.6931.743			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC348	8142827	Green Published			2023-01-03	WOS:A1994NC34800016
J	FERRER, M; TORRES, A; GONZALEZ, J; DELABELLACASA, JP; ELEBIARY, M; ROCA, M; GATELL, JM; RODRIGUEZROISIN, R				FERRER, M; TORRES, A; GONZALEZ, J; DELABELLACASA, JP; ELEBIARY, M; ROCA, M; GATELL, JM; RODRIGUEZROISIN, R			UTILITY OF SELECTIVE DIGESTIVE DECONTAMINATION IN MECHANICALLY VENTILATED PATIENTS	ANNALS OF INTERNAL MEDICINE			English	Article						RESPIRATION, ARTIFICIAL; GROSS INFECTION; PNEUMONIA; DECONTAMINATION; DIGESTIVE SYSTEM	PROTECTED SPECIMEN BRUSH; CRITICALLY ILL PATIENTS; INTENSIVE-CARE UNITS; QUANTITATIVE CULTURE TECHNIQUES; NOSOCOMIAL BACTERIAL PNEUMONIA; RESPIRATORY-TRACT INFECTIONS; MULTIPLE TRAUMA PATIENTS; GRAM-NEGATIVE BACILLI; DOUBLE-BLIND; INTUBATED PATIENTS	Objective: To assess selective digestive decontamination for preventing nosocomial pneumonia and mortality in mechanically ventilated patients. Design: Prospective, randomized, placebo-controlled, double-blind study. Setting: Respiratory intensive care unit of a 1000-bed teaching hospital. Patients: 80 patients receiving mechanical ventilation for more than 72 hours. Interventions: Patients received selective digestive decontamination using polymyxin E, tobramycin, and amphotericin B through a nasogastric tube and also topically in the oropharynx; control patients received placebo. All patients received intravenous cefotaxime for 4 days or other systemic antibiotics if required. Measurements: Bacteriologic surveillance (three times a week) was done by quantitatively culturing tracheal aspirates, pharyngeal swabs, and gastric juice. The diagnosis of pneumonia was based on quantitative cultures of protected specimen brush samples (greater than or equal to 10(3) CFU/mL [colony forming units/mL]) or bronchoalveolar lavage fluid (greater than or equal to 10(4) CFU/mL) and autopsy findings. Results: Bronchial, oropharyngeal, and gastric colonization by gram-negative bacilli and Candida species was lower in the selective digestive decontamination group compared with the placebo group. Nonsignificant differences were found in the incidence of nosocomial infections (28% compared with 37%; odds ratio, 0.66; 95% Cl, 0.35 to 1.25) and nosocomial pneumonia (18% compared with 24%; odds ratio, 0.7; Cl, 0.33 to 1.46) and in the crude mortality rate (31% compared with 27%; odds ratio, 1.21; Cl, 0.63 to 2.34) when comparing digestive decontamination with placebo, respectively. Conclusions: Selective digestive decontamination in our mechanically ventilated patients significantly decreased the colonization rate of gram-negative bacilli and of Candida species but not of Staphylococcus aureus. It did not decrease the incidence of nosocomial pneumonia, mortality, length of stay, or the duration of mechanical ventilation.	UNIV BARCELONA, HOSP CLIN, SERV PNEUMOL, E-08036 BARCELONA, SPAIN	University of Barcelona; Hospital Clinic de Barcelona			Gatell, Jose M/ABC-3607-2020; Torres, Antoni/H-6128-2017	Torres, Antoni/0000-0002-8643-2167; Ferrer, Miguel/0000-0001-8171-6673				AERDTS SJA, 1991, CHEST, V100, P783, DOI 10.1378/chest.100.3.783; ANDREWS CP, 1981, CHEST, V80, P254, DOI 10.1378/chest.80.3.254; Balows A, 1991, MANUAL CLIN MICROBIO; BELL RC, 1983, ANN INTERN MED, V99, P293, DOI 10.7326/0003-4819-99-3-293; BLAIR P, 1991, SURGERY, V110, P303; BROWN RB, 1985, CRIT CARE MED, V13, P472, DOI 10.1097/00003246-198506000-00006; BRUNBUISSON C, 1989, ANN INTERN MED, V110, P873, DOI 10.7326/0003-4819-110-11-873; CHANDRASEKAR PH, 1986, CRIT CARE MED, V14, P508, DOI 10.1097/00003246-198605000-00017; CHASTRE J, 1984, AM REV RESPIR DIS, V130, P924; CHASTRE J, 1988, AM J MED, V85, P499; COCKERILL FR, 1992, ANN INTERN MED, V117, P545, DOI 10.7326/0003-4819-117-7-545; DASCHNER F, 1985, INTENS CARE MED, V11, P284, DOI 10.1007/BF00273537; DOEBBELING BN, 1992, NEW ENGL J MED, V327, P88, DOI 10.1056/NEJM199207093270205; DRIKS MR, 1987, NEW ENGL J MED, V317, P1376, DOI 10.1056/NEJM198711263172204; FAGON JY, 1988, AM REV RESPIR DIS, V138, P110, DOI 10.1164/ajrccm/138.1.110; FAGON JY, 1989, AM REV RESPIR DIS, V139, P877, DOI 10.1164/ajrccm/139.4.877; FLAHERTY J, 1990, J INFECT DIS, V162, P1393, DOI 10.1093/infdis/162.6.1393; GARIBALDI RA, 1981, AM J MED, V70, P677, DOI 10.1016/0002-9343(81)90595-7; GASTINNE H, 1992, NEW ENGL J MED, V326, P594, DOI 10.1056/NEJM199202273260903; GASTINNE H, 1991, INTENS CARE MED, V17, P215, DOI 10.1007/BF01709880; GODARD J, 1990, INTENS CARE MED, V16, P307, DOI 10.1007/BF01706355; HAMMOND JMJ, 1992, LANCET, V340, P5, DOI 10.1016/0140-6736(92)92422-C; HARTENAUER U, 1991, CRIT CARE MED, V19, P463, DOI 10.1097/00003246-199104000-00003; Hunefeld G, 1989, Anaesthesiol Reanim, V14, P131; HUXLEY EJ, 1978, AM J MED, V64, P564, DOI 10.1016/0002-9343(78)90574-0; JIMENEZ P, 1989, CRIT CARE MED, V17, P882, DOI 10.1097/00003246-198909000-00007; JOHANSON WG, 1972, ANN INTERN MED, V77, P701, DOI 10.7326/0003-4819-77-5-701; KERVER AJH, 1988, CRIT CARE MED, V16, P1087, DOI 10.1097/00003246-198811000-00001; KONRAD F, 1989, ANAESTHESIST, V38, P99; LEDINGHAM IM, 1988, LANCET, V1, P785; LIBERATI A, 1992, REANIMATION URGENCES, V1, P521; LOIRAT P, 1992, INTENS CARE MED, V18, P182, DOI 10.1007/BF01709246; MAHUL P, 1992, INTENS CARE MED, V18, P20, DOI 10.1007/BF01706421; MCCLELLAND P, 1990, CRIT CARE MED, V18, P935, DOI 10.1097/00003246-199009000-00006; MURRAY AE, 1991, BAILLIERE CLIN ANAES, V5, P1, DOI 10.1016/S0950-3501(05)80202-8; PUGIN J, 1991, JAMA-J AM MED ASSOC, V265, P2704, DOI 10.1001/jama.265.20.2704; ROCHA LA, 1992, INTENS CARE MED, V18, P398, DOI 10.1007/BF01694341; RODRIGUEZROLDAN JM, 1990, CRIT CARE MED, V18, P1239, DOI 10.1097/00003246-199011000-00011; STOUTENBEEK CP, 1984, INTENS CARE MED, V10, P185, DOI 10.1007/BF00259435; STOUTENBEEK CP, 1987, J TRAUMA, V27, P357, DOI 10.1097/00005373-198704000-00003; Sydow M, 1990, Anasth Intensivther Notfallmed, V25, P416, DOI 10.1055/s-2007-1001091; TETTEROO GWM, 1990, LANCET, V335, P704, DOI 10.1016/0140-6736(90)90813-K; TORRES A, 1992, ANN INTERN MED, V116, P540, DOI 10.7326/0003-4819-116-7-540; TORRES A, 1989, AM REV RESPIR DIS, V140, P306, DOI 10.1164/ajrccm/140.2.306; TORRES A, 1993, AM REV RESPIR DIS, V147, P952, DOI 10.1164/ajrccm/147.4.952; ULRICH C, 1989, INTENS CARE MED, V15, P424, DOI 10.1007/BF00255597; UNERTL K, 1987, INTENS CARE MED, V13, P106; VANSAENE HF, 1992, CRIT CARE MED, V20, P691, DOI 10.1097/00003246-199205000-00024; WUNDERINK RG, 1992, CHEST, V101, P458, DOI 10.1378/chest.101.2.458; ZOBEL G, 1991, CRIT CARE MED, V19, P1242, DOI 10.1097/00003246-199110000-00005	50	98	104	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1994	120	5					389	395		10.7326/0003-4819-120-5-199403010-00006	http://dx.doi.org/10.7326/0003-4819-120-5-199403010-00006			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY497	8304656				2023-01-03	WOS:A1994MY49700006
J	ALOIA, JF; VASWANI, A; YEH, JK; ROSS, PL; FLASTER, E; DILMANIAN, FA				ALOIA, JF; VASWANI, A; YEH, JK; ROSS, PL; FLASTER, E; DILMANIAN, FA			CALCIUM SUPPLEMENTATION WITH AND WITHOUT HORMONE REPLACEMENT THERAPY TO PREVENT POSTMENOPAUSAL BONE LOSS	ANNALS OF INTERNAL MEDICINE			English	Article						OSTEOPOROSIS; POSTMENOPAUSAL; CALCIUM; ESTROGEN REPLACEMENT THERAPY; BONE DENSITY	CONTROLLED TRIAL; WOMEN; OSTEOPOROSIS; FRACTURES; ESTROGEN; HIP; FOREARM; SERUM; RISK	Objective: To determine whether augmentation of dietary calcium is effective in the prevention of early postmenopausal bone loss. Design: Three-arm, placebo-controlled, randomized parallel trial. The study duration was 2.9 +/- 1.1 (SD) years. Setting: General community. Participants: 118 healthy, white women 3 to 6 years after spontaneous menopause, recruited by community announcement. Interventions: Random allocation to daily intake of 1700 mg of calcium (calcium carbonate given in divided doses with meals); placebo; or conjugated equine estrogens (0.625 mg; days 1 to 25), progesterone (10 mg; days 16 to 25), and 1700 mg of elemental calcium daily. Each participant received 400 IU of vitamin D daily. Main Outcome Measures: Total body calcium measured by delayed gamma neutron activation analysis and whole-body counting; bone mineral density of the spine, femur, and radius measured by photon absorptiometry. Results: Bone mineral density declined in the placebo group for the lumbar spine (-2.1%/y; 95% CI, -3.3 to -0.9), femoral neck (-2.0%/y; CI,-2.6 to -1.2), trochanter (-1.6%/y; CI, -2.4 to -0.8), Ward triangle (-2.7%/y; CI, -3.7 to -1.7), and total body calcium (-2.0%/y; CI, -2.2 to -1.8). Rates of change were intermediate for calcium augmentation compared with placebo and estrogen-progesterone-calcium but statistically significant compared with placebo for total body calcium (-0.5%/y; CI, -0.9 to -0.1; P = 0.006) and the femoral neck (-0.8%/y; CI, -1.4 to -0.2; P = 0.03). Conclusions: Although less effective than estrogen-progesterone-calcium, calcium augmentation alone significantly retards bone loss from the femoral neck and improves calcium balance in recently postmenopausal women. Dietary calcium augmentation should be recommended as a strategic option in helping to prevent early postmenopausal bone loss.	BROOKHAVEN NATL LAB, UPTON, NY 11973 USA	United States Department of Energy (DOE); Brookhaven National Laboratory	ALOIA, JF (corresponding author), WINTHROP UNIV HOSP, DEPT MED, 259 1ST ST, MINEOLA, NY 11501 USA.		Dilmanian, Farrokh Avraham/AAD-5567-2019		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR037520] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01-AR37520-05] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALBANESE AA, 1975, NEW YORK STATE J MED, V75, P326; BARRETTCONNOR E, 1989, NEW ENGL J MED, V321, P319, DOI 10.1056/NEJM198908033210510; BEHR W, 1986, CLIN CHEM, V32, P1960; COHN SH, 1986, CALCIFIED TISSUE INT, V38, P9, DOI 10.1007/BF02556588; COHN SH, 1969, PHYS MED BIOL, V14, P645, DOI 10.1088/0031-9155/14/4/006; DAWSONHUGHES B, 1990, NEW ENGL J MED, V323, P878, DOI 10.1056/NEJM199009273231305; DILMANIAN FA, 1990, IN VIVO BODY COMPOSI, V55, P309; ELDERS PJM, 1991, J CLIN ENDOCR METAB, V73, P533, DOI 10.1210/jcem-73-3-533; ETTINGER B, 1987, ANN INTERN MED, V106, P40, DOI 10.7326/0003-4819-106-1-40; Fiske CH, 1925, J BIOL CHEM, V66, P375; HEANEY RP, 1977, AM J CLIN NUTR, V30, P1603, DOI 10.1093/ajcn/30.10.1603; HEINEGAR.D, 1973, CLIN CHIM ACTA, V43, P305, DOI 10.1016/0009-8981(73)90466-X; HUTCHINSON TA, 1979, LANCET, V2, P705; LAPORTE RE, 1982, J CHRON DIS, V35, P787, DOI 10.1016/0021-9681(82)90090-X; LINDSAY R, 1980, LANCET, V2, P1151; MATKOVIC V, 1979, AM J CLIN NUTR, V32, P540, DOI 10.1093/ajcn/32.3.540; NILAS L, 1984, BRIT MED J, V289, P1103, DOI 10.1136/bmj.289.6452.1103; NORDIN BEC, 1988, ANN CHIR GYNAECOL FE, V77, P212; OTT SM, 1987, J BONE MINER RES, V2, P201; PAGANINIHILL A, 1981, ANN INTERN MED, V95, P28, DOI 10.7326/0003-4819-95-1-28; POLLEY KJ, 1987, J NUTR, V117, P1929, DOI 10.1093/jn/117.11.1929; PRINCE RL, 1991, NEW ENGL J MED, V325, P1189, DOI 10.1056/NEJM199110243251701; PROCKOP DJ, 1960, ANAL BIOCHEM, V1, P228, DOI 10.1016/0003-2697(60)90050-6; RECKER RR, 1977, ANN INTERN MED, V87, P649, DOI 10.7326/0003-4819-87-6-649; REID IR, 1993, NEW ENGL J MED, V328, P460, DOI 10.1056/NEJM199302183280702; RIGGS BL, 1987, J CLIN INVEST, V80, P979, DOI 10.1172/JCI113191; RIIS B, 1987, NEW ENGL J MED, V316, P173, DOI 10.1056/NEJM198701223160401; SNEDECOR GW, 1972, STATISTICAL METHODS, P438; SNYDER WS, 1984, ICRP PUBLICATION, V23; SOMMER A J, 1954, Am J Med Technol, V20, P244; STEVENSON JC, 1988, BRIT MED J, V297, P15, DOI 10.1136/bmj.297.6640.15; WEISS NS, 1980, NEW ENGL J MED, V303, P1195, DOI 10.1056/NEJM198011203032102	32	180	187	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1994	120	2					97	103		10.7326/0003-4819-120-2-199401150-00001	http://dx.doi.org/10.7326/0003-4819-120-2-199401150-00001			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ671	8256988				2023-01-03	WOS:A1994MQ67100001
J	BRADLOW, J; COULTER, A				BRADLOW, J; COULTER, A			EFFECT OF FUNDHOLDING AND INDICATIVE PRESCRIBING SCHEMES ON GENERAL-PRACTITIONERS PRESCRIBING COSTS	BRITISH MEDICAL JOURNAL			English	Article								Objective-To compare general practitioners' prescribing costs in fundholding and non-fundholding practices before and after implementation of the NHS reforms in April 1991. Design-Analysis of prescribing and cost information (PACT data; levels 2 and 3) over two six month periods in 1991 and 1992. Setting-Oxford region. Participants-Three dispensing fundholding practices; five non-dispensing fundholding practices; and seven non-dispensing, non-fundholding practices. Main outcome measures-Percentage change in net cost of ingredients, number of items prescribed, average cost per item, and proportion of generic drugs prescribed after NHS reforms. Results-Prescribing costs increased in all practices in the six months after the reforms. The net costs of ingredients increased among dispensing fundholders by 10.2%, among non-dispensing fundholders by 13.2%, and among non-fundholders by 18.7%. The number of items prescribed also increased in all three groups (by 5.2%, 7.5%, and 6.1% respectively). The increase in average cost per item was 4.8% for dispensing fundholders, 5.3% for non-dispensing fundholders, and 11.9% for non-fundholders. Dispensing fundholders increased the proportion of generic drugs prescribed from 26.9% to 34.5% and non-dispensing fundholders from 44.5% to 48.7%; non-fundholders showed no change (47%). Five of the eight fundholding practices made savings in their drugs budgets at the end of the first year of fundholding (range 2.9-10.7%; the three other practices overspent by up to 3.6%). All non-fundholding practices exceeded their indicative prescribing amounts (range 3.2-20.0%). Conclusions-Fundholding has helped to curb increases in prescribing costs, even among dispensing general practitioners, for whom the incentives are different. Indicative prescribing amounts for non-fundholding practices do not seem to have had the same effect.			BRADLOW, J (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,HLTH SERV RES UNIT,OXFORD OX2 6HE,ENGLAND.		Coulter, Angela/N-6998-2019	Coulter, Angela/0000-0002-6308-8375				CHEW R, 1992, ABPI BRIEFING    JUL, P1; CHEW R, 1992, COMPENDIUM HLTH STAT; COULTER A, 1993, BRIT MED J, V306, P433, DOI 10.1136/bmj.306.6875.433; COULTER A, 1992, BRIT MED J, V304, P397, DOI 10.1136/bmj.304.6824.397; HARRIS C, 1991, FACTORS INFLUENCING; JONES T, 1993, PRIMARY CARE MANAGEM, V3, P5; MORTONJONES TJ, 1993, BRIT MED J, V306, P1244, DOI 10.1136/bmj.306.6887.1244; WEINER J, 1990, GP BUDGET HOLDING UK; 1993, STATISTICAL B; 1991, INDICATIVE PRESCRIBI; 1989, INDICATIVE PRESCRIBI; 1990, IMPROVING PRESCRIBIN	12	88	88	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 6	1993	307	6913					1186	1189		10.1136/bmj.307.6913.1186	http://dx.doi.org/10.1136/bmj.307.6913.1186			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF824	8251847	Green Published, Bronze			2023-01-03	WOS:A1993MF82400026
J	RONCO, JJ; FENWICK, JC; TWEEDDALE, MG; WIGGS, BR; PHANG, PT; COOPER, DJ; CUNNINGHAM, KF; RUSSELL, JA; WALLEY, KR				RONCO, JJ; FENWICK, JC; TWEEDDALE, MG; WIGGS, BR; PHANG, PT; COOPER, DJ; CUNNINGHAM, KF; RUSSELL, JA; WALLEY, KR			IDENTIFICATION OF THE CRITICAL OXYGEN DELIVERY FOR ANAEROBIC METABOLISM IN CRITICALLY ILL SEPTIC AND NONSEPTIC HUMANS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESPIRATORY-DISTRESS SYNDROME; PATHOLOGICAL SUPPLY DEPENDENCE; GLUCOSE TRANSPORTER; SKELETAL-MUSCLE; CRITICAL-LEVEL; O-2 UPTAKE; CONSUMPTION; SEPSIS; SHOCK; SURVIVORS	Objectives.-To determine the critical oxygen delivery threshold for anaerobic metabolism and to compare its value between septic and nonseptic critically ill patients. Design.-Cohort analytic study, consecutive sample. Setting.-Two tertiary care medical and surgical intensive care units in university hospitals. Patients.-Nine septic and nine nonseptic critically ill humans. A diagnosis of sepsis was established by the presence of sepsis syndrome, positive cultures obtained within 48 hours of study, and autopsy evidence of a source of infection. Methods and Interventions.-The O2 consumption (determined by indirect calorimetry), O2 delivery (calculated from the Fick equation), and concentration of arterial plasma lactate were simultaneously determined at 5- to 20-minute intervals while life support was discontinued. Main Outcome Measures.-Critical O2 delivery, critical O2 extraction ratio, and maximal O2 extraction ratio. Results.-In all septic and eight nonseptic patients, O2 delivery and O2 consumption displayed a biphasic relationship over the range of O2 delivery studied. There were no differences in critical O2 delivery threshold (3.8+/-1.5 vs 4.5+/-1.3 mL.min-1.kg-1; P>.28), Critical O2 extraction ratio (0.61+/-0.05 vs 0.59+/-0.16; P>.64), and maximal O2 extraction ratio (0.74+/-0.08 vs 0.80+/-0.11; P>.29) between septic and nonseptic patients. These data have greater than 90% power to detect a difference of 2 mL.min-1.kg-1 in the critical O2 delivery and 0.1 in the critical and maximal O2 extraction ratios between the septic and nonseptic groups. Conclusions.-The critical O2 delivery for anaerobic metabolism was identified from the biphasic relationship between O2 delivery and O2 consumption in individual humans. The critical O2 delivery is considerably lower than previously reported in humans with the use of pooled group data. Sepsis does not alter the critical O2 delivery for anaerobic metabolism or tissue O2 extraction ability. Interventions to increase O2 delivery to supranormal levels in critically ill humans in the hope of increasing O2 consumption may be inappropriate.	UNIV BRITISH COLUMBIA,ST PAULS HOSP,VANCOUVER V6T 1W5,BC,CANADA	St. Paul's Hospital; University of British Columbia; University of Saskatchewan	RONCO, JJ (corresponding author), UNIV BRITISH COLUMBIA,VANCOUVER GEN HOSP,PROGRAM CRIT CARE MED,INTENS CARE UNIT ADM,LSP 2,VANCOUVER V5Z 1M9,BC,CANADA.		Cooper, D. James/G-7961-2013	Cooper, D. James/0000-0002-5872-9051				BIHARI D, 1987, NEW ENGL J MED, V317, P397, DOI 10.1056/NEJM198708133170701; BONE RC, 1987, NEW ENGL J MED, V317, P653, DOI 10.1056/NEJM198709103171101; CURTIS SE, 1992, AM REV RESPIR DIS, V145, P348, DOI 10.1164/ajrccm/145.2_Pt_1.348; DANEK SJ, 1980, AM REV RESPIR DIS, V122, P387; DANTZKER DR, 1991, AM REV RESPIR DIS, V143, P675, DOI 10.1164/ajrccm/143.3.675; FENWICK JC, 1990, J CRIT CARE, V5, P81, DOI 10.1016/0883-9441(90)90052-B; GUTIERREZ G, 1992, LANCET, V339, P195, DOI 10.1016/0140-6736(92)90002-K; HARGROVE DM, 1988, AM J PHYSIOL, V254, pE16; HAUPT MT, 1985, AM REV RESPIR DIS, V131, P912; HOTCHKISS RS, 1992, JAMA-J AM MED ASSOC, V267, P1503, DOI 10.1001/jama.267.11.1503; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KOMATSU T, 1987, CRIT CARE MED, V15, P194, DOI 10.1097/00003246-198703000-00002; KRUSE JA, 1987, AM J MED, V83, P77, DOI 10.1016/0002-9343(87)90500-6; MOHSENIFAR Z, 1983, CHEST, V84, P267, DOI 10.1378/chest.84.3.267; NELSON DP, 1987, J APPL PHYSIOL, V63, P1487, DOI 10.1152/jappl.1987.63.4.1487; NELSON DP, 1988, J APPL PHYSIOL, V64, P2410, DOI 10.1152/jappl.1988.64.6.2410; RONCO JJ, 1993, AM REV RESPIR DIS, V147, P25, DOI 10.1164/ajrccm/147.1.25; RONCO JJ, 1991, J CRIT CARE, V6, P36, DOI 10.1016/0883-9441(91)90031-N; RONCO JJ, 1991, AM REV RESPIR DIS, V143, P1267, DOI 10.1164/ajrccm/143.6.1267; RUSSELL JA, 1990, AM REV RESPIR DIS, V141, P659, DOI 10.1164/ajrccm/141.3.659; SAMSEL RW, 1988, J APPL PHYSIOL, V65, P1377, DOI 10.1152/jappl.1988.65.3.1377; SCHUMACKER PT, 1989, J APPL PHYSIOL, V67, P1234, DOI 10.1152/jappl.1989.67.3.1234; SHIBUTANI K, 1983, CRIT CARE MED, V11, P640, DOI 10.1097/00003246-198308000-00010; SHOEMAKER WC, 1988, CHEST, V94, P1176, DOI 10.1378/chest.94.6.1176; TUCHSCHMIDT J, 1992, CHEST, V102, P216, DOI 10.1378/chest.102.1.216; VARY TC, 1986, AM J PHYSIOL, V250, pE634, DOI 10.1152/ajpendo.1986.250.6.E634; VERMEIJ CG, 1991, CHEST, V99, P1438, DOI 10.1378/chest.99.6.1438; VINCENT JL, 1990, AM REV RESPIR DIS, V142, P2, DOI 10.1164/ajrccm/142.1.2; WIDNELL CC, 1990, FASEB J, V4, P1634, DOI 10.1096/fasebj.4.6.2156742; WOLL PJ, 1979, EUR J CLIN INVEST, V9, P397, DOI 10.1111/j.1365-2362.1979.tb00903.x; Zar JH, 2010, BIOSTAT ANAL; ZELLER WP, 1991, BIOCHEM BIOPH RES CO, V176, P535, DOI 10.1016/0006-291X(91)90958-A	32	218	226	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 13	1993	270	14					1724	1730		10.1001/jama.270.14.1724	http://dx.doi.org/10.1001/jama.270.14.1724			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA294	8411504				2023-01-03	WOS:A1993MA29400030
J	FAYAD, IM; HASHEM, M; DUGGAN, C; REFAT, M; BAKIR, M; FONTAINE, O; SANTOSHAM, M				FAYAD, IM; HASHEM, M; DUGGAN, C; REFAT, M; BAKIR, M; FONTAINE, O; SANTOSHAM, M			COMPARATIVE EFFICACY OF RICE-BASED AND GLUCOSE-BASED ORAL REHYDRATION SALTS PLUS EARLY REINTRODUCTION OF FOOD	LANCET			English	Article							ACUTE DIARRHEA; ELECTROLYTE SOLUTION; THERAPY	The use of oral rehydration salts (ORS) to restore fluid balance in children with diarrhoea is universally accepted. However, there is uncertainty about whether glucose-based ORS or ORS based on precooked rice powder is more effective. In a randomised trial we compared the two types of ORS in children who were given food immediately after completion of rehydration. 460 boys aged 3-18 months, admitted to hospital with acute diarrhoea and signs of dehydration, were randomly assigned to groups receiving rice-based and glucose-based ORS solution (230 to each group). After full rehydration (4-12 h), a weaning food consisting of rice and mixed vegetables was given until the diarrhoea stopped. Continuing losses of liquid stool and vomitus were replaced with the assigned ORS solution. There were no differences between the groups during the rehydration phase in stool volume, volume of ORS solution taken, duration of rehydration phase, or weight gain. However, after initiation of feeding, the glucose-based ORS group had significantly lower stool volumes than the rice-based ORS group (142 [95% CI 117-173] vs 96 [77-120] g/kg); they also took a smaller amount of ORS solution (153 [127-185] vs 111 [90-136] mL/kg) and had a shorter duration of diarrhoea (55 [SD 35] vs 44 [35] h). Glucose-based ORS solution was more effective than rice-based ORS solution for the treatment of diarrhoea in children when feeding with a rice-based diet was started soon after correction of dehydration. These results support the continued recommendation of glucose-based ORS solution as standard therapy for treatment of children with acute diarrhoea and emphasise the importance of resuming feeding as soon as dehydration has been corrected.	JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT INT HLTH, 615 N WOLFE ST, BALTIMORE, MD 21205 USA; CAIRO UNIV, HOSP ABU EL REECHE, DEPT GASTROENTEROL, CAIRO, EGYPT; WHO, DIARRHOEAL DIS CONTROL PROGRAMME, CH-1211 GENEVA 27, SWITZERLAND	Johns Hopkins University; Egyptian Knowledge Bank (EKB); Cairo University; World Health Organization								ALAM AN, 1987, ARCH DIS CHILD, V62, P440, DOI 10.1136/adc.62.5.440; AVERY ME, 1990, NEW ENGL J MED, V323, P891, DOI 10.1056/NEJM199009273231307; BHAN MK, 1987, J PEDIATR GASTR NUTR, V6, P392, DOI 10.1097/00005176-198705000-00016; BROWN KH, 1984, PEDIATRICS, V73, P119; DUTTA P, 1988, INDIAN J MED RES, V87, P229; ELMOUGI M, 1988, J PEDIATR GASTROENTE, V7, P76; GARDNER MJ, 1989, STATISTICS CNFIDENCE; GORE SM, 1992, BMJ-BRIT MED J, V304, P287, DOI 10.1136/bmj.304.6822.287; HIRSCHHORN N, 1968, NEW ENGL J MED, V279, P176, DOI 10.1056/NEJM196807252790402; KHINMAUNGU, 1985, BMJ-BRIT MED J, V290, P587; Mahalanabis D, 1974, J Trop Pediatr Environ Child Health, V20, P82; MOHAN M, 1988, INDIAN J MED RES, V87, P234; MOLLA AM, 1989, LANCET, V2, P429; MOLLA AM, 1989, J PEDIATR GASTR NUTR, V8, P81, DOI 10.1097/00005176-198901000-00015; MOLLA AM, 1985, B WORLD HEALTH ORGAN, V63, P751; PATRA FC, 1982, ARCH DIS CHILD, V57, P12; PIERCE NF, 1968, GASTROENTEROLOGY, V55, P333; POCOCK SJ, 1987, CLIN TRIALS PRACTICA, P123; RAHAMAN MM, 1979, LANCET, V2, P809; RICHARDS L, 1993, PEDIATR INFECT DIS J, V12, P5, DOI 10.1097/00006454-199301000-00003; SACK DA, 1978, LANCET, V2, P280; Santosham M, 1987, Pediatr Rev, V8, P273, DOI 10.1542/pir.8-9-273; SANTOSHAM M, 1985, PEDIATRICS, V76, P292; SANTOSHAM M, 1990, J PEDIATR-US, V116, P868, DOI 10.1016/S0022-3476(05)80642-0	24	37	37	1	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 25	1993	342	8874					772	775		10.1016/0140-6736(93)91540-3	http://dx.doi.org/10.1016/0140-6736(93)91540-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LY868	8103876	hybrid			2023-01-03	WOS:A1993LY86800009
J	SUNG, JJY; CHUNG, SCS; LAI, CW; CHAN, FKL; LEUNG, JWC; YUNG, MY; KASSIANIDES, C; LI, AKC				SUNG, JJY; CHUNG, SCS; LAI, CW; CHAN, FKL; LEUNG, JWC; YUNG, MY; KASSIANIDES, C; LI, AKC			OCTREOTIDE INFUSION OR EMERGENCY SCLEROTHERAPY FOR VARICEAL HEMORRHAGE	LANCET			English	Article							BLEEDING ESOPHAGEAL-VARICES; CONTROLLED TRIAL; SOMATOSTATIN; CIRRHOSIS; MANAGEMENT; HEMORRHAGE	To compare octreotide with injection sclerotherapy in the treatment of acute variceal haemorrhage, patients admitted with gastrointestinal bleeding and oesophageal varices confirmed by endoscopy were randomised to receive either emergency sclerotherapy with 3% sodium tetradecyl sulphate or octreotide (50 mug intravenous bolus plus 50 mug per h intravenous infusion for 48 h). At the end of the study period (48 h), the octreotide group also had sclerotherapy to obliterate the varices. 100 patients were recruited. Demographic features including the aetiology of portal hypertension and the Child-Pugh's grading of the two groups were similar. Bleeding was initially controlled in 90% of patients by emergency sclerotherapy and in 84% by octreotide infusion (95% confidence interval 0-19.5, p=0.55). There were no significant differences between the two groups in early (within 48 h of randomisation) rebleeding (16% vs 14%), blood transfusion (3 units vs 3.5), hospital stay (5 days vs 6 days), or hospital mortality (27% vs 20%). No notable side-effects were associated with octreotide. We conclude that octreotide infusion and emergency sclerotherapy are equally effective in controlling variceal haemorrhage.	CHINESE UNIV HONG KONG,PRINCE WALES HOSP,DEPT SURG,SHA TIN,HONG KONG	Chinese University of Hong Kong; Prince of Wales Hospital	SUNG, JJY (corresponding author), CHINESE UNIV HONG KONG,PRINCE WALES HOSP,DEPT MED,SHA TIN,HONG KONG.		Sung, Joseph J. Y./R-3203-2018; Chan, Francis K. L./F-4851-2010	Sung, Joseph J. Y./0000-0003-3125-5199; Chan, Francis K. L./0000-0001-7388-2436				AVGERINOS A, 1991, J HEPATOL, V13, P78, DOI 10.1016/0168-8278(91)90867-B; BURROUGHS AK, 1990, GASTROENTEROLOGY, V99, P1388, DOI 10.1016/0016-5085(90)91166-4; FRANCO D, 1977, LANCET, V1, P218; GILBERT DA, 1981, GASTROINTEST ENDOSC, V27, P94; JENKINS SA, 1989, BRIT J SURG, V76, P49, DOI 10.1002/bjs.1800760115; JENKINS SA, 1985, BRIT MED J, V290, P270; LIN HC, 1992, GASTROENTEROLOGY, V103, P229, DOI 10.1016/0016-5085(92)91117-M; MASTAI R, 1986, Journal of Hepatology, V3, pS53; MCCORMICK PA, 1990, EUR J GASTROEN HEPAT, V2, P489; SHIELDS R, 1992, J HEPATOL, V16, P128, DOI 10.1016/S0168-8278(05)80105-9; SILVAIN C, 1991, HEPATOLOGY, V14, P1449; SONNENBERG GE, 1981, GASTROENTEROLOGY, V80, P526; TERBLANCHE J, 1989, NEW ENGL J MED, V320, P1393, DOI 10.1056/NEJM198905253202107; WALKER S, 1990, HEPATO-GASTROENTEROL, V37, P538	14	171	173	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 11	1993	342	8872					637	641		10.1016/0140-6736(93)91758-E	http://dx.doi.org/10.1016/0140-6736(93)91758-E			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX272	8103145				2023-01-03	WOS:A1993LX27200009
J	TENG, Q; SCARLATA, S				TENG, Q; SCARLATA, S			EFFECT OF HIGH-PRESSURE ON THE ASSOCIATION OF MELITTIN TO MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-RESOLUTION H-1-NMR; SELF-ASSOCIATION; PHOSPHOLIPID-MEMBRANES; FRICTIONAL RESISTANCE; THERMAL COEFFICIENT; MONOMERIC MELITTIN; AGGREGATION STATE; AQUEOUS-SOLUTION; ENERGY-TRANSFER; LIPID BILAYERS	To determine the underlying basis for the sensitivity of peripheral peptides to lipid packing, we monitored the change in association of melittin to different membranes under hydrostatic pressure by fluorescence polarization and by fluorescence intensity in the presence of aqueous quenchers. Association to lysophosphatidylcholine micelles or to membranes composed of dimyristoylphosphatidylcholine, dipalmitoylphosphatidylcholine, palmitoyloleoylphosphatidylcholine, or dioleoylphosphatidylcholine was found to be stable from 1 to 2000 atm. Similar results were obtained using multilamellar vesicles, small unilamellar vesicles, or large unilamellar vesicles. Thus, the increase in lipid chain packing induced by pressure does not alter the association of bound complexes. This result indicates similar compressibilities of the peptide and the head group binding region. Increasing the ionic strength to increase the charge of the free peptide also resulted in a pressure-insensitive complex showing that the hydration does not change upon binding. This conclusion is substantiated by a lack of van't Hoff DELTAH to dioleoylphosphatidylcholine large unilamellar vesicles. To gain a more molecular picture of these associations, the rotational properties of the tryptophan side chain of bound melittin as a function of lipid packing was also studied. These data indicate subtle differences in peptide orientation in different lipids.	SUNY,DEPT PHYSIOL & BIOPHYS,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; SUNY Maritime College					NIGMS NIH HHS [GM38824] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELLO J, 1982, BIOCHEMISTRY-US, V21, P461, DOI 10.1021/bi00532a007; BESCHIASCHVILI G, 1991, BIOCHIM BIOPHYS ACTA, V1068, P195, DOI 10.1016/0005-2736(91)90210-Y; BRADRICK TD, 1989, BIOCHIM BIOPHYS ACTA, V982, P94, DOI 10.1016/0005-2736(89)90179-X; BRIDGEMAN PW, 1970, PHYSICS HIGH PRESSUR, P346; BROWN LR, 1980, BIOCHIM BIOPHYS ACTA, V622, P231, DOI 10.1016/0005-2795(80)90034-3; DECKMANN M, 1986, BIOCHIM BIOPHYS ACTA, V821, P334; DEMPSEY CE, 1990, BIOCHIM BIOPHYS ACTA, V1031, P143, DOI 10.1016/0304-4157(90)90006-X; DUFOURC E, 1986, FEBS LETT, V101, P205; DUFOURCQ J, 1977, BIOCHIM BIOPHYS ACTA, V467, P1, DOI 10.1016/0005-2736(77)90236-X; FAUCON JF, 1979, FEBS LETT, V101, P187; FREY S, 1991, BIOPHYS J, V60, P922, DOI 10.1016/S0006-3495(91)82126-9; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HAMANN SD, 1980, REV PHYS CHEM JPN, V50, P147; HERMETTER A, 1986, J BIOL CHEM, V261, P8243; JOHN E, 1991, BIOPHYS J, V60, P319, DOI 10.1016/S0006-3495(91)82056-2; KASZYCKI P, 1990, BIOCHIM BIOPHYS ACTA, V1040, P337, DOI 10.1016/0167-4838(90)90131-X; KITCHEN DB, 1992, BIOCHEMISTRY-US, V31, P10083, DOI 10.1021/bi00156a031; KUCHINKA E, 1989, BIOCHEMISTRY-US, V28, P4216, DOI 10.1021/bi00436a014; LAUTERWEIN J, 1980, BIOCHIM BIOPHYS ACTA, V622, P219, DOI 10.1016/0005-2795(80)90033-1; LESTER DS, 1989, J NEUROCHEM, V52, P1950, DOI 10.1111/j.1471-4159.1989.tb07284.x; MATHIAS RT, 1991, ELECTRIFIED INTERFAC; MILLERO FJ, 1974, J PHYS CHEM-US, V78, P1636, DOI 10.1021/j100609a008; PALADINI AA, 1981, REV SCI INSTRUM, V52, P419, DOI 10.1063/1.1136596; PARASASSI T, 1990, BIOPHYS J, V57, P1179, DOI 10.1016/S0006-3495(90)82637-0; PLAGER DA, 1992, PROTEIN SCI, V1, P530; QUAY SC, 1983, BIOCHEMISTRY-US, V22, P695, DOI 10.1021/bi00272a026; SCARLATA S, 1984, BIOCHEMISTRY-US, V23, P6789, DOI 10.1021/bi00321a078; SCARLATA S, 1992, IN PRESS LIFE SCI AD; SCARLATA SF, 1989, BIOPHYS J, V55, P1215, DOI 10.1016/S0006-3495(89)82917-0; SCARLATA SF, 1991, BIOCHEMISTRY-US, V30, P9853, DOI 10.1021/bi00105a007; SCARLATA SF, 1991, BIOPHYS J, V60, P334, DOI 10.1016/S0006-3495(91)82058-6; SCARLATA SF, 1990, BIOCHEMISTRY-US, V29, P10233, DOI 10.1021/bi00496a012; SCARLATA SF, 1993, BIOPHYS J, V64, pA124; SCHUBERT D, 1985, BIOPHYS J, V48, P327, DOI 10.1016/S0006-3495(85)83786-3; SCHWARZ G, 1989, BIOCHIM BIOPHYS ACTA, V979, P82, DOI 10.1016/0005-2736(89)90526-9; STANKOWSKI S, 1990, BIOCHIM BIOPHYS ACTA, V1025, P164, DOI 10.1016/0005-2736(90)90094-5; SUNKARAM M, 1990, BIOCHEMISTRY-US, V29, P10676; TALBOT JC, 1979, FEBS LETT, V102, P191, DOI 10.1016/0014-5793(79)80957-6; TALBOT JC, 1987, EUR BIOPHYS J BIOPHY, V15, P147, DOI 10.1007/BF00263679; TERWILLIGER TC, 1982, BIOPHYS J, V37, P353, DOI 10.1016/S0006-3495(82)84683-3; THOMPSON RB, 1984, BIOCHEMISTRY-US, V23, P3411, DOI 10.1021/bi00310a005; TORGERSON PM, 1979, BIOCHEMISTRY-US, V18, P3079, DOI 10.1021/bi00581a026; VOGEL H, 1981, FEBS LETT, V134, P37, DOI 10.1016/0014-5793(81)80545-5; WEBER G, 1984, BIOCHEMISTRY-US, V23, P6785, DOI 10.1021/bi00321a077; WEBER G, 1983, Q REV BIOPHYS, V16, P89, DOI 10.1017/S0033583500004935; WONG PTT, 1982, J CHEM PHYS, V76, P5230, DOI 10.1063/1.442918; WONG PTT, 1988, BIOPHYS J, V54, P781, DOI 10.1016/S0006-3495(88)83016-9; YEAGLE PL, 1985, BIOCHIM BIOPHYS ACTA, V822, P267, DOI 10.1016/0304-4157(85)90011-5	48	7	7	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12434	12442						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509383				2023-01-03	WOS:A1993LG65800034
J	RUFF, HA; BIJUR, PE; MARKOWITZ, M; MA, YC; ROSEN, JF				RUFF, HA; BIJUR, PE; MARKOWITZ, M; MA, YC; ROSEN, JF			DECLINING BLOOD LEAD LEVELS AND COGNITIVE CHANGES IN MODERATELY LEAD-POISONED CHILDREN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PORT-PIRIE COHORT; EXPOSURE; MONKEYS; DEFICITS; REVERSAL; CHILDHOOD; INFANCY; BIRTH; IRON	Objective.-To determine whether chelation therapy or biochemical changes during a lead-lowering intervention was associated with changes in cognitive functioning of moderately lead-poisoned children. It was hypothesized that cognitive performance would improve as blood lead level declined over time. Design.-Short-term intervention study with measures obtained before and after intervention. Setting.-Hospital specialty clinic and university research center. Patients.-A total of 154 previously untreated children referred to clinic with blood lead levels between 1.21 and 2.66 mumol/L (25 and 55 mug/dL) at time of enrollment. Ages ranged from 13 to 87 months. Intervention.-Enrolled children were treated with edetate calcium disodium (EDTA) if eligible and/or with orally administered iron supplement if iron deficient. For all children, housing inspections and abatement procedures were performed as necessary. Main Outcome Measures.-Score on Bayley Mental Development Scale or Stanford-Binet Intelligence Scale (4th edition). Results.-There was no effect of edetate calcium disodium treatment per se. In the short term (7 weeks), changes in blood lead levels were not related to changes in cognitive scores. In the long term (6 months), however, changes in performance were significantly related to changes in blood lead level, even after controlling for confounding variables. The standardized score increased 1 point for every decrease of 0.14 mumol/L (3 mug/dL) in blood lead level. Conclusion.-The results suggest an association between decreases in blood lead level and cognitive improvements in moderately lead-poisoned children.			RUFF, HA (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED, MONTEFIORE MED CTR, DEPT PEDIAT, ROOM 222, KENNEDY CTR, BRONX, NY 10461 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004039] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K02MH000652] Funding Source: NIH RePORTER; NICHD NIH HHS [HD07199] Funding Source: Medline; NIEHS NIH HHS [ES04039] Funding Source: Medline; NIMH NIH HHS [MH00652] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BAGHURST PA, 1987, NEUROTOXICOLOGY, V8, P395; Bayley N., 1969, BAYLEY SCALES INFANT; BELLINGER D, 1991, PEDIATRICS, V87, P219; BELLINGER D, 1987, NEW ENGL J MED, V316, P1037, DOI 10.1056/NEJM198704233161701; BUSHNELL PJ, 1979, PHARMACOL BIOCHEM BE, V10, P733, DOI 10.1016/0091-3057(79)90326-5; BUSHNELL PJ, 1979, J TOXICOL ENV HEALTH, V5, P1015, DOI 10.1080/15287397909529810; COHEN J, 1983, APPLIED MULTIPLE REG, P145; DAVID OJ, 1985, ARCH ENVIRON HEALTH, V40, P109, DOI 10.1080/00039896.1985.10545899; DAVID OJ, 1976, AM J PSYCHIAT, V133, P1155; DIETRICH KN, 1990, ENVIRON HEALTH PERSP, V89, P13, DOI 10.2307/3430891; DIETRICH KN, 1987, PEDIATRICS, V80, P721; ERNHART CB, 1987, NEUROTOXICOL TERATOL, V9, P259, DOI 10.1016/0892-0362(87)90011-0; ESCALONA SK, 1982, PEDIATRICS, V70, P670; FULTON M, 1987, LANCET, V1, P1221; LEVIN ED, 1983, NEUROBEH TOXICOL TER, V5, P391; LOZOFF B, 1989, B NEW YORK ACAD MED, V65, P1050; MARKOWITZ ME, 1984, J PEDIATR-US, V104, P337, DOI 10.1016/S0022-3476(84)81091-4; MARKOWITZ ME, 1990, J PEDIATR-US, V116, P360, DOI 10.1016/S0022-3476(05)82821-5; MARKOWITZ ME, 1991, J PEDIATR-US, V119, P305, DOI 10.1016/S0022-3476(05)80750-4; MARKOWITZ ME, IN PRESS PEDIATRICS; MCMICHAEL AJ, 1988, NEW ENGL J MED, V319, P468, DOI 10.1056/NEJM198808253190803; NEEDLEMAN HL, 1990, JAMA-J AM MED ASSOC, V263, P673, DOI 10.1001/jama.263.5.673; NEEDLEMAN HL, 1979, NEW ENGL J MED, V300, P689, DOI 10.1056/NEJM197903293001301; PIOMELLI S, 1977, CLIN CHEM, V23, P264; RICE DC, 1985, TOXICOL APPL PHARM, V77, P201, DOI 10.1016/0041-008X(85)90319-9; RICE DC, 1984, TOXICOL APPL PHARM, V75, P337, DOI 10.1016/0041-008X(84)90216-3; RUFF HA, 1989, J DEV BEHAV PEDIATR, V10, P103; SCHWARTZ J, IN PRESS NEUROTOXICO; SILVERSTEIN AB, 1982, J CONSULT CLIN PSYCH, V50, P415, DOI 10.1037/0022-006X.50.3.415; THORNDIKE RL, 1986, STANFORDBINET INTELL	30	90	91	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 7	1993	269	13					1641	1646		10.1001/jama.269.13.1641	http://dx.doi.org/10.1001/jama.269.13.1641			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KV349	8455297				2023-01-03	WOS:A1993KV34900027
J	STERN, MC; JAGGER, C; CLARKE, M; ANDERSON, J; MCGROTHER, C; BATTOCK, T; MCDONALD, C				STERN, MC; JAGGER, C; CLARKE, M; ANDERSON, J; MCGROTHER, C; BATTOCK, T; MCDONALD, C			RESIDENTIAL CARE FOR ELDERLY PEOPLE - A DECADE OF CHANGE	BRITISH MEDICAL JOURNAL			English	Article							HOMES	Objective-To determine the changes between 1979 and 1990 in demography and dependency levels in elderly people in residential care. Design-Censuses of those aged 65 years and over in any type of residential care at midnight on 11 December 1979 and 27 November 1990. Setting-Leicestershire District Health Authority (population 865 133, 1991 census), coterminous with county and social services boundaries. Main outcome measures-Age, sex, length of stay, and dependency levels (measured by activities of daily living). Results-In 1990 (1979), 6079 (4678) elderly people were enumerated in 241 (133) establishments, a 30% increase in the numbers of elderly people in residential care and an 82% increase in the number of establishments between 1979 and 1990. Dependency levels rose between 1979 and 1990 in all but the geriatric sector, the greatest increases being found in private residential homes where the largest percentage increase in the number of residents had occurred. Conclusions-Dependency levels in residential care have risen substantially, particularly in the private sector, even beyond levels expected from the greater numbers of elderly people. With the impending move to community care, dependency levels are likely to rise further, and more appropriate staff training and medical input to homes will become necessary.	UNIV LEICESTER,LEICESTER ROYAL INFIRM,DEPT EPIDEMIOL & PUBL HLTH,POB 65,LEICESTER LE2 7LX,W YORKSHIRE,ENGLAND; DEPT HLTH,LONDON SW1A 2NS,ENGLAND; UNIV LEICESTER,DEPT PSYCHIAT,LEICESTER LE1 7RH,ENGLAND; UNIV LEICESTER,DEPT EPIDEMIOL & PUBL HLTH,LEICESTER LE1 7RH,ENGLAND; UNIV LEICESTER,DEPT MED ELDERLY,LEICESTER LE1 7RH,ENGLAND; LEICESTERSHIRE CTY COUNCIL,DEPT SOCIAL SERV,SERV OLDER PEOPLE,LEICESTER,ENGLAND	University of Leicester; University of Leicester; University of Leicester; University of Leicester				Jagger, Carol/0000-0002-6377-9926				BAKER RJ, 1985, GLIM 3 77 USER REFER; CAMPBELL H, 1990, AGE AGEING, V19, P318, DOI 10.1093/ageing/19.5.318; Clarke M, 1979, HLTH TRENDS, V11, P17; DAY P, 1987, BRIT MED J, V294, P384, DOI 10.1136/bmj.294.6568.384; Donaldson L J, 1983, Health Trends, V15, P58; DONALDSON LJ, 1983, PUBLIC HEALTH, V97, P257, DOI 10.1016/S0033-3506(83)80101-2; GODBER C, 1984, BRIT MED J, V288, P1473, DOI 10.1136/bmj.288.6429.1473; GOSNEY M, 1991, HLTH TRENDS, V22, P153; Griffiths R, 1988, COMMUNITY CARE AGEND; GRUNDY E, 1982, BRIT MED J, V284, P799, DOI 10.1136/bmj.284.6318.799; GRUNDY E, 1987, BRIT MED J, V294, P626, DOI 10.1136/bmj.294.6572.626; JAGGER C, 1991, INT J EPIDEMIOL, V20, P234, DOI 10.1093/ije/20.1.234; LAING, 1988, CARE ELDERLY PEOPLE; LOWY S, 1988, BMJ, V296, P541; STOTT D J, 1990, Health Bulletin (Edinburgh), V48, P17; SULLIVAN DF, 1971, HEALTH SERV REP, V86, P347, DOI 10.2307/4594169; WILKIN D, 1978, BRIT MED J, V2, P1274, DOI 10.1136/bmj.2.6147.1274; 1975, BETTER SERVICES MENT; 1991, NATIONAL POPULAT PP2; 1989, CARING PEOPLE COMMUN; 1988, POSITIVE CHOICE; 1990, MORTALITY STATIS DHI	22	36	36	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 27	1993	306	6881					827	830		10.1136/bmj.306.6881.827	http://dx.doi.org/10.1136/bmj.306.6881.827			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KV348	8490375	Bronze, Green Published			2023-01-03	WOS:A1993KV34800021
J	BANERJEE, A; JONES, R				BANERJEE, A; JONES, R			WHITHER IMMEDIATE FLUID RESUSCITATION	LANCET			English	Editorial Material											BANERJEE, A (corresponding author), ROTHERHAM DIST GEN HOSP,DEPT GEN SURG,ROTHERHAM,S YORKSHIRE,ENGLAND.		Banerjee, Anjan Kumar/AAL-6375-2020	Banerjee, Anjan Kumar/0000-0002-5935-3404				BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; BICKELL WH, 1992, ANN EMERG MED, V21, P1077, DOI 10.1016/S0196-0644(05)80648-1; CRAWFORD ES, 1991, J VASC SURG, V13, P348; DEMETRIADES D, 1993, BRIT J SURG, V80, P1534, DOI 10.1002/bjs.1800801213; DILLON J, 1966, ARCH SURG-CHICAGO, V93, P537; JACOBS LM, 1994, NEW ENGL J MED, V331, P1153, DOI 10.1056/NEJM199410273311710; SHIRES T, 1964, ARCH SURG-CHICAGO, V88, P688; SIRINEK KR, 1990, ARCH SURG-CHICAGO, V125, P844; 1993, ADV TRAUMA LIFE SUPP, P75	9	4	4	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 26	1994	344	8935					1450	1451		10.1016/S0140-6736(94)90283-6	http://dx.doi.org/10.1016/S0140-6736(94)90283-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT995	7968115				2023-01-03	WOS:A1994PT99500002
J	NYVAD, O; DANIELSEN, H; MADSEN, S				NYVAD, O; DANIELSEN, H; MADSEN, S			INTRAVENOUS IRON-SUCROSE COMPLEX TO REDUCE EPOETIN DEMAND IN DIALYSIS PATIENTS	LANCET			English	Letter											NYVAD, O (corresponding author), VIBORG CTY HOSP,DEPT NEPHROL,DK-8800 VIBORG,DENMARK.		Danielsen, Havard e/A-7540-2014; Danielsen, Havard/AAK-8489-2020					BAROSI G, 1993, ACTA HAEMATOL-BASEL, V90, P13; MacDougall I. C., 1993, Journal of the American Society of Nephrology, V4, P428; TERUEL JL, 1994, AM J NEPHROL, V14, P95, DOI 10.1159/000168696	3	55	55	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 5	1994	344	8932					1305	1306		10.1016/S0140-6736(94)90797-8	http://dx.doi.org/10.1016/S0140-6736(94)90797-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP701	7968018				2023-01-03	WOS:A1994PP70100058
J	HOUBIERS, JGA; BRAND, A; VANDEWATERING, LMG; HERMANS, J; VERWEY, PJM; BIJNEN, AB; PAHLPLATZ, P; SCHATTENKERK, ME; WOBBES, T; DEVRIES, JE; KLEMENTSCHITSCH, P; VANDEMAAS, AHM; VANDEVELDE, CJH				HOUBIERS, JGA; BRAND, A; VANDEWATERING, LMG; HERMANS, J; VERWEY, PJM; BIJNEN, AB; PAHLPLATZ, P; SCHATTENKERK, ME; WOBBES, T; DEVRIES, JE; KLEMENTSCHITSCH, P; VANDEMAAS, AHM; VANDEVELDE, CJH			RANDOMIZED CONTROLLED TRIAL COMPARING TRANSFUSION OF LEUKOCYTE-DEPLETED OR BUFFY-COAT-DEPLETED BLOOD IN SURGERY FOR COLORECTAL-CANCER	LANCET			English	Article							POSTOPERATIVE SEPTIC COMPLICATIONS; LARGE BOWEL-CANCER; INFECTIOUS COMPLICATIONS; MULTIVARIATE-ANALYSIS; SURVIVAL; CARCINOMA; ASSOCIATION; RECURRENCE; PROGNOSIS; RESECTION	In retrospective studies, perioperative blood transfusions were associated with poor prognosis after surgery for cancer and were a major independent risk factor for postoperative bacterial infection. Leucocyte-depleted, in contrast to buffy-coat-depleted, blood has no immunosuppressive effects in transplantation and so might lack detrimental effects on cancer prognosis and postoperative infections. We studied this hypothesis in a controlled trial by randomly allocating patients to receive either leucocyte-depleted red cells or packed cells without buffy coat when blood was needed. Between 1987 and 1990, 871 eligible patients with colorectal cancer, including 697 patients operated upon with curative intent, were randomised in the 16 participating hospitals. Neither the eligible group nor the curative group showed significant differences between the two trial transfusions in survival, disease-free survival, cancer recurrence rates, or overall infection rates after an average follow-up of 36 months. Patients who had a curative resection and who received blood of a ny sort had a lower 3-year survival than non-transfused patients (69% vs 81%, p=0.001) and a higher infection rate (39% vs 24%, p<0.001). Colorectal cancer recurrence rates, however, were not influenced by blood transfusion (30% vs 26%, p=0.22). These combined observations confirm the association between blood transfusion and poor patient survival but indicate that the relation is not due to promotion of cancer.	UNIV LEIDEN HOSP,DEPT SURG,2300 RC LEIDEN,NETHERLANDS; LEIDEN UNIV HOSP,DEPT IMMUNOHAEMATOL,2333 AA LEIDEN,NETHERLANDS; LEIDEN UNIV HOSP,BLOOD BANK,2333 AA LEIDEN,NETHERLANDS; LEIDEN UNIV,DEPT MED STAT,2300 RA LEIDEN,NETHERLANDS; MED CENTRUM ALKMAAR,ALKMAAR,NETHERLANDS; LEYENBURG ZIEKENHUIS,THE HAGUE,NETHERLANDS; STICHTING DEVENTER ZIEKENHUIS,DEVENTER,NETHERLANDS; UNIV NIJMEGEN HOSP,NIJMEGEN,NETHERLANDS; SOPHIA HOSP,ZWOLLE,NETHERLANDS; ZIEKENHUIS WEEZENLANDEN,ZWOLLE,NETHERLANDS; RIJNSTATE ZIEKENHUIZEN,ARNHEM,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University - Excl LUMC; Medical Center Of Alkmaar; Deventer Hospital; Radboud University Nijmegen; Rijnstate Hospital								ASTLER VB, 1954, ANN SURG, V139, P846, DOI 10.1097/00000658-195406000-00015; BRAGA M, 1992, EUR J SURG, V158, P531; BURROWS L, 1982, LANCET, V2, P662; BUSCH ORC, 1993, NEW ENGL J MED, V328, P1372, DOI 10.1056/NEJM199305133281902; CHAPUIS PH, 1985, BRIT J SURG, V72, P698, DOI 10.1002/bjs.1800720909; CHUNG M, 1993, BRIT J SURG, V80, P427, DOI 10.1002/bjs.1800800407; DAWES LG, 1986, SURGERY, V100, P796; FRANCIS DMA, 1991, BRIT J SURG, V78, P1420, DOI 10.1002/bjs.1800781205; GANTT CL, 1981, LANCET, V2, P363; HEISS MM, 1993, LANCET, V342, P1328, DOI 10.1016/0140-6736(93)92247-Q; HEISS MM, 1992, P AN M AM SOC CLIN, V11, P172; HOUBIERS JGA, 1994, LANCET, V343, P668; JAHNSON S, 1992, EUR J SURG, V158, P419; JENSEN LS, 1992, BRIT J SURG, V79, P513, DOI 10.1002/bjs.1800790613; JENSEN LS, 1990, BRIT J SURG, V77, P513, DOI 10.1002/bjs.1800770514; LAGAAIJ EL, 1989, NEW ENGL J MED, V321, P701, DOI 10.1056/NEJM198909143211101; LEARDI S, 1989, Annali Italiani di Chirurgia, V60, P537; LIEWALD F, 1990, EUR J CANCER, V26, P327, DOI 10.1016/0277-5379(90)90230-Q; MASSE M, 1991, TRANSFUSION, V31, P792, DOI 10.1046/j.1537-2995.1991.31992094664.x; PERSIJN GG, 1979, TRANSPLANTATION, V28, P396, DOI 10.1097/00007890-197911000-00010; PIETERSZ RNI, 1992, VOX SANG, V62, P76, DOI 10.1111/j.1423-0410.1992.tb01174.x; PINTO V, 1991, TRANSFUSION, V31, P114, DOI 10.1046/j.1537-2995.1991.31291142940.x; RAPAPORT FT, 1983, TRANSPLANT P, V15, P952; TANG RP, 1993, CANCER, V72, P341, DOI 10.1002/1097-0142(19930715)72:2<341::AID-CNCR2820720206>3.0.CO;2-E; TARTTER PI, 1988, BRIT J SURG, V75, P789, DOI 10.1002/bjs.1800750822; TARTTER PI, 1992, ANN SURG, V216, P633, DOI 10.1097/00000658-199212000-00004; TARTTER PI, 1988, AM J SURG, V155, P43, DOI 10.1016/S0002-9610(88)80256-3; TRIULZI DJ, 1992, TRANSFUSION, V32, P517, DOI 10.1046/j.1537-2995.1992.32692367194.x; VANPABST WPV, 1988, EUR J CANCER CLIN ON, V24, P741, DOI 10.1016/0277-5379(88)90309-4; VANTWUYVER E, 1991, NEW ENGL J MED, V325, P1210, DOI 10.1056/NEJM199110243251704; VOOGT PJ, 1987, CANCER, V59, P836, DOI 10.1002/1097-0142(19870215)59:4<836::AID-CNCR2820590430>3.0.CO;2-S; WIGGERS T, 1988, CANCER, V61, P386, DOI 10.1002/1097-0142(19880115)61:2<386::AID-CNCR2820610231>3.0.CO;2-J; WOBBES T, 1990, SURG GYNECOL OBSTET, V171, P59; WOBBES T, 1989, DIS COLON RECTUM, V32, P743, DOI 10.1007/BF02562121	34	313	317	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 27	1994	344	8922					573	578		10.1016/S0140-6736(94)91965-8	http://dx.doi.org/10.1016/S0140-6736(94)91965-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD424	7914960				2023-01-03	WOS:A1994PD42400009
J	ADAMS, S				ADAMS, S			SHOULD RELATIVES BE ALLOWED TO WATCH RESUSCITATION - A SISTERS EXPERIENCE	BRITISH MEDICAL JOURNAL			English	Article																			0	55	55	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 25	1994	308	6945					1687	1687		10.1136/bmj.308.6945.1687	http://dx.doi.org/10.1136/bmj.308.6945.1687			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU483	8025465	Green Published			2023-01-03	WOS:A1994NU48300026
J	STANDIFER, KM; CHIEN, CC; WAHLESTEDT, C; BROWN, GP; PASTERNAK, GW				STANDIFER, KM; CHIEN, CC; WAHLESTEDT, C; BROWN, GP; PASTERNAK, GW			SELECTIVE LOSS OF DELTA-OPIOID ANALGESIA AND BINDING BY ANTISENSE OLIGODEOXYNUCLEOTIDES TO A DELTA-OPIOID RECEPTOR	NEURON			English	Article							PHARMACOLOGICAL CHARACTERIZATION; OPIATE RECEPTOR; RAT-BRAIN; SUBTYPES; ANTINOCICEPTION; MOUSE; MICE; EXPRESSION; MEDIATION; MORPHINE	Antisense oligodeoxynucleotides (18-20 bases) to a cloned delta opioid receptor (DOR-1) lower delta binding in NG108-15 cells by 40%-50%. Changing 4 bases to generate a mismatch antisense oligodeoxynucleotide or mixing the corresponding sense and antisense oligodeoxynucleotides prior to treatment of the cells eliminates the inhibition of binding, confirming the specificity of the response. In vivo, an antisense oligodeoxynucleotide to DOR-1 given intrathecally lowers delta, but not mu or kappa(1) spinal analgesia. This mismatch antisense oligodeoxynucleotide is inactive. delta analgesic sensitivity gradually returns by 5 days after the last antisense treatment, indicating the lack of irreversible damage or toxicity. These studies demonstrate that DOR-1 mediates delta analgesia at the level of the spinal cord and confirm at the molecular level traditional pharmacological studies implying distinct receptor mechanisms for delta, mu, and kappa(1) analgesia. The use of antisense approaches may prove valuable in understanding the receptors mediating opioid pharmacology.	CORNELL UNIV,COLL MED,DEPT NEUROL & NEUROSCI,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,DEPT PHARMACOL,NEW YORK,NY 10021	Cornell University; Cornell University	STANDIFER, KM (corresponding author), MEM SLOAN KETTERING CANC CTR,COTZIAS LAB NEUROONCOL,NEW YORK,NY 10021, USA.		Wahlestedt, Claes/A-7039-2009		NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA007242, R01DA002615, R37DA007242] Funding Source: NIH RePORTER; NCI NIH HHS [CA08748] Funding Source: Medline; NIDA NIH HHS [DA02615, DA07242] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		BASBAUM AI, 1984, ANNU REV NEUROSCI, V7, P309, DOI 10.1146/annurev.ne.07.030184.001521; BLUME AJ, 1979, P NATL ACAD SCI USA, V76, P5626, DOI 10.1073/pnas.76.11.5626; CHEN Y, 1993, MOL PHARMACOL, V44, P8; CLARK JA, 1988, MOL PHARMACOL, V34, P308; CLARK JA, 1989, J PHARMACOL EXP THER, V251, P461; D'amour FE, 1941, J PHARMACOL EXP THER, V72, P74; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; FANTOZZI R, 1981, MOL PHARMACOL, V20, P8; FUKUDA K, 1993, FEBS LETT, V327, P311, DOI 10.1016/0014-5793(93)81011-N; HARRISON JK, 1991, MOL PHARMACOL, V40, P407; HEYMAN JS, 1988, J PHARMACOL EXP THER, V245, P238; HOLOPAINEN I, 1993, J PHARMACOL EXP THER, V264, P423; HYLDEN JLK, 1980, EUR J PHARMACOL, V67, P313, DOI 10.1016/0014-2999(80)90515-4; JIANG Q, 1991, J PHARMACOL EXP THER, V257, P1069; KIEFFER BL, 1992, P NATL ACAD SCI USA, V89, P12048, DOI 10.1073/pnas.89.24.12048; KLEE WA, 1974, P NATL ACAD SCI USA, V71, P3474, DOI 10.1073/pnas.71.9.3474; LI SX, 1993, BIOCHEM J, V295, P629, DOI 10.1042/bj2950629; LING GSF, 1983, BRAIN RES, V271, P152, DOI 10.1016/0006-8993(83)91376-8; MATTIA A, 1991, J PHARMACOL EXP THER, V258, P583; MATTIA A, 1992, J PHARMACOL EXP THER, V260, P518; MENG F, 1993, P NATL ACAD SCI USA, V90, P9954, DOI 10.1073/pnas.90.21.9954; MINAMI M, 1993, FEBS LETT, V329, P291, DOI 10.1016/0014-5793(93)80240-U; PASTERNAK GW, 1980, SCIENCE, V208, P514, DOI 10.1126/science.6245448; PASTERNAK GW, 1980, J PHARMACOL EXP THER, V214, P455; PASTERNAK GW, 1993, CLIN NEUROPHARMACOL, V16, P1, DOI 10.1097/00002826-199302000-00001; PAUL D, 1989, EUR J PHARMACOL, V168, P307, DOI 10.1016/0014-2999(89)90792-9; PERT CB, 1973, SCIENCE, V179, P1011, DOI 10.1126/science.179.4077.1011; PORRECA F, 1987, J PHARMACOL EXP THER, V241, P293; SIMON EJ, 1973, P NATL ACAD SCI USA, V70, P1947, DOI 10.1073/pnas.70.7.1947; STEIN CA, 1992, LEUKEMIA, V6, P967; TAKESHIMA H, 1993, FEBS LETT, V330, P77; TERENIUS L, 1973, ACTA PHARMACOL TOX, V33, P377; THOMPSON RC, 1993, NEURON, V11, P903, DOI 10.1016/0896-6273(93)90120-G; UHL GR, 1994, TRENDS NEUROSCI, V17, P89, DOI 10.1016/0166-2236(94)90110-4; WAHLESTEDT C, 1993, NATURE, V363, P260, DOI 10.1038/363260a0; WAHLESTEDT C, 1993, SCIENCE, V259, P528, DOI 10.1126/science.8380941; WANG JB, 1993, P NATL ACAD SCI USA, V90, P10230, DOI 10.1073/pnas.90.21.10230; WARD SJ, 1982, J PHARMACOL EXP THER, V220, P494; WEINTRAUB HM, 1990, SCI AM, V262, P40, DOI 10.1038/scientificamerican0190-40; YAKSH TL, 1977, J PHARMACOL EXP THER, V202, P411; YASUDA K, 1993, P NATL ACAD SCI USA, V90, P6736, DOI 10.1073/pnas.90.14.6736	41	195	198	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0896-6273			NEURON	Neuron	APR	1994	12	4					805	810		10.1016/0896-6273(94)90333-6	http://dx.doi.org/10.1016/0896-6273(94)90333-6			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	NH253	8161452				2023-01-03	WOS:A1994NH25300009
J	GOLDHIRSCH, A; GELBER, RD; PRICE, KN; CASTIGLIONE, M; COATES, AS; RUDENSTAM, CM; COLLINS, J; LINDTNER, J; HACKING, A; MARINI, G; BYRNE, M; CORTESFUNES, H; SCHNURCH, G; BRUNNER, KW; TATTERSALL, MHN; FORBES, J; SENN, HJ				GOLDHIRSCH, A; GELBER, RD; PRICE, KN; CASTIGLIONE, M; COATES, AS; RUDENSTAM, CM; COLLINS, J; LINDTNER, J; HACKING, A; MARINI, G; BYRNE, M; CORTESFUNES, H; SCHNURCH, G; BRUNNER, KW; TATTERSALL, MHN; FORBES, J; SENN, HJ			EFFECT OF SYSTEMIC ADJUVANT TREATMENT ON FIRST SITES OF BREAST-CANCER RELAPSE	LANCET			English	Article							PAST DECADE	Adjuvant systemic treatment for resectable breast cancer changes the natural history of the disease but provides only a small and delayed effect on survival. Evaluation of the types of first relapse avoided by available treatments may explain why effects on mortality are small and appear late during follow-up. In randomised clinical trials done by the International Breast Cancer Study Group (IBCSG) between 1978 and 1985, 2108 patients with node-positive disease received more-effective treatments (6 or more cycles of cyclophosphamide, methotrexate, fluorouracil and prednisone; with or without tamoxifen, or tamoxifen and prednisone alone), and 722 patients received less-effective treatments (no treatment or a single cycle of chemotherapy). 3 main categories of first site of relapse were defined and evaluated by cumulative incidence analysis: local or regional, and distant soft tissue,bone, and viscera. The more-effective treatments reduced the cumulative incidence of first relapse in local or regional and distant soft tissue sites at 10 years from 36% to 18% (p=00001); first relapse in bone and viscera was not altered by the more-effective treatments. These results were similar for premenopausal and postmenopausal women, and for patients with oestrogen-receptor-positive or oestrogen-receptor-negative tumours. Adjuvant systemic treatments in current use improve patient outcome mainly by reducing the incidence of first local or regional and distant soft-tissue relapses, while first recurrences in bone or viscera are influenced much less. More intensive treatments at present being tested in clinical trials might affect bone and visceral relapses and have a greater and earlier influence on survival.	DANA FARBER CANC INST,INT BREAST CANC STUDY GRP STAT CTR,DIV BIOSTAT,BOSTON,MA 02115; OSPED CIVICO,LUGANO,SWITZERLAND; IBCSG COORDINATING CTR,BERN,SWITZERLAND; ROYAL PRINCE ALFRED HOSP,CAMPERDOWN,NSW,AUSTRALIA; SAHLGRENS UNIV HOSP,GOTHENBURG,SWEDEN; ANTICANC COUNCIL VICTORIA,CARLTON,VIC,AUSTRALIA; INST ONCOL,LJUBLJANA,SLOVENIA; GROOTE SCHUUR HOSP,CAPE TOWN,SOUTH AFRICA; SPEDALI CIVIL BRESCIA,BRESCIA,ITALY; SIR CHARLES GALRDNER HOSP,NEDLANDS,WA,AUSTRALIA; MADRID BREAST CANC GRP,MADRID,SPAIN; UNIV DUSSELDORF,DUSSELDORF,GERMANY; INSELSPITAL BERN,CH-3010 BERN,SWITZERLAND; ROYAL PRINCE ALFRED HOSP,CAMPERDOWN,NSW,AUSTRALIA; MATER MISERICORDLAE HOSP,WARATAH,NSW,AUSTRALIA; KANTONSSPITAL,ST GALLEN,SWITZERLAND	Harvard University; Dana-Farber Cancer Institute; University of Sydney; Sahlgrenska University Hospital; Institute of Oncology - Slovenia; University of Cape Town; Hospital Spedali Civili Brescia; Heinrich Heine University Dusseldorf; University of Sydney; Kantonsspital Aarau AG (KSA); Kantonsspital St. Gallen								BUDMAN DR, 1992, P AN M AM SOC CLIN, V11, P51; COX DR, 1972, J R STAT SOC B, V34, P187; DONEGAN W L, 1970, Missouri Medicine, V67, P853; Early Breast Cancer Trialists' Collaborative Group, 1992, LANCET, V339, P1; FISHER B, 1989, NEW ENGL J MED, V320, P822, DOI 10.1056/NEJM198903303201302; GELBER RD, 1991, ANN INTERN MED, V114, P621, DOI 10.7326/0003-4819-114-8-621; GOLDHIRSCH A, 1988, J CLIN ONCOL, V6, P89, DOI 10.1200/JCO.1988.6.1.89; GOLDHIRSCH A, 1987, LANCET, V2, P151; GOLDHIRSCH A, 1986, NCI MONOGRAPHS, V1, P55; GOLDHIRSCH A, 1984, LANCET, V2, P922; Goldhirsch A, 1992, J NCI MONOGR, V11, P89; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; Greenwood M., 1926, REPORTS PUBLIC HLTH, V33, P1; HAYES DF, 1991, BREAST DISEASES, P505; HENDERSON IC, 1980, NEW ENGL J MED, V302, P17, DOI 10.1056/NEJM198001033020104; HENDERSON IC, 1980, NEW ENGL J MED, V302, P78, DOI 10.1056/NEJM198001103020203; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI, P169; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; PEDRAZZINI A, 1986, J CLIN ONCOL, V3, P389; VALAGUSSA P, 1982, BREAST CANCER RES TR, V1, P349; YUSUF S, 1984, STAT MED, V3, P409, DOI 10.1002/sim.4780030421; 1978, CANCER, V42, P2809; 1983, LANCET, V2, P542; 1984, LANCET, V1, P1256; 1989, NEW ENGL J MED, V320, P491; 1988, NEW ENGL J MED, V319, P677; 1992, LANCET, V339, P71	27	72	74	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 12	1994	343	8894					377	381		10.1016/S0140-6736(94)91221-1	http://dx.doi.org/10.1016/S0140-6736(94)91221-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW283	7905550				2023-01-03	WOS:A1994MW28300007
J	SOLOMON, T; FELIX, JM; SAMUEL, M; DENGO, GA; SALDANHA, RA; SCHAPIRA, A; PHILLIPS, RE				SOLOMON, T; FELIX, JM; SAMUEL, M; DENGO, GA; SALDANHA, RA; SCHAPIRA, A; PHILLIPS, RE			HYPOGLYCEMIA IN PEDIATRIC ADMISSIONS IN MOZAMBIQUE	LANCET			English	Note							SEVERE FALCIPARUM-MALARIA; HYPOGLYCEMIA; CHILDREN; CHILDHOOD	We studied the incidence and clinical associations of hypoglycaemia in an acute medical paediatric service in Maputo, Mozambique. Of 603 children, 43 (7.1%) were hypoglycaemic. 16 of these with Plasmodium falciparum malaria had a shorter illness, and a higher incidence of convulsions and focal neurological signs than those with other diagnoses, but were less likely to die. Hypoglycaemia also complicated protein energy malnutrition, pneumonia, encephalitis, intestinal parasite infection, and nephrotic syndrome. 25 of the 603 children died: 7 (16.3%) of 43 with hypoglycaemia and 18 (3.2%) of 560 who were normoglycaemic, (relative risk of death 5.8 [95% confidence interval 2.25 to 14.93]). Hypoglycaemia is common in children in hospital in Mozambique, and should be suspected in any acutely-ill child regardless of the primary disease.	JOHN RADCLIFFE HOSP,NUFFIELD DEPT CLIN MED,OXFORD OX3 9DU,ENGLAND; UNIV EDUARDO MONDLANE,FAC MED,MAPUTO,MOZAMBIQUE; HOSP CENT MAPUTO,MAPUTO,MOZAMBIQUE; UNIV OXFORD,DEPT STAT,OXFORD,ENGLAND	University of Oxford; Eduardo Mondlane University; University of Oxford			Schapira, Allan/AAZ-8116-2020	Solomon, Tom/0000-0001-7266-6547; Saldanha, Richard/0000-0002-4137-3917	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BENNISH ML, 1990, NEW ENGL J MED, V322, P1357, DOI 10.1056/NEJM199005103221905; FILKINS JP, 1974, AM J PHYSIOL, V227, P778, DOI 10.1152/ajplegacy.1974.227.4.778; GRAU GE, 1989, NEW ENGL J MED, V320, P1586, DOI 10.1056/NEJM198906153202404; MOLYNEUX ME, 1989, AM J TROP MED HYG, V40, P470, DOI 10.4269/ajtmh.1989.40.470; PAGLIARA AS, 1973, J PEDIATR-US, V82, P558, DOI 10.1016/S0022-3476(73)80581-5; PAGLIARA AS, 1973, J PEDIATR-US, V82, P365, DOI 10.1016/S0022-3476(73)80109-X; TAYLOR TE, 1988, NEW ENGL J MED, V319, P1040, DOI 10.1056/NEJM198810203191602; WHARTON B, 1970, LANCET, V1, P171; WHITE NJ, 1987, LANCET, V1, P708; 1990, T R SOC TROP MED H S, P1; 1972, LANCET, V2, P143	11	33	33	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 15	1994	343	8890					149	150		10.1016/S0140-6736(94)90937-7	http://dx.doi.org/10.1016/S0140-6736(94)90937-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ869	7904007				2023-01-03	WOS:A1994MQ86900013
J	ROSS, AM; SIMOONS, ML; LUNDERGAN, C; THOMPSON, M; REINER, J; DEYCHAK, Y; ROHRBECK, S; COYNE, K; WALKER, P; CHO, S; GREENHOUSE, S; LEE, K; GRANGER, C; WILDERMANN, N; FINK, C; HARRY, S; ALLISON, D; DRAOUI, Y; COSTIGAN, G; FOX, D; LEMPEL, M; WILLIAMS, M; ROSS, J; FLOURA, R; HICKS, J; VANDEBRAND, M; BALK, A; RODENBURG, L; BAARDMAN, T; HOEKMAN, I; AMO, D; VANOOSTEROM, I; VANHESSEM, G; DEZWART, I; JANSSEN, M; DEPUI, A; TERWOGT, C; HOUWELING, J; CORBEAU, N; IWEMA, J; PAMEIJER, J; DEJONG, R; TOPOL, E; CALIFF, R; ARMSTRONG, PW; AYLWARD, P; BARBASH, G; BATES, E; BETRIU, A; BOISSEL, J; CHESEBRO, J; COL, J; DEBONO, D; GORE, J; GUERCI, A; HAMPTON, A; HIRSH, J; HOLMES, D; HORGAN, J; KLEIMAN, N; MARDER, V; MORRIS, D; OHMAN, M; PFISTERER, M; RUTSCH, W; SADOWSKI, Z; SIMES, J; SIMOONS, ML; VAHANIAN, A; VANDEWERF, F; WEAVER, D; WHITE, H; WILCOX, R; KOPECKY, S; MCLAUGHLIN, A; BOWMAN, R; WASSERMAN, A; SEGAL, J; COYNE, K; WALKER, P; PICKERING, E; COTHAM, P; GABER, J; RIGBY, D; WHITEHEAD, S; PILCHER, G; GREENE, B; HIPPS, A; LANCASTER, L; LANSMAN, D; MITCHELL, J; STEGALL, G; SCHMIDT, P; MILLER, D; NESS, C; KRISHNASWAMI, V; HEYL, A; SIMONELLI, R; KAZMIERSKI, J; THOMPSON, L; HODGSON, J; HLADIK, L; DORCHAK, J; ROBINETTE, T; SMITH, J; HARRAH, L; BROWN, D; MCCARTER, T; GOSSMAN, D; WOODHEAD, G; BATES, E; KLINEROGERS, E; ISRAEL, N; LEBOEUF, R; PERRY, J; SCHVANEVELDT, W; MORRIS, D; BERNARD, W; PARRIS, T; STOAKES, K; SOLBERG, L; BROWN, A; GAINEY, P; GREENBUSH, R; WHITE, C; LEASURE, B; RAZAVI, A; ERTEL, P; HAMILTON, D; BLAKER, A; SHANE, J; SILVERMAN, I; WESZT, S; MCCORMICK, D; LUHMANN, S; JESSE, R; ROBERTS, C; SILVERMAN, I; WESZT, S; OTOOLE, J; HEILMAN, S; ANDRES, P; BAUER, D; LEW, B; MATVYA, C; SCHECHTER, C; KILLEBREW, K; HARNER, R; FISHER, M; SCHECHTER, C; KILLEBREW, K; KAVANAUGH, K; VOSS, M; MEENGS, W; STONE, B; ZIMMERMAN, J; HART, J; HSIEH, A; MCDERMOTT, B; PY, A; VAHANIAN, A; NALLET, O; GROLLIER, G; VALETTE, B; BESSE, P; DURRIEU, C; MOSSARD, M; ARBOGAST, R; BERNADET, P; CARRIE, D; CHARBONNIER, B; ALMANGE, C; LEBRETON, H; DAUBERT, J; CASSAGNES, J; BEAUFILS, P; RAPOPORT, P; JULIARD, J; STEG, G; GUERMONPREZ, J; GUIZE, L; ILIOU, M; GUEROT, C; GRENIER, O; BARRAINE, R; COISNE, D; BASSAND, J; SCHIELE, F; VANDEWERF, F; TENAERTS, P; BOLAND, J; CASTADOT, M; COLSOUL, D; SCHROEDER, E; VANDENHEUVEL, P; MOLHOEK, G; LALISANG, R; MULLER, E; SIMOONS, ML; VANDEBRAND, M; KINT, P; BURTON, J; KEE, C; KELLS, C; FAWCETT, T; FUNG, A; DAVIES, C; THOMPSON, C; HEINRICH, D; ROBSON, L; AYLWARD, P; THOMAS, C; NELSON, GIC; DWYER, B; PFISTERER, M; HAMMERLI, R; DISSMANN, W; TOPP, H; DJONLAGIC, H; KUROWSKI, V; DELCAN, J; GARCIA, E; WALSH, M; WALSH, N; SUGRUE, D				ROSS, AM; SIMOONS, ML; LUNDERGAN, C; THOMPSON, M; REINER, J; DEYCHAK, Y; ROHRBECK, S; COYNE, K; WALKER, P; CHO, S; GREENHOUSE, S; LEE, K; GRANGER, C; WILDERMANN, N; FINK, C; HARRY, S; ALLISON, D; DRAOUI, Y; COSTIGAN, G; FOX, D; LEMPEL, M; WILLIAMS, M; ROSS, J; FLOURA, R; HICKS, J; VANDEBRAND, M; BALK, A; RODENBURG, L; BAARDMAN, T; HOEKMAN, I; AMO, D; VANOOSTEROM, I; VANHESSEM, G; DEZWART, I; JANSSEN, M; DEPUI, A; TERWOGT, C; HOUWELING, J; CORBEAU, N; IWEMA, J; PAMEIJER, J; DEJONG, R; TOPOL, E; CALIFF, R; ARMSTRONG, PW; AYLWARD, P; BARBASH, G; BATES, E; BETRIU, A; BOISSEL, J; CHESEBRO, J; COL, J; DEBONO, D; GORE, J; GUERCI, A; HAMPTON, A; HIRSH, J; HOLMES, D; HORGAN, J; KLEIMAN, N; MARDER, V; MORRIS, D; OHMAN, M; PFISTERER, M; RUTSCH, W; SADOWSKI, Z; SIMES, J; SIMOONS, ML; VAHANIAN, A; VANDEWERF, F; WEAVER, D; WHITE, H; WILCOX, R; KOPECKY, S; MCLAUGHLIN, A; BOWMAN, R; WASSERMAN, A; SEGAL, J; COYNE, K; WALKER, P; PICKERING, E; COTHAM, P; GABER, J; RIGBY, D; WHITEHEAD, S; PILCHER, G; GREENE, B; HIPPS, A; LANCASTER, L; LANSMAN, D; MITCHELL, J; STEGALL, G; SCHMIDT, P; MILLER, D; NESS, C; KRISHNASWAMI, V; HEYL, A; SIMONELLI, R; KAZMIERSKI, J; THOMPSON, L; HODGSON, J; HLADIK, L; DORCHAK, J; ROBINETTE, T; SMITH, J; HARRAH, L; BROWN, D; MCCARTER, T; GOSSMAN, D; WOODHEAD, G; BATES, E; KLINEROGERS, E; ISRAEL, N; LEBOEUF, R; PERRY, J; SCHVANEVELDT, W; MORRIS, D; BERNARD, W; PARRIS, T; STOAKES, K; SOLBERG, L; BROWN, A; GAINEY, P; GREENBUSH, R; WHITE, C; LEASURE, B; RAZAVI, A; ERTEL, P; HAMILTON, D; BLAKER, A; SHANE, J; SILVERMAN, I; WESZT, S; MCCORMICK, D; LUHMANN, S; JESSE, R; ROBERTS, C; SILVERMAN, I; WESZT, S; OTOOLE, J; HEILMAN, S; ANDRES, P; BAUER, D; LEW, B; MATVYA, C; SCHECHTER, C; KILLEBREW, K; HARNER, R; FISHER, M; SCHECHTER, C; KILLEBREW, K; KAVANAUGH, K; VOSS, M; MEENGS, W; STONE, B; ZIMMERMAN, J; HART, J; HSIEH, A; MCDERMOTT, B; PY, A; VAHANIAN, A; NALLET, O; GROLLIER, G; VALETTE, B; BESSE, P; DURRIEU, C; MOSSARD, M; ARBOGAST, R; BERNADET, P; CARRIE, D; CHARBONNIER, B; ALMANGE, C; LEBRETON, H; DAUBERT, J; CASSAGNES, J; BEAUFILS, P; RAPOPORT, P; JULIARD, J; STEG, G; GUERMONPREZ, J; GUIZE, L; ILIOU, M; GUEROT, C; GRENIER, O; BARRAINE, R; COISNE, D; BASSAND, J; SCHIELE, F; VANDEWERF, F; TENAERTS, P; BOLAND, J; CASTADOT, M; COLSOUL, D; SCHROEDER, E; VANDENHEUVEL, P; MOLHOEK, G; LALISANG, R; MULLER, E; SIMOONS, ML; VANDEBRAND, M; KINT, P; BURTON, J; KEE, C; KELLS, C; FAWCETT, T; FUNG, A; DAVIES, C; THOMPSON, C; HEINRICH, D; ROBSON, L; AYLWARD, P; THOMAS, C; NELSON, GIC; DWYER, B; PFISTERER, M; HAMMERLI, R; DISSMANN, W; TOPP, H; DJONLAGIC, H; KUROWSKI, V; DELCAN, J; GARCIA, E; WALSH, M; WALSH, N; SUGRUE, D			THE EFFECTS OF TISSUE-PLASMINOGEN ACTIVATOR, STREPTOKINASE, OR BOTH ON CORONARY-ARTERY PATENCY, VENTRICULAR-FUNCTION, AND SURVIVAL AFTER ACUTE MYOCARDIAL-INFARCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTRAVENOUS STREPTOKINASE; THROMBOLYTIC THERAPY; INTRACORONARY STREPTOKINASE; PHASE-I; TRIAL; REPERFUSION; TIME; SIZE; ANGIOPLASTY; PREVENTION	Background. Although it is known that thrombolytic therapy improves survival after acute myocardial infarction, it has been debated whether the speed with which coronary-artery patency is restored after the initiation of therapy further affects outcome. Methods. To study this question, we randomly assigned 2431 patients to one of four treatment strategies for reperfusion: streptokinase with subcutaneous heparin; streptokinase with intravenous heparin; accelerated-dose tissue plasminogen activator (t-PA) with intravenous heparin; or a combination of both activators plus intravenous heparin. Patients were also randomly assigned to cardiac angiography at one of four times after the initiation of thrombolytic therapy: 90 minutes, 180 minutes, 24 hours, or 5 to 7 days. The group that underwent angiography at 90 minutes underwent it again after 5 to 7 days. Results. The rate of patency of the infarct-related artery at 90 minutes was highest in the group given accelerated-dose t-PA and heparin (81 percent), as compared with the group given streptokinase and subcutaneous heparin (54 percent, P<0.001), the group given streptokinase and intravenous heparin (60 percent, P<0.001), and the group given combination therapy (73 percent, P = 0.032). Flow through the infarct-related artery at 90 minutes was normal in 54 percent of the group given t-PA and heparin but in less than 40 percent of the three other groups (P<0.001). By 180 minutes, the patency rates were the same in the four treatment groups. Re-occlusion was infrequent and was similar in all four groups (range, 4.9 to 6.4 percent). Measures of left ventricular function paralleled the rate of patency at 90 minutes; ventricular function was best in the group given t-PA with heparin and in patients with normal flow through the infarct-related artery irrespective of treatment group. Mortality at 30 days was lowest (4.4 percent) among patients with normal coronary flow at 90 minutes and highest (8.9 percent) among patients with no flow (P = 0.009). Conclusions. This study supports the hypothesis that more rapid and complete restoration of coronary flow through the infarct-related artery results in improved ventricular performance and lower mortality among patients with myocardial infarction. This would appear to be the mechanism by which accelerated t-PA therapy produced the most favorable outcome in the GUSTO trial.	GEORGE WASHINGTON UNIV, ANGIOG SUBSTUDY COORDINATING CTR, WASHINGTON, DC 20052 USA; GEORGE WASHINGTON UNIV, CORE LAB, WASHINGTON, DC 20052 USA; NON-N AMER ANGIOG COORDINATING CTR CARDIALYSIS, ROTTERDAM, NETHERLANDS; ST MARYS HOSP, ROCHESTER, NY 14611 USA; GEORGE WASHINGTON UNIV HOSP, WASHINGTON, DC 20037 USA; TULSA REG MED CTR, TULSA, OK USA; MCKAY DEE HOSP, OGDEN, UT USA; ST VINCENTS MED CTR, JACKSONVILLE, FL USA; E ALABAMA MED CTR, OPELIKA, AL USA; ST MARYS HOSP, TUCSON, AL USA; PROCTOR COMMUNITY HOSP, PEORIA, IL USA; MERCY HOSP, PITTSBURGH, PA 15219 USA; MT CLEMENS GEN HOSP, MT CLEMENS, MI USA; UNIV HOSP CLEVELAND, CLEVELAND, OH 44106 USA; SPARTENBURG REG MED CTR, SPARTANBURG, SC USA; UNIV COMMUN HOSP, TAMPA, FL USA; HUMANA MED CITY, DALLAS, TX USA; LAHEY CLIN MED CTR, BURLINGTON, MA USA; UNIV MICHIGAN HOSP, ANN ARBOR, MI 48109 USA; MOTHER FRANCES HOSP, TYLER, TX USA; ST MARKS HOSP, SALT LAKE CITY, UT USA; CRAWFORD W LONG MEM HOSP, ATLANTA, GA USA; HAHNEMANN UNIV, PHILADELPHIA, PA 19102 USA; SIOUX VALLEY HOSP, SIOUX FALLS, SD USA; ST JOSEPHS HOSP, SAVANNAH, GA USA; OCHSNER FDN HOSP, NEW ORLEANS, GA USA; GOOD SAMARITAN HOSP, CINCINNATI, OH 45220 USA; MCLEOD REG MED CTR, FLORENCE, SC USA; EVANSTON HOSP CORP, EVANSTON, IL 60201 USA; ST AGNES MED CTR, PHILADELPHIA, PA USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, RICHMOND, VA 23298 USA; GLENBROOK HOSP, GLENVIEW, IL USA; SHADEYSIDE HOSP, PITTSBURGH, PA USA; TERRE HAUTE REG HOSP, TERRE HAUT, IN USA; LUTHERAN HOSP, FT WAYNE, IN USA; MEM MED CTR, CORPUS CHRISTI, TX USA; SWEDISH AMER HOSP, ROCKFORD, IL USA; SPOHN HOSP, CORPUS CHRISTI, TX USA; MCKENNAN HOSP, SIOUX FALLS, SD USA; NO MICHIGAN HOSP, PETOSKEY, MI USA; HACKENSACK MED CTR, HACKENSACK, NJ USA; LAKESIDE VET AFFAIRS MED CTR, CHICAGO, IL USA; HOP COCHIN, F-75674 PARIS 14, FRANCE; HOP TENON, F-75970 PARIS 20, FRANCE; CHU CAEN, F-14033 CAEN, FRANCE; HOP HAUT LEVEQUE, PESSAC, FRANCE; HOP HAUTE PIERRE, STRASBOURG, FRANCE; HOP PURPAN, TOULOUSE, FRANCE; HOP TROUSSEAU, TOURS, FRANCE; HOP HOTEL DIEU, RENNES, FRANCE; CTR HOSP RENNES, RENNES, FRANCE; HOP ST JACQUES, CLERMONT FERRAND, FRANCE; HOP LARIBOISIERE, F-75475 PARIS 10, FRANCE; HOP BICHAT, F-75877 PARIS 18, FRANCE; HOP BROUSSAIS, PARIS, FRANCE; HOP BOUCIAUT VAUGIRARD, PARIS, FRANCE; CHU LA MILETRIE, POITIERS, FRANCE; CTR HOSP REG BESANCON, BESANCON, FRANCE; UNIV ZIEKENHUIS RAPHAEL GASTHUISBERG, LOUVAIN, BELGIUM; HOP CITADELLE, LIEGE, BELGIUM; CLIN GEN ST JEAN, BRUSSELS, BELGIUM; CLIN UNIV MT GODINNE, YVOIR, BELGIUM; AKAD ZIEKENHUIS, ANTWERP, BELGIUM; MED SPECTRUM, ENSCHEDE, NETHERLANDS; SPAARNE ZIEKENHUIS, HEEMSTEDE, NETHERLANDS; DIJKZIGT, ROTTERDAM, NETHERLANDS; UNIV ALBERTA HOSP, EDMONTON T6G 2B7, ALBERTA, CANADA; VICTORIA GEN HOSP, HALIFAX B3H 2Y9, NS, CANADA; ST PAULS HOSP, VANCOUVER, BC, CANADA; FLINDERS UNIV S AUSTRALIA, MED CTR, BEDFORD PK, SA 5042, AUSTRALIA; ROYAL N SHORE HOSP, ST LEONARDS, NSW 2065, AUSTRALIA; UNIV CLIN BASEL, BASEL, SWITZERLAND; KRANKENHAUS URBAN, BERLIN, GERMANY; MED UNIV LUBEK, LUBECK, GERMANY; HOSP GEN GREGORIO MARANON, MADRID, SPAIN; ST JAMES HOSP, DUBLIN 8, IRELAND; MATER HOSP, DUBLIN, IRELAND	George Washington University; George Washington University; George Washington University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University Hospitals of Cleveland; Medical City Dallas Hospital; Lahey Hospital & Medical Center; University of Michigan System; University of Michigan; Drexel University; Good Samaritan Hospital - Cincinnati; NorthShore University Health System; Virginia Commonwealth University; NorthShore University Health System; Hackensack University Medical Center; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; CHU de Caen NORMANDIE; Universite de Caen Normandie; CHU Bordeaux; CHU Strasbourg; CHU de Toulouse; CHU Tours; CHU Rennes; CHU Rennes; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU Poitiers; Universite de Poitiers; Universite de Franche-Comte; CHU Besancon; Universite Catholique Louvain; Universite Catholique Louvain Hospital; Medical Spectrum Twente; Spaarne Hospital; University of Alberta; Dalhousie University; University of Victoria; St. Paul's Hospital; University of Saskatchewan; Flinders University South Australia; Royal North Shore Hospital; University of Basel; General University Gregorio Maranon Hospital; Trinity College Dublin; Mater Misericordiae University Hospital; University College Dublin	ROSS, AM (corresponding author), GEORGE WASHINGTON UNIV, DIV CARDIOL, 2150 PENN AVE NW, WASHINGTON, DC 20037 USA.		Smith, Jane/B-6254-2009; gaber, jaafar/B-1642-2010; Simes, Robert John/P-1497-2014	gaber, jaafar/0000-0003-4356-6760; 				[Anonymous], 1990, LANCET, V336, P65; [Anonymous], 1986, LANCET, V1, P397; BATES ER, 1989, J AM COLL CARDIOL, V13, P12, DOI 10.1016/0735-1097(89)90542-1; BELENKIE I, 1989, AM J CARDIOL, V63, P912, DOI 10.1016/0002-9149(89)90138-0; BOLSON EL, 1981, COMPUT CARDIOL, P245; CARNEY R, 1990, CIRCULATION, V82, P538; CHESEBRO JH, 1987, CIRCULATION, V76, P142, DOI 10.1161/01.CIR.76.1.142; Conover WJ, 1980, PRACTICAL NONPARAMET, P229; DAVIES GJ, 1984, NEW ENGL J MED, V311, P1488, DOI 10.1056/NEJM198412063112306; DEBONO DP, 1992, BRIT HEART J, V67, P122; DODGE HT, 1960, AM HEART J, V60, P762, DOI 10.1016/0002-8703(60)90359-8; ELLIS SG, 1983, J AM COLL CARDIOL, V1, P1047, DOI 10.1016/S0735-1097(83)80107-7; HSIA J, 1992, J AM COLL CARDIOL, V20, P31, DOI 10.1016/0735-1097(92)90133-8; KARAGOUNIS L, 1992, J AM COLL CARDIOL, V19, P1, DOI 10.1016/0735-1097(92)90043-M; KOREN G, 1985, NEW ENGL J MED, V313, P1384, DOI 10.1056/NEJM198511283132204; MATHEY DG, 1985, J AM COLL CARDIOL, V6, P518, DOI 10.1016/S0735-1097(85)80107-8; MORGAN CD, 1991, J AM COLL CARDIOL, V17, P1451, DOI 10.1016/0735-1097(91)90630-R; NETER J, 1985, APPLIED LINEAR STATI, P950; NEUHAUS KL, 1989, J AM COLL CARDIOL, V14, P1566, DOI 10.1016/0735-1097(89)90399-9; OHMAN EM, 1990, CIRCULATION, V82, P781, DOI 10.1161/01.CIR.82.3.781; SCHMIDT SB, 1986, CIRCULATION, V73, P1354, DOI 10.1161/01.CIR.73.6.1354; SERRUYS PW, 1988, CIRCULATION, V77, P361, DOI 10.1161/01.CIR.77.2.361; SHEEHAN FH, 1987, CIRCULATION, V75, P817, DOI 10.1161/01.CIR.75.4.817; STACK RS, 1983, J CLIN INVEST, V72, P84, DOI 10.1172/JCI110987; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; VANDEWERF F, 1989, LANCET, V1, P1367; VERSTRAETE M, 1985, LANCET, V1, P842, DOI 10.1016/S0140-6736(85)92208-1; VOGT A, 1993, J AM COLL CARDIOL, V21, P1391, DOI 10.1016/0735-1097(93)90314-Q; 1993, LANCET, V339, P753	29	1623	1672	0	32	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 25	1993	329	22					1615	1622						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ546	8232430				2023-01-03	WOS:A1993MJ54600004
J	WILSON, GT				WILSON, GT			RELATION OF DIETING AND VOLUNTARY WEIGHT-LOSS TO PSYCHOLOGICAL FUNCTIONING AND BINGE-EATING	ANNALS OF INTERNAL MEDICINE			English	Article							DIETARY RESTRAINT; BULIMIA-NERVOSA; FOLLOW-UP; OBESITY; DEPRESSION; BEHAVIOR; FAILURE; EPIDEMIOLOGY; ADOLESCENTS; RESPONSES	Voluntary weight loss in obese patients consistently reduces negative emotions such as depression and anxiety in the short term. Dieting by persons of normal weight is associated with low self-esteem and depressive symptoms. Dieting is linked to the development and maintenance of eating disorders such as anorexia nervosa and bulimia nervosa, although the precise nature of this association is unclear. Dieting cannot be a sufficient causal condition and must combine with other still undetermined vulnerabilities to cause eating disorders. Identification of these risk factors must precede the development of effective programs to prevent eating disorders.			WILSON, GT (corresponding author), RUTGERS UNIV, GSAPP, BOX 819, PISCATAWAY, NJ 08854 USA.							ABRAHAM SF, 1982, PSYCHOL MED, V12, P625, DOI 10.1017/S0033291700055732; BLUNDELL JE, 1990, APPETITE, V14, P113, DOI 10.1016/0195-6663(90)90006-T; BOOTH DA, 1990, APPETITE, V14, P116, DOI 10.1016/0195-6663(90)90007-U; BRODY M, 1992, 5TH INT C EAT DIS NE; BROWNELL KD, 1991, BEHAV THER, V22, P153, DOI 10.1016/S0005-7894(05)80174-1; COWAN PJ, 1992, BIOL FEAST FAMINE; DUBBERT PM, 1984, BEHAV RES THER, V22, P227, DOI 10.1016/0005-7967(84)90003-2; EBERT MH, 1984, PSYCHOBIOLOGY ANOREX; ELDREDGE K, 1990, INT J EAT DISORDER, V9, P37, DOI 10.1002/1098-108X(199001)9:1<37::AID-EAT2260090105>3.0.CO;2-3; FAIRBURN CG, 1990, AM J PSYCHIAT, V147, P401; FAIRBURN CG, 1982, BRIT MED J, V284, P1153, DOI 10.1136/bmj.284.6323.1153; FAIRBURN CG, IN PRESS BINGE EATIN; GARNER DM, 1987, PSYCHOTHER PSYCHOSOM, V48, P170, DOI 10.1159/000288049; GARNER DM, 1991, CLIN PSYCHOL REV, V11, P729, DOI 10.1016/0272-7358(91)90128-H; GOLDFEIN J, 1992, APR INT C EAT DIS NE; HALMI KA, 1980, AM J CLIN NUTR, V33, P446, DOI 10.1093/ajcn/33.2.446; HERMAN CP, 1988, PSYCHOL BULIMIA NERV; Hsu L. K. G., 1990, EATING DISORDERS; KAGAN DM, 1983, INT J EAT DISORDER, V3, P15, DOI 10.1002/1098-108X(198323)3:1<15::AID-EAT2260030103>3.0.CO;2-0; KENDLER KS, 1991, AM J PSYCHIAT, V148, P1627; LISSNER L, 1991, NEW ENGL J MED, V324, P1839, DOI 10.1056/NEJM199106273242602; LOWE MR, 1988, APPETITE, V10, P159, DOI 10.1016/0195-6663(88)90009-8; MARCUS MD, 1992, INT J EAT DISORDER, V12, P249, DOI 10.1002/1098-108X(199211)12:3&lt;249::AID-EAT2260120304&gt;3.0.CO;2-W; Marlatt GA., 1985, RELAPSE PREVENTION; OHNO M, 1991, PROGR OBESITY RES; ONEILL PM, 1992, TREATMENT OBESITY RE; PATTON GC, 1990, PSYCHOL MED, V20, P383, DOI 10.1017/S0033291700017700; PERRI MG, 1988, J CONSULT CLIN PSYCH, V56, P529, DOI 10.1037/0022-006X.56.4.529; POLIVY J, 1985, AM PSYCHOL, V40, P193, DOI 10.1037/0003-066X.40.2.193; RODIN J, 1990, INT J OBESITY, V14, P303; ROSEN JC, 1990, INT J EAT DISORDER, V9, P17, DOI 10.1002/1098-108X(199001)9:1&lt;17::AID-EAT2260090103&gt;3.0.CO;2-F; ROSEN JC, 1987, J CONSULT CLIN PSYCH, V55, P742; ROSEN JC, 1990, ADV PSYCHOL ASSESSME, V7; ROSSITER EM, 1992, INT J EAT DISORDER, V11, P111, DOI 10.1002/1098-108X(199203)11:2&lt;111::AID-EAT2260110203&gt;3.0.CO;2-J; RUDERMAN AJ, 1986, PSYCHOL BULL, V99, P247, DOI 10.1037/0033-2909.99.2.247; SMOLLER JW, 1987, J PSYCHOSOM RES, V31, P429, DOI 10.1016/0022-3999(87)90001-8; SPITZER RL, 1992, INT J EAT DISORDER, V11, P191, DOI 10.1002/1098-108X(199204)11:3&lt;191::AID-EAT2260110302&gt;3.0.CO;2-S; STUNKARD AJ, 1974, ANN INTERN MED, V81, P526, DOI 10.7326/0003-4819-81-4-526; STUNKARD AJ, 1986, AM J PSYCHIAT, V143, P417; STUNKARD AJ, 1985, J PSYCHOSOM RES, V29, P71, DOI 10.1016/0022-3999(85)90010-8; TELCH CF, 1993, IN PRESS BEHAV THER; TUSCHL RJ, 1990, APPETITE, V14, P105, DOI 10.1016/0195-6663(90)90004-R; TUSCHL RJ, 1990, APPETITE, V14, P9, DOI 10.1016/0195-6663(90)90050-I; WADDEN TA, 1988, J CONSULT CLIN PSYCH, V56, P925, DOI 10.1037/0022-006X.56.6.925; WADDEN TA, 1986, J CONSULT CLIN PSYCH, V54, P869, DOI 10.1037/0022-006X.54.6.869; WARDLE J, 1990, ADDICT BEHAV, V15, P387, DOI 10.1016/0306-4603(90)90047-2; WARDLE J, 1987, BRIT J CLIN PSYCHOL, V26, P47, DOI 10.1111/j.2044-8260.1987.tb00722.x; WILSON GT, 1993, INT J EAT DISORDER, V13, P25, DOI 10.1002/1098-108X(199301)13:1&lt;25::AID-EAT2260130104&gt;3.0.CO;2-T; WILSON GT, 1992, EATING BODY WEIGHT P; WING RR, 1992, TREATMENT OBESITY RE; WOOLEY SC, 1991, J AM DIET ASSOC, V91, P1248; IN PRESS DIAGNOSTIC	53	86	88	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1993	119	7	2				727	730		10.7326/0003-4819-119-7_Part_2-199310011-00020	http://dx.doi.org/10.7326/0003-4819-119-7_Part_2-199310011-00020			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA330	8363206				2023-01-03	WOS:A1993MA33000020
J	WEAVER, WD; CERQUEIRA, M; HALLSTROM, AP; LITWIN, PE; MARTIN, JS; KUDENCHUK, PJ; EISENBERG, M				WEAVER, WD; CERQUEIRA, M; HALLSTROM, AP; LITWIN, PE; MARTIN, JS; KUDENCHUK, PJ; EISENBERG, M			PREHOSPITAL-INITIATED VS HOSPITAL-INITIATED THROMBOLYTIC THERAPY - THE MYOCARDIAL-INFARCTION TRIAGE AND INTERVENTION TRIAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TISSUE PLASMINOGEN-ACTIVATOR; TIME DELAYS; STREPTOKINASE; PROJECT; FEASIBILITY; PERFUSION; DIAGNOSIS; ACCURACY; PHASE	Objective.- To determine the effect of prehospital-initiated vs hospital-initiated treatment of myocardial infarction on clinical outcome. Design.- Randomized, controlled clinical trial. Setting.- Multicenter study involving 19 hospitals and all paramedic systems in the Seattle, Wash, metropolitan area. Patients.- A total of 360 patients with symptoms for 6 hours or less, no risk factors for serious bleeding, and ST-segment elevation were selected by paramedics and a remote physician for inclusion into the trial. They represented 4% of patients with chest pain who were screened and 21% of those with acute infarction. Interventions.- Patients were allocated to have aspirin and alteplase treatment initiated before or after hospital arrival. Intravenous sodium heparin was administered to both groups in the hospital. Main Outcome Measure.- The primary endpoint was a ranked composite score (combining death, stroke, serious bleeding, and infarct size). The relation between time to treatment and outcome (composite score, infarct size, ejection fraction, and mortality) was also assessed. Results.- Initiating treatment before hospital arrival decreased the interval from symptom onset to treatment from 110 to 77 minutes (P<.001). Although more patients whose therapy was initiated before hospital arrival had resolution of pain by admission (23% vs 7%; P<.001), there were no significant differences in the composite score (P=.64), mortality (5.7% vs 8.1%), ejection fraction (53% vs 54%), or infarct size (6.1% vs 6.5%). A secondary analysis of time to treatment and outcome showed that treatment initiated within 70 minutes of symptom onset was associated with better outcome (composite score, P=.009; mortality, 1.2% vs 8.7%, P=.04; infarct size, 4.9% vs 11.2%, P<.001; and ejection fraction, 53% vs 49%, P=.03) than later treatment. Identification of patients eligible for thrombolysis by paramedics reduced the hospital treatment time from 60 minutes (for patients not in the study) to 20 minutes (for study patients allocated to begin treatment in the hospital). Conclusion.- There was no improvement in outcome associated with initiating treatment before hospital arrival; however, treatment within 70 minutes of symptom onset-whether in the hospital or in the field-minimized the infarct process and its complications.	UNIV WASHINGTON, SCH MED, DEPT MED, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH MED, DEPT RADIOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH MED, DEPT BIOSTAT, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle					NHLBI NIH HHS [R01HL38454] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038454] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, Lancet, V1, P397; AUFDERHEIDE TP, 1992, AM J CARDIOL, V69, P991, DOI 10.1016/0002-9149(92)90852-P; BARBASH GI, 1990, AM J CARDIOL, V66, P538, DOI 10.1016/0002-9149(90)90478-J; BOSSAERT LL, 1988, CRIT CARE MED, V16, P823, DOI 10.1097/00003246-198809000-00001; BOUTEN MJM, 1990, NED TIJDSCHR GENEES, V50, P2434; BRUGEMANN J, 1992, EUR HEART J, V13, P787; CALDWELL JH, 1984, CIRCULATION, V70, P1048, DOI 10.1161/01.CIR.70.6.1048; CERQUEIRA MD, 1991, CIRCULATION, V84, pI100; FINE DG, 1986, AM J CARDIOL, V58, P411, DOI 10.1016/0002-9149(86)90005-6; GIBLER WB, 1991, AM HEART J, V121, P1, DOI 10.1016/0002-8703(91)90948-H; HALLSTROM AP, 1992, CONTROL CLIN TRIALS, V13, P148, DOI 10.1016/0197-2456(92)90020-Z; HOLMBERG S, 1990, AM J CARDIOL, V65, P401; KEREIAKES DJ, 1990, AM HEART J, V120, P773, DOI 10.1016/0002-8703(90)90192-Z; KUDENCHUK PJ, 1991, J AM COLL CARDIOL, V17, P1486, DOI 10.1016/0735-1097(91)90636-N; MCNEILL AJ, 1989, BRIT HEART J, V61, P316; PELL ACH, 1992, BMJ-BRIT MED J, V304, P83, DOI 10.1136/bmj.304.6819.83; RITCHIE JL, 1984, CIRCULATION, V70, P867, DOI 10.1161/01.CIR.70.5.867; ROTH A, 1990, J AM COLL CARDIOL, V15, P932, DOI 10.1016/0735-1097(90)90219-F; SCHMIDT SB, 1990, AM J CARDIOL, V65, P1411, DOI 10.1016/0002-9149(90)91345-7; SCHOFER J, 1990, AM J CARDIOL, V66, P1429, DOI 10.1016/0002-9149(90)90528-9; SHARKEY SW, 1989, JAMA-J AM MED ASSOC, V262, P3171, DOI 10.1001/jama.262.22.3171; VARSHAVSKY SY, 1992, PREHOSPITAL DISASTER, V7, P57; VILLEMANT D, 1987, LANCET, V1, P228; WEAVER WD, 1990, J AM COLL CARDIOL, V15, P925, DOI 10.1016/0735-1097(90)90218-E; WEAVER WD, 1992, THROMBOSIS CARDIOVAS, P275; WEISS AT, 1987, CHEST, V92, P124, DOI 10.1378/chest.92.1.124; WILCOX RG, 1988, LANCET, V2, P525; WILLEMS JL, 1991, NEW ENGL J MED, V325, P1767, DOI 10.1056/NEJM199112193252503; 1985, NEW ENGL J MED, V313, P1384	30	513	527	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	1993	270	10					1211	1216		10.1001/jama.270.10.1211	http://dx.doi.org/10.1001/jama.270.10.1211			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV649	8355383				2023-01-03	WOS:A1993LV64900026
J	TEAHON, K; BATEMAN, DN				TEAHON, K; BATEMAN, DN			A SURVEY OF INTRAVENOUS DRUG ADMINISTRATION BY PREREGISTRATION HOUSE OFFICERS	BRITISH MEDICAL JOURNAL			English	Article							WORKLOAD				TEAHON, K (corresponding author), REG DRUG & THERAPEUT CTR,WOLFSON UNIT CLIN PHARMACOL,NEWCASTLE TYNE NE1 4LP,ENGLAND.			Bateman, David Nicholas/0000-0002-8971-862X				BAIN PG, 1990, BRIT MED J, V300, P1463; CUNNINGHAM S, 1990, BRIT MED J, V300, P1342; DYER C, 1991, BRIT MED J, V303, P1218, DOI 10.1136/bmj.303.6812.1218; LESLIE PJ, 1990, BRIT MED J, V300, P1038, DOI 10.1136/bmj.300.6731.1038; TOMFORD JW, 1984, ARCH INTERN MED, V144, P1191, DOI 10.1001/archinte.144.6.1191	5	16	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 4	1993	307	6904					605	606		10.1136/bmj.307.6904.605	http://dx.doi.org/10.1136/bmj.307.6904.605			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LW149	8401018	Bronze, Green Published			2023-01-03	WOS:A1993LW14900019
J	AERDTS, SJA; CLASENER, HAL; BLAIR, PHB; ROWLANDS, BJ; BRUNBUISSON, C; LEGRAND, P; CERRA, FB; DUNN, D; COCKERILL, FR; THOMPSON, RL; FERRER, M; TORRES, A; GASTINNE, H; WOLFF, M; GAUSSORGUES, P; GODARD, J; MOTIN, J; HAMMOND, JMJ; POTGIETER, PD; HUNEFELD, G; JACOBS, S; FOWERAKER, JE; KERVER, AJH; ROMMERS, JH; KORINEK, AM; LAISNE, MJ; MARTINEZPELLUZ, A; RODRIGUEZROLDAN, J; PALOMAR, M; ALVAREZ, F; PUGIN, J; SUTER, PM; ROCHA, LA; VILLANUEVA, R; ROLANDO, N; WILLIAMS, R; SANCHEZGARCIA, M; CAMBRONEROGALACHE, JA; TETTEROO, GWM; BRUINING, HA; ULRICH, C; DEWEERD, JEH; UNERTL, K; PETER, K; VERHAEGEN, J; VERWAEST, L; WINTER, R; HUMPHREYS, H				AERDTS, SJA; CLASENER, HAL; BLAIR, PHB; ROWLANDS, BJ; BRUNBUISSON, C; LEGRAND, P; CERRA, FB; DUNN, D; COCKERILL, FR; THOMPSON, RL; FERRER, M; TORRES, A; GASTINNE, H; WOLFF, M; GAUSSORGUES, P; GODARD, J; MOTIN, J; HAMMOND, JMJ; POTGIETER, PD; HUNEFELD, G; JACOBS, S; FOWERAKER, JE; KERVER, AJH; ROMMERS, JH; KORINEK, AM; LAISNE, MJ; MARTINEZPELLUZ, A; RODRIGUEZROLDAN, J; PALOMAR, M; ALVAREZ, F; PUGIN, J; SUTER, PM; ROCHA, LA; VILLANUEVA, R; ROLANDO, N; WILLIAMS, R; SANCHEZGARCIA, M; CAMBRONEROGALACHE, JA; TETTEROO, GWM; BRUINING, HA; ULRICH, C; DEWEERD, JEH; UNERTL, K; PETER, K; VERHAEGEN, J; VERWAEST, L; WINTER, R; HUMPHREYS, H			METAANALYSIS OF RANDOMIZED CONTROLLED TRIALS OF SELECTIVE DECONTAMINATION OF THE DIGESTIVE-TRACT	BRITISH MEDICAL JOURNAL			English	Article							INTENSIVE-CARE UNIT; CRITICALLY ILL PATIENTS; DOUBLE-BLIND; VENTILATED PATIENTS; CLINICAL-TRIALS; INTESTINAL DECONTAMINATION; NOSOCOMIAL INFECTION; PREVENTION; COLONIZATION; PROPHYLAXIS	Objective-To determine the clinical benefits of selective decontamination of the digestive tract in patients treated in intensive care units. Design-Meta-analysis of 22 randomised trials that compared different combinations of oral non-absorbable antibiotics, with or without a systemic component, with no treatment in controls. Subjects-4142 patients seen in general and specialised intensive care units around the world. 2047 received some form of antibiotic treatment, the remainder no prophylaxis. Data analysis-Each trial was reviewed through direct contact with study investigators. Data collected were: the randomisation procedure, number of patients, number excluded from the analysis, and numbers of respiratory tract infections and deaths. Data were combined according to an intention to treat analysis with the Mantel-Haenszel-Peto method. Main outcome measures-Respiratory tract infections and total mortality. Results-Selective decontamination of the digestive tract significantly reduced respiratory tract infections (odds ratio 0.37; 95% confidence interval 0.31 to 0.43). The value of the common odds ratio for total mortality (0.90; 0.79 to 1.04) suggested at best a moderate treatment effect, reaching statistical significance only when the subgroup of trials of topical and systemic treatment combined was considered separately (odds ratio 0.80; 0.67 to 0.97). No firm conclusions could be drawn owing to large variations in patient mix and severity within and between trials. Conclusions-The findings strongly indicate that selective decontamination significantly reduces infection related morbidity in patients receiving intensive care. They also highlight why definite conclusions about the effect of prophylaxis on mortality cannot be drawn despite the large number of trials available. Based on the most favourable results obtained by pooling data from trials in which combined topical and systemic treatment was used it may be estimated that 6 (range 5-9) and 23 (13-139) patients would need to be treated to prevent one respiratory tract infection and one death respectively.	SOPHIA HOSP,ZWOLLE,NETHERLANDS; ROYAL VICTORIA HOSP,BELFAST BT12 6BA,NORTH IRELAND; HOP HENRI MONDOR,F-94010 CRETEIL,FRANCE; UNIV MINNESOTA HOSP & CLIN,MINNEAPOLIS,MN 55455; MAYO CLIN & MAYO FDN,ROCHESTER,MN 55905; HOSP CLIN BARCELONA,BARCELONA 36,SPAIN; HOP CROIX ROUSSE,LYON,FRANCE; HOP EDOUARD HERRIOT,F-69374 LYON 08,FRANCE; GROOTE SCHUUR HOSP,CAPE TOWN 7925,SOUTH AFRICA; EVANGEL KRANKENHAUS,GOTTINGEN,GERMANY; UNIV HOSP WALES,CARDIFF,WALES; ST FRANCISKUS HOSP,ROTTERDAM,NETHERLANDS; HOP PITIE SALPETRIER,PARIS,FRANCE; GEN HOSP,MURCIA,SPAIN; HOSP VALLE DE HEBRON,BARCELONA,SPAIN; UNIV GENEVA,HOP CANTONAL,CH-1211 GENEVA 4,SWITZERLAND; HOSP JUAN CANALEJO,LA CORUNA,SPAIN; UNIV LONDON KINGS COLL HOSP,LONDON SE5 8RX,ENGLAND; HOSP PPE AUSTRIAS,ALCALA DE HENARES,SPAIN; UNIV HOSP DIJKZIGT,ROTTERDAM,NETHERLANDS; WESTEINDE ZIEKENHUIS,THE HAGUE,NETHERLANDS; KLINIKUM GROSSHADERN,MUNICH,GERMANY; UNIV HOSP LOUVAIN,LOUVAIN,BELGIUM; UNIV NOTTINGHAM HOSP,NOTTINGHAM NG7 2UH,ENGLAND	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota Hospital; Mayo Clinic; University of Barcelona; Hospital Clinic de Barcelona; CHU Lyon; CHU Lyon; University of Cape Town; Cardiff University; Franciscus Gasthuis; Hospital Universitari Vall d'Hebron; University of Geneva; Complejo Hospitalario Universitario A Coruna; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; Prince of Asturias University Hospital; Erasmus University Rotterdam; Erasmus MC; University of Munich; Universite Catholique Louvain; Universite Catholique Louvain Hospital; University of Nottingham			Humphreys, Hilary/C-9918-2012	Ferrer, Miguel/0000-0001-8171-6673				AERDTS SJA, 1991, CHEST, V100, P783, DOI 10.1378/chest.100.3.783; BEGG CB, 1985, STAT MED, V4, P1, DOI 10.1002/sim.4780040103; BLAIR P, 1991, SURGERY, V110, P303; BOISSEL JP, 1989, CONTROL CLIN TRIALS, V10, P254, DOI 10.1016/0197-2456(89)90067-6; BRAZZI L, 1992, REANIMATION URGENCES, V1, P501; BRUNBUISSON C, 1989, ANN INTERN MED, V110, P873, DOI 10.7326/0003-4819-110-11-873; CERRA FB, 1992, ARCH SURG-CHICAGO, V127, P163; COCKERILL FR, 1992, ANN INTERN MED, V117, P545, DOI 10.7326/0003-4819-117-7-545; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; FERRER M, 1992, American Review of Respiratory Disease, V145, pA112; GASTINNE H, 1992, NEW ENGL J MED, V326, P594, DOI 10.1056/NEJM199202273260903; Gaussorgues P., 1991, REANIMATION SOINS IN, V7, P169; GODARD J, 1990, INTENS CARE MED, V16, P307, DOI 10.1007/BF01706355; HAMMOND JMJ, 1992, LANCET, V340, P5, DOI 10.1016/0140-6736(92)92422-C; Hunefeld G, 1989, Anaesthesiol Reanim, V14, P131; Jacobs S., 1992, CLIN INTENSIVE CARE, V3, P52; KERVER AJH, 1988, CRIT CARE MED, V16, P1087, DOI 10.1097/00003246-198811000-00001; KORINEK AM, IN PRESS CRIT CARE M; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; LIBERATI A, 1992, REANIMATION URGENCES, V1, P521; McGlynn E A, 1990, Int J Technol Assess Health Care, V6, P450; PALOMAR M, 1992, MED INTENSIVA, V16, P81; PUGIN J, 1991, JAMA-J AM MED ASSOC, V265, P2704, DOI 10.1001/jama.265.20.2704; ROCHA LA, 1992, INTENS CARE MED, V18, P398, DOI 10.1007/BF01694341; RODRIGUEZROLDAN JM, 1990, CRIT CARE MED, V18, P1239, DOI 10.1097/00003246-199011000-00011; ROLANDO N, 1993, HEPATOLOGY, V17, P196, DOI 10.1016/0270-9139(93)90076-Y; SANCHEZ M, 1992, 32ND P INT C ANT AG; STEWART LA, 1993, LANCET, V341, P418, DOI 10.1016/0140-6736(93)93004-K; STOUTENBEEK CP, 1984, INTENS CARE MED, V10, P185, DOI 10.1007/BF00259435; TETTEROO GWM, 1990, LANCET, V335, P704, DOI 10.1016/0140-6736(90)90813-K; ULRICH C, 1989, INTENS CARE MED, V15, P424, DOI 10.1007/BF00255597; UNERTL K, 1987, INTENS CARE MED, V13, P106; VANDENBROUCKEGRAULS CMJE, 1991, LANCET, V338, P859, DOI 10.1016/0140-6736(91)91510-2; VANSAENE HF, 1992, CRIT CARE MED, V20, P691, DOI 10.1097/00003246-199205000-00024; VANSAENE HKF, 1993, J HOSP INFECT, V24, P158, DOI 10.1016/0195-6701(93)90079-F; VELLEMAN PF, 1981, AM STAT, V35, P234, DOI 10.2307/2683296; VERHAEGEN J, 1992, THESIS U LOUVAIN BEL; WEBB CH, 1992, J HOSP INFECT, V22, P1, DOI 10.1016/0195-6701(92)90125-6; WINTER R, 1992, J ANTIMICROB CHEMOTH, V30, P73, DOI 10.1093/jac/30.1.73; 1988, BMJ, V296, P320; 1992, INTENS CARE MED, V18, P182	41	153	155	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 28	1993	307	6903					525	532						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV180	8400971				2023-01-03	WOS:A1993LV18000014
J	KRAMER, MR; SPRINGER, C; BERKMAN, N; BARYISHAY, E; AVITAL, A; MANDELBERG, A; EFFRON, D; GODFREY, S				KRAMER, MR; SPRINGER, C; BERKMAN, N; BARYISHAY, E; AVITAL, A; MANDELBERG, A; EFFRON, D; GODFREY, S			EFFECT OF NATURAL OXYGEN ENRICHMENT AT LOW-ALTITUDE ON OXYGEN-DEPENDENT PATIENTS WITH END-STAGE LUNG-DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article						QUALITY OF LIFE; LUNG DISEASES; RESPIRATORY FUNCTION TESTS; ALTITUDE; ANOXEMIA	OBSTRUCTIVE PULMONARY-DISEASE; LONG-TERM OXYGEN; 60 MM HG; COR-PULMONALE; OXYHEMOGLOBIN DESATURATION; SUPPLEMENTAL OXYGEN; HYPOXEMIC PATIENTS; EXERCISE CAPACITY; THERAPY; HEMODYNAMICS	Objective: To assess the effect of lowering altitude to that of the lowest place on earth (Dead Sea) on arterial oxygenation and exercise performance in patients with hypoxemia and end-stage lung disease. Design: A cohort of 10 patients. Setting: Pulmonary function laboratories in Jerusalem, Israel, and at the Dead Sea. Patients: 10 patients with end-stage lung disease who were receiving long-term oxygen therapy. The 4 males and 6 females were 12 to 77 years old. Four patients had chronic obstructive pulmonary disease; 2 had cystic fibrosis; 3 had pulmonary fibrosis; and 1 had pulmonary hypertension (thromboembolic). Mean forced vital capacity was 1.54 L (54% of predicted value) and mean forced expiratory volume in 1 second was 0.85 L (35% of predicted value). Measurements: Spirometry, blood gas analysis, progressive exercise testing, and sleep oximetry were done in Jerusalem (altitude, 800 m above sea level; barometric pressure, 696 mm Hg); the same measurements were done 6 days after arrival at the Dead Sea (altitude, 402 m below sea level; barometric pressure, 800 mm Hg) and then 7 to 14 days later in Jerusalem. Results: Arterial oxygenation increased from a median partial pressure of arterial oxygen of 51.6 mm Hg in Jerusalem to 67.0 mm Hg at the Dead Sea, an increase of 15.2 mm Hg (95% CI of paired difference, 4.1 to 20.4 mm Hg; P = 0.001). Partial pressure of arterial carbon dioxide increased from a median of 43.2 to 45.9 mm Hg, an increase of 2.7 mm Hg (CI, 0.5 to 6.4 mm Hg; P = 0.004), with a borderline significant change in the alveolar-arterial gradient. Arterial oxygen saturation increased from a median of 87.7% to 92.8%, a change of 4.8% (CI, 1.9% to 9.8%; P = 0.003). Exercise performance also improved as maximum oxygen uptake increased from a median of 827 mL/min to 1056 mL/min, an increase of 203 mL/min (CI, 54 to 388 mL/min; P = 0.006). Sleep oximetry also improved as median arterial oxygen saturation measured during sleep increased from 85% to 90%, a change of 5% (CI, 2% to 7%; P = 0.005), and percentage of sleep time with an oxygen saturation rate of 90% or more increased from a median of 24% to 73%, a change of 49% (CI, 20% to 87%; P = 0.02). No change in spirometry was noted. All patients felt less dyspneic and reported improved functional capacity with reduced need for oxygen. Conclusion: Descent to low altitude can improve arterial oxygenation, exercise performance, and sleep oximetry and consequently the quality of life in patients with hypoxemia and advanced lung disease.			KRAMER, MR (corresponding author), HADASSAH UNIV HOSP, INST PULMONOL, POB 12000, IL-91120 JERUSALEM, ISRAEL.							ABRAHAM AS, 1968, CIRC RES, V23, P147, DOI 10.1161/01.RES.23.1.147; [Anonymous], 1980, Ann Intern Med, V93, P391; ASHUTOSH K, 1983, AM REV RESPIR DIS, V127, P399, DOI 10.1164/arrd.1983.127.4.399; BLOCK AJ, 1979, CHEST, V75, P109, DOI 10.1378/chest.75.2.109; BRADLEY BL, 1978, AM REV RESPIR DIS, V118, P239; COTE TR, 1993, CHEST, V103, P1194, DOI 10.1378/chest.103.4.1194; COTES JE, 1956, LANCET, V270, P872; FISHMAN AP, 1976, CIRC RES, V38, P221, DOI 10.1161/01.RES.38.4.221; FLENLEY DC, 1981, LANCET, V1, P681; FLETCHER EC, 1992, AM REV RESPIR DIS, V145, P1070, DOI 10.1164/ajrccm/145.5.1070; FLETCHER EC, 1989, CHEST, V95, P757, DOI 10.1378/chest.95.4.757; FLETCHER EC, 1984, CHEST, V85, P6, DOI 10.1378/chest.85.1.6; FLETCHER EC, 1987, CHEST, V92, P604, DOI 10.1378/chest.92.4.604; KAWAKAMI Y, 1983, NEW ENGL J MED, V308, P1045, DOI 10.1056/NEJM198305053081801; LEVINE BE, 1967, ANN INTERN MED, V66, P639, DOI 10.7326/0003-4819-66-4-639; LIGHT RW, 1989, CHEST, V95, P751, DOI 10.1378/chest.95.4.751; MCCULLOUGH RE, 1977, ARCH ENVIRON HEALTH, V32, P36, DOI 10.1080/00039896.1977.10667251; MOORE LG, 1982, AM REV RESPIR DIS, V126, P225; MORRISON DA, 1992, CHEST, V102, P542, DOI 10.1378/chest.102.2.542; MORRISON DA, 1987, J AM COLL CARDIOL, V9, P1219, DOI 10.1016/S0735-1097(87)80459-X; NEFF TA, 1970, ANN INTERN MED, V72, P621, DOI 10.7326/0003-4819-72-5-621; ODONOHUE WJ, 1991, CHEST, V100, P968, DOI 10.1378/chest.100.4.968; PETTY TL, 1985, AM REV RESPIR DIS, V131, P930; PETTY TL, 1968, AM J MED, V45, P242, DOI 10.1016/0002-9343(68)90042-9; RENZETTI AD, 1966, AM J MED, V41, P115, DOI 10.1016/0002-9343(66)90009-X; TIMMS RM, 1985, ANN INTERN MED, V102, P29, DOI 10.7326/0003-4819-102-1-29; Wasserman K., 1987, PRINCIPLES EXERCISE	27	18	18	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1994	121	9					658	662		10.7326/0003-4819-121-9-199411010-00005	http://dx.doi.org/10.7326/0003-4819-121-9-199411010-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN450	7944074				2023-01-03	WOS:A1994PN45000005
J	NIGHTINGALE, SL				NIGHTINGALE, SL			BROCHURES ON SEAFOOD SAFETY FOR PEOPLE WITH CERTAIN DISEASES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 24	1994	272	8					582	582		10.1001/jama.272.8.582	http://dx.doi.org/10.1001/jama.272.8.582			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC398	8057499				2023-01-03	WOS:A1994PC39800004
J	STRAUS, SE; COREY, L; BURKE, RL; SAVARESE, B; BARNUM, G; KRAUSE, PR; KOST, RG; MEIER, JL; SEKULOVICH, R; ADAIR, SF; DEKKER, CL				STRAUS, SE; COREY, L; BURKE, RL; SAVARESE, B; BARNUM, G; KRAUSE, PR; KOST, RG; MEIER, JL; SEKULOVICH, R; ADAIR, SF; DEKKER, CL			PLACEBO-CONTROLLED TRIAL OF VACCINATION WITH RECOMBINANT GLYCOPROTEIN-D OF HERPES-SIMPLEX VIRUS TYPE-2 FOR IMMUNOTHERAPY OF GENITAL HERPES	LANCET			English	Article							T-CELL CLONES; MONOCLONAL-ANTIBODIES; ORAL ACYCLOVIR; DOUBLE-BLIND; INFECTION; PROTECTION; EFFICACY; ANTIGEN; RISK; MICE	Immunotherapy of chronic viral diseases with vaccines is an important but unproven concept. We investigated the effect of a vaccine containing recombinant glycoprotein D (gD2) of herpes simplex virus type 2 (HSV-2) on the frequency of symptomatic outbreaks in patients with genital herpes. 98 patients with documented genital herpes who reported 4-14 recurrences per year were enrolled in a double-blind, placebo-controlled trial. Subjects received injections of either 100 mu g gD2 in alum or alum alone (placebo) at 0 and 2 months, and recurrences were documented for 1 year. The vaccine was well tolerated, gD2 recipients reported fewer recurrences per month than placebo recipients (mean 0.42 [SE 0.05] vs 0.55 [0.05]; p = 0.055), had fewer virologically confirmed recurrences per month (0.18 [0.03] vs 0.28 [0.03]; p = 0.019), and had a lower median number of recurrences for the study year (4 [range 0-17] vs 6 [0-15]; p = 0.039). Neither genital recurrence nor the placebo vaccine had any discernible effect on HSV-2-specific antibody responses, but gD2 vaccine boosted neutralising antibodies to HSV-2 fourfold and gD2-specific titres sevenfold over baseline levels. These results inspire optimism about the potential use of vaccine for the treatment of chronic,recurring viral diseases.	UNIV WASHINGTON,DEPT LAB MED,DIV VIROL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED,SEATTLE,WA; BIOCINE CO,EMERYVILLE,CA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	STRAUS, SE (corresponding author), NIAID,CLIN INVEST LAB,MED VIROL SECT,BLDG 10,ROOM 11N-228,BETHESDA,MD 20892, USA.		Corey, Lawrence/AAE-1796-2020	Corey, Lawrence/0000-0002-2179-2436; Krause, Philip/0000-0002-1045-7536; Meier, Jeffery/0000-0001-9491-1697				ASHLEY RL, 1988, J CLIN MICROBIOL, V26, P662, DOI 10.1128/JCM.26.4.662-667.1988; BALACHANDRAN N, 1982, INFECT IMMUN, V37, P1132, DOI 10.1128/IAI.37.3.1132-1137.1982; BERMAN PW, 1985, SCIENCE, V227, P1490, DOI 10.1126/science.2983428; BROWN ZA, 1991, NEW ENGL J MED, V324, P1247, DOI 10.1056/NEJM199105023241804; BURKE RL, 1991, REV INFECT DIS, V13, pS906; BURKE RL, 1992, HERPES SIMPLEX VIRUS, P137; DOUGLAS JM, 1984, NEW ENGL J MED, V310, P1545; HEBERKATZ E, 1988, J EXP MED, V167, P275, DOI 10.1084/jem.167.2.275; JOHNSON RE, 1989, NEW ENGL J MED, V321, P7, DOI 10.1056/NEJM198907063210102; JOHNSON RM, 1990, J IMMUNOL, V145, P702; KAVAKLOVA L, 1986, ACTA VIROL, V30, P402; KERN AB, 1964, ARCH DERMATOL, V89, P844, DOI 10.1001/archderm.1964.01590300072021; KUTINOVA L, 1988, VACCINE, V6, P223, DOI 10.1016/0264-410X(88)90215-0; MERTZ GJ, 1992, ANN INTERN MED, V116, P197, DOI 10.7326/0003-4819-116-3-197; MERTZ GJ, 1990, J INFECT DIS, V161, P653, DOI 10.1093/infdis/161.4.653; MERTZ GJ, 1986, J INFECT DIS, V150, P249; MINSON AC, 1986, J GEN VIROL, V67, P1001, DOI 10.1099/0022-1317-67-6-1001; REDFIELD RR, 1991, NEW ENGL J MED, V324, P1678; REICHMAN RC, 1984, JAMA-J AM MED ASSOC, V251, P2103, DOI 10.1001/jama.251.16.2103; SALK J, 1987, NATURE, V327, P473, DOI 10.1038/327473a0; SKINNER GRB, 1987, MED MICROBIOL IMMUN, V176, P161, DOI 10.1007/BF00193897; STANBERRY LR, 1987, J INFECT DIS, V155, P914, DOI 10.1093/infdis/155.5.914; STANBERRY LR, 1988, J INFECT DIS, V157, P156, DOI 10.1093/infdis/157.1.156; STANBERRY LR, 1989, J GEN VIROL, V70, P3177, DOI 10.1099/0022-1317-70-12-3177; STRAUS SE, 1993, J INFECT DIS, V167, P1045, DOI 10.1093/infdis/167.5.1045; STRAUS SE, 1984, NEW ENGL J MED, V310, P1545, DOI 10.1056/NEJM198406143102401; TIGGES MA, 1992, OCT P INT C ANT AG C; ZARLING JM, 1986, J IMMUNOL, V136, P4669	28	172	183	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 11	1994	343	8911					1460	1463		10.1016/S0140-6736(94)92581-X	http://dx.doi.org/10.1016/S0140-6736(94)92581-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ415	7911177				2023-01-03	WOS:A1994NQ41500008
J	LEE, KL; CALIFF, RM; SIMES, J; VANDEWERF, F; TOPOL, EJ				LEE, KL; CALIFF, RM; SIMES, J; VANDEWERF, F; TOPOL, EJ			HOLDING GUSTO UP TO THE LIGHT	ANNALS OF INTERNAL MEDICINE			English	Article							RANDOMIZED CLINICAL-TRIALS; PATIENT	The Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) trial, a recent randomized ''megatrial'' of thrombolytic therapies in acute myocardial infarction, showed a statistically significant decrease of 30-day mortality in patients treated with accelerated-dose tissue plasminogen activator (tPA) compared with streptokinase. The therapeutic and cost implications of the results have been intensely scrutinized, and several commentaries have been written on the interpretation of the study. Questions have been raised about the treatment benefit in certain subgroups, the validity of the results because of the open-label design, the relevance of a 1% absolute benefit in mortality rates, the cost-effectiveness of the drug, and the generalizability of the results. These issues are all important considerations for translating the results of this study into clinical practice worldwide. This article sheds additional light on the interpretation of GUSTO, clarifies misconceptions that may have clouded understanding of the trial results, and discusses the contributions of this trial in advancing our understanding of modern myocardial reperfusion therapy.	UNIV SYDNEY, CTR NHMRC CLIN TRIALS, SYDNEY, NSW 2006, AUSTRALIA; UNIV ZIEKENHUIZEN LEUVEN, UZ GASTHUISBERG, B-3000 LOUVAIN, BELGIUM; CLEVELAND CLIN FDN, CLEVELAND, OH 44195 USA	University of Sydney; KU Leuven; University Hospital Leuven; Cleveland Clinic Foundation	LEE, KL (corresponding author), DUKE UNIV, MED CTR, CTR CLIN TRIALS COORDINATING, BOX 3363, DURHAM, NC 27710 USA.		Simes, Robert John/P-1497-2014	Topol, Eric/0000-0002-1478-4729				[Anonymous], 1990, LANCET, V336, P65; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; BARBASH GI, 1993, J AM COLL CARDIOL, V21, P281, DOI 10.1016/0735-1097(93)90664-M; CONTI CR, 1993, CLIN CARDIOL, V16, P635, DOI 10.1002/clc.4960160902; FUSTER V, 1993, NEW ENGL J MED, V329, P723, DOI 10.1056/NEJM199309023291009; HUNT D, 1992, LANCET, V339, P753; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; LEE KL, 1980, CIRCULATION, V61, P508, DOI 10.1161/01.CIR.61.3.508; NEUHAUS KL, 1989, J AM COLL CARDIOL, V14, P1566, DOI 10.1016/0735-1097(89)90399-9; NEUHAUS KL, 1992, J AM COLL CARDIOL, V19, P885, DOI 10.1016/0735-1097(92)90265-O; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; Rapaport E., 1993, J MYOCARDIAL ISCHEMI, V5, P15; RIDKER PM, 1993, ANN INTERN MED, V119, P530, DOI 10.7326/0003-4819-119-6-199309150-00017; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; Sleight P, 1993, J MYOCARDIAL ISCHEMI, V5, P25; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; TOPOL EJ, 1992, J AM COLL CARDIOL, V19, P1123, DOI 10.1016/0735-1097(92)90312-B; VANDEWERF F, 1990, LANCET, V336, P71; YUSUF S, 1991, JAMA-J AM MED ASSOC, V266, P93, DOI 10.1001/jama.266.1.93	22	41	43	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1994	120	10					876	881		10.7326/0003-4819-120-10-199405150-00009	http://dx.doi.org/10.7326/0003-4819-120-10-199405150-00009			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK458	8154647				2023-01-03	WOS:A1994NK45800009
J	BARASH, PG				BARASH, PG			ANESTHESIOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									YALE NEW HAVEN MED CTR,NEW HAVEN,CT	Yale University	BARASH, PG (corresponding author), YALE UNIV,SCH MED,NEW HAVEN,CT 06510, USA.							ALON E, 1992, ANESTH ANALG, V75, P561; [Anonymous], 1993, ANESTHESIOLOGY, V78, P597; [Anonymous], 1992, ACUTE PAIN MANAGEMEN; BENNETT JA, 1992, J CLIN ANESTH, V4, P378, DOI 10.1016/0952-8180(92)90159-X; EJLERSEN E, 1992, ANESTH ANALG, V74, P495; GABA DM, 1992, ANESTHESIOLOGY, V76, P491; HALPERN NA, 1992, CRIT CARE MED, V20, P1637, DOI 10.1097/00003246-199212000-00006; HOWARD SK, 1992, AVIAT SPACE ENVIR MD, V63, P763; KATZ J, 1992, ANESTHESIOLOGY, V77, P439, DOI 10.1097/00000542-199209000-00006; MATHEW JP, 1992, ANESTHESIOLOGY, V77, P635, DOI 10.1097/00000542-199210000-00004; MCLINTIC AJ, 1992, ANESTH ANALG, V74, P51; MCQUAY HJ, 1992, BRIT J ANAESTH, V69, P1, DOI 10.1093/bja/69.1.1; ROBIN ED, 1992, CHEST, V102, P1842, DOI 10.1378/chest.102.6.1842; SCHWID HA, 1992, ANESTHESIOLOGY, V76, P495, DOI 10.1097/00000542-199204000-00002; ZAKOWSKI MI, 1993, ANESTH ANALG, V76, P162; 1993, ANESTHESIOLOGY, V78, P380	16	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1993	270	2					188	190		10.1001/jama.270.2.188	http://dx.doi.org/10.1001/jama.270.2.188			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL368	8315724				2023-01-03	WOS:A1993LL36800010
J	TENCATE, JW				TENCATE, JW			THROMBOLYSIS - THROMBOLYTIC TREATMENT OF PULMONARY-EMBOLISM	LANCET			English	Editorial Material											TENCATE, JW (corresponding author), UNIV AMSTERDAM HOSP,DEPT HAEMATOL,AMSTERDAM,NETHERLANDS.							CARSON JL, 1992, NEW ENGL J MED, V326, P1240, DOI 10.1056/NEJM199205073261902; GOLDHABER SZ, 1993, LANCET, V341, P507, DOI 10.1016/0140-6736(93)90274-K; HUISMAN MV, 1989, CHEST, V95, P498, DOI 10.1378/chest.95.3.498; HULL RD, 1992, NEW ENGL J MED, V326, P975, DOI 10.1056/NEJM199204093261502; KRUIT WHJ, 1991, J INTERN MED, V230, P333, DOI 10.1111/j.1365-2796.1991.tb00453.x; PRADONI P, 1992, LANCET, V339, P441	6	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 22	1993	341	8856					1315	1316		10.1016/0140-6736(93)90822-X	http://dx.doi.org/10.1016/0140-6736(93)90822-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD253	8098455				2023-01-03	WOS:A1993LD25300010
J	VANHERWEGHEM, JL; DEPIERREUX, M; TIELEMANS, C; ABRAMOWICZ, D; DRATWA, M; JADOUL, M; RICHARD, C; VANDERVELDE, D; VERBEELEN, D; VANHAELENFASTRE, R; VANHAELEN, M				VANHERWEGHEM, JL; DEPIERREUX, M; TIELEMANS, C; ABRAMOWICZ, D; DRATWA, M; JADOUL, M; RICHARD, C; VANDERVELDE, D; VERBEELEN, D; VANHAELENFASTRE, R; VANHAELEN, M			RAPIDLY PROGRESSIVE INTERSTITIAL RENAL FIBROSIS IN YOUNG-WOMEN - ASSOCIATION WITH SLIMMING REGIMEN INCLUDING CHINESE HERBS	LANCET			English	Article							NEPHRITIS; NEPHROPATHY; DISEASE	Two similar cases of rapidly progressive fibrosing interstitial nephritis in young women who followed the same slimming regimen prompted us to conduct an epidemiological survey of the nephrology centres of Brussels and to further investigate the exact nature of this slimming treatment. Seven other women under the age of 50 in terminal or preterminal renal failure were admitted for dialysis in 1991 and 1992. They had all followed a slimming regimen in the same medical clinic. Renal biopsy samples in eight of the nine cases showed extensive interstitial fibrosis without glomerular lesions. Two of the patients were seen for the first time in terminal renal failure and were started immediately on dialysis. For the seven other women, the nephropathy was characterised by a rapid deterioration in renal function, with initial serum creatinine doubling within about 3 months. The clinic had specialised in slimming treatments for the previous 15 years without any problems. In May, 1990, therapy was changed, with the introduction of two Chinese herbs (Stephania tetrandra and Magnolia officinalis). In June, 1992, three of twenty-five randomly selected women who had followed the same regimen during at least 3 months from 1990 had impaired renal function. Chemical analysis of some brands of these Chinese herbs did not show nephrotoxic contaminants of fungal or plant origin (ochratoxin or aristolochic acid) or adulteration by diuretics or antiinflammatory drugs. However, the medicinal preparation of the capsules taken by patients had different alkaloid profiles from those expected in Chinese plants. The striking relation between a specific type of fibrosing interstitial nephritis in young women and a slimming treatment involving Chinese herbs adds support to the arguments against uncontrolled therapy with herbal preparations.	UNIV LIBRE BRUXELLES,DEPT NEPHROL,B-1050 BRUSSELS,BELGIUM; UNIV LIBRE BRUXELLES,DEPT PATHOL,B-1050 BRUSSELS,BELGIUM; UNIV LIBRE BRUXELLES,PHARMACOGNOSY & BROMATOL LAB,B-1050 BRUSSELS,BELGIUM; UNIV LIBRE BRUXELLES,HOP BRUGMANN,B-1050 BRUSSELS,BELGIUM; UNIV LIBRE BRUXELLES,INST E CARELL,B-1050 BRUSSELS,BELGIUM; UNIV LIBRE BRUXELLES,HOP BRACEPS,B-1050 BRUSSELS,BELGIUM; AKAD ZICKENHUIS,BRUSSELS,BELGIUM; VRIJE UNIV BRUSSELS,B-1050 BRUSSELS,BELGIUM; UNIV CATHOLIQUE LOUVAIN,CLIN UNIV ST LUC,B-1200 BRUSSELS,BELGIUM	Universite Libre de Bruxelles; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Universite Libre de Bruxelles; Universite Libre de Bruxelles; Universite Libre de Bruxelles; Universite Libre de Bruxelles; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc			Jadoul, Michel/B-8779-2008; Abramowicz, Daniel/F-7578-2017	Abramowicz, Daniel/0000-0002-6556-9199				ARREY D, 1992, ANN INTERN MED, V117, P129; BARNES JM, 1977, LANCET, V1, P671; BENNETT WM, 1977, ANN INTERN MED, V87, P582, DOI 10.7326/0003-4819-87-5-582; CHANG HM, 1986, PHARM APPLICATION CH; CHE YH, 1985, HDB CHINESE HERBS FO; ELSEVIERS MM, 1988, NEPHROL DIAL TRANSPL, V2, P143; EMMERSON BT, 1970, ANN INTERN MED, V73, P854, DOI 10.7326/0003-4819-73-5-854; GUOSHI TU, 1988, PHARMACOPOEIA PEOPLE; HELD PJ, 1990, AM J KIDNEY DIS S2, V26, P22; HUXTABLE RJ, 1992, ANN INTERN MED, V117, P165, DOI 10.7326/0003-4819-117-2-165; HUXTABLE RJ, 1986, NEW ENGL J MED, V315, P1095; Ivic M, 1970, ACTA FAC MEICARE NA, V1, P9; Jackson BP, 1968, POWDERED VEGETABLE D; JORKASKY DK, 1988, SEMIN NEPHROL, V8, P62; KROCH P, 1977, ACTA PATH MICROBIO B, V85, P238; MURRAY T, 1975, ANN INTERN MED, V82, P453, DOI 10.7326/0003-4819-82-4-453; NEILSON EG, 1989, KIDNEY INT, V35, P1257, DOI 10.1038/ki.1989.118; SEGASOTHY M, 1991, NEPHRON, V59, P166, DOI 10.1159/000186543; STEFANOVIC V, 1991, AM J NEPHROL, V11, P1, DOI 10.1159/000168264; STILLMAN AE, 1977, GASTROENTEROLOGY, V73, P349; Tang W., 1992, CHINESE DRUGS PLANT, P639; Tang W.C., 1992, CHINESE DRUGS PLANT, P963; TOTO RD, 1990, AM J MED SCI, V299, P392, DOI 10.1097/00000441-199006000-00007; Tufveson G, 1989, NEPHROL DIAL TRAN S4, V4, P5; VANHERWEGHEM JL, 1982, CLIN NEPHROL, V17, P129; 1990, DRUG INFORMATION H A, V1, P813	26	823	955	6	101	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 13	1993	341	8842					387	391		10.1016/0140-6736(93)92984-2	http://dx.doi.org/10.1016/0140-6736(93)92984-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM416	8094166				2023-01-03	WOS:A1993KM41600001
J	Bindels, PJE; Krol, A; vanAmeijden, E; MulderFolkerts, DKF; vandenHoek, JAR; vanGriensven, GPJ; Coutinho, RA				Bindels, PJE; Krol, A; vanAmeijden, E; MulderFolkerts, DKF; vandenHoek, JAR; vanGriensven, GPJ; Coutinho, RA			Euthanasia and physician-assisted suicide in homosexual men with AIDS	LANCET			English	Article							IMMUNODEFICIENCY-SYNDROME AIDS; LONGITUDINAL DATA-ANALYSIS; RESPONSIVENESS; SURVIVAL	Background In the Netherlands a nationwide study has shown that, in 38% of deaths, there have been medical decisions concerning the end of life (MDEL); 2.1% of all deaths were brought about by euthanasia or physician-assisted suicide (PAS). We investigated the incidence of MDEL in homosexual men with AIDS, suspecting that it might be higher, and studied the effect of euthanasia/PAS on survival time. Methods The patients were 131 male homosexual participants in a cohort study in Amsterdam, diagnosed between 1985 and 1992 as having AIDS; all had died before Jan 1, 1995. Clinical and laboratory data and information on mode of death were obtained from their physicians and by review of hospital records. Those who died by euthanasia/PAS or in whom there had been other MDEL were then compared with those who died naturally. Findings 29 men (22%) had died by euthanasia/PAS and in 17 (13%) another MDEL had been made; thus, more than one-third of these men had made medical decisions concerning the end of life. The greatest difference between the groups was in age at time of diagnosis-72% aged 40 or more in the euthanasia/PAS group compared with 38% in the natural death group. The likelihood (relative risk) of euthanasia/PAS increased with duration of survival after AIDS diagnosis. Comparison of the groups in terms of three laboratory markers (CD4+ and CD8+ cells and phytohaemagglutinin responses) in the two years before death, and estimates of these markers at the time of death, did not indicate any substantial shortening of life by euthanasia/PAS; in the judgment of the physicians, most of these patients would have died naturally within one month. Interpretation A possible reason for the high incidence of MDEL in this cohort was a good knowledge of the characteristics of AIDS acquired through long-term awareness of HIV infection. The higher rate of euthanasia in those with long survival from AIDS diagnosis could reflect either additional suffering or the greater opportunity to discuss this option with friends and physicians. Our findings indicate that euthanasia and other MDEL did little to shorten life; rather, they were an extreme form of palliation, applied in the terminal phase of a lethal disease.			Bindels, PJE (corresponding author), DEPT PUBL HLTH,MUNICIPAL HLTH SERV,NIEUWE ACHTERGRACHT 100,POB 20244,1000 HE AMSTERDAM,NETHERLANDS.							Anderson PK, 1993, STAT MODELS BASED CO; BINDELS PJE, 1995, J INFECT DIS, V172, P97, DOI 10.1093/infdis/172.1.97; BLOEMENA E, 1989, J IMMUNOL METHODS, V122, P161, DOI 10.1016/0022-1759(89)90260-3; CHANG HGH, 1993, AM J EPIDEMIOL, V138, P341, DOI 10.1093/oxfordjournals.aje.a116864; FAHEY JL, 1989, NEW ENGL J MED, V321, P673; GRIENSVEN GP, 1987, AM J EPIDEMIOL, V125, P1048; JACOBSON LP, 1993, AM J EPIDEMIOL, V138, P952, DOI 10.1093/oxfordjournals.aje.a116815; KEET IPM, 1993, AIDS, V7, P51, DOI 10.1097/00002030-199301000-00008; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; LUNDGREN JD, 1994, BMJ-BRIT MED J, V308, P1068, DOI 10.1136/bmj.308.6936.1068; PIJNENBORG L, 1995, END LIFE DECISIONS M; SCHELLEKENS PTA, 1990, J CLIN IMMUNOL, V10, P121, DOI 10.1007/BF00918194; SEAGE GR, 1993, AM J PUBLIC HEALTH, V83, P72, DOI 10.2105/AJPH.83.1.72; SORGDRAGER W, 1995, MED CONTACT, V50, P381; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; VANDERWAL G, 1994, BRIT MED J, V308, P1346, DOI 10.1136/bmj.308.6940.1346; VANDERWAL G, 1991, MED CONTACT, V46, P174; VANLIER RAW, 1987, J IMMUNOL, V139, P2873; WARD BJ, 1994, BRIT MED J, V308, P1332, DOI 10.1136/bmj.308.6940.1332; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; 1987, MMWR-MORBID M      S, V36, pS1	21	27	27	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 24	1996	347	9000					499	504		10.1016/S0140-6736(96)91138-1	http://dx.doi.org/10.1016/S0140-6736(96)91138-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TW697	8596267				2023-01-03	WOS:A1996TW69700009
J	Merzenich, MM; Jenkins, WM; Johnston, P; Schreiner, C; Miller, SL; Tallal, P				Merzenich, MM; Jenkins, WM; Johnston, P; Schreiner, C; Miller, SL; Tallal, P			Temporal processing deficits of language-learning impaired children ameliorated by training	SCIENCE			English	Article							DEVELOPMENTAL DYSLEXIA; PERCEPTION; DISCRIMINATION; PERFORMANCE; APHASIA; TASK	Children with language-based learning impairments (LLIs) have major deficits in their recognition of some rapidly successive phonetic elements and nonspeech sound stimuli. In the current study, LLI children were engaged in adaptive training exercises mounted as computer ''games'' designed to drive improvements in their ''temporal processing'' skills. With 8 to 16 hours of training during a 20-day period, LLI children improved markedly in their abilities to recognize brief and fast sequences of nonspeech and speech stimuli.	UNIV CALIF SAN FRANCISCO, COLEMAN LAB, SAN FRANCISCO, CA 94143 USA; RUTGERS STATE UNIV, CTR MOLEC & BEHAV NEUROSCI, NEWARK, NJ 07102 USA	University of California System; University of California San Francisco; Rutgers State University Newark; Rutgers State University New Brunswick	Merzenich, MM (corresponding author), UNIV CALIF SAN FRANCISCO, WM KECK CTR INTEGRAT NEUROSCI, SAN FRANCISCO, CA 94143 USA.			Schreiner, Christoph/0000-0002-4571-4328	NIDCD NIH HHS [R01 DC002260] Funding Source: Medline; NINDS NIH HHS [R01 NS010414] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS010414] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC002260] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		AHISSAR M, 1993, P NATL ACAD SCI USA, V90, P5718, DOI 10.1073/pnas.90.12.5718; [Anonymous], 1982, ANN DYSLEXIA, DOI DOI 10.1007/BF02647960; BEITEL R, 1995, NEUR ABSTR, V21, P1180; BENESCISH AA, 1993, TEMPORALINFORMATION, P312; BENESCISH AA, IN PRESS INFANT BEHA; BERTINI G, 1995, NEUR ABSTR, V21, P276; BYL NN, IN PRESS J NEUROL; DUARA R, 1991, ARCH NEUROL-CHICAGO, V48, P410, DOI 10.1001/archneur.1991.00530160078018; FLYNN JM, 1992, J LEARN DISABIL, V25, P133, DOI 10.1177/002221949202500207; GALABURDA A, 1993, ANN NY ACAD SCI, V682, P70, DOI 10.1111/j.1749-6632.1993.tb22960.x; GALABURDA AM, 1985, ANN NEUROL, V18, P222, DOI 10.1002/ana.410180210; GALABURDA AM, 1993, NEUROL CLIN, V11, P161, DOI 10.1016/S0733-8619(18)30175-0; HAGMAN JO, 1992, ARCH NEUROL-CHICAGO, V49, P734, DOI 10.1001/archneur.1992.00530310082015; JERNIGAN TL, 1991, ARCH NEUROL-CHICAGO, V48, P539, DOI 10.1001/archneur.1991.00530170103028; KARNI A, 1991, P NATL ACAD SCI USA, V88, P4966, DOI 10.1073/pnas.88.11.4966; KARNI A, 1993, NATURE, V365, P250, DOI 10.1038/365250a0; KLATT DH, 1980, J ACOUST SOC AM, V67, P971, DOI 10.1121/1.383940; KUSCH A, 1993, NEUROPSYCHOLOGIA, V31, P811; LARSEN JP, 1990, BRAIN LANG, V39, P289, DOI 10.1016/0093-934X(90)90015-9; LEWIS BA, 1993, BEHAV GENET, V23, P291, DOI 10.1007/BF01082469; LEWIS BA, 1992, J LEARN DISABIL, V25, P486; MERZENICH M. M., 1994, MEMORY CONCEPTS, P437; MERZENICH MM, 1990, COLD SPRING HARB SYM, V55, P873; MERZENICH MM, 1993, ANN NY ACAD SCI, V682, P1; Merzenich MM., 1995, MATURATIONAL WINDOWS, P247; MERZENICH MM, IN PRESS MIND BRAIN; NAAS R, 1994, CURR OPIN NEUROL, V7, P179; PENNINGTON BF, 1995, J CHILD NEUROL, V10, pS69, DOI 10.1177/08830738950100S114; RECANZONE GH, 1992, J NEUROPHYSIOL, V67, P1071, DOI 10.1152/jn.1992.67.5.1071; TALLAL P, 1980, BRAIN LANG, V9, P182, DOI 10.1016/0093-934X(80)90139-X; Tallal P, 1996, SCIENCE, V271, P81, DOI 10.1126/science.271.5245.81; TALLAL P, 1973, NATURE, V241, P468, DOI 10.1038/241468a0; TALLAL P, 1991, BRAIN LANG, V41, P81, DOI 10.1016/0093-934X(91)90112-E; TALLAL P, 1975, NEUROPSYCHOLOGIA, V13, P69, DOI 10.1016/0028-3932(75)90049-4; TALLAL P, 1985, BRAIN LANG, V25, P314, DOI 10.1016/0093-934X(85)90087-2; TALLAL P, 1993, ANN NY ACAD SCI, V682, P27, DOI 10.1111/j.1749-6632.1993.tb22957.x; Tallal P., 1980, NONSPEECH LANGUAGE C, P449; WANG XQ, 1995, NATURE, V378, P71, DOI 10.1038/378071a0; 1978, TOKEN TEST CHILDREN	39	695	735	0	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 5	1996	271	5245					77	81		10.1126/science.271.5245.77	http://dx.doi.org/10.1126/science.271.5245.77			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TP022	8539603				2023-01-03	WOS:A1996TP02200047
J	STEWARTBROWN, S; SURENDER, R; BRADLOW, J; COULTER, A; DOLL, H				STEWARTBROWN, S; SURENDER, R; BRADLOW, J; COULTER, A; DOLL, H			THE EFFECTS OF FUNDHOLDING IN GENERAL-PRACTICE ON PRESCRIBING HABITS 3 YEARS AFTER INTRODUCTION OF THE SCHEME	BRITISH MEDICAL JOURNAL			English	Article							COSTS	Objective--To observe changes in prescribing practice that occurred after the introduction of fundholding in first wave practices and to contrast these with changes occurring in similar non-fundholding practices. Design--Prospective observational study. Setting--Oxford region fundholding study. Subjects--Eight first wave fundholding practices and five practices that were not interested in fundholding in 1990-1, which were similar in terms of practice size, training status, locality, and urban rural mix. Three of the fundholding and none of the non-fundholding practices were dispensing practices. Main outcome measures--Changes in prescribing practice as measured by net cost per prescribing unit, cost per item, number of items prescribed, and substitution rates for generic drugs three years after the introduction of fundholding. Data for fundholding practices were analysed separately according to whether they were dispensing or non-dispensing practices. Results--Prescribing costs rose by a third or more in all types of practice. The patterns of change observed in this cohort after one year of fundholding were reversed. No evidence existed that fundholding had controlled prescribing costs among non-dispensing fundholders; costs among dispensing fundholders rose least, but the differences were small compared with the overall increase in costs. Conclusions--Early reports of the effectiveness of fundholding in curbing prescribing costs have not been confirmed in this longer term study.	UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,HLTH CARE UNIT,OXFORD OX3 7LF,ENGLAND; KINGS FUND CTR,LONDON W1M 0AN,ENGLAND	University of Oxford	STEWARTBROWN, S (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,HLTH SERV RES,OXFORD OX2 6HE,ENGLAND.		Coulter, Angela/N-6998-2019	Coulter, Angela/0000-0002-6308-8375				BRADLOW J, 1993, BRIT MED J, V307, P1186, DOI 10.1136/bmj.307.6913.1186; CHEW R, 1992, COMPENDIUM HLTH STAT; COULTER A, IN PRESS EUROPEAN J; GLENNERSTER H, 1994, IMPLEMENTING GP FUND; MAXWELL M, 1993, BRIT MED J, V307, P1190, DOI 10.1136/bmj.307.6913.1190; ROBERTS SJ, 1993, BRIT MED J, V307, P485, DOI 10.1136/bmj.307.6902.485; 1993, EFFECTIVE HLTH CARE, V5	7	67	67	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 9	1995	311	7019					1543	1547		10.1136/bmj.311.7019.1543	http://dx.doi.org/10.1136/bmj.311.7019.1543			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK214	8520399	Green Published			2023-01-03	WOS:A1995TK21400027
J	MONTGOMERY, HE; MCINTYRE, CW; ALMOND, MK; DAVIES, K; PUMPHREY, CW; BENNETT, D				MONTGOMERY, HE; MCINTYRE, CW; ALMOND, MK; DAVIES, K; PUMPHREY, CW; BENNETT, D			RHABDOMYOLYSIS AND MULTIPLE SYSTEM ORGAN FAILURE WITH STREPTOKINASE	BRITISH MEDICAL JOURNAL			English	Letter							MYOCARDIAL-INFARCTION		SO GEN HOSP, RENAL UNIT, WESTCLIFF ON THE SEA, ESSEX, ENGLAND; HAMMERSMITH HOSP, DEPT RHEUMATOL, LONDON W12 0NN, ENGLAND; ST GEORGE HOSP, CARDIOL UNIT, LONDON SW17, ENGLAND; ST GEORGE HOSP, INTENS CARE UNIT, LONDON SW17, ENGLAND	Imperial College London; St Georges University London; St Georges University London	MONTGOMERY, HE (corresponding author), UCL HOSP, HATTER INST CARDIOVASC RES, LONDON WC1E 6AU, ENGLAND.		Montgomery, Hugh/L-1229-2019; McIntyre, Christopher W/O-8927-2014; Montgomery, Hugh/C-2592-2008	Montgomery, Hugh/0000-0001-8797-5019				DAVIES KA, 1990, CLIN EXP IMMUNOL, V80, P83; DICKINSON RJ, 1991, BRIT MED J, V302, P111; LYNCH M, 1993, CLIN EXP IMMUNOL, V94, P279; QUEEN M, 1990, AM J CARDIOL, V65, P1042, DOI 10.1016/0002-9149(90)91014-W; TIO RA, 1992, AM J CARDIOL, V70, P1632, DOI 10.1016/0002-9149(92)90477-G	5	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 2	1995	311	7018					1472	1472						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TJ044	8520338				2023-01-03	WOS:A1995TJ04400025
J	LIEBERMAN, EH; GERHARD, MD; UEHATA, A; WALSH, BW; SELWYN, AP; GANZ, P; YEUNG, AC; CREAGER, MA				LIEBERMAN, EH; GERHARD, MD; UEHATA, A; WALSH, BW; SELWYN, AP; GANZ, P; YEUNG, AC; CREAGER, MA			ESTROGEN IMPROVES ENDOTHELIUM-DEPENDENT, FLOW-MEDIATED VASODILATION IN POSTMENOPAUSAL WOMEN	ANNALS OF INTERNAL MEDICINE			English	Article						ESTROGEN REPLACEMENT THERAPY; MENOPAUSE; ENDOTHELIUM; VASODILATION; CORONARY DISEASE	ATHEROSCLEROTIC CORONARY-ARTERIES; SMOOTH-MUSCLE CELLS; NITRIC-OXIDE; RELAXING FACTOR; HEART-DISEASE; FOLLOW-UP; ESSENTIAL-HYPERTENSION; PLASMA-LIPOPROTEINS; RELAXANT FACTOR; ACETYLCHOLINE	Objective: To assess the effect of estrogen replacement therapy on endothelium-dependent vasodilation in postmenopausal women. Design: Double-blind, placebo-controlled, crossover trial. Setting: University medical center. Patients: 13 postmenopausal women aged 44 to 69 years (average age, 55 +/- 7 years). Intervention: Patients were randomly assigned to receive placebo, oral estradiol at a dose of 1 mg/d, and oral estradiol at a dose of 2 mg/d. Each treatment phase lasted 9 weeks. Measurements: High-resolution ultrasonography was used to measure vascular reactivity in a peripheral conduit vessel, the brachial artery. Endothelium-dependent vasodilation was determined by measuring the change in brachial artery diameter during increases in flow induced by reactive hyperemia. Endothelium-independent vasodilation was measured after sublingual nitroglycerin was administered. Results: Flow-mediated, endothelium-dependent vasodilation of the brachial artery was greater when patients received estradiol (13.5% and 11.6% for I-mg and 2-mg doses, respectively) than when patients received placebo (6.8%; P < 0.05 for each dose compared with placebo). In contrast, estrogen administration had no effect on endothelium-independent vasodilation as assessed by sublingual nitroglycerin. Conclusion: Short-term estrogen replacement therapy improves flow-mediated endothelium-dependent vasodilation in postmenopausal women. This improvement may be mediated by a direct effect of estrogen on vascular function or may be induced through modification of lipoprotein metabolism.	BRIGHAM & WOMENS HOSP, DIV CARDIOVASC, BOSTON, MA 02115 USA; MT SINAI HOSP, MIAMI, FL USA; NATL DEF MED COLL, TOKOROZAWA, SAITAMA 359, JAPAN; STANFORD UNIV, MED CTR, DIV CARDIOVASC, STANFORD, CA 94305 USA; BRIGHAM & WOMENS HOSP, DEPT OBSTET GYNECOL, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; National Defense Medical College - Japan; Stanford University; Harvard University; Brigham & Women's Hospital				Ganz, Peter/0000-0002-0437-8882	NHLBI NIH HHS [HL02566, HL02663, HL38780] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K04HL002566, R01HL038780] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS MR, 1990, ARTERIOSCLEROSIS, V10, P1051, DOI 10.1161/01.ATV.10.6.1051; BARRETTCONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1861, DOI 10.1001/jama.265.14.1861; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; BUSSE R, 1987, N-S ARCH PHARMACOL, V336, P566; CELERMAJER DS, 1993, CIRCULATION, V88, P2149, DOI 10.1161/01.CIR.88.5.2149; CELERMAJER DS, 1992, LANCET, V340, P1111, DOI 10.1016/0140-6736(92)93147-F; CHANG WC, 1980, BIOCHIM BIOPHYS ACTA, V619, P107; COLBURN P, 1978, SCIENCE, V201, P817, DOI 10.1126/science.684408; COLDITZ GA, 1987, NEW ENGL J MED, V316, P1105, DOI 10.1056/NEJM198704303161801; COX DA, 1989, CIRCULATION, V80, P458, DOI 10.1161/01.CIR.80.3.458; CREAGER MA, 1990, J CLIN INVEST, V86, P228, DOI 10.1172/JCI114688; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GISCLARD V, 1988, J PHARMACOL EXP THER, V244, P19; GRIFFITH TM, 1984, NATURE, V308, P645, DOI 10.1038/308645a0; GRUCHOW HW, 1988, AM HEART J, V115, P954, DOI 10.1016/0002-8703(88)90063-4; HONG MK, 1992, AM J CARDIOL, V69, P176, DOI 10.1016/0002-9149(92)91300-S; HORWITZ KB, 1982, J CLIN INVEST, V69, P750, DOI 10.1172/JCI110513; JIANG CW, 1992, AM J PHYSIOL, V263, pH271, DOI 10.1152/ajpheart.1992.263.1.H271; JOHNSTONE MT, 1993, CIRCULATION, V88, P2510, DOI 10.1161/01.CIR.88.6.2510; KANNEL WB, 1976, ANN INTERN MED, V85, P447, DOI 10.7326/0003-4819-85-4-447; KEANEY JF, 1994, CIRCULATION, V89, P2251, DOI 10.1161/01.CIR.89.5.2251; KLEINMAN DG, 1988, APPLIED REGRESSION A; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; KUHN FE, 1991, AM J CARDIOL, V68, P1425, DOI 10.1016/0002-9149(91)90274-O; KUSHWAHA RS, 1991, ARTERIOSCLER THROMB, V11, P23, DOI 10.1161/01.ATV.11.1.23; LERNER DJ, 1986, AM HEART J, V111, P383, DOI 10.1016/0002-8703(86)90155-9; LIAO JK, 1991, CIRC RES, V68, P1027, DOI 10.1161/01.RES.68.4.1027; LIEBERMAN EH, 1993, CIRCULATION, V88, P79; LINDER L, 1990, CIRCULATION, V81, P1762, DOI 10.1161/01.CIR.81.6.1762; LUDMER PL, 1986, NEW ENGL J MED, V315, P1046, DOI 10.1056/NEJM198610233151702; MACK TM, 1976, NEW ENGL J MED, V294, P1262, DOI 10.1056/NEJM197606032942304; MCDONALD TW, 1977, AM J OBSTET GYNECOL, V127, P572, DOI 10.1016/0002-9378(77)90351-9; MCGILL HC, 1981, CIRC RES, V48, P238, DOI 10.1161/01.RES.48.2.238; MILLER VM, 1990, AM J PHYSIOL, V258, pR1502, DOI 10.1152/ajpregu.1990.258.6.R1502; MILLER VM, 1988, PHLEBOLOGY, V3, P63; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PANZA JA, 1990, NEW ENGL J MED, V323, P22, DOI 10.1056/NEJM199007053230105; RADOMSKI MW, 1987, LANCET, V2, P1057, DOI 10.1016/S0140-6736(87)91481-4; RAINBOW TC, 1980, BRAIN RES, V198, P239, DOI 10.1016/0006-8993(80)90362-5; REIS SE, 1994, CIRCULATION, V89, P52, DOI 10.1161/01.CIR.89.1.52; SIMON DI, 1993, ARTERIOSCLER THROMB, V13, P791, DOI 10.1161/01.ATV.13.6.791; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; SULLIVAN JM, 1988, ANN INTERN MED, V108, P358, DOI 10.7326/0003-4819-108-3-358; UEHATA A, 1993, CIRCULATION, V88, P618; UEHATA A, 1992, CIRCULATION, V86, P620; VANHOUTTE PM, 1985, CIRCULATION, V72, P728, DOI 10.1161/01.CIR.72.4.728; VITA JA, 1990, CIRCULATION, V81, P491, DOI 10.1161/01.CIR.81.2.491; WALSH BW, 1991, NEW ENGL J MED, V325, P1196, DOI 10.1056/NEJM199110243251702; WILLIAMS JK, 1992, J AM COLL CARDIOL, V20, P452, DOI 10.1016/0735-1097(92)90116-5; WILLIAMS JK, 1990, CIRCULATION, V81, P1680, DOI 10.1161/01.CIR.81.5.1680; YAGI K, 1986, BIOCHEM INT, V13, P1051; ZEIHER AM, 1991, CIRCULATION, V84, P1984, DOI 10.1161/01.CIR.84.5.1984; 1986, MMWR-MORBID MORTAL W, V35, P653	54	605	614	0	16	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1994	121	12					936	941		10.7326/0003-4819-121-12-199412150-00005	http://dx.doi.org/10.7326/0003-4819-121-12-199412150-00005			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW083	7978718				2023-01-03	WOS:A1994PW08300005
J	MATSUDA, T; TAKAO, T; SHIMONISHI, Y; MURATA, M; ASANO, T; YOSHIZAWA, T; FUKADA, Y				MATSUDA, T; TAKAO, T; SHIMONISHI, Y; MURATA, M; ASANO, T; YOSHIZAWA, T; FUKADA, Y			CHARACTERIZATION OF INTERACTIONS BETWEEN TRANSDUCIN ALPHA/BETA-GAMMA-SUBUNITS AND LIPID-MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING REGULATORY PROTEINS; BETA-GAMMA; RAS PROTEINS; PLASMA-MEMBRANE; BOVINE BRAIN; ASSOCIATION; MOTIF; CDNA; PALMITOYLATION; IDENTIFICATION	The gamma-subunits of heterotrimeric guanine nucleotide binding regulatory proteins (G-proteins) are isoprenylated and alpha-carboxyl methylated at their COOH-terminal cysteine residues. These modifications are necessary for membrane attachment of the beta gamma complex, but a requirement of an additional factor has been proposed for the stable binding. We explored a possible contribution of the blocked amino terminus of beta-subunits of bovine photoreceptor G-protein, transducin (T alpha/T beta gamma = G(t) alpha/beta(1) gamma(1)), and of three beta gamma complexes (beta(1) gamma(2), beta(1) gamma(3), and beta(1) gamma(7)) purified from bovine brains. Structural analyses revealed that every beta(1)-subunit has an N-acetylated serine, which is unlikely to contribute to the membrane association. Since neither protease nor heat treatment of photoreceptor membranes affected the membrane binding of T beta gamma, it seems unlikely that rhodopsin (or other membrane proteins) serves as an anchor protein for accepting T beta gamma. In fact, T beta gamma bound to phospholipid large unilamellar vesicles (LUVs), of which the polar head groups strongly influenced the binding: T beta gamma alone showed 2-fold higher binding for negatively charged phosphatidylserine-LUVs than for neutral phosphatidylcholine (PC)-LUVs, while the affinity of T alpha/T beta gamma complex for the phosphatidylserine-LUVs was lower than that for the PC-LUVs. These results indicate that 1) an ionic interaction between T beta gamma and membrane surface plays an important role in the stable membrane association, and 2) the domain(s) of T beta gamma responsible for the association would be different between trimeric and dissociated states. We also found that synthetic peptides corresponding to the COOH terminal region of T gamma inhibited T alpha-T beta gamma interaction only when the peptides were isoprenylated. This suggests that the isoprenyl moiety is located at the contact site between the subunits, not at the membrane-binding domain, when T beta gamma is complexed with T alpha.	UNIV TOKYO,COLL ARTS & SCI,DEPT PURE & APPL SCI,MEGURO KU,TOKYO 153,JAPAN; OSAKA UNIV,INST PROT RES,OSAKA 565,JAPAN; KYOTO UNIV,FAC SCI,DEPT BIOPHYS,KYOTO 60601,JAPAN; AICHI PREFECTURAL COLONY,INST DEV RES,DEPT BIOCHEM,KASUGAI,AICHI 48003,JAPAN; OSAKA SANGYO UNIV,FAC ENGN,DEPT INFORMAT SYST ENGN,OSAKA 574,JAPAN	University of Tokyo; Osaka University; Kyoto University			吉孝, 深田/G-5090-2014					ASANO T, 1993, J BIOL CHEM, V268, P20512; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSS JE, 1987, P NATL ACAD SCI USA, V84, P7493, DOI 10.1073/pnas.84.21.7493; BUTRYNSKI JE, 1992, BIOCHEMISTRY-US, V31, P8030, DOI 10.1021/bi00149a037; CALI JJ, 1992, J BIOL CHEM, V267, P24023; COHN EJ, 1943, PROTEINS AMINO ACIDS, P445; DAEMEN FJM, 1973, BIOCHIM BIOPHYS ACTA, V300, P255, DOI 10.1016/0304-4157(73)90006-3; FISHER KJ, 1992, MOL CELL BIOL, V12, P1585, DOI 10.1128/MCB.12.4.1585; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; FUKADA Y, 1989, J BIOL CHEM, V264, P5937; FUKADA Y, 1994, J BIOL CHEM, V269, P5163; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; FUNG BKK, 1983, J BIOL CHEM, V258, P503; GAUTAM N, 1990, P NATL ACAD SCI USA, V87, P7973, DOI 10.1073/pnas.87.20.7973; GAUTAM N, 1989, SCIENCE, V244, P971, DOI 10.1126/science.2499046; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HARGRAVE P A, 1980, Neurochemistry International, V1, P231, DOI 10.1016/0197-0186(80)90063-7; HIGGINS JB, 1994, J BIOL CHEM, V269, P9067; HURLEY JB, 1984, P NATL ACAD SCI-BIOL, V81, P6948, DOI 10.1073/pnas.81.22.6948; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; KAMEYAMA K, 1993, J BIOL CHEM, V268, P7753; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KOKAME K, 1992, NATURE, V359, P749, DOI 10.1038/359749a0; Kuhn H., 1980, Neurochemistry International, V1, P269, DOI 10.1016/0197-0186(80)90066-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI RK, 1990, P NATL ACAD SCI USA, V87, P7673, DOI 10.1073/pnas.87.19.7673; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; MORISHITA R, 1992, EUR J BIOCHEM, V210, P1061, DOI 10.1111/j.1432-1033.1992.tb17512.x; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; MURATA M, 1992, BIOCHEMISTRY-US, V31, P1986, DOI 10.1021/bi00122a013; NEUBERT TA, 1992, J BIOL CHEM, V267, P18274; OHGURO H, 1990, BIOCHEM BIOPH RES CO, V167, P1235, DOI 10.1016/0006-291X(90)90656-8; OHGURO H, 1991, EMBO J, V10, P3669, DOI 10.1002/j.1460-2075.1991.tb04934.x; OKANO T, 1992, P NATL ACAD SCI USA, V89, P5932, DOI 10.1073/pnas.89.13.5932; OVCHINNIKOV YA, 1982, FEBS LETT, V148, P179, DOI 10.1016/0014-5793(82)80805-3; PARENTI M, 1993, BIOCHEM J, V291, P349, DOI 10.1042/bj2910349; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; RAHMATULLAH M, 1994, J BIOL CHEM, V269, P3574; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; RUEGG R, 1959, HELV CHIM ACTA, V42, P2616, DOI 10.1002/hlca.19590420733; SCHULTZ AM, 1987, BIOCHEM BIOPH RES CO, V146, P1234, DOI 10.1016/0006-291X(87)90780-7; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; SPIEGEL AM, 1991, TRENDS BIOCHEM SCI, V16, P338, DOI 10.1016/0968-0004(91)90139-M; STERNWEIS PC, 1986, J BIOL CHEM, V261, P631; UEDA N, 1994, J BIOL CHEM, V269, P4388; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868	51	64	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30358	30363						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982949				2023-01-03	WOS:A1994PU52500051
J	KOGAN, MD; PAPPAS, G; YU, SM; KOTELCHUCK, M				KOGAN, MD; PAPPAS, G; YU, SM; KOTELCHUCK, M			OVER-THE-COUNTER MEDICATION USE AMONG US PRESCHOOL-AGE CHILDREN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SELF-MEDICATION; COMMON COLD	Objective.-To estimate the prevalence of recent over-the-counter (OTC) medication use in a national sample of preschool-age children. Design.-Follow-up survey of a nationally representative sample of 3-year-old children in the US population by telephone or personal interview. Participants.-A total of 8145 children whose mothers were interviewed for the 1991 Longitudinal Follow-up to the National Maternal and Infant Health Survey. Main Outcome Measures.-Report of any OTC medications given in the past 30 days and the type of medications that the child received. Results.-During the past 30 days, 53.7% of all 3-year-old children in the United States were given some OTC medications. Among OTC medication users, the most common medications reported were Tylenol (66.7%) and cough or cold medicine (66.7%). Most respondents reported that recent child illness episodes (70%) were treated with OTC medications. After adjustment for recent child illness, women who were white (odds ratio [OR], 1.32; 95% confidence interval [Cl], 1.13 to 1.55), were more educated (OR, 1.58; 95% CI, 1.24 to 2.00), and had higher incomes (OR, 1.75; 95% Cl, 1.33 to 2.30) were more likely to have given their child OTC medications. Women without health insurance were also more likely to have given OTC medications (OR, 1.27; 95% Cl, 1.04 to 1.55). Provider visits, but not telephone calls, were associated with a reduction in OTC medication usage. Conclusions.-Over-the-counter medications are an important component of health care for treating illness in US preschool-age children. The high prevalence of use has occurred despite the dearth of scientific proof for the effectiveness of certain classes of OTC medications and the risks associated with improper use.	US HLTH RESOURCES & SERV ADM, BUR MATERNAL & CHILD HLTH, ROCKVILLE, MD USA; UNIV N CAROLINA, DEPT MATERNAL & CHILD HLTH, CHAPEL HILL, NC USA	United States Health Resources & Service Administration (HRSA); University of North Carolina; University of North Carolina Chapel Hill	KOGAN, MD (corresponding author), CTR DIS CONTROL & PREVENT, NATL CTR HLTH STAT, 6525 BELCREST RD, ROOM 840, HYATTSVILLE, MD 20782 USA.							BLAKE KD, 1993, LANCET, V341, P640, DOI 10.1016/0140-6736(93)90410-I; BONADIO WA, 1993, CLIN PEDIATR, V32, P343, DOI 10.1177/000992289303200604; BUSH PJ, 1976, MED CARE, V14, P1014; CHRISCHILLES EA, 1992, J GERONTOL, V47, pM137, DOI 10.1093/geronj/47.5.M137; CONN VS, 1991, J ADV NURS, V16, P1190, DOI 10.1111/j.1365-2648.1991.tb01528.x; CRAIG RS, 1992, J DRUG EDUC, V22, P303, DOI 10.2190/2NHN-NUY7-Q88U-CDJH; DRWALKLEIN LA, 1992, CLIN PHARMACY, V11, P1005; DUKES GE, 1990, AM J MED, V88, pS24, DOI 10.1016/0002-9343(90)90272-F; Dunnell Karen, 1972, MED TAKERS PRESCRIBE; FRIEDMAN A D, 1990, Pediatric Emergency Care, V6, P6, DOI 10.1097/00006565-199003000-00003; GINSBURG CM, 1973, AM J DIS CHILD, V125, P241, DOI 10.1001/archpedi.1973.04160020065012; HAGGERTY RJ, 1972, PEDIATR CLIN N AM, V19, P101; HUTTON N, 1991, J PEDIATR-US, V118, P125, DOI 10.1016/S0022-3476(05)81865-7; JEFFERYS M, 1960, Br J Prev Soc Med, V14, P64; JOHNSON RE, 1983, MED CARE, V21, P225, DOI 10.1097/00005650-198302000-00009; KNAPP DA, 1972, AM J HOSP PHARM, V29, P1004, DOI 10.1093/ajhp/29.12.1004; KOVAR MG, 1985, PUBLIC HEALTH REP, V100, P470; LITOVITZ T, 1992, PEDIATRICS, V89, P999; Lowenstein S R, 1987, Adv Intern Med, V32, P207; Maheady D C, 1989, J Pediatr Health Care, V3, P246; MAIMAN LA, 1986, SOC SCI MED, V22, P41, DOI 10.1016/0277-9536(86)90307-2; MAIMAN LA, 1982, PUBLIC HEALTH REP, V97, P140; PICKERING LK, 1991, J PEDIATR-US, V118, pS118, DOI 10.1016/S0022-3476(05)81439-8; Rosenthal I., 1988, DRUG TOPICS, V132, P62; RUMACK BH, 1974, PEDIATRICS, V53, P495; SAKCHAINANONT B, 1990, Journal of the Medical Association of Thailand, V73, P96; SANDERSON M, 1991, BIRTH-ISS PERINAT C, V18, P26, DOI 10.1111/j.1523-536X.1991.tb00050.x; SCHACHTEL BP, 1993, CLIN PHARMACOL THER, V53, P593, DOI 10.1038/clpt.1993.75; SMITH MBH, 1993, JAMA-J AM MED ASSOC, V269, P2258, DOI 10.1001/jama.269.17.2258; 1993, LONGITUDINAL FOLLOW; 1993, SURVEY DATA ANAL VER; 1993, PHYSICIANS DESK REFE	32	164	170	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 5	1994	272	13					1025	1030		10.1001/jama.272.13.1025	http://dx.doi.org/10.1001/jama.272.13.1025			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH775	8089884				2023-01-03	WOS:A1994PH77500027
J	ALS, H; LAWHON, G; DUFFY, FH; MCANULTY, GB; GIBESGROSSMAN, R; BLICKMAN, JG				ALS, H; LAWHON, G; DUFFY, FH; MCANULTY, GB; GIBESGROSSMAN, R; BLICKMAN, JG			INDIVIDUALIZED DEVELOPMENTAL CARE FOR THE VERY-LOW-BIRTH-WEIGHT PRETERM INFANT - MEDICAL AND NEUROFUNCTIONAL EFFECTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BRONCHOPULMONARY DYSPLASIA; INTRAVENTRICULAR HEMORRHAGE; PREMATURE-INFANTS; GESTATIONAL-AGE; RETINOPATHY; OUTCOMES; EQUALITY	Objective.-To investigate the effectiveness of individualized developmental care in reducing medical and neurodevelopmental sequelae for very low-birthweight infants. Design.-Randomized controlled trial. Setting.-Newborn intensive care unit. Patients.-Thirty-eight singleton preterm infants, free of known congenital abnormalities, weighing less than 1250 g, born before 30 weeks' gestation, mechanically ventilated within 3 hours of delivery and for more than 24 hours in the first 48 hours, randomly assigned to a control or an experimental group. Intervention.-Caregiving by nurses specifically trained in individualized developmental care; observation and documentation of the infants' behavior within 12 hours of admission, and subsequently every 10th day; developmental care recommendations and ongoing clinical support for the nurses and parents based on regular observation of the infant by developmental specialists; and the availability of special caregiving accessories. Main Outcome Measures.-Medical outcome, including average daily weight gain; number of days the infant required mechanical ventilation, oxygen, gavage tube feeding, and hospitalization; severity of retinopathy of prematurity, bronchopulmonary dysplasia, pneumothorax, and intraventricular hemorrhage; pediatric complications; age at discharge; and hospital charges. Neurodevelopmental outcome, including Assessment of Preterm Infants' Behavior scale and quantified electroencephalography (2 weeks after due date); and Bayley Scales of Infant Development and Kangaroo Box Paradigm (9 months after due date). Results.-The infants in the experimental group had a significantly shorter duration of mechanical ventilation and supplemental oxygen support; earlier oral feeding; reduced incidence of intraventricular hemorrhage, pneumothorax, and severe bronchopulmonary dysplasia; improved daily weight gain; shorter hospital stays; younger ages at hospital discharge; and reduced hospital charges compared with the infants in the control group. At 2 weeks after their due dates, these infants also showed improved autonomic regulation, motor system functioning, self-regulatory abilities, and visual evoked potential measures; and at 9 months, they had improved Bayley Mental and Psychomotor Developmental Index scores, as well as Kangaroo Box Paradigm scores. Conclusion.-Very low-birth-weight preterm infants may benefit from individualized developmental care in the neonatal intensive care unit in terms of medical and neurodevelopmental outcome.	HARVARD UNIV,SCH MED,DEPT PSYCHIAT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT RADIOL,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT NURSING,BOSTON,MA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital								ALS H, 1986, PEDIATRICS, V78, P1123; Als H., 1990, INFANT BEHAV DEV, V13, P159; Als H., 1992, ADV APPLIED DEV PSYC, V6, P341; ALS H, 1987, APIB FEATURES SUMMAR; Als H, 1984, MANUAL NATURALISTIC; Als H., 1989, STABILITY CONTINUITY, P3; ALS H, 1986, MANUAL SCORING SYSTE; Als H., 2006, NEWBORN INDIVIDUALIZ; Als H, 1982, THEORY RES BEHAVIORA, P65; APGAR V, 1953, ANESTH ANALG CLEVE, V32, P260, DOI DOI 10.1213/00000539-195301000-00041; BALLARD JL, 1977, PEDIATR RES, V11, P374, DOI 10.1203/00006450-197704000-00030; Bayley N., 1969, BAYLEY SCALES INFANT; BECKER PT, 1991, NURS RES, V40, P150; Brown M. B., 1979, J AM STAT ASSOC, V69, P364, DOI [10.2307/2285659, DOI 10.2307/2285659, DOI 10.1080/01621459.1974.10482955]; BROWN MB, 1974, TECHNOMETRICS, V16, P129, DOI 10.2307/1267501; COHEN J, 1969, STATISTICAL POWER AN; COOLEY WW, 1971, MULTIVARIATE DATA AN; DUFFY FH, 1990, CHILD DEV, V61, P1271, DOI 10.2307/1130893; DUNCAN OD, 1966, AM J SOCIOL, V72, P1, DOI 10.1086/224256; GARNER A, 1984, PEDIATRICS, V74, P127; GLASS P, 1985, NEW ENGL J MED, V313, P401, DOI 10.1056/NEJM198508153130701; Hollingshead A.B., 1975, YALE J SOCIOLOGY; KUBAN K, 1984, PEDIATRICS, V74, P358; LITTMAN B, 1974, MANUAL OBSTETRIC COM; LITTMAN B, 1974, MANUAL PEDIATRIC COM; MCCORMICK MC, 1992, ADV APPL DEV PSYCHOL, V6, P37; MERRITT TA, 1988, AM J DIS CHILD, V142, P1333, DOI 10.1001/archpedi.1988.02150120087047; NORTHWAY WH, 1979, J PEDIATR-US, V95, P815, DOI 10.1016/S0022-3476(79)80441-2; Paneth N, 1991, REPROD PERINATAL EPI, P371; PARAD R B, 1990, Current Opinion in Pediatrics, V2, P459, DOI 10.1097/00008480-199006000-00004; PERLMAN JM, 1989, PEDIATRICS, V84, P215; VOLPE JJ, 1983, PEDIATRICS, V72, P589; VOLPE JJ, 1989, ANN NEUROL, V25, P3, DOI 10.1002/ana.410250103; WARE J, 1990, PEDIATRICS, V85, P1103; WRIGHT S, 1960, BIOMETRICS, V16, P189, DOI 10.2307/2527551	35	427	438	3	41	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 21	1994	272	11					853	858		10.1001/jama.272.11.853	http://dx.doi.org/10.1001/jama.272.11.853			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PG182	8078162				2023-01-03	WOS:A1994PG18200023
J	ANNAS, GJ				ANNAS, GJ			ASKING THE COURTS TO SET THE STANDARD OF EMERGENCY CARE - THE CASE OF BABY-K	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material														Annas, George/0000-0001-5836-7831				Annas GJ, 1988, JUDGING MED; ELIAS S, 1987, REPRODUCTIVE GENETIC; INGELFINGER FJ, 1975, NEW ENGL J MED, V293, P825, DOI 10.1056/NEJM197510162931610; KRUSHE H, 1985, SHOULD BABY LIVE; MILES SH, 1991, NEW ENGL J MED, V325, P512, DOI 10.1056/NEJM199108153250713; PARIS JJ, 1993, NEW ENGL J MED, V329, P354, DOI 10.1056/NEJM199307293290512; 1984, FED REGISTER, V49, P1621; 1985, FED REGISTER, V50, P1488; 1990, NEW ENGL J MED, V322, P669	9	72	72	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 26	1994	330	21					1542	1545		10.1056/NEJM199405263302120	http://dx.doi.org/10.1056/NEJM199405263302120			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM068	8164726	Green Published			2023-01-03	WOS:A1994NM06800036
J	GENT, AE; HELLIER, MD; GRACE, RH; SWARBRICK, ET; COGGON, D				GENT, AE; HELLIER, MD; GRACE, RH; SWARBRICK, ET; COGGON, D			INFLAMMATORY BOWEL-DISEASE AND DOMESTIC HYGIENE IN INFANCY	LANCET			English	Note							ULCERATIVE-COLITIS; CROHNS-DISEASE; CHILDREN	To test the hypothesis that Crohn's disease is caused by delayed exposure to enteric infections, we did a case-control study. We compared 133 patients who have Crohn's disease and 231 with ulcerative colitis who have controls selected from the general population and matched for age and sex. Crohn's disease was more common in subjects whose first houses had a hot-water tap (odds ratio 5.0, 95% CI 1.4-17.3) and separate bathroom (3.3, 1.3-8.3). Ulcerative colitis showed no clear relation to household amenities in infancy. These findings may explain why the incidence of Crohn's disease has increased in developed countries over the past 50 years.	PRINCES MARGARET HOSP,SWINDON,WILTS,ENGLAND; NEW CROSS HOSP,WOLVERHAMPTON,ENGLAND; UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON S09 4XY,ENGLAND	New Cross Hospital; University of Southampton	GENT, AE (corresponding author), SALISBURY DIST HOSP,SALISBURY SP2 8BJ,WILTS,ENGLAND.							BARKER DJP, 1988, BMJ-BRIT MED J, V296, P956, DOI 10.1136/bmj.296.6627.956; BARTON JR, 1989, GUT, V30, P618, DOI 10.1136/gut.30.5.618; Breslow N, 1980, STAT METHODS CANC RE, P248; CALKINS BM, 1984, DIGEST DIS SCI, V29, P913, DOI 10.1007/BF01312480; GILAT T, 1987, SCAND J GASTROENTERO, V22, P1009, DOI 10.3109/00365528708991950; LANGMAN MJS, 1983, INFLAMM BOWEL DIS, P17; RUTGEERTS P, 1993, GASTROENTEROLOGY, V104, pA772; 1966, CLASSIFICATION OCCUP	8	293	299	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 26	1994	343	8900					766	767		10.1016/S0140-6736(94)91841-4	http://dx.doi.org/10.1016/S0140-6736(94)91841-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC351	7907734				2023-01-03	WOS:A1994NC35100013
J	HAIDER, R; KHAN, AKA; ROY, SK; DEWAN, N; ALAM, AN; MAHALANABIS, D				HAIDER, R; KHAN, AKA; ROY, SK; DEWAN, N; ALAM, AN; MAHALANABIS, D			MANAGEMENT OF ACUTE DIARRHEA IN DIABETIC-PATIENTS USING ORAL REHYDRATION SOLUTIONS CONTAINING GLUCOSE, RICE, OR GLYCINE	BRITISH MEDICAL JOURNAL			English	Article								Objective-To assess the risk of hyperglycaemia with two standard oral rehydration solutions that contain carbohydrate compared with a carbohydrate free solution during rehydration of diabetic patients with acute diarrhoea. Design-Prospective randomised allocation to one of three oral rehydration solutions (World Health Organisation (glucose), rice, or glycine) groups after admission to hospital with acute diarrhoea. Setting-Dhaka hospital of the International Centre for Diarrhoeal Disease Research, Bangladesh. Subjects-45 diabetic patients aged between 15 and 60 who had had diarrhoea for fewer than three days on admission. Main outcome measures-Fluctuation of blood glucose concentrations measured three times a day, daily stool output, and time taken for recovery from diarrhoea. Results-There were no significant differences in blood glucose concentrations, stool output, and duration of recovery from diarrhoea among the three groups. Conclusions-Oral rehydration solutions containing glucose, rice powder, or glycine can be safely administered to diabetic patients with acute diarrhoea and some dehydration.			HAIDER, R (corresponding author), INT CTR DIARRHOEAL DIS RES,GPO BOX 128,DHAKA 1000,BANGLADESH.							MOLLA AM, 1985, B WORLD HEALTH ORGAN, V63, P751; NALIN D R, 1987, Journal of Diarrhoeal Diseases Research, V5, P283; 1984, PROGRAMME CONTROL DI, P25; 1985, WHO TECH REP SER, P727	4	3	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 5	1994	308	6929					624	626		10.1136/bmj.308.6929.624	http://dx.doi.org/10.1136/bmj.308.6929.624			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MZ698	8148710	Green Published			2023-01-03	WOS:A1994MZ69800020
J	DEFIJTER, CWH; OE, LP; NAUTA, JJP; VANDERMEULEN, J; VERBRUGH, HA; VERHOEF, J; DONKER, AJM				DEFIJTER, CWH; OE, LP; NAUTA, JJP; VANDERMEULEN, J; VERBRUGH, HA; VERHOEF, J; DONKER, AJM			CLINICAL EFFICACY AND MORBIDITY ASSOCIATED WITH CONTINUOUS CYCLIC COMPARED WITH CONTINUOUS AMBULATORY PERITONEAL-DIALYSIS	ANNALS OF INTERNAL MEDICINE			English	Article						PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; PERITONEAL DIALYSIS, CONTINUOUS CYCLIC; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; PERITONITIS	CAPD; HEMODIALYSIS; EXPERIENCE; MULTICENTER; PATIENT; RATES; CCPD	Objective: To assess the clinical efficacy and morbidity of continuous cyclic peritoneal dialysis compared with continuous ambulatory peritoneal dialysis with a Y-connector as renal replacement therapy. Design: Prospective, randomized study. Setting: University hospital. Patients: All new patients with end-stage renal failure consecutively entering the dialysis program from January 1988 through July 1991 were randomly assigned to receive continuous ambulatory peritoneal dialysis with a Y-connector or continuous cyclic peritoneal dialysis and were followed prospectively. Measurements: Patient and technique survival, dialysis adequacy, and (infectious) morbidity. Results: Forty-one patients (median age, 56 years; range, 18 to 86 years) started continuous ambulatory peritoneal dialysis with a Y-connector (follow-up, 688 patient-months), and 41 patients (median age, 54 years; range 21 to 76 years) started continuous cyclic peritoneal dialysis (follow-up, 723 patient-months). The two groups showed no significant differences in adequacy of dialysis (as assessed by blood pressure control and laboratory and neurologic variables) and patient or technique survival. Renal transplant was the primary reason for discontinuing the assigned dialysis technique in both groups. The average number of hospitalizations per patient-year was 1.0 using continuous ambulatory peritoneal dialysis with a Y-connector and 0.6 per patient-year using continuous cyclic peritoneal dialysis (P = 0.02), with a mean duration of 10.8 and 9.6 days per admission, respectively (not significant). Peritonitis occurred significantly less often in those receiving continuous cyclic peritoneal dialysis (0.94 compared with 0.51 episodes per patient-year; P = 0.03). No difference in causative pathogens was observed. Exit site infection rate was 0.38 episodes per patient-year in both groups. Conclusion: In an unselected patient group, continuous cyclic peritoneal dialysis was accompanied by significantly lower rates of peritonitis and dialysis-related hospital admission, whereas it was as effective as continuous ambulatory peritoneal dialysis with a Y-connector for patient and technique survival.	STATE UNIV UTRECHT HOSP,DEPT MICROBIOL,3584 CK UTRECHT,NETHERLANDS	Utrecht University; Utrecht University Medical Center	DEFIJTER, CWH (corresponding author), FREE UNIV AMSTERDAM HOSP,DEPT INTERNAL MED,DIV NEPHROL,POB 7057,1007 MB AMSTERDAM,NETHERLANDS.							ABRAHAM G, 1988, PERITON DIALYSIS INT, V8, P211; [Anonymous], 1989, PERIT DIAL INT, V9, P159; BOEN ST, 1962, ASAIO T, V8, P256; BRESLOW N, 1970, BIOMETRIKA, V57, P579, DOI 10.1093/biomet/57.3.579; BUNCHMAN TE, 1987, PERITON DIALYSIS INT, V7, P237; Cavoretto C A, 1983, Nephrol Nurse, V5, P33; DEFIJTER CWH, 1992, KIDNEY INT, V42, P947, DOI 10.1038/ki.1992.371; DIAZBUXO JA, 1989, PERITON DIALYSIS INT, V9, P9; DIAZBUXO JA, 1981, ARTIF ORGANS, V5, P157, DOI 10.1111/j.1525-1594.1981.tb03978.x; DIAZBUXO JA, 1985, KIDNEY INT       S17, V28, pS26; DOMOTO DT, 1989, ADV PERIT D, V5, P212; DUNN OJ, 1974, APPLIED STATISTICS A, P236; GOKAL R, 1989, J NEPHROL, V2, P95; HOLLEY JL, 1990, AM J KIDNEY DIS, V16, P133, DOI 10.1016/S0272-6386(12)80567-1; HOWARD RL, 1990, AM J KIDNEY DIS, V16, P469, DOI 10.1016/S0272-6386(12)80061-8; HUME R, 1971, J CLIN PATHOL, V24, P234, DOI 10.1136/jcp.24.3.234; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KESHAVIAH PR, 1989, PERITON DIALYSIS INT, V9, P257; KREDIET RT, 1990, NETH J MED, V37, P215; LEVY M, 1990, PERITON DIALYSIS INT, V10, P263; LITTLE JA, 1987, STATISTICAL ANAL MIS, P195; LUPO A, 1988, ADV CONTINUOUS AMBUL, V4, P101; LUZAR MA, 1989, PERITON DIALYSIS INT, V9, P169; MAIORCA R, 1991, PERITON DIALYSIS INT, V11, P118; MAIORCA R, 1983, LANCET, V2, P642; MATTERN WD, 1988, CLIN NEPHROL, V30, pS49; NOLPH KD, 1991, AM J KIDNEY DIS, V17, P154, DOI 10.1016/S0272-6386(12)81121-8; NOLPH KD, 1988, DIALYSIS TRANSPLANT, V17, P457; OREOPOULOS DG, 1986, PERITON DIALYSIS B, V6, P2; POPOVICH RP, 1976, ABSTR AM SOC ART INT, V5, P64; PORT FK, 1992, KIDNEY INT, V42, P967, DOI 10.1038/ki.1992.375; PRICE CG, 1981, AM J NEPHROL, V1, P97, DOI 10.1159/000166501; ROCCO MV, 1985, PERITON DIALYSIS B, V5, P171; Rottembourg J, 1987, ADV CONTINUOUS AMBUL, P107; SCALAMOGNA A, 1990, NEPHRON, V55, P24, DOI 10.1159/000185913; SERKES KD, 1990, PERITON DIALYSIS INT, V10, P15; STRAUSS FG, 1991, ADV PERIT D, V7, P193; Suki W N, 1986, ASAIO Trans, V32, P572, DOI 10.1097/00002480-198609000-00041; VERGER C, 1987, PERIT DIAL B S, V7, pS82; VIGLINO G, 1989, PERITON DIALYSIS INT, V9, P165; WALLS J, 1981, ADV PERITONEAL DIALY, P141	41	100	104	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572	0003-4819			ANN INTERN MED	Ann. Intern. Med.	FEB 15	1994	120	4					264	271		10.7326/0003-4819-120-4-199402150-00002	http://dx.doi.org/10.7326/0003-4819-120-4-199402150-00002			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW103	8291819				2023-01-03	WOS:A1994MW10300002
J	PRITCHARD, KI				PRITCHARD, KI			ADJUVANT SYSTEMIC THERAPY FOR BREAST-CANCER - A TALE OF RELAPSE AND SURVIVAL	LANCET			English	Editorial Material							TRIAL				PRITCHARD, KI (corresponding author), UNIV TORONTO,DEPT MED,TORONTO,ON,CANADA.		Pritchard, Kathleen I/I-2184-2014	Pritchard, Kathleen I/0000-0003-0758-9666				BONADONNA G, 1980, DIAGNOSIS THERAPY BR, P727; Cuzick J, 1988, Recent Results Cancer Res, V111, P108; Early Breast Cancer Trialists' Collaborative Group, 1992, LANCET, V339, P1; FISHER B, 1986, J CLIN ONCOL, V4, P929, DOI 10.1200/JCO.1986.4.6.929; MCDONALD CC, 1991, BRIT MED J, V303, P435, DOI 10.1136/bmj.303.6800.435; MORRISON JM, 1989, BRIT J CANCER, V60, P911, DOI 10.1038/bjc.1989.389; PRITCHARD KI, 1987, ADJUVANT THERAPY CAN, P391; ROSE C, 1985, LANCET, V1, P16; 1992, LANCET, V339, P71	9	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 12	1994	343	8894					370	371		10.1016/S0140-6736(94)91217-3	http://dx.doi.org/10.1016/S0140-6736(94)91217-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW283	7905546				2023-01-03	WOS:A1994MW28300003
J	ROBINSON, R				ROBINSON, R			ECONOMIC-EVALUATION AND HEALTH-CARE - COST-EFFECTIVENESS ANALYSIS	BRITISH MEDICAL JOURNAL			English	Article							PREVENTION; DISEASE	When different health care interventions are not expected to produce the same outcomes both the costs and the consequences of the options need to be assessed. This can be done by cost-effectiveness analysis, whereby the costs are compared with outcomes measured in natural units-for example, per life saved, per life year gained, and per pain or symptom free day. Many cost-effective analyses rely on existing published studies for effectiveness data as it is often too costly or time consuming to collect data on cost and effectiveness during a clinical trial. Where there is uncertainty about the costs and effectiveness of procedures sensitivity analysis can be used, which examines the sensitivity of the results to alternative assumptions about key variables. In this article Ray Robinson describes these methods of analysis and discusses possibilities for how the benefits of alternative interventions should be valued.			ROBINSON, R (corresponding author), UNIV SOUTHAMPTON,INST HLTH POLICY STUDIES,SOUTHAMPTON SO9 5NH,HANTS,ENGLAND.							BOYLE MH, 1983, NEW ENGL J MED, V308, P1330, DOI 10.1056/NEJM198306023082206; BRIGGS A, 1993, JAN JOINT M HLTH EC; Cairns J, 1992, Health Econ, V1, P76, DOI 10.1002/hec.4730010111; CHURCHILL DN, 1984, MED DECIS MAKING, V4, P489, DOI 10.1177/0272989X8400400411; CULYER AJ, 1981, SOC SCI MED-MED ECON, V15, P3, DOI 10.1016/0160-7995(81)90003-4; CULYER AJ, 1982, RESOURCES HLTH TECHN; Drummond MF, 1987, METHOD EC EVALUATION; HULL R, 1981, NEW ENGL J MED, V304, P1561, DOI 10.1056/NEJM198106253042602; LUDBROOK A, 1981, APPL ECON, V13, P337, DOI 10.1080/00036848100000004; MAGID D, 1992, NEW ENGL J MED, V327, P534, DOI 10.1056/NEJM199208203270806; MANDELBLATT JS, 1988, JAMA-J AM MED ASSOC, V259, P2409, DOI 10.1001/jama.259.16.2409; OSTER G, 1987, JAMA-J AM MED ASSOC, V258, P2381, DOI 10.1001/jama.258.17.2381; Parsonage M, 1992, Health Econ, V1, P71, DOI 10.1002/hec.4730010110; Percival S P, 1992, Qual Health Care, V1, P38, DOI 10.1136/qshc.1.1.38; SCULPHER MJ, 1993, BRIT J OBSTET GYNAEC, V100, P244, DOI 10.1111/j.1471-0528.1993.tb15238.x; SINTONEN H, 1990, J HEALTH ECON, V9, P85, DOI 10.1016/0167-6296(90)90042-2; SUDRE P, 1992, INT J EPIDEMIOL, V21, P146, DOI 10.1093/ije/21.1.146; UDVARHELYI IS, 1992, ANN INTERN MED, V116, P238, DOI 10.7326/0003-4819-116-3-238	18	125	132	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 25	1993	307	6907					793	795		10.1136/bmj.307.6907.793	http://dx.doi.org/10.1136/bmj.307.6907.793			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LZ478	8219957	Green Published, Bronze			2023-01-03	WOS:A1993LZ47800036
J	SOUTHALL, DP; CRONIN, BC; HARTMANN, H; HARRISONSEWELL, C; SAMUELS, MP				SOUTHALL, DP; CRONIN, BC; HARTMANN, H; HARRISONSEWELL, C; SAMUELS, MP			INVASIVE PROCEDURES IN CHILDREN RECEIVING INTENSIVE-CARE	BRITISH MEDICAL JOURNAL			English	Article							PAIN				SOUTHALL, DP (corresponding author), N STAFFORDSHIRE HOSP,ACAD DEPT PAEDIAT,STOKE ON TRENT ST4 6QG,STAFFS,ENGLAND.							ANAND KJS, 1992, NEW ENGL J MED, V326, P1, DOI 10.1056/NEJM199201023260101; ANAND KJS, 1987, NEW ENGL J MED, V317, P1321, DOI 10.1056/NEJM198711193172105; HARPIN VA, 1983, ARCH DIS CHILD, V58, P226, DOI 10.1136/adc.58.3.226; McGrath PJ., 1987, PAIN CHILDREN ADOLES; TOHILL J, 1990, LANCET, V336, P569, DOI 10.1016/0140-6736(90)92127-4	5	25	25	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 5	1993	306	6891					1512	1513		10.1136/bmj.306.6891.1512-a	http://dx.doi.org/10.1136/bmj.306.6891.1512-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF940	8518680	Green Published, Bronze			2023-01-03	WOS:A1993LF94000026
J	VANDERHULST, RRWJ; VANKREEL, BK; VONMEYENFELDT, MF; BRUMMER, RJM; ARENDS, JW; DEUTZ, NEP; SOETERS, PB				VANDERHULST, RRWJ; VANKREEL, BK; VONMEYENFELDT, MF; BRUMMER, RJM; ARENDS, JW; DEUTZ, NEP; SOETERS, PB			GLUTAMINE AND THE PRESERVATION OF GUT INTEGRITY	LANCET			English	Article							NITROGEN-BALANCE; PERMEABILITY; SURGERY; MUSCLE; FALL	Parenteral glutamine dipeptide improves nitrogen balance in postoperative patients on total parenteral nutrition (TPM). Animal studies show that the structure and function of the gut is preserved by glutamine. It is not known if this is the case in human beings. 20 patients admitted to hospital for total parenteral nutrition were randomly allocated to receive parenteral nutrition enriched with glycyl-L-glutamine (Gln TPN), or standard parenteral nutrition (STPN). Mucosal biopsy specimens were taken from the second part of the duodenum before starting parenteral nutrition, and after two weeks. The ratio between the urine concentrations of lactulose and mannitol after enteral administration was used to measure intestinal permeability. After two weeks of parenteral nutrition in the GlnTPN group, intestinal permeability was unchanged, whereas permeability in the STPN group increased. Villus height was unaltered in the GlnTPN group but in the STPN group it decreased. The addition of glutamine to parenteral nutrition prevents deterioration of gut permeability and preserves mucosal structure.	ACAD ZIEKENHUIS,DEPT GASTROENTEROL,6202 AZ MAASTRICHT,NETHERLANDS; ACAD ZIEKENHUIS,DEPT PATHOL,6202 AZ MAASTRICHT,NETHERLANDS; ACAD ZIEKENHUIS,DEPT CLIN CHEM,6202 AZ MAASTRICHT,NETHERLANDS	Maastricht University; Maastricht University; Maastricht University	VANDERHULST, RRWJ (corresponding author), ACAD ZIEKENHUIS,DEPT SURG,POB 5800,6202 AZ MAASTRICHT,NETHERLANDS.		Deutz, Nicolaas E/J-5200-2012; Brummer, Robert JM/A-3137-2009	Brummer, Robert JM/0000-0002-0362-0008; Deutz, Nicolaas/0000-0001-5845-6447				ADIBI SA, 1987, DIPEPTIDES NEW SUBST; EBERTS TJ, 1979, CLIN CHEM, V25, P1440; EPSTEIN MD, 1991, ARCH SURG-CHICAGO, V126, P198; HAMMARQVIST F, 1989, ANN SURG, V209, P455, DOI 10.1097/00000658-198904000-00011; HOLLANDER D, 1992, SCAND J GASTROENTERO, V27, P721, DOI 10.3109/00365529209011172; LO CW, 1989, NUTR REV, V47, P193, DOI 10.1111/j.1753-4887.1989.tb02837.x; MENZIES IS, 1979, LANCET, V2, P1107; SHIPPEE RL, 1992, CLIN CHEM, V38, P343; SOUBA WW, 1990, J SURG RES, V48, P383, DOI 10.1016/0022-4804(90)90080-L; STEHLE P, 1989, LANCET, V1, P231; TAMADA H, 1992, JPEN-PARENTER ENTER, V16, P110, DOI 10.1177/0148607192016002110; VANEIJK HMH, 1988, CLIN CHEM, V34, P2510; WALSER M, 1991, AM J CLIN NUTR, V53, P1337, DOI 10.1093/ajcn/53.6.1337; WILMORE DW, 1988, SURGERY, V104, P917; ZIEGLER TR, 1992, ANN INTERN MED, V116, P821, DOI 10.7326/0003-4819-116-10-821	15	470	483	1	21	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 29	1993	341	8857					1363	1365		10.1016/0140-6736(93)90939-E	http://dx.doi.org/10.1016/0140-6736(93)90939-E			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE180	8098788				2023-01-03	WOS:A1993LE18000002
J	LANZAVECCHIA, A				LANZAVECCHIA, A			IDENTIFYING STRATEGIES FOR IMMUNE INTERVENTION	SCIENCE			English	Article							MHC CLASS-II; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; HUMAN-IMMUNODEFICIENCY-VIRUS; MYELIN BASIC-PROTEIN; TOXIC LYMPHOCYTES-T; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; ANTIGEN-PRESENTING CELL; LISTERIA-MONOCYTOGENES; MONOCLONAL-ANTIBODIES; SURFACE-ANTIGEN	In recent years the molecular basis of antigen recognition by T cells has been unraveled and the various pathways that control T cell activation and functional specialization have been defined. Consequently, it is now possible to delineate various strategies for intervention with the immune system to design protective vaccines, to induce an effective response to tumor antigens, and to control graft rejection and autoimmune diseases.			LANZAVECCHIA, A (corresponding author), BASEL INST IMMUNOL, CH-4005 BASEL, SWITZERLAND.							ABRIGNANI S, 1990, P NATL ACAD SCI USA, V87, P6136, DOI 10.1073/pnas.87.16.6136; ACHAORBEA H, 1988, CELL, V54, P263, DOI 10.1016/0092-8674(88)90558-2; AICHELE P, 1990, J EXP MED, V171, P1815, DOI 10.1084/jem.171.5.1815; BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BARNABA V, 1990, NATURE, V345, P258, DOI 10.1038/345258a0; BARON JL, 1993, J EXP MED, V177, P57, DOI 10.1084/jem.177.1.57; BENJAMIN RJ, 1986, J EXP MED, V163, P1539, DOI 10.1084/jem.163.6.1539; BERG J, 1991, P NATL ACAD SCI USA, V88, P4723, DOI 10.1073/pnas.88.11.4723; BEVAN MJ, 1987, NATURE, V325, P192, DOI 10.1038/325192b0; BEVAN MJ, 1976, J EXP MED, V143, P1283, DOI 10.1084/jem.143.5.1283; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BLOOM BR, 1992, ANNU REV IMMUNOL, V10, P453, DOI 10.1146/annurev.iy.10.040192.002321; BLOOM BR, 1992, IMMUNOL TODAY, V13, P131, DOI 10.1016/0167-5699(92)90110-S; BOSCO M, 1990, J IMMUNOL, V145, P3136; BRETSCHER P, 1970, SCIENCE, V169, P1042, DOI 10.1126/science.169.3950.1042; BRETSCHER PA, 1992, SCIENCE, V257, P539, DOI 10.1126/science.1636090; BRETT SJ, 1988, J EXP MED, V168, P357, DOI 10.1084/jem.168.1.357; BROCKER A, IN PRESS EUR J IMMUN; BRUNT LM, 1990, J IMMUNOL, V145, P3540; BURSTEIN HJ, 1993, J EXP MED, V177, P457, DOI 10.1084/jem.177.2.457; BURSTEIN HJ, 1992, J IMMUNOL, V148, P3687; BUUS S, 1987, SCIENCE, V235, P1353, DOI 10.1126/science.2435001; CAPRA JD, 1993, IMMUNOLOGIST, V1, P16; CARAYANNIOTIS G, 1991, MOL IMMUNOL, V28, P261, DOI 10.1016/0161-5890(91)90072-R; CARBONE FR, 1989, J EXP MED, V169, P603, DOI 10.1084/jem.169.3.603; CARBONE FR, 1990, J EXP MED, V171, P377, DOI 10.1084/jem.171.2.377; CARDING SR, 1993, J EXP MED, V177, P475, DOI 10.1084/jem.177.2.475; CARMAN W, 1993, LANCET, V341, P349, DOI 10.1016/0140-6736(93)90146-8; CELIS E, 1984, SCIENCE, V224, P297, DOI 10.1126/science.6231724; CHEN LP, 1992, CELL, V71, P1093, DOI 10.1016/S0092-8674(05)80059-5; CLAYTON JP, 1989, J EXP MED, V169, P1681, DOI 10.1084/jem.169.5.1681; CLERICI M, 1993, IMMUNOL TODAY, V14, P107, DOI 10.1016/0167-5699(93)90208-3; COHEN IR, 1989, COLD SPRING HARB SYM, V54, P879; DAMLE NK, 1992, J IMMUNOL, V148, P1985; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DAY MJ, 1992, J EXP MED, V175, P655, DOI 10.1084/jem.175.3.655; DEBRUIJN MLH, 1991, EUR J IMMUNOL, V21, P2963, DOI 10.1002/eji.1830211210; DELVAL M, 1991, CELL, V66, P1145, DOI 10.1016/0092-8674(91)90037-Y; DEMAGISTRIS MT, 1992, CELL, V68, P625, DOI 10.1016/0092-8674(92)90139-4; DEMOTZ S, 1993, EUR J IMMUNOL, V23, P425, DOI 10.1002/eji.1830230219; DERES K, 1989, NATURE, V342, P561, DOI 10.1038/342561a0; DEWIT D, 1992, J EXP MED, V175, P9, DOI 10.1084/jem.175.1.9; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; ESHHAR Z, 1993, P NATL ACAD SCI USA, V90, P720, DOI 10.1073/pnas.90.2.720; EVAVOLD BD, 1991, SCIENCE, V252, P1308, DOI 10.1126/science.1833816; EYNON EE, 1992, J EXP MED, V175, P131, DOI 10.1084/jem.175.1.131; FEARON ER, 1990, CELL, V60, P397, DOI 10.1016/0092-8674(90)90591-2; FINK PJ, 1988, ANNU REV IMMUNOL, V6, P115; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.immunol.8.1.303; FIORENTINO DF, 1991, J IMMUNOL, V146, P3444; FORNI G, 1985, J IMMUNOL, V134, P1305; FRANCO A, 1992, J EXP MED, V175, P1195, DOI 10.1084/jem.175.5.1195; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; FUCHS EJ, 1992, SCIENCE, V258, P1156, DOI 10.1126/science.1439825; GAJEWSKI TF, 1991, J IMMUNOL, V146, P1750; GAMMON G, 1986, NATURE, V319, P413, DOI 10.1038/319413a0; GANSBACHER B, 1990, J EXP MED, V172, P1217, DOI 10.1084/jem.172.4.1217; GAUR A, 1992, SCIENCE, V258, P1491, DOI 10.1126/science.1279812; GAUR A, 1993, SCIENCE, V259, P91, DOI 10.1126/science.8418501; GAUTAM AM, 1992, J IMMUNOL, V148, P3049; GEORGE AJT, 1988, J IMMUNOL, V141, P2168; GOLUMBEK PT, 1991, SCIENCE, V254, P713, DOI 10.1126/science.1948050; GUERDER S, 1989, COLD SPRING HARB SYM, V54, P799; HAMMER J, 1992, J EXP MED, V176, P1007, DOI 10.1084/jem.176.4.1007; HERMAN A, 1991, ANNU REV IMMUNOL, V9, P745, DOI 10.1146/annurev.iy.09.040191.003525; HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0; HOWELL MD, 1989, SCIENCE, V246, P668, DOI 10.1126/science.2814489; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; HUTCHINGS P, 1992, EUR J IMMUNOL, V22, P1913, DOI 10.1002/eji.1830220735; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; ISOBE M, 1992, SCIENCE, V255, P1125, DOI 10.1126/science.1347662; ITAYA T, 1987, CANCER RES, V47, P3136; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; JIN Y, 1988, J EXP MED, V168, P293, DOI 10.1084/jem.168.1.293; JORGENSEN T, 1980, SCAND J IMMUNOL, V11, P29, DOI 10.1111/j.1365-3083.1980.tb00205.x; KAST WM, 1991, P NATL ACAD SCI USA, V88, P2283, DOI 10.1073/pnas.88.6.2283; KAST WM, 1989, CELL, V59, P603, DOI 10.1016/0092-8674(89)90006-8; KAUFMANN SHE, 1988, J IMMUNOL, V140, P3173; KAUFMANN SHE, 1993, ANNU REV IMMUNOL, V11, P129, DOI 10.1146/annurev.immunol.11.1.129; KAWAMURA H, 1986, J IMMUNOL, V136, P58; KEENE JA, 1982, J EXP MED, V155, P768, DOI 10.1084/jem.155.3.768; KENNEY JS, 1989, J IMMUNOL METHODS, V121, P157, DOI 10.1016/0022-1759(89)90156-7; KHOURI SJ, 1991, J EXP MED, V174, P1355; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; KRUSKALL MS, 1992, J EXP MED, V175, P495, DOI 10.1084/jem.175.2.495; KWAK LW, 1992, NEW ENGL J MED, V327, P1209, DOI 10.1056/NEJM199210223271705; LAFFERTY KJ, 1983, ANNU REV IMMUNOL, V1, P143, DOI 10.1146/annurev.iy.01.040183.001043; LAKE P, 1976, IMMUNOL COMMUN, V5, P795, DOI 10.3109/08820137609047620; LAMONT AG, 1990, J IMMUNOL, V145, P1687; LANE P, COMMUNICATION; LANZAVECCHIA A, 1992, NATURE, V357, P249, DOI 10.1038/357249a0; LANZAVECCHIA A, 1990, ANNU REV IMMUNOL, V8, P773, DOI 10.1146/annurev.immunol.8.1.773; LANZAVECCHIA A, 1988, J EXP MED, V167, P345, DOI 10.1084/jem.167.2.345; LEBMAN DA, 1990, J IMMUNOL, V144, P952; LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; LINSLEY PS, 1992, SCIENCE, V257, P792, DOI 10.1126/science.1496399; LIU Y, 1992, J EXP MED, V175, P437, DOI 10.1084/jem.175.2.437; LOCKSLEY RM, 1991, IMMUNOPARASITOLOGY T; MACATONIA SE, 1989, J EXP MED, V169, P1255, DOI 10.1084/jem.169.4.1255; MALEFYT RD, 1991, J EXP MED, V174, P915; MANCA F, 1991, J EXP MED, V173, P37, DOI 10.1084/jem.173.1.37; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; MARGOLIN KA, 1989, J CLIN ONCOL, V7, P486, DOI 10.1200/JCO.1989.7.4.486; MELIEF CJM, 1992, ADV CANCER RES, V58, P143, DOI 10.1016/S0065-230X(08)60294-8; MILLER A, 1991, J EXP MED, V174, P791, DOI 10.1084/jem.174.4.791; MILLER RG, 1980, NATURE, V287, P544, DOI 10.1038/287544a0; MITCHISON NA, 1964, PROC R SOC SER B-BIO, V161, P275, DOI 10.1098/rspb.1964.0093; MOREIN B, 1988, NATURE, V332, P287, DOI 10.1038/332287a0; MOSKOPHIDIS D, 1993, NATURE, V362, P758, DOI 10.1038/362758a0; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; MOSS B, 1991, SCIENCE, V252, P1662, DOI 10.1126/science.2047875; MULLER I, 1989, EUR J IMMUNOL, V19, P865, DOI 10.1002/eji.1830190513; NAIR S, 1992, J EXP MED, V175, P609, DOI 10.1084/jem.175.2.609; NEEFJES JJ, 1993, CURR OPIN IMMUNOL, V5, P27, DOI 10.1016/0952-7915(93)90077-6; OFFNER H, 1991, SCIENCE, V251, P430, DOI 10.1126/science.1989076; OKI A, 1985, J EXP MED, V161, P897, DOI 10.1084/jem.161.5.897; OLDSTONE MBA, 1986, NATURE, V321, P239, DOI 10.1038/321239a0; OSULLIVAN D, 1991, J IMMUNOL, V147, P2663; PAMER EG, 1991, NATURE, V353, P852, DOI 10.1038/353852a0; PANINABORDIGNON P, 1989, EUR J IMMUNOL, V19, P2237, DOI 10.1002/eji.1830191209; PARDOLL D, 1992, CURR OPIN IMMUNOL, V4, P619, DOI 10.1016/0952-7915(92)90037-F; PARISH CR, 1972, TRANSPLANT REV-DENMA, V13, P35; PARKER CM, 1992, P NATL ACAD SCI USA, V89, P1924, DOI 10.1073/pnas.89.5.1924; PETERS M, 1991, HEPATOLOGY, V13, P977, DOI 10.1016/0270-9139(91)90273-X; PFEIFER JD, 1993, NATURE, V361, P359, DOI 10.1038/361359a0; PFEIFFER C, 1991, IMMUNOL REV, V123, P65, DOI 10.1111/j.1600-065X.1991.tb00606.x; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; PORTNOY DA, 1988, J EXP MED, V167, P1459, DOI 10.1084/jem.167.4.1459; QIN SX, 1989, J EXP MED, V169, P779, DOI 10.1084/jem.169.3.779; QIN SX, 1993, SCIENCE, V259, P974, DOI 10.1126/science.8094901; RACIOPPI L, 1993, J EXP MED, V177, P1047, DOI 10.1084/jem.177.4.1047; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAMMENSEE HG, 1993, CURR OPIN IMMUNOL, V5, P35, DOI 10.1016/0952-7915(93)90078-7; RAMMENSEE HG, 1989, NATURE, V339, P541, DOI 10.1038/339541a0; RAMMENSEE HG, 1991, BONE MARROW TRANSPL, V7, P26; REDDY R, 1991, J IMMUNOL METHODS, V141, P157, DOI 10.1016/0022-1759(91)90142-3; REININGER L, 1992, J EXP MED, V176, P1343, DOI 10.1084/jem.176.5.1343; RIA F, 1990, NATURE, V343, P381, DOI 10.1038/343381a0; RIDDELL SR, 1992, SCIENCE, V257, P238; ROCHA B, 1991, SCIENCE, V251, P1225, DOI 10.1126/science.1900951; ROMAGNANI S, 1992, IMMUNOL TODAY, V13, P379, DOI 10.1016/0167-5699(92)90083-J; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; ROOSNEK E, 1989, J EXP MED, V170, P297, DOI 10.1084/jem.170.1.297; ROSENBERG SA, 1988, NEW ENGL J MED, V319, P1676, DOI 10.1056/NEJM198812223192527; ROSENFELD MA, 1991, SCIENCE, V252, P431, DOI 10.1126/science.2017680; SADICK MD, 1990, J EXP MED, V171, P115, DOI 10.1084/jem.171.1.115; SAKAI K, 1988, P NATL ACAD SCI USA, V85, P8608, DOI 10.1073/pnas.85.22.8608; SALGAME PR, 1991, SCIENCE, V274, P259; SASAZUKI T, 1989, IMMUNOLOGY, P21; SCHERER MT, 1989, COLD SPRING HARB SYM, V54, P497; SCHONRICH G, 1992, INT IMMUNOL, V4, P581, DOI 10.1093/intimm/4.5.581; SCHONRICH G, 1991, CELL, V65, P293, DOI 10.1016/0092-8674(91)90163-S; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SEDER RA, 1992, J IMMUNOL, V148, P1652; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; SERCARZ E, 1991, IMMUNOL TODAY, V12, P111, DOI 10.1016/0167-5699(91)90094-A; SHIMONKEVITZ R, 1983, J EXP MED, V158, P303, DOI 10.1084/jem.158.2.303; SIBILLE C, 1990, J EXP MED, V172, P35, DOI 10.1084/jem.172.1.35; SINIGAGLIA F, 1988, NATURE, V336, P778, DOI 10.1038/336778a0; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; SOLOWAY P, 1991, J EXP MED, V174, P847, DOI 10.1084/jem.174.4.847; STAERZ UD, 1986, IMMUNOL TODAY, V7, P241, DOI 10.1016/0167-5699(86)90112-X; STEINMAN L, 1981, P NATL ACAD SCI-BIOL, V78, P7111, DOI 10.1073/pnas.78.11.7111; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; SWAIN SL, 1990, J IMMUNOL, V145, P3796; TAKAHASHI H, 1990, NATURE, V344, P873, DOI 10.1038/344873a0; TAN P, 1993, J EXP MED, V177, P165, DOI 10.1084/jem.177.1.165; TANG DC, 1992, NATURE, V356, P152, DOI 10.1038/356152a0; TEPPER RI, 1989, CELL, V57, P503, DOI 10.1016/0092-8674(89)90925-2; TEW JG, 1989, IMMUNOL TODAY, V10, P229, DOI 10.1016/0167-5699(89)90258-2; TODD JA, 1988, SCIENCE, V240, P1003, DOI 10.1126/science.3368786; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TOWNSEND ARM, 1984, CELL, V39, P13, DOI 10.1016/0092-8674(84)90187-9; TOWNSEND SE, 1993, SCIENCE, V259, P368, DOI 10.1126/science.7678351; TRAUNECKER A, 1991, EMBO J, V10, P3655, DOI 10.1002/j.1460-2075.1991.tb04932.x; TRAUNECKER A, 1991, TRENDS BIOTECHNOL, V9, P109, DOI 10.1016/0167-7799(91)90038-J; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; TRAVERSARI C, 1992, J EXP MED, V176, P1453, DOI 10.1084/jem.176.5.1453; TURKA LA, 1992, P NATL ACAD SCI USA, V89, P11102, DOI 10.1073/pnas.89.22.11102; Uhr J W, 1968, Adv Immunol, V8, P81, DOI 10.1016/S0065-2776(08)60465-4; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; URBAN JF, 1991, P NATL ACAD SCI USA, V88, P5513, DOI 10.1073/pnas.88.13.5513; VANBINNENDIJK RS, 1992, J EXP MED, V176, P119, DOI 10.1084/jem.176.1.119; VANDENBARK AA, 1989, NATURE, V341, P541, DOI 10.1038/341541a0; VANDENEYNDE B, 1991, J EXP MED, V173, P1373, DOI 10.1084/jem.173.6.1373; VANDERBRUGGEN P, 1992, CURR OPIN IMMUNOL, V4, P608, DOI 10.1016/0952-7915(92)90035-D; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; VANPEL A, 1982, P NATL ACAD SCI-BIOL, V79, P4718; VITETTA ES, 1989, ADV IMMUNOL, V45, P1, DOI 10.1016/S0065-2776(08)60692-6; WALDMANN TA, 1991, SCIENCE, V252, P1657, DOI 10.1126/science.2047874; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WATTS C, UNPUB; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEINER AJ, 1991, VIROLOGY, V180, P842, DOI 10.1016/0042-6822(91)90104-J; WEISS S, 1991, CELL, V64, P767, DOI 10.1016/0092-8674(91)90506-T; WIDMANN C, 1992, J IMMUNOL METHODS, V155, P95, DOI 10.1016/0022-1759(92)90275-X; WILBANKS GA, 1992, EUR J IMMUNOL, V22, P1031, DOI 10.1002/eji.1830220423; WILBANKS GA, 1992, EUR J IMMUNOL, V22, P165, DOI 10.1002/eji.1830220125; WRAITH DC, 1989, CELL, V59, P247, DOI 10.1016/0092-8674(89)90287-0; WUCHERPFENNIG KW, 1991, IMMUNOL TODAY, V12, P277, DOI 10.1016/0167-5699(91)90126-E; YANG L, 1992, CURR OPIN IMMUNOL, V4, P265, DOI 10.1016/0952-7915(92)90075-P; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0; ZALLER DM, 1990, J EXP MED, V171, P1943, DOI 10.1084/jem.171.6.1943	208	210	250	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 14	1993	260	5110					937	944		10.1126/science.8493532	http://dx.doi.org/10.1126/science.8493532			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LB791	8493532				2023-01-03	WOS:A1993LB79100034
J	DURACK, DT				DURACK, DT			DRUG-THERAPY - PREVENTION OF INFECTIVE ENDOCARDITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							EXPERIMENTAL STREPTOCOCCAL ENDOCARDITIS; EXPERIMENTAL BACTERIAL-ENDOCARDITIS; POST-EXTRACTION BACTEREMIA; AMERICAN-HEART-ASSOCIATION; MITRAL-VALVE PROLAPSE; ANTIBIOTIC-PROPHYLAXIS; VIRIDANS STREPTOCOCCI; DENTAL PROCEDURES; AMOXICILLIN PROPHYLAXIS; VANCOMYCIN PROPHYLAXIS				DURACK, DT (corresponding author), HLTHCARE INT MED CTR,DEPT MED,BEARDMORE ST,CLYDEBANK G81 4DY,SCOTLAND.							[Anonymous], 1982, Lancet, V2, P1323; BALTCH AL, 1988, ARCH INTERN MED, V148, P1084, DOI 10.1001/archinte.148.5.1084; BARCO CT, 1991, J PERIODONTOL, V62, P510, DOI 10.1902/jop.1991.62.8.510; BASKIN G, 1989, AM J GASTROENTEROL, V84, P311; BAYLISS R, 1983, BRIT HEART J, V50, P513, DOI 10.1136/hrt.50.6.513; Bender I B, 1989, Compendium, V10, P475; BENDER I. B., 1958, JOUR AMER DENTAL ASSOC, V57, P54; BENDER IB, 1984, J AM DENT ASSOC, V109, P415, DOI 10.14219/jada.archive.1984.0432; BERNARD JP, 1981, J CLIN INVEST, V68, P1113, DOI 10.1172/JCI110337; BERNEY P, 1990, J INFECT DIS, V161, P281; Bernstein M, 1932, ANN INTERN MED, V5, P1138, DOI 10.7326/0003-4819-5-9-1138; BOR DH, 1984, AM J MED, V767, P711; BROOKS RG, 1988, AM J MED, V84, P617, DOI 10.1016/0002-9343(88)90145-3; BROOKS SL, 1980, J AM DENT ASSOC, V101, P41, DOI 10.14219/jada.archive.1980.0361; Burket LW, 1937, J DENT RES, V16, P521; BUTT J, 1978, AM J ROENTGENOL, V130, P715, DOI 10.2214/ajr.130.4.715; CAMARA DS, 1983, ARCH INTERN MED, V143, P1350, DOI 10.1001/archinte.143.7.1350; CLEMENS JD, 1984, J CHRON DIS, V37, P531, DOI 10.1016/0021-9681(84)90004-3; DAJANI A S, 1991, Circulation, V83, P1174; DAJANI AS, 1990, JAMA-J AM MED ASSOC, V264, P2919, DOI 10.1001/jama.264.22.2919; DELAYE J, 1985, EUR HEART J, V6, P826, DOI 10.1093/oxfordjournals.eurheartj.a061767; DENNING DW, 1984, BRIT MED J, V289, P1499, DOI 10.1136/bmj.289.6457.1499; Durack D T, 1972, Trans Assoc Am Physicians, V85, P222; DURACK DT, 1975, J PATHOL, V115, P81, DOI 10.1002/path.1711150204; DURACK DT, 1975, BRIT HEART J, V37, P478; DURACK DT, 1973, J CLIN INVEST, V52, P592, DOI 10.1172/JCI107220; DURACK DT, 1985, AM J MED, V78, P149, DOI 10.1016/0002-9343(85)90377-8; DURACK DT, 1972, BRIT J EXP PATHOL, V53, P50; DURACK DT, 1983, JAMA-J AM MED ASSOC, V250, P2318, DOI 10.1001/jama.250.17.2318; DURACK DT, 1972, BRIT J EXP PATHOL, V53, P44; DURACK DT, 1973, BRIT J EXP PATHOL, V54, P142; DURACK DT, 1977, J LAB CLIN MED, V90, P171; DURACK DT, 1990, HEART, P1230; DURACK DT, 1990, PRINCIPLES PRACTICE, P716; DURACK DT, 1977, AM HEART ASS MONOGRA, V52, P28; ENG RHK, 1986, ANTIMICROB AGENTS CH, V29, P699, DOI 10.1128/AAC.29.4.699; EVERETT ED, 1977, MEDICINE, V56, P61; Feldman L, 1938, ANN INTERN MED, V11, P2124, DOI 10.7326/0003-4819-11-12-2124; FRANCIOLI P, 1985, J INFECT DIS, V152, P83, DOI 10.1093/infdis/152.1.83; FRANCIOLI P, 1985, J ANTIMICROB CHEMOTH, V15, P297, DOI 10.1093/jac/15.suppl_A.297; FRANCIOLI PB, 1979, INFECT IMMUN, V24, P483, DOI 10.1128/IAI.24.2.483-491.1979; GARRISON PK, 1970, YALE J BIOL MED, V42, P394; GLAUSER MP, 1983, J INFECT DIS, V147, P568, DOI 10.1093/infdis/147.3.568; GLAUSER MP, 1987, J ANTIMICROB CHEMOTH, V20, P87, DOI 10.1093/jac/20.suppl_A.87; GLAUSER MP, 1982, J INFECT DIS, V146, P806, DOI 10.1093/infdis/146.6.806; Green J G, 1988, Gen Dent, V36, P131; GUNTHEROTH WG, 1984, AM J CARDIOL, V54, P797, DOI 10.1016/S0002-9149(84)80211-8; GUTSCHIK E, 1990, SCAND J DENT RES, V98, P144; HARVEY WP, 1961, AM J CARDIOL, V7, P793, DOI 10.1016/0002-9149(61)90397-6; HESS J, 1983, J ANTIMICROB CHEMOTH, V11, P555, DOI 10.1093/jac/11.6.555; HOFFMAN BI, 1978, ANN INTERN MED, V88, P658, DOI 10.7326/0003-4819-88-5-658; HOLBROOK WP, 1987, J ANTIMICROB CHEMOTH, V20, P439, DOI 10.1093/jac/20.3.439; Horder TJ, 1909, Q J MED, V2, P289; HORSTKOTTE D, 1987, EUR HEART J, V8, P379, DOI 10.1093/eurheartj/8.suppl_J.379; IMPERIALE TF, 1990, AM J MED, V88, P131, DOI 10.1016/0002-9343(90)90461-L; IVERT TSA, 1984, CIRCULATION, V69, P223, DOI 10.1161/01.CIR.69.2.223; JOKINEN MA, 1978, INT J ORAL MAXILLOF, V7, P450, DOI 10.1016/S0300-9785(78)80036-2; KAYE D, 1991, ANN INTERN MED, V114, P803, DOI 10.7326/0003-4819-114-9-803; KHAIRAT O, 1966, J CLIN PATHOL, V19, P561, DOI 10.1136/jcp.19.6.561; KUNZEL C, 1989, J HEALTH SOC BEHAV, V30, P330, DOI 10.2307/2136964; LAVIE CJ, 1989, JAMA-J AM MED ASSOC, V262, P3308, DOI 10.1001/jama.262.23.3308; MACFARLANE TW, 1984, BRIT DENT J, V156, P179, DOI 10.1038/sj.bdj.4805302; MALINVERNI R, 1987, CIRCULATION, V76, P376, DOI 10.1161/01.CIR.76.2.376; MALINVERNI R, 1988, CIRCULATION, V77, P182, DOI 10.1161/01.CIR.77.1.182; MALINVERNI R, 1987, J INFECT DIS, V156, P151, DOI 10.1093/infdis/156.1.151; MOREILLON P, 1986, J INFECT DIS, V154, P801, DOI 10.1093/infdis/154.5.801; Murrah V A, 1987, J Dent Educ, V51, P229; Okell CC, 1935, LANCET, V2, P869; ORMISTON JA, 1981, AUST NZ J MED, V11, P620, DOI 10.1111/j.1445-5994.1981.tb03536.x; PARRILLO JE, 1979, NEW ENGL J MED, V300, P296, DOI 10.1056/NEJM197902083000608; POGREL MA, 1975, BRIT DENT J, V139, P12, DOI 10.1038/sj.bdj.4803485; RICHARDSON JV, 1978, CIRCULATION, V58, P589, DOI 10.1161/01.CIR.58.4.589; ROBERTS GJ, 1992, INT J CARDIOL, V35, P311, DOI 10.1016/0167-5273(92)90228-U; Rushton MA, 1930, GUYS HOSP REP, V10, P39; SACKETT DL, 1979, J CHRON DIS, V32, P51, DOI 10.1016/0021-9681(79)90012-2; SADOWSKY D, 1988, CIRCULATION, V77, P1316, DOI 10.1161/01.CIR.77.6.1316; SADOWSKY D, 1984, J AM DENT ASSOC, V109, P425, DOI 10.14219/jada.archive.1984.0402; SCHIRGER A, 1960, J LAB CLIN MED, V53, P376; SCOPP IW, 1971, J AM DENT ASSOC, V83, P1294, DOI 10.14219/jada.archive.1971.0463; SEAWORTH BJ, 1986, AM J OBSTET GYNECOL, V154, P180, DOI 10.1016/0002-9378(86)90422-9; SHULMAN ST, 1984, CIRCULATION, V70, P1123; SIMMONS NA, 1993, J ANTIMICROB CHEMOTH, V31, P437, DOI 10.1093/jac/31.3.437; SLAVIN S, 1979, ARCH SURG-CHICAGO, V114, P937; SMITH RH, 1976, THORAX, V31, P373, DOI 10.1136/thx.31.4.373; SOUTHWICK FS, 1974, J CLIN PATHOL, V27, P261, DOI 10.1136/jcp.27.4.261; STARKEBAUM M, 1977, YALE J BIOL MED, V50, P49; STECKELBERG JM, 1993, INFECT DIS CLIN N AM, V7, P9; TANDBERG D, 1978, JAMA-J AM MED ASSOC, V239, P1789; TORNOS MP, 1992, ANN INTERN MED, V117, P567, DOI 10.7326/0003-4819-117-7-567; VANDERMEER JTM, 1992, LANCET, V339, P135, DOI 10.1016/0140-6736(92)90207-J; VANDERMEER JTM, 1992, ARCH INTERN MED, V152, P1869, DOI 10.1001/archinte.152.9.1869; VANDERMEER JTM, 1992, J ANTIMICROB CHEMOTH, V29, P187, DOI 10.1093/jac/29.2.187; VANDERMEER JTM, 1992, ARCH INTERN MED, V152, P1863, DOI 10.1001/archinte.152.9.1863; VANDERMEER JTM, 1991, EUR J CLIN MICROBIOL, V10, P728; VLAY SC, 1990, AM HEART J, V120, P1490, DOI 10.1016/0002-8703(90)90288-9; VOORN GP, 1994, ANTIMICROB AGENTS CH, V38, P487, DOI 10.1128/AAC.38.3.487; Weiss H, 1934, ARCH INTERN MED, V54, P710, DOI 10.1001/archinte.1934.00160170053005; WITZENBERGER T, 1982, J PERIODONTOL, V53, P172, DOI 10.1902/jop.1982.53.3.172; YIN TP, 1983, ENDOSCOPY, V15, P27, DOI 10.1055/s-2007-1018601; 1989, MED LETT DRUG THER, V31, P112	100	283	292	3	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 5	1995	332	1					38	44		10.1056/NEJM199501053320107	http://dx.doi.org/10.1056/NEJM199501053320107			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PZ497	7990863				2023-01-03	WOS:A1995PZ49700007
J	CHIRUVOLU, S; WARRINER, HE; NARANJO, E; IDZIAK, SHJ; RADLER, JO; PLANO, RJ; ZASADZINSKI, JA; SAFINYA, CR				CHIRUVOLU, S; WARRINER, HE; NARANJO, E; IDZIAK, SHJ; RADLER, JO; PLANO, RJ; ZASADZINSKI, JA; SAFINYA, CR			A PHASE OF LIPOSOMES WITH ENTANGLED TUBULAR VESICLES	SCIENCE			English	Article							THERMAL FLUCTUATIONS; MEMBRANES; LECITHIN; TRANSITION; ADHESION; SYSTEM; L3	An equilibrium phase belonging to the family of bilayer liposomes in ternary mixtures of dimyristoylphosphatidylcholine (DMPC), water, and geraniol (a biological alcohol derived from oil-soluble vitamins that acts as a cosurfactant) has been identified. Electron and optical microscopy reveal the phase, labeled L(tv), to be composed of highly entangled tubular vesicles. In situ x-ray diffraction confirms that the tubule walls are multilamellar with the lipids in the chain-melted state. Macroscopic observations show that the L(tv) phase coexists with the well-known L(4) phase of spherical vesicles and a bulk L(alpha) phase. However, the defining characteristic oi the L(tv) phase is the Weissenberg rod climbing effect under shear, which results from its polymer-like entangled microstructure.	UNIV CALIF SANTA BARBARA, DEPT CHEM ENGN,MAT RES LAB, SANTA BARBARA, CA 93106 USA; UNIV CALIF SANTA BARBARA, DEPT MAT,MAT RES LAB, SANTA BARBARA, CA 93106 USA; UNIV CALIF SANTA BARBARA, DEPT PHYS, SANTA BARBARA, CA 93106 USA; UNIV CALIF SANTA BARBARA, BIOCHEM & MOLEC BIOL PROGRAM, SANTA BARBARA, CA 93106 USA; EXXON RES & ENGN CO, ANNANDALE, NJ 08801 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; Exxon Mobil Corporation			Rädler, Joachim/AAD-8747-2019	Rädler, Joachim/0000-0002-5846-1489	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047334] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47334] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1992, INTERMOLECULAR SURFA; Bangham A.D., 1973, METHODS MEMBR BIOL, V1, P1; BELLARE JR, 1988, J ELECTRON MICR TECH, V10, P87, DOI 10.1002/jemt.1060100111; Ben-Shaul A., 1994, MICELLES MEMBRANES M; Bird RB, 1977, DYNAMICS POLYM LIQUI, V1; CANTU L, 1990, EUROPHYS LETT, V13, P561, DOI 10.1209/0295-5075/13/6/015; CATES ME, 1990, J PHYS-CONDENS MAT, V2, P6869, DOI 10.1088/0953-8984/2/33/001; COULON C, 1991, PHYS REV LETT, V66, P1709, DOI 10.1103/PhysRevLett.66.1709; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P7132, DOI 10.1073/pnas.83.19.7132; HARBICH W, 1990, J PHYS-PARIS, V51, P1027, DOI 10.1051/jphys:0199000510100102700; HARBICH W, 1984, CHEM PHYS LIPIDS, V36, P39, DOI 10.1016/0009-3084(84)90089-6; HELFRICH W, 1985, CHEM SCRIPTA, V25, P32; HELFRICH W, 1986, J PHYS-PARIS, V47, P321, DOI 10.1051/jphys:01986004702032100; HELFRICH W, 1978, Z NATURFORSCH A, V33, P305; HERVE P, 1993, J PHYS II, V3, P1255, DOI 10.1051/jp2:1993196; HOFFMANN H, 1992, LANGMUIR, V8, P2629, DOI 10.1021/la00047a011; JANIAK MJ, 1979, J BIOL CHEM, V254, P6068; KALER EW, 1989, SCIENCE, V245, P1371, DOI 10.1126/science.2781283; KLOSGEN B, 1993, EUR BIOPHYS J, V22, P340; LASIC DD, 1993, LIPOSOMES PHYSICS AP; MCINTOSH TJ, 1989, BIOPHYS J, V55, P897, DOI 10.1016/S0006-3495(89)82888-7; Papahadjopoulos D., 1978, ANN NY ACAD SCI, V308, P1, DOI [10.1111/j.1749-6632.1978.tb22009.x, DOI 10.1111/J.1749-6632.1978.TB22009.X]; PORTE G, 1988, EUROPHYS LETT, V7, P713, DOI 10.1209/0295-5075/7/8/008; PORTE G, 1989, J PHYS-PARIS, V50, P1335, DOI 10.1051/jphys:0198900500110133500; ROUX D, 1988, J PHYS-PARIS, V49, P307, DOI 10.1051/jphys:01988004902030700; SAFINYA CR, 1986, PHYS REV LETT, V57, P2718, DOI 10.1103/PhysRevLett.57.2718; SAFINYA CR, 1989, PHYS REV LETT, V62, P1134, DOI 10.1103/PhysRevLett.62.1134; Safran S.A., 1994, STAT THERMODYNAMICS; SCHNEIDER MB, 1984, J PHYS-PARIS, V45, P1457, DOI 10.1051/jphys:019840045090145700; SCHNEIDER MB, 1984, BIOPHYS J, V45, P891, DOI 10.1016/S0006-3495(84)84235-6; SERVUSS RM, 1989, J PHYS-PARIS, V50, P809, DOI 10.1051/jphys:01989005007080900; SERVUSS RM, 1987, PHYSICS COMPLEX SUPR; SPECTOR M, UNPUB; STREY R, 1990, J CHEM SOC FARADAY T, V86, P2253, DOI 10.1039/ft9908602253; TARDIEU A, 1973, J MOL BIOL, V75, P711, DOI 10.1016/0022-2836(73)90303-3; WEISSENBERG K, 1947, NATURE, V159, P310, DOI 10.1038/159310a0	36	89	91	1	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 18	1994	266	5188					1222	1225		10.1126/science.7973704	http://dx.doi.org/10.1126/science.7973704			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT132	7973704	Green Submitted			2023-01-03	WOS:A1994PT13200049
J	KESSLER, DA; ROSE, JL; TEMPLE, RJ; SCHAPIRO, R; GRIFFIN, JP				KESSLER, DA; ROSE, JL; TEMPLE, RJ; SCHAPIRO, R; GRIFFIN, JP			THERAPEUTIC-CLASS WARS - DRUG PROMOTION IN A COMPETITIVE MARKETPLACE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									US FDA,DIV DRUG MKT ADVERTISING & COMMUN,ROCKVILLE,MD 20857	US Food & Drug Administration (FDA)								ANDERS G, 1994, WALL STREET J   0628, pB1; CHREN MM, 1990, JAMA-J AM MED ASSOC, V263, P2178, DOI 10.1001/jama.1990.03440160039021; GOLDFINGER SE, 1987, NEW ENGL J MED, V316, P1408, DOI 10.1056/NEJM198705283162211; KASSIRER JP, 1994, NEW ENGL J MED, V331, P669, DOI 10.1056/NEJM199409083311009; KESSLER DA, 1991, NEW ENGL J MED, V325, P201, DOI 10.1056/NEJM199107183250310; Kolata Gina, 1994, N Y Times Web, pA12; TANOUYE E, 1994, WALL ST J       0531, pA1; WAUD DR, 1992, NEW ENGL J MED, V327, P351, DOI 10.1056/NEJM199207303270511; WILKES MS, 1992, ANN INTERN MED, V116, P912, DOI 10.7326/0003-4819-116-11-912; WOOSLEY RL, 1994, ISSUES SCI TECHNOL, V10, P59; 1993, US ETHICAL PHARM PLY; 1993, EARNING FAILING GRAD; 1993, STATISTICAL REPORT; 1994, MED ADVERTISING NEWS, P10	14	106	107	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 17	1994	331	20					1350	1353		10.1056/NEJM199411173312007	http://dx.doi.org/10.1056/NEJM199411173312007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR216	7935706	Bronze			2023-01-03	WOS:A1994PR21600007
J	SINGER, PA				SINGER, PA			DISEASE-SPECIFIC ADVANCE DIRECTIVES	LANCET			English	Editorial Material											SINGER, PA (corresponding author), UNIV TORONTO,CTR BIOETH,88 COLL ST,TORONTO M5G 1L4,ON,CANADA.								0	40	43	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 27	1994	344	8922					594	596		10.1016/S0140-6736(94)91971-2	http://dx.doi.org/10.1016/S0140-6736(94)91971-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD424	7914966				2023-01-03	WOS:A1994PD42400015
J	HALLISSEY, MT; DUNN, JA; WARD, LC; ALLUM, WH; ARNOTT, S; BAKER, P; BROOKES, VS; CRAVEN, JL; ELLIS, DJ; FIELDING, JWL; FAGG, SL; HOCKEY, MS; LEVISON, D; JONES, BG; KELLY, K; MASON, MC; MINAWA, A; MCADAM, A; TIMOTHY, A; WATERHOUSE, JAH; WINSEY, S; WRIGLEY, PFM				HALLISSEY, MT; DUNN, JA; WARD, LC; ALLUM, WH; ARNOTT, S; BAKER, P; BROOKES, VS; CRAVEN, JL; ELLIS, DJ; FIELDING, JWL; FAGG, SL; HOCKEY, MS; LEVISON, D; JONES, BG; KELLY, K; MASON, MC; MINAWA, A; MCADAM, A; TIMOTHY, A; WATERHOUSE, JAH; WINSEY, S; WRIGLEY, PFM			THE 2ND BRITISH STOMACH-CANCER GROUP TRIAL OF ADJUVANT RADIOTHERAPY OR CHEMOTHERAPY IN RESECTABLE GASTRIC-CANCER - 5-YEAR FOLLOW-UP	LANCET			English	Article							MITOMYCIN-C; RANDOMIZED TRIAL; INTERIM-REPORT; 5-FLUOROURACIL; DOXORUBICIN; THERAPY	The overall survival in patients with gastric cancer is low, even among those undergoing resection. It has been hoped that the development of adjuvant therapy might improve survival in patients following surgery when tumour burden was minimal and both chemotherapy and radiotherapy have been proposed as suitable for use in gastric cancer. Their value has been evaluated by the British Stomach Cancer Group Second adjuvant therapy trial. 436 patients entered a prospective, randomised, controlled trial of adjuvant radiotherapy or cytotoxic chemotherapy with mitomycin, doxorubicin, and fluorouracil after gastrectomy for adenocarcinoma. After at least 5 years, there have been 372 deaths of which 7 were due to surgical complications and 327 from recurrent cancer. Following stratified randomisation, 145 patients were allocated to surgery alone, 153 to receive adjuvant radiotherapy, and 138 to adjuvant combination chemotherapy. The overall 2-year and 5-year survival were 33% (95% confidence interval 31-35%) and 17% (13-21%). No survival advantage has been shown for those patients receiving either adjuvant therapy compared to those undergoing surgery alone. The 5-year survival for surgery alone was 20%, for surgery plus radiotherapy 12%, and for surgery plus chemotherapy 19%. Surgery, therefore, remains the standard treatment for this condition and the use of adjuvant treatments should be restricted to controlled trials.	QUEEN ELIZABETH HOSP,CRC,TRIALS UNIT,BIRMINGHAM,W MIDLANDS,ENGLAND; EPSOM GEN HOSP,DEPT SURG,EPSOM,SURREY,ENGLAND	University of Birmingham	HALLISSEY, MT (corresponding author), QUEEN ELIZABETH HOSP,DEPT SURG,WARD W 6,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND.		Hallissey, Mike T/AAW-6797-2021	Dunn, Janet/0000-0001-7313-4446				ALLUM WH, 1989, BRIT J CANCER, V60, P739, DOI 10.1038/bjc.1989.350; ALLUM WH, 1989, LANCET, V1, P571; ALLUM WH, 1989, BRIT J SURG, V76, P535, DOI 10.1002/bjs.1800760604; BITRAN JD, 1979, CANCER TREAT REP, V63, P2049; COOMBES RC, 1990, J CLIN ONCOL, V8, P1362, DOI 10.1200/JCO.1990.8.8.1362; CROCKER J, 1983, J CLIN PATHOL, V36, P24, DOI 10.1136/jcp.36.1.24; CUSCHIERI A, 1986, BRIT J SURG, V73, P513; FIELDING JWL, 1983, WORLD J SURG, V7, P390, DOI 10.1007/BF01658089; FINDLAY M, 1993, BR J CANCER S20, V67, P15; Freedman L S, 1982, Stat Med, V1, P121, DOI 10.1002/sim.4780010204; GUNDERSON LL, 1982, INT J RADIAT ONCOL, V8, P1, DOI 10.1016/0360-3016(82)90377-7; HALLISSEY MT, 1990, BRIT MED J, V301, P513, DOI 10.1136/bmj.301.6751.513; HOCKEY M S, 1984, British Medical Journal, V289, P601; JONES BG, 1980, LANCET, V1, P1275; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; MACDONALD JS, 1992, P AN M AM SOC CLIN, P168; PREUSSER P, 1988, CANCER TREAT REV, V15, P257, DOI 10.1016/0305-7372(88)90025-4; PRIESTMAN TJ, 1986, CANCER STOMACH, P231; SASAKO M, 1992, JPN J CLIN ONCOL, V22, P41; SCHEIN PS, 1981, ADV BIOSCI, V32, P139; TONNESEN H, 1988, LANCET, V2, P990; WILKE H, 1989, J CLIN ONCOL, V7, P1318, DOI 10.1200/JCO.1989.7.9.1318; 1981, JAP J SURG, V11, P127	23	225	236	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 28	1994	343	8909					1309	1312		10.1016/S0140-6736(94)92464-3	http://dx.doi.org/10.1016/S0140-6736(94)92464-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN217	7910321				2023-01-03	WOS:A1994NN21700007
J	BURGAN, S; URBAN, P; CHEVROLET, J; UNGER, P; RUTISHAUSER, W				BURGAN, S; URBAN, P; CHEVROLET, J; UNGER, P; RUTISHAUSER, W			IMPACT OF A MULTICENTER RANDOMIZED TRIAL ON DOOR-TO-NEEDLE TIME FOR ACUTE MYOCARDIAL-INFARCTION	LANCET			English	Letter											BURGAN, S (corresponding author), UNIV HOSP GENEVA, CTR CARDIOL, MED INTENS CARE & MED POLICLIN, CH-1211 GENEVA 14, SWITZERLAND.							CHATELAIN P, 1992, REAN URG, V1, P241; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001	2	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 21	1994	343	8908					1300	1300		10.1016/S0140-6736(94)92192-X	http://dx.doi.org/10.1016/S0140-6736(94)92192-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM144	7910311				2023-01-03	WOS:A1994NM14400061
J	NEUENSCHWANDER, PF; MORRISSEY, JH				NEUENSCHWANDER, PF; MORRISSEY, JH			ROLES OF THE MEMBRANE-INTERACTIVE REGIONS OF FACTOR VIIA AND TISSUE FACTOR - THE FACTOR VIIA GLA DOMAIN IS DISPENSABLE FOR BINDING TO TISSUE FACTOR BUT IMPORTANT FOR ACTIVATION OF FACTOR-X	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; COAGULATION FACTOR-XA; BOVINE FACTOR-X; BLOOD-COAGULATION; COFACTOR FUNCTION; CELLULAR RECEPTOR; PROTEIN; CALCIUM; COMPLEX; PHOSPHOLIPIDS	The roles of the putative membrane-interactive regions of factor VIIa (fVIIa) and tissue factor (TF) have been examined. Enzymatic removal of the 4-carboxyglutamic acid (Gla) domain of fVIIa had no effect on hydrolysis of a tripeptidyl chromogenic substrate in the absence or presence of TF. Additionally, Gla-domainless fVIIa (GdVIIa) was similar to native fVIIa in activating factor X in the absence of TF and phospholipid. However, GdVIIa in complex with recombinant soluble TF (sTF) was 76-fold less efficient in factor X activation than was fVIIa.sTF. The difference increased to 740-fold using TF relipidated in vesicles composed of 80% phosphatidylcholine and 20% phosphatidylserine (TF/PCPS). While Gla domain deletion produced a 10(3)-fold increase in the K-d for binding to TF/PCPS, the K-d for binding to TF/PC increased only 20-fold, and that for sTF in the absence of phospholipid increased 10-fold. K-d values for GdVIIa binding to TF/PCPS, TF/PC, or sTF were nearly identical. Thus, most of the binding energy required for formation of the fVIIa.TF complex was present even after Gla domain deletion. Both fVIIa and GdVIIa were capable of binding sTF in the presence of excess divalent metal-ion chelator, suggesting Ca2+-independent binding or the presence of a novel very high affinity Ca2+ binding site in fVIIa. The results demonstrate that the effect of the Gla domain on the K-d is apparent only in the presence of PS, and that interactions involving the fVIIa Gla domain and phospholipid are critical for efficient proteolysis of factor X on a membrane surface.	OKLAHOMA MED RES FDN, CARDIOVASC BIOL RES PROGRAM, OKLAHOMA CITY, OK 73104 USA	Oklahoma Medical Research Foundation			Morrissey, James H/H-4933-2011; Morrissey, James H./GLR-5645-2022	Morrissey, James H/0000-0002-1570-1569; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047014, F32HL008710] Funding Source: NIH RePORTER; NHLBI NIH HHS [F32 HL08710, R01 HL47014] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; BACH R, 1988, BIOCHEMISTRY-US, V27, P4227, DOI 10.1021/bi00412a004; Bevington P.R., 1969, DATA REDUCTION ERROR; BOM VJJ, 1990, BIOCHEM J, V265, P327, DOI 10.1042/bj2650327; BROZE GJ, 1985, J BIOL CHEM, V260, P917; CHASE T, 1969, BIOCHEMISTRY-US, V8, P2212, DOI 10.1021/bi00833a063; CROMPTON IE, 1986, BIOCHEM J, V239, P221, DOI 10.1042/bj2390221; CUTSFORTH GA, 1989, BIOCHEMISTRY-US, V28, P7453, DOI 10.1021/bi00444a045; DAHLBACK B, 1990, J BIOL CHEM, V265; ESMON NL, 1983, J BIOL CHEM, V258, P5548; FIORE MM, 1994, J BIOL CHEM, V269, P143; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; HAGEN FS, 1986, P NATL ACAD SCI USA, V83, P2412, DOI 10.1073/pnas.83.8.2412; HIGASHI S, 1992, J BIOL CHEM, V267, P17990; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; Jesty J, 1988, Thromb Res, V50, P745, DOI 10.1016/0049-3848(88)90333-7; Jesty J, 1976, Methods Enzymol, V45, P95; KOMIYAMA Y, 1990, BIOCHEMISTRY-US, V29, P9418, DOI 10.1021/bi00492a016; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P23696; LAWSON JH, 1992, J BIOL CHEM, V267, P4834; LEBONNIEC BF, 1992, J BIOL CHEM, V267, P6970; MANN KG, 1984, PROG HEMOST THROMB, V7, P1; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; MORITA T, 1986, J BIOL CHEM, V261, P4015; MORRISON SA, 1983, BIOCHEMISTRY-US, V22, P4053, DOI 10.1021/bi00286a010; MORRISSEY JH, 1987, CELL, V50, P129, DOI 10.1016/0092-8674(87)90669-6; MORRISSEY JH, 1988, THROMB RES, V50, P481, DOI 10.1016/0049-3848(88)90197-1; MUTUCUMARANA VP, 1992, J BIOL CHEM, V267; NELSESTUEN GL, 1978, BIOCHEMISTRY-US, V17, P2134, DOI 10.1021/bi00604a017; NEMERSON Y, 1988, BLOOD, V71, P1; NEUENSCHWANDER P, 1988, BLOOD, V72, P1761; NEUENSCHWANDER PF, 1992, J BIOL CHEM, V267, P14477; NEUENSCHWANDER PF, 1993, THROMB HAEMOSTASIS, V70, P970; RAPAPORT SI, 1991, ANN NY ACAD SCI, V614, P51, DOI 10.1111/j.1749-6632.1991.tb43691.x; RAWALASHEIKH R, 1992, BLOOD, V79, P398; REZAIE AR, 1992, PROTEIN EXPRES PURIF, V3, P453, DOI 10.1016/1046-5928(92)90062-2; ROY S, 1991, J BIOL CHEM, V266, P4665; ROY S, 1991, J BIOL CHEM, V266, P22063; RUF W, 1992, J BIOL CHEM, V267, P6375; RUF W, 1991, J BIOL CHEM, V266, P2158; RUF W, 1991, J BIOL CHEM, V266, P15719; RUF W, 1991, J BIOL CHEM, V266, P16256; SAKAI T, 1990, J BIOL CHEM, V265, P1890; SCHIODT J, 1992, FEBS LETT, V306, P265, DOI 10.1016/0014-5793(92)81014-D; SKOGEN WF, 1984, J BIOL CHEM, V259, P2306; SMITH RL, 1973, J BIOL CHEM, V248, P2418; TOOMEY JR, 1991, J BIOL CHEM, V266, P19198; WAXMAN E, 1992, BIOCHEMISTRY-US, V31, P3998, DOI 10.1021/bi00131a015; WILDGOOSE P, 1993, BIOCHEMISTRY-US, V32, P114, DOI 10.1021/bi00052a016; WILDGOOSE P, 1990, P NATL ACAD SCI USA, V87, P7290, DOI 10.1073/pnas.87.18.7290; WILDGOOSE P, 1992, THROMB HAEMOSTASIS, V67, P679; ZUR M, 1978, J BIOL CHEM, V253, P2203	53	106	116	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8007	8013						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132522				2023-01-03	WOS:A1994NB40900030
J	LURIE, N; CHRISTIANSON, J; FINCH, M; MOSCOVICE, I				LURIE, N; CHRISTIANSON, J; FINCH, M; MOSCOVICE, I			THE EFFECTS OF CAPITATION ON HEALTH AND FUNCTIONAL STATUS OF THE MEDICAID ELDERLY - A RANDOMIZED TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article							FEE-FOR-SERVICE; MAINTENANCE-ORGANIZATIONS; AMBULATORY CARE; PREPAID; QUALITY; PLANS	Purpose: To determine the effect on health and functional status outcomes of enrollment of noninstitutionalized elderly Medicaid recipients in prepaid plans compared with traditional fee-for-service Medicaid. Design: A randomized controlled trial. Beneficiaries were randomly assigned to prepaid care in one of seven capitated health plans compared with fee-for-service care. Only the Medicaid portion of their care was capitated. Patients were followed for 1 year. Setting: The Medicaid Demonstration Project in Hennepin County, Minnesota, which includes Minneapolis. Patients: 800 Medicaid beneficiaries who were 65 years or older at the beginning of the evaluation. Beneficiaries were interviewed at baseline (time 1) and 1 year later (time 2). Ninety-six percent of beneficiaries were available for follow-up interviews at time 2. Main Outcome Measures: General health status, physical functioning, mental health status, activities of daily living, instrumental activities of daily living, corrected visual acuity, and blood pressure and glycosylated hemoglobin measurements for hypertensive and diabetic persons, respectively. Results:There were no differences between prepaid and fee-for-service groups in the number of deaths (20 compared with 24, P > 0.2), the proportion in fair or poor health (56.5% compared with 59.7%, P > 0.2), physical functioning, activities of daily living, visual acuity, or blood pressure or diabetic control. Patients in the prepaid group reported a trend toward better general health rating scores (10.2 compared with 9.8, P = 0.06) and well-being scores (10.0 compared with 9.7, P = 0.07) than patients in the fee-for-service group. The difference in the likelihood of a patient in the prepaid group having a physician visit relative to the fee-for-service group was -16.5% (adjusted odds ratio, 0.46; 95% CI, 0.29 to 0.74) and for an inpatient visit was -11.2% (adjusted odds ratio, 0.55; CI, 0.32 to 0.94). Conclusions: There was no evidence of harmful effects of enrolling elderly Medicaid patients in prepaid plans, at least in the short run. Whether these findings also apply to settings in which health maintenance organizations are formed exclusively for Medicaid patients should be studied further.	UNIV MINNESOTA, SCH MED, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, SCH PUBL HLTH, INST HLT SERV RES, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	LURIE, N (corresponding author), HENNEPIN CTY MED CTR, DEPT MED, 701 PK AVE, MINNEAPOLIS, MN 55415 USA.		Finch, Michael/AAN-7772-2021	Finch, Michael/0000-0001-7770-1102				[Anonymous], 1948, CONSTITUTION WHO; BATES EW, 1988, MED CARE, V26, P488, DOI 10.1097/00005650-198805000-00005; Bindman A B, 1993, Fam Med, V25, P114; BROOK RH, 1983, NEW ENGL J MED, V309, P1426, DOI 10.1056/NEJM198312083092305; CAREY T, 1990, J CLIN EPIDEMIOL, V43, P1213, DOI 10.1016/0895-4356(90)90022-H; CAREY TS, 1990, ARCH INTERN MED, V150, P2369, DOI 10.1001/archinte.150.11.2369; CHRISTIANSON J, 1987, SEP P NAT I MENT HLT; DEROGATIS LR, 1974, BEHAV SCI, V19, P1, DOI 10.1002/bs.3830190102; FREEBORN DK, 1990, MED CARE, V28, P527, DOI 10.1097/00005650-199006000-00005; KANE RA, 1985, ADM851384 USDHHS; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; LAWTON MP, 1982, J GERONTOL, V37, P91, DOI 10.1093/geronj/37.1.91; LURIE N, 1984, NEW ENGL J MED, V311, P480, DOI 10.1056/NEJM198408163110735; LURIE N, 1989, AM J PUBLIC HEALTH, V79, P640, DOI 10.2105/AJPH.79.5.640; LURIE N, 1992, JAMA-J AM MED ASSOC, V267, P3300, DOI 10.1001/jama.267.24.3300; MANNING WG, 1984, NEW ENGL J MED, V310, P1505, DOI 10.1056/NEJM198406073102305; RETCHIN SM, 1990, AM J PUBLIC HEALTH, V80, P411, DOI 10.2105/AJPH.80.4.411; RETCHIN SM, 1990, J GEN INTERN MED, V5, P110, DOI 10.1007/BF02600509; RETCHIN SM, 1992, HEALTH SERV RES, V27, P651; RETCHIN SM, 1991, AM J MED, V90, P236; SLOSS EM, 1987, ANN INTERN MED, V106, P130, DOI 10.7326/0003-4819-106-1-130; STEWART AL, 1982, CONSTRUCTION SCORING; TOBIN J, 1958, ECONOMETRICA, V26, P24, DOI 10.2307/1907382; UDVARHELYI IS, 1991, ANN INTERN MED, V115, P394, DOI 10.7326/0003-4819-115-5-394; WARE JE, 1986, LANCET, V1, P1017; ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/archpsyc.1965.01720310065008; 1976, HRP0015709 ANN REP; 1992, MED HLTH PERSPECTIVE	28	64	64	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1994	120	6					506	511		10.7326/0003-4819-120-6-199403150-00010	http://dx.doi.org/10.7326/0003-4819-120-6-199403150-00010			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB625	8311374				2023-01-03	WOS:A1994NB62500010
J	MURPHY, DJ; BURROWS, D; SANTILLI, S; KEMP, AW; TENNER, S; KRELING, B; TENO, J				MURPHY, DJ; BURROWS, D; SANTILLI, S; KEMP, AW; TENNER, S; KRELING, B; TENO, J			THE INFLUENCE OF THE PROBABILITY OF SURVIVAL ON PATIENTS PREFERENCES REGARDING CARDIOPULMONARY-RESUSCITATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LIFE-SUSTAINING TREATMENTS; HOSPITAL CARDIAC-ARREST; ADVANCE DIRECTIVES; ELDERLY OUTPATIENTS; MEDICAL-CARE; ATTITUDES; OUTCOMES; OLDER; PHYSICIANS; DECISIONS	Background. Studies suggest that a majority of elderly patients would want to undergo cardiopulmonary resuscitation (CPR) if they had a cardiac arrest. Yet few studies have examined their preferences after clinicians have informed them about the outcomes of CPR. Methods. To study older patients' preferences regarding CPR, we interviewed as many ambulatory patients as possible in one geriatrics practice in Denver from August 1, 1991, through July 31, 1992. Results. A total of 371 patients at least 60 years of age were eligible; 287 completed the interview (mean age, 77 years; range, 60 to 99). When asked about their wishes if they had cardiac arrest during an acute illness, 41 percent opted for CPR before learning the probability of survival to discharge. After learning the probability of survival (10 to 17 percent), 22 percent opted for CPR. Only 6 percent of patients 86 years of age or older opted for CPR under these conditions. When asked about a chronic illness in which the life expectancy was less than one year, 11 percent of the 287 patients opted for CPR before learning the. probability of survival to discharge. After teaming the probability of survival (0 to 5 percent), 5 percent said they would want CPR. Conclusions. Older patients readily understand prognostic information, which influences their preferences with respect to CPR. Most do not want to undergo CPR once a clinician explains the probability of survival after the procedure.	GEORGE WASHINGTON UNIV,DEPT HLTH CARE SCI,WASHINGTON,DC; GEORGE WASHINGTON UNIV,INTENS CARE UNIT RES UNIT,WASHINGTON,DC	George Washington University; George Washington University	MURPHY, DJ (corresponding author), PRESBYTERIAN ST LUKES MED CTR,SENIOR CITIZENS HLTH CTR,1801 HIGH ST,DENVER,CO 80218, USA.		Murphy, Denis J/ABC-1734-2020					APPLEBAUM GE, 1990, J AM GERIATR SOC, V38, P197, DOI 10.1111/j.1532-5415.1990.tb03490.x; AWOKE S, 1992, J AM GERIATR SOC, V40, P593, DOI 10.1111/j.1532-5415.1992.tb02109.x; BEDELL SE, 1983, NEW ENGL J MED, V309, P569, DOI 10.1056/NEJM198309083091001; BONNIN MJ, 1993, JAMA-J AM MED ASSOC, V270, P1457, DOI 10.1001/jama.270.12.1457; BRUNETTI LL, 1991, J GEN INTERN MED, V6, P323, DOI 10.1007/BF02597430; COGEN R, 1992, ARCH INTERN MED, V152, P1885, DOI 10.1001/archinte.152.9.1885; COHENMANSFIELD J, 1992, GERONTOLOGIST, V32, P89, DOI 10.1093/geront/32.1.89; DANIS M, 1991, NEW ENGL J MED, V324, P882, DOI 10.1056/NEJM199103283241304; DEGROSS JM, 1990, SOUTHERN MED J, V83, P733, DOI 10.1097/00007611-199007000-00001; DOUKAS DJ, 1993, J CLIN ETHIC, V4, P41; EMANUEL LL, 1989, JAMA-J AM MED ASSOC, V261, P3288, DOI 10.1001/jama.261.22.3288; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; EVERHART MA, 1990, CHEST, V97, P159, DOI 10.1378/chest.97.1.159; FINUCANE TE, 1988, J GEN INTERN MED, V3, P322, DOI 10.1007/BF02595788; FRANKL D, 1989, AM J MED, V86, P645, DOI 10.1016/0002-9343(89)90436-1; JECKER NS, 1993, J CLIN ETHIC, V4, P16; Kielstein Rita, 1993, Kennedy Institute of Ethics Journal, V3, P303; LONGSTRETH WT, 1990, JAMA-J AM MED ASSOC, V264, P2109, DOI 10.1001/jama.264.16.2109; MALLOY TR, 1992, J AM GERIATR SOC, V40, P1255, DOI 10.1111/j.1532-5415.1992.tb03652.x; MICHELSON C, 1991, GERONTOLOGIST, V31, P358, DOI 10.1093/geront/31.3.358; MILLER DL, 1993, ARCH INTERN MED, V153, P1999, DOI 10.1001/archinte.153.17.1999; MILLER DL, 1992, ARCH INTERN MED, V152, P578, DOI 10.1001/archinte.152.3.578; MOWER MR, 1993, ARCH INTERN MED, V153, P375; MURPHY DJ, 1988, JAMA-J AM MED ASSOC, V260, P2098, DOI 10.1001/jama.260.14.2098; MURPHY DJ, 1990, JAMA-J AM MED ASSOC, V264, P2103, DOI 10.1001/jama.264.16.2103; MURPHY DJ, 1989, ANN INTERN MED, V111, P199, DOI 10.7326/0003-4819-111-3-199; OCONNOR AM, 1989, J CLIN EPIDEMIOL, V42, P119, DOI 10.1016/0895-4356(89)90085-1; PEARLMAN RA, 1993, J CLIN ETHIC, V4, P33; QUILL TE, 1992, ARCH INTERN MED, V152, P569, DOI 10.1001/archinte.152.3.569; SACHS GA, 1992, J AM GERIATR SOC, V40, P269, DOI 10.1111/j.1532-5415.1992.tb02081.x; SCHNEIDERMAN LJ, 1992, ARCH INTERN MED, V152, P2114, DOI 10.1001/archinte.152.10.2114; SCHONWETTER RS, 1993, J GEN INTERN MED, V8, P295, DOI 10.1007/BF02600139; SCHONWETTER RS, 1991, J AM GERIATR SOC, V39, P372, DOI 10.1111/j.1532-5415.1991.tb02902.x; SECKLER AB, 1991, ANN INTERN MED, V115, P92, DOI 10.7326/0003-4819-115-2-92; SEHGAL A, 1992, JAMA-J AM MED ASSOC, V267, P59, DOI 10.1001/jama.267.1.59; SHMERLING RH, 1988, J GEN INTERN MED, V3, P317, DOI 10.1007/BF02595786; TAFFET GE, 1988, JAMA-J AM MED ASSOC, V260, P2069, DOI 10.1001/jama.260.14.2069; TORIAN LV, 1992, ARCH INTERN MED, V152, P1659; TRESCH DD, 1988, AM J CARDIOL, V61, P1120, DOI 10.1016/0002-9149(88)90141-5; TRESCH DD, 1989, AM J MED, V86, P145, DOI 10.1016/0002-9343(89)90259-3; TRESCH DD, 1990, AM J CARDIOL, V65, P453, DOI 10.1016/0002-9149(90)90809-F; TRIAN LV, 1992, ARCH INTERNMED, V152, P561; UHLMANN RF, 1989, WESTERN J MED, V150, P705; WAGNER A, 1984, NEW ENGL J MED, V310, P1129, DOI 10.1056/NEJM198404263101732; 1987, CRUNC STATISTICAL PA	45	439	443	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 24	1994	330	8					545	549		10.1056/NEJM199402243300807	http://dx.doi.org/10.1056/NEJM199402243300807			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MX436	8302322				2023-01-03	WOS:A1994MX43600007
J	SAUTER, C				SAUTER, C			DOXORUBICIN ADJUVANT COMBINATIONS FOR BREAST-CANCER	LANCET			English	Letter							THERAPY				SAUTER, C (corresponding author), UNIV HOSP ZURICH,DEPT MED,DIV ONCOL,CH-8091 ZURICH,SWITZERLAND.							BONADONNA G, 1989, J CLIN ONCOL, V7, P1380, DOI 10.1200/JCO.1989.7.10.1380; CARPENTER JT, 1991, P ASCO, V10, P45; DOROSHOW JH, 1991, NEW ENGL J MED, V324, P843, DOI 10.1056/NEJM199103213241210; ETTINGHAUSEN SE, 1986, ARCH SURG-CHICAGO, V121, P1445; FISHER B, 1990, J CLIN ONCOL, V8, P1483, DOI 10.1200/JCO.1990.8.9.1483; HENDERSON IC, 1980, AM HEART J, V99, P671, DOI 10.1016/0002-8703(80)90743-7; OBRIAN R, 1992, P AM SOC CLIN ONCOL, V11, P61	7	5	5	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 18	1993	342	8886-7					1550	1551		10.1016/S0140-6736(05)80116-3	http://dx.doi.org/10.1016/S0140-6736(05)80116-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM402	7902917				2023-01-03	WOS:A1993MM40200035
J	SCANLON, TJ; LUBEN, RN; SCANLON, FL; SINGLETON, N				SCANLON, TJ; LUBEN, RN; SCANLON, FL; SINGLETON, N			IS FRIDAY THE 13TH BAD FOR YOUR HEALTH	BRITISH MEDICAL JOURNAL			English	Article							SUPERNATURAL BELIEFS	Objective-To, examine the relation between health, behaviour, and superstition surrounding Friday 13th in the United Kingdom. Design-Retrospective study of paired data comparing driving and shopping patterns and accidents. Subjects-Drivers, shoppers, and residents. Setting-South West Thames region. Main outcome measures-Numbers of vehicles on motorways; numbers of shoppers in supermarkets; and hospital admissions due to accidents. Results-There were consistently and significantly fewer vehicles on the southern section of the M25 on Friday the 13th compared with Friday the 6th. The numbers of shoppers were not significantly different on the two days. Admissions due to transport accidents were significantly increased on Friday 13th (total 65 v 45; p < 0.05). Conclusions-Friday 13th is unlucky for some. The risk of hospital admission as a result of a transport accident may be increased by as much as 52%. Staving at home is recommended.			SCANLON, TJ (corresponding author), MID DOWNS HLTH AUTHOR,DEPT PUBL HLTH,HAYWARDS HEATH RH16 4BE,W SUSSEX,ENGLAND.		Luben, Robert N/H-5519-2015	Luben, Robert N/0000-0002-5088-6343				Aderinokun G A, 1991, Afr Dent J, V5, P26; Burleigh E, 1990, Med Anthropol, V12, P419; GOUTEUX JP, 1992, B SOC PATHOL EXOT, V85, P256; LaPiere RT, 1934, SOC FORCES, V13, P230, DOI 10.2307/2570339; LEYGUES M, 1989, SOC SCI MED, V28, P1255, DOI 10.1016/0277-9536(89)90344-4; Lorie P., 1992, SUPERSTITIONS; MAHDIHASSAN S, 1990, AM J CHINESE MED, V18, P87, DOI 10.1142/S0192415X90000125; RADFORD A, 1961, ENCYCLOPEDIA SUPERSI	8	26	26	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 18	1993	307	6919					1584	1586		10.1136/bmj.307.6919.1584	http://dx.doi.org/10.1136/bmj.307.6919.1584			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN107	8292946	Green Published, Bronze			2023-01-03	WOS:A1993MN10700009
J	TOPOL, E; CALIFF, R; VANDEWERF, F; ARMSTRONG, PW; AYLWARD, P; BARBASH, G; BATES, E; BETRIU, A; BOISSEL, JP; CHESEBRO, J; COL, J; DEBONO, D; GORE, J; GUERCI, A; HAMPTON, J; HIRSH, J; HOLMES, D; HORGAN, J; KLEIMAN, N; MARDER, V; MORRIS, D; OHMAN, M; PFISTERER, M; ROSS, A; RUTSCH, W; SADOWSKI, Z; SIMOONS, M; VAHANIAN, A; WEAVER, WD; WHITE, H; WILCOX, R				TOPOL, E; CALIFF, R; VANDEWERF, F; ARMSTRONG, PW; AYLWARD, P; BARBASH, G; BATES, E; BETRIU, A; BOISSEL, JP; CHESEBRO, J; COL, J; DEBONO, D; GORE, J; GUERCI, A; HAMPTON, J; HIRSH, J; HOLMES, D; HORGAN, J; KLEIMAN, N; MARDER, V; MORRIS, D; OHMAN, M; PFISTERER, M; ROSS, A; RUTSCH, W; SADOWSKI, Z; SIMOONS, M; VAHANIAN, A; WEAVER, WD; WHITE, H; WILCOX, R			AN INTERNATIONAL RANDOMIZED TRIAL COMPARING 4 THROMBOLYTIC STRATEGIES FOR ACUTE MYOCARDIAL-INFARCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TISSUE PLASMINOGEN-ACTIVATOR; CLINICAL-TRIALS; ALTEPLASE; PATENCY; HEPARIN; THERAPY	Background. The relative efficacy of streptokinase and tissue plasminogen activator and the roles of intravenous as compared with subcutaneous heparin as adjunctive therapy in acute myocardial infarction are unresolved questions. The current trial was designed to compare new, aggressive thrombolytic strategies with standard thrombolytic regimens in the treatment of acute myocardial infarction. Our hypothesis was that newer thrombolytic strategies that produce earlier and sustained reperfusion would improve survival. Methods. In 15 countries and 1081 hospitals, 41,021 patients with evolving myocardial infarction were randomly assigned to four different thrombolytic strategies, consisting of the use of streptokinase and subcutaneous heparin, streptokinase and intravenous heparin, accelerated tissue plasminogen activator (t-PA) and intravenous heparin, or a combination of streptokinase plus t-PA with intravenous heparin. (''Accelerated'' refers to the administration of t-PA over a period of 1 1/2 hours - with two thirds of the dose given in the first 30 minutes - rather than the conventional period of 3 hours.) The primary end point was 30-day mortality. Results. The mortality rates in the four treatment groups were as follows: streptokinase and subcutaneous heparin, 7.2 percent; streptokinase and intravenous heparin, 7.4 percent; accelerated t-PA and intravenous heparin, 6.3 percent; and the combination of both thrombolytic agents with intravenous heparin, 7.0 percent. This represented a 14 percent reduction (95 percent confidence interval, 5.9 to 21.3 percent) in mortality for accelerated t-PA as compared with the two streptokinase-only strategies (P = 0.001). The rates of hemorrhagic stroke were 0.49 percent, 0.54 percent, 0.72 percent, and 0.94 percent in the four groups, respectively, which represented a significant excess of hemorrhagic strokes for accelerated t-PA (P = 0.03) and for the combination strategy (P<0.001), as compared with streptokinase only. A combined end point of death or disabling stroke was significantly lower in the accelerated-t-PA group than in the streptokinase-only groups (6.9 percent vs. 7.8 percent, P = 0.006). Conclusions. The findings of this large-scale trial indicate that accelerated t-PA given with intravenous heparin provides a survival benefit over previous standard thrombolytic regimens.	DUKE UNIV, MED CTR, COORDINATING CTR, DURHAM, NC 27710 USA; CATHOLIC UNIV LEUVEN, INTERMEDIATE COORDINATING CTR, B-3000 LOUVAIN, BELGIUM	Duke University; KU Leuven	TOPOL, E (corresponding author), CLEVELAND CLIN FDN, DEPT CARDIOL, 1 CLIN CTR, CLEVELAND, OH 44195 USA.		Simes, Robert John/P-1497-2014					[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1990, Lancet, V336, P65; [Anonymous], 1986, Lancet, V1, P397; BLEICH SD, 1990, AM J CARDIOL, V66, P1412, DOI 10.1016/0002-9149(90)90525-6; CALIFF RM, 1991, CIRCULATION, V83, P1543, DOI 10.1161/01.CIR.83.5.1543; CARNEY RJ, 1992, J AM COLL CARDIOL, V20, P17, DOI 10.1016/0735-1097(92)90131-6; DEBONO DP, 1992, BRIT HEART J, V67, P122; GRANGER C, 1991, CIRCULATION S2, V84, P573; GRINES CL, 1991, CIRCULATION, V84, P540, DOI 10.1161/01.CIR.84.2.540; HSIA J, 1990, NEW ENGL J MED, V323, P1433, DOI 10.1056/NEJM199011223232101; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; LINCOFF AM, 1993, CIRCULATION, V87, P1792; NEUHAUS KL, 1989, J AM COLL CARDIOL, V14, P1566, DOI 10.1016/0735-1097(89)90399-9; NEUHAUS KL, 1992, J AM COLL CARDIOL, V19, P885, DOI 10.1016/0735-1097(92)90265-O; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; TOPOL EJ, 1988, CIRCULATION, V77, P1100, DOI 10.1161/01.CIR.77.5.1100; TOPOL EJ, 1992, J AM COLL CARDIOL, V19, P1123, DOI 10.1016/0735-1097(92)90312-B; TOPOL EJ, 1991, PROG CARDIOVASC DIS, V34, P165, DOI 10.1016/0033-0620(91)90011-A; VANDEWERF F, 1990, LANCET, V336, P71; 1993, LANCET, V339, P753	20	3197	3298	0	31	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 2	1993	329	10					673	682		10.1056/nejm199309023291001	http://dx.doi.org/10.1056/nejm199309023291001			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU583	8204123	Green Published, Bronze			2023-01-03	WOS:A1993LU58300001
J	ROSEMOND, RL				ROSEMOND, RL			CARDIOVERSION DURING PREGNANCY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											ROSEMOND, RL (corresponding author), VANDERBILT UNIV,MED CTR,NASHVILLE,TN 37240, USA.							DESILVA RA, 1980, AM HEART J, V100, P881, DOI 10.1016/0002-8703(80)90071-X; SANCHEZDIAZ CJ, 1957, ARCH I CARDIOL MEX, V57, P387; UELAND K, 1981, Clinical Obstetrics and Gynecology, V24, P809, DOI 10.1097/00003081-198109000-00008	3	21	21	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 23	1993	269	24					3167	3167						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH145	8505820				2023-01-03	WOS:A1993LH14500037
J	BOTT, J; CARROLL, MP; CONWAY, JH; KEILTY, SEJ; WARD, EM; BROWN, AM; PAUL, EA; ELLIOTT, MW; GODFREY, RC; WEDZICHA, JA; MOXHAM, J				BOTT, J; CARROLL, MP; CONWAY, JH; KEILTY, SEJ; WARD, EM; BROWN, AM; PAUL, EA; ELLIOTT, MW; GODFREY, RC; WEDZICHA, JA; MOXHAM, J			RANDOMIZED CONTROLLED TRIAL OF NASAL VENTILATION IN ACUTE VENTILATORY FAILURE DUE TO CHRONIC OBSTRUCTIVE AIRWAYS DISEASE	LANCET			English	Article							POSITIVE PRESSURE VENTILATION; NONINVASIVE MECHANICAL VENTILATION; ACUTE RESPIRATORY-FAILURE	Acute exacerbations of chronic obstructive airways disease (COAD) are a common cause of admission to hospital, and have a high mortality. Nasal intermittent positive pressure ventilation (NIPPV) has been used successfully in patients with respiratory failure due to neuromuscular and skeletal disorders, but the outcome of treatment in patients with COAD is less well known. We carried out a prospective randomised controlled trial of conventional treatment versus conventional treatment plus NIPPV, in 60 patients with acute ventilatory failure due to exacerbations of COAD. For the NIPPV group there was a rise in pH, compared with a fall in the controls (mean difference of change between the groups 0.046 [95% Cl 0.06-0.02, p < 0.001]), and a larger fall in PaCO2 (mean difference in change between the groups 1.2 kPa [95% Cl 0.45 to 2.03, p < 0.011]). Median visual analogue scores over the first 3 days of admission showed less breathlessness in the NIPPV group (2.3 cm [range 0.1-5.5]) than in the control group (4.5 cm [range 0.9-8.8]) (p < 0.025). Survival rates at 30 days were compared for intention-to-treat and efficacy populations. In the efficacy mortality comparison, mortality in the NIPPV group was reduced: 1/26 vs 9/30 (relative risk = 0.13, Cl = 0.02-0.95, p = 0.014). This effect was less in the intention-to-treat analysis: 3/30 vs 9/30 (relative risk = 0.33, Cl = 0.10-1.11, p = 0.106). In patients with acute ventilatory failure due to COAD who received NIPPV there was a significant rise in pH, a reduction in PaCO2 and breathlessness, and reduced mortality.	KINGS COLL, SCH MED & DENT, DEPT THORAC MED, BESSEMER RD, LONDON SE5 9JP, ENGLAND; SOUTHAMPTON GEN HOSP, SOUTHAMPTON SO9 4XY, HANTS, ENGLAND; LONDON CHEST HOSP, LONDON, ENGLAND	University of London; King's College London; University of Southampton; University of London; Queen Mary University London				Conway, Joy/0000-0001-6464-1526				AHMED AH, 1992, THORAX, V47, pP858; BOTT J, 1991, THORAX, V46, P457, DOI 10.1136/thx.46.6.457; CHEVROLET JC, 1991, CHEST, V100, P775, DOI 10.1378/chest.100.3.775; ELLIOTT MW, 1990, BRIT MED J, V300, P358, DOI 10.1136/bmj.300.6721.358; ELLIS ER, 1988, CHEST, V94, P811, DOI 10.1378/chest.94.4.811; HODSON ME, 1991, EUR RESPIR J, V4, P524; JEFFREY AA, 1992, THORAX, V47, P34, DOI 10.1136/thx.47.1.34; KERBY GR, 1987, AM REV RESPIR DIS, V135, P738; KETTEL LJ, 1971, J AMER MED ASSOC, V217, P1503, DOI 10.1001/jama.217.11.1503	9	600	616	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 19	1993	341	8860					1555	1557		10.1016/0140-6736(93)90696-E	http://dx.doi.org/10.1016/0140-6736(93)90696-E			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH550	8099639				2023-01-03	WOS:A1993LH55000003
J	RIDKER, PM; HEBERT, PR; FUSTER, V; HENNEKENS, CH				RIDKER, PM; HEBERT, PR; FUSTER, V; HENNEKENS, CH			ARE BOTH ASPIRIN AND HEPARIN JUSTIFIED AS ADJUNCTS TO THROMBOLYTIC THERAPY FOR ACUTE MYOCARDIAL-INFARCTION	LANCET			English	Review							TISSUE PLASMINOGEN-ACTIVATOR; ENTERIC-COATED ASPIRIN; LOW-DOSE ASPIRIN; INTRAVENOUS HEPARIN; INHIBITION		BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT PREVENT MED, BOSTON, MA 02115 USA; MASSACHUSETTS GEN HOSP, DEPT MED, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School			Fuster, Valentin/H-4319-2015	Fuster, Valentin/0000-0002-9043-9986				[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1990, Lancet, V336, P65; BLEICH SD, 1990, AM J CARDIOL, V66, P1412, DOI 10.1016/0002-9149(90)90525-6; COL J, 1992, CIRCULATION, V86, P259; DEBONO DP, 1992, BRIT HEART J, V67, P122; GUNNAR RM, 1990, J AM COLL CARDIOL, V16, P249, DOI 10.1016/0735-1097(90)90575-A; HSIA J, 1990, NEW ENGL J MED, V323, P1433, DOI 10.1056/NEJM199011223232101; HUNT D, 1992, LANCET, V339, P753; JAKUBOWSKI JA, 1985, BRIT J HAEMATOL, V60, P635, DOI 10.1111/j.1365-2141.1985.tb07467.x; LAMAS GA, 1992, NEW ENGL J MED, V327, P241, DOI 10.1056/NEJM199207233270405; OCONNOR C, 1992, AM HEART ASS ANAHEIM; PATRIGNANI P, 1982, J CLIN INVEST, V69, P1366, DOI 10.1172/JCI110576; REILLY IAG, 1987, BLOOD, V69, P180; SOBEL BE, 1992, AM J CARDIOL, V70, P385, DOI 10.1016/0002-9149(92)90624-8; TAVAZZI L, 1989, LANCET, V2, P182; THOMPSON PL, 1991, CIRCULATION, V83, P1534, DOI 10.1161/01.CIR.83.5.1534; TOPOL EJ, 1989, CIRCULATION, V79, P281, DOI 10.1161/01.CIR.79.2.281; TOPOL EJ, 1992, J AM COLL CARDIOL, V19, P1123, DOI 10.1016/0735-1097(92)90312-B; VANAGS D, 1990, THROMB RES, V59, P995, DOI 10.1016/0049-3848(90)90123-T; VANDEWERF F, 1990, LANCET, V336, P71; 1991, UPDATE, V2, P1	21	46	46	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 19	1993	341	8860					1574	1577		10.1016/0140-6736(93)90707-N	http://dx.doi.org/10.1016/0140-6736(93)90707-N			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH550	8099650				2023-01-03	WOS:A1993LH55000014
J	SESSLER, DI				SESSLER, DI			PERIANESTHETIC THERMOREGULATION AND HEAT-BALANCE IN HUMANS	FASEB JOURNAL			English	Article						SPINAL ANESTHESIA; ISOFLURANE; HALOTHANE; HYPOTHALAMUS; HYPOTHERMIA; THERMOREGULATION; SKIN; SETPOINT; SHIVERING	EPIDURAL-ANESTHESIA; ISOFLURANE ANESTHESIA; BODY-TEMPERATURE; THRESHOLD; HYPOTHERMIA; BUPIVACAINE; METABOLISM; VOLUNTEERS; BLOCKADE	General anesthesia markedly impairs normal control of body temperature, reducing the threshold (triggering core temperature) for thermoregulatory vasoconstriction from almost-equal-to 37 to almost-equal-to 34.5-degrees-C. Sweating and active vasodilation thresholds similarly are increased, widening the range of temperatures not triggering regulatory compensations from almost-equal-to 0.2 to is-approximately-equal-to 4-degrees-C. However, once initiated, the gains (slopes of response intensity vs. core temperature curves) and maximum intensities of thermoregulatory responses are nearly normal. Intraoperative core temperature initially decreases rapidly because anesthetic-induced inhibition of tonic thermoregulatory vasoconstriction causes a core-to-peripheral redistribution of body heat. The subsequent slower, linear decrease in body temperature results from heat loss exceeding metabolic heat production. And finally, after 3-4 h of anesthesia, core temperature stabilizes at an abnormally low value. In patients experiencing minimal heat loss, and therefore not becoming sufficiently hypothermic to trigger vasoconstriction, this plateau can be passive steady state in which heat loss equals production. Conversely, patients becoming sufficiently hypothermic will trigger thermoregulatory vasoconstriction that both decreases cutaneous heat loss and sequesters some metabolic heat in the core. Epidural and spinal anesthesia also cause core hypothermia by inhibiting tonic thermoregulatory vasoconstriction, producing an internal redistribution of heat from the warm core to cooler peripheral tissues. Core hypothermia provokes thermoregulatory responses including vasoconstriction (above the block level) and shivering. Nonetheless, many patients feel warmer after induction of regional anesthesia, apparently because perceived skin temperature is elevated. The following review will focus on anesthetic-induced impairment of normal thermoregulatory control and the resulting alterations in heat balance.			SESSLER, DI (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT ANESTHESIA,ROOM C-214,SAN FRANCISCO,CA 94143, USA.		Sessler, Daniel/D-3504-2011	Sessler, Daniel/0000-0001-9932-3077	NIGMS NIH HHS [R29 GM39723] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM039723] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAIR ER, 1977, DRUGS BIOGENIC AMINE, P84; BALDWIN BA, 1967, J PHYSIOL-LONDON, V191, P375, DOI 10.1113/jphysiol.1967.sp008256; BELANI K, IN PRESS ANESTHESIOL; BENZINGER T, 1961, P NATL ACAD SCI USA, V47, P730, DOI 10.1073/pnas.47.5.730; BICKLER PE, 1990, ANESTH ANALG, V71, P415; BISSONNETTE B, 1990, ANESTHESIOLOGY, V73, P1114, DOI 10.1097/00000542-199012000-00008; BISSONNETTE B, 1992, ANESTHESIOLOGY, V76, P387, DOI 10.1097/00000542-199203000-00011; BROWNRIDGE P, 1986, ANAESTH INTENS CARE, V14, P412, DOI 10.1177/0310057X8601400414; BRUCK K, 1978, TEMPERATURE REGULATI, P157; CARLI F, 1989, BRIT J ANAESTH, V63, P276, DOI 10.1093/bja/63.3.276; COLIN J, 1971, J APPL PHYSIOL, V31, P484, DOI 10.1152/jappl.1971.31.3.484; COOPER J O, 1990, Anesthesiology (Hagerstown), V73, pA230; DAWKINS MJR, 1965, NATURE, V206, P201, DOI 10.1038/206201b0; DOWNEY JA, 1969, J APPL PHYSIOL, V27, P209, DOI 10.1152/jappl.1969.27.2.209; DUCHARME MB, 1991, J APPL PHYSIOL, V70, P2682, DOI 10.1152/jappl.1991.70.6.2682; FARR LA, 1986, CHRONOBIOLOGIA, V13, P105; GLOSTEN B, 1992, ANESTHESIOLOGY, V77, P10, DOI 10.1097/00000542-199207000-00003; GLOSTEN B, 1991, ANESTHESIOLOGY, V75, pA854; Guffin A, 1987, J Cardiothorac Anesth, V1, P24, DOI 10.1016/S0888-6296(87)92593-2; HAMMEL HT, 1968, ANNU REV PHYSIOL, V30, P641, DOI 10.1146/annurev.ph.30.030168.003233; Hardy JD, 1936, PHYSICS-J GEN APPL P, V7, P466, DOI 10.1063/1.1745358; HARRIS MM, 1989, REGION ANESTH, V14, P13; HEIER T, 1991, ANESTHESIOLOGY, V74, P815, DOI 10.1097/00000542-199105000-00003; Hynson J M, 1992, J Clin Anesth, V4, P194, DOI 10.1016/0952-8180(92)90064-8; HYNSON JM, 1991, ANESTHESIOLOGY, V74, P680, DOI 10.1097/00000542-199104000-00011; HYNSON JM, 1992, ANESTH ANALG, V75, P947; HYNSON JM, 1991, ANESTH ANALG, V72, pS119; ISRAEL DJ, 1989, J APPL PHYSIOL, V66, P2358, DOI 10.1152/jappl.1989.66.5.2358; JESSEN C, 1971, PFLUG ARCH EUR J PHY, V324, P189, DOI 10.1007/BF00586418; JUST B, 1992, ANESTHESIOLOGY, V76, P60, DOI 10.1097/00000542-199201000-00009; MACINTYRE PE, 1987, ANESTH ANALG, V66, P751; MEKJAVIC IB, 1985, IEEE T BIO-MED ENG, V32, P407, DOI 10.1109/TBME.1985.325467; MEKJAVIC IB, 1991, J APPL PHYSIOL, V71, P1289, DOI 10.1152/jappl.1991.71.4.1289; MERCER JB, 1978, PFLUG ARCH EUR J PHY, V374, P179, DOI 10.1007/BF00581299; MOAYERI A, 1991, ANESTHESIOLOGY, V75, P1004; MORA F, 1983, BRAIN RES BULL, V11, P613, DOI 10.1016/0361-9230(83)90132-6; MORRIS RH, 1972, ANESTHESIOLOGY, V36, P408, DOI 10.1097/00000542-197204000-00020; Ozuna J M, 1978, AORN J, V28, P240, DOI 10.1016/S0001-2092(07)61369-6; PASSIAS TC, 1992, ANESTHESIOLOGY, V76, P550, DOI 10.1097/00000542-199204000-00011; PONTE J, 1986, ACTA ANAESTH SCAND, V30, P584, DOI 10.1111/j.1399-6576.1986.tb02480.x; PONTE J, 1990, BRIT J ANAESTH, V64, P731, DOI 10.1093/bja/64.6.731; QUINTIN L, 1991, ANESTHESIOLOGY, V74, P236, DOI 10.1097/00000542-199102000-00008; ROE CF, 1972, SURG GYNECOL OBSTETR, V135, P577; SATINOFF E, 1978, SCIENCE, V201, P16, DOI 10.1126/science.351802; SESSLER DI, 1991, ANESTHESIOLOGY, V75, P985, DOI 10.1097/00000542-199112000-00010; SESSLER DI, 1990, ANESTHESIOLOGY, V72, P816, DOI 10.1097/00000542-199005000-00008; SESSLER DI, 1991, ANESTHESIOLOGY, V75, P594, DOI 10.1097/00000542-199110000-00009; SESSLER DI, 1991, ANESTHESIOLOGY, V74, P875, DOI 10.1097/00000542-199105000-00012; SESSLER DI, 1992, ANESTHESIOLOGY, V76, P670, DOI 10.1097/00000542-199205000-00002; SESSLER DI, 1991, ANESTHESIOLOGY, V74, P226, DOI 10.1097/00000542-199102000-00006; SESSLER DI, 1988, ANESTHESIOLOGY, V68, P836, DOI 10.1097/00000542-198806000-00002; SESSLER DI, 1988, ANESTHESIOLOGY, V69, P357, DOI 10.1097/00000542-198809000-00012; Sessler DI, 1990, ANESTHESIA, VThird, P1227; SEVARINO FB, 1989, ANESTH ANALG, V68, P530; SHARKEY A, 1987, ANESTHESIOLOGY, V66, P249, DOI 10.1097/00000542-198702000-00029; SIMON E, 1974, REV PHYSIOL BIOCH P, V71, P1, DOI 10.1007/BFb0027660; SOLIMAN MG, 1972, CAN ANAESTH SOC J, V19, P529, DOI 10.1007/BF03005813; STEVENS WC, 1971, ANESTHESIOLOGY, V35, P8, DOI 10.1097/00000542-197107000-00005; STOEN R, 1990, ANESTHESIOLOGY, V72, P822, DOI 10.1097/00000542-199005000-00009; VALERI CR, 1987, ANN SURG, V205, P175, DOI 10.1097/00000658-198702000-00012; VAUGHN LK, 1980, BRAIN RES BULL, V5, P69, DOI 10.1016/0361-9230(80)90285-3; WASHINGTON D, 1993, IN PRESS J APPL PHYS; WASHINGTON DE, 1992, ANESTHESIOLOGY, V77, P286, DOI 10.1097/00000542-199208000-00011; WISSLER EH, 1971, J PHYSIOL-PARIS, V63, P455	64	167	170	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1993	7	8					638	644		10.1096/fasebj.7.8.8500688	http://dx.doi.org/10.1096/fasebj.7.8.8500688			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LE290	8500688				2023-01-03	WOS:A1993LE29000005
J	FERGUSON, JH; DUBINSKY, M; KIRSCH, PJ				FERGUSON, JH; DUBINSKY, M; KIRSCH, PJ			COURT-ORDERED REIMBURSEMENT FOR UNPROVED MEDICAL TECHNOLOGY - CIRCUMVENTING TECHNOLOGY-ASSESSMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							AMYGDALIN	Objective.-Because we found examples where courts ot law ruled against insurance carriers that had been sued for reimbursement for unproven medical procedures, we conducted a case study to determine the reasoning behind these decisions that run counter to accepted medical science. Such actions circumvent health technology assessment and could contribute to escalating health care costs and poorer quality health care. Data Sources.-A literature search identified 17 cases between 1980 and 1989 in which an insurance company was sued to reimburse a patient who had received an unproven or questionable health technology; 14 of these suits were decided in favor of the plaintiff, and the insurance company was ordered to pay. Discussed in this article are six of these cases, two involving Laetrile (amygdalin), two involving immunoaugmentative therapy, and two involving thermography, technologies that had previously been assessed as not safe, not effective, or inadequately evaluated. Data Synthesis and Conclusions.-The circumstances determining how the courts arrive at these ''unscientific'' decisions fall into three general categories: (1) for legal reasons, the insurance contract is interpreted in favor of the insured; (2) the reluctance and/or inability, legal or otherwise, of the courts to use published scientific literature; and (3) the use of adversarial ''expert'' witnesses with potential conflicts of interest. To address this situation, we first urge the legal and insurance industries to cooperate in improving the contract language and process in a way that would be both legally and scientifically appropriate. Second, we encourage the courts to use and foster the use of published peer-reviewed scientific material as evidence whenever possible. Third, we recommend that the courts choose their own unbiased expert witnesses to interpret scientific material.	ADM CHILDREN & FAMILIES, WASHINGTON, DC USA; CUTLER & STANFIELD, WASHINGTON, DC USA		FERGUSON, JH (corresponding author), NIH, OFF MED APPLICAT RES, FED BLDG, RM 618, BETHESDA, MD 20892 USA.							[Anonymous], 1989, GUIDE CLIN PREVENTIV; BAILAR JC, 1992, MED USES STATISTICS; CLINE JS, 1985, TORT INSUR LAW J, V21, P120; CURT GA, 1986, JAMA-J AM MED ASSOC, V255, P505, DOI 10.1001/jama.255.4.505; ELLISON NM, 1978, NEW ENGL J MED, V299, P549, DOI 10.1056/NEJM197809072991013; HUBER PW, 1991, GALILEOS REVENGE JUN, P206; Larson E B, 1989, Int J Technol Assess Health Care, V5, P195; MOERTEL CG, 1982, NEW ENGL J MED, V306, P201, DOI 10.1056/NEJM198201283060403; MOERTEL CG, 1981, JAMA-J AM MED ASSOC, V245, P591, DOI 10.1001/jama.245.6.591; MONACO GP, 1985, FORUM, V20, P400; 1990, OTAH4045 PUBL; 1979, CAN MED ASS J, V121, P1193; 1983, NCHSR HLTH TECHNOL A, V22, P1; 1989, NCHSR HLTH TECHNOL A, V2, P1	14	41	41	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 28	1993	269	16					2116	2121		10.1001/jama.269.16.2116	http://dx.doi.org/10.1001/jama.269.16.2116			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY366	8468767				2023-01-03	WOS:A1993KY36600035
J	GATTINONI, L; DANDREA, L; PELOSI, P; VITALE, G; PESENTI, A; FUMAGALLI, R				GATTINONI, L; DANDREA, L; PELOSI, P; VITALE, G; PESENTI, A; FUMAGALLI, R			REGIONAL EFFECTS AND MECHANISM OF POSITIVE END-EXPIRATORY PRESSURE IN EARLY ADULT RESPIRATORY-DISTRESS SYNDROME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FAILURE; VENTILATION; SCAN	Objective.-To test the hypothesis that positive end-expiratory pressure (PEEP) prevents the collapse of a given lung region when it is equal to or greater than the hydrostatic pressure superimposed (SPL) to that region. Design.-Intervention study with sequential levels of PEEP applied in random order to a cohort of patients with adult respiratory distress syndrome (ARDS). Setting.-Referral center for ARDS in a university hospital. Patients.-Ten ARDS patients (with Murray scores >2.5). Intervention.-Basal computed tomographic (CT) section taken at 0, 2, 4, 5, 6, 8, 10, 12, 14, 15, and 20 cm H2O PEEP. Main Outcome Measures.-Basal lung CT sections were divided into 1 0 equal levels from the ventral to dorsal surfaces. In each level SPL was measured from density and height. The inflation of the level was measured as the gas/tissue ratio (g/t); g/t changes with PEEP were defined as the g/t-P curve. The slope of the g/t-P curve was defined as level compliance (ie, the ratio of change in the g/t of the level to the change in pressure). A linear g/t-P curve was the criterion to detect inflation without recruitment (ie, new pulmonary units opening at a given pressure). A biphasic g/t-P curve (change of compliance after an inflection point) was the criterion to detect recruitment. Pflex was defined as the pressure at which the inflection point occurred. Results.-The SPL increased from level 1 (ventral) to level 10 (dorsal) (r=.91; P<.01). The number of linear g/t-P curves decreased from level 1 to level 10 (r=.98; P<.01), while the number of biphasic g/t-P curves increased (r=.95; P<.01). The Pflex increased from level 1 to 10 (r=.97; P<.01) and Pflex was similar to SPL (Pflex=1.05+0.9 SPL; r=.75; P<0.01). Conclusions.-The increased SPL causes compression atelectasis; this is prevented when PEEP to a given lung region is equal to or greater than the SPL.	UNIV MILAN,OSPED S GERARDO MONZA,IST ANESTESIA & RIANIMAZIONE,I-20122 MILAN,ITALY	University of Milan			Fumagalli, Roberto/AAB-9746-2019; Pesenti, Antonio/H-7483-2012; Rocco, Patricia/I-7460-2012	Fumagalli, Roberto/0000-0003-0398-1329; Pesenti, Antonio/0000-0003-2593-729X; Rocco, Patricia/0000-0003-1412-7136; Pelosi, Paolo/0000-0001-5055-3023; Gattinoni, Luciano/0000-0001-5380-2494				ASHBAUGH DG, 1967, LANCET, V2, P319; Beydon L, 1991, ADULT RESP DISTRESS, P139; BRISMAR B, 1985, ANESTHESIOLOGY, V62, P422, DOI 10.1097/00000542-198504000-00009; DANTZKER DR, 1980, CHEST, V77, P636, DOI 10.1378/chest.77.5.636; DEMEDTS M, 1975, J APPL PHYSIOL, V38, P228, DOI 10.1152/jappl.1975.38.2.228; FALKE KJ, 1972, J CLIN INVEST, V51, P2315, DOI 10.1172/JCI107042; GATTINONI L, 1987, AM REV RESPIR DIS, V136, P730, DOI 10.1164/ajrccm/136.3.730; GATTINONI L, 1991, ANESTHESIOLOGY, V74, P15, DOI 10.1097/00000542-199101000-00004; GATTINONI L, 1988, ANESTHESIOLOGY, V69, P824, DOI 10.1097/00000542-198812000-00005; Gattinoni L, 1988, J Thorac Imaging, V3, P59, DOI 10.1097/00005382-198807000-00013; GATTINONI L, 1991, ACTA ANAESTH SCAND, V35, P87, DOI 10.1111/j.1399-6576.1991.tb03404.x; GATTINONI L, 1986, J THORAC IMAG, V3, P25; INGRAM RH, 1974, J APPL PHYSIOL, V36, P135, DOI 10.1152/jappl.1974.36.2.135; KRUGGER JJ, 1961, J APPL PHYSIOL, V16, P465; LAMY M, 1976, AM REV RESPIR DIS, V114, P267; MATAMIS D, 1984, CHEST, V86, P58, DOI 10.1378/chest.86.1.58; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; PEPE PE, 1982, AM REV RESPIR DIS, V126, P166; PESENTI A, 1985, CRIT CARE MED, V13, P34, DOI 10.1097/00003246-198501000-00009; SALMON RB, 1981, J APPL PHYSIOL, V51, P353, DOI 10.1152/jappl.1981.51.2.353; Snedecor G.W., 1967, STAT METHODS; ZAPOL WM, 1979, AM REV RESPIR DIS, V119, P547	22	301	310	2	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 28	1993	269	16					2122	2127		10.1001/jama.269.16.2122	http://dx.doi.org/10.1001/jama.269.16.2122			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY366	8468768				2023-01-03	WOS:A1993KY36600036
J	THIERRY, AR; VIGE, D; COUGHLIN, SS; BELLI, JA; DRITSCHILO, A; RAHMAN, A				THIERRY, AR; VIGE, D; COUGHLIN, SS; BELLI, JA; DRITSCHILO, A; RAHMAN, A			MODULATION OF DOXORUBICIN RESISTANCE IN MULTIDRUG-RESISTANT CELLS BY LIPOSOMES	FASEB JOURNAL			English	Note						DRUG RESISTANCE; DOXORUBICIN; LIPOSOMES; P-GLYCOPROTEIN; DRUG INTRACELLULAR DISTRIBUTION	P-GLYCOPROTEIN EXPRESSION; BREAST CANCER-CELLS; PLASMA-MEMBRANE; HL-60 CELLS; ENCAPSULATED DOXORUBICIN; GLUTATHIONE TRANSFERASE; VINCRISTINE BINDING; DRUG ACCUMULATION; K562 CELLS; ADRIAMYCIN	In this study, we have confirmed the ability of liposome-encapsulated doxorubicin to modulate drug resistance, as previously observed in CH LZ cells (Thierry et al., Cancer Commun. 1, 311-316, 1989), in two human multidrug-resistant (MDR) cell lines, the breast cancer MCF-7/ADR cell line, and the ovarian carcinoma SKVLB cell line. This effect was specific to MDR cells, as liposomally encapsulated doxorubicin did not enhance cell sensitivity to the drug in the parental cell lines. Cytotoxicity assays demonstrated that empty liposomes in the presence of free doxorubicin (Dox) reversed resistance to the drug at a level that may be higher than that observed when liposome-encapsulated Dox is used. This effect seems to be due to the high affinity of Dox for cardiolipin, one of the liposome components, which leads to the association of the drug and the cardiolipin-containing liposomes in the culture medium before entry into the cells. Neither pretreatment of empty liposomes before drug treatment nor combined incubation of vincristine and empty liposomes alter MDR in CH LZ cells, suggesting that the drug must be encapsulated or complexed to the liposomes to overcome MDR. Because MDR in CH LZ cells does not seem to be related to GSH level, MDR modulation by liposome-encapsulated Dox apparently may not be effected by altering the GSH function. These results suggest that the enhancement of sensitivity of MDR cells using Dox encapsulated in liposomes or complexed with liposomes may be explained by an increase in cell drug incorporation and by an intracellular drug redistribution. Fluorescence confocal microscopy study indicated that Dox is transported and distributed mainly in intracytoplasmic vesicles in SKVLB and MCF-7/ADR cells, whereas in parental cells the drug is located mainly in the nucleus. In addition, presentation of Dox in liposomes modifies the drug distribution pattern in MDR cells by partially shifting the drug to nuclear compartments. Thus, liposome-associated Dox may bypass the vesicular drug transport in MDR cells, resulting in the enhancement of the drug biological activity.	GEORGETOWN UNIV,SCH MED,DEPT MED,WASHINGTON,DC 20007; GEORGETOWN UNIV,SCH MED,LOMBARDI CANC RES CTR,BIOSTAT & EPIDEMIOL UNIT,WASHINGTON,DC 20007; UNIV TEXAS,MED BRANCH,DEPT RADIAT THERAPY,GALVESTON,TX 77550	Georgetown University; Georgetown University; University of Texas System; University of Texas Medical Branch Galveston	THIERRY, AR (corresponding author), GEORGETOWN UNIV,SCH MED,DEPT RADIAT MED,3800 RESERVOIR RD NW,WASHINGTON,DC 20007, USA.		thierry, alain/F-9492-2014					BATIST G, 1986, J BIOL CHEM, V261, P5544; BECK WT, 1987, BIOCHEM PHARMACOL, V36, P2879, DOI 10.1016/0006-2952(87)90198-5; BRADLEY G, 1989, CANCER RES, V49, P2790; CHABNER BA, 1989, J NATL CANCER I, V81, P910, DOI 10.1093/jnci/81.12.910; CORNWELL MM, 1987, FASEB J, V1, P51, DOI 10.1096/fasebj.1.1.2886389; DEFFIE AM, 1988, CANCER RES, V48, P3595; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FAIRCHILD CR, 1987, CANCER RES, V47, P5141; FAN D, 1990, CANCER RES, V50, P3619; FOJO A, 1985, CANCER RES, V45, P3002; GOORMAGHTIGH E, 1980, BIOCHIM BIOPHYS ACTA, V597, P1, DOI 10.1016/0005-2736(80)90145-5; GOTTESMAN MM, 1989, J CLIN ONCOL, V7, P409, DOI 10.1200/JCO.1989.7.4.409; GROS P, 1986, P NATL ACAD SCI USA, V83, P337, DOI 10.1073/pnas.83.2.337; HARRIS JR, 1979, INT J RADIAT ONCOL, V5, P1235, DOI 10.1016/0360-3016(79)90645-X; HINDENBURG AA, 1989, CANCER RES, V49, P4607; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; HOWELL N, 1984, CANCER RES, V44, P4023; KEIZER HG, 1989, CANCER RES, V49, P2988; KLOHS WD, 1988, CANCER RES, V48, P3025; LIU DX, 1989, BIOCHIM BIOPHYS ACTA, V981, P254, DOI 10.1016/0005-2736(89)90035-7; MARQUARDT D, 1991, JNCI-J NATL CANCER I, V83, P1098, DOI 10.1093/jnci/83.15.1098; NAITO M, 1989, CANCER RES, V49, P1452; NAITO M, 1988, J BIOL CHEM, V263, P11887; NOGAE I, 1989, BIOCHEM PHARMACOL, V38, P519; OUDARD S, 1991, CANCER CHEMOTH PHARM, V28, P259; PAPAHADJ.D, 1974, NATURE, V252, P163, DOI 10.1038/252163a0; QUIAN XD, 1990, CANCER RES, V50, P1132; Roninson, 1991, MOL CELLULAR BIOL MU, P263; SADASIVAN R, 1991, CANCER LETT, V57, P165, DOI 10.1016/0304-3835(91)90211-Y; SEHESTED M, 1989, BRIT J CANCER, V60, P809, DOI 10.1038/bjc.1989.371; SHUMAN H, 1989, BIOTECHNIQUES, V7, P154; SHUURHUIS GJ, 1989, J NATL CANCER I, V81, P1887; Thierry A R, 1989, Cancer Commun, V1, P311; Thierry A. R., 1992, Gene regulation: biology of antisense RNA and DNA., P147; THIERRY AR, 1992, BIOCHEM BIOPH RES CO, V187, P1098, DOI 10.1016/0006-291X(92)91310-M; TREAT J, 1990, J NATL CANCER I, V82, P1706, DOI 10.1093/jnci/82.21.1706; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; VERELLE P, 1991, J NATL CANCER I, V83, P111; YANOVICH S, 1989, CANCER RES, V49, P4499	40	101	106	2	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR 1	1993	7	6					572	579		10.1096/fasebj.7.6.8097173	http://dx.doi.org/10.1096/fasebj.7.6.8097173			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KY009	8097173				2023-01-03	WOS:A1993KY00900011
J	KELLETT, J				KELLETT, J			FOR DEBATE - LONG-TERM CARE ON THE NHS - A VANISHING PROSPECT	BRITISH MEDICAL JOURNAL			English	Article											KELLETT, J (corresponding author), ST GEORGE HOSP,SCH MED,LONDON SW17 0RE,ENGLAND.							JOLLY DJ, 1992, PSYCHIATRIC B, V16, P567; 1992, HOSPITAL HLTH SERVIC; 1992, DIRECTORY INDEPENDEN	3	8	8	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 27	1993	306	6881					846	848		10.1136/bmj.306.6881.846	http://dx.doi.org/10.1136/bmj.306.6881.846			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KV348	8490381	Green Published, Bronze			2023-01-03	WOS:A1993KV34800028
J	Pisetsky, DS				Pisetsky, DS			The breakthrough	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											Pisetsky, DS (corresponding author), DUKE UNIV, MED CTR,VET AFFAIRS MED CTR,BOX 151G,ROOM E-1008, 508 FULTON ST, DURHAM, NC 27705 USA.								0	4	4	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1996	124	3					345	347		10.7326/0003-4819-124-3-199602010-00013	http://dx.doi.org/10.7326/0003-4819-124-3-199602010-00013			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TR596	8554234				2023-01-03	WOS:A1996TR59600013
J	Ryan, CJ; Kaye, M				Ryan, CJ; Kaye, M			Euthanasia in Australia - The Northern Territory rights of the terminally ill act	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									UNIV SYDNEY,SYDNEY,NSW 2000,AUSTRALIA	University of Sydney	Ryan, CJ (corresponding author), WESTMEAD HOSP,SYDNEY,NSW 2145,AUSTRALIA.		Ryan, Christopher/B-4095-2010	Kaye, Miranda/0000-0003-4484-1904; Ryan, Christopher/0000-0003-2158-9427				BATTIN MP, 1994, LEAST WORST DEATH, P123; BAUME P, 1994, MED J AUSTRALIA, V161, P137, DOI 10.5694/j.1326-5377.1994.tb127345.x; BAUME P, 1994, MED J AUSTRALIA, V161, P142; BAUME P, 1994, MED J AUSTRALIA, V161, P140; GLOVER J, 1988, CAUSING DEATH SAVING, P188; Griffiths John, 1994, Med Law Int, V1, P137; KUHSE H, 1988, MED J AUSTRALIA, V148, P623, DOI 10.5694/j.1326-5377.1988.tb116334.x; OGILVIE AD, 1994, BRIT MED J, V309, P492, DOI 10.1136/bmj.309.6953.492; Ryan CJ, 1995, AUST NZ J PSYCHIAT, V29, P580, DOI 10.3109/00048679509064970; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; 1995, NO TERRITORY RIGHTS	11	46	46	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 1	1996	334	5					326	328		10.1056/NEJM199602013340512	http://dx.doi.org/10.1056/NEJM199602013340512			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TV695	8532033				2023-01-03	WOS:A1996TV69500012
J	ASSENDELFT, WJJ; KOES, BW; KNIPSCHILD, PG; BOUTER, LM				ASSENDELFT, WJJ; KOES, BW; KNIPSCHILD, PG; BOUTER, LM			THE RELATIONSHIP BETWEEN METHODOLOGICAL QUALITY AND CONCLUSIONS IN REVIEWS OF SPINAL MANIPULATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							LOW-BACK-PAIN; RANDOMIZED CLINICAL-TRIALS; MANUAL THERAPY; MANAGEMENT; ARTICLES; EFFICACY; METAANALYSIS; MOBILIZATION; SCIENCE; STATE	Objective.-To study the relationship between the methodological quality and other characteristics of reviews of spinal manipulation for low back pain on the one hand and the reviewers' conclusions on the effectiveness of manipulation on the other hand. Data Sources.-Reviews identified by MEDLINE search, citation tracking, library search, and correspondence with experts. Study Selection.-English- or Dutch-language reviews published up to 1993 dealing with spinal manipulation for low back pain that include at least two randomized clinical trials (RCTs). Data Extraction.-Methodological quality was assessed using a standardized criteria list applied independently by two assessors (range, 0% to 100%). Other extracted characteristics were the comprehensiveness of the search, selective citation of studies, language, inclusion of non-RCTs, type of publication, reviewers' professional backgrounds, and publication in a spinal manipulation journal or book. The reviewers' conclusions were classified as negative, neutral, or positive. Data Synthesis.-A total of 51 reviews were assessed, 17 of which were neutral and 34 positive. The methodological quality was low, with a median score of 23%. Nine of the 10 methodologically best reviews were positive. Other factors associated with a positive reviewers' conclusion were review of spinal manipulation only, inclusion of a spinal manipulator in the review team, and a comprehensive literature search. Conclusions.-The majority of the reviews concluded that spinal manipulation is an effective treatment for low back pain. Although, in particular, the reviews with a relatively high methodological quality had a positive conclusion, strong conclusions were precluded by the overall low quality of the reviews. More empirical research on the review methods applied to other therapies in other professional fields is needed to further explore our findings about the factors related to a positive reviewers' conclusion.	UNIV LIMBURG,DEPT EPIDEMIOL,MAASTRICHT,NETHERLANDS; FREE UNIV AMSTERDAM,DEPT BIOSTAT & EPIDEMIOL,AMSTERDAM,NETHERLANDS	Hasselt University; Vrije Universiteit Amsterdam	ASSENDELFT, WJJ (corresponding author), FREE UNIV AMSTERDAM,INST RES EXTRAMURAL MED,VAN DER BOECHORSTSTRAAT 7,1081 BT AMSTERDAM,NETHERLANDS.		assendelft, willem/AAW-1854-2021; Assendelft, W.J.J./H-8008-2014; Koes, Bart w/K-4614-2016	assendelft, willem/0000-0002-2966-3778; Assendelft, W.J.J./0000-0002-2966-3778; Koes, Bart w/0000-0002-0450-9969; Bouter, Lex/0000-0002-2659-5482				ABENHAIM L, 1992, CLIN INVEST MED, V15, P527; ANDERSON R, 1992, J MANIP PHYSIOL THER, V15, P181; ASSENDELFT WJJ, 1992, J MANIP PHYSIOL THER, V15, P487; AUFDEMKAMPE G, 1991, ORTHOPEDISCHE GENEES, P115; BLOCH R, 1987, SPINE, V12, P430, DOI 10.1097/00007632-198706000-00002; BOUTER LM, 1990, 3RD P INT PHYS C SYD, P438; BOUTER LM, 1985, MED CONTACT, V40, P357; BRANSON MH, 1984, CONCEPTS MECHANISMS, P90; Bronfort G, 1992, PRINCIPLES PRACTICE, P415; BRUNARSKI DJ, 1984, J MANIP PHYSIOL THER, V7, P243; CHAPMANSMITH D, 1989, J MANIP PHYSIOL THER, V12, P142; CONLON J, 1992, CHIROPRACTIC TREATME; COULEHAN JL, 1985, CULT MED PSYCHIAT, V9, P353; CURTIS P, 1988, OCCUP MED, V3, P31; DEYO RA, 1988, ARCH PHYS MED REHAB, V69, P1044; DEYO RA, 1983, JAMA-J AM MED ASSOC, V250, P1057; DEYO RA, 1991, CONT CONSERVATIVE CA, P169; DICKERSIN K, 1992, EPIDEMIOL REV, V14, P154, DOI 10.1093/oxfordjournals.epirev.a036084; DICKERSIN K, 1994, BRIT MED J, V309, P286; DIFABIO RP, 1992, PHYS THER, V72, P853, DOI 10.1093/ptj/72.12.853; DIFABIO RP, 1986, PHYS THER, V66, P51, DOI 10.1093/ptj/66.1.51; EVANS DP, 1985, EMPIRICAL APPROACHES, P228; FLOR H, 1984, PAIN, V19, P105, DOI 10.1016/0304-3959(84)90831-5; FRYMOYER JW, 1988, NEW ENGL J MED, V318, P291, DOI 10.1056/NEJM198802043180506; GATTERMAN MI, 1990, CHIROPRACTIC MANAGEM, P397; GEIRINGER SR, 1993, REHABILITATION MED P, P451; GILBERT JR, 1986, CAN FAM PHYSICIAN, V32, P1855; GOLDSCHMIDT PG, 1986, HEALTH SERV RES, V21, P215; GOTZSCHE PC, 1987, BRIT MED J, V295, P654, DOI 10.1136/bmj.295.6599.654; GRAHAME R, 1980, CLIN RHEUM DIS, V6, P143; GREENLAND S, 1980, J OCCUP ENVIRON MED, V22, P670, DOI 10.1097/00043764-198010000-00014; GREGOIRE G, 1995, J CLIN EPIDEMIOL, V48, P159, DOI 10.1016/0895-4356(94)00098-B; GUYAT GH, 1993, JAMA-J AM MED ASSOC, V270, P2096, DOI 10.1001/jama.270.17.2096; HALDEMAN S, 1986, CLIN SPORT MED, V5, P277; HALDEMAN S, 1991, ADULT SPINE PRINCIPL, P1581; HALDEMAN S, 1980, LOW BACK PAIN, P245; HALDEMAN S, 1983, CLIN ORTHOP RELAT R, V179, P62; HAYNES RB, 1992, BRIT MED J, V304, P330, DOI 10.1136/bmj.304.6823.330; HOFFMAN RM, 1994, SPINE, V19, pS2068; INGLIS BD, 1979, CHIROPRACTIC NZ REPO, P200; Jacobs J W, 1991, Ned Tijdschr Geneeskd, V135, P317; JAYSON MIV, 1986, BRIT MED J, V293, P1454, DOI 10.1136/bmj.293.6560.1454; JULL GA, 1986, MODERN MANUAL THERAP, P740; KOES BW, 1991, BRIT MED J, V303, P1298, DOI 10.1136/bmj.303.6813.1298; KUKURIN GW, 1985, AM CHIROPR ASS J, V19, P41; LABAN MM, 1992, ORTHOP CLIN N AM, V23, P451; Lankhorst G J, 1987, Ned Tijdschr Geneeskd, V131, P898; LAWRENCE VA, 1992, J CLIN EPIDEMIOL, V45, P301, DOI 10.1016/0895-4356(92)90091-Z; LEBOEUF C, 1990, J MANIP PHYSIOL THER, V13, P89; LEE CK, 1988, ORTHOP CLIN N AM, V19, P797; Light R., 1984, SUMING UP SCI REV RE, P160; LYNOU N, 1987, LEGITIMATION REGISTR, P135; MACDONALD MJ, 1988, J CHIROPRACTIC R AUT, P2; MANGA P, 1993, EFFECTIVENESS COST E, P35; MILNE R, 1993, J EPIDEMIOL COMMUN H, V47, P169, DOI 10.1136/jech.47.3.169; MOHER D, 1995, CONTROL CLIN TRIALS, V16, P62, DOI 10.1016/0197-2456(94)00031-W; MORITZ U, 1979, SCAND J REHABIL MED, V11, P173; MULROW CD, 1987, ANN INTERN MED, V106, P485, DOI 10.7326/0003-4819-106-3-485; NACHEMSON A, 1985, INT ORTHOP, V9, P1, DOI 10.1007/BF00267031; NACHEMSON A, 1969, Scandinavian Journal of Rehabilitation Medicine, V1, P85; NACHEMSON A, 1969, SCAND J REHABIL MED, P85; NACHEMSON A, 1977, APROACHES VALIDATION, P42; NACHEMSON A, 1980, LUMBAR SPINE BACK PA, P453; NACHEMSON AL, 1992, CLIN ORTHOP RELAT R, V279, P8; NACHEMSON AL, 1985, CLIN ORTHOPAEDICS, V200, P266; ODONOGHUE CE, 1986, MODERN MANUAL THERAP, P849; OROURKE K, 1989, J CLIN EPIDEMIOL, V42, P1021, DOI 10.1016/0895-4356(89)90168-6; OTTENBACHER K, 1985, SPINE, V10, P833, DOI 10.1097/00007632-198511000-00010; OXMAN A, 1994, PREPARING MAINTAININ; OXMAN AD, 1994, BMJ-BRIT MED J, V309, P648, DOI 10.1136/bmj.309.6955.648; OXMAN AD, 1988, CAN MED ASSOC J, V138, P697; PARIS SV, 1983, CLIN ORTHOPAEDICS, V179, P55; Pedersen P, 1990, EUR J CHIROPRACTIC, V38, P41; QUINET RJ, 1979, SEMIN ARTHRITIS RHEU, V8, P261, DOI 10.1016/0049-0172(79)90005-2; SACKETT DL, 1991, CLIN EPIDEMIOLOGY BA, P359; SACKS HS, 1987, NEW ENGL J MED, V316, P450, DOI 10.1056/NEJM198702193160806; SHEKELLE PG, 1992, ANN INTERN MED, V117, P590, DOI 10.7326/0003-4819-117-7-590; SHEKELLE PG, 1991, APPROPRIIATENESS SPI; SILAGY CA, 1993, FAM PRACT, V10, P337, DOI 10.1093/fampra/10.3.337; TAN JC, 1992, BAILLIERE CLIN RHEUM, V6, P629, DOI 10.1016/S0950-3579(05)80131-1; WARDWELL W, 1992, CHIROPRACTIC HIST EV; WILLIAMSON JW, 1986, MED USE STATISTICS, P370; WINER CER, 1985, ASPECTS MANIPULATIVE, P97; YATES AAH, 1980, LUMBAR SPINE BACK PA, P437; ZINN WM, 1981, THER UMSCH, V38, P642; 1987, SPINE S, V12, P9; 1994, JAMA-J AM MED ASSOC, V272, P1926	87	89	91	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	1995	274	24					1942	1948		10.1001/jama.274.24.1942	http://dx.doi.org/10.1001/jama.274.24.1942			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL169	8568990	Green Submitted			2023-01-03	WOS:A1995TL16900038
J	HAKIM, RM; WINGARD, RL; PARKER, RA				HAKIM, RM; WINGARD, RL; PARKER, RA			EFFECT OF THE DIALYSIS MEMBRANE IN THE TREATMENT OF PATIENTS WITH ACUTE-RENAL-FAILURE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CRITICALLY-ILL PATIENTS; RISK-FACTORS; APACHE-II; HEMODIALYSIS; RAT; SURVIVAL; BIOCOMPATIBILITY; PREDICTION; VARIABLES; RECOVERY	Background. The mortality rate among patients with acute renal failure remains high, and the role of the biocompatibility of the dialysis membrane in the resolution of this disorder is not known. Methods. We prospectively studied 72 patients with acute renal failure who required hemodialysis and assigned them to two treatment groups. One group underwent dialysis with the widely used cuprophane dialysis membrane, which activates the complement system and leukocytes, and the other group underwent dialysis with a synthetic polymethyl methacrylate membrane, which has a more limited effect on complement and leukocytes. Scores on the Acute Physiology, Age, and Chronic Health Evaluation (APACHE II) were calculated at the initiation of dialysis. Survival and the recovery of renal function were determined with the use of proportional-hazards and exact logistic-regression analyses. Results. When dialysis was initiated, the patients in the two groups were similar in terms of age, APACHE II scores, the prevalence of oliguria, and biochemical indexes of renal failure. Twenty-three of the 37 patients (62 percent) in the group undergoing dialysis with the polymethyl methacrylate membrane recovered renal function, as compared with 13 of the 35 patients (37 percent) in the group undergoing dialysis with the cuprophane membrane (P = 0.04 after adjustment for the APACHE II score). The median number of dialysis treatments required before the recovery of renal function was 5 in the former group and 17 in the latter group (P = 0.02). Twenty-one patients (57 percent) undergoing dialysis with the polymethyl methacrylate membrane survived, as compared with 13 patients (37 percent) undergoing dialysis with the cuprophane membrane (P = 0.11). Of the 20 patients in each group who initially had nonoliguric acute renal failure, the survival rates were 80 percent with the polymethyl methacrylate membrane and 40 percent with the cuprophane membrane (P = 0.01). Conclusions. Among patients with acute renal failure requiring hemodialysis, the use of the polymethyl methacrylate membrane, as compared with the cuprophane membrane, resulted in improved recovery of renal function.	VANDERBILT UNIV,MED CTR,DEPT MED,DIV NEPHROL,NASHVILLE,TN; VANDERBILT UNIV,MED CTR,DEPT PREVENT MED,DIV BIOSTAT,NASHVILLE,TN	Vanderbilt University; Vanderbilt University					NHLBI NIH HHS [1R01-HL-36015-9] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036015] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BADR KF, 1988, J CLIN INVEST, V81, P1702, DOI 10.1172/JCI113509; BARTLETT RH, 1986, SURGERY, V100, P400; BREZIS M, 1991, J CLIN INVEST, V88, P390, DOI 10.1172/JCI115316; BREZIS M, 1993, ANNU REV MED, V44, P27, DOI 10.1146/annurev.me.44.020193.000331; BULLOCK ML, 1985, AM J KIDNEY DIS, V5, P97, DOI 10.1016/S0272-6386(85)80003-2; CHEUNG AK, 1986, KIDNEY INT, V29, P799, DOI 10.1038/ki.1986.69; CHEW SL, 1993, NEPHROL DIAL TRANSPL, V8, P101; CIOFFI WG, 1984, ANN SURG, V200, P205, DOI 10.1097/00000658-198408000-00015; CONGER JD, 1990, SEMIN DIALYSIS, V3, P146, DOI 10.1111/j.1525-139X.1990.tb00031.x; CONGER JD, 1991, KIDNEY INT, V39, P1087, DOI 10.1038/ki.1991.138; CORWIN HL, 1987, AM J NEPHROL, V7, P8, DOI 10.1159/000167421; DAVENPORT A, 1993, KIDNEY INT, V43, pS230; FISCHEREDER M, 1994, SEMIN NEPHROL, V14, P41; HAKIM RM, 1993, KIDNEY INT, V44, P484, DOI 10.1038/ki.1993.272; HARRIS KPG, 1989, KIDNEY INT, V36, P210, DOI 10.1038/ki.1989.181; HIMMELFARB J, 1993, J AM SOC NEPHROL, V4, P178; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LIAFIO F, 1989, NEPHRON, V51, P307; LIEN J, 1985, ARCH INTERN MED, V145, P2067, DOI 10.1001/archinte.145.11.2067; LINAS SL, 1992, KIDNEY INT, V42, P610, DOI 10.1038/ki.1992.325; LOWRIE EG, 1990, AM J KIDNEY DIS, V15, P458, DOI 10.1016/S0272-6386(12)70364-5; MAHER ER, 1989, Q J MED, V72, P857; McCarthy James T., 1993, Journal of the American Society of Nephrology, V4, P367; MENASHE PI, 1988, CRIT CARE MED, V16, P1106, DOI 10.1097/00003246-198811000-00005; MYERS BD, 1986, NEW ENGL J MED, V314, P97; RASMUSSEN HH, 1985, ARCH INTERN MED, V145, P2015, DOI 10.1001/archinte.145.11.2015; SCHIFFL H, 1994, LANCET, V344, P570, DOI 10.1016/S0140-6736(94)91964-X; SCHULMAN G, 1991, KIDNEY INT, V40, P1069, DOI 10.1038/ki.1991.316; SPIEGEL DM, 1991, AM J NEPHROL, V11, P44, DOI 10.1159/000168271; STRASSER T, 1991, KLIN WOCHENSCHR, V69, P808, DOI 10.1007/BF01744274; TURNEY JH, 1990, LANCET, V335, P971, DOI 10.1016/0140-6736(90)91033-7; WOODROW G, 1992, NEPHROL DIAL TRANSPL, V7, P230, DOI 10.1093/oxfordjournals.ndt.a092111; YOSHIOKA T, 1989, AM J PHYSIOL, V257, pF53, DOI 10.1152/ajprenal.1989.257.1.F53	33	332	338	0	14	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 17	1994	331	20					1338	1342		10.1056/NEJM199411173312003	http://dx.doi.org/10.1056/NEJM199411173312003			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR216	7935703				2023-01-03	WOS:A1994PR21600003
J	HELLMAN, S; WEICHSELBAUM, RR				HELLMAN, S; WEICHSELBAUM, RR			RADIATION ONCOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							B-CELL LYMPHOMA; IONIZING-RADIATION; THERAPY; RADIOTHERAPY; EXPERIENCE; ANTIBODY; CANCER				HELLMAN, S (corresponding author), UNIV CHICAGO,PRITZKER SCH MED,CHICAGO,IL 60637, USA.							[Anonymous], 1991, NEW ENGL J MED, V324, P1685; AUSTINSEYMOUR M, 1989, J NEUROSURG, V70, P13, DOI 10.3171/jns.1989.70.1.0013; CUMMINGS BJ, 1991, INT J RADIAT ONCOL, V21, P1115, DOI 10.1016/0360-3016(91)90265-6; GILL SS, 1991, INT J RADIAT ONCOL, V20, P599, DOI 10.1016/0360-3016(91)90076-G; HAIMOVITZFRIEDMAN A, 1991, CANCER RES, V51, P2552; HORIOT JC, 1992, RADIOTHER ONCOL, V25, P231, DOI 10.1016/0167-8140(92)90242-M; KAMINSKI MS, 1993, NEW ENGL J MED, V329, P459, DOI 10.1056/NEJM199308123290703; KAUFMAN DS, 1993, NEW ENGL J MED, V329, P1377, DOI 10.1056/NEJM199311043291903; LOEFFLER JS, 1990, RADIOTHER ONCOL, V17, P311, DOI 10.1016/0167-8140(90)90005-H; PRESS OW, 1993, NEW ENGL J MED, V329, P1219, DOI 10.1056/NEJM199310213291702; SAUNDERS MI, 1991, INT J RADIAT ONCOL, V21, P871, DOI 10.1016/0360-3016(91)90722-G; SCHARFEN CO, 1992, INT J RADIAT ONCOL, V24, P583; SEDDON JM, 1990, OPHTHALMOLOGY, V97, P769; VOKES EE, 1990, J CLIN ONCOL, V8, P911, DOI 10.1200/JCO.1990.8.5.911; WEICHSELBAUM RR, 1991, J NATL CANCER I, V83, P480, DOI 10.1093/jnci/83.7.480; WEICHSELBAUM RR, 1992, INT J RADIAT ONCOL, V24, P565, DOI 10.1016/0360-3016(92)91075-X	16	5	5	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 1	1994	271	21					1712	1714		10.1001/jama.271.21.1712	http://dx.doi.org/10.1001/jama.271.21.1712			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN117	8182867				2023-01-03	WOS:A1994NN11700046
J	POSTHUMA, WFM; WESTENDORP, RG; VANDENBROUCKE, JP				POSTHUMA, WFM; WESTENDORP, RG; VANDENBROUCKE, JP			CARDIOPROTECTIVE EFFECT OF HORMONE REPLACEMENT THERAPY IN POSTMENOPAUSAL WOMEN - THE EVIDENCE BIASED	BRITISH MEDICAL JOURNAL			English	Article							LONG-TERM ESTROGEN; CARDIOVASCULAR-DISEASE; FOLLOW-UP; MORTALITY; INEQUALITIES; PREVENTION; COHORT; CANCER; USERS; RISK	Objective-To quantify the effect of selection of relatively: healthy women in studies reporting reduced relative risk for cardiovascular disease in postmenopausal women taking hormone replacement therapy. Design-Review of the follow up studies reported in three recent meta-analyses to determine the effect of oestrogen therapy on both total cancer and cardiovascular disease. The same standard statistical:methods as in the original analyses were used. Main outcome measures-Relative risks of total cancer and cardiovascular disease. Results-In most of the follow up studies the relative risk for total cancer was below 1. The studies that showed the largest reduction in cardiovascular disease also showed the largest reduction in cancer, indicating a healthy cohort effect. Although heterogeneity within the studies prevented pooling, the best estimate for the protective effect on total cancer was a relative risk of 0.83 among women taking oestrogen (95% confidence interval 0.71 to 0.96), while in the same studies the relative risk for cardiovascular disease was 0.57 (0.50 to 0.64). Conclusions-Unintended selection of relatively healthy women for oestrogen therapy may have influenced the reported beneficial effect of oestrogen therapy on cardiovascular disease. It is unclear how much of the cardioprotection is due to this selection. Universal preventive hormonal replacement therapy for postmenopausal women is unwarranted at present.	LEIDEN UNIV HOSP,DEPT CLIN EPIDEMIOL,2300 RC LEIDEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC)			Posthuma, Ward/AAW-3740-2021; Vandenbroucke, Jan/AAM-3928-2020	Vandenbroucke, Jan/0000-0001-5668-6716				ADAMI HO, 1989, INT J CANCER, V44, P833, DOI 10.1002/ijc.2910440515; ADAMI HO, 1992, CANCER CAUSE CONTROL, V3, P83, DOI 10.1007/BF00051917; AVILA MH, 1990, EPIDEMIOLOGY, V1, P128; BARRETTCONNOR E, 1991, ANN INTERN MED, V115, P455, DOI 10.7326/0003-4819-115-6-455; BRESLOW NE, 1987, STAT METHODS CANC RE, V2, P11; BURCH JC, 1974, AM J OBSTET GYNECOL, V118, P778, DOI 10.1016/0002-9378(74)90487-6; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; BUSH TL, 1990, MENOPAUSE BIOL CLIN, P211; BYRD BF, 1977, ANN SURG, V185, P574, DOI 10.1097/00000658-197705000-00010; CAULEY JA, 1990, AM J OBSTET GYNECOL, V163, P1438, DOI 10.1016/0002-9378(90)90602-4; COLDITZ GA, 1990, JAMA-J AM MED ASSOC, V264, P2648, DOI 10.1001/jama.264.20.2648; COOPE J, 1991, LANCET, V337, P1162; CRIQUI MH, 1988, AM J EPIDEMIOL, V128, P606, DOI 10.1093/oxfordjournals.aje.a115008; EAKER ED, 1987, CORONARY HEART DISEA, P122; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GREENLAND S, 1987, EPIDEMIOL REV, V9, P1; HAMMOND CB, 1979, AM J OBSTET GYNECOL, V133, P525, DOI 10.1016/0002-9378(79)90288-6; HEMMINKI E, 1993, J CLIN EPIDEMIOL, V46, P211, DOI 10.1016/0895-4356(93)90068-C; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; HERNBERG S, 1986, EPIDEMIOLOGY OCCUPAT, P269; HUNT K, 1990, BRIT J OBSTET GYNAEC, V97, P1080, DOI 10.1111/j.1471-0528.1990.tb02494.x; JACOBS HS, 1992, BMJ-BRIT MED J, V305, P1403, DOI 10.1136/bmj.305.6866.1403; KUNST AE, 1990, SOC SCI MED, V31, P141, DOI 10.1016/0277-9536(90)90055-W; LAFFERTY FW, 1985, MATURITAS, V7, P147, DOI 10.1016/0378-5122(85)90021-0; LAYDE P M, 1981, Lancet, V1, P541; MACMAHON B, 1978, CORONARY HEART DISEA, P197; MARMOT MG, 1984, LANCET, V1, P1003; MARMOT MG, 1986, LANCET, V2, P274; MEADE TW, 1992, BRIT MED BULL, V48, P276, DOI 10.1093/oxfordjournals.bmb.a072548; MONSON RR, 1990, OCCUPATIONAL EPIDEMI, P114; PETTITI DB, 1987, OBSTET GYNECOL, V70, P289; Potocki J, 1971, Pol Tyg Lek, V26, P1812; SALKEBORN M, 1992, BRIT J OBSTET GYNAEC, V99, P821; SHAPIRO S, 1979, LANCET, V1, P743; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; SULLIVAN JM, 1990, ARCH INTERN MED, V150, P2557, DOI 10.1001/archinte.150.12.2557; VANDENBROUCKE JP, 1991, LANCET, V337, P833, DOI 10.1016/0140-6736(91)92526-8; WILSON PWF, 1985, NEW ENGL J MED, V313, P1038, DOI 10.1056/NEJM198510243131702; WOLF PH, 1991, AM J OBSTET GYNECOL, V164, P489, DOI 10.1016/S0002-9378(11)80006-2; 1992, ANN INTERN MED, V117, P1038	41	148	154	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 14	1994	308	6939					1268	1269						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM147	8205018				2023-01-03	WOS:A1994NM14700017
J	KOGAN, MD; ALEXANDER, GR; KOTELCHUCK, M; NAGEY, DA				KOGAN, MD; ALEXANDER, GR; KOTELCHUCK, M; NAGEY, DA			RELATION OF THE CONTENT OF PRENATAL-CARE TO THE RISK OF LOW-BIRTH-WEIGHT - MATERNAL REPORTS OF HEALTH BEHAVIOR ADVICE AND INITIAL PRENATAL-CARE PROCEDURES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMPACT; POPULATION; PROGRAMS; OUTCOMES; WOMEN	Objective.-Numerous studies have found a relationship between the quantity of prenatal care received and birth outcomes. Few studies have had the opportunity to examine the content of prenatal care. This study examined the relationship between two components of the content of prenatal care: maternal reports of health behavior advice received and initial prenatal care procedures performed during the first two visits and low birth weight in a national sample of women. Advice and initial procedures were categorized based on the recommendations of the US Public Health Service Expert Panel on the Content of Prenatal Care. Design.-Interview survey of a nationally representative sample of women who had live births in 1988. Participants.-A total of 9394 women, with data from the National Maternal and Infant Health Survey. Main Outcome Measure.-Low birth weight (<2500 g) as reported on the birth certificate. Results.-After controlling for other sociodemographic, utilization, medical, and behavioral factors, women who reported not receiving all the types of advice recommended by the Expert Panel on the Content of Prenatal Care were more likely to have a low-birth-weight infant compared with women who reported receiving the optimal level of advice (odds ratio=1.38; 95% confidence interval, 1.18 to 1.60). There were no differences between women who reported receiving all the recommended initial prenatal care procedures and those who reported not receiving all recommended prenatal care (odds ratio=1.00; 95% confidence interval, 0.87 to 1.14). Conclusion.-These data suggest that women who report receiving sufficient health behavior advice as part of their prenatal care are at lower risk of delivering a low-birth-weight infant.	UNIV MINNESOTA,DEPT MATERNAL & CHILD HLTH,MINNEAPOLIS,MN 55455; UNIV N CAROLINA,DEPT MATERNAL & CHILD HLTH,CHAPEL HILL,NC; UNIV MARYLAND,SCH MED,DEPT OBSTET & GYNECOL,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,DEPT PREVENT MED,BALTIMORE,MD 21201	University of Minnesota System; University of Minnesota Twin Cities; University of North Carolina; University of North Carolina Chapel Hill; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	KOGAN, MD (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR HLTH STAT,6525 BELCREST RD,ROOM 840,HYATTSVILLE,MD 20782, USA.							ALEXANDER GR, 1987, AM J PREV MED, V3, P243; DAVIDSON EC, 1992, NEW ENGL J MED, V327, P1022, DOI 10.1056/NEJM199210013271409; FINK A, 1992, OBSTET GYNECOL, V80, P867; FISHER ES, 1985, AM J PUBLIC HEALTH, V75, P866, DOI 10.2105/AJPH.75.8.866; GORTMAKER SL, 1979, AM J PUBLIC HEALTH, V69, P653, DOI 10.2105/AJPH.69.7.653; GREENBERG RS, 1983, AM J OBSTET GYNECOL, V145, P797, DOI 10.1016/0002-9378(83)90681-6; HEMMINKI E, 1988, MED CARE, V26, P199, DOI 10.1097/00005650-198802000-00010; KESSEL SS, 1988, CLIN PERINATOL, V15, P745, DOI 10.1016/S0095-5108(18)30671-7; Kessner DM, 1973, CONTRASTS HLTH STATU; KOGAN MD, 1994, AM J PUBLIC HEALTH, V84, P82, DOI 10.2105/AJPH.84.1.82; Koonin L M, 1991, MMWR CDC Surveill Summ, V40, P1; KOTELCHUCK M, IN PRESS AM J PUBLIC; LIBBUS MK, 1991, BIRTH-ISS PERINAT C, V18, P78, DOI 10.1111/j.1523-536X.1991.tb00064.x; LIEBERMAN E, 1987, NEW ENGL J MED, V317, P743, DOI 10.1056/NEJM198709173171206; MCLAUGHLIN FJ, 1992, PEDIATRICS, V89, P128; MOORE TR, 1986, AM J OBSTET GYNECOL, V154, P29, DOI 10.1016/0002-9378(86)90387-X; NAGEY DA, 1989, OBSTET GYNECOL, V74, P516; PEOPLES MD, 1983, MED CARE, V21, P586, DOI 10.1097/00005650-198306000-00002; PEOPLESSHEPS MD, 1991, AM J OBSTET GYNECOL, V164, P514, DOI 10.1016/S0002-9378(11)80011-6; PEOPLESSHEPS MD, 1988, HEALTH SERV RES, V23, P359; PETTITI DB, 1991, BIRTH-ISS PERINAT C, V18, P21; POLAND ML, 1991, J PERINAT MED, V19, P427, DOI 10.1515/jpme.1991.19.6.427; QUICK JD, 1981, AM J PUBLIC HEALTH, V71, P381, DOI 10.2105/AJPH.71.4.381; SANDERSON M, 1991, BIRTH-ISS PERINAT C, V18, P26, DOI 10.1111/j.1523-536X.1991.tb00050.x; SHIONO PH, 1986, JAMA-J AM MED ASSOC, V255, P48, DOI 10.1001/jama.255.1.48; SHOWSTACK JA, 1984, AM J PUBLIC HEALTH, V74, P1003, DOI 10.2105/AJPH.74.9.1003; SOKOL RJ, 1980, OBSTET GYNECOL, V56, P150; 1993, SURVEY DATA ANAL VER; 1989, CARING OUR FUTURE CO	29	153	156	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 4	1994	271	17					1340	1345		10.1001/jama.271.17.1340	http://dx.doi.org/10.1001/jama.271.17.1340			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NH487	8158819				2023-01-03	WOS:A1994NH48700026
J	SACK, MN; RADER, DJ; CANNON, RO				SACK, MN; RADER, DJ; CANNON, RO			ESTROGEN AND INHIBITION OF OXIDATION OF LOW-DENSITY LIPOPROTEINS IN POSTMENOPAUSAL WOMEN	LANCET			English	Note							17-BETA ESTRADIOL	Oxidative modification of low-density lipoprotein (LDL) may be atherogenic. We studied the time of onset of LDL oxidation (lag) in 18 postmenopausal women before and after intraarterial infusion of 17beta-oestradiol, after 3 weeks' patch administration ir 12 of these women, and 1. month after discontinuation in 10. The lag increased from baseline after acute infusion (from 134 [SD 41] to 167 [36] min, p = 0.01) and after the patch (132 [31] to 178 [45] min, p = 0.009). After discontinuation of oestradiol, the lag returned to baseline. This study shows an antioxidant effect of physiological levels of 17beta-oestradiol, which may contribute to an anti-atherogenic action.	NHLBI,CARDIOL BRANCH,BLDG 10,ROOM 7B-15,BETHESDA,MD 20892; NHLBI,MOLEC DIS BRANCH,BETHESDA,MD 20892; GEORGETOWN UNIV HOSP,WASHINGTON,DC 20007	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Georgetown University								ADAMS MR, 1990, ARTERIOSCLEROSIS, V10, P1051, DOI 10.1161/01.ATV.10.6.1051; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; CARR BR, 1992, WILLIAMS TXB ENDOCRI, P733; ESTERBAUER H, 1989, FREE RADICAL RES COM, V6, P67, DOI 10.3109/10715768909073429; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HOUGH JL, 1986, ARTERIOSCLEROSIS, V6, P57, DOI 10.1161/01.ATV.6.1.57; MAZIERE C, 1991, ATHEROSCLEROSIS, V89, P175, DOI 10.1016/0021-9150(91)90058-B; RIFICI VA, 1992, METABOLISM, V41, P1110, DOI 10.1016/0026-0495(92)90295-L; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499	9	483	493	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 29	1994	343	8892					269	270		10.1016/S0140-6736(94)91117-7	http://dx.doi.org/10.1016/S0140-6736(94)91117-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT440	7905101	hybrid			2023-01-03	WOS:A1994MT44000015
J	TURNER, R				TURNER, R			BIG-BROTHER IS LOOKING AFTER YOUR HEALTH	BRITISH MEDICAL JOURNAL			English	Article											TURNER, R (corresponding author), E RIDING HLTH,KINGSTON HULL HU10 6DT,ENGLAND.								0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 18	1993	307	6919					1623	1624		10.1136/bmj.307.6919.1623	http://dx.doi.org/10.1136/bmj.307.6919.1623			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN107	8292961	Green Published, Bronze			2023-01-03	WOS:A1993MN10700029
J	SMITH, MBH; FELDMAN, W				SMITH, MBH; FELDMAN, W			OVER-THE-COUNTER COLD MEDICATIONS - A CRITICAL-REVIEW OF CLINICAL-TRIALS BETWEEN 1950 AND 1991	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EXPERIMENTAL RHINOVIRUS COLDS; DATA-COLLECTION-SYSTEM; COMMON COLD; SYMPTOMATIC MANAGEMENT; ACUTE COUGH; CHILDREN; ANTIHISTAMINES; COMBINATION; PSEUDOEPHEDRINE; BEHAVIOR	Objective.-To determine whether over-the-counter cold medications have been shown to be effective in relieving symptoms in children, adolescents, and adults. Data Sources.-The MEDLINE database using the key words combined with medications and research and review articles. Articles were retrieved if they were written in English and published between January 1950 and January 1991. Study Selection.-Articles were selected if they described a controlled clinical trial on the treatment of the common cold. Forty-eight percent of 106 articles met the selection criteria, and these were grouped by age into child studies (<5 years old and <12 years old) and adolescent (aged 12 years and older)/adult studies. Data Extraction.-Each article was scored on 11 criteria to determine scientific validity. Those articles scoring above 70% were included in the final analysis. Two authors independently scored a sample of articles to determine interrater reliability. Data Synthesis.-Very few studies have been performed on children. Of those, two done on preschool children demonstrated no symptom relief, whereas two done on older children showed some benefit. In the adolescent/adult studies, chlorpheniramine maleate, pseudoephedrine hydrochloride, oxymetazoline hydrochloride, phenylpropanolamine hydrochloride, ipratropium bromide, and atropine methonitrate all improved nasal symptoms. Combination therapy (using an antihistamine-decongestant mix) was shown to relieve a variety of symptoms. Conclusions.-No good evidence has demonstrated the effectiveness of over-the-counter cold medications in preschool children. Further studies are required to clarify the role of these medications in children. Certain single over-the-counter medications and combinations have been shown to reduce cold symptoms in adolescents and adults.	HOSP SICK CHILDREN, DIV GEN PEDIAT, TORONTO M5G 1X8, ONTARIO, CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	SMITH, MBH (corresponding author), IZAAK WALTON KILLAM HOSP CHILDREN, DIV PEDIAT MED, HALIFAX B3J 3G9, NS, CANADA.							AKERLUND A, 1989, J LARYNGOL OTOL, V103, P743, DOI 10.1017/S0022215100109958; ASCHAN G., 1964, EYE EAR NOSE THROAT MON, V43, P66; BERKOWITZ RB, 1989, ANN ALLERGY, V63, P336; BEWS D. C., 1951, CANADIAN JOUR PUBL HEALTH, V42, P117; BORUM P, 1981, AM REV RESPIR DIS, V123, P418; BROWNING RH, 1950, NEW ENGL J MED, V243, P994, DOI 10.1056/NEJM195012212432504; BYE CE, 1980, BRIT MED J, V281, P189, DOI 10.1136/bmj.281.6234.189; COWAN DW, 1950, JAMA-J AM MED ASSOC, V143, P421, DOI 10.1001/jama.1950.02910400013004; CRUTCHER JE, 1981, J CLIN PHARMACOL, V21, P9, DOI 10.1002/j.1552-4604.1981.tb01725.x; CURLEY FJ, 1988, AM REV RESPIR DIS, V138, P305, DOI 10.1164/ajrccm/138.2.305; DIERCKX P, 1981, INT J CLIN PHARM TH, V19, P396; DIWAN J, 1982, INT J CLIN PHARM TH, V20, P373; DOYLE WJ, 1988, PEDIATR INFECT DIS J, V7, P229, DOI 10.1097/00006454-198803000-00033; FABRICANT ND, 1950, AMA ARCH OTOLARYNGOL, V52, P888; FELLER AE, 1950, NEW ENGL J MED, V242, P737, DOI 10.1056/NEJM195005112421901; FISHER P, 1951, AMA AM J DIS CHILD, V81, P530, DOI 10.1001/archpedi.1951.02040030541006; GADOMSKI A, 1992, PEDIATRICS, V89, P774; GAFFEY MJ, 1987, AM REV RESPIR DIS, V135, P241; GAFFEY MJ, 1987, AM REV RESPIR DIS, V136, P556, DOI 10.1164/ajrccm/136.3.556; GAFFEY MJ, 1988, PEDIATR INFECT DIS J, V7, P223, DOI 10.1097/00006454-198803000-00032; GRONBORG H, 1983, Rhinology (Utrecht), V21, P3; HAGGERTY RJ, 1972, PEDIATR CLIN N AM, V19, P101; HAMILTON LH, 1982, ANN OTO RHINOL LARYN, V91, P106, DOI 10.1177/000348948209100124; HENAUER SA, 1988, EUR J CLIN PHARMACOL, V34, P35, DOI 10.1007/BF01061414; HILL AB, 1962, STATISTICAL METHODS; HOAGLAND RJ, 1950, JAMA-J AM MED ASSOC, V143, P157, DOI 10.1001/jama.1950.02910370007003; HOWARD JC, 1979, JAMA-J AM MED ASSOC, V242, P2414, DOI 10.1001/jama.242.22.2414; HUTTON N, 1991, J PEDIATR-US, V118, P125, DOI 10.1016/S0022-3476(05)81865-7; JAFFE G, 1983, CURR MED RES OPIN, V8, P594, DOI 10.1185/03007998309109803; JAFFE GV, 1985, BRIT J CLIN PRACT, V39, P238; KAMINSZCZIK I, 1983, J INT MED RES, V11, P101, DOI 10.1177/030006058301100207; KANE FJ, 1966, AM J PSYCHIAT, V123, P484, DOI 10.1176/ajp.123.4.484; KUHN JJ, 1982, CHEST, V82, P713, DOI 10.1378/chest.82.6.713; LEA P, 1984, J INT MED RES, V12, P124, DOI 10.1177/030006058401200211; LEWISON E, 1970, EYE EAR NOSE THROAT, V49, P16; LITOVITZ TL, 1991, AM J EMERG MED, V9, P461, DOI 10.1016/0735-6757(91)90216-7; LITOVITZ TL, 1990, AM J EMERG MED, V8, P394, DOI 10.1016/0735-6757(90)90234-Q; LITOVITZ TL, 1989, AM J EMERG MED, V7, P495, DOI 10.1016/0735-6757(89)90252-0; LOWELL FC, 1951, NEW ENGL J MED, V244, P132, DOI 10.1056/NEJM195101252440403; Lowenstein S R, 1987, Adv Intern Med, V32, P207; MAIMAN LA, 1986, SOC SCI MED, V22, P41, DOI 10.1016/0277-9536(86)90307-2; MAIMAN LA, 1982, PUBLIC HEALTH REP, V97, P140; MATTS SGF, 1977, J INT MED RES, V5, P470; MCGUINNESS BW, 1976, BRIT J CLIN PRACT, V30, P15; MCLAURIN JW, 1966, LARYNGOSCOPE, V76, P1612, DOI 10.1002/lary.5540760914; MCLAURIN JW, 1961, LARYNGOSCOPE, V741, P54; MIDDLETON RSW, 1981, BRIT J CLIN PRACT, V35, P297; ORSON J, 1987, CLIN PEDIATR, V26, P287; PARKIN JB, 1962, PRACTITIONER, V189, P348; ROTH RP, 1977, ANN OTO RHINOL LARYN, V86, P235, DOI 10.1177/000348947708600216; SAKCHAINANONT B, 1990, Journal of the Medical Association of Thailand, V73, P96; Sengelmann H P, 1966, Ohio State Med J, V62, P141; SHAW CR, 1951, NEW YORK STATE J MED, V51, P387; SHAW CR, 1950, NEW YORK STATE J MED, V50, P1109; SILLS JA, 1984, BRIT MED J, V288, P1912, DOI 10.1136/bmj.288.6434.1912-c; SLODKI SJ, 1965, CURR THER RES CLIN E, V7, P19; SPERBER SJ, 1989, B NEW YORK ACAD MED, V65, P145; SPERBER SJ, 1988, ANTIMICROB AGENTS CH, V32, P409, DOI 10.1128/AAC.32.4.409; STRAPKOVA A, 1987, ACTA PHYSIOL HUNG, V70, P207; TAYLOR JG, 1992, SELF MED REFERENCE H, P191; THACKRAY P, 1978, J INT MED RES, V6, P161, DOI 10.1177/030006057800600218; THOMSON ME, 1984, PEDIATRICS, V73, P294; TUKIAINEN H, 1986, EUR J RESPIR DIS, V69, P95; VIRTANEN H, 1983, J LARYNGOL OTOL, V97, P159, DOI 10.1017/S0022215100093932; WEIPPL G, 1984, CLIN THER, V6, P475; WEST S, 1975, PEDIATRICS, V56, P100; WINTHER B, 1983, EUR J RESPIR DIS, V64, P447; 1950, BMJ, V2, P425; 1950, J LAB CLIN MED, V36, P555	69	168	174	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 5	1993	269	17					2258	2263		10.1001/jama.269.17.2258	http://dx.doi.org/10.1001/jama.269.17.2258			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ406	8097268				2023-01-03	WOS:A1993KZ40600035
J	JONES, RVH; HANSFORD, J; FISKE, J				JONES, RVH; HANSFORD, J; FISKE, J			DEATH FROM CANCER AT HOME - THE CARERS PERSPECTIVE	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To collect information from principal carers of people who had died at home with cancer; to identify areas of support which need improvement. Design-Semistructured interviews with carers two to four months after the death. Setting-38 general practices in the Exeter, Torbay, and Plymouth health districts. Subjects-207 carers. Main outcome measures-Services received by carers and quality of support. Results-161 of 207 patients were aged 60 or over. 88 carers were aged under 60, 110 were 60-80, and 9 were > 80. Carers had difficulty in getting urgent professional help in only 15 out of 177 cases. 124 carers were not given advice on financial help and 174 were not told of support available from local charities. Although pain was well controlled, 25% of patients had no relief of other symptoms. Overall, 150 carers considered the support excellent, 45 good, 8 moderate, 2 poor, and 2 had no comment. Conclusions-Although care has improved in recent years, health professionals need to give carers more advice about help available outside health services. Domestic help was often needed earlier. Better appreciation of carers' problems is needed.			JONES, RVH (corresponding author), UNIV EXETER,POSTGRAD MED SCH,DEPT GEN PRACTICE,EXETER EX2 5DW,ENGLAND.							CARTWRIGHT A, 1973, LIFE DEATH; HERD EB, 1990, BRIT J GEN PRACT, V40, P248; HIGGINSON I, 1990, BRIT MED J, V301, P277, DOI 10.1136/bmj.301.6746.277; HIGGINSON I, 1989, J R SOC MED, V82, P2264; JONES R, 1992, EUR J CANCER CARE, V1, P9; JONES RVH, 1992, BRIT J GEN PRACT, V42, P419; Parkes C M, 1978, J R Coll Gen Pract, V28, P19; SYKES N P, 1992, Palliative Medicine, V6, P227, DOI 10.1177/026921639200600307; WILKES E, 1984, LANCET, V1, P950; 1987, CARE DYING GUIDE HLT; 1989, MORTALITY UK; 1980, TERMINAL CARE REPORT	12	86	87	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 23	1993	306	6872					249	251		10.1136/bmj.306.6872.249	http://dx.doi.org/10.1136/bmj.306.6872.249			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ591	8443527	Green Published, Bronze			2023-01-03	WOS:A1993KJ59100024
J	Turpie, AGG				Turpie, AGG			Hirudin and thrombosis prophylaxis	LANCET			English	Editorial Material							HEPARIN; INHIBITORS				Turpie, AGG (corresponding author), HGH MCMASTER CLIN,HAMILTON,ON,CANADA.							CLAGETT GP, 1995, CHEST, V108, P371; HARKER LA, 1994, HEMOSTASIS THROMBOSI; HIRSH J, 1992, BLOOD, V79, P1; HIRSH J, 1991, NEW ENGL J MED, V324, P1565; KLEMENT P, 1992, THROMB HAEMOSTASIS, V68, P64; NEUHAUS KL, 1994, CIRCULATION, V90, P1632; WEITZ JI, 1990, J CLIN INVEST, V86, P385, DOI 10.1172/JCI114723; 1994, CIRCULATION, V90, P1631; 1992, BRIT MED J, V305, P567; 1994, CIRCULATION, V90, P1624; 1992, INT ANGIOL, V11, P151	11	2	2	1	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 9	1996	347	9002					632	633		10.1016/S0140-6736(96)91197-6	http://dx.doi.org/10.1016/S0140-6736(96)91197-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ285	8596373				2023-01-03	WOS:A1996TZ28500005
J	PAL, B; HUTCHINSON, A; BHATTACHARYA, A; RALSTON, A				PAL, B; HUTCHINSON, A; BHATTACHARYA, A; RALSTON, A			LESSON OF THE WEEK - CARDIAC-ARREST DUE TO SEVERE HYPERKALEMIA IN PATIENT TAKING NABUMETONE AND LOW-SALT DIET	BRITISH MEDICAL JOURNAL			English	Article							ANTI-INFLAMMATORY DRUGS; KIDNEY				PAL, B (corresponding author), WITHINGTON HOSP,MANCHESTER M20 2LR,LANCS,ENGLAND.							BOERS M, 1990, SEMIN ARTHRITIS RHEU, V20, P57, DOI 10.1016/0049-0172(90)90095-W; HYNECK ML, 1992, J RHEUMATOL, V19, P20; PAL B, 1985, ANN RHEUM DIS, V44, P212, DOI 10.1136/ard.44.3.212-b; REEVES WB, 1984, ARCH INTERN MED, V144, P1943, DOI 10.1001/archinte.144.10.1943; SEGASOTHY M, 1995, BRIT J RHEUMATOL, V34, P162; STILLMAN MT, 1984, MED CLIN N AM, V68, P371; SWALES JD, 1991, BMJ-BRIT MED J, V303, P1084, DOI 10.1136/bmj.303.6810.1084; WHELTON A, 1991, J CLIN PHARMACOL, V31, P588, DOI 10.1002/j.1552-4604.1991.tb03743.x	8	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 2	1995	311	7018					1486	1487		10.1136/bmj.311.7018.1486	http://dx.doi.org/10.1136/bmj.311.7018.1486			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TJ044	8520342	Green Published			2023-01-03	WOS:A1995TJ04400033
J	MORGAN, R; KING, D; PRAJAPATI, C; ROWE, J				MORGAN, R; KING, D; PRAJAPATI, C; ROWE, J			VIEWS OF ELDERLY PATIENTS AND THEIR RELATIVES ON CARDIOPULMONARY-RESUSCITATION	BRITISH MEDICAL JOURNAL			English	Article							ATTITUDES; DECISIONS		BROADGREEN HOSP,DEPT MED,LIVERPOOL L14 3LB,MERSEYSIDE,ENGLAND	Royal Liverpool & Broadgreen University Hospitals NHS Trust; University of Liverpool								DAVIES KN, 1993, J ROY COLL PHYS LOND, V27, P127; DOYAL L, 1993, BRIT MED J, V306, P1593, DOI 10.1136/bmj.306.6892.1593; SCHADE SG, 1989, J MED ETHICS, V15, P186, DOI 10.1136/jme.15.4.186; STEWART K, 1990, BRIT MED J, V300, P785, DOI 10.1136/bmj.300.6727.785; STOLMAN CJ, 1990, ARCH INTERN MED, V150, P653, DOI 10.1001/archinte.150.3.653	5	70	70	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 25	1994	308	6945					1677	1678		10.1136/bmj.308.6945.1677a	http://dx.doi.org/10.1136/bmj.308.6945.1677a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU483	7993423	Green Published			2023-01-03	WOS:A1994NU48300022
J	FABIAN, CJ; MANSFIELD, CM; DAHLBERG, S; JONES, SE; MILLER, TP; VANSLYCK, E; GROZEA, PN; MORRISON, FS; COLTMAN, CA; FISHER, RI				FABIAN, CJ; MANSFIELD, CM; DAHLBERG, S; JONES, SE; MILLER, TP; VANSLYCK, E; GROZEA, PN; MORRISON, FS; COLTMAN, CA; FISHER, RI			LOW-DOSE INVOLVED FIELD RADIATION AFTER CHEMOTHERAPY IN ADVANCED HODGKIN DISEASE - A SOUTHWEST-ONCOLOGY-GROUP RANDOMIZED STUDY	ANNALS OF INTERNAL MEDICINE			English	Article							COMBINED MODALITY THERAPY; ALLOGENEIC MARROW TRANSPLANTATION; FOLLOW-UP DATA; COMBINATION CHEMOTHERAPY; MOPP CHEMOTHERAPY; LUNG-CANCER; RADIOTHERAPY; WR-2721; ABVD; RADIOPROTECTION	Objective: To determine if low-dose involved field radiation after complete remission induction with chemotherapy is effective in preventing relapse and improving survival in patients with stage III or IV Hodgkin disease. Design: A randomized controlled trial with a median follow-up time of 8.1 years. Setting: A Southwest Oncology Group multiinstitutional study. Patients were entered from university- and community-based practices. Patients: 278 adults with clinical or pathologic stage III or IV Hodgkin disease, who achieved complete responses after 6 cycles of MOP-BAP (nitrogen mustard, vincristine, prednisone, bleomycin, doxorubicin, and procarbazine) and who agreed to be randomly assigned to either radiation or no further treatment. Intervention: Patients were assigned to either no further treatment or low-dose radiation to all initially involved sites (radiation dose, 2000 cGy to lymph node areas and 1000 to 1500 cGy to other involved organ sites). Measurements: Differences in remission duration, relapse-free survival, and survival. Results: Remission duration, relapse-free survival, and overall survival were similar for the two groups (P = 0.09, P > 0.2, and P = 0.14, respectively). Factors that predicted shorter remission duration in a multivariate analysis were nodular sclerosis histology, bulky disease, and receipt of less than 85% of planned chemotherapy. Low-dose radiation improved remission duration in the subgroups of patients with nodular sclerosis and bulky disease. For the 169 patients with nodular sclerosis, the 5-year remission-duration estimate was 82% for the low-dose radiation group and 60% for the no further treatment group (P = 0.002). For all patients with bulky disease, the 5-year remission-duration estimate was 75% for the low-dose radiation group and 57% for the no further treatment group (P = 0.05). No difference in overall survival was noted between low-dose radiation and no further treatment in all patients or major subgroups. The 5-year survival was 86% for all patients who had a complete response as well as for patients in the nodular sclerosis subgroup. Conclusions: Low-dose involved field radiation after MOP-BAP chemotherapy in patients with stage III or IV Hodgkin disease did not prolong remission duration or overall survival in randomized patients. However, remission duration was prolonged in several subgroups of patients, most prominently in those with nodular sclerosis histology.	UNIV KANSAS, MED CTR, KANSAS CITY, KS 66103 USA; SW ONCOL GRP, CTR STAT, SEATTLE, WA USA; UNIV ARIZONA, CTR CANC, TUCSON, AZ USA; HENRY FORD HOSP, DETROIT, MI USA; UNIV OKLAHOMA, HLTH SCI CTR, OKLAHOMA CITY, OK USA; UNIV MISSISSIPPI, MED CTR, JACKSON, MS 39216 USA; UNIV TEXAS, HLTH SCI CTR, SAN ANTONIO, TX USA; LOYOLA UNIV, STRITCH SCH MED, MAYWOOD, IL 60153 USA	University of Kansas; University of Kansas Medical Center; Southwest Oncology Group; University of Arizona; Henry Ford Health System; Henry Ford Hospital; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Mississippi; University of Mississippi Medical Center; University of Texas System; University of Texas Health San Antonio; Loyola University Chicago	FABIAN, CJ (corresponding author), SW ONCOL GRP, SWOG 7808, OPERAT OFF, 14980 OMICRON DR, SAN ANTONIO, TX 78229 USA.				NCI NIH HHS [CA-12644, CA-37429, CA-13612] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA013612, U10CA012644, U10CA037429] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLALUNISTURNER MJ, 1989, RADIAT RES, V118, P581, DOI 10.2307/3577415; APPELBAUM FR, 1985, J CLIN ONCOL, V3, P1490, DOI 10.1200/JCO.1985.3.11.1490; BAKEMEIER RF, 1984, ANN INTERN MED, V101, P447, DOI 10.7326/0003-4819-101-4-447; BONADONNA G, 1986, ANN INTERN MED, V104, P739, DOI 10.7326/0003-4819-104-6-739; BUESA JM, 1984, CANCER TREAT REP, V68, P683; CANELLOS GP, 1992, NEW ENGL J MED, V327, P1478, DOI 10.1056/NEJM199211193272102; CANELLOS GP, 1990, SEMIN ONCOL, V17, P2; CANELLOS GP, 1988, SEMIN HEMATOL, V25, P58; CARBONE PP, 1971, CANCER RES, V31, P1860; CARDE P, 1983, J CLIN ONCOL, V1, P146, DOI 10.1200/JCO.1983.1.2.146; CIONINI L, 1982, EUR J RADIOL, V2, P301; COSSET JM, 1989, P AN M AM SOC CLIN, V8, P253; COX DR, 1972, J R STAT SOC B, V34, P187; DEVI PU, 1990, RADIAT RES, V124, P165, DOI 10.2307/3577861; DEVITA VT, 1980, ANN INTERN MED, V92, P587, DOI 10.7326/0003-4819-92-5-587; DEVITA VT, 1981, CANCER, V47, P1, DOI 10.1002/1097-0142(19810101)47:1<1::AID-CNCR2820470102>3.0.CO;2-2; DIEHL LF, 1983, CANCER TREAT REP, V67, P827; DURAND RE, 1989, BRIT J CANCER, V60, P517, DOI 10.1038/bjc.1989.305; FABIAN C, 1989, P AN M AM SOC CLIN, V8, P253; FISHER RI, 1979, ANN INTERN MED, V90, P761, DOI 10.7326/0003-4819-90-5-761; FLOERSHEIM GL, 1990, BRIT J RADIOL, V63, P468, DOI 10.1259/0007-1285-63-750-468; FOX KA, 1987, J CLIN ONCOL, V5, P38, DOI 10.1200/JCO.1987.5.1.38; GAREWAL HS, 1990, J CLIN ONCOL, V8, P1715, DOI 10.1200/JCO.1990.8.10.1715; GLICK J, 1984, P AN M AM SOC CLIN, V3, P237; GLICK J, 1988, P AN M AM SOC CLIN, V7, P223; GLICK JH, 1986, ANN INTERN MED, V104, P876, DOI 10.7326/0003-4819-104-6-876; GROZEA PN, 1985, P AN M AM SOC CLIN, V4, P201; HANCOCK SL, 1988, ANN INTERN MED, V109, P183, DOI 10.7326/0003-4819-109-3-183; HARKER WG, 1984, ANN INTERN MED, V101, P440, DOI 10.7326/0003-4819-101-4-440; HONG WK, 1990, P AN M AM SOC CLIN, V9, P171; HOPPE RT, 1980, CANCER, V46, P1240, DOI 10.1002/1097-0142(19800901)46:5<1240::AID-CNCR2820460526>3.0.CO;2-T; JONES SE, 1983, CANCER, V51, P1339, DOI 10.1002/1097-0142(19830415)51:8<1339::AID-CNCR2820510803>3.0.CO;2-8; KALDOR JM, 1990, NEW ENGL J MED, V322, P7, DOI 10.1056/NEJM199001043220102; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAPLAN HS, 1966, CANCER RES, V26, P1221; KOLETSKY AJ, 1986, J CLIN ONCOL, V4, P311, DOI 10.1200/JCO.1986.4.3.311; KUENTZ M, 1983, CANCER, V52, P780, DOI 10.1002/1097-0142(19830901)52:5<780::AID-CNCR2820520504>3.0.CO;2-1; LIST AF, 1985, J CLIN ONCOL, V3, P215, DOI 10.1200/JCO.1985.3.2.215; LONGO DL, 1991, J CLIN ONCOL, V9, P1409, DOI 10.1200/JCO.1991.9.8.1409; LONGO DL, 1991, J CLIN ONCOL, V9, P227, DOI 10.1200/JCO.1991.9.2.227; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MAUCH P, 1987, J CLIN ONCOL, V5, P544, DOI 10.1200/JCO.1987.5.4.544; OREILLY SE, 1991, ANN ONCOL, V2, P17, DOI 10.1093/annonc/2.suppl_1.17; PATCHEN ML, 1990, INT J RADIAT ONCOL, V18, P1069, DOI 10.1016/0360-3016(90)90442-M; PHILLIPS GL, 1989, J CLIN ONCOL, V7, P1039, DOI 10.1200/JCO.1989.7.8.1039; PROSNITZ LR, 1973, RADIOLOGY, V107, P187, DOI 10.1148/107.1.187; PROSNITZ LR, 1988, J CLIN ONCOL, V6, P603, DOI 10.1200/JCO.1988.6.4.603; PROSNITZ LR, 1982, CANCER TREAT REP, V66, P871; ROACH M, 1987, J CLIN ONCOL, V5, P550, DOI 10.1200/JCO.1987.5.4.550; ROSKOS RR, 1982, CANCER TREAT REP, V66, P961; Schein P S, 1990, Cancer Invest, V8, P265, DOI 10.3109/07357909009017579; STEWART FA, 1989, INT J RADIAT ONCOL, V16, P1195, DOI 10.1016/0360-3016(89)90282-4; TUCKER MA, 1988, NEW ENGL J MED, V318, P76, DOI 10.1056/NEJM198801143180203; VALAGUSSA P, 1986, J CLIN ONCOL, V4, P830, DOI 10.1200/JCO.1986.4.6.830; VANLEEUWEN FE, 1989, J CLIN ONCOL, V7, P1046, DOI 10.1200/JCO.1989.7.8.1046; VANRIJSWIJK REN, 1987, J CLIN ONCOL, V5, P1624, DOI 10.1200/JCO.1987.5.10.1624; VANRIJSWIJK REN, 1989, J CLIN ONCOL, V7, P1776, DOI 10.1200/JCO.1989.7.12.1776; VIVIANI S, 1991, ANN ONCOL, V2, P55, DOI 10.1093/annonc/2.suppl_2.55; YELLE L, 1991, J CLIN ONCOL, V9, P1983, DOI 10.1200/JCO.1991.9.11.1983; YOUNG RC, 1978, CANCER, V42, P1001, DOI 10.1002/1097-0142(197808)42:2+<1001::AID-CNCR2820420723>3.0.CO;2-Z	61	133	139	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1994	120	11					903	912		10.7326/0003-4819-120-11-199406010-00002	http://dx.doi.org/10.7326/0003-4819-120-11-199406010-00002			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN110	8172436				2023-01-03	WOS:A1994NN11000002
J	HAEFNER, HK				HAEFNER, HK			ITS A BOY	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											HAEFNER, HK (corresponding author), UNIV MICHIGAN, MED CTR, DIV GYNECOL, MED PROFESS BLDG D2202-0718, 1500 E MED CTR DR, ANN ARBOR, MI 48109 USA.								0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1994	120	9					806	806		10.7326/0003-4819-120-9-199405010-00013	http://dx.doi.org/10.7326/0003-4819-120-9-199405010-00013			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH251	8147554				2023-01-03	WOS:A1994NH25100013
J	FENAUX, P; CHASTANG, C; CHOMIENNE, C; DEGOS, L				FENAUX, P; CHASTANG, C; CHOMIENNE, C; DEGOS, L			TRETINOIN WITH CHEMOTHERAPY IN NEWLY-DIAGNOSED ACUTE PROMYELOCYTIC LEUKEMIA	LANCET			English	Letter							TRANS-RETINOIC ACID		HOP ST LOUIS,DBIM,PARIS,FRANCE; HOP ST LOUIS,BIOL CELLULAIRE HEMATOL LAB,PARIS,FRANCE; HOP ST LOUIS,SERV CLIN MALAD SANG,PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	FENAUX, P (corresponding author), CHU LILLE,SERV MALAD SANG,F-59037 LILLE,FRANCE.			CHOMIENNE, Christine/0000-0001-5513-5752				CHOMIENNE C, 1990, BLOOD, V76, P1710; FENAUX P, 1993, BLOOD, V82, P3241; FENAUX P, 1992, BLOOD, V80, P2176; FRANKEL SR, 1994, ANN INTERN MED, V120, P278, DOI 10.7326/0003-4819-120-4-199402150-00004; OHNO R, 1993, LEUKEMIA, V7, P1722	5	41	41	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 23	1994	343	8904					1033	1033		10.1016/S0140-6736(94)90151-1	http://dx.doi.org/10.1016/S0140-6736(94)90151-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NG682	7909058				2023-01-03	WOS:A1994NG68200031
J	OBRIEN, S; KANTARJIAN, H; ESTEY, E; KOLLER, C; ROBERTSON, B; BERAN, M; ANDREEFF, M; PIERCE, S; KEATING, M				OBRIEN, S; KANTARJIAN, H; ESTEY, E; KOLLER, C; ROBERTSON, B; BERAN, M; ANDREEFF, M; PIERCE, S; KEATING, M			LACK OF EFFECT OF 2-CHLORODEOXYADENOSINE THERAPY IN PATIENTS WITH CHRONIC LYMPHOCYTIC-LEUKEMIA REFRACTORY TO FLUDARABINE THERAPY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HAIRY-CELL LEUKEMIA; PLASMA; AGENT	Background. Fludarabine and 2-chlorodeoxyadenosine are nucleoside analogues that have proved effective in patients with chronic lymphocytic leukemia (CLL). Although their mechanism of action is thought to be similar, a small number of patients who do not respond to fludarabine do respond to 2-chlorodeoxyadenosine. The extent to which 2-chlorodeoxyadenosine is effective in patients who do not respond to fludarabine is not known, however. Methods. We treated 28 patients with CLL refractory to fludarabine therapy with a continuous infusion of 2-chlorodeoxyadenosine at a daily dose of 4 mg per square meter of body-surface area for seven days. The treatment could be repeated monthly. The number of treatments ranged from one to five; patients who responded continued to receive treatment until the maximal response was achieved. Results. Two patients (7 percent) had partial remissions, but no patients had complete remissions. One other patient had a substantial response but had residual thrombocytopenia. The rate of response in most affected organs was 20 percent, but anemia or thrombocytopenia rarely improved. Myelosuppression was frequent, and 65 percent of the courses of 2-chlorodeoxyadenosine therapy were accompanied by febrile episodes or infections. Ten patients died within 60 days of starting therapy with 2-chlorodeoxyadenosine; eight deaths were related to infection. The median platelet count at the start of 2-chlorodeoxyadenosine therapy in these 10 patients was 24,000 per cubic millimeter, as compared with 109,000 per cubic millimeter in the other 18 patients. Five patients were alive after a median follow-up of 24 months. Conclusions. Patients with advanced CLL refractory to fludarabine therapy are unlikely to benefit from treatment with 2-chlorodeoxyadenosine. Although 20 percent of the patients have some response, thrombocytopenia and anemia are rarely corrected and may be made worse by 2-chlorodeoxyadenosine therapy.			OBRIEN, S (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT HEMATOL,BOX 61,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.							CHESON BD, 1988, AM J HEMATOL, V29, P152, DOI 10.1002/ajh.2830290307; DANHAUSER L, 1986, CANCER CHEMOTH PHARM, V18, P145; DELANNOY A, 1993, NEW ENGL J MED, V328, P812; ESTEY EH, 1992, BLOOD, V79, P882; GANDHI V, 1993, LEUKEMIA LYMPHOMA, V10, P49, DOI 10.3109/10428199309147356; JULIUSSON G, 1993, J CLIN ONCOL, V11, P679, DOI 10.1200/JCO.1993.11.4.679; JULIUSSON G, 1992, NEW ENGL J MED, V327, P1056, DOI 10.1056/NEJM199210083271504; KEATING MJ, 1989, BLOOD, V74, P19; LILIEMARK J, 1991, BLOOD S, V78, pA33; LILIEMARK JO, 1985, CANCER RES, V45, P5952; PIRO LD, 1990, NEW ENGL J MED, V322, P1117, DOI 10.1056/NEJM199004193221605; PIRO LD, 1988, BLOOD, V72, P1069; PLUNKETT W, 1993, CHRONIC LYMPHOCYTIC, V1, P197; ROBERTSON LE, 1993, BLOOD, V81, P143; SAVEN A, 1991, LEUKEMIA LYMPHOMA, V5, P133, DOI 10.3109/10428199109103394	15	82	84	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 3	1994	330	5					319	322		10.1056/NEJM199402033300504	http://dx.doi.org/10.1056/NEJM199402033300504			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU489	7904047				2023-01-03	WOS:A1994MU48900004
J	HOGERZEIL, HV; BIMO; ROSSDEGNAN, D; LAING, RO; OFORIADJEI, D; SANTOSO, B; CHOWDHURY, AKA; DAS, AM; KAFLE, KK; MABADEJE, AFB; MASSELE, AY				HOGERZEIL, HV; BIMO; ROSSDEGNAN, D; LAING, RO; OFORIADJEI, D; SANTOSO, B; CHOWDHURY, AKA; DAS, AM; KAFLE, KK; MABADEJE, AFB; MASSELE, AY			FIELD-TESTS FOR RATIONAL DRUG-USE IN 12 DEVELOPING-COUNTRIES	LANCET			English	Article								Increasing efforts are being made to improve drug-use practices and prescribing behaviour in developing countries. An essential tool for such work is an objective and standard method of assessment. We present here a set of drug-use indicators produced and tested in twelve developing countries. We describe practical applications, which include the use of indicators to increase awareness among prescribers in Malawi and Bangladesh, to identify priorities for action (eg, polypharmacy in Indonesia and Nigeria, overuse of injections in Uganda, Sudan, and Nigeria, and low percentage of patients who understood the dosage schedule in Malawi), and to quantify the impact of interventions in Yemen, Uganda, Sudan, and Zimbabwe.	YAYASAN INDONESIA SEJAHTERA,DIV HLTH,JAKARTA,INDONESIA; HARVARD UNIV,SCH MED,DRUG POLICY GRP,BOSTON,MA 02115; MANAGEMENT SCI HLTH,INT NETWORK RAT USE DRUGS,BOSTON,MA; UNIV GHANA,SCH MED,CTR TROP CLIN PHARMACOL,ACCRA,GHANA; GADJAH MADA UNIV,DEPT CLIN PHARMACOL,YOGYAKARTA,INDONESIA; NATL INST PREVENT & SOCIAL MED,DEPT BIOSTAT,DHAKA,BANGLADESH; UNIV DHAKA,DEPT PHARM,DHAKA,BANGLADESH; TRIBHUVAN UNIV HOSP,DEPT CLIN PHARMACOL,KATMANDU,NEPAL; UNIV LAGOS,COLL MED,DEPT PHARMACOL,LAGOS,NIGERIA; MAHIMBILL MED CTR,DEPT CLIN PHARMACOL,DAR ES SALAAM,TANZANIA	Harvard University; Harvard Medical School; University of Ghana; Gadjah Mada University; University of Dhaka; Tribhuvan University; Institute of Medicine (IoM) - Nepal; University of Lagos	HOGERZEIL, HV (corresponding author), WHO,ACT PROGRAMME ESSENTIAL DRUGS,CH-1211 GENEVA 27,SWITZERLAND.			Ofori-Adjei, David/0000-0003-1912-4188; Massele, Amos/0000-0003-3816-2040				Bannenberg WJ, 1991, WHODAP9110; BATES JA, 1992, GUATEMALA FIELD TEST; Bimo, 1992, INRUD NEWS, V3, P9; Christensen Rene Flamsholt, 1990, STRATEGY IMPROVEMENT; Gelders S, 1992, MALAWI ESSENTIAL DRU; HOGERZEIL HV, 1989, LANCET, V1, P141; KAFLE KK, 1992, INRUD NEWS, V3, P15; LAING RO, 1990, TROP DOCT, V20, P101, DOI 10.1177/004947559002000303; Ofori-Adjei D, 1992, INRUD NEWS, V3, P9; ROSSDEGNAN D, 1992, SOC SCI MED, V35, P1329, DOI 10.1016/0277-9536(92)90037-Q; SALLET JP, 1992, ECUADOR FIELD TEST P; 1991, FIELD TESTING DRUG I; 1993, WHODAP931, P1; 1993, BASELINE SURVEY DRUG; 1987, 1985 C EXP NAIR; 1991, ESSENTIAL DRUGS SURV	16	162	178	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 4	1993	342	8884					1408	1410		10.1016/0140-6736(93)92760-Q	http://dx.doi.org/10.1016/0140-6736(93)92760-Q			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK095	7901689				2023-01-03	WOS:A1993MK09500017
J	BONNIN, MJ; PEPE, PE; KIMBALL, KT; CLARK, PS				BONNIN, MJ; PEPE, PE; KIMBALL, KT; CLARK, PS			DISTINCT CRITERIA FOR TERMINATION OF RESUSCITATION IN THE OUT-OF-HOSPITAL SETTING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SUDDEN CARDIAC-ARREST; IMPROVING SURVIVAL; LIFE-SUPPORT; EMERGENCY; FIELD; GUIDELINES; CPR	Objective.-To identify distinct criteria for appropriate on-scene termination of resuscitation efforts for out-of-hospital cardiac arrest when on-scene interventions fail to restore spontaneous circulation. Design.-For 18 months, all out-of-hospital cardiac arrests were evaluated prospectively for survival to hospital discharge and for all established survival predictors including age, gender, presenting cardiac rhythm, whether it was a witnessed event, performance of basic cardiopulmonary resuscitation by bystanders, and interval to paramedic arrival and return of spontaneous circulation (ROSC). Setting.-A large municipality with a single, centralized emergency medical services program. Patients.-All normothermic adults treated for out-of-hospital, unmonitored, primary cardiac arrest. Interventions.-Standard advanced cardiac life support provided at the scene by paramedics. Main Outcome Measures.-The number and circumstances of patients achieving survival to hospital discharge following failure to achieve on-scene ROSC. Results.-Of 1461 consecutive primary cardiac arrests, 139 were monitored (paramedic witnessed), including 59 that occurred en route to the hospital. Of the 1322 unmonitored patients, 370 achieved ROSC at the scene. Only six (0.6%) of the 952 who did not achieve ROSC at the scene survived, and all six were readily identifiable as having persistent ventricular fibrillation. Excluding those patients with persistent ventricular fibrillation, all survivors achieved ROSC within 25 minutes after paramedic arrival. Conclusions.-Excluding patients with persistent ventricular fibrillation, resuscitative efforts can be terminated at the scene when normothermic adults with unmonitored, out-of-hospital, primary cardiac arrest do not regain spontaneous circulation within 25 minutes following standard advanced cardiac life support. These criteria should now be validated in several large centers with high survival rates.	CITY HOUSTON CTR RESUSCITAT & EMERGENCY MED SERV,410 BAGBY,SUITE 300,HOUSTON,TX 77002; BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030	Baylor College of Medicine								APRAHAMIAN C, 1986, ANN EMERG MED, V15, P445, DOI 10.1016/S0196-0644(86)80185-8; AUERBACH PS, 1987, JAMA-J AM MED ASSOC, V258, P1487, DOI 10.1001/jama.258.11.1487; BECKER LB, 1993, ANN EMERG MED, V22, P354, DOI 10.1016/S0196-0644(05)80465-2; BONNIN MJ, 1989, ANN EMERG MED, V18, P507, DOI 10.1016/S0196-0644(89)80834-0; COBB LA, 1976, MED CLIN N AM, V60, P283, DOI 10.1016/S0025-7125(16)31909-5; CUMMINS RO, 1991, CIRCULATION, V83, P1832, DOI 10.1161/01.CIR.83.5.1832; CUMMINS RO, 1991, ANN EMERG MED, V20, P861; CURRY DG, 1989, MED CONTROL MANUAL; EISENBERG MS, 1985, ANN EMERG MED, V14, P1106, DOI 10.1016/S0196-0644(85)80932-X; Eliastam M, 1977, JACEP, V6, P525, DOI 10.1016/S0361-1124(77)80422-X; FOSNOCHT DE, 1993, ANN EMERG MED, V22, P919; FRANK M, 1989, ANN EMERG MED, V18, P594, DOI 10.1016/S0196-0644(89)80853-4; GEEHR EC, 1986, NEW ENGL J MED, V314, P1189; GRAY WA, 1991, NEW ENGL J MED, V325, P1393, DOI 10.1056/NEJM199111143252001; JAKOBSSON J, 1987, ACTA MED SCAND, V222, P123; KELLERMANN AL, 1993, ANN EMERG MED, V22, P47, DOI 10.1016/S0196-0644(05)80249-5; KELLERMANN AL, 1988, ANN EMERG MED, V17, P589, DOI 10.1016/S0196-0644(88)80398-6; KELLERMANN AL, 1987, AM J EMERG MED, V5, P548, DOI 10.1016/0735-6757(87)90197-5; LEVINE RL, 1992, JAMA-J AM MED ASSOC, V267, P2935, DOI 10.1001/jama.267.21.2935; LEWIS LM, 1990, AM J EMERG MED, V8, P118, DOI 10.1016/0735-6757(90)90196-7; LOW R, 1993, PREHOSPITAL DISAST S, V8, pS69; MOORE TJ, 1989, HEART FAILURE CRITIC, P186; OCONNOR R, 1993, PREHOSP DISAST ME S2, V8, pS57; OMARCAIGH AS, 1993, MAYO CLIN PROC, V68, P332, DOI 10.1016/S0025-6196(12)60126-8; PEPE PE, 1993, ANN EMERG MED, V22, P17, DOI 10.1016/S0196-0644(05)80244-6; PEPE PE, 1993, CRIT CARE MED, V21, P1279, DOI 10.1097/00003246-199309000-00009; PEPE PE, 1985, ANN EMERG MED, V14, P1085, DOI 10.1016/S0196-0644(85)80927-6; PEPE PE, 1990, PROBL CRIT CARE, V4, P470; PEPE PE, 1990, UPDATE EMERGENCY INT, P565; PEPE PE, 1990, PREHOSP DISASTER MED, V5, P59; SCHMIDT TA, 1993, ANN EMERG MED, V22, P918; SMITH JP, 1985, ANN EMERG MED, V14, P1093; SMITH JP, 1985, WESTERN J MED, V143, P402; STONE CK, 1993, PREHOSP DISAST ME S2, V8, pS68; VANHOEYWEGHEN R, 1989, RESUSCITATION, V17, pS137, DOI 10.1016/0300-9572(89)90098-1; WARNER LL, 1985, CHEST, V87, P22, DOI 10.1378/chest.87.1.22; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; WEAVER WD, 1986, ANN EMERG MED, V15, P1181; WEAVER WD, 1991, NEW ENGL J MED, V325, P1437, DOI 10.1056/NEJM199111143252008; WOLFORD RW, 1988, ANN EMERG MED, V17, P410; 1986, JAMA-J AM MED ASSOC, V255, P2841; 1992, JAMA-J AM MED ASSOC, V268, P2171; 1989, RESPONSE TIME 1ST RE; 1989, PREHOSP DISAST MED, V4, P163; 1991, CPH145 US DEP COMM E	45	148	149	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 22	1993	270	12					1457	1462		10.1001/jama.270.12.1457	http://dx.doi.org/10.1001/jama.270.12.1457			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX173	8204131				2023-01-03	WOS:A1993LX17300031
J	GREENBERG, S; REISER, IW; CHOU, SY; PORUSH, JG				GREENBERG, S; REISER, IW; CHOU, SY; PORUSH, JG			TRIMETHOPRIM-SULFAMETHOXAZOLE INDUCES REVERSIBLE HYPERKALEMIA	ANNALS OF INTERNAL MEDICINE			English	Article						TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; HYPERKALEMIA; POTASSIUM; ACQUIRED IMMUNODEFICIENCY SYNDROME; PNEUMONIA, PNEUMOCYSTIS-CARINII	ACQUIRED-IMMUNODEFICIENCY-SYNDROME; PNEUMOCYSTIS-CARINII PNEUMONIA; IMMUNE-DEFICIENCY SYNDROME; CO-TRIMOXAZOLE; INTERSTITIAL NEPHRITIS; ADVERSE REACTIONS; MINERALOCORTICOID DEFICIENCY; HIV INFECTION; NEPHROTOXICITY; CREATININE	Objective: To determine the effect of trimethoprim-sulfamethoxazole (Tmp-Smx) on serum potassium concentration. Design: Retrospective cohort study. Setting: An urban teaching hospital. Patients: Fifty-one persons hospitalized for symptomatic infection with human immunodeficiency virus (HIV). Twenty-five patients who were taking high-dose Tmp-Smx (trimethoprim 20 mg/kg per day; sulfamethoxazole, 100 mg/kg per day) for Pneumocystis carinii pneumonia were the study group. Twenty-six patients who had not received the drug were the control group. Patients who received potassium supplements, those taking medications known to alter potassium homeostasis or renal function, or those with a serum creatinine level more than 186 mumol/L were excluded. Measurements and Main Results: Serum potassium concentration in the study group was 4.1 +/- 0.1 mmol/L (mean +/- SE) and increased by 1.1 mmol/L (CI, 0.8 to 1.5 mmol/L) (P < 0.0001) 9.8 +/- 0.5 days after starting Tmp-Smx therapy. Patients followed longitudinally showed a progressive increase in serum potassium levels during therapy and a progressive decline after discontinuing Tmp-Smx. Blood urea nitrogen and serum creatinine levels increased mildly from 4.3 +/- 0.5 mmol/L and 85 +/- 6 mumol/L to 6.4 +/- 0.7 mmol/L and 113 +/- 8 mumol/L, respectively. The serum potassium level in the control group was 4.3 +/- 0.1 mmol/L and remained unchanged during hospitalization. Conclusions: High-dose Tmp-Smx therapy used for the treatment of P. carinii pneumonia in HIV-infected patients leads to an increase in the serum potassium concentration and may result in life-threatening hyperkalemia. Patients receiving high doses of Tmp-Smx require close monitoring of their serum potassium concentration, particularly 7 to 10 days after the start of therapy.	BROOKDALE HOSP MED CTR, DIV NEPHROL & HYPERTENS, BROOKLYN, NY 11212 USA									APPEL GB, 1977, NEW ENGL J MED, V296, P784, DOI 10.1056/NEJM197704072961404; BERGLUND F, 1975, J UROLOGY, V114, P802, DOI 10.1016/S0022-5347(17)67149-0; CHOI M J, 1992, Journal of the American Society of Nephrology, V3, P325; CRYST C, 1988, AM J NEPHROL, V8, P483, DOI 10.1159/000167666; GORDIN FM, 1984, ANN INTERN MED, V100, P495, DOI 10.7326/0003-4819-100-4-495; GREENE LW, 1984, ANN INTERN MED, V101, P497, DOI 10.7326/0003-4819-101-4-497; GUY RJC, 1989, BRIT MED J, V298, P496, DOI 10.1136/bmj.298.6672.496; JAFFE HS, 1983, LANCET, V2, P1109; JICK H, 1982, REV INFECT DIS, V4, P426; KALIN MF, 1987, AM J MED, V82, P1035, DOI 10.1016/0002-9343(87)90171-9; LACHAAL M, 1989, AM J MED, V87, P260, DOI 10.1016/S0002-9343(89)80147-0; LAWSON DH, 1978, AM J MED SCI, V275, P53, DOI 10.1097/00000441-197801000-00005; LAWSON DH, 1982, REV INFECT DIS, V4, P429; LINTON AL, 1980, ANN INTERN MED, V93, P735, DOI 10.7326/0003-4819-93-5-735; MEDINA I, 1990, NEW ENGL J MED, V323, P776, DOI 10.1056/NEJM199009203231202; MEMBRENO L, 1987, J CLIN ENDOCR METAB, V65, P482, DOI 10.1210/jcem-65-3-482; MURPHY CF, 1989, BRIT MED J, V298, P1181, DOI 10.1136/bmj.298.6681.1181-b; REVERT L, 1988, SEMIN NEPHROL, V8, P82; RICHMOND JM, 1979, LANCET, V1, P493; SCHOENFELD P, 1990, AM J KIDNEY DIS, V16, P14, DOI 10.1016/S0272-6386(12)80780-3; SENEY FD, 1990, AM J KIDNEY DIS, V16, P1; SHOUVAL D, 1978, LANCET, V1, P244; SMITH EJ, 1980, JAMA-J AM MED ASSOC, V244, P360, DOI 10.1001/jama.244.4.360; VAZIRI ND, 1985, J NATL MED ASSOC, V77, P369; VELAZQUEZ H, 1992, Journal of the American Society of Nephrology, V3, P322	25	88	92	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1993	119	4					291	295		10.7326/0003-4819-119-4-199308150-00007	http://dx.doi.org/10.7326/0003-4819-119-4-199308150-00007			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV525	8328737				2023-01-03	WOS:A1993LV52500007
J	STEVENSON, R; RANJADAYALAN, K; WILKINSON, P; ROBERTS, R; TIMMIS, AD				STEVENSON, R; RANJADAYALAN, K; WILKINSON, P; ROBERTS, R; TIMMIS, AD			SHORT AND LONG-TERM PROGNOSIS OF ACUTE MYOCARDIAL-INFARCTION SINCE INTRODUCTION OF THROMBOLYSIS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TISSUE PLASMINOGEN-ACTIVATOR; MINNESOTA-HEART-SURVEY; FOLLOW-UP; SURVIVAL; TRIAL; MORTALITY; THERAPY; RECOVERY; STRATIFICATION; STREPTOKINASE	Objective-To record prognosis and determinants of outcome in patients with acute myocardial infarction since thrombolysis was introduced. Design-Observational study. Setting-London district general hospital. Patients-608 consecutive patients admitted to the coronary care unit with acute myocardial infarction between 1 January 1988 and 31 December 1991. Main outcome measure-All cause mortality, non-fatal ischaemic events (myocardial infarction, unstable angina), and revascularisation. Results-Of the 608 patients, 89 (14.6%) died in hospital. 596 patients were followed up after discharge from hospital. Mortality (95% confidence interval) at 30 days, one year, and three years was 16.0% (13.4% to 19.2%), 21.7% (18.6% to 25.2%), and 29.4% (25.3% to 33.9%) respectively. Event free survival (survival without a non-fatal ischaemic event) was 80.4% (77.0% to 83.4%) at 30 days, 66.8% (62.8% to 70.5%) at one year, and 56.1% (51.3% to 60.6%) at three years. Survival in patients treated with thrombolysis was considerably higher than in those not given thrombolysis (three year survival: 76.7% v 54.3%), although the incidence of non-fatal ischaemic events was the same in the two groups. Multivariate determinants of six month survival were left ventricular failure, treatment with thrombolysis and aspirin, smoking history, bundle branch block, and age. For patients who survived six months, age was the only factor related to long term survival. Conclusions-Although patients treated by thrombolysis had a relatively good prognosis, long term mortality and the incidence of non-fatal recurrent ischaemic events remained high. Effective strategies for the identification and treatment of high risk patients need to be reassessed.	NEWHAM DIST GEN HOSP, DEPT CARDIOL, LONDON E13, ENGLAND; LONDON CHEST HOSP, EPIDEMIOL RES UNIT, LONDON E2, ENGLAND		STEVENSON, R (corresponding author), LONDON CHEST HOSP, DEPT CARDIOL, LONDON E2, ENGLAND.			Wilkinson, Paul/0000-0001-7456-259X				[Anonymous], 1987, LANCET, V2, P871; BARBASH GI, 1992, J AM COLL CARDIOL, V20, P36, DOI 10.1016/0735-1097(92)90134-9; CHAMBERLAIN DA, 1990, LANCET, V335, P427; CLEEMPOEL H, 1988, BRIT HEART J, V60, P98; COX DR, 1972, J R STAT SOC B, V34, P187; DECKERS JW, 1987, AM HEART J, V113, P90, DOI 10.1016/0002-8703(87)90014-7; DEVREEDE JJM, 1991, J AM COLL CARDIOL, V18, P698, DOI 10.1016/0735-1097(91)90792-8; DUBOIS C, 1988, AM J CARDIOL, V61, P216, DOI 10.1016/0002-9149(88)90918-6; ELLIS SG, 1989, CIRCULATION, V80, P1159, DOI 10.1161/01.CIR.80.5.1159; FRABICIUSBJERRE N, 1979, AM J MED, V66, P986; GOMEZMARIN O, 1987, NEW ENGL J MED, V316, P1353, DOI 10.1056/NEJM198705283162201; HARRISON DG, 1984, CIRCULATION, V69, P991, DOI 10.1161/01.CIR.69.5.991; HENNING H, 1979, CIRCULATION, V59, P1124, DOI 10.1161/01.CIR.59.6.1124; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI, P10; KRONE RJ, 1983, AM J CARDIOL, V52, P234, DOI 10.1016/0002-9149(83)90114-5; MARTIN CA, 1983, CIRCULATION, V68, P961, DOI 10.1161/01.CIR.68.5.961; MCGOVERN PG, 1992, CIRCULATION, V85, P172, DOI 10.1161/01.CIR.85.1.172; MUELLER HS, 1992, CIRCULATION, V85, P1254, DOI 10.1161/01.CIR.85.4.1254; MURRAY DP, 1987, BRIT HEART J, V57, P313; NORRIS RM, 1984, AM J CARDIOL, V53, P408, DOI 10.1016/0002-9149(84)90003-1; POHJOLA S, 1980, BRIT HEART J, V43, P176, DOI 10.1136/hrt.43.2.176; RIVERS JT, 1990, J AM COLL CARDIOL, V16, P340, DOI 10.1016/0735-1097(90)90583-B; SANZ G, 1982, NEW ENGL J MED, V306, P1065, DOI 10.1056/NEJM198205063061801; SCHRODER R, 1986, NEW ENGL J MED, V314, P1465; SIMOONS ML, 1985, LANCET, V2, P578; SIMOONS ML, 1989, J AM COLL CARDIOL, V14, P1609, DOI 10.1016/0735-1097(89)90003-X; WHITE HD, 1987, CIRCULATION, V76, P44, DOI 10.1161/01.CIR.76.1.44; WILCOX RG, 1988, LANCET, V2, P525; WILLIAMS DO, 1986, CIRCULATION, V73, P338, DOI 10.1161/01.CIR.73.2.338; WOLFFENBUTTEL BHR, 1983, BRIT HEART J, V50, P266; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; 1990, LANCET, V335, P545; 1968, LANCET, V2, P349	33	147	150	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 7	1993	307	6900					349	353		10.1136/bmj.307.6900.349	http://dx.doi.org/10.1136/bmj.307.6900.349			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR768	8374415	Bronze, Green Published			2023-01-03	WOS:A1993LR76800016
J	DAVID, J; PRIORWILLEARD, PFS				DAVID, J; PRIORWILLEARD, PFS			RESUSCITATION SKILLS OF MRCP CANDIDATES	BRITISH MEDICAL JOURNAL			English	Article									ROYAL BERKSHIRE HOSP,DEPT MED,READING RG3 1AG,BERKS,ENGLAND	Royal Berkshire Hospital	DAVID, J (corresponding author), BATTLE HOSP,DEPT MED,READING RG3 1AG,BERKS,ENGLAND.							MCINTYRE AS, 1993, J ROY COLL PHYS LOND, V27, P34; THWAITES BC, 1992, J ROY COLL PHYS LOND, V26, P265; TUNSTALLPEDOE H, 1992, BRIT MED J, V304, P1347, DOI 10.1136/bmj.304.6838.1347; WYNNE G, 1992, J ROY COLL PHYS LOND, V26, P372; 1987, J R COLL PHYSICIANS, V21, P2	5	31	31	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1993	306	6892					1578	1579		10.1136/bmj.306.6892.1578	http://dx.doi.org/10.1136/bmj.306.6892.1578			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH128	8329919	Green Published, Bronze			2023-01-03	WOS:A1993LH12800019
J	BARRETTCONNOR, E; KRITZSILVERSTEIN, D				BARRETTCONNOR, E; KRITZSILVERSTEIN, D			ESTROGEN REPLACEMENT THERAPY AND COGNITIVE FUNCTION IN OLDER WOMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALZHEIMERS-DISEASE; ESTRADIOL; MEMORY; MORTALITY; DEMENTIA; BRAIN	Objective.-To determine whether replacement estrogen delays or prevents loss of cognitive function in elderly women. Design.-A 15-year prospective and cross-sectional study. Setting.-Rancho Bernardo, a geographically defined community in Southern California. Participants.-Eight hundred women (80% of local surviving women from the original Rancho Bernardo cohort) aged 65 to 95 years. Estrogen use was evaluated at baseline between 1972 and 1974 and at follow-up between 1988 and 1991. Main Outcome Measures.-Twelve tests of cognitive function from eight standard instruments administered at follow-up between 1988 and 1991. Results.-Almost half of this older, educated cohort had used estrogen at some time after menopause, and one third were current users. The age-related decrement in cognitive function was similar for women who were current, past, or never users of estrogen. Age- and education-adjusted comparisons also failed to show any consistent association between performance on tests of cognitive function and baseline, past, current, or never estrogen use; estrogen dose; or duration of use. Among 132 statistical comparisons, only five statistically significant differences were observed, less than the number expected by chance alone. Furthermore, these significant differences occurred with different tests of cognitive function, and in only one instance was the better test score associated with current estrogen use. No biases were identified that could explain these negative results. Conclusions.-No compelling or internally consistent evidence for an effect of estrogen on cognitive function was found in these older women. These data do not support the hypothesis that estrogen use after the menopause preserves cognitive function in old age.	UNIV CALIF SAN DIEGO,DEPT FAMILY & PREVENT MED,LA JOLLA,CA 92093	University of California System; University of California San Diego								ANDERSON E, 1987, AM J OBSTET GYNECOL, V156, P428, DOI 10.1016/0002-9378(87)90298-5; AYLWARD M, 1973, INT RESEARCH COMMUNI, V1, P30; BARRETTCONNOR E, 1992, ANNU REV MED, V43, P239, DOI 10.1146/annurev.med.43.1.239; BARTUS RT, 1982, SCIENCE, V217, P408, DOI 10.1126/science.7046051; BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; BORKOWSKI JG, 1967, NEUROPSYCHOLOGIA, V5, P135, DOI 10.1016/0028-3932(67)90015-2; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; BUSH TL, 1983, JAMA-J AM MED ASSOC, V249, P903, DOI 10.1001/jama.249.7.903; CAMPBELL S, 1977, CLIN OBSTET GYNAECOL, V4, P31; DITKOFF EC, 1991, OBSTET GYNECOL, V78, P991; ERNSTER VL, 1988, PREV MED, V17, P201, DOI 10.1016/0091-7435(88)90064-3; EVANS DA, 1991, AM J EPIDEMIOL, V134, P403, DOI 10.1093/oxfordjournals.aje.a116102; Fedor-Freybergh P., 1977, ACTA OBSTET GYNECOL, V64, P5; FILLIT H, 1986, PSYCHONEUROENDOCRINO, V11, P337, DOI 10.1016/0306-4530(86)90019-3; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GANGAR KF, 1991, LANCET, V338, P839; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; HACKMAN BW, 1977, CURR MED RES OPIN, V4, P21, DOI 10.1185/03007997709109380; HONJO H, 1989, J STEROID BIOCHEM, V34, P511; KITTNER SJ, 1986, J CHRON DIS, V39, P163, DOI 10.1016/0021-9681(86)90019-6; KLAIBER EL, 1979, ARCH GEN PSYCHIAT, V36, P550; LIU IY, 1990, AM J EPIDEMIOL, V132, P136, DOI 10.1093/oxfordjournals.aje.a115625; LUINE V, 1980, BRAIN RES, V191, P273, DOI 10.1016/0006-8993(80)90332-7; LUINE VN, 1975, BRAIN RES, V86, P293, DOI 10.1016/0006-8993(75)90704-0; MALLESON J, 1953, LANCET, V2, P158; MALLESON J, 1973, FRONT HORM RES, V2, P118; MCEWEN BS, 1991, TRENDS ENDOCRIN MET, V2, P62, DOI 10.1016/1043-2760(91)90042-L; MEADE TW, 1992, BRIT MED BULL, V48, P276, DOI 10.1093/oxfordjournals.bmb.a072548; PALINKAS LA, 1992, OBSTET GYNECOL, V80, P30; RASKIN A, 1982, Psychopharmacology Bulletin, V18, P196; RAURAMO L, 1975, FRONT HORM RES, V8, P133; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; RUSSELL EW, 1975, J CONSULT CLIN PSYCH, V43, P800, DOI 10.1037/0022-006X.43.6.800; SHERWIN BB, 1988, PSYCHONEUROENDOCRINO, V13, P345, DOI 10.1016/0306-4530(88)90060-1; Vanhulle G., 1976, CONSENSUS MENOPAUSE, P94; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; WEISS BL, 1987, AM J PSYCHIAT, V144, P386; WHITEHOUSE PJ, 1981, ANN NEUROL, V10, P122, DOI 10.1002/ana.410100203; WONG M, 1992, J NEUROSCI, V12, P3217, DOI 10.1523/JNEUROSCI.12-08-03217.1992	39	331	337	1	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 26	1993	269	20					2637	2641		10.1001/jama.269.20.2637	http://dx.doi.org/10.1001/jama.269.20.2637			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LC865	8487446				2023-01-03	WOS:A1993LC86500027
J	SHIVDASANI, RA; HALUSKA, FG; DOCK, NL; DOVER, JS; KINEKE, EJ; ANDERSON, KC				SHIVDASANI, RA; HALUSKA, FG; DOCK, NL; DOVER, JS; KINEKE, EJ; ANDERSON, KC			GRAFT-VERSUS-HOST DISEASE ASSOCIATED WITH TRANSFUSION OF BLOOD FROM UNRELATED HLA-HOMOZYGOUS DONORS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							AUTOLOGOUS BONE-MARROW; IMMUNOCOMPETENT PATIENT; NEURO-BLASTOMA; FATAL GRAFT; PRODUCTS; IRRADIATION; PREVENTION; SURGERY; CHILD		HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR IMMUNOL,44 BINNEY ST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV MED ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV IMMUNOGENET,BOSTON,MA 02115; NEW ENGLAND DEACONESS HOSP,DIV DERMATOL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; AMER RED CROSS,BLOOD SERV,SYRACUSE,NY	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; American Red Cross								AKAHOSHI M, 1992, TRANSFUSION, V32, P169, DOI 10.1046/j.1537-2995.1992.32292180149.x; ANDERSON K, 1991, J CLIN ONCOL, V9, P1727, DOI 10.1200/JCO.1991.9.10.1727; ANDERSON KC, 1991, BLOOD, V77, P2096; ANDERSON KC, 1990, NEW ENGL J MED, V323, P315; Anderson KC, 1992, IRRADIATION BLOOD CO, P31; ARSURA EL, 1988, ARCH INTERN MED, V148, P1941, DOI 10.1001/archinte.148.9.1941; BRUBAKER DB, IN PRESS SCI BASIS T; BURDICK JF, 1988, NEW ENGL J MED, V318, P689, DOI 10.1056/NEJM198803173181107; CAPON SM, 1991, ANN INTERN MED, V114, P1025, DOI 10.7326/0003-4819-114-12-1025; CHARPENTIER F, 1990, TRANSFUSION, V30, P850, DOI 10.1046/j.1537-2995.1990.30991048796.x; COLLINS RH, 1992, ANN INTERN MED, V116, P391, DOI 10.7326/0003-4819-116-5-391; DEEG HJ, 1989, BLOOD, V74, P2592; FERRARA JLM, 1991, NEW ENGL J MED, V324, P667; GREENBAUM BH, 1991, J CLIN ONCOL, V9, P1889, DOI 10.1200/JCO.1991.9.10.1889; JUJI T, 1989, NEW ENGL J MED, V321, P56; KANTER MH, 1992, TRANSFUSION, V32, P323, DOI 10.1046/j.1537-2995.1992.32492263445.x; KASLOW RA, 1987, ANN INTERN MED, V107, P474, DOI 10.7326/0003-4819-107-4-474; KENNEDY JS, 1986, J PEDIATR SURG, V21, P1108, DOI 10.1016/0022-3468(86)90019-9; KESSINGER A, 1987, J SURG ONCOL, V36, P206, DOI 10.1002/jso.2930360311; LANE TA, 1992, ANN INTERN MED, V117, P151, DOI 10.7326/0003-4819-117-2-151; MATSUSHITA H, 1988, VIRCHOWS ARCH B, V55, P237; MULDER NH, 1989, LANCET, V1, P735; OCONNOR NTJ, 1992, J CLIN PATHOL, V45, P621, DOI 10.1136/jcp.45.7.621; OHTO H, 1992, TRANSFUSION, V32, P691, DOI 10.1046/j.1537-2995.1992.32792391051.x; OTSUKA S, 1989, TRANSFUSION, V29, P544, DOI 10.1046/j.1537-2995.1989.29689318456.x; PERKINS HA, 1992, TRANSFUSION, V32, P302, DOI 10.1046/j.1537-2995.1992.32492263440.x; POSTMUS PE, 1988, EUR J CANCER CLIN ON, V24, P889, DOI 10.1016/0277-5379(88)90198-8; SUZUKI K, 1992, TRANSFUSION, V32, P358, DOI 10.1046/j.1537-2995.1992.32492263452.x; THALER M, 1989, NEW ENGL J MED, V321, P25, DOI 10.1056/NEJM198907063210105; TKAAHASHI K, 1991, TRANSFUS SCI, V12, P281; TWOMEY JJ, 1980, SEMIN ONCOL, V7, P114; VOGELSANG GB, 1990, TRANSFUSION, V30, P101, DOI 10.1046/j.1537-2995.1990.30290162892.x; WOODS WG, 1981, PEDIATRICS, V67, P217	33	61	63	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 18	1993	328	11					766	770		10.1056/NEJM199303183281105	http://dx.doi.org/10.1056/NEJM199303183281105			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR848	8437597				2023-01-03	WOS:A1993KR84800005
J	WASSER, KB				WASSER, KB			INFORMED CONSENT	ANNALS OF INTERNAL MEDICINE			English	Editorial Material						INFORMED CONSENT; MUSCULAR DYSTROPHY; RESUSCITATION ORDERS		A mother faces the dilemma of either continuing medical care of her hopelessly ill child or putting an end to what she considers his ''high-tech medical torture.'' Finally, a wise clinician helps release her from her terrible conflict.										WASSER KB, 1993, ANN INTERN MED, V118, P224, DOI 10.7326/0003-4819-118-3-199302010-00012	1	2	2	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1993	118	3					224	224		10.7326/0003-4819-118-3-199302010-00012	http://dx.doi.org/10.7326/0003-4819-118-3-199302010-00012			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ439	8417640				2023-01-03	WOS:A1993KJ43900012
J	Erwin, J; Britten, N; Jones, R				Erwin, J; Britten, N; Jones, R			General practitioners' views on over the counter sales by community pharmacists	BRITISH MEDICAL JOURNAL			English	Article									UNITED MED & DENT SCH,GUYS & ST THOMAS HOSP,DEPT GEN PRACTICE,LONDON SE11 6SP,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London								BRADLOW J, 1993, BRIT MED J, V307, P1186, DOI 10.1136/bmj.307.6913.1186; Department of Health, 1994, HLTH PERS SOC SERV S; FORD S, 1995, BRIT MED J, V310, P1620, DOI 10.1136/bmj.310.6995.1620; SPENCER JA, 1992, BRIT MED J, V304, P1670, DOI 10.1136/bmj.304.6843.1670; WILSON RPH, 1995, BRIT MED J, V311, P1347, DOI 10.1136/bmj.311.7016.1347	5	27	28	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 9	1996	312	7031					617	618						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ840	8595339				2023-01-03	WOS:A1996TZ84000029
J	Hirschl, RB; Pranikoff, T; Wise, C; Overbeck, MC; Gauger, P; Schreiner, RJ; Dechert, R; Bartlett, RH				Hirschl, RB; Pranikoff, T; Wise, C; Overbeck, MC; Gauger, P; Schreiner, RJ; Dechert, R; Bartlett, RH			Initial experience with partial liquid ventilation in adult patients with the acute respiratory distress syndrome	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							END-EXPIRATORY PRESSURE; GAS-EXCHANGE; LUNG; SUPPORT; FAILURE	Objective.-To evaluate the safety and efficacy of partial liquid ventilation (PLV). Design.-Before-after trial. Setting.-The surgical intensive care unit at the University of Michigan, Ann Arbor, from April to December 1994. Patients.-A consecutive sample of 10 patients aged 19 to 55 years with the acute respiratory distress syndrome who were receiving extracorporeal life support. Intervention.-Perflubron was administered into the trachea until the dependent zone of the lung was filled. Gas ventilation of the perflubron-filled lung was then performed (PLV). Volatilized perflubron replacement was repeated daily for from 1 to 7 days with a median cumulative dose of 38 mL/kg (range, 15 to 62 mL/kg). Main Outcome Measures.-Physiologic shunt and static pulmonary compliance. Results.-Physiologic shunt decreased from a median of 0.72 (range, 0.37 to 1.0) to 0.46 (range, 0.21 to 0.96) over the 72 hours following initiation of PLV (P=.01 by repeated measures analysis of variance). Static pulmonary compliance corrected for patient weight increased from a median of 0.16 mL/cm H2O per kilogram (range, 0.01 to 0.48 mL/cm H2O per kilogram) to 0.27 mL/cm H2O per kilogram (range, 0.05 to 1.11 mL/cm H2O per kilogram) over the same time period (P=.04 by repeated measures analysis of variance). Overall survival was five (50%) of 10 patients. Complications that were potentially associated with PLV included pneumothorax development in one patient and mucus plug formation in one patient. Conclusions.-Perflubron may be safely administered into the lungs of patients with severe respiratory failure receiving extracorporeal life support and may be associated with improvement in gas exchange and pulmonary compliance.	UNIV MICHIGAN,DEPT RESP CARE,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	Hirschl, RB (corresponding author), UNIV MICHIGAN,DEPT SURG,PEDIAT SURG SECT,F3970 MOTT,BOX 0245,1500 E MED CTR DR,ANN ARBOR,MI 48109, USA.		Gauger, Paul/W-8176-2019		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD015434] Funding Source: NIH RePORTER; NICHD NIH HHS [R01HD15434] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSON H, 1993, SURGERY, V114, P161; CALDERWOOD HW, 1973, ANESTHESIOLOGY, V38, P141, DOI 10.1097/00000542-197302000-00008; CLARK LC, 1966, SCIENCE, V152, P1755, DOI 10.1126/science.152.3730.1755; CURTIS SE, 1993, J APPL PHYSIOL, V75, P2696, DOI 10.1152/jappl.1993.75.6.2696; FUHRMAN BP, 1991, CRIT CARE MED, V19, P712, DOI 10.1097/00003246-199105000-00019; GATTINONI L, 1993, JAMA-J AM MED ASSOC, V269, P2122, DOI 10.1001/jama.269.16.2122; GREENSPAN JS, 1990, J PEDIATR-US, V117, P106, DOI 10.1016/S0022-3476(05)82457-6; HERMAN LJ, 1995, CRIT CARE MED S1, V23, pA264; HIRSCHL RB, 1994, SURGERY, V116, P159; HIRSCHL RB, 1995, ANN SURG, V221, P79, DOI 10.1097/00000658-199501000-00010; HIRSCHL RB, 1995, LANCET, V346, P1201, DOI 10.1016/S0140-6736(95)92903-7; HIRSCHL RB, 1995, CHEST, V108, P500, DOI 10.1378/chest.108.2.500; KAZEROONI E, IN PRESS RADIOLOGY; KYLSTRA JA, 1962, T AM SOC ART INT ORG, V8, P378; LACHMANN B, 1980, ACTA ANAESTH SCAND, V24, P231, DOI 10.1111/j.1399-6576.1980.tb01541.x; LEACH CL, 1993, CRIT CARE MED, V21, P1270, DOI 10.1097/00003246-199309000-00008; LOWE C, 1979, J APPL PHYSIOL, V47, P1051, DOI 10.1152/jappl.1979.47.5.1051; LOWE CA, 1986, J APPL PHYSIOL, V60, P154, DOI 10.1152/jappl.1986.60.1.154; MODELL JH, 1970, FED PROC, V29, P1731; NESTI FD, 1994, CRIT CARE MED, V22, P1445, DOI 10.1097/00003246-199409000-00015; OVERBECK MC, IN PRESS CRIT CARE M; Pranikoff T, 1994, ASAIO J, V40, pM339, DOI 10.1097/00002480-199407000-00020; RICHMAN PS, 1993, CRIT CARE MED, V21, P768, DOI 10.1097/00003246-199305000-00022; SHAFFER TH, 1992, PEDIATR PULM, V14, P102, DOI 10.1002/ppul.1950140208; SHAFFER TH, 1984, PEDIATR RES, V18, P47; SHAFFER TH, 1978, PEDIATR RES, V12, P695, DOI 10.1203/00006450-197806000-00003; SHAPIRO BA, 1984, CRIT CARE MED, V12, P127, DOI 10.1097/00003246-198402000-00011; TOOLEY R, IN PRESS CRIT CARE M; TUTUNCU AS, 1993, AM REV RESPIR DIS, V148, P785; TUTUNCU AS, 1992, CLIN INTENSIVE CAR S, V3, P72	30	203	212	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 7	1996	275	5					383	389		10.1001/jama.275.5.383	http://dx.doi.org/10.1001/jama.275.5.383			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT303	8569018				2023-01-03	WOS:A1996TT30300032
J	Judd, HL; Wasilauskas, C; Johnson, S; Merino, M; BarrettConnor, E; Trabal, J; Miller, VT; Barnabei, V; Levin, G; Bush, T; Foster, D; Zacur, H; Woodruff, JD; Stefanick, M; Akana, A; Heinrichs, WL; OHanlan, K; Buyalos, RP; Greendale, G; Lozano, K; CarrionPetersen, L; Cavero, C; Langer, R; Schrott, HG; Benda, JA; deProsse, C; Fedderson, D; Johnson, SR; Ahmad, MM; Brown, HP; Schenken, RS; RodriguezSifuentes, M; Valente, PT; Espeland, M; Lane, K; Legault, C; MebaneSims, IL; Kelaghan, J; McGowan, J; Fradkin, J; Sherman, S; Scully, R				Judd, HL; Wasilauskas, C; Johnson, S; Merino, M; BarrettConnor, E; Trabal, J; Miller, VT; Barnabei, V; Levin, G; Bush, T; Foster, D; Zacur, H; Woodruff, JD; Stefanick, M; Akana, A; Heinrichs, WL; OHanlan, K; Buyalos, RP; Greendale, G; Lozano, K; CarrionPetersen, L; Cavero, C; Langer, R; Schrott, HG; Benda, JA; deProsse, C; Fedderson, D; Johnson, SR; Ahmad, MM; Brown, HP; Schenken, RS; RodriguezSifuentes, M; Valente, PT; Espeland, M; Lane, K; Legault, C; MebaneSims, IL; Kelaghan, J; McGowan, J; Fradkin, J; Sherman, S; Scully, R			Effects of hormone replacement therapy on endometrial histology in postmenopausal women - The Postmenopausal Estrogen Progestin Interventions (PEPI) trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONJUGATED ESTROGENS; MENOPAUSAL WOMEN; CANCER; RISK; CARCINOMA; ASSOCIATION; DISEASE	Objective.-To report the histological findings of the endometrium of postmenopausal women who were randomized to receive placebo, estrogen only, or one of three estrogen plus progestin (EI-P) regimens in the Postmenopausal Estrogen/ Progestin Interventions (PEPI) Trial. Design.-A 3-year multicenter, randomized, double-masked, placebo-controlled trial. Participants-A total of 596 postmenopausal women aged 45 through 64 years without contraindication to hormone therapy. Intervention.-Participants were randomized and stratified in equal numbers to one of the following treatments in 28-day cycles: placebo, 0.625 mg/d of conjugated equine estrogens (GEE), 0.625 mg/d of CEE plus 10 mg/d of medroxyprogesterone acetate (MPA)for the first 12 days, 0.625 mg/d of CEE plus 2.5 mg/d of MPA, or 0.625 mg/d of CEE plus 200 mg/d of micronized progesterone (MP) for the first 12 days. Outcome Measure.-Histology of endometrium collected at baseline, annual, or unscheduled Visits by biopsy, curettage, or hysterectomy. Analysis.-Intention to treat. Results.-During follow-up women assigned to estrogen atone were more likely to develop simple (cystic), complex (adenomatous), or atypical hyperplasia than those given placebo (27.7% vs 0.8%, 22.7% vs 0.8%, and 11.8% vs 0%, respectively) for the same types of hyperplasia (P<.001). Participants administered one of the three E+P regimens had similar rates of hyperplasia as those given placebo (P=.16). The occurrence of hyperplasia was distributed evenly across the 3 years of the trial. Women taking estrogens alone also had more unscheduled biopsies (66.4% vs 8.4%; P<.001) and curettages (17.6% vs 0.8%; P<.001) than women receiving placebo. The number of surgical procedures was similar for women receiving placebo and women receiving the E+P regimens (P=.38). Of the 45 women with complex (adenomatous) or atypical hyperplasia, study medications were discontinued in all, and the biopsy results of 34 (94%) of 36 women with hyperplasia reverted to normal with progestin therapy. The remainder had dilatation and curettage (n=2) or hysterectomy with (n=2) or without (n=6) prior medical therapy, or refused further biopsies (n=1). One woman developed adenocarcinoma of the endometrium while receiving placebo. Conclusions.-At a dosage of 0.625 mg, the daily administration of CEE enhanced the development of endometrial hyperplasia. Combining CEE with cyclic or continuous MPA or cyclic MP protected the endometrium from hyperplastic changes associated with estrogen-only therapy.			Judd, HL (corresponding author), NHLBI,2 ROCKLEDGE CTR,SUITE 10193,6701 ROCKLEDGE DR,MSC,BETHESDA,MD 20892, USA.		zacur, howard/W-2170-2019		NHLBI NIH HHS [U01-HL40154, U01-HL40185, U01-HL40195] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL040185, U01HL040195, U01HL040154] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRINTON LA, 1993, OBSTET GYNECOL, V81, P265; BUSH TL, 1990, MENOPAUSE BIOL CLIN, P211; CAMPBELL PE, 1961, J OBSTET GYN BR COMM, V68, P668; GELFAND MM, 1989, OBSTET GYNECOL, V74, P398; GIBBONS WE, 1986, AM J OBSTET GYNECOL, V154, P456, DOI 10.1016/0002-9378(86)90690-3; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GUSBERG SB, 1947, AM J OBSTET GYNECOL, V54, P905, DOI 10.1016/S0002-9378(16)39706-X; HALL KARL VICTOR, 1957, ACTA OBSTET ET GYNECOL SCAND, V36, P306; HENDERSON BE, 1989, AM J OBSTET GYNECOL, V161, P1859, DOI 10.1016/S0002-9378(89)80007-9; HENDRICKSON M, 1980, MAJOR PROBLEMS PATHO, V12, P285; HULKA BS, 1980, AM J OBSTET GYNECOL, V137, P92, DOI 10.1016/0002-9378(80)90391-9; JENSEN J, 1987, AM J OBSTET GYNECOL, V156, P66, DOI 10.1016/0002-9378(87)90204-3; KENNEDY DL, 1985, OBSTET GYNECOL, V65, P441; MACK TM, 1976, NEW ENGL J MED, V294, P1262, DOI 10.1056/NEJM197606032942304; MOORJANI S, 1991, J CLIN ENDOCR METAB, V73, P373, DOI 10.1210/jcem-73-2-373; PERSSON I, 1989, BRIT MED J, V298, P141; SCHIFF I, 1982, FERTIL STERIL, V37, P79; SHAPIRO S, 1985, NEW ENGL J MED, V313, P969, DOI 10.1056/NEJM198510173131601; SHERMAN AI, 1979, AM J OBSTET GYNECOL, V135, P947, DOI 10.1016/0002-9378(79)90821-4; SMITH DC, 1975, NEW ENGL J MED, V293, P1164, DOI 10.1056/NEJM197512042932302; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; STURDEE DW, 1978, BRIT MED J, V1, P1575, DOI 10.1136/bmj.1.6127.1575; THOM M, 1978, LANCET, V1, P455; THOM M, 1979, AM J OBSTET GYNECOL, V135, P947; VOIGT LF, 1991, LANCET, V338, P274, DOI 10.1016/0140-6736(91)90417-N; WEINSTEIN L, 1987, OBSTET GYNECOL, V69, P929; WENTZ WB, 1966, AM J OBSTET GYNECOL, V96, P999, DOI 10.1016/0002-9378(66)90447-9; WOODRUFF JD, 1994, AM J OBSTET GYNECOL, V170, P1212; ZIEL HK, 1975, NEW ENGL J MED, V293, P1167, DOI 10.1056/NEJM197512042932303; 1995, J CONTROLLED CLIN S, V16, pS36; 1995, J CONTROLLED CLIN S, V16, pS20; 1995, JAMA-J AM MED ASSOC, V273, P199; 1995, J CONTROLLED CLIN S, V16, pS54; 1995, J CONTROLLED CLIN S, V16, pS3	34	462	472	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 7	1996	275	5					370	375		10.1001/jama.1996.03530290040035	http://dx.doi.org/10.1001/jama.1996.03530290040035			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT303	8569016				2023-01-03	WOS:A1996TT30300030
J	KIM, JY; SHISHIDO, T; JIANG, XL; ADEREM, A; MCLAUGHLIN, S				KIM, JY; SHISHIDO, T; JIANG, XL; ADEREM, A; MCLAUGHLIN, S			PHOSPHORYLATION, HIGH IONIC-STRENGTH, AND CALMODULIN REVERSE THE BINDING OF MARCKS TO PHOSPHOLIPID-VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PROMINENT CELLULAR SUBSTRATE; LARGE UNILAMELLAR VESICLES; BACTERIAL LIPOPOLYSACCHARIDE; MEMBRANE PHOSPHOLIPIDS; PLASMA-MEMBRANE; RAT-BRAIN; ACTIVATION; FAMILY; EXTRUSION	The myristoylated alanine-rich protein kinase C substrate (MARCKS) is a major cellular substrate of protein kinase C (PKC), and PKC phosphorylation produces translocation of MARCKS from membrane to cytoplasm in many cells. Our working hypothesis is that binding of MARCKS to biological membranes requires both hydrophobic insertion of its myristoyl chain into the lipid bilayer and electrostatic interaction of its basic domain with acidic lipids. We tested this hypothesis by measuring the binding of murine MARCKS to large unilamellar phospholipid vesicles (LUVs). me estimated the partition coefficient of the myristoyl moiety of MARCKS (K-H) by measuring the binding of MARCKS to electrically neutral LUVs (K-H = 3 x 10(3) M(-1)). We examined the effect of electrostatic interactions by measuring the binding of MARCKS to LUVs containing 20% acidic lipid and obtained four results. First, incorporating 20% acidic lipid into the LUVs increased binding of MARCKS about 100-fold. Second, PKC phosphorylation, which added 3 negatively charged phosphate groups to the basic domain, reduced 20-fold the binding of MARCKS to these negatively charged vesicles. Third, increasing the KCl concentration from 0.1 to 0.5 M reduced the binding 15-fold. Fourth, Ca2+-calmodulin reduced the binding 20-fold We present a simple theoretical model that explains these results, which are all consistent with the working hypothesis.	SUNY STONY BROOK,HLTH SCI CTR,DEPT PHYSIOL & BIOPHYS,STONY BROOK,NY 11794; ROCKEFELLER UNIV,SIGNAL TRANSDUCT LAB,NEW YORK,NY 10021	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Rockefeller University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025032, R37AI025032] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024971, R01GM024971] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-25032] Funding Source: Medline; NIGMS NIH HHS [GM24971] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BUSER CA, 1994, IN PRESS BIOCHEMISTR; DEVAUX PF, 1992, ANNU REV BIOPH BIOM, V21, P417, DOI 10.1146/annurev.bb.21.060192.002221; DURONIO RJ, 1992, P NATL ACAD SCI USA, V89, P4129, DOI 10.1073/pnas.89.9.4129; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; GRAFF JM, 1989, J BIOL CHEM, V264, P11912; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HARLAN DM, 1991, J BIOL CHEM, V266, P14399; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HEEMSKERK FMJ, 1993, BIOCHEM BIOPH RES CO, V190, P236, DOI 10.1006/bbrc.1993.1036; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; KAIBUCHI K, 1981, J BIOL CHEM, V256, P7146; KIM JY, 1994, BIOPHYS J, V67, P227, DOI 10.1016/S0006-3495(94)80473-4; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI JX, 1992, CELL, V70, P791, DOI 10.1016/0092-8674(92)90312-Z; MCILROY BK, 1991, J BIOL CHEM, V266, P4959; MCLAUGHLIN S, 1977, CURR TOP MEMBR TRANS, V9, P1; MCLAUGHLIN S, 1989, ANNU REV BIOPHYS BIO, V18, P13; MOSIOR M, 1992, BIOCHIM BIOPHYS ACTA, V1105, P185, DOI 10.1016/0005-2736(92)90178-O; MUI BLS, 1993, BIOPHYS J, V64, P443, DOI 10.1016/S0006-3495(93)81385-7; NAKAOKA T, 1993, J BIOCHEM-TOKYO, V114, P449, DOI 10.1093/oxfordjournals.jbchem.a124196; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; RANDAZZO PA, 1993, J BIOL CHEM, V268, P9555; REED JC, 1991, CELL SIGNAL, V3, P569, DOI 10.1016/0898-6568(91)90033-Q; ROSEN A, 1989, J BIOL CHEM, V264, P9118; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; SAWAI T, 1993, J BIOL CHEM, V268, P1995; SEYKORA JT, 1991, P NATL ACAD SCI USA, V88, P2505, DOI 10.1073/pnas.88.6.2505; SILVIUS JR, 1994, BIOCHEMISTRY-US, V33, P3014, DOI 10.1021/bi00176a034; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; VERGHESE GM, 1994, J BIOL CHEM, V269, P9361; WANG JKT, 1989, P NATL ACAD SCI USA, V86, P2253, DOI 10.1073/pnas.86.7.2253; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	39	184	184	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28214	28219						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961759				2023-01-03	WOS:A1994PV77200067
J	SADEK, CM; ALLENHOFFMANN, BL				SADEK, CM; ALLENHOFFMANN, BL			CYTOCHROME P450IA1 IS RAPIDLY INDUCED IN NORMAL HUMAN KERATINOCYTES IN THE ABSENCE OF XENOBIOTICS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE S-TRANSFERASES; HEAT-SHOCK PROTEIN; PLASMINOGEN-ACTIVATOR INHIBITOR-2; LIVER NAD(P)H-QUINONE REDUCTASE; ANTIOXIDANT RESPONSIVE ELEMENT; HUMAN EPIDERMAL-KERATINOCYTES; SUBUNIT GENE-EXPRESSION; AH-RECEPTOR; TERMINAL DIFFERENTIATION; SIGNAL-TRANSDUCTION	Cytochrome P450IA1 is a polycyclic aromatic hydrocarbon (PAH)-responsive monooxygenase enzyme with no known endogenous inducer or substrate. We investigated the effect of suspension on P450IA1 gene (CYP1A1) expression in cultured human keratinocytes without the addition of xenobiotics, To prohibit adhesion and trigger differentiation, human keratinocytes or dermal fibroblasts were suspended in medium made semisolid with methylcellulose. Following suspension, we observed dramatic increases (> 100-fold) in steady state P450IA1 mRNA in keratinocytes within 1 h; however, dermal fibroblasts were nonresponsive. This effect was not dependent on methylcellulose itself and could be achieved by suspension in medium alone or in Percoll solution. The induction of P450IA1 mRNA was independent of exogenous calcium or serum concentrations, agents commonly used to signal differentiation. Adherent keratinocytes overlaid with methylcellulose exhibited slight morphological changes accompanied by increased P450IA1 mRNA. The activity of the P450IA1 enzyme was found to parallel Northern analysis data. Changes in keratinocyte adhesion or shape also affect other PAH-responsive genes suggesting Ah receptor involvement. We report a novel mechanism for cell type-specific induction of CYP1A1 expression without the addition of xenobiotic inducers. These findings suggest a possible endogenous role for P450IA1 in stratified squamous epithelia.	UNIV WISCONSIN,CTR ENVIRONM TOXICOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison	SADEK, CM (corresponding author), UNIV WISCONSIN,DEPT PATHOL,MADISON,WI 53706, USA.		Sadek, Christine/A-7356-2010		NIAMS NIH HHS [AR40284] Funding Source: Medline; NIEHS NIH HHS [T32 ES07015] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR040284, R01AR040284] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007015] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADAMS JC, 1991, J CELL BIOL, V115, P829, DOI 10.1083/jcb.115.3.829; ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; ALLENHOFFMANN BL, 1984, P NATL ACAD SCI-BIOL, V81, P7802, DOI 10.1073/pnas.81.24.7802; BADLEY JE, 1988, BIOTECHNIQUES, V6, P114; BAYNEY RM, 1987, J BIOL CHEM, V262, P572; BERGHARD A, 1990, J BIOL CHEM, V265, P21086; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; BURKE MD, 1985, BIOCHEM PHARMACOL, V34, P3337, DOI 10.1016/0006-2952(85)90355-7; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; CARTER WG, 1990, J CELL BIOL, V110, P1387, DOI 10.1083/jcb.110.4.1387; CARTER WG, 1990, J CELL BIOL, V111, P3141, DOI 10.1083/jcb.111.6.3141; CAYLEY S, 1991, J MOL BIOL, V222, P281, DOI 10.1016/0022-2836(91)90212-O; COOMES MW, 1983, J PHARMACOL EXP THER, V255, P770; DANIEL V, 1993, CRIT REV BIOCHEM MOL, V28, P173, DOI 10.3109/10409239309086794; DENIS M, 1988, BIOCHEM BIOPH RES CO, V155, P801, DOI 10.1016/S0006-291X(88)80566-7; DIGIOVANNI J, 1989, CANCER RES, V49, P5567; ECKERT RL, 1989, PHYSIOL REV, V69, P1316, DOI 10.1152/physrev.1989.69.4.1316; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GONZALEZ FJ, 1989, PHARMACOL REV, V40, P243; GRADIN K, 1993, J BIOL CHEM, V268, P4061; GREEN H, 1977, CELL, V11, P405, DOI 10.1016/0092-8674(77)90058-7; GUO JF, 1990, J INVEST DERMATOL, V94, P86, DOI 10.1111/1523-1747.ep12873939; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; JAISWAL AK, 1985, NUCLEIC ACIDS RES, V13, P4503, DOI 10.1093/nar/13.12.4503; JAISWAL AK, 1991, BIOCHEMISTRY-US, V30, P10647, DOI 10.1021/bi00108a007; JONES PH, 1993, CELL, V73, P713, DOI 10.1016/0092-8674(93)90251-K; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; KRUITHOF EKO, 1988, BIOCHEM BIOPH RES CO, V156, P383, DOI 10.1016/S0006-291X(88)80852-0; KURPAKUS MA, 1991, J CELL BIOL, V115, P1737, DOI 10.1083/jcb.115.6.1737; LAI HCJ, 1984, J BIOL CHEM, V259, P5536; MANOHARAN TH, 1987, J BIOL CHEM, V262, P3739; MARCHISIO PC, 1991, J CELL BIOL, V112, P761, DOI 10.1083/jcb.112.4.761; MENON GK, 1985, J INVEST DERMATOL, V84, P508, DOI 10.1111/1523-1747.ep12273485; MINTON AP, 1983, MOL CELL BIOCHEM, V55, P119, DOI 10.1007/BF00673707; MOREL F, 1993, CANCER RES, V53, P231; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; NEBERT DW, 1989, INT J BIOCHEM, V21, P243, DOI 10.1016/0020-711X(89)90182-1; NEBERT DW, 1993, ANN NY ACAD SCI, V685, P624, DOI 10.1111/j.1749-6632.1993.tb35928.x; NGUYEN T, 1992, J BIOL CHEM, V267, P13535; PAINE AJ, 1991, INT J EXP PATHOL, V72, P349; PAULSON KE, 1990, MOL CELL BIOL, V10, P1841, DOI 10.1128/MCB.10.5.1841; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; PERDEW GH, 1988, J BIOL CHEM, V263, P9848; PETERSEN DD, 1991, AM J HUM GENET, V48, P720; POHL RJ, 1984, DRUG METAB DISPOS, V12, P25; PONGRATZ I, 1992, J BIOL CHEM, V267, P13728; REINERS JJ, 1990, P NATL ACAD SCI USA, V87, P1825, DOI 10.1073/pnas.87.5.1825; REINERS JJ, 1992, DRUG METAB DISPOS, V20, P360; REINERS JJ, 1991, CHEM INDUCED CELL PR, P123; ROZEN F, 1992, ARCH BIOCHEM BIOPHYS, V292, P589, DOI 10.1016/0003-9861(92)90035-U; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; SONNENBERG A, 1991, J CELL BIOL, V113, P907, DOI 10.1083/jcb.113.4.907; STAQUET MJ, 1990, EXP CELL RES, V187, P277, DOI 10.1016/0014-4827(90)90092-O; STEPP MA, 1990, P NATL ACAD SCI USA, V87, P8970, DOI 10.1073/pnas.87.22.8970; SUTTER TR, 1991, SCIENCE, V254, P415, DOI 10.1126/science.1925598; TU CPD, 1986, BIOCHEM BIOPH RES CO, V141, P229, DOI 10.1016/S0006-291X(86)80358-8; TU CPD, 1986, J BIOL CHEM, V261, P9540; Watt FM, 1989, CURR OPIN CELL BIOL, V1, P1107, DOI 10.1016/S0955-0674(89)80058-4; WATT FM, 1984, J CELL BIOL, V98, P16, DOI 10.1083/jcb.98.1.16; WATT FM, 1982, NATURE, V295, P434, DOI 10.1038/295434a0; WATT FM, 1987, J CELL SCI S, V8, P313; WILLIAMS JB, 1986, J BIOL CHEM, V261, P5524; YE RD, 1987, J BIOL CHEM, V262, P3718	66	94	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16067	16074						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206906				2023-01-03	WOS:A1994NQ72900021
J	MEADOR, CK				MEADOR, CK			THE LAST WELL PERSON	NEW ENGLAND JOURNAL OF MEDICINE			English	Note									VANDERBILT UNIV,NASHVILLE,TN 37205	Vanderbilt University								BARSKY AJ, 1988, WORRIED SICK OUR TRO; MEADOR CK, 1991, JAMA-J AM MED ASSOC, V265, P1374, DOI 10.1001/jama.265.11.1374	2	33	32	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 10	1994	330	6					440	441		10.1056/NEJM199402103300618	http://dx.doi.org/10.1056/NEJM199402103300618			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MV279	8284021				2023-01-03	WOS:A1994MV27900032
J	GRUBER, A; PAL, A; KISS, RG; SAS, G; GRIFFIN, JH				GRUBER, A; PAL, A; KISS, RG; SAS, G; GRIFFIN, JH			GENERATION OF ACTIVATED PROTEIN-C DURING THROMBOLYSIS	LANCET			English	Note								The observation that urokinase infusion increases circulating levels of the anticoagulant activated protein C (APC) in baboons implies that APC might be elevated during thrombolytic therapy. Patients undergoing coronary thrombolysis showed an 11-fold increase (means from 6 to 69 mug/L) in APC during infusion of streptokinase. Thrombolytic therapy thus generates at least two potent antithrombotic factors in the circulation-the fibrinolytic enzyme, plasmin, and the anticoagulant enzyme, APC. APC may help prevent reocclusion during or after thrombolysis.	Scripps Res Inst, RES INST, LA JOLLA, CA 92037 USA; POSTGRAD MED UNIV, H-1389 BUDAPEST, HUNGARY	Scripps Research Institute				Griffin, John/0000-0002-4302-2547	NHLBI NIH HHS [HL-31950] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031950] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRANSON HE, 1983, LANCET, V2, P1165; COLLEN D, 1993, LANCET, V342, P34, DOI 10.1016/0140-6736(93)91888-S; EISENBERG PR, 1987, J AM COLL CARDIOL, V10, P527, DOI 10.1016/S0735-1097(87)80194-8; ESMON CT, 1981, P NATL ACAD SCI-BIOL, V78, P2249, DOI 10.1073/pnas.78.4.2249; ESPANA F, 1991, BLOOD, V77, P1754; GEIGER M, 1989, THROMB HAEMOSTASIS, V61, P86; GRUBER A, 1991, CIRCULATION, V84, P2454, DOI 10.1161/01.CIR.84.6.2454; GRUBER A, 1992, BLOOD, V79, P2340; HANSON SR, 1993, J CLIN INVEST, V92, P2003, DOI 10.1172/JCI116795; VARADI K, 1992, CIRCULATION, V86, pA736	10	25	25	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 20	1993	342	8882					1275	1276		10.1016/0140-6736(93)92364-Y	http://dx.doi.org/10.1016/0140-6736(93)92364-Y			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH566	7901587				2023-01-03	WOS:A1993MH56600014
J	BLACKBURN, GL				BLACKBURN, GL			COMPARISON OF MEDICALLY SUPERVISED AND UNSUPERVISED APPROACHES TO WEIGHT-LOSS AND CONTROL	ANNALS OF INTERNAL MEDICINE			English	Article							LOW-CALORIE DIETS; CONTROLLED TRIAL; BLOOD-PRESSURE; OBESITY; HYPERTENSION; REDUCTION; PROGRAMS	The rising incidence of obesity in the United States has given physicians an increased role in its treatment. Although unsupervised programs can produce significant weight losses, the lack of medical supervision increases the potential for health problems. As with other lifestyle changes (for example, smoking cessation and blood pressure control), even minimal physician involvement may enhance outcome. In published clinical trials, the absence of contact with health professionals among control group participants may account in part for their poor success at weight loss or for their weight gain. Smaller trials examining the value of physician advice and encouragement among dieting patients have shown promising results. Physicians should monitor the health of obese and overweight patients during and after weight loss as is appropriate for the patient, depending on caloric levels, rate of weight loss, weight-loss goals, and intercurrent health events. Medical supervision is necessary for patients on very-low-calorie diets, for severely obese patients (body mass index >35), and for patients with other health problems.			BLACKBURN, GL (corresponding author), HARVARD UNIV, NEW ENGLAND DEACONESS HOSP, SCH MED, 194 PILGRIM RD, BOSTON, MA 02215 USA.							ANDERSON JW, 1992, AM J GASTROENTEROL, V87, P6; BLACKBURN GL, 1988, CIRCULATION, V78, P568; Bray, 1985, MANAGEMENT OBESITY S; BRAY GA, 1989, MED CLIN N AM, V73, P161, DOI 10.1016/S0025-7125(16)30697-6; BRAY GA, 1992, AM J CLIN NUTR, V55, P488, DOI 10.1093/ajcn/55.2.488s; Cohen M D, 1991, Fam Med, V23, P25; CUMMINGS SR, 1989, JAMA-J AM MED ASSOC, V261, P75, DOI 10.1001/jama.261.1.75; DAVIS PG, 1990, INT J OBESITY, V14, P779; GOLDSTEIN DJ, 1992, INT J OBESITY, V16, P397; GREEN LW, 1986, PUBLIC HLTH PREVENTI; HENDEE WR, 1988, JAMA-J AM MED ASSOC, V260, P2547; HOLMES MD, 1989, J FAM PRACTICE, V28, P610; INUI TS, 1976, ANN INTERN MED, V84, P646, DOI 10.7326/0003-4819-84-6-646; KANDERS BS, 1992, TREATMENT SERIOUSLY, P213; KANDERS BS, 1991, CONNS CURRENT THERAP; KAPLAN RM, 1985, DIABETES CARE, V8, P343, DOI 10.2337/diacare.8.4.343; KLAWANSKY S, 1992, JAMA-J AM MED ASSOC, V268, P873, DOI 10.1001/jama.1992.03490070051035; LI VC, 1987, AM J PREV MED, V3, P81; PALGI A, 1985, AM J PUBLIC HEALTH, V75, P1190, DOI 10.2105/AJPH.75.10.1190; RAMSAY LE, 1978, BRIT MED J, V2, P244, DOI 10.1136/bmj.2.6132.244; ROCCHINI AP, 1987, HYPERTENSION, V10, P267, DOI 10.1161/01.HYP.10.3.267; SICHIERI R, 1991, AM J PUBLIC HEALTH, V81, P880, DOI 10.2105/AJPH.81.7.880; STAMLER R, 1989, JAMA-J AM MED ASSOC, V262, P1801, DOI 10.1001/jama.262.13.1801; WADDEN TA, 1990, JAMA-J AM MED ASSOC, V263, P83, DOI 10.1001/jama.263.1.83; WADDEN TA, 1992, ARCH INTERN MED, V152, P961, DOI 10.1001/archinte.152.5.961; WADDEN TA, 1983, ANN INTERN MED, V99, P675, DOI 10.7326/0003-4819-99-5-675; WADDEN TA, 1992, METHODS VOLUNTARY WE, P64; WASSERTHEILSMOLLER S, 1992, ARCH INTERN MED, V152, P131, DOI 10.1001/archinte.152.1.131; WEINSIER RL, 1984, AM J CLIN NUTR, V40, P865, DOI 10.1093/ajcn/40.4.865; WHELTON PK, 1992, JAMA-J AM MED ASSOC, V267, P1213, DOI 10.1001/jama.1992.03480090061028; WILLIAMSON DF, 1990, ARCH INTERN MED, V150, P665, DOI 10.1001/archinte.150.3.665; WILLIAMSON PS, 1988, J FAM PRACTICE, V27, P187; 1989, MED LETT DRUGS THER, V31, P22; 1991, REPORT TASK FORCE TR; 1990, SAFE WEIGHT LOSS E L; 1990, DIETARY GUIDELINES A	36	29	29	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1993	119	7	2				714	718		10.7326/0003-4819-119-7_Part_2-199310011-00017	http://dx.doi.org/10.7326/0003-4819-119-7_Part_2-199310011-00017			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA330	8363203				2023-01-03	WOS:A1993MA33000017
J	ANDERSON, HV; WILLERSON, JT				ANDERSON, HV; WILLERSON, JT			CURRENT CONCEPTS - THROMBOLYSIS IN ACUTE MYOCARDIAL-INFARCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							TISSUE PLASMINOGEN-ACTIVATOR; RANDOMIZED CONTROLLED TRIALS; CORONARY-ARTERY; THROMBIN INHIBITION; DELAYS REOCCLUSION; PROSTAGLANDIN ENDOPEROXIDES; ENHANCES THROMBOLYSIS; CANINE MODEL; THERAPY; HEPARIN		HERMANN HOSP, HOUSTON, TX 77030 USA; ST LUKES EPISCOPAL HOSP, TEXAS HEART INST, HOUSTON, TX 77030 USA	Saint Lukes Episcopal Hospital; Texas Heart Institute	ANDERSON, HV (corresponding author), UNIV TEXAS, HLTH SCI CTR, DEPT INTERNAL MED, DIV CARDIOL, 6431 FANNIN ST, HOUSTON, TX 77030 USA.							[Anonymous], 1990, LANCET, V336, P65; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1989, NEW ENGL J MED, V320, P618; ARNOUT J, 1992, J AM COLL CARDIOL, V20, P513, DOI 10.1016/0735-1097(92)90001-4; ARONSON DL, 1992, CIRCULATION, V85, P1706, DOI 10.1161/01.CIR.85.5.1706; BECKER RC, 1993, CORONARY ARTERY DIS, V4, P293, DOI 10.1097/00019501-199303000-00010; BLEICH SD, 1990, AM J CARDIOL, V66, P1412, DOI 10.1016/0002-9149(90)90525-6; CALIFF RM, 1992, AM J CARDIOL, V69, pA12, DOI 10.1016/0002-9149(92)91168-4; Cannon Christopher P., 1993, Journal of the American College of Cardiology, V21, p136A; COLLEN D, 1991, BLOOD, V78, P3114; COLLER BS, 1992, CORONARY ARTERY DIS, V3, P1016, DOI 10.1097/00019501-199211000-00005; CRAGG DR, 1991, ANN INTERN MED, V115, P173, DOI 10.7326/0003-4819-115-3-173; DAVIES MJ, 1985, BRIT HEART J, V53, P363; DEBONO DP, 1992, BRIT HEART J, V67, P122; ECKMAN MH, 1992, ANN INTERN MED, V117, P667, DOI 10.7326/0003-4819-117-8-667; EITZMAN DT, 1993, J AM COLL CARDIOL  S, V21, pZ276; FITZGERALD DJ, 1988, J CLIN INVEST, V82, P1708, DOI 10.1172/JCI113784; FITZGERALD DJ, 1989, CIRC RES, V65, P83, DOI 10.1161/01.RES.65.1.83; FLETCHER AP, 1958, T ASSOC AM PHYSICIAN, V71, P287; FORTIN DF, 1990, AM J MED, V88, pN9; FREEMAN MR, 1992, CIRCULATION, V85, P150, DOI 10.1161/01.CIR.85.1.150; GALVANI M, 1993, AM J CARDIOL, V71, P1, DOI 10.1016/0002-9149(93)90700-M; Gil Victor, 1993, Journal of the American College of Cardiology, V21, p300A; GOLD HK, 1988, CIRCULATION, V77, P670, DOI 10.1161/01.CIR.77.3.670; GOLINO P, 1989, CIRCULATION, V79, P911, DOI 10.1161/01.CIR.79.4.911; GOLINO P, 1990, J CLIN INVEST, V86, P1095, DOI 10.1172/JCI114813; GORE JM, 1991, J INVASIVE CARDIOL, V3, pA21; GRINES CL, 1990, J AM COLL CARDIOL, V16, P223, DOI 10.1016/0735-1097(90)90482-5; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; GUIDERA SA, 1993, J AM COLL CARDIOL, V21, P1645, DOI 10.1016/0735-1097(93)90381-A; GUNNAR RM, 1990, J AM COLL CARDIOL, V16, P249, DOI 10.1016/0735-1097(90)90575-A; GURWITZ JH, 1991, JAMA-J AM MED ASSOC, V265, P1720, DOI 10.1001/jama.265.13.1720; HASKEL EJ, 1991, CIRCULATION, V83, P1048, DOI 10.1161/01.CIR.83.3.1048; HIRSH PD, 1981, NEW ENGL J MED, V304, P687; HSIA J, 1992, J AM COLL CARDIOL, V20, P31, DOI 10.1016/0735-1097(92)90133-8; HSIA J, 1990, NEW ENGL J MED, V323, P1433, DOI 10.1056/NEJM199011223232101; HUNT D, 1992, LANCET, V339, P753; JANG IK, 1990, CIRC RES, V67, P1552, DOI 10.1161/01.RES.67.6.1552; KLEIMAN NS, 1992, CIRCULATION, V86, P260; KROON C, 1992, CIRCULATION, V86, P1370, DOI 10.1161/01.CIR.86.5.1370; Lidon Rosa-Maria, 1993, Journal of the American College of Cardiology, V21, p419A; MACMAHON S, 1988, CIRCULATION S2, V78, P98; MATHEY DG, 1988, AM J CARDIOL, V61, P524, DOI 10.1016/0002-9149(88)90758-8; MULLER DWM, 1990, ANN INTERN MED, V113, P949, DOI 10.7326/0003-4819-113-12-949; Neuhaus Karl-L., 1993, Journal of the American College of Cardiology, V21, p418A; ROUX S, 1992, J AM COLL CARDIOL, V19, P671, DOI 10.1016/S0735-1097(10)80290-6; RUDD MA, 1992, CIRC RES, V70, P829, DOI 10.1161/01.RES.70.4.829; SLOAN MA, 1992, AM J CARDIOL, V69, pA21, DOI 10.1016/0002-9149(92)91169-5; STUMP DC, 1989, CIRCULATION, V80, P1222, DOI 10.1161/01.CIR.80.5.1222; SUTHERLAND JE, 1990, JAMA-J AM MED ASSOC, V264, P3178, DOI 10.1001/jama.264.24.3178; TIEFENBRUNN AJ, 1991, FIBRINOLYSIS, V5, P1, DOI 10.1016/0268-9499(91)90073-D; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; VANDEWERF F, 1990, LANCET, V336, P71; WHITE HD, 1987, NEW ENGL J MED, V317, P850, DOI 10.1056/NEJM198710013171402; WILLERSON JT, 1989, CIRCULATION, V80, P198, DOI 10.1161/01.CIR.80.1.198; Willerson JT, 1992, TREATMENT HEART DISE, V1, P43; YAO SK, 1992, CIRCULATION, V86, P1993, DOI 10.1161/01.CIR.86.6.1993; YAO SK, 1992, AM J PHYSIOL, V262, pH374, DOI 10.1152/ajpheart.1992.262.2.H374; YAO SK, 1993, CLIN RES, V41, pA228; YUSUF S, 1985, EUR HEART J, V6, P556, DOI 10.1093/oxfordjournals.eurheartj.a061905; YUSUF S, 1990, CIRCULATION, V82, P117	61	171	177	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 2	1993	329	10					703	709						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU583	8345856				2023-01-03	WOS:A1993LU58300006
J	Livingston, G; Manela, M; Katona, C				Livingston, G; Manela, M; Katona, C			Depression and other psychiatric morbidity in carers of elderly people living at home	BRITISH MEDICAL JOURNAL			English	Article							PREVALENCE RATES; COMMUNITY; DEMENTIA; RELATIVES	Objective-To describe the mental health of a community sample of carers of elderly people with dementia, depression, or physical disability and to compare that with the mental health of other adults living in the household and of those living alone. Design-Assessment of psychiatric morbidity and physical disability with standardised questionnaire in randomly selected enumeration districts; subjects were interviewed at home. Setting-London Borough of Islington. Subjects-700 people aged greater than or equal to 65 and other co-residents. Main outcome measure-Depression measured with standardised interview. Results-The prevalence of depression was not significantly higher in carers overall (15%) than in coresidents (11%). Being a woman carer was a significant predictor of psychiatric illness. Depression was more common in the carers of people with a psychiatric disorder than in coresidents (24% v 11%, P < 0.05) and in those living alone (19%). Depression was most common (47%) in women carers of people with dementia. Conclusion-The increase in psychiatric morbidity reported in carers of people with psychiatric disorders may reflect the lack of a confiding relationship.			Livingston, G (corresponding author), UCL, SCH MED, DEPT PSYCHIAT, MORTIMER ST, LONDON W1N 8AA, ENGLAND.		Livingston, G/C-7081-2008	Katona, Cornelius/0000-0001-7451-0167; Livingston, Gill/0000-0001-6741-5516				[Anonymous], 1993, ICD 10 CLASSIFICATIO; BERGMANN K, 1983, ELDERLY PEOPLE COMMU; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; COLLINS C, 1992, RECENT ADV PSYCHOGER, P153; COPELAND JRM, 1987, BRIT J PSYCHIAT, V150, P815, DOI 10.1192/bjp.150.6.815; EAGLES JM, 1987, BRIT J PSYCHIAT, V150, P293, DOI 10.1192/bjp.150.3.293; Foulds G. A, 1976, HIERARCHICAL NATURE; GEORGE LK, 1986, GERONTOLOGIST, V26, P253, DOI 10.1093/geront/26.3.253; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; GURLAND B, 1984, J GERONTOL, V39, P166, DOI 10.1093/geronj/39.2.166; JARMAN B, 1983, BRIT MED J, V286, P1705, DOI 10.1136/bmj.286.6379.1705; KAY DWK, 1985, PSYCHOL MED, V15, P771, DOI 10.1017/S0033291700005006; LEVIN E, 1989, FAMILIES SERVICES CO; LEWIS G, 1992, PSYCHOL MED, V22, P465, DOI 10.1017/S0033291700030415; LINDESAY J, 1989, BRIT J PSYCHIAT, V155, P317, DOI 10.1192/bjp.155.3.317; LIVINGSTON G, 1990, PSYCHOL MED, V20, P137, DOI 10.1017/S0033291700013313; MANELA M, IN PRESS INT J GERIA; Murray J., 1995, PREVENTION ANXIETY D; NORUSIS MJ, SPSSPC4; OCONNOR DW, 1990, BRIT J PSYCHIAT, V156, P835, DOI 10.1192/bjp.156.6.835; PARKER G, DHSS715 U YORK SOC P; WADE DT, 1986, BRIT MED J, V293, P418, DOI 10.1136/bmj.293.6544.418; WING JK, 1976, PSYCHOL MED, V6, P665; 1987, GENERAL HOUSEHOLD SU	24	111	111	0	9	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 20	1996	312	7024					153	156						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TR325	8563534				2023-01-03	WOS:A1996TR32500022
J	STEIN, PD; HULL, RD; RASKOB, G				STEIN, PD; HULL, RD; RASKOB, G			RISKS FOR MAJOR BLEEDING FROM THROMBOLYTIC THERAPY IN PATIENTS WITH ACUTE PULMONARY-EMBOLISM - CONSIDERATION OF NONINVASIVE MANAGEMENT	ANNALS OF INTERNAL MEDICINE			English	Article						PULMONARY EMBOLISM; HEMORRHAGE; THROMBOLYTIC THERAPY; ANGIOGRAPHY; ALTEPLASE	CONTINUOUS INTRAVENOUS HEPARIN; TISSUE PLASMINOGEN-ACTIVATOR; PROXIMAL-VEIN THROMBOSIS; PERFUSION LUNG SCANS; RANDOMIZED TRIAL; SUBCUTANEOUS HEPARIN; VENOUS THROMBOSIS; INITIAL TREATMENT; ALTEPLASE; UROKINASE	Objective: To assess the relative risks for bleeding with thrombolytic therapy in patients who are managed using pulmonary angiograms compared with those managed using noninvasive tests, primarily the ventilation-perfusion lung scan. Design: A decision analysis based on data from other studies. Methods: The risk for major bleeding in patients with pulmonary embolism who receive thrombolytic therapy after a noninvasive diagnosis was assessed from complications of thrombolytic therapy in patients with myocardial infarction, assuming that the same risk ratio for major bleeding when comparing an invasive with a noninvasive approach applied to patients with pulmonary embolism. The risk ratio was 3.3 (95% CI, 1.5 to 9.8) for major bleeding in patients with myocardial infarction. One or more major complications of pulmonary angiography occurred in 1.3% of patients (CI, 0.6% to 1.9%). Results: The average reported risk was 14% (18 of 129 patients) (CI, 7.9% to 20.1%) for major bleeding in patients who had pulmonary angiography before receiving tissue plasminogen activator (tPA). The estimated risk was 4.2% (estimated CI, 1.4% to 9.3%) for major bleeding with tPA after a noninvasive diagnosis of pulmonary embolism. Assuming a risk of 1.3% for major complications from pulmonary angiography, a risk for major hemorrhage of 14.0% for an invasive diagnosis, and a risk of 4.2% for a noninvasive diagnosis, fewer complications would occur with noninvasive management if the prevalence of pulmonary embolism exceeded 21%. Conclusion: Among patients with suspected pulmonary embolism who are candidates for thrombolytic therapy, it is safer to use noninvasive diagnostic tests in many patients.	HENRY FORD HEART & VASC INST, DETROIT, MI USA	Henry Ford Health System								[Anonymous], 1990, LANCET, V336, P65; [Anonymous], 1990, CHEST, V97, P528; CALIFF RM, 1988, AM J MED, V85, P353, DOI 10.1016/0002-9343(88)90586-4; DALLAVOLTA S, 1992, J AM COLL CARDIOL, V20, P520, DOI 10.1016/0735-1097(92)90002-5; DOYLE DJ, 1987, ANN INTERN MED, V107, P441, DOI 10.7326/0003-4819-107-4-441; GOLDHABER SZ, 1992, J AM COLL CARDIOL, V20, P24, DOI 10.1016/0735-1097(92)90132-7; GOLDHABER SZ, 1993, LANCET, V341, P507, DOI 10.1016/0140-6736(93)90274-K; GOLDHABER SZ, 1988, LANCET, V2, P293; HULL R, 1982, NEW ENGL J MED, V307, P1676, DOI 10.1056/NEJM198212303072704; HULL RD, 1990, NEW ENGL J MED, V322, P1260, DOI 10.1056/NEJM199005033221802; HULL RD, 1986, NEW ENGL J MED, V315, P1109, DOI 10.1056/NEJM198610303151801; HULL RD, 1992, NEW ENGL J MED, V326, P975, DOI 10.1056/NEJM199204093261502; HUNT D, 1992, LANCET, V339, P753; KNATTERUD G, 1988, JAMA-J AM MED ASSOC, V260, P2849; LEVINE M, 1990, CHEST, V98, P1473, DOI 10.1378/chest.98.6.1473; LEVINE MN, 1992, CHEST, V102, pS364, DOI 10.1378/chest.102.4_Supplement.364S; MARINI C, 1988, RESPIRATION, V54, P162, DOI 10.1159/000195517; PATIL S, 1993, CHEST, V104, P1685, DOI 10.1378/chest.104.6.1685; PINI M, 1990, THROMB HAEMOSTASIS, V64, P222; SCHLESSELMAN JJ, 1982, CASE CONTROL STUDIES, P176; STEIN PD, 1993, CHEST, V104, P1472, DOI 10.1378/chest.104.5.1472; STEIN PD, 1993, CHEST, V104, P1468, DOI 10.1378/chest.104.5.1468; STEINPD, 1992, CIRCULATION, V85, P462; STEINPD, 1993, CHEST, V104, P1461; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; VERSTRAETE M, 1988, CIRCULATION, V77, P353, DOI 10.1161/01.CIR.77.2.353; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x	28	76	79	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1994	121	5					313	317		10.7326/0003-4819-121-5-199409010-00001	http://dx.doi.org/10.7326/0003-4819-121-5-199409010-00001			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD701	8042819				2023-01-03	WOS:A1994PD70100001
J	DOYAL, L; WILSHER, D				DOYAL, L; WILSHER, D			WITHHOLDING AND WITHDRAWING LIFE-SUSTAINING TREATMENT FROM ELDERLY PEOPLE - TOWARDS FORMAL GUIDELINES	BRITISH MEDICAL JOURNAL			English	Article							ETHICS	Clinicians often decide either to withhold or to withdraw lifesaving treatment in elderly patients. Considerable disagreement exists about the circumstances in which such actions can be defended. Debates about the scarcity of resources in the NHS add urgency to the need to resolve this disagreement. Competent elderly patients have a legal and moral right to decide whether to receive life sustaining treatment. Such treatment should not be withheld or withdrawn on the basis of a patient's age alone. Principles for making decisions about Life sustaining treatment in incompetent elderly patients can be defended and should exist as written guidelines.	UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL,DEP HUMAN SCI & MED ETH,LONDON E1 2AD,ENGLAND	University of London; Queen Mary University London	DOYAL, L (corresponding author), LONDON MED COLL,DEPT HUMAN SCI & MED ETH,LONDON E1 2AD,ENGLAND.							[Anonymous], 1993, LANCET, V342, P1; ASPLUND K, 1989, STROKE, V20, P1107, DOI 10.1161/01.STR.20.8.1107; Buchanan Allen E., 1989, DECIDING OTHERS ETHI; DOYAL L, 1993, BRIT MED J, V306, P1593, DOI 10.1136/bmj.306.6892.1593; DOYAL L, 1990, J LAW SOC, V17, P1, DOI 10.2307/1409951; DOYAL L, 1994, ARCH DIS CHILD, V70, P66; Doyal L., 1991, THEORY HUMAN NEED, DOI DOI 10.1007/978-1-349-21500-3; Dworkin R., 1993, LIFES DOMINION; EVANS JG, 1989, AGE AGEING, V18, P217, DOI 10.1093/ageing/18.4.217; FRASER M, 1987, DEMENTIA ITS NATURE; Harris J., 1985, VALUE LIFE; Parfit Derek, 1987, REASONS PERSONS; RACHELS J., 1986, END LIFE EUTHANASIA; VOLICER L, 1986, JAMA-J AM MED ASSOC, V256, P2210, DOI 10.1001/jama.256.16.2210; Wicclair M., 1993, ETHICS ELDERLY; WILLIAMS F, 1993, BRIT J HOSP MED, V50, P50; 1994, ENSURING EQUITY QUAL; 1994, REPORT; 1988, LIVING WILL CONSENT; 1994, BUTTERWORTHS MEDICOL, V15, P77	20	36	36	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 25	1994	308	6945					1689	1692		10.1136/bmj.308.6945.1689	http://dx.doi.org/10.1136/bmj.308.6945.1689			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU483	8025466	Green Published			2023-01-03	WOS:A1994NU48300031
J	BELCHETZ, PE				BELCHETZ, PE			DRUG-THERAPY - HORMONAL TREATMENT OF POSTMENOPAUSAL WOMEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ESTROGEN REPLACEMENT THERAPY; POST-MENOPAUSAL WOMEN; NON-CONTRACEPTIVE ESTROGENS; CORONARY HEART-DISEASE; BREAST-CANCER RISK; ACUTE MYOCARDIAL-INFARCTION; LONG-TERM ESTROGEN; ENDOMETRIAL CANCER; BONE LOSS; EXOGENOUS ESTROGENS				BELCHETZ, PE (corresponding author), GEN INFIRM, DEPT ENDOCRINOL, GREAT GEORGE ST, LEEDS LS1 3EX, ENGLAND.							ADAM S, 1981, BRIT MED J, V282, P1277, DOI 10.1136/bmj.282.6272.1277; ADAMI S, 1989, BONE MINER, V7, P79, DOI 10.1016/0169-6009(89)90064-0; AITKEN JM, 1973, BRIT MED J, V2, P325, DOI 10.1136/bmj.2.5862.325; AITKEN JM, 1973, BMJ-BRIT MED J, V3, P515, DOI 10.1136/bmj.3.5879.515; ALAZZAWI F, 1987, BRIT MED J, V294, P1261, DOI 10.1136/bmj.294.6582.1261-a; [Anonymous], 1974, N Engl J Med, V290, P15; ARAFAT ES, 1988, AM J OBSTET GYNECOL, V159, P1203, DOI 10.1016/0002-9378(88)90448-6; ARMSTRONG BK, 1988, MED J AUSTRALIA, V148, P213, DOI 10.5694/j.1326-5377.1988.tb99424.x; ASTEDT B, 1977, ACTA OBSTET GYN SCAN, P45; BAIN C, 1981, CIRCULATION, V64, P42, DOI 10.1161/01.CIR.64.1.42; BARRETTCONNOR E, 1991, ANN INTERN MED, V115, P455, DOI 10.7326/0003-4819-115-6-455; BEAGLEHOLE R, 1988, BRIT MED J, V297, P571, DOI 10.1136/bmj.297.6648.571; BELCHETZ P, 1990, PRACTITIONER, V234, P491; BELCHETZ P, 1989, BMJ-BRIT MED J, V298, P1467, DOI 10.1136/bmj.298.6686.1467; BERGKVIST L, 1990, NEW ENGL J MED, V322, P204; BERGKVIST L, 1989, NEW ENGL J MED, V321, P293, DOI 10.1056/NEJM198908033210505; BERGKVIST L, 1989, AM J EPIDEMIOL, V130, P221, DOI 10.1093/oxfordjournals.aje.a115328; BHAVNANI BR, 1983, J CLIN ENDOCR METAB, V56, P1048, DOI 10.1210/jcem-56-5-1048; BRINTON LA, 1986, BRIT J CANCER, V54, P825, DOI 10.1038/bjc.1986.246; BRINTON LA, 1981, CANCER-AM CANCER SOC, V47, P2517, DOI 10.1002/1097-0142(19810515)47:10<2517::AID-CNCR2820471035>3.0.CO;2-L; BUNGAY GT, 1980, BRIT MED J, V281, P181, DOI 10.1136/bmj.281.6234.181; BURCH JC, 1974, AM J OBSTET GYNECOL, V118, P778, DOI 10.1016/0002-9378(74)90487-6; BURING JE, 1987, AM J EPIDEMIOL, V125, P939, DOI 10.1093/oxfordjournals.aje.a114632; BUSH TL, 1983, JAMA-J AM MED ASSOC, V249, P903, DOI 10.1001/jama.249.7.903; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; CAMPBELL S, 1977, CLIN OBSTET GYNAECOL, V4, P31; CASAGRANDE J, 1976, J NATL CANCER I, V56, P839, DOI 10.1093/jnci/56.4.839; CHRISTIANSEN C, 1982, J CLIN ENDOCR METAB, V55, P1124, DOI 10.1210/jcem-55-6-1124; CHRISTIANSEN C, 1981, LANCET, V1, P459; CHU J, 1982, AM J OBSTET GYNECOL, V143, P569, DOI 10.1016/0002-9378(82)90549-X; CLAYDEN JR, 1974, BRIT MED J, V1, P409, DOI 10.1136/bmj.1.5905.409; COLDITZ GA, 1990, JAMA-J AM MED ASSOC, V264, P2648, DOI 10.1001/jama.264.20.2648; COLDITZ GA, 1987, NEW ENGL J MED, V316, P1105, DOI 10.1056/NEJM198704303161801; COLDITZ GA, 1992, HORMONE REPLACEMENT THERAPY AND BREAST CANCER RISK, P63; COOPE J, 1975, BRIT MED J, V4, P139, DOI 10.1136/bmj.4.5989.139; CRAIG TJ, 1974, J NATL CANCER I, V53, P1577; CREASMAN WT, 1986, OBSTET GYNECOL, V67, P326; CREASMAN WT, 1991, OBSTET GYNECOL, V77, P308, DOI 10.1097/00006250-199102000-00031; CRIQUI MH, 1988, AM J EPIDEMIOL, V128, P606, DOI 10.1093/oxfordjournals.aje.a115008; CROFT P, 1989, BRIT MED J, V298, P165, DOI 10.1136/bmj.298.6667.165; DENNERSTEIN L, 1979, MATURITAS, V1, P247, DOI 10.1016/0378-5122(79)90015-X; DRAPER J, 1990, BRIT MED J, V300, P786, DOI 10.1136/bmj.300.6727.786; DRIFE JO, 1990, HRT OSTEOPOROSIS, P241; DUPONT WD, 1991, ARCH INTERN MED, V151, P67, DOI 10.1001/archinte.151.1.67; DUPONT WD, 1989, CANCER-AM CANCER SOC, V63, P948, DOI 10.1002/1097-0142(19890301)63:5<948::AID-CNCR2820630527>3.0.CO;2-U; EAKER ED, 1987, CORONARY HEART DISEA, P122; EDELSON RN, 1985, HEADACHE, V25, P376, DOI 10.1111/j.1526-4610.1985.hed2507376.x; ELWOOD JM, 1980, GYNECOL ONCOL, V10, P173, DOI 10.1016/0090-8258(80)90079-7; ERNSTER VL, 1988, PREV MED, V17, P201, DOI 10.1016/0091-7435(88)90064-3; ETTINGER B, 1985, ANN INTERN MED, V102, P319, DOI 10.7326/0003-4819-102-3-319; ETTINGER B, 1987, ANN INTERN MED, V106, P40, DOI 10.7326/0003-4819-106-1-40; EWERTZ M, 1988, INT J CANCER, V42, P832, DOI 10.1002/ijc.2910420606; FALKEBORN M, 1992, BRIT J OBSTET GYNAEC, V99, P821, DOI 10.1111/j.1471-0528.1992.tb14414.x; GAMBRELL RD, 1986, MATURITAS, V8, P159, DOI 10.1016/0378-5122(86)90022-8; GANGAR K, 1989, BRIT MED J, V299, P601, DOI 10.1136/bmj.299.6699.601-a; GANGAR KF, 1991, LANCET, V338, P839; GENANT HK, 1982, ANN INTERN MED, V97, P699, DOI 10.7326/0003-4819-97-5-699; GOLDMAN L, 1991, NEW ENGL J MED, V325, P800, DOI 10.1056/NEJM199109123251108; GOODMAN HM, 1989, J REPROD MED, V34, P231; Gordan G S, 1973, Trans Assoc Am Physicians, V86, P326; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GRADY D, 1992, ANN INTERN MED, V117, P1038; Hallstrom T, 1973, MENTAL DISORDER SEXU; HAMMOND CB, 1979, AM J OBSTET GYNECOL, V133, P525, DOI 10.1016/0002-9378(79)90288-6; HART DM, 1987, OSTEOPOROSIS; HENDERSON, 1988, AM J OBSTET GYNECOL, V159, P1574; HENDERSON BE, 1988, AM J OBSTET GYNECOL, V159, P312, DOI 10.1016/S0002-9378(88)80074-7; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; HIATT RA, 1984, CANCER, V54, P139, DOI 10.1002/1097-0142(19840701)54:1<139::AID-CNCR2820540128>3.0.CO;2-X; HILLNER BE, 1986, AM J MED, V80, P1115, DOI 10.1016/0002-9343(86)90674-1; HOOVER R, 1976, NEW ENGL J MED, V295, P401, DOI 10.1056/NEJM197608192950801; HOOVER R, 1981, J NATL CANCER I, V67, P815; HORWITZ RI, 1978, NEW ENGL J MED, V299, P1089, DOI 10.1056/NEJM197811162992001; HULKA BS, 1982, AM J OBSTET GYNECOL, V143, P638, DOI 10.1016/0002-9378(82)90108-9; HUNT K, 1987, BRIT J OBSTET GYNAEC, V94, P620, DOI 10.1111/j.1471-0528.1987.tb03166.x; HUTCHINSON TA, 1979, LANCET, V2, P705; HUTTON JD, 1979, J ROY SOC MED, V72, P835; JICK H, 1980, AM J EPIDEMIOL, V112, P586, DOI 10.1093/oxfordjournals.aje.a113031; JICK H, 1978, JAMA-J AM MED ASSOC, V239, P1407, DOI 10.1001/jama.239.14.1407; JOHNSTON CC, 1991, NEW ENGL J MED, V324, P1105; KANNEL WB, 1976, ANN INTERN MED, V85, P447, DOI 10.7326/0003-4819-85-4-447; KAUFMAN DW, 1984, JAMA-J AM MED ASSOC, V252, P63, DOI 10.1001/jama.252.1.63; KELSEY JL, 1981, JNCI-J NATL CANCER I, V67, P327; Kicovic P M, 1989, Minerva Endocrinol, V14, P63; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; KUHL H, 1990, MATURITAS, V12, P171, DOI 10.1016/0378-5122(90)90003-O; Lang W R, 1967, Clin Obstet Gynecol, V10, P454, DOI 10.1097/00003081-196709000-00003; LAVECCHIA C, 1986, INT J CANCER, V38, P853, DOI 10.1002/ijc.2910380612; LEIBLUM S, 1983, JAMA-J AM MED ASSOC, V249, P2195, DOI 10.1001/jama.249.16.2195; LHERMITE M, 1990, MATURITAS, V12, P215, DOI 10.1016/0378-5122(90)90005-Q; Lind T, 1979, Br J Obstet Gynaecol, V86 Suppl 3, P1, DOI 10.1111/j.1471-0528.1979.tb16232.x; LINDSAY R, 1978, CLIN SCI MOL MED, V54, P193, DOI 10.1042/cs0540193; LINDSAY R, 1984, OBSTET GYNECOL, V63, P759; LINDSAY R, 1988, MENOPAUSE, P156; LOBO RA, 1991, J CLIN ENDOCR METAB, V73, P925, DOI 10.1210/jcem-73-5-925; LOVE RR, 1988, BREAST CANCER RES TR, V12, P297, DOI 10.1007/BF01811242; MARKIEWICZ L, 1990, J STEROID BIOCHEM, V35, P535, DOI 10.1016/0022-4731(90)90196-Y; MCDONALD JA, 1986, BREAST CANCER RES TR, V7, P193, DOI 10.1007/BF01806250; MCKINLAY SM, 1974, BRIT J PREV SOC MED, V28, P108; MEADE TW, 1990, HRT AND OSTEOPOROSIS, P223; MILLS PK, 1989, CANCER, V64, P591, DOI 10.1002/1097-0142(19890801)64:3<591::AID-CNCR2820640305>3.0.CO;2-U; MOON TE, 1991, ARCH INTERN MED, V151, P17, DOI 10.1001/archinte.151.1.17; MUNKJENSEN N, 1988, BRIT MED J, V296, P1150, DOI 10.1136/bmj.296.6630.1150; NABULSI AA, 1993, NEW ENGL J MED, V328, P1069, DOI 10.1056/NEJM199304153281501; NACHTIGALL LE, 1979, OBSTET GYNECOL, V53, P277; NOMURA AMY, 1986, INT J CANCER, V37, P49, DOI 10.1002/ijc.2910370109; PAGANINIHILL A, 1981, ANN INTERN MED, V95, P28, DOI 10.7326/0003-4819-95-1-28; PAGANINIHILL A, 1988, BMJ-BRIT MED J, V297, P519, DOI 10.1136/bmj.297.6647.519; PATERSON MEL, 1982, BRIT J OBSTET GYNAEC, V89, P464, DOI 10.1111/j.1471-0528.1982.tb03638.x; PERSSON I, 1983, ACTA OBSTET GYN SCAN, V62, P289, DOI 10.3109/00016348309156224; PERSSON I, 1989, BRIT MED J, V298, P147, DOI 10.1136/bmj.298.6667.147; PERSSON I, 1990, J CLIN EPIDEMIOL, V43, P677; PETITTI DB, 1979, JAMA-J AM MED ASSOC, V242, P1150, DOI 10.1001/jama.242.11.1150; PETITTI DB, 1987, OBSTET GYNECOL, V70, P289; PETITTI DB, 1986, NEW ENGL J MED, V315, P131; PFEFFER RI, 1978, AM J EPIDEMIOL, V107, P479, DOI 10.1093/oxfordjournals.aje.a112567; POWERS MS, 1985, AM J OBSTET GYNECOL, V152, P1099, DOI 10.1016/0002-9378(85)90569-1; PURDIE DW, 1990, OSTEOPOROSIS, P251; RAVNIHAR B, 1979, EUR J CANCER, V15, P395, DOI 10.1016/0014-2964(79)90074-4; RAVNIKAR VA, 1987, AM J OBSTET GYNECOL, V156, P1332, DOI 10.1016/0002-9378(87)90173-6; RIIS BJ, 1987, AM J OBSTET GYNECOL, V156, P61, DOI 10.1016/0002-9378(87)90203-1; RIJPKEMA AHM, 1990, MATURITAS, V12, P259, DOI 10.1016/0378-5122(90)90007-S; ROBBOY SJ, 1979, OBSTET GYNECOL, V54, P269; ROCHE M, 1990, HRT OSTEOPOROSIS, P362; ROSENBERG L, 1976, NEW ENGL J MED, V294, P1256, DOI 10.1056/NEJM197606032942302; ROSENBERG L, 1980, JAMA-J AM MED ASSOC, V244, P339, DOI 10.1001/jama.244.4.339; ROSS RK, 1980, JAMA-J AM MED ASSOC, V243, P1635, DOI 10.1001/jama.243.16.1635; ROSS RK, 1981, LANCET, V1, P858; SARREL PM, 1990, MATURITAS, V12, P287, DOI 10.1016/0378-5122(90)90008-T; SARTWELL PE, 1977, JNCI-J NATL CANCER I, V59, P1589, DOI 10.1093/jnci/59.6.1589; SAVVAS M, 1988, BRIT MED J, V297, P331, DOI 10.1136/bmj.297.6644.331; SEMMENS JP, 1982, JAMA-J AM MED ASSOC, V248, P445; SHAPIRO S, 1980, NEW ENGL J MED, V303, P485, DOI 10.1056/NEJM198008283030903; SHERWIN BB, 1989, OBSTET GYNECOL, V73, P759; SHOUPE D, 1991, NEW ENGL J MED, V325, P1811; SMITH DC, 1975, NEW ENGL J MED, V293, P1164, DOI 10.1056/NEJM197512042932302; SMITH PJB, 1976, MANAGEMENT MENOPAUSE, P291; SPECTOR TD, 1989, BRIT MED J, V299, P1434, DOI 10.1136/bmj.299.6713.1434; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; STAMPFER MJ, 1985, NEW ENGL J MED, V313, P1044, DOI 10.1056/NEJM198510243131703; STANWELLSMITH R, 1984, ADVERSE DRUG REACT T, V3, P187; STEINBERG KK, 1991, JAMA-J AM MED ASSOC, V266, P1362; STEINBERG KK, 1991, JAMA-J AM MED ASSOC, V265, P1985, DOI 10.1001/jama.265.15.1985; STEVENSON JC, 1989, BRIT MED J, V298, P924, DOI 10.1136/bmj.298.6678.924; STOLL BA, 1988, LANCET, V1, P1278; SZKLO M, 1984, PREV MED, V13, P510, DOI 10.1016/0091-7435(84)90019-7; TALAMINI R, 1985, INT J EPIDEMIOL, V14, P70, DOI 10.1093/ije/14.1.70; THOMAS DB, 1982, JNCI-J NATL CANCER I, V69, P1017; THOMPSON SG, 1989, J EPIDEMIOL COMMUN H, V43, P173, DOI 10.1136/jech.43.2.173; TURKEN S, 1989, J NATL CANCER I, V81, P1086, DOI 10.1093/jnci/81.14.1086; UTIAN WH, 1988, MENOPAUSE, P262; VANDENBROUCKE JP, 1991, LANCET, V337, P1482, DOI 10.1016/0140-6736(91)93173-7; VARNER RE, 1990, POSTREPRODUCTIVE GYN, P143; VOIGT LF, 1991, LANCET, V338, P274, DOI 10.1016/0140-6736(91)90417-N; VONSCHOULTZ B, 1988, MENOPAUSE, P130; WALLACE WA, 1990, J ROY SOC MED, V83, P699, DOI 10.1177/014107689008301109; WALSH BW, 1991, NEW ENGL J MED, V325, P1196, DOI 10.1056/NEJM199110243251702; WALTER S, 1978, UROL INT, V33, P135, DOI 10.1159/000280190; Weinstein M C, 1983, Obstet Gynecol Surv, V38, P445, DOI 10.1097/00006254-198308000-00001; WEINSTEIN MC, 1980, NEW ENGL J MED, V303, P308, DOI 10.1056/NEJM198008073030604; WEISS NS, 1980, NEW ENGL J MED, V303, P1195, DOI 10.1056/NEJM198011203032102; WHITEHEAD MI, 1981, NEW ENGL J MED, V305, P1599, DOI 10.1056/NEJM198112313052701; WILSON PD, 1987, BRIT J OBSTET GYNAEC, V94, P568, DOI 10.1111/j.1471-0528.1987.tb03152.x; WILSON PWF, 1985, NEW ENGL J MED, V313, P1038, DOI 10.1056/NEJM198510243131702; WINGO PA, 1987, JAMA-J AM MED ASSOC, V257, P209, DOI 10.1001/jama.257.2.209; WINGO PA, 1987, JAMA-J AM MED ASSOC, V257, P2438; Wren BG, 1988, MENOPAUSE, P181; WUEST JH, 1953, CIRCULATION, V7, P801, DOI 10.1161/01.CIR.7.6.801; ZIEL HK, 1975, NEW ENGL J MED, V293, P1167, DOI 10.1056/NEJM197512042932303	170	320	323	1	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 14	1994	330	15					1062	1071						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF022	8127335				2023-01-03	WOS:A1994NF02200008
J	LEIZOROVICZ, A; BOISSEL, JP; JULIAN, D; CASTAIGNE, A; HAUGH, MC				LEIZOROVICZ, A; BOISSEL, JP; JULIAN, D; CASTAIGNE, A; HAUGH, MC			PREHOSPITAL THROMBOLYTIC THERAPY IN PATIENTS WITH SUSPECTED ACUTE MYOCARDIAL-INFARCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							STREPTOKINASE ACTIVATOR COMPLEX; TISSUE PLASMINOGEN-ACTIVATOR; FEASIBILITY; REDUCTION; PROJECT; TRIAL; TIME	Background, The efficacy of thrombolytic therapy for acute myocardial infarction depends partly on how soon after the onset of symptoms it is administered. We therefore studied the efficacy and safety of thrombolytic therapy administered before hospital admission and thrombolytic therapy administered after admission in patients with suspected myocardial infarction. Methods. In a multicenter, double-blind study, patients seen within six hours of the onset of symptoms who had a qualifying 12-lead electrocardiogram were randomly assigned to receive either anistreplase before admission, followed by placebo in the hospital (prehospital group), or placebo before admission, followed by anistreplase in the hospital (hospital group). Prehospital therapy was administered by emergency medical personnel. Results. A total of 2750 patients were randomly assigned to the prehospital group, and 2719 to the hospital group. The patients in the prehospital group received thrombolytic therapy a median of 55 minutes earlier than those in the hospital group. We observed a nonsignificant reduction in overall mortality at 30 days in the prehospital group (9.7 percent vs. 11.1 percent in the hospital group; reduction in risk, 13 percent; 95 percent confidence interval, -1 to 26 percent; P = 0.08). Death from cardiac causes was significantly less frequent in the prehospital group than in the hospital group (8.3 percent vs. 9.8 percent; reduction in risk, 16 percent; 95 percent confidence interval, 0 to 29 percent; P = 0.049). Particular adverse events occurred more frequently in the prehospital group during the period before hospitalization; among these events were ventricular fibrillation (P = 0.02), shock (P<0.001), symptomatic hypotension (P<0.001), and symptomatic bradycardia (P = 0.001). With the exception of symptomatic hypotension, however, the overall incidence of these events was similar for both groups. Conclusions. Prehospital thrombolytic therapy for patients with suspected myocardial infarction is both feasible and safe when administered by well-equipped, well-trained mobile emergency medical staff. Although such therapy appears to reduce mortality from cardiac causes, our data do not definitely establish that it reduces overall mortality.			LEIZOROVICZ, A (corresponding author), EUROPEAN MYOCARDIAL INFARCT PROJECT GRP, UNITE PHARMACOL CLIN, BP 3041, F-69394 LYON 03, FRANCE.							[Anonymous], 1987, Lancet, V2, P871; [Anonymous], 1988, LANCET, V2, P349; APPLEBAUM D, 1986, AM J EMERG MED, V4, P201, DOI 10.1016/0735-6757(86)90065-3; BARBASH GI, 1990, AM J CARDIOL, V66, P261, DOI 10.1016/0002-9149(90)90832-L; BIPPUS P-H, 1987, European Heart Journal, V8, P103; BOISSEL JP, 1988, EUR J CLIN PHARMACOL, V34, P535, DOI 10.1007/BF00615213; BOISSEL JP, 1988, CONTROL CLIN TRIALS, V9, P285; BOISSEL JP, 1990, THROMBOLYSIS DAWN NE, P96; BOSSAERT L, 1991, EUR HEART J, V12, P965; BOSSAERT LL, 1988, CRIT CARE MED, V16, P823, DOI 10.1097/00003246-198809000-00001; CASTAIGNE AD, 1989, AM J CARDIOL, V64, pA30, DOI 10.1016/0002-9149(89)90927-2; CHAMBERLAIN DA, 1988, LANCET, V1, P545; FLEISS JL, 1973, STATISTICAL METHODS; GATENBY R, 1992, BMJ-BRIT MED J, V305, P548; HOLMBERG S, 1990, AM J CARDIOL, V65, P401; HUNT D, 1992, LANCET, V339, P753; KEREIAKES DJ, 1990, AM HEART J, V120, P773, DOI 10.1016/0002-8703(90)90192-Z; KOREN G, 1985, NEW ENGL J MED, V313, P1384, DOI 10.1056/NEJM198511283132204; LEIZOROVICZ A, 1988, EUR HEART J, V9, P118; MACCALLUM AG, 1990, EUR HEART J, V11, P48, DOI 10.1093/eurheartj/11.suppl_F.48; Martin J S, 1990, J Emerg Nurs, V16, P195; MEINERTZ T, 1988, AM J CARDIOL, V62, P347, DOI 10.1016/0002-9149(88)90956-3; O'ROURKE M, 1991, Journal of the American College of Cardiology, V17, p246A; ROTH A, 1990, J AM COLL CARDIOL, V15, P932, DOI 10.1016/0735-1097(90)90219-F; SCHOFER J, 1990, AM J CARDIOL, V66, P1429, DOI 10.1016/0002-9149(90)90528-9; SCHRODER R, 1986, NEW ENGL J MED, V314, P1465; WEAVER DW, IN PRESS JAMA; WEAVER WD, 1990, J AM COLL CARDIOL, V15, P925, DOI 10.1016/0735-1097(90)90218-E; WEISS AT, 1987, CHEST, V92, P124, DOI 10.1378/chest.92.1.124; WILCOX RG, 1988, LANCET, V2, P525	30	350	360	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 5	1993	329	6					383	389						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ339	8326971				2023-01-03	WOS:A1993LQ33900002
J	REGEVIK, NK				REGEVIK, NK			MY HEROES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 9	1993	269	22					2910	2910		10.1001/jama.269.22.2910	http://dx.doi.org/10.1001/jama.269.22.2910			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE936	8497097				2023-01-03	WOS:A1993LE93600031
J	NABULSI, AA; FOLSOM, AR; WHITE, A; PATSCH, W; HEISS, G; WU, KK; SZKLO, M				NABULSI, AA; FOLSOM, AR; WHITE, A; PATSCH, W; HEISS, G; WU, KK; SZKLO, M			ASSOCIATION OF HORMONE-REPLACEMENT THERAPY WITH VARIOUS CARDIOVASCULAR RISK-FACTORS IN POSTMENOPAUSAL WOMEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DENSITY LIPOPROTEIN CHOLESTEROL; IMPROVED LIPOLYTIC EFFICIENCY; CORONARY HEART-DISEASE; ESTROGEN REPLACEMENT; BLOOD COLLECTION; PROTEIN-C; ENZYMATIC DETERMINATION; ANTITHROMBIN-III; HEPATIC LIPASE; SERUM-LIPIDS	Background. Most epidemiologic studies of cardiovascular disease in postmenopausal women suggest that estrogen-replacement therapy has a protective effect. The effects of the use of estrogen combined with progestin are less well studied. Methods. To examine the associations of hormone-replacement therapy with concentrations of plasma lipids and hemostatic factors, fasting serum concentrations of glucose and insulin, and blood pressure, we studied 4958 postmenopausal women participating in a population-based investigation. Using cross-sectional data, we classified the women into four groups according to their use of hormone-replacement therapy: current users of estrogen alone, current users of estrogen with progestin, nonusers who had formerly used these hormones, and nonusers who had never used them. Results. Current users had higher mean levels of high-density lipoprotein cholesterol, its subfractions high-density lipoprotein2 and high-density lipoprotein3, and apolipoprotein A-1 than nonusers, and lower mean levels of low-density lipoprotein cholesterol, apolipoprotein B, lipoprotein(a), fibrinogen, antithrombin III, and fasting serum glucose and insulin. However, current users of estrogen alone had higher triglyceride, factor VII, and protein C levels than either nonusers or current users of estrogen with progestin. After making certain assumptions, we estimated that the findings, if causal, would translate into a reduction of 42 percent in the risk of coronary heart disease in users of hormones as compared with nonusers. Women using estrogen with progestin would have an even greater estimated benefit. Conclusions. A randomized trial is needed to eliminate possible selection biases in our observational study that are related to the prescription of replacement hormones. Nevertheless, hormone-replacement therapy appears to be associated with a favorable physiologic profile, which probably mediates its protective effects on cardiovascular disease. The use of estrogen combined with progestin appears to be associated with a better profile than the use of estrogen alone.	UNIV MINNESOTA, SCH PUBL HLTH,DIV EPIDEMIOL,1300 S 2ND ST, SUITE 300, MINNEAPOLIS, MN 55454 USA; BURROUGHS WELLCOME CO, DIV ESP, RES TRIANGLE PK, NC 27709 USA; METHODIST HOSP, ATHEROSCLEROSIS CLIN LAB, HOUSTON, TX 77030 USA; UNIV N CAROLINA, SCH PUBL HLTH, DEPT EPIDEMIOL, CHAPEL HILL, NC 27514 USA; UNIV TEXAS, SCH MED, DIV HEMATOL ONCOL, HOUSTON, TX 77025 USA; JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, BALTIMORE, MD 21218 USA	University of Minnesota System; University of Minnesota Twin Cities; Burroughs Wellcome Fund; The Methodist Hospital System; The Methodist Hospital - Houston; University of North Carolina; University of North Carolina Chapel Hill; University of Texas System; Johns Hopkins University			Wu, Kenneth Kun-Yu/B-1070-2010	Szklo, Moyses/0000-0001-9433-6266	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC055016, N01HC055015, N01HC055018] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC-55018, N01-HC-55016, N01-HC-55015] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1989, AM J EPIDEMIOL, V129, P687; BAECKE JAH, 1982, AM J CLIN NUTR, V36, P936; BALLEISEN L, 1987, LANCET, V2, P461; Barrett-Connor E L, 1989, Public Health Rep, V104 Suppl, P62; BARRETTCONNOR E, 1989, JAMA-J AM MED ASSOC, V261, P2095, DOI 10.1001/jama.261.14.2095; BARRETTCONNOR E, 1990, ARTERIOSCLEROSIS, V10, P531, DOI 10.1161/01.ATV.10.4.531; BARRETTCONNOR E, 1990, MENOPAUSE, P199; BROWN SA, 1988, CLIN CHEM, V34, P920; BROWN SA, 1990, CLIN CHEM, V36, P1662; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; ESMON CT, 1983, BLOOD, V62, P1155; FARISH E, 1986, ACTA ENDOCRINOL-COP, V113, P123, DOI 10.1530/acta.0.1130123; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; GORDON EM, 1988, J LAB CLIN MED, V111, P52; HEGELE RA, 1989, CAN J CARDIOL, V5, P263; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; KENNEDY DL, 1985, OBSTET GYNECOL, V65, P441; LAPIDUS L, 1985, ACTA MED SCAND, V217, P481; LINDBERG UB, 1989, THROMB HAEMOSTASIS, V61, P65; LOBO RA, 1987, POSTGRAD MED    0914, P48; Lobo RA, 1990, ANN NY ACAD SCI, V592, P334; LOBO RA, 1990, ANN NY ACAD SCI, V592, P286; MALM J, 1988, BRIT J HAEMATOL, V68, P437, DOI 10.1111/j.1365-2141.1988.tb04232.x; MEADE TW, 1985, THROMB HAEMOSTASIS, V53, P198; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; MEADE TW, 1984, ANTICOAGULANTS MYOCA, P91; NAGELE U, 1984, J CLIN CHEM CLIN BIO, V22, P165; NIKKILA EA, 1983, PROGESTERONE PROGEST, P411; NOTELOVITZ M, 1989, AM J OBSTET GYNECOL, V161, P1832, DOI 10.1016/S0002-9378(89)80003-1; NOTELOVITZ M, 1983, OBSTET GYNECOL, V62, P596; NOTELOVITZ M, 1984, OBSTET GYNECOL, V63, P621; PAPP AC, 1989, THROMB HAEMOSTASIS, V61, P15; Rose GA, 1982, WHO MONOGRAPH SERIES, V56; SACKS FM, 1990, ANN NY ACAD SCI, V592, P334; SACKS FM, 1990, ANN NY ACAD SCI, V592, P272; SIEDEL J, 1983, CLIN CHEM, V29, P1075; SILFVERSTOLPE G, 1982, MATURITAS, V4, P103, DOI 10.1016/0378-5122(82)90036-6; SKARTLIEN AH, 1989, ARTERIOSCLEROSIS, V9, P798, DOI 10.1161/01.ATV.9.6.798; SOMA M, 1991, LANCET, V337, P612, DOI 10.1016/0140-6736(91)91674-J; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; THALER E, 1981, CLIN HAEMATOL, V10, P369; TIKKANEN MJ, 1982, J CLIN ENDOCR METAB, V54, P1113, DOI 10.1210/jcem-54-6-1113; TIKKANEN MJ, 1981, ATHEROSCLEROSIS, V40, P365, DOI 10.1016/0021-9150(81)90147-7; TIKKANEN MJ, 1986, MATURITAS, V8, P7, DOI 10.1016/0378-5122(86)90003-4; WALSH BW, 1991, NEW ENGL J MED, V325, P1196, DOI 10.1056/NEJM199110243251702; WARNICK GR, 1982, CLIN CHEM, V28, P1574; WEINSTEIN L, 1987, OBSTET GYNECOL, V69, P929; 1987, ARIC ATHEROSCLEROSIS, V8; [No title captured]; 1988, SAS USERS GUIDE STAT; 1987, VITAL HLTH STATIS 11, V238	52	858	874	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 15	1993	328	15					1069	1075		10.1056/NEJM199304153281501	http://dx.doi.org/10.1056/NEJM199304153281501			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KX178	8384316	Bronze			2023-01-03	WOS:A1993KX17800001
J	MacLennan, AH; Wilson, DH; Taylor, AW				MacLennan, AH; Wilson, DH; Taylor, AW			Prevalence and cost of alternative medicine in Australia	LANCET			English	Article								Background To determine the prevalence and cost of alternative medicines and alternative practitioner use in an Australian population. Methods We conducted a representative population survey of persons aged 15 or older living in South Australia, which required 3004 personal interviews, We assessed the rates of use and types of alternative medicine and therapists used by this population in 1993, and correlations with other demographic and medical variables. Findings The overall use of at least one non-medically prescribed alternative medicine (excluding calcium, iron and prescribed vitamins) was 48.5%. The users were more likely to be perimenopausal females, better educated, have a higher alcohol intake, be of normal weight and more likely to be employed than non-users, 20.3% of respondents had visited at least one alternative practitioner, most commonly chiropractors (15%). The users of alternative practitioners were more likely to be younger, live in the country and be overweight, Women were more likely to consult naturopaths, iridiologists, and reflexologists than men. Interpretation Extrapolation of the costs to the Australian population gives a natural expenditure in 1993, for alternative medicines, of $621 million (Australian dollars) and for alternative therapists of $AU309 million per annum. This compares to the $AU360 million of patient contributions for all classes of pharmaceutical drugs purchased in Australia in 1992/93, The public health and economic ramifications of these huge costs are questioned in view of the paucity of sound safety and efficacy data for many of the therapies and products of the alternative medicine industry.	S AUSTRALIAN HLTH COMMISS,PUBL & ENVIRONM HLTH SERV,ADELAIDE,SA,AUSTRALIA		MacLennan, AH (corresponding author), UNIV ADELAIDE,DEPT OBSTET & GYNAECOL,ADELAIDE,SA 5000,AUSTRALIA.		Taylor, Anne w/F-5708-2010	Taylor, Anne w/0000-0002-4422-7974				CHENOY R, 1994, BRIT MED J, V308, P501, DOI 10.1136/bmj.308.6927.501; CUI J, 1994, LANCET, V344, P134, DOI 10.1016/S0140-6736(94)91322-6; DESMET PAGM, 1995, BRIT MED J, V310, P1023, DOI 10.1136/bmj.310.6986.1023; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; ERNST E, 1993, LANCET, V341, P1626, DOI 10.1016/0140-6736(93)90763-7; KELLY JL, 1988, USING ASCO SOCIO EC; LLOYD P, 1993, AUST J PUBLIC HEALTH, V17, P135; LOHR SL, 1994, J QUANT CRIMINOL, V10, P343, DOI 10.1007/BF02221280; MOULDS RFW, 1988, MED J AUSTRALIA, V149, P572, DOI 10.5694/j.1326-5377.1988.tb120789.x; ONEILL A, 1994, SOC SCI MED, V38, P497, DOI 10.1016/0277-9536(94)90246-1; PERHARIC L, 1993, LANCET, V342, P180, DOI 10.1016/0140-6736(93)91389-4; STARK DJ, 1981, MED J AUSTRALIA, V2, P676, DOI 10.5694/j.1326-5377.1981.tb113049.x; SWAYNE JMD, 1989, J ROY COLL GEN PRACT, V39, P503; TORO T, 1992, NEW SCI, V1831, P10; WIESNER D, 1995, AUSTR DOCT       MAR, P44; 1994, AUSTR HLTH; 1990, 12220 AUSTR BUR STAT; 1986, INQUIRY ALTERNATIVE; 1990, 27100 AUSTR BUR STAT	19	664	672	0	29	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 2	1996	347	9001					569	573		10.1016/S0140-6736(96)91271-4	http://dx.doi.org/10.1016/S0140-6736(96)91271-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX694	8596318				2023-01-03	WOS:A1996TX69400009
J	Sikorski, J; Wilson, J; Clement, S; Das, S; Smeeton, N				Sikorski, J; Wilson, J; Clement, S; Das, S; Smeeton, N			A randomised controlled trial comparing two schedules of antenatal visits: The antenatal care project	BRITISH MEDICAL JOURNAL			English	Article							PREGNANCY	Objective-To compare the clinical and psychosocial effectiveness of the traditional British antenatal visit schedule (traditional care) with a reduced schedule of visits (new style care) for low risk women, together with maternal and professional satisfaction with care. Design-Randomised controlled trial. Setting-Places in south east London providing antenatal care for women receiving shared care and planning to deliver in one of three hospitals or at home. Subjects-2794 women at low risk fulfilling the trial's inclusion criteria between June 1993 and July 1994. Main outcome measures-Measures of fetal and maternal morbidity, health service use, psychosocial outcomes, and maternal and professional satisfaction. Results-Pregnant women allocated to new style care had fewer day admissions (0.8 v 1.0; P=0.002) and ultrasound scans (1.6 v 1.7; P=0.003) and were less often suspected of carrying fetuses that were small for gestational age (odds ratio 0.73; 95% confidence interval 0.54 to 0.99). They also had some poorer psychosocial outcomes: for example, they were more worried about fetal wellbeing antenatally and coping with the baby postnatally, and they had more negative attitudes to their babies, both in pregnancy and postnatally. These women were also more dissatisfied with the number of visits they received (odds ratio 2.50; 2.00 to 3.11). Conclusions Patterns of antenatal care involving fewer routine visits for women at low risk may lead to reduced psychosocial effectiveness and dissatisfaction with frequency of visits. The number of antenatal day admissions and ultrasound scans performed may also be reduced. For the variables reported, the visit schedules studied are similar in their clinical effectiveness. Uncertainty remains as to the clinical effectiveness of reduced visit schedules for rare pregnancy problems.	UNITED MED & DENT SCH,GUYS HOSP,DEPT PUBL HLTH MED,LONDON SE1 9RT,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Sikorski, J (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMASS HOSP,DEPT GEN PRACTICE,ANTENATAL CARE PROJECT,LONDON SE11 6SP,ENGLAND.		Clement, Sarah/E-9601-2010					BINSTOCK MA, 1995, J REPROD MED, V40, P507; BLONDEL B, 1985, BRIT J OBSTET GYNAEC, V92, P565, DOI 10.1111/j.1471-0528.1985.tb01393.x; *CDC, 1991, EP INF VERS 5 01; CHITTY LS, 1994, BRIT J OBSTET GYNAEC, V101, P125, DOI 10.1111/j.1471-0528.1994.tb13077.x; Cochran W.G., 1957, EXPT DESIGNS, V2nd; COX JL, 1987, BRIT J PSYCHIAT, V150, P782, DOI 10.1192/bjp.150.6.782; DAVEY DA, 1988, AM J OBSTET GYNECOL, V158, P892, DOI 10.1016/0002-9378(88)90090-7; Department of Health, 1993, CHANGING CHILDBIRTH; DOUGLAS KA, 1994, BMJ-BRIT MED J, V309, P1395, DOI 10.1136/bmj.309.6966.1395; Fleiss JL, 1981, STAT METHODS RATES P; FRANCOME C, 1993, CAESAREAN BIRTH BRIT; GARDNER J, 1992, CONFIDENCE INTERVAL; GREEN JM, 1988, GREAT EXPECTATIONS P; HALL M, 1985, ANTENATAL CARE ASSES; HALL MH, 1980, LANCET, V2, P78; Kaminski M, 1988, Paediatr Perinat Epidemiol, V2, P13, DOI 10.1111/j.1365-3016.1988.tb00177.x; MARSH GN, 1985, BRIT MED J, V29, P646; MASON V, 1989, WOMENS EXPERIENCES M; Murray D., 1990, J REPROD INFANT PSYC, V8, P99, DOI [DOI 10.1080/02646839008403615, 10.1080/02646839008403615]; PORTER M, 1984, SOC SCI MED, V19, P1197, DOI 10.1016/0277-9536(84)90370-8; READING AE, 1984, HEALTH PSYCHOL, V3, P211, DOI 10.1037/0278-6133.3.3.211; *ROYAL COLL OBST G, 1982, REP RCOG WORK PART A; SIKORSKI J, 1993, BRIT MED J, V307, P1064, DOI 10.1136/bmj.307.6911.1064; SIKORSKI J, 1995, MIDWIFERY, V11, P61, DOI 10.1016/0266-6138(95)90068-3; *SPSS INC, 1990, SPSS PC PLUS VERS 4; THOMAS P, 1991, SOC SCI MED, V32, P715, DOI 10.1016/0277-9536(91)90151-2; THORLEY K, 1993, BR J MIDWIFERY, V1, P216; WALLENBURG HCS, 1989, EFFECTIVE CARE PREGN, P382	28	135	137	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 2	1996	312	7030					546	553		10.1136/bmj.312.7030.546	http://dx.doi.org/10.1136/bmj.312.7030.546			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TY885	8595286	Green Published			2023-01-03	WOS:A1996TY88500027
J	ISAACS, AJ; BRITTON, AR; MCPHERSON, K				ISAACS, AJ; BRITTON, AR; MCPHERSON, K			UTILIZATION OF HORMONE REPLACEMENT THERAPY BY WOMEN DOCTORS	BRITISH MEDICAL JOURNAL			English	Article							ESTROGEN REPLACEMENT; HEART-DISEASE; HRT	Objectives-To ascertain the prevalence and duration of use of hormone replacement therapy by menopausal women doctors. Design-Postal questionnaire. Setting-General practices in the United Kingdom. Subjects-Randomised stratified sample of women doctors who obtained full registration between 1952 and 1976, taken from the current principal list of the Medical Register. Main outcome measures- Prevalence and duration of use of hormone replacement therapy; menopausal status. Results-Overall, 45.7% (436/954) of women doctors aged between 45 and 65 years had ever used hormone replacement therapy. When the results from women still menstruating regularly were excluded, 55.2% (428) were ever users and 41.2% (319) current users. The cumulative probability of remaining on hormone replacement therapy was 0.707 at five years and 0.576 at 10 years. Conclusions-Women doctors have a higher prevalence of use of hormone replacement therapy than has been reported for other women in the United Kingdom, and most users seem to be taking hormone replacement therapy for more than five years. The results may become generalisable to the wider population as information on the potential benefits of hormone replacement therapy is disseminated.	UNIV LONDON LONDON SCH HYG & TROP MED,DEPT PUBL HLTH & POLICY,LONDON WC1E 7HT,ENGLAND	University of London; London School of Hygiene & Tropical Medicine								BARRETTCONNOR E, 1989, JAMA-J AM MED ASSOC, V261, P2095, DOI 10.1001/jama.261.14.2095; BUNKER JP, 1974, NEW ENGL J MED, V290, P1051, DOI 10.1056/NEJM197405092901905; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; COOPE J, 1992, MATURITAS, V15, P151, DOI 10.1016/0378-5122(92)90249-4; COOPE J, 1991, LANCET, V337, P1162; DALY E, 1992, BRIT MED BULL, V48, P368, DOI 10.1093/oxfordjournals.bmb.a072552; DEAN AD, 1990, EPI INFO; DOLL R, 1980, BRIT MED J, V1, P967; DUGOWSON CE, 1987, WESTERN J MED, V146, P494; ETTINGER B, 1985, ANN INTERN MED, V102, P319, DOI 10.7326/0003-4819-102-3-319; FERGUSON KJ, 1989, ARCH INTERN MED, V49, P132; HAHN RG, 1989, AM J OBSTET GYNECOL, V161, P1854, DOI 10.1016/S0002-9378(89)80006-7; HAMMOND CB, 1979, AM J OBSTET GYNECOL, V133, P537, DOI 10.1016/0002-9378(79)90289-8; HARRIS RB, 1990, AM J PUBLIC HEALTH, V80, P1266, DOI 10.2105/AJPH.80.10.1266; HEMMINKI E, 1988, AM J PUBLIC HEALTH, V78, P1478, DOI 10.2105/AJPH.78.11.1479; HUNT K, 1987, BRIT J OBSTET GYNAEC, V94, P620, DOI 10.1111/j.1471-0528.1987.tb03166.x; JANNAUSCH ML, 1992, MATURITAS, V14, P161, DOI 10.1016/0378-5122(92)90111-G; MCPHERSON K, 1994, CORONARY HEART DISEA, P141; ODDENS BJ, 1992, MATURITAS, V15, P171, DOI 10.1016/0378-5122(92)90200-N; RAVNIKAR VA, 1987, AM J OBSTET GYNECOL, V156, P1332, DOI 10.1016/0002-9378(87)90173-6; ROSENBERG L, 1993, AM J PUBLIC HEALTH, V3, P1670; ROSS RK, 1989, LANCET, V1, P505; SINCLAIR HK, 1993, BRIT J GEN PRACT, V43, P365; SPECTOR TD, 1989, BRIT MED J, V299, P1434, DOI 10.1136/bmj.299.6713.1434; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; WILKES HC, 1991, BRIT MED J, V302, P1317, DOI 10.1136/bmj.302.6788.1317	26	54	55	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 25	1995	311	7017					1399	1401		10.1136/bmj.311.7017.1399	http://dx.doi.org/10.1136/bmj.311.7017.1399			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG902	8520274	Green Published			2023-01-03	WOS:A1995TG90200020
J	REILLY, D; TAYLOR, MA; BEATTIE, NGM; CAMPBELL, JH; MCSHARRY, C; AITCHISON, TC; CARTER, R; STEVENSON, RD				REILLY, D; TAYLOR, MA; BEATTIE, NGM; CAMPBELL, JH; MCSHARRY, C; AITCHISON, TC; CARTER, R; STEVENSON, RD			IS EVIDENCE FOR HOMEOPATHT REPRODUCIBLE	LANCET			English	Article							HORMESIS; THERAPY	We tested, under independent conditions, the reproducibility of evidence from two previous trials that homoeopathy differs from placebo. The test model was again homoeopathic immunotherapy. 28 patients with allergic asthma, most of them sensitive to house-dust mite, were randomly allocated to receive either oral homoeopathic imm;notherapy to their principal allergen or identical placebo. The test treatments were given as a complement to their unaltered conventional care. A daily visual analogue scale of overall symptom intensity was the outcome measure. A difference in visual analogue score in favour of homoeopathic immunotherapy appeared within one week of starting treatment and persisted for up to 8 weeks (p=0.003). There were similar trends in respiratory function and bronchial reactivity tests. A meta-analysis of all three trials strengthened the evidence that homoeopathy does more than placebo (p=0.0004). Is the reproducibility of evidence in favour of homoeopathy proof of its activity or proof of the clinical trial's capacity to produce false-positive results?	GLASGOW ROYAL INFIRM, DEPT MED RES, GLASGOW G31 2ER, LANARK, SCOTLAND; UNIV GLASGOW, WESTERN INFIRM, DEPT IMMUNOL, GLASGOW, LANARK, SCOTLAND; UNIV GLASGOW, DEPT STAT, GLASGOW, LANARK, SCOTLAND	University of Glasgow; University of Glasgow; University of Glasgow	REILLY, D (corresponding author), UNIV GLASGOW, DEPT MED, GLASGOW, LANARK, SCOTLAND.			McSharry, Charles/0000-0003-4758-9038				ADAMS L, 1985, CLIN SCI, V69, P7, DOI 10.1042/cs0690007; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; CARTER R, 1986, BREATH, V29, P8; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; DERNANGEAT JL, 1992, J MED NUCL BIOPHY, V16, P135; DHAND R, 1988, RESPIRATION, V54, P255, DOI 10.1159/000195533; DSOUZA MF, 1983, CLIN ALLERGY, V13, P329, DOI 10.1111/j.1365-2222.1983.tb02608.x; ENDLER PC, 1994, ULTRA HIGH DILUTION; GIBSON RG, 1980, BR HOMOEOPATHIC J, V69, P151; GLEIK J, 1988, CHAOS; GRACELY RH, 1985, LANCET, V1, P43; HARDY J, 1984, COMMUNICATIONS, V11, P75; KLEIJNEN J, 1991, BRIT MED J, V302, P316, DOI 10.1136/bmj.302.6772.316; KNIPSCHILD P, 1991, J CLIN EPIDEMIOL, V44, P461, DOI 10.1016/0895-4356(91)90208-Q; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; MACKLIS RM, 1991, J NUCL MED, V32, P350; Meyers D A, 1990, Agents Actions Suppl, V30, P87; MORRISOWEN RM, 1981, BR HOMOEOPATHIC J, V70, P70; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V80, P129, DOI 10.1016/0091-6749(87)90120-5; Pocock SJ., 2013, CLIN TRIALS PRACTICA; REIL GH, 1985, Z KARDIOL, V74, P65; REILLY DT, 1986, LANCET, V2, P881; SCADDING GK, 1986, CLIN ALLERGY, V16, P483, DOI 10.1111/j.1365-2222.1986.tb01983.x; STARK RD, 1982, BRIT J DIS CHEST, V76, P269, DOI 10.1016/S0007-0971(82)80031-4; STARK RD, 1980, J CLIN RESP PHYSL, V16, P244; STEBBING ARD, 1982, SCI TOTAL ENVIRON, V22, P213, DOI 10.1016/0048-9697(82)90066-3; THOMPSON RA, 1989, LANCET, V1, P259; VELLEMAN PF, 1980, J AM STAT ASSOC, V75, P609, DOI 10.2307/2287657; VITHOULKAS G, 1985, HOMOEOPATHY, P72; 1855, HOMOEOPATHY, V13, P674; 1983, BR J HOSP MED, V30, P377; 1988, NATURE, V30, P787	32	167	171	0	21	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 10	1994	344	8937					1601	1606		10.1016/S0140-6736(94)90407-3	http://dx.doi.org/10.1016/S0140-6736(94)90407-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW051	7983994				2023-01-03	WOS:A1994PW05100010
J	ANDERSEN, HR; THUESEN, L; BAGGER, JP; VESTERLUND, T; THOMSEN, PEB				ANDERSEN, HR; THUESEN, L; BAGGER, JP; VESTERLUND, T; THOMSEN, PEB			PROSPECTIVE RANDOMIZED TRIAL OF ATRIAL VERSUS VENTRICULAR PACING IN SICK-SINUS SYNDROME	LANCET			English	Article							NODE DISEASE; ATRIOVENTRICULAR-BLOCK; STIMULATION MODE; DUAL-CHAMBER; FOLLOW-UP; NATURAL-HISTORY; FIBRILLATION; RISK; IMPLANTATION; DYSFUNCTION	In patients with sick-sinus syndrome, single-chamber atrial pacing has been reported, in retrospective studies, to be associated with lower frequencies of atrial fibrillation, thromboembolism, heart failure, and mortality than ventricular pacing; although single-chamber ventricular pacing is most commonly used. We did a prospective randomised trial in 225 consecutive patients (142 women, 83 men; mean age 76 years) with the sick-sinus syndrome, randomised to atrial (n=110) or ventricular (n=115) pacing and followed for up to 5 years (mean 40 [SD 18] months). During follow-up, the frequency of atrial fibrillation was higher in the ventricular group, except at the first follow-up at 3 months. Thromboembolic events (stroke or peripheral arterial embolus) occurred in 20 patients in the ventricular group and in 6 patients in the atrial group (p=0.0083). 25 patients died in the ventricular group compared with 21 in the atrial group (p=0.74). Heart failure estimated by the New York Heart Association classification and by the daily doses of diuretics did not differ between the two groups. Atrioventricular block occurred in 2 patients in the atrial group. Patients with sick-sinus syndrome should be treated with atrial pacing rather than ventricular pacing because atrial pacing is associated with lower frequencies of atrial fibrillation, thromboembolic complications, and a low risk of atrioventricular block.	CARDIOVASC RES CTR,AARHUS,DENMARK		ANDERSEN, HR (corresponding author), AARHUS UNIV HOSP,SKEJBY SYGEHUS,DEPT CARDIOL,DK-8200 AARHUS N,DENMARK.							ASKENAZI J, 1984, AM J CARDIOL, V53, P99, DOI 10.1016/0002-9149(84)90691-X; BEDOTTO JB, 1990, J AM COLL CARDIOL, V15, P658, DOI 10.1016/0735-1097(90)90642-3; BERNSTEIN AD, 1992, AM J CARDIOL, V69, P331, DOI 10.1016/0002-9149(92)90229-R; BERNSTEIN SB, 1988, AM J CARDIOL, V61, P113, DOI 10.1016/0002-9149(88)91315-X; BRANDT J, 1992, J AM COLL CARDIOL, V20, P633, DOI 10.1016/0735-1097(92)90018-I; BREIVIK K, 1979, ACTA MED SCAND, V206, P153; CABIN HS, 1990, AM J CARDIOL, V65, P1112, DOI 10.1016/0002-9149(90)90323-S; CAIRNS JA, 1991, CIRCULATION, V84, P469, DOI 10.1161/01.CIR.84.2.469; CAMM AJ, 1990, PACE, V13, P695, DOI 10.1111/j.1540-8159.1990.tb02091.x; ELSHOT SRE, 1993, INT J CARDIOL, V38, P303, DOI 10.1016/0167-5273(93)90249-G; HAYWOOD GA, 1990, PACE, V13, P2054, DOI 10.1111/j.1540-8159.1990.tb06941.x; HESSELSON AB, 1992, J AM COLL CARDIOL, V19, P1542, DOI 10.1016/0735-1097(92)90616-U; KERR CR, 1989, PACE, V12, P1049, DOI 10.1111/j.1540-8159.1989.tb01925.x; KUBICA J, 1990, PACE, V13, P1737, DOI 10.1111/j.1540-8159.1990.tb06882.x; LAMAS GA, 1992, PACE, V15, P1109, DOI 10.1111/j.1540-8159.1992.tb03112.x; LEE MA, 1994, J AM COLL CARDIOL, V24, P225, DOI 10.1016/0735-1097(94)90567-3; MARKEWITZ A, 1986, PACE, V9, P1115, DOI 10.1111/j.1540-8159.1986.tb06679.x; PETERSEN P, 1989, LANCET, V1, P175; ROSENQVIST M, 1988, AM HEART J, V116, P16, DOI 10.1016/0002-8703(88)90244-X; ROSENQVIST M, 1991, AM J CARDIOL, V67, P148, DOI 10.1016/0002-9149(91)90437-P; SANFILIPPO AJ, 1990, CIRCULATION, V82, P792, DOI 10.1161/01.CIR.82.3.792; SANTINI M, 1990, AM J CARDIOL, V65, P729, DOI 10.1016/0002-9149(90)91379-K; SASAKI Y, 1988, PACE, V11, P1575, DOI 10.1111/j.1540-8159.1988.tb06277.x; SIMON AB, 1979, PACE, V2, P305, DOI 10.1111/j.1540-8159.1979.tb03650.x; STANGL K, 1990, PACE, V13, P2080, DOI 10.1111/j.1540-8159.1990.tb06946.x; STONE JM, 1982, AM HEART J, V104, P1319, DOI 10.1016/0002-8703(82)90162-4; ZANINI R, 1989, PACE, V12, P1065, DOI 10.1111/j.1540-8159.1989.tb01927.x; ZANINI R, 1990, PACE, V13, P2076, DOI 10.1111/j.1540-8159.1990.tb06945.x; ZEHENDER M, 1992, CIRCULATION, V85, P596, DOI 10.1161/01.CIR.85.2.596; 1992, ANN INTERN MED, V116, P6; 1991, CIRCULATION, V84, P527; 1992, ANN INTERN MED, V116, P1	32	348	358	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 3	1994	344	8936					1523	1528		10.1016/S0140-6736(94)90347-6	http://dx.doi.org/10.1016/S0140-6736(94)90347-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PV017	7983951				2023-01-03	WOS:A1994PV01700007
J	COHEN, JS; FIHN, SD; BOYKO, EJ; JONSEN, AR; WOOD, RW				COHEN, JS; FIHN, SD; BOYKO, EJ; JONSEN, AR; WOOD, RW			ATTITUDES TOWARD ASSISTED SUICIDE AND EUTHANASIA AMONG PHYSICIANS IN WASHINGTON-STATE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HOPELESSLY ILL; AID	Background. Despite considerable public interest in legalizing physician-assisted suicide and euthanasia, little is known about physicians' attitude's toward these practices. Methods. We sent questionnaires to 1355 randomly selected physicians in the state of Washington, including all hematologists and oncologists and a disproportionately high number of internists, family practitioners, psychiatrists, and general surgeons. To avoid ambiguity in our survey, instead of ''physician-assisted suicide,'' we used the phrase ''prescription of medication [e.g., narcotics or barbiturates] or the counseling of an ill patient so he or she may use an overdose to end his or her own life.'' Instead of ''euthanasia,'' we used the phrase ''deliberate administration of an overdose of medication to an ill patient at his or her request with the primary intent to end his or her life.'' Results. Of the 1355 eligible physicians who received our questionnaire, 938 (69 percent) responded. Forty-eight percent of the respondents agreed with the statement that euthanasia is never ethically justified, and 42 percent disagreed. Fifty-four percent thought euthanasia should be legal in some situations, but only 33 percent stated that they would be willing to perform euthanasia. Thirty-nine percent of respondents agreed with the statement that physician-assisted suicide is never ethically justified, and 50 percent disagreed. Fifty-three percent thought assisted suicide should be legal in some situations, but only 40 percent stated that they would be willing to assist a patient in committing suicide. Of the groups surveyed, hematologists and oncologists were most likely to oppose euthanasia and assisted suicide, and psychiatrists were most likely to support these practices. Conclusions. The attitudes toward physician-assisted suicide and euthanasia of physicians in Washington State are polarized. A slight majority favors legalizing physician-assisted suicide and euthanasia in at least some situations, but most would be unwilling to participate in these practices themselves.	UNIV MINNESOTA, MINNEAPOLIS, MN 55455 USA; VET AFFAIRS MED CTR, DIV GEN MED, SEATTLE, WA 98108 USA; UNIV WASHINGTON, DEPT MED, SEATTLE, WA USA; UNIV WASHINGTON, DEPT MED HIST & ETH, SEATTLE, WA 98195 USA	University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	COHEN, JS (corresponding author), VET AFFAIRS MED CTR, GEN INTERNAL MED SECT, 1 VET DR, MINNEAPOLIS, MN 55417 USA.		Boyko, Edward J/G-2484-2017; Fihn, Stephan/ABA-1040-2020	Boyko, Edward J/0000-0002-3695-192X; 				ANNAS GJ, 1993, NEW ENGL J MED, V328, P1573, DOI 10.1056/NEJM199305273282121; Battin M, 1992, Law Med Health Care, V20, P133; BENRUBI GI, 1992, NEW ENGL J MED, V326, P197, DOI 10.1056/NEJM199201163260311; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2658, DOI 10.1001/jama.267.19.2658; BRODY H, 1992, NEW ENGL J MED, V327, P1384, DOI 10.1056/NEJM199211053271912; CARALIS PV, 1992, CRIT CARE MED, V20, P683, DOI 10.1097/00003246-199205000-00023; CASSEL CK, 1990, NEW ENGL J MED, V323, P750, DOI 10.1056/NEJM199009133231110; CELOCRUZ MT, 1992, AM J LAW MED, V18, P369; CONVERSE PE, 1964, IDEOLOGY DISCONTENT; CROSBY C, 1992, INTERNIST        MAR, P16; FRIED TR, 1993, ARCH INTERN MED, V153, P722, DOI 10.1001/archinte.153.6.722; HEILIG S, 1988, SAN FRANCISCO MED, V61, P24; HEILIG S, 1988, SAN FRANCISCO MED, V61, P34; HENDIN H, 1993, AM J PSYCHIAT, V150, P143; KAMISAR Y, 1993, HASTINGS CENT REP, V23, P32, DOI 10.2307/3563366; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P419; MISBIN RI, 1991, NEW ENGL J MED, V325, P1307, DOI 10.1056/NEJM199110313251811; ORENTLICHER D, 1992, JAMA-J AM MED ASSOC, V267, P2229; OVERMYER M, 1991, PHYSICIANS MANAGE, V31, P40; QUILL TE, 1993, JAMA-J AM MED ASSOC, V270, P870, DOI 10.1001/jama.270.7.870; QUILL TE, 1992, NEW ENGL J MED, V327, P1380, DOI 10.1056/NEJM199211053271911; SINGER PA, 1990, NEW ENGL J MED, V322, P1881, DOI 10.1056/NEJM199006283222610; SNEDECOR GW, 1980, STATISTICAL METHODS, P93; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; Weir R F, 1992, Law Med Health Care, V20, P116, DOI 10.1111/j.1748-720X.1992.tb01178.x; 1988, WITHHOLDING WITHDRAW; 1991, INFORMAL SURVEY WSMA; 1992, ANN INTERN MED, V117, P947	28	197	198	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 14	1994	331	2					89	94		10.1056/NEJM199407143310206	http://dx.doi.org/10.1056/NEJM199407143310206			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW712	8208272				2023-01-03	WOS:A1994NW71200006
J	OLIVOTTO, IA; BAJDIK, CD; PLENDERLEITH, IH; COPPIN, CM; GELMON, KA; JACKSON, SM; RAGAZ, J; WILSON, KS; WORTH, A				OLIVOTTO, IA; BAJDIK, CD; PLENDERLEITH, IH; COPPIN, CM; GELMON, KA; JACKSON, SM; RAGAZ, J; WILSON, KS; WORTH, A			ADJUVANT SYSTEMIC THERAPY AND SURVIVAL AFTER BREAST-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHEMOTHERAPY	Background and Methods. We examined the effect of adjuvant systemic therapy on survival after breast cancer among the residents of the Canadian province of British Columbia. Data on survival were collected for all women in whom breast cancer was diagnosed in British Columbia during each of three calendar years chosen to represent different province-wide treatment recommendations: 1974, when no adjuvant systemic therapy was recommended; 1980, when adjuvant chemotherapy was recommended only for premenopausal women with node-positive disease; and 1984, when adjuvant chemotherapy was also recommended for premenopausal women with node-negative disease and lymphatic, vascular, or neural invasion and tamoxifen was recommended for postmenopausal women with involved lymph nodes or lymphatic, vascular, or neural invasion unless their tumors were negative for estrogen receptors. Results. For women less than 50 years of age, disease-specific survival at seven years (i.e., with censoring of data on women who died from causes other than breast cancer) improved from 65.2 to 76.3 percent between 1974 and 1984 (P = 0.008), and overall survival improved from 64.8 to 74.6 percent (P = 0.02). For women from 50 through 89 years of age, disease-specific survival at seven years improved from 62.5 to 70.4 percent between 1980 and 1984 (P = 0.001), and overall survival improved from 53.9 to 58.3 percent (P = 0.05). The timing of the improvements in survival correlated with the introduction of adjuvant systemic therapy in each group. Conclusions. Survival among women with breast cancer improved significantly in a geographically defined population during the period when adjuvant systemic therapy became widely used.	BRITISH COLUMBIA CANC AGCY,DIV EPIDEMIOL,VANCOUVER,BC,CANADA; BRITISH COLUMBIA CANC AGCY,DIV MED ONCOL,VANCOUVER,BC,CANADA; BRITISH COLUMBIA CANC AGCY,DIV LAB MED,VANCOUVER,BC,CANADA; UNIV BRITISH COLUMBIA,VANCOUVER,BC,CANADA	British Columbia Cancer Agency; British Columbia Cancer Agency; British Columbia Cancer Agency; University of British Columbia	OLIVOTTO, IA (corresponding author), BRITISH COLUMBIA CANC AGCY,DIV RADIAT ONCOL,600 W 10TH AVE,VANCOUVER V5Z 4E6,BC,CANADA.							BONADONNA G, 1976, NEW ENGL J MED, V294, P405, DOI 10.1056/NEJM197602192940801; BORING CC, 1993, CA-CANCER J CLIN, V43, P7, DOI 10.3322/canjclin.43.1.7; BURHENNE LJW, 1992, AM J ROENTGENOL, V158, P45, DOI 10.2214/ajr.158.1.1307850; COPPIN C, 1989, P AM SOC CLIN ONCOL, V8, P20; Early Breast Cancer Trialists' Collaborative Group, 1992, LANCET, V339, P1; ELWOOD JM, 1980, BRIT J CANCER, V42, P635, DOI 10.1038/bjc.1980.296; HARRIS JR, 1992, NEW ENGL J MED, V327, P319, DOI 10.1056/NEJM199207303270505; HOWARD J, 1987, CA-CANCER J CLIN, V37, P33, DOI 10.3322/canjclin.37.1.33; JOENSUU H, 1991, BRIT MED J, V303, P155, DOI 10.1136/bmj.303.6795.155; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MCBRIDE ML, 1987, BC MED J, V29, P30; MCGUIRE WL, 1978, CANCER RES, V38, P4289; MILLER BA, 1991, CANCER CAUSE CONTROL, V2, P67, DOI 10.1007/BF00053123; Paterson A H, 1981, Breast Cancer Res Treat, V1, P357, DOI 10.1007/BF01806751; POWLES TJ, 1980, LANCET, V1, P580; RAGAZ J, 1991, 3RD P INT C NEOADJ C, P186; 1976, B C MED J, V18, P288; 1992, CANADIAN CANCER STAT; 1992, 93310 STAT CAN CAT; 1992, LANCET, V339, P71	21	72	72	1	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 24	1994	330	12					805	810		10.1056/NEJM199403243301201	http://dx.doi.org/10.1056/NEJM199403243301201			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB803	8114832				2023-01-03	WOS:A1994NB80300001
J	ROBERTS, WM; RIVERA, GK; RAIMONDI, SC; SANTANA, VM; SANDLUND, JT; CRIST, WM; PUI, CH				ROBERTS, WM; RIVERA, GK; RAIMONDI, SC; SANTANA, VM; SANDLUND, JT; CRIST, WM; PUI, CH			INTENSIVE CHEMOTHERAPY FOR PHILADELPHIA-CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC-LEUKEMIA	LANCET			English	Note							LEUKEMIA	Childhood acute lymphoblastic leukaemia with the classic Philadelphia chromosome translocation is fatal in patients treated with chemotherapy alone. We report probable cures in three adolescents and one child who received extensively reinforced, early chemotherapy followed by rotational treatment with pairs of non-cross-resistant drugs. The median duration of leukaemia-free survival in this subgroup is 6.5 years (range 6-8 years). The two patients with long-term bone marrow surveillance for residual disease showed no evidence of the Philadelphia chromosome at 31 and 53 months post-remission. Such intensive chemotherapy is a reasonable option for patients who are not able to undergo bone marrow transplantation.	ST JUDE CHILDRENS RES HOSP, DEPT PATHOL & LAB MED, MEMPHIS, TN 38101 USA; UNIV TENNESSEE, CTR HLTH SCI, COLL MED, DEPT PEDIAT, MEMPHIS, TN 38163 USA; UNIV TENNESSEE, CTR HLTH SCI, COLL MED, DEPT PATHOL, MEMPHIS, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	ROBERTS, WM (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, 332 N LAUDERDALE, POB 318, MEMPHIS, TN 38101 USA.		Raimondi, Susana C/N-8166-2018; Pui, Ching-Hon/N-8076-2018	Pui, Ching-Hon/0000-0003-0303-5658	NATIONAL CANCER INSTITUTE [P01CA020180, P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA20180, P30 CA 21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARRETT AJ, 1992, BLOOD, V79, P3067; CRIST W, 1990, BLOOD, V76, P489; DOW LW, 1989, BLOOD, V73, P1291; FLETCHER JA, 1992, LEUKEMIA LYMPHOMA, V8, P75, DOI 10.3109/10428199209049820; MIYAMURA K, 1993, BLOOD, V81, P1089; PRIEST JR, 1980, BLOOD, V56, P15; PUI CH, 1991, NEW ENGL J MED, V325, P1682, DOI 10.1056/NEJM199112123252402; RIBEIRO RC, 1993, HEMATOL PATHOL, V7, P121; RIBEIRO RC, 1987, BLOOD, V70, P948; RIVERA GK, 1991, LANCET, V337, P61, DOI 10.1016/0140-6736(91)90733-6; SURYANARAYAN K, 1991, BLOOD, V77, P324	11	48	48	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	FEB 5	1994	343	8893					331	332		10.1016/S0140-6736(94)91166-5	http://dx.doi.org/10.1016/S0140-6736(94)91166-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU985	7905148				2023-01-03	WOS:A1994MU98500012
J	BASTARRACHEA, J; HORTOBAGYI, GN; SMITH, TL; KAU, SWC; BUZDAR, AU				BASTARRACHEA, J; HORTOBAGYI, GN; SMITH, TL; KAU, SWC; BUZDAR, AU			OBESITY AS AN ADVERSE PROGNOSTIC FACTOR FOR PATIENTS RECEIVING ADJUVANT CHEMOTHERAPY FOR BREAST-CANCER	ANNALS OF INTERNAL MEDICINE			English	Article							BODY-WEIGHT; STAGE-II; DOXORUBICIN; CARCINOMA; SURVIVAL; CYCLOPHOSPHAMIDE; MASTECTOMY; RELAPSE; THERAPY; TABLES	Objective: To determine whether obesity is an independent prognostic factor among women receiving adjuvant chemotherapy for lymph node-positive breast cancer and to determine how obesity relates to other commonly used prognostic indicators. Design: Retrospective review of the clinical characteristics and clinical course of 735 patients with stages II and III primary breast cancer who were treated using three consecutive postoperative adjuvant chemotherapy protocols. Univariate and multivariate analyses were used to determine the prognostic implications of obesity defined by weight and height tables and body mass index. In addition, we analyzed the relation between obesity and other known prognostic indicators for patients with primary breast cancer. Setting: A comprehensive cancer center. Patients: 735 patients with lymph node-positive primary breast cancer who were treated using three consecutive fluorouracil-doxorubicin-cyclophosphamide-containing adjuvant chemotherapy protocols and for whom complete data on weight, height, standard prognostic factors, and outcome were available. Main Outcome Measurements: Disease-free and overall survival for the entire group and obese and nonobese subgroups. Results: 24 percent of patients were more than 20% overweight. With a median follow-up of 10.7 years, the estimated 10-year, disease-free rate for patients not more than 20% overweight was 54% (95% CI, 50% to 58%) compared with 40% (CI, 33% to 47%) for remaining patients classified as obese. Although obese patients tended to have somewhat less favorable prognoses based on standard prognostic criteria, a proportional-hazards regression model adjusting for other factors indicated that risk for disease recurrence among obese patients was 1.33 times that of the nonobese population (CI, 1.05 to 1.68). Conclusions: Obesity is an indicator of poor prognosis for patients with primary breast cancer even after the administration of adjuvant chemotherapy. The effect of dietary interventions to reduce body weight on the outcome of breast cancer therapy must be investigated.	UNIV TEXAS, MD ANDERSON CANC CTR, 1515 HOLCOMBE BLVD, BOX 56, HOUSTON, TX 77025 USA	University of Texas System; UTMD Anderson Cancer Center					NCI NIH HHS [CA-16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE R, 1976, TOHOKU J EXP MED, V120, P351, DOI 10.1620/tjem.120.351; ANG PT, 1989, J CLIN ONCOL, V7, P1677, DOI 10.1200/JCO.1989.7.11.1677; [Anonymous], 1983, Stat Bull Metrop Life Found, V64, P3; BEAHRS OH, 1988, AM JOINT COMMITTEE C; BOYD NF, 1981, JNCI-J NATL CANCER I, V67, P785; BURT JR, 1983, P AN M AM SOC CLIN, pC6; BUZDAR A, 1981, ADJUVANT THERAPY CAN, V3, P419; BUZDAR AU, 1978, CANCER, V41, P1064, DOI 10.1002/1097-0142(197803)41:3<1064::AID-CNCR2820410340>3.0.CO;2-Q; BUZDAR AU, 1984, CANCER, V53, P384, DOI 10.1002/1097-0142(19840201)53:3<384::AID-CNCR2820530303>3.0.CO;2-G; BUZDAR AU, 1987, ADJUVANT THERAPY CAN, V5, P411; CAMORIANO JK, 1990, J CLIN ONCOL, V8, P1327, DOI 10.1200/JCO.1990.8.8.1327; CHLEBOWSKI RT, 1986, BREAST CANCER RES TR, V7, P23, DOI 10.1007/BF01886732; COX DR, 1972, J R STAT SOC B, V34, P187; de Waard F, 1982, Nutr Cancer, V4, P85, DOI 10.1080/01635588209513743; DEWAARD F, 1964, CANCER, V17, P141, DOI 10.1002/1097-0142(196402)17:2<141::AID-CNCR2820170202>3.0.CO;2-Z; DONEGAN WL, 1978, CANCER, V41, P1590, DOI 10.1002/1097-0142(197804)41:4<1590::AID-CNCR2820410449>3.0.CO;2-N; EBERLEIN T, 1985, BREAST CANCER RES TR, V5, P81, DOI 10.1007/BF01807654; GARFINKEL L, 1988, CANCER, V62, P1844, DOI 10.1002/1097-0142(19881015)62:1+<1844::AID-CNCR2820621328>3.0.CO;2-O; GARN SM, 1984, AM J CLIN NUTR, V39, P490, DOI 10.1093/ajcn/39.3.490; GOODWIN PJ, 1988, BREAST CANCER RES TR, V11, P59, DOI 10.1007/BF01807559; GOODWIN PJ, 1990, BREAST CANCER RES TR, V16, P205, DOI 10.1007/BF01806329; HEASMAN KZ, 1985, BREAST CANCER RES TR, V5, P195, DOI 10.1007/BF01805994; HEBERT JR, 1988, INT J CANCER, V42, P315, DOI 10.1002/ijc.2910420302; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KODAMA M, 1987, ANTICANCER RES, V559, P71; LIPPMAN ME, 1978, NEW ENGL J MED, V298, P1223, DOI 10.1056/NEJM197806012982203; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MCGUIRE WL, 1987, BREAST CANCER RES TR, V10, P5, DOI 10.1007/BF01806129; MOORE DH, 1983, ADV CANCER RES, V40, P189, DOI 10.1016/S0065-230X(08)60681-8; NEWMAN SC, 1986, AM J EPIDEMIOL, V123, P767, DOI 10.1093/oxfordjournals.aje.a114305; POWIS G, 1987, CANCER CHEMOTH PHARM, V20, P219, DOI 10.1007/BF00570489; RODVOLD KA, 1988, J CLIN ONCOL, V6, P1321, DOI 10.1200/JCO.1988.6.8.1321; SENIE RT, 1992, ANN INTERN MED, V116, P26, DOI 10.7326/0003-4819-116-1-26; SUISSA S, 1989, CANCER RES, V49, P3113; TARTTER PI, 1981, CANCER, V47, P2222, DOI 10.1002/1097-0142(19810501)47:9<2222::AID-CNCR2820470919>3.0.CO;2-5; THIJSSEN JHH, 1975, J STEROID BIOCHEM, V6, P729, DOI 10.1016/0022-4731(75)90060-6; ZUMOFF B, 1983, J SURG ONCOL, V22, P217, DOI 10.1002/jso.2930220402; 1973, VITAL HLTH STATIST 1; 1942, STAT B METROP LIFE F, V23, P6; 1959, STAT B METROP LIFE F, V40, P1	40	124	128	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1994	120	1					18	25		10.7326/0003-4819-120-1-199401010-00004	http://dx.doi.org/10.7326/0003-4819-120-1-199401010-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MP280	8250452				2023-01-03	WOS:A1994MP28000004
J	HILL, JO; DROUGAS, H; PETERS, JC				HILL, JO; DROUGAS, H; PETERS, JC			OBESITY TREATMENT - CAN DIET COMPOSITION PLAY A ROLE	ANNALS OF INTERNAL MEDICINE			English	Article							RESTRICTED HYPOCALORIC DIETS; LIBITUM FED MICE; ENERGY-EXPENDITURE; FAT OXIDATION; NUTRIENT BALANCE; BODY-WEIGHT; FOOD-INTAKE; CARBOHYDRATE; HUMANS; EXERCISE	Diet composition can play a role in obesity treatment because it can influence energy intake and nutrient balance. The greatest potential effect of diet composition occurs not during weight reduction but during maintenance of a reduced body weight. During weight reduction, the extent of negative energy balance is the greatest determinant of the amount and rate of weight loss, and any effects of diet composition are likely to be very small. Conversely, during the maintenance period after weight reduction, maintenance energy requirements are reduced and the rate of fat oxidation may be low. Prevention of fat storage and regain of body weight can be achieved either by increasing fat oxidation (for example, by increasing exercise) or by reducing the fat content of the habitual diet. The treatment with the greatest chance for success combines a reduced-fat diet with aerobic exercise.	PROCTER & GAMBLE CO, ROSS, OH USA; VANDERBILT UNIV, NASHVILLE, TN 37240 USA	Procter & Gamble; Vanderbilt University	HILL, JO (corresponding author), UNIV COLORADO, HLTH SCI CTR, CTR HUMAN NUTR, CAMPUS BOX C225, 4200 E 9TH AVE, DENVER, CO 80262 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038088, R01DK042549, R37DK042549] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38088, DK42549] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACHESON KJ, 1988, AM J CLIN NUTR, V48, P240, DOI 10.1093/ajcn/48.2.240; BENNETT C, 1992, AM J CLIN NUTR, V55, P1071, DOI 10.1093/ajcn/55.6.1071; BOGARDUS C, 1981, J CLIN INVEST, V68, P399, DOI 10.1172/JCI110268; BOOTH DA, 1970, PHYSIOL BEHAV, V5, P1299, DOI 10.1016/0031-9384(70)90044-2; DAUNCEY MJ, 1990, CAN J PHYSIOL PHARM, V68, P17, DOI 10.1139/y90-002; Flatt J., 1978, REC ADV OBES RES, V2, P211; Flatt J. P, 1985, SUBSTRATE ENERGY MET, P58; FLATT JP, 1991, J NUTR BIOCHEM, V2, P186, DOI 10.1016/0955-2863(91)90015-W; FLATT JP, 1985, J CLIN INVEST, V76, P1019, DOI 10.1172/JCI112054; FLATT JP, 1987, ANN NY ACAD SCI, V499, P104, DOI 10.1111/j.1749-6632.1987.tb36202.x; FLATT JP, 1988, DIABETES METAB REV, V4, P571, DOI 10.1002/dmr.5610040603; FLETCHER SW, 1992, ANN INTERN MED, V116, P942, DOI 10.7326/0003-4819-116-11-951; HILL JO, 1991, AM J CLIN NUTR, V54, P10, DOI 10.1093/ajcn/54.1.10; HILL JO, 1987, AM J CLIN NUTR, V46, P622, DOI 10.1093/ajcn/46.4.622; HILL JO, 1984, METABOLISM, V33, P743, DOI 10.1016/0026-0495(84)90216-6; HORTON TJ, 1993, OBESITY RES S1, V1, P115; KENDALL A, 1991, AM J CLIN NUTR, V53, P1124, DOI 10.1093/ajcn/53.5.1124; PETERS JC, 1985, J NUTR, V115, P382, DOI 10.1093/jn/115.3.382; RAMIREZ I, 1990, PHYSIOL BEHAV, V47, P1157, DOI 10.1016/0031-9384(90)90367-D; RAVUSSIN E, 1986, J CLIN INVEST, V78, P1568, DOI 10.1172/JCI112749; ROSEN JC, 1982, AM J CLIN NUTR, V36, P463, DOI 10.1093/ajcn/36.3.463; SALMON DMW, 1985, INT J OBESITY, V9, P443; SCHUTZ Y, 1992, AM J CLIN NUTR, V55, P670, DOI 10.1093/ajcn/55.3.670; SCHUTZ Y, 1989, AM J CLIN NUTR, V50, P307, DOI 10.1093/ajcn/50.2.307; THOMAS CD, 1992, AM J CLIN NUTR, V55, P934, DOI 10.1093/ajcn/55.5.934; TREMBLAY A, 1989, AM J CLIN NUTR, V49, P799, DOI 10.1093/ajcn/49.5.799; WEIGLE DS, 1988, INT J OBESITY, V12, P567; 1985, USDA CSFII853 HUM NU	28	51	51	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1993	119	7	2				694	697		10.7326/0003-4819-119-7_Part_2-199310011-00013	http://dx.doi.org/10.7326/0003-4819-119-7_Part_2-199310011-00013			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA330	8363199				2023-01-03	WOS:A1993MA33000013
J	SHANN, F				SHANN, F			AUSTRALIAN VIEW OF PEDIATRIC INTENSIVE-CARE IN BRITAIN	LANCET			English	Editorial Material											SHANN, F (corresponding author), ROYAL CHILDRENS HOSP,PAEDIAT INTENS CARE UNIT,PARKVILLE,VIC 3052,AUSTRALIA.		Shann, Frank/C-9510-2011					EDGE WE, 1992, CRIT CARE MED, V20, pS38; FARLEY DE, 1992, MED CARE, V30, P77, DOI 10.1097/00005650-199201000-00009; POLLACK MM, 1988, CRIT CARE MED, V16, P11, DOI 10.1097/00003246-198801000-00003; POLLACK MM, 1991, CRIT CARE MED, V19, P150, DOI 10.1097/00003246-199102000-00007; RAMSEY CB, 1993, TXB PEDIATRIC CRITIC, P1108; REYNOLDS HN, 1988, JAMA-J AM MED ASSOC, V260, P3446, DOI 10.1001/jama.260.23.3446; YEH TS, 1992, CRIT CARE CLIN, V8, P23, DOI 10.1016/S0749-0704(18)30265-3; 1987, REPORT WORKING PARTY; 1982, MANAGEMENT SERIOUSLY	9	19	19	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 10	1993	342	8863					68	68		10.1016/0140-6736(93)91282-Q	http://dx.doi.org/10.1016/0140-6736(93)91282-Q			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LL789	8100909				2023-01-03	WOS:A1993LL78900006
J	JANKOWSKI, RF; MANDALIA, S				JANKOWSKI, RF; MANDALIA, S			COMPARISON OF ATTENDANCE AND EMERGENCY ADMISSION PATTERNS AT ACCIDENT AND EMERGENCY DEPARTMENTS IN AND OUT OF LONDON	BRITISH MEDICAL JOURNAL			English	Article								Objective-To compare the sociodemographic characteristics, diagnoses, and mode of referral of people and emergency admissions between an accident and emergency department in inner London and one in a town outside London. Design-Standardised questionnaire completed prospectively over two weeks by fieldworkers in each accident and emergency department. Setting-Accident and emergency departments in an inner London teaching hospital and an associated teaching hospital outside London. Subjects-3039 adults newly attending the departments, 1476 in inner London and 1563 outside London. Main outcome measures-Sociodemographic characteristics, diagnosis, mode of referral, and whether the patient was admitted. Results-General practitioner referrals accounted for similar proportions of the adult attendances (12% in inner London, 15% outside London). People attending at the inner London department were more likely to be tourists or long distance commuters (12% (179/1476) v 6% (95/1563)), single (43% (643) v 32% (505)), to live alone (24% (360) v 14% (225)), to have moved recently (13% (194) v 7% (107)), or to be homeless (3.3% (48) v 0.6% (10)). Broad clinical groupings of patients were similar in both departments. 291 people were admitted in inner London and 284 outside London. The proportions admitted from each sociodemographic group were similar in the two hospitals. Conclusion-Differences in sociodemographic characteristics were more important than general practice referral patterns in determining the differences in people attending at accident and emergency departments inside and outside London. Many of these characteristics are likely to be found in other inner city populations. A strategy to improve acute care in inner London should take account of the needs of these sociodemographically different groups.			JANKOWSKI, RF (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,DIV COMMUNITY HLTH,ST THOMAS CAMPUS,LONDON SE1 7EH,ENGLAND.							FARMER DT, 1982, RELATIONSHIP ACCIDEN; Inwald A C, 1980, J R Coll Gen Pract, V30, P220; LAMBERTS H, 1987, ICPC INT CLASSFICATI; MILNER PC, 1988, J EPIDEMIOL COMMUN H, V42, P274, DOI 10.1136/jech.42.3.274; Tomlinson B., 1992, REPORT INQUIRY LONDO; 1992, USER PERSPECTIVE VIE; 1992, NHS ACCIDENT EMERGEN	7	18	18	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 8	1993	306	6887					1241	1243		10.1136/bmj.306.6887.1241	http://dx.doi.org/10.1136/bmj.306.6887.1241			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB804	8123074	Green Published, Bronze			2023-01-03	WOS:A1993LB80400018
J	TODD, KH; SAMAROO, N; HOFFMAN, JR				TODD, KH; SAMAROO, N; HOFFMAN, JR			ETHNICITY AS A RISK FACTOR FOR INADEQUATE EMERGENCY DEPARTMENT ANALGESIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							PAIN	Objective.-To determine whether Hispanic patients with isolated long-bone fractures are less likely to receive emergency department (ED) analgesics than similar non-Hispanic white patients. Design.-Retrospective cohort study. Setting.-The UCLA Emergency Medicine Center, a level I trauma center. Participants.-All Hispanic and non-Hispanic white ED patients aged 15 to 55 years, seen between January 1, 1990, and December 31, 1991, with isolated long-bone fractures, identified by ICD-9 codes 812, 813, 821, and 823, were eligible for inclusion. Exclusion criteria included injury more than 6 hours prior to presentation, ''possible'' or chip fractures only, altered mentation, or ethanol intoxication. Main Outcome Measures.-Emergency department administration of analgesic or no analgesic. Results.-The study group consisted of 139 patients meeting inclusion criteria, of whom 31 were Hispanic and 108 non-Hispanic white. Non-Hispanic whites were significantly more likely to speak English, be insured, and suffer nonoccupational injuries, Hispanics were twice as likely as non-Hispanic whites to receive no ED pain medication (crude relative risk [RR], 2.12; 95% confidence interval [CI], 1.35 to 3.32; P=.003). The RR for ethnicity was similar and significant (P<.05) after controlling by stratification for covariates related to patient, injury, or physician characteristics. After controlling for several covariates simultaneously through multiple logistic regression, ethnicity remained the strongest predictor of ED analgesic administration (odds ratio [OR], 7.46; 95% CI, 2.22 to 25.04; P<.01). Conclusions.-Hispanics with isolated long-bone fractures are twice as likely as non-Hispanic whites to receive no pain medication in the UCLA Emergency Medicine Center. No covariate measured in this study could account for this effect. An ethnic basis for variability in analgesic practice needs to be further characterized.			TODD, KH (corresponding author), UNIV CALIF LOS ANGELES, CTR EMERGENCY MED, 924 WESTWOOD BLVD, SUITE 300, LOS ANGELES, CA 90024 USA.							Dean A. G., 1990, EPI INFO VERSION 5 W; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; GREENWALD HP, 1991, PAIN, V44, P157, DOI 10.1016/0304-3959(91)90130-P; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; KIRKMANLIFF B, 1991, AM J PUBLIC HEALTH, V81, P1399, DOI 10.2105/AJPH.81.11.1399; PFEFFERBAUM B, 1990, J AM ACAD CHILD PSY, V29, P642, DOI 10.1097/00004583-199007000-00020; SELBST SM, 1990, ANN EMERG MED, V19, P1010, DOI 10.1016/S0196-0644(05)82565-X; WILSON JE, 1989, AM J EMERG MED, V7, P620, DOI 10.1016/0735-6757(89)90286-6; ZATZICK DF, 1990, PSYCHOSOM MED, V52, P544, DOI 10.1097/00006842-199009000-00007; 1992, STATE REFERENCE MANU	10	589	593	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 24	1993	269	12					1537	1539		10.1001/jama.269.12.1537	http://dx.doi.org/10.1001/jama.269.12.1537			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR803	8445817				2023-01-03	WOS:A1993KR80300027
J	BRAVEMAN, P; BENNETT, T; LEWIS, C; EGERTER, S; SHOWSTACK, J				BRAVEMAN, P; BENNETT, T; LEWIS, C; EGERTER, S; SHOWSTACK, J			ACCESS TO PRENATAL-CARE FOLLOWING MAJOR MEDICAID ELIGIBILITY EXPANSIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BIRTH-WEIGHT; INSURANCE; HEALTH; WOMEN	Objective.-To determine whether lack of financial access was a significant barrier to prenatal care following major expansions of Medicaid eligibility in California. Design.-Retrospective analysis of birth certificates, assessing risks of inadequate prenatal care by insurance, controlling for maternal race/ethnicity, birthplace, age, parity, education, and marital status. Sample.-Singleton live births to California residents occurring in-state in 1990 (N=593510). Outcome Measures.-Untimely initiation of care, too few visits, and no prenatal care. Results.-Despite major Medicaid expansions, nearly 11% of live births were uninsured for prenatal care. Being uninsured and having Medi-Cal were both risk factors of sizable magnitude, controlling for,maternal characteristics. Compared with women who had private fee-for-service coverage, uninsured women were at elevated risk of untimely initiation (odds ratio [OR], 2.54; 95% confidence interval [Cl], 2.47 to 2.60) and too few visits (OR, 2.49; 95% Cl, 2.44 to 2.55). Women with Medi-Cal had a high risk of untimely care (OR, 3.33; 95% Cl, 3.26 to 3.40); their risk of too few visits was also elevated (OR, 1.63; 95% Cl, 1.60 to 1.66) but less than for the uninsured. Lack of private insurance was a strong risk factor for no care (OR, 6.70; 95% Cl, 6.00 to 7.47). Conclusions.-In spite of major Medicaid expansions, access to prenatal care was limited for women without private insurance. Medicaid was associated with untimely entry but with improved continuity. The findings suggest that financial barriers were salient even when controlling for many factors related to care-seeking behavior. Policy initiatives need to address continuing financial barriers along with other obstacles.	UNIV CALIF SAN FRANCISCO,SCH MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	BRAVEMAN, P (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT FAMILY & COMMUNITY MED,BOX 0900,SAN FRANCISCO,CA 94143, USA.		Showstack, Jonathan/L-6556-2013	Showstack, Jonathan/0000-0002-1367-419X				BRAVEMAN P, 1988, WESTERN J MED, V149, P708; BROWN ER, 1988, CHANGES HLTH INSURAN; BROWN SS, 1989, FAM PLANN PERSPECT, V21, P73, DOI 10.2307/2135557; COONEY JP, 1985, MED CARE, V23, P986, DOI 10.1097/00005650-198508000-00006; DAVID RJ, 1980, AM J PUBLIC HEALTH, V70, P964, DOI 10.2105/AJPH.70.9.964; GREENBERG RS, 1983, AM J OBSTET GYNECOL, V145, P797, DOI 10.1016/0002-9378(83)90681-6; HAAS JS, 1993, JAMA-J AM MED ASSOC, V269, P87, DOI 10.1001/jama.269.1.87; HUGHES D, 1988, HLTH AM CHILDREN MAT; JAMISON H, UNPUB BIRTH CERTIFIC; KOTELCHUCK M, 1987, 115TH ANN M AM PUBL; MURRAY JL, 1988, NEW ENGL J MED, V319, P1385, DOI 10.1056/NEJM198811243192105; Oberg C N, 1991, J Health Care Poor Underserved, V2, P270; PIPER JM, 1990, JAMA-J AM MED ASSOC, V264, P2219, DOI 10.1001/jama.264.17.2219; SCHWETHELM B, 1989, AM J PREV MED, V5, P157, DOI 10.1016/S0749-3797(18)31097-3; WILLIAMS RL, 1982, OBSTET GYNECOL, V59, P624; [No title captured]; 1985, SAS USERS GUIDE STAT; 1987, PRENATAL CARE MEDICA; [No title captured]; 1988, PRENATAL CARE REACHI	20	105	105	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 10	1993	269	10					1285	1289		10.1001/jama.269.10.1285	http://dx.doi.org/10.1001/jama.269.10.1285			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP885	8437308				2023-01-03	WOS:A1993KP88500029
J	Fazel, M				Fazel, M			Now show me your tongue: A taste of medicine in China	LANCET			English	Editorial Material											Fazel, M (corresponding author), LINCOLN COLL,OXFORD OX1 3DR,ENGLAND.			Fazel, Mina/0000-0001-9342-2365				WILSON A, 1991, BRIT J GEN PRACT, V41, P119	1	9	9	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 23	1995	346	8991-2					1687	1688		10.1016/S0140-6736(95)92847-2	http://dx.doi.org/10.1016/S0140-6736(95)92847-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL423	8551831				2023-01-03	WOS:A1995TL42300017
J	Groves, KE				Groves, KE			How I'd like to be treated if I was terminally ill	BRITISH MEDICAL JOURNAL			English	Article											Groves, KE (corresponding author), QUEENSCOURT HOSPICE,SOUTHPORT PR8 6RE,MERSEYSIDE,ENGLAND.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	1995	311	7021					1690	1691		10.1136/bmj.311.7021.1690	http://dx.doi.org/10.1136/bmj.311.7021.1690			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL942	8541760	Green Published			2023-01-03	WOS:A1995TL94200020
J	Vaccaro, AM; Ciaffoni, F; Tatti, M; Salvioli, R; Barca, A; Tognozzi, D; Scerch, C				Vaccaro, AM; Ciaffoni, F; Tatti, M; Salvioli, R; Barca, A; Tognozzi, D; Scerch, C			pH-dependent conformational properties of saposins and their interactions with phospholipid membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATOR PROTEIN-DEFICIENCY; GAUCHERS-DISEASE; GLUCOCEREBROSIDASE; GLUCOSYLCERAMIDASE; LIPOSOMES; BINDING; PROSAPOSIN; SEPARATION; VESICLES; PATIENT	Saposins A, B, C, and D are small lysosomal glycoproteins released by proteolysis from a single precursor polypeptide, prosaposin. We have presently investigated the conformational states of saposins and their interaction with membranes at acidic pH values similar to those present in lysosomes. With the use of phase partitioning in Triton X-114, experimental evidence was provided that, upon acidification, saposins (Sap) A, C, and D acquire hydrophobic properties, while the hydrophilicity of Sap B is apparently unchanged. The pH-dependent exposure of hydrophobic domains of Sap C and D paralleled their pH-dependent binding to large unilamellar vesicles composed of phosphatidyl-choline, phosphatidylserine, and cholesterol. In contrast, the binding of Sap A to the vesicles was very restricted, in spite of its increased hydrophobicity at low pH. A low affinity for the vesicles was also shown by Sap B, a finding consistent with its apparent hydrophilicity both at neutral and acidic pH. At the acidic pH values needed for binding, Sap C and D powerfully destabilized the phospholipid membranes, while Sap A and B minimally affected the bilayer integrity. In the absence of the acidic phospholipid phosphatidylserine, the induced destabilization markedly decreased. Of the four saposins, only Sap C was able to promote the binding of glucosylceramidase to phosphatidylserine containing membranes. This result is consistent with the notion that Sap C is specifically required by glucosylceramidase to exert its activity. Our finding that an acidic environment induces an increased hydrophobicity in Sap A, C, and D, making the last two saposins able to interact and perturb phospholipid membranes, suggests that this mechanism might be relevant to the mode of action of saposins in lysosomes.			Vaccaro, AM (corresponding author), IST SUPER SANITA,DEPT METAB & PATHOL BIOCHEM,VIALE REGINA ELENA 299,I-00161 ROME,ITALY.		tatti, Massimo/N-1382-2017					AZUMA N, 1994, ARCH BIOCHEM BIOPHYS, V311, P354, DOI 10.1006/abbi.1994.1248; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BOHLEY P, 1992, EXPERIENTIA, V48, P151, DOI 10.1007/BF01923508; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRADOVA V, 1993, HUM GENET, V92, P143, DOI 10.1007/BF00219682; CHIAO YB, 1978, ARCH BIOCHEM BIOPHYS, V186, P42, DOI 10.1016/0003-9861(78)90461-7; CHRISTOMANOU H, 1989, KLIN WOCHENSCHR, V67, P999, DOI 10.1007/BF01716064; DOMS RW, 1985, J BIOL CHEM, V260, P2973; ESCUYER V, 1986, J BIOL CHEM, V261, P891; FRICKER LD, 1990, J BIOL CHEM, V265, P2476; FUJIBAYASHI S, 1986, BIOCHIM BIOPHYS ACTA, V875, P554; FUJIBAYASHI S, 1986, J BIOL CHEM, V261, P15389; FURST W, 1992, BIOCHIM BIOPHYS ACTA, V1126, P1, DOI 10.1016/0005-2760(92)90210-M; GLEW RH, 1988, LAB INVEST, V58, P5; HARZER K, 1989, EUR J PEDIATR, V149, P31, DOI 10.1007/BF02024331; HIRAIWA M, 1992, P NATL ACAD SCI USA, V89, P11254, DOI 10.1073/pnas.89.23.11254; Holtzman E, 1989, LYSOSOMES; KISHIMOTO Y, 1992, J LIPID RES, V33, P1255; KLEIN A, 1994, BIOCHEM BIOPH RES CO, V200, P1140; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MORIMOTO S, 1989, P NATL ACAD SCI USA, V86, P3389, DOI 10.1073/pnas.86.9.3389; MORIMOTO S, 1990, J BIOL CHEM, V265, P1933; MURRAY GJ, 1985, ANAL BIOCHEM, V147, P301, DOI 10.1016/0003-2697(85)90276-3; OBRIEN JS, 1991, FASEB J, V5, P301, DOI 10.1096/fasebj.5.3.2001789; PAPAHADJOPOULOS D, 1975, BIOCHIM BIOPHYS ACTA, V401, P317, DOI 10.1016/0005-2736(75)90233-3; PATON BC, 1989, EUR J CELL BIOL, V51, P157; REDINBAUGH MG, 1986, ANAL BIOCHEM, V153, P267, DOI 10.1016/0003-2697(86)90091-6; SANDHOFF K, 1995, METABOLIC MOL BASES, P2427; SANO A, 1988, J BIOL CHEM, V263, P19597; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHLOTE W, 1991, EUR J PEDIATR, V150, P584, DOI 10.1007/BF02072213; SCHNABEL D, 1992, J BIOL CHEM, V267, P3312; STRAUBINGER RM, 1983, CELL, V32, P1069, DOI 10.1016/0092-8674(83)90291-X; TAMARU T, 1985, HISTOCHEMISTRY, V86, P195; VACCARO AM, 1993, BIOCHIM BIOPHYS ACTA, V1149, P55, DOI 10.1016/0005-2736(93)90024-T; VACCARO AM, 1994, FEBS LETT, V349, P181, DOI 10.1016/0014-5793(94)00659-8; VACCARO AM, 1990, BIOCHIM BIOPHYS ACTA, V1033, P73, DOI 10.1016/0304-4165(90)90196-4; VACCARO AM, 1995, J BIOL CHEM, V270, P9953, DOI 10.1074/jbc.270.17.9953; VACCARO AM, 1991, BIOCHIM BIOPHYS ACTA, V1119, P239; VACCARO AM, 1993, FEBS LETT, V1, P159; WENGER DA, 1989, AM J MED GENET, V33, P255, DOI 10.1002/ajmg.1320330223; YOSHIMURA T, 1987, J BIOCHEM-TOKYO, V101, P1265, DOI 10.1093/oxfordjournals.jbchem.a121990	43	86	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	1995	270	51					30576	30580		10.1074/jbc.270.51.30576	http://dx.doi.org/10.1074/jbc.270.51.30576			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TL675	8530492	hybrid			2023-01-03	WOS:A1995TL67500057
J	NELSON, HD; NEVITT, MC; SCOTT, JC; STONE, KL; CUMMINGS, SR				NELSON, HD; NEVITT, MC; SCOTT, JC; STONE, KL; CUMMINGS, SR			SMOKING, ALCOHOL, AND NEUROMUSCULAR AND PHYSICAL FUNCTION OF OLDER WOMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK-FACTORS; CIGARETTE-SMOKING; MAINTAINING MOBILITY; POSTMENOPAUSAL WOMEN; ARTERIAL-DISEASE; ALAMEDA COUNTY; HEART-DISEASE; BREAST-CANCER; LATE-LIFE; CONSUMPTION	Objective.-To determine the associations of current and lifetime smoking and alcohol use with physical function in an older population. Design.-Survey. Setting.-Four clinic centers in the United States. Participants.-A total of 9704 community-dwelling, ambulatory white women 65 years or older recruited from four areas of the United States. Main Outcome Measures.-Twelve performance tests of muscle strength, agility and coordination, gait and balance, and self-reported functional status. Results.-Compared with women who never smoked, current smokers had significantly poorer function on all of the performance measures except grip strength after adjusting for age, history of stroke, body mass index, clinic site, physical activity, and alcohol use (P<.05). This decrease in function was 50% to 100% as great as that associated with a 5-year increase in age, and most measures worsened with increasing numbers of pack-years. Compared with current moderate drinkers, nondrinkers had significantly poorer function on all of the performance measures except tandem walk (P<.05). Evaluation of a dose effect with alcohol was limited by the small number of heavy drinkers in the study. Conclusions.-In this population, women who currently smoke are weaker and have poorer balance and poorer performance on measures of integrated physical function than nonsmokers. Smoking is associated with a decline in physical function. Current moderate drinkers have better physical function compared with nondrinkers, but associations of function with heavy drinkers could not be assessed.	UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143; UNIV MARYLAND,DEPT EPIDEMIOL & PREVENT MED,BALTIMORE,MD	University of California System; University of California San Francisco; University System of Maryland; University of Maryland Baltimore	NELSON, HD (corresponding author), OREGON HLTH SCI UNIV,DIV GEN INTERNAL MED,3181 SW SAM JACKSON PK RD,L475,PORTLAND,OR 97201, USA.			Ensrud, Kristine/0000-0002-9069-3036; Cauley, Jane A/0000-0003-0752-4408				ADAMS RD, 1977, PRINCIPLES NEUROLOGY, P812; ALANKO T, 1984, RES ADV ALCOHOL DRUG, V8, P209; ARMOR D, 1982, ENCY HDB ALCOHOLISM; BAER L, 1985, AM J MED, V78, P564, DOI 10.1016/0002-9343(85)90396-1; BALFOUR DJK, 1982, PHARMACOL THERAPEUT, V16, P269, DOI 10.1016/0163-7258(82)90058-4; BELCH JJF, 1984, THROMB HAEMOSTASIS, V51, P6; BENOWITZ NL, 1988, NEW ENGL J MED, V319, P1318; BOHANNON RW, 1986, PHYS THER, V66, P206, DOI 10.1093/ptj/66.2.206; BRANCH LG, 1982, AM J PUBLIC HEALTH, V72, P1373, DOI 10.2105/AJPH.72.12.1373; BRANCH LG, 1984, AM J PUBLIC HEALTH, V74, P266, DOI 10.2105/AJPH.74.3.266; BUSBY WJ, 1988, J AM GERIATR SOC, V36, P301, DOI 10.1111/j.1532-5415.1988.tb02355.x; CASSIDENTI DL, 1990, AM J OBSTET GYNECOL, V163, P1953, DOI 10.1016/0002-9378(90)90780-B; CAULEY JA, 1987, J CHRON DIS, V40, P115, DOI 10.1016/0021-9681(87)90062-2; CERHAN JR, 1993, AM J EPIDEMIOL, V137, P870, DOI 10.1093/oxfordjournals.aje.a116748; COLDITZ GA, 1988, NEW ENGL J MED, V318, P937, DOI 10.1056/NEJM198804143181501; CRIQUI MH, 1989, AM J EPIDEMIOL, V129, P1110, DOI 10.1093/oxfordjournals.aje.a115233; FITTI JE, 1987, VITAL HEALTH STAT, V21, P1; FORTMANN SP, 1986, AM J EPIDEMIOL, V124, P706, DOI 10.1093/oxfordjournals.aje.a114445; FOWKES FGR, 1989, BRIT MED J, V298, P405, DOI 10.1136/bmj.298.6671.405; FREZZA M, 1990, NEW ENGL J MED, V322, P95, DOI 10.1056/NEJM199001113220205; GARG R, 1993, ARCH INTERN MED, V153, P1211, DOI 10.1001/archinte.153.10.1211; GAVALER JS, 1985, J STUD ALCOHOL, V46, P495, DOI 10.15288/jsa.1985.46.495; GURALNIK JM, 1989, AM J PUBLIC HEALTH, V79, P703, DOI 10.2105/AJPH.79.6.703; GURALNIK JM, 1993, AM J EPIDEMIOL, V137, P845, DOI 10.1093/oxfordjournals.aje.a116746; HARRIS T, 1989, AM J PUBLIC HEALTH, V79, P698, DOI 10.2105/AJPH.79.6.698; HATCHER EM, 1977, ALCOHOL CLIN EXP RES, V1, P371; HOFSTETTER A, 1986, NEW ENGL J MED, V314, P79, DOI 10.1056/NEJM198601093140204; KANNEL WB, 1985, J AM GERIATR SOC, V33, P13, DOI 10.1111/j.1532-5415.1985.tb02853.x; KAPLAN GA, 1987, AM J PUBLIC HEALTH, V77, P307, DOI 10.2105/AJPH.77.3.307; KAWACHI I, 1993, JAMA-J AM MED ASSOC, V269, P232, DOI 10.1001/jama.269.2.232; KIRCH DG, 1988, CELL MOL NEUROBIOL, V8, P285, DOI 10.1007/BF00711170; KLATSKY AL, 1992, ANN INTERN MED, V117, P646, DOI 10.7326/0003-4819-117-8-646; KRISKA AM, 1988, AM J EPIDEMIOL, V127, P1053, DOI 10.1093/oxfordjournals.aje.a114881; LACROIX AZ, 1991, NEW ENGL J MED, V324, P1619, DOI 10.1056/NEJM199106063242303; LACROIX AZ, 1993, AM J EPIDEMIOL, V137, P858, DOI 10.1093/oxfordjournals.aje.a116747; LAPORTE RE, 1983, J GERONTOL, V38, P394, DOI 10.1093/geronj/38.4.394; Leveille S. G., 1992, J WOMENS HEALTH, V1, P53; Lohman TG, 1988, ANTHROPOMETRIC STAND, P177, DOI DOI 10.1002/AJHB.1310040323; MCBRIDE PE, 1992, MED CLIN N AM, V76, P333, DOI 10.1016/S0025-7125(16)30356-X; MOR V, 1989, J CLIN EPIDEMIOL, V42, P895, DOI 10.1016/0895-4356(89)90103-0; NEVITT JC, 1990, 2ND 50 YEARS PROMOTI, P263; NEVITT MC, 1989, JAMA-J AM MED ASSOC, V261, P2663, DOI 10.1001/jama.261.18.2663; NOWAK J, 1987, CIRCULATION, V76, P6, DOI 10.1161/01.CIR.76.1.6; OLOUGHLIN JL, 1993, AM J EPIDEMIOL, V137, P342, DOI 10.1093/oxfordjournals.aje.a116681; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; PINSKY JL, 1987, J CHRON DIS, V40, pS159, DOI 10.1016/S0021-9681(87)80045-0; SCHATZKIN A, 1987, NEW ENGL J MED, V316, P1169, DOI 10.1056/NEJM198705073161901; SCHERR PA, 1992, J AM GERIATR SOC, V40, P651, DOI 10.1111/j.1532-5415.1992.tb01954.x; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; TARTER RE, 1975, DIS NERV SYST, V36, P185; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; URBANOMARQUEZ A, 1989, NEW ENGL J MED, V320, P409, DOI 10.1056/NEJM198902163200701; VOGT MT, 1993, AM J EPIDEMIOL, V137, P559, DOI 10.1093/oxfordjournals.aje.a116709; WAGENKNECHT LE, 1992, AM J PUBLIC HEALTH, V82, P33, DOI 10.2105/AJPH.82.1.33; WILLETT WC, 1987, NEW ENGL J MED, V316, P1174, DOI 10.1056/NEJM198705073161902; WILLETT WC, 1987, NEW ENGL J MED, V317, P1303, DOI 10.1056/NEJM198711193172102; 1980, HLTH CONSEQUENCES SM	57	145	149	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 21	1994	272	23					1825	1831		10.1001/jama.272.23.1825	http://dx.doi.org/10.1001/jama.272.23.1825			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PW980	7990216				2023-01-03	WOS:A1994PW98000030
J	DINUBILE, MJ				DINUBILE, MJ			SHORT-COURSE ANTIBIOTIC-THERAPY FOR RIGHT-SIDED ENDOCARDITIS CAUSED BY STAPHYLOCOCCUS-AUREUS IN INJECTION-DRUG USERS	ANNALS OF INTERNAL MEDICINE			English	Article							COMBINATION THERAPY; RESISTANT; GENTAMICIN; VANCOMYCIN; ADDICTS; SYNERGISM; VARIANTS	Right-sided endocarditis caused by Staphylococcus aureus is a frequent complication of injection drug use. Fortunately, the prognosis for this infection when treated with the standard regimen of 4 to 6 weeks od parenteral antistaphylococcal antibiotics is favorable. Nevertheless, in many cases, once drug users feel better, they leave the hospital against medical advice before completing the full course of antibiotic therapy. This problem has stimulated interest in shortening the duration of antibiotic treatment by adding an aminoglycoside antibiotic to a penicillinase-resistant penicillin. Data from in vitro synergy studies and animal models of endocarditis suggest that S. aureus can be eradicated more quickly by combination therapy than by monotherapy. Reports of three prospective, nonrandomized clinical trials have been published that support the use of a a-week course of a penicillinase-resistant penicillin and an aminoglycoside antibiotic to treat uncomplicated, exclusively right-sided endocarditis caused by methicillin-susceptibte S. aureus in injection drug users.			DINUBILE, MJ (corresponding author), UNIV MED & DENT NEW JERSEY, COOPER HOSP UNIV MED CTR, ROBERT WOOD JOHNSON MED SCH, DIV INFECT DIS, CAMDEN, NJ 08103 USA.							ALDRIDGE KE, 1992, DIAGN MICR INFEC DIS, V15, P517, DOI 10.1016/0732-8893(92)90101-X; BAYER AS, 1990, CHEST, V98, P200, DOI 10.1378/chest.98.1.200; BRUMFITT W, 1989, NEW ENGL J MED, V320, P1188, DOI 10.1056/NEJM198905043201806; BRYANT RE, 1977, JAMA-J AM MED ASSOC, V237, P569, DOI 10.1001/jama.237.6.569; CHAMBERS HF, 1988, ANN INTERN MED, V109, P619, DOI 10.7326/0003-4819-109-8-619; CHRISTIE RV, 1948, BRIT MED J, V1, P1, DOI 10.1136/bmj.1.4539.1; COKER AO, 1989, E AFR MED J, V66, P141; DWORKIN RJ, 1989, LANCET, V2, P1071; Espinosa F J, 1993, Enferm Infecc Microbiol Clin, V11, P235; GERACI JE, 1953, CIRCULATION, V8, P494, DOI 10.1161/01.CIR.8.4.494; HAMBURGER M, 1952, JAMA-J AM MED ASSOC, V149, P542, DOI 10.1001/jama.1952.02930230016005; HECHT SR, 1992, ANN INTERN MED, V117, P560, DOI 10.7326/0003-4819-117-7-560; HODELCHRISTIAN SL, 1990, ANTIMICROB AGENTS CH, V34, P1278, DOI 10.1128/AAC.34.6.1278; KARCHMER AW, 1979, JAMA-J AM MED ASSOC, V241, P1801, DOI 10.1001/jama.241.17.1801; KERNODLE DS, 1989, J INFECT DIS, V159, P103, DOI 10.1093/infdis/159.1.103; KORZENIOWSKI O, 1982, ANN INTERN MED, V97, P496, DOI 10.7326/0003-4819-97-4-496; LAPUMA J, 1988, ARCH INTERN MED, V148, P1809, DOI 10.1001/archinte.148.8.1809; LEVINE DP, 1991, ANN INTERN MED, V115, P674, DOI 10.7326/0003-4819-115-9-674; LEVINE DP, 1986, REV INFECT DIS, V8, P374; MALACOFF RF, 1979, JAMA-J AM MED ASSOC, V241, P1807, DOI 10.1001/jama.241.17.1807; MANOLIS AS, 1988, ARCH INTERN MED, V148, P2461, DOI 10.1001/archinte.148.11.2461; MEDERSKISAMORAJ BD, 1983, J INFECT DIS, V147, P751, DOI 10.1093/infdis/147.4.751; PARKER RH, 1980, ANN INTERN MED, V93, P832, DOI 10.7326/0003-4819-93-6-832; RADBERG G, 1992, J ANTIMICROB CHEMOTH, V30, P489, DOI 10.1093/jac/30.4.489; ROBBINS MJ, 1986, AM HEART J, V111, P128, DOI 10.1016/0002-8703(86)90564-8; SANDE MA, 1976, J LAB CLIN MED, V88, P118; SMALL PM, 1990, ANTIMICROB AGENTS CH, V34, P1227, DOI 10.1128/AAC.34.6.1227; SPIEGEL CA, 1988, J CLIN MICROBIOL, V26, P2270, DOI 10.1128/JCM.26.11.2270-2274.1988; TORRESTORTOSA M, 1994, EUR J CLIN MICROBIOL, V13, P533; Uete Tetsuo, 1992, Japanese Journal of Antibiotics, V45, P943; WATANAKUNAKORN C, 1974, ANTIMICROB AGENTS CH, V6, P802, DOI 10.1128/AAC.6.6.802; WILSON WR, 1984, ANN INTERN MED, V100, P816, DOI 10.7326/0003-4819-100-6-816; WILSON WR, 1978, CIRCULATION, V57, P1158, DOI 10.1161/01.CIR.57.6.1158; WOLFE JC, 1974, ANN INTERN MED, V81, P178, DOI 10.7326/0003-4819-81-2-178	34	66	70	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1994	121	11					873	876		10.7326/0003-4819-121-11-199412010-00009	http://dx.doi.org/10.7326/0003-4819-121-11-199412010-00009			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT628	7978701				2023-01-03	WOS:A1994PT62800009
J	STURDEE, DW; BARLOW, DH; ULRICH, LG; WELLS, M; GYDESEN, H; CAMPBELL, M; OBRIEN, K; VESSEY, M				STURDEE, DW; BARLOW, DH; ULRICH, LG; WELLS, M; GYDESEN, H; CAMPBELL, M; OBRIEN, K; VESSEY, M			IS THE TIMING OF WITHDRAWAL BLEEDING A GUIDE TO ENDOMETRIAL SAFETY DURING SEQUENTIAL ESTROGEN-PROGESTAGEN REPLACEMENT THERAPY	LANCET			English	Article							POST-MENOPAUSAL ENDOMETRIUM; POSTMENOPAUSAL WOMEN; LONG-TERM; ESTROGENS; PROGESTOGENS; HYPERPLASIA; MORPHOLOGY; DISEASE; CANCER; RISK	Current regimens of sequential hormone replacement therapy are based on data that show a protective effect on the endometrium of at least 10 days of progestagen. In clinical practice, onset of bleeding on or after day 11 of the progestagen phase is taken as reassurance of a normal endometrium. 413 postmenopausal women taking oestrogen-progestagen hormone replacement thera py with 10 or 12 days of progestagen per cycle completed bleeding diaries for 3 months before endometrial biopsy. For most women, bleeding started around the 13th day after starting progestagen. There was no correlation between endometrial histology and timing of onset of bleeding. 11 (2.7%) women had complex endometrial hyperplasia. The presence of hyperplasia was 2.4% with onset of bleeding after 10 days of progestagen and 2.8% after 12 days. The timing of onset of withdrawal bleeding during oestrogen-progestagen HRT does not predict endometrial hyperplasia.	UNIV OXFORD,NUFFIELD DEPT OBSTET & GYNAECOL,OXFORD,ENGLAND; NOVO NORDISK AS,DIV PHARMACEUT,BAGSVAERD,DENMARK; ST JAMESS UNIV HOSP,DEPT PATHOL,LEEDS,W YORKSHIRE,ENGLAND; UNIV SOUTHAMPTON,DEPT MED STAT,SOUTHAMPTON,HANTS,ENGLAND; NOVO NORDISK PHARMACEUT LTD,CRAWLEY,W SUSSEX,ENGLAND; UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,OXFORD,ENGLAND	University of Oxford; Novo Nordisk; Saint James's University Hospital; University of Leeds; University of Southampton; Novo Nordisk; University of Oxford	STURDEE, DW (corresponding author), SOLIHULL HOSP,LODE LANE,SOLIHULL B91 2JL,W MIDLANDS,ENGLAND.		Sturdee, David/ABF-9792-2020; Barlow, David/F-8738-2011; Campbell, Michael J/I-4253-2014	Campbell, Michael J/0000-0003-3529-2739				ARCHER DF, 1991, AM J OBSTET GYNECOL, V165, P317, DOI 10.1016/0002-9378(91)90084-5; FERENCZY A, 1989, AM J OBSTET GYNECOL, V160, P126, DOI 10.1016/0002-9378(89)90103-8; GAMBRELL RD, 1974, J AM GERIATR SOC, V22, P337, DOI 10.1111/j.1532-5415.1974.tb04838.x; GAMBRELL RD, 1988, MENOPAUSE, P247; GREENBLATT RB, 1965, NEW ENGL J MED, V272, P305, DOI 10.1056/NEJM196502112720608; KOSS LG, 1984, OBSTET GYNECOL, V64, P1; KURMAN RJ, 1985, CANCER, V56, P403, DOI 10.1002/1097-0142(19850715)56:2<403::AID-CNCR2820560233>3.0.CO;2-X; NORRIS HJ, 1986, CLIN OBSTET GYNAECOL, V13, P725; PADWICK ML, 1986, NEW ENGL J MED, V315, P930, DOI 10.1056/NEJM198610093151504; PATERSON MEL, 1980, BRIT MED J, V280, P822, DOI 10.1136/bmj.280.6217.822; PERSSON I, 1989, BRIT MED J, V298, P147, DOI 10.1136/bmj.298.6667.147; SCHIFF I, 1982, FERTIL STERIL, V37, P79; STURDEE DW, 1978, BRIT MED J, V1, P1575, DOI 10.1136/bmj.1.6127.1575; THOM MH, 1979, LANCET, V2, P455; TREVOUX R, 1986, MATURITAS, V8, P309, DOI 10.1016/0378-5122(86)90039-3; VARMA TR, 1985, ACTA OBSTET GYN SCAN, V64, P41, DOI 10.3109/00016348509154686; VOIGT LF, 1991, LANCET, V338, P274, DOI 10.1016/0140-6736(91)90417-N; WHITEHEAD MI, 1981, NEW ENGL J MED, V305, P1599, DOI 10.1056/NEJM198112313052701; WHITEHEAD MI, 1978, MATURITAS, V1, P87, DOI 10.1016/0378-5122(78)90015-4; WILSON RA, 1962, JAMA-J AM MED ASSOC, V182, P327, DOI 10.1001/jama.1962.03050430001001	20	69	71	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 8	1994	344	8928					979	982		10.1016/S0140-6736(94)91640-3	http://dx.doi.org/10.1016/S0140-6736(94)91640-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK978	7934429				2023-01-03	WOS:A1994PK97800008
J	ROUSSELET, J; SALOME, L; AJDARI, A; PROST, J				ROUSSELET, J; SALOME, L; AJDARI, A; PROST, J			DIRECTIONAL MOTION OF BROWNIAN PARTICLES INDUCED BY A PERIODIC ASYMMETRIC POTENTIAL	NATURE			English	Article								STRUCTURES possessing spatial asymmetry should act as pumps in the presence of dissipation alone(1-4), without the need for macroscopic forces or temperature differences(5) to drive vectorial motion. It has been shown theoretically(2-4,6,7) that particles subjected to an asymmetric periodic potential can display net directional motion even if the space-averaged forte is zero. Here we demonstrate such behaviour experimentally. We have studied the behaviour of colloidal particles suspended in solution and exposed to a sawtooth dielectric potential which is turned on and off periodically. The particles exhibit net motion with a velocity that depends on their size, suggesting applications in separation processes for objects in the size range 0.1-5 mu m-a range that includes biological structures such as viruses, cells and chromosomes(8). We furthermore point out the analogy between our device and motor protein assemblies.	ECOLE SUPER PHYS & CHIM IND VILLE PARIS, PHYSICOCHIM THEOR GRP, CNRS, URA 1382, F-75231 PARIS 05, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI)	ROUSSELET, J (corresponding author), CTR RECH PAUL PASCAL, AVE A SCHWEITZER, F-33600 PESSAC, FRANCE.			SALOME, Laurence/0000-0001-9667-4154				AJDARI A, 1992, CR ACAD SCI II, V315, P1635; AJDARI A, 1993, Patent No. 9311346; AJDARI A, 1992, THESIS U PARIS 6; ASTUMIAN RD, 1994, PHYS REV LETT, V72, P1766, DOI 10.1103/PhysRevLett.72.1766; CORDOVA NJ, 1991, NATO ADV SCI I B-PHY, V263, P207; Curie P., 1894, J PHYS-PARIS, V3, P393, DOI DOI 10.1051/JPHYSTAP:018940030039300; DOERING CR, 1994, PHYS REV LETT, V72, P2984, DOI 10.1103/PhysRevLett.72.2984; FELICI N, 1971, CR ACAD SCI B PHYS, V273, P1004; FEYNMAN RP, 1966, FEYNMAN LECT PHYS, V1, pCH46; MAGNASCO MO, 1993, PHYS REV LETT, V71, P1477, DOI 10.1103/PhysRevLett.71.1477; PESKIN CS, 1994, CELL MECHANICS CELLU; PROST J, 1994, PHYS REV LETT, V72, P2652, DOI 10.1103/PhysRevLett.72.2652	12	575	595	5	74	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 11	1994	370	6489					446	448		10.1038/370446a0	http://dx.doi.org/10.1038/370446a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB407	8047163				2023-01-03	WOS:A1994PB40700051
J	FISHER, P; WARD, A				FISHER, P; WARD, A			MEDICINE IN EUROPE .8. COMPLEMENTARY MEDICINE IN EUROPE	BRITISH MEDICAL JOURNAL			English	Article							ALTERNATIVE MEDICINE; PRACTITIONERS	Complementary or unconventional treatments are used by many doctors and other therapists throughout Europe, The major forms are acupuncture, homoeopathy, manual therapy or manipulation, and phytotherapy or herbal medicine. The relative popularity of therapies differs between countries, but public demand is strong and growing. Regulation of practitioners varies widely: in most countries only registered health professionals may practice, but in the United Kingdom practice is virtually unregulated. Germany and some Scandinavian countries have intermediate systems. Legal reforms are in progress in the Netherlands and the United Kingdom. European institutions are starting to influence the development of complementary medicine. Harmonisation of training and regulation of practitioners is the challenge for the future.			FISHER, P (corresponding author), ROYAL LONDON HOMOEOPATH HOSP,GREAT ORMOND ST,LONDON WC1N 3HR,ENGLAND.							ANDERSON E, 1988, J R COLL GEN PRACT, V38, P511; BOUCHAYER F, 1991, COMPLEMENTARY MED EU; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; FULDER S, 1981, STATUS COMPLEMENTARY; FULDER SJ, 1985, LANCET, V2, P542; HALPERN S, 1985, HLTH SOCIAL SER 0606, P702; HUGGON T, 1990, J ALTERNATIVE CO JAN; KNIPSCHILD P, 1990, SOC SCI MED, V31, P625, DOI 10.1016/0277-9536(90)90099-E; MATTHIESSEN P, 1992, MATERIALIEN GESUNDHE, V21; PIETRONI PC, 1992, BRIT MED J, V305, P564, DOI 10.1136/bmj.305.6853.564; RASMUSSEN N, 1991, COMPLEMENTARY MED EU; REILLY DT, 1983, BRIT MED J, V287, P337, DOI 10.1136/bmj.287.6388.337; SERMEUS G, 1991, COMPLEMENTARY MED EU; SWAYNE JMD, 1989, J ROY COLL GEN PRACT, V39, P503; VANDIJK P, 1993, GENEWIJZEN NEDERLAND; VASKILAMPI T, 1991, COMPLEMENTARY MED EU; VISSER J, 1991, COMPLEMENTARY MED EU; WHARTON R, 1986, BRIT MED J, V292, P1498, DOI 10.1136/bmj.292.6534.1498; 1989, TIMES           1113; 1992, OFFICIAL J EURO 1013; 1992, DOCTOR          0716, P17; 1992, EEC MARKET HOMOEOPAT; 1989, REPORT ALTERNATIVE M; 1993, COMPLEMENTARY MED NE; 1993, HOMEOPATHIE 1993; 1993, COMPLEMENTARY THERAP; 1992, REGULATON PRACTITION	27	496	512	1	44	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 9	1994	309	6947					107	111		10.1136/bmj.309.6947.107	http://dx.doi.org/10.1136/bmj.309.6947.107			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW716	8038643	Green Published			2023-01-03	WOS:A1994NW71600028
J	TAKAYAMA, JI; BERGMAN, AB; CONNELL, FA				TAKAYAMA, JI; BERGMAN, AB; CONNELL, FA			CHILDREN IN FOSTER-CARE IN THE STATE OF WASHINGTON - HEALTH-CARE UTILIZATION AND EXPENDITURES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SUPERVISION; CALIFORNIA; SERVICES; SYSTEM; POLICY	Objective.-To determine and compare health care utilization and expenditures of children in foster care with those of other children and to identify and describe high-cost children in foster care. Design.-Analysis of the Medicaid program claims data in the state of Washington. Population.-A total of 1631 children in foster care and 5316 children in the Aid to Families With Dependent Children (AFDC) program in 1990. The children were ages O through 7 years and eligible for Medicaid continuously during the study year. Main Outcome Measures.-Health care utilization and expenditures classified by types of health service and health care provider; proportion of children with 1990 expenditures exceeding $10 000 and most prominent diagnoses associated with their health care utilization. Results.-Mental health services were used by 25% of children in foster care compared with 3% of AFDC children (P<.001), and supportive services of visiting nurses and physical therapists were used by 13% of children in foster care and 1% of AFDC children (P<.001). Twice as many children in foster care than AFDC children used medical equipment or specialist services or were hospitalized (P<.001). Mean health care expenditures in 1990 were $3075 for children in foster care and $543 for AFDC children (P<.001). High-cost children included 8% of children in foster care and 0.4% of AFDC children. Among the high-cost children in foster care (n=106), 59% had mental disorders and 31% had congenital conditions. Conclusions.-Results suggest a higher prevalence and greater complexity of illnesses, particularly mental disorders, among children in foster care. Despite the high utilization and cost of mental health services, previous research suggests there may be underutilization of these services compared with need. Appropriate allocation of resources is essential if foster care agencies are to adequately meet the diverse and compelling needs of children in foster care.	UNIV WASHINGTON,ROBERT WOOD JOHNSON CLIN SCHOLARS PROGRAM,SEATTLE,WA; UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,SEATTLE,WA 98195; UNIV WASHINGTON,HARBORVIEW MED CTR,DEPT PEDIAT,SEATTLE,WA 98104	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Harborview Medical Center; University of Washington; University of Washington Seattle								BENEDICT MI, 1991, CHILD WELFARE, V70, P45; BRIGHT RA, 1989, J CLIN EPIDEMIOL, V42, P937, DOI 10.1016/0895-4356(89)90158-3; BUTLER JA, 1985, PEDIATRICS, V76, P495; CURTIS PA, 1993, CHILD WELFARE, V72, P533; DUGGER CW, 1991, NY TIMES        0908, pA17; FAMULARO R, 1992, J AM ACAD CHILD PSY, V31, P863, DOI 10.1097/00004583-199209000-00013; HALFON N, 1987, PEDIATRICS, V80, P183; HALFON N, 1992, PEDIATRICS, V89, P1238; HALFON N, 1992, PEDIATRICS, V89, P1230; HOCHSTADT NJ, 1987, CHILD ABUSE NEGLECT, V11, P53, DOI 10.1016/0145-2134(87)90033-0; JACOBS J, 1988, J CLIN EPIDEMIOL, V41, P215, DOI 10.1016/0895-4356(88)90124-2; JENKINS S, 1985, AM J ORTHOPSYCHIAT, V55, P267, DOI 10.1111/j.1939-0025.1985.tb03441.x; LEFKOWITZ DC, 1991, 14 DEP HLTH HUM SERV; Lewis Neil A., 1991, NEW YORK TIMES  0714, pA1; LOWRY MA, 1989, CHILDRENS RIGHTS PRO; MARCUS FF, 1989, NY TIMES        0109, pA15; Moffatt M E, 1985, Health Soc Work, V10, P129; PELTON LH, 1987, J SOC SOC WELFARE, V16, P37; Rosner B., 2010, FUNDAMENTALS BIOSTAT; SAUNDERS EJ, 1993, CHILD WELFARE, V72, P341; Schor E L, 1989, Pediatr Rev, V10, P209, DOI 10.1542/pir.10-7-209; SCHOR EL, 1981, CHILD WELFARE, V60, P313; SCHOR EL, 1982, PEDIATRICS, V69, P521; SHAH CP, 1974, CAN J PUBLIC HEALTH, V65, P34; SWIRE MR, 1978, CHILD WELFARE, V57, P563; SWIRE MR, 1977, CHILD WELFARE, V56, P635; TATARA T, 1993, 9 AM PUBL WELF ASS; TRUPIN E, 1988, WASHINGTON STATE CHI; WEINSTEIN J, 1990, CALIFORNIA W LAW REV, V26, P319; WHITE RB, 1987, CHILD WELFARE, V66, P387; ZILL N, 1990, HLTH OUR NATIONS CHI, V190, P1; 1991, STATE AM CHILDREN 19; 1987, PEDIATRICS, V79, P644; 1992, PEDIATRICS, V89, P681; 1988, STANDARDS HLTH CARE; 1992, NY TIMES        1213, pA48; 1991, COSTS LENGTHS STAY C	37	100	100	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 15	1994	271	23					1850	1855		10.1001/jama.271.23.1850	http://dx.doi.org/10.1001/jama.271.23.1850			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NP959	8196142				2023-01-03	WOS:A1994NP95900029
J	DEBUSK, RF; MILLER, NH; SUPERKO, HR; DENNIS, CA; THOMAS, RJ; LEW, HT; BERGER, WE; HELLER, RS; ROMPF, J; GEE, D; KRAEMER, HC; BANDURA, A; GHANDOUR, G; CLARK, M; SHAH, RV; FISHER, L; TAYLOR, CB				DEBUSK, RF; MILLER, NH; SUPERKO, HR; DENNIS, CA; THOMAS, RJ; LEW, HT; BERGER, WE; HELLER, RS; ROMPF, J; GEE, D; KRAEMER, HC; BANDURA, A; GHANDOUR, G; CLARK, M; SHAH, RV; FISHER, L; TAYLOR, CB			A CASE-MANAGEMENT SYSTEM FOR CORONARY RISK FACTOR MODIFICATION AFTER ACUTE MYOCARDIAL-INFARCTION	ANNALS OF INTERNAL MEDICINE			English	Article						MYOCARDIAL INFARCTION; RISK FACTORS; SMOKING CESSATION; HYPERLIPIDEMIA; EXERCISE THERAPY	ARTERY DISEASE; HEART-DISEASE; FOLLOW-UP; CHOLESTEROL; EXERCISE; THERAPY; INTERVENTION; MEN; HYPERCHOLESTEROLEMIA; PROGRESSION	Objective: To evaluate the efficacy of a physician-directed, nurse-managed, home-based case-management system for coronary risk factor modification. Design: Randomized clinical trial in which patients received a special intervention (n = 293) or usual medical Care (n = 292) during the first year after acute myocardial infarction. n Setting: 5 Kaiser Permanents Medical Centers in the San Francisco Bay area. Patients: 585 men and women aged 70 years or younger who were hospitalized for acute myocardial infarction. Intervention: In the hospital, specially trained nurses initiated interventions for smoking cessation, exercise training, and diet-drug therapy for hyperlipidemia. Intervention after discharge was implemented primarily by telephone and mail contact with patients in their homes. All medically eligible patients received exercise training; all smokers received the smoking cessation intervention; and all patients received dietary counseling and, if needed, lipid-lowering drug therapy. Outcome: Smoking prevalence and plasma low-density lipoprotein cholesterol (LDL) concentrations were measured 2 months alter infarction, and functional capacity was measured 6 months after infarction. Results: In the special intervention and usual care groups, the cotinine-confirmed smoking cessation rates were 70% and 53% (P = 0.03), plasma LDL cholesterol levels were 2.77 +/- 0.69 mmol/L and 3.41 +/- 0.90 mmol/L (107 +/- 30 mg/dL and 132 +/- 30 mg/dL) (P = 0.001), and functional capacities were 9.3 +/- 2.4 METS and 8.4 +/- 2.5 METS (P = 0.001), respectively. Conclusion: In a large health maintenance organization, a case-management system was considerably more effective than usual medical care for modification of coronary risk factors after myocardial infarction.	STANFORD UNIV, SCH MED, STANFORD, CA USA; KAISER PERMANENTE MED CARE PROGRAM, SANTA CLARA, CA USA; KAISER PERMANENTE MED CARE PROGRAM, REDWOOD CITY, CA USA; KAISER PERMANENTE MED CARE PROGRAM, HAYWARD, CA USA; KAISER PERMANENTE MED CARE PROGRAM, SAN JOSE, CA USA; KAISER PERMANENTE MED CARE PROGRAM, WALNUT CREEK, CA USA; DEBORAH HEART & LUNG INST, BROWNS MILLS, NJ USA; NORTHWESTERN UNIV, SCH MED, CHICAGO, IL USA; LAWRENCE BERKELEY LAB, BERKELEY, CA USA	Stanford University; Kaiser Permanente; Kaiser Permanente; Kaiser Permanente; Kaiser Permanente; Kaiser Permanente; Northwestern University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory				Superko, H. Robert/0000-0002-3542-0393; Thomas, Randal/0000-0003-1448-7182; Taylor, C. Barr/0000-0002-4564-6548	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R55HL038874, R01HL038874] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL38874] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHNVE S, 1989, J INTERN MED, V226, P297, DOI 10.1111/j.1365-2796.1989.tb01399.x; ALDERMAN EL, 1991, CIRCULATION S2, V84, P560; BANDURA A, 1986, SOCIAL FDN THOUGHT A, P393; Bandura A., 1991, SELF EFFICACY MECH P, P229, DOI DOI 10.4135/9781412952576.N182; BLAIR TP, 1988, ARCH INTERN MED, V148, P1046, DOI 10.1001/archinte.148.5.1046; BLANKENHORN DH, 1987, JAMA-J AM MED ASSOC, V257, P3233, DOI 10.1001/jama.257.23.3233; BRENSIKE JF, 1984, CIRCULATION, V69, P313, DOI 10.1161/01.CIR.69.2.313; BRESLOW L, 1990, HEALTH AFFAIR, V9, P6, DOI 10.1377/hlthaff.9.2.6; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; BURNS D, 1992, TOBACCO USE CALIFORN, P1; CAVENDER JB, 1992, J AM COLL CARDIOL, V20, P287, DOI 10.1016/0735-1097(92)90092-2; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; COHEN MV, 1991, CIRCULATION, V83, P1294, DOI 10.1161/01.CIR.83.4.1294; CONNOR SL, 1989, J AM DIET ASSOC, V89, P807; DEBUSK RF, 1979, AM J CARDIOL, V44, P1223, DOI 10.1016/0002-9149(79)90433-8; DEBUSK RF, 1983, CIRCULATION, V68, P245, DOI 10.1161/01.CIR.68.2.245; EFRON B, 1971, BIOMETRIKA, V58, P403, DOI 10.1093/biomet/58.3.403; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GOLDMAN L, 1992, CIRCULATION, V85, P1960, DOI 10.1161/01.CIR.85.5.1960; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; HODIS HN, 1992, MANAGEMENT ATHEROSCL, V3, P67; HOLME I, 1990, CIRCULATION, V82, P1916, DOI 10.1161/01.CIR.82.6.1916; HUNNINGHAKE DB, 1993, NEW ENGL J MED, V328, P1213, DOI 10.1056/NEJM199304293281701; MARTIN MJ, 1986, LANCET, V2, P933; MILLER NH, 1984, CIRCULATION, V70, P645, DOI 10.1161/01.CIR.70.4.645; MYERS GL, 1989, CLIN LAB MED, V9, P105, DOI 10.1016/S0272-2712(18)30645-0; ORNISH D, 1990, LANCET, V336, P129, DOI 10.1016/0140-6736(90)91656-U; RUSSELL ML, 1985, AM J MED, V78, P277, DOI 10.1016/0002-9343(85)90438-3; SCHULER G, 1992, CIRCULATION, V86, P1, DOI 10.1161/01.CIR.86.1.1; SUPERKO HR, 1988, AM HEART J, V116, P849, DOI 10.1016/0002-8703(88)90347-X; TAYLOR CB, 1990, ANN INTERN MED, V113, P118, DOI 10.7326/0003-4819-113-2-118; TAYLOR CB, 1988, AM COLLEGE SPORTS ME, P329; WASSON J, 1992, JAMA-J AM MED ASSOC, V267, P1788, DOI 10.1001/jama.267.13.1788; 1989, PHS DHHS898411 US DE, P11	34	557	561	2	18	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1994	120	9					721	729		10.7326/0003-4819-120-9-199405010-00001	http://dx.doi.org/10.7326/0003-4819-120-9-199405010-00001			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH251	8147544				2023-01-03	WOS:A1994NH25100001
J	LI, CY; WATKINS, JA; GLASS, J				LI, CY; WATKINS, JA; GLASS, J			THE H+-ATPASE FROM RETICULOCYTE ENDOSOMES RECONSTITUTED INTO LIPOSOMES ACTS AS AN IRON TRANSPORTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOCYTIC VESICLES; ADENOSINE-TRIPHOSPHATASE; TRANSFERRIN; MEMBRANE; SUBUNIT; MOBILIZATION; BINDING; F1	The H+-ATPase from reticulocyte endosomes was purified and reconstituted into liposomes, and protein-dependent iron transport was observed. Reconstitution of the H+-ATPase into liposomes was performed by sonicating a lipid mixture, with a composition similar to the reticulocyte plasma membrane, in a buffer containing ferric citrate. The nonencapsulated iron:citrate was removed by gel filtration and the proteoliposomes diluted into 1 mM FerroZine. Upon addition of ascorbate, an initial efflux of 2.9 +/- 0.3 x 10(-2) mu mol of iron/mg of ATPase/min and 56 +/- 7% of total internal Fe(II) was detected by formation of the Fe(II)-FerroZine complex with an absorbance at 562 nm or radioactivity of Fe-59(II)-FerroZine following separation using gel filtration. Both thiosulfate and ferrocyanide could substitute for ascorbate. Citrate or EGTA could substitute for FerroZine. The initial rate of Fe(II) efflux was decreased by 41 or 17% using 100 mu M of the cation channel inhibitor N,N'-dicyclohexylcarbodiimide or 70 mu M of the ATP hydrolysis inhibitor N-ethylmaleimide, respectively, but was unaffected by the presence of ATP. The amount of iron transported was decreased 51 or 39% by 100 mu M N,N'-dicyclohexylcarbodiimide or 70 mu M of the ATPase inhibitor 7-chloro-4-nitrobenz-2-oxa-1,3-dazole. The amount of Fe(III) transport was 80% lower than Fe(II) when reductants were not present internally or externally although the apparent rate constants were identical when ascorbate was externally present. These results suggest that this vacuolar H+-ATPase may transport iron.	LOUISIANA STATE UNIV,CTR MED,CTR EXCELLENCE CANC RES TREATMENT & EDUC,DEPT MED,DIV HEMATOL ONCOL,SHREVEPORT,LA 71130	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK037866, R01DK037866] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-37866] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAI H, 1987, BIOCHEMISTRY-US, V26, P6632, DOI 10.1021/bi00395a011; CHEN JW, 1984, BIOCHIM BIOPHYS ACTA, V777, P151, DOI 10.1016/0005-2736(84)90508-X; CHOE HR, 1987, BLOOD, V70, P1035; COWART RE, 1993, ANAL BIOCHEM, V211, P151, DOI 10.1006/abio.1993.1246; EGYED A, 1988, BRIT J HAEMATOL, V68, P483, DOI 10.1111/j.1365-2141.1988.tb04241.x; FENG Y, 1992, J BIOL CHEM, V267, P5817; HAMAZAKI S, 1992, EXP HEMATOL, V20, P436; HANADA H, 1991, BIOCHEM BIOPH RES CO, V176, P1062, DOI 10.1016/0006-291X(91)90391-J; INMAN RS, 1993, J BIOL CHEM, V268, P8521; KOHLBRENNER WE, 1982, J BIOL CHEM, V257, P3441; LI CY, 1993, FASEB J, V7, pA817; LI CY, 1993, BIOPHYS J, V64, pA335; LI CY, 1991, FASEB J, V5, pA749; LI CY, 1991, BLOOD, V78, pA87; LIPPE G, 1991, BIOCHEM BIOPH RES CO, V181, P764, DOI 10.1016/0006-291X(91)91256-C; MORGAN EH, 1988, BIOCHIM BIOPHYS ACTA, V943, P428, DOI 10.1016/0005-2736(88)90374-4; NUMA MS, 1991, EUR J CELL BIOL, V56, P19; NUNEZ MT, 1990, J BIOL CHEM, V265, P6688; SENIOR AE, 1980, J BIOL CHEM, V255, P7211; SIMPSON RJ, 1987, BIOCHIM BIOPHYS ACTA, V898, P187, DOI 10.1016/0005-2736(87)90037-X; STOOKEY LL, 1970, ANAL CHEM, V42, P779, DOI 10.1021/ac60289a016; SUUN SZ, 1987, J BIOL CHEM, V262, P14790; THORSTENSEN K, 1988, J BIOL CHEM, V263, P16837; WATKINS JA, 1992, BIOCHEMISTRY-US, V31, P5820, DOI 10.1021/bi00140a018; WHITE MD, 1976, BIOCHIM BIOPHYS ACTA, V436, P567, DOI 10.1016/0005-2736(76)90441-7	25	38	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10242	10246						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144605				2023-01-03	WOS:A1994NF01700014
J	LEFRERE, JJ; MARIOTTI, M; THAUVIN, M				LEFRERE, JJ; MARIOTTI, M; THAUVIN, M			B19 PARVOVIRUS DNA IN SOLVENT DETERGENT-TREATED ANTI-HEMOPHILIA CONCENTRATES	LANCET			English	Note							INFECTION	A transfusional B19 parvovirus infection may have severe consequences in immunocompromised hosts. The presence of B19 DNA was investigated with a polymerase chain reaction (PCR) assay in 30 batches of solvent/detergent-treated clotting factor concentrates (12 batches of factor VIII, 16 batches of factor IX, 1 batch of factor VII, and 1 batch of PPSB). B19 DNA was detected in 6 (20%) batches, including 3 factor VIII and 3 factor IX concentrates. Because of the frequency of B19 DNA in batches of clotting factors, measures to prevent transfusional risk of B19 infection via these blood products are justified, especially in recipients immunocompromised by HIV infection.			LEFRERE, JJ (corresponding author), HOP ST ANTOINE,INST NATL TRANSFUS SANGUINE,53 BLVD DIDEROT,F-75571 PARIS 12,FRANCE.							AZZI A, 1992, AM J HEMATOL, V39, P228, DOI 10.1002/ajh.2830390315; CORSI OB, 1988, J MED VIROL, V25, P165, DOI 10.1002/jmv.1890250206; LEFRERE JJ, 1992, BRIT J HAEMATOL, V82, P467, DOI 10.1111/j.1365-2141.1992.tb06446.x; LEFRERE JJ, 1986, BRIT J HAEMATOL, V62, P653, DOI 10.1111/j.1365-2141.1986.tb04088.x; MCOMISH F, 1993, J CLIN MICROBIOL, V31, P323, DOI 10.1128/JCM.31.2.323-328.1993; MORFINI M, 1992, AM J HEMATOL, V39, P149, DOI 10.1002/ajh.2830390217; MORTIMER PP, 1983, LANCET, V2, P482; NAIDES SJ, 1993, J INFECT DIS, V168, P101, DOI 10.1093/infdis/168.1.101; SOL N, 1993, J GEN VIROL, V74, P2011, DOI 10.1099/0022-1317-74-9-2011; ZAKRZEWSKA K, 1992, BRIT J HAEMATOL, V81, P407, DOI 10.1111/j.1365-2141.1992.tb08248.x	10	81	82	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 22	1994	343	8891					211	212		10.1016/S0140-6736(94)90993-8	http://dx.doi.org/10.1016/S0140-6736(94)90993-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT332	7904670				2023-01-03	WOS:A1994MT33200012
J	BYRNE, C; VERNON, P; COHEN, JJ				BYRNE, C; VERNON, P; COHEN, JJ			EFFECT OF AGE AND DIAGNOSIS ON SURVIVAL OF OLDER PATIENTS BEGINNING CHRONIC DIALYSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To assess the survival of elderly patients in the United States beginning chronic dialysis for end-stage renal disease caused by diabetes mellitus, hypertension, glomerulonephritis, polycystic kidney disease, and other causes. Design.-A secondary analysis of data obtained from the Health Care Financing Administration. Patients.-All Medicare end-stage renal disease patients 55 years of age or older (n=95 394) who began chronic dialysis treatment in the US between 1982 and 1987. Main Outcome Measures.-The l-, 3-, and 5-year survival rates for each of six age strata and, within each strata, for each of the four most frequent causes of renal failure. Results.-Survival rates of dialysis patients fell precipitously, and much more rapidly for the study group than for the general population, as a function of advancing age. Older patients with diabetic nephropathy fared particularly badly, such that no patients with diabetic nephropathy aged 85 years or more survived 5 years. Conclusions.-Mortality rates of patients older than 55 years beginning chronic dialysis treatment increased dramatically as age at initiation of dialysis increased. Clinically meaningful survival data should prove useful to persons making decisions about the initiation of chronic dialysis.	SUNY STONY BROOK,SCH MED,STONY BROOK,NY 11794; NEW YORK STATE DEPT HLTH,STONY BROOK,NY	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook								BLAGG CR, 1991, AM J KIDNEY DIS, V17, P458, DOI 10.1016/S0272-6386(12)80641-X; Callahan D., 1987, SETTING LIMITS MED G; CALLAHAN D, 1990, WHAT KIND LIFE LIMIT; HELD PJ, 1991, JAMA-J AM MED ASSOC, V265, P871, DOI 10.1001/jama.265.7.871; INGLEHART JK, 1993, NEW ENGL J MED, V328, P366; LO B, 1986, ARCH INTERN MED, V146, P1613, DOI 10.1001/archinte.146.8.1613; LOWRANCE DC, 1993, AM J KIDNEY DIS, V21, P679; LOWRIE EG, 1990, AM J KIDNEY DIS, V15, P458, DOI 10.1016/S0272-6386(12)70364-5; RETTIG RA, 1976, LAW CONTEMP PROBL, V40, P196, DOI 10.2307/1191314; RUBIN R, 1991, AM KIDNEY FUND NEWSL, V7, P1; RUBIN R, 1991, AM KIDNEY FUND NEWSL, V7, P3; SLEPIAN F, 1991, AM KIDNEY FUND NEWSL, V7, P1; 1988, PHS881104 US DEP HLT; 1993, USRDS1993 NIH NAT I; 1989, SAS SAT USERS GUIDE, V2; 1991, MONOGRAPH SERIES, V1	16	67	68	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	1994	271	1					34	36						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN725	8258884				2023-01-03	WOS:A1994MN72500027
J	BOWLING, TE; RAIMUNDO, AH; GRIMBLE, GK; SILK, DBA				BOWLING, TE; RAIMUNDO, AH; GRIMBLE, GK; SILK, DBA			REVERSAL BY SHORT-CHAIN FATTY-ACIDS OF COLONIC FLUID SECRETION INDUCED BY ENTERAL FEEDING	LANCET			English	Article							ABSORPTION; DIET; NUTRITION; INTESTINE; DIARRHEA; RAT	Diarrhoea complicates enteral feeding in up to 25% of patients. In-vivo perfusion studies in healthy subjects have shown secretion of salt and water in the ascending colon in response to enteral feeding. This study investigated the effect of short-chain fatty acids (SCFA) on this secretory response. Six healthy volunteers underwent segmental in-vivo colonic perfusion. First, baseline fasting colonic water and electrolyte movement was established, then a standard polymeric enteral diet was infused into the stomach while the colon was perfused with either a control electrolyte solution or a test solution containing SCFA. The electrolyte concentrations and osmolality of the two perfusates were identical. In the fasting state water was absorbed throughout the colon. During the control infusion there was significant (p < 0.05) secretion of water in the ascending colon (median rate 1.0 mL per min [95% CI 2.8 mL per min secretion to 0.8 mL per min absorption]). During the SCFA infusion the secretion was significantly reversed (p < 0.05) and there was net absorption (1.6 [0.8-3.7] mL per min). In the distal colon water absorption was significantly greater during the control infusion than during fasting (3.7 [2.5-4.6] vs 1.3 [0.3-2.2] mL per min); during the test infusion this absorption persisted (2.8 [1.3-3.6] mL per min). Movement of sodium, chloride, and potassium ions was similar to that of water in all stages of the study. Bicarbonate movement did not significantly change at any stage. Infusion of SCFA directly into the caecum reverses the fluid secretion seen in the ascending colon during enteral feeding. This finding could have implications for the management of diarrhoea related to enteral feeding.			SILK, DBA (corresponding author), CENT MIDDLESEX HOSP TRUST,DEPT GASTROENTEROL & NUTR,LONDON NW10 7NS,ENGLAND.							BINDER HJ, 1989, GASTROENTEROLOGY, V96, P989, DOI 10.1016/0016-5085(89)91614-4; BOWLING TE, 1993, EUR J GASTROEN HEPAT, V5, P809; BOWLING TE, 1993, GUT               S1, V34, pA54; BOWLING TE, 1993, CLIN NUTR S2, V12, P23; CUMMINGS JH, 1984, SCAND J GASTROENTERO, V19, P89; CUMMINGS JH, 1987, GUT, V28, P1221, DOI 10.1136/gut.28.10.1221; DEVROEDE GJ, 1969, GASTROENTEROLOGY, V56, P92; DOBB GJ, 1986, INTENS CARE MED, V12, P113; FORD EG, 1987, J PEDIATR SURG, V22, P597, DOI 10.1016/S0022-3468(87)80106-9; JACOBS LR, 1983, AM J CLIN NUTR, V37, P954, DOI 10.1093/ajcn/37.6.954; JONES BJM, 1983, GUT, V24, P78, DOI 10.1136/gut.24.1.78; KEOHANE PP, 1984, BMJ-BRIT MED J, V288, P678, DOI 10.1136/bmj.288.6418.678; Kritchevsky D., 1986, DIETARY FIBER, P131, DOI DOI 10.1007/978-1-4613-2111-8_10; LEVITAN R, 1962, J CLIN INVEST, V41, P1754, DOI 10.1172/JCI104634; MACFARLANE GT, 1992, J APPL BACTERIOL, V72, P57, DOI 10.1111/j.1365-2672.1992.tb05187.x; OKEEFE SJD, 1984, GUT, V25, P942, DOI 10.1136/gut.25.9.942; PHILLIPS SF, 1973, J LAB CLIN MED, V81, P733; RAIMUNDO AH, 1988, GUT, V29, pA1469; RAIMUNDO AH, 1990, GUT, V31, pA1195; ROEDIGER WEW, 1980, GUT, V21, P793, DOI 10.1136/gut.21.9.793; RUPPIN H, 1980, GASTROENTEROLOGY, V78, P1500; SILK DBA, 1987, CLIN NUTR, V6, P61, DOI 10.1016/0261-5614(87)90023-9; WAITZBERG D, 1988, CLIN NUTR S1, V7, P58; WHALEN GE, 1966, GASTROENTEROLOGY, V51, P975	24	97	99	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 20	1993	342	8882					1266	1268		10.1016/0140-6736(93)92360-6	http://dx.doi.org/10.1016/0140-6736(93)92360-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH566	7901584				2023-01-03	WOS:A1993MH56600010
J	OSHAUGHNESSY, JA; COWAN, KH				OSHAUGHNESSY, JA; COWAN, KH			DOSE-INTENSIVE THERAPY FOR BREAST-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Discussion							COLONY-STIMULATING FACTOR; BONE-MARROW TRANSPLANTATION; ADJUVANT CHEMOTHERAPY; PROGENITOR CELLS; SOLID TUMORS; STAGE-II; PHASE-II; DOXORUBICIN; CYCLOPHOSPHAMIDE; CARBOPLATIN				OSHAUGHNESSY, JA (corresponding author), NCI,MED BRANCH,MED BREAST CANC SECT,BLDG 10,ROOM 12N226,BETHESDA,MD 20892, USA.							ABRAMS J, 1991, P AM SOC CLIN ONCOL, V10, pA3247; ANG PT, 1989, J CLIN ONCOL, V7, P1677, DOI 10.1200/JCO.1989.7.11.1677; ANTMAN K, 1992, J CLIN ONCOL, V10, P102, DOI 10.1200/JCO.1992.10.1.102; ANTMAN KH, 1992, HIGH DOSE CANCER THE, P701; BASTHOLT L, 1992, P AM SOC CLIN ONCOL, V11, pA51; BRONCHUD MH, 1989, BRIT J CANCER, V60, P121, DOI 10.1038/bjc.1989.234; BUDMAN DR, 1992, P AN M AM SOC CLIN, V11, pA29; CARMOPEREIRA J, 1987, BRIT J CANCER, V56, P471, DOI 10.1038/bjc.1987.226; CARMOPEREIRA J, 1992, P AN M AM SOC CLIN, V11, pA121; CHAUDHARY PM, 1991, CELL, V66, P85, DOI 10.1016/0092-8674(91)90141-K; DEMETRI G, 1992, P ASCO, V11, pA255; DEMETRI GD, 1992, P ASCO, V11, pA370; DUNPHY FR, 1992, J NATL CANCER I, V84, P128, DOI 10.1093/jnci/84.2.128; EDDY DM, 1992, J CLIN ONCOL, V10, P657, DOI 10.1200/JCO.1992.10.4.657; ELIAS AD, 1992, BLOOD, V79, P3036; FREI E, 1989, J CLIN ONCOL, V7, P515, DOI 10.1200/JCO.1989.7.4.515; GALSKI H, 1989, MOL CELL BIOL, V9, P4357, DOI 10.1128/MCB.9.10.4357; GORDON MS, 1992, BLOOD, V80, P302; HOEKMAN K, 1991, J NATL CANCER I, V83, P1546, DOI 10.1093/jnci/83.21.1546; HRYNIUK W, 1986, J CLIN ONCOL, V4, P1162, DOI 10.1200/JCO.1986.4.8.1162; HRYNIUK W, 1984, J CLIN ONCOL, V2, P1281, DOI 10.1200/JCO.1984.2.11.1281; HUDIS C, 1992, P AN M AM SOC CLIN, V11, pA48; JONES RB, 1987, J CLIN ONCOL, V5, P172, DOI 10.1200/JCO.1987.5.2.172; LIND MJ, 1992, P AM ASSOC CANC RES, V33, pA1447; LUIKART SD, 1991, P AN M AM SOC CLIN, V10, P242; NEIDHART JA, 1991, BREAST CANCER RES S, V20, P515; PETERS WP, 1993, J CLIN ONCOL, V11, P1132, DOI 10.1200/JCO.1993.11.6.1132; PETERS WP, 1992, ANN ONCOL         S1, V3, P164; PETERS WP, 1990, P ASCO, V9, pA31; SAVARESE DMF, 1993, J CLIN ONCOL, V11, P1795, DOI 10.1200/JCO.1993.11.9.1795; SORRENTINO BP, 1992, SCIENCE, V257, P99, DOI 10.1126/science.1352414; STEWARD WP, 1993, J CLIN ONCOL, V11, P15, DOI 10.1200/JCO.1993.11.1.15; SUNDERLAND M, 1991, Breast Cancer Research and Treatment, V19, P158; SWAIN S, 1992, P AM ASSOC CANC RES, V33, pA1533; TANNOCK IF, 1988, J CLIN ONCOL, V6, P1377, DOI 10.1200/JCO.1988.6.9.1377; TJULANDIN S, 1992, P AN M AM SOC CLIN, V11, pA125; VENKURIN M, 1992, P AM SOC CLIN ONCOL, V11, pA36; VERFAILLIE C, 1990, J EXP MED, V172, P509, DOI 10.1084/jem.172.2.509; WATANAKE T, 1992, P AM SOC CLIN ONCOL, V11, pA178; WHEELER RH, 1982, CANCER TREAT REP, V66, P493; WILLIAMS SF, 1989, J CLIN ONCOL, V7, P1824, DOI 10.1200/JCO.1989.7.12.1824; WILSON WH, 1992, J CLIN ONCOL, V10, P1712, DOI 10.1200/JCO.1992.10.11.1712	42	6	6	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	1993	270	17					2089	2092						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD882	8411576				2023-01-03	WOS:A1993MD88200030
J	CUJEC, B; POLASEK, P; MAYERS, I; JOHNSON, D				CUJEC, B; POLASEK, P; MAYERS, I; JOHNSON, D			POSITIVE END-EXPIRATORY PRESSURE INCREASES THE RIGHT-TO-LEFT SHUNT IN MECHANICALLY VENTILATED PATIENTS WITH PATENT FORAMEN OVALE	ANNALS OF INTERNAL MEDICINE			English	Article						POSITIVE-PRESSURE RESPIRATION; HEART SEPTAL DEFECTS, ATRIAL; RESPIRATORY INSUFFICIENCY; RESPIRATION, ARTIFICIAL; ASTERISK-SHUNTING, RIGHT TO LEFT	RIGHT VENTRICULAR INFARCTION; REDUCE INTRAPULMONARY SHUNT; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; CONTRAST ECHOCARDIOGRAPHY; CARDIAC-OUTPUT; SITTING POSITION; PULMONARY-EDEMA; HYPOXEMIA; PEEP; PERFORMANCE	Objective: To determine the effect of the presence of a patent foramen ovale on the right-to-left shunt in patients with respiratory failure who receive positive end-expiratory pressure (PEEP). Design: Convenience sample with randomized application of PEEP. Setting: General intensive care unit of a university teaching hospital. Patients: A total of 46 mechanically ventilated patients with respiratory failure requiring an inspired oxygen concentration of at least 50% and a PEEP of at least 5 cm of H2O. Intervention: Randomized application of PEEP (0 and 10 cm of H2O). Measurements: A patent foramen ovale was detected by saline contrast transesophageal echocardiography. The alveolar-to-arterial oxygen difference and the right-to-left shunt were calculated from arterial and venous blood gas sampling. Results: In patients without a patent foramen ovale (n =39), the alveolar-to-arterial oxygen difference and the shunt fraction decreased (-50 mm Hg [95% CI, -21 to -67] and -0.05 [CI, -0.03 to -0.07], respectively) after adding PEEP (10 cm of H2O). In patients with a patent foramen ovale (n = 7), minimal changes were noted in the alveolar-to-arterial oxygen difference (4 mm Hg, P > 0.2), but the shunt fraction increased (0.05, CI, 0 to 0.09). Adding PEEP (10 cm of H2O) increased the shunt fraction in 6 of 7 (86%) patients with a patent foramen ovale, whereas the shunt increased in only 7 of 39 (18%) patients without a patent foramen ovale (P < 0.007). Conclusions: A patent foramen ovale was found in 7 of 46 patients (15%; CI, 6% to 29%) with acute respiratory failure. This condition is a common cause of lack of improvement in oxygenation with the addition of PEEP in the mechanically ventilated patient. In patients with a patent foramen ovale, the right-to-left shunt is usually increased by using PEEP.			CUJEC, B (corresponding author), UNIV SASKATCHEWAN, ROYAL UNIV HOSP, DIV CARDIOL, SASKATOON S7N 0W0, SASKATCHEWAN, CANADA.							BALDWIN RT, 1991, ANN THORAC SURG, V52, P865, DOI 10.1016/0003-4975(91)91230-S; BERK JL, 1982, HDB CRITICAL CARE, P87; BLACK S, 1990, ANESTHESIOLOGY, V72, P436, DOI 10.1097/00000542-199003000-00007; BONE RC, 1989, CHEST, V96, P114, DOI 10.1378/chest.96.1.114; BRANDT L, 1990, ADV EXP MED BIOL, V277, P489; BURNETT RW, 1974, CLIN CHEM, V20, P1499; CLEMENTS FM, 1990, BRIT J ANAESTH, V64, P331, DOI 10.1093/bja/64.3.331; COX D, 1991, AM J MED, V91, P653, DOI 10.1016/0002-9343(91)90220-R; DANTZKER DR, 1980, CHEST, V77, P636, DOI 10.1378/chest.77.5.636; DORINSKY PM, 1983, CHEST, V84, P210, DOI 10.1378/chest.84.2.210; FESSLER HE, 1992, AM REV RESPIR DIS, V146, P4, DOI 10.1164/ajrccm/146.1.4; GOLDMAN AP, 1991, AM HEART J, V121, P1224, DOI 10.1016/0002-8703(91)90685-B; GUDIPATI CV, 1991, AM HEART J, V121, P919, DOI 10.1016/0002-8703(91)90212-Z; GUGGIARI M, 1988, ANESTH ANALG, V67, P192; HAGEN PT, 1984, MAYO CLIN PROC, V59, P17, DOI 10.1016/S0025-6196(12)60336-X; HUGOD C, 1979, ARCH ENVIRON HEALTH, V34, P12, DOI 10.1080/00039896.1979.10667360; JARDIN F, 1981, NEW ENGL J MED, V304, P387, DOI 10.1056/NEJM198102123040703; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KONSTADT SN, 1991, ANESTHESIOLOGY, V74, P212, DOI 10.1097/00000542-199102000-00003; LANGHOLZ D, 1991, J AM COLL CARDIOL, V18, P1112, DOI 10.1016/0735-1097(91)90775-5; LEJEUNE P, 1991, J APPL PHYSIOL, V70, P1867, DOI 10.1152/jappl.1991.70.4.1867; LEMAIRE F, 1982, ANESTHESIOLOGY, V57, P233, DOI 10.1097/00000542-198209000-00016; LEVINE BD, 1991, ANN INTERN MED, V114, P569, DOI 10.7326/0003-4819-114-7-569; LIGHT RB, 1986, AM REV RESPIR DIS, V134, P520; LYNCH JJ, 1984, AM J CARDIOL, V53, P1478, DOI 10.1016/S0002-9149(84)91617-5; LYNCH JP, 1979, J APPL PHYSIOL, V46, P315, DOI 10.1152/jappl.1979.46.2.315; MALO J, 1984, J APPL PHYSIOL, V57, P1002, DOI 10.1152/jappl.1984.57.4.1002; MATSUMOTO M, 1980, AM J CARDIOL, V46, P95, DOI 10.1016/0002-9149(80)90611-6; MAYERS I, 1989, RESP PHYSIOL, V75, P247, DOI 10.1016/0034-5687(89)90068-6; MINK SN, 1981, J APPL PHYSIOL, V50, P517, DOI 10.1152/jappl.1981.50.3.517; MOORTHY SS, 1974, ANESTHESIOLOGY, V41, P405, DOI 10.1097/00000542-197410000-00022; Movsowitz C, 1992, J Am Soc Echocardiogr, V5, P259; PICK RA, 1982, CHEST, V82, P345, DOI 10.1378/chest.82.3.345; RAVENSCRAFT SA, 1992, CRIT CARE MED, V20, P434, DOI 10.1097/00003246-199203000-00023; ROHLF FJ, 1981, STATISTICAL TABLES, P81; ROSSAINT R, 1993, NEW ENGL J MED, V328, P399, DOI 10.1056/NEJM199302113280605; SCHARF SM, 1982, J APPL PHYSIOL, V52, P254, DOI 10.1152/jappl.1982.52.1.254; SEWARD JB, 1990, MAYO CLIN PROC, V65, P1193, DOI 10.1016/S0025-6196(12)62744-X; SIOSTRZONEK P, 1992, J AM COLL CARDIOL, V19, P1192, DOI 10.1016/0735-1097(92)90323-F; SIOSTRZONEK P, 1991, AM J CARDIOL, V68, P1247, DOI 10.1016/0002-9149(91)90206-Z; STETZ CW, 1982, AM REV RESPIR DIS, V126, P1001; TAHVANAINEN J, 1982, CRIT CARE MED, V10, P758, DOI 10.1097/00003246-198211000-00012; TEICHHOLZ LE, 1976, AM J CARDIOL, V37, P7, DOI 10.1016/0002-9149(76)90491-4; THOMPSON RC, 1991, MAYO CLIN PROC, V66, P391, DOI 10.1016/S0025-6196(12)60663-6	44	63	64	2	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1993	119	9					887	894		10.7326/0003-4819-119-9-199311010-00004	http://dx.doi.org/10.7326/0003-4819-119-9-199311010-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD711	8215000				2023-01-03	WOS:A1993MD71100004
J	FELSON, DT; ZHANG, YQ; HANNAN, MT; KIEL, DP; WILSON, PWF; ANDERSON, JJ				FELSON, DT; ZHANG, YQ; HANNAN, MT; KIEL, DP; WILSON, PWF; ANDERSON, JJ			THE EFFECT OF POSTMENOPAUSAL ESTROGEN THERAPY ON BONE-DENSITY IN ELDERLY WOMEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HIP FRACTURE; CIGARETTE-SMOKING; OSTEOPOROSIS; RISK; MENOPAUSE; CALCIUM	Background. Estrogen therapy prevents bone loss in postmenopausal women who take it early in the postmenopausal period. The risk of fracture is highest much later in life, however. We studied whether bone mass in elderly women was affected by earlier estrogen use and how long women needed to take estrogen for it to have a beneficial effect on bone density later in life. Methods. In 1988 and 1989, we measured bone mineral density at the femur, spine, shaft of the radius, and ultradistal radius in 670 white women in the Framingham Study cohort (mean age, 76 years; range, 68 to 96). These women had been followed prospectively through menopause and had been asked repeatedly about estrogen therapy. After excluding women who began taking estrogen after a fracture, we investigated whether postmenopausal estrogen therapy affected bone density; in these analyses we adjusted for age, weight, height, cigarette smoking, physical activity, and age at menopause. Results. A total of 212 women (31.6 percent) had received estrogen therapy (mean estimated duration of treatment, 5 years). Only women who had taken estrogen for 7 to 9 years or for 10 or more years had significantly higher bone mineral density than women who had not taken estrogen (7 to 9 years of treatment, P<0.05 at sites in the femur and the spine; greater-than-or-equal-to 10 years, P<0.05 at all sites except the spine). In the women less than 75 years of age who had taken estrogen for seven or more years, the bone density was, averaging all sites, 11.2 percent greater than in women who had never received estrogen. Among women 75 years of age and older in whom the duration of therapy was comparable, bone density was only 3.2 percent higher than in women who had never taken estrogen. Conclusions. For long-term preservation of bone mineral density, women should take estrogen for at least seven years after menopause. Even this duration of therapy may have little residual effect on bone density among women 75 years of age and older, who have the highest risk of fracture.	HEBREW REHABIL CTR AGED, BOSTON, MA USA; BOSTON CITY HOSP, DEPT MED, BOSTON, MA 02118 USA; UNIV HOSP BOSTON, DEPT MED, BOSTON, MA 02118 USA; FRAMINGHAM STUDY, FRAMINGHAM, MA USA	Boston Medical Center	FELSON, DT (corresponding author), BOSTON UNIV, SCH MED, CTR ARTHRITIS, 80 E CONCORD ST, A203, BOSTON, MA 02118 USA.		Wilson, Peter W.F./J-2455-2016	Hannan, Marian/0000-0002-9586-6928; Felson, David/0000-0002-2668-2447; Kiel, Douglas/0000-0001-8474-0310; Zhang, Yuqing/0000-0001-7954-1149	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020613] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG009300] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR20613] Funding Source: Medline; NIA NIH HHS [R01AG09300] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARZEL US, 1988, AM J MED, V85, P847; BENGNER U, 1988, CLIN ORTHOP RELAT R, V231, P179; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; ETTINGER B, 1985, ANN INTERN MED, V102, P319, DOI 10.7326/0003-4819-102-3-319; FARMER ME, 1984, AM J PUBLIC HEALTH, V74, P1374, DOI 10.2105/AJPH.74.12.1374; HANNAN MT, 1992, J BONE MINER RES, V7, P547; HEANEY RP, 1990, BONE MINER, V11, P67, DOI 10.1016/0169-6009(90)90016-9; HUTCHINSON TA, 1979, LANCET, V2, P705; JENSEN GF, 1982, CLIN ENDOCRINOL, V16, P515, DOI 10.1111/j.1365-2265.1982.tb02769.x; JENSEN J, 1985, NEW ENGL J MED, V313, P973, DOI 10.1056/NEJM198510173131602; JENSEN JS, 1979, ACTA ORTHOP SCAND, V50, P161, DOI 10.3109/17453677908989751; JOHNSON RE, 1981, AM J PUBLIC HEALTH, V71, P138, DOI 10.2105/AJPH.71.2.138; KANIS JA, 1992, BRIT MED J, V305, P1124, DOI 10.1136/bmj.305.6862.1124; KANNEL WB, 1979, ARCH INTERN MED, V139, P857, DOI 10.1001/archinte.139.8.857; KEY TJA, 1991, J STEROID BIOCHEM, V39, P529, DOI 10.1016/0960-0760(91)90247-3; KIEL DP, 1992, ANN INTERN MED, V116, P716, DOI 10.7326/0003-4819-116-9-716; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; LINDSAY R, 1991, BAILLIERE CLIN OB GY, V5, P837, DOI 10.1016/S0950-3552(05)80291-3; MELTON LJ, 1987, CALCIFIED TISSUE INT, V41, P57; MELTON LJ, 1989, AM J EPIDEMIOL, V129, P1000, DOI 10.1093/oxfordjournals.aje.a115204; MICHNOVICZ JJ, 1986, NEW ENGL J MED, V315, P1305, DOI 10.1056/NEJM198611203152101; NORDIN BEC, 1990, J CLIN ENDOCR METAB, V70, P83, DOI 10.1210/jcem-70-1-83; Paganini-Hill A, 1991, Epidemiology, V2, P16; PAGANINIHILL A, 1981, ANN INTERN MED, V95, P28, DOI 10.7326/0003-4819-95-1-28; PETITTI DB, 1989, CLIN ORTHOP RELAT R, P150; SERNBO I, 1988, ACTA ORTHOP SCAND, V59, P382, DOI 10.3109/17453678809149386; WEISS NS, 1980, NEW ENGL J MED, V303, P1195, DOI 10.1056/NEJM198011203032102	27	520	531	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 14	1993	329	16					1141	1146		10.1056/NEJM199310143291601	http://dx.doi.org/10.1056/NEJM199310143291601			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA667	8377776				2023-01-03	WOS:A1993MA66700001
J	HELLINGER, FJ				HELLINGER, FJ			THE LIFETIME COST OF TREATING A PERSON WITH HIV	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICAL-CARE COSTS; AIDS; EXPERIENCE; FORECASTS	Objective.-To estimate the cost (total charges for services) of medical care for persons with human immunodeficiency virus (HIV) from the time of infection until death. Design and Setting.-Data from the AIDS (acquired immunodeficiency syndrome) Cost and Service Utilization Survey were used. Patients.-Data from interviews conducted during the spring and early summer of 1992 with 1164 respondents with HIV were analyzed. The respondents were recruited at 26 sites (hospitals, clinics, and physicians' offices) in 10 cities. Billing data from a survey of providers also were used. Outcome Measures.-Estimates of the mean occupancy time in each of four disease stages were obtained from the San Francisco Men's Health Study. These estimates were multiplied by the monthly cost in each stage and summed to derive a synthetic estimate of the lifetime medical care costs of treating a person with HIV. Results.-It is estimated herein that the lifetime cost of treating a person with HIV from the time of infection until death is approximately $119 000. The estimated cost of care from HIV infection until the development of AIDS is $50 000, while the estimated cost from Al DS development until death is approximately $69 000. These estimates define upper bounds because they assume persons receive treatment continuously from the moment of infection until death. Conclusions.-This study found that the cost of treating a person with AIDS, which has risen rapidly in the past, has fallen as a result of a reduction in the use of inpatient hospital services.			HELLINGER, FJ (corresponding author), US PHS,AGCY HLTH CARE POLICY & RES,CTR GEN HLTH SERV EXTRAMURAL RES,ROCKVILLE,MD 20852, USA.							ANDRULIS DP, 1987, JAMA-J AM MED ASSOC, V258, P1343; ANDRULIS DP, 1989, JAMA-J AM MED ASSOC, V262, P784, DOI 10.1001/jama.262.6.784; BACCHETTI P, 1989, NATURE, V338, P251, DOI 10.1038/338251a0; BARTLETT JG, 1992, 1992 1993 RECOMMENDA; BENNETT CL, 1992, J ACQ IMMUN DEF SYND, V5, P1; BENNETT CL, 1991, J ACQ IMMUN DEF SYND, V4, P197; EISENHANDLER J, 1992, AIDS UPDATE; GREEN J, 1990, JAMA-J AM MED ASSOC, V264, P1261, DOI 10.1001/jama.264.10.1261; HELLINGER FJ, 1992, INQUIRY-J HEALTH CAR, V29, P356; HELLINGER FJ, 1991, INQUIRY-J HEALTH CAR, V28, P213; HELLINGER FJ, 1990, PUBLIC HEALTH REP, V105, P1; ROTHENBERG R, 1987, NEW ENGL J MED, V317, P1297, DOI 10.1056/NEJM198711193172101; SATTEN GA, 1992, 8TH INT C AIDS AMST; SCITOVSKY AA, 1989, MILBANK Q, V67, P318, DOI 10.2307/3350143; STONE VE, 1992, JAMA-J AM MED ASSOC, V268, P2655, DOI 10.1001/jama.268.19.2655; 1992, DISTRICT COLUMBIA CO; 1992, AIDS NEW YORK STATE; 1990, AIDS NEW YORK STATE	18	241	243	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 28	1993	270	4					474	478		10.1001/jama.270.4.474	http://dx.doi.org/10.1001/jama.270.4.474			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LN426	8320787				2023-01-03	WOS:A1993LN42600027
J	DOYAL, L; WILSHER, D				DOYAL, L; WILSHER, D			WITHHOLDING CARDIOPULMONARY-RESUSCITATION - PROPOSALS FOR FORMAL GUIDELINES	BRITISH MEDICAL JOURNAL			English	Article							DECISIONS; SURVIVAL; ORDERS; ETHICS; DNR	Working with members of the Royal London Trust and its medical council, Len Doyal and Daniel Wilsher have composed a set of guidelines governing the making of decisions to withhold resuscitation from patients. The guidelines describe the procedures that should be followed when giving orders for non-resuscitation and the clinical, legal, and moral criteria that should be satisfied before such orders arc issued. The authors hope that these guidelines will be of help to those responsible for the creation of hospitals' policies for non-resuscitation.	ST BARTHOLOMEWS HOSP,COLL MED,JOINT DEPT HUMAN SCI & MED ETH,LONDON E1 2AD,ENGLAND	University of London; Queen Mary University London	DOYAL, L (corresponding author), UNIV LONDON LONDON HOSP,COLL MED,JOINT DEPT HUMAN SCI & MED ETH,LONDON E1 2AD,ENGLAND.							AARONS EJ, 1991, BRIT MED J, V303, P1504, DOI 10.1136/bmj.303.6816.1504; [Anonymous], 1989, ALL ER, V2, P782; BEDELL SE, 1983, NEW ENGL J MED, V309, P569, DOI 10.1056/NEJM198309083091001; DOYAL LT, IN PRESS SURGERY NEW; EVANS TR, 1990, ABS RESUSCITATION, P66; GEORGE AL, 1989, AM J MED, V87, P28; Great Britain. England. Court of Appeal Civil Division, 1990, All Engl Law Rep, V[1990] 3, P930; HOLMBERG S, 1992, RESUSCITATION, V24, P239, DOI 10.1016/0300-9572(92)90184-E; KENNEDY I, 1990, MED LAW TEST MATERIA, P936; LOEWY EH, 1991, J MED ETHICS, V17, P156, DOI 10.1136/jme.17.3.156; Re T, 1992, WLR, V3, P782; SAUNDERS J, 1992, J ROY COLL PHYS LOND, V26, P254; SCHADE SG, 1989, J MED ETHICS, V15, P186, DOI 10.1136/jme.15.4.186; TOMLINSON T, 1990, JAMA-J AM MED ASSOC, V264, P1276, DOI 10.1001/jama.264.10.1276; TOMLINSON T, 1988, NEW ENGL J MED, V318, P43, DOI 10.1056/NEJM198801073180109; WALKER RM, 1991, JAMA-J AM MED ASSOC, V266, P2407, DOI 10.1001/jama.266.17.2407; 1993, BMLR, V9, P20; 1983, DECIDING FOREGO LIFE, P231; 1993, DECISIONS RELATING C; 1991, 1990 1991 HLTH SERV, P12; 1991, PLCMO9122 DEP HLTH	21	64	64	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1993	306	6892					1593	1596		10.1136/bmj.306.6892.1593	http://dx.doi.org/10.1136/bmj.306.6892.1593			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH128	8329925	Green Published, Bronze			2023-01-03	WOS:A1993LH12800025
J	SRA, JS; JAZAYERI, MR; AVITALL, B; DHALA, A; DESHPANDE, S; BLANCK, Z; AKHTAR, M				SRA, JS; JAZAYERI, MR; AVITALL, B; DHALA, A; DESHPANDE, S; BLANCK, Z; AKHTAR, M			COMPARISON OF CARDIAC PACING WITH DRUG-THERAPY IN THE TREATMENT OF NEUROCARDIOGENIC (VASOVAGAL) SYNCOPE WITH BRADYCARDIA OR ASYSTOLE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEAD-UP TILT; VAGAL C-FIBERS; UNEXPLAINED SYNCOPE; RECURRENT SYNCOPE; ISOPROTERENOL; DISOPYRAMIDE; HYPOTENSION	Background. The efficacy of permanent cardiac pacing in patients with neurocardiogenic (or vasovagal) syncope associated with bradycardia or asystole is not clear. We compared the efficacy of cardiac pacing with that of oral drug therapy in the prevention of hypotension and syncope during head-up tilt testing. Methods. Among 70 patients with a history of syncope in whom hypotension and syncope could be provoked during head-up tilt testing, 22 had bradycardia (a heart rate <60 beats per minute, with a decline in the rate by at least 20 beats per minute) or asystole along with hypotension during testing. There were 9 men and 13 women, with a mean (+/- SD) age of 41 +/- 17 years. Head-up tilt testing was repeated during atrioventricular sequential pacing (in 20 patients with sinus rhythm) or ventricular pacing (in 2 patients with atrial fibrillation). Regardless of the results obtained during artificial pacing, all the patients subsequently had upright-tilt testing repeated during therapy with oral metroprolol, theophylline, or disopyramide. Results. During the initial tilt test, 6 patients had asystole and 16 had bradycardia along with hypotension. Despite artificial pacing, the mean arterial pressure during head-up tilt testing still fell significantly, from 97 +/- 19 to 57+/-19 mm Hg (P < 0.001); 5 patients had syncope, and 15 had presyncope By contrast, 19 patients who later received only medical therapy (metoprolol in 10, theophylline in 3, and disopyramide in 6), 2 patients who received both metoprolol and atrioventricular sequential pacing, and 1 patient who received only atrioventricular sequential pacing had negative head-up tilt tests. After a median follow-up of 16 months, 18 of the 19 patients who were treated with drugs alone (94 percent) remained free of recurrent syncope or presyncope, whereas the patient treated only with a permanent dual-chamber pacemaker had recurrent syncope. Conclusions. Ir patients with neurocardiogenic syncope associated with bradycardia or asystole, drug therapy is often effective in preventing syncope, whereas artificial pacing is not.			SRA, JS (corresponding author), SINAI SAMARITAN MED CTR, 945 N 12TH ST, MILWAUKEE, WI 53233 USA.			Deshpande, Sanjay/0000-0002-6153-2444				ABBOUD FM, 1976, PROG CARDIOVASC DIS, V18, P371, DOI 10.1016/0033-0620(76)90003-7; ABISAMRA F, 1988, PACE, V11, P1202, DOI 10.1111/j.1540-8159.1988.tb03973.x; AKHTAR M, 1983, PACE, V6, P192, DOI 10.1111/j.1540-8159.1983.tb04346.x; ALMQUIST A, 1989, NEW ENGL J MED, V320, P346, DOI 10.1056/NEJM198902093200603; DANILO P, 1976, AM HEART J, V92, P532; DERMKSIAN G, 1958, JAMA-J AM MED ASSOC, V168, P1200, DOI 10.1001/jama.1958.03000090030007; DIMARCO JP, 1981, ANN INTERN MED, V95, P542, DOI 10.7326/0003-4819-95-5-542; FITZPATRICK A, 1989, LANCET, V1, P658, DOI 10.1016/S0140-6736(89)92155-7; FUJIMURA O, 1989, NEW ENGL J MED, V321, P1703, DOI 10.1056/NEJM198912213212503; KAPOOR WN, 1983, NEW ENGL J MED, V309, P197, DOI 10.1056/NEJM198307283090401; LERMAN BB, 1991, CIRCULATION, V83, P1499, DOI 10.1161/01.CIR.83.5.1499; Lewis T, 1932, BRIT MED J, V1932, P873, DOI 10.1136/bmj.1.3723.873; LUDBROOK J, 1989, NEWS PHYSIOL SCI, V4, P120; MILSTEIN S, 1990, AM J CARDIOL, V65, P1339, DOI 10.1016/0002-9149(90)91324-Y; NELSON SD, 1990, CIRCULATION, V82, P707; OBERG B, 1972, ACTA PHYSIOL SCAND, V85, P164, DOI 10.1111/j.1748-1716.1972.tb05247.x; SHALEV Y, 1991, J AM COLL CARDIOL, V18, P746, DOI 10.1016/0735-1097(91)90798-E; SHARPEYSCHAFER EP, 1958, BMJ-BRIT MED J, V2, P878, DOI 10.1136/bmj.2.5101.878; SRA J, 1991, J AM COLL CARDIOL, V17, pA216; SRA JS, 1992, J AM COLL CARDIOL, V19, P402, DOI 10.1016/0735-1097(92)90498-C; SRA JS, 1991, ANN INTERN MED, V114, P1013, DOI 10.7326/0003-4819-114-12-1013; THAMES MD, 1980, AM J PHYSIOL, V238, pH465, DOI 10.1152/ajpheart.1980.238.4.H465; Thoren P, 1979, Rev Physiol Biochem Pharmacol, V86, P1, DOI 10.1007/BFb0031531; WAXMAN MB, 1989, AM J CARDIOL, V63, P58, DOI 10.1016/0002-9149(89)91076-X; 1989, SAS STAT USERS GUIDE, P261	25	211	214	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 15	1993	328	15					1085	1090		10.1056/NEJM199304153281504	http://dx.doi.org/10.1056/NEJM199304153281504			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KX178	8455666	Bronze			2023-01-03	WOS:A1993KX17800004
J	EISENBERG, DM; KESSLER, RC; FOSTER, C; NORLOCK, FE; CALKINS, DR; DELBANCO, TL				EISENBERG, DM; KESSLER, RC; FOSTER, C; NORLOCK, FE; CALKINS, DR; DELBANCO, TL			UNCONVENTIONAL MEDICINE IN THE UNITED-STATES - PREVALENCE, COSTS, AND PATTERNS OF USE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ALTERNATIVE MEDICINE; PRIMARY CARE; PRACTITIONERS; THERAPIES; REMEDIES; PATIENT	Background. Many people use unconventional therapies for health problems, but the extent of this use and the costs are not known. We conducted a national survey to determine the prevalence, costs, and patterns of use of unconventional therapies, such as acupuncture and chiropractic. Methods. We limited the therapies studied to 16 commonly used interventions neither taught widely in U.S. medical schools nor generally available in U.S. hospitals. We completed telephone interviews with 1539 adults (response rate, 67 percent) in a national sample of adults 18 years of age or older in 1990. We asked respondents to report any serious or bothersome medical conditions and details of their use of conventional medical services; we then inquired about their use of unconventional therapy. Results. One in three respondents (34 percent) reported using at least one unconventional therapy in the past year, and a third of these saw providers for unconventional therapy. The latter group had made an average of 19 visits to such providers during the preceding year, with an average charge per visit of $27.60. The frequency of use of unconventional therapy varied somewhat among sociodemographic groups, with the highest use reported by nonblack persons from 25 to 49 years of age who had relatively more education and higher incomes. The majority used unconventional therapy for chronic, as opposed to life-threatening, medical conditions. Among those who used unconventional therapy for serious medical conditions, the vast majority (83 percent) also sought treatment for the same condition from a medical doctor; however, 72 percent of the respondents who used unconventional therapy did not inform their medical doctor that they had done so. Extrapolation to the U.S. population suggests that in 1990 Americans made an estimated 425 million visits to providers of unconventional therapy. This number exceeds the number of visits to all U.S. primary care physicians (388 million). Expenditures associated with use of unconventional therapy in 1990 amounted to approximately $13.7 billion, three quarters of which ($10.3 billion) was paid out of pocket. This figure is comparable to the $12.8 billion spent out of pocket annually for all hospitalizations in the United States. Conclusions. The frequency of use of unconventional therapy in the United States is far higher than previously reported. Medical doctors should ask about their patients' use of unconventional therapy whenever they obtain a medical history.	HARVARD UNIV,SCH MED,BOSTON,MA 02115; UNIV MICHIGAN,INST SOCIAL RES,ANN ARBOR,MI 48109; NEW ENGLAND DEACONESS HOSP,DEPT MED,DIV GEN MED,BOSTON,MA 02215; CHICAGO COLL OSTEOPATH MED,CHICAGO,IL 60615	Harvard University; Harvard Medical School; University of Michigan System; University of Michigan; Midwestern University; Midwestern University - Chicago College of Osteopathic Medicine	EISENBERG, DM (corresponding author), BETH ISRAEL HOSP,DEPT MED,DIV GEN MED & PRIMARY CARE,330 BROOKLINE AVE,BOSTON,MA 02215, USA.		Fahimifar, Sepideh/M-5303-2019					BRIGDEN ML, 1987, POSTGRAD MED, V81, P271, DOI 10.1080/00325481.1987.11699682; CASSILETH BR, 1989, CANCER, V63, P1247, DOI 10.1002/1097-0142(19890401)63:7<1247::AID-CNCR2820630703>3.0.CO;2-3; CASSILETH BR, 1984, ANN INTERN MED, V101, P105, DOI 10.7326/0003-4819-101-1-105; CHERKIN DC, 1989, WESTERN J MED, V150, P351; CLEARY PD, 1982, AM J PUBLIC HEALTH, V72, P727, DOI 10.2105/AJPH.72.7.727; COHEN CJ, 1990, CLIN RES, V38, pA692; COOK C, 1986, SOUTH MED J, V79, P1098, DOI 10.1097/00007611-198609000-00014; CRONAN TA, 1989, ARTHRITIS RHEUM, V32, P1604, DOI 10.1002/anr.1780321217; Gevitz N, 1988, OTHER HEALERS UNORTH, P1; GILLICK MR, 1985, NEW ENGL J MED, V313, P700, DOI 10.1056/NEJM198509123131120; KLEINMAN A, 1978, ANN INTERN MED, V88, P251, DOI 10.7326/0003-4819-88-2-251; KRONENFELD JJ, 1982, SOC SCI MED, V16, P1119, DOI 10.1016/0277-9536(82)90114-9; LEPKOWSKI JM, 1988, TELEPHONE SURVEY MET, P73; Levit K R, 1991, Health Care Financ Rev, V13, P29; McGuire Meredith, 1988, RITUAL HEALING SUBUR; MURRAY RH, 1992, NEW ENGL J MED, V326, P61, DOI 10.1056/NEJM199201023260113; Schappert SM, 1992, ADV DATA VITAL HLTH, V213; SMART HL, 1986, GUT, V27, P826, DOI 10.1136/gut.27.7.826; SNYDER P, 1983, CULT MED PSYCHIAT, V7, P57, DOI 10.1007/BF00249999; VERHOEF MJ, 1990, CAN MED ASSOC J, V142, P121; YAGER J, 1989, J NERV MENT DIS, V177, P632, DOI 10.1097/00005053-198910000-00006; 1984, SUBCOMMITTEE HLTH LO; 1987, NZ MED J, V100, P110; 1989, SUDAAN PROFESSIONAL; 1987, HLTH INFORMATION USE; 1990, OTAH405 US C OFF TEC; 1984, HLTH NUTRITION EXAMI; 1980, PATIENTS HEALERS CON, P50; 1989, NATIONAL HLTH INTERV	29	2925	2975	5	201	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 28	1993	328	4					246	252		10.1056/NEJM199301283280406	http://dx.doi.org/10.1056/NEJM199301283280406			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ442	8418405	Bronze			2023-01-03	WOS:A1993KJ44200006
J	HARRIES, AD; CULLINAN, T				HARRIES, AD; CULLINAN, T			HERBIS ET ORBIS - THE DANGERS OF TRADITIONAL EYE MEDICINES	LANCET			English	Editorial Material									COLL MED,DEPT COMMUNITY HLTH,BLANTYRE,MALAWI	University of Malawi	HARRIES, AD (corresponding author), COLL MED,DEPT MED,BLANTYRE,MALAWI.							CHIRAMBO MC, 1976, BRIT J OPHTHALMOL, V60, P665, DOI 10.1136/bjo.60.9.665; COURTRIGHT P, 1994, BRIT J OPHTHALMOL, V74, P810; MCMOLI TE, 1984, BRIT J OPHTHALMOL, V68, P401, DOI 10.1136/bjo.68.6.401; YORSTON D, 1994, J TROP MED HYG, V97, P211	4	7	8	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 10	1994	344	8937					1588	1588		10.1016/S0140-6736(94)90403-0	http://dx.doi.org/10.1016/S0140-6736(94)90403-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW051	7983991				2023-01-03	WOS:A1994PW05100006
J	FISHER, ES; WENNBERG, JE; STUKEL, TA; SHARP, SM				FISHER, ES; WENNBERG, JE; STUKEL, TA; SHARP, SM			HOSPITAL READMISSION RATES FOR COHORTS OF MEDICARE BENEFICIARIES IN BOSTON AND NEW-HAVEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MORTALITY; SERVICES; MODELS	Background. Geographic variations in the use of hospital services are associated with differences in the availability of hospital beds. There continues to be uncertainty about the extent to which unmeasured case-mix differences explain these findings. Previous research showed that the number of occupied beds per capita in Boston was substantially higher than the number of occupied beds per capita in New Haven, Connecticut, and that overall rates of hospital utilization were higher for Boston residents than for New Haven residents. Methods. We used Medicare claims data to study cohorts of Medicare beneficiaries 65 years of age or older and residing in Boston or New Haven who were initially hospitalized for one of five indications (acute myocardial infarction, stroke, gastrointestinal bleeding, hip fracture, or potentially curative surgery for breast, colon, or lung cancer). Residents of Boston or New Haven who were discharged between October 1, 1987, and September 30, 1989, were enrolled in the cohort corresponding to the earliest such admission and followed for up to 35 months. Results. The relative rate of readmission in Boston as compared with New Haven was 1.64 (95 percent confidence interval, 1.53 to 1.76) for all cohorts combined, with a similarly elevated rate for each of the five clinical cohorts and each age, sex, and race subgroup examined. Hospital-specific readmission rates varied substantially among the hospitals in Boston and were higher than those in New Haven. No relation was found between mortality (during the first 30 days after discharge or over the entire study period) and either community or hospital-specific readmission rates. Conclusions. Regardless of the initial cause of admission, Medicare beneficiaries who were initially hospitalized in Boston had consistently higher rates of readmission than did Medicare beneficiaries hospitalized in New Haven. Differences in the severity of illness are unlikely to explain these findings. One possible explanation is a threshold effect of hospital-bed availability on decisions to admit patients.	VET AFFAIRS MED CTR,WHITE RIVER JCT,VT; DARTMOUTH COLL SCH MED,DEPT MED,HANOVER,NH; DARTMOUTH COLL SCH MED,CTR EVALUAT CLIN SCI,HANOVER,NH	US Department of Veterans Affairs; Veterans Health Administration (VHA); Dartmouth College; Dartmouth College				Stukel, Therese/0000-0002-2951-1360	AHRQ HHS [R18-HS05745] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		AITKIN M, 1980, BIOMETRICS, V36, P173, DOI 10.2307/2530509; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; COX DR, 1972, J R STAT SOC B, V34, P187; CREDITOR MC, 1993, ANN INTERN MED, V118, P219, DOI 10.7326/0003-4819-118-3-199302010-00011; DALEY J, 1988, JAMA-J AM MED ASSOC, V260, P3617, DOI 10.1001/jama.260.24.3617; FISHER ES, 1992, JAMA-J AM MED ASSOC, V267, P1925, DOI 10.1001/jama.267.14.1925; HIATT HH, 1989, NEW ENGL J MED, V321, P480, DOI 10.1056/NEJM198908173210725; KEELER EB, 1990, JAMA-J AM MED ASSOC, V264, P1962, DOI 10.1001/jama.264.15.1962; KRONICK R, 1993, NEW ENGL J MED, V328, P148, DOI 10.1056/NEJM199301143280225; ROMANO PS, 1993, J CLIN EPIDEMIOL, V46, P1075, DOI 10.1016/0895-4356(93)90103-8; Roos N P, 1988, Health Care Financ Rev, V9, P53; STUKEL TA, IN PRESS STAT MED; WELCH WP, 1993, NEW ENGL J MED, V328, P621, DOI 10.1056/NEJM199303043280906; WENNBERG JE, 1987, LANCET, V1, P1185, DOI 10.1016/s0140-6736(87)92152-0; WENNBERG JE, 1989, NEW ENGL J MED, V321, P1168, DOI 10.1056/NEJM198910263211706; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; 1988, AM HOSPITAL ASS GUID; 1989, AM HOSPITAL ASS GUID; 1988, MEDICARE STATISTICAL; 1990, AM HOSPITAL ASS GUID	20	180	180	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 13	1994	331	15					989	995		10.1056/NEJM199410133311506	http://dx.doi.org/10.1056/NEJM199410133311506			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK504	8084356				2023-01-03	WOS:A1994PK50400006
J	HOWIE, JGR; HEANEY, DJ; MAXWELL, M				HOWIE, JGR; HEANEY, DJ; MAXWELL, M			EVALUATING CARE OF PATIENTS REPORTING PAIN IN FUNDHOLDING PRACTICES	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; NHS; PATTERNS; COSTS	Objective-To compare quality of care between 1990 and 1992 in patients with self diagnosed joint pain. Design-Questionnaire and record based study. Subjects-Patients identified at consecutive consultations during two weeks in 1990, 1991, and 1992. Setting-Six practice groups in pilot fundholding scheme in Scotland. Main outcome measures-length of consultation; numbers referred or investigated or prescribed drugs; responses to questions about enablement and satisfaction. Results-About 15% of patients consulted with joint pain each year. 25% (316) of them had social problems in 1990 and 37% (370) in 1992; about a fifth wanted to discuss their social problems. Social problems were associated with a raised general health questionnaire score. The mean length of consultation for patients with pain was 7.6 min in 1990 and 7.7 min in 1992. Patients wishing to discuss social problems received longer consultations (8.5 min 1990; 10.4 min 1992); but other patients with social problems received shorter consultations (7.4 min; 7.2 min). The level of prescribing was stable but the proportion of patients having investigations or attending hospital fell significantly from 1990 to 1992 (31% to 24%; 31% to 13% respectively). Fewer patients responded ''much better'' to six questions about enablement in 1992 than in 1990. Enablement was better after longer than shorter consultations for patients with social problems. Conclusions-Quality of care for patients with pain has been broadly maintained in terms of consultation times. The effects of lower rates of investigation and referral need to be investigated further.			HOWIE, JGR (corresponding author), UNIV EDINBURGH,DEPT GEN PRACTICE,EDINBURGH EH8 9DX,SCOTLAND.			Maxwell, Margaret/0000-0003-3318-9500				BAIN J, 1993, BRIT MED J, V306, P1185, DOI 10.1136/bmj.306.6886.1185; BAIN J, 1992, BRIT MED J, V304, P971, DOI 10.1136/bmj.304.6832.971; BAIN J, 1991, BRIT MED J, V302, P771, DOI 10.1136/bmj.302.6779.771; BAZANGER I, 1989, SOC SCI MED, V29, P425; BOWIE C, 1994, BRIT J GEN PRACT, V44, P38; CORNEY R, 1994, BRIT J GEN PRACT, V44, P34; COULTER A, 1993, BRIT MED J, V306, P433, DOI 10.1136/bmj.306.6875.433; COULTER A, 1992, BRIT MED J, V304, P397, DOI 10.1136/bmj.304.6824.397; COULTER A, 1993, BRIT MED J, V307, P1186; CROOK J, 1984, PAIN, V18, P299, DOI 10.1016/0304-3959(84)90824-8; CRUMP BJ, 1991, BRIT MED J, V302, P1582, DOI 10.1136/bmj.302.6792.1582; DAY P, 1991, BRIT MED J, V303, P168, DOI 10.1136/bmj.303.6795.168; GLENNERSTER H, 1992, FOOTHOLD FUNDHOLDING; HOPTON JL, 1991, FAM PRACT, V8, P253, DOI 10.1093/fampra/8.3.253; Howie J G, 1993, Health Bull (Edinb), V51, P94; Howie J G, 1992, Health Bull (Edinb), V50, P316; HOWIE JGR, 1991, BRIT J GEN PRACT, V41, P48; MAXWELL M, 1993, BRIT MED J, V307, P1190, DOI 10.1136/bmj.307.6913.1190; NEWTON J, 1993, BRIT MED J, V306, P375, DOI 10.1136/bmj.306.6874.375; PURVES IN, 1993, BRIT MED J, V306, P496, DOI 10.1136/bmj.306.6876.496; 1986, MORBIDITY STATISTICS	21	24	24	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 17	1994	309	6956					705	710		10.1136/bmj.309.6956.705	http://dx.doi.org/10.1136/bmj.309.6956.705			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH407	7950524	Green Published			2023-01-03	WOS:A1994PH40700018
J	GRINES, CL; WEAVER, WD				GRINES, CL; WEAVER, WD			TREATING MYOCARDIAL-INFARCTION - AND IMPORTANCE OF EARLY REPERFUSION	LANCET			English	Editorial Material							THROMBOLYSIS; ANGIOPLASTY		UNIV WASHINGTON, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle	GRINES, CL (corresponding author), WILLIAM BEAUMONT HOSP, DEPT MED, DIV CARDIOL, ROYAL OAK, MI 48072 USA.							BADIMON L, 1991, TRENDS CARDIOVAS MED, V1, P261, DOI 10.1016/1050-1738(91)90032-A; BECKER RC, 1991, CARDIOLOGY, V79, P49, DOI 10.1159/000174860; Cannon Christopher P., 1993, Journal of the American College of Cardiology, V21, p136A; DEBONO DP, 1992, BRIT HEART J, V67, P122; GATENBY R, 1992, BMJ-BRIT MED J, V305, P548; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; HERLITZ J, 1992, EUR HEART J, V13, P171, DOI 10.1093/oxfordjournals.eurheartj.a060142; KLEIMAN NS, 1992, CIRCULATION, V86, P260; LIDON RM, 1994, CIRCULATION, V89, P1567, DOI 10.1161/01.CIR.89.4.1567; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; ROUX S, 1992, J AM COLL CARDIOL, V19, P671, DOI 10.1016/S0735-1097(10)80290-6; TCHENG JE, 1993, CIRCULATION, V88, P1; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; TOPOL EJ, 1994, CIRCULATION, V89, P1557, DOI 10.1161/01.CIR.89.4.1557; TOPOL EJ, 1994, LANCET, V343, P881, DOI 10.1016/S0140-6736(94)90007-8; ZIJLSTRA F, 1993, NEW ENGL J MED, V328, P680, DOI 10.1056/NEJM199303113281002; 1993, EUR HEART J        S, V14, P48	17	7	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 20	1994	344	8921					490	491		10.1016/S0140-6736(94)91893-7	http://dx.doi.org/10.1016/S0140-6736(94)91893-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC535	7914609				2023-01-03	WOS:A1994PC53500004
J	COBLEIGH, MA; BERRIS, RF; BUSH, T; DAVIDSON, NE; ROBERT, NJ; SPARANO, JA; TORMEY, DC; WOOD, WC				COBLEIGH, MA; BERRIS, RF; BUSH, T; DAVIDSON, NE; ROBERT, NJ; SPARANO, JA; TORMEY, DC; WOOD, WC			ESTROGEN REPLACEMENT THERAPY IN BREAST-CANCER SURVIVORS - A TIME FOR CHANGE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							MAMMOGRAPHIC PARENCHYMAL PATTERNS; POSTMENOPAUSAL WOMEN; PREMENOPAUSAL WOMEN; EXOGENOUS ESTROGEN; CONTRACEPTIVE STEROIDS; ADJUVANT CHEMOTHERAPY; TAMOXIFEN THERAPY; HORMONE USE; RISK; CARCINOMA		HEMATOL ONCOL ASSOCIATES, DENVER, CO USA; JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, BALTIMORE, MD USA; JOHNS HOPKINS UNIV, CTR ONCOL, BALTIMORE, MD 21205 USA; FAIRFAX ONCOL ASSOCIATES, ANNANDALE, VA USA; ALBERT EINSTEIN CANC CTR, BRONX, NY USA; EASTERN COOPERAT ONCOL GRP, OPERAT OFF, DENVER, CO USA; EMORY UNIV, SCH MED, ATLANTA, GA USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Yeshiva University; Emory University	COBLEIGH, MA (corresponding author), RUSH PRESBYTERIAN ST LUKES MED CTR, DEPT INTERNAL MED, DIV HEMATOL ONCOL, MED ONCOL SECT, CHICAGO, IL 60612 USA.							ADAMI HO, 1987, NEW ENGL J MED, V316, P752; ADAMI HO, 1986, NEW ENGL J MED, V315, P559, DOI 10.1056/NEJM198608283150906; [Anonymous], 1992, Lancet, V339, P1; ARMSTRONG BK, 1988, MED J AUSTRALIA, V148, P213, DOI 10.5694/j.1326-5377.1988.tb99424.x; BARRETTCONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1861, DOI 10.1001/jama.265.14.1861; BERGKVIST L, 1989, NEW ENGL J MED, V321, P293, DOI 10.1056/NEJM198908033210505; BERGKVIST L, 1989, AM J EPIDEMIOL, V130, P221, DOI 10.1093/oxfordjournals.aje.a115328; BERKOWITZ JE, 1990, RADIOLOGY, V174, P199, DOI 10.1148/radiology.174.1.2152982; BLAND KI, 1980, CANCER, V45, P3027, DOI 10.1002/1097-0142(19800615)45:12<3027::AID-CNCR2820451225>3.0.CO;2-2; BONADONNA G, 1979, ADJUVANT THERAPY CAN, V2, P227; BRINTON LA, 1986, BRIT J CANCER, V54, P825, DOI 10.1038/bjc.1986.246; BROWNSON RC, 1988, ARCH INTERN MED, V148, P140, DOI 10.1001/archinte.148.1.140; BURING JE, 1987, AM J EPIDEMIOL, V125, P939, DOI 10.1093/oxfordjournals.aje.a114632; BUSH TL, 1993, EPIDEMIOL REV, V15, P233, DOI 10.1093/oxfordjournals.epirev.a036110; COLDITZ GA, 1990, JAMA-J AM MED ASSOC, V264, P2648, DOI 10.1001/jama.264.20.2648; CREASMAN WT, 1991, OBSTET GYNECOL, V77, P308, DOI 10.1097/00006250-199102000-00031; CRIQUI MH, 1988, AM J EPIDEMIOL, V128, P606, DOI 10.1093/oxfordjournals.aje.a115008; DAVIDSON JA, 1992, MED J AUSTRALIA, V157, P429, DOI 10.5694/j.1326-5377.1992.tb137283.x; DEVOR M, 1992, AM J MED, V92, P275, DOI 10.1016/0002-9343(92)90077-O; DISAIA PJ, 1993, CANCER-AM CANCER SOC, V71, P1490, DOI 10.1002/cncr.2820710414; DUPONT WD, 1991, ARCH INTERN MED, V151, P67, DOI 10.1001/archinte.151.1.67; DUPONT WD, 1989, CANCER-AM CANCER SOC, V63, P948, DOI 10.1002/1097-0142(19890301)63:5<948::AID-CNCR2820630527>3.0.CO;2-U; EDEN JA, 1992, MED J AUSTRALIA, V157, P247, DOI 10.5694/j.1326-5377.1992.tb137129.x; EDEN JA, 1992, MED J AUSTRALIA, V157, P175, DOI 10.5694/j.1326-5377.1992.tb137081.x; EDEN JA, IN PRESS MED J AUST; EWERTZ M, 1988, INT J CANCER, V42, P832, DOI 10.1002/ijc.2910420606; FISHER B, 1989, NEW ENGL J MED, V320, P479, DOI 10.1056/NEJM198902233200802; FISHER B, 1989, NEW ENGL J MED, V320, P474; FORNANDER T, 1989, LANCET, V1, P117; GAMBRELL RD, 1984, AM J OBSTET GYNECOL, V150, P119; GAMBRELL RD, 1983, OBSTET GYNECOL, V62, P435; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GRADY D, 1992, ANN INTERN MED, V117, P1038; Harvey E B, 1985, Natl Cancer Inst Monogr, V68, P99; HENDERSON BE, 1983, BRIT J CANCER, V47, P749, DOI 10.1038/bjc.1983.127; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; HENDERSON IC, 1993, CANCER-AM CANCER SOC, V71, P2127, DOI 10.1002/1097-0142(19930315)71:6+<2127::AID-CNCR2820711602>3.0.CO;2-2; HENRICH JB, 1992, JAMA-J AM MED ASSOC, V268, P1900, DOI 10.1001/jama.268.14.1900; HEUSON JC, 1976, CANCER TREAT REP, V60, P1463; HIATT RA, 1984, CANCER, V54, P139, DOI 10.1002/1097-0142(19840701)54:1<139::AID-CNCR2820540128>3.0.CO;2-X; HOOGSTRATEN B, 1982, CANCER RES, V42, P4788; HOOGSTRATEN B, 1984, CANCER, V54, P2248, DOI 10.1002/1097-0142(19841115)54:10<2248::AID-CNCR2820541031>3.0.CO;2-D; HOOVER R, 1981, J NATL CANCER I, V67, P815; HORWITZ RI, 1984, AM J MED, V76, P192, DOI 10.1016/0002-9343(84)90773-3; HUG V, 1985, J CLIN ONCOL, V3, P1672, DOI 10.1200/JCO.1985.3.12.1672; HULKA BS, 1982, AM J OBSTET GYNECOL, V143, P638, DOI 10.1016/0002-9378(82)90108-9; HUNT K, 1987, BRIT J OBSTET GYNAEC, V94, P620, DOI 10.1111/j.1471-0528.1987.tb03166.x; HUTCHINSONWILLIAMS KA, 1991, YALE J BIOL MED, V64, P607; JORDAN VC, 1987, CANCER RES, V47, P624; KAUFMAN DW, 1984, JAMA-J AM MED ASSOC, V252, P63, DOI 10.1001/jama.252.1.63; KAUFMAN DW, 1991, AM J EPIDEMIOL, V134, P1375, DOI 10.1093/oxfordjournals.aje.a116041; KAUFMAN Z, 1991, CLIN RADIOL, V43, P389, DOI 10.1016/S0009-9260(05)80566-5; KELSEY JL, 1988, CANCER RES, V48, P5615; KELSEY JL, 1981, JNCI-J NATL CANCER I, V67, P327; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; KING RM, 1985, SURG GYNECOL OBSTET, V160, P228; LAM HYP, 1984, BIOCHEM BIOPH RES CO, V118, P27, DOI 10.1016/0006-291X(84)91062-3; LIPPMAN M, 1976, CANCER RES, V36, P4595; LOBO RA, 1990, OBSTET GYNECOL, V75, pS18; LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302; MANDEVILLE R, 1984, EUR J CANCER CLIN ON, V20, P983, DOI 10.1016/0277-5379(84)90174-3; MANNI A, 1980, CANCER TREAT REP, V64, P779; MANSOUR EG, 1989, NEW ENGL J MED, V320, P485, DOI 10.1056/NEJM198902233200803; MARCHANT DJ, 1993, CANCER, V71, P2169, DOI 10.1002/1097-0142(19930315)71:6+<2169::AID-CNCR2820711608>3.0.CO;2-B; MARGREITER R, 1984, BREAST CANCER RES TR, V4, P45, DOI 10.1007/BF01806987; MATTHEWS PN, 1981, BRIT MED J, V282, P774, DOI 10.1136/bmj.282.6266.774; MCDONALD CC, 1991, BRIT MED J, V303, P435, DOI 10.1136/bmj.303.6800.435; MEHTA RR, 1992, BREAST CANCER RES TR, V20, P125; MERRILL JM, 1992, JAMA-J AM MED ASSOC, V267, P568; MILLER BA, 1993, CA-CANCER J CLIN, V43, P27, DOI 10.3322/canjclin.43.1.27; MILLS PK, 1989, CANCER, V64, P591, DOI 10.1002/1097-0142(19890801)64:3<591::AID-CNCR2820640305>3.0.CO;2-U; NAYFIELD SG, 1991, J NATL CANCER I, V83, P1450, DOI 10.1093/jnci/83.20.1450; NOMURA AMY, 1986, INT J CANCER, V37, P49, DOI 10.1002/ijc.2910370109; OBRIAN CA, 1985, CANCER RES, V45, P2462; PALMER JR, 1991, AM J EPIDEMIOL, V134, P1386, DOI 10.1093/oxfordjournals.aje.a116042; PLANTING AST, 1985, CANCER TREAT REP, V69, P363; POWLES TJ, 1988, LANCET, V2, P344; POWLES TJ, 1990, LANCET, V336, P48, DOI 10.1016/0140-6736(90)91555-O; PRITCHARD KI, 1980, CANCER TREAT REP, V64, P787; RIBEIRO G, 1986, BRIT J SURG, V73, P607, DOI 10.1002/bjs.1800730805; ROHAN TE, 1988, MED J AUSTRALIA, V148, P217; ROSEN PP, 1993, J CLIN ONCOL, V11, P2090, DOI 10.1200/JCO.1993.11.11.2090; ROSS RK, 1980, JAMA-J AM MED ASSOC, V243, P1635, DOI 10.1001/jama.243.16.1635; SAWKA CA, 1986, CANCER RES, V46, P3152; SHERMAN B, 1983, CANCER, V51, P1527, DOI 10.1002/1097-0142(19830415)51:8<1527::AID-CNCR2820510828>3.0.CO;2-T; SHERMAN BM, 1979, J CLIN INVEST, V64, P398, DOI 10.1172/JCI109475; SMITH DC, 1975, NEW ENGL J MED, V293, P1164, DOI 10.1056/NEJM197512042932302; SPENCER JD, 1978, BRIT MED J, V1, P1024, DOI 10.1136/bmj.1.6119.1024; SPICER DV, 1991, J NATL CANCER I, V83, P63, DOI 10.1093/jnci/83.1.63; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; STEINBERG KK, 1991, JAMA-J AM MED ASSOC, V265, P1985, DOI 10.1001/jama.265.15.1985; STOLL BA, 1988, LANCET, V1, P1278; STOLL BA, 1967, BRIT MED J, V1, P150, DOI 10.1136/bmj.1.5533.150; STOLL BA, 1989, EUR J CANCER CLIN ON, V25, P1909, DOI 10.1016/0277-5379(89)90372-6; STOMPER PC, 1990, RADIOLOGY, V174, P487, DOI 10.1148/radiology.174.2.2136958; SUNDERLAND MC, 1991, J CLIN ONCOL, V9, P1283, DOI 10.1200/JCO.1991.9.7.1283; THERIAULT RL, 1991, ANN ONCOL, V2, P709, DOI 10.1093/oxfordjournals.annonc.a057847; THOMAS DB, 1982, JNCI-J NATL CANCER I, V69, P1017; VIGNON F, 1987, BIOCHEM BIOPH RES CO, V146, P1502, DOI 10.1016/0006-291X(87)90819-9; WADA T, 1981, CANCER TREAT REP, V65, P728; WILE AG, 1993, AM J SURG, V165, P372, DOI 10.1016/S0002-9610(05)80848-7; WILE AG, 1991, P AN M AM SOC CLIN, V10, P58; WILKUND I, 1992, MATURITAS, V14, P211; WINGO PA, 1987, JAMA-J AM MED ASSOC, V257, P209, DOI 10.1001/jama.257.2.209; YOSHIDA M, 1982, JPN J CLIN ONCOL, V12, P57; 1992, HORMONE REPLACEMENT, P166; 1989, N ENGL JMED, V320, P491	107	135	136	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 17	1994	272	7					540	545		10.1001/jama.272.7.540	http://dx.doi.org/10.1001/jama.272.7.540			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB229	8046809				2023-01-03	WOS:A1994PB22900032
J	RAPHAEL, JC; CHEVRET, S; CHASTANG, C; BOUVET, F				RAPHAEL, JC; CHEVRET, S; CHASTANG, C; BOUVET, F			RANDOMIZED TRIAL OF PREVENTIVE NASAL VENTILATION IN DUCHENNE MUSCULAR-DYSTROPHY	LANCET			English	Article							RESPIRATORY MUSCLE WEAKNESS; FAILURE; PREDNISONE; MANAGEMENT; THERAPY; DISEASE; SLEEP	Duchenne muscular dystrophy (DMD) is the most common muscular dystrophy in children. Paralysis of respiratory muscles causes a decrease in forced vital capacity (FVC) from age 12 years, and death occurs between 20 and 25 years old and is usually related to respiratory insufficiency. Uncontrolled studies suggest that early home use of nasal intermittent positive-pressure ventilation (NIPPV) in DMD patients free of respiratory failure could limit progression of the restrictive syndrome and therefore improve survival Because efficacy of preventive NIPPV has not been demonstrated in a controlled trial, we undertook a randomised multicentre study in which 70 patients with DMD were included. Patients were free of daytime respiratory failure and FVC was between 20 and 50% of predicted values. At least 6 h of nocturnal NIPPV (n=35) was compared with conventional treatment (n=35). During a mean follow-up of 52 months, 10 patients died, 8 in the NIPPV group and 2 in the control group (p=0.05, log-rank test). No differences were observed between the two groups for occurrence of hypercapnia, decrease of FVC below 20% of initial values, or use of necessary mechanical ventilation. Preventive NIPPV did not improve respiratory handicap and reduced survival of DMD patients. Use of NIPPV for preventive purposes should be avoided in patients with FVC between 20 and 50% of predicted values.	HOP ST LOUIS,DEPT BIOSTAT & INFORMAT MED,PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	RAPHAEL, JC (corresponding author), HOP RAY POINCARE,SERV REANIMAT MED,F-92380 GARCHES,FRANCE.			chevret, sylvie/0000-0001-6449-4730				BACH JR, 1990, CHEST, V97, P52, DOI 10.1378/chest.97.1.52; BRAUN NMT, 1979, AM REV RESPIR DIS, V119, P123; BROOKE MH, 1989, NEUROLOGY, V39, P475, DOI 10.1212/WNL.39.4.475; BYE PTP, 1990, THORAX, V45, P241, DOI 10.1136/thx.45.4.241; CHERNIACK RM, 1972, AM REV RESPIR DIS, V106, P38, DOI 10.1164/arrd.1972.106.1.38; Delaubier A, 1987, Agressologie, V28, P737; DEMEDTS M, 1982, EUR J RESPIR DIS, V63, P62; DETROYER A, 1980, THORAX, V35, P603, DOI 10.1136/thx.35.8.603; DETROYER A, 1981, AM REV RESPIR DIS, V124, P132; ESTENNE M, 1983, AM REV RESPIR DIS, V128, P1002; FENICHEL GM, 1991, NEUROLOGY, V41, P1874, DOI 10.1212/WNL.41.12.1874; FERRIS BG, 1960, J CLIN INVEST, V39, P143, DOI 10.1172/JCI104012; GAFFNEY JF, 1989, ARCH NEUROL-CHICAGO, V46, P1249, DOI 10.1001/archneur.1989.00520470123039; GEORGE SL, 1974, J CHRON DIS, V27, P15, DOI 10.1016/0021-9681(74)90004-6; GILGOFF I, 1989, CHEST, V95, P519, DOI 10.1378/chest.95.3.519; GRANATA C, 1989, SEM HOP PARIS, V65, P1037; HECKMATT JZ, 1987, BRIT MED J, V295, P1014, DOI 10.1136/bmj.295.6605.1014; HOFFMAN EP, 1988, NEW ENGL J MED, V318, P1363, DOI 10.1056/NEJM198805263182104; INKLEY SR, 1974, AM J MED, V56, P297, DOI 10.1016/0002-9343(74)90611-1; MENDELL JR, 1989, NEW ENGL J MED, V320, P1592, DOI 10.1056/NEJM198906153202405; MILLER JR, 1988, DEV MED CHILD NEUROL, V30, P200; NAGAI T, 1989, JPN CIRC J, V53, P406, DOI 10.1253/jcj.53.406; NOLTE D, 1983, EUR J RESPIR DIS, V64, P110; RAPHAEL JC, 1987, REV MAL RESPIR, V4, P195; Raphael JC, 1992, EUR RESPIR REV, V2, P312; RIDEAU Y, 1988, MUSCLE NERVE, V11, P407; SMITH PEM, 1989, CHEST, V96, P1346, DOI 10.1378/chest.96.6.1346; SMITH PEM, 1988, AM REV RESPIR DIS, V137, P884, DOI 10.1164/ajrccm/137.4.884; YAN K, 1983, EUR J RESPIR DIS, V64, P105	29	171	174	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 25	1994	343	8913					1600	1604						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU354	7911921				2023-01-03	WOS:A1994NU35400011
J	KATAN, MB				KATAN, MB			FATS FOR DIABETICS	LANCET			English	Editorial Material							DIET				KATAN, MB (corresponding author), AGR UNIV WAGENINGEN,DEPT HUMAN NUTR,WAGENINGEN,NETHERLANDS.							Bose RKC, 1907, BRIT MED J, V2, P1053; BURR ML, 1989, LANCET, V2, P757; CRAPO PA, 1985, ANNU REV NUTR, V5, P95, DOI 10.1146/annurev.nutr.5.1.95; GARG A, 1994, JAMA-J AM MED ASSOC, V271, P1421, DOI 10.1001/jama.271.18.1421; GLATZ JFC, 1989, AM J CLIN NUTR, V49, P269, DOI 10.1093/ajcn/49.2.269; GLAUBER H, 1988, ANN INTERN MED, V108, P663, DOI 10.7326/0003-4819-108-5-663; TAYLOR R, 1983, DIABETES EPIDEMIOLOG, P58; VESSBY B, 1994, AM J CLIN NUTR, V59, p742S, DOI 10.1093/ajcn/59.3.742S	8	2	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 18	1994	343	8912					1518	1518		10.1016/S0140-6736(94)92934-3	http://dx.doi.org/10.1016/S0140-6736(94)92934-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR329	7911867				2023-01-03	WOS:A1994NR32900004
J	NAYLOR, M; BROOTEN, D; JONES, R; LAVIZZOMOUREY, R; MEZEY, M; PAULY, M				NAYLOR, M; BROOTEN, D; JONES, R; LAVIZZOMOUREY, R; MEZEY, M; PAULY, M			COMPREHENSIVE DISCHARGE PLANNING FOR THE HOSPITALIZED ELDERLY - A RANDOMIZED CLINICAL-TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article						COST SAVINGS; OUTCOME ASSESSMENT (HEALTH CARE)	PROSPECTIVE PAYMENT SYSTEM; POSTHOSPITAL NEEDS; CARE; READMISSIONS; QUALITY	Objective: To study the effects of a comprehensive discharge planning protocol, designed specifically for the elderly and implemented by nurse specialists, on patient and caregiver outcomes and cost of care. Design: Randomized clinical trial. Setting: Hospital of the University of Pennsylvania. Patients: 276 patients and 125 caregivers. Patients were 70 years and older and were placed in selected medical and surgical cardiac diagnostic-related groups. Measurements: Group differences in patient outcomes (length of initial hospital stay, length of time between initial hospital discharge and readmission, and rehospitalization rates) and charges for care (charges for initial hospitalization, rehospitalizations, health services after discharge, and nurse specialist services) were measured 2, 6, and 12 weeks after discharge. Results: From the initial hospital discharge to 6 weeks after discharge, patients in the medical intervention group had fewer readmissions, fewer total days rehospitalized, lower readmission charges, and lower charges for health care services after discharge. No differences in these outcomes were found between the surgical intervention and control groups during this period. Conclusions: Study findings support the need for comprehensive discharge planning designed for the elderly and implemented by nurse specialists to improve their outcomes after hospital discharge and to achieve cost savings. The findings also suggest that this intervention had its greatest effect in delaying or preventing rehospitalization of patients in the medical intervention group during the first 6 weeks after discharge.	US DEPT HHS, AGCY HLTH CARE POLICY & RES, ROCKVILLE, MD 20852 USA; NYU, DIV NURSING, NEW YORK, NY 10003 USA; UNIV PENN, WHARTON SCH, PHILADELPHIA, PA 19104 USA; UNIV PENN, LEONARD DAVIS INST HLTH ECON, PHILADELPHIA, PA 19104 USA	Agency for Healthcare Research & Quality; New York University; University of Pennsylvania; University of Pennsylvania	NAYLOR, M (corresponding author), UNIV PENN, SCH NURSING, 420 GUARDIAN DR, PHILADELPHIA, PA 19104 USA.				NINR NIH HHS [NR02095-05] Funding Source: Medline; NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR002095] Funding Source: NIH RePORTER	NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		ANDERSON GF, 1984, NEW ENGL J MED, V311, P1349, DOI 10.1056/NEJM198411223112105; Brooten D, 1988, Image J Nurs Sch, V20, P64; FINK A, 1987, JAMA-J AM MED ASSOC, V258, P1905, DOI 10.1001/jama.258.14.1905; JOHNSON H, 1985, CONTINUITY CARE ADV, P229; JONES EW, 1989, HEALTH SERV RES, V24, P643; KENNEDY L, 1987, GERONTOLOGIST, V27, P577, DOI 10.1093/geront/27.5.577; MANTON KG, 1993, HEALTH SERV RES, V28, P269; NAYLOR M, 1991, CRITICAL CARE NURSIN; NAYLOR M, 1986, HLTH STATUS HLTH CAR; NEIDLINGER L, 1987, NURS ECON, V5, P225; PAULY M, 1992, IMPROVING HLTH POLIC, P155; ROGERS WH, 1990, JAMA-J AM MED ASSOC, V264, P1989, DOI 10.1001/jama.264.15.1989; SMITH DM, 1988, MED CARE, V26, P699, DOI 10.1097/00005650-198807000-00005; Van Gelder S, 1986, Pride Inst J Long Term Home Health Care, V5, P3; WEINBERGER M, 1988, MED CARE, V26, P1092, DOI 10.1097/00005650-198811000-00007; WERTHEIMER DS, 1990, GERONTOLOGIST, V30, P837; WOLOCK I, 1987, SOC WORK HEALTH CARE, V12, P61, DOI 10.1300/J010v12n04_05; 1989, MEDICARE PROSPECTIVE; 1993, MEDICARE PROSPECTIVE; 1992, VITAL HLTH STATIS 13, V112; 1992, MEDICARE PROSPECTIVE	21	490	511	2	23	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1994	120	12					999	1006		10.7326/0003-4819-120-12-199406150-00005	http://dx.doi.org/10.7326/0003-4819-120-12-199406150-00005			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ964	8185149				2023-01-03	WOS:A1994NQ96400005
J	VANDERMAST, BJ; HORNSTRA, N; RUIGROK, MB; CLAAS, FHJ; VANROOD, JJ; LAGAAIJ, EL				VANDERMAST, BJ; HORNSTRA, N; RUIGROK, MB; CLAAS, FHJ; VANROOD, JJ; LAGAAIJ, EL			TRANSFUSION-ASSOCIATED GRAFT-VERSUS-HOST DISEASE IN IMMUNOCOMPETENT PATIENTS - A SELF-PROTECTIVE MECHANISM	LANCET			English	Article							NONIMMUNOCOMPROMISED HOSTS; BLOOD-TRANSFUSIONS; T-CELLS; RESISTANCE; TRANSPLANTATION; HEART; RATS	Transfusion-associated graft-versus-host disease (TA-GVHD) is a rare but hazardous complication caused by transfusion of leucocyte-containing blood. It is not clear why some patients are at risk for TA-GVHD, but others are not. We studied TA-GVHD in immunocompetent individuals by looking at donor-anti-host reactivity after transfusion of leucocyte-containing blood. We tested reactivity in 62 donor-recipient combinations in vitro before and at different times after blood transfusion with mixed lymphocyte culture. One patient was studied in more detail. Reactivity of blood donors against hosts gradually decreased after blood transfusion. This decrease significantly correlated with time (p<0.001). Studies in a single patient showed that absence of donor-host reactivity was due to host T cells that inhibited the response. These data indicate that an active mechanism exists in immunocompetent individuals which inhibits the graft-versus-host reaction of the donor against the host. This mechanism might be exploited in organ transplantation by pre-transplant blood transfer.	UNIV HOSP LEIDEN,DEPT IMMUNOHAEMATOL & BLOOD BANK,2333 AA LEIDEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC)								ANDERSEN CB, 1992, HUM PATHOL, V23, P831, DOI 10.1016/0046-8177(92)90355-7; AVOY DR, 1990, TRANSFUSION, V30, P849, DOI 10.1046/j.1537-2995.1990.30991048795.x; BELGRAU DL, 1978, J EXP MED, V148, P103; BURDICK JF, 1988, NEW ENGL J MED, V318, P689, DOI 10.1056/NEJM198803173181107; DEGAST GC, 1991, BONE MARROW TRANSPL, V7, P293; DESFORGES JF, 1990, NEW ENGL J MED, V323, P315; GOULMY E, 1983, HLA TYPING METHODOLO, V2, P105; GREENBAUM BH, 1991, J CLIN ONCOL, V9, P1889, DOI 10.1200/JCO.1991.9.10.1889; KIMURA H, 1984, J EXP MED, V160, P652, DOI 10.1084/jem.160.3.652; KIMURA H, 1984, NATURE, V308, P463, DOI 10.1038/308463a0; KOSMATOPOULOS K, 1987, J IMMUNOL, V138, P1038; KOSMATOPOULOS K, 1988, TRANSPLANTATION, V46, P570, DOI 10.1097/00007890-198810000-00021; KOSMATOPOULOS K, 1987, TRANSPLANTATION, V44, P267, DOI 10.1097/00007890-198708000-00018; LAGAAIJ EL, 1989, NEW ENGL J MED, V321, P701, DOI 10.1056/NEJM198909143211101; LEHMANN PV, 1991, J EXP MED, V173, P333, DOI 10.1084/jem.173.2.333; MARCUS JN, 1989, NEW ENGL J MED, V322, P1004; OHTO H, 1992, TRANSFUSION, V32, P691, DOI 10.1046/j.1537-2995.1992.32792391051.x; OPELZ G, 1973, TRANSPLANT P, V5, P253; PIRENNE J, 1991, TRANSPLANTATION, V51, P51, DOI 10.1097/00007890-199101000-00007; SAKAKIBARA T, 1986, LANCET, V2, P1099; SAZAMA K, 1990, TRANSFUSION, V30, P583, DOI 10.1046/j.1537-2995.1990.30790385515.x; SHIVDASANI RA, 1993, NEW ENGL J MED, V328, P766, DOI 10.1056/NEJM199303183281105; SPITZER TR, 1990, CANCER-AM CANCER SOC, V66, P2346, DOI 10.1002/1097-0142(19901201)66:11<2346::AID-CNCR2820661116>3.0.CO;2-T; SUZUKI K, 1992, TRANSFUSION, V32, P358, DOI 10.1046/j.1537-2995.1992.32492263452.x; VOGELSANG GB, 1990, TRANSFUSION, V30, P101, DOI 10.1046/j.1537-2995.1990.30290162892.x; WILSON DB, 1989, IMMUNOL REV, V107, P159, DOI 10.1111/j.1600-065X.1989.tb00008.x; 1989, LANCET, V2, P529	27	32	32	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 26	1994	343	8900					753	757		10.1016/S0140-6736(94)91836-8	http://dx.doi.org/10.1016/S0140-6736(94)91836-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC351	7907730				2023-01-03	WOS:A1994NC35100008
J	OWEN, WF; LEW, NL; LIU, Y; LOWRIE, EG; LAZARUS, JM				OWEN, WF; LEW, NL; LIU, Y; LOWRIE, EG; LAZARUS, JM			THE UREA REDUCTION RATIO AND SERUM-ALBUMIN CONCENTRATION AS PREDICTORS OF MORTALITY IN PATIENTS UNDERGOING HEMODIALYSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEATH RISK; DIALYSIS; VARIABLES	Background. Among patients with end-stage renal disease who are treated with hemodialysis, solute clearance during dialysis and nutritional adequacy are determinants of mortality. We determined the effects of reductions in blood urea nitrogen concentrations during dialysis and changes in serum albumin concentrations, as an indicator of nutritional status, on mortality in a large group of patients treated with hemodialysis. Methods. We analyzed retrospectively the demographic characteristics, mortality rate, duration of hemodialysis, serum albumin concentration, and urea reduction ratio (defined as the percent reduction in blood urea nitrogen concentration during a single dialysis treatment) in 13,473 patients treated from October 1, 1990, through March 31, 1991. The risk of death was determined as a function of the urea reduction ratio and serum albumin concentration. Results. As compared with patients with urea reduction ratios of 65 to 69 percent, patients with values below 60 percent had a higher risk of death during follow-up (odds ratio, 1.28 for urea reduction ratios of 55 to 59 percent and 1.39 for ratios below 55 percent). Fifty-five percent of the patients had urea reduction ratios below 60 percent. The duration of dialysis was not predictive of mortality. The serum albumin concentration was a more powerful (21 times greater) predictor of death than the urea reduction ratio, and 60 percent of the patients had serum albumin concentrations predictive of an increased risk of death (values below 4.0 g per deciliter). The odds ratio for death was 1.48 for serum albumin concentrations of 3.5 to 3.9 g per deciliter and 3.13 for concentrations of 3.0 to 3.4 g per deciliter. Diabetic patients had lower serum albumin concentrations and urea reduction ratios than nondiabetic patients. Conclusions. Low urea reduction ratios during dialysis are associated with increased odds ratios for death. These risks are worsened by inadequate nutrition.	HARVARD UNIV,SCH MED,BOSTON,MA 02115; NATL MED CARE INC,WALTHAM,MA	Harvard University; Harvard Medical School	OWEN, WF (corresponding author), BRIGHAM & WOMENS HOSP,SEELEY MUDD BLDG,250 LONGWOOD AVE,BOSTON,MA 02115, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045656] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45656-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1989, SAS STAT USERS GUIDE, V2, P1071; BASILE C, 1990, AM J KIDNEY DIS, V15, P40, DOI 10.1016/S0272-6386(12)80590-7; Daugirdas J T, 1989, ASAIO Trans, V35, P336, DOI 10.1097/00002480-198907000-00052; FLANIGAN MJ, 1991, AM J KIDNEY DIS, V17, P295, DOI 10.1016/S0272-6386(12)80477-X; FLEISS JL, 1986, DESIGN ANAL CLIN EXP, P156; GOTCH FA, 1985, KIDNEY INT, V28, P526, DOI 10.1038/ki.1985.160; HARTER HR, 1983, KIDNEY INT S13, V23, pS107; HELD PJ, 1991, JAMA-J AM MED ASSOC, V265, P871, DOI 10.1001/jama.265.7.871; HELD PJ, 1990, AM J KIDNEY DIS, V15, P451, DOI 10.1016/S0272-6386(12)70363-3; HERRMANN FR, 1992, ARCH INTERN MED, V152, P125, DOI 10.1001/archinte.152.1.125; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; HULL AR, 1990, AM J KIDNEY DIS, V15, P375, DOI 10.1016/S0272-6386(12)70354-2; JINDAL KK, 1987, T AM SOC ART INT ORG, V33, P286; LAIRD NM, 1983, KIDNEY INT, pS101; LINDSAY RM, 1992, KIDNEY INT, V42, pS32; LINDSAY RM, 1989, AM J KIDNEY DIS, V13, P382, DOI 10.1016/S0272-6386(89)80021-6; Lowrie E.G., 1991, CONTEMP DIAL NEPHROL, V12, P11; LOWRIE EG, 1992, KIDNEY INT, V42, pS22; LOWRIE EG, 1992, SEMIN NEPHROL, V12, P276; LOWRIE EG, 1990, AM J KIDNEY DIS, V15, P458, DOI 10.1016/S0272-6386(12)70364-5; Lowrie EG, 1983, KIDNEY INT S, V13, pS11; MURRAY MJ, 1988, MAYO CLIN PROC, V63, P1106, DOI 10.1016/S0025-6196(12)65505-0; PARKER TF, 1983, KIDNEY INT S13, V23, pS42; PARKER TF, 1983, KIDNEY INT S, V13, pS37; 1992, US RENAL DATA SYSTEM	25	1152	1181	0	28	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 30	1993	329	14					1001	1006		10.1056/NEJM199309303291404	http://dx.doi.org/10.1056/NEJM199309303291404			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LY587	8366899				2023-01-03	WOS:A1993LY58700004
J	BERRY, ZS; LYNN, J				BERRY, ZS; LYNN, J			HOSPICE MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CANCER; PAIN		DARTMOUTH COLL,HITCHCOCK MED CTR,HANOVER,NH 03756	Dartmouth College	BERRY, ZS (corresponding author), GEORGE WASHINGTON UNIV,WASHINGTON,DC 20052, USA.							[Anonymous], 1992, J Clin Oncol, V10, P1976; Bonica J., 1953, MANAGEMENT PAIN; BRODY H, 1992, NEW ENGL J MED, V327, P1384, DOI 10.1056/NEJM199211053271912; BURCHMAN SL, 1992, PRACTICAL MANAGEMENT; DAUT RL, 1982, CANCER-AM CANCER SOC, V50, P1913, DOI 10.1002/1097-0142(19821101)50:9<1913::AID-CNCR2820500944>3.0.CO;2-R; Fields HE, 1991, CORE CURRICULUM PROF; FOLEY KM, 1985, NEW ENGL J MED, V313, P84, DOI 10.1056/NEJM198507113130205; LYNN J, 1983, HASTINGS CENT REP, V13, P17, DOI 10.2307/3560572; MARKS RM, 1973, ANN INTERN MED, V78, P173, DOI 10.7326/0003-4819-78-2-173; PORTER J, 1980, NEW ENGL J MED, V302, P123; RHYMES J, 1990, JAMA-J AM MED ASSOC, V264, P369, DOI 10.1001/jama.264.3.369; SAUNDERS CM, 1981, THERAPY PAIN; SOLOMON MZ, 1993, AM J PUBLIC HEALTH, V83, P14, DOI 10.2105/AJPH.83.1.14; SULLIVAN RJ, 1993, J GEN INTERN MED, V8, P220, DOI 10.1007/BF02599271; TWYCROSS RG, 1974, INT J CLIN PHARM TH, V9, P184; TWYCROSS RG, 1982, PAIN, V14, P303, DOI 10.1016/0304-3959(82)90137-3; 1990, CANCER PAIN RELIEF P	17	8	8	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1993	270	2					221	223		10.1001/jama.270.2.221	http://dx.doi.org/10.1001/jama.270.2.221			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL368	8315738				2023-01-03	WOS:A1993LL36800024
J	BARLOW, DH				BARLOW, DH			MANAGING THE MENOPAUSE - FROM PUMPKINS TO HRT	LANCET			English	Editorial Material											BARLOW, DH (corresponding author), JOHN RADCLIFFE HOSP,NUFFIELD DEPT OBSTET & GYNAECOL,OXFORD OX3 9DU,ENGLAND.		Barlow, David/F-8738-2011					BARLOW DH, 1989, BRIT J OBSTET GYNAEC, V96, P1192, DOI 10.1111/j.1471-0528.1989.tb03195.x; BARLOW DH, 1992, BRIT MED BULL, V48, P356, DOI 10.1093/oxfordjournals.bmb.a072551; BUNGAY GT, 1980, BRIT MED J, V2, P181; CHAKRAVARTI S, 1977, BRIT J OBSTET GYNAEC, V84, P769, DOI 10.1111/j.1471-0528.1977.tb12491.x; GARNETT T, 1991, J ROY SOC MED, V84, P128, DOI 10.1177/014107689108400304; GATH D, 1990, HRT AND OSTEOPOROSIS, P35; OLDENHAVE A, 1993, AM J OBSTET GYNECOL, V168, P765, DOI 10.1016/S0002-9378(12)90816-9; OLDENHAVE A, 1993, AM J OBSTET GYNECOL, V168, P772, DOI 10.1016/S0002-9378(12)90817-0; SPECTOR TD, 1989, BRIT MED J, V299, P1434, DOI 10.1136/bmj.299.6713.1434	9	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 10	1993	342	8863					66	67		10.1016/0140-6736(93)91280-Y	http://dx.doi.org/10.1016/0140-6736(93)91280-Y			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LL789	8100907				2023-01-03	WOS:A1993LL78900004
J	MORTONJONES, T; PRINGLE, M				MORTONJONES, T; PRINGLE, M			EXPLAINING VARIATIONS IN PRESCRIBING COSTS ACROSS ENGLAND	BRITISH MEDICAL JOURNAL			English	Article								Objective-To derive a predictive model for national prescribing behaviour in terms of basic morbidity and demographic factors. Design-24 demographic, morbidity, and practice factors were entered into a multiple regression analysis to determine the net ingredient cost per patient. Setting-The 90 family health service authorities in England for 1989. Results-For net ingredient cost per patient only two demographic factors (numbers of pensioners and the mobility of the registered population measured by list inflation) and two morbidity related factors (standardised mortality ratios and numbers of prepayment certificates issued) significantly contributed to a multiple regression model. This model explained 81% of the variation in net ingredient cost per registered patient between family health services authorities. The model also enabled a weighting factor of 4.6 (95% confidence interval 3.2 to 6.7) to be derived for the net ingredient cost for elderly patients (compared with the existing prescribing unit factor of 3). Conclusions-The model shows that variations in prescribing costs essentially reflect demand. It also suggests that the current prescribing unit value of 3 for patients aged 65 or more underestimates the extra costs of prescribing for elderly patients.			MORTONJONES, T (corresponding author), QUEENS MED CTR,DEPT GEN PRACTICE,NOTTINGHAM NG7 2UH,ENGLAND.							BAKER D, 1991, BRIT MED J, V303, P225, DOI 10.1136/bmj.303.6796.225; BRADLEY CP, 1991, FAM PRACT, V8, P276, DOI 10.1093/fampra/8.3.276; BRENNAN ME, 1980, J EPIDEMIOL COMMUN H, V34, P134, DOI 10.1136/jech.34.2.134; EDWARDS C, 1991, INT J PHARM PRACTICE, V1, P73; FORSTER DP, 1991, BRIT J GEN PRACT, V41, P67; GILLEGHAN JD, 1991, 54 ROYAL COLL GEN PR; HARRIS CM, 1984, RCGP24 OCC PAP; HARRIS CM, 1986, BR J GEN PRACT, V36, P148; HARRIS CM, 1990, ANAL PRESCRIBING GEN; HARRIS JF, 1990, SOMAT CELL MOLEC GEN, V16, P39, DOI 10.1007/BF01650478; Marinker M, 1973, J R Coll Gen Pract, V23 Suppl 2, P26; MAYS N, 1992, J EPIDEMIOL COMMUN H, V46, P38, DOI 10.1136/jech.46.1.38; MAYS N, 1989, J EPIDEMIOL COMMUN H, V43, P191, DOI 10.1136/jech.43.2.191; MORTONJONES AJ, 1993, BRIT MED J, V306, P1244; MORTONJONES AJ, IN PRESS BR J GEN PR; Taylor R J, 1977, J R Coll Gen Pract, V27, P79; TAYLOR RJ, 1991, BRIT J GEN PRACT, V41, P244; VIRJI A, 1991, FAM PRACT, V8, P314, DOI 10.1093/fampra/8.4.314; 1991, ANN REPORT 1 APRIL 1, P9; 1991, NHLTH SERVICES INDIC; 1991, REGIONAL TRENDS, V26	21	35	36	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 26	1993	306	6894					1731	1734		10.1136/bmj.306.6894.1731	http://dx.doi.org/10.1136/bmj.306.6894.1731			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK367	8343631	Green Published, Bronze			2023-01-03	WOS:A1993LK36700024
J	BRADLEY, TD; SHAPIRO, CM				BRADLEY, TD; SHAPIRO, CM			ABC OF SLEEP DISORDERS - UNEXPECTED PRESENTATIONS OF SLEEP-APNEA - USE OF CPAP IN TREATMENT	BRITISH MEDICAL JOURNAL			English	Article									UNIV TORONTO,TORONTO M5S 1A1,ONTARIO,CANADA	University of Toronto	BRADLEY, TD (corresponding author), MINIST HLTH ONTARIO,TORONTO,ON,CANADA.								0	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 8	1993	306	6887					1260	1262		10.1136/bmj.306.6887.1260	http://dx.doi.org/10.1136/bmj.306.6887.1260			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB804	8499860	Bronze, Green Published			2023-01-03	WOS:A1993LB80400025
J	PURVES, IN; EDWARDS, C				PURVES, IN; EDWARDS, C			COMPARISON OF PRESCRIBING UNIT WITH INDEX INCLUDING BOTH AGE AND SEX IN ASSESSING GENERAL-PRACTICE PRESCRIBING COSTS	BRITISH MEDICAL JOURNAL			English	Article								Objective-To examine and compare the prescribing unit and a new prescribing index adjusting for age and sex in assessing general practice prescribing. Design-Analysis of all prescriptions issued by two practices in one year. Use of data to derive a prescribing index adjusting for age and sex. Comparison of effect of prescribing unit and new index on relation between 80 practices' prescribing data and family health services authority average. Setting-Newcastle and Gateshead Family Health Services Authorities. Two urban practices with eight doctors and combined list size of 16300 patients. Main outcome measures-Cost and number of prescriptions issued to each age and sex group. Effect of index on relation between practice data and family health services authority average. Results-The number of items prescribed and total costs rose with age. Although total costs were greater for women than for men, individual items cost more for men aged 25-84. Comparison of data adjusted by the prescribing unit and the new index with authority averages produced no significant differences except in a few practices with skewed age-sex demography. Results with the two indexes differed by over 5% in 34% (27/80) of practices for costs and in 14% (11/80) for items prescribed. Conclusions-The age and sex profile of a practice does not explain interpractice variation in prescribing patterns. Other unidentified factors need to be considered.	CHAINBRIDGE MED PARTNERSHIP,BLAYDON ON TYNE,ENGLAND; UNIV NEWCASTLE UPON TYNE,WOLFSON UNIT CLIN PHARMACOL,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND	Newcastle University - UK								EDWARDS C, 1991, INT J PHARM PRACTICE, V1, P73; EDWARDS C, 1992, PRESCRIBER, V3, P103; GRIFFIN JP, 1990, ABPI BRIEFING; Hall M S, 1981, Practitioner, V225, P271; HARRIS JF, 1990, SOMAT CELL MOLEC GEN, V16, P39, DOI 10.1007/BF01650478; SKEGG DCG, 1977, BRIT MED J, V1, P1561, DOI 10.1136/bmj.1.6076.1561; 1988, ANN REPORT 1 APRIL 1, P12; 1990, STATISTICAL B   0422, P3; 1989, COMPENDIUM HLTH STAT, P45	9	17	18	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 20	1993	306	6876					496	498		10.1136/bmj.306.6876.496	http://dx.doi.org/10.1136/bmj.306.6876.496			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN786	8448463	Green Published, Bronze			2023-01-03	WOS:A1993KN78600022
